<SEC-DOCUMENT>0001129928-25-000019.txt : 20250307
<SEC-HEADER>0001129928-25-000019.hdr.sgml : 20250307
<ACCEPTANCE-DATETIME>20250307124858
ACCESSION NUMBER:		0001129928-25-000019
CONFORMED SUBMISSION TYPE:	20-F
PUBLIC DOCUMENT COUNT:		110
CONFORMED PERIOD OF REPORT:	20241231
FILED AS OF DATE:		20250307
DATE AS OF CHANGE:		20250307

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ONCOLYTICS BIOTECH INC
		CENTRAL INDEX KEY:			0001129928
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		20-F
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38512
		FILM NUMBER:		25718731

	BUSINESS ADDRESS:	
		STREET 1:		804, 322 - 11 AVENUE SW
		CITY:			CALGARY
		STATE:			A0
		ZIP:			T2R 0C5
		BUSINESS PHONE:		4036707380

	MAIL ADDRESS:	
		STREET 1:		804, 322 - 11 AVENUE SW
		CITY:			CALGARY
		STATE:			A0
		ZIP:			T2R 0C5
</SEC-HEADER>
<DOCUMENT>
<TYPE>20-F
<SEQUENCE>1
<FILENAME>oncyf-20241231.htm
<DESCRIPTION>20-F
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:f2389c06-29ac-4823-bdfc-c1b39bddff80,g:9bb1793d-cf33-41ae-b11c-eb401ad874b8,d:17734265916144358581fdce5df64f78-->
<html xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:oncyf="http://www.oncolyticsbiotech.com/20241231" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>oncyf-20241231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-37">0001129928</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-38">2024</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-39">FY</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-40">false</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" id="f-41">A0</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-42">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="c-189" name="oncyf:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1" id="f-735">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="c-203" name="oncyf:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:duryear" id="f-779">2</ix:nonNumeric><ix:nonNumeric contextRef="c-204" name="oncyf:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:duryear" id="f-780">2</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="c-1" decimals="4" name="oncyf:PurchaseObligationCommitmentProductionServiceAgreementPercentage" scale="0" id="f-800">0.3333</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="oncyf-20241231.xsd"/></ix:references><ix:resources><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="cad"><xbrli:measure>iso4217:CAD</xbrli:measure></xbrli:unit><xbrli:unit id="cadPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:CAD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="plan"><xbrli:measure>oncyf:plan</xbrli:measure></xbrli:unit><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="d"><xbrli:measure>utr:D</xbrli:measure></xbrli:unit><xbrli:unit id="year"><xbrli:measure>oncyf:year</xbrli:measure></xbrli:unit><xbrli:unit id="eur"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:unit id="manufacturer"><xbrli:measure>oncyf:manufacturer</xbrli:measure></xbrli:unit><xbrli:unit id="segment"><xbrli:measure>oncyf:segment</xbrli:measure></xbrli:unit><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderPublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderPublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ifrs-full:MajorOrdinaryShareTransactionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">oncyf:ClinicalTrialMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">oncyf:ClinicalTrialMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-08-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-09-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-08</xbrli:startDate><xbrli:endDate>2023-08-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingWarrantDerivativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-07</xbrli:startDate><xbrli:endDate>2023-09-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingWarrantDerivativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:SharesPublicOfferingWarrantDerivativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:SharesPublicOfferingWarrantDerivativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:SharesPublicOfferingWarrantDerivativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:SharesPublicOfferingWarrantDerivativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:SharesPublicOfferingWarrantDerivativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:SharesPublicOfferingWarrantDerivativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:SharesUnderStockOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:SharesUnderIncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:SharesUnderStockOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:SharesUnderIncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingWarrantDerivativesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2021SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2021SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-05</xbrli:startDate><xbrli:endDate>2021-03-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2021SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2021SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2022SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2022SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-17</xbrli:startDate><xbrli:endDate>2022-06-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2022SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2022SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2022SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2022SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2022SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2022SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:CompensationWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-08</xbrli:startDate><xbrli:endDate>2023-08-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:CompensationWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-07</xbrli:startDate><xbrli:endDate>2023-09-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:CompensationWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-08</xbrli:startDate><xbrli:endDate>2023-08-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:CompensationWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-07</xbrli:startDate><xbrli:endDate>2023-09-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-161"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-07</xbrli:startDate><xbrli:endDate>2023-09-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-08</xbrli:startDate><xbrli:endDate>2023-08-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-163"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2024SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-08-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-164"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2024SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-08-02</xbrli:startDate><xbrli:endDate>2024-08-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-165"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2024SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-166"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2024SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-167"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-168"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-169"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-170"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-171"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-172"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-173"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-174"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-175"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-176"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-177"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-178"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-179"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-180"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-181"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-182"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-183"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-184"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-185"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-186"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-187"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-188"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-189"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-190"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-191"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-192"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-193"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-194"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-195"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-196"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-197"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-198"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-199"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-200"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:CompensationWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:CompensationWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:CompensationWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-205"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-206"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BB</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-208"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BB</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnusedNetOperatingLossCarryForwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnusedNetOperatingLossCarryForwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnusedNetOperatingLossCarryForwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-219"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:InvestmentTaxCreditsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:InvestmentTaxCreditsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:InvestmentTaxCreditsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:PropertyPlantEquipmentRelatedTemporaryDifferencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:PropertyPlantEquipmentRelatedTemporaryDifferencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:PropertyPlantEquipmentRelatedTemporaryDifferencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-227"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:ShareIssueCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:ShareIssueCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:ShareIssueCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnusedCapitalLossCarryForwardNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnusedCapitalLossCarryForwardNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-232"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnusedCapitalLossCarryForwardNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-233"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-06-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-234"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-235"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-236"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-237"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-238"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-239"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-240"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-241"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-242"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:ConcentrationRiskType1Axis">oncyf:SupplierConcentrationRisk1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-243"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:IncomeStatementLocation1Axis">oncyf:ResearchAndDevelopmentExpense1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-244"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:IncomeStatementLocation1Axis">oncyf:ResearchAndDevelopmentExpense1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-245"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:IncomeStatementLocation1Axis">oncyf:ResearchAndDevelopmentExpense1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-246"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:IncomeStatementLocation1Axis">oncyf:GeneralAndAdministrativeExpense1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-247"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:IncomeStatementLocation1Axis">oncyf:GeneralAndAdministrativeExpense1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-248"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:IncomeStatementLocation1Axis">oncyf:GeneralAndAdministrativeExpense1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-249"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-250"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-251"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">oncyf:RestOfWorldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-252"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">oncyf:RestOfWorldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i17734265916144358581fdce5df64f78_1"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center;text-indent:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">20-F</ix:nonNumeric></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:13.687%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.853%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:80.160%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentRegistrationStatement" format="ixt:fixed-false" id="f-2">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OR</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentAnnualReport" format="ixt:fixed-true" id="f-3">x</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For fiscal year ended</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-4"><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="f-5">December&#160;31</ix:nonNumeric>, 2024</ix:nonNumeric></span></div></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OR</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-6">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;<br/>For the transition period from ____ to ____</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OR</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentShellCompanyReport" format="ixt:fixed-false" id="f-7">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;<br/>Date of event requiring this shell company report:</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission file number: <ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-8">001-38512</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-9">ONCOLYTICS BIOTECH INC.</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of Registrant as specified in its charter)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Province of Alberta, Canada</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Jurisdiction of incorporation or organization)</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-10">804, 322 11th Avenue SW</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-11">Calgary</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-12">Alberta</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCountry" format="ixt-sec:countrynameen" id="f-13">Canada</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-14">T2R 0C5</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Address of principal executive offices)</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-2" name="dei:ContactPersonnelName" id="f-15">Kirk Look</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-2" name="dei:EntityAddressAddressLine1" id="f-16">804, 322 11th Avenue SW</ix:nonNumeric>, <ix:nonNumeric contextRef="c-2" name="dei:EntityAddressCityOrTown" id="f-17">Calgary</ix:nonNumeric>, <ix:nonNumeric contextRef="c-2" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-18">Alberta</ix:nonNumeric>, <ix:nonNumeric contextRef="c-2" name="dei:EntityAddressCountry" format="ixt-sec:countrynameen" id="f-19">Canada</ix:nonNumeric>  <ix:nonNumeric contextRef="c-2" name="dei:EntityAddressPostalZipCode" id="f-20">T2R 0C5</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tel: (<ix:nonNumeric contextRef="c-2" name="dei:CityAreaCode" id="f-21">403</ix:nonNumeric>) <ix:nonNumeric contextRef="c-2" name="dei:LocalPhoneNumber" id="f-22">670-7377</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">E-mail: <ix:nonNumeric contextRef="c-2" name="dei:ContactPersonnelEmailAddress" id="f-23">info@oncolytics.ca</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Name, Telephone, E-mail and/or Facsimile number and Address of Company Contact Person)</span></div><div><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.578%"><tr><td style="width:1.0%"/><td style="width:29.186%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.735%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:44.779%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trading Symbol</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common Shares, <ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-24">no</ix:nonNumeric> par value</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-25">ONCY</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The <ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-26">Nasdaq</ix:nonNumeric> Stock Market LLC</span></div></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(g) of the Act:  None</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act: &#160;None</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate the number of outstanding shares of each of the Registrant&#8217;s classes of capital or common stock as of the close of the period covered by the annual report: <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-27">80,020,131</ix:nonFraction> common shares as at December&#160;31, 2024</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="c-1" name="dei:EntityWellKnownSeasonedIssuer" id="f-28">No</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#253;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If this report is an annual or transition report, indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="c-1" name="dei:EntityVoluntaryFilers" id="f-29">No</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#253;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-30">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#253; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every&#160;Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-31">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#253;  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or an emerging growth company.&#160;&#160;See definition of &#8220;large accelerated filer,&#8221;  &#8220;accelerated filer,&#8221; and &#8220;emerging growth company in Rule 12b-2 of the Exchange Act.&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:31.842%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.721%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.137%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Large accelerated filer </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-32">Accelerated filer</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">x</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Non-accelerated filer&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">o</span></div></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-true" id="f-33">x</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">registrant included in the filing reflect the correction of an error to previously issued financial statements. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt:fixed-false" id="f-34">o</ix:nonNumeric></span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;U.S. GAAP</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentAccountingStandard" id="f-35">International Financial Reporting Standards</ix:nonNumeric> as issued&#160;&#160;by the International Accounting Standards Board</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Other&#160;&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">o</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">x</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">o</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If &#8220;Other&#8221; has been checked in response to the previous question, indicate by check mark which financial statement item the registrant has elected to follow:</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Item 17 </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Item 18&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If this is an annual report, indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-36">o</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#253;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i17734265916144358581fdce5df64f78_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORM 20-F</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.119%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.681%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i17734265916144358581fdce5df64f78_16">&#160;Item 1. &#160;&#160;&#160;&#160; Identity of Directors, Senior Management and Advisers</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i17734265916144358581fdce5df64f78_16">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i17734265916144358581fdce5df64f78_19">&#160;Item 2.&#160; &#160;&#160;&#160; Offer Statistics and Expected Timetable</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i17734265916144358581fdce5df64f78_19">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i17734265916144358581fdce5df64f78_22">&#160;Item 3. &#160;&#160;&#160; &#160;Key Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i17734265916144358581fdce5df64f78_22">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i17734265916144358581fdce5df64f78_37">&#160;Item 4.&#160;&#160;&#160;&#160;&#160; Information on the Company</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i17734265916144358581fdce5df64f78_37">29</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i17734265916144358581fdce5df64f78_52">&#160;Item 4A.    Unresolved Staff Comments</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i17734265916144358581fdce5df64f78_52">39</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i17734265916144358581fdce5df64f78_55">&#160;Item 5.&#160; &#160;&#160;&#160; Operating and Financial Review and Prospects</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i17734265916144358581fdce5df64f78_55">39</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i17734265916144358581fdce5df64f78_61">&#160;Item 6.&#160; &#160;&#160; &#160;Directors, Senior Management and Employees</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i17734265916144358581fdce5df64f78_61">40</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i17734265916144358581fdce5df64f78_82">&#160;Item 7.&#160; &#160;&#160;&#160; Major Shareholders and Related Party Transactions</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i17734265916144358581fdce5df64f78_82">53</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i17734265916144358581fdce5df64f78_94">&#160;Item 8.&#160;&#160; &#160;&#160;&#160;Financial Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i17734265916144358581fdce5df64f78_94">54</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i17734265916144358581fdce5df64f78_103">&#160;Item 9.&#160;&#160;&#160;&#160;&#160; The Offer and Listing</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i17734265916144358581fdce5df64f78_103">55</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i17734265916144358581fdce5df64f78_106">&#160;Item 10.&#160;&#160;&#160; Additional Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i17734265916144358581fdce5df64f78_106">55</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i17734265916144358581fdce5df64f78_136">&#160;Item 11.&#160;&#160;&#160; Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i17734265916144358581fdce5df64f78_136">66</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i17734265916144358581fdce5df64f78_139">&#160;Item 12.&#160;&#160;&#160; Description of Securities Other Than Equity Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i17734265916144358581fdce5df64f78_139">66</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i17734265916144358581fdce5df64f78_145">&#160;Item 13.&#160;&#160;&#160; Defaults, Dividend Arrearages and Delinquencies</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i17734265916144358581fdce5df64f78_145">66</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i17734265916144358581fdce5df64f78_148">&#160;Item 14.&#160;&#160;&#160; Material Modifications to the Rights of Security Holders and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i17734265916144358581fdce5df64f78_148">66</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i17734265916144358581fdce5df64f78_151">&#160;Item 15.&#160;&#160;&#160;&#160; Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i17734265916144358581fdce5df64f78_151">66</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i17734265916144358581fdce5df64f78_154">&#160;Item 16.     [Reserved]</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i17734265916144358581fdce5df64f78_154">67</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i17734265916144358581fdce5df64f78_157">&#160;Item 16A. &#160;Audit Committee Financial Expert</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i17734265916144358581fdce5df64f78_157">67</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i17734265916144358581fdce5df64f78_160">&#160;Item 16B.&#160;&#160; Code of Ethics</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i17734265916144358581fdce5df64f78_160">67</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i17734265916144358581fdce5df64f78_163">&#160;Item 16C.&#160;&#160;&#160;Principal Accountant Fees and Services</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i17734265916144358581fdce5df64f78_163">67</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i17734265916144358581fdce5df64f78_166">&#160;Item 16D.&#160; &#160;Exemptions from the Listing Standards for Audit Committees</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i17734265916144358581fdce5df64f78_166">68</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i17734265916144358581fdce5df64f78_169">&#160;Item 16E.&#160;&#160; Purchase of Equity Securities by the Issuer and Affiliated Purchases</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i17734265916144358581fdce5df64f78_169">68</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i17734265916144358581fdce5df64f78_172">&#160;Item 16F.&#160;&#160; Change in Registrant's Certifying Accountants</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i17734265916144358581fdce5df64f78_172">68</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i17734265916144358581fdce5df64f78_175">&#160;Item 16G.&#160; Corporate Governance</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i17734265916144358581fdce5df64f78_175">68</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i17734265916144358581fdce5df64f78_178">&#160;Item 16H.   Mine Safety Disclosure</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i17734265916144358581fdce5df64f78_178">68</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i17734265916144358581fdce5df64f78_181">&#160;Item 16I.   Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i17734265916144358581fdce5df64f78_181">68</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i17734265916144358581fdce5df64f78_184">&#160;Item 16J.   Insider Trading Policies</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i17734265916144358581fdce5df64f78_184">69</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i17734265916144358581fdce5df64f78_187">&#160;Item 16K.   Cybersecurity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i17734265916144358581fdce5df64f78_187">69</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i17734265916144358581fdce5df64f78_193">&#160;Item 17.&#160;&#160;&#160;&#160;&#160; Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i17734265916144358581fdce5df64f78_193">70</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i17734265916144358581fdce5df64f78_196">&#160;Item 18&#160;&#160;&#160;&#160;&#160;&#160; Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i17734265916144358581fdce5df64f78_196">70</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i17734265916144358581fdce5df64f78_199">&#160;Item 19.&#160;&#160;&#160;&#160;&#160;&#160;Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i17734265916144358581fdce5df64f78_199">70</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i17734265916144358581fdce5df64f78_202">&#160;Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i17734265916144358581fdce5df64f78_202">71</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i17734265916144358581fdce5df64f78_205">&#160;Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i17734265916144358581fdce5df64f78_205">F1 - F28</a></span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i17734265916144358581fdce5df64f78_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All references in this annual report on Form 20-F to the terms "we," "our," "us," "the Company," and "Oncolytics" refer to Oncolytics Biotech Inc. Unless otherwise indicated, all references to "$" and "dollars" in this annual report mean Canadian dollars. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain statements in this annual report on Form 20-F and the documents attached as exhibits to this annual report, constitute "forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Oncolytics Biotech Inc., or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements are statements that are not historical facts, and include, but are not limited to, estimates and their underlying assumptions; statements regarding plans, objectives and expectations with respect to the efficacy of our technologies; the timing and results of clinical studies related to our technologies; future operations, products and services; the impact of regulatory initiatives on our operations; the size of and opportunities related to the markets for our technologies; general industry and macroeconomic growth rates; expectations related to possible joint and/or strategic ventures and statements regarding future performance. Forward-looking statements generally, but not always, are identified by the words "expects," "anticipates," "believes," "intends," "estimates," "projects," "potential," "possible" and similar expressions, or that events or conditions "will," "may," "could" or "should" occur.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The forward-looking statements in this annual report on Form 20-F are subject to various risks and uncertainties, most of which are difficult to predict and generally beyond our control. Some of the important risks and uncertainties that could affect forward-looking statements are described further under the section heading "Item 3. Key Information &#8211; D. Risk Factors" below.&#160;If one or more of these risks or uncertainties materializes, or if underlying assumptions prove incorrect, our actual results may vary materially from those expected, estimated or projected.&#160;Forward-looking statements in this document are not a prediction of future events or circumstances, and those future events or circumstances may not occur.&#160;Given these uncertainties, users of the information included herein, including investors and prospective investors are cautioned not to place undue reliance on such forward-looking statements.&#160;Investors should consult our quarterly and annual filings with the securities commissions or similar regulatory authorities in Canada and the SEC for additional information on risks and uncertainties relating to forward-looking statements.&#160;We do not assume responsibility for the accuracy and completeness of these statements.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forward-looking statements are based on our beliefs, opinions and expectations at the time they are made, and we do not assume any obligation to update our forward-looking statements if those beliefs, opinions, or expectations, or other circumstances, should change, except as required by applicable law.</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SUMMARY OF RISK FACTORS </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investing in our securities, including our common shares ("Common Shares"), involves a high degree of risk.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You should carefully consider the risks summarized below and other risks that we face, a detailed discussion of which can be found under "Item 3. Key Information &#8211; D. Risk Factors" below, together with other information in this annual report on Form 20-F and our other filings with the SEC. This summary list of risks is not exhaustive of the factors that may affect any of the Company&#8217;s forward-looking statements and our business and financial results. If any of these risks actually occur, our business, financial condition, and financial performance would likely be materially adversely affected. In such case, the trading price of our common shares would likely decline and you may lose part or all of your investment. Below is a summary of some of the principal risks we face: </span></div><div><span><br/></span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">There is substantial doubt that we can remain a going concern over the next twelve months.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">All of our potential products, including pelareorep, are in the research and development stage and will require further development and testing before they can be marketed commercially;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Any failure or delay in clinical trials for our products, including pelareorep, may cause us to incur additional costs or delay or prevent the commercialization of our products and could severely harm our business;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our candidate product, pelareorep, is being and will continue to be used in combination with other therapies, which exposes us to additional risks; </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our business, including our research and development operations, has been and may continue to be adversely affected by a variety of external factors outside our control;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our product candidate may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following any potential marketing approval;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may expend our limited resources to pursue a particular indication and fail to capitalize on indications that may be more profitable or for which there is a greater likelihood of success;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may not be able to secure a partnership for pelareorep, which could halt future development;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may need additional financing in the future to fund the research and development of our products and to meet our ongoing capital requirements;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Pharmaceutical products are subject to intense regulatory approval processes;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our operations and products may be subject to other government manufacturing and testing regulations;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have conducted, and may in the future conduct, clinical trials for pelareorep in sites outside the United States and the FDA may not accept data from trials conducted in such locations;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We rely on patents and proprietary rights to protect our technology;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Third parties may choose to file patent infringement claims against us; defending ourselves from such allegations would be costly, time-consuming, distracting to management and could materially affect our business;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are unable to protect the confidentiality of our proprietary information and know-how, the value of our technology and products could be adversely affected;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Developments in patent law could have a negative impact on our business;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we do not obtain protection under the Hatch-Waxman amendments and similar foreign legislation for extending the term of patents covering our product candidate, our business may be materially harmed;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Intellectual property rights do not necessarily address all potential threats to our business.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our products may fail or cause harm, subjecting us to product liability claims;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">New products may not be accepted by the medical community or consumers;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Interim "top-line" and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our technologies may become obsolete;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We rely on third-party manufacturers to produce our clinical products and on other third parties to store, monitor and transport bulk drug substance, and drug product. We and our third-party partners may encounter difficulties with respect to these activities that could delay or impair our ability to initiate or complete our clinical trials;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We rely on third parties to produce and provide suitable raw materials for pelareorep production, packaging, and testing as well as clinical trial-related testing. We and our third-party partners may encounter difficulties with sourcing these materials that could delay or impair our ability to manufacture pelareorep or complete product or clinical sample testing;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We rely on third parties to monitor, support, conduct, and oversee clinical trials of the products that we are developing and, in some cases, to maintain regulatory files for our product candidate. We may not be able to obtain regulatory approval for our products that may result from our development efforts if we are not able to maintain or secure agreements with such third parties on acceptable terms, if these third parties do not perform their services as required, or if these third parties fail to timely transfer any regulatory information held by them to us;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our license, development, supply, and distribution agreement with Adlai Nortye Biopharma Co. is subject to certain risks and uncertainties related to our dependence on Adlai and doing business in foreign jurisdictions;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our employees, independent contractors, principal investigators, contract research organizations, consultants, and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements and insider trading; </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Director and officer liability insurance is costly;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are dependent on our key employees and collaborators;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Company is likely a "passive foreign investment company" which may have adverse U.S. federal income tax consequences for U.S. shareholders;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we fail to meet all applicable Nasdaq Capital Market requirements and Nasdaq determines to delist our common shares, the delisting could adversely affect the market liquidity of our common shares and the market price of our common shares could decrease and our ability to access the capital markets could be negatively impacted;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Potential dilution of present and prospective shareholdings; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our operations may be adversely affected by disruptions to our information technology ("IT") systems or those of any of our CROs, manufacturers, other contractors or consultants or potential future collaborators, including disruptions from cybersecurity breaches of our IT infrastructure.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i17734265916144358581fdce5df64f78_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i17734265916144358581fdce5df64f78_16"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1. IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not Applicable.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i17734265916144358581fdce5df64f78_19"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2. OFFER STATISTICS AND EXPECTED TIMETABLE</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not Applicable.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i17734265916144358581fdce5df64f78_22"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3. KEY INFORMATION</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i17734265916144358581fdce5df64f78_25"></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt">[RESERVED]</span></div><div><span><br/></span></div><div id="i17734265916144358581fdce5df64f78_28"></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.84pt">Capitalization and Indebtedness</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not Applicable.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i17734265916144358581fdce5df64f78_31"></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">C.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt">Reasons for the Offer and Use of Proceeds</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not Applicable.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i17734265916144358581fdce5df64f78_34"></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">D.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt">Risk Factors</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investment in our common shares ("Common Shares") involves a high degree of risk. You should carefully consider, among other matters, the following risk factors in addition to the other information in this annual report on Form 20-F when evaluating our business because these risk factors may have a significant impact on our business, financial condition, operating results or cash flow. If any of the material risks described below or in subsequent reports we file with the SEC actually occur, they may materially harm our business, financial condition, operating results, or cash flow. Additional risks and uncertainties that we have not yet identified or that we presently consider to be immaterial may also materially harm our business, financial condition, operating results, or cash flow.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Risks</span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">There is substantial doubt that we can remain a going concern over the next twelve months.</span></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate we have sufficient cash and cash equivalents to fund our operations into the third quarter of 2025, without raising additional funding or reducing or eliminating our planned expenditures. Our ability to continue as a going concern is dependent upon raising additional financing through equity or strategic collaborations and transactions. We plan on raising additional funds through the sale of our common shares or other capital resources, such as collaborations and debt, to fund our ongoing operations. However, given the difficulty for micro-cap market capitalization companies to raise significant capital, there can be no assurance that additional liquidity will be available under acceptable terms or at all. Furthermore, if we are unable to obtain additional financing when required, there can be no assurance that we will be able to sufficiently reduce or eliminate our planned expenditures to extend our operating runway. These material uncertainties raise substantial doubt on our ability to meet our obligations as they come due. These consolidated financial statements do not reflect the adjustments to the carrying values of assets and liabilities and the reported expenses and statements of financial position classifications that would be necessary if we were unable to realize our assets and settle our liabilities as a going concern in the normal course of operations. Such adjustments could be material. See note 1 of our consolidated financial statements, Nature of Operations. </span></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">All of our potential products, including pelareorep, are in the research and development stage and will require further development and testing before they can be marketed commercially.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prospects for companies in the biotechnology industry generally may be regarded as uncertain given the nature of the industry and, accordingly, investments in biotechnology companies should be regarded as speculative. We are currently in the research and development stage on one product, pelareorep, for human application, the riskiest stage for a company in the biotechnology industry. It is not possible to predict, based upon studies in animals and early-stage human clinical trials, whether pelareorep will prove to be safe and effective in humans. Pelareorep will require later-stage and pivotal clinical trials before we will be able to obtain the approvals of the relevant regulatory authorities in applicable countries to market pelareorep commercially. Carrying out later-stage clinical trials and submission of a successful Biologics License Application ("BLA") or other </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">comparable foreign regulatory submission is a complicated process. We plan to conduct registration-enabling trials for pelareorep over the next several years, which may be a difficult process to manage with our limited resources and which may divert attention of management. We also have limited experience as a company in preparing, submitting and prosecuting regulatory filings and have not previously submitted a BLA or other comparable foreign regulatory submission for pelareorep. In addition, we have had limited interactions with the FDA and cannot be certain how many additional clinical trials of pelareorep will be required or how such trials should be designed. There can be no assurance that the research and development programs we conduct will result in pelareorep or any other products becoming commercially viable products, and in the event that any product or products result from the research and development program, it is unlikely they will be commercially available for a number of years.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To achieve profitable operations we, alone or with others, must successfully develop, introduce and market our products. To obtain regulatory approvals for products being developed for human use, and to achieve commercial success, human clinical trials must demonstrate that the product is safe for human use and that the product shows efficacy. Unsatisfactory results obtained from a particular study relating to a program may cause us to abandon our commitment to that program or the product being tested. No assurances can be provided that any current or future animal or human test, if undertaken, will yield favorable results. If we are unable to establish that pelareorep is a safe, effective treatment for cancer, we may be required to abandon further development of the product and develop a new business strategy.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">There are inherent risks in pharmaceutical research and development.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical research and development is highly speculative and involves a high and significant degree of risk. The marketability of any product we develop will be affected by numerous factors beyond our control, including but not limited to:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the discovery of unexpected toxicities or lack of sufficient efficacy of products which make them unattractive or unsuitable for human use;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">preliminary results as seen in animal and/or limited human testing may not be substantiated in larger, controlled clinical trials;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manufacturing costs or other production factors may make manufacturing of products ineffective, impractical, and non-competitive;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">proprietary rights of third parties or competing products or technologies may preclude commercialization;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">requisite regulatory approvals for the commercial distribution of products may not be obtained; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">other factors may become apparent during the course of research, up-scaling, or manufacturing which may result in the discontinuation of research and other critical projects.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products under development have never been manufactured on a commercial scale, and there can be no assurance that such products can be manufactured at a cost or in a quantity to render such products commercially viable. Production and utilization of our products may require the development of new manufacturing technologies and expertise. The impact on our business in the event that new manufacturing technologies and expertise are required to be developed is uncertain. There can be no assurance that we will successfully meet any of these technological challenges or others that may arise in the course of development.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Any failure or delay in clinical trials for our products, including pelareorep, may cause us to incur additional costs or delay or prevent the commercialization of our products and could severely harm our business.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We must conduct extensive clinical trials to demonstrate the safety and efficacy of our products in humans. Clinical testing, in particular, is expensive, difficult to design and implement, can take many years to complete, and is uncertain as to the outcome.&#160;A failure of one or more of our clinical trials can occur at any stage of testing. We may experience numerous unforeseen events during, or as a result of, the clinical trial process, which could delay or prevent us from receiving marketing approval or commercializing our product candidate, including the following:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our clinical trials may produce negative or inconclusive results, and we may decide, or regulatory authorities may require us, to conduct additional clinical trials, or we may abandon projects that we expect to be promising;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The number of subjects required for our clinical trials may be larger than we anticipate, enrollment in our clinical trials may be slower than we anticipate, or participants may drop out of our clinical trials at a higher rate than we anticipate;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We might have to suspend or terminate our clinical trials if the participants are being exposed to unacceptable health risks;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Regulators or institutional review boards may require that we hold, suspend, or terminate clinical research for various reasons, including noncompliance with regulatory requirements or our clinical protocols;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Regulators may refuse to accept or consider data from clinical trials for various reasons, including noncompliance with regulatory requirements or our clinical protocols;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may be subject to governmental or regulatory delays and changes in regulatory requirements, policy, and guidelines, including guidelines specifically addressing requirements for the development of treatments for our product candidate;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We might have difficulty adding new clinical trial sites on a timely basis, or at all;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The cost of our clinical trials may be greater than we anticipate;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The supply, storage, distribution, or quality of our products or other materials necessary to conduct our clinical trials may be insufficient or inadequate</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, subject enrollment, which is a significant factor in the timing of clinical trials, is affected by a variety of factors, including the following:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The size and nature of the subject population;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The proximity of subjects to clinical sites;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The eligibility criteria for the trial;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The design of the clinical trial;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Competing clinical trials; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Clinicians&#8217; and subjects&#8217; perceptions as to the potential advantages of the medication being studied in relation to other available therapies, including any new medications that may be approved for the indications we are investigating.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, we plan to rely on clinical trial sites to ensure the proper and timely conduct of our clinical trials, and while we have agreements governing their committed activities, we have limited influence over their actual performance. Any delays, concerns over the quality of the clinical data, or unanticipated problems during clinical testing, such as enrollment in our clinical trials being slower than we anticipate or participants dropping out of our clinical trials at a higher rate than we anticipate, could increase our costs, slow down our product development and approval process, and jeopardize our ability to commence product sales and generate revenues.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the federal Right to Try Act, among other things, provides a federal framework for patients to access certain investigational new drug products that have completed a Phase 1 clinical trial. Under certain circumstances, eligible patients can seek treatment without enrolling in clinical trials and without obtaining FDA approval under the FDA expanded access program. While there is no obligation to make product candidates available to eligible patients as a result of the Right to Try Act, new and emerging legislation regarding expanded access to unapproved drugs could negatively impact enrollment in our clinical trials and our business in the future.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our candidate product, pelareorep, is being and will continue to be used in combination with other therapies, which exposes us to additional risks.  </span></div><div><span><br/></span></div><div><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our current and planned studies, pelareorep is being or will be administered in combination with other approved cancer therapies, including immune checkpoint inhibitors ("ICIs"). ICIs are a class of drugs intended to stop tumor cells from interfering with the ability of the patient&#8217;s immune system to attack their tumor. We have entered into an agreement with Roche to supply its ICIs, atezolizumab, for use in our ongoing Oncolytics-sponsored studies. Specifically, atezolizumab is being used in our ongoing Phase 1/2 study in gastrointestinal cancer (GOBLET study). Additionally, we may enter into future agreements for the supply of ICIs for use in connection with the development of pelareorep.</span></div><div><span><br/></span></div><div><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to develop pelareorep for use in combination with other therapies depends on our ability to access these drugs for use in our clinical trials on commercially reasonable terms. We cannot be certain that current or potential future commercial relationships will provide us with a steady supply of such drugs on commercially reasonable terms or at all. Any failure to maintain or enter into new successful commercial relationships or the expense of purchasing these other therapies in the market may delay our development timelines, increase our costs, and jeopardize our ability to develop pelareorep as a commercially viable therapy. If any of these occur, our business, financial condition, results of operations, stock price, and prospects may be materially harmed. </span></div><div><span><br/></span></div><div><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any current or any future collaborator or supplier cannot continue to supply their products on commercially reasonable terms, we would need to identify alternatives for accessing appropriate agents. Additionally, should the supply of products from any current or future collaborator or supplier be interrupted, delayed, or otherwise be unavailable to us, our clinical trials may be delayed. In the event we are unable to source a supply of an alternative appropriate drug or are unable to do so on commercially reasonable terms, our business, financial condition, results of operations, stock price, and prospects may be materially harmed.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:10pt"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, the development of pelareorep for use in combination with other cancer therapies may present risks that are not faced for single agent product candidates, such as the requirement that we demonstrate the safety, purity, and efficacy of each active component of any combination regimen we may develop. Developments related to the other product may also impact our clinical trials as well as our commercial prospects should we receive marketing approval. Such developments may include changes to the other product's safety or efficacy profile, changes to the availability of the approved product, and changes to the standard of care.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">While we have chosen to test pelareorep in specific clinical indications based in part on our understanding of its mechanisms of action, our understanding may be incorrect or incomplete and, therefore, our pelareorep may not be effective against the diseases tested in our clinical trials.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our rationale for selecting the particular therapeutic indications for pelareorep is based in part on our understanding of its mechanism of action. However, our understanding of pelareorep's mechanism of action may be incomplete or incorrect, or the mechanism may not be clinically relevant to the diseases treated. In such cases, pelareorep may prove to be ineffective in the clinical trials for treating those diseases, and adverse clinical trial results would likely negatively impact our business and results from operations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The incidence and prevalence for target patient populations of our product candidate is based on estimates and third-party sources. If the market opportunities for our product candidate is smaller than we estimate or if any approval that we obtain is based on a narrower definition of the patient population, our business, financial condition, results of operations, and prospects may be materially adversely affected.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Periodically, we make estimates regarding the incidence and prevalence of target patient populations for particular diseases based on various third-party sources and internally generated analysis and use such estimates in making decisions regarding our product development strategy, including determining indications on which to focus in preclinical or clinical trials.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These estimates may be inaccurate or based on imprecise data. For example, the total addressable market opportunity will depend on, among other things, the acceptance of such data by the medical community and patient access, product pricing and reimbursement, any limitations on populations and indications in approved product labeling, as well as the approval of new or competing medicines. The number of patients in the addressable markets may turn out to be lower than expected, patients may not be otherwise amenable to treatment with our products, or new patients may become increasingly difficult to identify or gain access to, all of which could materially adversely affect our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business, including our research and development operations, has been and may continue to be adversely affected by a variety of external factors outside our control.</span></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2024, general market conditions resulting from high inflation, high interest rates, global supply chain issues, global political conflicts, general economic uncertainty, and other macroeconomic factors, as well as market conditions affecting companies in the life sciences industry in general, have touched elements of our business operations. These events have caused and may continue to cause significant fluctuations in stock markets, global economic activity, including inflation and fluctuating interest rates, and healthcare systems. The scale and duration of these developments remain uncertain and could affect our ability to finance and execute our operations, including our ongoing and planned clinical studies and manufacturing activities. These future developments are highly uncertain, cannot be predicted, and could negatively impact our business.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current global economic conditions are highly volatile due to a number of reasons, including geopolitical instability, such as the military conflicts between Russia and Ukraine, the conflicts between Israel and Hamas, recent inflation that increased our operating expenses and disruptions in the capital and credit markets that may reduce our ability to raise additional capital when needed on acceptable terms, if at all.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging international trade relations, new legislation and tariffs may also adversely impact our operations and/or financial condition by limiting or preventing the activities of third parties that we engage, increasing import costs or increasing the cost of our operations. New or increased tariffs, export controls or other trade barriers could result in higher prices for the materials we use and the investigational products we are developing and could materially impact our supply chain and manufacturing costs. Recent congressional legislative actions, proposed executive orders, sanctions, tariffs and other measures discourage contracting with Chinese companies on the development or manufacturing of pharmaceutical products and may restrict trade with China. We currently have a licensing agreement with Adlai Nortye Biopharma Co., Ltd, pursuant to which Adlai will have exclusive development and commercialization rights to pelareorep in China, Hong Kong, Macau, Singapore, South Korea, and Taiwan. If Adlai becomes subject to trade restrictions, sanctions, increased tariffs or other regulatory requirements by the U.S. government, or if the U.S. or Chinese government take retaliatory actions due to recent or increased tensions between the U.S. and mainland China, it could materially impact licensing agreement with Adlai. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, the recent inflationary environment related to increased aggregate demand and supply chain constraints has increased our operating expenses and may continue to affect our operating expenses. Economic conditions may also strain our suppliers, possibly resulting in supply disruptions that impact our ongoing clinical trials and other operations. A significant worsening of global economic conditions could materially increase these risks we face.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any new or prolonged downturn of global economic conditions could harm our business operations, and we cannot anticipate all of the ways in which the current economic climate and financial market conditions could adversely impact our business.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The increasing use of social media platforms presents new risks and challenges.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Social media is increasingly being used to communicate about our clinical development programs and the diseases our product candidate is being developed to treat. We intend to utilize appropriate social media in connection with communicating about our development programs. Social media practices in the biopharmaceutical industry continue to evolve and regulations relating to such use are not always clear. This evolution creates uncertainty and risk of noncompliance with regulations applicable to our business. For example, patients may use social media channels to report an alleged adverse event during a clinical trial. When such disclosures occur, we may fail to monitor and comply with applicable adverse event reporting obligations, or we may not be able to defend our business or the public&#8217;s legitimate interests in the face of the political and market pressures generated by social media due to restrictions on what we may say about our investigational products. There is also a risk of inappropriate disclosure of sensitive information or negative or inaccurate posts or comments about us on any social networking website, or a risk that a post on a social networking website by any of our employees may be construed as inappropriate promotion. If any of these events were to occur or we otherwise failed to comply with applicable regulations, we could incur liability, face regulatory actions, or incur other harm to our business.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our product candidate may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following any potential marketing approval.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, pelareorep is generally well-tolerated and has a manageable side effect profile for most patients. However, there can be no assurance that additional undesirable side effects or serious adverse events will not be caused by or associated with pelareorep as it continues through its clinical development, including when co-administered with approved products. As with many pharmaceutical and biological products, treatment with our product candidate may produce undesirable side effects or adverse reactions or events, including potential adverse side effects related to cytokine release, and may exacerbate known adverse events associated with co-administered approved products. If our product candidate or similar products or product candidates under development by third parties demonstrate unacceptable adverse events or unacceptably exacerbate adverse events associated with co-administered approved products, we may be required to halt or delay further clinical development of our product candidate. The FDA, the EMA, or other foreign regulatory authorities could order us to cease further development of or deny approval of our product candidate for any or all targeted indications.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The product-related side effects could affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. In addition, these side effects may not be appropriately or timely recognized or managed by the treating medical staff, particularly outside of the institutions that collaborate with us, as toxicities resulting from our novel technologies may not be normally encountered in the general patient population and by medical personnel. We expect to have to train medical personnel using our product candidate to understand its side effect profiles, both for our planned clinical trials and upon any commercialization. Inadequate training in recognizing or managing the potential side effects of our product candidate could result in adverse effects on patients, including death.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, if our product candidate receives marketing approval, and we or others later identify undesirable side effects caused or exacerbated by such product, including during any long-term follow-up observation period recommended or required for patients who receive treatment using our product, a number of potentially significant negative consequences could result, including:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may withdraw approvals of such product;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may require additional warnings on the label;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be required to create a risk evaluation and mitigation strategy plan, which could include a medication guide outlining the risks of such side effects for distribution to patients, a communication plan for healthcare providers, and/or other elements to assure safe use;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we could be sued and held liable for harm caused to patients; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our reputations may suffer.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of the foregoing could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved. Furthermore, any of these occurrences may harm our business, financial condition, and prospects significantly.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may expend our limited resources to pursue a particular indication and fail to capitalize on indications that may be more profitable or for which there is a greater likelihood of success. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we have limited financial and managerial resources, we focus on research programs and therapeutic platforms that we identify for specific indications. As a result, we may forego or delay the pursuit of opportunities with other therapeutic platforms or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and therapeutic platforms for specific indications may not yield any commercially viable products.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to secure a partnership for pelareorep, which could halt future development.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are seeking a partner to continue the clinical development and commercialization of pelareorep. We do not have the financial resources to complete the necessary development work internally, and should we not be able to secure a partnership, future development of pelareorep may not continue. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not achieve our projected development milestones in the time frames we announce and expect.</span></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We set goals for and make public statements regarding the expected timing of the accomplishment of objectives material to our success, such as the commencement and completion of clinical trials, the submission of a drug-regulatory application, and the expected costs to develop our product candidate. The actual timing and costs of these events can vary dramatically due to factors within and beyond our control, such as delays or failures in our IND submissions or clinical trials, issues related to the manufacturing of drug supply, uncertainties inherent in the regulatory approval process, market conditions and interest by partners in our product candidate, among other things. Our clinical trials may not be completed, we may not make regulatory submissions or receive regulatory approvals as planned, or we may not secure partnerships for any of our product candidate. Any failure to achieve one or more of these milestones as planned would have a material adverse effect on our business, financial condition, and results of operations.</span></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Condition Risks</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have no operating revenues and a history of losses. We have no products approved for commercial sale, and we may never achieve or sustain profitability.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage biopharmaceutical company. We have incurred significant losses since our inception. To date, we have not generated sufficient revenues to offset our research and development costs and accordingly have not generated positive cash flow or made an operating profit. As of December&#160;31, 2024, we had an accumulated deficit of $477.7 million and we incurred net losses of $31.7 million, $27.8 million, and $24.8 million for the years ended December&#160;31, 2024, 2023, and 2022, respectively. We anticipate that we will continue to incur significant losses during 2025 and in the foreseeable future. The amount of future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenue. Because of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve profitability. We do not expect to reach profitability at least until after the successful and profitable commercialization of one or more of our products. Even if one or more of our products are profitably commercialized, the initial losses incurred by us may never be recovered. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may need additional financing in the future to fund the research and development of our products and to meet our ongoing capital requirements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, we had cash and cash equivalents of $15.9 million. We anticipate that we will need additional financing in the future to fund research and development and to meet our ongoing capital requirements.&#160;The amount of future capital requirements will depend on many factors, including continued scientific progress in our drug discovery and development programs, progress in our preclinical and clinical evaluation of drug candidates, time and expense associated with filing, prosecuting, and enforcing our patent claims, and costs associated with obtaining regulatory approvals.&#160;In order to meet such capital requirements, we will consider contract fees, collaborative research and development arrangements, and additional public or private financings (including the incurrence of debt and the issuance of additional equity securities) to fund all or a part of particular programs as well as potential partnering or licensing opportunities.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Oncolytics, from time to time, along with all other pharmaceutical research and development entities, may have restricted access to capital, bank debt, and equity and, from time to time, may face increased borrowing costs. Although our business and asset base have not changed, the lending capacity of all financial institutions fluctuates, causing a corresponding change in risk premiums. As future operations will be financed out of funds generated from financing activities, our ability to do so is dependent on, among other factors, the overall state of capital markets and investor appetite for investments in the pharmaceutical industry and our securities in particular.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Should we elect to satisfy our cash commitments through the issuance of securities, by way of either private placement or public offering or otherwise, there can be no assurance that our efforts to raise such funding will be successful or achieved on terms favorable to us or our existing shareholders.&#160;If adequate funds are not available on terms favorable to us, we may have to reduce substantially or eliminate expenditures for research and development, testing, production, and marketing of our proposed product, or obtain funds through arrangements with corporate partners that require us to relinquish rights to certain of our technologies or product. There can be no assurance that we will be able to raise additional capital if our current capital resources are exhausted.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We incur some of our expenses in foreign currencies and therefore, we are exposed to foreign currency exchange rate fluctuations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incur some of our research and development and general and administrative expenses in foreign currencies, primarily the U.S. dollar and Euro.&#160;We are, therefore, exposed to foreign currency rate fluctuations.&#160;Also, as we expand to other foreign jurisdictions, there may be an increase in our foreign exchange exposure.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Third-party credit risk</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of our business, we have entered into contractual arrangements with third parties, which subject us to the risk that such parties may default on their obligations. Oncolytics may be exposed to third-party credit risk through our contractual arrangements with our current contract manufacturer, the institutions which operate our clinical trials, or our contract research organizations and other parties.&#160;In the event such entities fail to meet their contractual obligations to Oncolytics, such failures could have a material adverse effect on Oncolytics and our operations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to obtain third-party reimbursement for the cost of our product. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels. A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Government authorities and these third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Uncertainty exists regarding the reimbursement status of newly-approved pharmaceutical products and reimbursement may not be available for pelareorep.&#160;Any reimbursements granted may not be maintained or limits on reimbursements available from third-party payors may reduce the demand for, or negatively affect the price of, these products. If pelareorep does not qualify for reimbursement, if reimbursement levels diminish, or if reimbursement is denied, our sales and profitability would be adversely affected.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Regulatory Risks</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pharmaceutical products are subject to intense regulatory approval processes.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The regulatory process for pharmaceuticals, which includes preclinical studies and multiple phases of clinical trials of each compound to establish its safety and efficacy, takes many years and requires the expenditure of substantial resources. Moreover, if regulatory approval of a drug is granted, such approval may entail limitations on the indicated uses for which it may be marketed. Failure to comply with applicable regulatory requirements can, among other things, result in suspension of regulatory approvals, product recalls, seizure of products, operating restrictions, and criminal prosecution. Further, government policy may change, and additional government regulations may be established that could prevent or delay regulatory approvals for our products. In addition, a marketed drug and its manufacturer are subject to continual review. Later discovery of previously unknown problems with the product or manufacturer may result in restrictions on such product or manufacturer, including withdrawal of the product from the market.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The United States Food and Drug Administration ("FDA") and similar regulatory authorities in other countries may deny approval of a new drug application if required regulatory criteria are not satisfied, or may require additional testing. Product approvals may be withdrawn if compliance with regulatory standards is not maintained or if problems occur after the product reaches the market. The FDA and similar regulatory authorities in other countries may require further testing and surveillance </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">programs to monitor the pharmaceutical product that has been commercialized. Non-compliance with applicable requirements can result in fines and other judicially imposed sanctions, including product withdrawals, product seizures, injunction actions, and criminal prosecutions.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and other governmental regulators have increased requirements for drug purity and have increased environmental burdens upon the pharmaceutical industry. Because pharmaceutical drug manufacturing is a highly regulated industry, requiring significant documentation and validation of manufacturing processes and quality control assurance prior to the approval of the facility to manufacture a specific drug, our manufacturing facilities may never become approved of, or there can be considerable transition time between the initiation of a contract to manufacture a product and the actual initiation of manufacture of that product. Any lag time in the initiation of a contract to manufacture product and the actual initiation of manufacture could cause us to lose profits or incur liabilities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pharmaceutical regulatory regime in Europe and other countries is generally similar to that of the United States. We could face similar risks in these other jurisdictions as the risks described above.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The design or execution of our clinical trials may not support regulatory approval.</span></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The design or execution of a clinical trial can determine whether its results will support regulatory approval and flaws in the design or execution of a clinical trial may not become apparent until the clinical trial is well advanced. In some instances, there can be significant variability in safety or efficacy results between different trials of the same product candidate due to numerous factors, including changes in trial protocols, differences in size and type of the patient populations, adherence to the dosing regimen and other trial protocols and the rate of dropout among clinical trial participants. We do not know whether any Phase 2, Phase 3, or other clinical trials that we may conduct will demonstrate consistent or adequate efficacy and safety to obtain regulatory approval to market our product candidate.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, the FDA and comparable foreign regulatory authorities will have some discretion in the approval process and in determining when or whether regulatory approval will be obtained for any of our product candidate. Our product candidate may not be approved even if they achieve their primary endpoints in future registration trials. The FDA or other regulatory authorities may disagree with our trial design and our interpretation of data from preclinical studies and clinical trials. In addition, any of these regulatory authorities may change requirements for the approval of a product candidate even after reviewing and providing comments or advice on a protocol for a pivotal registration clinical trial that has the potential to result in approval by the FDA or another regulatory agency. In addition, any of these regulatory authorities may also approve a product candidate for fewer or more limited indications than we request or may grant approval contingent on the performance of costly post-marketing clinical trials. The FDA or other regulatory authorities may not approve the labeling claims that we believe would be necessary or desirable for the successful commercialization of our product candidate.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our operations and products may be subject to other government manufacturing and testing regulations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securing regulatory approval for the marketing of therapeutics by the FDA in the United States and similar regulatory agencies in other countries is a long and expensive process, which can delay or prevent product development and marketing. Approval to market products may be for limited applications or may not be received at all.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The products we anticipate manufacturing will have to comply with the FDA's current Good Manufacturing Practices ("cGMP") and other FDA and local government guidelines and regulations, including other international regulatory requirements and guidelines. Additionally, certain customers may require the manufacturing facilities we contract to adhere to additional manufacturing standards, even if the FDA does not require them. Compliance with cGMP regulations requires manufacturers to expend time, money, and effort in production, and to maintain precise records and quality control to ensure that the product meets applicable specifications and other requirements. The FDA and other regulatory bodies periodically inspect drug-manufacturing facilities to ensure compliance with applicable cGMP requirements. If the manufacturing facilities contracted by us fail to comply with the cGMP requirements, the facilities may become subject to possible FDA or other regulatory action and manufacturing at the facility could consequently be suspended. We may not be able to contract suitable alternative or back-up manufacturing facilities on terms acceptable to us or at all.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA or other regulatory agencies may also require the submission of any lot of a particular product for inspection. If the lot product fails to meet the FDA requirements, then the FDA could take any of the following actions: (i) restrict the release of the product; (ii) suspend manufacturing of the specific lot of the product; (iii) order a recall of the lot of the product; or (iv) order a seizure of the lot of the product.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to government regulation in many jurisdictions.&#160;If we do not comply with healthcare, drug, manufacturing, and environmental regulations, among others, in such jurisdiction, our existing and future operations may be curtailed, and we could be subject to liability.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the regulatory approval process, we may be subject to regulations under local, provincial, state, federal, and foreign law, including, but not limited to, requirements regarding occupational health, safety, laboratory practices, healthcare fraud and abuse, environmental protection, and hazardous substance control, and may be subject to other present and future local, provincial, state, federal, and foreign regulations.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have conducted, and may in the future conduct, clinical trials for pelareorep in sites outside the United States and the FDA may not accept data from trials conducted in such locations. </span></div><div><span><br/></span></div><div><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have conducted, and may in the future choose to conduct, clinical trials outside the United States. Although the FDA may accept data from clinical trials conducted outside the United States, acceptance of this data is subject to certain conditions imposed by the FDA. For example, the clinical trial must be well designed and conducted and performed by qualified investigators in accordance with ethical principles. The trial population must adequately represent the U.S. population, and the data must be applicable to the U.S. population and U.S. medical practice in ways that the FDA deems clinically meaningful. Generally, the patient population for any clinical trials conducted outside of the United States must be representative of the population for whom we intend to label the product in the United States. In addition, while these clinical trials are subject to the applicable local laws, FDA acceptance of the data will depend on its determination that the trials also complied with all applicable U.S. laws and regulations. There can be no assurance the FDA will accept data from trials conducted outside the United States. If the FDA does not accept the data from any clinical trials we may conduct outside the United States, it would likely result in the need for additional trials, which would be costly and time-consuming and would delay or permanently halt our development of pelareorep.</span></div><div><span><br/></span></div><div><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A Fast Track designation from the FDA, even if granted, may not lead to a faster development, regulatory review, or approval process, and does not increase the likelihood that our product candidate will receive marketing approval.</span></div><div><span><br/></span></div><div><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have received Fast Track designations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the treatment of advanced/metastatic unresectable pancreatic ductal adenocarcinoma (PDAC) using pelareorep in combination with atezolizumab, gemcitabine, and nab-paclitaxel, and for the treatment of metastatic breast cancer using pelareorep in combination with paclitaxel. We may seek additional Fast Track designations for our other programs. Fast Track designation is designed to facilitate the development and expedite the review of therapies to treat serious conditions and fill an unmet medical need. A clinical program that receives Fast Track designation may benefit from more frequent meetings and communications with the FDA to discuss development plans and ensure the collection of appropriate data needed to support approval. </span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has broad discretion on whether or not to grant this designation. Even if we believe a particular program is eligible for this designation, we cannot assure you that the FDA would decide to grant it. Although we have received Fast Track designation for pelareorep in combination with atezolizumab, gemcitabine, and nab-paclitaxe for the treatment of advanced/metastatic PDAC, and even if we receive additional Fast Track designations for our product candidate, we may not experience a faster development process, review or approval compared to conventional FDA procedures. The FDA may also withdraw Fast Track designation if it believes that the designation is no longer supported by data from our clinical development program. Furthermore, such a designation does not increase the likelihood that pelareorep will receive marketing approval in the United States. Many product candidates that have received Fast Track Designation have ultimately failed to obtain approval.</span></div><div style="margin-bottom:10pt"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may attempt to secure approval from the FDA through the use of the accelerated approval pathway. If we are unable to obtain such approval, we may be required to conduct additional clinical trials beyond those that we contemplate, which could increase the expense of obtaining, and delay the receipt of, necessary regulatory approvals. Even if we receive accelerated approval from the FDA, if our confirmatory trials do not verify clinical benefit, or if we do not comply with rigorous post-marketing requirements, the FDA may seek to withdraw any accelerated approval we have obtained.</span></div><div style="margin-bottom:10pt"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may in the future seek an accelerated approval for pelareorep. Under the accelerated approval program,the FDA may grant accelerated approval to a product candidate designed to treat a serious or life-threatening condition that provides meaningful therapeutic benefit over available therapies upon a determination that such product candidate has an effect on a surrogate endpoint or intermediate clinical endpoint that is reasonably likely to predict clinical benefit. </span></div><div style="margin-bottom:10pt"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA considers a clinical benefit to be a positive therapeutic effect that is clinically meaningful in the context of a given disease, such as irreversible morbidity or mortality. For the purposes of accelerated approval, a surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign, or other measure, that is thought to predict clinical </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:10pt"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">benefit, but is not itself a measure of clinical benefit. An intermediate clinical endpoint is a clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit. The accelerated approval pathway may be used in cases in which the advantage of a new drug over available therapy may not be a direct therapeutic advantage, but is a clinically important improvement from a patient and public health perspective. If granted, accelerated approval is usually contingent on the sponsor&#8217;s agreement to conduct, in a diligent manner, additional post-approval confirmatory studies to verify and describe the drug&#8217;s clinical benefit. If such confirmatory studies fail to confirm the drug&#8217;s clinical benefit or are not completed in a timely manner, the FDA may withdraw its approval of the drug on an expedited basis. In addition, in December 2022, the Food and Drug Omnibus Reform Act of 2022 was enacted, which, among other things, provided the FDA new statutory authority to mitigate potential risks to patients from continued marketing of ineffective drugs previously granted accelerated approval, and additional oversight over confirmatory trials. Under these provisions, the FDA may, among other things,require a sponsor of a product seeking accelerated approval to have a confirmatory trial underway prior to such approval being granted. </span></div><div><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to seeking approval for pelareorep we intend to seek feedback from the FDA and will otherwise evaluate our ability to seek and receive accelerated approval. There can be no assurance that after our evaluation of the feedback and other factors we will decide to pursue or submit a BLA for accelerated approval or obtain any other form of expedited development, review, or approval. Furthermore, if we decide to submit an application for accelerated approval for pelareorep, there can be no assurance that such submission or application will be accepted or that any expedited development, review, or approval will be granted on a timely basis, or at all. The FDA could also require us to conduct further studies prior to considering our application or granting approval of any type. A failure to obtain accelerated approval or any other form of expedited development, review, or approval for pelareorep would result in a longer time period to commercialization of such product candidate, if any, could increase the cost of development of such product candidate, and could harm our competitive position in the marketplace.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property Risks</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on patents and proprietary rights to protect our technology.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success will depend, in part, on our ability to obtain patents, maintain trade secret protection, and operate without infringing the rights of third parties. We have received Granted Patents in countries throughout the world, including the United States, Canada, Europe, and Japan.&#160;We file our Applications for Patent in the United States and under the PCT, allowing us to subsequently file in other jurisdictions.&#160;Our success will depend, in part, on our ability to obtain, enforce, and maintain patent protection for our technology in Canada, the United States, and other countries. We cannot be assured that patents will be issue from any pending applications or that claims now or in the future, if any, allowed under issued patents will be sufficiently broad to protect our technology. In addition, no assurance can be given that any patents issued to, or licensed by us, will not be challenged, invalidated, infringed, or circumvented, or that the rights granted thereunder will provide continuing competitive advantages to us.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent positions of pharmaceutical and biotechnology firms, including us, are generally uncertain and involve complex legal and factual questions. In addition, it is not known whether any of our current research endeavors will result in the issuance of patents in Canada, the United States, or elsewhere, or if any patents already issued will provide significant proprietary protection or will be circumvented or invalidated. Since patent applications in the United States and Canada may be maintained in secrecy until at least 18 months after filing of the original priority application, and since publication of discoveries in the scientific or patent literature tends to lag behind actual discoveries by several months, we cannot be certain that we or any licensor were the first to create inventions claimed by pending patent applications or that we or the licensor were the first to file patent applications for such inventions. Loss of patent protection could lead to generic competition for these products, and others in the future, which would materially and adversely affect our financial prospects for these products.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similarly, since patent applications filed before November 29, 2000 in the United States may be maintained in secrecy until the patents issue or foreign counterparts, if any, publish, we cannot be certain that we or any licensor were the first creator of inventions covered by pending patent applications or that we or such licensor were the first to file patent applications for such inventions. There is no assurance that our patents, if issued, would be held valid or enforceable by a court or that a competitor&#8217;s technology or product would be found to infringe such patents.</span></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, we may not be able to obtain and enforce effective patents to protect our proprietary rights from use by competitors.&#160;If other such parties obtain patents for certain information relied on by us in conducting our business, then we may be required to stop using, or pay to use, certain intellectual property, and as such, our competitive position and profitability could suffer as a result.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our success depends on our ability to obtain and maintain protection for our intellectual property and our proprietary technologies and to avoid infringing the rights of others. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success depends in part on our ability to obtain and maintain patent, trademark, trade secret and other intellectual property protection for our product candidate and proprietary technologies, as well as our ability to operate without infringing upon the proprietary rights of others. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have applied, and we intend to continue applying, for patents covering important aspects of our product candidates, proprietary technologies and their uses as we deem appropriate. However, the patent prosecution process is expensive, time-consuming and complex, and we may not be able to apply for patents on certain aspects of our current or future product candidates and proprietary technologies in a timely fashion, at a reasonable cost, in all jurisdictions, or at all. If we cannot adequately obtain, maintain and enforce our intellectual property rights and proprietary technology, competitors may be able to use our technologies or the goodwill we have acquired in the marketplace and erode or negate any competitive advantage we may have and our ability to compete, which could harm our business and ability to achieve profitability and/or cause us to incur significant expenses. Failure to obtain, maintain and/or enforce intellectual property rights necessary to our business and failure to protect, monitor and control the use of our intellectual property rights could negatively impact our ability to compete and cause us to incur significant expenses. The intellectual property laws and other statutory and contractual arrangements in the United States and other jurisdictions we depend upon may not provide sufficient protection in the future to prevent the infringement, use, violation or misappropriation of our patents, trademarks, data, technology and other intellectual property rights and products by others, and may not provide an adequate remedy if our intellectual property rights are infringed, misappropriated or otherwise violated by others.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Third parties may choose to file patent infringement claims against us; defending ourselves from such allegations would be costly, time-consuming, distracting to management, and could materially affect our business.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our development and commercialization activities, as well as any product candidates or products resulting from these activities, may infringe or be claimed to infringe patents and other intellectual property rights of third parties under which we do not hold sufficient licenses or other rights. Additionally, third parties may be successful in obtaining patent protection for technologies that cover development activities in which we are already engaged. Third parties may own or control these patents and intellectual property rights in the United States and abroad. These third parties may have substantially greater financial resources than us and could bring claims against us that could cause us to incur substantial expenses to defend against these claims and, if successful against us, could cause us to pay substantial damages. Further, if a patent infringement or other similar suit were brought against us, we could be forced to stop or delay development, manufacturing, or sales of the product or product candidate that is the subject of the suit. Our patent applications cannot be enforced against third parties practicing the inventions claimed in such applications unless, and until, patents issue from such applications, and then only to the extent the issued claims cover the invention as claimed. The patent application process is subject to numerous risks and uncertainties, and there can be no assurance that we or any of our actual or potential future collaborators or licensors will be successful in protecting our product candidate and proprietary technologies by obtaining and defending patents Intellectual property litigation in the biopharmaceutical industry is common, and we expect this trend to continue.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of patent infringement or other similar claims, or to avoid potential claims, we may choose or be required to seek a license from a third party and be required to pay license fees or royalties, or both. These licenses may not be available on acceptable terms, or at all. Even if we were able to obtain a license, the rights may be non-exclusive, which could result in our competitors gaining access to the same intellectual property. Ultimately, we could be prevented from commercializing a product, or be forced to cease some aspect of our business operations, if, as a result of actual or threatened patent infringement claims, we are unable to enter into licenses on acceptable terms, if at all, or if an injunction is granted against us, which could harm our business significantly.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to protect the confidentiality of our proprietary information and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">know-how, the value of our technology and products could be adversely affected.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to patented technology, we rely upon unpatented proprietary technology, processes, and know-how. However, these types of trade secrets can be difficult to protect. We seek to protect this confidential information, in part, through agreements with our employees, consultants, and third parties, as well as confidentiality policies and audits, although these may not be successful in protecting our trade secrets and confidential information.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These agreements may be breached, and we may not have adequate remedies for any such breach. In addition, our trade secrets may otherwise become known, including through a potential cybersecurity breach, or may be independently developed by </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">competitors. If we are unable to protect the confidentiality of our proprietary information and know-how, competitors may be able to use this information to develop products that compete with our products, which could adversely impact our business.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed.</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we rely on third parties to research and develop and to manufacture pelareorep, we must, at times, share trade secrets with them. We seek to protect our proprietary technology in part by entering into confidentiality agreements and, if applicable, consulting agreements or other similar agreements with our advisors, employees, third-party contractors, and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of third parties to use or disclose our confidential information, including our trade secrets. Despite the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our know-how and trade secrets, a competitor&#8217;s discovery of our trade secrets or other unauthorized use or disclosure would impair our competitive position and may have a material adverse effect on our business. Moreover, enforcing a claim that a third party illegally obtained and is using any of our trade secrets is expensive and time-consuming, and the outcome is unpredictable. In addition, courts outside the United States are sometimes less willing to protect trade secrets. If we choose to go to court to stop a third party from using any of our trade secrets, we may incur substantial costs. These lawsuits may consume our time and other resources even if we are successful. These lawsuits also may impact our ability to pursue agreements with third parties in the future.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Developments in patent law could have a negative impact on our business.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, authorities in the United States, the European Union, and other government authorities may change the standards of patentability, and any such changes could have a negative impact on our business. For example, in the United States, the Leahy-Smith America Invents Act, or the America Invents Act, which was signed into law in 2011, includes a number of significant changes to U.S. patent law. These changes include a transition from a "first-to-invent" system to a "first-to-file" system, changes to the way issued patents are challenged, and changes to the way patent applications are disputed during the examination process. As a result of these changes, patent law in the United States may favor larger and more established companies that have greater resources to devote to patent application filing and prosecution. The USPTO has developed new and untested regulations and procedures to govern the full implementation of the America Invents Act, and many of the substantive changes to patent law associated with the America Invents Act, and, in particular, the first-to-file provisions became effective on March 16, 2013. Substantive changes to patent law associated with the America Invents Act may affect our ability to obtain patents, and if obtained, to enforce or defend them. Also, case law may have a substantial impact on the way patents are prosecuted, examined, and litigated. This also affects the scope of protection that is available in a specific jurisdiction. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Developments of patent law in other jurisdictions may impact our business. For example, it is currently not clear what impact the planned introduction of the Unified Patent Court in the European Union will have. Patents that are valid and enforceable under the current system may be considered invalid and/or unenforceable under the new system. Also, patents may be invalidated not just in one single jurisdiction, but across multiple countries of the European Union in one single trial. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we do not obtain protection under the Hatch-Waxman amendments and similar foreign legislation for extending the term of patents covering our product candidate, our business may be materially harmed. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depending upon the timing, duration, and conditions of FDA marketing approval of pelareorep, one or more of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent term extension of up to five years for a patent covering an approved product as compensation for effective patent term lost during product development and the FDA regulatory review process. However, we may not receive an extension if we fail to apply within applicable deadlines, fail to apply prior to expiration of relevant patents, or otherwise fail to satisfy applicable requirements. Moreover, the length of the extension could be less than we request. If we are unable to obtain patent term extension or the term of any such extension is less than we request, the period during which we can enforce our patent rights for pelareorep will be shortened. If this occurs, our competitors may take advantage of our investment in development and trials by referencing our clinical and preclinical data and launch their product earlier than might otherwise be the case.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intellectual property rights do not necessarily address all potential threats to our business. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business. The following examples are illustrative:</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">others may be able to make compounds or formulations that are similar to pelareorep but that are not covered by the claims of any patents, should they issue, that we own or control;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we might not have been the first to make the inventions covered by the issued patents or pending patent applications that we own or control;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we might not have been the first to file patent applications covering certain of our inventions;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">it is possible that our pending patent applications will not lead to issued patents;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">issued patents that we own or control may not provide us with any competitive advantages, or may be held invalid or unenforceable as a result of legal challenges;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our competitors might conduct research and development activities in the United States and other countries that provide a safe harbor from patent infringement claims for certain research and development activities, as well as in countries where we do not have patent rights and then use the information learned from such activities to develop competitive drugs for sale in our major commercial markets;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not develop additional proprietary technologies that are patentable; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the patents of others may have an adverse effect on our business.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Should any of these events occur, they could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Business Risks</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The biotechnology industry is extremely competitive and if our competitors develop and market products that are more effective, safer, or less expensive than our products, our business could be adversely impacted.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Technological competition in the pharmaceutical industry is intense and we expect competition to increase. Other companies are conducting research on therapeutics involving innate and adaptive immune responses as well as other novel treatments or therapeutics for the treatment of cancer which may compete with our product. Many of these competitors are more established, benefit from greater name recognition, and have substantially greater financial, manufacturing, technical, marketing, drug development, and human resources than us. In addition, many of these competitors have significantly greater experience in undertaking research, preclinical studies, and human clinical trials of new pharmaceutical products, obtaining regulatory approvals, manufacturing, and marketing such products. In addition, there are several other companies and products with which we may compete from time to time, and which may have significantly better and larger resources than we do. Accordingly, our competitors may succeed in manufacturing and/or commercializing products more rapidly or effectively, which could have a material adverse effect on our business, financial condition, or results of operations.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Smaller and other early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. In addition, the biopharmaceutical industry is characterized by rapid technological change. If we fail to stay at the forefront of technological change, we may be unable to compete effectively. Technological advances or products developed by our competitors may render our technologies or product candidate obsolete, less competitive, or not economical.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate that we will face increased competition in the future as new products enter the market and advanced technologies become available. There can be no assurance that existing products or new products developed by our competitors will not be more effective, or be more effectively manufactured, marketed, and sold, than any that may be developed or sold by us. Competitive products may render our products obsolete and uncompetitive prior to recovering research, development, or commercialization expenses incurred with respect to any such products.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our products may fail or cause harm, subjecting us to product liability claims.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Use of our product during current clinical trials may entail the risk of product liability. We maintain clinical trial liability insurance; however, it is possible this coverage may not provide full protection against all risks.&#160;Given the scope and complexity of the clinical development process, the uncertainty of product liability litigation, and the shrinking capacity of </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">insurance underwriters, it is not possible at this time to assess the adequacy of current clinical trial coverage, nor the ability to secure continuing coverage at the same level and at reasonable cost in the foreseeable future.&#160;While we carry, and intend to continue carrying amounts believed to be appropriate under the circumstances, it is not possible at this time to determine the adequacy of such coverage.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the sale and commercial use of our product entails risk of product liability. We currently do not carry any product liability insurance for this purpose. There can be no assurance that we will be able to obtain appropriate levels of product liability insurance prior to any sale of our pharmaceutical products. An inability to obtain insurance on economically feasible terms or to otherwise protect against potential product liability claims could inhibit or prevent the commercialization of products developed by us. The obligation to pay any product liability claim or a recall of a product could have a material adverse effect on our business, financial condition, and future prospects.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future legal proceedings and the impact of any finding of liability or damages could adversely impact the company and its financial condition and results of operations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may be named as a defendant in various legal actions or other proceedings, including class action lawsuits. Certain of these actions include, and future actual or threatened legal actions may include, claims for substantial and indeterminate amounts of damages, or may result in other results adverse to us. Management does not currently know of any pending, material legal proceedings against the Company, but such legal action could be brought in the future.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of possible future legal proceedings cannot be predicted with certainty. Accordingly, we cannot determine whether our insurance coverage would be sufficient to cover the costs or potential losses, if any. Regardless of merit, litigation may be both time-consuming and disruptive to our operations and cause significant expense and diversion of management attention. If we do not prevail in future legal proceedings, we may be faced with significant monetary damages or injunctive relief against us that may adversely affect our business, financial condition, and results of operations, possibly materially.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">New products may not be accepted by the medical community or consumers.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary activity to date has been research and development, and we have no experience in marketing or commercializing products. We will likely partner with or rely on third parties to market our products, assuming that they receive regulatory approvals. If we partner with or rely on third parties to market our products, the commercial success of such products will be subject to a number of risks that may be outside of our control, including:</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">competition in relation to alternative treatments, including efficacy advantages and cost advantages;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">perceived ease of use;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of coverage or reimbursement by third-party payors;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">uncertainties regarding marketing and distribution support; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">distribution or use restrictions imposed by regulatory authorities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, there can be no assurance that physicians, patients, or the medical community will accept our product, even if it proves to be safe and effective and is approved for marketing by the FDA, Health Canada, and other regulatory authorities. A failure to successfully market our product would have a material adverse effect on our revenue.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interim "top-line" and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may publicly disclose interim, top-line, or preliminary data from our clinical trials, which is based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial. We also make assumptions, estimations, calculations, and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the top-line or preliminary results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results once additional data have been received and fully evaluated. Top-line or preliminary data also remain subject to audit and verification procedures that may result in the final data being materially different from the top-line or preliminary data we previously published. As a result, top-line and preliminary data should be viewed with caution until the final data are available.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may also disclose interim data from our preclinical studies and clinical trials. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">enrollment continues and more patient data become available. Adverse differences between interim data and final data could significantly harm our business prospects. Further, disclosure of interim data by us or by our competitors could result in volatility in the price of our common stock.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions, or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is material or otherwise appropriate information to include in our disclosure.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the interim, top-line, or preliminary data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, pelareorep may be harmed, which could harm our business, operating results, prospects or financial condition.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our technologies may become obsolete. </span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pharmaceutical industry is characterized by rapidly changing markets, technology, emerging industry standards, and frequent introduction of new products. The introduction of new products embodying new technologies, including new manufacturing processes, and the emergence of new industry standards may render our products obsolete, less competitive, or less marketable. The process of developing our products is extremely complex and requires significant continuing development efforts, and third-party commitments. Our failure to develop new technologies and products and the obsolescence of existing technologies could adversely affect our business.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be unable to anticipate changes in our potential customer requirements that could make our existing technology obsolete. Our success will depend, in part, on our ability to continue to enhance our existing technologies, develop new technology that addresses the increasing sophistication and varied needs of the market, and respond to technological advances and emerging industry standards and practices on a timely and cost-effective basis. The development of our proprietary technology entails significant technical and business risks. We may not be successful in using our new technologies or exploiting our niche markets effectively, or adapting our businesses to evolving customer or medical requirements or preferences or emerging industry standards.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in methods of pelareorep manufacturing or formulation may result in additional costs or delay. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As pelareorep is developed through preclinical to late-stage clinical trials toward approval and commercialization, it is common that various aspects of the development program, such as manufacturing methods and formulation, are altered along the way in an effort to optimize processes and results. Such changes carry the risk that they will not achieve these intended objectives or be acceptable to the FDA or similar regulatory authorities in other countries. Any of these changes could cause pelareorep to perform differently and affect the results of planned clinical trials or other future clinical trials conducted with the altered materials. This could delay the completion of clinical trials, require the conduct of bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our product candidate and jeopardize our ability, or our strategic partners&#8217; ability, to commence product sales and generate revenue.</span></div><div><span><br/></span></div><div><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on third-party manufacturers to produce our clinical products and on other third parties to test, package, store, monitor, and transport bulk drug substance and drug product. We and our third-party partners may encounter difficulties with respect to these activities that could delay or impair our ability to initiate or complete our clinical trials.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not currently own or operate any manufacturing facilities. We rely on a contract manufacturer to source suitable raw materials and produce sufficient quantities of pelareorep for preclinical testing and clinical trials, in compliance with applicable regulatory and quality standards. If we are unable to arrange for such third-party manufacturing sources or materials are not available in a timely manner, or fail to do so on commercially reasonable terms, we may not be able to successfully produce sufficient supply of pelareorep or we may be delayed in doing so. The manufacture of biopharmaceutical products is complex and requires significant expertise and capital investment, including the development of advanced manufacturing techniques and process controls. The process of manufacturing pelareorep is extremely susceptible to product loss due to contamination, equipment failure or improper installation or operation of equipment, vendor or operator error, contamination and inconsistency in yields, variability in product characteristics, and difficulties in scaling the production process. Even minor deviations from normal manufacturing processes could result in reduced production yields, product defects, and other supply disruptions. If microbial, viral, or other contaminations are discovered in our product candidate or in the third-party manufacturing facilities in which our product candidate are made, such manufacturing facilities may need to be closed for an extended period of time to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">investigate and remedy the contamination. Any failure by our third-party manufacturers to comply with applicable regulatory and quality standards or any failure to deliver sufficient quantities of product candidate in a timely manner, could lead to a delay in, or failure to obtain, regulatory approval of our product candidate.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have relied upon a contract manufacturer to manufacture small quantities of pelareorep. The manufacturer may encounter difficulties in scaling up production, including production yields, quality control, and quality assurance. Only a limited number of manufacturers can supply therapeutic viruses and failure by the manufacturer to deliver the required quantities of pelareorep on a timely basis at a commercially reasonable price may have a material adverse effect on us. We have completed a program for the development of a commercial process for manufacturing pelareorep and have filed a number of patent applications related to the process. There can be no assurance that we will successfully obtain sufficient patent protection related to our manufacturing process.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to third-party manufacturers, we rely on other third parties to test, package, store, monitor, and transport bulk drug substance and drug product. If we are unable to arrange for such third-party sources, or fail to do so on commercially reasonable terms, we may not be able to successfully supply sufficient product candidate or we may be delayed in doing so. Such failure or substantial delay could materially harm our business.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on third parties to produce and provide suitable raw materials for pelareorep production, packaging, and testing as well as clinical trial-related testing. We and our third-party partners may encounter difficulties with sourcing these materials that could delay or impair our ability to manufacture pelareorep or complete product or clinical sample testing.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on contract manufacture and testing facilities to source required materials for production and evaluation of pelareorep, as well as testing of clinical trial-related samples. As a result, we have less control over the supply timing and cost of these materials than if we sourced these materials directly. In addition, these are often specialized materials and third-party suppliers may also encounter challenges in producing, testing, or distributing materials that can impact delivery quantities and timeframes. If we are unable to arrange for sufficient supply or materials are not available in a timely manner, or fail to do so on commercially reasonable terms, we may not be able to successfully produce sufficient supply of pelareorep or we may be delayed in doing so. If we are unable to arrange for appropriate testing materials or they are not available in a timely manner, we may be unable to execute some clinical trial testing or we may be delayed in doing so.</span></div><div style="margin-top:10pt"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on third parties to monitor, support, conduct, and oversee clinical trials of the products that we are developing and, in some cases, to maintain regulatory files for our product candidate. We may not be able to obtain regulatory approval for our products that may result from our development efforts if we are not able to maintain or secure agreements with such third parties on acceptable terms, if these third parties do not perform their services as required, or if these third parties fail to timely transfer any regulatory information held by them to us.</span></div><div><span><br/></span></div><div><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on entities outside of our control, which may include clinical and research consultants, academic institutions, and contract research organizations ("CROs"), to perform, monitor, support, conduct, and oversee preclinical studies and clinical trials of pelareorep. As a result, we have less control over the timing and cost of these studies and the ability to recruit trial subjects than if we conducted these trials with our own personnel.</span></div><div><span><br/></span></div><div><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to maintain or enter into agreements with these third parties on acceptable terms, or if any such engagement is terminated prematurely, we may be unable to enroll patients on a timely basis or otherwise conduct our trials in the manner we anticipate. In addition, there is no guarantee that these third parties will devote adequate time and resources to our studies or perform as required by our contract or in accordance with regulatory requirements, including maintenance of clinical trial information regarding our products. If these third parties fail to meet expected deadlines, fail to transfer to us any regulatory information in a timely manner, fail to adhere to protocols, or fail to act in accordance with regulatory requirements or our agreements with them, or if they otherwise perform in a substandard manner or in a way that compromises the quality or accuracy of their activities or the data they obtain, then clinical trials of our product candidate may be extended or delayed with additional costs incurred, or our data may be rejected by the FDA, EMA or other regulatory agencies. Ultimately, we are responsible for ensuring that each of our clinical trials is conducted in accordance with the applicable protocol, legal, regulatory, and scientific standards, and our reliance on third parties does not relieve us of our regulatory responsibilities.</span></div><div><span><br/></span></div><div><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or any of our CROs fail to comply with applicable regulatory regulations, the clinical data generated in our clinical trials may be deemed unreliable, and our submission of marketing applications may be delayed, or we may be required to perform additional clinical trials before approving our marketing applications. Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process and increase our costs. Moreover, our business may be implicated if any of our CROs violates federal or state fraud and abuse or false claims laws and regulations or healthcare privacy and security laws.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div><span><br/></span></div><div><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our clinical trial sites terminate for any reason, we may experience the loss of follow-up information on patients enrolled in our ongoing clinical trials unless we are able to transfer the care of those patients to another qualified clinical trial site. Further, if our relationship with any of our CROs is terminated, we may be unable to enter into arrangements with alternative CROs on commercially reasonable terms, or at all. As a result, delays may occur, which can materially impact our ability to meet our desired clinical development timelines.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our license, development, supply, and distribution agreement with Adlai Nortye Biopharma Co. is subject to certain risks and uncertainties related to our dependence on Adlai and doing business in foreign jurisdictions.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 16, 2017, we announced that we had entered into a license, development, supply, and distribution agreement (the "Licensing Agreement") with Adlai Nortye Biopharma Co., Ltd. ("Adlai"). Under the terms of the Licensing Agreement, Adlai will have exclusive development and commercialization rights to pelareorep in China, Hong Kong, Macau, Singapore, South Korea, and Taiwan (the "Territories"). Pursuant to the Licensing Agreement, along with payments to be received by us upon meeting certain requirements and milestones, we are also eligible to receive royalty payments in excess of 10% associated with the commercialization of pelareorep for all indications, subject to regulatory approval. Under the terms of the Licensing Agreement, Adlai will be responsible for all clinical, regulatory, and commercialization activities respecting pelareorep in the Territories and therefore the Company will be dependent upon Adlai in successfully undertaking those actions in a timely and economic manner and in compliance with all applicable legal and regulatory requirements within the Territories. If Adlai is unable to fulfill its obligations under the terms of the Licensing Agreement and in compliance with all applicable legal and regulatory requirements, including clinical, regulatory and commercialization of pelareorep, our prospective revenue from royalty payments related to the commercialization of pelareorep in the Territories may be materially diminished, delayed or never realized, which could negatively affect our operating results and financial condition.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, conducting business with Adlai within the Territories, and specifically China, subjects us to certain economic, political, currency, and legal risks, and uncertainties regarding, among other things, the development and commercialization of pelareorep and the release and receipt of payments under the terms of the Licensing Agreement, including the payment of royalties upon commercialization of pelareorep. These risks include:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">different regulatory requirements for drug approvals in foreign countries;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">different standards of care in various countries that could complicate the evaluation of our product candidate;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">different U.S. and foreign drug import and export rules;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reduced protection for intellectual property rights in certain countries;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unexpected changes in tariffs, trade barriers, and regulatory requirements;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">different reimbursement systems and different competitive drugs indicated to treat the indications for which our product candidate are being developed;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">economic weakness, including inflation, or political instability in particular foreign economies and markets;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">compliance with the FCPA, and other anti-corruption and anti-bribery laws;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">U.S. and foreign taxes;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">foreign currency fluctuations, which could result in reduced revenues, and other obligations incident to doing business in another country;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a reliance on CROs, clinical trial sites, principal investigators, and other third parties that may be less experienced with clinical trials or have different methods of performing such clinical trials than we are used to in the U.S.;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential liability resulting from development work conducted by foreign distributors; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">business interruptions resulting from geopolitical actions, including war and terrorism or natural disasters.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The governments of the Territories, and specifically the Chinese government, exercise significant control over all aspects of their respective economies.&#160;Accordingly, any adverse change in the economy, the legal system, or governmental, economic or other policies could have a material adverse effect on the business prospects of the Licensing Agreement with Adlai, including our ability to receive money out of China under the terms of the Licensing Agreement. Any disruption in relations, inability to work efficiently, or disadvantageous treatment of Adlai by the governments of the Territories or other authorities could have a material adverse effect on our business prospects under the Licensing Agreement. Additionally, the regulatory environment in the Territories is evolving, and officials in the governments in the Territories exercise broad discretion in deciding how to interpret and apply regulations. There can be no assurance that Adlai will be successful in the development and commercialization of pelareorep in the Territories.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to the restrictions and conditions of the Pancreatic Cancer Action Network (PanCAN) Therapeutic Accelerator Award Agreement. Failure to comply with the agreement may adversely affect our financial condition and results of operations. </span></div><div><span><br/></span></div><div><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We received a grant from PanCAN to fund a Phase 1/2 pancreatic cancer study investigating pelareorep in combination with modified FOLFIRINOX. If we are found to have used any grant proceeds for purposes other than intended or is in violation of the terms of the grant, then we may be required to repay the grant proceeds received. A failure to maintain compliance with the grant may require us to reimburse all or a portion of the PanCAN grant, which may cause a halt of delay in ongoing operations, which may adversely affect our financial condition and operating results.  </span></div><div><span><br/></span></div><div><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Negative developments in the field of immuno-oncology, in particular, viral immunotherapy, could damage public perception of pelareorep and negatively affect our business.</span></div><div><span><br/></span></div><div><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The commercial success of pelareorep depends in part on public acceptance of the use of cancer immunotherapies, and in particular, viral immunotherapy. Adverse events in clinical trials of pelareorep or in clinical trials of similar products and the resulting publicity, as well as any other negative developments in the field of immuno-oncology that may occur in the future including in connection with competitor therapies, could result in decreased acceptance of and demand for pelareorep. These events could also result in the suspension, discontinuation, or clinical hold of or modification to our clinical trials. If public perception is influenced by claims that the use of viral immunotherapies are unsafe, whether related to pelareorep or to competitors&#8217; products, pelareorep may not be accepted by the general public or the medical community, and potential clinical trial participants may be discouraged from enrolling in our trials. In addition, responses by national or state governments to negative public perception may result in new legislation or regulations that could limit our ability to develop or commercialize any product candidates, obtain or maintain regulatory approval or otherwise achieve profitability. More restrictive statutory regimes, government regulations, or negative public opinion would have an adverse effect on our business, financial condition, results of operations and prospects and may delay or impair the development and commercialization of pelareorep or demand for any products we may develop. As a result, we may not be able to continue or may be delayed in conducting our development programs.</span></div><div><span><br/></span></div><div><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pelareorep is an oncolytic virus and, as such, adverse developments related to vaccines for viral diseases or in clinical trials of other virus-based oncolytic immunotherapy products may result in a disproportionately negative effect on the perception of pelareorep compared to other products in the field of immuno-oncology that are not based on viruses. Future negative developments in the field of immuno-oncology or the biopharmaceutical industry could also result in greater governmental regulation, stricter labeling requirements, and potential regulatory delays in the testing or approval of pelareorep. Any increased scrutiny could delay or increase the costs of obtaining marketing approval for pelareorep.</span></div><div style="margin-top:10pt"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our employees, independent contractors, principal investigators, contract research organizations, consultants, and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements and insider trading. </span></div><div style="margin-top:10pt"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the risk that our employees, independent contractors, principal investigators, CROs, consultants, and vendors may engage in fraudulent conduct or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct or unauthorized activities that violate: (1) FDA regulations, including those laws that require the reporting of true, complete, and accurate information to the FDA, (2) manufacturing standards, (3) federal and state healthcare fraud and abuse laws and regulations, or (4) laws that require the reporting of true and accurate financial information and data. Specifically, sales, marketing, and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing, and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs, and other business arrangements. It is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us, and if we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of civil, criminal, and administrative penalties, damages, monetary fines, possible exclusion from participation in Medicare, Medicaid, and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims that our employees, consultants, or independent contractors have wrongfully used or disclosed confidential information of third parties. </span></div><div style="margin-top:10pt"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have received confidential and proprietary information from collaborators, prospective licensees, and other third parties. In addition, we employ individuals who were previously employed at other biotechnology or pharmaceutical companies. We may be subject to claims that we or our employees, consultants, or independent contractors have inadvertently or otherwise used or disclosed confidential information of these third parties or our employees&#8217; former employers. We may also be subject to claims that former employees, collaborators, or other third parties have an ownership interest in our patents or other intellectual property. We may be subject to ownership disputes in the future arising, for example, from conflicting obligations of consultants or others who are involved in developing our drug candidate. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to our management and employees.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Director and officer liability insurance is costly. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We carry liability insurance on behalf of our directors and officers. Given the number of large director and officer liability insurance claims in the U.S. equity markets, director and officer liability insurance has become costly. Because we have limited financial resources, we may forego or delay pursuit of certain opportunities, which could later have a material adverse impact on our business, operating results, and financial condition. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are dependent on our key employees and collaborators.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to develop the product will depend, to a great extent, on our ability to attract and retain highly qualified scientific personnel and to develop and maintain relationships with leading research institutions. Intense competition for attracting key skill-sets may limit our ability to retain and motivate key personnel on acceptable terms. We are highly dependent on the principal members of our management staff as well as our advisors and collaborators, the loss of whose services might impede the achievement of development objectives. The persons working with us are affected by a number of influences outside of our control. In the U.S., the SEC recently adopted mandatory clawback rules which requires listed companies to adopt a clawback policy providing for recovery of incentive-based compensation awarded to executive officers if we are required to prepare an accounting restatement resulting from material noncompliance with financial reporting requirements. There is the potential that new compensation rules will make it more difficult for us to attract and retain executive officers. The loss of key employees and/or key collaborators may affect the speed and success of product development.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may experience difficulties in managing growth-related risks, which could negatively affect our operating results and business.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future financial performance and our ability to commercialize pelareorep and compete effectively will depend, in part, on our ability to effectively manage any future growth. We may be subject to growth-related risks including pressure on its internal systems and controls. Our ability to manage its growth effectively will require us to continue to implement and improve our operational and financial systems and to expand, train and manage our employee base. Inability to deal with this growth could have a material adverse impact on our business, operations and prospects. We may experience growth in the number of our employees and the scope of its operating and financial systems, resulting in increased responsibilities for its personnel, the hiring of additional personnel and, in general, higher levels of operating expenses. In order to manage our current operations and any future growth effectively, we will also need to continue to implement and improve its operational, financial, and management information systems and to hire, train, motivate, manage, and retain its employees. There can be no assurance that we will be able to manage such growth effectively, that our management, personnel, or systems will be adequate to support our operations or that we will be able to achieve the ability to generate the levels of funding commensurate with the increased levels of operating expenses associated with this growth.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Barbados law differs from the laws in effect in Canada and the United States and may afford less protection to holders of our securities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our assets and intellectual property are held by our wholly-owned subsidiary, Oncolytics Biotech (Barbados) Inc., which is organized under the laws of Barbados. It may not be possible to enforce court judgments obtained in Canada or the United States against Oncolytics Biotech (Barbados) Inc. in Barbados based on the civil liabilities provisions of applicable securities laws. In addition, there is some doubt as to whether the courts of Barbados would recognize or enforce judgments of </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">courts in Canada or the United States obtained against us or our directors or officers based on the civil liabilities provisions of Canadian and United States securities laws or hear actions against us or those persons based on such laws.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our failure to comply with data protection laws and regulations could lead to government enforcement actions (which could include civil or criminal penalties), private litigation, and/or adverse publicity and could negatively affect our operating results and business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to complex laws and regulations that address privacy and data security. The legislative and regulatory landscape for data protection continues to evolve, and in recent years there has been an increasing focus on privacy and data security issues. In the U.S., numerous federal and state laws and regulations, including state data breach notification laws, state health information privacy laws, and federal and state consumer protection laws, govern the collection, use, disclosure, and protection of health-related and other personal information. For example, the State of California enacted the California Consumer Privacy Act of 2018 (the &#8220;CCPA&#8221;), which came into effect on January 1, 2020, and provides new data privacy rights for consumers and new operational requirements for companies, which may increase our compliance costs and potential liability. The CCPA gives California residents expanded rights to access and delete their personal information, opt out of certain personal information sharing, and receive detailed information about how their personal information is used. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. Further, the California Privacy Rights Act, or CPRA, generally went into effect on January 1, 2023, and significantly amends the CCPA. It imposes additional data protection obligations on covered companies doing business in California, including additional consumer rights processes, limitations on data uses, new audit requirements for higher risk data, and opt outs for certain uses of sensitive data. It also created a new California data protection agency specifically tasked to issue substantive regulations and enforce the CCPA and CPRA, which has increased regulatory scrutiny of covered businesses in the areas of data protection and security. Additional compliance investment and potential business process changes may also be required. Similar laws have passed in other states, and continue to be proposed at the state and federal level, reflecting a trend toward more stringent privacy legislation in the U.S. The enactment of such laws could have potentially conflicting requirements that would make compliance challenging.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in the course of our business, we may obtain health information from third parties that are subject to privacy and security requirements under the Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;), as amended by the Health Information Technology for Economic and Clinical Health Act (&#8220;HITECH&#8221;). Although we are not directly subject to HIPAA (other than potentially with respect to providing certain employee benefits) we could be subject to criminal penalties if we knowingly obtain or disclose individually identifiable health information maintained by a HIPAA-covered entity in a manner that is not authorized or permitted by HIPAA/HITECH.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We could also be negatively impacted by existing and proposed laws and regulations, as well as government policies and practices related to cybersecurity, data privacy, data localization, and data protection outside of the U.S., such as the General Data Protection Regulation (&#8220;GDPR&#8221;), which took effect in the EU in May 2018. The GDPR extends the geographical scope of EU data protection law to non-EU entities under certain conditions, tightens existing EU data protection principles, and creates new obligations for companies and new rights for individuals. The GDPR may increase our responsibility and potential liability in relation to personal data that we process, expose us to substantial potential fines, and increase our compliance costs.&#160;The GDPR could also cause our development costs to increase in connection with clinical trials we are currently conducting and may conduct in the future in the EU for our product and product candidate. Further, recent legal developments in Europe have created complexity and uncertainty regarding transfers of personal data from the EU to the United States. As well, from January 1, 2021, the GDPR and the United Kingdom (&#8220;UK&#8221;) GDPR, which, together with the amended UK Data Protection Act 2018, retains the GDPR in UK national law.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, the U.S. and EU announced a new regulatory regime intended to replace the invalidated regulations. In October 2022, President Biden signed an Executive Order on &#8216;Enhancing Safeguards for United States Signals Intelligence Activities&#8217; which introduced new redress mechanisms and binding safeguards to address the concerns raised by the Court of Justice of the EU in relation to data transfers from the EEA to the U.S. and which formed the basis of the new EU-US Data Privacy Framework, or DPF, as released in December 2022. The European Commission adopted its Adequacy Decision in relation to</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the DPF in July 2023, rendering the DPF effective as a GDPR transfer mechanism to U.S. entities self-certified under the DPF. To the extent we are unable to transfer personal data between and among regions in which we operate or intend to operate as a result of regulatory authorities issuing further guidance on personal data export mechanisms, including circumstances where the standard contractual clauses cannot be used, and/or start taking enforcement action, it could affect the manner in which we operate and could adversely affect our financial results.  </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to comply with data protection laws and regulations both within and outside of the U.S. could result in government enforcement actions (which could include civil or criminal penalties), private litigation, and/or adverse publicity and could negatively affect our operating results and business.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Company may fail to achieve and maintain adequate internal control over financial reporting pursuant to the requirements of the Sarbanes-Oxley Act and equivalent Canadian legislation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company documented and tested during its most recent fiscal year its internal control procedures in order to satisfy the requirements of Section&#160;404 of the Sarbanes-Oxley Act of 2002 (&#8220;SOX&#8221;) and equivalent Canadian legislation. SOX requires an annual assessment by management of the effectiveness of the Company&#8217;s internal control over financial reporting and an attestation report by the Company&#8217;s independent auditors addressing this assessment, if applicable. The Company may fail to achieve and maintain the adequacy of its internal control over financial reporting as such standards are modified, supplemented, or amended from time to time, and the Company may not be able to ensure that it can conclude, on an ongoing basis, that it has effective internal control over financial reporting in accordance with Section&#160;404 of SOX. The Company&#8217;s failure to satisfy the requirements of Section&#160;404 of SOX on an ongoing, timely basis could result in the loss of investor confidence in the reliability of its financial statements, which in turn could harm the Company&#8217;s business and negatively impact the trading price of the common shares or the market value of its other securities. In addition, any failure to implement required new or improved controls, or difficulties encountered in their implementation, could harm the Company&#8217;s operating results or cause it to fail to meet its reporting obligations. Future acquisitions of companies, if any, may provide the Company with challenges in implementing the required processes, procedures, and controls in its acquired operations. No evaluation can provide complete assurance that the Company&#8217;s internal control over financial reporting will detect or uncover all failures of persons within the Company to disclose material information otherwise required to be reported. The effectiveness of the Company&#8217;s processes, procedures, and controls could also be limited by simple errors or faulty judgments. In addition, if the Company expands, the challenges involved in implementing appropriate internal control over financial reporting will increase and will require that the Company continue to improve its internal control over financial reporting.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Because the Company is a Canadian Company and some of its directors and officers are residents outside the United States, it may be difficult for investors in the United States to enforce civil liabilities against the Company based solely upon the federal securities laws of the United States.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is a Canadian company, with its principal place of business in Canada. At at December 31, 2024, some of the Company&#8217;s directors and officers, including the Company's Chief Executive Officer and Chief Financial Officer, are residents outside the United States and a significant portion of the Company&#8217;s assets are located outside the United States. Consequently, it may be difficult for U.S. investors to effect service of process within the United States upon the Company or these directors or officers who are not residents of the United States, or to realize in the United States upon judgments of courts of the United States predicated upon civil liabilities under the U.S. Securities Act of 1933, as amended. Investors should not assume that Canadian courts (1)&#160;would enforce judgments of U.S. courts obtained in actions against the Company or such directors or officers predicated upon the civil liability provisions of the U.S. federal securities laws or the securities or &#8220;blue sky&#8221; laws of any state within the United States or (2)&#160;would enforce, in original actions, liabilities against the Company or such directors or officers predicated upon the U.S. federal securities laws or any such state securities or &#8220;blue sky&#8221; laws. In addition, the protections afforded by Canadian securities laws may not be available to investors in the United States.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">As a foreign private issuer, our shareholders may have less complete and timely data.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is a &#8220;foreign private issuer&#8221; as defined in Rule&#160;3b-4 under the United States Securities Exchange Act of 1934, as amended (the &#8220;U.S. Exchange Act&#8221;). Equity securities of the Company are accordingly exempt from Sections&#160;14(a), 14(b), 14(c), 14(f), and 16 of the U.S. Exchange Act pursuant to Rule&#160;3a12-3 of the U.S. Exchange Act. Therefore, the Company is not required to file a Schedule&#160;14A proxy statement in relation to its annual meeting of shareholders. The submission of proxy and annual meeting of&#160;shareholder information on Form 6-K may result in shareholders having less complete and timely information in connection with shareholder actions. The exemption from Section&#160;16 rules regarding reports of beneficial ownership and purchases and sales of common shares by insiders and restrictions on insider trading in our securities may result in shareholders having less data and there being fewer restrictions on insiders&#8217; activities in our securities.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we were to lose our foreign private issuer status under U.S. federal securities law, we would likely incur additional expenses associated with compliance with the U.S. securities law applicable to U.S. domestic issuers.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a foreign private issuer, as discussed above under the risk factor titled &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">As a foreign private issuer, our shareholders may have less complete and timely data,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; we are exempt from certain provisions of the U.S. federal securities law. The determination of foreign private issuer status is made annually on the last business day of an issuer&#8217;s most recently completed </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">second fiscal quarter. We would lose our foreign private issuer status if, for example, more than 50% of our common shares are directly or indirectly held by residents of the United States and we fail to meet additional requirements necessary to maintain our foreign private issuer status. If we lose our foreign private issuer status on this date, we will be required to file with the SEC periodic reports and registration statements on U.S. domestic issuer forms, which are more detailed and extensive than the forms available to a foreign private issuer. We will also have to mandatorily comply with U.S. federal proxy requirements, and our officers, directors, and principal shareholders will become subject to the short-swing profit disclosure and recovery provisions of Section 16 of the Exchange Act. In addition, we will lose our ability to rely upon exemptions from certain corporate governance requirements under the Nasdaq listing rules. As a U.S. listed public company that is not a foreign private issuer, we will incur significant additional legal, accounting, and other expenses that we will not incur as a foreign private issuer, and accounting, reporting, and other expenses in order to maintain a listing on a U.S. securities exchange. These rules and regulations could also make it more difficult for us to attract and retain qualified members of our board of directors and more expensive to procure director and officer liability insurance. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Company is likely a "passive foreign investment company" which may have adverse U.S. federal income tax consequences for U.S. Holders.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. holders of Common Shares should be aware that the Company believes it was classified as a passive foreign investment company (&#8220;PFIC&#8221;) during its most recently completed tax year, and based on current business plans and financial expectations, the Company expects that it will be a PFIC for the current tax year and may be a PFIC in future taxable years.&#160;If the Company is a PFIC for any year during a U.S. Holder&#8217;s (as defined below) holding period of the Common Shares, then such U.S. Holder generally will be required to treat any gain realized upon a disposition of Common Shares, or any &#8220;excess distribution&#8221; received on its Common Shares, as ordinary income, and to pay an interest charge on a portion of such gain or distribution, unless the U.S. Holder makes a timely and effective qualified electing fund election (&#8220;QEF Election&#8221;) or a mark-to-market election with respect to the Common Shares.&#160;A U.S. Holder who makes a QEF Election generally must report on a current basis its share of the Company's net capital gain and ordinary earnings for any year in which the Company is a PFIC, whether or not the Company distributes any amounts to its shareholders.&#160;A U.S. Holder who makes the mark-to-market election generally must include as ordinary income each year the excess of the fair market value of the Common Shares over the taxpayer&#8217;s adjusted tax basis therein.&#160;This paragraph is qualified in its entirety by the discussion below under the heading &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Material United States Federal Income Tax Considerations.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;&#160;Each U.S. Holder should consult its own tax advisors regarding the PFIC rules and the U.S. federal income tax consequences of the acquisition, ownership, and disposition of Common Shares.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks related to our Common Shares </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Volatility of market price of the Common Shares.</span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market price of the Common Shares may be volatile. The volatility may affect the ability of holders of Common Shares to sell the Common Shares at an advantageous price. Market price fluctuations in the Common Shares may be due to the Company&#8217;s operating results failing to meet the expectations of securities analysts or investors in any quarter, downward revision in securities analysts&#8217; estimates, governmental regulatory action, adverse change in general market conditions or economic trends, acquisitions, dispositions or other material public announcements by the Company or its competitors, along with a variety of additional factors, including, without limitation, those set forth under &#8220;Cautionary Note Regarding Forward-Looking Statements&#8221; in this annual report on Form 20-F. In addition, the market price for securities in the stock markets, including the NASDAQ and the TSX, recently experienced significant price and trading fluctuations. These fluctuations have resulted in volatility in the market prices of securities that often has been unrelated or disproportionate to changes in operating performance. These broad market fluctuations may adversely affect the market price of the Common Shares</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to meet all applicable Nasdaq Capital Market requirements and Nasdaq determines to delist our common shares, the delisting could adversely affect the market liquidity of our common shares and the market price of our common shares could decrease and our ability to access the capital markets could be negatively impacted.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common shares are listed on The Nasdaq Capital Market. We must satisfy the continued listing requirements of The Nasdaq Capital Market, to maintain the listing of our common shares on The Nasdaq Capital Market. On February 13, 2025, we received a delinquency notification letter (the "Notice") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") indicating that, for the prior 30 consecutive business days, the closing bid price for our ordinary shares listed on the Nasdaq Capital Market was below the minimum $1.00 per share required for continued listing on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2). The Notice provides that we have a period of 180 calendar days from the date of the Notice, or until August 12, 2025, to regain compliance with the minimum bid price requirement. The receipt of the Notice has no immediate effect on our business operations or the listing of our ordinary shares, which will continue to trade uninterrupted on the Nasdaq under the ticker "ONCY." If at any time before August 12, 2025, the bid price of </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our ordinary shares closes at or above $1.00 per share for a minimum of 10 consecutive business days, Nasdaq will provide written confirmation of compliance to us. In the event that we do not regain compliance by August 12, 2025, we may be eligible for additional time to regain compliance. To qualify, we would be required to meet the continued listing requirement for the market value of publicly held shares and all other initial listing standards for the Nasdaq Capital Market, except for the minimum bid price requirement. In addition, we would be required to notify Nasdaq of its intent to cure the deficiency during the second compliance period.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There can be no assurance that we will be able to regain or subsequently maintain compliance with the Nasdaq continued listing requirements, and if we are unable to regain or maintain compliance with the continued listing requirements, our securities may be delisted from Nasdaq, which could reduce the liquidity of our common shares materially and result in a corresponding material reduction in the price of our common shares. Delisting could harm our ability to raise capital through alternative financing sources on terms acceptable to us, or at all, and may result in the potential loss of confidence by investors, employees, suppliers and business development opportunities. Such a delisting likely would impair your ability to sell or purchase our common shares when you wish to do so. Further, if we were to be delisted from Nasdaq, our common shares may no longer be recognized as a &#8220;covered security&#8221; and we would be subject to regulation in each state in which we offer our securities. Thus, delisting from Nasdaq could adversely affect our ability to raise additional financing through the public or private sale of equity securities, would significantly impact the ability of investors to trade our securities and would negatively impact the value and liquidity of our common shares</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Potential dilution of present and prospective shareholdings.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to finance future operations and development efforts, the Company may raise funds through the issue of common shares or the issue of securities convertible into common shares. The Company cannot predict the size of future issues of common shares or the issue of securities convertible into common shares or the effect, if any, that future issues and sales of the Company&#8217;s common shares will have on the market price of its common shares. Any transaction involving the issue of previously authorized but unissued shares, or securities convertible into shares, would result in dilution, possibly substantial, to present and prospective holders of shares.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Company does not intend to pay cash dividends in the foreseeable future.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has not declared or paid any dividends since its incorporation. The Company intends to retain earnings, if any, to finance the growth and development of its business and does not intend to pay cash dividends on the Common Shares in the foreseeable future. Any return on an investment in the common shares will come from the appreciation, if any, in the value of the Common Shares. The payment of future cash dividends, if any, will be reviewed periodically by the board of directors and will depend upon, among other things, conditions then existing including earnings, financial condition, and capital requirements, restrictions in financing agreements, business opportunities and conditions, and other factors.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Risks </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in law could adversely affect our business and corporate structure.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There can be no assurances that changes will not occur in corporate, tax, property, and other laws in Canada and/or Barbados (or the interpretation thereof by regulatory or tax authorities) which may materially and adversely affect our businesses and corporate structure.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to securities litigation, which is expensive and could divert our management&#8217;s attention.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the past, companies that have experienced volatility in the market price of their securities have been subject to securities class action litigation. We may be the target of this type of litigation in the future. Regardless of the merits or the ultimate results of such litigation, securities litigation brought against us could result in substantial costs and divert our management&#8217;s attention from other business concerns.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our operations may be adversely affected by disruptions to our information technology ("IT") systems or those of any of our CROs, manufacturers, other contractors or consultants or potential future collaborators, including disruptions from cybersecurity breaches of our IT infrastructure.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on information technology networks and systems, including those of third-party service providers, to process, transmit, and store electronic information. In particular, we depend on our information technology infrastructure for a variety of functions, including financial reporting, data management, and email communications. Any of these systems may be susceptible to outages due to fire, floods, power loss, telecommunications failures, terrorist attacks, sabotage, and similar </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">events. Global cybersecurity threats and incidents can range from uncoordinated individual attempts to gain unauthorized access to our information technology systems to sophisticated and targeted measures known as advanced persistent threats. The ever-increasing use and evolution of technology, including cloud-based computing, creates opportunities for the unintentional dissemination or intentional destruction of confidential information stored in our systems or in non-encrypted portable media or storage devices. We could also experience a business interruption, information theft of confidential information, or reputational damage from industrial espionage attacks, malware or other cyber-attacks, which may compromise our system infrastructure or lead to data leakage, either internally or at our third-party providers. Despite the implementation of network security measures and disaster recovery plans, our systems and those of third parties on which we rely may also be vulnerable to computer viruses, break-ins, and similar disruptions. If we or our vendors are unable (or are perceived as unable) to prevent such outages and breaches, our operations may be disrupted, and our business reputation could be adversely affected. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that risks and exposures related to cybersecurity attacks will remain high for the foreseeable future due to the rapidly evolving nature and sophistication of these threats. In addition, we may face increased cybersecurity risks due to our reliance on internet technology and the number of our employees who are working remotely, which may create additional opportunities for cybercriminals to exploit vulnerabilities. We maintain cyber liability insurance; however, this insurance may not be sufficient to cover the financial, legal, business, or reputational losses that may result from an interruption or breach of our systems.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Failure to meet regulatory or ethical expectations on environmental impact, including climate change. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Environmental issues will become more material in the marketplace as the wider healthcare system embraces net -zero climate targets. The environmental targets and performance of our business will come under increased scrutiny by investors, governments, and non-governmental organizations. Environmental considerations are starting to become embedded in the public procurement of goods and services, including medicinal products and devices. Specific intermediates used to manufacture medicines, or those used as excipients or propellants, are coming under increased regulation and some may be subject to time-limited exemptions or potential phase-out. The physical impacts of climate change could impact the resilience of our business operations and supply chain.</span></div><div><span><br/></span></div><div id="i17734265916144358581fdce5df64f78_37"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4.&#160;&#160;INFORMATION ON THE COMPANY</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i17734265916144358581fdce5df64f78_40"></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt">History and Development of the Company</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Oncolytics Biotech Inc. was formed under the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Corporations Act</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Alberta) on April 2, 1998 as 779738 Alberta Ltd.&#160;On April 8, 1998, we changed our name to Oncolytics Biotech Inc.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our principal place of business is located at 804, 322 11</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Avenue SW, Calgary, Alberta, Canada T2R 0C5, telephone (403) 670-7377. Our agent for service in the U.S. is Registered Agent Solutions, Inc., 838 Walker Road Suite 21-2 Delaware 19904.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A description of the important events in our development including licensing transactions, our principal capital expenditures and divestitures and a description of acquisitions of material assets can be found in our MD&amp;A and in the notes to our financial statements included elsewhere in this annual report.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The SEC maintains a Website that contains reports, proxy and information statements, and other information regarding registrants that file electronically with the SEC at http://www.sec.gov. The filings are also contained on the Company&#8217;s website at www.oncolyticsbiotech.com. Information on the Company's website is not incorporated by reference herein. </span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><div id="i17734265916144358581fdce5df64f78_43"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.84pt">Business Overview </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage biopharmaceutical company developing pelareorep, a well-tolerated intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pelareorep is a proprietary isolate of reovirus, a naturally occurring, non-pathogenic double-stranded RNA (dsRNA) virus commonly found in environmental waters. Pelareorep has shown promising results in changing the tumor microenvironment (TME). This creates a more immunologically favorable TME, which in turn makes the tumor more susceptible to various treatment combinations. These treatments include chemotherapies, checkpoint inhibitors, and other immuno-oncology approaches such as CAR T therapies, bispecific antibodies, and CDK4/6 inhibitors. Pelareorep induces a new army of tumor-reactive T cells, helps these cells to infiltrate the tumor through an inflammatory process, and promotes the overexpression of PD-1/PD-L1. By priming the immune system with pelareorep, we believe we can increase the proportion of patients who respond to various cancer treatments, including immunotherapies, especially in cancers where existing treatment regimens have failed or provided limited benefit.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not been profitable since our inception and expect to continue to incur substantial losses as we continue research and development efforts. We do not expect to generate significant revenues until and unless pelareorep becomes commercially viable. As a clinical-stage drug development company, we consistently discuss and pursue potential partnerships, licensing agreements and other strategic transactions with third parties. Due to the capital intensive nature of early stage drug development, we continuously analyze our available cash and projected operating costs to determine whether to seek additional funds via the capital markets. To date, we have funded our operations mainly through the issuance of additional capital via public offerings, equity distribution arrangements, and through the exercise of warrants and stock options. There can be no assurance that we will be able to raise additional funds through the sale of our common shares. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Business Strategy</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business strategy is to develop and seek regulatory approval to market pelareorep in an effective and timely manner, and access additional technologies at a time and in a manner that we believe is best for our development.&#160;We intend to achieve our business strategy by focusing on these key areas:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Continue to assess the safety and efficacy of pelareorep in human subjects through our clinical development program;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Maintain existing and establish new collaborations with experts to assist us with scientific and clinical developments of this new potential pharmaceutical product;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Implement strategic alliances with select biopharmaceutical companies and laboratories, at a time and in a manner whereby such alliances may complement and expand our own research and development efforts. Such alliances may also result in an eventual expansion to include providing additive sales and marketing capabilities;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Use our broadening patent base and collaborator network as a mechanism to meet our strategic objectives; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Develop relationships with companies that could be instrumental in assisting us to access other innovative therapeutics.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As our clinical development program advances, we anticipate pelareorep's ability to enhance innate and adaptive immune responses within the TME will play an increasingly important role. This greatly increases opportunities for expanding our clinical program, business development, and partnering opportunities to address a broad range of cancers in combination with various other therapies. We believe this approach has the most promise for generating clinically impactful data and offers the most expeditious path to regulatory approval. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary focus is to advance our programs in hormone receptor-positive / human epidermal growth factor 2-negative (HR+/HER2-) advanced and metastatic breast cancer (mBC) and metastatic pancreatic ductal adenocarcinoma (PDAC) to registration-enabled clinical studies. In addition, we are exploring opportunities for registrational programs in other gastrointestinal cancers, including anal cancer, through our GOBLET platform study.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business strategy is based on attaining a number of commercial objectives, which, in turn, are supported by a number of product development goals.&#160;In the context of this annual report, statements of our "belief" are based primarily upon our results derived to date from our research and development program in animals, early-stage human trials, and our most recent data from mid-stage clinical trials, upon which we believe that we have a reasonable scientific basis to expect the particular results to occur.&#160;It is not possible to predict, based upon studies in animals, or early to mid-stage human trials, whether a new therapeutic will ultimately prove to be safe and effective in humans.&#160;There are no assurances that the particular result we expect will occur.</span></div><div style="height:33.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are pursuing a strategy of establishing relationships with larger companies as strategic partners.&#160;It is anticipated that future clinical development into large international or pivotal trials would generally occur in conjunction with a strategic partner or partners, who would contribute expertise and financial assistance.&#160;In exchange for certain product rights and commitments to market our products, the strategic partners would be expected to share in proceeds from the sale of our product or products.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Scientific Background &amp; Summary of Research and Development Highlights </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pelareorep&#8217;s anti-tumor activity is based on three complementary modes of action (Figure 1): </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Selective viral replication in permissive cancer cells leading to tumor cell lysis.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Modification of the tumor microenvironment by upregulating chemokine/cytokine expression, which makes the tumor more visible to the immune system and stimulates innate immunity that can directly target the tumor. </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Induction of adaptive immune responses, including the expansion of tumor-infiltrating lymphocyte populations in the blood that can attack tumors by targeting tumor- and virus-specific antigens.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preclinical and translational research to date indicates the following:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Pelareorep has anticancer effects in a variety of animal models demonstrating that it can reduce tumor burden and prolong survival in these models. </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The anticancer effects in animal models can be enhanced when pelareorep is given in combination with chemotherapy, immunotherapy, radiotherapy, and other targeted cancer therapies, highlighting the ability of pelareorep to enhance the anticancer effects of a broad range of cancer therapeutics.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">A toxic dose of pelareorep has not been reached/established in animal models and doses as high as 9.0 x 10</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">10 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">TCID</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:1.4pt;vertical-align:baseline">50 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">have been well-tolerated in humans. Treatment with pelareorep causes manageable side-effects.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical data to date indicate the following:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">More than 1,600 patients have received at least one dose of study treatment in clinical studies with pelareorep. Of these, more than 1,200 patients received pelareorep, including over 600 patients in Oncolytics-sponsored trials, and over 500 in investigator-sponsored trials.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Pelareorep has been administered as single or multiple doses (intratumoral or intravenous), either as a monotherapy or in combination with chemotherapy, immunotherapy (e.g., checkpoint inhibitors), and/or radiotherapy.  </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Pelareorep is generally well-tolerated and has a manageable side effect profile. </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">When combined with chemotherapy or immunotherapy, pelareorep does not appear to enhance either the frequency or severity of the adverse effects of these agents.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Efficacy results from clinical studies show that treatment with pelareorep can improve the outcome of cancer patients with a variety of different tumors: </span></div><div style="margin-top:3pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In the randomized Phase 2 IND.213 study, 74 mBC patients were treated with pelareorep plus paclitaxel (PTX) versus PTX alone (standard of care control chemotherapy). The patients treated with PTX + pelareorep demonstrated a statistically significant improvement in median overall survival (OS) compared to those treated with PTX alone: 17.4 months versus 10.4 months, respectively (HR = 0.65; 80% CI 0.46&#8211;0.91; p=0.1). In a post hoc subgroup analysis of patients with HR+/HER2- disease, the median OS benefit from the addition of pelareorep to PTX was even greater compared to PTX alone: 21.0 months versus 10.8 months, respectively (HR = 0.60; p=0.1). </span></div><div style="margin-top:3pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In the subsequent Phase 2 BRACELET-1 study, 48 patients with HR+/HER2- mBC were randomized to receive one of three treatments: PTX alone, PTX + pelareorep, or PTX + pelareorep + avelumab, a licensed anti-PD-L1 antibody. Final efficacy results from the BRACELET-1 study demonstrated that the median OS in the PTX alone control arm was 18.2 months. However, the median OS could not be calculated in the PTX + pelareorep arm due to the number of patients still alive at the time of the analysis. A conservative estimate of median OS for the PTX + pelareorep arm is 32.1 months, indicating that PTX + pelareorep delivered a greater than 12-month survival advantage compared to PTX alone. This survival benefit is further illustrated by the 24-month overall survival rate, which showed that 64% of patients treated with PTX + pelareorep survived at least 2 years compared to 33% of patients treated with PTX alone. In addition, the final median PFS was 12.1 months for PTX + pelareorep compared to 6.4 months for PTX alone, a benefit of 5.7 months. These results substantiated the statistically significant near doubling of median OS observed in the earlier randomized IND-213 study in HR+/HER2- patients treated with PTX + pelareorep compared to PTX alone. </span></div><div style="margin-top:3pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In the AWARE-1 window-of-opportunity study, most HR+/HER2- early breast cancer patients treated with pelareorep showed an increase in CeLTIL score, a measure of tumor cellularity and tumor infiltrating lymphocytes (TILs) that is associated with a better prognosis in breast cancer. Importantly, the addition of the immune checkpoint inhibitor atezolizumab to pelareorep increased both the magnitude of the increase in </span></div><div style="height:33.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:3pt;padding-left:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CeLTIL score and the proportion of patients with a positive CelTIL score thereby achieving the study&#8217;s primary endpoint. Biomarker data from AWARE-1 further demonstrated that pelareorep treatment modified the TME to make it more visible to the immune system, generated and expanded TIL clones in the blood, upregulated PD-L1 expression, and promoted CD8+ T cell infiltration into tumors. Some of these effects were even more prominent when pelareorep was combined with atezolizumab demonstrating synergy between the two agents.</span></div><div style="margin-top:3pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In the GOBLET platform study, the objective response rate (ORR) and disease control rate (DCR) were 62% and 85%, respectively, in first-line advanced/metastatic pancreatic ductal adenocarcinoma (PDAC) patients treated with the combination of pelareorep, atezolizumab, and gemcitabine/nab-paclitaxel. The observed ORR is substantially higher than the typical ORR of ~25% reported in historical trials of gemcitabine and nab-paclitaxel in metastatic pancreatic cancer. In a single-arm study of gemcitabine plus pelareorep, known as REO 017, first-line patients with metastatic PDAC, had a median OS of 10.2 months with 1-year and 2-year survival rates of 45% and 24%, respectively. These results were encouraging when compared to an average median OS of less than 7 months, and 1-year and 2-year survival rates of approximately 22% and 6%, respectively, for metastatic PDAC patients treated with gemcitabine alone in benchmark studies.  </span></div><div style="margin-top:3pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In a two-arm Phase 2 study (NCI 8601), patients with metastatic PDAC were randomized to receive either carboplatin, paclitaxel and pelareorep (test arm) or carboplatin and paclitaxel alone (control arm). Evaluation of patient samples collected during this clinical trial identified the immunomodulatory CEA cell adhesion molecule 6 (CEACAM6) as a potential predictive biomarker for response to pelareorep therapy. Specifically, low levels of CEACAM6 mRNA expression were associated with prolonged progression-free survival in pelareorep-treated patients (10.3 months in CEACAM6 low versus 5.7 months in CEACAM6 high patients, p=0.05); importantly, this effect was not seen in the control arm.</span></div><div style="margin-top:3pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Preliminary results from the anal carcinoma cohort of the GOBLET platform study showed ORR of 33% in second-line or later patients with squamous cell carcinoma of the anus treated with pelareorep plus atezolizumab, which compares favorably to the 10-24% ORRs reported in recent clinical trials of checkpoint inhibitor therapy is a similar second-line or later anal carcinoma populations. This cohort has exceeded the Stage 1 success criterion of &#8805;2 responses in the first 10 patients, and Stage 2 enrollment of 18 additional evaluable patients is ongoing. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Mechanism of Action</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Figure 1. Proposed mechanism of action for pelareorep</span></div><div style="text-align:justify"><img src="oncyf-20241231_g1.jpg" alt="reolysinmoapanel4smalla02.jpg" style="height:341px;margin-bottom:5pt;vertical-align:text-bottom;width:424px"/></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Direct cell lysis - Pelareorep Replication in Permissive Cancer Cells</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selective viral replication and lysis of cancer cells and not of normal cells is mediated by the host cellular protein dsRNA-activated protein kinase (PKR). PKR is activated in non-cancer cells infected with reovirus, which in turn inhibits viral gene </span></div><div style="height:33.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">translation. However, in permissive cancer cells, PKR activation is inhibited, allowing viral gene translation and eventual cell lysis. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It was originally established that selective lysis of tumor cells was mediated by the activated rat sarcoma virus oncogene (RAS)-pathway, since active RAS inhibits PKR activation. However, more recent investigations have revealed that reovirus replication is not restricted to cells with an active RAS pathway; rather oncogenic mutations and amplifications in upstream and downstream mediators of the RAS-pathway also allow viral replication and oncolysis. Moreover, active RAS is known to stimulate over 18 downstream effector proteins, many of which have been shown to facilitate viral replication. Cells bearing dysfunctional or deleted tumor suppressor genes and/or undergoing chemo- or radiation-induced cell stress also show increased sensitivity to reovirus replication and lysis.</span></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Induction of Innate Immunity</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preclinical and clinical studies provide compelling evidence that pelareorep functions as a systemically delivered immunogenic agent that acts locally at the site of the tumor. Indeed, preclinical studies demonstrated that cancer cells infected with pelareorep can produce an innate immune response triggering the release of inflammatory cytokines. This inflammatory environment promotes a chemotactic response in NK cells, dendritic cells, and cytotoxic T cells, altering the tumor microenvironment to support bystander immune-mediated cancer cell death. Intriguingly, preclinical studies have also demonstrated that the beneficial immunogenic functions of pelareorep can occur independently of viral replication. Pelareorep performs this immunogenic function, in part, by activating dendritic cells, key regulators of both adaptive and innate immunity. Dendritic cells activated by reovirus, in turn, stimulate the innate antitumor activity of NK cells and aid in the priming of specific antitumor cytotoxic lymphocyte, demonstrating that dendritic cell recognition of reovirus may trigger a beneficial innate immune response.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A clinical trial with pelareorep (REO 013) provided an opportunity to study human NK cell activation in a controlled manner. Ten colorectal cancer patients with liver metastases received between one and five doses of pelareorep prior to surgical resection of their tumor. NK cell activation peaked 24-48 hours post-infection, coincident with a peak in pro-inflammatory cytokines. NK cells within a population of reovirus-treated blood mononuclear cells were stimulated to kill tumor targets, but not normal hepatocytes. Moreover, peripheral blood mononuclear cells were able to hand-off virus to tumors for direct oncolytic killing. Similarly, NK cells within a liver mononuclear cell population became selectively cytotoxic toward tumor cells when activated by reovirus. These results showed that reovirus modulates human NK cell activity in vivo and suggest that this may contribute to the therapeutic effect of pelareorep.</span></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Induction of Adaptive Immunity</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The selective replication of pelareorep in cancer cells can result in cell death, also known as oncolysis. In addition, tumor cells, like all cells, are sensitive to the presence pelareorep&#8217;s dsRNA genome leading to the upregulation of type 1 interferon expression that activates a cascade of cytokines and chemokines to effectively turns the TME from an immunologically inactive (&#8220;cold&#8221;) to an immunologically active (&#8220;hot&#8221;). In this way, pelareorep makes the TME more visible to the immune system. Because pelareorep is administered intravenously, it is also carried to lymph nodes where it can stimulate the production and activation and anti-viral T cells. This potent anti-viral T cell activation has a the effect of inducing the expansion of TIL clonal populations in the blood. This has been confirmed by T cell receptor sequencing of pre-treatment tumor tissue and post-treatment blood samples from multiple clinical studies. Ultimately, pelareorep-induced production of interferons and activation of innate immune responses along with the expression of PD-L1, CXCL10, and CXCL11 collectively serves to make the tumor visible to the immune system. This, in turn, allows increased activation and infiltration of the anti-tumor T cells into the tumor resulting in suppression and even elimination of tumor growth. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pelareorep also enhances the expression of &#8216;foreign&#8217; antigens/markers on tumor cells. Oncolysis of tumor cells exposes tumor-associated antigens (TAAs) and viral-associated antigens (VAAs) for processing and presentation by APCs, such as dendritic cells. Through this process, pelareorep facilitates the display of existing tumor specific antigens and novel &#8216;foreign&#8217; antigens on the surface of infected tumor cells and APCs resulting in the expansion of these tumor specific T cell subsets. While it is difficult to identify the expansion of novel tumor T cell specific clones, we have identified expansion of pre-existing tumor specific T cell clones in the blood of pelareorep treated patients. Preliminary data suggest that the expansion of these clones correlates with reductions in tumor size. Simultaneously, pelareorep induces an increase in inflammatory response including the expression of co-stimulatory molecules and inflammatory cytokines. Together, these pelareorep-mediated immunological events initiate adaptive anti-tumor immunity.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By promoting the expansion of existing tumor specific T cells and the release of inflammatory cytokines, pelareorep, promotes an inflamed tumor phenotype. An inflamed tumor phenotype is characterized by NK and T cell infiltration, increased expression of chemokines/cytokines, and increased expression of checkpoint ligands such as PD-L1. This phenotype correlates with an increase in overall survival and has a positive prognostic value for early-stage cancers. In patients with metastatic </span></div><div style="height:33.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cancer, an inflamed tumor phenotype is associated with better clinical outcomes when treated with immunotherapies, including immune checkpoint inhibitors, cancer vaccines, and adaptive T cell therapies. By promoting an inflamed tumor phenotype, pelareorep primes an anti-cancer immune response (Figure 2).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Figure 2. Pelareorep primes an anti-cancer immune response</span></div><div style="margin-bottom:8pt"><img src="oncyf-20241231_g2.jpg" alt="pelareorep-lga02.jpg" style="height:316px;margin-bottom:5pt;vertical-align:text-bottom;width:470px"/></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical Development </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Breast Cancer Program</span></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the second quarter of 2024, we held a Type C meeting with the U.S. Food and Drug Administration (FDA) to discuss our planned potential registration-enabling trial for pelareorep in HR+/HER2- mBC. The FDA provided its feedback including support for progression-free survival (PFS) as the study's primary endpoint, with overall survival (OS) as a key secondary endpoint.  </span></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the third quarter of 2024, we announced the final BRACELET-1 results. BRACELET-1 was a randomized open-label study that enrolled 48 patients with HR+/HER2- mBC into three cohorts: paclitaxel (PTX) alone, PTX in combination with pelareorep, and PTX in combination with both pelareorep and avelumab, a human anti-PD-L1 antibody. The results were based on efficacy data collected and analyzed two years after the last patient was enrolled as specified by the protocol. Results of the final BRACELET-1 analysis demonstrated that the median OS could not be calculated in the PTX + pelareorep arm due to the number of patients still alive at the time of the final analysis, in contrast with a median OS of 18.2 months in the PTX monotherapy arm. A conservative estimate of median OS for the pelareorep arm is 32.1 months, demonstrating that PTX + pelareorep delivered a greater than 12-month survival advantage compared to PTX alone. This survival benefit is further illustrated by the 24-month overall survival rate, which showed that 64% of patients treated with PTX + pelareorep survived at least 2 years compared to only 33% of patients treated with PTX alone. In addition, final PFS was 12.1 months for PTX + pelareorep compared to 6.4 months for PTX alone, a benefit of 5.7 months. These results substantiated the statistically significant near doubling of median OS observed in our earlier randomized IND.213 study in a similar HR+/HER2- patient population treated with PTX + pelareorep compared to PTX alone. The strong survival data from the BRACELET-1 and IND.213 studies, along with the FDA's guidance on our registration study plan from the Type C meeting, provided the foundation for our plan to conduct a registration-enabling study to assess pelareorep-based combination therapy in patients with advanced or metastatic HR+/HER2- breast cancer.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Gastrointestinal Cancer Program</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our breast cancer program, we continued to explore pelareorep in gastrointestinal cancers through our GOBLET (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">G</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">astrointestinal tum</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">O</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rs exploring the treatment com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">inations with pe</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">L</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ar</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">E</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">orep and an</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">T</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i-PD-L1) platform study. The following were the key highlights of the GOBLET study in 2024:</span></div><div style="height:33.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Enrollment expansion of GOBLET anal cancer cohort</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the positive Stage 1 interim data presented at the 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">nd</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> International Multidisciplinary Anal Cancer Conference 2023, where we showed a tripling of objective response compared to similar studies investigating checkpoint inhibitor therapy alone, we expanded enrollment into GOBLET's anal cancer cohort. As there is currently no established standard therapy for anal carcinoma patients who have failed first-line treatment, continued positive results in the anal cancer cohort could potentially expand pelareorep's opportunity beyond breast and pancreatic cancers. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Initiation of new pancreatic cancer GOBLET cohort</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We initiated, commenced enrollment, and dosed patients in GOBLET's new PDAC mFOLFIRINOX cohort (GOBLET Cohort 5). We completed the safety run-in for this cohort and received favorable feedback from the GOBLET Data Safety Monitoring Board. In January 2025, we received regulatory approval to allow GOBLET Cohort 5 to progress to full enrollment and presented the safety run-in results at the 2025 ASCO Gastrointestinal Cancers Symposium. </span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2024, we also entered into a preliminary collaboration with the Global Coalition for Adaptive Research (GCAR) to incorporate a pelareorep combination therapy arm into GCAR's anticipated master protocol for the evaluation of new therapeutic approaches in metastatic pancreatic cancer patients. Compared to a chemotherapy control arm, the investigational treatment regimen is expected to be pelareorep combined with chemotherapy, either with or without a checkpoint inhibitor. This adaptively designed trial could accelerate the registrational timeline and provide substantial cost savings compared to traditional trial designs. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Patents and Trade Secrets</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on our patent portfolio to protect the development of pelareorep. At December&#160;31, 2024, we have 147 issued patents including 12 issued in the U.S. and 7 in Canada. We also have 14 patents pending in the U.S., Canada, and other jurisdictions. We have an extensive patent portfolio covering pelareorep and formulations that we use in our clinical trial program. We also have patents covering methods for manufacturing pelareorep and screening for susceptibility to pelareorep. These patent rights extend to at least the end of 2031. In addition, we have ongoing patent applications that may extend the patent rights beyond 2031.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not currently aware of competing intellectual property relating to our pelareorep project. While we believe that we have the necessary freedom to operate in these areas, there can be no assurance that others will not challenge our position in the future. Litigation to defend our position could be costly and time-consuming and we cannot be certain we will be successful.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also rely on unpatented trade secrets and improvements, unpatented know-how, and continuing technological innovation to develop and maintain our competitive position. No assurance can be given that others will not independently develop substantially equivalent proprietary information and techniques, or otherwise gain access to our trade secrets or disclose such technology, or that we can meaningfully protect our rights to our unpatented trade secrets.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We require our employees and consultants to execute confidentiality agreements upon the commencement of employment and consulting relationships with us. These agreements provide that all confidential information developed by or made known to an individual during the course of their employment or consulting relationship generally must be kept confidential. In the case of employees, the agreements provide that all inventions conceived by the individual, while employed by us, relating to our business are our exclusive property. While we have implemented reasonable business processes and agreements with which to protect confidential information, these actions may not provide meaningful protection for our trade secrets in the event of unauthorized use or disclosure of such information.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulatory Requirements</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The development of new pharmaceuticals is strongly influenced by a country's regulatory environment.&#160;The primary regulatory body in the United States is the FDA and in Europe is the European Medicines Agency (the &#8220;EMA&#8221;). The drug approval process in Canada is regulated by Health Canada.&#160;Similar processes are conducted in specific countries by equivalent regulatory bodies.&#160;Regulations in each jurisdiction require the licensing of manufacturing facilities and mandate strict research and product testing standards.&#160;Companies must establish the safety and efficacy of their products, comply with cGMP and potentially submit marketing materials before being allowed to market pharmaceutical products.&#160;While we plan to pursue or support the pursuit of the approval of our product, success in acquiring regulatory approval for any product is not assured.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to market our pharmaceutical product in Canada, the United States, Europe, and other jurisdictions, we must successfully meet the requirements of those jurisdictions. The requirements of the appropriate regulatory authority will generally include the following stages as part of the regulatory process:</span></div><div style="height:33.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Pre-Pharmacological Studies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- Pre-Pharmacological studies involve extensive testing on laboratory animals to determine if a potential therapeutic product has utility in an </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> disease model and has any adverse toxicology in a disease model.</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Investigational New Drug Application</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - An Investigational New Drug (IND) Submission, or the equivalent, must be submitted to the appropriate regulatory authority prior to conducting Pharmacological Studies.</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Pharmacological Studies&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(or Phase 1 Clinical Trials)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- Pharmacological studies are designed to assess the potential harmful or other side effects that an individual receiving the therapeutic compound may experience.&#160;These studies, usually short in duration, are often conducted with healthy volunteers or actual patients and use up to the maximum expected therapeutic dose.</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Therapeutic Studies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;(or Phase 2 and 3 Clinical Trials) - Therapeutic studies are designed primarily to determine the appropriate manner for administering a drug to produce a preventive action or a significant beneficial effect against a disease.&#160;These studies are conducted using actual patients with the condition that the therapeutic is designed to remedy. Prior to initiating these studies, the organization sponsoring the program is required to satisfy a number of requirements via the submission of documentation to support the approval for a clinical trial.</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Expedited Development and Review Programs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- The FDA has several programs intended to facilitate and expedite development and review of new drugs to address unmet medical needs in the treatment of serious or life-threatening diseases or conditions. These programs include Fast Track designation, Breakthrough Therapy designation, Priority Review, and Accelerated Approval. Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or the time period for FDA review or approval may not be shortened. Furthermore, eligibility for these programs does not change the scientific or medical standards for approval or the quality of evidence necessary to support approval, though they may expedite the development or review process.</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">New Drug Submission </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- After all three phases of a clinical trial have been completed, the results are submitted with the original IND Submission to the appropriate regulatory authority for marketing approval.&#160;Once marketing approval is granted, the product is approved for commercial sales.</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Manufacturing and Controls</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Concurrent with pharmacological and therapeutic studies, the manufacturing process is developed, and applicable controls implemented. This information is submitted to the appropriate regulatory authority with more defined requirements for process and product control by later stage studies and prior to New Drug Submission. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Marketing Approvals</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of the preclinical and clinical testing, together with manufacturing and controls information, are submitted to regulatory agencies in order to obtain approval to commence commercial sales. In responding to such an application, regulatory agencies may grant marketing approval, request additional information or further research, or deny the application if they determine that the application does not satisfy their regulatory approval criteria. Approval for a pharmaceutical or biologic product may not be granted on a timely basis, if at all. If granted, the approval may not cover all the clinical indications for which approval is sought, or may contain significant limitations in the form of warnings, precautions, or contraindications with respect to conditions of use.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The satisfaction of pre-market approval requirements for new drugs and biologics typically takes several years, with the actual time required varying substantially based upon the type, complexity, and novelty of the product or targeted disease. Government regulation may delay or prevent marketing of potential products for a considerable period of time and impose costly procedures upon our activities. Success in early-stage clinical trials or with prior versions of products does not assure success in later-stage clinical trials. Data obtained from clinical activities are not always conclusive and may be susceptible to varying interpretations that could delay, limit or prevent regulatory approval.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Post-Marketing Regulations</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once approved, regulatory agencies may withdraw the product approval if compliance with pre- and/or post-marketing regulatory standards is not maintained or if problems occur after the product reaches the marketplace. In addition, they may require post-marketing studies, referred to as Phase 4 studies, to monitor the effect of an approved product, and may limit further marketing of the product based on the results of these post-market studies. The FDA and other foreign regulatory agencies have broad post-market regulatory and enforcement powers, including the ability to levy fines and penalties, suspend or delay issuance of approvals, seize or recall products, or withdraw approvals.</span></div><div style="height:33.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Manufacturing Regulations</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are economically dependent on our toll manufacturers. We primarily use one toll manufacturer in the U.S. to produce the clinical grade pelareorep active ingredient and a second toll manufacturer to formulate finished product required for our clinical trial program.&#160;Any significant disruption of the services provided by our primary toll manufacturers has the potential to delay the progress of our clinical trial program.&#160;We have attempted to mitigate this risk by identifying an alternative toll manufacturer, establishing stability profiles for long-term storage of pelareorep, and producing sufficient pelareorep in advance of patient enrollment in a particular clinical trial.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our toll manufacturers are subject to periodic inspection by the FDA, the United States Drug Enforcement Administration, or DEA, and other domestic and foreign authorities where applicable, and must comply with cGMP regulations. Manufacturers of biologics also must comply with general biological product standards. Failure to comply with the statutory and regulatory requirements subjects the manufacturer to possible legal or regulatory action, such as suspension of manufacturing, seizure of product, or mandatory or voluntary recall of a product.&#160;Adverse experiences with the product must be reported to the FDA and foreign agencies and could result in the imposition of market restrictions through labeling changes or in product removal. Product approvals may be withdrawn if compliance with regulatory requirements is not maintained or if problems concerning safety or efficacy of the product occur following approval.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Advertising and Promotion Regulations</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to both pre- and post-market product advertising and promotion, the FDA and similar foreign agencies impose a number of complex regulations on entities that advertise and promote pharmaceuticals and biologics, which include, among other things, standards and regulations relating to direct-to-consumer advertising, on vs. off-label promotion, industry-sponsored scientific and educational activities, and promotional activities involving the internet. These agencies have very broad enforcement authority and failure to abide by these regulations can result in penalties including the issuance of a warning letter directing the entity to correct deviations from requisite standards, a requirement that future advertising and promotional materials be pre-cleared by the FDA or relevant foreign agencies. Foreign, state, and federal civil and criminal investigations, fines, and prosecutions are also possible if advertising and promotion regulations are breached.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Other Government Regulations</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to various laws and regulations regarding laboratory practices, the experimental use of animals, and the use and disposal of hazardous or potentially hazardous substances in connection with our research. In each of these areas, as above, the government has broad regulatory and enforcement powers, including the ability to levy fines and civil penalties, suspend or delay issuance of approvals, seize or recall products, and withdraw approvals, any one or more of which could have a material adverse effect upon us.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Market and Competition </span></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">According to estimates for 2025 from the American Cancer Society, more than 2.0 million Americans are expected to be diagnosed with cancer in the year, and approximately 618,000 Americans are expected to die of cancer.&#160;In the United States, the relative lifetime risk of a male or female developing cancer is 1 in 3 and 1 in 3, respectively</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. It was projected that there will be 217,507 new patients with HR+/HER2- mBC in 2024</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While pelareorep has not been approved yet by the FDA, market research performed in 2024 has determined that the addressable population for the pelareorep-based combination therapy in patients with advanced or metastatic HR+/HER2- breast cancer is estimated to be around 55,000 patients annually in the U.S. only. This indication could generate up to $2.4 billion in peak sales across U.S. and EU5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="border-bottom:1pt solid #000000;margin-bottom:5pt;margin-top:10pt;opacity:1;width:150pt"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> American Cancer Society's Cancer Facts &amp; Figures 2025</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> https://seer.cancer.gov/statfacts/html/breast-subtypes.html (accessed January 27, 2025)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Gampenrieder, Simon Peter et al. &#8220;Landscape of HER2-low metastatic breast cancer (MBC): results from the Austrian AGMT_MBC-Registry.&#8221;Breast cancer research : BCR vol. 23,1 112. 14 Dec. 2021, doi:10.1186/s13058-021-01492-x; Schettini, Francesco et al. &#8220;Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer.&#8221; NPJ breast cancer vol. 7,1 1. 4 Jan. 2021, doi:10.1038/s41523-020-00208-2 Mehta, Sandhya et al. &#8220;Prevalent of &#8216;HER2 ultra-low&#8217; among patients with advanced breast cancer with historical IHC0 status.&#8221; Journal of Clinical Oncology vol. 42, 16. 29 May 2024, doi.org/10.1200/JCO.2024.42.16_suppl.e1315; Tarantino, Paolo et al. &#8220;HER2-Low Breast Cancer: Pathological and Clinical Landscape.&#8221; Journal of clinical oncology : official journal of the American Society of Clinical Oncology vol. 38,17 (2020): 1951-1962. doi:10.1200/JCO.19.02488; DESTINY-BREAST04; DESTINY-BREAST06; GlobalData HER2 negative BC Global Drug Forecast &amp; Market Analysis to 2030; GlobalData Price Intelligence Database; Redbook; ICER</span></div><div style="height:33.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The costs of this disease state are also significant.&#160;In the United States, the American Cancer Society reported in its Cancer Facts &amp; Figures 2025 that The National Cancer Institute estimated that the 2020 cancer-related medical costs were $208.9 billion.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biotechnology industry emphasizes the importance of proprietary rights and is typically defined by fast-paced advancements in technologies with intense competition. We do business in an extremely competitive oncology market and face significant competition from many sources, including pharmaceutical, biopharmaceutical, and biotechnology companies as well as universities and private and public research institutions. Many of our competitors have significantly greater financial, manufacturing, marketing, and drug development resources than we do. Large biopharmaceutical companies in particular have extensive experience in clinical development and in obtaining regulatory approvals for drugs and biologicals. These companies also have significantly greater research capabilities than we do. Smaller or early-stage companies may also prove to be significant competitors, particularly those with collaborative arrangements with large and established companies or universities and research institutions. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our competitors fall primarily into the following groups of treatment: </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">traditional cancer therapies, including chemotherapy, surgery, radiation therapy, and targeted therapies;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approved immunotherapy antibodies and immunotherapy antibodies in clinical trials; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">other approved oncolytic virus-based immunotherapies and those in clinical trials;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">cancer vaccines including personalized vaccines and those targeting tumor neo-antigens; and </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">cell-based therapies, such as CAR-T, T cell receptor-based, and NK cell therapies. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business opportunity will be limited, or possibility eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer side effects, or are less expensive alone or in combination with other therapies than pelareorep especially if these get to market sooner than our product. Our competitors also compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient enrollment for clinical trials, as well as in acquiring technologies and technology licenses complementary to our programs or advantageous to our business. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pelareorep, if and when sold, will compete with a number of drugs that are currently marketed or in development that also target cancer but utilize different mechanisms of action. To compete effectively with these agents, pelareorep will need to show improved clinical efficacy and/or safety compared to competing products. We believe that pelareorep, if and when ultimately marketed, will likely be used in combination with other existing cancer treatments like checkpoint blockade therapies, surgery, chemotherapy, radiation therapy and other biological therapies. Consequently, we believe pelareorep, if and when marketed, would largely complement rather than compete directly with these existing treatment options. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do, however, expect to face direct and increasing competition from a number of companies that are also seeking to develop cancer therapies based on oncolytic viruses and other ways to prime the immune system. We believe that our ability to successfully compete will depend, among other things, on our ability to:</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">effectively advance the development of pelareorep;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">design, enroll patients in and successfully complete appropriate clinical trials in an efficient manner;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">gain regulatory approval for pelareorep;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establish collaborations and partnerships for the development of pelareorep;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">commercialize successfully, including demonstrating the safety and efficacy of pelareorep over currently approved therapies to physicians, insurers, and third-party payors;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">secure sufficient coverage from insurers and other payors;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">secure, maintain, and protect intellectual property rights based on our innovations; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manufacture and sell commercial quantities of pelareorep to the market.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Marketing Strategy</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The markets for the cancer product being developed by us may be large and could require substantial sales and marketing capability.&#160;Before or upon successful completion of the development of a cancer product, we intend to enter into one or more strategic partnerships or other collaborative arrangements with a pharmaceutical company or other company with marketing and distribution expertise to address this need.&#160;If necessary, we will establish arrangements with various partners for different geographical areas or specific applications at various times in the development process.&#160;Our management and consultants have relevant experience with the partnering process of oncology products.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Seasonality</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our results of operations have not been materially impacted by seasonality.</span></div><div style="height:33.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Raw Materials</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that sources of raw material pertinent for manufacturing our pelareorep product are generally available. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Corporate Social Responsibility and ESG </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a rapidly growing, clinical-stage biotech company, we are not yet in a position to implement a broad-based ESG policy and program. However, our corporate goals are inspired by our potential to impact the care of patients with cancer, especially those with late-stage breast and pancreatic cancers and are informed by our corporate values of acting with integrity, collaboration, innovation, and embracing diversity. In 2024, our corporate goals focused on certain clinical, manufacturing, and business operations and support our desire to obtain an approval for an innovative cancer treatment that extends patient lives. Each year we work hard to achieve our goals and objectives while maintaining a respectful, collaborative, and caring work environment. While we do not formally report on our ESG policies and compliance, we publicly disclose elements of our ESG activities. Our governance policies like our board mandates, code of ethics and conduct, and our public filings are all on our website at https://oncolyticsbiotech.com/investor-overview/corporate-governance/. Our website is not incorporated herein by reference.</span></div><div><span><br/></span></div><div id="i17734265916144358581fdce5df64f78_46"></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">C.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt">Organizational Structure</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;31, 2024, we had one material wholly-owned operating subsidiary; Oncolytics Biotech (Barbados) Inc. (&#8220;OBB&#8221;), a Barbados company.&#160;In addition, Oncolytics Biotech (U.S.) Inc., a Delaware corporation, is a material wholly-owned subsidiary of OBB.</span></div><div><span><br/></span></div><div id="i17734265916144358581fdce5df64f78_49"></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">D.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt">Property, Plant and Equipment</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently lease our head office in Calgary, Alberta, Canada as well as our office spaces in San Diego, California, U.S. and Barbados. We do not own or lease any other office space, manufacturing facilities or equipment and do not have any current plans to construct or acquire any facilities.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i17734265916144358581fdce5df64f78_52"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4A.&#160;&#160;UNRESOLVED STAFF COMMENTS</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i17734265916144358581fdce5df64f78_55"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 5. OPERATING AND FINANCIAL REVIEW AND PROSPECTS</span></div><div><span><br/></span></div><div id="i17734265916144358581fdce5df64f78_58"></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">A. - D. Operating Results, Liquidity and Capital Resources, Research and Development, Patents and Licenses, Trend Information </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please see our 2024 Management Discussion and Analysis in Exhibit 15.1, which is incorporated herein by reference.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">E.  Critical Accounting Estimates </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not Applicable.</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="height:33.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><div id="i17734265916144358581fdce5df64f78_61"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 6. DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i17734265916144358581fdce5df64f78_64"></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt">Directors and Senior Management</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the names and places of residence of all our directors and senior management as at February&#160;27, 2025, as well as the positions and offices held by such persons and their principal occupations. </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.666%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:54.455%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name and Place of Residence&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Position with the Company</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Principal Occupations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Director of the Company Since</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patricia Andrews</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New York, USA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ms. Andrews was the CEO of Sumitomo Pharma Oncology, Inc., a clinical-stage research and development biopharmaceutical company,  and an Executive Officer of Sumitomo Pharma Co., Ltd., a global healthcare corporation, from 2017 to 2023, as well as the Global Head of Oncology for Sumitomo Pharma Co., Ltd. from 2020 to 2023. Prior to joining this organization in 2013, she was Executive Vice President and Chief Commercial Officer at Incyte for four years, where she established the commercial organization and launched its first product, the first-in-class, first-in-disease, oncology product Jakafi&#174;. She was also responsible for business development and completed multiple significant product licensing deals for Incyte. Ms. Andrews held increasing leadership positions at Pfizer from 1991-2008, with her final role being Vice President and General Manager of the U.S. Oncology Business Unit. Ms. Andrews received her M.B.A. from the University of Michigan and her B.A. from Brown University. Ms. Andrews has been a Director on the board of GlycoMimetics (NASDAQ: GLYC) since 2017.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 5, 2024</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deborah M. Brown, MBA, ICD.D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)(2)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ontario, Canada</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ms. Brown has held senior leadership roles in both pharmaceutical companies and professional healthcare service firms, most recently at Eversana. She was an executive at EMD Serono from 2000 to 2014, holding the positions of Executive Vice President of Neuroimmunology for the company's U.S. operations, and President and Managing Director of the company's Canadian operations. In 2012, Ms. Brown served as Chair of the National Pharmaceutical Organization (now Innovative Medicines Canada) and served on its Board of Directors from 2007 to 2014. She currently sits on the Board of the HBSPCA. Ms. Brown holds an MBA from the Ivey School of Business, an Hons B.Sc, and has completed the Institute of Corporate Directors Designation (ICD.D) at the University of Toronto.</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2, 2017</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Christophe Degois<br/>California, USA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vice President, Business Development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior to joining Oncolytics, Mr. Degois was Vice President, Business Development at Dantari, a series A biotech developing novel antibody-drug conjugates for cancer. Mr. Degois started his career in the pharmaceutical industry at Eli Lilly and Co., both in Paris and in Indianapolis. He was Business Director at Schering Plough (now Merck) in Paris, where he was responsible for the launch of Remicade for rheumatoid arthritis.<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">He brings more than twenty years of experience in business development acquired at Genentech, PDL, Xoma, Geron, and Aimmune Therapeutics. He has closed multiple deals valued at over $3 billion, such as co-development, out-licensing, research collaborations, in-licensing, and global distribution agreements.<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mr. Degois holds an MBA with a Marketing Major from Ecole Sup&#233;rieure de Commerce-SKEMA, Nice, France.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allison Hagerman, P.Eng., PMP, MBT <br/>Alberta, Canada</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vice President, Product Development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A Professional Engineer focused on biotechnology, Ms. Hagerman joined Oncolytics in 2010. Prior to being appointed as Vice President of Product Development, Ms. Hagerman was the Director, Manufacturing and Engineering from 2013-2017 and Project Manager from 2010-2013. Ms. Hagerman is a Professional Engineer (P.Eng., APEGA) and Project Management Professional (PMP, PMI). She holds a Master of Biomedical Technology (MBT) degree from the University of Calgary, and B.Sc. degrees in both Chemical Engineering and Biological Sciences.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr></table></div><div style="height:33.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.666%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:54.455%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name and Place of Residence&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Position with the Company</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Principal Occupations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Director of the Company Since</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thomas C. Heineman, MD, PhD<br/>California, USA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Medical Officer</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior to joining Oncolytics, Dr. Heineman most recently served as Senior Vice President and Head of Clinical Development at Denovo Biopharma. Prior to his time at Denovo, Dr. Heineman served as Vice President and Head of Clinical Development at Genocea Biosciences and Halozyme Therapeutics, where he was also the Head of Translational Medicine, and oversaw clinical trials in indications such as breast and pancreatic cancer. Dr. Heineman&#8217;s experience further extends to big pharma and academia where he previously held roles as Senior Director, Global Clinical Research and Development at GlaxoSmithKline and Associate Professor at the Saint Louis University School of Medicine. Dr. Heineman has co-authored over 60 peer-reviewed publications and is board certified in Internal Medicine and Infectious Diseases. He completed his fellowship in Infectious Diseases at the National Institutes of Health and his internship and residency at the University of Maryland. Dr. Heineman earned his MD at the University of Chicago, where he also received a PhD in molecular genetics.</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Angela Holtham, MBA, FCPA, ICD.D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)(2)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ontario, Canada</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ms. Holtham held a number of financial positions over a 19-year career with the Canadian subsidiary of Nabisco Inc., rising to become Senior Vice President and Chief Financial Officer. In 2002, she joined Toronto, Ontario-based Hospital for Sick Children as Vice President, Finance and Chief Financial Officer, a position she held for eight years. Through her career she has participated in myriad initiatives ranging from traditional finance functions and operations oversight to intellectual property portfolio management and mergers and acquisitions. In more recent years she has held numerous governance roles on various Boards in both the publicly traded and not-for-profit sectors and held short term contract positions. Ms. Holtham is an FCPA, FCMA, holds an MBA from the University of Toronto - Rotman School of Management and has completed the Institute of Corporate Directors Designation (ICD.D).</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 18, 2014</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amy G. Levin, RN, BSN<br/>California, USA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vice President, Clinical Operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ms. Levin brings over two decades of clinical research and development operations experience investigating a broad range of oncology drug candidates. Prior to joining Oncolytics in 2020, Ms. Levin was the Senior Director of Clinical Operations at Puma Biotechnology, where she established the clinical operations team and was responsible for multiple global clinical programs leading to the approval of neratinib (Nerlynx</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">). She also held increasing leadership positions in her role as Director, Clinical Program Leader at Cougar Biotechnology (Janssen, Pharmaceutical Companies of J&amp;J), working on their lead drug candidate abiraterone acetate (ZYTIGA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">). Earlier in her career, Ms. Levin held several different clinical research and sales roles at Merck Vaccines and Amgen. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ms. Levin earned a Bachelor of Science degree in Nursing (BSN) from the University of Texas at Austin.</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kirk Look, CPA, CA, MSJ<br/>Alberta, Canada</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mr. Look joined Oncolytics as the Company's Controller in April 2003, and assumed the role of Chief Financial Officer in November 2012. Prior to joining Oncolytics, from 2000 to April 2003, Mr. Look was Manager of Audit and Assurance Services with Ernst &amp; Young LLP in Canada. From 1998 to the end of 1999, Mr. Look held the positions of Audit Manager and Senior Accountant at Ernst &amp; Young LLP in Chile. Mr. Look is a Chartered Professional Accountant, and holds a Master of Science in Jurisprudence (MSJ) from the Seton Hall University School of Law and a Bachelor of Commerce from the University of Calgary.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr></table></div><div style="height:33.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.666%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:54.455%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name and Place of Residence&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Position with the Company</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Principal Occupations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Director of the Company Since</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">James T. Parsons, MAcc, CPA, CA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)(3)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ontario, Canada</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mr. Parsons is the Chief Financial Officer (CFO) of Sernova Biotherapeutics., a TSX-listed clinical stage regenerative medicine company, since October 2024. He previously served as the CFO of Trillium Therapeutics Inc. (TSX: TRIL) (NASDAQ: TRIL) from August 2011 through its acquisition by Pfizer in November 2021 for an aggregate purchase price of approximately U.S.$2.2 billion. Prior to his time at Trillium, Mr. Parsons served as Vice President, Finance, at DiaMedica Therapeutics Inc, CFO of ProMIS Neurosciences (formerly Amorfix Life Sciences Ltd.), and CFO and Vice President, Finance and Administration, at Aptose Biosciences Inc. (formerly Lorus Therapeutics). Mr. Parsons is the Chair of the Board and Chair of the Audit Committee of DiaMedica Therapeutics Inc. (NASDAQ: DMAC).</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 16, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wayne Pisano, MBA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">                                                            Pennsylvania, USA</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interim Chief Executive Officer and Chair of the Board</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mr. Pisano was appointed as Interim Chief Executive Officer in June 2024. Mr. Pisano has served as a Director/Chairman of several publicly traded companies in the US and Canada and has more than 30 years of experience as a pharmaceutical industry executive. He served as the president and CEO of VaxInnate, a privately held biotech company from January 2012 to November 2016. Mr. Pisano is the former president and CEO of Sanofi Pasteur, one of the largest vaccine companies in the world. He joined Sanofi Pasteur in 1997, assuming increasing levels of responsibility. He was promoted to President and CEO in 2007, the position he successfully held until his retirement in 2011. Prior to joining Sanofi Pasteur, he spent 11 years with Novartis (formerly Sandoz). He has a bachelor's degree in biology from St. John Fisher College, New York and an MBA from the University of Dayton, Ohio.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 9, 2013</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jonathan Rigby, MBA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Louisiana, USA</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mr. Rigby is currently an advisor to Guidepoint and CEO of Sernova Biotherapeutics. Previously he was the Group Chief Executive Officer (CEO) of Revolo Biotherapeutics, where he led a team focused on the development of therapies for autoimmune and allergic diseases. Previously, he was the CEO of SteadyMed Ltd., which he led through a NASDAQ listing and sale to United Therapeutics Corporation. Prior to his time at SteadyMed, Mr. Rigby co-founded Zogenix, Inc., a CNS-focused specialty pharmaceutical company that was acquired by UCB in a transaction valued at up to approximately U.S. $1.9 billion. Before co-founding Zogenix, Mr. Rigby held roles of increasing responsibility in commercial and business development functions at large pharmaceutical companies such as Merck, Bristol Myers Squibb, and Profile Therapeutics (now Phillips Medical). In addition to his Oncolytics appointment, Mr. Rigby is also a member of the ImmunoMolecular Therapeutics Board of Directors and was the Chairman of BioPlus Acquisition Corp., a Nasdaq-listed biotech acquisition company. He holds a B.S. with Honors in Biological Sciences from Sheffield University, UK, and an M.B.A. from Portsmouth University, UK.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bernd R. Seizinger, MD, PhD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)(4)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New Jersey, USA and Munich, Germany</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dr. Seizinger has been board member/chairman in multiple public and private biotech companies in the US and Europe. From 1998 to 2009, he served as President and Chief Executive Officer of GPC Biotech. He also served as Vice President of Oncology Drug Discovery and, in parallel, Vice President of Corporate and Academic Alliances at Bristol-Myers Squibb. Prior to his appointments in the biotechnology and pharmaceuticals sectors, Dr. Seizinger held professorships and senior staff appointments at Harvard Medical School, Princeton University, and Massachusetts General Hospital. He also currently sits on multiple biotech boards, including three additional public boards: Aptose Biosciences, Aprea Therapeutics, and BioInvent.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 8, 2015</span></td></tr></table></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes:</span></div><div style="padding-left:40.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.84pt">Member of the Audit Committee.&#160;Ms. Holtham is Chair of this Committee.</span></div><div style="padding-left:40.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.84pt">Member of the Compensation Committee.&#160;Ms. Brown is Chair of this Committee. </span></div><div style="padding-left:40.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.84pt">Member of the Governance Committee.&#160;Mr. Rigby is Chair of this Committee. </span></div><div style="padding-left:40.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.84pt">Member of the Science &amp; Development Committee. Dr. Seizinger is Chair of this Committee.</span></div><div style="height:33.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="padding-left:40.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.84pt">Mr. Pisano, as Chair of the Board, served as an ex-officio member of the Compensation, Audit, Governance, and Science &amp; Development Committees prior to his appointment as Interim Chief Executive Officer ("Interim CEO") in June 2024. </span></div><div style="padding-left:40.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10.84pt">During the second quarter of 2024, Dr. Matt Coffey, PhD, the former President and Chief Executive Officer of Oncolytics commenced a medical leave of absence. Mr. Pisano, Chair of Oncolytics&#8217; Board of Directors, was appointed as Interim CEO during Dr. Coffey&#8217;s absence. In February 2025, Dr. Coffey resigned as President, Chief Executive Officer, and director of Oncolytics due to ongoing health concerns. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our directors are associated with other companies, which may give rise to conflicts of interest.&#160;In accordance with the Alberta Business Corporations Act</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ABCA), directors who have a material interest in any person who is a party to a material contract or a proposed material contract with us are required, subject to certain exceptions, to disclose that interest and abstain from voting on any resolution to approve that contract.&#160;In addition, the directors are required to act honestly and in good faith with a view to the best interests of Oncolytics Biotech Inc.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None of our directors or officers are related by blood, marriage, or adoption to any other director or officer.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not aware of any arrangement or understanding with major shareholders, suppliers or others, pursuant to which any person referred to above was selected as a director or senior management.</span></div><div id="i17734265916144358581fdce5df64f78_67"></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.84pt">Compensation </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Board of Directors</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, only the Company's independent directors receive compensation for their service on our board of directors. During the second quarter of 2024, Mr. Pisano, Chair of Oncolytics&#8217; Board of Directors, was appointed Interim CEO during Dr. Coffey&#8217;s leave of absence. Because of the uncertainty regarding Dr. Coffey's potential return to full-time duty as CEO, Mr. Pisano continued to receive compensation in 2024 for his service as Chair of our board of directors notwithstanding his appointment as Interim CEO. The following table sets forth information concerning the total compensation paid in 2024 to each member serving as director as at December&#160;31, 2024.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:17.759%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fees Earned</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">($)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Share-</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">based awards</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">($)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Option-</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">based awards</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">($)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-equity incentive plan compensation<br/>($)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pension value<br/>($)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">All other compensation<br/>($)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total<br/>($)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patricia Andrews</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,945</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,417</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,362</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deborah M. Brown</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,212</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Nil </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,578</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Nil </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Nil </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,790</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Angela Holtham</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,967</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Nil </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,578</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Nil </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Nil </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,545</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">James T. Parsons</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,140</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Nil </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,578</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,718</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wayne Pisano</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,112</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Nil </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,472</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,584</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jonathan Rigby</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,945</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Nil </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,578</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,523</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bernd R. Seizinger</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,773</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Nil </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,578</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,351</span></td></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes:</span></div><div style="padding-left:36pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.84pt">Directors are paid fees in U.S. Dollars.&#160;These amounts are presented in Canadian dollars and have been converted at a U.S./CDN exchange rate of $1.4389.</span></div><div style="padding-left:36pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.84pt">The value of share-based and option-based awards are based on the grant date assumptions as disclosed in note 11 "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share-Based Compensation" </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in our 2024 audited consolidated financial statements.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-4.5pt"><span><br/></span></div><div style="height:33.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each independent director receives a base retainer of US$40,000. In addition to the base retainer, directors are eligible to receive the following additional fees depending on committee involvement:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional Retainers (USD):</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.455%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.345%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Board chair</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$40,000</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Audit Committee chair</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$20,000</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Governance Committee chair</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$10,000</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation Committee chair</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$12,000</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Science &amp; Development Committee chair</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$15,000</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-chair member of the Audit Committee</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$10,000</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-chair member of the Governance or Science &amp; Development Committee</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$5,000</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-chair member of the Compensation Committee</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$6,000</span></td></tr></table></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the combined retainer, the Company will grant 30,000 options annually for directors other than the Chair. The Chair will receive 37,500 options annually. All such options vest in their entirety one year following the grant date. New directors will be entitled to receive an initial grant of 45,000 options, which vest immediately. The Company does not provide pension plan benefits to its directors.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commencing effective January 1, 2025, until such time as Mr. Pisano ceases to serve as Interim CEO, Mr. Pisano will no longer receive compensation for serving as Chair, rather, all compensation received by Mr. Pisano will be for serving in the role of Interim CEO.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also reimburse the directors for any reasonable expenses incurred by them while acting in their directors' capacity.&#160;During the year ended December 31, 2024, total compensation of $743,873 was paid to the independent directors which consisted of fee payments of $610,094 and option-based awards of $133,779. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth for each director, other than Dr. Coffey, all option-based awards outstanding as at December&#160;31, 2024: </span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.970%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.544%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">securities</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">underlying</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">unexercised</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">options </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(#)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Option exercise<br/>price<br/>($)</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Option expiration date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patricia Andrews</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,000</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.76</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/5/2029</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deborah M. Brown</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,263</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.42</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/7/2027</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.40</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/8/2026</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,000</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.14</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/16/2026</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.76</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/15/2028</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,000</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.13</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/18/2029</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Angela Holtham</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.40</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/8/2026</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,000</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.14</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/16/2026</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.76</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/15/2028</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,000</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.13</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/18/2029</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">James T. Parsons</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.14</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/16/2026</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,000</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.76</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/15/2028</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.13</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/18/2029</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wayne Pisano</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,500</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.40</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/8/2026</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,500</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.14</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/16/2026</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,500</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.76</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/15/2028</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,500</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.13</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/18/2029</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jonathan Rigby</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,000</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.84</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/30/2026</span></td></tr></table></div><div style="height:33.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.970%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.544%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">securities</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">underlying</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">unexercised</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">options </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(#)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Option exercise<br/>price<br/>($)</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Option expiration date</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.76</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/15/2028</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,000</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.13</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/18/2029</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bernd R. Seizinger</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,263</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.60</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/8/2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,000</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.40</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/8/2026</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.14</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/16/2026</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,000</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.76</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/15/2028</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.13</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/18/2029</span></td></tr></table></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">As at December 31, 2024, all options granted to our directors had fully vested except for the options granted on December 18, 2024 (expiring December 18, 2029).</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than Mr. Pisano, who in his capacity as Interim CEO was granted share awards (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Named Executive Officers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section below), none of our directors held share awards as at December&#160;31, 2024. </span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Named Executive Officers</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables and discussion relate to compensation paid or earned by our Chief Executive Officer (CEO), Interim CEO, Chief Financial Officer (CFO), and our three most highly compensated officers (other than CEO, Interim CEO, and CFO) who were serving as officers as at December&#160;31, 2024 (collectively the "Named Executive Officers").</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth information concerning the total compensation paid to our Named Executive Officers in 2024. </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:23.315%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.379%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.746%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Name and principal position</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Salary<br/>($)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Share-<br/>based awards<br/>($)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Option-<br/>based </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">awards </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;&#160;&#160;($)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Bonus</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">($)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-equity incentive<br/>plan compensation<br/>($)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pension value<br/>($)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">All other compensation<br/>  ($)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total<br/>compensation <br/>($)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dr. Matthew Coffey</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">President and Chief Executive Officer</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">709,950</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">156,887</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">106,500</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90,881</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,064,218</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Wayne Pisano</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)(4)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interim Chief Executive Officer</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">102,200</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">92,806</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">195,006</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Kirk Look<br/>Chief Financial Officer</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">597,479</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">210,496</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">126,491</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77,636</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,012,102</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dr. Thomas C. Heineman</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(5)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Chief Medical Officer</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">749,706</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">240,701</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">126,491</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54,675</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,171,573</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Allison Hagerman<br/>Vice President, Product Development</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">422,622</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">107,531</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,256</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66,426</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">635,835</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amy G. Levin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(5)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vice President, Clinical Operations</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">474,261</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83,823</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,532</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66,090</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">654,706</span></td></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes:</span></div><div style="padding-left:40.5pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">The value of share- and option-based awards are based on the grant date assumptions as disclosed in note 11 "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share-Based Compensation" </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in our 2024 audited consolidated financial statements.</span></div><div style="padding-left:40.5pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">The dollar amounts set forth under this column are related to contributions to the senior management's respective retirement savings plan and amounts provided for health care benefits by the Company. </span></div><div style="padding-left:40.5pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">None of the compensation paid to Dr. Coffey and Mr. Pisano related to their roles as directors of the Company.</span></div><div style="padding-left:40.5pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">During the second quarter of 2024, Dr. Coffey commenced a medical leave of absence. Wayne Pisano, Chair of Oncolytics&#8217; Board of Directors, was appointed Interim CEO during Dr. Coffey&#8217;s absence. </span></div><div style="padding-left:40.5pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">U.S. Employees are paid salaries, bonuses, and other compensation in U.S. Dollars.&#160;These amounts are presented in Canadian dollars and have been converted at a U.S./CDN exchange rate of $1.4389.  </span></div><div style="padding-left:40.5pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">In 2024, Restricted Share Awards were issued to our Named Executive Officers in lieu of cash under our short-term incentive program. </span></div><div style="padding-left:4.5pt;text-align:justify;text-indent:-9pt"><span><br/></span></div><div style="height:33.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into employment agreements with our Named Executive Officers (each an "Employment Agreement") other than Mr. Pisano. Dr. Coffey's employment agreement with Oncolytics terminated upon his resignation as President and Chief Executive Officer in February 2025. The Chief Financial Officer and Chief Medical Officer are eligible for a cash bonus of up to 40% of their respective base salary, the Vice President, Product Development is eligible for a cash bonus of up to 35% of her base salary, and the Vice President, Clinical Operations is eligible for a cash bonus of up to 25% of her base salary. In addition, when available, the officers are eligible for a combination of Option and Share Award grants. The amount of each grant is determined and approved by the Board with the actual bonus provided and the number of Options and Share Awards granted based upon the overall performance of the Company as assessed by the Compensation Committee and approved by the Board. The overall performance of the Company is determined by the annual goals and objectives approved by the Board and includes specific objectives with respect to the clinical, manufacturing, and intellectual property plans in combination with financial goals. Previous grants are taken into account when considering new grants of Options and Share Awards. As well, the Employment Agreements provide that each member of the Company's senior management is subject to certain confidentiality and non-competition restrictions during and following the course of their respective employment with the Company. Each Employment Agreement shall continue until terminated by either party in accordance with the notice provisions thereof.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not provide pension plan benefits to its Named Executive Officers and employees. The Company does not currently have a stock appreciation rights plan.&#160;</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth for each Named Executive Officer all option-based and share-based awards outstanding as at December&#160;31, 2024:</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:22.653%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.149%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.149%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.149%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.149%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.151%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">securities</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">underlying</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">unexercised</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">options </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(#)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Option exercise<br/>price<br/>($)</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Option expiration date</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of shares or units of shares that have not vested <br/>(#)</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Market or payout value of share-based awards that have not vested</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">($)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dr. Matthew Coffey</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,263</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.99</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/1/2025</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255,171</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339,377</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,105</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.66</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/16/2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">420,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.40</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/8/2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,000</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.08</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/10/2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.31</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/9/2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">301,000</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.76</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/15/2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.91</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/8/2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205,100</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.13</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/18/2029</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wayne Pisano</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,004</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,125</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kirk Look</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,842</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.99</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/1/2025</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246,480</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">327,818</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,578</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.66</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/16/2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155,000</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.40</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/8/2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.08</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/10/2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,000</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.31</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/9/2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.76</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/15/2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231,700</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.91</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/8/2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243,600</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.13</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/18/2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dr. Thomas C. Heineman</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,000</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.84</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/1/2025</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270,344</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">359,558</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.40</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/8/2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,000</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.08</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/10/2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.31</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/9/2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,900</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.76</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/15/2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231,700</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.91</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/8/2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243,600</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.13</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/18/2029</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allison Hagerman</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,263</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.90</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/9/2025</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,094</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149,085</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,894</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.66</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/28/2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.40</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/8/2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,000</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.08</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/10/2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="height:33.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:22.653%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.149%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.149%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.149%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.149%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.151%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">securities</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">underlying</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">unexercised</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">options </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(#)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Option exercise<br/>price<br/>($)</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Option expiration date</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of shares or units of shares that have not vested <br/>(#)</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Market or payout value of share-based awards that have not vested</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">($)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.31</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/9/2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,700</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.76</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/15/2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,800</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.91</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/8/2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,600</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.13</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/18/2029</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amy G. Levin</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.27</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9/1/2025</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,247</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,369</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,000</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.08</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/10/2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.31</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/9/2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,700</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.76</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/15/2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,700</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.91</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/8/2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,800</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.13</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/18/2029</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">As at December 31, 2024, all options granted to our Named Executive Officers had fully vested except for the options granted on August 15, 2023 (expiring August 15, 2028), December 8, 2023 (expiring December 8, 2028), and December 18, 2024 (expiring December 18, 2029). </span></div><div style="padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">These amounts are calculated based on the closing price of the Common Shares on the TSX on December 29, 2024 ($1.33). </span></div><div style="padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">During the second quarter of 2024, Dr. Coffey commenced a medical leave of absence. Dr. Coffey resigned as President, Chief Executive Officer, and director of Oncolytics in February 2025. </span></div><div style="padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">During the second quarter of 2024, Dr. Coffey commenced a medical leave of absence. Mr. Pisano, Chair of Oncolytics&#8217; Board of Directors, was appointed Interim CEO during Dr. Coffey&#8217;s absence.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Termination of Employment or Change of Control </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects amounts payable to each member of the Company's Named Executive Officers, other than Dr. Coffey whose employment agreement with Oncolytics terminated upon his resignation as President and Chief Executive Officer in February 2025, based on their respective Employment Agreements assuming that their employment was terminated on December 31, 2024, without cause or due to a change of control of the Company.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.011%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.345%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name and principal position</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Termination without Cause Severance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)(2)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">($)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change of Control Severance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">($)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wayne Pisano</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)(5)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interim Chief Executive Officer</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kirk Look<br/>Chief Financial Officer</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">716,432</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,432,864</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dr. Thomas C. Heineman</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Medical Officer</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">550,971</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">550,971</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allison Hagerman<br/>Vice President, Product Development</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">489,978</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">489,978</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amy G. Levin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vice President, Clinical Operations</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">329,600</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">329,600</span></td></tr></table></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes:</span></div><div style="padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Named Executive Officers are entitled to exercise all or any part of their vested Options, within the period ending on the earlier of the date of expiration of the Option and the 90th day after the date such member is terminated unless otherwise approved by the Board of Directors.</span></div><div style="padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Upon termination, unless otherwise approved by the Board of Directors, Named Executive Officers are entitled to receive the number of shares equal to the number of RSAs granted multiplied by a fraction (A) the numerator of which is the number of days from the grant date in respect of the applicable share award to the termination date; and (B) the denominator of which is the total number of days comprising the vesting period in respect of such share award. The shares will be issued at the earlier of the 31st day following the completion of the vesting period and the 90th day after the date such member is terminated.  </span></div><div style="height:33.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">On a change of control of the Company, Named Executive Officers shall be entitled to exercise all or a part of their Options, whether vested or not, within the period ending on the earlier of the date of expiration of the Option and the 90th day after the date such member is terminated. On a change of control of the Company, Named Executive Officers shall be entitled to all shares equal to the number of RSAs granted, whether vested or not. All applicable shares shall be issued effective immediately prior to the completion of the change of control transaction. </span></div><div style="padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">During the second quarter of 2024, Dr. Coffey commenced a medical leave of absence. Wayne Pisano, Chair of Oncolytics&#8217; Board of Directors, was appointed Interim CEO during Dr. Coffey&#8217;s absence. </span></div><div style="padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">U.S. Employees are paid in U.S. Dollars and are presented in U.S. dollars.</span></div><div id="i17734265916144358581fdce5df64f78_70"></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">C.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt">Board Practices</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Board of Directors are elected by the shareholders at each Annual General Meeting (or Annual Special Meeting) and typically hold office until the next meeting, at which time they may be re-elected or replaced.&#160;Casual vacancies on the board are filled by the remaining directors and the persons filling those vacancies hold office until the next Annual General Meeting (or Annual Special Meeting), at which time they may be re-elected or replaced.&#160;The chief executive officer, chief financial officer, and chief medical officer are appointed by the Board of Directors and hold office indefinitely at the pleasure of the Board of Directors.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Directors&#8217; Contracts</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We receive a director&#8217;s consent from each of the independent directors upon their acceptance of their director&#8217;s position.&#160;We also enter into an Indemnity Agreement and Directors Confidentiality and Intellectual Property Assignment Agreement with each director.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not have any contracts with any of its directors which provide for benefits upon the termination of employment.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compensation Committee</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has formed a compensation committee (the &#8220;Compensation Committee&#8221;) in accordance with Rule 5605(d)(1) of the Nasdaq Capital Market which consists of three outside, independent directors, Dr. Seizinger, Ms. Holtham, and Ms. Brown, each of whom is independent in accordance with Rule 5605(a)(2) and Rule 5605(d)(2)(A) of the Nasdaq Capital Market. Ms. Brown is the Chair of the Compensation Committee. No member of the Compensation Committee has been an employee or officer of the Company or any of its affiliates. Mr. Pisano was formerly a member of the Compensation Committee but no longer serves due to his appointment as Interim CEO in June 2024.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The compensation committee's primary purpose is to assist our Board of Directors in carrying out its responsibility for the Company's human resources and compensation policies and processes. The Compensation Committee's written mandate is located on the Company&#8217;s website at https://oncolyticsbiotech.com/investor-overview/corporate-governance/. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Audit Committee</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has formed an Audit Committee in accordance with Section 3(a)(58)(A) of the United States Securities Exchange Act of 1934, as amended ("Exchange Act"), consisting of three independent directors pursuant to the Rule 5605(a)(2) and Rule 5605(c)(2) of the Nasdaq Capital Market and Rule 10A-3 of the Exchange Act: Ms. Brown, Ms. Holtham, and Mr. Parsons, none of whom are nor have been employees or officers of the Company or any of its affiliates.&#160;&#160;Ms. Holtham is presently the Chair of the Audit Committee.&#160;Each Audit Committee member is financially literate. Mr. Pisano was formerly a member of the Audit Committee but no longer serves due to his appointment as Interim CEO in June 2024.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audit committee reviews and approves the scope of the annual audits of our financial statements, reviews our internal control over financial reporting, reviews and approves services performed by the independent auditors, reviews the findings and recommendations of the independent auditors, and periodically reviews major accounting policies.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Audit Committee's written mandate is located on the Company&#8217;s website at https://oncolyticsbiotech.com/investor-overview/corporate-governance/.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:33.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><div id="i17734265916144358581fdce5df64f78_73"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">D.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:12.78pt">Employees</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets out the number of our employees at the end of each of the last three fiscal years by activity and geographic location:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.514%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.696%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">By Function:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.514%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.696%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">By Geographic Location:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States of America</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 37pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29</span></td></tr></table></div><div id="i17734265916144358581fdce5df64f78_76"></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">E.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.84pt">Share Ownership</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Item 6.B. and Item 7.A.</span></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Compensation Plan Information</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have two share-based compensation plans: the Stock Option Plan and the Share Award Plan.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Option Plan</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the Company&#8217;s Amended and Restated Stock Option Plan (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Option Plan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) dated effective as of May 9, 2023.  </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company, with the approval of its Shareholders, has established the Stock Option Plan. The number of Common Shares reserved for issuance under the Stock Option Plan and all other security based compensation arrangements of the Company (including the Share Award Plan) in aggregate shall not exceed 14% of the total number of issued and outstanding Common Shares from time to time. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Stock Option Plan, the Board of Directors or the Compensation Committee may from time to time designate directors, officers, employees of, or consultants to, the Company or any subsidiary of the Company (such persons being &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Eligible Persons</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) to whom Options may be granted and the number of Options to be granted to each. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options may be exercised at a price (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exercise Price</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) which shall be fixed by the Board at the time the Option is granted. No Option can be granted with an Exercise Price at a discount to the market, which shall be the closing price of the Common Shares on the stock exchange upon which the Common Shares are listed on the first day preceding the date of grant on which at least one board lot of Common Shares traded on such exchange.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any Option shall be exercised or shall expire or terminate for any reason without having been exercised in full, any Common Shares to which such Option relates shall be available for the purposes of the granting of Options under the Stock Option Plan.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of Shares that may be acquired under an Option granted to a participant under the Stock Option Plan shall be determined by the Board as at the time the Option is granted, provided that the aggregate number of Shares reserved for issuance to any one participant under the Stock Option Plan or any other security based compensation arrangement of the Company, shall not exceed five percent (5%) of the total number of issued and outstanding Common Shares (calculated on a non-diluted basis).</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Without obtaining the approval of Shareholders in accordance with the rules of the TSX or the requirements of any other stock exchange on which the Common Shares are then listed, no Options shall be granted pursuant to the Stock Option Plan, if such grant together with grants pursuant to all other share compensation arrangements of the Company, could result, at any time, in:</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;a number of Common Shares issuable pursuant to Options granted to insiders exceeding ten percent (10%) of the number of outstanding Common Shares at any time;</span></div><div style="height:33.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;the issuance within a one year period to insiders, of a number of Common Shares exceeding ten percent (10%) of the number of outstanding Common Shares; or</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;the issuance to any one insider and such insider&#8217;s associates, within a one year period, of a number of Common Shares exceeding five percent (5%) of the number of outstanding Common Shares.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The value of Option grants to each non-employee director shall not exceed $150,000 annually for any individual non-employee director (other than initial Option grants to new directors).</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expiration of options is to be no greater than ten years from the date of grant and typically either vest immediately or as to one-third on each of the first, second and third anniversary following the date of grant, as determined by the Board at the time the Option is granted. Options are not transferable or assignable except to the person or persons to whom the participant&#8217;s rights pass by the participant&#8217;s will or applicable law following the death or permanent disability of a participant. The Stock Option Plan provides that if the expiration date of an Option occurs during a "blackout period" or within five (5) business days after a blackout period, such expiration date shall be deemed to be extended to the date which is the tenth (10</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) business day after the last day of the applicable blackout period.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to any written agreement between the Company and a participant providing otherwise, if any participant shall cease to be an Eligible Person for any reason other than the termination for cause or the death or permanent disability of the participant, such participant&#8217;s Option will terminate immediately as to the then unvested portion thereof and at 5:00 p.m. (Calgary time) on the earlier of the date of the expiration of the applicable option period and the ninetieth (90</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) day after the date such participant ceases to be an Eligible Person as to the then vested portion of the Option. If a participant ceases to be an Eligible Person as a result of the termination of such participant for cause, effective as of the date notice is given to the participant of such termination, all outstanding Options shall be terminated and all rights to receive Common Shares thereunder shall be forfeited by such participant, and the participant shall not be entitled to receive any Common Shares or other compensation in lieu thereof.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to any written agreement between the Company and a participant providing otherwise, if in the event of the death or permanent disability of a participant, any Option previously granted to such participant shall be exercisable until the end of the applicable option period or until the expiration of 12 months after the date of death or permanent disability of such participant, whichever is earlier, and then only: (i) by the person or persons to whom the participant&#8217;s rights under the Option shall pass by the participant&#8217;s will or applicable law; (ii) to the extent that he or she was entitled to exercise the Option as at the date of the participant&#8217;s death or permanent disability.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding the foregoing, the Board may, at its sole discretion, extend the period during which any Options may be exercised, in the case of Options held by non-employee directors, by not more than one year, and in the case of Options held by other persons, by not more than three years, but in no case longer than the normal expiry of the Options.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event of a change of control of the Company (as such term is defined in the Stock Option Plan), all Options which have not otherwise vested in accordance with their terms shall immediately vest and be exercisable, notwithstanding the other terms of the Options or the Stock Option Plan for a period of time ending on the earlier of the expiry time of the Option and the ninetieth (90</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) day following the change of control.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to any required approval of the TSX and any other stock exchange on which the Common Shares are then listed, the Stock Option Plan and any Options granted thereunder may be amended, modified or terminated by the Board without approval of any participant or Shareholder (provided that no such amendment may be made that will materially prejudice the rights of any participant under any Option previously granted to the participant without consent by such participant). Such changes may include, without limitation: </span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;amending, modifying or terminating the Stock Option Plan with respect to all Common Shares in respect of Options which have not yet been granted thereunder; </span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;making any amendment of a &#8220;housekeeping nature&#8221;; </span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;changing the provisions relating to the manner of exercise of Options; </span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iv)&#160;&#160;&#160;&#160;accelerating vesting or extending the expiration date of any Option (provided that such Option is not held by an insider), provided that the period during which an Option is exercisable does not exceed 10 years from the date the Option is granted;</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(v)&#160;&#160;&#160;&#160;adding a cashless exercise feature, payable in cash or securities, whether or not providing for a full deduction of the number of underlying Common Shares from the Stock Option Plan reserve; and</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(vi)&#160;&#160;&#160;&#160;making any addition to, deletion from or alteration of the provisions of the Stock Option Plan or any Option that are necessary to comply with applicable law, the rules of the TSX, or the requirements of any other exchange on which the Shares are then listed and to avoid unanticipated consequences deemed by the Board to be inconsistent with the purpose of the Stock Option Plan.</span></div><div style="height:33.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding the foregoing, Shareholder approval is required for any change to the Stock Option Plan or Options granted under it which:</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;increases the number of Common Shares reserved for issuance under the Stock Option Plan;</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;extends eligibility to participate in the Stock Option Plan to persons other than Eligible Persons;</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;permits Options to be transferred, other than for normal estate settlement purposes or to an RRSP or similar plan;</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iv)&#160;&#160;&#160;&#160;permits awards other than Options to be made under the Stock Option Plan;</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(v)&#160;&#160;&#160;&#160;extends the term of an Option beyond the maximum expiry date set out in the Stock Option Plan (except where an expiry date would have fallen within a blackout period;</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(vi)&#160;&#160;&#160;&#160;reduces the exercise price of an Option, except for the purpose of maintaining Option value in connection with a conversion, change, reclassification, redivision, redesignation, subdivision or consolidation of shares or a reorganization, amalgamation, consolidation, merger, takeover bid or similar transaction involving the Company (for this purpose, cancellation or termination of an Option prior to its expiry date for the purpose of reissuing Options to the same Option-holder with a lower exercise price will be considered an amendment to reduce the exercise price of an Option);</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(vi)&#160;&#160;&#160;&#160;changes the insider participation limitation at any time under the Stock Option Plan; or</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(vii)&#160;&#160;&#160;&#160;amends the amending provision of the Stock Option Plan. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Share Award Plan</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the Company&#8217;s Amended and Restated Incentive Share Award Plan (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Share Award Plan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) dated effective as of May 9, 2023.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company, with the approval of its Shareholders, has established the Share Award Plan. Under the Share Award Plan, the Board may, at such times and in such amounts as the Board may deem advisable in its sole and absolute discretion, issue Performance Share Awards (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PSAs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) to eligible employees, including officers, and Restricted Share Awards (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RSAs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; and, together with PSAs, &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Share Awards</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) to Eligible Persons. The number of Common Shares reserved for issuance under the Share Award Plan and all other security based compensation arrangements of the Company (including the Stock Option Plan) in aggregate shall not exceed 14% of the total number of issued and outstanding Common Shares from time to time.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to earlier vesting in accordance with the terms of the Share Award Plan and unless otherwise determined by the Board, Share Awards granted under the Share Award Plan vest on the third anniversary date of the date of grant. Upon vesting, each RSA is deemed to be redeemed for no further consideration for one&#160;Common Share (subject to adjustment for dividend equivalents) and each PSA is deemed to be redeemed for no further consideration for one&#160;Common Share (subject to adjustment for dividend equivalents) multiplied by the percentage (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Vesting Percentage</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) of outstanding PSAs that will vest based upon the relative achievement of any performance-related measures or criteria as determined by the Board in its sole discretion, which may include the Company&#8217;s performance compared to identified operational or financial targets and the Company&#8217;s shareholder return.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate number of Common Shares issuable at any time to insiders, under all security based compensation arrangements of the Company shall not exceed 10% of the issued and outstanding Common Shares (calculated on a non-diluted basis). The aggregate number of Common Shares issued pursuant to all security based compensation arrangements of the Company, within a one year period, shall not exceed 10% of the issued and outstanding Common Shares (calculated on a non-diluted basis). The Share Award Plan further provides that the aggregate number of Common Shares reserved for issuance to any one participant under all security based compensation arrangements of the Company, shall not exceed 5% of the total number of issued and outstanding Common Shares (calculated on a non-diluted basis).</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The maximum number of Common Shares that may be reserved for issuance to non-employee directors pursuant to RSAs under the Share Award Plan is 1% of the Common Shares outstanding at the time of the grant (on a non-diluted basis), less the aggregate number of Common Shares reserved for issuance to such non-employee director under any other security based compensation arrangement, and the total annual grant of RSAs to any one non-employee director cannot exceed a grant value of $150,000 (less the amount awarded to such non-employee director).</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Share Award Plan provides that if the issue date of any Share Award occurs during a blackout period, then the issue date for such Share Award shall not occur until the date which is the tenth (10</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) business day after the last day of the such blackout period.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless otherwise determined by the Board in its sole discretion, upon a Change of Control (as such term is defined in the Share Award Plan), all unvested Share Awards shall become automatically vested (in the case of PSAs, with a deemed Vesting Percentage of 100). Common Shares issuable in respect of Share Awards shall be, and shall be deemed to be, issued to participants effective immediately prior to the completion of the transaction which would result in the Change of Control unless issued prior thereto in accordance with the Share Award Plan.</span></div><div style="height:33.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless otherwise determined by the Board or unless otherwise expressly set forth in a Share Award agreement pertaining to a particular Share Award or any written employment or other agreement governing a participant&#8217;s role as an Eligible Person if a participant ceases to be an Eligible Person as a result of the termination of such participant for cause or if a participant voluntarily ceases to be an Eligible Person for any reason other than as a result of the death, permanent disability or retirement of the participant, all outstanding Share Awards Agreements under which Share Awards have been granted to such participant shall be terminated. Upon the death, permanent disability or retirement of a participant (other than the early retirement of an eligible employees), all outstanding Share Awards shall immediately vest. If a participant ceases to be an Eligible Person other than in the circumstances provided above, all Share Awards awarded to such participant under any outstanding Share Awards shall fully vest effective as of the date of cessation of employment (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cessation Date</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), unless otherwise determined by the Board, and the participant shall be entitled to receive the number of Common Shares equal to the number of Share Awards granted multiplied by a fraction (A) the numerator of which is the number of days from the date of grant thereof to the Cessation Date; and (B) the denominator of which is the total number of days during which such Share Award were scheduled to vest upon grant. In such circumstances, the Vesting Percentage in respect of PSAs shall be determined as of the Cessation Date.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Share Award Plan and any Share Awards granted thereunder may be amended, modified or terminated by the Board without approval of Shareholders, subject to any required approval of the TSX. Such changes may include, without limitation: </span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;amending, modifying or terminating the Share Award Plan with respect to all Common Shares in respect of Share Awards which have not yet been granted thereunder; </span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;making any amendment of a &#8220;housekeeping nature&#8221;; and</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;making any addition to, deletion from or alteration of the provisions of this Plan or any Share Award that are necessary to comply with applicable law, the rules of the TSX, or the requirements of any other stock exchange on which the Common Shares are then listed and to avoid unanticipated consequences deemed by the Board to be inconsistent with the purpose of this Plan. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding the foregoing, the Share Award Plan or a Share Award may not be amended without shareholder approval to:</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iv)&#160;&#160;&#160;&#160;increase the number of Common Shares issuable pursuant to outstanding Share Awards at any time;</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(v)&#160;&#160;&#160;&#160;change the insider participation limit under the Share Award Plan;</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(vi)&#160;&#160;&#160;&#160;expand the categories of individuals who are &#8220;eligible employees&#8221; who are eligible to participate in the Share Award Plan;</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(vii)&#160;&#160;&#160;&#160;extend the term of any Share Award beyond the term of such awards provided for under the terms and conditions of the Share Award Plan;</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(viii)&#160;&#160;&#160;&#160;permit the transfer or assignment of Share Awards, except to permit a transfer to a family member, an entity controlled by the holder of the Share Awards or a family member, a charity or for estate planning or estate settlement purposes; or</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ix)&#160;&#160;&#160;&#160;change the amendment provisions of the Share Award Plan.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, no amendment to the Share Award Plan or any Share Awards granted pursuant thereto may be made without the consent of an Share Award Plan participant if it adversely alters or impairs the rights of such participant in respect of any Share Award previously granted to such participant under the Share Award Plan.</span></div><div id="i17734265916144358581fdce5df64f78_79"></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">F.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:9.4pt">Disclosure of a Registrant's Action to Recover Erroneously Awarded Compensation</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Clawback Policy</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 2, 2023, the Board adopted a Policy for the Recovery of Erroneously Awarded Incentive-Based Compensation (the "Clawback Policy") providing for the recovery of certain incentive-based compensation from current and former executive officers of the Company in the event the Company is required to restate any of its financial statements filed with the SEC under the Exchange Act in order to correct an error that is material to the previously-issued financial statements, or that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period. Adoption of the Clawback Policy was mandated by new Nasdaq listing standards introduced pursuant to Exchange Act Rule 10D-1. The Clawback Policy is in addition to Section 304 of the Sarbanes-Oxley Act of 2002 which permits the SEC to order the disgorgement of bonuses and incentive-based compensation earned by a registrant issuer's chief executive officer and chief financial officer in the year following the filing of any financial statement that the issuer is required to restate because of misconduct, and the reimbursement of those funds to the issuer. A copy of the Clawback Policy has been filed herewith as Exhibit 97.1.</span></div><div><span><br/></span></div><div style="height:33.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><div id="i17734265916144358581fdce5df64f78_82"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 7. MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i17734265916144358581fdce5df64f78_85"></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt">Major Shareholders</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Security Ownership</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth information relating to the beneficial ownership of our shares as at February&#160;27, 2025, for: </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">each person who is known by us to beneficially own more than 5% of our common shares;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">each of our directors;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">each Named Executive Officer (other than Dr. Coffey who resigned as CEO in February 2025); and</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">all of our directors and Named Executive Officers (other than Dr. Coffey) as a group.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless otherwise indicated in the footnotes to the table, and subject to community property laws where applicable, the following persons have sole voting and investment control with respect to the shares beneficially owned by them. In accordance with SEC rules, if a person has a right to acquire beneficial ownership of any common shares on or within 60 days upon conversion or exercise of outstanding securities or otherwise, the shares are deemed beneficially owned by that person and are deemed to be outstanding solely for the purpose of determining the percentage of our shares that person beneficially owns. These shares are not included in the computations of percentage ownership for any other person. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as otherwise indicated, the address of each person in the table below is 804, 322 11</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Avenue SW, Calgary, Alberta, Canada T2R 0C5.</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.250%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.299%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name and Address of Beneficial Owner</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares Beneficially Owned</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Percentage of Shares Beneficially Owned</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5% and Greater Shareholders:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anson Funds Management LP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,185,743</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.47%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Directors and Named Executive Officers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patricia Andrews</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deborah M. Brown</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,211</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Angela Holtham</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217,238</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">James T. Parsons</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,000</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wayne Pisano</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302,441</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jonathan Rigby</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,000</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bernd R. Seizinger</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410,126</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kirk Look</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">813,351</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dr. Thomas C. Heineman</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">753,034</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allison Hagerman</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344,632</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amy G. Levin</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,152</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All directors and Named Executive Officers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> as a group</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,388,185</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.82%</span></td></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">** Less than 1% ownership</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes:</span></div><div style="margin-top:5pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Based on information obtained from Schedule 13G jointly filed by Anson Funds Management LP, Anson Management GP LLC, Mr. Tony Moore, Anson Advisors Inc., Mr. Amin Nathoo, and Mr. Moez Kassam (together "Anson") on February 14, 2025. In addition, according to that report, Anson Funds Management LP, Anson Management GP LLC and Mr. Moore's business address is 16000 Dallas Parkway, Suite 800 Dallas, Texas 75248, and Anson Advisors Inc., Mr. Nathoo and Mr. Kassam's business address is 181 Bay Street, Suite 4200 Toronto, ON M5J 2T3. As disclosed in our Form 20-F dated March 12, 2024, Anson Funds Management LP beneficially owned 3,814,299 shares which equated to 5.06% of shares beneficially owned. </span></div><div style="margin-top:5pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Does not include shares owned by Dr. Coffey who resigned as CEO in February 2025. </span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None of Anson, our directors, nor our Named Executive Officers have different voting rights. </span></div><div style="height:33.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shares Held in the United States</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table indicates, as of February&#160;27, 2025, the total number of common shares issued and outstanding, the approximate total number of holders of record of common shares, the number of holders of record of common shares with U.S.&#160;addresses, the portion of the outstanding common shares held by U.S.&#160;holders of record, and the percentage of common shares held by U.S.&#160;holders of record. This table does not indicate beneficial ownership of common&#160;shares.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:43.409%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.784%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.689%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total number of holders of record</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total number of common shares issued and outstanding</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of U.S.&#160;holders of record</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of common shares held by U.S.&#160;holders of record</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Percentage of common shares held by U.S.&#160;holders of record&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,421,592</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,950,482&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79.78&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Change of Control</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February&#160;27, 2025, there were no arrangements known to the Company which may, at a subsequent date, result in a change of control of the Company.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Control by Others</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the best of the Company&#8217;s knowledge, the Company is not directly or indirectly owned or controlled by another corporation(s), any foreign government, or any other natural or legal person, severally or jointly.</span></div><div><span><br/></span></div><div id="i17734265916144358581fdce5df64f78_88"></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.84pt">Related Party Transactions</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into employment contracts with each of our named executive officers, except Mr. Pisano (see Item 6).&#160;&#160;</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since the beginning of the fiscal year ended December 31, 2024, up to March&#160;7, 2025, we did not enter into any other related party transactions and we do not have any loans outstanding with any officer, director or major shareholder.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i17734265916144358581fdce5df64f78_91"></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">C.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt">Interests of Experts and Counsel</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not Applicable.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i17734265916144358581fdce5df64f78_94"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 8. FINANCIAL INFORMATION</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i17734265916144358581fdce5df64f78_97"></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt">Consolidated Statements and Other Financial Statements</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Statements</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements filed as part of this annual report are filed under Item 18.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The directors and the management of the Company do not know of any material, active or pending, legal and bankruptcy proceedings against them; nor is the Company involved as a plaintiff in any material proceeding or pending litigation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The directors and the management of the Company know of no active or pending proceedings against anyone that might materially adversely affect an interest of the Company.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dividend Policy</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has not paid any dividends on its common shares.&#160;The Company may pay dividends on its common shares in the future if it generates profits.&#160;Any decision to pay dividends on common shares in the future will be made by the board of directors on the basis of the earnings, financial requirements and other conditions existing at such time.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div id="i17734265916144358581fdce5df64f78_100"></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.84pt">Significant Changes</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No significant changes have occurred since the date of our annual financial statements included in this annual report on Form 20-F.</span></div><div style="height:33.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i17734265916144358581fdce5df64f78_103"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9. THE OFFER AND LISTING</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable except for Item 9.A.4 and Item 9.C.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Common Shares, no par value, are traded/quoted on the Nasdaq and the TSX under the symbols &#8220;ONCY" and &#8220;ONC&#8221;, respectively.</span></div><div><span><br/></span></div><div id="i17734265916144358581fdce5df64f78_106"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 10.&#160; ADDITIONAL INFORMATION</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i17734265916144358581fdce5df64f78_109"></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt">Share Capital</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not Applicable.</span></div><div><span><br/></span></div><div id="i17734265916144358581fdce5df64f78_112"></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.84pt">Memorandum and Articles of Association</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Articles of Continuance</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are governed by our amended articles of incorporation (the "Articles") under the Business Corporations Act of Alberta (the &#8220;Act&#8221;) and by our by-laws (the&#160;"By-laws"). Our Alberta corporate access number is 207797382. Our Articles provide that there are no restrictions on the business we may carry on or on the powers we may exercise. Companies incorporated under the Act are not required to include specific objects or purposes in their articles or by-laws.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Directors</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to certain exceptions, including in respect of voting on any resolution to approve a contract that relates primarily to the director's remuneration, directors may not vote on resolutions to approve a material contract or material transaction if the director is a party to such contract or transaction. The directors are entitled to remuneration as shall from time to time be determined by the Board of Directors with no requirement for a quorum of independent directors. The directors have the ability under the Act to exercise our borrowing power, without authorization of the shareholders. The Act permits shareholders to restrict this authority through a company's articles or by-laws (or through a unanimous shareholder agreement), but no such restrictions are in place for us. Our Articles and By-laws do not require directors to hold shares for qualification. Neither the Articles or the By-laws contain an age limit requirement for the retirement of directors. The Company actively encourages independent board member renewal through its formal term limit policy, adopted on June 30, 2015, whereby the independent director term limit is set at 12 years. Under the policy, the Board of Directors maintains the discretion to extend a directors&#8217; term, if under the circumstances, it is in the best interest of the Company and its shareholders. This in practice ensures that new independent directors are appointed regularly, without losing the experience base of long serving directors.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rights, Preferences, and Dividends Attaching to Shares</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The holders of common shares have the right to receive dividends if and when declared. Each holder of common shares, as of the record date prior to a meeting, is entitled to attend and to cast one vote for each common share held as of such record date at such annual and/or special meeting, including with respect to the election or re-election of directors. Subject to the provisions of our By-laws, all directors may, if still qualified to serve as directors, stand for re-election. The numbers of our Board of Directors are not replaced at staggered intervals but are elected annually.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On a distribution of assets on a winding-up, dissolution, or other return of capital (subject to certain exceptions) the holders of common shares shall have a right to receive their </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">pro&#160;rata</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> share of such distribution. There are no sinking fund or redemption provisions in respect of the common shares. Our shareholders have no liability to further capital calls as all shares issued and outstanding are fully paid and non-assessable.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No other classes of shares are currently permitted to be issued.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Action Necessary to Change the Rights of Shareholders</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The rights attaching to the different classes of shares may be varied by special resolution passed at a meeting of that class's shareholders.</span></div><div style="height:33.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Annual and Special Meetings of Shareholders</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Act and our By-laws, we are required to mail a Notice of Meeting and Management Information Circular to registered shareholders not less than 21&#160;days and not more than 50 days prior to the date of the meeting. Such materials must be filed concurrently with the applicable securities regulatory authorities in Canada and the U.S..&#160;Subject to certain provisions of the By-laws, a quorum of two or more shareholders in person or represented by proxy holding or representing by proxy not less than five (5%) percent of the total number of issued and outstanding shares enjoying voting rights at such meeting is required to properly constitute a meeting of shareholders.&#160;Shareholders and their duly appointed proxies and corporate representatives are entitled to be admitted to our annual and/or special meetings.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Limitations on the Rights to Own Shares</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Articles do not contain any limitations on the rights to own shares. Except as described below, there are currently no limitations imposed by Canadian federal or provincial laws on the rights of non-resident or foreign owners of Canadian securities to hold or vote the securities held. There are also no such limitations imposed by the Articles and By-laws with respect to our common&#160;shares.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disclosure of Share Ownership</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In general, under applicable securities regulation in Canada, a person or company who beneficially owns, directly or indirectly, voting securities of an issuer or who exercises control or direction over voting securities of an issuer or a combination of both, carrying more than 10% of the voting rights attached to all the issuer's outstanding voting securities is an insider and must, within 10&#160;days of becoming an insider, file&#160;a report in the required form effective the date on which the person became an insider. The report must disclose any direct or indirect beneficial ownership of, or control or direction over, securities of the reporting issuer. Additionally, securities regulation in Canada provides for the filing of a report by an insider of a reporting issuer whose holdings change, which report must be filed within 5&#160;days from the day on which the change takes place.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The rules in the U.S. governing the ownership threshold above which shareholder ownership must be disclosed are more stringent than those discussed above. Section 13 of the Exchange Act imposes reporting requirements on persons who acquire beneficial ownership (as such term is defined in Rule 13d-3 under the Exchange Act) of more than 5% of a class of an equity security registered under Section 12 of the Exchange Act.&#160;In general, such persons must file, within 10&#160;days after such acquisition, a report of beneficial ownership with the SEC containing the information prescribed by the regulations under Section&#160;13 of the Exchange Act. This information is also required to be sent to the issuer of the securities and to each exchange where the securities are&#160;traded.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Provisions of Articles and By-laws</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no provisions in the Articles or By-laws:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delaying or prohibiting a change in control of our company that operate only with respect to a merger, acquisition or corporate restructuring;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">discriminating against any existing or prospective holder of shares as a result of such shareholder owning a substantial number of&#160;shares;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">requiring disclosure of share ownership; or</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">governing changes in capital, where such provisions are more stringent than those required by&#160;law.</span></div><div><span><br/></span></div><div id="i17734265916144358581fdce5df64f78_115"></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">C.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt">Material Contracts</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have employment contracts with each of our officers as summarized in Item 6B. Other than these employment contracts, we have not entered into any other contract other than in the ordinary course of business over the last two years.  </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div id="i17734265916144358581fdce5df64f78_118"></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">D.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt">Exchange Controls </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Canada presently has no system of exchange controls. There are no Canadian restrictions on the repatriation of capital or earnings of a Canadian public company to non-resident investors. There are no laws in Canada or exchange restrictions affecting the remittance of dividends, profits, interest, royalties, and other payments to non-resident holders of our securities, except as discussed below in Section E, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Taxation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restrictions on Share Ownership by Non-Canadians</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no limitations under the laws of Canada or in our organizing documents on the right of foreigners to hold or vote securities of our company, except that the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investment Canada Act</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> may require review and approval by the Minister of Industry </span></div><div style="height:33.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Canada) of certain acquisitions of &#8220;control&#8221; of our company by a &#8220;non-Canadian&#8221;. The threshold for acquisitions of control is generally defined as being one-third or more of the voting shares of the company. &#8220;Non-Canadian&#8221; generally means an individual who is not a Canadian citizen, or a corporation, partnership, trust, or joint venture that is ultimately controlled by non-Canadians.</span></div><div id="i17734265916144358581fdce5df64f78_121"></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">E.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.84pt">Taxation  </span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MATERIAL CANADIAN FEDERAL INCOME TAX CONSIDERATIONS</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is, as of the date of this annual report, a summary of the principal Canadian federal income tax considerations under the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Tax Act</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Canada) (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tax Act</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) and the regulations thereunder (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Regulations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) generally applicable to an investor who acquires Common Shares as beneficial owner  and who, for the purposes of the Tax Act and the Regulations and at all relevant times deals at arm&#8217;s length with the Company and any underwriters that we have recently use, is not affiliated with the Company or the underwriters we have recently used, is not exempt from tax under Part I of the Tax Act, and who acquires and holds the Common Shares, as capital property (a &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Holder</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). Generally, the Common Shares will be considered to be capital property to a Holder provided that the Holder does not hold the Common Shares in the course of carrying on a business as part of an adventure or concern in the nature of trade. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This summary is generally applicable to a Holder who, at all relevant times, for purposes of the Tax Act: (i) is not, and is not deemed to be, resident in Canada for the purposes of the Tax Act or any applicable income tax treaty or convention; and (ii) does not and will not use or hold, and is not and will not be deemed to hold, the Common Shares in connection with carrying on a business in Canada. Holders who meet all of the foregoing requirements are referred to in this summary as a &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-Resident Holder</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;, and this summary only addresses such Non-Resident Holders. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Special rules, which are not discussed in this summary, may apply to certain holders that are insurers carrying on an insurance business in Canada and elsewhere or an authorized foreign bank. Such Holders should consult their own tax advisors with respect to an investment in Common Shares.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This summary is based upon the current provisions of the Tax Act and the Regulations in force as of the date hereof and counsel&#8217;s understanding of the current administrative policies and assessing practices of the Canada Revenue Agency (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) published in writing by the CRA prior to the date hereof. This summary takes into account all specific proposals to amend the Tax Act and the Regulations publicly announced by or on behalf of the Minister of Finance (Canada) prior to the date hereof (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tax Proposals</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) and assumes that the Tax Proposals will be enacted in the form proposed, although no assurance can be given that the Tax Proposals will be enacted in their current form or at all. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than the Tax Proposals, this summary does not otherwise take into account or anticipate any changes in law, whether by legislative, governmental, administrative, or judicial decision or action, nor does it take into account or consider any other federal or any provincial, territorial or foreign income tax considerations (other than those described below under &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MATERIAL UNITED STATES FEDERAL INCOME TAX CONSIDERATIONS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), which considerations may differ significantly from the Canadian federal income tax considerations discussed in this summary. This summary also does not take into account any change in the administrative policies or assessing practices of the CRA. No assurances can be given that the subsequent changes in law or administrative policy will not affect or modify the contents of this summary. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">This summary is of a general nature only, is not exhaustive of all possible Canadian federal income tax considerations and is not intended to be, nor should it be construed to be, legal or tax advice to any particular Holder. Holders should consult their own tax advisors with respect to their particular circumstances.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Currency</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In general, for purposes of the Tax Act, all amounts relating to the acquisition, holding or disposition of the Common Shares (including dividends, adjusted cost base and proceeds of disposition) must, to the extent such amounts are not otherwise expressed in Canadian dollars, be converted into Canadian dollars based on an exchange rate quoted by the Bank of Canada for the date such amount arose or such other rate of exchange that is acceptable to the CRA. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dividends</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dividends paid or credited or deemed to be paid or credited on the Common Shares to a Non-Resident Holder by the Company are subject to Canadian withholding tax at the rate of 25% on the gross amount of the dividend, unless such rate is reduced by the terms of an applicable tax treaty or convention between Canada and the country of residence of the Non-Resident Holder. For example, under the Canada-United States Tax Convention (1980), as amended (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Treaty</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), the rate of withholding tax on dividends paid or credited to a Non-Resident Holder who is: (i) a beneficial owner of dividends, (ii) resident in the United </span></div><div style="height:33.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">States for purposes of the Treaty, (iii) and entitled to the benefits of the Treaty, is generally reduced to 15% of the gross amount of the dividend (or 5% in the case of a U.S. Holder that is a company beneficially owning at least 10% of the Company&#8217;s voting shares). </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-Resident Holders are urged to consult their own tax advisors to determine their entitlement to relief under an applicable income tax treaty. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dispositions</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon a disposition (or a deemed disposition) of a Common Share (other than to the Company unless purchased by the Company in the open market in the manner in which shares are normally purchased by any member of the public in the open market), by a Non-Resident Holder generally will realize a capital gain (or a capital loss) equal to the amount by which the proceeds of disposition of such Common Shares, net of any reasonable costs of disposition, are greater (or are less) than the adjusted cost base of such Common Share to the Non-Resident Holder.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A Non-Resident Holder generally will not be subject to tax under the Tax Act in respect of a capital gain realized (nor will a capital loss arising therefrom be recognized under the Tax Act) on the disposition or deemed disposition of a Common Share unless the Common Share is or is deemed to be &#8220;taxable Canadian property&#8221; and is not &#8220;treaty-protected property&#8221; (each as defined under the Tax Act) of the Non-Resident Holder at the time of disposition.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provided the Common Shares are listed on a &#8220;designated stock exchange&#8221;, as defined in the Tax Act (which currently includes NASDAQ and TSX), at the time of disposition, the Common Shares generally will not constitute taxable Canadian property of a Non-Resident Holder at that time, unless at any time during the 60 month period immediately preceding the disposition the following two conditions are met concurrently: (i) one or any combination of (a) the Non-Resident Holder, (b) persons with whom the Non-Resident Holder did not deal at arm&#8217;s length, and (c) partnerships in which the Non-Resident Holder or a person with whom the Non-Resident Holder did not deal at arm&#8217;s length held a membership interest directly or indirectly through one or more partnerships, owned 25% or more of the issued shares of any class or series of shares of the Company; and (ii) more than 50% of the fair market value of such shares was derived directly or indirectly from one or any combination of (a) real or immovable property situated in Canada, (b) &#8220;Canadian resource properties&#8221; (as defined in the Tax Act), (c) &#8220;timber resource properties&#8221; (as defined in the Tax Act) or (d) an option in respect of, an interest in, or for civil law a right in any of the foregoing property, whether or not such property exists. Notwithstanding the foregoing, a Common Share may otherwise be deemed to be taxable Canadian property to a Non-Resident Holder for purposes of the Tax Act.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-Resident Holders whose Common Shares may be taxable Canadian property should consult their own tax advisors.</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MATERIAL UNITED STATES FEDERAL INCOME TAX CONSIDERATIONS</span></div><div><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a general summary of certain material U.S. federal income tax considerations applicable to a U.S. Holder (as defined below) arising from and relating to the acquisition, ownership and disposition of Common Shares.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This summary is for general information purposes only and does not purport to be a complete analysis or listing of all potential U.S. federal income tax considerations that may apply to a U.S. Holder arising from and relating to the acquisition, ownership, and disposition of Common Shares. In addition, this summary does not take into account the individual facts and circumstances of any particular U.S. Holder that may affect the U.S. federal income tax consequences to such U.S. Holder,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">including, without limitation, specific tax consequences to a U.S. Holder under an applicable income tax treaty. Accordingly, this summary is not intended to be, and should not be construed as, legal or U.S. federal income tax advice with respect to any U.S. Holder. This summary does not address the U.S. federal alternative minimum, U.S. federal net investment income, U.S. federal estate and gift, U.S. state and local, and non-U.S. tax consequences to U.S. Holders of the acquisition, ownership, and disposition of Common Shares. In addition, except as specifically set forth below, this summary does not discuss applicable tax reporting requirements. Each prospective U.S. Holder should consult its own tax advisors regarding the U.S. federal, U.S. federal alternative minimum, U.S. federal net investment income, U.S. federal estate and gift, U.S. state and local, and non-U.S. tax consequences relating to the acquisition, ownership and disposition of Common Shares.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No legal opinion from U.S. legal counsel or ruling from the Internal Revenue Service (the &#8220;IRS&#8221;) has been requested, or will be obtained, regarding the U.S. federal income tax consequences of the acquisition, ownership, and disposition of Common Shares. This summary is not binding on the IRS, and the IRS is not precluded from taking a position that is different from, and contrary to, the positions taken in this summary. In addition, because the authorities on which this summary is based are subject to various interpretations, the IRS and the U.S. courts could disagree with one or more of the conclusions described in this summary.</span></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="height:33.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Scope of this Summary</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Authorities</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This summary is based on the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;), Treasury Regulations (whether final, temporary, or proposed), published rulings of the IRS, published administrative positions of the IRS, the Treaty, and U.S. court decisions that are applicable, and, in each case, as in effect and available, as of the date of this document. Any of the authorities on which this summary is based could be changed in a material and adverse manner at any time, and any such change could be applied on a retroactive or prospective basis, which could affect the U.S. federal income tax considerations described in this summary. Except as provided herein, this summary does not discuss the potential effects, whether adverse or beneficial, of any proposed legislation that, if enacted, could be applied on a retroactive or prospective basis.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">U.S. Holders</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For purposes of this summary, the term &#8220;U.S. Holder&#8221; means a beneficial owner of Common Shares that is for U.S. federal income tax purposes:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an individual who is a citizen or resident of the United States;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a corporation (or other entity treated as a corporation for U.S. federal income tax purposes) organized under the laws of the United States, any state thereof, or the District of Columbia;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an estate whose income is subject to U.S. federal income taxation regardless of its source; or</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a trust that (1) is subject to the primary supervision of a court within the U.S. and the control of one or more U.S. persons for all substantial decisions or (2) has a valid election in effect under applicable Treasury Regulations to be treated as a U.S. person.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">U.S. Holders Subject to Special U.S. Federal Income Tax Rules Not Addressed</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This summary does not address the U.S. federal income tax considerations applicable to U.S. Holders that are subject to special provisions under the Code, including, but not limited to, U.S. Holders that: (a) are tax-exempt organizations, qualified retirement plans, individual retirement accounts, or other tax-deferred accounts; (b) are financial institutions, underwriters, insurance companies, real estate investment trusts, or regulated investment companies; (c) are broker-dealers, dealers, or traders in securities or currencies that elect to apply a mark-to-market accounting method; (d) have a &#8220;functional currency&#8221; other than the U.S. dollar; (e) own Common Shares as part of a straddle, hedging transaction, conversion transaction, constructive sale, or other integrated transaction; (f) acquire Common Shares in connection with the exercise of employee stock options or otherwise as compensation for services; (g) hold Common Shares other than as a capital asset within the meaning of Section 1221 of the Code (generally, property held for investment purposes); (h) are partnerships or other flow-through entities (and partners or other owners thereof); (i) are S corporations (and shareholders thereof); (i) are subject to special tax accounting rules </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with respect to Common Shares; or (j) own, have owned or will own (directly, indirectly, or by attribution) 10% or more of the total combined voting power or value of the outstanding shares of the Company; (k) hold Common Shares in connection with a trade or business, permanent establishment, or fixed base outside the United States; (l) are U.S. expatriates or former long-term residents of the United States subject to Section 877 or 877A of the Code; or (m) are subject to the alternative minimum tax. U.S. Holders that are subject to special provisions under the Code, including, but not limited to, U.S. Holders described immediately above, should consult their own tax advisors regarding the U.S. federal, U.S. federal alternative minimum, U.S. federal net investment income, U.S. federal estate and gift, U.S. state and local, and non-U.S. tax consequences relating to the acquisition, ownership, and disposition of Common Shares.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an entity or arrangement that is classified as a partnership (or other &#8220;pass-through&#8221; entity) for U.S. federal income tax purposes holds Common Shares, the U.S. federal income tax consequences to such entity or arrangement and the partners (or other owners or participants) of such entity or arrangement generally will depend on the activities of the entity or arrangement and the status of such partners (or owners or participants). This summary does not address the tax consequences to any such partner (or owner or participants). Partners (or other owners or participants) of entities or arrangements that are classified as partnerships or as &#8220;pass-through&#8221; entities for U.S. federal income tax purposes should consult their own tax advisors regarding the U.S. federal income tax consequences arising from and relating to the acquisition, ownership, and disposition of Common Shares.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Passive Foreign Investment Company Rules</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">PFIC Status of the Company</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company were to constitute a &#8220;passive foreign investment company&#8221; under the meaning of Section 1297 of the Code (a &#8220;PFIC&#8221;, as defined below) for any year during a U.S. Holder&#8217;s holding period, then certain potentially adverse rules would </span></div><div style="height:33.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">affect the U.S. federal income tax consequences to a U.S. Holder as a result of the acquisition, ownership and disposition of Common Shares. The Company believes that it was classified as a PFIC during its most recently completed tax year, and based on current business plans and financial expectations, the Company expects that it will be a PFIC for the current tax year and may be a PFIC in future tax years. No opinion of legal counsel or ruling from the IRS concerning the status of the Company as a PFIC has been obtained or is currently planned to be requested. The determination of whether any corporation was, or will be, a PFIC for a tax year depends, in part, on the application of complex U.S. federal income tax rules, which are subject to differing interpretations. In addition, whether any corporation will be a PFIC for any tax year depends on the assets and income of such corporation over the course of each such tax year and, as a result, cannot be predicted with certainty as of the date of this document. Accordingly, there can be no assurance that the IRS will not challenge any determination made by the Company (or any subsidiary of the Company) concerning its PFIC status. Each U.S. Holder should consult its own tax advisors regarding the PFIC status of the Company and each subsidiary of the Company.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In any year in which the Company is classified as a PFIC, a U.S. Holder will be required to file an annual report with the IRS containing such information as Treasury Regulations and/or other IRS guidance may require. In addition to penalties, a failure to satisfy such reporting requirements may result in an extension of the time period during which the IRS can assess a tax. U.S. Holders should consult their own tax advisors regarding the requirements of filing such information returns under these rules, including the requirement to file an IRS Form 8621 annually.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generally will be a PFIC if, for a tax year, (a) 75% or more of the gross income of the Company is passive income (the &#8220;PFIC income test&#8221;) or (b) 50% or more of the value of the Company&#8217;s assets either produce passive income or are held for the production of passive income, based on the quarterly average of the fair market value of such assets (the &#8220;PFIC asset test&#8221;). &#8220;Gross income&#8221; generally includes all sales revenues less the cost of goods sold, plus income from investments and from incidental or outside operations or sources, and &#8220;passive income&#8221; generally includes, for example, dividends, interest, certain rents and royalties, certain gains from the sale of stock and securities, and certain gains from commodities transactions.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For purposes of the PFIC income test and PFIC asset test described above, if the Company owns, directly or indirectly, 25% or more of the total value of the outstanding shares of another corporation, the Company will be treated as if it (a) held a proportionate share of the assets of such other corporation and (b) received directly a proportionate share of the income of such other corporation. In addition, for purposes of the PFIC income test and PFIC asset test described above, and assuming certain other requirements are met, &#8220;passive income&#8221; does not include certain interest, dividends, rents, or royalties that are received or accrued by the Company from certain &#8220;related persons&#8221; (as defined in Section 954(d)(3) of the Code) also organized in Canada, to the extent such items are properly allocable to the income of such related person that is not passive income.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under certain attribution rules, if the Company is a PFIC, U.S. Holders will generally be deemed to own their proportionate share of the Company&#8217;s direct or indirect equity interest in any company that is also a PFIC (a &#8216;&#8216;Subsidiary PFIC&#8217;&#8217;), and will generally be subject to U.S. federal income tax on their proportionate share of (a) any &#8220;excess distributions,&#8221; as described below, on the stock of a Subsidiary PFIC and (b) a disposition or deemed disposition of the stock of a Subsidiary PFIC by the Company or another Subsidiary PFIC, both as if such U.S. Holders directly held the shares of such Subsidiary PFIC. In addition, U.S. Holders may be subject to U.S. federal income tax on any indirect gain realized on the stock of a Subsidiary PFIC on the sale or disposition of Common Shares. Accordingly, U.S. Holders should be aware that they could be subject to tax under the PFIC rules even if no distributions are received and no redemptions or other dispositions of Common Shares are made.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Default PFIC Rules Under Section 1291 of the Code</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company is a PFIC for any tax year during which a U.S. Holder owns Common Shares, the U.S. federal income tax consequences to such U.S. Holder of the acquisition, ownership, and disposition of Common Shares will depend on whether and when such U.S. Holder makes an election to treat the Company and each Subsidiary PFIC, if any, as a &#8220;qualified electing fund&#8221; or &#8220;QEF&#8221; under Section 1295 of the Code (a &#8220;QEF Election&#8221;) or makes a mark-to-market election under Section 1296 of the Code (a &#8220;Mark-to-Market Election&#8221;). A U.S. Holder that does not make either a QEF Election or a Mark-to-Market Election will be referred to in this summary as a &#8220;Non-Electing U.S. Holder.&#8221;</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A Non-Electing U.S. Holder will be subject to the rules of Section 1291 of the Code (described below) with respect to (a) any gain recognized on the sale or other taxable disposition of Common Shares and (b) any &#8220;excess distribution&#8221; received on the Common Shares. A distribution generally will be an &#8220;excess distribution&#8221; to the extent that such distribution (together with all other distributions received in the current tax year) exceeds 125% of the average distributions received during the three preceding tax years (or during a U.S. Holder&#8217;s holding period for the Common Shares, if shorter).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Section 1291 of the Code, any gain recognized on the sale or other taxable disposition of Common Shares (including an indirect disposition of the stock of any Subsidiary PFIC), and any &#8220;excess distribution&#8221; received on Common Shares or with </span></div><div style="height:33.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">respect to the stock of a Subsidiary PFIC, must be ratably allocated to each day in a Non-Electing U.S. Holder&#8217;s holding period for the respective Common Shares. The amount of any such gain or excess distribution allocated to the tax year of disposition or distribution of the excess distribution and to years before the entity became a PFIC, if any, would be taxed as ordinary income (and not eligible for certain preferred rates). The amounts allocated to any other tax year would be subject to U.S. federal income tax at the highest tax rate applicable to ordinary income in each such year, and an interest charge would be imposed on the tax liability for each such year, calculated as if such tax liability had been due in each such year. A Non-Electing U.S. Holder that is not a corporation must treat any such interest paid as &#8220;personal interest,&#8221; which is not deductible.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company is a PFIC for any tax year during which a Non-Electing U.S. Holder holds Common Shares, the Company will continue to be treated as a PFIC with respect to such Non-Electing U.S. Holder, regardless of whether the Company ceases to be a PFIC in one or more subsequent tax years. A Non-Electing U.S. Holder may terminate this deemed PFIC status by electing to recognize gain (which will be taxed under the rules of Section 1291 of the Code discussed above), but not loss, as if such Common Shares were sold on the last day of the last tax year for which the Company was a PFIC.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">QEF Election</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A U.S. Holder that makes a timely and effective QEF Election for the first tax year in which the holding period of its Common Shares begins generally will not be subject to the rules of Section 1291 of the Code discussed above with respect to its Common Shares. A U.S. Holder that makes a timely and effective QEF Election will be subject to U.S. federal income tax on such U.S. Holder&#8217;s pro rata share of (a) the net capital gain of the Company, which will be taxed as long-term capital gain to such U.S. Holder, and (b) the ordinary earnings of the Company, which will be taxed as ordinary income to such U.S. Holder. Generally, &#8220;net capital gain&#8221; is the excess of (a) net long-term capital gain over (b) net short-term capital loss, and &#8220;ordinary earnings&#8221; are the excess of (a) &#8220;earnings and profits&#8221; over (b) net capital gain. A U.S. Holder that makes a QEF Election will be subject to U.S. federal income tax on such amounts for each tax year in which the Company is a PFIC, regardless of whether such amounts are actually distributed to such U.S. Holder by the Company. However, for any tax year in which the Company is a PFIC and has no net income or gain, U.S. Holders that have made a QEF Election would not have any income inclusions as a result of the QEF Election. If a U.S. Holder that made a QEF Election has an income inclusion, such a U.S. Holder may, subject to certain limitations, elect to defer payment of current U.S. federal income tax on such amounts, subject to an interest charge. If such U.S. Holder is not a corporation, any such interest paid will be treated as &#8220;personal interest,&#8221; which is not deductible.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A U.S. Holder that makes a timely and effective QEF Election with respect to the Company generally (a) may receive a tax-free distribution from the Company to the extent that such distribution represents &#8220;earnings and profits&#8221; of the Company that were previously included in income by the U.S. Holder because of such QEF Election and (b) will adjust such U.S. Holder&#8217;s tax basis in the Common Shares to reflect the amount included in income or allowed as a tax-free distribution because of such QEF Election. In addition, a U.S. Holder that makes a QEF Election generally will recognize capital gain or loss on the sale or other taxable disposition of Common Shares.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The procedure for making a QEF Election, and the U.S. federal income tax consequences of making a QEF Election, will depend on whether such QEF Election is timely. A QEF Election will be treated as &#8220;timely&#8221; if such QEF Election is made for the first year in the U.S. Holder&#8217;s holding period for the Common Shares in which the Company was a PFIC. A U.S. Holder may make a timely QEF Election by filing the appropriate QEF Election documents at the time such U.S. Holder files a U.S. federal income tax return for such year. If a U.S. Holder does not make a timely and effective QEF Election for the first year in the U.S. Holder&#8217;s holding period for the Common Shares, the U.S. Holder may still be able to make a timely and effective QEF Election in a subsequent year if such U.S. Holder meets certain requirements and makes a &#8220;purging&#8221; election to recognize gain (which will be taxed under the rules of Section 1291 of the Code discussed above) as if such Common Shares were sold for their fair market value on the day the QEF Election is effective. If a U.S. Holder makes a QEF Election but does not make a &#8220;purging&#8221; election to recognize gain as discussed in the preceding sentence, then such U.S. Holder shall be subject to the QEF Election rules and shall continue to be subject to tax under the rules of Section 1291 discussed above with respect to its Common Shares. If a U.S. Holder owns PFIC stock indirectly through another PFIC, separate QEF Elections must be made for the PFIC in which the U.S. Holder is a direct shareholder and the Subsidiary PFIC for the QEF rules to apply to both PFICs. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A QEF Election will apply to the tax year for which such QEF Election is timely made and to all subsequent tax years, unless such QEF Election is invalidated or terminated or the IRS consents to revocation of such QEF Election. If a U.S. Holder makes a QEF Election and, in a subsequent tax year, the Company ceases to be a PFIC, the QEF Election will remain in effect (although it will not be applicable) during those tax years in which the Company is not a PFIC. Accordingly, if the Company becomes a PFIC in another subsequent tax year, the QEF Election will be effective and the U.S. Holder will be subject to the QEF rules described above during any subsequent tax year in which the Company qualifies as a PFIC.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company: (a) will make available to U.S. Holders, upon their written request, information as to its status as a PFIC and the PFIC status of any subsidiary in which the Company owns more than 50% of such subsidiary&#8217;s total aggregate voting power </span></div><div style="height:33.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and (b) for each year in which the Company is a PFIC, provide to a U.S. Holder, upon written request, such information and documentation that a U.S. Holder making a QEF Election with respect to the Company and such more than 50% owned subsidiary which constitutes a PFIC is reasonably required to obtain for U.S. federal income tax purposes. The Company may elect to provide such information on its website. With respect to any Subsidiary PFIC in which the Company owns 50% or less of the aggregate voting power, upon the written request of a U.S. Holder acquiring Common Shares, the Company will request that such Subsidiary PFIC provide such U.S. Holder with the information that such U.S. Holder requires to report under the QEF rules; provided, however, the Company can provide no assurances that such Subsidiary PFIC will provide such information.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A U.S. Holder makes a QEF Election by attaching a completed IRS Form 8621, including a PFIC Annual Information Statement, to a timely filed United States federal income tax return. However, if the Company does not provide the required information with regard to the Company or any of its Subsidiary PFICs, U.S. Holders will not be able to make a QEF Election for such entity and will continue to be subject to the rules of Section 1291 of the Code discussed above that apply to Non-Electing U.S. Holders with respect to the taxation of gains and excess distributions. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Mark-to-Market Election</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A U.S. Holder may make a Mark-to-Market Election only if the Common Shares are marketable stock. The Common Shares generally will be &#8220;marketable stock&#8221; if the Common Shares are regularly traded on (a) a national securities exchange that is registered with the Securities and Exchange Commission, (b) the national market system established pursuant to section 11A of the U.S. Exchange Act, or (c) a foreign securities exchange that is regulated or supervised by a governmental authority of the country in which the market is located, provided that (i) such foreign exchange has trading volume, listing, financial disclosure, and surveillance requirements, and meets other requirements, and the laws of the country in which such foreign exchange is located, together with the rules of such foreign exchange, ensure that such requirements are actually enforced and (ii) the rules of such foreign exchange effectively promote active trading of listed stocks. If such stock is traded on such a qualified exchange or other market, such stock generally will be &#8220;regularly traded&#8221; for any calendar year during which such stock is traded, other than in de minimis quantities, on at least 15 days during each calendar quarter. Provided that the Common Shares are &#8220;regularly traded&#8221; as described in the preceding sentence, the Common Shares are expected to be marketable stock. However, each U.S. Holder should consult its own tax advisor in this matter. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A U.S. Holder that makes a Mark-to-Market Election with respect to its Common Shares generally will not be subject to the rules of Section 1291 of the Code discussed above with respect to such Common Shares. However, if a U.S. Holder does not make a Mark-to-Market Election beginning in the first tax year of such U.S. Holder&#8217;s holding period for the Common Shares for which the Company is a PFIC and such U.S. Holder has not made a timely QEF Election, the rules of Section 1291 of the Code discussed above will apply to certain dispositions of, and distributions on, the Common Shares.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A U.S. Holder that makes a Mark-to-Market Election will include in ordinary income, for each tax year in which the Company is a PFIC, an amount equal to the excess, if any, of (a) the fair market value of the Common Shares, as of the close of such tax year over (b) such U.S. Holder&#8217;s adjusted tax basis in such Common Shares. A U.S. Holder that makes a Mark-to-Market Election will be allowed a deduction in an amount equal to the excess, if any, of (a) such U.S. Holder&#8217;s adjusted tax basis in the Common Shares, over (b) the fair market value of such Common Shares (but only to the extent of the net amount of previously included income as a result of the Mark-to-Market Election for prior tax years).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A U.S. Holder that makes a Mark-to-Market Election generally also will adjust such U.S. Holder&#8217;s tax basis in the Common Shares to reflect the amount included in gross income or allowed as a deduction because of such Mark-to-Market Election. In addition, upon a sale or other taxable disposition of Common Shares, a U.S. Holder that makes a Mark-to-Market Election will recognize ordinary income or ordinary loss (not to exceed the excess, if any, of (a) the amount included in ordinary income because of such Mark-to-Market Election for prior tax years over (b) the amount allowed as a deduction because of such Mark-to-Market Election for prior tax years). Losses that exceed this limitation are subject to the rules generally applicable to losses provided in the Code and Treasury Regulations. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A U.S. Holder makes a Mark-to-Market Election by attaching a completed IRS Form 8621 to a timely filed United States federal income tax return. A Mark-to-Market Election applies to the tax year in which such Mark-to-Market Election is made and to each subsequent tax year unless the Common Shares cease to be &#8220;marketable stock&#8221; or the IRS consents to revocation of such election. Each U.S. Holder should consult its own tax advisors regarding the availability of, and procedure for making, a Mark-to-Market Election.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although a U.S. Holder may be eligible to make a Mark-to-Market Election with respect to the Common Shares, no such election may be made with respect to the stock of any Subsidiary PFIC that a U.S. Holder is treated as owning, because such stock is not marketable. Hence, the Mark-to-Market Election will not be effective to avoid the application of the default rules of </span></div><div style="height:33.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 1291 of the Code described above with respect to deemed dispositions of Subsidiary PFIC stock or excess distributions from a Subsidiary PFIC to its shareholder.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other PFIC Rules</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Section 1291(f) of the Code, the IRS has issued proposed Treasury Regulations that, subject to certain exceptions, would cause a U.S. Holder that had not made a timely QEF Election to recognize gain (but not loss) upon certain transfers of Common Shares that would otherwise be tax-deferred (e.g., gifts and exchanges pursuant to corporate reorganizations). However, the specific U.S. federal income tax consequences to a U.S. Holder may vary based on the manner in which Common Shares are transferred.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain additional adverse rules may apply with respect to a U.S. Holder if the Company is a PFIC, regardless of whether such U.S. Holder makes a QEF Election. For example, under Section 1298(b)(6) of the Code, a U.S. Holder that uses Common Shares as security for a loan will, except as may be provided in Treasury Regulations, be treated as having made a taxable disposition of such Common Shares.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, a U.S. Holder who acquires Common Shares from a decedent will not receive a &#8220;step up&#8221; in tax basis of such Common Shares to fair market value unless such decedent had a timely and effective QEF Election in place.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Special rules also apply to the amount of foreign tax credit that a U.S. Holder may claim on a distribution from a PFIC. Subject to such special rules, foreign taxes paid with respect to any distribution in respect of stock in a PFIC are generally eligible for the foreign tax credit. The rules relating to distributions by a PFIC and their eligibility for the foreign tax credit are complicated, and a U.S. Holder should consult with its own tax advisors regarding the availability of the foreign tax credit with respect to distributions by a PFIC.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The PFIC rules are complex, and each U.S. Holder should consult its own tax advisors regarding the PFIC rules and how the PFIC rules may affect the U.S. federal income tax consequences of the acquisition, ownership, and disposition of Common Shares.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Rules Applicable to the Ownership and Disposition of Common Shares</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following discussion describes the general rules applicable to the ownership and disposition of the Common Shares but is subject in its entirety to the special rules described above under the heading &#8220;Passive Foreign Investment Company Rules.&#8221;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Distributions on Common Shares</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A U.S. Holder that receives a distribution, including a constructive distribution, with respect to a Common Share will be required to include the amount of such distribution in gross income as a dividend (without reduction for any Canadian income tax withheld from such distribution) to the extent of the current and accumulated &#8220;earnings and profits&#8221; of the Company, as computed for U.S. federal income tax purposes. A dividend generally will be taxed to a U.S. Holder at ordinary income tax rates if the Company is a PFIC for the tax year of such distribution or the preceding tax year. To the extent that a distribution exceeds the current and accumulated &#8220;earnings and profits&#8221; of the Company, such distribution will be treated first as a tax-free return of capital to the extent of a U.S. Holder&#8217;s tax basis in the Common Shares and thereafter as gain from the sale or exchange of such Common Shares. (See &#8220;Sale or Other Taxable Disposition of Common Shares&#8221; below). However, the Company may not maintain the calculations of its earnings and profits in accordance with U.S. federal income tax principles, and each U.S. Holder may have to assume that any distribution by the Company with respect to the Common Shares will constitute ordinary dividend income. Dividends received on Common Shares by corporate U.S. Holders generally will not be eligible for the &#8220;dividends received deduction.&#8221; Subject to applicable limitations and provided the Company is eligible for the benefits of the Treaty or the Common Shares are readily tradable on a United States securities market, dividends paid by the Company to non-corporate U.S. Holders, including individuals, generally will be eligible for the preferential tax rates applicable to long-term capital gains for dividends, provided certain holding period and other conditions are satisfied, including that the Company not be classified as a PFIC in the tax year of distribution or in the preceding tax year. The dividend rules are complex, and each U.S. Holder should consult its own tax advisors regarding the application of such rules.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Sale or Other Taxable Disposition of Common Shares</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the sale or other taxable disposition of Common Shares, a U.S. Holder generally will recognize capital gain or loss in an amount equal to the difference between the U.S. dollar value of cash received plus the fair market value of any property received and such U.S. Holder&#8217;s tax basis in such Common Shares sold or otherwise disposed of. A U.S. Holder&#8217;s tax basis in Common Shares generally will be such U.S. Holder&#8217;s U.S. dollar cost for such Common Shares. Gain or loss recognized on </span></div><div style="height:33.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">such sale or other disposition generally will be long-term capital gain or loss if, at the time of the sale or other disposition, the Common Shares have been held for more than one year.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preferential tax rates currently apply to long-term capital gain of a U.S. Holder that is an individual, estate, or trust. There are currently no preferential tax rates for long-term capital gain of a U.S. Holder that is a corporation. Deductions for capital losses are subject to significant limitations under the Code.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Additional Considerations</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Receipt of Foreign Currency</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of any distribution paid to a U.S. Holder in foreign currency, or on the sale, exchange or other taxable disposition of Common Shares, generally will be equal to the U.S. dollar value of such foreign currency based on the exchange rate applicable on the date of receipt (regardless of whether such foreign currency is converted into U.S. dollars at that time). A U.S. Holder will have a tax basis in the foreign currency equal to its U.S. dollar value on the date of receipt. Any U.S. Holder who converts or otherwise disposes of the foreign currency after the date of receipt may have a foreign currency exchange gain or loss that would be treated as ordinary income or loss, and generally will be U.S. source income or loss for foreign tax credit purposes. Different rules apply to U.S. Holders who use the accrual method of tax accounting. Each U.S. Holder should consult its own U.S. tax advisors regarding the U.S. federal income tax consequences of receiving, owning, and disposing of foreign currency.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Foreign Tax Credit</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dividends paid on the Common Shares will be treated as foreign-source income, and generally will be treated as &#8220;passive category income&#8221; or &#8220;general category income&#8221; for U.S. foreign tax credit purposes. Any gain or loss recognized on a sale or other disposition of Common Shares generally will be United States source gain or loss. Certain U.S. Holders that are eligible for the benefits of the Treaty may elect to treat such gain or loss as Canadian source gain or loss for U.S. foreign tax credit purposes. The Code applies various complex limitations on the amount of foreign taxes that may be claimed as a credit by U.S. taxpayers. In addition, Treasury Regulations that apply to foreign taxes paid or accrued (the &#8220;Foreign Tax Credit Regulations&#8221;) impose additional requirements for Canadian withholding taxes to be eligible for a foreign tax credit, and there can be no assurance that those requirements will be satisfied. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">T</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he Treasury Department has recently released guidance temporarily pausing the application of certain of the Foreign Tax Credit Regulations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the PFIC rules and the Foreign Tax Credit Regulations, each as discussed above, a U.S. Holder that pays (whether directly or through withholding) Canadian income tax with respect to dividends paid on the Common Shares generally will be entitled, at the election of such U.S. Holder, to receive either a deduction or a credit for such Canadian income tax. Generally, a credit will reduce a U.S. Holder&#8217;s U.S. federal income tax liability on a dollar-for-dollar basis, whereas a deduction will reduce a U.S. Holder&#8217;s income that is subject to U.S. federal income tax. This election is made on a year-by-year basis and applies to all foreign taxes paid (whether directly or through withholding) by a U.S. Holder during a year. The foreign tax credit rules are complex and involve the application of rules that depend on a U.S. Holder&#8217;s particular circumstances. Accordingly, each U.S. Holder should consult its own U.S. tax advisors regarding the foreign tax credit rules.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Backup Withholding and Information Reporting</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under U.S. federal income tax law, certain categories of U.S. Holders must file information returns with respect to their investment in, or involvement in, a foreign corporation. For example, U.S. return disclosure obligations (and related penalties) are imposed on individuals who are U.S. Holders that hold certain specified foreign financial assets in excess of certain threshold amounts. The definition of specified foreign financial assets includes not only financial accounts maintained in foreign financial institutions, but also, unless held in accounts maintained by a financial institution, any stock or security issued by a non-U.S. person, any financial instrument or contract held for investment that has an issuer or counterparty other than a U.S. person and any interest in a foreign entity. U.S. Holders may be subject to these reporting requirements unless their Common Shares are held in an account at certain financial institutions. Penalties for failure to file certain of these information returns are substantial. U.S. Holders should consult with their own tax advisors regarding the requirements of filing information returns, including the requirement to file an IRS Form 8938.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments made within the U.S., or by a U.S. payor or U.S. middleman, of dividends on, and proceeds arising from the sale or other taxable disposition of, Common Shares will generally be subject to information reporting and backup withholding tax if a U.S. Holder (a) fails to furnish such U.S. Holder&#8217;s correct U.S. taxpayer identification number (generally on IRS Form W-9), (b) furnishes an incorrect U.S. taxpayer identification number, (c) is notified by the IRS that such U.S. Holder has previously </span></div><div style="height:33.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">failed to properly report items subject to backup withholding tax, or (d) fails to certify, under penalty of perjury, that such U.S. Holder has furnished its correct U.S. taxpayer identification number and that the IRS has not notified such U.S. Holder that it is subject to backup withholding tax. However, certain exempt persons generally are excluded from these information reporting and backup withholding rules. Backup withholding is not an additional tax. Any amounts withheld under the U.S. backup withholding tax rules will be allowed as a credit against a U.S. Holder&#8217;s U.S. federal income tax liability, if any, or will be refunded, if such U.S. Holder furnishes required information to the IRS in a timely manner. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The discussion of reporting requirements set forth above is not intended to constitute a complete description of all reporting requirements that may apply to a U.S. Holder. A failure to satisfy certain reporting requirements may result in an extension of the time period during which the IRS can assess a tax and, under certain circumstances, such an extension may apply to assessments of amounts unrelated to any unsatisfied reporting requirement. Each U.S. Holder should consult its own tax advisors regarding the information reporting and backup withholding rules.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">THE ABOVE SUMMARY IS NOT INTENDED TO CONSTITUTE A COMPLETE ANALYSIS OF ALL TAX CONSIDERATIONS APPLICABLE TO U.S. HOLDERS WITH RESPECT TO THE ACQUISITION, OWNERSHIP, AND DISPOSITION OF COMMON SHARES. U.S. HOLDERS SHOULD CONSULT THEIR OWN TAX ADVISORS AS TO THE TAX CONSIDERATIONS APPLICABLE TO THEM IN LIGHT OF THEIR OWN PARTICULAR CIRCUMSTANCES.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i17734265916144358581fdce5df64f78_124"></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">F.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:9.4pt">Dividends and Paying Agents</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Not Applicable.</span></div><div><span><br/></span></div><div id="i17734265916144358581fdce5df64f78_127"></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">G.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:7.73pt">Statements by Experts</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not Applicable.</span></div><div id="i17734265916144358581fdce5df64f78_130"></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">H.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:7.73pt">Documents on Display</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to the informational requirements of the Exchange Act and file reports and other information with the SEC. The SEC maintains a Website that contains reports, proxy and information statements, and other information regarding registrants that file electronically with the SEC at www.sec.gov. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are required to file reports and other information with the securities commissions in Canada. You are invited to read and copy any reports, statements, or other information, other than confidential filings, that we file with the provincial securities commissions. These filings are also electronically available from the Canadian System for Electronic Document Analysis and Retrieval ("SEDAR+") (www.sedarplus.ca), the Canadian equivalent of the SEC's electronic document gathering and retrieval system.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We "incorporate by reference" information that we file with the SEC, which means that we can disclose important information to you by referring you to those documents. The information incorporated by reference is an important part of this Form&#160;20-F and&#160;more recent information automatically updates and supersedes more dated information contained or incorporated by reference in this Form&#160;20-F.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a foreign private issuer, we are exempt from the rules under the Exchange Act prescribing the furnishing and content of proxy statements to shareholders.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will provide without charge to each person, including any beneficial owner, to whom a copy of this annual report has been delivered, on the written or oral request of such person, a copy of any or all documents referred to above which have been or may be incorporated by reference in this annual report (not&#160;including exhibits to such incorporated information that are not specifically incorporated by reference into such information). Requests for such copies should be directed to us at the following address: Oncolytics Biotech Inc., 804, 322 11</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Avenue SW, Calgary, Alberta, Canada T2R 0C5, Attention:&#160;Kirk Look.&#160;Telephone (403) 670 - 7377. Facsimile (403)&#160;283-0858 EMAIL: info@oncolyticsbiotech.com.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i17734265916144358581fdce5df64f78_133"></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">I.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:11.61pt">Subsidiary Information</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div><span><br/></span></div><div style="height:33.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><div id="i17734265916144358581fdce5df64f78_1649267444079"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">J.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Annual Report to Security Holders</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div><span><br/></span></div><div id="i17734265916144358581fdce5df64f78_136"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 11.&#160;&#160; QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Please see Item 4 &#8211; "Information on the Company" and Note 17 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> in our audited consolidated financial statements beginning on page F-1 of this annual report on Form 20-F.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not currently have any long-term debt, nor do we currently utilize interest rate swap contracts to hedge against interest rate&#160;risk.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not use financial instruments for trading purposes and are not parties to any leverage derivatives.&#160;We do not currently engage in hedging transactions. </span></div><div><span><br/></span></div><div id="i17734265916144358581fdce5df64f78_139"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 12.&#160;&#160; DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i17734265916144358581fdce5df64f78_142"></div><div style="text-align:center;text-indent:36pt"><span><br/></span></div><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i17734265916144358581fdce5df64f78_145"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 13.&#160; &#160;DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div><span><br/></span></div><div id="i17734265916144358581fdce5df64f78_148"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 14.&#160;&#160; MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">A. - D. Material Modification to the Rights of Security Holders</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">E. Use of Proceeds</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not Applicable.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i17734265916144358581fdce5df64f78_151"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 15.&#160;&#160;CONTROLS AND PROCEDURES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disclosure Controls and Procedures</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is the conclusion of our Chief Executive Officer and Chief Financial Officer that our Company's disclosure controls and procedures (as defined in Exchange Act rules 13a-15(e) and 15d-15(e)), based on their evaluation of these controls and procedures as of the end of the period covered by this annual report, are effective in ensuring that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission&#8217;s rules and forms, and that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Management's Annual Report on Internal Control Over Financial Reporting</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining adequate internal control over financial reporting. As defined in Exchange Act Rule 13a-15(f), internal control over financial reporting is a process designed by, or under the supervision of, our Chief Executive Officer and Chief Financial Officer and effected by the board of directors, management, and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with International Reporting Standards as issued by the International Accounting Standards Board ("IFRS"), and includes those policies and procedures that (i) pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of our assets; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with IFRS, and </span></div><div style="height:33.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that receipts and expenditures of the Company are being made only in accordance with authorizations of our management and directors; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the financial statements. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management, including the Company&#8217;s Chief Executive Officer and Chief Financial Officer, assessed the effectiveness of the Company&#8217;s internal control over financial reporting as of December 31, 2024. In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission, 2013 Framework, (COSO) in Internal Control-Integrated Framework.&#160;Based on this assessment, management believes that, as of December 31, 2024, the Company&#8217;s internal control over financial reporting was effective based on those criteria.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Attestation Report of the Registered Public Accounting Firm</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Auditor Attestation Report is included in the Ernst &amp; Young LLP Independent Auditor's Report, included in the Company's financial statements, beginning on page F-1 of this annual report on Form 20-F.</span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting that occurred during the period that is covered by this annual report that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.&#160;</span></div><div><span><br/></span></div><div id="i17734265916144358581fdce5df64f78_154"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 16 .&#160; [RESERVED]</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i17734265916144358581fdce5df64f78_157"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 16A.&#160; AUDIT COMMITTEE FINANCIAL EXPERT</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Board has determined that each of the Audit Committee members, Angela Holtham, Wayne Pisano, Deborah M. Brown, and James T. Parsons is an audit committee financial expert and each is independent pursuant to the Rule 5605(d)(2) of the Nasdaq Capital Market and Rule 10A-3 of the Exchange Act. For a description of the education and experience of each member of the Audit Committee, see "Item 6A. Directors, Senior Management and Employees."</span></div><div><span><br/></span></div><div id="i17734265916144358581fdce5df64f78_160"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 16B.&#160; CODE OF ETHICS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Board of Directors has adopted a Code of Ethics for the Company that includes our Chief Executive Officer, Chief Financial Officer and Accounting Officer that applies to our Chief Executive Officer, Chief Financial Officer, and Controller.&#160;A copy of this Code of Ethics may be found on the Company&#8217;s website at www.oncolyticsbiotech.com.&#160;Requests for such copies should be directed to us at the following address: Oncolytics Biotech Inc., 804, 322 11</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Avenue SW, Calgary, Alberta, Canada T2R 0C5, Attention:&#160;Kirk Look Telephone (403) 670 - 7377. Facsimile (403)&#160;283-0858 EMAIL: info@oncolyticsbiotech.com.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no amendments to our Code of Ethics during the fiscal year ended December 31, 2024. We did not grant any waivers to the provisions of our Code of Ethics during the fiscal year ended December 31, 2024.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i17734265916144358581fdce5df64f78_163"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 16C.&#160; PRINCIPAL ACCOUNTANT FEES AND SERVICES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Audit Fees and Services</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the financial years ended December 31, 2024 and 2023, Ernst &amp; Young LLP (PCAOB ID: <ix:nonNumeric contextRef="c-1" name="dei:AuditorFirmId" id="f-43">1263</ix:nonNumeric>) received the following fees:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.707%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.497%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Audit fees</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408,648&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">411,435&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Audit-related fees</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax fees</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,399&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,013&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All other fees</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Audit fees were for professional services rendered for the audit of our annual financial statements and services provided in connection with statutory and regulatory filings or engagements, including review of interim financial statements, accounting consultations, assistance with prospectus filings, and matters relating to the provision of a consent letter for various filings.</span></div><div style="height:33.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Audit-related fees were for assurance and related services reasonably related to the performance of the audit or review of the annual statements and are not reported under the heading Audit Fees above.&#160;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Tax fees were for tax return preparations, scientific research and development return, and other tax consultation fees.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Other fees are for products and services other than those described under the headings Audit Fees, Audit-Related Fees and Tax Fees above.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Audit Committee pre-approves all audit services to be provided to us by our independent auditors. The Audit Committee&#8217;s policy regarding the pre-approval of non-audit services to be provided to us by our independent auditors is that all such services shall be pre-approved by the Audit Committee or by the Chair of the Audit Committee, who must report all such pre-approvals to the Audit Committee at their next meeting following the granting thereof. Non-audit services that are prohibited to be provided to us by our independent auditors may not be pre-approved. In addition, prior to the granting of any pre-approval, the Audit Committee or the Chair, as the case may be, must be satisfied that the performance of the services in question will not compromise the independence of the independent auditors.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i17734265916144358581fdce5df64f78_166"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 16D. EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not Applicable.</span></div><div><span><br/></span></div><div id="i17734265916144358581fdce5df64f78_169"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 16E. PURCHASE OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i17734265916144358581fdce5df64f78_172"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 16F.&#160; CHANGE IN REGISTRANT&#8217;S CERTIFYING ACCOUNTANT</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div><span><br/></span></div><div id="i17734265916144358581fdce5df64f78_175"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 16G. CORPORATE GOVERNANCE</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NASDAQ CORPORATE GOVERNANCE</span></div><div style="margin-top:3.4pt;padding-left:4.5pt;padding-right:333pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common shares are quoted for trading on the Nasdaq Capital Market. Section 5615(a)(3) of the Nasdaq Marketplace Rules permits the Nasdaq to grant exemptions to a foreign private issuer for the provisions of the Rule 5600 series, Rule 5250 (d), and Rules 5210(c) and 5255 related to qualitative listing requirements. We are organized under the laws of the Province of Alberta and our common shares are listed for trading on The Toronto Stock Exchange. We comply with the laws of the Province of Alberta and rules and regulations of The Toronto Stock Exchange, including rules related to corporate governance practices. A description of the significant ways in which our governance practices differ from those followed by domestic companies pursuant to the Nasdaq Marketplace Rules is as follows:</span></div><div><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Shareholder Meeting Quorum Requirement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The Nasdaq minimum quorum requirement for a shareholder meeting under Section 5620(c) of the Nasdaq Marketplace Rules is one-third of the outstanding shares of common stock. In addition, a company listed on Nasdaq is required to state our quorum requirement in our bylaws. Our quorum requirement is set forth in our corporate bylaws. A quorum for our shareholder meeting is two persons present and being, or representing by proxy, members holding not less than 5% of the issued shares entitled to be voted at such meeting.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foregoing is consistent with the laws, customs and practices in Canada and the rules of The Toronto Stock Exchange.</span></div><div><span><br/></span></div><div id="i17734265916144358581fdce5df64f78_178"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 16H.&#160; MINE SAFETY DISCLOSURE</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i17734265916144358581fdce5df64f78_181"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 16I.&#160; DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:33.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><div id="i17734265916144358581fdce5df64f78_184"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 16J.&#160; INSIDER TRADING POLICIES</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 5, 2020, the Company approved its amended Corporate Trading Policy, which sets forth guidelines that apply to directors, officers and employees of the Company and its subsidiaries. There are also specific guidelines that apply to directors and officers, as follows:</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The <ix:nonNumeric contextRef="c-1" name="ecd:InsiderTrdPoliciesProcAdoptedFlag" format="ixt:fixed-true" id="f-44">Insider Trading Policy</ix:nonNumeric> provides for quarterly trading blackouts for all directors, officers and employees beginning five days prior to the meeting of the Audit Committee where the Financial Information will be reviewed and ending one day after public dissemination of the financial results of the fiscal quarter.</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Directors and officers should obtain pre-clearance for all trading activities from either the Chief Executive Officer or the Chief Financial Officer. This pre-clearance is intended to provide an additional review of current business initiatives to ensure that trading does not occur while material non-public information exists.</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Directors and officers must report all trading in securities to the Chief Financial Officer within 24 hours of the transaction taking place. Trading includes purchase and sale of securities, exercise of options, and transfer of securities.  </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The policy prohibits trading while in possession of material non-public information regarding the Company and prohibits short selling, trading in derivative securities, hedging transactions and other similar types of speculative trading in the Company&#8217;s securities.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A copy of the Insider Trading Policy has been filed herewith as Exhibit 11.1.</span></div><div><span><br/></span></div><div id="i17734265916144358581fdce5df64f78_187"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 16K.&#160; CYBERSECURITY</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Description of Processes for Assessing, Identifying and Managing Cybersecurity Risks</span></div><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" id="f-45" continuedAt="f-45-1" escape="true"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock" id="f-47" escape="true"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementProcessesIntegratedFlag" format="ixt:fixed-true" id="f-46"><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a cybersecurity program, which uses technology and Governance, Risk, and Compliance processes to help mitigate cybersecurity risks, with our management team working to monitor, assess, identify, and respond to potential cybersecurity incidents that threaten the Company. The program also focuses on security awareness and training for employees and contractors with access to Company facilities or systems. Cybersecurity risks for the Company include financial loss, loss of data, and business interruption. The Company maintains technology and non-technology based system controls, cybersecurity insurance, a robust backup program, and disaster recovery testing to mitigate these risks.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company has implemented a comprehensive cybersecurity risk management program to identify, assess, and manage material risks from cybersecurity threats. This program is integrated into our overall enterprise risk management framework and includes the following key components:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">Risk Assessment Process: We conduct regular cybersecurity risk assessments using industry-standard frameworks such as NIST CSF and CIS. These assessments help us identify potential vulnerabilities and prioritize our mitigation efforts.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">Threat Detection and Response: We have deployed advanced threat detection technologies and maintain an incident response plan that is regularly tested and updated.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">Third-Party Risk Management: We assess and monitor the cybersecurity practices of our key vendors and partners to mitigate supply chain risks.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">Employee Training and Awareness: We provide ongoing cybersecurity awareness training to all employees and conduct simulated phishing exercises to reinforce best practices.</span></div></ix:nonNumeric></ix:nonNumeric><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cybersecurity program also follows defense in depth principles, which aim to implement various layered access control, detection, prevention, and response measures. <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" format="ixt:fixed-true" id="f-48">We also engage with independent third parties to assess our vulnerabilities and help us mitigate cybersecurity-related risks. Our security posture is also tested by internal personnel and independent third parties to gauge its effectiveness from time to time.</ix:nonNumeric> </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Management&#8217;s Role in Assessing and Managing Cybersecurity Risks </span></div><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" id="f-50" continuedAt="f-50-1" escape="true"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskRoleOfManagementTextBlock" id="f-49" continuedAt="f-49-1" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s cybersecurity risk management and strategy processes for assessing, identifying, and managing material risks from cybersecurity threats are managed by members of the Company&#8217;s <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" format="ixt:fixed-true" id="f-51">management team</ix:nonNumeric>, primarily the Chief Executive Officer and the Chief Financial Officer. <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" format="ixt:fixed-true" id="f-52">Per the Company&#8217;s policies, cybersecurity incidents are to be immediately reported to the management team for resolution with outsourced IT support team.</ix:nonNumeric> Information technology general controls, including controls to mitigate cybersecurity risks, are included with management&#8217;s testing of internal control over financial reporting. <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" id="f-53" continuedAt="f-53-1" escape="true">A virtual Chief Information Security Officer is in place to help lead the Company's cybersecurity program. This individual, who </ix:nonNumeric></span></div></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric><div style="height:33.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="f-50-1"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-53-1"><ix:continuation id="f-49-1"><ix:continuation id="f-45-1">reports directly to the Chief Financial Officer, is well positioned, with over 25 years of experience in the field. He holds various industry-leading certifications along with a Master of Laws in cybersecurity and privacy law.</ix:continuation></ix:continuation></ix:continuation>  </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Board of Director&#8217;s Oversight of Risks from Cybersecurity</span></div><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" id="f-56" escape="true"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock" id="f-55" escape="true"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" id="f-54" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cybersecurity risks are included in an overall risk management assessment, which is reviewed annually by the Company&#8217;s audit committee. <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementThirdPartyEngagedFlag" format="ixt:fixed-true" id="f-57">The Company engages third-party specialists on a periodic basis to review key information technology systems and provide recommendations for system updates and improvements.</ix:nonNumeric> Results of these reviews are used to update information technology systems within the Company&#8217;s information system governance policies. <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" id="f-58" escape="true">The Company's management regularly discusses cyber trends and, should they arise, any material incidents with audit committee. The Company&#8217;s management will also review the Company&#8217;s cybersecurity program with the Board once every year.</ix:nonNumeric></span></div></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:continuation><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">No Previous Material Cybersecurity Threats</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" format="ixt:fixed-false" id="f-59">We are not aware of any previous cybersecurity threats that have materially affected or are reasonably likely to materially affect the Company.</ix:nonNumeric> Despite the security and risk management measures that we have implemented and any additional measures we may implement or adopt in the future, our facilities and systems, and those of our third-party service providers, have been and are vulnerable to security breaches, computer viruses, lost or misplaced data, programming errors, scams, burglary, human errors, acts of vandalism, misdirected wire transfers, or other malicious or criminal activities. A successful attack on our information or operational technology systems could have material consequences to the Company. While we devote resources to our security measures to protect our systems and information, these measures cannot provide absolute security. See &#8220;Item 3D. Risk Factors&#8221; for additional information about the risks to our business associated with a breach or compromise to our information technology systems. We acknowledge that cybersecurity threats are constantly evolving, and we remain vigilant in our efforts to protect our systems and data. </span></div><div><span><br/></span></div><div id="i17734265916144358581fdce5df64f78_190"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III</span></div><div><span><br/></span></div><div id="i17734265916144358581fdce5df64f78_193"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 17.  FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Item 18. &#8211; &#8220;Financial Statements&#8221;</span></div><div style="text-align:justify"><span><br/></span></div><div id="i17734265916144358581fdce5df64f78_196"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 18.  FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial statements appear on pages F-1 through F-27.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div id="i17734265916144358581fdce5df64f78_199"></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 19.  EXHIBITS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following exhibits are filed as part of this annual report:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:13.709%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:84.091%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EXHIBIT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">NUMBER</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">DESCRIPTION</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Constating Documents</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1129928/000112992822000017/articles.htm">Articles of Incorporation</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1129928/000112992822000017/ex12onc-2017byxlaws1636459.htm">By-laws</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description of Securities</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex21exdescriptionofsecurit.htm">Description of Securities Registered Under Section 12 of the Exchange Act</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Material Contracts</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1129928/000112992820000012/ex41august2013hagerman.htm">Employment Agreement, dated August 1, 2013 between Oncolytics Biotech Inc. and its Director, Manufacturing and Engineering, Allison Hagerman</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)#</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1129928/000112992818000028/ex444regionallicensingagre.htm">License, development, supply and distribution agreement with Adlai Nortye Biopharma Co., Ltd dated November 14, 2017 </a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1129928/000112992820000012/ex47hagermanamendment2019.htm">Amending Agreement, dated January 1, 2019 between Oncolytics Biotech Inc. and its Vice President, Product Development, Allison Hagerman</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1129928/000112992820000012/ex48kirklook2019.htm">Executive Employment Agreement, dated January 1, 2019 between Oncolytics Biotech Inc. and its Chief Financial Officer, Kirk Look</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1129928/000112992821000013/ex412employmentagreementth.htm">Employment Agreement, dated August 3, 2020 between Oncolytics Biotech (U.S.) Inc. and its Global Head of Clinical Development and Operations, Thomas C. Heineman </a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1129928/000112992823000008/ex421allisonhagermanamendm.htm">Amending Agreement, dated January 1, 2023 between Oncolytics Biotech Inc. and its Vice President, Product Development, Allison Hagerman</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1129928/000112992823000008/ex423thomasheinemanamendme.htm">Amending Agreement, dated January 1, 2023 between Oncolytics Biotech (U.S.) Inc. and its Chief Medical Officer, Thomas C. Heineman </a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1129928/000112992824000018/ex412employmentagreementam.htm">Employment Agreement, dated September 1, 2020 between Oncolytics Biotech (U.S.) Inc. and its Executive Director, Clinical Operations, Amy Goodowitz Levin</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1129928/000112992824000018/ex413-amylevinamendment1xe.htm">Amending Agreement, dated January 1, 2023 between Oncolytics Biotech (U.S.) Inc. and its Vice President, Clinical Operations, Amy Goodowitz Levin</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subsidiaries</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex80subsidiaries2024.htm">List of subsidiaries</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Certifications</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex121ceocertification2024.htm">Certificate of the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex122cfocertification2024.htm">Certificate of the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex131ceocertification2024.htm">Certificate of the Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex132cfocertification2024.htm">Certificate of the Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Exhibits</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(e)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1129928/000112992824000018/ex161-corptradingpolicyrev.htm">Insider Trading Policy</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex151-2024mda.htm">The Registrant's Management's Discussion and Analysis for the Year Ended December 31, 2024</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex152ey2024consent.htm">Consent of Ernst &amp; Young LLP</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(e)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1129928/000112992824000018/ex971oncolyticsclawbackpol.htm">Clawback Policy</a></span></div></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:13.709%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:84.091%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File as its XBRL tags are embedded within the Inline XBRL document.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Inline XBRL Taxonomy Extension Schema.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Inline XBRL Taxonomy Extension Scheme Calculation Linkbase.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Inline XBRL Taxonomy Extension Scheme Definition Linkbase.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Inline XBRL Taxonomy Extension Scheme Label Linkbase.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Inline XBRL Taxonomy Extension Scheme Presentation Linkbase.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Cover page interactive data file (formatted as Inline XBRL and included in Exhibit 101)</span></div></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">* - Denotes management contract or agreement</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"># - Certain portions of this exhibit have been redacted pursuant to a confidential treatment request filed with the SEC on March 19, 2018</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Previously filed with the SEC on Form 20-F dated March 19, 2018, and incorporated by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Previously filed with the SEC on Form 20-F dated March 6, 2020, and incorporated by reference.  </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c) Previously filed with the SEC on Form 20-F dated March 5, 2021, and incorporated by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) Previously filed with the SEC on Form 20-F dated March 3, 2022, and incorporated by reference. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(e) Previously filed with the SEC on Form 20-F dated March 12, 2024, and incorporated by reference.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:33.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><div id="i17734265916144358581fdce5df64f78_202"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURE</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The registrant hereby certifies that it meets all of the requirements for filing on Form 20-F and that it has duly caused and authorized the undersigned to sign this annual report on its behalf.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date: March&#160;7, 2025 </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/Wayne Pisano&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/Kirk Look&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wayne Pisano</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kirk Look, CA</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interim Chief Executive Officer&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><div id="i17734265916144358581fdce5df64f78_205"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Consolidated Financial Statements</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Oncolytics Biotech</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> Inc.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2024</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i17734265916144358581fdce5df64f78_208"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">STATEMENT OF MANAGEMENT&#8217;S RESPONSIBILITY</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management is responsible for the preparation and presentation of the consolidated financial statements, Management&#8217;s Discussion and Analysis (&#8220;MD&amp;A&#8221;), and all other information in the annual report.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In management&#8217;s opinion, the accompanying consolidated financial statements have been properly prepared within reasonable limits of materiality and in accordance with the appropriately selected International Financial Reporting Standards as issued by the International Accounting Standards Board consistently applied and summarized in the consolidated financial statements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include estimates that are necessary when transactions affecting the current accounting period cannot be finalized with certainty until after the balance sheet date.&#160;Based on careful judgments by management, such estimates have been properly reflected in the accompanying consolidated financial statements.&#160;The financial information presented elsewhere in the annual report has been reviewed to ensure consistency with that in the consolidated financial statements. The MD&amp;A also includes information regarding the impact of current transactions and events, sources of liquidity and capital resources, and risks and uncertainty.&#160;Actual results in the future may differ materially from our present assessment of this information because future events and circumstances may not occur as expected.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Systems of internal controls, including organizational and procedural controls and internal controls over financial reporting, assessed as reasonable and appropriate in the circumstances, are designed and maintained by management to provide reasonable assurance that assets are safeguarded from loss or unauthorized use and to produce reliable records for preparation of financial statements. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:AuditorName" id="f-60">Ernst &amp; Young LLP</ix:nonNumeric>, an independent firm of Chartered Professional Accountants, has been engaged, as approved by a vote of the shareholders at the Company's most recent Annual General Meeting, to audit and provide their independent audit opinion on the following: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">Company's consolidated financial statements as at and for the year ended December&#160;31, 2024; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">the effectiveness of the Company's internal control over financial reporting as at December&#160;31, 2024.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ernst &amp; Young has full and free access to our Board of Directors and its Committees to discuss audit, financial reporting, and related matters.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Board of Directors is responsible for ensuring that management fulfills its responsibilities for financial reporting and internal control.&#160;The Board exercises this responsibility through the Audit Committee of the Board, which is comprised entirely of independent directors.&#160;This Committee meets with management and the external auditors to satisfy itself that management&#8217;s responsibilities are properly discharged and to review the consolidated financial statements and MD&amp;A before they are presented to the Board of Directors for approval. The consolidated financial statements have been approved by the Board on the recommendation of the Audit Committee.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;/s/Wayne Pisano&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;/s/Kirk Look&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wayne Pisano</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kirk Look, CA</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interim Chief Executive Officer&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-1</span></div></div></div><div id="i17734265916144358581fdce5df64f78_211"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following report is provided by management in respect of the Company&#8217;s internal control over financial reporting (as defined in Rule 13a-15(f) and 15d-15(f) under the U.S. Securities Exchange Act of 1934):</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MANAGEMENT&#8217;S REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Management is responsible for establishing and maintaining adequate internal control over the Company&#8217;s financial reporting.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Management has used the Committee of Sponsoring Organizations of the Treadway Commission (COSO) framework (2013) in Internal Control - Integrated Framework to evaluate the effectiveness of the Company&#8217;s internal control over financial reporting.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Management has assessed the effectiveness of the Company&#8217;s internal control over financial reporting as at December&#160;31, 2024, and has concluded that such internal control over financial reporting was effective as of that date. Additionally, based on this assessment, management determined that there were no material weaknesses in internal control over financial reporting as at December&#160;31, 2024. Because of inherent limitations, systems of internal control over financial reporting may not prevent or detect misstatements and even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The effectiveness of the Company&#8217;s internal control over financial reporting as at December&#160;31, 2024, has been audited by Ernst &amp; Young, independent auditor, as stated in their report which appears herein.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;/s/Wayne Pisano&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;/s/Kirk Look&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wayne Pisano</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kirk Look, CA</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interim Chief Executive Officer&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-2</span></div></div></div><div id="i17734265916144358581fdce5df64f78_214"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Shareholders and the Board of Directors of Oncolytics Biotech Inc. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on the Financial Statements</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated statements of financial position of Oncolytics Biotech Inc. (the Company) as of December 31, 2024 and 2023, the related consolidated statements of loss and comprehensive loss, changes in equity and cash flows for each of the three years in the period ended December 31, 2024, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2024 and 2023, and its financial performance and its cash flows for each of the three years in the period ended December 31, 2024, in conformity with International Financial Reporting Standards (IFRSs) as issued by the International Accounting Standards Board.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December 31, 2024, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework),</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and our report dated March 6, 2025 expressed an unqualified opinion thereon.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The Company&#8217;s ability to Continue as a Going Concern</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements, the Company has suffered recurring losses from operations, has a working capital deficiency, and has stated that substantial doubt exists about the Company&#8217;s ability to continue as a going concern. Management's evaluation of the events and conditions and management&#8217;s plans regarding these matters are also described in Note 1. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Audit Matters</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Critical audit matters are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. We determined that there are no critical audit matters.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Ernst &amp; Young LLP</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chartered Professional Accountants </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company's auditor since 1999. </span></div><div style="margin-bottom:4pt;margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:47.953%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:AuditorLocation" id="f-61">Calgary, Canada</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 6, 2025</span></td></tr></table></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-3</span></div></div></div><div id="i17734265916144358581fdce5df64f78_217"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Shareholders and Board of Directors of Oncolytics Biotech Inc.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on Internal Control Over Financial Reporting </span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited Oncolytics Biotech Inc.&#8217;s internal control over financial reporting as of December 31, 2024, based on criteria established in Internal Control&#8212;Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework), (the COSO criteria). In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2024 based on the COSO criteria</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">. </span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated statements of financial position of Oncolytics Biotech Inc. as of December 31, 2024 and 2023, the related consolidated statements of loss and comprehensive loss, changes in equity and cash flows for each of the three years in the period ended December 31, 2024, and the related notes, and our report dated March 6, 2025 expressed an unqualified opinion thereon that included an explanatory paragraph regarding the Company&#8217;s ability to continue as a going concern.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion </span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management&#8217;s Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion. </span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Definition and Inherent Limitations of Internal Control Over Financial Reporting </span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the consolidated financial statements. </span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Ernst &amp; Young LLP</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chartered Professional Accountants</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:47.953%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Calgary, Canada</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 6, 2025</span></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-4</span></div></div></div><div id="i17734265916144358581fdce5df64f78_220"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF FINANCIAL POSITION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(in thousands of Canadian dollars, except share amounts) </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.081%"><tr><td style="width:1.0%"/><td style="width:67.439%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.309%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.442%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.310%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at December 31, </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-62">15,942</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-4" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-63">34,912</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:OtherCurrentReceivables" scale="3" id="f-64">68</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-4" decimals="-3" name="ifrs-full:OtherCurrentReceivables" scale="3" id="f-65">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:CurrentPrepayments" format="ixt:num-dot-decimal" scale="3" id="f-66">1,885</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-4" decimals="-3" name="ifrs-full:CurrentPrepayments" format="ixt:num-dot-decimal" scale="3" id="f-67">3,246</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant derivative (notes 9, 17)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:CurrentDerivativeFinancialAssets" scale="3" id="f-68">980</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-4" decimals="-3" name="ifrs-full:CurrentDerivativeFinancialAssets" format="ixt:fixed-zero" scale="3" id="f-69">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:CurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-70">18,875</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-4" decimals="-3" name="ifrs-full:CurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-71">38,173</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment (note 6)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-72">411</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-4" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-73">282</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets (note 8)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:RightofuseAssets" scale="3" id="f-74">901</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-4" decimals="-3" name="ifrs-full:RightofuseAssets" scale="3" id="f-75">365</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:Assets" format="ixt:num-dot-decimal" scale="3" id="f-76">20,187</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-4" decimals="-3" name="ifrs-full:Assets" format="ixt:num-dot-decimal" scale="3" id="f-77">38,820</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities And Shareholders&#8217; Equity</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities (note 7)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:TradeAndOtherCurrentPayables" format="ixt:num-dot-decimal" scale="3" id="f-78">4,792</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-4" decimals="-3" name="ifrs-full:TradeAndOtherCurrentPayables" format="ixt:num-dot-decimal" scale="3" id="f-79">3,572</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities (note 5)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:OtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-80">1,618</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-4" decimals="-3" name="ifrs-full:OtherCurrentLiabilities" scale="3" id="f-81">332</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities (note 8)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:CurrentLeaseLiabilities" scale="3" id="f-82">277</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-4" decimals="-3" name="ifrs-full:CurrentLeaseLiabilities" scale="3" id="f-83">133</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant derivative (notes 9, 17)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:CurrentDerivativeFinancialLiabilities" format="ixt:fixed-zero" scale="3" id="f-84">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-4" decimals="-3" name="ifrs-full:CurrentDerivativeFinancialLiabilities" scale="3" id="f-85">200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:CurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-86">6,687</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-4" decimals="-3" name="ifrs-full:CurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-87">4,237</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liability (note 13)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:NoncurrentContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-88">6,730</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-4" decimals="-3" name="ifrs-full:NoncurrentContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-89">6,730</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities (note 8)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:NoncurrentLeaseLiabilities" scale="3" id="f-90">787</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-4" decimals="-3" name="ifrs-full:NoncurrentLeaseLiabilities" scale="3" id="f-91">290</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-92">14,204</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-4" decimals="-3" name="ifrs-full:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-93">11,257</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies (note 14)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="cad" contextRef="c-3" xsi:nil="true" name="oncyf:CommitmentsAndContingencies1" id="f-94"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="cad" contextRef="c-4" xsi:nil="true" name="oncyf:CommitmentsAndContingencies1" id="f-95"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shareholders&#8217; equity</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share capital (note 10)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Authorized: unlimited</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Issued: December&#160;31, 2024 &#8211; <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="ifrs-full:NumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-96">80,020,131</ix:nonFraction></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;December&#160;31, 2023 &#8211; <ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="ifrs-full:NumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-97">74,423,960</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:IssuedCapital" format="ixt:num-dot-decimal" scale="3" id="f-98">438,193</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-4" decimals="-3" name="ifrs-full:IssuedCapital" format="ixt:num-dot-decimal" scale="3" id="f-99">430,906</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contributed surplus (note 11)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:AdditionalPaidinCapital" format="ixt:num-dot-decimal" scale="3" id="f-100">44,542</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-4" decimals="-3" name="ifrs-full:AdditionalPaidinCapital" format="ixt:num-dot-decimal" scale="3" id="f-101">42,116</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:AccumulatedOtherComprehensiveIncome" scale="3" id="f-102">961</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-4" decimals="-3" name="ifrs-full:AccumulatedOtherComprehensiveIncome" scale="3" id="f-103">544</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" sign="-" name="ifrs-full:RetainedEarnings" format="ixt:num-dot-decimal" scale="3" id="f-104">477,713</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-4" decimals="-3" sign="-" name="ifrs-full:RetainedEarnings" format="ixt:num-dot-decimal" scale="3" id="f-105">446,003</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total shareholders&#8217; equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-106">5,983</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-4" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-107">27,563</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities and shareholders' equity </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:EquityAndLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-108">20,187</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-4" decimals="-3" name="ifrs-full:EquityAndLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-109">38,820</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">          See accompanying notes</span></div><div style="padding-left:22.5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span></div><div style="margin-top:5pt;padding-left:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:65.204%"><tr><td style="width:1.0%"/><td style="width:46.209%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:51.591%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;On behalf of the Board:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/Angela Holtham</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/Deborah M. Brown</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Director&#160;&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Director&#160;&#160;&#160;</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-5</span></div></div></div><div id="i17734265916144358581fdce5df64f78_223"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF LOSS AND COMPREHENSIVE LOSS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(in thousands of Canadian dollars, except share amounts) </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.940%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.793%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the years ended December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expenses</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Research and development (note 20)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-110">21,647</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" name="ifrs-full:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-111">17,709</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" name="ifrs-full:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-112">15,432</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;General and administrative (note 20)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-113">13,335</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" name="ifrs-full:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-114">16,082</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" name="ifrs-full:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-115">11,492</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss before the following</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:ProfitLossFromOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-116">34,982</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" sign="-" name="ifrs-full:ProfitLossFromOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-117">33,791</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" sign="-" name="ifrs-full:ProfitLossFromOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-118">26,924</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Change in fair value of warrant derivative (notes 9, 17)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives" format="ixt:num-dot-decimal" scale="3" id="f-119">1,242</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" name="ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives" format="ixt:num-dot-decimal" scale="3" id="f-120">5,285</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" sign="-" name="ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives" scale="3" id="f-121">20</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Foreign exchange gain (loss)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" scale="3" id="f-122">961</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" sign="-" name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" scale="3" id="f-123">475</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" format="ixt:num-dot-decimal" scale="3" id="f-124">1,665</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Interest income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:InterestIncomeOnCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-125">1,199</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" name="ifrs-full:InterestIncomeOnCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-126">1,326</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" name="ifrs-full:InterestIncomeOnCashAndCashEquivalents" scale="3" id="f-127">528</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss before income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:ProfitLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="f-128">31,580</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" sign="-" name="ifrs-full:ProfitLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="f-129">27,655</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" sign="-" name="ifrs-full:ProfitLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="f-130">24,751</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Income tax expense (note 15)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:IncomeTaxExpenseContinuingOperations" scale="3" id="f-131">130</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" name="ifrs-full:IncomeTaxExpenseContinuingOperations" scale="3" id="f-132">97</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" name="ifrs-full:IncomeTaxExpenseContinuingOperations" scale="3" id="f-133">84</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-134">31,710</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-135">27,752</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-136">24,835</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other comprehensive income (loss) items that may be reclassified to net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Translation adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" scale="3" id="f-137">417</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" sign="-" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" scale="3" id="f-138">118</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" scale="3" id="f-139">274</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Comprehensive loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="f-140">31,293</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" sign="-" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="f-141">27,870</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" sign="-" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="f-142">24,561</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic and diluted loss per common share (note 12)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cadPerShare" contextRef="c-1" decimals="2" sign="-" name="ifrs-full:DilutedEarningsLossPerShare" scale="0" id="f-143"><ix:nonFraction unitRef="cadPerShare" contextRef="c-1" decimals="2" sign="-" name="ifrs-full:BasicEarningsLossPerShare" scale="0" id="f-144">0.41</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cadPerShare" contextRef="c-7" decimals="2" sign="-" name="ifrs-full:BasicEarningsLossPerShare" scale="0" id="f-145"><ix:nonFraction unitRef="cadPerShare" contextRef="c-7" decimals="2" sign="-" name="ifrs-full:DilutedEarningsLossPerShare" scale="0" id="f-146">0.41</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cadPerShare" contextRef="c-8" decimals="2" sign="-" name="ifrs-full:BasicEarningsLossPerShare" scale="0" id="f-147"><ix:nonFraction unitRef="cadPerShare" contextRef="c-8" decimals="2" sign="-" name="ifrs-full:DilutedEarningsLossPerShare" scale="0" id="f-148">0.43</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average number of shares (basic and diluted) (note 12)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="ifrs-full:AdjustedWeightedAverageShares" format="ixt:num-dot-decimal" scale="0" id="f-149"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="ifrs-full:WeightedAverageShares" format="ixt:num-dot-decimal" scale="0" id="f-150">76,482,914</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="0" name="ifrs-full:WeightedAverageShares" format="ixt:num-dot-decimal" scale="0" id="f-151"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="0" name="ifrs-full:AdjustedWeightedAverageShares" format="ixt:num-dot-decimal" scale="0" id="f-152">67,624,036</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="0" name="ifrs-full:WeightedAverageShares" format="ixt:num-dot-decimal" scale="0" id="f-153"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="0" name="ifrs-full:AdjustedWeightedAverageShares" format="ixt:num-dot-decimal" scale="0" id="f-154">58,029,745</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:45pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-6</span></div></div></div><div id="i17734265916144358581fdce5df64f78_226"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(in thousands of Canadian dollars) </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.350%"><tr><td style="width:1.0%"/><td style="width:35.174%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.030%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.235%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.030%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.235%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.030%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.235%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.793%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.235%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.030%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.235%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Share Capital</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Warrants</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contributed Surplus</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2021</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-9" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-155">391,348</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-10" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-156">3,618</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-11" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-157">34,161</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-12" decimals="-3" name="ifrs-full:Equity" scale="3" id="f-158">388</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-13" decimals="-3" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-159">393,416</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-14" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-160">36,099</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss and other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-15" decimals="-3" name="ifrs-full:ComprehensiveIncome" scale="3" id="f-161">274</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-16" decimals="-3" sign="-" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="f-162">24,835</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" sign="-" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="f-163">24,561</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to stock option plan (note 11)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-17" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="3" id="f-164">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-18" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="3" id="f-165">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="3" id="f-166">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to incentive share award plan (note 11)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-17" decimals="-3" name="oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity" scale="3" id="f-167">98</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-18" decimals="-3" sign="-" name="oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity" scale="3" id="f-168">98</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" name="oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity" format="ixt:fixed-zero" scale="3" id="f-169">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expiry of equity warrant agreement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-19" decimals="-3" sign="-" name="oncyf:IncreaseDecreaseThroughExpirationOfWarrantEquity" format="ixt:num-dot-decimal" scale="3" id="f-170">3,618</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-18" decimals="-3" name="oncyf:IncreaseDecreaseThroughExpirationOfWarrantEquity" format="ixt:num-dot-decimal" scale="3" id="f-171">3,618</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" name="oncyf:IncreaseDecreaseThroughExpirationOfWarrantEquity" format="ixt:fixed-zero" scale="3" id="f-172">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to "At the Market" Agreement (note 10)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-17" decimals="-3" name="ifrs-full:IssueOfEquity" format="ixt:num-dot-decimal" scale="3" id="f-173">13,338</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" name="ifrs-full:IssueOfEquity" format="ixt:num-dot-decimal" scale="3" id="f-174">13,338</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share issue costs (note 10)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-17" decimals="-3" name="ifrs-full:ShareIssueRelatedCost" scale="3" id="f-175">764</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" name="ifrs-full:ShareIssueRelatedCost" scale="3" id="f-176">764</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense (note 11)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-18" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" format="ixt:num-dot-decimal" scale="3" id="f-177">2,378</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" format="ixt:num-dot-decimal" scale="3" id="f-178">2,378</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2022</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-20" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-179">404,040</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-21" decimals="-3" name="ifrs-full:Equity" format="ixt:fixed-zero" scale="3" id="f-180">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-22" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-181">40,051</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-23" decimals="-3" name="ifrs-full:Equity" scale="3" id="f-182">662</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-24" decimals="-3" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-183">418,251</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-25" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-184">26,502</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss and other comprehensive income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-26" decimals="-3" sign="-" name="ifrs-full:ComprehensiveIncome" scale="3" id="f-185">118</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-27" decimals="-3" sign="-" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="f-186">27,752</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" sign="-" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="f-187">27,870</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to stock option plan (note 11)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-28" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" format="ixt:num-dot-decimal" scale="3" id="f-188">1,271</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-29" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="3" id="f-189">490</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="3" id="f-190">781</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to "At the Market" Agreement (note 10)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-30" decimals="-3" name="ifrs-full:IssueOfEquity" format="ixt:num-dot-decimal" scale="3" id="f-191">10,676</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-31" decimals="-3" name="ifrs-full:IssueOfEquity" format="ixt:num-dot-decimal" scale="3" id="f-192">10,676</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to public offering (note 10)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-32" decimals="-3" name="ifrs-full:IssueOfEquity" format="ixt:num-dot-decimal" scale="3" id="f-193">17,724</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-33" decimals="-3" name="ifrs-full:IssueOfEquity" scale="3" id="f-194">638</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-34" decimals="-3" name="ifrs-full:IssueOfEquity" format="ixt:num-dot-decimal" scale="3" id="f-195">18,362</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share issue costs (note 10)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-28" decimals="-3" name="ifrs-full:ShareIssueRelatedCost" format="ixt:num-dot-decimal" scale="3" id="f-196">2,805</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" name="ifrs-full:ShareIssueRelatedCost" format="ixt:num-dot-decimal" scale="3" id="f-197">2,805</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense (note 11)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-29" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" format="ixt:num-dot-decimal" scale="3" id="f-198">1,917</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" format="ixt:num-dot-decimal" scale="3" id="f-199">1,917</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2023</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-6" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-200">430,906</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-35" decimals="-3" name="ifrs-full:Equity" format="ixt:fixed-zero" scale="3" id="f-201">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-36" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-202">42,116</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-37" decimals="-3" name="ifrs-full:Equity" scale="3" id="f-203">544</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-38" decimals="-3" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-204">446,003</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-4" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-205">27,563</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss and other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-39" decimals="-3" name="ifrs-full:ComprehensiveIncome" scale="3" id="f-206">417</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-40" decimals="-3" sign="-" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="f-207">31,710</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="f-208">31,293</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to incentive share award plan (note 11)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-41" decimals="-3" name="oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity" scale="3" id="f-209">297</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-42" decimals="-3" sign="-" name="oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity" scale="3" id="f-210">297</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity" format="ixt:fixed-zero" scale="3" id="f-211">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to warrant derivative exercised (notes 9, 10)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-41" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" scale="3" id="f-212">71</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" scale="3" id="f-213">71</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to "At the Market" Agreement (note 10)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-43" decimals="-3" name="ifrs-full:IssueOfEquity" format="ixt:num-dot-decimal" scale="3" id="f-214">7,670</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-44" decimals="-3" name="ifrs-full:IssueOfEquity" format="ixt:num-dot-decimal" scale="3" id="f-215">7,670</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share issue costs (note 10)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-41" decimals="-3" name="ifrs-full:ShareIssueRelatedCost" scale="3" id="f-216">751</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:ShareIssueRelatedCost" scale="3" id="f-217">751</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense (note 11)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-42" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" format="ixt:num-dot-decimal" scale="3" id="f-218">2,723</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" format="ixt:num-dot-decimal" scale="3" id="f-219">2,723</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at December 31, 2024</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-5" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-220">438,193</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-45" decimals="-3" name="ifrs-full:Equity" format="ixt:fixed-zero" scale="3" id="f-221">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-46" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-222">44,542</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-47" decimals="-3" name="ifrs-full:Equity" scale="3" id="f-223">961</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-48" decimals="-3" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-224">477,713</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-225">5,983</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-7</span></div></div></div><div id="i17734265916144358581fdce5df64f78_229"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(in thousands of Canadian dollars)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:58.458%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.988%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.388%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.988%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.388%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.990%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the years ended December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss for the year</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-226">31,710</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-227">27,752</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-228">24,835</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation - property and equipment (notes 6, 20)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense" scale="3" id="f-229">120</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" name="ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense" scale="3" id="f-230">81</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" name="ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense" scale="3" id="f-231">93</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation - right-of-use assets (notes 8, 20)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="oncyf:AdjustmentsForDepreciationRightOfUseAssets" scale="3" id="f-232">304</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" name="oncyf:AdjustmentsForDepreciationRightOfUseAssets" scale="3" id="f-233">322</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" name="oncyf:AdjustmentsForDepreciationRightOfUseAssets" scale="3" id="f-234">299</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense (notes 11, 20, 22)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:AdjustmentsForSharebasedPayments" format="ixt:num-dot-decimal" scale="3" id="f-235">2,723</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" name="ifrs-full:AdjustmentsForSharebasedPayments" format="ixt:num-dot-decimal" scale="3" id="f-236">1,917</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" name="ifrs-full:AdjustmentsForSharebasedPayments" format="ixt:num-dot-decimal" scale="3" id="f-237">2,378</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation warrant expenses (note 11)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="3" id="f-238">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="3" id="f-239">151</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="3" id="f-240">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense (income), net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:InterestRevenueExpense" scale="3" id="f-241">139</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" sign="-" name="ifrs-full:InterestRevenueExpense" scale="3" id="f-242">71</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" name="ifrs-full:InterestRevenueExpense" scale="3" id="f-243">76</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized foreign exchange (gain) loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains" scale="3" id="f-244">838</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" name="ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains" scale="3" id="f-245">282</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" sign="-" name="ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains" format="ixt:num-dot-decimal" scale="3" id="f-246">1,625</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of warrant derivative (notes 9, 17)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives" format="ixt:num-dot-decimal" scale="3" id="f-247">1,242</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" name="ifrs-full:AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives" format="ixt:num-dot-decimal" scale="3" id="f-248">5,285</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" sign="-" name="ifrs-full:AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives" scale="3" id="f-249">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change in non-cash working capital (note 18)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseInWorkingCapital" format="ixt:num-dot-decimal" scale="3" id="f-250">3,538</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseInWorkingCapital" format="ixt:num-dot-decimal" scale="3" id="f-251">1,765</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseInWorkingCapital" scale="3" id="f-252">391</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash used in operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:CashFlowsFromUsedInOperations" format="ixt:num-dot-decimal" scale="3" id="f-253">26,966</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" sign="-" name="ifrs-full:CashFlowsFromUsedInOperations" format="ixt:num-dot-decimal" scale="3" id="f-254">28,448</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" sign="-" name="ifrs-full:CashFlowsFromUsedInOperations" format="ixt:num-dot-decimal" scale="3" id="f-255">23,355</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Investing Activities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" format="ixt:fixed-zero" scale="3" id="f-256">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" name="ifrs-full:PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" format="ixt:fixed-zero" scale="3" id="f-257">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" name="ifrs-full:PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-258">20,348</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturities of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" format="ixt:fixed-zero" scale="3" id="f-259">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" name="ifrs-full:ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-260">20,230</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" name="ifrs-full:ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" format="ixt:fixed-zero" scale="3" id="f-261">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition of property and equipment (note 6)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" scale="3" id="f-262">239</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" scale="3" id="f-263">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" scale="3" id="f-264">55</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash (used in) provided by investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" scale="3" id="f-265">239</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-266">20,222</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" sign="-" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-267">20,403</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financing Activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from exercise of stock options (note 11)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:ProceedsFromExerciseOfOptions" format="ixt:fixed-zero" scale="3" id="f-268">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" name="ifrs-full:ProceedsFromExerciseOfOptions" scale="3" id="f-269">781</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" name="ifrs-full:ProceedsFromExerciseOfOptions" scale="3" id="f-270">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from exercise of warrant derivative (note 9)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:ProceedsFromExerciseOfWarrants" scale="3" id="f-271">65</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" name="ifrs-full:ProceedsFromExerciseOfWarrants" format="ixt:fixed-zero" scale="3" id="f-272">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" name="ifrs-full:ProceedsFromExerciseOfWarrants" format="ixt:fixed-zero" scale="3" id="f-273">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from "At the Market" equity distribution agreement (note 10)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-44" decimals="-3" name="ifrs-full:ProceedsFromIssuingShares" format="ixt:num-dot-decimal" scale="3" id="f-274">6,919</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-31" decimals="-3" name="ifrs-full:ProceedsFromIssuingShares" format="ixt:num-dot-decimal" scale="3" id="f-275">10,261</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-49" decimals="-3" name="ifrs-full:ProceedsFromIssuingShares" format="ixt:num-dot-decimal" scale="3" id="f-276">12,574</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from public offering (note 10)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-50" decimals="-3" name="ifrs-full:ProceedsFromIssuingShares" format="ixt:fixed-zero" scale="3" id="f-277">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-51" decimals="-3" name="ifrs-full:ProceedsFromIssuingShares" format="ixt:num-dot-decimal" scale="3" id="f-278">21,359</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-52" decimals="-3" name="ifrs-full:ProceedsFromIssuingShares" format="ixt:fixed-zero" scale="3" id="f-279">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment of lease liabilities (note 8)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:CashOutflowForLeases" scale="3" id="f-280">348</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" name="ifrs-full:CashOutflowForLeases" scale="3" id="f-281">407</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" name="ifrs-full:CashOutflowForLeases" scale="3" id="f-282">381</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-283">6,636</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-284">31,994</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-285">12,205</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Decrease) increase in cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-286">20,569</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-287">23,768</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-288">31,553</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents, beginning of year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-4" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-289">34,912</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-25" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-290">11,666</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-14" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-291">41,262</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of foreign exchange on cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-292">1,599</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" sign="-" name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" scale="3" id="f-293">522</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-294">1,957</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash and cash equivalents, end of year</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-295">15,942</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-4" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-296">34,912</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-25" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-297">11,666</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:36pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-8</span></div></div></div><div id="i17734265916144358581fdce5df64f78_232"></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2024</span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands of Canadian dollars, except share amounts and where indicated)</span></div><div style="margin-bottom:10pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><div id="i17734265916144358581fdce5df64f78_235"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Note 1: <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" id="f-298" continuedAt="f-298-1" escape="true">Nature of Operations and Going Concern</ix:nonNumeric></span></div><ix:continuation id="f-298-1" continuedAt="f-298-2"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Oncolytics Biotech Inc. was incorporated on April 2, 1998, under the Business Corporations Act (Alberta) as 779738 Alberta Ltd. On April 8, 1998, we changed our name to Oncolytics Biotech Inc. We are a limited company incorporated and domiciled in Canada. Our shares are publicly traded on the Nasdaq Capital Market and the Toronto Stock Exchange. Our principal place of business is located at 804, 322 11</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Avenue S.W., Calgary, Alberta, Canada.   </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage biopharmaceutical company developing pelareorep, a well-tolerated intravenously delivered</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. Our primary focus is to advance our programs in hormone receptor-positive / human epidermal growth factor 2-negative (HR+/HER2-) advanced and metastatic breast cancer and metastatic pancreatic ductal adenocarcinoma to registration-enabled clinical studies. In addition, we are exploring opportunities for registrational programs in other gastrointestinal cancers through our GOBLET platform study. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not been profitable since our inception and expect to continue to incur substantial losses as we continue our research and development efforts. As at December&#160;31, 2024, we had an accumulated deficit of $<ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" sign="-" name="ifrs-full:RetainedEarnings" format="ixt:num-dot-decimal" scale="3" id="f-299">477,713</ix:nonFraction>. We do not expect to generate significant revenues until and unless pelareorep becomes commercially viable. To date, we have funded our operations mainly through issuing additional capital via public offerings, equity distribution arrangements, and the exercise of warrants and stock options. </span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfUncertaintiesOfEntitysAbilityToContinueAsGoingConcern" id="f-300" continuedAt="f-300-1" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Going concern</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management assesses our ability to continue as a going concern when preparing our consolidated financial statements. In assessing whether the going concern assumption is appropriate, management takes into account all available information about the future, which is at least, but not limited to, twelve months from the end of the reporting period. As at December&#160;31, 2024, we had cash and cash equivalents of $<ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-301">15,942</ix:nonFraction>. Subsequent to December&#160;31, 2024, we further raised net proceeds of $<ix:nonFraction unitRef="cad" contextRef="c-53" decimals="-3" name="ifrs-full:ProceedsFromIssueOfOrdinaryShares" format="ixt:num-dot-decimal" scale="3" id="f-302">6,041</ix:nonFraction> (see note 23). Without raising additional funding or reducing or eliminating our planned expenditures, we estimated our cash and cash equivalents to fund our operations into the third quarter of 2025. Factors that will affect our anticipated cash needs for the next twelve months include, but are not limited to, expansion of our clinical trial program, the timing of patient enrollment in our clinical trials, the actual costs incurred to support each clinical trial, the number of treatments each patient will receive, the timing of activity with our clinical trial research collaborations, the number, timing and costs of manufacturing runs required to conclude the validation process and supply product to our clinical trial program, and the level of collaborative activity undertaken. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to continue as a going concern is dependent upon raising additional financing through equity or strategic collaborations and transactions. We plan on raising additional funds through the sale of our common shares or other capital resources, such as collaborations and debt, to fund our ongoing operations. However, given the difficulty for micro-cap market capitalization companies to raise significant capital and the matter in note 23(b), there can be no assurance that additional liquidity will be available under acceptable terms or at all. Furthermore, if we are unable to obtain additional financing when required, there can be no assurance that we will be able to sufficiently reduce or eliminate our planned expenditures to extend our operating runway. These material uncertainties raise substantial doubt on our ability to continue as a going concern and meet our obligations as they come due and, accordingly, the appropriateness of the use of accounting principles applicable to a going concern.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These consolidated financial statements were prepared in accordance with International Financial Reporting Standards ("IFRS") applicable to a going concern. However, the use of the going concern assumption on which these consolidated financial statements are prepared may not be appropriate based on the factors described above.</span></div></ix:nonNumeric></ix:continuation><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-300-1"><ix:continuation id="f-298-2">These consolidated financial statements do not reflect the adjustments to the carrying values of assets and liabilities and the reported expenses and statements of financial position classifications that would be necessary if we were unable to realize our assets and settle our liabilities as a going concern in the normal course of operations. Such adjustments could be material.</ix:continuation></ix:continuation> </span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-9</span></div></div></div><div id="i17734265916144358581fdce5df64f78_238"></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2024</span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands of Canadian dollars, except share amounts and where indicated)</span></div><div style="margin-bottom:10pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Note 2: <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" id="f-303" continuedAt="f-303-1" escape="true">Basis of Presentation</ix:nonNumeric></span></div><ix:continuation id="f-303-1" continuedAt="f-303-2"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Statement of compliance</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These consolidated financial statements have been prepared in accordance with IFRS as issued by the International Accounting Standards Board ("IASB"). </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated financial statements for the year ended December&#160;31, 2024, were authorized for issue in accordance with a resolution of the Board of Directors (the "Board") on March&#160;6, 2025. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of presentation</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated financial statements include our financial statements and the financial statements of our subsidiaries, Oncolytics Biotech (Barbados) Inc. and Oncolytics Biotech (U.S.) Inc., and are presented in Canadian dollars, our functional currency. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsidiaries are entities over which we have control which is achieved when we are exposed, or have the rights, to variable returns from our involvement with the investee and have the ability to affect those returns through our power to govern. The accounting policies of our subsidiaries are consistent with our accounting policies, and all intercompany transactions, balances, income, and expenses are eliminated on consolidation. </span></div></ix:continuation><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-303-2">Our accounts are prepared on the historical cost basis, except for certain assets and liabilities, which are measured at fair value as explained in the notes to these financial statements.</ix:continuation>  </span></div><div><span><br/></span></div><div id="i17734265916144358581fdce5df64f78_241"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Note 3: <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory" id="f-304" continuedAt="f-304-1" escape="true">Summary of Material Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="f-304-1" continuedAt="f-304-2"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements have, in management's opinion, been properly prepared within reasonable limits of materiality and within the framework of the material accounting policies summarized below.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and cash equivalents </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="oncyf:DescriptionOfAccountingPolicyForDeterminingComponentsOfCashAndCashEquivalentsPolicyTextBlock" id="f-305" escape="true">Cash equivalents include interest-bearing deposits with our bank</ix:nonNumeric> totaling $<ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:CashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-306">12,312</ix:nonFraction> as at December&#160;31, 2024 (December&#160;31, 2023 - $<ix:nonFraction unitRef="cad" contextRef="c-4" decimals="-3" name="ifrs-full:CashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-307">31,534</ix:nonFraction>). </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Deferred income taxes</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory" id="f-308" escape="true">We follow the liability method of accounting for income taxes. Under the liability method, deferred income taxes are recognized for the difference between the financial statement carrying values and the respective income tax basis of assets and liabilities (temporary differences). Deferred income tax assets and liabilities are measured using substantively enacted income tax rates and laws expected to apply in the years in which temporary differences are expected to be recovered or settled. The effect on deferred income tax assets and liabilities of a change in tax rates is charged or credited to income, except when it is related to items charged or credited to either other comprehensive income or directly to equity.</ix:nonNumeric>  </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial instruments </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Classification and measurement</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial assets</span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfAccountingPolicyForFinancialAssetsExplanatory" id="f-309" continuedAt="f-309-1" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets are initially measured at fair value. In the case of a financial asset not at fair value through profit or loss, the financial asset is initially measured at fair value plus or minus transaction costs. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets are subsequently measured at amortised cost, fair value through profit or loss (FVPL), or fair value through other comprehensive income (FVOCI). The classification is based on two criteria: the Company&#8217;s business model for managing the assets; and whether the financial asset&#8217;s contractual cash flows represent 'solely payments of principal and interest' on the principal amount outstanding (the 'SPPI criterion'). </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2024</span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands of Canadian dollars, except share amounts and where indicated)</span></div><div style="margin-bottom:10pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="f-304-2" continuedAt="f-304-3"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-309-1">The classification and measurement of our cash and cash equivalents and other receivables are financial assets at amortized cost, as these assets are held within our business model with the objective to hold the financial assets in order to collect contractual cash flows that meet the SPPI criterion.</ix:continuation> </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial liabilities</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory" id="f-310" escape="true">Financial liabilities are initially measured at fair value and are subsequently measured at amortised cost or FVPL. The classification and measurement of our accounts payable and accrued liabilities and other liabilities are financial liabilities at amortized cost. The classification and measurement of the warrant derivative is financial liabilities at FVPL.</ix:nonNumeric>  </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment</span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory" id="f-311" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounting for impairment losses for financial assets uses a forward-looking expected credit loss (ECL) approach. We are required to record a loss allowance for ECLs on all financial assets not held at FVPL. ECLs are based on the difference between the contractual cash flows due in accordance with the contract and all the cash flows that the Company expects to receive. The shortfall is then discounted at an approximation to the asset&#8217;s original effective interest rate.</span></div></ix:nonNumeric><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derecognition</span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfAccountingPolicyForDerecognitionOfFinancialInstrumentsExplanatory" id="f-312" continuedAt="f-312-1" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A financial asset is derecognized when the contractual rights to the cash flows from the financial asset expire, or we transfer the financial asset and substantially all the risks and rewards of ownership of the financial asset to another entity. </span></div></ix:nonNumeric><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-312-1">A financial liability is derecognized when our obligations specified in the contract are discharged or canceled, or expired.</ix:continuation> </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurement</span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" id="f-313" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is the price that would be received to sell an asset, or paid to transfer a liability in an orderly transaction between market participants, at the measurement date. In determining the fair value measurement of our financial instruments, we prioritize the related inputs used in measuring fair value into the following hierarchy: </span></div><div style="margin-top:10pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities;</span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 - Inputs other than quoted prices included within Level 1 that are either directly or indirectly observable;</span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 - Unobservable inputs in which little or no market activity exists, therefore requiring an entity to develop its own assumptions about the assumptions that market participants would use in pricing.</span></div></ix:nonNumeric><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign currency translation</span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" id="f-314" continuedAt="f-314-1" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial statements for each of our subsidiaries are prepared using their functional currency. Our functional and presentation currency is the Canadian dollar. Foreign currency transactions are translated into the functional currency using exchange rates prevailing at the dates of the transactions. Exchange differences resulting from the settlement of such transactions and from the translation at exchange rates ruling at the statement of financial position date of monetary assets and liabilities denominated in currencies other than the functional currency are recognized directly in the consolidated statement of loss and comprehensive loss.  </span></div></ix:nonNumeric><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-314-1">Exceptions to this are where the monetary items form part of the net investment in a foreign operation, and the foreign operation's functional currency is the local currency. These exchange differences are initially recognized in equity. The statement of financial position of foreign operations is translated into Canadian dollars using the exchange rate at the statement of financial position date and the income statements are translated into Canadian dollars using the average exchange rate for the period. Where this average is not a reasonable approximation of the cumulative effect of the rates prevailing on the transaction dates, the exchange rate on the transaction date is used. Exchange differences on translation into Canadian dollars are recognized as a separate component of equity. On disposal of a foreign operation, any cumulative exchange differences held in equity are transferred to the consolidated statement of loss and comprehensive loss.</ix:continuation>  </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2024</span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands of Canadian dollars, except share amounts and where indicated)</span></div><div style="margin-bottom:10pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="f-304-3" continuedAt="f-304-4"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases</span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory" id="f-315" continuedAt="f-315-1" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of a contract, we assess whether a contract is, or contains, a lease by determining whether the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. To assess whether a contract conveys the right to control the use of an identified asset, we assess whether:</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the contract involves the use of an identified asset;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we have the right to obtain substantially all of the economic benefits from the use of the identified asset throughout the period of use; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we have the right to direct the use of the identified asset. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A right-of-use asset and corresponding lease liability are recognized on the lease commencement date. The right-of-use asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, plus any initial direct costs incurred and an estimate of costs to dismantle and remove the underlying asset or to restore the underlying asset or the site on which it is located, less any lease incentives received. The right-of-use asset is subsequently depreciated using the straight-line method from the commencement date to the end of the lease term. In addition, the right-of-use asset is reduced by impairment losses and adjusted for certain remeasurements of the lease liabilities, if any. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date. The lease payments are discounted using the implicit interest rate in the lease. If the rate cannot be readily determined, our incremental rate of borrowing is used. The lease liability is subsequently measured at amortized cost using the effective interest method. The lease liability is remeasured when there is a change in future lease payments arising from a change in an index or rate, if there is a change in our estimate of the amount expected to be payable under a residual value guarantee, if we change our assessment of whether we will exercise a purchase, extension or termination option, or if the underlying lease contract is amended.  </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have elected not to separate fixed non-lease components from lease components and instead account for each lease component and associated fixed non-lease components as a single lease component.  </span></div></ix:nonNumeric><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-315-1">We have elected not to recognize right-of-use assets and lease liabilities for short-term leases that have a lease term of 12 months or less. We recognize the lease payments associated with these leases as an expense on a straight-line basis over the lease term.</ix:continuation> </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Loss per share</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" id="f-316" escape="true">Basic loss per share is calculated by dividing the loss attributable to common shareholders by the weighted average number of common shares outstanding during the year. Diluted loss per share is computed in a manner consistent with basic loss per share except that the weighted average common shares outstanding are adjusted to include the effects of all dilutive potential common shares, which comprise stock options, share awards, and warrants.</ix:nonNumeric> </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property and equipment </span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" id="f-317" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are recorded at cost. Depreciation is provided on bases and at rates designed to amortize the cost of the assets over their estimated useful lives. <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" id="f-318" continuedAt="f-318-1" escape="true">Depreciation is recorded using the declining balance method at the following annual rates:</ix:nonNumeric></span></div><ix:continuation id="f-318-1" continuedAt="f-318-2"><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.192%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.608%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment and furniture</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-54" decimals="INF" name="oncyf:PropertyPlantandEquipmentAnnualDepreciationRate" scale="-2" id="f-319">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-55" decimals="INF" name="oncyf:PropertyPlantandEquipmentAnnualDepreciationRate" scale="-2" id="f-320">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-56" decimals="INF" name="oncyf:PropertyPlantandEquipmentAnnualDepreciationRate" scale="-2" id="f-321">30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Straight-line over the term of the lease</span></td></tr></table></div></ix:continuation></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2024</span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands of Canadian dollars, except share amounts and where indicated)</span></div><div style="margin-bottom:10pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="f-304-4" continuedAt="f-304-5"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and development costs</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" id="f-322" escape="true">Research and development costs are expensed as incurred, net of recoveries. We record accruals for the estimated costs of our research and development activities performed by third parties. Advance payments for goods or services that will be used or rendered for future research and development activities are capitalized as prepaid expenses and recognized as an expense as the related goods are delivered or the related services are performed. Development costs that meet specific criteria related to technical, market, and financial feasibility will be capitalized. To date, all development costs have been expensed.</ix:nonNumeric> </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue recognition</span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue" id="f-323" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue relates to a long-term contract associated with a regional licensing agreement (the "Licensing Agreement") with Adlai Nortye Biopharma Co., Ltd. ("Adlai"). The pricing for the contract was based on the specific negotiations with Adlai and included non-refundable upfront license fees, development and regulatory milestone payments, royalties, and sales-based milestone payments. We account for a contract with a customer when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance, and the collectability of consideration is probable.</span></div><div style="margin-bottom:8pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Licensing Agreement, we have granted a regional license to our intellectual property. The granting of this license is accounted for as one performance obligation. We have determined that we provide Adlai with a right to access our intellectual property and, therefore, recognize revenue related to the upfront license fee over time. Revenue is recognized based on the extent of progress toward completion of the performance obligation using the input method. Under the input method, the extent of progress toward completion is measured based on the ratio of costs incurred to date to the total estimated costs at completion of the performance obligation. We use this method because Adlai receives and consumes the benefit of our intellectual property as we undertake activities that impact the intellectual property. Management must use judgment in making assumptions and estimates regarding total estimated costs, the complexity of the work to be performed, and the length of time to complete the performance obligation, among other variables.</span></div><div style="margin-bottom:8pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contract also provides for development and regulatory milestone payments, royalties, and sales-based milestone payments. These amounts are contingent on the occurrence of a future event and, therefore, give rise to variable consideration. We estimate variable consideration at the most likely amount to which we expect to be entitled. We include estimated amounts in the transaction price when it becomes highly probable that the amount will not be subject to significant reversal when the uncertainty associated with the variable consideration is resolved. Our estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of our anticipated performance and all information (historical, current, and forecasted) that is reasonably available to us. Based on this information and related analysis, any quarterly adjustments to revenue are recognized as necessary in the period they become known.</span></div><div style="margin-bottom:8pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The upfront license fee is not considered a significant financing component because it is used to meet working capital demands that can be higher in the early stages of a contract and to protect us from the other party failing to adequately complete some or all of its obligations under the contract. </span></div><div style="margin-bottom:8pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from sales-based royalties and the achievement of annual sales volumes will be recognized when the subsequent sale occurs, as the license of the intellectual property is the predominant item to which the royalty relates. We consider payments associated with the achievement of annual sales volumes to be, in substance, royalty payments, and we will recognize such sales-based payments upon achievement of such sales volumes, provided that collection is reasonably assured.</span></div><div style="margin-bottom:8pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contract liability</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Our contract liability includes upfront license fees and billings in excess of the revenue recognized. Contract liabilities are recognized as revenue as or when we perform under the contract. We classify our contract liability as current or non-current based on the timing of when we expect to recognize revenue.</span></div></ix:nonNumeric><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Share-based compensation </span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" id="f-324" continuedAt="f-324-1" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock option plan</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have <ix:nonFraction unitRef="plan" contextRef="c-3" decimals="INF" name="oncyf:NumberOfStockOptionPlans" format="ixt-sec:numwordsen" scale="0" id="f-325">one</ix:nonFraction> stock option plan (the "Stock Option Plan") available to directors, officers, employees, and consultants with grants under the Stock Option Plan approved from time to time by our Board of Directors (the "Board"). Under the Stock Option Plan, no option shall be granted with an exercise price at a discount to the closing price of our stock on the Toronto Stock Exchange </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2024</span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands of Canadian dollars, except share amounts and where indicated)</span></div><div style="margin-bottom:10pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="f-304-5"><ix:continuation id="f-324-1" continuedAt="f-324-2"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on the last trading date prior to the date of the grant. Vesting is provided at the discretion of the Board, and the expiration of options is to be no greater than <ix:nonNumeric contextRef="c-1" name="oncyf:MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement" format="ixt-sec:durwordsen" id="f-326">ten years</ix:nonNumeric> from the date of grant. Exercised stock options are settled with common shares issued from treasury. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the fair value-based method of accounting for stock option awards granted under the Stock Option Plan. We recognize compensation expense and a corresponding adjustment to contributed surplus equal to the fair value of the stock options granted using the Black-Scholes valuation model over the vesting periods of the respective options. Compensation expense is adjusted for subsequent changes in management&#8217;s estimate of the number of options that are expected to vest.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options awarded to non-employees are accounted for at the fair value of the goods received or the services rendered. The fair value is measured at the date the Company obtains the goods or the date the counterparty renders the service. If the fair value of the goods or services cannot be reliably measured, the fair value of the options granted will be used.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share award plan</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our share award plan (the "Share Award Plan") is available to directors, officers, employees, and consultants. Under our Share Award Plan, performance and restricted share awards may be approved from time to time by the Board. Performance share awards  ("PSAs") can be awarded to certain officers and employees to which common shares shall be issued based upon achieving the applicable performance criteria. Restricted share awards ("RSAs") can be awarded to certain officers, employees, non-employee directors, and consultants to which common shares shall be issued in accordance with the Share Award Plan.  </span></div></ix:continuation><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-324-2">We recognize compensation expense and a corresponding adjustment to contributed surplus equal to the market value of our common shares at the grant date based on the number of PSAs/RSAs expected to vest, recognized over the vesting period. Compensation expense is adjusted for subsequent changes in management&#8217;s estimate of the number of PSAs/RSAs that are expected to vest. The effect of these changes is recognized in the period of the change.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfInitialApplicationOfStandardsOrInterpretations" id="f-327" continuedAt="f-327-1" escape="true"><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adoption of New Accounting Standards</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IAS 1 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Classification of Liabilities as Current or Non-Current</span></div></ix:nonNumeric><div><ix:continuation id="f-327-1" continuedAt="f-327-2"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2022, the IASB issued amendments to clarify how conditions with which an entity must comply within 12 months after the reporting period affect the classification of a liability. This is in addition to the amendment from January 2020 where the IASB issued amendments to IAS 1 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Presentation of Financial Statements</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-327-2">, to provide a more general approach to the presentation of liabilities as current or non-current based on contractual arrangements in place at the reporting date. These amendments specify that the rights and conditions existing at the end of the reporting period are relevant in determining whether the Company has a right to defer settlement of a liability by at least 12 months, provided that management's expectations are not a relevant consideration as to whether the Company will exercise its rights to defer settlement of a liability and clarify when a liability is considered settled. The amendments became effective on January 1, 2024. Adopting the amendments did not have a material impact on our consolidated financial statements.</ix:continuation>   </span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" id="f-328" escape="true"><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounting Standards and Interpretations Issued but Not Yet Effective</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IFRS 18 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Presentation and Disclosure in Financial Statements</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2024, the IASB issued IFRS 18 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Presentation and Disclosure in Financial Statements </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which replaces IAS 1 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Presentation of Financial Statements. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IFRS 18 introduces new requirements on presentation within the statement of profit or loss, including specified totals and subtotals. It also requires disclosure of management-defined performance measures and includes new requirements for aggregation and disaggregation of financial information based on the identified roles of the primary financial statements and the notes. Narrow scope amendments have been made to IAS 7 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Statement of Cash Flows</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and some requirements previously included within IAS 1 have been moved to IAS 8 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting Policies, Changes in Accounting Estimates and Errors, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which has also been renamed IAS 8 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Preparation of Financial Statements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. IAS 34 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interim Financial Reporting </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">has also been amended to require disclosure of management-defined performance measures. IFRS 18 and the amendments to the other standards are effective for annual periods beginning on or after January 1, 2027, with early application permitted. IFRS 18 applies retrospectively to both annual and interim financial statements. We are assessing the impact of adopting this standard on our consolidated financial statements.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-14</span></div></div></div><div id="i17734265916144358581fdce5df64f78_244"></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2024</span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands of Canadian dollars, except share amounts and where indicated)</span></div><div style="margin-bottom:10pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Note 4:  <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory" id="f-329" continuedAt="f-329-1" escape="true">Significant Judgments, Estimates, and Assumptions</ix:nonNumeric></span></div><ix:continuation id="f-329-1" continuedAt="f-329-2"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The preparation of our consolidated financial statements in conformity with IFRS requires us to make judgments, estimates, and assumptions that affect the application of accounting policies, the reported amount, and disclosures in our consolidated financial statements and accompanying notes. Management makes estimates based on our best knowledge of current events and actions that the Company may undertake in the future. We consider the potential impact of certain external factors outside of our control, including global political conflicts, supply chain disruptions, inflation, fluctuating interest rates, and liquidity, when making certain estimates and judgments relating to the preparation of these consolidated financial statements. Estimates and underlying assumptions are reviewed on an ongoing basis. Actual results could differ from these estimates, and such differences could be material. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant estimates made by management affecting our consolidated financial statements include:</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue recognition</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We entered into a Licensing Agreement which provides, among other payments, upfront license fees in exchange for a regional license to our intellectual property. Management uses its judgment in applying the input method when determining the extent of progress toward completion of the performance obligation. Revenue recognition requires assumptions and estimates regarding total estimated costs, the complexity of the work to be performed, and the length of time to complete the performance obligation, among other variables.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clinical trial and manufacturing expenses</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trial and manufacturing expenses represent significant components of our research and development expenses, and we outsource a significant portion of these activities to third-party contract research/manufacturing organizations. The financial terms of these agreements are subject to negotiation, vary from contract to contract, and may result in uneven payment flows to these organizations. Payments under the contracts depend on factors such as achieving certain milestones. As part of preparing the consolidated financial statements, we estimate the expense to recognize based on services that the contract research/manufacturing organizations have performed. When making these estimates, we use operational and contractual information from third-party service providers, operational data from internal personnel, and considerable judgment. We base our estimates on the best information available at the time. However, additional information may become available to us which may allow us to make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain. Such increases or decreases in cost are generally considered to be changes in estimates and will be reflected in research and development expenses in the period identified.   </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Valuation of share-based compensation </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimating the fair value of share-based compensation requires determining the most appropriate valuation model, which is dependent on the terms and conditions of the grant. This estimate also requires determining the most appropriate inputs to the valuation model, including the expected life, volatility, and dividend yield, and making assumptions about them. The assumptions and inputs used for estimating fair value of share-based compensation are disclosed in note 11. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Valuation of warrant derivative </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimating the fair value of the warrant derivative at initial measurement, at each exercise date and at each reporting period requires determining the most appropriate valuation model. This estimate also requires determining the most appropriate inputs to the valuation model, including the expected life, volatility, and dividend yield, and making assumptions about them. The assumptions and inputs used for estimating fair value for warrant derivative issued are disclosed in note 9.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income taxes</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Uncertainties exist with respect to the interpretation of complex tax regulations and the amount and timing of future taxable income. Currently, we are accumulating tax loss carry-forward balances in various tax jurisdictions creating a deferred tax asset. Deferred tax assets are recognized for all unused tax losses to the extent that it is probable that taxable profit will be available against which the losses can be utilized. Management's judgment is required to determine the amount of deferred tax assets that can be recognized based on the likely timing and the level of future taxable profits together with future tax planning strategies.  </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have determined that none of our deferred tax assets should be recognized. Our deferred tax assets are mainly comprised of our net operating losses from prior years, prior year research and development expenses, and non-refundable </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2024</span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands of Canadian dollars, except share amounts and where indicated)</span></div><div style="margin-bottom:10pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="f-329-2" continuedAt="f-329-3"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">investment tax credits. These tax pools relate to entities that have a history of losses, have varying expiry dates, and may not be used to offset taxable income within our other subsidiaries. There are also no taxable temporary differences or any tax planning opportunities available that could partly support the recognition of these losses as deferred tax assets.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Functional currency</span></div></ix:continuation><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-329-3">We assess the relevant factors related to the primary economic environment in which our entities operate to determine the functional currency. Where the assessment of primary indicators are mixed, we assess the secondary indicators, including the relationship between the foreign operations and reporting entity.</ix:continuation> </span></div><div style="text-align:justify"><span><br/></span></div><div id="i17734265916144358581fdce5df64f78_250"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Note 5: <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfOtherLiabilitiesExplanatory" id="f-330" continuedAt="f-330-1" escape="true">Other Liabilities </ix:nonNumeric></span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-330-1">In 2023, we were selected by the Pancreatic Cancer Action Network (PanCAN) as the recipient of its Therapeutic Accelerator Award to conduct a clinical trial with pelareorep in combination with modified FOLFIRINOX chemotherapy with or without an immune checkpoint inhibitor in pancreatic cancer patients. Under the terms of the award agreement, we are entitled to receive up to US$<ix:nonFraction unitRef="cad" contextRef="c-57" decimals="-6" name="ifrs-full:OtherReceivables" format="ixt:num-dot-decimal" scale="6" id="f-331">5</ix:nonFraction>&#160;million in funding for eligible research expenses, and we must comply with the conditions set out with the award agreement, including providing periodic performance progress reports. As at December&#160;31, 2024, we recorded US$<ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-3" name="ifrs-full:OtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-332">1,125</ix:nonFraction> ($<ix:nonFraction unitRef="cad" contextRef="c-57" decimals="-3" name="ifrs-full:OtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-333">1,618</ix:nonFraction>) (December&#160;31, 2023 - US$<ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-3" name="ifrs-full:OtherCurrentLiabilities" scale="3" id="f-334">225</ix:nonFraction> ($<ix:nonFraction unitRef="cad" contextRef="c-58" decimals="-3" name="ifrs-full:OtherCurrentLiabilities" scale="3" id="f-335">298</ix:nonFraction>)) in other liabilities representing unapplied funding received from PanCAN.</ix:continuation>  </span></div><div style="text-align:justify"><span><br/></span></div><div id="i17734265916144358581fdce5df64f78_253"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Note 6: <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory" id="f-336" continuedAt="f-336-1" escape="true">Property and Equipment</ix:nonNumeric></span></div><ix:continuation id="f-336-1" continuedAt="f-336-2"><ix:continuation id="f-318-2" continuedAt="f-318-3"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.328%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.042%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.371%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.042%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.371%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.471%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.371%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.471%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.371%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.762%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Medical Equipment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Computer Equipment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Office Equipment and Furniture</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Leasehold Improvements</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2022</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-59" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-337">62</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-60" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-338">429</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-61" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-339">248</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-62" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-340">231</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-63" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-341">970</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions, net of foreign exchange impact</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-64" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-342">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-65" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" id="f-343">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-66" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-344">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-67" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-345">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-68" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" id="f-346">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2023</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-69" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-347">62</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-70" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-348">436</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-71" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-349">248</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-72" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-350">231</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-73" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-351">977</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-74" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-352">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-75" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" id="f-353">71</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-76" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" id="f-354">168</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-77" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-355">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-78" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" id="f-356">239</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disposals, net of foreign exchange impact</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-74" decimals="-3" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="3" id="f-357">59</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-75" decimals="-3" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="3" id="f-358">43</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-76" decimals="-3" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="3" id="f-359">24</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-77" decimals="-3" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="3" id="f-360">47</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-78" decimals="-3" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="3" id="f-361">173</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at December 31, 2024</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-79" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-362">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-80" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-363">464</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-81" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-364">392</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-82" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-365">184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-83" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-366">1,043</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2022</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-84" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-367">53</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-85" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-368">321</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-86" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-369">92</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-87" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-370">148</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-88" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-371">614</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-89" decimals="-3" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="3" id="f-372">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-90" decimals="-3" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="3" id="f-373">30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-91" decimals="-3" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="3" id="f-374">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-92" decimals="-3" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="3" id="f-375">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-93" decimals="-3" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="3" id="f-376">81</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2023</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-94" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-377">55</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-95" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-378">351</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-96" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-379">120</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-97" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-380">169</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-98" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-381">695</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-99" decimals="-3" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="3" id="f-382">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-100" decimals="-3" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="3" id="f-383">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-101" decimals="-3" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="3" id="f-384">45</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-102" decimals="-3" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="3" id="f-385">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-103" decimals="-3" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="3" id="f-386">102</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disposals, net of foreign exchange impact</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-99" decimals="-3" sign="-" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="3" id="f-387">54</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-100" decimals="-3" sign="-" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="3" id="f-388">41</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-101" decimals="-3" sign="-" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="3" id="f-389">23</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-102" decimals="-3" sign="-" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="3" id="f-390">47</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-103" decimals="-3" sign="-" name="ifrs-full:DisposalsPropertyPlantAndEquipment" scale="3" id="f-391">165</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at December 31, 2024</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-104" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-392">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-105" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-393">345</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-106" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-394">142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-107" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-395">143</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-108" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-396">632</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net book value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2023</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-109" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-397">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-110" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-398">85</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-111" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-399">128</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-112" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-400">62</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-4" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-401">282</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at December 31, 2024</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-113" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-402">1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-114" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-403">119</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-115" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-404">250</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-116" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-405">41</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-406">411</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:continuation><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-336-2"><ix:continuation id="f-318-3">For the year ended December&#160;31, 2024, we incurred losses on disposal of property and equipment of $<ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:LossesOnDisposalsOfPropertyPlantAndEquipment" scale="3" id="f-407">18</ix:nonFraction>, which was included in depreciation expense on our consolidated statement of cash flows.</ix:continuation></ix:continuation> </span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-16</span></div></div></div><div id="i17734265916144358581fdce5df64f78_256"></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2024</span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands of Canadian dollars, except share amounts and where indicated)</span></div><div style="margin-bottom:10pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Note 7: <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory" id="f-408" continuedAt="f-408-1" escape="true">Accounts payable and accrued liabilities</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="oncyf:DetailedDisclosureOfTradeAndOtherPayablesExplanatoryTableTextBlock" id="f-409" escape="true"><ix:continuation id="f-408-1"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.250%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.861%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade payables</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers" format="ixt:num-dot-decimal" scale="3" id="f-410">1,087</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-4" decimals="-3" name="ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers" format="ixt:num-dot-decimal" scale="3" id="f-411">1,082</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:AccrualsClassifiedAsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-412">3,705</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-4" decimals="-3" name="ifrs-full:AccrualsClassifiedAsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-413">2,490</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:TradeAndOtherCurrentPayables" format="ixt:num-dot-decimal" scale="3" id="f-414">4,792</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-4" decimals="-3" name="ifrs-full:TradeAndOtherCurrentPayables" format="ixt:num-dot-decimal" scale="3" id="f-415">3,572</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div id="i17734265916144358581fdce5df64f78_259"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Note 8: <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfLeasesExplanatory" id="f-416" continuedAt="f-416-1" escape="true">Leases</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="f-416-1"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have office space leases with initial lease terms generally between <ix:nonNumeric contextRef="c-117" name="oncyf:OperatingLeaseLeaseTerm" format="ixt-sec:duryear" id="f-417">3</ix:nonNumeric> to <ix:nonNumeric contextRef="c-118" name="oncyf:OperatingLeaseLeaseTerm" format="ixt-sec:duryear" id="f-418">6</ix:nonNumeric> years. We currently do not have leases with residual value guarantees or leases not yet commenced to which we have committed. We have variable lease payments related to office space lease operating costs that are not material. Lease liabilities have been measured by discounting future lease payments using our incremental borrowing rate as rates implicit in the leases were not readily determinable. The weighted-average rate applied was <ix:nonFraction unitRef="number" contextRef="c-3" decimals="2" name="ifrs-full:WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16" scale="-2" id="f-419">15</ix:nonFraction>%. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2024, we recorded an addition of $<ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:AdditionsToRightofuseAssets" scale="3" id="f-420">794</ix:nonFraction> to the right-of-use asset and $<ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" scale="3" id="f-421">785</ix:nonFraction> to the lease liabilities relating to one of our subsidiaries' office leases. </span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" id="f-422" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our right-of-use assets activity for the years ended December&#160;31:      </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">         </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.274%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.422%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at beginning of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-4" decimals="-3" name="ifrs-full:RightofuseAssets" scale="3" id="f-423">365</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-25" decimals="-3" name="ifrs-full:RightofuseAssets" scale="3" id="f-424">296</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:AdditionsToRightofuseAssets" scale="3" id="f-425">794</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" name="ifrs-full:AdditionsToRightofuseAssets" scale="3" id="f-426">392</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:DepreciationRightofuseAssets" scale="3" id="f-427">304</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" name="ifrs-full:DepreciationRightofuseAssets" scale="3" id="f-428">322</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange impact</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="oncyf:ForeignExchangeImpactRightofUseAssets" scale="3" id="f-429">46</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" sign="-" name="oncyf:ForeignExchangeImpactRightofUseAssets" scale="3" id="f-430">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at end of year</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:RightofuseAssets" scale="3" id="f-431">901</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-4" decimals="-3" name="ifrs-full:RightofuseAssets" scale="3" id="f-432">365</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="oncyf:DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTextBlock" id="f-433" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our lease liabilities activity for the years ended December&#160;31:    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">              </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.274%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.422%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at beginning of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-4" decimals="-3" name="ifrs-full:LeaseLiabilities" scale="3" id="f-434">423</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-25" decimals="-3" name="ifrs-full:LeaseLiabilities" scale="3" id="f-435">373</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" scale="3" id="f-436">785</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" name="ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" scale="3" id="f-437">392</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment of lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:CashOutflowForLeases" scale="3" id="f-438">348</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" name="ifrs-full:CashOutflowForLeases" scale="3" id="f-439">407</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense on lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:InterestExpenseOnLeaseLiabilities" scale="3" id="f-440">139</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" name="ifrs-full:InterestExpenseOnLeaseLiabilities" scale="3" id="f-441">71</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange impact</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="oncyf:GainsLossesFromForeignExchangeImpact" scale="3" id="f-442">65</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" sign="-" name="oncyf:GainsLossesFromForeignExchangeImpact" scale="3" id="f-443">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at end of year</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:LeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-444">1,064</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-4" decimals="-3" name="ifrs-full:LeaseLiabilities" scale="3" id="f-445">423</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory" id="f-446" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our total undiscounted lease liabilities as at December&#160;31, 2024 was as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:81.252%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.548%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than one year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-119" decimals="-3" name="ifrs-full:GrossLeaseLiabilities" scale="3" id="f-447">418</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">One to five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-120" decimals="-3" name="ifrs-full:GrossLeaseLiabilities" scale="3" id="f-448">995</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">More than five years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-121" decimals="-3" name="ifrs-full:GrossLeaseLiabilities" format="ixt:fixed-zero" scale="3" id="f-449">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total undiscounted lease liabilities </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:GrossLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-450">1,413</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-17</span></div></div></div><div id="i17734265916144358581fdce5df64f78_262"></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2024</span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands of Canadian dollars, except share amounts and where indicated)</span></div><div style="margin-bottom:10pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Note 9: <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory" id="f-451" continuedAt="f-451-1" escape="true">Warrant Derivative</ix:nonNumeric></span></div><ix:continuation id="f-451-1" continuedAt="f-451-2"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common share purchase warrants ("warrants") with a U.S. dollar exercise price, which differs from our functional currency, are treated as a derivative measured at fair value, and revalued each period end at fair value through profit and loss. There is no cash flow impact as a result of the accounting treatment for changes in the fair value of the warrant derivative or when warrants expire unexercised. </span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory" id="f-452" continuedAt="f-452-1" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the value of our warrant derivative were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:64.098%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.080%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.935%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Warrants Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value of Warrant Derivative</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-25" decimals="INF" name="oncyf:NumberOfWarrantsOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-453">64,035</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-25" decimals="-3" name="ifrs-full:DerivativeFinancialLiabilities" scale="3" id="f-454">79</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to public offering</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-122" decimals="INF" name="oncyf:IssueOfEquityShares" format="ixt:num-dot-decimal" id="f-455">7,667,050</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-122" decimals="-3" name="ifrs-full:IssueOfEquity" format="ixt:num-dot-decimal" scale="3" id="f-456">7,360</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount on warrants issued</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-122" decimals="-3" name="oncyf:WarrantLiabilityUnamortizedDiscount" format="ixt:num-dot-decimal" scale="3" id="f-457">1,822</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of discount on warrants issued</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-122" decimals="-3" name="oncyf:WarrantLiabilityAmortizedDiscount" scale="3" id="f-458">146</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-122" decimals="-3" sign="-" name="ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives" format="ixt:num-dot-decimal" scale="3" id="f-459">5,431</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange impact</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-122" decimals="-3" sign="-" name="oncyf:GainsLossesFromForeignExchangeImpact" scale="3" id="f-460">132</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="oncyf:NumberOfWarrantsOutstanding" format="ixt:num-dot-decimal" id="f-461">7,731,085</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-4" decimals="-3" name="ifrs-full:DerivativeFinancialLiabilities" scale="3" id="f-462">200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-123" decimals="0" name="oncyf:NumberOfWarrantsExercised" format="ixt:num-dot-decimal" id="f-463">52,456</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-123" decimals="-3" name="oncyf:FairValueOfWarrantDerivativeExercised" scale="3" id="f-464">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-123" decimals="INF" name="oncyf:NumberOfWarrantsExpired" format="ixt:num-dot-decimal" id="f-465">11,579</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-123" decimals="-3" name="oncyf:FairValueOfWarrantDerivativeExpired" scale="3" id="f-466">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of discount on warrants issued</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-123" decimals="-3" name="oncyf:WarrantLiabilityAmortizedDiscount" scale="3" id="f-467">365</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-123" decimals="-3" sign="-" name="ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives" format="ixt:num-dot-decimal" scale="3" id="f-468">1,605</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange impact</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-123" decimals="-3" name="oncyf:GainsLossesFromForeignExchangeImpact" scale="3" id="f-469">67</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at December 31, 2024</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="oncyf:NumberOfWarrantsOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-470">7,667,050</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" sign="-" name="ifrs-full:DerivativeFinancialLiabilities" scale="3" id="f-471">980</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our outstanding warrant derivative as at December&#160;31, 2024:</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.724%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.291%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.291%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.542%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercise price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Issuance date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expiry date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Warrants Outstanding</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US$<ix:nonFraction unitRef="usdPerShare" contextRef="c-124" decimals="2" name="oncyf:WarrantExercisePrice" scale="0" id="f-472">2.81</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 8, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 8, 2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-124" decimals="INF" name="oncyf:NumberOfWarrantsOutstanding" format="ixt:num-dot-decimal" id="f-473">6,667,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US$<ix:nonFraction unitRef="usdPerShare" contextRef="c-125" decimals="2" name="oncyf:WarrantExercisePrice" scale="0" id="f-474">2.81</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 7, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 8, 2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-125" decimals="INF" name="oncyf:NumberOfWarrantsOutstanding" format="ixt:num-dot-decimal" id="f-475">1,000,050</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="oncyf:NumberOfWarrantsOutstanding" format="ixt:num-dot-decimal" id="f-476">7,667,050</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 8, 2023, pursuant to an underwritten public offering, we issued <ix:nonFraction unitRef="shares" contextRef="c-124" decimals="INF" name="oncyf:NumberOfWarrantsAndSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-477">6,667,000</ix:nonFraction> units for gross proceeds of $<ix:nonFraction unitRef="cad" contextRef="c-126" decimals="-3" name="oncyf:ProceedsFromIssueOfOrdinarySharesGross" format="ixt:num-dot-decimal" scale="3" id="f-478">20,185</ix:nonFraction> (US$<ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-3" name="oncyf:ProceedsFromIssueOfOrdinarySharesGross" format="ixt:num-dot-decimal" scale="3" id="f-479">15,001</ix:nonFraction>) at a price of US$<ix:nonFraction unitRef="usdPerShare" contextRef="c-127" decimals="2" name="oncyf:SharesIssuedPricePerShare1" scale="0" id="f-480">2.25</ix:nonFraction> per unit. On September 7, 2023, pursuant to the over-allotment option exercised by the underwriter, we issued an additional <ix:nonFraction unitRef="shares" contextRef="c-125" decimals="INF" name="oncyf:NumberOfWarrantsAndSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-481">1,000,050</ix:nonFraction> units for gross proceeds of $<ix:nonFraction unitRef="cad" contextRef="c-128" decimals="-3" name="oncyf:ProceedsFromIssueOfOrdinarySharesGross" format="ixt:num-dot-decimal" scale="3" id="f-482">3,077</ix:nonFraction> (US$<ix:nonFraction unitRef="usd" contextRef="c-128" decimals="-3" name="oncyf:ProceedsFromIssueOfOrdinarySharesGross" format="ixt:num-dot-decimal" scale="3" id="f-483">2,250</ix:nonFraction>) at a price of US$<ix:nonFraction unitRef="usdPerShare" contextRef="c-129" decimals="2" name="oncyf:SharesIssuedPricePerShare1" scale="0" id="f-484">2.25</ix:nonFraction> per unit. Each unit consisted of <ix:nonFraction unitRef="shares" contextRef="c-130" decimals="INF" name="oncyf:CommonSharesPerUnit" format="ixt-sec:numwordsen" scale="0" id="f-485"><ix:nonFraction unitRef="shares" contextRef="c-131" decimals="INF" name="oncyf:CommonSharesPerUnit" format="ixt-sec:numwordsen" scale="0" id="f-486">one</ix:nonFraction></ix:nonFraction> common share and <ix:nonFraction unitRef="shares" contextRef="c-132" decimals="INF" name="oncyf:CommonSharesPerUnit" format="ixt-sec:numwordsen" scale="0" id="f-487"><ix:nonFraction unitRef="shares" contextRef="c-133" decimals="INF" name="oncyf:CommonSharesPerUnit" format="ixt-sec:numwordsen" scale="0" id="f-488">one</ix:nonFraction></ix:nonFraction> warrant, which were immediately separable and issued separately in this offering. Each warrant entitles the holder to purchase <ix:nonFraction unitRef="shares" contextRef="c-134" decimals="INF" name="oncyf:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight1" format="ixt-sec:numwordsen" scale="0" id="f-489"><ix:nonFraction unitRef="shares" contextRef="c-135" decimals="INF" name="oncyf:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight1" format="ixt-sec:numwordsen" scale="0" id="f-490">one</ix:nonFraction></ix:nonFraction> common share at an exercise price of US$<ix:nonFraction unitRef="usdPerShare" contextRef="c-136" decimals="2" name="oncyf:WarrantExercisePrice" scale="0" id="f-491"><ix:nonFraction unitRef="usdPerShare" contextRef="c-137" decimals="2" name="oncyf:WarrantExercisePrice" scale="0" id="f-492">2.81</ix:nonFraction></ix:nonFraction> up to <ix:nonNumeric contextRef="c-126" name="oncyf:ExpirationPeriodOfOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement" format="ixt-sec:durmonth" id="f-493"><ix:nonNumeric contextRef="c-128" name="oncyf:ExpirationPeriodOfOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement" format="ixt-sec:durmonth" id="f-494">60</ix:nonNumeric></ix:nonNumeric> months from the date of issuance. The expiry of the warrants may be accelerated by the Company at any time prior to the expiry date if the volume weighted average price (if applicable, as converted to U.S. dollars at the Bank of Canada posted rate for the respective trading day) of the issued and outstanding common shares on the Toronto Stock Exchange or such other principal stock exchange on which the common shares are listed and posted for trading is greater than US$<ix:nonFraction unitRef="usdPerShare" contextRef="c-124" decimals="2" name="oncyf:OtherEquityInstrumentsInShareBasedPaymentArrangementThresholdTradingPrice" scale="0" id="f-495"><ix:nonFraction unitRef="usdPerShare" contextRef="c-125" decimals="2" name="oncyf:OtherEquityInstrumentsInShareBasedPaymentArrangementThresholdTradingPrice" scale="0" id="f-496">6.50</ix:nonFraction></ix:nonFraction> for any <ix:nonFraction unitRef="d" contextRef="c-126" decimals="INF" name="oncyf:OtherEquityInstrumentsInShareBasedPaymentArrangementThresholdConsecutiveTradingDays" scale="0" id="f-497"><ix:nonFraction unitRef="d" contextRef="c-128" decimals="INF" name="oncyf:OtherEquityInstrumentsInShareBasedPaymentArrangementThresholdConsecutiveTradingDays" scale="0" id="f-498">20</ix:nonFraction></ix:nonFraction> consecutive trading days, at which time the Company may, within <ix:nonFraction unitRef="d" contextRef="c-126" decimals="INF" name="oncyf:OtherEquityInstrumentsInShareBasedPaymentArrangementAcceleratedThresholdTradingDays" scale="0" id="f-499"><ix:nonFraction unitRef="d" contextRef="c-128" decimals="INF" name="oncyf:OtherEquityInstrumentsInShareBasedPaymentArrangementAcceleratedThresholdTradingDays" scale="0" id="f-500">10</ix:nonFraction></ix:nonFraction> business days, accelerate the expiry date by issuing a press release announcing the reduced warrant term whereupon the warrants will expire on or after the <ix:nonFraction unitRef="d" contextRef="c-126" decimals="INF" name="oncyf:OtherEquityInstrumentsInShareBasedPaymentArrangementExpirationDays" scale="0" id="f-501"><ix:nonFraction unitRef="d" contextRef="c-128" decimals="INF" name="oncyf:OtherEquityInstrumentsInShareBasedPaymentArrangementExpirationDays" scale="0" id="f-502">75</ix:nonFraction></ix:nonFraction>th calendar day after the date of such press release.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proceeds were allocated amongst common shares and warrants by applying a relative fair value approach, which resulted in $<ix:nonFraction unitRef="cad" contextRef="c-126" decimals="-3" name="ifrs-full:IssueOfEquity" format="ixt:num-dot-decimal" scale="3" id="f-503"><ix:nonFraction unitRef="cad" contextRef="c-128" decimals="-3" name="ifrs-full:IssueOfEquity" format="ixt:num-dot-decimal" scale="3" id="f-504">17,724</ix:nonFraction></ix:nonFraction> recorded in share capital and an initial warrant derivative liability of $<ix:nonFraction unitRef="cad" contextRef="c-124" decimals="-3" name="ifrs-full:WarrantLiability" format="ixt:num-dot-decimal" scale="3" id="f-505"><ix:nonFraction unitRef="cad" contextRef="c-125" decimals="-3" name="ifrs-full:WarrantLiability" format="ixt:num-dot-decimal" scale="3" id="f-506">7,360</ix:nonFraction></ix:nonFraction>. The difference between the fair value of the warrants and their allocated proceeds was a discount of $<ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" name="oncyf:WarrantLiabilityUnamortizedDiscount" format="ixt:num-dot-decimal" scale="3" id="f-507">1,822</ix:nonFraction>, which is amortized on a straight-line basis over the <ix:nonNumeric contextRef="c-7" name="oncyf:WarrantsTerm" format="ixt-sec:durwordsen" id="f-508">five-year</ix:nonNumeric> </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2024</span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands of Canadian dollars, except share amounts and where indicated)</span></div><div style="margin-bottom:10pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="f-451-2"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expected life of the warrants and recorded under change in fair value of warrant derivative on our consolidated statement of loss and comprehensive loss.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2024, as the unamortized discount balance was greater than the fair value of the warrant derivative liability, the net balance was presented as an asset on our consolidated statement of financial position. </span></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the Black-Scholes valuation model to estimate fair value. The expected volatility is based on the Company's common share historical volatility less an estimated market participant risk adjustment. The risk-free interest rate is based on the Government of Canada benchmark bond yield rates with an approximate equivalent remaining term in effect at the time of valuation, and the expected life represents the estimated length of time the warrants are expected to remain outstanding. </span></div><ix:continuation id="f-452-1"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of the warrant derivative with an exercise price of US$<ix:nonFraction unitRef="usdPerShare" contextRef="c-136" decimals="2" name="oncyf:WarrantExercisePrice" scale="0" id="f-509"><ix:nonFraction unitRef="usdPerShare" contextRef="c-137" decimals="2" name="oncyf:WarrantExercisePrice" scale="0" id="f-510">2.81</ix:nonFraction></ix:nonFraction> was determined using the following assumptions: </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.104%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.007%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Underlying share price</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">US$<ix:nonFraction unitRef="usdPerShare" contextRef="c-123" decimals="2" name="oncyf:WeightedAverageSharePriceOtherEquityInstrumentsGranted" scale="0" id="f-511">0.92</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US$<ix:nonFraction unitRef="usdPerShare" contextRef="c-122" decimals="2" name="oncyf:WeightedAverageSharePriceOtherEquityInstrumentsGranted" scale="0" id="f-512">1.35</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-123" decimals="3" name="oncyf:RiskFreeInterestRateOtherEquityInstrumentsGranted" scale="-2" id="f-513">2.9</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-122" decimals="3" name="oncyf:RiskFreeInterestRateOtherEquityInstrumentsGranted" scale="-2" id="f-514">3.2</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="year" contextRef="c-123" decimals="1" name="oncyf:OtherEquityInstrumentsLifeOtherEquityInstrumentsGranted" scale="0" id="f-515">3.6</ix:nonFraction> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="year" contextRef="c-122" decimals="1" name="oncyf:OtherEquityInstrumentsLifeOtherEquityInstrumentsGranted" scale="0" id="f-516">4.6</ix:nonFraction> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-123" decimals="3" name="oncyf:ExpectedVolatilityOtherEquityInstrumentsGranted" scale="-2" id="f-517">36.5</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-122" decimals="3" name="oncyf:ExpectedVolatilityOtherEquityInstrumentsGranted" scale="-2" id="f-518">36.5</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-123" decimals="INF" name="oncyf:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted" format="ixt:fixed-zero" scale="3" id="f-519">Nil</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-122" decimals="INF" name="oncyf:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted" format="ixt:fixed-zero" scale="3" id="f-520">Nil</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value per warrant</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">US$<ix:nonFraction unitRef="usdPerShare" contextRef="c-123" decimals="2" name="oncyf:WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted" scale="0" id="f-521">0.03</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US$<ix:nonFraction unitRef="usdPerShare" contextRef="c-122" decimals="2" name="oncyf:WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted" scale="0" id="f-522">0.18</ix:nonFraction></span></td></tr></table></div></ix:continuation></ix:continuation><div id="i17734265916144358581fdce5df64f78_265"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Note 10: <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" id="f-523" continuedAt="f-523-1" escape="true">Share Capital</ix:nonNumeric></span></div><ix:continuation id="f-523-1" continuedAt="f-523-2"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Authorized:</span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory" id="f-524" continuedAt="f-524-1" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unlimited number of no par value common shares</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.104%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.007%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-9" decimals="INF" name="ifrs-full:NumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-525">55,043,789</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-9" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-526">391,348</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to stock option plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-138" decimals="INF" name="oncyf:IssueOfEquityShares" format="ixt:num-dot-decimal" scale="0" id="f-527">8,333</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-138" decimals="-3" name="ifrs-full:IssueOfEquity" scale="3" id="f-528">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to incentive share award plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-139" decimals="INF" name="oncyf:IssueOfEquityShares" format="ixt:num-dot-decimal" scale="0" id="f-529">40,560</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-139" decimals="-3" name="ifrs-full:IssueOfEquity" scale="3" id="f-530">98</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to "At the Market" (ATM) equity distribution agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)(b)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-140" decimals="INF" name="oncyf:IssueOfEquityShares" format="ixt:num-dot-decimal" scale="0" id="f-531">6,235,232</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-140" decimals="-3" name="ifrs-full:IssueOfEquity" format="ixt:num-dot-decimal" scale="3" id="f-532">13,338</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share issue costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-17" decimals="-3" name="ifrs-full:ShareIssueRelatedCost" scale="3" id="f-533">764</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2022</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-20" decimals="INF" name="ifrs-full:NumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-534">61,327,914</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-20" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-535">404,040</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to stock option plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-141" decimals="INF" name="oncyf:IssueOfEquityShares" format="ixt:num-dot-decimal" scale="0" id="f-536">450,391</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-141" decimals="-3" name="ifrs-full:IssueOfEquity" format="ixt:num-dot-decimal" scale="3" id="f-537">1,271</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to "At the Market" (ATM) equity distribution agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-30" decimals="INF" name="oncyf:IssueOfEquityShares" format="ixt:num-dot-decimal" scale="0" id="f-538">4,978,605</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-30" decimals="-3" name="ifrs-full:IssueOfEquity" format="ixt:num-dot-decimal" scale="3" id="f-539">10,676</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to public offering</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-142" decimals="INF" name="oncyf:IssueOfEquityShares" format="ixt:num-dot-decimal" scale="0" id="f-540">7,667,050</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-142" decimals="-3" name="ifrs-full:IssueOfEquity" format="ixt:num-dot-decimal" scale="3" id="f-541">17,724</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share issue costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-28" decimals="-3" name="ifrs-full:ShareIssueRelatedCost" format="ixt:num-dot-decimal" scale="3" id="f-542">2,805</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="ifrs-full:NumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-543">74,423,960</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-6" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-544">430,906</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to incentive share award plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-143" decimals="INF" name="oncyf:IssueOfEquityShares" format="ixt:num-dot-decimal" scale="0" id="f-545">133,572</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-143" decimals="-3" name="ifrs-full:IssueOfEquity" scale="3" id="f-546">297</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to "At the Market" (ATM) equity distribution agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)(d)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-43" decimals="INF" name="oncyf:IssueOfEquityShares" format="ixt:num-dot-decimal" scale="0" id="f-547">5,410,143</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-43" decimals="-3" name="ifrs-full:IssueOfEquity" format="ixt:num-dot-decimal" scale="3" id="f-548">7,670</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to warrant derivative exercised</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(e)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-144" decimals="INF" name="oncyf:IssueOfEquityShares" format="ixt:num-dot-decimal" scale="0" id="f-549">52,456</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-144" decimals="-3" name="ifrs-full:IssueOfEquity" scale="3" id="f-550">71</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share issue costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-41" decimals="-3" name="ifrs-full:ShareIssueRelatedCost" scale="3" id="f-551">751</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at December 31, 2024</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="ifrs-full:NumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-552">80,020,131</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-5" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-553">438,193</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">On March 5, 2021, we entered into an ATM equity distribution agreement with Canaccord Genuity Inc. The ATM allowed us to issue common shares, at prevailing market prices, with an aggregate offering value of up to US$<ix:nonFraction unitRef="usd" contextRef="c-145" decimals="-3" name="oncyf:SharePurchaseAgreementAmount" format="ixt:num-dot-decimal" scale="3" id="f-554">80,000</ix:nonFraction> over a <ix:nonNumeric contextRef="c-146" name="oncyf:SharePurchaseAgreementTerm" format="ixt-sec:durwordsen" id="f-555">16-month</ix:nonNumeric> period through the facilities of the Nasdaq Capital Market in the United States. This sales agreement was terminated on June 16, 2022. During the year ended December&#160;31, 2022, we sold <ix:nonFraction unitRef="shares" contextRef="c-147" decimals="INF" name="oncyf:IssueOfEquityShares" format="ixt:num-dot-decimal" scale="0" id="f-556">2,719,770</ix:nonFraction> common shares for gross proceeds of </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2024</span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands of Canadian dollars, except share amounts and where indicated)</span></div><div style="margin-bottom:10pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="f-524-1" continuedAt="f-524-2"><ix:continuation id="f-523-2" continuedAt="f-523-3"><div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="cad" contextRef="c-147" decimals="-3" name="oncyf:ProceedsFromIssueOfOrdinarySharesGross" format="ixt:num-dot-decimal" scale="3" id="f-557">5,744</ix:nonFraction> (US$<ix:nonFraction unitRef="usd" contextRef="c-147" decimals="-3" name="oncyf:ProceedsFromIssueOfOrdinarySharesGross" format="ixt:num-dot-decimal" scale="3" id="f-558">4,560</ix:nonFraction>) at an average price of $<ix:nonFraction unitRef="cadPerShare" contextRef="c-148" decimals="2" name="oncyf:SharesIssuedPricePerShare1" scale="0" id="f-559">2.11</ix:nonFraction> (US$<ix:nonFraction unitRef="usdPerShare" contextRef="c-148" decimals="2" name="oncyf:SharesIssuedPricePerShare1" scale="0" id="f-560">1.68</ix:nonFraction>). We received proceeds of $<ix:nonFraction unitRef="cad" contextRef="c-147" decimals="-3" name="ifrs-full:ProceedsFromIssueOfOrdinaryShares" format="ixt:num-dot-decimal" scale="3" id="f-561">5,572</ix:nonFraction> (US$<ix:nonFraction unitRef="usd" contextRef="c-147" decimals="-3" name="ifrs-full:ProceedsFromIssueOfOrdinaryShares" format="ixt:num-dot-decimal" scale="3" id="f-562">4,423</ix:nonFraction>) after commissions of $<ix:nonFraction unitRef="cad" contextRef="c-147" decimals="-3" name="oncyf:ShareIssueRelatedCostCommissions" scale="3" id="f-563">172</ix:nonFraction> (US$<ix:nonFraction unitRef="usd" contextRef="c-147" decimals="-3" name="oncyf:ShareIssueRelatedCostCommissions" scale="3" id="f-564">137</ix:nonFraction>). In total, we incurred share issue costs (including commissions) of $<ix:nonFraction unitRef="cad" contextRef="c-147" decimals="-3" name="ifrs-full:ShareIssueRelatedCost" scale="3" id="f-565">209</ix:nonFraction>. </span></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">On June 17, 2022, we entered into an ATM equity distribution agreement with Canaccord Genuity Inc. The ATM allowed us to issue common shares, at prevailing market prices, with an aggregate offering value of up to US$<ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-3" name="oncyf:SharePurchaseAgreementAmount" format="ixt:num-dot-decimal" scale="3" id="f-566">65,000</ix:nonFraction> over a <ix:nonNumeric contextRef="c-150" name="oncyf:SharePurchaseAgreementTerm" format="ixt-sec:durwordsen" id="f-567">25-month</ix:nonNumeric> period through the facilities of the Nasdaq Capital Market in the United States. This sales agreement was terminated on July 17, 2024. During the year ended December&#160;31, 2024, we sold <ix:nonFraction unitRef="shares" contextRef="c-151" decimals="INF" name="oncyf:IssueOfEquityShares" format="ixt:num-dot-decimal" scale="0" id="f-568">2,560,933</ix:nonFraction> (2023 - <ix:nonFraction unitRef="shares" contextRef="c-152" decimals="INF" name="oncyf:IssueOfEquityShares" format="ixt:num-dot-decimal" scale="0" id="f-569">4,978,605</ix:nonFraction>; 2022 - <ix:nonFraction unitRef="shares" contextRef="c-153" decimals="INF" name="oncyf:IssueOfEquityShares" format="ixt:num-dot-decimal" scale="0" id="f-570">3,515,462</ix:nonFraction>) common shares for gross proceeds of $<ix:nonFraction unitRef="cad" contextRef="c-151" decimals="-3" name="oncyf:ProceedsFromIssueOfOrdinarySharesGross" format="ixt:num-dot-decimal" scale="3" id="f-571">4,016</ix:nonFraction> (US$<ix:nonFraction unitRef="usd" contextRef="c-151" decimals="-3" name="oncyf:ProceedsFromIssueOfOrdinarySharesGross" format="ixt:num-dot-decimal" scale="3" id="f-572">2,964</ix:nonFraction>) (2023 - $<ix:nonFraction unitRef="cad" contextRef="c-152" decimals="-3" name="oncyf:ProceedsFromIssueOfOrdinarySharesGross" format="ixt:num-dot-decimal" scale="3" id="f-573">10,676</ix:nonFraction> (US$<ix:nonFraction unitRef="usd" contextRef="c-152" decimals="-3" name="oncyf:ProceedsFromIssueOfOrdinarySharesGross" format="ixt:num-dot-decimal" scale="3" id="f-574">7,904</ix:nonFraction>); 2022 - $<ix:nonFraction unitRef="cad" contextRef="c-153" decimals="-3" name="oncyf:ProceedsFromIssueOfOrdinarySharesGross" format="ixt:num-dot-decimal" scale="3" id="f-575">7,594</ix:nonFraction> (US$<ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-3" name="oncyf:ProceedsFromIssueOfOrdinarySharesGross" format="ixt:num-dot-decimal" scale="3" id="f-576">5,632</ix:nonFraction>)) at an average price of $<ix:nonFraction unitRef="cadPerShare" contextRef="c-154" decimals="2" name="oncyf:SharesIssuedPricePerShare1" scale="0" id="f-577">1.57</ix:nonFraction> (US$<ix:nonFraction unitRef="usdPerShare" contextRef="c-154" decimals="2" name="oncyf:SharesIssuedPricePerShare1" scale="0" id="f-578">1.16</ix:nonFraction>) (2023 - $<ix:nonFraction unitRef="cadPerShare" contextRef="c-155" decimals="2" name="oncyf:SharesIssuedPricePerShare1" scale="0" id="f-579">2.14</ix:nonFraction> (US$<ix:nonFraction unitRef="usdPerShare" contextRef="c-155" decimals="2" name="oncyf:SharesIssuedPricePerShare1" scale="0" id="f-580">1.59</ix:nonFraction>); 2022 - $<ix:nonFraction unitRef="cadPerShare" contextRef="c-156" decimals="2" name="oncyf:SharesIssuedPricePerShare1" scale="0" id="f-581">2.16</ix:nonFraction> (US$<ix:nonFraction unitRef="usdPerShare" contextRef="c-156" decimals="2" name="oncyf:SharesIssuedPricePerShare1" scale="0" id="f-582">1.60</ix:nonFraction>)). We received proceeds of $<ix:nonFraction unitRef="cad" contextRef="c-151" decimals="-3" name="ifrs-full:ProceedsFromIssueOfOrdinaryShares" format="ixt:num-dot-decimal" scale="3" id="f-583">3,895</ix:nonFraction> (US$<ix:nonFraction unitRef="usd" contextRef="c-151" decimals="-3" name="ifrs-full:ProceedsFromIssueOfOrdinaryShares" format="ixt:num-dot-decimal" scale="3" id="f-584">2,875</ix:nonFraction>) (2023 - $<ix:nonFraction unitRef="cad" contextRef="c-152" decimals="-3" name="ifrs-full:ProceedsFromIssueOfOrdinaryShares" format="ixt:num-dot-decimal" scale="3" id="f-585">10,356</ix:nonFraction> (US$<ix:nonFraction unitRef="usd" contextRef="c-152" decimals="-3" name="ifrs-full:ProceedsFromIssueOfOrdinaryShares" format="ixt:num-dot-decimal" scale="3" id="f-586">7,667</ix:nonFraction>); 2022 - $<ix:nonFraction unitRef="cad" contextRef="c-153" decimals="-3" name="ifrs-full:ProceedsFromIssueOfOrdinaryShares" format="ixt:num-dot-decimal" scale="3" id="f-587">7,366</ix:nonFraction> (US$<ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-3" name="ifrs-full:ProceedsFromIssueOfOrdinaryShares" format="ixt:num-dot-decimal" scale="3" id="f-588">5,463</ix:nonFraction>)) after commissions of $<ix:nonFraction unitRef="cad" contextRef="c-151" decimals="-3" name="oncyf:ShareIssueRelatedCostCommissions" scale="3" id="f-589">121</ix:nonFraction> (US$<ix:nonFraction unitRef="usd" contextRef="c-151" decimals="-3" name="oncyf:ShareIssueRelatedCostCommissions" scale="3" id="f-590">89</ix:nonFraction>) (2023 - $<ix:nonFraction unitRef="cad" contextRef="c-152" decimals="-3" name="oncyf:ShareIssueRelatedCostCommissions" scale="3" id="f-591">320</ix:nonFraction> (US$<ix:nonFraction unitRef="usd" contextRef="c-152" decimals="-3" name="oncyf:ShareIssueRelatedCostCommissions" scale="3" id="f-592">237</ix:nonFraction>); 2022 - $<ix:nonFraction unitRef="cad" contextRef="c-153" decimals="-3" name="oncyf:ShareIssueRelatedCostCommissions" scale="3" id="f-593">228</ix:nonFraction> (US$<ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-3" name="oncyf:ShareIssueRelatedCostCommissions" scale="3" id="f-594">169</ix:nonFraction>)). In total, we incurred share issue costs (including commissions) of $<ix:nonFraction unitRef="cad" contextRef="c-151" decimals="-3" name="ifrs-full:ShareIssueRelatedCost" scale="3" id="f-595">187</ix:nonFraction> (2023 - $<ix:nonFraction unitRef="cad" contextRef="c-152" decimals="-3" name="ifrs-full:ShareIssueRelatedCost" scale="3" id="f-596">415</ix:nonFraction>; 2022 - $<ix:nonFraction unitRef="cad" contextRef="c-153" decimals="-3" name="ifrs-full:ShareIssueRelatedCost" scale="3" id="f-597">555</ix:nonFraction>).</span></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">On August 8, 2023, pursuant to an underwritten public offering, we issued <ix:nonFraction unitRef="shares" contextRef="c-124" decimals="INF" name="oncyf:NumberOfWarrantsAndSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-598">6,667,000</ix:nonFraction> units for gross proceeds of $<ix:nonFraction unitRef="cad" contextRef="c-126" decimals="-3" name="oncyf:ProceedsFromIssueOfOrdinarySharesGross" format="ixt:num-dot-decimal" scale="3" id="f-599">20,185</ix:nonFraction> (US$<ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-3" name="oncyf:ProceedsFromIssueOfOrdinarySharesGross" format="ixt:num-dot-decimal" scale="3" id="f-600">15,001</ix:nonFraction>) at a price of US$<ix:nonFraction unitRef="usdPerShare" contextRef="c-124" decimals="2" name="oncyf:SharesIssuedPricePerShare1" scale="0" id="f-601">2.25</ix:nonFraction> per unit. On September 7, 2023, pursuant to the over-allotment option exercised by the underwriter, we issued an additional <ix:nonFraction unitRef="shares" contextRef="c-125" decimals="INF" name="oncyf:NumberOfWarrantsAndSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-602">1,000,050</ix:nonFraction> units for gross proceeds of $<ix:nonFraction unitRef="cad" contextRef="c-128" decimals="-3" name="oncyf:ProceedsFromIssueOfOrdinarySharesGross" format="ixt:num-dot-decimal" scale="3" id="f-603">3,077</ix:nonFraction> (US$<ix:nonFraction unitRef="usd" contextRef="c-128" decimals="-3" name="oncyf:ProceedsFromIssueOfOrdinarySharesGross" format="ixt:num-dot-decimal" scale="3" id="f-604">2,250</ix:nonFraction>) at a price of US$<ix:nonFraction unitRef="usdPerShare" contextRef="c-125" decimals="2" name="oncyf:SharesIssuedPricePerShare1" scale="0" id="f-605">2.25</ix:nonFraction> per unit. Each unit consisted of <ix:nonFraction unitRef="shares" contextRef="c-125" decimals="INF" name="oncyf:IssueOfEquitySharesNumberOfCommonShares" format="ixt-sec:numwordsen" scale="0" id="f-606"><ix:nonFraction unitRef="shares" contextRef="c-124" decimals="INF" name="oncyf:IssueOfEquitySharesNumberOfCommonShares" format="ixt-sec:numwordsen" scale="0" id="f-607">one</ix:nonFraction></ix:nonFraction> common share and <ix:nonFraction unitRef="shares" contextRef="c-124" decimals="INF" name="oncyf:IssueOfEquitySharesNumberOfWarrants" format="ixt-sec:numwordsen" scale="0" id="f-608"><ix:nonFraction unitRef="shares" contextRef="c-125" decimals="INF" name="oncyf:IssueOfEquitySharesNumberOfWarrants" format="ixt-sec:numwordsen" scale="0" id="f-609">one</ix:nonFraction></ix:nonFraction> warrant, which were immediately separable and issued separately in this offering. These warrants were classified as a financial liability (see note 9). Proceeds were allocated amongst common shares and warrants by applying a relative fair value approach, which resulted in $<ix:nonFraction unitRef="cad" contextRef="c-126" decimals="-3" name="ifrs-full:IssueOfEquity" format="ixt:num-dot-decimal" scale="3" id="f-610"><ix:nonFraction unitRef="cad" contextRef="c-128" decimals="-3" name="ifrs-full:IssueOfEquity" format="ixt:num-dot-decimal" scale="3" id="f-611">17,724</ix:nonFraction></ix:nonFraction> recorded in share capital and an initial warrant derivative liability of $<ix:nonFraction unitRef="cad" contextRef="c-124" decimals="-3" name="ifrs-full:WarrantLiability" format="ixt:num-dot-decimal" scale="3" id="f-612"><ix:nonFraction unitRef="cad" contextRef="c-125" decimals="-3" name="ifrs-full:WarrantLiability" format="ixt:num-dot-decimal" scale="3" id="f-613">7,360</ix:nonFraction></ix:nonFraction>. In consideration of the services rendered by the underwriter, we issued <ix:nonFraction unitRef="shares" contextRef="c-157" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-614"><ix:nonFraction unitRef="shares" contextRef="c-158" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-615">536,693</ix:nonFraction></ix:nonFraction> compensation warrants (see note 11). In total, we incurred transaction costs of $<ix:nonFraction unitRef="cad" contextRef="c-159" decimals="-3" name="oncyf:ShareWarrantsIssuedTransactionCosts" format="ixt:num-dot-decimal" scale="3" id="f-616"><ix:nonFraction unitRef="cad" contextRef="c-160" decimals="-3" name="oncyf:ShareWarrantsIssuedTransactionCosts" format="ixt:num-dot-decimal" scale="3" id="f-617">3,130</ix:nonFraction></ix:nonFraction> (including a fair value of $<ix:nonFraction unitRef="cad" contextRef="c-161" decimals="-3" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees" scale="3" id="f-618"><ix:nonFraction unitRef="cad" contextRef="c-162" decimals="-3" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees" scale="3" id="f-619">638</ix:nonFraction></ix:nonFraction> (US$<ix:nonFraction unitRef="usd" contextRef="c-162" decimals="-3" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees" scale="3" id="f-620"><ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-3" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees" scale="3" id="f-621">473</ix:nonFraction></ix:nonFraction>) for the compensation warrants), of which $<ix:nonFraction unitRef="cad" contextRef="c-160" decimals="-3" name="ifrs-full:ShareIssueRelatedCost" format="ixt:num-dot-decimal" scale="3" id="f-622"><ix:nonFraction unitRef="cad" contextRef="c-159" decimals="-3" name="ifrs-full:ShareIssueRelatedCost" format="ixt:num-dot-decimal" scale="3" id="f-623">2,390</ix:nonFraction></ix:nonFraction> were allocated to share issue costs and $<ix:nonFraction unitRef="cad" contextRef="c-159" decimals="-3" name="oncyf:ShareWarrantsIssuedOperatingExpense" scale="3" id="f-624"><ix:nonFraction unitRef="cad" contextRef="c-160" decimals="-3" name="oncyf:ShareWarrantsIssuedOperatingExpense" scale="3" id="f-625">740</ix:nonFraction></ix:nonFraction> were allocated to operating expenses, based on the relative fair values of the common share and warrant of each unit.</span></div><div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">On August 2, 2024, we entered into an ATM equity distribution agreement with Cantor Fitzgerald &amp; Co. The ATM allows us to issue common shares, at prevailing market prices, with an aggregate offering value of up to US$<ix:nonFraction unitRef="usd" contextRef="c-163" decimals="-3" name="oncyf:SharePurchaseAgreementAmount" format="ixt:num-dot-decimal" scale="3" id="f-626">50,000</ix:nonFraction> over a <ix:nonNumeric contextRef="c-164" name="oncyf:SharePurchaseAgreementTerm" format="ixt-sec:durwordsen" id="f-627">25-month</ix:nonNumeric> period through the facilities of the Nasdaq Capital Market in the United States. During the year ended December&#160;31, 2024, we sold <ix:nonFraction unitRef="shares" contextRef="c-165" decimals="INF" name="oncyf:IssueOfEquityShares" format="ixt:num-dot-decimal" scale="0" id="f-628">2,849,210</ix:nonFraction> common shares for gross proceeds of $<ix:nonFraction unitRef="cad" contextRef="c-165" decimals="-3" name="oncyf:ProceedsFromIssueOfOrdinarySharesGross" format="ixt:num-dot-decimal" scale="3" id="f-629">3,654</ix:nonFraction> (US$<ix:nonFraction unitRef="usd" contextRef="c-165" decimals="-3" name="oncyf:ProceedsFromIssueOfOrdinarySharesGross" format="ixt:num-dot-decimal" scale="3" id="f-630">2,562</ix:nonFraction>) at an average price of $<ix:nonFraction unitRef="cadPerShare" contextRef="c-166" decimals="2" name="oncyf:SharesIssuedPricePerShare1" scale="0" id="f-631">1.28</ix:nonFraction> (US$<ix:nonFraction unitRef="usdPerShare" contextRef="c-166" decimals="2" name="oncyf:SharesIssuedPricePerShare1" scale="0" id="f-632">0.90</ix:nonFraction>). We received proceeds of $<ix:nonFraction unitRef="cad" contextRef="c-165" decimals="-3" name="ifrs-full:ProceedsFromIssueOfOrdinaryShares" format="ixt:num-dot-decimal" scale="3" id="f-633">3,544</ix:nonFraction> (US$<ix:nonFraction unitRef="usd" contextRef="c-165" decimals="-3" name="ifrs-full:ProceedsFromIssueOfOrdinaryShares" format="ixt:num-dot-decimal" scale="3" id="f-634">2,485</ix:nonFraction>) after commissions of $<ix:nonFraction unitRef="cad" contextRef="c-165" decimals="-3" name="oncyf:ShareIssueRelatedCostCommissions" scale="3" id="f-635">110</ix:nonFraction> (US$<ix:nonFraction unitRef="usd" contextRef="c-165" decimals="-3" name="oncyf:ShareIssueRelatedCostCommissions" scale="3" id="f-636">77</ix:nonFraction>). In total, we incurred share issue costs (including commissions) of $<ix:nonFraction unitRef="cad" contextRef="c-165" decimals="-3" name="ifrs-full:ShareIssueRelatedCost" scale="3" id="f-637">564</ix:nonFraction>. </span></div></ix:continuation></ix:continuation><div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"><ix:continuation id="f-524-2" continuedAt="f-524-3"><ix:continuation id="f-523-3" continuedAt="f-523-4"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(e)</span></ix:continuation></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt"><ix:continuation id="f-524-3"><ix:continuation id="f-523-4">On August 16, 2019, pursuant to an underwritten public offering, we issued units consisting of common shares and warrants. During the year ended December&#160;31, 2024, <ix:nonFraction unitRef="shares" contextRef="c-123" decimals="INF" name="oncyf:NumberOfWarrantsExercised" format="ixt:num-dot-decimal" scale="0" id="f-638">52,456</ix:nonFraction> warrants with a fair value of $<ix:nonFraction unitRef="cad" contextRef="c-123" decimals="-3" sign="-" name="oncyf:WarrantsExercised" scale="3" id="f-639">6</ix:nonFraction> were exercised for gross proceeds of $<ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="oncyf:ProceedsfromWarrantExercises1" scale="3" id="f-640">65</ix:nonFraction> (US$<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="oncyf:ProceedsfromWarrantExercises1" scale="3" id="f-641">47</ix:nonFraction>). During the years ended December&#160;31, 2023 and 2022, <ix:nonFraction unitRef="shares" contextRef="c-122" decimals="INF" name="oncyf:NumberOfWarrantsExercised" format="ixt:fixed-zero" scale="0" id="f-642"><ix:nonFraction unitRef="shares" contextRef="c-167" decimals="INF" name="oncyf:NumberOfWarrantsExercised" format="ixt:fixed-zero" scale="0" id="f-643">no</ix:nonFraction></ix:nonFraction> warrants were exercised.</ix:continuation></ix:continuation> </span></div><div id="i17734265916144358581fdce5df64f78_268"></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Note 11: <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory" id="f-644" continuedAt="f-644-1" escape="true">Share-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="f-644-1" continuedAt="f-644-2"><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock options and share awards</span></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Our amended and restated Stock Option Plan and Share Award Plan (collectively, the "Equity Incentive Plans") were approved by our shareholders at the annual general meeting of shareholders on May 9, 2023. Pursuant to our Equity Incentive Plans, we may grant stock options, restricted share awards, and performance share awards. The number of common shares reserved for issuance under our Equity Incentive Plans in aggregate shall not exceed <ix:nonFraction unitRef="number" contextRef="c-3" decimals="2" name="oncyf:NumberOfSharesReservedForIssueUnderOptionsAndContractsForSaleOfSharesPercentageOfCommonSharesMaximum" scale="-2" id="f-645">14</ix:nonFraction>% of the total number of issued and outstanding common shares from time to time. As at December&#160;31, 2024, we reserved <ix:nonFraction unitRef="shares" contextRef="c-168" decimals="INF" name="ifrs-full:SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares" format="ixt:num-dot-decimal" scale="0" id="f-646">11,202,818</ix:nonFraction> common shares for issuance relating to our Equity Incentive Plans. Our share-based compensation expense for the year ended December&#160;31, 2024, was $<ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" format="ixt:num-dot-decimal" scale="3" id="f-647">2,723</ix:nonFraction> (2023 - $<ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" format="ixt:num-dot-decimal" scale="3" id="f-648">1,917</ix:nonFraction>; 2022 - $<ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" format="ixt:num-dot-decimal" scale="3" id="f-649">2,378</ix:nonFraction>). </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2024</span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands of Canadian dollars, except share amounts and where indicated)</span></div><div style="margin-bottom:10pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="f-644-2" continuedAt="f-644-3"><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</span><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" id="f-650" continuedAt="f-650-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Our stock option activity for the years ended December&#160;31 was as follows:</span></ix:nonNumeric></div><ix:continuation id="f-650-1"><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.039%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of options</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price<br/>$</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of options</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price<br/>$</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of options</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price<br/>$</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, beginning of year</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="f-651">7,063,333</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-4" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" id="f-652">2.72</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-25" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="f-653">5,963,185</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-25" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" id="f-654">2.91</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-14" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="f-655">5,334,420</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-14" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" id="f-656">3.53</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-657">2,016,800</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-1" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" scale="0" id="f-658">1.22</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-659">2,145,400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-7" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" scale="0" id="f-660">2.23</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-661">1,005,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-8" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" scale="0" id="f-662">2.04</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-663">175,534</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-1" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" scale="0" id="f-664">2.46</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-665">280,288</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-7" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" scale="0" id="f-666">2.86</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-8" decimals="INF" name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-667">62,962</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-8" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" scale="0" id="f-668">3.83</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-669">2,028,254</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-1" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" scale="0" id="f-670">3.22</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-671">314,573</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-7" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" scale="0" id="f-672">4.17</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-8" decimals="INF" name="ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-673">304,940</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-8" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" scale="0" id="f-674">10.80</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-675">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-1" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" format="ixt:fixed-zero" scale="0" id="f-676">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-677">450,391</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-7" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" scale="0" id="f-678">1.74</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-8" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-679">8,333</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-8" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" scale="0" id="f-680">1.45</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, end of year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="f-681">6,876,345</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-3" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" id="f-682">2.14</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="f-683">7,063,333</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-4" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" id="f-684">2.72</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-25" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="f-685">5,963,185</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-25" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" id="f-686">2.91</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable, end of year</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-687">4,718,058</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-3" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" scale="0" id="f-688">2.43</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-689">5,039,604</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-4" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" scale="0" id="f-690">2.85</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-25" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-691">4,420,482</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-25" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" scale="0" id="f-692">3.01</ix:nonFraction></span></td></tr></table></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory" id="f-694" escape="true"><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" id="f-693" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information about the stock options outstanding and exercisable at December&#160;31, 2024:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:23.208%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.456%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.456%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.456%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.456%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.458%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Range of Exercise Prices</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Life (years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price<br/>$</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number Exercisable</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price<br/>$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="cadPerShare" contextRef="c-169" decimals="2" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" id="f-695">1.13</ix:nonFraction> - $<ix:nonFraction unitRef="cadPerShare" contextRef="c-170" decimals="2" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" id="f-696">1.50</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-171" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="f-697">1,799,300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-172" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" format="ixt-sec:duryear" id="f-698">4.6</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-171" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" id="f-699">1.14</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-171" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-700">637,257</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-171" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" scale="0" id="f-701">1.13</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="cadPerShare" contextRef="c-173" decimals="2" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" id="f-702">1.51</ix:nonFraction> - $<ix:nonFraction unitRef="cadPerShare" contextRef="c-174" decimals="2" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" id="f-703">2.20</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-175" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="f-704">2,232,850</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-176" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" format="ixt-sec:duryear" id="f-705">3.3</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-175" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" id="f-706">1.88</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-175" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-707">1,434,792</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-175" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" scale="0" id="f-708">1.94</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="cadPerShare" contextRef="c-177" decimals="2" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" id="f-709">2.21</ix:nonFraction> - $<ix:nonFraction unitRef="cadPerShare" contextRef="c-178" decimals="2" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" id="f-710">2.70</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-179" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="f-711">699,689</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-180" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" format="ixt-sec:duryear" id="f-712">1.9</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-179" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" id="f-713">2.36</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-179" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-714">699,689</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-179" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" scale="0" id="f-715">2.36</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="cadPerShare" contextRef="c-181" decimals="2" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" id="f-716">2.71</ix:nonFraction> - $<ix:nonFraction unitRef="cadPerShare" contextRef="c-182" decimals="2" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" id="f-717">3.11</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-183" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="f-718">940,800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-184" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" format="ixt-sec:duryear" id="f-719">3.2</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-183" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" id="f-720">2.78</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-183" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-721">742,614</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-183" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" scale="0" id="f-722">2.78</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="cadPerShare" contextRef="c-185" decimals="2" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" id="f-723">3.12</ix:nonFraction> - $<ix:nonFraction unitRef="cadPerShare" contextRef="c-186" decimals="2" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" id="f-724">7.60</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-187" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="f-725">1,203,706</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-188" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" format="ixt-sec:duryear" id="f-726">1.2</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-187" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" id="f-727">3.51</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-187" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-728">1,203,706</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-187" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" scale="0" id="f-729">3.51</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="f-730">6,876,345</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" format="ixt-sec:duryear" id="f-731">3.1</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-3" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" id="f-732">2.14</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-733">4,718,058</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-3" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" scale="0" id="f-734">2.43</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Option grants vest either immediately or annually over periods ranging from <span style="-sec-ix-hidden:f-735">one</span> to <ix:nonNumeric contextRef="c-190" name="oncyf:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-736">three years</ix:nonNumeric>.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the Black-Scholes valuation model to estimate fair value. We use historical data to estimate the expected dividend yield</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and expected volatility of our stock in determining the fair value of the stock options. The risk-free interest rate is based on the</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government of Canada benchmark bond yield rates in effect at the time of grant. The expected life of the options represents the</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">estimated length of time the options are expected to remain outstanding. </span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" id="f-737" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of stock options granted during the years ended December&#160;31 were determined using the following weighted average assumptions: </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.642%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="4" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" id="f-738">3.1</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-7" decimals="4" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" id="f-739">4.1</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-8" decimals="4" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" id="f-740">3.4</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="year" contextRef="c-1" decimals="1" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" scale="0" id="f-741">3.0</ix:nonFraction> years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="year" contextRef="c-7" decimals="1" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" scale="0" id="f-742">3.0</ix:nonFraction> years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="year" contextRef="c-8" decimals="1" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" scale="0" id="f-743">3.0</ix:nonFraction> years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="4" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" id="f-744">66.4</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-7" decimals="4" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" id="f-745">72.0</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-8" decimals="4" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" id="f-746">96.0</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="INF" name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" format="ixt:fixed-zero" scale="3" id="f-747">Nil</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-7" decimals="INF" name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" format="ixt:fixed-zero" scale="0" id="f-748">Nil</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-8" decimals="INF" name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" format="ixt:fixed-zero" scale="3" id="f-749">Nil</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average fair value of options</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$<ix:nonFraction unitRef="cad" contextRef="c-3" decimals="2" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" scale="0" id="f-750">0.57</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="cad" contextRef="c-4" decimals="2" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" scale="0" id="f-751">1.12</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="cad" contextRef="c-25" decimals="2" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" scale="0" id="f-752">1.24</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2024</span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands of Canadian dollars, except share amounts and where indicated)</span></div><div style="margin-bottom:10pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="f-644-3" continuedAt="f-644-4"><div style="margin-top:5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</span><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" id="f-753" continuedAt="f-753-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Our share award activity for the years ended December&#160;31 was as follows:</span></ix:nonNumeric></div><ix:continuation id="f-753-1"><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.642%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, beginning of year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-191" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-754">398,440</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-192" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-755">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-193" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-756">40,560</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-194" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-757">853,642</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-195" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-758">403,200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-196" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:fixed-zero" scale="0" id="f-759">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-194" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-760">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-195" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-761">4,760</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-196" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-762">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Released</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-194" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-763">133,572</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-195" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-764">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-196" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-765">40,560</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, end of year</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-197" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-766">1,118,510</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-191" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-767">398,440</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-192" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-768">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> (1) The weighted average fair value of the RSAs granted was $<ix:nonFraction unitRef="cad" contextRef="c-197" decimals="2" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted" scale="0" id="f-769">1.15</ix:nonFraction> in 2024 (2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="cad" contextRef="c-191" decimals="2" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted" scale="0" id="f-770">2.23</ix:nonFraction>).</span></div></ix:continuation><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2024 and 2023, we granted restricted share awards to officers and a board of director member in his capacity as interim chief executive officer of the Company. Restricted share award granted to officers vest immediately or over a <ix:nonNumeric contextRef="c-198" name="oncyf:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-771"><ix:nonNumeric contextRef="c-199" name="oncyf:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-772">three-year</ix:nonNumeric></ix:nonNumeric> period. Restricted share award granted to the board of director member vest on the second anniversary from the grant date. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Compensation warrants </span></div></ix:continuation><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-644-4">In consideration of the services rendered by the underwriter as part of a public offering in 2023 (see note 10(c)), we issued <ix:nonFraction unitRef="shares" contextRef="c-200" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-773">536,693</ix:nonFraction> compensation warrants. Each compensation warrant is exercisable into <ix:nonFraction unitRef="shares" contextRef="c-201" decimals="INF" name="oncyf:IssueOfEquitySharesNumberOfCommonShares" format="ixt-sec:numwordsen" scale="0" id="f-774">one</ix:nonFraction> common share at an exercise price of US$<ix:nonFraction unitRef="usdPerShare" contextRef="c-200" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" scale="0" id="f-775">2.25</ix:nonFraction> up to <ix:nonNumeric contextRef="c-200" name="oncyf:ExpirationPeriodOfOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement" format="ixt-sec:durmonth" id="f-776">60</ix:nonNumeric> months from the date of issuance. At issuance date, we used the Black-Scholes valuation model to estimate the fair value of the services rendered. As at December&#160;31, 2024 and 2023, there were <ix:nonFraction unitRef="shares" contextRef="c-202" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-777"><ix:nonFraction unitRef="shares" contextRef="c-200" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-778">536,693</ix:nonFraction></ix:nonFraction> compensation warrants outstanding.</ix:continuation> </span></div><div><span><br/></span></div><div id="i17734265916144358581fdce5df64f78_271"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Note 12: <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfEarningsPerShareExplanatory" id="f-781" continuedAt="f-781-1" escape="true">Loss Per Share</ix:nonNumeric></span></div><ix:continuation id="f-781-1"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss per common share is calculated by dividing net loss for the year by the weighted average number of common shares outstanding for the year ended December&#160;31, 2024, of <ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="ifrs-full:AdjustedWeightedAverageShares" format="ixt:num-dot-decimal" scale="0" id="f-782"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="ifrs-full:WeightedAverageShares" format="ixt:num-dot-decimal" scale="0" id="f-783">76,482,914</ix:nonFraction></ix:nonFraction> (2023 - <ix:nonFraction unitRef="shares" contextRef="c-7" decimals="0" name="ifrs-full:WeightedAverageShares" format="ixt:num-dot-decimal" scale="0" id="f-784"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="0" name="ifrs-full:AdjustedWeightedAverageShares" format="ixt:num-dot-decimal" scale="0" id="f-785">67,624,036</ix:nonFraction></ix:nonFraction>; 2022 - <ix:nonFraction unitRef="shares" contextRef="c-8" decimals="0" name="ifrs-full:WeightedAverageShares" format="ixt:num-dot-decimal" scale="0" id="f-786"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="0" name="ifrs-full:AdjustedWeightedAverageShares" format="ixt:num-dot-decimal" scale="0" id="f-787">58,029,745</ix:nonFraction></ix:nonFraction>). The effect of any potential exercise of our stock options, share awards, and warrants outstanding during the year has been excluded from the calculation of diluted loss per common share, as it would be anti-dilutive.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="i17734265916144358581fdce5df64f78_274"></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Note 13: <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory" id="f-788" continuedAt="f-788-1" escape="true">Contract Liability</ix:nonNumeric></span></div><ix:continuation id="f-788-1"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We entered into a regional licensing agreement (the "Licensing Agreement") with Adlai Nortye Biopharma Co., Ltd. ("Adlai") in November 2017. Under the terms of the Licensing Agreement, Adlai will have exclusive development and commercialization rights to pelareorep in China, Hong Kong, Macau, Singapore, South Korea, and Taiwan. We are entitled to receive upfront license fees, development and regulatory milestone payments, royalties, and sales-based milestone payments. </span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory" id="f-789" escape="true"><div><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contract liability balance at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31</span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which w</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e expect to record in revenue over the next <ix:nonNumeric contextRef="c-1" name="oncyf:ContractLiabilityRecognitionPeriod" format="ixt-sec:durwordsen" id="f-790">five years</ix:nonNumeric>, is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.104%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.007%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, beginning of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="ifrs-full:ContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-791">6,730</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="ifrs-full:ContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-792">6,730</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue recognized </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities" format="ixt:fixed-zero" scale="3" id="f-793">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ifrs-full:DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities" format="ixt:fixed-zero" scale="3" id="f-794">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, end of year</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="ifrs-full:ContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-795">6,730</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="ifrs-full:ContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-796">6,730</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:5pt"><span><br/></span></div><div id="i17734265916144358581fdce5df64f78_277"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Note 14: <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" id="f-797" continuedAt="f-797-1" escape="true">Commitments and Contingencies </ix:nonNumeric></span></div><ix:continuation id="f-797-1" continuedAt="f-797-2"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are committed to payments of approximately $<ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="oncyf:PurchaseObligation1" format="ixt:num-dot-decimal" scale="3" id="f-798">7,793</ix:nonFraction> for activities mainly related to our clinical trial and manufacturing programs, which are expected to occur over the next <ix:nonNumeric contextRef="c-1" name="oncyf:PurchaseObligationCommitmentTerm" format="ixt-sec:durwordsen" id="f-799">two years</ix:nonNumeric>. Approximately one-third of the committed payments relate to a</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">production service agreement with our primary toll manufacturer, which cannot be canceled without a significant penalty. We</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are able to cancel most of the remaining agreements with notice. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2024</span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands of Canadian dollars, except share amounts and where indicated)</span></div><div style="margin-bottom:10pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="f-797-2"><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Indemnification of Officers and Directors</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our corporate by-laws require that, except to the extent expressly prohibited by law, we will indemnify our officers and directors against all costs, charges, and expenses, including an amount paid to settle an action or satisfy a judgment reasonably incurred in respect of any civil, criminal, or administrative action or proceeding as it relates to their services to the Company.&#160;The by-laws provide no limit to the amount of the indemnification.&#160;We have purchased directors&#8217; and officers&#8217; insurance coverage to cover claims made against the directors and officers during the applicable policy periods.&#160;The amounts and types of coverage have varied from period to period as dictated by market conditions.&#160;We believe that we have adequate insurance coverage; however, there is no guarantee that all indemnification payments will be covered under our existing insurance policies.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is no pending litigation or proceeding involving any of our officers or directors as to which indemnification is being sought, nor are we aware of any threatened litigation that may result in claims for indemnification.</span></div></ix:continuation><div><span><br/></span></div><div id="i17734265916144358581fdce5df64f78_280"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Note 15: <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfIncomeTaxExplanatory" id="f-801" continuedAt="f-801-1" escape="true">Income Taxes</ix:nonNumeric></span></div><ix:continuation id="f-801-1" continuedAt="f-801-2"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><ix:nonNumeric contextRef="c-1" name="oncyf:ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock" id="f-802" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes recorded in the consolidated financial statements differs from the amount which would be obtained by applying the statutory income tax rate to the loss before income taxes as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.379%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.353%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:AccountingProfit" format="ixt:num-dot-decimal" scale="3" id="f-803">31,580</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" sign="-" name="ifrs-full:AccountingProfit" format="ixt:num-dot-decimal" scale="3" id="f-804">27,655</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" sign="-" name="ifrs-full:AccountingProfit" format="ixt:num-dot-decimal" scale="3" id="f-805">24,751</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Statutory Canadian corporate tax rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="INF" name="ifrs-full:ApplicableTaxRate" scale="-2" id="f-806">23.00</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-7" decimals="INF" name="ifrs-full:ApplicableTaxRate" scale="-2" id="f-807">23.00</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-8" decimals="INF" name="ifrs-full:ApplicableTaxRate" scale="-2" id="f-808">23.00</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anticipated tax recovery</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:TaxExpenseIncomeAtApplicableTaxRate" format="ixt:num-dot-decimal" scale="3" id="f-809">7,263</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" sign="-" name="ifrs-full:TaxExpenseIncomeAtApplicableTaxRate" format="ixt:num-dot-decimal" scale="3" id="f-810">6,361</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" sign="-" name="ifrs-full:TaxExpenseIncomeAtApplicableTaxRate" format="ixt:num-dot-decimal" scale="3" id="f-811">5,693</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Difference in tax rates</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:TaxEffectOfForeignTaxRates" format="ixt:num-dot-decimal" scale="3" id="f-812">3,323</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" name="ifrs-full:TaxEffectOfForeignTaxRates" format="ixt:num-dot-decimal" scale="3" id="f-813">2,841</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" name="ifrs-full:TaxEffectOfForeignTaxRates" format="ixt:num-dot-decimal" scale="3" id="f-814">3,552</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" sign="-" name="oncyf:TaxEffectOfStockBasedCompensation" scale="3" id="f-815">668</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" sign="-" name="oncyf:TaxEffectOfStockBasedCompensation" scale="3" id="f-816">441</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" sign="-" name="oncyf:TaxEffectOfStockBasedCompensation" scale="3" id="f-817">547</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revaluation of tax balances</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" sign="-" name="oncyf:TaxEffectOfTaxPools" scale="3" id="f-818">639</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" name="oncyf:TaxEffectOfTaxPools" scale="3" id="f-819">2</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" sign="-" name="oncyf:TaxEffectOfTaxPools" scale="3" id="f-820">338</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of Barbados rate change</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:TaxEffectFromChangeInTaxRate" format="ixt:fixed-zero" scale="3" id="f-821">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" sign="-" name="ifrs-full:TaxEffectFromChangeInTaxRate" format="ixt:num-dot-decimal" scale="3" id="f-822">9,088</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" name="ifrs-full:TaxEffectFromChangeInTaxRate" format="ixt:fixed-zero" scale="3" id="f-823">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other permanent differences</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" scale="3" id="f-824">94</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" name="ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" scale="3" id="f-825">325</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" sign="-" name="ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" scale="3" id="f-826">368</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expiry of tax benefits</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="oncyf:TaxEffectOfExpirationOfTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-827">1,804</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" name="oncyf:TaxEffectOfExpirationOfTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-828">3,382</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" name="oncyf:TaxEffectOfExpirationOfTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-829">1,614</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of warrant derivative</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" sign="-" name="oncyf:TaxEffectOfChangeinFairValueOfWarrantDerivative" scale="3" id="f-830">286</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" sign="-" name="oncyf:TaxEffectOfChangeinFairValueOfWarrantDerivative" format="ixt:num-dot-decimal" scale="3" id="f-831">1,215</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" name="oncyf:TaxEffectOfChangeinFairValueOfWarrantDerivative" scale="3" id="f-832">5</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision to offset deferred tax asset</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" sign="-" name="oncyf:ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1" format="ixt:num-dot-decimal" scale="3" id="f-833">2,429</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" sign="-" name="oncyf:ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1" format="ixt:num-dot-decimal" scale="3" id="f-834">9,770</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" sign="-" name="oncyf:ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1" scale="3" id="f-835">765</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current income taxes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:IncomeTaxExpenseContinuingOperations" scale="3" id="f-836">130</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" name="ifrs-full:IncomeTaxExpenseContinuingOperations" scale="3" id="f-837">97</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" name="ifrs-full:IncomeTaxExpenseContinuingOperations" scale="3" id="f-838">84</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2024, we have non-capital losses of $<ix:nonFraction unitRef="cad" contextRef="c-205" decimals="-3" name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" format="ixt:num-dot-decimal" scale="3" id="f-839">117,096</ix:nonFraction> and $<ix:nonFraction unitRef="cad" contextRef="c-206" decimals="-3" name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" format="ixt:num-dot-decimal" scale="3" id="f-840">145,104</ix:nonFraction> in Canada and Barbados, respectively (December&#160;31, 2023 - $<ix:nonFraction unitRef="cad" contextRef="c-207" decimals="-3" name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" format="ixt:num-dot-decimal" scale="3" id="f-841">110,450</ix:nonFraction> and $<ix:nonFraction unitRef="cad" contextRef="c-208" decimals="-3" name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" format="ixt:num-dot-decimal" scale="3" id="f-842">129,884</ix:nonFraction>, respectively). These losses are expected to expire between 2025 and 2044, if not utilized. At December&#160;31, 2024, we have Canadian investment tax credits of $<ix:nonFraction unitRef="cad" contextRef="c-209" decimals="-3" name="ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised" format="ixt:num-dot-decimal" scale="3" id="f-843">3,839</ix:nonFraction> (December&#160;31, 2023 - $<ix:nonFraction unitRef="cad" contextRef="c-210" decimals="-3" name="ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised" format="ixt:num-dot-decimal" scale="3" id="f-844">4,056</ix:nonFraction>) that are expected to expire between 2025 and 2044, if not utilized. As well, we have unclaimed Canadian scientific research and experimental development expenditures available to reduce future years' taxable income of $<ix:nonFraction unitRef="cad" contextRef="c-211" decimals="-3" name="ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised" format="ixt:num-dot-decimal" scale="3" id="f-845">28,470</ix:nonFraction> (December&#160;31, 2023 - $<ix:nonFraction unitRef="cad" contextRef="c-212" decimals="-3" name="ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised" format="ixt:num-dot-decimal" scale="3" id="f-846">28,376</ix:nonFraction>).&#160;We also have unclaimed U.S. credits for research activities available to reduce future years' taxable income of $<ix:nonFraction unitRef="cad" contextRef="c-213" decimals="-3" name="ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised" format="ixt:num-dot-decimal" scale="3" id="f-847">1,313</ix:nonFraction> (December&#160;31, 2023 - $<ix:nonFraction unitRef="cad" contextRef="c-214" decimals="-3" name="ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised" format="ixt:num-dot-decimal" scale="3" id="f-848">1,232</ix:nonFraction>) expiring between 2031 and 2044. We have not recorded the potential benefits of these tax pools in these consolidated financial statements. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2024</span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands of Canadian dollars, except share amounts and where indicated)</span></div><div style="margin-bottom:10pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" id="f-849" escape="true"><ix:continuation id="f-801-2" continuedAt="f-801-3"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets are recognized, to the extent that it is probable that taxable income will be available to utilize the deductible temporary differences. The components of our unrecognized deferred tax asset are as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.379%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.353%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-capital losses carried forward</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-215" decimals="-3" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" format="ixt:num-dot-decimal" scale="3" id="f-850">40,078</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-216" decimals="-3" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" format="ixt:num-dot-decimal" scale="3" id="f-851">37,174</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-217" decimals="-3" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" format="ixt:num-dot-decimal" scale="3" id="f-852">26,726</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Scientific research and experimental development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-218" decimals="-3" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" format="ixt:num-dot-decimal" scale="3" id="f-853">7,861</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-219" decimals="-3" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" format="ixt:num-dot-decimal" scale="3" id="f-854">7,742</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-220" decimals="-3" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" format="ixt:num-dot-decimal" scale="3" id="f-855">7,648</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment tax credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-221" decimals="-3" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" format="ixt:num-dot-decimal" scale="3" id="f-856">2,956</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-222" decimals="-3" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" format="ixt:num-dot-decimal" scale="3" id="f-857">3,123</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-223" decimals="-3" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" format="ixt:num-dot-decimal" scale="3" id="f-858">3,363</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-224" decimals="-3" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" scale="3" id="f-859">453</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-225" decimals="-3" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" scale="3" id="f-860">382</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-226" decimals="-3" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" scale="3" id="f-861">366</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share issue costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-227" decimals="-3" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" scale="3" id="f-862">666</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-228" decimals="-3" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" scale="3" id="f-863">833</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-229" decimals="-3" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" scale="3" id="f-864">518</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net capital losses carried forward</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-230" decimals="-3" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" scale="3" id="f-865">6</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-231" decimals="-3" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" scale="3" id="f-866">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-232" decimals="-3" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" scale="3" id="f-867">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized deferred tax asset</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" format="ixt:num-dot-decimal" scale="3" id="f-868">52,020</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-4" decimals="-3" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" format="ixt:num-dot-decimal" scale="3" id="f-869">49,260</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-25" decimals="-3" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" format="ixt:num-dot-decimal" scale="3" id="f-870">38,627</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-801-3">The Company currently files income tax returns in the various jurisdictions in which it operates. These tax returns are subject to periodic examinations in the normal course by the applicable tax authorities. Management is not aware of any material income tax examinations currently in progress by any taxing jurisdiction.</ix:continuation> </span></div><div style="text-align:justify"><span><br/></span></div><div id="i17734265916144358581fdce5df64f78_283"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Note 16: <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory" id="f-871" continuedAt="f-871-1" escape="true">Capital Disclosures</ix:nonNumeric></span></div><ix:continuation id="f-871-1" continuedAt="f-871-2"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our objective when managing capital is to maintain adequate cash resources to support planned activities, including our clinical trial program, product manufacturing, administrative costs, and intellectual property expansion and protection.&#160;See note 1 for the discussion on our ability to continue as a going concern. We include shareholders' equity and cash and cash equivalents in the definition of capital.    </span></div><ix:nonNumeric contextRef="c-1" name="oncyf:DisclosureOfCapitalComponentsTableTextBlock" id="f-872" escape="true"><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.104%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.007%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-873">15,942</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-4" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-874">34,912</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shareholders' equity</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-875">5,983</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-4" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-876">27,563</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no debt other than accounts payable and accrued liabilities and lease liabilities. We also have commitments and potential contingent obligations relating to the completion of our research and development of pelareorep.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In managing our capital, we estimate our future cash requirements by preparing a budget and a multi-year plan annually for review and approval by our Board. The budget establishes the approved activities for the upcoming year and estimates the associated costs. The multi-year plan estimates future activity along with the potential cash requirements and is based on our assessment of our current clinical trial progress along with the expected results from the coming year&#8217;s activity.&#160;Budget to actual variances are prepared and reviewed by management and are presented quarterly to the Board.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, funding for our plan is primarily managed through the issuance of additional common shares and common share purchase warrants that upon exercise are converted to common shares.&#160;Management regularly monitors the capital markets attempting to balance the timing of issuing additional equity with our progress through our clinical trial program, general market conditions, and the availability of capital.&#160;There are no assurances that funds will be made available to us when required.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 19, 2024, we renewed our short form base shelf prospectus (the "Base Shelf") that qualifies for distribution of up to $<ix:nonFraction unitRef="cad" contextRef="c-233" decimals="-6" name="oncyf:EquityAuthorized" scale="6" id="f-877">150</ix:nonFraction> million of common shares, subscription receipts, warrants, or units (the "Securities") in either Canada, the U.S. or both. The Base Shelf will be effective until August 19, 2026. Under the Base Shelf, we may sell Securities to or through underwriters, dealers, placement agents, or other intermediaries. We may also sell Securities directly to purchasers or through agents, subject to obtaining any applicable exemption from registration requirements. The distribution of Securities may be performed from time to time in one or more transactions at a fixed price or prices, which may be subject to change, at market prices prevailing at the time of sale, or at prices related to such prevailing market prices to be negotiated with purchasers and as set forth in an accompanying Prospectus Supplement.  </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Renewing our Base Shelf provides additional flexibility when managing our cash resources as, under certain circumstances, it shortens the time required to close a financing and is expected to increase the number of potential investors that may be </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2024</span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands of Canadian dollars, except share amounts and where indicated)</span></div><div style="margin-bottom:10pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="f-871-2"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">prepared to invest in the Company. Funds received from using our Base Shelf would be used in line with our Board approved budget and multi-year plan.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Base Shelf allowed us to enter into our ATM equity distribution agreement (see note 10). We plan on using this equity arrangement to assist us in achieving our capital objectives. This arrangement provided us with the opportunity to raise capital and better manage our cash resources.   </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not subject to externally imposed capital requirements, and there have been no changes in how we define or manage our capital in 2024.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="i17734265916144358581fdce5df64f78_286"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Note 17: <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfFinancialInstrumentsExplanatory" id="f-878" continuedAt="f-878-1" escape="true">Financial Instruments</ix:nonNumeric></span></div><ix:continuation id="f-878-1" continuedAt="f-878-2"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair value of financial instruments</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As at December&#160;31, 2024, and December&#160;31, 2023, the carrying amount of our cash and cash equivalents, other receivables, accounts payable and accrued liabilities, and other liabilities approximated their fair value due to their short-term maturity. The warrant derivative is a recurring Level 2 fair value measurement as these warrants have not been listed on an exchange and, therefore, do not trade on an active market. As at December&#160;31, 2024, the fair value of our warrant derivative was presented as an asset of $<ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:CurrentDerivativeFinancialAssets" scale="3" id="f-879">980</ix:nonFraction> (December&#160;31, 2023 - liability of $<ix:nonFraction unitRef="cad" contextRef="c-4" decimals="-3" name="ifrs-full:CurrentDerivativeFinancialLiabilities" scale="3" id="f-880">200</ix:nonFraction>) (see note 9). </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial risk management</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit risk</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Credit risk is the risk of a financial loss if a counterparty to a financial instrument fails to meet its contractual obligations.&#160;As at December&#160;31, 2024, we were exposed to credit risk on our cash and cash equivalents in the event of non-performance by counterparties, but we do not anticipate such non-performance. Our maximum exposure to credit risk at the end of the period is the carrying value of our cash and cash equivalents. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We mitigate our exposure to credit risk connected to our cash and cash equivalents by maintaining our primary operating and investment bank accounts with Schedule I banks in Canada.&#160;For our foreign-domiciled bank accounts, we use referrals or recommendations from our Canadian banks to open foreign bank accounts. Our foreign-domiciled bank accounts are used solely for the purpose of settling accounts payable and accrued liabilities or payroll.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest rate risk </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates.&#160;We hold our cash and cash equivalents in bank accounts or high-interest investment accounts with variable interest rates. We mitigate interest rate risk through our investment policy that only allows the investment of excess cash resources in investment-grade vehicles while matching maturities with our operational requirements.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fluctuations in market interest rates do not significantly impact our results of operations due to the short-term maturity of the investments held.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign exchange risk</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign exchange risk arises from changes in foreign exchange rates that may affect the fair value or future cash flows of our financial assets or liabilities. For the year ended December&#160;31, 2024, we were primarily exposed to the risk of changes in the Canadian dollar relative to the U.S. dollar and Euro as a portion of our financial assets and liabilities were denominated in such currencies. The impact of a $<ix:nonFraction unitRef="cad" contextRef="c-234" decimals="2" name="oncyf:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount" scale="0" id="f-881">0.01</ix:nonFraction> increase in the value of the U.S. dollar against the Canadian dollar would have increased our comprehensive loss for the year ended December&#160;31, 2024, by approximately $<ix:nonFraction unitRef="cad" contextRef="c-234" decimals="-3" name="oncyf:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings" scale="3" id="f-882">34</ix:nonFraction> (December&#160;31, 2023 - decreased by approximately $<ix:nonFraction unitRef="cad" contextRef="c-235" decimals="-3" sign="-" name="oncyf:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings" scale="3" id="f-883">139</ix:nonFraction>). The impact of a $<ix:nonFraction unitRef="cad" contextRef="c-236" decimals="2" name="oncyf:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount" scale="0" id="f-884">0.01</ix:nonFraction> increase in the value of the Euro against the Canadian dollar would have increased our comprehensive loss for the year ended December&#160;31, 2024, by approximately $<ix:nonFraction unitRef="cad" contextRef="c-236" decimals="-3" name="oncyf:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings" scale="3" id="f-885">30</ix:nonFraction> (December&#160;31, 2023 - $<ix:nonFraction unitRef="cad" contextRef="c-237" decimals="-3" name="oncyf:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings" scale="3" id="f-886">15</ix:nonFraction>). </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2024</span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands of Canadian dollars, except share amounts and where indicated)</span></div><div style="margin-bottom:10pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="f-878-2" continuedAt="f-878-3"><ix:nonNumeric contextRef="c-1" name="oncyf:ScheduleOfForeignCurrencyHeldTableTextBlock" id="f-887" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant balances denominated in U.S. dollars were as follows:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.104%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.007%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-238" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-888">9,534</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-239" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-889">24,294</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-238" decimals="-3" name="ifrs-full:TradeAndOtherCurrentPayables" format="ixt:num-dot-decimal" scale="3" id="f-890">1,722</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-239" decimals="-3" name="ifrs-full:TradeAndOtherCurrentPayables" format="ixt:num-dot-decimal" scale="3" id="f-891">1,476</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-238" decimals="-3" name="ifrs-full:OtherLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-892">1,125</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-239" decimals="-3" name="ifrs-full:OtherLiabilities" scale="3" id="f-893">251</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-238" decimals="-3" name="oncyf:BalanceHeldInForeignCurrencyNet" format="ixt:num-dot-decimal" scale="3" id="f-894">6,687</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-239" decimals="-3" name="oncyf:BalanceHeldInForeignCurrencyNet" format="ixt:num-dot-decimal" scale="3" id="f-895">22,567</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant balances denominated in Euros were as follows:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.104%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.007%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-240" decimals="-3" name="ifrs-full:TradeAndOtherCurrentPayables" format="ixt:num-dot-decimal" scale="3" id="f-896">1,114</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="c-241" decimals="-3" name="ifrs-full:TradeAndOtherCurrentPayables" scale="3" id="f-897">673</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We mitigate our foreign exchange risk by maintaining sufficient foreign currencies by purchasing foreign currencies or receiving foreign currencies from financing activities to settle our foreign accounts payable and accrued liabilities.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity risk</span></div></ix:continuation><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-878-3">Liquidity risk is the risk that we will encounter difficulty in meeting obligations associated with financial liabilities. See note 1 for the discussion on our ability to continue as a going concern.&#160;We manage liquidity risk by managing our capital structure as outlined in note 16. Accounts payable and accrued liabilities are all due within the current operating period. Other liabilities associated with funding received from PanCAN (see note 5) are expected to be applied within the current operating period. See note 8 for a maturity analysis of our lease liabilities.</ix:continuation> </span></div><div style="text-align:justify"><span><br/></span></div><div id="i17734265916144358581fdce5df64f78_289"></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Note 18: <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfCashFlowStatementExplanatory" id="f-898" continuedAt="f-898-1" escape="true">Additional Cash Flow Disclosures</ix:nonNumeric></span></div><ix:continuation id="f-898-1"><ix:nonNumeric contextRef="c-1" name="oncyf:CashFlowOperatingCapital1TableTextBlock" id="f-899" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Change In Non-Cash Working Capital</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.379%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.353%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Change in:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" scale="3" id="f-900">53</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" name="ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" scale="3" id="f-901">506</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" name="ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" scale="3" id="f-902">345</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:AdjustmentsForDecreaseIncreaseInPrepaidExpenses" format="ixt:num-dot-decimal" scale="3" id="f-903">1,361</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" name="ifrs-full:AdjustmentsForDecreaseIncreaseInPrepaidExpenses" scale="3" id="f-904">777</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" sign="-" name="ifrs-full:AdjustmentsForDecreaseIncreaseInPrepaidExpenses" format="ixt:num-dot-decimal" scale="3" id="f-905">1,247</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" format="ixt:num-dot-decimal" scale="3" id="f-906">1,220</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" sign="-" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" scale="3" id="f-907">78</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" format="ixt:num-dot-decimal" scale="3" id="f-908">1,662</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:AdjustmentsForIncreaseDecreaseInOtherOperatingPayables" format="ixt:num-dot-decimal" scale="3" id="f-909">1,286</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" name="ifrs-full:AdjustmentsForIncreaseDecreaseInOtherOperatingPayables" scale="3" id="f-910">332</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" sign="-" name="ifrs-full:AdjustmentsForIncreaseDecreaseInOtherOperatingPayables" scale="3" id="f-911">352</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash impact of foreign exchange</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" sign="-" name="oncyf:IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet" scale="3" id="f-912">276</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" name="oncyf:IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet" scale="3" id="f-913">228</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" sign="-" name="oncyf:IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet" scale="3" id="f-914">17</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in non-cash working capital related to operating activities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseInWorkingCapital" format="ixt:num-dot-decimal" scale="3" id="f-915">3,538</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseInWorkingCapital" format="ixt:num-dot-decimal" scale="3" id="f-916">1,765</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseInWorkingCapital" scale="3" id="f-917">391</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="oncyf:ScheduleofCashFlowSupplementalDisclosures1TableTextBlock" id="f-918" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Cash Flow Disclosures</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.379%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.353%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash interest received</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="oncyf:ProceedsfromInterestReceived" format="ixt:num-dot-decimal" scale="3" id="f-919">1,339</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" name="oncyf:ProceedsfromInterestReceived" format="ixt:num-dot-decimal" scale="3" id="f-920">1,554</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" name="oncyf:ProceedsfromInterestReceived" scale="3" id="f-921">452</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash taxes paid</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:IncomeTaxesPaidRefund" scale="3" id="f-922">184</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" name="ifrs-full:IncomeTaxesPaidRefund" scale="3" id="f-923">120</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" name="ifrs-full:IncomeTaxesPaidRefund" scale="3" id="f-924">46</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:center"><span><br/></span></div><div id="i17734265916144358581fdce5df64f78_292"></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Note 19: <ix:nonNumeric contextRef="c-1" name="oncyf:DisclosureOfEconomicDependenceTextBlock" id="f-925" continuedAt="f-925-1" escape="true">Economic Dependence</ix:nonNumeric></span></div><ix:continuation id="f-925-1"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are economically dependent on our toll manufacturers. We primarily use <ix:nonFraction unitRef="manufacturer" contextRef="c-242" decimals="INF" name="oncyf:ConcentrationRiskNumber" format="ixt-sec:numwordsen" scale="0" id="f-926">one</ix:nonFraction> toll manufacturer in the U.S. to produce the clinical-grade pelareorep active ingredient and a second toll manufacturer to formulate finished product required for our clinical trial program.&#160;Any significant disruption of the services provided by our primary toll manufacturers has the potential to delay the progress of our clinical trial program.&#160;We have attempted to mitigate this risk by identifying an alternative toll manufacturer, establishing stability profiles for long-term storage of pelareorep, and producing sufficient pelareorep in advance of patient enrollment in a particular clinical trial.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-26</span></div></div></div><div id="i17734265916144358581fdce5df64f78_295"></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2024</span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands of Canadian dollars, except share amounts and where indicated)</span></div><div style="margin-bottom:10pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Note 20:  <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfExpensesByNatureExplanatory" id="f-927" continuedAt="f-927-1" escape="true">Components of Expenses</ix:nonNumeric></span></div><ix:continuation id="f-927-1" continuedAt="f-927-2"><ix:nonNumeric contextRef="c-1" name="oncyf:OtherExpensesAndAdjustmentsTableTextBlock" id="f-928" escape="true"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.379%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.353%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Research and development expenses</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trial expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-243" decimals="-3" name="oncyf:ClinicalTrialExpense" format="ixt:num-dot-decimal" scale="3" id="f-929">5,463</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-244" decimals="-3" name="oncyf:ClinicalTrialExpense" format="ixt:num-dot-decimal" scale="3" id="f-930">3,675</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-245" decimals="-3" name="oncyf:ClinicalTrialExpense" format="ixt:num-dot-decimal" scale="3" id="f-931">4,970</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing &amp; related process development expenses</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-243" decimals="-3" name="oncyf:ManufacturingExpense" format="ixt:num-dot-decimal" scale="3" id="f-932">8,267</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-244" decimals="-3" name="oncyf:ManufacturingExpense" format="ixt:num-dot-decimal" scale="3" id="f-933">5,789</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-245" decimals="-3" name="oncyf:ManufacturingExpense" format="ixt:num-dot-decimal" scale="3" id="f-934">2,148</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intellectual property expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-243" decimals="-3" name="oncyf:IntellectualPropertyExpense" scale="3" id="f-935">433</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-244" decimals="-3" name="oncyf:IntellectualPropertyExpense" scale="3" id="f-936">397</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-245" decimals="-3" name="oncyf:IntellectualPropertyExpense" scale="3" id="f-937">544</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Translational science expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-243" decimals="-3" name="oncyf:TranslationalScienceExpense" scale="3" id="f-938">101</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-244" decimals="-3" name="oncyf:TranslationalScienceExpense" format="ixt:fixed-zero" scale="3" id="f-939">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-245" decimals="-3" name="oncyf:TranslationalScienceExpense" scale="3" id="f-940">264</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Personnel-related expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-243" decimals="-3" name="ifrs-full:OtherEmployeeExpense" format="ixt:num-dot-decimal" scale="3" id="f-941">5,451</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-244" decimals="-3" name="ifrs-full:OtherEmployeeExpense" format="ixt:num-dot-decimal" scale="3" id="f-942">6,324</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-245" decimals="-3" name="ifrs-full:OtherEmployeeExpense" format="ixt:num-dot-decimal" scale="3" id="f-943">6,023</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-243" decimals="-3" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" format="ixt:num-dot-decimal" scale="3" id="f-944">1,717</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-244" decimals="-3" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" format="ixt:num-dot-decimal" scale="3" id="f-945">1,305</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-245" decimals="-3" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" format="ixt:num-dot-decimal" scale="3" id="f-946">1,371</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-243" decimals="-3" name="ifrs-full:MiscellaneousOtherOperatingExpense" scale="3" id="f-947">215</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-244" decimals="-3" name="ifrs-full:MiscellaneousOtherOperatingExpense" scale="3" id="f-948">219</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-245" decimals="-3" name="ifrs-full:MiscellaneousOtherOperatingExpense" scale="3" id="f-949">112</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-950">21,647</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" name="ifrs-full:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-951">17,709</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" name="ifrs-full:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-952">15,432</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">General and administrative expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Public company-related expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-246" decimals="-3" name="oncyf:PublicCompanyExpense" format="ixt:num-dot-decimal" scale="3" id="f-953">8,565</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-247" decimals="-3" name="oncyf:PublicCompanyExpense" format="ixt:num-dot-decimal" scale="3" id="f-954">11,278</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-248" decimals="-3" name="oncyf:PublicCompanyExpense" format="ixt:num-dot-decimal" scale="3" id="f-955">6,790</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Personnel-related expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-246" decimals="-3" name="ifrs-full:OtherEmployeeExpense" format="ixt:num-dot-decimal" scale="3" id="f-956">2,848</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-247" decimals="-3" name="ifrs-full:OtherEmployeeExpense" format="ixt:num-dot-decimal" scale="3" id="f-957">3,332</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-248" decimals="-3" name="ifrs-full:OtherEmployeeExpense" format="ixt:num-dot-decimal" scale="3" id="f-958">2,870</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-246" decimals="-3" name="oncyf:OfficeExpenses" scale="3" id="f-959">492</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-247" decimals="-3" name="oncyf:OfficeExpenses" scale="3" id="f-960">457</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-248" decimals="-3" name="oncyf:OfficeExpenses" scale="3" id="f-961">433</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-246" decimals="-3" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" format="ixt:num-dot-decimal" scale="3" id="f-962">1,006</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-247" decimals="-3" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" scale="3" id="f-963">612</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-248" decimals="-3" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" format="ixt:num-dot-decimal" scale="3" id="f-964">1,007</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation - property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-246" decimals="-3" name="ifrs-full:AmortisationExpense" scale="3" id="f-965">120</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-247" decimals="-3" name="ifrs-full:AmortisationExpense" scale="3" id="f-966">81</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-248" decimals="-3" name="ifrs-full:AmortisationExpense" scale="3" id="f-967">93</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation - right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-246" decimals="-3" name="ifrs-full:DepreciationRightofuseAssets" scale="3" id="f-968">304</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-247" decimals="-3" name="ifrs-full:DepreciationRightofuseAssets" scale="3" id="f-969">322</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-248" decimals="-3" name="ifrs-full:DepreciationRightofuseAssets" scale="3" id="f-970">299</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-971">13,335</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" name="ifrs-full:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-972">16,082</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" name="ifrs-full:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-973">11,492</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2024, our research and development personnel-related expenses included employee compensation and benefits of $<ix:nonFraction unitRef="cad" contextRef="c-243" decimals="-3" name="ifrs-full:EmployeeBenefitsExpense" format="ixt:num-dot-decimal" scale="3" id="f-974">5,328</ix:nonFraction> (2023 - $<ix:nonFraction unitRef="cad" contextRef="c-244" decimals="-3" name="ifrs-full:EmployeeBenefitsExpense" format="ixt:num-dot-decimal" scale="3" id="f-975">6,324</ix:nonFraction>; 2022 - $<ix:nonFraction unitRef="cad" contextRef="c-245" decimals="-3" name="ifrs-full:EmployeeBenefitsExpense" format="ixt:num-dot-decimal" scale="3" id="f-976">5,983</ix:nonFraction>).</span></div></ix:continuation><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-927-2">For the year ended December&#160;31, 2024, our general and administrative office expenses included employee compensation and benefits of $<ix:nonFraction unitRef="cad" contextRef="c-246" decimals="-3" name="ifrs-full:EmployeeBenefitsExpense" format="ixt:num-dot-decimal" scale="3" id="f-977">2,650</ix:nonFraction> (2023 - $<ix:nonFraction unitRef="cad" contextRef="c-247" decimals="-3" name="ifrs-full:EmployeeBenefitsExpense" format="ixt:num-dot-decimal" scale="3" id="f-978">3,332</ix:nonFraction>; 2022 - $<ix:nonFraction unitRef="cad" contextRef="c-248" decimals="-3" name="ifrs-full:EmployeeBenefitsExpense" format="ixt:num-dot-decimal" scale="3" id="f-979">2,870</ix:nonFraction>).</ix:continuation> </span></div><div style="text-align:center"><span><br/></span></div><div id="i17734265916144358581fdce5df64f78_549755816280"></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Note 21: <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory" id="f-980" continuedAt="f-980-1" escape="true">Segment Disclosures</ix:nonNumeric></span></div><ix:continuation id="f-980-1"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations have <ix:nonFraction unitRef="segment" contextRef="c-3" decimals="INF" name="oncyf:NumberOfReportableSegments1" format="ixt-sec:numwordsen" scale="0" id="f-981">one</ix:nonFraction> reportable segment engaged in the research and development and commercialization of oncology</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">treatments, which is consistent with the way we report information to our chief decision maker and Board of Directors.</span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfGeographicalAreasExplanatory" id="f-982" escape="true"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following geographic information reflects non-current assets by location:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.104%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.007%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Property and equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-249" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-983">203</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-250" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-984">246</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of world</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-251" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-985">208</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-252" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-986">36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-987">411</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-4" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-988">282</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.104%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.007%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Right-of-use-assets</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-249" decimals="-3" name="ifrs-full:RightofuseAssets" scale="3" id="f-989">74</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-250" decimals="-3" name="ifrs-full:RightofuseAssets" scale="3" id="f-990">111</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of world</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-251" decimals="-3" name="ifrs-full:RightofuseAssets" scale="3" id="f-991">827</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-252" decimals="-3" name="ifrs-full:RightofuseAssets" scale="3" id="f-992">254</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:RightofuseAssets" scale="3" id="f-993">901</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-4" decimals="-3" name="ifrs-full:RightofuseAssets" scale="3" id="f-994">365</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:5pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-27</span></div></div></div><div id="i17734265916144358581fdce5df64f78_298"></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2024</span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands of Canadian dollars, except share amounts and where indicated)</span></div><div style="margin-bottom:10pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Note 22:  <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfRelatedPartyExplanatory" id="f-995" continuedAt="f-995-1" escape="true">Related Party Transactions</ix:nonNumeric></span></div><ix:continuation id="f-995-1"><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Compensation of Key Management Personnel</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Key management personnel are those persons having authority and responsibility for planning, directing, and controlling our activities as a whole. <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" id="f-996" continuedAt="f-996-1" escape="true">We have determined that key management personnel comprise the Board of Directors, Executive Officers, President, and Vice Presidents. </ix:nonNumeric></span></div><ix:continuation id="f-996-1"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.379%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.353%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term employee compensation and benefits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" format="ixt:num-dot-decimal" scale="3" id="f-997">4,267</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" format="ixt:num-dot-decimal" scale="3" id="f-998">4,870</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" format="ixt:num-dot-decimal" scale="3" id="f-999">4,308</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Termination benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationTerminationBenefits" format="ixt:fixed-zero" scale="3" id="f-1000">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationTerminationBenefits" scale="3" id="f-1001">319</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationTerminationBenefits" format="ixt:fixed-zero" scale="3" id="f-1002">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" format="ixt:num-dot-decimal" scale="3" id="f-1003">2,349</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" format="ixt:num-dot-decimal" scale="3" id="f-1004">1,496</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" format="ixt:num-dot-decimal" scale="3" id="f-1005">1,615</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensation" format="ixt:num-dot-decimal" scale="3" id="f-1006">6,616</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensation" format="ixt:num-dot-decimal" scale="3" id="f-1007">6,685</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensation" format="ixt:num-dot-decimal" scale="3" id="f-1008">5,923</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="i17734265916144358581fdce5df64f78_301"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Note 23:  <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory" id="f-1009" continuedAt="f-1009-1" escape="true">Subsequent Events</ix:nonNumeric></span></div><ix:continuation id="f-1009-1" continuedAt="f-1009-2"><div style="margin-bottom:3pt;margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">From January 1, 2025, to March&#160;6, 2025, we sold <ix:nonFraction unitRef="shares" contextRef="c-53" decimals="INF" name="oncyf:IssueOfEquityShares" format="ixt:num-dot-decimal" scale="0" id="f-1010">5,302,950</ix:nonFraction> shares for gross proceeds of $<ix:nonFraction unitRef="cad" contextRef="c-53" decimals="-3" name="oncyf:ProceedsFromIssueOfOrdinarySharesGross" format="ixt:num-dot-decimal" scale="3" id="f-1011">6,228</ix:nonFraction> (US$<ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" name="oncyf:ProceedsFromIssueOfOrdinarySharesGross" format="ixt:num-dot-decimal" scale="3" id="f-1012">4,327</ix:nonFraction>) at an average price of $<ix:nonFraction unitRef="cadPerShare" contextRef="c-53" decimals="2" name="oncyf:IssueOfOrdinarySharesPerShare" scale="0" id="f-1013">1.17</ix:nonFraction> (US$<ix:nonFraction unitRef="usdPerShare" contextRef="c-53" decimals="2" name="oncyf:IssueOfOrdinarySharesPerShare" scale="0" id="f-1014">0.82</ix:nonFraction>). We received proceeds of $<ix:nonFraction unitRef="cad" contextRef="c-53" decimals="-3" name="ifrs-full:ProceedsFromIssueOfOrdinaryShares" format="ixt:num-dot-decimal" scale="3" id="f-1015">6,041</ix:nonFraction> (US$<ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" name="ifrs-full:ProceedsFromIssueOfOrdinaryShares" format="ixt:num-dot-decimal" scale="3" id="f-1016">4,197</ix:nonFraction>), after commissions of $<ix:nonFraction unitRef="cad" contextRef="c-53" decimals="-3" name="oncyf:ShareIssueRelatedCostCommissions" scale="3" id="f-1017">187</ix:nonFraction> (US$<ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" name="oncyf:ShareIssueRelatedCostCommissions" scale="3" id="f-1018">130</ix:nonFraction>). </span></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">On February 13, 2025, we received a delinquency notification letter (the "Notice") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") indicating that, for the prior 30 consecutive business days, the closing bid price for our ordinary shares listed on the Nasdaq Capital Market was below the minimum $1.00 per share required for continued listing on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2). The Notice provides that we have a period of 180 calendar days from the date of the Notice, or until August 12, 2025, to regain compliance with the minimum bid price requirement. The receipt of the Notice has no immediate effect on our business operations or the listing of our ordinary shares, which will continue to trade uninterrupted on the Nasdaq under the ticker "ONCY." If at any time before August 12, 2025, the bid price of our ordinary shares closes at or above $1.00 per share for a minimum of 10 consecutive business days, Nasdaq will provide written confirmation of compliance to us. In the event that we do not regain compliance by August 12, 2025, we may be eligible for additional time to regain compliance. To qualify, we would be required to meet the continued listing requirement for the market value of publicly held shares and all other initial listing standards for the Nasdaq Capital Market, except for the minimum bid price requirement. In addition, we would be required to notify Nasdaq of its intent to cure the deficiency during the second compliance period.</span></div></ix:continuation><div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"><ix:continuation id="f-1009-2" continuedAt="f-1009-3"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt"><ix:continuation id="f-1009-3">In early 2025, the President of the United States issued executive orders directing the United States to impose new tariffs on imports originating from Canada, Mexico, and China. The impacts of these tariffs on our operations remain uncertain. New or increased tariffs, export controls, or other measures discouraging contracts with Chinese companies could materially impact our supply chain and manufacturing costs and our licensing agreement with Adlai. We are assessing the direct and indirect impacts of such trade protectionist measures to our operations as this situation develops.</ix:continuation>   </span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-28</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-2.1
<SEQUENCE>2
<FILENAME>ex21exdescriptionofsecurit.htm
<DESCRIPTION>EX-2.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i54b5515c6ca94b4f8b45c9f0a647ad01_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:8pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:138%">EXHIBIT 2.1</font></div><div style="margin-bottom:8pt;text-align:justify"><font><br></font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:138%">DESCRIPTION OF RIGHTS OF SECURITIES REGISTERED UNDER SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 </font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%">Our authorized capital consists of an unlimited number of Common Shares. The following is a summary of the provisions attached to our Common Shares&#58;</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%">The holders of our Common Shares are entitled to one vote per share at meetings of shareholders, to receive such dividends as declared by the Board and to receive our remaining property and assets upon dissolution or wind up. Our Common Shares are not subject to any future call or assessment and there are no pre-emptive, conversion or redemption rights attached to such shares. As at March&#160;6, 2025, we have 86,421,592 Common Shares issued and outstanding. After giving effect to the exercise or distribution of all outstanding options to acquire Common Shares, all outstanding share awards granted under the Corporation&#8217;s Incentive Share Award Plan, Common Share purchase warrants, and compensation warrants we would have 101,858,551 Common Shares issued and outstanding. As at March&#160;6, 2025, we have 8,203,743 Common Share purchase warrants issued in 2023 (the &#34;2023 Warrants&#34;) and compensation warrants issued in 2023 outstanding. Each 2023 Warrant entitles the holder to purchase one Common Share until August 8, 2028, at an exercise price of US$2.81. Each compensation warrant entitles the holder to purchase one Common Share until August 8, 2028, at an exercise price of US$2.25.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:137%">The Corporation has neither declared nor paid dividends on the Common Shares and has no present intention of paying dividends on the Common Shares for the foreseeable future.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-8.0
<SEQUENCE>3
<FILENAME>ex80subsidiaries2024.htm
<DESCRIPTION>EX-8.0
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="icc49412c1d3742d2bb0d4280c1be82a0_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 8.0</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LIST OF SUBSIDIARIES</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.222%"><tr><td style="width:1.0%"></td><td style="width:71.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.824%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jurisdiction</font></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oncolytics Biotech (Barbados) Inc.</font></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Barbados</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oncolytics Biotech (US) Inc.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr></table></div><div style="margin-bottom:5pt;margin-top:3pt"><font><br></font></div><div style="margin-bottom:5pt;margin-top:5pt"><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.1
<SEQUENCE>4
<FILENAME>ex121ceocertification2024.htm
<DESCRIPTION>EX-12.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i175091c5fbe54ce3a18e09847c58fc61_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">EXHIBIT 12.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">CERTIFICATION</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">I, Wayne Pisano, certify that&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:28.5pt">I have reviewed this annual report on Form 20-F of Oncolytics Biotech Inc.&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:28.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:28.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:28.5pt">The company's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:24.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:24.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:24.91pt">Evaluated the effectiveness of the company's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:24.34pt">Disclosed in this report any change in the company's internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company's internal control over financial reporting&#59; and</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">5. &#160;&#160;&#160;&#160;The company's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company's auditors and the audit committee of the company's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:24.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company's ability to record, process, summarize and report financial information&#59; and</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:24.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the company's internal control over financial reporting.</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:6.074%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.895%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.850%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 7, 2025</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;Wayne Pisano</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wayne Pisano<br>Interim Chief Executive Officer<br>Interim Principal Executive Officer</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.2
<SEQUENCE>5
<FILENAME>ex122cfocertification2024.htm
<DESCRIPTION>EX-12.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i31cbe7d2ae8e43378ca7f788d03e3c5e_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">EXHIBIT 12.2</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">CERTIFICATION</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">I, Kirk Look, certify that&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:28.5pt">I have reviewed this annual report on Form 20-F of Oncolytics Biotech Inc.&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:28.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:28.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:28.5pt">The company's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:24.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:24.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:24.91pt">Evaluated the effectiveness of the company's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:24.34pt">Disclosed in this report any change in the company's internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company's internal control over financial reporting&#59; and</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">5. &#160;&#160;&#160;&#160;The company's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company's auditors and the audit committee of the company's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:24.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company's ability to record, process, summarize and report financial information&#59; and</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:24.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the company's internal control over financial reporting.</font></div><div style="margin-bottom:2pt;padding-left:36pt;padding-right:36pt;text-align:center;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:5.842%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.815%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.365%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.578%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 7, 2025</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;Kirk Look</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kirk Look, CA<br>Chief Financial Officer<br>Principal Accounting and Financial Officer</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.1
<SEQUENCE>6
<FILENAME>ex131ceocertification2024.htm
<DESCRIPTION>EX-13.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="ib0ca4fd1faa64651a006ff6b8597a5ea_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">EXHIBIT 13.1</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">18 U.S.C. &#167;1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">In connection with the annual report of Oncolytics Biotech Inc. (the &#8220;Company&#8221;) on Form 20-F for the fiscal year ended December&#160;31, 2024, as filed with the Securities and Exchange Commission on the date here of (the &#8220;Report&#8221;), I, Wayne Pisano, Interim Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. &#167;1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">(1)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">(2)&#160;&#160;&#160;&#160;&#160;&#160;&#160; The information contained in this Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">&#47;s&#47;Wayne Pisano</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">________________________________</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">Wayne Pisano</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">Interim Chief Executive Officer</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">Interim Principal Executive Officer</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">March&#160;7, 2025 </font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">A signed original of this written statement required by Section 906 has been provided to Oncolytics Biotech Inc. and will be retained by Oncolytics Biotech Inc. and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:right"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.2
<SEQUENCE>7
<FILENAME>ex132cfocertification2024.htm
<DESCRIPTION>EX-13.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i217330b9871c494581dfb7d79e20e98f_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">EXHIBIT 13.2</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">18 U.S.C. &#167;1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">In connection with the annual report of Oncolytics Biotech Inc. (the &#8220;Company&#8221;) on Form 20-F for the fiscal year ended December&#160;31, 2024, as filed with the Securities and Exchange Commission on the date here of (the &#8220;Report&#8221;), I, Kirk Look, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. &#167;1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">(1)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">(2)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The information contained in this Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">&#47;s&#47;Kirk Look</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">__________________________________</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">Kirk Look, CA</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">Chief Financial Officer</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">Principal Accounting and Financial Officer</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">March&#160;7, 2025 </font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">A signed original of this written statement required by Section 906 has been provided to Oncolytics Biotech Inc. and will be retained by Oncolytics Biotech Inc. and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-15.1
<SEQUENCE>8
<FILENAME>ex151-2024mda.htm
<DESCRIPTION>EX-15.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i967b84de73e64fc9ab595bed11d15ebe_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div><img alt="oncolyticslogotaglineblueaa.jpg" src="oncolyticslogotaglineblueaa.jpg" style="height:298px;margin-bottom:5pt;vertical-align:text-bottom;width:682px"></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">MANAGEMENT'S DISCUSSION &#38; ANALYSIS</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">2024 </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i967b84de73e64fc9ab595bed11d15ebe_4"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">March&#160;6, 2025 </font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">BASIS OF PRESENTATION </font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Management's Discussion and Analysis of Financial Condition and Results of Operations (&#34;MD&#38;A&#34;) should be read in conjunction with our audited consolidated financial statements and notes thereto as at and for the year ended December&#160;31, 2024, which have been prepared in accordance with International Financial Reporting Standards (&#34;IFRS&#34;) as issued by the International Accounting Standards Board (&#34;IASB&#34;). Our IFRS accounting policies are set in note 3 in our audited consolidated financial statements for the year ended December&#160;31, 2024. This MD&#38;A, along with our audited consolidated financial statements for the year ended December&#160;31, 2024, were authorized for issue in accordance with a resolution of the Board of Directors (the &#34;Board&#34;) on March&#160;6, 2025. Unless otherwise indicated, all references to &#34;$&#34; and &#34;dollars&#34; in this discussion and analysis mean thousands of Canadian dollars.  </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All references in this MD&#38;A to &#34;the Company&#34;, &#34;Oncolytics&#34;, &#34;we&#34;, &#34;us&#34;, or &#34;our&#34; and similar expressions refer to Oncolytics Biotech Inc. and the subsidiaries through which it conducts its business, unless otherwise indicated.  </font></div><div style="text-align:justify"><font><br></font></div><div id="i967b84de73e64fc9ab595bed11d15ebe_7"></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">FORWARD-LOOKING STATEMENTS</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following discussion contains forward-looking statements, within the meaning of Section 21E of the United States </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Securities Exchange Act of 1934, as ame</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">nded</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and forward-looking information under applicable Canadian securities laws (such forward-looking statements and forward-looking information are collectively referred to herein as &#34;forward-looking statements&#34;). Forward-looking statements, including&#58; our belief as to the potential and mechanism of action of pelareorep, an intravenously delivered immunotherapeutic agent, as a cancer therapeutic&#59; our business strategy, goals, focus, and objectives for the development of pelareorep, including our immediate primary focus on advancing our programs in hormone receptor-positive &#47; human epidermal growth factor 2-negative advanced and metastatic breast cancer and metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies and our exploration of opportunities for registrational programs in other gastrointestinal cancers through our GOBLET platform study&#59; our expectation that pelareorep&#8217;s ability to enhance innate and adaptive immune responses within the TME will play an increasingly important role as our clinical development program advances, and our belief that this approach increases opportunities for expanding our clinical program and business development and partnering opportunities, has the most promise for generating clinically impactful data and offers the most expeditious path to regulatory approval&#59; our belief that by priming the immunce system with pelareorep, we can increase the proportion of patients who respond to various cancer treatments, including immunotherapies, especially in cancers where existing treatment regimens have failed or provided limited benefit&#59; our expectation that we will incur substantial losses and will not generate significant revenues until and unless pelareorep becomes commercially viable&#59; our estimations regarding cash and cash equivalents on hand being sufficient to fund operations into the third quarter of 2025&#59; our plans to fund ongoing operations by raising additional funds through the sale of our common shares or other capital resources, such as strategic collaborations and debt&#59; the availability of additional liquidity and the terms thereof&#59; our ability to reduce or eliminate planned expenditures to extend our operating runway if additional financing cannot be obtained when required&#59; the anticipated design and outcomes of our various planned studies&#59; our plans to finalize our submission to the FDA for a randomized phase 2 trial examining pelareorep + paclitaxel combination therapy in breast cancer and enroll the first patient&#59; our belief that using PFS as our primary endpoint will allow us to reach the final analysis within two years of the start of the proposed study's enrollment&#59; our belief that continued positive results in the anal cancer cohort could potentially expand pelareorep's opportunity beyond breast and pancreatic cancers and that anal cancer has the potential for accelerated approval, based on a relatively small clinical study&#59; our plans to continue to enrol GOBLET&#8217;s expanded anal cancer and newly added pancreatic cancer cohorts&#59; our expectations regarding the announcement of interim efficacy data from GOBLET Cohort 5 in the second half of 2025&#59; our plans to finalize the master protocol associated with a pancreatic study with GCAR and to engage the FDA to discuss the adaptive design&#59; the focus of and plans for our manufacturing program&#59; our plans for our intellectual property program&#59; our ongoing evaluation of all types of financing arrangements&#59; the sale of securities under the Base Shelf (as defined herein) and our expectations regarding the ability of the Base Shelf to shorten the time required to close a financing and increase the number of potential investors that may be prepared to invest in the Company&#59; our plans to use our ATM equity distribution agreement to assist us in achieving our capital objective&#59; our expectation that we will continue to access equity arrangements to help support our operations&#59; our assessment of marketable securities&#59; our objective to maintain adequate cash reserves to support our planned activities, including our clinical trial program, product manufacturing, administrative costs and intellectual property protection and the methods used to achieve such objective&#59; our continued management of our research and development plan&#59; our </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expectation to fund our expenditure requirements and commitments with existing working capital&#59; the judgment applied in assessing our ability to continue as a going concern and the material uncertainties that raise substantial doubt on our ability to continue as a going concern&#59; our belief that we are not able to fund our operations for at least the next twelve months from the balance sheet date with the cash and cash equivalents on hand&#59; the factors that affect our cash usage&#59; our expectation that we will increase our spending in connection with the research and development of pelareorep over the next several years as we look to advance our breast and gastrointestinal cancer programs into later stages of clinical development and the increased costs associated with later stages of clinical development&#59; our expectation that we will continue to incur additional costs associated with operating as a public company&#59; our plans for raising additional funds&#59; the potential for adjustments to our audited consolidated financial statements&#59; the dilutive effects of raising funds by issuing equity&#59; the potential that debt financing may involve restrictive covenants that may impact our ability to conduct our business&#59; making reductions in spending, including potentially delaying, scaling back or eliminating certain of our development programs, extending payment terms with suppliers, or liquidating assets in the event we are unable to secure additional funding, and the effects thereof on our business, results of operations and future prospects&#59; the cost and time associated with conducting clinical trials and obtaining regulatory approval&#59; the factors that may affect the probability of successful commercialization of our drug candidates&#59; potential changes to the amount and timing of payments under our contractual obligations and commitments&#59; the expectation that counterparties to financial instruments will meet their contractual obligations&#59; our approach to credit rate, interest rate, foreign exchange, and liquidity risk mitigation&#59; our anticipated use of the remaining proceeds raised as part of our 2023 public offering of common shares and warrants&#59; the effectiveness of our internal control systems&#59; and other statements that are not historical facts or which are related to anticipated developments in our business and technologies. In any forward-looking statement in which we express an expectation or belief as to future results, such expectations or beliefs are expressed in good faith and are believed to have a reasonable basis, but there can be no assurance that the statement or expectation, or belief will be achieved. Forward-looking statements involve known and unknown risks and uncertainties, which could cause our actual results to differ materially from those in the forward-looking statements.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Such risks and uncertainties include, among others, the need for and availability of funds and resources to pursue research and development projects, the efficacy of pelareorep as a cancer treatment, the success and timely completion of clinical studies and trials, our ability to successfully commercialize pelareorep, uncertainties related to the research, development, and manufacturing of pelareorep, uncertainties related to competition, changes in technology, the regulatory process, and general changes to the economic environment.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to the forward-looking statements made within this MD&#38;A, we have made numerous assumptions regarding, among other things&#58; our ability to recruit and retain employees, our continued ability to obtain financing to fund our clinical development plan, our ability to receive regulatory approval to commence enrollment in the clinical studies which are part of our clinical development plan, our ability to maintain our supply of pelareorep, and future expense levels being within our current expectations.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investors should consult our quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Forward-looking statements are based on assumptions, projections, estimates, and expectations of management at the time such forward-looking statements are made, and such assumptions, projections, estimates and&#47;or expectations could change or prove to be incorrect or inaccurate. Investors are cautioned against placing undue reliance on forward-looking statements. We do not undertake any obligation to update these forward-looking statements except as required by applicable law.</font></div><div id="i967b84de73e64fc9ab595bed11d15ebe_10"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Company Overview</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage biopharmaceutical company developing pelareorep, a well-tolerated intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pelareorep is a proprietary isolate of reovirus, a naturally occurring, non-pathogenic double-stranded RNA (dsRNA) virus commonly found in environmental waters. Pelareorep has shown promising results in changing the tumor microenvironment (TME). This creates a more immunologically favorable TME, which in turn makes the tumor more susceptible to various treatment combinations. These treatments include chemotherapies, checkpoint inhibitors, and other immuno-oncology approaches such as CAR T therapies, bispecific antibodies, and CDK4&#47;6 inhibitors. Pelareorep induces a new army of tumor-reactive T cells, helps these cells to infiltrate the tumor through an inflammatory process, and promotes the overexpression of PD-1&#47;PD-L1. By priming the immune system with pelareorep, we believe we can increase the proportion of patients who respond to various cancer treatments, including immunotherapies, especially in cancers where existing treatment regimens have failed or provided limited benefit.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As our clinical development program advances, we anticipate pelareorep's ability to enhance innate and adaptive immune responses within the TME will play an increasingly important role. This greatly increases opportunities for expanding our clinical program, business development, and partnering opportunities to address a broad range of cancers in combination with various other therapies. We believe this approach has the most promise for generating clinically impactful data and offers the most expeditious path to regulatory approval. </font></div><div style="margin-bottom:10pt;margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary focus is to advance our programs in hormone receptor-positive &#47; human epidermal growth factor 2-negative (HR+&#47;HER2-) advanced and metastatic breast cancer (mBC) and metastatic pancreatic ductal adenocarcinoma (PDAC) to registration-enabling clinical studies. In addition, we are exploring opportunities for registrational programs in other gastrointestinal cancers, including anal cancer, through our GOBLET platform study. </font></div><div style="margin-bottom:12pt;margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Going Concern</font></div><div style="margin-bottom:10pt;margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not been profitable since our inception and expect to continue to incur substantial losses as we continue research and development efforts. We do not expect to generate significant revenues until and unless pelareorep becomes commercially viable. As at December&#160;31, 2024, we had cash and cash equivalents of $15,942. Subsequent to December&#160;31, 2024, we raised net proceeds of $6,041 (see </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#34;Cash Resources&#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). Without raising additional funding or reducing or eliminating our planned expenditures, we estimate our cash and cash equivalents to fund our operations into the third quarter of 2025. We plan on raising additional funds through the sale of our common shares or other capital resources, such as collaborations and debt, to fund our ongoing operations. However, given the difficulty for micro-cap market capitalization companies to raise significant capital and the Nasdaq delinquency notification matter discussed below, there can be no assurance that additional liquidity will be available under acceptable terms or at all. Furthermore, if we are unable to obtain additional financing when required, there can be no assurance that we will be able to sufficiently reduce or eliminate our planned expenditures to extend our operating runway. These material uncertainties raise substantial doubt on our ability to continue as a going concern. See further discussion in &#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Liquidity and Capital Resources&#34;.</font></div><div id="i967b84de73e64fc9ab595bed11d15ebe_13"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Program Development Updates and Outlook </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following are the development updates and outlook for each of our programs for the year ended December&#160;31, 2024, through to the date hereof&#58; </font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Clinical Trial Program</font></div><div style="margin-top:10pt;text-align:justify"><img alt="pipelinea.jpg" src="pipelinea.jpg" style="height:305px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Breast cancer program</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Defining a path to registration&#58; Type C meeting with the FDA and BRACELET-1 final results  </font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the second quarter of 2024, we held a Type C meeting with the U.S. Food and Drug Administration (FDA) to discuss our planned potential registration-enabling trial for pelareorep in HR+&#47;HER2- mBC. The FDA provided its feedback including </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">support for progression-free survival (PFS) as the study's primary endpoint, with overall survival (OS) as a key secondary endpoint. </font></div><div style="margin-bottom:10pt;margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the third quarter of 2024, we announced the final BRACELET-1 results. BRACELET-1 was a randomized open-label study that enrolled 48 patients with HR+&#47;HER2- mBC into three cohorts&#58; paclitaxel (PTX) alone, PTX in combination with pelareorep, and PTX in combination with both pelareorep and avelumab, a human anti-PD-L1 antibody. The results were based on efficacy data collected and analyzed two years after the last patient was enrolled as specified by the protocol. Results of the final BRACELET-1 analysis demonstrated that the median OS could not be calculated in the PTX + pelareorep arm due to the number of patients still alive at the time of the final analysis, in contrast with a median OS of 18.2 months in the PTX monotherapy arm. A conservative estimate of median OS for the pelareorep arm is 32.1 months, demonstrating that PTX + pelareorep delivered a greater than 12-month survival advantage compared to PTX alone. This survival benefit is further illustrated by the 24-month overall survival rate, which showed that 64% of patients treated with PTX + pelareorep survived at least 2 years compared to only 33% of patients treated with PTX alone. In addition, final PFS was 12.1 months for PTX + pelareorep compared to 6.4 months for PTX alone, a benefit of 5.7 months. These results substantiated the statistically significant near doubling of median OS observed in our earlier randomized IND.213 study in a similar HR+&#47;HER2- patient population treated with PTX + pelareorep compared to PTX alone. The strong survival data from the BRACELET-1 and IND.213 studies, along with the FDA's guidance on our registration study plan from the Type C meeting, provided the foundation for our plan to conduct a registration-enabling study to assess pelareorep-based combination therapy in patients with advanced or metastatic HR+&#47;HER2- breast cancer.</font></div><div style="margin-bottom:10pt;margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2025, we intend to finalize our submission to the FDA for a randomized phase 2 trial examining pelareorep + paclitaxel combination therapy in breast cancer and enroll the first patient. This registration-enabling trial will enroll approximately 180 patients with HR+&#47;HER2- advanced&#47;metastatic breast cancer who have progressed on antibody-drug conjugates (ADCs) like Enhertu, who are not eligible for ADCs, or who cannot tolerate ADCs. We believe that using PFS as our primary endpoint will allow us to reach the final analysis within two years of the start of the proposed study's enrollment.</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gastrointestinal cancer program  </font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration with Roche and AIO-Studien-gGmbH&#58; GOBLET platform study</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our GOBLET platform study is a collaboration with Roche and AIO-Studien-gGmbH, a leading academic cooperative medical oncology group based in Germany. The study is investigating the use of pelareorep, in combination with Roche's anti-PD-L1 checkpoint inhibitor atezolizumab (Tecentriq</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) and&#47;or chemotherapy (gemcitabine and nab-paclitaxel, TAS-102, or modified FOLFIRINOX (mFOLFIRINOX)), where appropriate, in advanced or metastatic gastrointestinal tumors. The study is being conducted at 17 centers in Germany. The study's co-primary endpoints are safety and objective response rate and&#47;or disease control rate at week 16. Key secondary and exploratory endpoints include additional efficacy assessments and evaluation of potential biomarkers. The study employs a two-stage design comprising patients with first-line advanced&#47;metastatic and newly diagnosed metastatic PDAC, first- and third-line metastatic colorectal (CRC), and second-line or later anal cancer. Any cohort meeting pre-specified efficacy criteria in Stage 1 may be advanced to Stage 2 and enroll additional patients. Our first-line advanced&#47;metastatic PDAC, third-line metastatic CRC, and second-line or later anal cancer cohorts have completed Stage 1 and met the pre-specified success criteria. Our cohort evaluating newly diagnosed metastatic PDAC patients treated with pelareorep in combination with mFOLFIRINOX with or without atezolizumab (Tecentriq</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) is supported by the Pancreatic Cancer Action Network (PanCAN) Therapeutic Accelerator Award for up to US$5 million.</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following were the key highlights of the GOBLET study&#58;</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Enrollment expansion of GOBLET anal cancer cohort</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2024, based on the positive Stage 1 interim data presented at the 2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">nd</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> International Multidisciplinary Anal Cancer Conference 2023, where we showed a tripling of objective response rate compared to similar studies investigating checkpoint inhibitor therapy alone, we began expanded enrollment into GOBLET's anal cancer cohort. Stage 2 will enroll 18 additional evaluable patients. As there is currently no established standard therapy for anal carcinoma patients who have failed first-line treatment, continued positive results in the anal cancer cohort could potentially expand pelareorep's opportunity beyond breast and pancreatic cancers. Due to the current lack of treatment options, anal cancer has the potential for accelerated approval, based on a relatively small clinical study. </font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2025, we presented updated results from this cohort at the 2025 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium. The updated results showed that four of twelve evaluable patients achieved a partial response for an objective response rate of 33%. This includes one patient with a prolonged complete response that persisted for over 15 months. This was notable because historical response rates to checkpoint inhibitor monotherapy were low, generally 10-24%</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1-3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. There continued to be no safety concerns with the treatment regimen. At treatment cycle four, tumor-infiltrating lymphocyte (TIL) clonal expansion has been observed in the three responding patients for which data is available. It is </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">anticipated that the additional data from Stage 2 of this cohort will provide a sufficiently strong efficacy signal to move this treatment regimen into a registration-enabling study.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reference&#58;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Rao S, et al. Phase II study of retifanlimab in patients (pts) with squamous carcinoma of the anal canal (SCAC) who progressed following platinum-based chemotherapy. Annals of Oncology. 2020 September. doi&#58; https&#58;&#47;&#47;doi.org&#47;10.1016&#47;j.annonc.2020.08.2272.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Marabelle A, et al. Pembrolizumab for previously treated advanced anal squamous cell carcinoma&#58; results from the non-randomised, multicohort, multicentre, phase 2 KEYNOTE-158 study. Lancet Gastroenterol Hepatol. 2022 May&#59;7(5)&#58;446-454. doi&#58; 10.1016&#47;S2468-1253(21)00382-4.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Lonardi S, et al. Randomized phase II trial of avelumab alone or in combination with cetuximab for patients with previously treated, locally advanced, or metastatic squamous cell anal carcinoma&#58; the CARACAS study. J Immunother Cancer. 2021 November&#59;9(11)&#58;e002996. doi&#58; 10.1136&#47;jitc-2021-002996. PMID&#58; 34815354&#59; PMCID&#58; PMC8611452.</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Initiation of new pancreatic cancer GOBLET cohort</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2024, we initiated, commenced enrollment, and dosed patients in GOBLET's new PDAC mFOLFIRINOX cohort (GOBLET Cohort 5). We completed the safety run-in for this cohort and received favorable feedback from the GOBLET Data Safety Monitoring Board. In January 2025, we received regulatory approval to allow GOBLET Cohort 5 to progress to full enrollment and presented the safety run-in results at the 2025 ASCO Gastrointestinal Cancers Symposium. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2025, we plan to continue enrolling GOBLET's expanded anal cancer and newly added pancreatic cancer cohorts. We also anticipate announcing interim efficacy data from GOBLET Cohort 5 in the second half of 2025. </font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preliminary collaboration agreement with GCAR for inclusion in anticipated pancreatic cancer trial</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2024, we entered into a preliminary collaboration with the Global Coalition for Adaptive Research (GCAR) to incorporate a pelareorep combination therapy arm into GCAR's anticipated master protocol for the evaluation of new therapeutic approaches in metastatic pancreatic cancer patients. Compared to a chemotherapy control arm, the investigational treatment regimen is expected to be pelareorep combined with chemotherapy, either with or without a checkpoint inhibitor. This adaptively designed trial could accelerate the registrational timeline and provide substantial cost savings compared to traditional trial designs. </font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2025, working with GCAR, we intend to finalize the master protocol associated with a pancreatic cancer study and engage the FDA to discuss the adaptive design.</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pelareorep&#8217;s mechanism of action</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2024, we presented data showing pelareorep&#8217;s ability to induce the expansion of tumor-infiltrating lymphocytes (TILs) across multiple cancers and the correlation between TIL expansion and tumor response at the American Society of Clinical Oncology Annual Meeting.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pelareorep&#8217;s ability to expand TILs highlights its immunotherapeutic mechanism of action and potential as a backbone immunotherapy for multiple indications. </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Highlights include&#58;</font></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The presence and expansion of TILs are associated with a better prognosis and response to treatment in cancer patients.</font></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Pelareorep treatment increased TIL expansion in the blood in all pancreatic, breast, and colorectal cancer patients evaluated after one cycle of treatment.</font></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Pre-existing TIL clonal expansion in the blood appears to correlate with tumor responses in pancreatic cancer patients.</font></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The addition of the PD-L1 inhibitor avelumab, unlike atezolizumab, eliminated pre-existing TIL expansion in the blood and reduced pelareorep&#8217;s clinical activity.</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These data suggest that pelareorep offers a simple, reliable way to expand TILs to provide clinical benefit.</font></div><div><font><br></font></div><div id="i967b84de73e64fc9ab595bed11d15ebe_16"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Manufacturing and Process Development </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we currently have sufficient drug product supply to support our clinical development program, we continued our activities to expand our production capabilities as we focus on advancing our active drug substance and finished drug product towards registration and commercial readiness. In 2024, we executed two scaled-up cGMP (current Good Manufacturing Practice) production runs and the related batch testing. We initiated potency assay validation using the master cell bank created in 2023 and completed production of a new working cell bank. We also sourced materials required for our planned product fills, </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">executed one product fill, and incurred storage and distribution costs to maintain our product supply. Ongoing bulk manufacturing and expanded filling capabilities are both part of the planned process validation. Process validation is required to ensure that the resulting product meets the specifications and quality standards and will form part of our submission to regulators, including the FDA, for product approval.  </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2025, our manufacturing program will focus on filling product with a secondary fill&#47;finish supplier, executing a formal assessment of the drug substance production process in preparation for performance qualification, executing a cGMP production run, completing the potency assay validation, and supply distribution for our ongoing and planned studies. </font></div><div style="text-align:justify"><font><br></font></div><div id="i967b84de73e64fc9ab595bed11d15ebe_19"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Intellectual Property</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the end of 2024, we had 147 patents, including 12 U.S. and 7 Canadian patents, as well as issuances in other jurisdictions. We have an extensive patent portfolio covering pelareorep and formulations that we use in our clinical trial program. We also have patents covering methods for manufacturing pelareorep and screening for susceptibility to pelareorep. These patent rights extend to at least the end of 2031. In addition, we have ongoing patent applications that may extend the patent rights beyond 2031.  </font></div><div style="text-align:justify"><font><br></font></div><div id="i967b84de73e64fc9ab595bed11d15ebe_25"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Financing Activity</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">U.S. &#34;at-the-market&#34; (ATM) equity distribution agreement</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2024, we sold 5,410,143 common shares for gross proceeds of $7,670 (US$5,526) at an average price of $1.42 (US$1.02). We received proceeds of $7,439 (US$5,360) after commissions of $231 (US$166). In total, we incurred share issue costs (including commissions) of $751.</font></div><div style="margin-bottom:3pt;margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From January 1, 2025, to March&#160;6, 2025, we sold 5,302,950 shares for gross proceeds of $6,228 (US$4,327) at an average price of $1.17 (US$0.82). We received proceeds of $6,041 (US$4,197), after commissions of $187 (US$130). </font></div><div style="text-align:justify"><font><br></font></div><div id="i967b84de73e64fc9ab595bed11d15ebe_31"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Cash Resources </font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We ended 2024 with cash and cash equivalents of $15,942 (see </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#34;Liquidity and Capital Resources&#34;)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div id="i967b84de73e64fc9ab595bed11d15ebe_34"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Other Corporate Matters</font></div><div style="margin-bottom:12pt;margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 7, 2025, we announced that Dr. Matt Coffey, President and Chief Executive Officer (CEO), will not be returning following a medical leave of absence announced in the second quarter of 2024 and ongoing health concerns. Wayne Pisano, Chair of Oncolytics' Board of Directors, will remain Interim CEO until the new CEO is hired. We have commenced a search for a CEO. </font></div><div style="margin-bottom:3pt;margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 13, 2025, we received a delinquency notification letter (the &#34;Notice&#34;) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (&#34;Nasdaq&#34;) indicating that, for the prior 30 consecutive business days, the closing bid price for our ordinary shares listed on the Nasdaq Capital Market was below the minimum $1.00 per share required for continued listing on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2). The Notice provides that we have a period of 180 calendar days from the date of the Notice, or until August 12, 2025, to regain compliance with the minimum bid price requirement. The receipt of the Notice has no immediate effect on our business operations or the listing of our ordinary shares, which will continue to trade uninterrupted on the Nasdaq under the ticker &#34;ONCY.&#34; If at any time before August 12, 2025, the bid price of our ordinary shares closes at or above $1.00 per share for a minimum of 10 consecutive business days, Nasdaq will provide written confirmation of compliance to us. In the event that we do not regain compliance by August 12, 2025, we may be eligible for additional time to regain compliance. To qualify, we would be required to meet the continued listing requirement for the market value of publicly held shares and all other initial listing standards for the Nasdaq Capital Market, except for the minimum bid price requirement. In addition, we would be required to notify Nasdaq of its intent to cure the deficiency during the second compliance period.</font></div><div style="margin-bottom:10pt;margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In early 2025, the President of the United States issued executive orders directing the United States to impose new tariffs on imports originating from Canada, Mexico, and China. The impacts of these tariffs on our operations remain uncertain. New or increased tariffs, export controls, or other measures discouraging contracts with Chinese companies could materially impact our supply chain and manufacturing costs and our licensing agreement with Adlai Nortye Biopharma Co., Ltd. (&#34;Adlai&#34;). We are assessing the direct and indirect impacts of such trade protectionist measures to our operations as this situation develops.  </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</font></div></div></div><div id="i967b84de73e64fc9ab595bed11d15ebe_43"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Selected Annual Information</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless otherwise indicated, all amounts below are presented in thousands of Canadian dollars, except for share amounts.</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.353%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)(2)(3)(4)</font></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(31,710)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,752)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,835)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted loss per share</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)(2)(3)(4)</font></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.41)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.41)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.43)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</font></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20,187</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,820&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,334&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total non-current financial liabilities</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">787</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash dividends declared per share</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nil</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</font></td></tr><tr><td colspan="18" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notes&#58;</font></td></tr><tr><td colspan="18" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)  Included in consolidated net loss and loss per common share for 2024, 2023, and 2022 were non-cash changes in fair value of warrant derivative gain (loss) of $1,242, $5,285, and $(20), respectively. </font></div></td></tr><tr><td colspan="18" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)  Included in consolidated net loss and loss per common share for 2024, 2023, and 2022 were share-based compensation expenses of $2,723, $1,917, and $2,378, respectively.</font></div></td></tr><tr><td colspan="18" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3)  Included in consolidated net loss and loss per common share for 2024, 2023, and 2022 were foreign exchange (losses) gains of $961, $(475), and $1,665, respectively.</font></div></td></tr><tr><td colspan="18" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3)  Included in consolidated net loss and loss per common share for 2024, 2023, and 2022 was interest income of $1,339, $1,398, and $609, respectively.</font></div></td></tr><tr><td colspan="18" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5)   We issued 5,596,171 common shares for net cash proceeds of $7.0 million in 2024 (2023 - 13,096,046 common shares for net cash proceeds of $31.8 million&#59; 2022 - 6,284,125 common shares for net cash proceeds of $12.6 million).  </font></div></td></tr><tr><td colspan="18" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-18pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6)  We have not declared or paid any dividends since incorporation.</font></td></tr></table></div><div style="text-align:center"><font><br></font></div><div id="i967b84de73e64fc9ab595bed11d15ebe_46"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Components of Results of Operations</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses (&#34;R&#38;D&#34;)</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our R&#38;D expenses consist primarily of costs incurred to conduct research and development on pelareorep. </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trial expenses include the preparation and development of our breast and gastrointestinal cancer programs. Clinical trial expenses include regulatory and consulting activities, contract research organization expenses, data management expenses, and other costs associated with our clinical trial program.</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturing &#38; related process development (&#8220;M&#38;P&#8221;) expenses include product manufacturing and process development activities. Product manufacturing expenses include third-party direct manufacturing costs, quality control testing, filling, labeling, packaging, and storage costs. Process development expenses include costs associated with studies examining components of our manufacturing and analytical processes and costs associated with planned process validation and related conformity testing.  </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intellectual property expenses include legal and filing fees associated with our patent portfolio.  </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Translational science expenses are intended to expand our intellectual property related to pelareorep and identify potential licensing opportunities arising from our technology base.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Personnel-related, share-based compensation, and other expenses are employee-related expenses. </font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses (&#34;G&#38;A&#34;)</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our G&#38;A expenses consist primarily of public company-related expenses, personnel-related, office expenses, share-based compensation expense, and depreciation. </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Public company-related expenses include investor, media, and public rela</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">tions, marketing communications, </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">business development, financial advisory activities, legal and accounting fees, corporate insurance, director fees and transfer agent, and other fees relating to our U.S. and Canadian stock listings.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Office expenses include rent related to short-term leases and other office-related costs. </font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Change in Fair Value of Warrant Derivative</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants issued with an exercise price denominated in a foreign currency are reported as a liability until exercised or expired. These warrants are adjusted to fair value at each exercise date and reporting period. Any change in fair value is recorded in the </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consolidated statements of loss and comprehensive loss. Gains and losses resulting from the revaluation of the warrant derivative are non-cash and do not impact our cash flows.</font></div><div><font><br></font></div><div id="i967b84de73e64fc9ab595bed11d15ebe_49"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Results of Operations</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless otherwise indicated, all amounts below are presented in thousands of Canadian dollars, except for share amounts.</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss for the year ended December&#160;31, 2024, was $31,710 compared to $27,752 and $24,835 for the years ended December&#160;31, 2023, and December&#160;31, 2022, respectively. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses (&#34;R&#38;D&#34;)</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our R&#38;D expenses increased by $3,938 for the year ended December&#160;31, 2024, compared to 2023, and increased by $2,277 for the year ended December&#160;31, 2023, compared to 2022. The following table summarizes our R&#38;D expenses for the years ended December&#160;31, 2024, 2023, and 2022&#58;</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:37.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.616%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change</font></td></tr><tr><td colspan="3" style="padding:0 10pt 0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023 to 2024</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022 to 2023</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trial expenses</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,463</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,675&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,970&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,788&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,295)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">M&#38;P expenses</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,267</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,789&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,148&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,478&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,641&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intellectual property expenses</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">433</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">397&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">544&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(147)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Translational science expenses</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">101</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(264)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Personnel-related expenses</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,451</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,324&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,023&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(873)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">301&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,717</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,305&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,371&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">412&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expenses</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">215</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21,647</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,709&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,432&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,938&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,277&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in our R&#38;D expenses for the year ended </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2024, was primarily due to the following&#58;</font></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Increased M&#38;P expenses associated with completing two cGMP production runs compared to an engineering production run during the same period in the prior year&#59;</font></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Increased clinical trial expenses related to planning activities as part of GCAR&#8217;s anticipated pancreatic cancer master protocol and BRACELET-1's patient data management and analysis. The increase was partly offset by lower GOBLET study costs as we focus on enrolling the new mFOLFIRINOX cohort, which is supported by the PanCAN Therapeutic Accelerator Award ($1,609 of the funds received were applied)&#59; and</font></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Increased share-based compensation expense resulting from the impact of the vesting of options and share awards granted. In 2024, share awards were granted to senior management in lieu of cash annual short-term incentive awards. </font></div><div style="margin-top:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The above increases were partly offset by decreased personnel-related expenses mainly due to lower cash annual short-term incentive awards. </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in our R&#38;D expenses for the year ended December&#160;31, 2023, was primarily due to the following&#58;</font></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Increased M&#38;P expenses associated with completing a process development and a scaled-up engineering production run, along with the related batch testing. We also initiated a scaled-up cGMP production run. As part of the production runs, we also implemented new procedures to match evolving industry standards and environmental regulations as we focus on advancing toward registration readiness&#59; and</font></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Increased personnel-related expenses due to changes in salary levels and the strengthening of the U.S. dollar.</font></div><div style="margin-top:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The above increases were partly offset by the following&#58;</font></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Decreased clinical trial expenses due to lower BRACELET-1, GOBLET, and AWARE-1 study costs, as well as reduced clinical and safety data management. The BRACELET-1 trial was in the patient follow-up phase throughout 2023, whereas patients were enrolled and treated during the same period in the previous year. Enrollment and treatment for GOBLET's advanced&#47;metastatic PDAC and third-line metastatic CRC cohorts largely occurred in 2022. We incurred AWARE-1 data analysis costs during 2022 for various conference presentations&#59; and</font></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Decreased translational science expenses as we focus on biomarker activities related to our ongoing clinical trials. In 2022, we incurred costs related to our bispecific antibodies and CAR T studies.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses (&#34;G&#38;A&#34;)</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our G&#38;A expenses decreased by $2,747 for the year ended December&#160;31, 2024, compared to 2023, and increased by $4,590 for the year ended December&#160;31, 2023, compared to 2022. The following table summarizes our G&#38;A expenses for the years ended December&#160;31, 2024, 2023, and 2022&#58;</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:37.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.616%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023 to 2024</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022 to 2023</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Public company-related expenses</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,565</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,278&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,790&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,713)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,488&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Personnel-related expenses</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,848</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,332&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,870&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(484)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">462&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office expenses</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">492</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">457&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">433&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,006</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">612&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,007&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">394&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(395)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation - property and equipment</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">120</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation - right-of-use assets</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">304</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13,335</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,082&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,492&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,747)</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,590&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in our G&#38;A expenses for the year ended December&#160;31, 2024, was primarily due to the following&#58;</font></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Decreased public company-related expenses associated with lower investor, media and public relations activities, lower financing-related transaction costs, and lower directors and officers liability insurance premiums&#59; and</font></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Decreased personnel-related expense due to changes in personnel costs incurred in 2023 and lower cash annual short-term incentive awards. </font></div><div style="margin-top:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The above decrease was partly offset by increased share-based compensation expense resulting from the impact of the vesting of options and share awards granted. In 2024, share awards were granted to senior management in lieu of cash annual short-term incentive awards. </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in our G&#38;A expenses for the year ended December&#160;31, 2023, was primarily due to the following&#58;</font></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Increased public company-related expenses due to higher investor relations activities along with media and public relations activities associated with our BRACELET data presented at 2023 ASCO. In addition, a portion of the 2023 public offering transaction costs allocated to warrants were treated as public company-related expenses (see note 10 in our audited consolidated financial statements)&#59; and</font></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Increased personnel-related expenses due to changes in personnel costs and a change in salary level. </font></div><div style="margin-top:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The above increases were partly offset by decreased share-based compensation expense reflecting the impact of changes in personnel, including a recovery due to the forfeiture of unvested options.</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Change in Fair Value of Warrant Derivative</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2024, we recognized a gain of $1,242 on the change in fair value of our warrant derivative compared to a gain and loss of $5,285 and $20 for the years ended December&#160;31, 2023, and December&#160;31, 2022, respectively. The gains recognized in 2024 and 2023 primarily related to the 7,667,050 warrants issued as part of our 2023 financing, where the underlying market price of these warrants changed from a weighted average price of US$2.28 at issuance to US$1.35 at December 31, 2023, and to US$0.92 at December&#160;31, 2024. The number of outstanding warrants was 7,667,050, 7,731,085, and 64,035 as at December&#160;31, 2024, December&#160;31, 2023, and December&#160;31, 2022, respectively.</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Exchange </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2024, our foreign exchange gains were $961 compared to losses and gains of $475 and $1,665 for the years ended December 31, 2023, and December&#160;31, 2022, respectively. The foreign exchange gains&#47;losses incurred in all three years mainly reflected the fluctuation of the U.S. dollar versus the Canadian dollar throughout the respective periods, primarily on our U.S. dollar-denominated cash and cash equivalents and marketable securities balances. </font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</font></div></div></div><div id="i967b84de73e64fc9ab595bed11d15ebe_52"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Summary of Quarterly Results</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historical patterns of expenditures cannot be taken as an indication of future expenditures. Our current and future expenditures are subject to numerous uncertainties, including the duration, timing, and costs of R&#38;D activities ongoing during each period and the availability of funding from investors and prospective partners. As a result, the amount and timing of expenditures and, therefore, liquidity and capital resources may vary substantially from period to period.</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:36.820%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.659%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.659%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.659%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.659%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.659%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.659%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.659%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.667%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</font></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dec.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</font></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sept.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</font></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</font></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</font></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dec.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</font></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sept.</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)(2)(3)</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,017)</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,543)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,256)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,894)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,949)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,925)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,441)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,437)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted loss per common share</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)(2)(3)</font></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.10)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.12)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.10)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.09)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.05)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.14)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.12)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.10)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,187</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,262&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,069&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,750&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,820&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,089&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,966&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,328&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and marketable securities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,942&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,598&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,850&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,603&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,912&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,981&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,351&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,670&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash dividends declared</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</font></td></tr></table></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Included in consolidated net loss and loss per common share were share-based compensation expenses of $1,196, $445, $506, $576, $759, $599, $242, and $317, respectively.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Included in consolidated net loss and loss per common share were foreign exchange gains (losses) of $382, </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$(122)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, $184, $517, $(392), </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$310,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> $(394), and $1, respectively.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Included in consolidated net loss and loss per common share was interest income of $193, $303, $382, $461, $508, $324, $286, and $280, respectively. </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Included in consolidated net loss and loss per common share were (losses) gains resulting from a change in fair value of warrant derivative of $(91), $229, $235, $869, and $4,846, respectively.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(5)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">We raised net cash proceeds of $3,439, nil, $2,040, $1,598, $1,846, $20,802, $3,792, and $5,372, respectively, from issuing common shares. </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(6)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">We have not declared or paid any dividends since incorporation.</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the quarter ended September 30, 2023, we completed an engineering production run, resulting in higher manufacturing and related process development expenses. We also incurred higher public company-related expenses associated with higher investor relations activities and the portion of the 2023 public offering transaction costs allocated to warrants (see note 7(b) in our audited consolidated financial statements). During the quarter ended September 30, 2024, we completed a cGMP production run, resulting in higher manufacturing and related process development expenses. During the quarters ended December 31, 2024, and 2023, we incurred expenses related to annual short-term incentive awards.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</font></div></div></div><div id="i967b84de73e64fc9ab595bed11d15ebe_55"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Fourth Quarter</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Statement of loss for the three months ended December&#160;31, 2024, and 2023, was as follows&#58;</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.104%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.007%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expenses</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Research and development</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,552</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,658&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;General and administrative</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,885</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,191&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss before the following</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(8,437)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,849)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of warrant derivative</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(91)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,846&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Foreign exchange gain (loss)</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">382</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(392)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Interest income, net</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">152</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">489&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss before income taxes</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(7,994)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,906)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Income tax expense</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(23)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(8,017)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,949)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Other comprehensive income (loss) - translation adjustment</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">308</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(111)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Comprehensive loss</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(7,709)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,060)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic and diluted loss per common share</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.10)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.05)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average number of shares (basic and diluted)</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">77,721,690</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,731,359&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div id="i967b84de73e64fc9ab595bed11d15ebe_58"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Fourth Quarter Review of Operations</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss for the three months ended December&#160;31, 2024, was $8,017 compared to $3,949 for the three months ended December&#160;31, 2023. </font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses (&#34;R&#38;D&#34;)</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our R&#38;D expenses decreased by $106 from $4,658 for the three months ended December&#160;31, 2023, to $4,552 for the three months ended December&#160;31, 2024. The following table summarizes our R&#38;D expenses for the three months ended December&#160;31, 2024, and 2023&#58;</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:50.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.422%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended December 31,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trial expenses</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,078</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">734&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">M&#38;P expenses</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">842</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">933&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(91)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intellectual property expenses</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">134</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Translational science expenses</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">54</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Personnel-related expenses</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,595</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,253&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(658)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">785</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">570&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expenses</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">64</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,552</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,658&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(106)</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in our R&#38;D expenses for the three months ended December&#160;31, 2024, was primarily due to lower personnel-related expenses related to lower cash annual short-term incentive awards.</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease was partly offset by the following&#58; </font></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Increased clinical trial expenses associated with planning activities as part of GCAR&#8217;s anticipated metastatic pancreatic cancer master protocol. The increase was partly offset by lower GOBLET study costs as we focus on enrolling the new mFOLFIRINOX cohort, which is supported by the PanCAN Therapeutic Accelerator Award ($390 of the funds received were applied)&#59; and</font></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Increased shared-based compensation expenses resulting from the impact of the vesting of options and share awards granted.  In 2024, share awards were granted to senior management in lieu of cash annual short-term incentive awards.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses (&#34;G&#38;A&#34;)</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our G&#38;A expenses decreased by $306 from $4,191 for the three months ended December&#160;31, 2023, to $3,885 for the three months ended December&#160;31, 2024. The following table summarizes our G&#38;A expenses for the three months ended December&#160;31, 2024, and 2023&#58; </font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:50.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.422%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Public company-related expenses</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,405</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,410&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Personnel-related expenses</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">848</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,360&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(512)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office expenses</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">123</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">411</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation - property and equipment</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">28</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation - right-of-use assets</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">70</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,885</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,191&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(306)</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in our G&#38;A expenses for the three months ended December&#160;31, 2024, was primarily due to lower personnel-related expenses due to changes in personnel costs incurred in 2023 and lower cash annual short-term incentive awards. The decrease was partly offset by higher share-based compensation expense resulting from the impact of the vesting of share awards granted. In 2024, share awards were granted to senior management in lieu of cash annual short-term incentive awards.</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Change in Fair Value of Warrant Derivative</font></div><div style="margin-bottom:10pt;margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended December&#160;31, 2024, we recorded a loss of $91 on the change in fair value of our warrant derivative compared to a gain of $4,846 for the three months ended December&#160;31, 2023. The gain recognized in 2023 primarily related to the 7,667,050 warrants issued as part of our 2023 financing, where the underlying market price of these warrants changed from US$2.20 at September 30, 2023, to US$1.35 at December&#160;31, 2023.</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Exchange </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended December&#160;31, 2024, our foreign exchange gains were $382 compared to losses of $392. The foreign exchange gains&#47;losses incurred mainly reflected the fluctuation of the U.S. dollar versus the Canadian dollar throughout the respective periods, primarily on our U.S. dollar-denominated cash and cash equivalents.</font></div><div style="margin-top:3pt;text-align:justify"><font><br></font></div><div id="i967b84de73e64fc9ab595bed11d15ebe_61"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font></div><div id="i967b84de73e64fc9ab595bed11d15ebe_70"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a clinical-stage biopharmaceutical company, we have not been profitable since our inception. We expect to continue to incur substantial losses as we continue our research and development efforts. We do not expect to generate significant revenues until and unless pelareorep becomes commercially viable. See &#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Capital Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34; below for the discussion on our ability to continue as a going concern. To date, we have funded our operations mainly through issuing additional capital via public offerings, equity distribution arrangements, and the exercise of warrants and stock options. For the year ended December&#160;31, 2024, we were able to raise funds through our U.S. ATM.  </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no assurances that we will be able to raise additional funds through the sale of our common shares. Consequently, we will continue to evaluate all types of financing arrangements. </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 19, 2024, we renewed our short form base shelf prospectus (the &#34;Base Shelf&#34;) that qualifies for distribution of up to $150&#160;million of common shares, subscription receipts, warrants, or units (the &#34;Securities&#34;) in either Canada, the U.S. or both. The Base Shelf will be effective until August 19, 2026. Under the Base Shelf, we may sell Securities to or through underwriters, dealers, placement agents, or other intermediaries. We may also sell Securities directly to purchasers or through agents, subject to obtaining any applicable exemption from registration requirements. The distribution of Securities may be performed from time to time in one or more transactions at a fixed price or prices, which may be subject to change, at market prices prevailing at the time of sale or at prices related to such prevailing market prices to be negotiated with purchasers and as set forth in an accompanying Prospectus Supplement.  </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Renewing our Base Shelf provides additional flexibility when managing our cash resources as, under certain circumstances, it shortens the time required to close a financing and is expected to increase the number of potential investors that may be prepared to invest in the Company. Funds received from using our Base Shelf would be used in line with our Board-approved budget and multi-year plan.  </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Base Shelf allowed us to enter into our ATM equity distribution agreement (see note 10 in our audited consolidated financial statements). We plan to use this equity arrangement to assist us in achieving our capital objective. This arrangement provided us with the opportunity to raise capital and better manage our cash resources. We expect to continue to access equity arrangements to help support our operations.</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As at December&#160;31, 2024, and 2023, we had cash and cash equivalents as follows&#58; </font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.861%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15,942</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,912&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no debt other than accounts payable and accrued liabilities and lease liabilities. We also have commitments and potential contingent obligations relating to the completion of our research and development of pelareorep.</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash flows for the periods indicated&#58;</font></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:37.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.616%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023 to 2024</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022 to 2023</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash used in operating activities</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(26,966)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,448)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,355)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,482&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,093)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash (used in) provided by investing activities</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(239)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,222&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,403)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,461)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,625&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash provided by financing activities</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,636</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,994&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,205&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,358)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,789&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of foreign exchange on cash and cash equivalents</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,599</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(522)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,957&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,121&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,479)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Decrease) increase in cash and cash equivalents</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(18,970)</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,246&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,596)</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42,216)</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,842&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash used in operating activities</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes between 2024, 2023, and 2022 reflected higher net operating activities and non-cash working capital changes. </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities for the year ended December&#160;31, 2024, consisted of a net loss of $31,710 offset by non-cash adjustments of $1,206 and non-cash working capital changes of $3,538. Non-cash items primarily included share-based compensation expense, change in fair value of warrant derivative, and unrealized foreign exchange gains. Non-cash working capital changes mainly reflected decreased prepaid expenses, increased accounts payable and accrued liabilities, and increased other liabilities with unapplied funding received from PanCAN.</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities for the year ended December&#160;31, 2023, included a net loss of $27,752 less non-cash adjustments of $2,461 offset by non-cash working capital changes of $1,765. Non-cash items primarily included change in fair value of warrant derivative and share-based compensation expense. Non-cash working capital changes mainly reflected decreased prepaid expenses, decreased other receivables with cash collected from Pfizer, and increased other liabilities with unapplied funding received from PanCAN.</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities for the year ended December&#160;31, 2022, comprised a net loss of $24,835 offset by non-cash adjustments of $1,089 and non-working capital changes of $391. Non-cash items primarily included share-based compensation expense and unrealized foreign exchange gains. Non-cash working capital changes were mainly due to additions to accounts payable and accrued liabilities and prepaid expenses.    </font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash (used in) provided by investing activities </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes between 2024, 2023, and 2022 were mainly due to the acquisition and maturities of marketable securities. The acquisition of marketable securities was based on a comparative analysis of the anticipated yield from an investment in marketable securities versus the interest earnings from our cash deposits in interest-bearing accounts.</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash provided by financing activities</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2024, we sold 5,410,143 common shares for gross proceeds of $7,670 (US$5,526) at an average price of $1.42 (US$1.02) through our U.S. ATM. During the year ended December 31, 2023, pursuant to an underwritten public offering, we issued 7,667,050 units for gross proceeds of $23,262 (US$17,251) at a price of US$2.25 per unit. We also sold 4,978,605 common shares for gross proceeds of $10,676 (US$7,904) at an average price of $2.14 (US$1.59) through our U.S. ATM. During the year ended December 31, 2022, we sold 6,235,232 common shares for gross proceeds of $13,338 (US$10,192) at an average price of $2.14 (US$1.63) through our U.S. ATM.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating Capital Requirements</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our objective is to maintain adequate cash reserves to support our planned activities, including our clinical trial program, product manufacturing, administrative costs, and intellectual property protection. To do so, we estimate our future cash requirements by preparing a budget and a multi-year plan annually for review and approval by our Board. The budget establishes the approved activities for the upcoming year and estimates the associated costs. The multi-year plan estimates future activity along with the potential cash requirements and is based on our assessment of our current clinical trial progress along with the expected results from the coming year&#8217;s activity. Budget to actual variances are prepared and reviewed by management and are presented quarterly to the Board. We continue to manage our research and development plan to ensure optimal use of our existing resources as we expect to fund our expenditure requirements and commitments with existing working capital.</font><font style="color:#ff0090;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management assesses our ability to continue as a going concern. In our going concern assessment, management takes into account all available information about the future, which is at least, but not limited to, twelve months from the end of the reporting period. We have concluded that our cash and cash equivalents is not sufficient to fund our planned operations and meet our obligations for the twelve months following the balance sheet date without raising additional funding or reducing or eliminating our planned expenditures. Factors that will affect our anticipated cash usage for which additional funding might be required include, but are not limited to, expansion of our clinical trial program, the timing of patient enrollment in our clinical trials, the actual costs incurred to support each clinical trial, the number of treatments each patient will receive, the timing of R&#38;D activity with our clinical trial research collaborations, the number, timing and costs of manufacturing runs required to conclude the validation process and supply product to our clinical trial program, and the level of collaborative activity undertaken, and other factors described in the &#34;Risk Factors&#34; section of our most recent annual report on Form 20-F. The judgment and assumptions applied by management may prove to be wrong, and actual results could vary materially from our expectations as significant risks and uncertainties are involved.   </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to increase our spending in connection with the research and development of pelareorep over the next several years as we look to advance our breast and gastrointestinal cancer programs into later stages of clinical development. A product candidate in later stages of clinical development generally has higher costs than those in earlier stages, primarily due to the increased size and duration of later-stage clinical trials. Additionally, we expect to continue to incur additional costs associated with operating as a public company.</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan on raising additional funds through the sale of our common shares or other capital resources, such as strategic collaborations and debt, to fund our ongoing operations. However, given the difficulty for micro-cap market capitalization companies to raise significant capital, there can be no assurance that additional liquidity will be available under acceptable terms or at all. Furthermore, if we are unable to obtain additional financing when required, there can be no assurance that we will be able to sufficiently reduce or eliminate our planned expenditures to extend our operating runway until we obtain sufficient financing. These material uncertainties raise substantial doubt on our ability to continue as a going concern. Our audited consolidated financial statements do not reflect the adjustments that may result from the outcome of these uncertainties. Such adjustments could be material. </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that we can raise additional funds by issuing equity, our shareholders may experience significant dilution. Any debt financing, if available, may involve restrictive covenants that may impact our ability to conduct our business. If we are unable to secure adequate additional funding, we may be forced to make reductions in spending, including potentially delaying, scaling back or eliminating certain of our development programs, extending payment terms with suppliers, or liquidating assets where possible. Any of these actions could materially harm our business, results of operations and future prospects.</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Conducting clinical trials necessary to obtain regulatory approval is costly and time-consuming. We may never succeed in achieving marketing approval. The probability of successful commercialization of our drug candidates may be affected by numerous factors, including clinical data obtained in future trials, competition, manufacturing capability and commercial viability. As a result, we are unable to determine the duration and completion costs of our research and development projects or when and to what extent we will generate revenue from the commercialization and sale of any of our product candidates. </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not subject to externally imposed capital requirements, and there have been no changes in how we define or manage our capital in 2024.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</font></div></div></div><div id="i967b84de73e64fc9ab595bed11d15ebe_73"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Contractual Obligations and Commitments</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our significant contractual obligations as at December&#160;31, 2024&#58;</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.666%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Less than 1 year</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1 - 3 years</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4 - 5 years</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">More than <br>5 years</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,792&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,792&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease obligations</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,413&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">418&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">862&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total contractual obligations</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,205&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,210&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">862&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we are committed to payments of approximately $7,793 for activities mainly related to our clinical trial and manufacturing programs, which are expected to occur over the next two years. Approximately one-third of the committed payments relate to a production service agreement with our primary toll manufacturer, which cannot be canceled without a significant penalty. We are able to cancel most of the remaining agreements with notice. The ultimate amount and timing of these payments are subject to changes in our research and development plan.   </font></div><div><font><br></font></div><div id="i967b84de73e64fc9ab595bed11d15ebe_76"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As at December&#160;31, 2024, we had not entered into any off-balance sheet arrangements.</font></div><div><font><br></font></div><div id="i967b84de73e64fc9ab595bed11d15ebe_79"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Transactions with Related Parties</font></div><div style="margin-bottom:5pt;margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2024, 2023, and 2022, we did not enter into any related party transactions other than compensation paid to key management personnel. Key management personnel are those persons having authority and responsibility for planning, directing, and controlling our activities as a whole. We have determined that key management personnel comprise the Board of Directors, Executive Officers, President, and Vice Presidents.</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.353%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term employee compensation and benefits</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,267</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,870&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,308&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Termination benefits</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,349</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,496&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,615&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,616</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,685&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,923&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font><br></font></div><div id="i967b84de73e64fc9ab595bed11d15ebe_82"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Critical Accounting Estimates</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In preparing our audited consolidated financial statements, we use IFRS as issued by the IASB. IFRS requires us to make certain estimates, judgements, and assumptions that we believe are reasonable based upon the information available in applying our accounting policies. These estimates and assumptions affect the reported amounts and disclosures in our audited consolidated financial statements and accompanying notes. Actual results could differ from those estimates, and such differences could be material. </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Judgment, estimates and assumptions made by management that are significant to the financial statements are described below and in note 4 in our audited consolidated financial statements for the year ended December&#160;31, 2024.</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue recognition</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We entered into a Licensing Agreement with Adlai, which provides, among other payments, upfront license fees in exchange for a regional license to our intellectual property. Management uses its judgment in applying the input method when determining the extent of progress toward completion of the performance obligation. Revenue recognition requires assumptions and estimates regarding total estimated costs, the complexity of the work to be performed, and the length of time to complete the performance obligation, among other variables.</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clinical trial and manufacturing expenses</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trial and manufacturing expenses represent significant components of our research and development expenses, and we outsource a significant portion of these activities to third-party contract research&#47;manufacturing organizations. The financial terms of these agreements are subject to negotiation, vary from contract to contract, and may result in uneven payment flows to these organizations. Payments under the contracts depend on factors such as achieving certain milestones. As part of preparing our audited consolidated financial statements, we estimate the expense to recognize based on services that the contract research&#47;manufacturing organizations have performed. When making these estimates, we use operational and contractual information </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from third-party service providers, operational data from internal personnel, and considerable judgment. We base our estimates on the best information available at the time. However, additional information may become available to us which may allow us to make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain. Such increases or decreases in cost are generally considered to be changes in estimates and will be reflected in research and development expenses in the period identified.    </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Valuation of share-based compensation</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimating the fair value of share-based compensation requires determining the most appropriate valuation model which is dependent on the terms and conditions of the grant. We have chosen to use the Black-Scholes valuation model (&#34;Black-Scholes&#34; or the &#34;Model&#34;) to calculate the fair value of our stock options. Black-Scholes is widely used and accepted by other publicly traded companies. Therefore, we have concluded that Black-Scholes is the appropriate option pricing model to use for our stock options at this time. This estimate also requires determining the most appropriate inputs to the model, including the expected life, share price volatility, and dividend yield, and making assumptions about them. The assumptions and inputs used for estimating fair value for stock options granted are disclosed in note 11 in our audited consolidated financial statements. Consequently, in complying with IFRS and selecting what we believe are the most appropriate assumptions under the circumstances, we recorded non-cash share-based compensation expense for the years ended December&#160;31, 2024, 2023, and 2022, of $2,723, $1,917, and $2,378, respectively. </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Valuation of warrant derivative </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimating the fair value of the warrant derivative at initial measurement, at each exercise date and at each reporting period requires determining the most appropriate valuation model. We have chosen to use Black-Scholes to calculate the fair value of our warrant derivative. This estimate also requires determining the most appropriate inputs to the model including, the expected life, share price volatility, and dividend yield, and making assumptions about them, as discussed in note 9 in our audited consolidated financial statements. Consequently, in complying with IFRS and selecting what we believe are the most appropriate assumptions under the circumstances, we recorded a non-cash change in fair value of warrant derivative for the years ended December&#160;31, 2024, 2023, and 2022, of $1,242, $5,285, and $(20), respectively. </font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income taxes</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Uncertainties exist with respect to the interpretation of complex tax regulations and the amount and timing of future taxable income. Currently, we are accumulating tax loss carry-forward balances in various tax jurisdictions creating a deferred tax asset. Deferred tax assets are recognized for all unused tax losses to the extent that it is probable that taxable profit will be available against which the losses can be utilized. Management's judgment is required to determine the amount of deferred tax assets that can be recognized based on the likely timing and the level of future taxable profits together with future tax planning strategies.  </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have determined that none of our deferred tax assets should be recognized. Our deferred tax assets are mainly comprised of our net operating losses from prior years, prior year research and development expenses, and non-refundable investment tax credits. These tax pools relate to entities that have a history of losses, have varying expiry dates, and may not be used to offset taxable income within our other subsidiaries. There are also no taxable temporary differences or any tax planning opportunities available that could partly support the recognition of these losses as deferred tax assets.</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Functional currency</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess the relevant factors related to the primary economic environment in which our entities operate to determine the functional currency. Where the assessment of primary indicators are mixed, we assess the secondary indicators, including the relationship between the foreign operations and reporting entity.</font></div><div id="i967b84de73e64fc9ab595bed11d15ebe_85"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Accounting Policies </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our material accounting policies are described in note 3 in our audited consolidated financial statements for the year ended December&#160;31, 2024. </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adoption of new accounting standards</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IAS 1 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Classification of Liabilities as Current or Non-Current</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2022, the IASB issued amendments to clarify how conditions with which an entity must comply within 12 months after the reporting period affect the classification of a liability. This is in addition to the amendment from January 2020 where the IASB issued amendments to IAS 1 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Presentation of Financial Statements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to provide a more general approach to the presentation of liabilities as current or non-current based on contractual arrangements in place at the reporting date. These amendments specify that the rights and conditions existing at the end of the reporting period are relevant in determining </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">whether the Company has a right to defer settlement of a liability by at least 12 months, provided that management's expectations are not a relevant consideration as to whether the Company will exercise its rights to defer settlement of a liability and clarify when a liability is considered settled. The amendments became effective on January 1, 2024. Adopting the amendments did not have a material impact on our audited consolidated financial statements. </font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounting standards and interpretations issued but not yet effective</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IFRS 18 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Presentation and Disclosure in Financial Statements</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2024, the IASB issued IFRS 18 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Presentation and Disclosure in Financial Statements </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which replaces IAS 1 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Presentation of Financial Statements. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IFRS 18 introduces new requirements on presentation within the statement of profit or loss, including specified totals and subtotals. It also requires disclosure of management-defined performance measures and includes new requirements for aggregation and disaggregation of financial information based on the identified roles of the primary financial statements and the notes. Narrow scope amendments have been made to IAS 7 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Statement of Cash Flows</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and some requirements previously included within IAS 1 have been moved to IAS 8 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting Policies, Changes in Accounting Estimates and Errors, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which has also been renamed IAS 8 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Preparation of Financial Statements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. IAS 34 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interim Financial Reporting </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">has also been amended to require disclosure of management-defined performance measures. IFRS 18 and the amendments to the other standards are effective for annual periods beginning on or after January 1, 2027, with early application permitted. IFRS 18 applies retrospectively to both annual and interim financial statements. We are assessing the impact of adopting this standard on our audited consolidated financial statements.</font></div><div id="i967b84de73e64fc9ab595bed11d15ebe_88"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Financial Instruments and Other Instruments</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair value of financial instruments</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As at December&#160;31, 2024, and December&#160;31, 2023, the carrying amount of our cash and cash equivalents, other receivables, accounts payable and accrued liabilities, and other liabilities approximated their fair value due to their short-term maturity. The warrant derivative is a recurring Level 2 fair value measurement as these warrants have not been listed on an exchange and, therefore, do not trade on an active market. As at December 31, 2024, the fair value of our warrant derivative was presented as an asset of $980 (December&#160;31, 2023 - liability of $200). The change was mainly due to the revaluation of our warrants issued as part of our 2023 public offering. As the unamortized discount balance was greater than the fair value of the warrant derivative liability at December&#160;31, 2024, the net balance was presented as an asset on our audited consolidated statement of financial position. An initial discount was recognized as the difference between the fair value of the warrants and their allocated proceeds, which is amortized on a straight-line basis over the expected life of the warrants (see note 9 in our audited consolidated financial statements). We use the Black-Scholes valuation model to estimate fair value.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial risk management</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit risk</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Credit risk is the risk of a financial loss if a counterparty to a financial instrument fails to meet its contractual obligations.&#160;As at December&#160;31, 2024, we were exposed to credit risk on our cash and cash equivalents in the event of non-performance by counterparties, but we do not anticipate such non-performance. Our maximum exposure to credit risk at the end of the period is the carrying value of our cash and cash equivalents. </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We mitigate our exposure to credit risk connected to our cash and cash equivalents by maintaining our primary operating and investment bank accounts with Schedule I banks in Canada.&#160;For our foreign-domiciled bank accounts, we use referrals or recommendations from our Canadian banks to open foreign bank accounts. Our foreign-domiciled bank accounts are used solely for the purpose of settling accounts payable and accrued liabilities or payroll.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest rate risk </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates.&#160;We hold our cash and cash equivalents in bank accounts or high-interest investment accounts with variable interest rates. We mitigate interest rate risk through our investment policy that only allows the investment of excess cash resources in investment-grade vehicles while matching maturities with our operational requirements.</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fluctuations in market interest rates do not significantly impact our results of operations due to the short-term maturity of the investments held.</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign exchange risk</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign exchange risk arises from changes in foreign exchange rates that may affect the fair value or future cash flows of our financial assets or liabilities. For the year ended December&#160;31, 2024, we were primarily exposed to the risk of changes in the </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Canadian dollar relative to the U.S. dollar and Euro as a portion of our financial assets and liabilities were denominated in such currencies. The impact of a $0.01 increase in the value of the U.S. dollar against the Canadian dollar would have increased our comprehensive loss for the year ended December&#160;31, 2024, by approximately $34 (December&#160;31, 2023 - decrease by approximately $139). The impact of a $0.01 increase in the value of the Euro against the Canadian dollar would have increased our comprehensive loss for the year ended December&#160;31, 2024, by approximately $30 (December&#160;31, 2023 - $15). </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant balances denominated in U.S. dollars were as follows&#58;</font></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.104%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.007%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2024</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,534</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,294&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,722)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,476)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,125)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(251)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,687</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,567&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant balances denominated in Euros were as follows&#58;</font></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.104%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.007%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2024</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,114)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(673)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We mitigate our foreign exchange risk by maintaining sufficient foreign currencies by purchasing foreign currencies or receiving foreign currencies from financing activities to settle our foreign accounts payable and accrued liabilities.</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity risk</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liquidity risk is the risk that we will encounter difficulty in meeting obligations associated with financial liabilities. We manage liquidity risk through the management of our capital structure as outlined in the notes to our audited financial statements.  Accounts payable and accrued liabilities are all due within the current operating period. Other liabilities associated with funding received from PanCAN (see note 5 in our audited consolidated financial statements) are expected to be applied within the current operating period. See note 8 in our audited financial statements for a maturity analysis of our lease liabilities. </font></div><div style="text-align:justify"><font><br></font></div><div id="i967b84de73e64fc9ab595bed11d15ebe_91"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Use of Proceeds </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023 Public Offering and Use of Proceeds</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides an update on the anticipated use of proceeds raised as part of our 2023 public offering of common shares and warrants along with amounts actually expended. Following the announcement of our final BRACELET-1 results in the third quarter of 2024, we redirected proceeds to the breast cancer program. As at December&#160;31, 2024, the following expenditures have been incurred (in thousands of U.S. dollars)&#58; </font></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.946%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.452%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.452%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.452%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.455%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount to Spend</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Spent to Date</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjustments</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Remaining to Spend</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pancreatic Cancer Program</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,500&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,716)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,846)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,938&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Breast Cancer Program</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,028)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,846&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,318&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and Administrative Expenses</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,650&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(690)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,960&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,650&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,434)</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,216&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ATM Facility</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 2, 2024, we entered into an ATM equity distribution agreement with Cantor Fitzgerald &#38; Co. The ATM allows us to issue common shares, at prevailing market prices, with an aggregate offering value of up to US$50.0 million through the facilities of the Nasdaq Capital Market in the United States until August 19, 2026. During the year ended December&#160;31, 2024, we sold  2,849,210 common shares for gross proceeds of $3,654 (US$2,562). As at December&#160;31, 2024, approximately $68.3 million (US$47.4 million) remains unused under the ATM equity distribution agreement.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</font></div></div></div><div id="i967b84de73e64fc9ab595bed11d15ebe_94"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Other MD&#38;A Requirements</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have 86,421,592 common shares outstanding at March&#160;6, 2025. If all of our options and restricted share awards (7,233,216) and warrants and compensation warrants (8,203,743) were exercised or were to vest, we would have 101,858,551 common shares outstanding.</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our most recent annual report on Form 20-F is available on SEDAR+ at www.sedarplus.ca and EDGAR at www.sec.gov&#47;edgar.</font></div><div style="text-align:justify"><font><br></font></div><div id="i967b84de73e64fc9ab595bed11d15ebe_97"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Disclosure Controls and Procedures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Evaluation of Disclosure Controls and Procedures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our chief executive and financial officers reviewed and evaluated our disclosure controls and procedures. Based on that evaluation, they have concluded that our disclosure controls and procedures are effective in providing timely material information relating to the Company.  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management's Annual Report on Internal Control Over Financial Reporting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining adequate internal control over financial reporting and has designed such internal control over financial reporting to provide reasonable assurance regarding the reliability of financial reporting and the preparation and fair presentation of financial statements for external purposes in accordance with International Financial Reporting Standards.   </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management, including the Chief Executive Officer and Chief Financial Officer, does not expect that our internal controls and procedures over financial reporting will prevent all errors and all fraud. A control system can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple errors or mistakes. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving our stated goals under all potential future conditions. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that the controls may become inadequate because of changes in conditions or that the degree of compliance with the policies or procedures may deteriorate.  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management has evaluated the design and operation of our internal control over financial reporting as of December&#160;31, 2024, and has concluded that such internal control over financial reporting is effective as of December&#160;31, 2024. There are no material weaknesses that have been identified by management in this regard. This assessment was based on criteria for effective internal control over financial reporting described in Internal Control - Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 Framework).  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Changes in Internal Controls over Financial Reporting</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting that occurred during the year ended December&#160;31, 2024, that have materially affected or are reasonably likely to materially affect, our internal control over financial reporting.</font></div><div><font><br></font></div><div id="i967b84de73e64fc9ab595bed11d15ebe_100"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Risks and Uncertainties</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage biopharmaceutical company. Prospects for biotechnology companies in the research and development stage should generally be regarded as speculative. It is not possible to predict, based on studies in animals, or early studies in humans, whether a new therapeutic will ultimately prove to be safe and effective in humans, or whether necessary and sufficient data can be developed through the clinical trial process to support a successful product application and approval. If a product is approved for sale, product manufacturing at a commercial scale and significant sales to end users at a commercially reasonable price may not be successful. There can be no assurance that we will generate adequate funds to continue development, or will ever achieve significant revenues or profitable operations. Many factors (e.g., competition, patent protection, appropriate regulatory approvals) can influence the revenue and product profitability potential. In developing a pharmaceutical product, we rely on our employees, contractors, consultants and collaborators, and other third-party relationships, including the ability to obtain appropriate product liability insurance. There can be no assurance that this reliance and these relationships will continue as required. In addition to developmental and operational considerations, market prices for securities of biotechnology companies generally are volatile, and may or may not move in a manner consistent with the progress we have made or are making.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investment in our common shares involves a high degree of risk. An investor should carefully consider, among other matters, the risk factors in addition to the other information in our annual report on Form 20-F filed with the U.S. Securities and Exchange Commission (the &#34;SEC&#34;), as well as our other public filings with the Canadian securities regulatory authorities and the SEC, when evaluating our business because these risk factors may have a significant impact on our business, financial condition, operating results or cash flow. If any of the described material risks in our annual report or in subsequent reports we file with the regulatory authorities actually occur, they may materially harm our business, financial condition, operating results or cash flow. Additional risks and uncertainties that we have not yet identified or that we presently consider to be immaterial may also materially harm our business, financial condition, operating results, or cash flow. For information on risks and uncertainties, please refer to the &#34;Risk Factors&#34; section of our most recent annual report on Form 20-F and our other public filings available on www.sedarplus.ca and www.sec.gov&#47;edgar.  </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-15.2
<SEQUENCE>9
<FILENAME>ex152ey2024consent.htm
<DESCRIPTION>EX-15.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i9e2efbee1fd248a5b139a65412427ac9_1"></div><div style="min-height:42.7pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 15.2</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:118%">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We consent to the incorporation by reference in the following Registration Statements&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10.5pt">Form S-8 nos. 333-171625, 333-205708 and 333-279926</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10.5pt">Form F-10 no. 333-281009</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">of Oncolytics Biotech Inc. (the &#8220;Company&#8221;) of our reports dated March 6, 2025, with respect to the consolidated statements of financial position as at December 31, 2024 and December 31, 2023 and the consolidated statements of loss and comprehensive loss, changes in equity and cash flows for each of the years in the three-year period ended December 31, 2024, and the effectiveness of internal control over financial reporting of the Company as of December 31, 2024, included in this Annual Report on Form 20-F.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.295%"><tr><td style="width:1.0%"></td><td style="width:57.949%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.851%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Calgary, Alberta</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#47;s&#47;Ernst &#38; Young LLP</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 7, 2025</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Chartered Professional Accountants</font></td></tr></table></div><div style="text-align:right"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:324pt;text-indent:36pt"><font><br></font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>oncyf-20241231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:f2389c06-29ac-4823-bdfc-c1b39bddff80,g:9bb1793d-cf33-41ae-b11c-eb401ad874b8-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:oncyf="http://www.oncolyticsbiotech.com/20241231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.oncolyticsbiotech.com/20241231">
  <xs:import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/currency/2024" schemaLocation="https://xbrl.sec.gov/currency/2024/currency-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/cyd-af-sub/2024" schemaLocation="https://xbrl.sec.gov/cyd/2024/cyd-af-sub-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd-sub/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd"/>
  <xs:import namespace="https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full" schemaLocation="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="oncyf-20241231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="oncyf-20241231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="oncyf-20241231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="oncyf-20241231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.oncolyticsbiotech.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.oncolyticsbiotech.com/role/AuditInformation">
        <link:definition>0000002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" roleURI="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION">
        <link:definition>9952151 - Statement - CONSOLIDATED STATEMENTS OF FINANCIAL POSITION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITIONParenthetical" roleURI="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITIONParenthetical">
        <link:definition>9952152 - Statement - CONSOLIDATED STATEMENTS OF FINANCIAL POSITION (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS" roleURI="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS">
        <link:definition>9952153 - Statement - CONSOLIDATED STATEMENTS OF LOSS AND COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" roleURI="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY">
        <link:definition>9952154 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>9952155 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NatureofOperationsandGoingConcern" roleURI="http://www.oncolyticsbiotech.com/role/NatureofOperationsandGoingConcern">
        <link:definition>9952156 - Disclosure - Nature of Operations and Going Concern</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentation" roleURI="http://www.oncolyticsbiotech.com/role/BasisofPresentation">
        <link:definition>9952157 - Disclosure - Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofMaterialAccountingPolicies" roleURI="http://www.oncolyticsbiotech.com/role/SummaryofMaterialAccountingPolicies">
        <link:definition>9952158 - Disclosure - Summary of Material Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantJudgmentsEstimatesandAssumptions" roleURI="http://www.oncolyticsbiotech.com/role/SignificantJudgmentsEstimatesandAssumptions">
        <link:definition>9952159 - Disclosure - Significant Judgments, Estimates and Assumptions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherLiabilities" roleURI="http://www.oncolyticsbiotech.com/role/OtherLiabilities">
        <link:definition>9952160 - Disclosure - Other Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipment" roleURI="http://www.oncolyticsbiotech.com/role/PropertyandEquipment">
        <link:definition>9952161 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsPayableandAccruedLiabilities" roleURI="http://www.oncolyticsbiotech.com/role/AccountsPayableandAccruedLiabilities">
        <link:definition>9952162 - Disclosure - Accounts Payable and Accrued Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.oncolyticsbiotech.com/role/Leases">
        <link:definition>9952163 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantDerivative" roleURI="http://www.oncolyticsbiotech.com/role/WarrantDerivative">
        <link:definition>9952164 - Disclosure - Warrant Derivative</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareCapital" roleURI="http://www.oncolyticsbiotech.com/role/ShareCapital">
        <link:definition>9952165 - Disclosure - Share Capital</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensation" roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedCompensation">
        <link:definition>9952166 - Disclosure - Share-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LossPerShare" roleURI="http://www.oncolyticsbiotech.com/role/LossPerShare">
        <link:definition>9952167 - Disclosure - Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContractLiability" roleURI="http://www.oncolyticsbiotech.com/role/ContractLiability">
        <link:definition>9952168 - Disclosure - Contract Liability</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.oncolyticsbiotech.com/role/CommitmentsandContingencies">
        <link:definition>9952169 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxes">
        <link:definition>9952170 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CapitalDisclosures" roleURI="http://www.oncolyticsbiotech.com/role/CapitalDisclosures">
        <link:definition>9952171 - Disclosure - Capital Disclosures</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstruments" roleURI="http://www.oncolyticsbiotech.com/role/FinancialInstruments">
        <link:definition>9952172 - Disclosure - Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AdditionalCashFlowDisclosures" roleURI="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosures">
        <link:definition>9952173 - Disclosure - Additional Cash Flow Disclosures</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EconomicDependence" roleURI="http://www.oncolyticsbiotech.com/role/EconomicDependence">
        <link:definition>9952174 - Disclosure - Economic Dependence</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ComponentsofExpenses" roleURI="http://www.oncolyticsbiotech.com/role/ComponentsofExpenses">
        <link:definition>9952175 - Disclosure - Components of Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentDisclosures" roleURI="http://www.oncolyticsbiotech.com/role/SegmentDisclosures">
        <link:definition>9952176 - Disclosure - Segment Disclosures</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactions" roleURI="http://www.oncolyticsbiotech.com/role/RelatedPartyTransactions">
        <link:definition>9952177 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.oncolyticsbiotech.com/role/SubsequentEvents">
        <link:definition>9952178 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofMaterialAccountingPoliciesPolicies" roleURI="http://www.oncolyticsbiotech.com/role/SummaryofMaterialAccountingPoliciesPolicies">
        <link:definition>9955511 - Disclosure - Summary of Material Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofMaterialAccountingPoliciesTables" roleURI="http://www.oncolyticsbiotech.com/role/SummaryofMaterialAccountingPoliciesTables">
        <link:definition>9955512 - Disclosure - Summary of Material Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentTables" roleURI="http://www.oncolyticsbiotech.com/role/PropertyandEquipmentTables">
        <link:definition>9955513 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsPayableandAccruedLiabilitiesTables" roleURI="http://www.oncolyticsbiotech.com/role/AccountsPayableandAccruedLiabilitiesTables">
        <link:definition>9955514 - Disclosure - Accounts Payable and Accrued Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.oncolyticsbiotech.com/role/LeasesTables">
        <link:definition>9955515 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantDerivativeTables" roleURI="http://www.oncolyticsbiotech.com/role/WarrantDerivativeTables">
        <link:definition>9955516 - Disclosure - Warrant Derivative (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareCapitalTables" roleURI="http://www.oncolyticsbiotech.com/role/ShareCapitalTables">
        <link:definition>9955517 - Disclosure - Share Capital (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationTables" roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedCompensationTables">
        <link:definition>9955518 - Disclosure - Share-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContractLiabilityTables" roleURI="http://www.oncolyticsbiotech.com/role/ContractLiabilityTables">
        <link:definition>9955519 - Disclosure - Contract Liability (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxesTables">
        <link:definition>9955520 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CapitalDisclosuresTables" roleURI="http://www.oncolyticsbiotech.com/role/CapitalDisclosuresTables">
        <link:definition>9955521 - Disclosure - Capital Disclosures (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsTables" roleURI="http://www.oncolyticsbiotech.com/role/FinancialInstrumentsTables">
        <link:definition>9955522 - Disclosure - Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AdditionalCashFlowDisclosuresTables" roleURI="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresTables">
        <link:definition>9955523 - Disclosure - Additional Cash Flow Disclosures (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ComponentsofExpensesTables" roleURI="http://www.oncolyticsbiotech.com/role/ComponentsofExpensesTables">
        <link:definition>9955524 - Disclosure - Components of Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentDisclosuresTables" roleURI="http://www.oncolyticsbiotech.com/role/SegmentDisclosuresTables">
        <link:definition>9955525 - Disclosure - Segment Disclosures (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsTables" roleURI="http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsTables">
        <link:definition>9955526 - Disclosure - Related Party Transactions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NatureofOperationsandGoingConcernDetails" roleURI="http://www.oncolyticsbiotech.com/role/NatureofOperationsandGoingConcernDetails">
        <link:definition>9955527 - Disclosure - Nature of Operations and Going Concern (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofMaterialAccountingPoliciesNarrativeDetails" roleURI="http://www.oncolyticsbiotech.com/role/SummaryofMaterialAccountingPoliciesNarrativeDetails">
        <link:definition>9955528 - Disclosure - Summary of Material Accounting Policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofMaterialAccountingPoliciesScheduleofDepreciationRatesDetails" roleURI="http://www.oncolyticsbiotech.com/role/SummaryofMaterialAccountingPoliciesScheduleofDepreciationRatesDetails">
        <link:definition>9955529 - Disclosure - Summary of Material Accounting Policies - Schedule of Depreciation Rates (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherLiabilitiesDetails" roleURI="http://www.oncolyticsbiotech.com/role/OtherLiabilitiesDetails">
        <link:definition>9955530 - Disclosure - Other Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentDetails" roleURI="http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails">
        <link:definition>9955531 - Disclosure - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsPayableandAccruedLiabilitiesDetails" roleURI="http://www.oncolyticsbiotech.com/role/AccountsPayableandAccruedLiabilitiesDetails">
        <link:definition>9955532 - Disclosure - Accounts Payable and Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://www.oncolyticsbiotech.com/role/LeasesNarrativeDetails">
        <link:definition>9955533 - Disclosure - Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesRightofuseAssetsandLeaseLiabilitiesDetails" roleURI="http://www.oncolyticsbiotech.com/role/LeasesRightofuseAssetsandLeaseLiabilitiesDetails">
        <link:definition>9955534 - Disclosure - Leases - Right-of-use Assets and Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTotalUndiscountedLeaseLiabilityDetails" roleURI="http://www.oncolyticsbiotech.com/role/LeasesTotalUndiscountedLeaseLiabilityDetails">
        <link:definition>9955535 - Disclosure - Leases - Total Undiscounted Lease Liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantDerivativeReconciliationofChangeinFairValueofWarrantDerivativeDetails" roleURI="http://www.oncolyticsbiotech.com/role/WarrantDerivativeReconciliationofChangeinFairValueofWarrantDerivativeDetails">
        <link:definition>9955536 - Disclosure - Warrant Derivative - Reconciliation of Change in Fair Value of Warrant Derivative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantDerivativeWarrantDerivativeOutstandingDetails" roleURI="http://www.oncolyticsbiotech.com/role/WarrantDerivativeWarrantDerivativeOutstandingDetails">
        <link:definition>9955537 - Disclosure - Warrant Derivative - Warrant Derivative Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantDerivativeNarrativeDetails" roleURI="http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails">
        <link:definition>9955538 - Disclosure - Warrant Derivative - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantDerivativeSummaryofAssumptionsUsedintheBlackScholesOptionPricingModelforWarrantsDetails" roleURI="http://www.oncolyticsbiotech.com/role/WarrantDerivativeSummaryofAssumptionsUsedintheBlackScholesOptionPricingModelforWarrantsDetails">
        <link:definition>9955539 - Disclosure - Warrant Derivative - Summary of Assumptions Used in the Black Scholes Option Pricing Model for Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareCapitalScheduleofShareCapitalDetails" roleURI="http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails">
        <link:definition>9955540 - Disclosure - Share Capital - Schedule of Share Capital (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareCapitalScheduleofShareCapitalFootnotesDetails" roleURI="http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails">
        <link:definition>9955541 - Disclosure - Share Capital - Schedule of Share Capital Footnotes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationNarrativeDetails" roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedCompensationNarrativeDetails">
        <link:definition>9955542 - Disclosure - Share-Based Compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationScheduleofStockOptionsandWeightedAverageExercisePricesDetails" roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsandWeightedAverageExercisePricesDetails">
        <link:definition>9955543 - Disclosure - Share-Based Compensation - Schedule of Stock Options and Weighted Average Exercise Prices (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails" roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails">
        <link:definition>9955544 - Disclosure - Share-Based Compensation - Schedule of Stock Options Outstanding and Exercisable by Range of Exercise Price (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationDisclosureWeightedAverageAssumptionsandFairValueofOptionsDetails" roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedCompensationDisclosureWeightedAverageAssumptionsandFairValueofOptionsDetails">
        <link:definition>9955545 - Disclosure - Share-Based Compensation - Disclosure Weighted Average Assumptions and Fair Value of Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationScheduleofNumberofOtherEquityInstrumentsDetails" roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofNumberofOtherEquityInstrumentsDetails">
        <link:definition>9955546 - Disclosure - Share-Based Compensation - Schedule of Number of Other Equity Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LossPerShareDetails" roleURI="http://www.oncolyticsbiotech.com/role/LossPerShareDetails">
        <link:definition>9955547 - Disclosure - Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContractLiabilityNarrativeDetails" roleURI="http://www.oncolyticsbiotech.com/role/ContractLiabilityNarrativeDetails">
        <link:definition>9955548 - Disclosure - Contract Liability - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContractLiabilityScheduleofContractRevenuesandLiabilitiesDetails" roleURI="http://www.oncolyticsbiotech.com/role/ContractLiabilityScheduleofContractRevenuesandLiabilitiesDetails">
        <link:definition>9955549 - Disclosure - Contract Liability - Schedule of Contract Revenues and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesDetails" roleURI="http://www.oncolyticsbiotech.com/role/CommitmentsandContingenciesDetails">
        <link:definition>9955550 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesProvisionforIncomeTaxesDetails" roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails">
        <link:definition>9955551 - Disclosure - Income Taxes - Provision for Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNarrativeDetails" roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxesNarrativeDetails">
        <link:definition>9955552 - Disclosure - Income Taxes - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofUnrecognizedDeferredTaxAssetsDetails" roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxesScheduleofUnrecognizedDeferredTaxAssetsDetails">
        <link:definition>9955553 - Disclosure - Income Taxes - Schedule of Unrecognized Deferred Tax Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CapitalDisclosuresDetails" roleURI="http://www.oncolyticsbiotech.com/role/CapitalDisclosuresDetails">
        <link:definition>9955554 - Disclosure - Capital Disclosures (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsNarrativeDetails" roleURI="http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails">
        <link:definition>9955555 - Disclosure - Financial Instruments - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsScheduleofBalancesinForeignCurrenciesDetails" roleURI="http://www.oncolyticsbiotech.com/role/FinancialInstrumentsScheduleofBalancesinForeignCurrenciesDetails">
        <link:definition>9955556 - Disclosure - Financial Instruments - Schedule of Balances in Foreign Currencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails" roleURI="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails">
        <link:definition>9955557 - Disclosure - Additional Cash Flow Disclosures - Net Change In Non-Cash Working Capital (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AdditionalCashFlowDisclosuresOtherCashFlowDisclosuresDetails" roleURI="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresOtherCashFlowDisclosuresDetails">
        <link:definition>9955558 - Disclosure - Additional Cash Flow Disclosures - Other Cash Flow Disclosures (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EconomicDependenceDetails" roleURI="http://www.oncolyticsbiotech.com/role/EconomicDependenceDetails">
        <link:definition>9955559 - Disclosure - Economic Dependence (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ComponentsofExpensesDetails" roleURI="http://www.oncolyticsbiotech.com/role/ComponentsofExpensesDetails">
        <link:definition>9955560 - Disclosure - Components of Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentDisclosuresDetails" roleURI="http://www.oncolyticsbiotech.com/role/SegmentDisclosuresDetails">
        <link:definition>9955561 - Disclosure - Segment Disclosures (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsDetails" roleURI="http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsDetails">
        <link:definition>9955562 - Disclosure - Related Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsDetails" roleURI="http://www.oncolyticsbiotech.com/role/SubsequentEventsDetails">
        <link:definition>9955563 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="oncyf_AuditorInformationAbstract" abstract="true" name="AuditorInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_CommitmentsAndContingencies1" abstract="false" name="CommitmentsAndContingencies1" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_SaleOfStockAxis" abstract="true" name="SaleOfStockAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_SaleOfStockDomain" abstract="true" name="SaleOfStockDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="oncyf_SharesUnderAtthemarketAgreementMember" abstract="true" name="SharesUnderAtthemarketAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="oncyf_SharesUnderPublicOfferingMember" abstract="true" name="SharesUnderPublicOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity" abstract="false" name="IncreaseDecreaseThroughIncentiveShareAwardsEquity" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_IncreaseDecreaseThroughExpirationOfWarrantEquity" abstract="false" name="IncreaseDecreaseThroughExpirationOfWarrantEquity" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_Statement1Table" abstract="true" name="Statement1Table" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_SharesPublicOfferingMember" abstract="true" name="SharesPublicOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="oncyf_Statement1LineItems" abstract="true" name="Statement1LineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_AdjustmentsForDepreciationRightOfUseAssets" abstract="false" name="AdjustmentsForDepreciationRightOfUseAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract" abstract="true" name="DisclosureOfNotesAndOtherExplanatoryInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_SummaryOfSignificantAccountingPoliciesAbstract" abstract="true" name="SummaryOfSignificantAccountingPoliciesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_SignificantJudgmentsEstimatesAndAssumptionsAbstract" abstract="true" name="SignificantJudgmentsEstimatesAndAssumptionsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract" abstract="true" name="DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract" abstract="true" name="DisclosureOfShareBasedPaymentArrangementsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract" abstract="true" name="DisclosureofrevenuefromcontractswithcustomersAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_ContingenciesAbstract" abstract="true" name="ContingenciesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_DisclosureofincometaxAbstract" abstract="true" name="DisclosureofincometaxAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_AdditionalCashFlowDisclosuresAbstract" abstract="true" name="AdditionalCashFlowDisclosuresAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_DisclosureOfEconomicDependenceAbstract" abstract="true" name="DisclosureOfEconomicDependenceAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_DisclosureOfEconomicDependenceTextBlock" abstract="false" name="DisclosureOfEconomicDependenceTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="oncyf_SegmentDisclosuresAbstract" abstract="true" name="SegmentDisclosuresAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_DisclosureofrelatedpartyAbstract" abstract="true" name="DisclosureofrelatedpartyAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_DisclosureofeventsafterreportingperiodAbstract" abstract="true" name="DisclosureofeventsafterreportingperiodAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_DescriptionOfAccountingPolicyForDeterminingComponentsOfCashAndCashEquivalentsPolicyTextBlock" abstract="false" name="DescriptionOfAccountingPolicyForDeterminingComponentsOfCashAndCashEquivalentsPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="oncyf_DetailedDisclosureOfTradeAndOtherPayablesExplanatoryTableTextBlock" abstract="false" name="DetailedDisclosureOfTradeAndOtherPayablesExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="oncyf_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTextBlock" abstract="false" name="DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="oncyf_DisclosureofsharebasedpaymentarrangementAbstract" abstract="true" name="DisclosureofsharebasedpaymentarrangementAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock" abstract="false" name="ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="oncyf_DisclosureOfCapitalComponentsTableTextBlock" abstract="false" name="DisclosureOfCapitalComponentsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock" abstract="false" name="ScheduleOfForeignCurrencyHeldTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="oncyf_CashFlowOperatingCapital1TableTextBlock" abstract="false" name="CashFlowOperatingCapital1TableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock" abstract="false" name="ScheduleofCashFlowSupplementalDisclosures1TableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="oncyf_OtherExpensesAndAdjustmentsTableTextBlock" abstract="false" name="OtherExpensesAndAdjustmentsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="oncyf_NumberOfStockOptionPlans" abstract="false" name="NumberOfStockOptionPlans" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement" abstract="false" name="MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="oncyf_MedicalEquipmentMember" abstract="true" name="MedicalEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="oncyf_PropertyPlantandEquipmentAnnualDepreciationRate" abstract="false" name="PropertyPlantandEquipmentAnnualDepreciationRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="oncyf_Currency1Table" abstract="true" name="Currency1Table" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_ClinicalTrialMember" abstract="true" name="ClinicalTrialMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="oncyf_Currency1LineItems" abstract="true" name="Currency1LineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_OfficeEquipmentAndFurnitureMember" abstract="true" name="OfficeEquipmentAndFurnitureMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="oncyf_OperatingLeaseLeaseTerm" abstract="false" name="OperatingLeaseLeaseTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="oncyf_RightOfUseAssetsAbstract" abstract="true" name="RightOfUseAssetsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_ForeignExchangeImpactRightofUseAssets" abstract="false" name="ForeignExchangeImpactRightofUseAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_GainsLossesFromForeignExchangeImpact" abstract="false" name="GainsLossesFromForeignExchangeImpact" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_NumberOfWarrantsOutstandingRollForward" abstract="true" name="NumberOfWarrantsOutstandingRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_NumberOfWarrantsOutstanding" abstract="false" name="NumberOfWarrantsOutstanding" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="oncyf_IssueOfEquityShares" abstract="false" name="IssueOfEquityShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="oncyf_NumberOfWarrantsExercised" abstract="false" name="NumberOfWarrantsExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="oncyf_NumberOfWarrantsExpired" abstract="false" name="NumberOfWarrantsExpired" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="oncyf_ChangeInFairValueWarrantDerivativeRollForward" abstract="true" name="ChangeInFairValueWarrantDerivativeRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_WarrantLiabilityUnamortizedDiscount" abstract="false" name="WarrantLiabilityUnamortizedDiscount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_FairValueOfWarrantDerivativeExercised" abstract="false" name="FairValueOfWarrantDerivativeExercised" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_FairValueOfWarrantDerivativeExpired" abstract="false" name="FairValueOfWarrantDerivativeExpired" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_WarrantLiabilityAmortizedDiscount" abstract="false" name="WarrantLiabilityAmortizedDiscount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_WarrantExercisePrice" abstract="false" name="WarrantExercisePrice" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="oncyf_SharesPublicOfferingWarrantDerivativesMember" abstract="true" name="SharesPublicOfferingWarrantDerivativesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="oncyf_NumberOfWarrantsAndSharesOutstanding" abstract="false" name="NumberOfWarrantsAndSharesOutstanding" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="oncyf_ProceedsFromIssueOfOrdinarySharesGross" abstract="false" name="ProceedsFromIssueOfOrdinarySharesGross" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_SharesIssuedPricePerShare1" abstract="false" name="SharesIssuedPricePerShare1" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="oncyf_CommonSharesPerUnit" abstract="false" name="CommonSharesPerUnit" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="oncyf_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight1" abstract="false" name="ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight1" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="oncyf_ExpirationPeriodOfOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement" abstract="false" name="ExpirationPeriodOfOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementThresholdTradingPrice" abstract="false" name="OtherEquityInstrumentsInShareBasedPaymentArrangementThresholdTradingPrice" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementThresholdConsecutiveTradingDays" abstract="false" name="OtherEquityInstrumentsInShareBasedPaymentArrangementThresholdConsecutiveTradingDays" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementAcceleratedThresholdTradingDays" abstract="false" name="OtherEquityInstrumentsInShareBasedPaymentArrangementAcceleratedThresholdTradingDays" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementExpirationDays" abstract="false" name="OtherEquityInstrumentsInShareBasedPaymentArrangementExpirationDays" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="oncyf_WarrantsTerm" abstract="false" name="WarrantsTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="oncyf_WeightedAverageSharePriceOtherEquityInstrumentsGranted" abstract="false" name="WeightedAverageSharePriceOtherEquityInstrumentsGranted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="oncyf_RiskFreeInterestRateOtherEquityInstrumentsGranted" abstract="false" name="RiskFreeInterestRateOtherEquityInstrumentsGranted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="oncyf_OtherEquityInstrumentsLifeOtherEquityInstrumentsGranted" abstract="false" name="OtherEquityInstrumentsLifeOtherEquityInstrumentsGranted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:decimalItemType"/>
  <xs:element id="oncyf_ExpectedVolatilityOtherEquityInstrumentsGranted" abstract="false" name="ExpectedVolatilityOtherEquityInstrumentsGranted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="oncyf_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted" abstract="false" name="ExpectedDividendAsPercentageOtherEquityInstrumentsGranted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="oncyf_WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted" abstract="false" name="WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="oncyf_SharesUnderStockOptionPlanMember" abstract="true" name="SharesUnderStockOptionPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="oncyf_SharesUnderIncentiveAwardPlanMember" abstract="true" name="SharesUnderIncentiveAwardPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="oncyf_ShareCapitalNumberSharesAbstract" abstract="true" name="ShareCapitalNumberSharesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_ShareCapitalAmountAbstract" abstract="true" name="ShareCapitalAmountAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_A2021SharesUnderAtTheMarketAgreementUnitedStatesMember" abstract="true" name="A2021SharesUnderAtTheMarketAgreementUnitedStatesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="oncyf_A2022SharesUnderAtTheMarketAgreementUnitedStatesMember" abstract="true" name="A2022SharesUnderAtTheMarketAgreementUnitedStatesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="oncyf_A2024SharesUnderAtTheMarketAgreementUnitedStatesMember" abstract="true" name="A2024SharesUnderAtTheMarketAgreementUnitedStatesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="oncyf_CompensationWarrantsMember" abstract="true" name="CompensationWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="oncyf_SharePurchaseAgreementAmount" abstract="false" name="SharePurchaseAgreementAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_SharePurchaseAgreementTerm" abstract="false" name="SharePurchaseAgreementTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="oncyf_ShareIssueRelatedCostCommissions" abstract="false" name="ShareIssueRelatedCostCommissions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_IssueOfEquitySharesNumberOfCommonShares" abstract="false" name="IssueOfEquitySharesNumberOfCommonShares" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="oncyf_IssueOfEquitySharesNumberOfWarrants" abstract="false" name="IssueOfEquitySharesNumberOfWarrants" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="oncyf_ShareWarrantsIssuedTransactionCosts" abstract="false" name="ShareWarrantsIssuedTransactionCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_ShareWarrantsIssuedOperatingExpense" abstract="false" name="ShareWarrantsIssuedOperatingExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_WarrantsExercised" abstract="false" name="WarrantsExercised" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_ProceedsfromWarrantExercises1" abstract="false" name="ProceedsfromWarrantExercises1" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_NumberOfSharesReservedForIssueUnderOptionsAndContractsForSaleOfSharesPercentageOfCommonSharesMaximum" abstract="false" name="NumberOfSharesReservedForIssueUnderOptionsAndContractsForSaleOfSharesPercentageOfCommonSharesMaximum" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="oncyf_StockOptionsOutstandingAbstract" abstract="true" name="StockOptionsOutstandingAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_WeightedAverageExercisePriceOutstandingAbstract" abstract="true" name="WeightedAverageExercisePriceOutstandingAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_ExercisePriceRangeOneMember" abstract="true" name="ExercisePriceRangeOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="oncyf_ExercisePriceRangeTwoMember" abstract="true" name="ExercisePriceRangeTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="oncyf_ExercisePriceRangeThreeMember" abstract="true" name="ExercisePriceRangeThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="oncyf_ExercisePriceRangeFourMember" abstract="true" name="ExercisePriceRangeFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="oncyf_ExercisePriceRangeFiveMember" abstract="true" name="ExercisePriceRangeFiveMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="oncyf_ContractLiabilityRecognitionPeriod" abstract="false" name="ContractLiabilityRecognitionPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="oncyf_PurchaseObligation1" abstract="false" name="PurchaseObligation1" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_PurchaseObligationCommitmentTerm" abstract="false" name="PurchaseObligationCommitmentTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="oncyf_PurchaseObligationCommitmentProductionServiceAgreementPercentage" abstract="false" name="PurchaseObligationCommitmentProductionServiceAgreementPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="oncyf_TaxEffectOfStockBasedCompensation" abstract="false" name="TaxEffectOfStockBasedCompensation" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_TaxEffectOfTaxPools" abstract="false" name="TaxEffectOfTaxPools" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_TaxEffectOfExpirationOfTaxBenefits" abstract="false" name="TaxEffectOfExpirationOfTaxBenefits" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative" abstract="false" name="TaxEffectOfChangeinFairValueOfWarrantDerivative" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1" abstract="false" name="ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember" abstract="true" name="UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="oncyf_UnusedNetOperatingLossCarryForwardsMember" abstract="true" name="UnusedNetOperatingLossCarryForwardsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="oncyf_InvestmentTaxCreditsMember" abstract="true" name="InvestmentTaxCreditsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="oncyf_PropertyPlantEquipmentRelatedTemporaryDifferencesMember" abstract="true" name="PropertyPlantEquipmentRelatedTemporaryDifferencesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="oncyf_ShareIssueCostsMember" abstract="true" name="ShareIssueCostsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="oncyf_UnusedCapitalLossCarryForwardNetMember" abstract="true" name="UnusedCapitalLossCarryForwardNetMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="oncyf_EquityAuthorized" abstract="false" name="EquityAuthorized" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount" abstract="false" name="SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings" abstract="false" name="SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_BalanceHeldInForeignCurrencyNet" abstract="false" name="BalanceHeldInForeignCurrencyNet" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet" abstract="false" name="IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_ProceedsfromInterestReceived" abstract="false" name="ProceedsfromInterestReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_ConcentrationRisk1Table" abstract="true" name="ConcentrationRisk1Table" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_ConcentrationRiskType1Axis" abstract="true" name="ConcentrationRiskType1Axis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_ConcentrationRiskType1Domain" abstract="true" name="ConcentrationRiskType1Domain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="oncyf_SupplierConcentrationRisk1Member" abstract="true" name="SupplierConcentrationRisk1Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="oncyf_ConcentrationRiskType1LineItems" abstract="true" name="ConcentrationRiskType1LineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_ConcentrationRiskNumber" abstract="false" name="ConcentrationRiskNumber" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="oncyf_OtherExpensesAndAdjustmentsTable" abstract="true" name="OtherExpensesAndAdjustmentsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_IncomeStatementLocation1Axis" abstract="true" name="IncomeStatementLocation1Axis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_IncomeStatementLocation1Domain" abstract="true" name="IncomeStatementLocation1Domain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="oncyf_ResearchAndDevelopmentExpense1Member" abstract="true" name="ResearchAndDevelopmentExpense1Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="oncyf_GeneralAndAdministrativeExpense1Member" abstract="true" name="GeneralAndAdministrativeExpense1Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="oncyf_OtherExpensesAndAdjustmentsLineItems" abstract="true" name="OtherExpensesAndAdjustmentsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_ResearchAndDevelopmentExpense1Abstract" abstract="true" name="ResearchAndDevelopmentExpense1Abstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_ClinicalTrialExpense" abstract="false" name="ClinicalTrialExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_ManufacturingExpense" abstract="false" name="ManufacturingExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_IntellectualPropertyExpense" abstract="false" name="IntellectualPropertyExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_TranslationalScienceExpense" abstract="false" name="TranslationalScienceExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_GeneralAndAdministrativeExpense1Abstract" abstract="true" name="GeneralAndAdministrativeExpense1Abstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_PublicCompanyExpense" abstract="false" name="PublicCompanyExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_OfficeExpenses" abstract="false" name="OfficeExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_RestOfWorldMember" abstract="true" name="RestOfWorldMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="oncyf_NumberOfReportableSegments1" abstract="false" name="NumberOfReportableSegments1" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="oncyf_IssueOfOrdinarySharesPerShare" abstract="false" name="IssueOfOrdinarySharesPerShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>11
<FILENAME>oncyf-20241231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:f2389c06-29ac-4823-bdfc-c1b39bddff80,g:9bb1793d-cf33-41ae-b11c-eb401ad874b8-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" xlink:type="simple" xlink:href="oncyf-20241231.xsd#CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"/>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssets_5100c67f-45ec-4993-8e3b-0888bc0f923f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_e9e7678f-124f-4d1f-8142-e44b13229a2b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets_5100c67f-45ec-4993-8e3b-0888bc0f923f" xlink:to="loc_ifrs-full_CashAndCashEquivalents_e9e7678f-124f-4d1f-8142-e44b13229a2b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentReceivables_eea4775e-faf1-41da-ad37-3a4cf9f62721" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentReceivables"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets_5100c67f-45ec-4993-8e3b-0888bc0f923f" xlink:to="loc_ifrs-full_OtherCurrentReceivables_eea4775e-faf1-41da-ad37-3a4cf9f62721" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentPrepayments_ee8d9541-0067-4fdf-b75d-74b7fe84f830" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentPrepayments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets_5100c67f-45ec-4993-8e3b-0888bc0f923f" xlink:to="loc_ifrs-full_CurrentPrepayments_ee8d9541-0067-4fdf-b75d-74b7fe84f830" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentDerivativeFinancialAssets_bd3b67e1-1389-4d26-9dfd-8d5434c53783" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentDerivativeFinancialAssets"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets_5100c67f-45ec-4993-8e3b-0888bc0f923f" xlink:to="loc_ifrs-full_CurrentDerivativeFinancialAssets_bd3b67e1-1389-4d26-9dfd-8d5434c53783" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_3a12cab1-8e4b-4cab-a216-dd4df7b72b27" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Equity"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapital_321a5a3b-f6d9-46b5-a8f0-36c92cd0a9e7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssuedCapital"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Equity_3a12cab1-8e4b-4cab-a216-dd4df7b72b27" xlink:to="loc_ifrs-full_IssuedCapital_321a5a3b-f6d9-46b5-a8f0-36c92cd0a9e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionalPaidinCapital_2c7266f1-b078-4c25-970f-54f3efbf2e03" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdditionalPaidinCapital"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Equity_3a12cab1-8e4b-4cab-a216-dd4df7b72b27" xlink:to="loc_ifrs-full_AdditionalPaidinCapital_2c7266f1-b078-4c25-970f-54f3efbf2e03" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedOtherComprehensiveIncome_a73b6323-a5af-44ae-b94d-f98df7680dd9" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AccumulatedOtherComprehensiveIncome"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Equity_3a12cab1-8e4b-4cab-a216-dd4df7b72b27" xlink:to="loc_ifrs-full_AccumulatedOtherComprehensiveIncome_a73b6323-a5af-44ae-b94d-f98df7680dd9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetainedEarnings_33c12238-b76e-4f34-ba5f-9fe263b3a2fd" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RetainedEarnings"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Equity_3a12cab1-8e4b-4cab-a216-dd4df7b72b27" xlink:to="loc_ifrs-full_RetainedEarnings_33c12238-b76e-4f34-ba5f-9fe263b3a2fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Liabilities_e8ee96b0-49f0-4a46-8fb2-79ac6321a3e2" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLiabilities_334d0d4c-4f66-4b8a-8cab-5eead2b90333" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Liabilities_e8ee96b0-49f0-4a46-8fb2-79ac6321a3e2" xlink:to="loc_ifrs-full_CurrentLiabilities_334d0d4c-4f66-4b8a-8cab-5eead2b90333" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentContractLiabilities_19238fb1-16cb-46e0-9f06-56c7d44c66ae" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentContractLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Liabilities_e8ee96b0-49f0-4a46-8fb2-79ac6321a3e2" xlink:to="loc_ifrs-full_NoncurrentContractLiabilities_19238fb1-16cb-46e0-9f06-56c7d44c66ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLeaseLiabilities_b4bd838b-edb6-4ae9-a3f8-41c571fcf3d6" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentLeaseLiabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Liabilities_e8ee96b0-49f0-4a46-8fb2-79ac6321a3e2" xlink:to="loc_ifrs-full_NoncurrentLeaseLiabilities_b4bd838b-edb6-4ae9-a3f8-41c571fcf3d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLiabilities_dce217ce-3fa0-4032-bec3-6cc102ad7207" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayables_3e0b96c1-4bc1-4e21-af47-5df643e8e81a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities_dce217ce-3fa0-4032-bec3-6cc102ad7207" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayables_3e0b96c1-4bc1-4e21-af47-5df643e8e81a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentLiabilities_36e04c1b-a057-497e-b430-6ec6a05e0611" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities_dce217ce-3fa0-4032-bec3-6cc102ad7207" xlink:to="loc_ifrs-full_OtherCurrentLiabilities_36e04c1b-a057-497e-b430-6ec6a05e0611" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLeaseLiabilities_38cf71c6-6d8a-49dc-89b4-203201d639e9" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLeaseLiabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities_dce217ce-3fa0-4032-bec3-6cc102ad7207" xlink:to="loc_ifrs-full_CurrentLeaseLiabilities_38cf71c6-6d8a-49dc-89b4-203201d639e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentDerivativeFinancialLiabilities_19089627-686d-42b8-8d21-4e46e3aeca16" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentDerivativeFinancialLiabilities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities_dce217ce-3fa0-4032-bec3-6cc102ad7207" xlink:to="loc_ifrs-full_CurrentDerivativeFinancialLiabilities_19089627-686d-42b8-8d21-4e46e3aeca16" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Assets_e5e3a497-45d6-482f-9f99-80ba38687c66" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssets_5bf8b779-dbed-4e94-b56e-8de02c528d5b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Assets_e5e3a497-45d6-482f-9f99-80ba38687c66" xlink:to="loc_ifrs-full_CurrentAssets_5bf8b779-dbed-4e94-b56e-8de02c528d5b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_ff637696-0dee-4e29-903c-9c4a4dcfc97e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Assets_e5e3a497-45d6-482f-9f99-80ba38687c66" xlink:to="loc_ifrs-full_PropertyPlantAndEquipment_ff637696-0dee-4e29-903c-9c4a4dcfc97e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RightofuseAssets_2482c243-90c2-4873-97ae-7950fdeff28e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RightofuseAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Assets_e5e3a497-45d6-482f-9f99-80ba38687c66" xlink:to="loc_ifrs-full_RightofuseAssets_2482c243-90c2-4873-97ae-7950fdeff28e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAndLiabilities_2027ae7b-1898-4db3-b538-ffd2dc9cf4fa" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAndLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Liabilities_1e568431-b21f-42c9-85a6-610d60a286d0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_EquityAndLiabilities_2027ae7b-1898-4db3-b538-ffd2dc9cf4fa" xlink:to="loc_ifrs-full_Liabilities_1e568431-b21f-42c9-85a6-610d60a286d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CommitmentsAndContingencies1_9211ad45-f89d-48a3-a882-b0d81d0a7b10" xlink:href="oncyf-20241231.xsd#oncyf_CommitmentsAndContingencies1"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_EquityAndLiabilities_2027ae7b-1898-4db3-b538-ffd2dc9cf4fa" xlink:to="loc_oncyf_CommitmentsAndContingencies1_9211ad45-f89d-48a3-a882-b0d81d0a7b10" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_33dcd75d-ee18-4683-b775-fc3d57781aa5" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Equity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_EquityAndLiabilities_2027ae7b-1898-4db3-b538-ffd2dc9cf4fa" xlink:to="loc_ifrs-full_Equity_33dcd75d-ee18-4683-b775-fc3d57781aa5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="oncyf-20241231.xsd#CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS"/>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossFromOperatingActivities_4e72d856-ccab-472f-b4c9-cd4259a79031" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense_a93ad5ea-dffa-4c56-9656-f3c3f516480c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_4e72d856-ccab-472f-b4c9-cd4259a79031" xlink:to="loc_ifrs-full_ResearchAndDevelopmentExpense_a93ad5ea-dffa-4c56-9656-f3c3f516480c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeneralAndAdministrativeExpense_3d62d91c-5f88-46b8-8b8b-c978d6833317" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_4e72d856-ccab-472f-b4c9-cd4259a79031" xlink:to="loc_ifrs-full_GeneralAndAdministrativeExpense_3d62d91c-5f88-46b8-8b8b-c978d6833317" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncome_251760e5-b9ad-40c7-8b5f-e078b02f9832" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComprehensiveIncome"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_0ed882d8-5fff-4361-aaf5-2c7538ad518b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ComprehensiveIncome_251760e5-b9ad-40c7-8b5f-e078b02f9832" xlink:to="loc_ifrs-full_ProfitLoss_0ed882d8-5fff-4361-aaf5-2c7538ad518b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_a2c768a6-a95c-4986-b35d-fe398591eb83" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ComprehensiveIncome_251760e5-b9ad-40c7-8b5f-e078b02f9832" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_a2c768a6-a95c-4986-b35d-fe398591eb83" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossBeforeTax_8d00e9cd-21a1-4709-a5f7-9c3438cb5aaa" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossFromOperatingActivities_687833fc-97f5-481f-ae42-b6da3b27b32b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossBeforeTax_8d00e9cd-21a1-4709-a5f7-9c3438cb5aaa" xlink:to="loc_ifrs-full_ProfitLossFromOperatingActivities_687833fc-97f5-481f-ae42-b6da3b27b32b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_fa147006-eb5f-48d8-934a-8aaee1288c3a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossBeforeTax_8d00e9cd-21a1-4709-a5f7-9c3438cb5aaa" xlink:to="loc_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_fa147006-eb5f-48d8-934a-8aaee1288c3a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_c53370c0-cdee-42b9-a7cf-1694da268110" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossBeforeTax_8d00e9cd-21a1-4709-a5f7-9c3438cb5aaa" xlink:to="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_c53370c0-cdee-42b9-a7cf-1694da268110" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestIncomeOnCashAndCashEquivalents_04bd22b2-ad11-42a3-b187-bdcccecddcb0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InterestIncomeOnCashAndCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossBeforeTax_8d00e9cd-21a1-4709-a5f7-9c3438cb5aaa" xlink:to="loc_ifrs-full_InterestIncomeOnCashAndCashEquivalents_04bd22b2-ad11-42a3-b187-bdcccecddcb0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_cace1c56-30af-4846-ad06-9779b59d0888" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossBeforeTax_a54e0dc0-7c40-471a-a532-0f190d5c79ef" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLoss_cace1c56-30af-4846-ad06-9779b59d0888" xlink:to="loc_ifrs-full_ProfitLossBeforeTax_a54e0dc0-7c40-471a-a532-0f190d5c79ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_85af09ea-3390-4cfe-98dd-fbc267ae9745" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLoss_cace1c56-30af-4846-ad06-9779b59d0888" xlink:to="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_85af09ea-3390-4cfe-98dd-fbc267ae9745" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="oncyf-20241231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperations_ec8ad78b-2359-4a4b-b566-912f6f84ccb4" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_4db0e05a-61c6-49f5-b73d-a42fea222f01" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperations_ec8ad78b-2359-4a4b-b566-912f6f84ccb4" xlink:to="loc_ifrs-full_ProfitLoss_4db0e05a-61c6-49f5-b73d-a42fea222f01" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_cc43f81e-74d3-440e-98fb-123eee67017e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperations_ec8ad78b-2359-4a4b-b566-912f6f84ccb4" xlink:to="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_cc43f81e-74d3-440e-98fb-123eee67017e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_AdjustmentsForDepreciationRightOfUseAssets_cc0ed028-fd27-46b6-81a2-429cd8b04599" xlink:href="oncyf-20241231.xsd#oncyf_AdjustmentsForDepreciationRightOfUseAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperations_ec8ad78b-2359-4a4b-b566-912f6f84ccb4" xlink:to="loc_oncyf_AdjustmentsForDepreciationRightOfUseAssets_cc0ed028-fd27-46b6-81a2-429cd8b04599" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForSharebasedPayments_22b2995f-4991-4816-b1d1-4bba26231a39" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperations_ec8ad78b-2359-4a4b-b566-912f6f84ccb4" xlink:to="loc_ifrs-full_AdjustmentsForSharebasedPayments_22b2995f-4991-4816-b1d1-4bba26231a39" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_5a8edbc8-a33e-4383-9b7d-47999eb0dd1d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperations_ec8ad78b-2359-4a4b-b566-912f6f84ccb4" xlink:to="loc_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_5a8edbc8-a33e-4383-9b7d-47999eb0dd1d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestRevenueExpense_4f1074ab-cf06-4492-b098-8a196e91df70" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InterestRevenueExpense"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperations_ec8ad78b-2359-4a4b-b566-912f6f84ccb4" xlink:to="loc_ifrs-full_InterestRevenueExpense_4f1074ab-cf06-4492-b098-8a196e91df70" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_671cd2f9-69cb-44ed-8fd7-2c4d1f511620" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperations_ec8ad78b-2359-4a4b-b566-912f6f84ccb4" xlink:to="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_671cd2f9-69cb-44ed-8fd7-2c4d1f511620" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives_92ca6cda-aa99-44f3-9439-be8a4529af57" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperations_ec8ad78b-2359-4a4b-b566-912f6f84ccb4" xlink:to="loc_ifrs-full_AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives_92ca6cda-aa99-44f3-9439-be8a4529af57" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_8006d037-53f3-42c0-b023-be6902795b69" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseInWorkingCapital"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperations_ec8ad78b-2359-4a4b-b566-912f6f84ccb4" xlink:to="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_8006d037-53f3-42c0-b023-be6902795b69" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_306f8dab-328f-44ec-b580-e6dd1b19460f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities_858c3030-46db-49c9-abf7-e43e0405778d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_306f8dab-328f-44ec-b580-e6dd1b19460f" xlink:to="loc_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities_858c3030-46db-49c9-abf7-e43e0405778d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities_6c0a628d-2777-4e15-8a91-4d9d5181bf88" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_306f8dab-328f-44ec-b580-e6dd1b19460f" xlink:to="loc_ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities_6c0a628d-2777-4e15-8a91-4d9d5181bf88" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_186661df-bb44-42f5-9e69-9a075dfa90aa" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_306f8dab-328f-44ec-b580-e6dd1b19460f" xlink:to="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_186661df-bb44-42f5-9e69-9a075dfa90aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_df7c50f8-a11f-4fcf-8a81-d7d8ec609aae" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperations_c04d28d8-3fc5-47f8-8d4d-27c6676cd521" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperations"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_df7c50f8-a11f-4fcf-8a81-d7d8ec609aae" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperations_c04d28d8-3fc5-47f8-8d4d-27c6676cd521" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_58d6ea9e-1519-49ff-b9f8-55e490629a0b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_df7c50f8-a11f-4fcf-8a81-d7d8ec609aae" xlink:to="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_58d6ea9e-1519-49ff-b9f8-55e490629a0b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_77d1c41a-a212-4127-b65b-76808a9908c7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_df7c50f8-a11f-4fcf-8a81-d7d8ec609aae" xlink:to="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_77d1c41a-a212-4127-b65b-76808a9908c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_f546df54-6fe3-4979-87fa-7f428342634a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromExerciseOfOptions_c14b5d82-89a7-44b1-8de1-bf4c95237bd9" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromExerciseOfOptions"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_f546df54-6fe3-4979-87fa-7f428342634a" xlink:to="loc_ifrs-full_ProceedsFromExerciseOfOptions_c14b5d82-89a7-44b1-8de1-bf4c95237bd9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromExerciseOfWarrants_a13873cd-50ed-4447-a6b3-cd9c1cec4dee" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromExerciseOfWarrants"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_f546df54-6fe3-4979-87fa-7f428342634a" xlink:to="loc_ifrs-full_ProceedsFromExerciseOfWarrants_a13873cd-50ed-4447-a6b3-cd9c1cec4dee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromIssuingShares_1941f72b-844d-4bb2-bf4f-a0cab450a9ab" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromIssuingShares"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_f546df54-6fe3-4979-87fa-7f428342634a" xlink:to="loc_ifrs-full_ProceedsFromIssuingShares_1941f72b-844d-4bb2-bf4f-a0cab450a9ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashOutflowForLeases_c656fca4-8d58-4d1d-bb69-c7cef8369bd7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashOutflowForLeases"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_f546df54-6fe3-4979-87fa-7f428342634a" xlink:to="loc_ifrs-full_CashOutflowForLeases_c656fca4-8d58-4d1d-bb69-c7cef8369bd7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/AccountsPayableandAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="oncyf-20241231.xsd#AccountsPayableandAccruedLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/AccountsPayableandAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayables_e59d4628-3614-431a-b872-be6d8654d105" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_2ff70869-ae2f-4025-93f6-fb13ce87c9f2" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_TradeAndOtherCurrentPayables_e59d4628-3614-431a-b872-be6d8654d105" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_2ff70869-ae2f-4025-93f6-fb13ce87c9f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccrualsClassifiedAsCurrent_c3355ad3-5dfe-44bb-b2da-c0967010c07c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AccrualsClassifiedAsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_TradeAndOtherCurrentPayables_e59d4628-3614-431a-b872-be6d8654d105" xlink:to="loc_ifrs-full_AccrualsClassifiedAsCurrent_c3355ad3-5dfe-44bb-b2da-c0967010c07c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails" xlink:type="simple" xlink:href="oncyf-20241231.xsd#IncomeTaxesProvisionforIncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_332fb897-97a1-4932-a206-2bc80d1c3338" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_398201bb-807c-4559-9764-65b4428c5503" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TaxExpenseIncomeAtApplicableTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_332fb897-97a1-4932-a206-2bc80d1c3338" xlink:to="loc_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_398201bb-807c-4559-9764-65b4428c5503" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TaxEffectOfForeignTaxRates_ef6a8149-2c5f-48e4-93f3-57173001906b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TaxEffectOfForeignTaxRates"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_332fb897-97a1-4932-a206-2bc80d1c3338" xlink:to="loc_ifrs-full_TaxEffectOfForeignTaxRates_ef6a8149-2c5f-48e4-93f3-57173001906b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TaxEffectOfStockBasedCompensation_47c4536a-8fe7-4d77-9b8f-901b36e4742e" xlink:href="oncyf-20241231.xsd#oncyf_TaxEffectOfStockBasedCompensation"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_332fb897-97a1-4932-a206-2bc80d1c3338" xlink:to="loc_oncyf_TaxEffectOfStockBasedCompensation_47c4536a-8fe7-4d77-9b8f-901b36e4742e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TaxEffectOfTaxPools_e7c160d4-aec4-4f11-9c6a-b1c9c568b706" xlink:href="oncyf-20241231.xsd#oncyf_TaxEffectOfTaxPools"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_332fb897-97a1-4932-a206-2bc80d1c3338" xlink:to="loc_oncyf_TaxEffectOfTaxPools_e7c160d4-aec4-4f11-9c6a-b1c9c568b706" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TaxEffectFromChangeInTaxRate_cf6b4a92-3157-4f1c-98c8-72103afa977b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TaxEffectFromChangeInTaxRate"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_332fb897-97a1-4932-a206-2bc80d1c3338" xlink:to="loc_ifrs-full_TaxEffectFromChangeInTaxRate_cf6b4a92-3157-4f1c-98c8-72103afa977b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_dbff3a4c-8600-4f1c-9f31-692ed344bd05" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_332fb897-97a1-4932-a206-2bc80d1c3338" xlink:to="loc_ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_dbff3a4c-8600-4f1c-9f31-692ed344bd05" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TaxEffectOfExpirationOfTaxBenefits_16e75e45-16f7-42be-917d-531db8ada1c6" xlink:href="oncyf-20241231.xsd#oncyf_TaxEffectOfExpirationOfTaxBenefits"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_332fb897-97a1-4932-a206-2bc80d1c3338" xlink:to="loc_oncyf_TaxEffectOfExpirationOfTaxBenefits_16e75e45-16f7-42be-917d-531db8ada1c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative_df93d29f-55ab-49d9-a34f-198fbbcc63fa" xlink:href="oncyf-20241231.xsd#oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_332fb897-97a1-4932-a206-2bc80d1c3338" xlink:to="loc_oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative_df93d29f-55ab-49d9-a34f-198fbbcc63fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1_100cab92-513a-4e39-9f4c-ed83bbead249" xlink:href="oncyf-20241231.xsd#oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_332fb897-97a1-4932-a206-2bc80d1c3338" xlink:to="loc_oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1_100cab92-513a-4e39-9f4c-ed83bbead249" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails" xlink:type="simple" xlink:href="oncyf-20241231.xsd#AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails"/>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_7903b4a2-d291-4289-aeb7-52311164656c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseInWorkingCapital"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables_aaac037c-55ef-44c8-930a-41d98644065b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_7903b4a2-d291-4289-aeb7-52311164656c" xlink:to="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables_aaac037c-55ef-44c8-930a-41d98644065b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses_e468dfe1-7cb4-4ac7-b277-d9e32b71c4fb" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_7903b4a2-d291-4289-aeb7-52311164656c" xlink:to="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses_e468dfe1-7cb4-4ac7-b277-d9e32b71c4fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_c0fd6426-bf43-4557-a8b3-9f3610674a07" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_7903b4a2-d291-4289-aeb7-52311164656c" xlink:to="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_c0fd6426-bf43-4557-a8b3-9f3610674a07" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables_95982c67-93da-4c3f-8847-0b69805e3268" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_7903b4a2-d291-4289-aeb7-52311164656c" xlink:to="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables_95982c67-93da-4c3f-8847-0b69805e3268" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet_2fd57325-08cd-404d-b48e-faafec1a2f06" xlink:href="oncyf-20241231.xsd#oncyf_IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_7903b4a2-d291-4289-aeb7-52311164656c" xlink:to="loc_oncyf_IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet_2fd57325-08cd-404d-b48e-faafec1a2f06" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="oncyf-20241231.xsd#RelatedPartyTransactionsDetails"/>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensation_43024a35-10d1-4e2a-9dee-1d9aea84a247" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensation"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_0cf8adaa-7ae3-4a24-853b-4303407a7af7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensation_43024a35-10d1-4e2a-9dee-1d9aea84a247" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_0cf8adaa-7ae3-4a24-853b-4303407a7af7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits_72e069b0-7790-4a80-99a1-f9e3282124fe" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensation_43024a35-10d1-4e2a-9dee-1d9aea84a247" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits_72e069b0-7790-4a80-99a1-f9e3282124fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_e5789791-fa04-418a-95e6-3903958db468" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensation_43024a35-10d1-4e2a-9dee-1d9aea84a247" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_e5789791-fa04-418a-95e6-3903958db468" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>12
<FILENAME>oncyf-20241231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:f2389c06-29ac-4823-bdfc-c1b39bddff80,g:9bb1793d-cf33-41ae-b11c-eb401ad874b8-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/Cover" xlink:type="simple" xlink:href="oncyf-20241231.xsd#Cover"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_42708aea-bd65-45df-830c-e698caebd2ed" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_9065b503-4370-4d21-99d3-804452f5c816" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_DocumentInformationLineItems_42708aea-bd65-45df-830c-e698caebd2ed" xlink:to="loc_dei_DocumentInformationTable_9065b503-4370-4d21-99d3-804452f5c816" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressesAddressTypeAxis_4b664284-8f94-4b68-a848-f2a8821625dd" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_9065b503-4370-4d21-99d3-804452f5c816" xlink:to="loc_dei_EntityAddressesAddressTypeAxis_4b664284-8f94-4b68-a848-f2a8821625dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AddressTypeDomain_4b664284-8f94-4b68-a848-f2a8821625dd_default" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AddressTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_4b664284-8f94-4b68-a848-f2a8821625dd" xlink:to="loc_dei_AddressTypeDomain_4b664284-8f94-4b68-a848-f2a8821625dd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AddressTypeDomain_01eda1ea-4897-4c82-981d-e8a7f0f744c5" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AddressTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_4b664284-8f94-4b68-a848-f2a8821625dd" xlink:to="loc_dei_AddressTypeDomain_01eda1ea-4897-4c82-981d-e8a7f0f744c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_BusinessContactMember_f80e7397-ef72-491d-a784-008bc815c218" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_BusinessContactMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_AddressTypeDomain_01eda1ea-4897-4c82-981d-e8a7f0f744c5" xlink:to="loc_dei_BusinessContactMember_f80e7397-ef72-491d-a784-008bc815c218" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_8f3990bf-93e3-457b-ac86-b3f534ad0fb8" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_42708aea-bd65-45df-830c-e698caebd2ed" xlink:to="loc_dei_DocumentType_8f3990bf-93e3-457b-ac86-b3f534ad0fb8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentRegistrationStatement_08cf1535-07a4-444d-80a7-b3043b358a43" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_42708aea-bd65-45df-830c-e698caebd2ed" xlink:to="loc_dei_DocumentRegistrationStatement_08cf1535-07a4-444d-80a7-b3043b358a43" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_ab90873d-5b4d-4bc5-8584-bf69262ccbda" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_42708aea-bd65-45df-830c-e698caebd2ed" xlink:to="loc_dei_DocumentAnnualReport_ab90873d-5b4d-4bc5-8584-bf69262ccbda" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_84ae2929-41b9-40ae-9465-7748156a60b9" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_42708aea-bd65-45df-830c-e698caebd2ed" xlink:to="loc_dei_DocumentPeriodEndDate_84ae2929-41b9-40ae-9465-7748156a60b9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_b82ccdf7-19d1-467d-b754-f2058ed33094" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_42708aea-bd65-45df-830c-e698caebd2ed" xlink:to="loc_dei_CurrentFiscalYearEndDate_b82ccdf7-19d1-467d-b754-f2058ed33094" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_9fa636ad-daee-45f0-9a84-09e9b16f68a6" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_42708aea-bd65-45df-830c-e698caebd2ed" xlink:to="loc_dei_DocumentTransitionReport_9fa636ad-daee-45f0-9a84-09e9b16f68a6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentShellCompanyReport_8fb84a43-4c91-42d2-8795-b5d2d4d34e9d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_42708aea-bd65-45df-830c-e698caebd2ed" xlink:to="loc_dei_DocumentShellCompanyReport_8fb84a43-4c91-42d2-8795-b5d2d4d34e9d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_ac8b1ebb-5d88-4173-8577-96f49f21e6ef" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_42708aea-bd65-45df-830c-e698caebd2ed" xlink:to="loc_dei_EntityFileNumber_ac8b1ebb-5d88-4173-8577-96f49f21e6ef" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_5c3d50c0-58fc-4a97-8ac9-10da9c75a409" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_42708aea-bd65-45df-830c-e698caebd2ed" xlink:to="loc_dei_EntityRegistrantName_5c3d50c0-58fc-4a97-8ac9-10da9c75a409" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_a3ea0c22-4640-4195-b511-1264c4204864" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_42708aea-bd65-45df-830c-e698caebd2ed" xlink:to="loc_dei_EntityIncorporationStateCountryCode_a3ea0c22-4640-4195-b511-1264c4204864" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_9eb06344-0c29-46a1-8391-327a84c04937" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_42708aea-bd65-45df-830c-e698caebd2ed" xlink:to="loc_dei_EntityAddressAddressLine1_9eb06344-0c29-46a1-8391-327a84c04937" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_940b7d4e-6c9c-4a65-9e9f-1d693c63700c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_42708aea-bd65-45df-830c-e698caebd2ed" xlink:to="loc_dei_EntityAddressCityOrTown_940b7d4e-6c9c-4a65-9e9f-1d693c63700c" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_ecc5a0e2-7f3f-4094-98e2-5f24220133ad" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_42708aea-bd65-45df-830c-e698caebd2ed" xlink:to="loc_dei_EntityAddressStateOrProvince_ecc5a0e2-7f3f-4094-98e2-5f24220133ad" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry_109a97e1-af49-4b72-826e-7a3ae11c7054" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_42708aea-bd65-45df-830c-e698caebd2ed" xlink:to="loc_dei_EntityAddressCountry_109a97e1-af49-4b72-826e-7a3ae11c7054" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_4105b63e-1d6a-4b42-82a4-a9bc3137b5e1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_42708aea-bd65-45df-830c-e698caebd2ed" xlink:to="loc_dei_EntityAddressPostalZipCode_4105b63e-1d6a-4b42-82a4-a9bc3137b5e1" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ContactPersonnelName_7016a003-6fe6-468e-b48a-3a14046e36b0" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_ContactPersonnelName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_42708aea-bd65-45df-830c-e698caebd2ed" xlink:to="loc_dei_ContactPersonnelName_7016a003-6fe6-468e-b48a-3a14046e36b0" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_ec46ab5a-4b12-418a-9c76-6980f482d526" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_42708aea-bd65-45df-830c-e698caebd2ed" xlink:to="loc_dei_CityAreaCode_ec46ab5a-4b12-418a-9c76-6980f482d526" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_e58861c1-6997-468c-85ba-1306b71218bb" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_42708aea-bd65-45df-830c-e698caebd2ed" xlink:to="loc_dei_LocalPhoneNumber_e58861c1-6997-468c-85ba-1306b71218bb" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ContactPersonnelEmailAddress_aa8a753d-c544-4367-bdce-80b68d926109" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_ContactPersonnelEmailAddress"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_42708aea-bd65-45df-830c-e698caebd2ed" xlink:to="loc_dei_ContactPersonnelEmailAddress_aa8a753d-c544-4367-bdce-80b68d926109" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_e693fdb1-a53b-4b60-8406-a898294b9251" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_42708aea-bd65-45df-830c-e698caebd2ed" xlink:to="loc_dei_Security12bTitle_e693fdb1-a53b-4b60-8406-a898294b9251" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_abf4500c-9acd-44d1-b229-759f72d2d836" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_42708aea-bd65-45df-830c-e698caebd2ed" xlink:to="loc_dei_TradingSymbol_abf4500c-9acd-44d1-b229-759f72d2d836" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_160aa766-7ce4-4a43-ad90-eb17ff7672fa" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_42708aea-bd65-45df-830c-e698caebd2ed" xlink:to="loc_dei_SecurityExchangeName_160aa766-7ce4-4a43-ad90-eb17ff7672fa" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_49d84196-bb05-4f8f-8872-583e4fa1c64d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_42708aea-bd65-45df-830c-e698caebd2ed" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_49d84196-bb05-4f8f-8872-583e4fa1c64d" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_129ff5d7-8570-40bc-920a-4278c393ce5c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_42708aea-bd65-45df-830c-e698caebd2ed" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_129ff5d7-8570-40bc-920a-4278c393ce5c" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_f7d98cce-a8de-47ad-8770-f69a55afe182" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_42708aea-bd65-45df-830c-e698caebd2ed" xlink:to="loc_dei_EntityVoluntaryFilers_f7d98cce-a8de-47ad-8770-f69a55afe182" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_c948ce1d-76ba-485d-abc5-729034e2d5ee" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_42708aea-bd65-45df-830c-e698caebd2ed" xlink:to="loc_dei_EntityCurrentReportingStatus_c948ce1d-76ba-485d-abc5-729034e2d5ee" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_0a90a16f-83a2-444e-a7df-fddd07e599d0" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_42708aea-bd65-45df-830c-e698caebd2ed" xlink:to="loc_dei_EntityInteractiveDataCurrent_0a90a16f-83a2-444e-a7df-fddd07e599d0" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_34f3cf9e-2179-41db-89ef-708509ff2afb" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_42708aea-bd65-45df-830c-e698caebd2ed" xlink:to="loc_dei_EntityFilerCategory_34f3cf9e-2179-41db-89ef-708509ff2afb" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_1574b965-ec0d-4395-a93a-67a767ab3661" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_42708aea-bd65-45df-830c-e698caebd2ed" xlink:to="loc_dei_EntityEmergingGrowthCompany_1574b965-ec0d-4395-a93a-67a767ab3661" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_e0ef2eba-1d7e-4603-8c0f-c920e5026605" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_42708aea-bd65-45df-830c-e698caebd2ed" xlink:to="loc_dei_IcfrAuditorAttestationFlag_e0ef2eba-1d7e-4603-8c0f-c920e5026605" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag_00446a2d-d73c-4232-9f2a-c4f89edd6837" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_42708aea-bd65-45df-830c-e698caebd2ed" xlink:to="loc_dei_DocumentFinStmtErrorCorrectionFlag_00446a2d-d73c-4232-9f2a-c4f89edd6837" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAccountingStandard_4a798e85-6518-4aa1-bc92-197bfecfa87c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_42708aea-bd65-45df-830c-e698caebd2ed" xlink:to="loc_dei_DocumentAccountingStandard_4a798e85-6518-4aa1-bc92-197bfecfa87c" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_ce9fdf91-5bb0-4e34-a817-5d52c049bfb5" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_42708aea-bd65-45df-830c-e698caebd2ed" xlink:to="loc_dei_EntityShellCompany_ce9fdf91-5bb0-4e34-a817-5d52c049bfb5" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_ec92ed22-1e89-471b-8c6e-5e9c4d0fd62b" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_42708aea-bd65-45df-830c-e698caebd2ed" xlink:to="loc_dei_EntityCentralIndexKey_ec92ed22-1e89-471b-8c6e-5e9c4d0fd62b" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_93ec7050-400d-4dea-b081-1eefb83f6b28" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_42708aea-bd65-45df-830c-e698caebd2ed" xlink:to="loc_dei_DocumentFiscalYearFocus_93ec7050-400d-4dea-b081-1eefb83f6b28" xlink:type="arc" order="34"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_0ecf8d3d-4dfc-496a-833a-e58af6e8952a" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_42708aea-bd65-45df-830c-e698caebd2ed" xlink:to="loc_dei_DocumentFiscalPeriodFocus_0ecf8d3d-4dfc-496a-833a-e58af6e8952a" xlink:type="arc" order="35"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_ca88c859-b304-4433-ac3e-a70e4ec604cf" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_42708aea-bd65-45df-830c-e698caebd2ed" xlink:to="loc_dei_AmendmentFlag_ca88c859-b304-4433-ac3e-a70e4ec604cf" xlink:type="arc" order="36"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_9e71d5e6-cde4-4746-80df-218a2bfefebc" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_42708aea-bd65-45df-830c-e698caebd2ed" xlink:to="loc_dei_EntityPublicFloat_9e71d5e6-cde4-4746-80df-218a2bfefebc" xlink:type="arc" order="37"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" xlink:type="simple" xlink:href="oncyf-20241231.xsd#CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityLineItems_129db49e-c3f1-443d-8ae4-6449f4a9ab21" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfChangesInEquityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityTable_05bc91ac-be2a-4dbf-ab0b-6961e7a911d9" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfChangesInEquityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_129db49e-c3f1-443d-8ae4-6449f4a9ab21" xlink:to="loc_ifrs-full_StatementOfChangesInEquityTable_05bc91ac-be2a-4dbf-ab0b-6961e7a911d9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_c5021a96-e0c1-4268-9c5e-58a558057605" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_05bc91ac-be2a-4dbf-ab0b-6961e7a911d9" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_c5021a96-e0c1-4268-9c5e-58a558057605" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityDomain_c5021a96-e0c1-4268-9c5e-58a558057605_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_c5021a96-e0c1-4268-9c5e-58a558057605" xlink:to="loc_ifrs-full_ComponentsOfEquityDomain_c5021a96-e0c1-4268-9c5e-58a558057605_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityDomain_6d83655d-020c-4244-8bb0-ddb9721009b3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_c5021a96-e0c1-4268-9c5e-58a558057605" xlink:to="loc_ifrs-full_ComponentsOfEquityDomain_6d83655d-020c-4244-8bb0-ddb9721009b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember_04fdee9b-111f-48c8-9826-88cc6ac673f9" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_6d83655d-020c-4244-8bb0-ddb9721009b3" xlink:to="loc_ifrs-full_IssuedCapitalMember_04fdee9b-111f-48c8-9826-88cc6ac673f9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WarrantsMember_bd44702f-5751-4e3f-8832-f4c3eece05fc" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_6d83655d-020c-4244-8bb0-ddb9721009b3" xlink:to="loc_ifrs-full_WarrantsMember_bd44702f-5751-4e3f-8832-f4c3eece05fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharePremiumMember_e08dc1c3-82f0-45a5-9f93-5501085e9312" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SharePremiumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_6d83655d-020c-4244-8bb0-ddb9721009b3" xlink:to="loc_ifrs-full_SharePremiumMember_e08dc1c3-82f0-45a5-9f93-5501085e9312" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_7e99e126-a0ba-4393-b72f-aa4fc7aec928" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_6d83655d-020c-4244-8bb0-ddb9721009b3" xlink:to="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_7e99e126-a0ba-4393-b72f-aa4fc7aec928" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetainedEarningsMember_66b23594-d86e-4f52-9938-19bbee3ed57c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_6d83655d-020c-4244-8bb0-ddb9721009b3" xlink:to="loc_ifrs-full_RetainedEarningsMember_66b23594-d86e-4f52-9938-19bbee3ed57c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockAxis_b0065312-ed7a-4d3a-abf8-d3deebe6a50b" xlink:href="oncyf-20241231.xsd#oncyf_SaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_05bc91ac-be2a-4dbf-ab0b-6961e7a911d9" xlink:to="loc_oncyf_SaleOfStockAxis_b0065312-ed7a-4d3a-abf8-d3deebe6a50b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockDomain_b0065312-ed7a-4d3a-abf8-d3deebe6a50b_default" xlink:href="oncyf-20241231.xsd#oncyf_SaleOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_oncyf_SaleOfStockAxis_b0065312-ed7a-4d3a-abf8-d3deebe6a50b" xlink:to="loc_oncyf_SaleOfStockDomain_b0065312-ed7a-4d3a-abf8-d3deebe6a50b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockDomain_017f7e0f-9099-439e-819b-2d2904e982bd" xlink:href="oncyf-20241231.xsd#oncyf_SaleOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_oncyf_SaleOfStockAxis_b0065312-ed7a-4d3a-abf8-d3deebe6a50b" xlink:to="loc_oncyf_SaleOfStockDomain_017f7e0f-9099-439e-819b-2d2904e982bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesUnderAtthemarketAgreementMember_62a3a456-ae4f-43a8-ac57-3258c97c9dd6" xlink:href="oncyf-20241231.xsd#oncyf_SharesUnderAtthemarketAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SaleOfStockDomain_017f7e0f-9099-439e-819b-2d2904e982bd" xlink:to="loc_oncyf_SharesUnderAtthemarketAgreementMember_62a3a456-ae4f-43a8-ac57-3258c97c9dd6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesUnderPublicOfferingMember_80dec0b2-94e8-4581-bcc0-9ac6832109e4" xlink:href="oncyf-20241231.xsd#oncyf_SharesUnderPublicOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SaleOfStockDomain_017f7e0f-9099-439e-819b-2d2904e982bd" xlink:to="loc_oncyf_SharesUnderPublicOfferingMember_80dec0b2-94e8-4581-bcc0-9ac6832109e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_b7d6a9ea-de8b-4557-9d84-6e8091cdbf16" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Equity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_129db49e-c3f1-443d-8ae4-6449f4a9ab21" xlink:to="loc_ifrs-full_Equity_b7d6a9ea-de8b-4557-9d84-6e8091cdbf16" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncome_e933a5c5-d5f2-418d-bea4-81075d1cb2cb" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComprehensiveIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_129db49e-c3f1-443d-8ae4-6449f4a9ab21" xlink:to="loc_ifrs-full_ComprehensiveIncome_e933a5c5-d5f2-418d-bea4-81075d1cb2cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_c4da153f-6ed2-41d4-91a4-f9d320679d4a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_129db49e-c3f1-443d-8ae4-6449f4a9ab21" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_c4da153f-6ed2-41d4-91a4-f9d320679d4a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity_e22ee65c-147b-486c-85fb-b00647470a47" xlink:href="oncyf-20241231.xsd#oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_129db49e-c3f1-443d-8ae4-6449f4a9ab21" xlink:to="loc_oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity_e22ee65c-147b-486c-85fb-b00647470a47" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IncreaseDecreaseThroughExpirationOfWarrantEquity_dc872d0d-dfe6-4e5c-84ac-adf7cc3a4596" xlink:href="oncyf-20241231.xsd#oncyf_IncreaseDecreaseThroughExpirationOfWarrantEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_129db49e-c3f1-443d-8ae4-6449f4a9ab21" xlink:to="loc_oncyf_IncreaseDecreaseThroughExpirationOfWarrantEquity_dc872d0d-dfe6-4e5c-84ac-adf7cc3a4596" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_e6923413-f3eb-486e-91f7-5ff764c2887e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_129db49e-c3f1-443d-8ae4-6449f4a9ab21" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_e6923413-f3eb-486e-91f7-5ff764c2887e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssueOfEquity_46f0de32-309e-472e-a5ed-9e657a8d9d5c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssueOfEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_129db49e-c3f1-443d-8ae4-6449f4a9ab21" xlink:to="loc_ifrs-full_IssueOfEquity_46f0de32-309e-472e-a5ed-9e657a8d9d5c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareIssueRelatedCost_926a6228-7ade-42dc-9db0-88537491348e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShareIssueRelatedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_129db49e-c3f1-443d-8ae4-6449f4a9ab21" xlink:to="loc_ifrs-full_ShareIssueRelatedCost_926a6228-7ade-42dc-9db0-88537491348e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_792155f3-32f2-499f-851c-e179bb77a5ee" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_129db49e-c3f1-443d-8ae4-6449f4a9ab21" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_792155f3-32f2-499f-851c-e179bb77a5ee" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_4fafa1cc-b2cf-47db-89d8-dd56575e9692" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Equity"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="oncyf-20241231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_Statement1LineItems_3b200002-44b9-436e-a6fe-a649bc7c1482" xlink:href="oncyf-20241231.xsd#oncyf_Statement1LineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_Statement1Table_6fd615fb-244a-4f3e-b8e0-6129c942852e" xlink:href="oncyf-20241231.xsd#oncyf_Statement1Table"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_oncyf_Statement1LineItems_3b200002-44b9-436e-a6fe-a649bc7c1482" xlink:to="loc_oncyf_Statement1Table_6fd615fb-244a-4f3e-b8e0-6129c942852e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockAxis_7dec98cd-724a-408e-b3c9-7b63dac198f7" xlink:href="oncyf-20241231.xsd#oncyf_SaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_oncyf_Statement1Table_6fd615fb-244a-4f3e-b8e0-6129c942852e" xlink:to="loc_oncyf_SaleOfStockAxis_7dec98cd-724a-408e-b3c9-7b63dac198f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockDomain_7dec98cd-724a-408e-b3c9-7b63dac198f7_default" xlink:href="oncyf-20241231.xsd#oncyf_SaleOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_oncyf_SaleOfStockAxis_7dec98cd-724a-408e-b3c9-7b63dac198f7" xlink:to="loc_oncyf_SaleOfStockDomain_7dec98cd-724a-408e-b3c9-7b63dac198f7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockDomain_73107b11-7ab5-430f-873a-f2004f44daa3" xlink:href="oncyf-20241231.xsd#oncyf_SaleOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_oncyf_SaleOfStockAxis_7dec98cd-724a-408e-b3c9-7b63dac198f7" xlink:to="loc_oncyf_SaleOfStockDomain_73107b11-7ab5-430f-873a-f2004f44daa3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesUnderAtthemarketAgreementMember_a563d0db-cb69-43cd-b454-682e7fb79602" xlink:href="oncyf-20241231.xsd#oncyf_SharesUnderAtthemarketAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SaleOfStockDomain_73107b11-7ab5-430f-873a-f2004f44daa3" xlink:to="loc_oncyf_SharesUnderAtthemarketAgreementMember_a563d0db-cb69-43cd-b454-682e7fb79602" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesPublicOfferingMember_35f5291d-f8d8-4078-93cc-5da3b153efbf" xlink:href="oncyf-20241231.xsd#oncyf_SharesPublicOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SaleOfStockDomain_73107b11-7ab5-430f-873a-f2004f44daa3" xlink:to="loc_oncyf_SharesPublicOfferingMember_35f5291d-f8d8-4078-93cc-5da3b153efbf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_9b6957e8-bcd4-4f14-8c73-52a2a9e8bf72" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_Statement1LineItems_3b200002-44b9-436e-a6fe-a649bc7c1482" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_9b6957e8-bcd4-4f14-8c73-52a2a9e8bf72" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_7705e43e-b6d2-4b71-8a13-9b127a86ba81" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_9b6957e8-bcd4-4f14-8c73-52a2a9e8bf72" xlink:to="loc_ifrs-full_ProfitLoss_7705e43e-b6d2-4b71-8a13-9b127a86ba81" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_f5241b7f-d325-4e1d-8349-bfb441f10d29" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_9b6957e8-bcd4-4f14-8c73-52a2a9e8bf72" xlink:to="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_f5241b7f-d325-4e1d-8349-bfb441f10d29" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_AdjustmentsForDepreciationRightOfUseAssets_87517d66-6bfd-4cfc-b451-9f1dcbb96648" xlink:href="oncyf-20241231.xsd#oncyf_AdjustmentsForDepreciationRightOfUseAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_9b6957e8-bcd4-4f14-8c73-52a2a9e8bf72" xlink:to="loc_oncyf_AdjustmentsForDepreciationRightOfUseAssets_87517d66-6bfd-4cfc-b451-9f1dcbb96648" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForSharebasedPayments_a1a20e60-0ff5-487c-83fc-df57717a9bdd" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_9b6957e8-bcd4-4f14-8c73-52a2a9e8bf72" xlink:to="loc_ifrs-full_AdjustmentsForSharebasedPayments_a1a20e60-0ff5-487c-83fc-df57717a9bdd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_c65f948c-6aae-4d69-a135-6833bda643c7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_9b6957e8-bcd4-4f14-8c73-52a2a9e8bf72" xlink:to="loc_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_c65f948c-6aae-4d69-a135-6833bda643c7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestRevenueExpense_f0c27acc-8079-48ab-bcfc-4a6b7a9acdc2" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InterestRevenueExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_9b6957e8-bcd4-4f14-8c73-52a2a9e8bf72" xlink:to="loc_ifrs-full_InterestRevenueExpense_f0c27acc-8079-48ab-bcfc-4a6b7a9acdc2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_27b2c4f0-7ea8-4023-b868-27cb521d00ef" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_9b6957e8-bcd4-4f14-8c73-52a2a9e8bf72" xlink:to="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_27b2c4f0-7ea8-4023-b868-27cb521d00ef" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives_ee0efc89-2032-4256-b5ef-f98919f40c23" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_9b6957e8-bcd4-4f14-8c73-52a2a9e8bf72" xlink:to="loc_ifrs-full_AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives_ee0efc89-2032-4256-b5ef-f98919f40c23" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_713cd881-58e2-4c26-a43b-ccce4c8136a3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseInWorkingCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_9b6957e8-bcd4-4f14-8c73-52a2a9e8bf72" xlink:to="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_713cd881-58e2-4c26-a43b-ccce4c8136a3" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperations_b4238d5d-740a-46ff-94a1-d42091f5a164" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_9b6957e8-bcd4-4f14-8c73-52a2a9e8bf72" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperations_b4238d5d-740a-46ff-94a1-d42091f5a164" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_232e60a6-8bb2-424f-b417-c3e79bcb8179" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_Statement1LineItems_3b200002-44b9-436e-a6fe-a649bc7c1482" xlink:to="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_232e60a6-8bb2-424f-b417-c3e79bcb8179" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities_3341a953-addc-4bc8-b1d5-e3e9ecbcc4a1" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_232e60a6-8bb2-424f-b417-c3e79bcb8179" xlink:to="loc_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities_3341a953-addc-4bc8-b1d5-e3e9ecbcc4a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities_9d1e1e73-07f4-452c-b8f9-396ca3415c10" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_232e60a6-8bb2-424f-b417-c3e79bcb8179" xlink:to="loc_ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities_9d1e1e73-07f4-452c-b8f9-396ca3415c10" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_f535ec7e-39a4-4e36-b210-08fba84f6764" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_232e60a6-8bb2-424f-b417-c3e79bcb8179" xlink:to="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_f535ec7e-39a4-4e36-b210-08fba84f6764" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_75ed489f-6137-4604-b969-9c88fe95292a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_232e60a6-8bb2-424f-b417-c3e79bcb8179" xlink:to="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_75ed489f-6137-4604-b969-9c88fe95292a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_2efc79cf-b409-4ef7-87ea-e3e3fceaf5db" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_Statement1LineItems_3b200002-44b9-436e-a6fe-a649bc7c1482" xlink:to="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_2efc79cf-b409-4ef7-87ea-e3e3fceaf5db" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromExerciseOfOptions_decb4891-aa49-41e1-becc-c7bba0c9f0b2" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromExerciseOfOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_2efc79cf-b409-4ef7-87ea-e3e3fceaf5db" xlink:to="loc_ifrs-full_ProceedsFromExerciseOfOptions_decb4891-aa49-41e1-becc-c7bba0c9f0b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromExerciseOfWarrants_40746820-d6c9-462e-a214-183d14c580a7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromExerciseOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_2efc79cf-b409-4ef7-87ea-e3e3fceaf5db" xlink:to="loc_ifrs-full_ProceedsFromExerciseOfWarrants_40746820-d6c9-462e-a214-183d14c580a7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromIssuingShares_ae70d3fc-d32c-4db6-a513-b4338924f214" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromIssuingShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_2efc79cf-b409-4ef7-87ea-e3e3fceaf5db" xlink:to="loc_ifrs-full_ProceedsFromIssuingShares_ae70d3fc-d32c-4db6-a513-b4338924f214" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashOutflowForLeases_686bbf4f-b7e9-4995-80e7-84afd27df182" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashOutflowForLeases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_2efc79cf-b409-4ef7-87ea-e3e3fceaf5db" xlink:to="loc_ifrs-full_CashOutflowForLeases_686bbf4f-b7e9-4995-80e7-84afd27df182" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_d757db46-4bc1-46f2-aa76-87878f1adbfd" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_2efc79cf-b409-4ef7-87ea-e3e3fceaf5db" xlink:to="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_d757db46-4bc1-46f2-aa76-87878f1adbfd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_b24d8711-2b41-40f0-83be-1c6e9001ceaa" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_Statement1LineItems_3b200002-44b9-436e-a6fe-a649bc7c1482" xlink:to="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_b24d8711-2b41-40f0-83be-1c6e9001ceaa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_1e89a0d1-a62c-4abf-9b44-b3bc3b77ebef" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_Statement1LineItems_3b200002-44b9-436e-a6fe-a649bc7c1482" xlink:to="loc_ifrs-full_CashAndCashEquivalents_1e89a0d1-a62c-4abf-9b44-b3bc3b77ebef" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_884ad793-4465-4a83-abb8-286faead4d24" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_Statement1LineItems_3b200002-44b9-436e-a6fe-a649bc7c1482" xlink:to="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_884ad793-4465-4a83-abb8-286faead4d24" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_09ba697f-c9f4-4ac3-983d-59aee17b4a2b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/NatureofOperationsandGoingConcernDetails" xlink:type="simple" xlink:href="oncyf-20241231.xsd#NatureofOperationsandGoingConcernDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/NatureofOperationsandGoingConcernDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_ad691967-7677-46b9-95c1-580431b08033" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_ff0c2ff5-587b-44dc-8199-0aec99cdd993" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_ad691967-7677-46b9-95c1-580431b08033" xlink:to="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_ff0c2ff5-587b-44dc-8199-0aec99cdd993" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_d906e5e7-907c-469f-987b-e41bd3241cea" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_ff0c2ff5-587b-44dc-8199-0aec99cdd993" xlink:to="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_d906e5e7-907c-469f-987b-e41bd3241cea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_d906e5e7-907c-469f-987b-e41bd3241cea_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_d906e5e7-907c-469f-987b-e41bd3241cea" xlink:to="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_d906e5e7-907c-469f-987b-e41bd3241cea_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_32423a50-cccb-4c7b-aab8-8ccdceefaa46" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_d906e5e7-907c-469f-987b-e41bd3241cea" xlink:to="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_32423a50-cccb-4c7b-aab8-8ccdceefaa46" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MajorOrdinaryShareTransactionsMember_329a8ee1-73f2-408e-a461-1b156a4f95e2" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MajorOrdinaryShareTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_32423a50-cccb-4c7b-aab8-8ccdceefaa46" xlink:to="loc_ifrs-full_MajorOrdinaryShareTransactionsMember_329a8ee1-73f2-408e-a461-1b156a4f95e2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetainedEarnings_cd4a9d8a-9400-45d9-924d-c01ccba15b6e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RetainedEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_ad691967-7677-46b9-95c1-580431b08033" xlink:to="loc_ifrs-full_RetainedEarnings_cd4a9d8a-9400-45d9-924d-c01ccba15b6e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_0bcf7909-7f2a-4f76-aedd-693d5be29217" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_ad691967-7677-46b9-95c1-580431b08033" xlink:to="loc_ifrs-full_CashAndCashEquivalents_0bcf7909-7f2a-4f76-aedd-693d5be29217" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromIssueOfOrdinaryShares_c21e41ee-98e0-4c25-b336-57b826a5d5ae" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromIssueOfOrdinaryShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_ad691967-7677-46b9-95c1-580431b08033" xlink:to="loc_ifrs-full_ProceedsFromIssueOfOrdinaryShares_c21e41ee-98e0-4c25-b336-57b826a5d5ae" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/SummaryofMaterialAccountingPoliciesScheduleofDepreciationRatesDetails" xlink:type="simple" xlink:href="oncyf-20241231.xsd#SummaryofMaterialAccountingPoliciesScheduleofDepreciationRatesDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/SummaryofMaterialAccountingPoliciesScheduleofDepreciationRatesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_3bc23387-5832-42f3-8d83-ec646bfba35e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_67630b9c-e53f-42ca-88cc-cd187f4c4bf5" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_3bc23387-5832-42f3-8d83-ec646bfba35e" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_67630b9c-e53f-42ca-88cc-cd187f4c4bf5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_8745e9af-d167-40d0-87bc-1233b4b0e06c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_67630b9c-e53f-42ca-88cc-cd187f4c4bf5" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_8745e9af-d167-40d0-87bc-1233b4b0e06c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_8745e9af-d167-40d0-87bc-1233b4b0e06c_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_8745e9af-d167-40d0-87bc-1233b4b0e06c" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_8745e9af-d167-40d0-87bc-1233b4b0e06c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_46de004d-143d-4ebb-86c6-21d7984fcb71" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_8745e9af-d167-40d0-87bc-1233b4b0e06c" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_46de004d-143d-4ebb-86c6-21d7984fcb71" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OfficeEquipmentMember_4cb04fd0-0f2d-4dba-b86f-a90ebbe8bb7b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OfficeEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_46de004d-143d-4ebb-86c6-21d7984fcb71" xlink:to="loc_ifrs-full_OfficeEquipmentMember_4cb04fd0-0f2d-4dba-b86f-a90ebbe8bb7b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_MedicalEquipmentMember_45cc275c-005a-4b74-8f9d-f7dc31470a2f" xlink:href="oncyf-20241231.xsd#oncyf_MedicalEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_46de004d-143d-4ebb-86c6-21d7984fcb71" xlink:to="loc_oncyf_MedicalEquipmentMember_45cc275c-005a-4b74-8f9d-f7dc31470a2f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComputerEquipmentMember_db3d1386-d752-4c65-963c-d953a9c81b08" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_46de004d-143d-4ebb-86c6-21d7984fcb71" xlink:to="loc_ifrs-full_ComputerEquipmentMember_db3d1386-d752-4c65-963c-d953a9c81b08" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_PropertyPlantandEquipmentAnnualDepreciationRate_24d191ab-2d08-448b-b16d-e5b2a4b182f2" xlink:href="oncyf-20241231.xsd#oncyf_PropertyPlantandEquipmentAnnualDepreciationRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_3bc23387-5832-42f3-8d83-ec646bfba35e" xlink:to="loc_oncyf_PropertyPlantandEquipmentAnnualDepreciationRate_24d191ab-2d08-448b-b16d-e5b2a4b182f2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/OtherLiabilitiesDetails" xlink:type="simple" xlink:href="oncyf-20241231.xsd#OtherLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/OtherLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_Currency1LineItems_bd9956e0-2f2e-4d3b-acd2-a8581df35763" xlink:href="oncyf-20241231.xsd#oncyf_Currency1LineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_Currency1Table_31fe1db2-031f-46a0-8af2-f39acaca1114" xlink:href="oncyf-20241231.xsd#oncyf_Currency1Table"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_oncyf_Currency1LineItems_bd9956e0-2f2e-4d3b-acd2-a8581df35763" xlink:to="loc_oncyf_Currency1Table_31fe1db2-031f-46a0-8af2-f39acaca1114" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfProvisionsAxis_ce16c17a-d312-4a2c-80a8-512e8bc102b2" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfProvisionsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_oncyf_Currency1Table_31fe1db2-031f-46a0-8af2-f39acaca1114" xlink:to="loc_ifrs-full_ClassesOfProvisionsAxis_ce16c17a-d312-4a2c-80a8-512e8bc102b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfOtherProvisionsDomain_ce16c17a-d312-4a2c-80a8-512e8bc102b2_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfOtherProvisionsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfProvisionsAxis_ce16c17a-d312-4a2c-80a8-512e8bc102b2" xlink:to="loc_ifrs-full_ClassesOfOtherProvisionsDomain_ce16c17a-d312-4a2c-80a8-512e8bc102b2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfOtherProvisionsDomain_e7f288e5-688b-41c7-b647-ded4e4844c50" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfOtherProvisionsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfProvisionsAxis_ce16c17a-d312-4a2c-80a8-512e8bc102b2" xlink:to="loc_ifrs-full_ClassesOfOtherProvisionsDomain_e7f288e5-688b-41c7-b647-ded4e4844c50" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ClinicalTrialMember_e29ade36-836f-4fda-a373-c3624f7e6ed2" xlink:href="oncyf-20241231.xsd#oncyf_ClinicalTrialMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfOtherProvisionsDomain_e7f288e5-688b-41c7-b647-ded4e4844c50" xlink:to="loc_oncyf_ClinicalTrialMember_e29ade36-836f-4fda-a373-c3624f7e6ed2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherReceivables_2dd59c03-bf51-4eb2-bba8-d79c58d104a7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_Currency1LineItems_bd9956e0-2f2e-4d3b-acd2-a8581df35763" xlink:to="loc_ifrs-full_OtherReceivables_2dd59c03-bf51-4eb2-bba8-d79c58d104a7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentLiabilities_744cbb4f-2e51-45e3-ad7f-956369e0b8f9" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_Currency1LineItems_bd9956e0-2f2e-4d3b-acd2-a8581df35763" xlink:to="loc_ifrs-full_OtherCurrentLiabilities_744cbb4f-2e51-45e3-ad7f-956369e0b8f9" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails" xlink:type="simple" xlink:href="oncyf-20241231.xsd#PropertyandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_edd63d4b-aea1-422f-814f-c338242475f3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_10ee54c3-3fd0-443a-bbce-1c10e2b6bd11" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_edd63d4b-aea1-422f-814f-c338242475f3" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_10ee54c3-3fd0-443a-bbce-1c10e2b6bd11" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_3c2781db-c855-46b5-aae7-9afbf5ede828" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_10ee54c3-3fd0-443a-bbce-1c10e2b6bd11" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_3c2781db-c855-46b5-aae7-9afbf5ede828" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_3c2781db-c855-46b5-aae7-9afbf5ede828_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_3c2781db-c855-46b5-aae7-9afbf5ede828" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_3c2781db-c855-46b5-aae7-9afbf5ede828_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_97949ae2-a2b8-4236-b6c0-5177b061036e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_3c2781db-c855-46b5-aae7-9afbf5ede828" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_97949ae2-a2b8-4236-b6c0-5177b061036e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_MedicalEquipmentMember_c8547435-f387-4a31-bc85-efe5eb0fdcb5" xlink:href="oncyf-20241231.xsd#oncyf_MedicalEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_97949ae2-a2b8-4236-b6c0-5177b061036e" xlink:to="loc_oncyf_MedicalEquipmentMember_c8547435-f387-4a31-bc85-efe5eb0fdcb5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComputerEquipmentMember_8dd33f4f-bb62-4d20-be57-3734b5984c9f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_97949ae2-a2b8-4236-b6c0-5177b061036e" xlink:to="loc_ifrs-full_ComputerEquipmentMember_8dd33f4f-bb62-4d20-be57-3734b5984c9f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OfficeEquipmentAndFurnitureMember_ab0eb0ce-bb1c-4c91-a61e-e10ddfbed877" xlink:href="oncyf-20241231.xsd#oncyf_OfficeEquipmentAndFurnitureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_97949ae2-a2b8-4236-b6c0-5177b061036e" xlink:to="loc_oncyf_OfficeEquipmentAndFurnitureMember_ab0eb0ce-bb1c-4c91-a61e-e10ddfbed877" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseholdImprovementsMember_1c0dcaaa-1d21-4592-bbcb-1cf967cd4bce" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_97949ae2-a2b8-4236-b6c0-5177b061036e" xlink:to="loc_ifrs-full_LeaseholdImprovementsMember_1c0dcaaa-1d21-4592-bbcb-1cf967cd4bce" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_5b1eef15-e79d-44ce-b848-1481aa8af886" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_10ee54c3-3fd0-443a-bbce-1c10e2b6bd11" xlink:to="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_5b1eef15-e79d-44ce-b848-1481aa8af886" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_5b1eef15-e79d-44ce-b848-1481aa8af886_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_5b1eef15-e79d-44ce-b848-1481aa8af886" xlink:to="loc_ifrs-full_CarryingAmountMember_5b1eef15-e79d-44ce-b848-1481aa8af886_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_31710b31-4b9e-4b30-a26a-b9809885b229" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_5b1eef15-e79d-44ce-b848-1481aa8af886" xlink:to="loc_ifrs-full_CarryingAmountMember_31710b31-4b9e-4b30-a26a-b9809885b229" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossCarryingAmountMember_adc1c8f0-77b8-4320-a7ff-418d12f262d9" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GrossCarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_31710b31-4b9e-4b30-a26a-b9809885b229" xlink:to="loc_ifrs-full_GrossCarryingAmountMember_adc1c8f0-77b8-4320-a7ff-418d12f262d9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember_071d3605-b065-41b1-a525-cfc15d6a8a39" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AccumulatedDepreciationAndAmortisationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_31710b31-4b9e-4b30-a26a-b9809885b229" xlink:to="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember_071d3605-b065-41b1-a525-cfc15d6a8a39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_1d04d0ce-7685-48c8-a7cb-0931d792ce58" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_edd63d4b-aea1-422f-814f-c338242475f3" xlink:to="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_1d04d0ce-7685-48c8-a7cb-0931d792ce58" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_7920ab6d-7ce2-4b6b-9ad9-4e43118a789c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_1d04d0ce-7685-48c8-a7cb-0931d792ce58" xlink:to="loc_ifrs-full_PropertyPlantAndEquipment_7920ab6d-7ce2-4b6b-9ad9-4e43118a789c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_5d88e1f6-8733-4ad6-b930-fd4a8f1d2b2a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_1d04d0ce-7685-48c8-a7cb-0931d792ce58" xlink:to="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_5d88e1f6-8733-4ad6-b930-fd4a8f1d2b2a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DepreciationPropertyPlantAndEquipment_574b32fa-2443-4cca-9c8a-810e9c56b031" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DepreciationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_1d04d0ce-7685-48c8-a7cb-0931d792ce58" xlink:to="loc_ifrs-full_DepreciationPropertyPlantAndEquipment_574b32fa-2443-4cca-9c8a-810e9c56b031" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisposalsPropertyPlantAndEquipment_31b1bcbb-c358-465b-98f2-409edfeeffd1" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisposalsPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_1d04d0ce-7685-48c8-a7cb-0931d792ce58" xlink:to="loc_ifrs-full_DisposalsPropertyPlantAndEquipment_31b1bcbb-c358-465b-98f2-409edfeeffd1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_2ebe5726-8d60-4564-82c4-0e37a4a9aa29" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LossesOnDisposalsOfPropertyPlantAndEquipment_724bcc8f-808e-4659-8b2f-3e9900c62d7f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LossesOnDisposalsOfPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_edd63d4b-aea1-422f-814f-c338242475f3" xlink:to="loc_ifrs-full_LossesOnDisposalsOfPropertyPlantAndEquipment_724bcc8f-808e-4659-8b2f-3e9900c62d7f" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="oncyf-20241231.xsd#LeasesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_315940d2-3f86-4a8d-9b73-73616a682872" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_9af68229-b09e-456d-8b80-f794a7ecb85b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_315940d2-3f86-4a8d-9b73-73616a682872" xlink:to="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_9af68229-b09e-456d-8b80-f794a7ecb85b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0b4fa815-4a26-4ee4-83b9-b5373878b7ae" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_9af68229-b09e-456d-8b80-f794a7ecb85b" xlink:to="loc_srt_RangeAxis_0b4fa815-4a26-4ee4-83b9-b5373878b7ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0b4fa815-4a26-4ee4-83b9-b5373878b7ae_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_0b4fa815-4a26-4ee4-83b9-b5373878b7ae" xlink:to="loc_srt_RangeMember_0b4fa815-4a26-4ee4-83b9-b5373878b7ae_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_69218ddc-a5f6-4e7b-b692-4bd6af3f34e7" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_0b4fa815-4a26-4ee4-83b9-b5373878b7ae" xlink:to="loc_srt_RangeMember_69218ddc-a5f6-4e7b-b692-4bd6af3f34e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_fbd24d8b-210b-461e-9a77-a0ab4e860259" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_69218ddc-a5f6-4e7b-b692-4bd6af3f34e7" xlink:to="loc_srt_MinimumMember_fbd24d8b-210b-461e-9a77-a0ab4e860259" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c1990435-4929-4a73-a20e-b1f2af832cb1" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_69218ddc-a5f6-4e7b-b692-4bd6af3f34e7" xlink:to="loc_srt_MaximumMember_c1990435-4929-4a73-a20e-b1f2af832cb1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OperatingLeaseLeaseTerm_aa9d3899-aa65-4f7f-9d4f-1933887d994c" xlink:href="oncyf-20241231.xsd#oncyf_OperatingLeaseLeaseTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_315940d2-3f86-4a8d-9b73-73616a682872" xlink:to="loc_oncyf_OperatingLeaseLeaseTerm_aa9d3899-aa65-4f7f-9d4f-1933887d994c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16_020a76d1-ee3c-46cf-85f3-73abf03355da" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_315940d2-3f86-4a8d-9b73-73616a682872" xlink:to="loc_ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16_020a76d1-ee3c-46cf-85f3-73abf03355da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsToRightofuseAssets_81cee3b4-65cf-48fa-a790-7113465f33ad" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdditionsToRightofuseAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_315940d2-3f86-4a8d-9b73-73616a682872" xlink:to="loc_ifrs-full_AdditionsToRightofuseAssets_81cee3b4-65cf-48fa-a790-7113465f33ad" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities_5dacd89d-a9ef-4261-b456-4f83b00cd1f7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_315940d2-3f86-4a8d-9b73-73616a682872" xlink:to="loc_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities_5dacd89d-a9ef-4261-b456-4f83b00cd1f7" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/LeasesTotalUndiscountedLeaseLiabilityDetails" xlink:type="simple" xlink:href="oncyf-20241231.xsd#LeasesTotalUndiscountedLeaseLiabilityDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/LeasesTotalUndiscountedLeaseLiabilityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems_3d3dc0dd-5048-4ff8-9a14-449a9f09a92d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable_2fab28b1-f1e9-4d9c-a19f-d1eb9a047183" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems_3d3dc0dd-5048-4ff8-9a14-449a9f09a92d" xlink:to="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable_2fab28b1-f1e9-4d9c-a19f-d1eb9a047183" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis_bd744922-943b-478f-ad8f-d63a1fcfff53" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MaturityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable_2fab28b1-f1e9-4d9c-a19f-d1eb9a047183" xlink:to="loc_ifrs-full_MaturityAxis_bd744922-943b-478f-ad8f-d63a1fcfff53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityDomain_bd744922-943b-478f-ad8f-d63a1fcfff53_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MaturityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MaturityAxis_bd744922-943b-478f-ad8f-d63a1fcfff53" xlink:to="loc_ifrs-full_MaturityDomain_bd744922-943b-478f-ad8f-d63a1fcfff53_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityDomain_956a361d-f41c-49fe-b944-66b84d39f1a3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MaturityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MaturityAxis_bd744922-943b-478f-ad8f-d63a1fcfff53" xlink:to="loc_ifrs-full_MaturityDomain_956a361d-f41c-49fe-b944-66b84d39f1a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember_bd5659af-1183-43c7-a516-1ba84b2c63c5" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NotLaterThanOneYearMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MaturityDomain_956a361d-f41c-49fe-b944-66b84d39f1a3" xlink:to="loc_ifrs-full_NotLaterThanOneYearMember_bd5659af-1183-43c7-a516-1ba84b2c63c5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_fa567fb4-ca49-4ba1-9ac7-440e3e773601" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MaturityDomain_956a361d-f41c-49fe-b944-66b84d39f1a3" xlink:to="loc_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_fa567fb4-ca49-4ba1-9ac7-440e3e773601" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanFiveYearsMember_27350e14-031f-4c39-b121-7917a28ebfa3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LaterThanFiveYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_MaturityDomain_956a361d-f41c-49fe-b944-66b84d39f1a3" xlink:to="loc_ifrs-full_LaterThanFiveYearsMember_27350e14-031f-4c39-b121-7917a28ebfa3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossLeaseLiabilities_bfa64410-fac5-4f20-a7dd-dd0bab9180f4" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GrossLeaseLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems_3d3dc0dd-5048-4ff8-9a14-449a9f09a92d" xlink:to="loc_ifrs-full_GrossLeaseLiabilities_bfa64410-fac5-4f20-a7dd-dd0bab9180f4" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/WarrantDerivativeReconciliationofChangeinFairValueofWarrantDerivativeDetails" xlink:type="simple" xlink:href="oncyf-20241231.xsd#WarrantDerivativeReconciliationofChangeinFairValueofWarrantDerivativeDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/WarrantDerivativeReconciliationofChangeinFairValueofWarrantDerivativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_5f64db07-5a22-4871-8543-841ed3745768" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_ebcf3929-eed5-49b7-921a-520ed50db3f1" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_5f64db07-5a22-4871-8543-841ed3745768" xlink:to="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_ebcf3929-eed5-49b7-921a-520ed50db3f1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesAxis_9a078e6d-e774-4f32-b060-8607bb7f7cf7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfLiabilitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_ebcf3929-eed5-49b7-921a-520ed50db3f1" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesAxis_9a078e6d-e774-4f32-b060-8607bb7f7cf7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesDomain_9a078e6d-e774-4f32-b060-8607bb7f7cf7_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfLiabilitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_9a078e6d-e774-4f32-b060-8607bb7f7cf7" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesDomain_9a078e6d-e774-4f32-b060-8607bb7f7cf7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesDomain_d22403a2-e174-49f3-a4fb-87804030b7ff" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfLiabilitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_9a078e6d-e774-4f32-b060-8607bb7f7cf7" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesDomain_d22403a2-e174-49f3-a4fb-87804030b7ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WarrantsMember_87f2329e-8f38-469c-9db5-52bc8f28e07a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesDomain_d22403a2-e174-49f3-a4fb-87804030b7ff" xlink:to="loc_ifrs-full_WarrantsMember_87f2329e-8f38-469c-9db5-52bc8f28e07a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_NumberOfWarrantsOutstandingRollForward_b6414dbd-c1af-46f0-b74a-47a07edc1f22" xlink:href="oncyf-20241231.xsd#oncyf_NumberOfWarrantsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_5f64db07-5a22-4871-8543-841ed3745768" xlink:to="loc_oncyf_NumberOfWarrantsOutstandingRollForward_b6414dbd-c1af-46f0-b74a-47a07edc1f22" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_NumberOfWarrantsOutstanding_5d8d5342-308a-4564-baaf-fecdccea4fcf" xlink:href="oncyf-20241231.xsd#oncyf_NumberOfWarrantsOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_NumberOfWarrantsOutstandingRollForward_b6414dbd-c1af-46f0-b74a-47a07edc1f22" xlink:to="loc_oncyf_NumberOfWarrantsOutstanding_5d8d5342-308a-4564-baaf-fecdccea4fcf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IssueOfEquityShares_3b6d55c1-baaa-41f4-8417-a6b2b3a46940" xlink:href="oncyf-20241231.xsd#oncyf_IssueOfEquityShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_NumberOfWarrantsOutstandingRollForward_b6414dbd-c1af-46f0-b74a-47a07edc1f22" xlink:to="loc_oncyf_IssueOfEquityShares_3b6d55c1-baaa-41f4-8417-a6b2b3a46940" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_NumberOfWarrantsExercised_af869e0b-ba0b-4f10-9195-13dfd74b5c25" xlink:href="oncyf-20241231.xsd#oncyf_NumberOfWarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_NumberOfWarrantsOutstandingRollForward_b6414dbd-c1af-46f0-b74a-47a07edc1f22" xlink:to="loc_oncyf_NumberOfWarrantsExercised_af869e0b-ba0b-4f10-9195-13dfd74b5c25" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_NumberOfWarrantsExpired_69944826-ca81-4023-bab8-d3d48787e244" xlink:href="oncyf-20241231.xsd#oncyf_NumberOfWarrantsExpired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_NumberOfWarrantsOutstandingRollForward_b6414dbd-c1af-46f0-b74a-47a07edc1f22" xlink:to="loc_oncyf_NumberOfWarrantsExpired_69944826-ca81-4023-bab8-d3d48787e244" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_NumberOfWarrantsOutstanding_2d0dca9b-98fb-4a06-a017-987f7775322e" xlink:href="oncyf-20241231.xsd#oncyf_NumberOfWarrantsOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ChangeInFairValueWarrantDerivativeRollForward_004b1347-bd7b-4e08-a3e6-cb2826cd484a" xlink:href="oncyf-20241231.xsd#oncyf_ChangeInFairValueWarrantDerivativeRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_5f64db07-5a22-4871-8543-841ed3745768" xlink:to="loc_oncyf_ChangeInFairValueWarrantDerivativeRollForward_004b1347-bd7b-4e08-a3e6-cb2826cd484a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DerivativeFinancialLiabilities_4abd9745-c027-4f70-bc6a-cbd2b31f463f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DerivativeFinancialLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_ChangeInFairValueWarrantDerivativeRollForward_004b1347-bd7b-4e08-a3e6-cb2826cd484a" xlink:to="loc_ifrs-full_DerivativeFinancialLiabilities_4abd9745-c027-4f70-bc6a-cbd2b31f463f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssueOfEquity_e00846af-fd61-4d1b-9698-3df20bdd02be" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssueOfEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_ChangeInFairValueWarrantDerivativeRollForward_004b1347-bd7b-4e08-a3e6-cb2826cd484a" xlink:to="loc_ifrs-full_IssueOfEquity_e00846af-fd61-4d1b-9698-3df20bdd02be" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantLiabilityUnamortizedDiscount_0f01ed16-6219-431b-ac07-2b87db09bd48" xlink:href="oncyf-20241231.xsd#oncyf_WarrantLiabilityUnamortizedDiscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_ChangeInFairValueWarrantDerivativeRollForward_004b1347-bd7b-4e08-a3e6-cb2826cd484a" xlink:to="loc_oncyf_WarrantLiabilityUnamortizedDiscount_0f01ed16-6219-431b-ac07-2b87db09bd48" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_FairValueOfWarrantDerivativeExercised_11eca7d4-688f-409e-b73e-3afd07f6f65c" xlink:href="oncyf-20241231.xsd#oncyf_FairValueOfWarrantDerivativeExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_ChangeInFairValueWarrantDerivativeRollForward_004b1347-bd7b-4e08-a3e6-cb2826cd484a" xlink:to="loc_oncyf_FairValueOfWarrantDerivativeExercised_11eca7d4-688f-409e-b73e-3afd07f6f65c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_FairValueOfWarrantDerivativeExpired_e6e484e8-2838-4166-967b-f467474e2b87" xlink:href="oncyf-20241231.xsd#oncyf_FairValueOfWarrantDerivativeExpired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_ChangeInFairValueWarrantDerivativeRollForward_004b1347-bd7b-4e08-a3e6-cb2826cd484a" xlink:to="loc_oncyf_FairValueOfWarrantDerivativeExpired_e6e484e8-2838-4166-967b-f467474e2b87" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantLiabilityAmortizedDiscount_05b8f104-349a-44ff-b041-bb70cd84e48e" xlink:href="oncyf-20241231.xsd#oncyf_WarrantLiabilityAmortizedDiscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_ChangeInFairValueWarrantDerivativeRollForward_004b1347-bd7b-4e08-a3e6-cb2826cd484a" xlink:to="loc_oncyf_WarrantLiabilityAmortizedDiscount_05b8f104-349a-44ff-b041-bb70cd84e48e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_26499101-f287-49d2-9cdf-b02400d0cfc6" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_ChangeInFairValueWarrantDerivativeRollForward_004b1347-bd7b-4e08-a3e6-cb2826cd484a" xlink:to="loc_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_26499101-f287-49d2-9cdf-b02400d0cfc6" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_GainsLossesFromForeignExchangeImpact_4fcf885d-9eb9-4bb4-9c45-890e20732bdf" xlink:href="oncyf-20241231.xsd#oncyf_GainsLossesFromForeignExchangeImpact"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_ChangeInFairValueWarrantDerivativeRollForward_004b1347-bd7b-4e08-a3e6-cb2826cd484a" xlink:to="loc_oncyf_GainsLossesFromForeignExchangeImpact_4fcf885d-9eb9-4bb4-9c45-890e20732bdf" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DerivativeFinancialLiabilities_ae706b75-a855-4646-bbcc-8165f6ecf651" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DerivativeFinancialLiabilities"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails" xlink:type="simple" xlink:href="oncyf-20241231.xsd#WarrantDerivativeNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_9458dace-7945-4b5a-9452-759c0ee33544" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_7ec3d1f7-be8d-4976-993f-63c22c9a5b09" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_9458dace-7945-4b5a-9452-759c0ee33544" xlink:to="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_7ec3d1f7-be8d-4976-993f-63c22c9a5b09" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_961ecf1c-2d2f-41c0-aa73-3e8afefa87e7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_7ec3d1f7-be8d-4976-993f-63c22c9a5b09" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_961ecf1c-2d2f-41c0-aa73-3e8afefa87e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_961ecf1c-2d2f-41c0-aa73-3e8afefa87e7_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_961ecf1c-2d2f-41c0-aa73-3e8afefa87e7" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_961ecf1c-2d2f-41c0-aa73-3e8afefa87e7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_3ccffb74-96e6-4937-9fdc-0725ad322ea7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_961ecf1c-2d2f-41c0-aa73-3e8afefa87e7" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_3ccffb74-96e6-4937-9fdc-0725ad322ea7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesPublicOfferingWarrantDerivativesMember_20e5957c-7688-45fc-84fd-a76c27962c21" xlink:href="oncyf-20241231.xsd#oncyf_SharesPublicOfferingWarrantDerivativesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_3ccffb74-96e6-4937-9fdc-0725ad322ea7" xlink:to="loc_oncyf_SharesPublicOfferingWarrantDerivativesMember_20e5957c-7688-45fc-84fd-a76c27962c21" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesPublicOfferingMember_4369404e-f33f-48ac-8853-c33ad8aa57cb" xlink:href="oncyf-20241231.xsd#oncyf_SharesPublicOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_3ccffb74-96e6-4937-9fdc-0725ad322ea7" xlink:to="loc_oncyf_SharesPublicOfferingMember_4369404e-f33f-48ac-8853-c33ad8aa57cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_c7821665-82dc-41c2-ab4b-be7c26288bf2" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_7ec3d1f7-be8d-4976-993f-63c22c9a5b09" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_c7821665-82dc-41c2-ab4b-be7c26288bf2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalDomain_c7821665-82dc-41c2-ab4b-be7c26288bf2_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_c7821665-82dc-41c2-ab4b-be7c26288bf2" xlink:to="loc_ifrs-full_ClassesOfShareCapitalDomain_c7821665-82dc-41c2-ab4b-be7c26288bf2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalDomain_0174ebb6-5416-4608-9e02-30f3f54d3e3f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_c7821665-82dc-41c2-ab4b-be7c26288bf2" xlink:to="loc_ifrs-full_ClassesOfShareCapitalDomain_0174ebb6-5416-4608-9e02-30f3f54d3e3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember_2ebb9fde-8c5d-434c-bd36-02b423e8ba70" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfShareCapitalDomain_0174ebb6-5416-4608-9e02-30f3f54d3e3f" xlink:to="loc_ifrs-full_IssuedCapitalMember_2ebb9fde-8c5d-434c-bd36-02b423e8ba70" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesAxis_b55dac26-9c7f-498a-8d9d-3c463c66ac53" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfLiabilitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_7ec3d1f7-be8d-4976-993f-63c22c9a5b09" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesAxis_b55dac26-9c7f-498a-8d9d-3c463c66ac53" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesDomain_b55dac26-9c7f-498a-8d9d-3c463c66ac53_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfLiabilitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_b55dac26-9c7f-498a-8d9d-3c463c66ac53" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesDomain_b55dac26-9c7f-498a-8d9d-3c463c66ac53_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesDomain_a3bdf26d-43c2-4f04-9600-3c3c7e51bfeb" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfLiabilitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_b55dac26-9c7f-498a-8d9d-3c463c66ac53" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesDomain_a3bdf26d-43c2-4f04-9600-3c3c7e51bfeb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WarrantsMember_1159d38e-7538-4f86-b368-0dcc44f7f2b6" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesDomain_a3bdf26d-43c2-4f04-9600-3c3c7e51bfeb" xlink:to="loc_ifrs-full_WarrantsMember_1159d38e-7538-4f86-b368-0dcc44f7f2b6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_75f8f8e3-7bd7-4ba9-9233-924d8cfc08a8" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_7ec3d1f7-be8d-4976-993f-63c22c9a5b09" xlink:to="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_75f8f8e3-7bd7-4ba9-9233-924d8cfc08a8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LevelsOfFairValueHierarchyDomain_75f8f8e3-7bd7-4ba9-9233-924d8cfc08a8_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LevelsOfFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_75f8f8e3-7bd7-4ba9-9233-924d8cfc08a8" xlink:to="loc_ifrs-full_LevelsOfFairValueHierarchyDomain_75f8f8e3-7bd7-4ba9-9233-924d8cfc08a8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LevelsOfFairValueHierarchyDomain_85357a87-4896-481b-b1ee-82523048c250" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LevelsOfFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_75f8f8e3-7bd7-4ba9-9233-924d8cfc08a8" xlink:to="loc_ifrs-full_LevelsOfFairValueHierarchyDomain_85357a87-4896-481b-b1ee-82523048c250" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Level2OfFairValueHierarchyMember_13185351-b8d1-4a3d-9bf4-51e251735e6e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Level2OfFairValueHierarchyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LevelsOfFairValueHierarchyDomain_85357a87-4896-481b-b1ee-82523048c250" xlink:to="loc_ifrs-full_Level2OfFairValueHierarchyMember_13185351-b8d1-4a3d-9bf4-51e251735e6e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_8cef4b9d-5f34-461d-9174-cf76dd241979" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_7ec3d1f7-be8d-4976-993f-63c22c9a5b09" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_8cef4b9d-5f34-461d-9174-cf76dd241979" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityDomain_8cef4b9d-5f34-461d-9174-cf76dd241979_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_8cef4b9d-5f34-461d-9174-cf76dd241979" xlink:to="loc_ifrs-full_ComponentsOfEquityDomain_8cef4b9d-5f34-461d-9174-cf76dd241979_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityDomain_a50805e7-96ee-49a1-8270-c085fde7b611" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_8cef4b9d-5f34-461d-9174-cf76dd241979" xlink:to="loc_ifrs-full_ComponentsOfEquityDomain_a50805e7-96ee-49a1-8270-c085fde7b611" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember_9fe27aa8-95c7-4f8d-9cb9-6024ed9139ed" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_a50805e7-96ee-49a1-8270-c085fde7b611" xlink:to="loc_ifrs-full_IssuedCapitalMember_9fe27aa8-95c7-4f8d-9cb9-6024ed9139ed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockAxis_6d1d893b-31f7-4a36-8100-bfd095b267e1" xlink:href="oncyf-20241231.xsd#oncyf_SaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_7ec3d1f7-be8d-4976-993f-63c22c9a5b09" xlink:to="loc_oncyf_SaleOfStockAxis_6d1d893b-31f7-4a36-8100-bfd095b267e1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockDomain_6d1d893b-31f7-4a36-8100-bfd095b267e1_default" xlink:href="oncyf-20241231.xsd#oncyf_SaleOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_oncyf_SaleOfStockAxis_6d1d893b-31f7-4a36-8100-bfd095b267e1" xlink:to="loc_oncyf_SaleOfStockDomain_6d1d893b-31f7-4a36-8100-bfd095b267e1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockDomain_26ec3a56-9ff5-49d5-80c2-bb7414e682c7" xlink:href="oncyf-20241231.xsd#oncyf_SaleOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_oncyf_SaleOfStockAxis_6d1d893b-31f7-4a36-8100-bfd095b267e1" xlink:to="loc_oncyf_SaleOfStockDomain_26ec3a56-9ff5-49d5-80c2-bb7414e682c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesPublicOfferingWarrantDerivativesMember_ccd2e716-b105-48fd-94e6-2034d7dcedeb" xlink:href="oncyf-20241231.xsd#oncyf_SharesPublicOfferingWarrantDerivativesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SaleOfStockDomain_26ec3a56-9ff5-49d5-80c2-bb7414e682c7" xlink:to="loc_oncyf_SharesPublicOfferingWarrantDerivativesMember_ccd2e716-b105-48fd-94e6-2034d7dcedeb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_NumberOfWarrantsAndSharesOutstanding_cde85d38-f163-4a46-9740-f20df67ba3c3" xlink:href="oncyf-20241231.xsd#oncyf_NumberOfWarrantsAndSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_9458dace-7945-4b5a-9452-759c0ee33544" xlink:to="loc_oncyf_NumberOfWarrantsAndSharesOutstanding_cde85d38-f163-4a46-9740-f20df67ba3c3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ProceedsFromIssueOfOrdinarySharesGross_0d99c964-1fb1-487e-9f30-745ff7d07a34" xlink:href="oncyf-20241231.xsd#oncyf_ProceedsFromIssueOfOrdinarySharesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_9458dace-7945-4b5a-9452-759c0ee33544" xlink:to="loc_oncyf_ProceedsFromIssueOfOrdinarySharesGross_0d99c964-1fb1-487e-9f30-745ff7d07a34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesIssuedPricePerShare1_51828fd5-fd52-4c3c-ba77-1a885f9f8b3a" xlink:href="oncyf-20241231.xsd#oncyf_SharesIssuedPricePerShare1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_9458dace-7945-4b5a-9452-759c0ee33544" xlink:to="loc_oncyf_SharesIssuedPricePerShare1_51828fd5-fd52-4c3c-ba77-1a885f9f8b3a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CommonSharesPerUnit_2eba0443-6427-4cfa-93b9-5d75d48cd972" xlink:href="oncyf-20241231.xsd#oncyf_CommonSharesPerUnit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_9458dace-7945-4b5a-9452-759c0ee33544" xlink:to="loc_oncyf_CommonSharesPerUnit_2eba0443-6427-4cfa-93b9-5d75d48cd972" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight1_1681a959-1b9b-4099-ab4d-8bad381efb4a" xlink:href="oncyf-20241231.xsd#oncyf_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_9458dace-7945-4b5a-9452-759c0ee33544" xlink:to="loc_oncyf_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight1_1681a959-1b9b-4099-ab4d-8bad381efb4a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantExercisePrice_69c942d7-7881-41b1-92a4-d96fdc243d29" xlink:href="oncyf-20241231.xsd#oncyf_WarrantExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_9458dace-7945-4b5a-9452-759c0ee33544" xlink:to="loc_oncyf_WarrantExercisePrice_69c942d7-7881-41b1-92a4-d96fdc243d29" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ExpirationPeriodOfOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement_8489ca19-9616-4eaf-abb2-5d9d9e436e8c" xlink:href="oncyf-20241231.xsd#oncyf_ExpirationPeriodOfOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_9458dace-7945-4b5a-9452-759c0ee33544" xlink:to="loc_oncyf_ExpirationPeriodOfOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement_8489ca19-9616-4eaf-abb2-5d9d9e436e8c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementThresholdTradingPrice_b4c647ed-83fb-4979-bbe6-3e03a0d40435" xlink:href="oncyf-20241231.xsd#oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementThresholdTradingPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_9458dace-7945-4b5a-9452-759c0ee33544" xlink:to="loc_oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementThresholdTradingPrice_b4c647ed-83fb-4979-bbe6-3e03a0d40435" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementThresholdConsecutiveTradingDays_0bb95f9e-77ab-45fa-a181-9b282fe1119d" xlink:href="oncyf-20241231.xsd#oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementThresholdConsecutiveTradingDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_9458dace-7945-4b5a-9452-759c0ee33544" xlink:to="loc_oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementThresholdConsecutiveTradingDays_0bb95f9e-77ab-45fa-a181-9b282fe1119d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementAcceleratedThresholdTradingDays_2ba12abc-cbc3-436c-a8cc-9b2ceb2813b0" xlink:href="oncyf-20241231.xsd#oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementAcceleratedThresholdTradingDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_9458dace-7945-4b5a-9452-759c0ee33544" xlink:to="loc_oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementAcceleratedThresholdTradingDays_2ba12abc-cbc3-436c-a8cc-9b2ceb2813b0" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementExpirationDays_e00c7d72-2413-4dc4-8d87-369ad69197f2" xlink:href="oncyf-20241231.xsd#oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementExpirationDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_9458dace-7945-4b5a-9452-759c0ee33544" xlink:to="loc_oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementExpirationDays_e00c7d72-2413-4dc4-8d87-369ad69197f2" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssueOfEquity_47a243ff-5725-47b3-b5e0-fae7f6b166bf" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssueOfEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_9458dace-7945-4b5a-9452-759c0ee33544" xlink:to="loc_ifrs-full_IssueOfEquity_47a243ff-5725-47b3-b5e0-fae7f6b166bf" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WarrantLiability_5da6a6fc-f42b-41ec-88ea-5d3247b59f11" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WarrantLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_9458dace-7945-4b5a-9452-759c0ee33544" xlink:to="loc_ifrs-full_WarrantLiability_5da6a6fc-f42b-41ec-88ea-5d3247b59f11" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantLiabilityUnamortizedDiscount_b087d9e1-2424-4615-9a75-1f9f1eba094f" xlink:href="oncyf-20241231.xsd#oncyf_WarrantLiabilityUnamortizedDiscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_9458dace-7945-4b5a-9452-759c0ee33544" xlink:to="loc_oncyf_WarrantLiabilityUnamortizedDiscount_b087d9e1-2424-4615-9a75-1f9f1eba094f" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantsTerm_229d463c-5995-4ea3-ab8e-5c847f3a3777" xlink:href="oncyf-20241231.xsd#oncyf_WarrantsTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_9458dace-7945-4b5a-9452-759c0ee33544" xlink:to="loc_oncyf_WarrantsTerm_229d463c-5995-4ea3-ab8e-5c847f3a3777" xlink:type="arc" order="14"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/WarrantDerivativeSummaryofAssumptionsUsedintheBlackScholesOptionPricingModelforWarrantsDetails" xlink:type="simple" xlink:href="oncyf-20241231.xsd#WarrantDerivativeSummaryofAssumptionsUsedintheBlackScholesOptionPricingModelforWarrantsDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/WarrantDerivativeSummaryofAssumptionsUsedintheBlackScholesOptionPricingModelforWarrantsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_153113ce-24b6-4f26-8f9d-5375ea6033fa" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_6a28a068-17cd-4330-bd2f-f91362034600" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_153113ce-24b6-4f26-8f9d-5375ea6033fa" xlink:to="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_6a28a068-17cd-4330-bd2f-f91362034600" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesAxis_0a47d6ba-795a-4bf4-952f-c323d37596d5" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfLiabilitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_6a28a068-17cd-4330-bd2f-f91362034600" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesAxis_0a47d6ba-795a-4bf4-952f-c323d37596d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesDomain_0a47d6ba-795a-4bf4-952f-c323d37596d5_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfLiabilitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_0a47d6ba-795a-4bf4-952f-c323d37596d5" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesDomain_0a47d6ba-795a-4bf4-952f-c323d37596d5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesDomain_2131f597-813c-47cc-933e-f49cf2cb26d3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfLiabilitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_0a47d6ba-795a-4bf4-952f-c323d37596d5" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesDomain_2131f597-813c-47cc-933e-f49cf2cb26d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WarrantsMember_5fb203eb-b2c2-43f2-b008-e766f835f1b7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesDomain_2131f597-813c-47cc-933e-f49cf2cb26d3" xlink:to="loc_ifrs-full_WarrantsMember_5fb203eb-b2c2-43f2-b008-e766f835f1b7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WeightedAverageSharePriceOtherEquityInstrumentsGranted_4ac20eb6-8261-4e92-bb00-ee81241e43cf" xlink:href="oncyf-20241231.xsd#oncyf_WeightedAverageSharePriceOtherEquityInstrumentsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_153113ce-24b6-4f26-8f9d-5375ea6033fa" xlink:to="loc_oncyf_WeightedAverageSharePriceOtherEquityInstrumentsGranted_4ac20eb6-8261-4e92-bb00-ee81241e43cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_RiskFreeInterestRateOtherEquityInstrumentsGranted_cbac7794-3221-4335-9a62-f1eb817d4067" xlink:href="oncyf-20241231.xsd#oncyf_RiskFreeInterestRateOtherEquityInstrumentsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_153113ce-24b6-4f26-8f9d-5375ea6033fa" xlink:to="loc_oncyf_RiskFreeInterestRateOtherEquityInstrumentsGranted_cbac7794-3221-4335-9a62-f1eb817d4067" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OtherEquityInstrumentsLifeOtherEquityInstrumentsGranted_4941f384-b6c6-4a86-a43d-6e88e1daf40e" xlink:href="oncyf-20241231.xsd#oncyf_OtherEquityInstrumentsLifeOtherEquityInstrumentsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_153113ce-24b6-4f26-8f9d-5375ea6033fa" xlink:to="loc_oncyf_OtherEquityInstrumentsLifeOtherEquityInstrumentsGranted_4941f384-b6c6-4a86-a43d-6e88e1daf40e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ExpectedVolatilityOtherEquityInstrumentsGranted_cf7ac625-40fa-40d7-8aee-0702aae90291" xlink:href="oncyf-20241231.xsd#oncyf_ExpectedVolatilityOtherEquityInstrumentsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_153113ce-24b6-4f26-8f9d-5375ea6033fa" xlink:to="loc_oncyf_ExpectedVolatilityOtherEquityInstrumentsGranted_cf7ac625-40fa-40d7-8aee-0702aae90291" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted_aa199a42-8817-4471-96d4-5c07d6f28be8" xlink:href="oncyf-20241231.xsd#oncyf_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_153113ce-24b6-4f26-8f9d-5375ea6033fa" xlink:to="loc_oncyf_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted_aa199a42-8817-4471-96d4-5c07d6f28be8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted_2c581523-804e-4f2c-83f2-96c87ee0e57d" xlink:href="oncyf-20241231.xsd#oncyf_WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_153113ce-24b6-4f26-8f9d-5375ea6033fa" xlink:to="loc_oncyf_WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted_2c581523-804e-4f2c-83f2-96c87ee0e57d" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails" xlink:type="simple" xlink:href="oncyf-20241231.xsd#ShareCapitalScheduleofShareCapitalDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_5d935d0c-44e8-4d52-96aa-37a3025ff305" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_e92a8ee5-eb02-4b93-b44a-a10beeb94814" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_5d935d0c-44e8-4d52-96aa-37a3025ff305" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_e92a8ee5-eb02-4b93-b44a-a10beeb94814" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_c1acdbc7-cf1f-4e74-9a6b-06134eb6f82d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_e92a8ee5-eb02-4b93-b44a-a10beeb94814" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_c1acdbc7-cf1f-4e74-9a6b-06134eb6f82d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_c1acdbc7-cf1f-4e74-9a6b-06134eb6f82d_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_c1acdbc7-cf1f-4e74-9a6b-06134eb6f82d" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_c1acdbc7-cf1f-4e74-9a6b-06134eb6f82d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_b420cc40-f631-4301-be1d-8d11d4bc817d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_c1acdbc7-cf1f-4e74-9a6b-06134eb6f82d" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_b420cc40-f631-4301-be1d-8d11d4bc817d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesUnderStockOptionPlanMember_2b66803d-d3e1-499c-bb0e-2cc6c1f583f2" xlink:href="oncyf-20241231.xsd#oncyf_SharesUnderStockOptionPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_b420cc40-f631-4301-be1d-8d11d4bc817d" xlink:to="loc_oncyf_SharesUnderStockOptionPlanMember_2b66803d-d3e1-499c-bb0e-2cc6c1f583f2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesUnderIncentiveAwardPlanMember_1ed32200-3010-4787-9328-413b0bde62f1" xlink:href="oncyf-20241231.xsd#oncyf_SharesUnderIncentiveAwardPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_b420cc40-f631-4301-be1d-8d11d4bc817d" xlink:to="loc_oncyf_SharesUnderIncentiveAwardPlanMember_1ed32200-3010-4787-9328-413b0bde62f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesPublicOfferingMember_9703667b-bccb-448a-b82b-de847d26f7e7" xlink:href="oncyf-20241231.xsd#oncyf_SharesPublicOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_b420cc40-f631-4301-be1d-8d11d4bc817d" xlink:to="loc_oncyf_SharesPublicOfferingMember_9703667b-bccb-448a-b82b-de847d26f7e7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesPublicOfferingWarrantDerivativesMember_9b884cb0-8273-444c-a375-8b2ad6199329" xlink:href="oncyf-20241231.xsd#oncyf_SharesPublicOfferingWarrantDerivativesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_b420cc40-f631-4301-be1d-8d11d4bc817d" xlink:to="loc_oncyf_SharesPublicOfferingWarrantDerivativesMember_9b884cb0-8273-444c-a375-8b2ad6199329" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_6a259025-6dfa-419e-acf7-a9f3dd29adef" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_e92a8ee5-eb02-4b93-b44a-a10beeb94814" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_6a259025-6dfa-419e-acf7-a9f3dd29adef" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityDomain_6a259025-6dfa-419e-acf7-a9f3dd29adef_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_6a259025-6dfa-419e-acf7-a9f3dd29adef" xlink:to="loc_ifrs-full_ComponentsOfEquityDomain_6a259025-6dfa-419e-acf7-a9f3dd29adef_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityDomain_4e525b1f-232f-4207-a6b8-fc6f43126f02" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_6a259025-6dfa-419e-acf7-a9f3dd29adef" xlink:to="loc_ifrs-full_ComponentsOfEquityDomain_4e525b1f-232f-4207-a6b8-fc6f43126f02" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember_fd1c4432-f5ea-4660-b297-99a1fe4fd09a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_4e525b1f-232f-4207-a6b8-fc6f43126f02" xlink:to="loc_ifrs-full_IssuedCapitalMember_fd1c4432-f5ea-4660-b297-99a1fe4fd09a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockAxis_de1c4325-6b21-4e62-ae91-83bfe3834c4a" xlink:href="oncyf-20241231.xsd#oncyf_SaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_e92a8ee5-eb02-4b93-b44a-a10beeb94814" xlink:to="loc_oncyf_SaleOfStockAxis_de1c4325-6b21-4e62-ae91-83bfe3834c4a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockDomain_de1c4325-6b21-4e62-ae91-83bfe3834c4a_default" xlink:href="oncyf-20241231.xsd#oncyf_SaleOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_oncyf_SaleOfStockAxis_de1c4325-6b21-4e62-ae91-83bfe3834c4a" xlink:to="loc_oncyf_SaleOfStockDomain_de1c4325-6b21-4e62-ae91-83bfe3834c4a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockDomain_531cef6a-184d-475b-a29a-ff75470eb3e0" xlink:href="oncyf-20241231.xsd#oncyf_SaleOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_oncyf_SaleOfStockAxis_de1c4325-6b21-4e62-ae91-83bfe3834c4a" xlink:to="loc_oncyf_SaleOfStockDomain_531cef6a-184d-475b-a29a-ff75470eb3e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesUnderAtthemarketAgreementMember_4d378817-d018-4b5f-bfbe-05d83374da02" xlink:href="oncyf-20241231.xsd#oncyf_SharesUnderAtthemarketAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SaleOfStockDomain_531cef6a-184d-475b-a29a-ff75470eb3e0" xlink:to="loc_oncyf_SharesUnderAtthemarketAgreementMember_4d378817-d018-4b5f-bfbe-05d83374da02" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesPublicOfferingWarrantDerivativesMember_34bcb33e-efbc-414c-a2ec-5b667e7442a2" xlink:href="oncyf-20241231.xsd#oncyf_SharesPublicOfferingWarrantDerivativesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SaleOfStockDomain_531cef6a-184d-475b-a29a-ff75470eb3e0" xlink:to="loc_oncyf_SharesPublicOfferingWarrantDerivativesMember_34bcb33e-efbc-414c-a2ec-5b667e7442a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesPublicOfferingMember_0d867ab1-8613-43ab-b86e-2d66bd321834" xlink:href="oncyf-20241231.xsd#oncyf_SharesPublicOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SaleOfStockDomain_531cef6a-184d-475b-a29a-ff75470eb3e0" xlink:to="loc_oncyf_SharesPublicOfferingMember_0d867ab1-8613-43ab-b86e-2d66bd321834" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ShareCapitalNumberSharesAbstract_6fbc3ae9-fb16-4a98-903f-c260befd2856" xlink:href="oncyf-20241231.xsd#oncyf_ShareCapitalNumberSharesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_5d935d0c-44e8-4d52-96aa-37a3025ff305" xlink:to="loc_oncyf_ShareCapitalNumberSharesAbstract_6fbc3ae9-fb16-4a98-903f-c260befd2856" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesIssued_f3cf7167-9c74-4dfa-845f-2c986414e7fb" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_ShareCapitalNumberSharesAbstract_6fbc3ae9-fb16-4a98-903f-c260befd2856" xlink:to="loc_ifrs-full_NumberOfSharesIssued_f3cf7167-9c74-4dfa-845f-2c986414e7fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IssueOfEquityShares_93205b5b-4143-4fee-9eb1-7220a9564fb8" xlink:href="oncyf-20241231.xsd#oncyf_IssueOfEquityShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_ShareCapitalNumberSharesAbstract_6fbc3ae9-fb16-4a98-903f-c260befd2856" xlink:to="loc_oncyf_IssueOfEquityShares_93205b5b-4143-4fee-9eb1-7220a9564fb8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesIssued_9da19cfc-5965-4127-9d57-bc23b062eb62" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ShareCapitalAmountAbstract_f7e575a4-0f80-4cf3-b897-9a8cdfd85f63" xlink:href="oncyf-20241231.xsd#oncyf_ShareCapitalAmountAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_5d935d0c-44e8-4d52-96aa-37a3025ff305" xlink:to="loc_oncyf_ShareCapitalAmountAbstract_f7e575a4-0f80-4cf3-b897-9a8cdfd85f63" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_9518798f-b59b-4ce2-83b0-f0d644115347" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Equity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_ShareCapitalAmountAbstract_f7e575a4-0f80-4cf3-b897-9a8cdfd85f63" xlink:to="loc_ifrs-full_Equity_9518798f-b59b-4ce2-83b0-f0d644115347" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssueOfEquity_10d2536b-1cf6-4294-b98d-0bc1e1aafb13" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssueOfEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_ShareCapitalAmountAbstract_f7e575a4-0f80-4cf3-b897-9a8cdfd85f63" xlink:to="loc_ifrs-full_IssueOfEquity_10d2536b-1cf6-4294-b98d-0bc1e1aafb13" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareIssueRelatedCost_85a8115a-08d5-4146-b5be-8d6dd414e9e6" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShareIssueRelatedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_ShareCapitalAmountAbstract_f7e575a4-0f80-4cf3-b897-9a8cdfd85f63" xlink:to="loc_ifrs-full_ShareIssueRelatedCost_85a8115a-08d5-4146-b5be-8d6dd414e9e6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_95d827cb-bd55-41de-ae75-0f38c8fb9f84" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Equity"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails" xlink:type="simple" xlink:href="oncyf-20241231.xsd#ShareCapitalScheduleofShareCapitalFootnotesDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6e045800-7923-4b53-a96a-dc99be153fd6" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_1e751f8c-c2cc-45e3-a5c9-4dfe36c0c0af" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6e045800-7923-4b53-a96a-dc99be153fd6" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_1e751f8c-c2cc-45e3-a5c9-4dfe36c0c0af" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockAxis_29b271c0-6611-4e48-a67d-f44101334988" xlink:href="oncyf-20241231.xsd#oncyf_SaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_1e751f8c-c2cc-45e3-a5c9-4dfe36c0c0af" xlink:to="loc_oncyf_SaleOfStockAxis_29b271c0-6611-4e48-a67d-f44101334988" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockDomain_29b271c0-6611-4e48-a67d-f44101334988_default" xlink:href="oncyf-20241231.xsd#oncyf_SaleOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_oncyf_SaleOfStockAxis_29b271c0-6611-4e48-a67d-f44101334988" xlink:to="loc_oncyf_SaleOfStockDomain_29b271c0-6611-4e48-a67d-f44101334988_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockDomain_eb76200b-dffe-42d6-99d8-1e14489518a8" xlink:href="oncyf-20241231.xsd#oncyf_SaleOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_oncyf_SaleOfStockAxis_29b271c0-6611-4e48-a67d-f44101334988" xlink:to="loc_oncyf_SaleOfStockDomain_eb76200b-dffe-42d6-99d8-1e14489518a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_A2021SharesUnderAtTheMarketAgreementUnitedStatesMember_1170b158-0f3f-4914-83d5-3cf7485ab3f7" xlink:href="oncyf-20241231.xsd#oncyf_A2021SharesUnderAtTheMarketAgreementUnitedStatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SaleOfStockDomain_eb76200b-dffe-42d6-99d8-1e14489518a8" xlink:to="loc_oncyf_A2021SharesUnderAtTheMarketAgreementUnitedStatesMember_1170b158-0f3f-4914-83d5-3cf7485ab3f7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_A2022SharesUnderAtTheMarketAgreementUnitedStatesMember_e4034eea-9452-4403-9772-038948601a8a" xlink:href="oncyf-20241231.xsd#oncyf_A2022SharesUnderAtTheMarketAgreementUnitedStatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SaleOfStockDomain_eb76200b-dffe-42d6-99d8-1e14489518a8" xlink:to="loc_oncyf_A2022SharesUnderAtTheMarketAgreementUnitedStatesMember_e4034eea-9452-4403-9772-038948601a8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesPublicOfferingMember_4f49afc3-7c8b-421f-912b-444dad4610f5" xlink:href="oncyf-20241231.xsd#oncyf_SharesPublicOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SaleOfStockDomain_eb76200b-dffe-42d6-99d8-1e14489518a8" xlink:to="loc_oncyf_SharesPublicOfferingMember_4f49afc3-7c8b-421f-912b-444dad4610f5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_A2024SharesUnderAtTheMarketAgreementUnitedStatesMember_1455b0d5-330a-43b2-9d08-33b7a208a670" xlink:href="oncyf-20241231.xsd#oncyf_A2024SharesUnderAtTheMarketAgreementUnitedStatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SaleOfStockDomain_eb76200b-dffe-42d6-99d8-1e14489518a8" xlink:to="loc_oncyf_A2024SharesUnderAtTheMarketAgreementUnitedStatesMember_1455b0d5-330a-43b2-9d08-33b7a208a670" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesAxis_f332b20b-9848-4c4d-aa74-4dcc37621ebd" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfLiabilitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_1e751f8c-c2cc-45e3-a5c9-4dfe36c0c0af" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesAxis_f332b20b-9848-4c4d-aa74-4dcc37621ebd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesDomain_f332b20b-9848-4c4d-aa74-4dcc37621ebd_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfLiabilitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_f332b20b-9848-4c4d-aa74-4dcc37621ebd" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesDomain_f332b20b-9848-4c4d-aa74-4dcc37621ebd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesDomain_dc39673d-ee3d-47cc-ab71-588a8a0d63c2" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfLiabilitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_f332b20b-9848-4c4d-aa74-4dcc37621ebd" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesDomain_dc39673d-ee3d-47cc-ab71-588a8a0d63c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WarrantsMember_6790771d-cc42-4aa2-8658-06607cfc1609" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesDomain_dc39673d-ee3d-47cc-ab71-588a8a0d63c2" xlink:to="loc_ifrs-full_WarrantsMember_6790771d-cc42-4aa2-8658-06607cfc1609" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_0f3db73a-3ef4-4ec0-9e8f-586a42160370" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_1e751f8c-c2cc-45e3-a5c9-4dfe36c0c0af" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_0f3db73a-3ef4-4ec0-9e8f-586a42160370" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_0f3db73a-3ef4-4ec0-9e8f-586a42160370_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_0f3db73a-3ef4-4ec0-9e8f-586a42160370" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_0f3db73a-3ef4-4ec0-9e8f-586a42160370_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_6ade69a2-a41f-4780-9ef1-8cdabe894a44" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_0f3db73a-3ef4-4ec0-9e8f-586a42160370" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_6ade69a2-a41f-4780-9ef1-8cdabe894a44" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CompensationWarrantsMember_b43480bb-b302-4935-8108-bd0d4989365a" xlink:href="oncyf-20241231.xsd#oncyf_CompensationWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_6ade69a2-a41f-4780-9ef1-8cdabe894a44" xlink:to="loc_oncyf_CompensationWarrantsMember_b43480bb-b302-4935-8108-bd0d4989365a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_6056e39c-5f4a-4225-9724-aff0d8cd0101" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_1e751f8c-c2cc-45e3-a5c9-4dfe36c0c0af" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_6056e39c-5f4a-4225-9724-aff0d8cd0101" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityDomain_6056e39c-5f4a-4225-9724-aff0d8cd0101_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_6056e39c-5f4a-4225-9724-aff0d8cd0101" xlink:to="loc_ifrs-full_ComponentsOfEquityDomain_6056e39c-5f4a-4225-9724-aff0d8cd0101_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityDomain_e69b0ff7-fbbc-4769-b051-99ae25c5e3f3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_6056e39c-5f4a-4225-9724-aff0d8cd0101" xlink:to="loc_ifrs-full_ComponentsOfEquityDomain_e69b0ff7-fbbc-4769-b051-99ae25c5e3f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharePremiumMember_8861108d-25f4-467f-bc13-b40498738f5e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SharePremiumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_e69b0ff7-fbbc-4769-b051-99ae25c5e3f3" xlink:to="loc_ifrs-full_SharePremiumMember_8861108d-25f4-467f-bc13-b40498738f5e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharePurchaseAgreementAmount_bb80b48c-dc8a-45ee-a89d-ddd53f4885c9" xlink:href="oncyf-20241231.xsd#oncyf_SharePurchaseAgreementAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6e045800-7923-4b53-a96a-dc99be153fd6" xlink:to="loc_oncyf_SharePurchaseAgreementAmount_bb80b48c-dc8a-45ee-a89d-ddd53f4885c9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharePurchaseAgreementTerm_7004ddd5-a1da-4a35-88d7-993cc9859afb" xlink:href="oncyf-20241231.xsd#oncyf_SharePurchaseAgreementTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6e045800-7923-4b53-a96a-dc99be153fd6" xlink:to="loc_oncyf_SharePurchaseAgreementTerm_7004ddd5-a1da-4a35-88d7-993cc9859afb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IssueOfEquityShares_e2f16619-2be1-4aaf-aad3-d8a46b0a406e" xlink:href="oncyf-20241231.xsd#oncyf_IssueOfEquityShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6e045800-7923-4b53-a96a-dc99be153fd6" xlink:to="loc_oncyf_IssueOfEquityShares_e2f16619-2be1-4aaf-aad3-d8a46b0a406e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ProceedsFromIssueOfOrdinarySharesGross_4d054e5c-6ff0-40b1-85b3-6b6036300cc5" xlink:href="oncyf-20241231.xsd#oncyf_ProceedsFromIssueOfOrdinarySharesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6e045800-7923-4b53-a96a-dc99be153fd6" xlink:to="loc_oncyf_ProceedsFromIssueOfOrdinarySharesGross_4d054e5c-6ff0-40b1-85b3-6b6036300cc5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesIssuedPricePerShare1_361e719a-d24a-48dc-aacb-684e0f8f0c06" xlink:href="oncyf-20241231.xsd#oncyf_SharesIssuedPricePerShare1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6e045800-7923-4b53-a96a-dc99be153fd6" xlink:to="loc_oncyf_SharesIssuedPricePerShare1_361e719a-d24a-48dc-aacb-684e0f8f0c06" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromIssueOfOrdinaryShares_eca6fe0b-febd-4587-9359-8fc222c81d8b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromIssueOfOrdinaryShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6e045800-7923-4b53-a96a-dc99be153fd6" xlink:to="loc_ifrs-full_ProceedsFromIssueOfOrdinaryShares_eca6fe0b-febd-4587-9359-8fc222c81d8b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ShareIssueRelatedCostCommissions_5db29b5b-0a3a-4fff-90e3-2953077cfed0" xlink:href="oncyf-20241231.xsd#oncyf_ShareIssueRelatedCostCommissions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6e045800-7923-4b53-a96a-dc99be153fd6" xlink:to="loc_oncyf_ShareIssueRelatedCostCommissions_5db29b5b-0a3a-4fff-90e3-2953077cfed0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareIssueRelatedCost_b5d0e328-16bb-40ed-aae8-b2a74bfdb145" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShareIssueRelatedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6e045800-7923-4b53-a96a-dc99be153fd6" xlink:to="loc_ifrs-full_ShareIssueRelatedCost_b5d0e328-16bb-40ed-aae8-b2a74bfdb145" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_NumberOfWarrantsAndSharesOutstanding_15dad989-cc5c-4cfe-a799-9cb151b1aa87" xlink:href="oncyf-20241231.xsd#oncyf_NumberOfWarrantsAndSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6e045800-7923-4b53-a96a-dc99be153fd6" xlink:to="loc_oncyf_NumberOfWarrantsAndSharesOutstanding_15dad989-cc5c-4cfe-a799-9cb151b1aa87" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IssueOfEquitySharesNumberOfCommonShares_bd985b8d-b1ce-47f9-96dd-218a22e30645" xlink:href="oncyf-20241231.xsd#oncyf_IssueOfEquitySharesNumberOfCommonShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6e045800-7923-4b53-a96a-dc99be153fd6" xlink:to="loc_oncyf_IssueOfEquitySharesNumberOfCommonShares_bd985b8d-b1ce-47f9-96dd-218a22e30645" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IssueOfEquitySharesNumberOfWarrants_8c149078-d9ed-4b70-b834-b6a5261f3bc1" xlink:href="oncyf-20241231.xsd#oncyf_IssueOfEquitySharesNumberOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6e045800-7923-4b53-a96a-dc99be153fd6" xlink:to="loc_oncyf_IssueOfEquitySharesNumberOfWarrants_8c149078-d9ed-4b70-b834-b6a5261f3bc1" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssueOfEquity_a1af974a-3700-41ab-8b49-8275950c460d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssueOfEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6e045800-7923-4b53-a96a-dc99be153fd6" xlink:to="loc_ifrs-full_IssueOfEquity_a1af974a-3700-41ab-8b49-8275950c460d" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WarrantLiability_5e9ce00f-e394-4631-88fa-42d8876185a8" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WarrantLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6e045800-7923-4b53-a96a-dc99be153fd6" xlink:to="loc_ifrs-full_WarrantLiability_5e9ce00f-e394-4631-88fa-42d8876185a8" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_832c2202-5932-4bf7-b08c-ea52c502e8c6" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6e045800-7923-4b53-a96a-dc99be153fd6" xlink:to="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_832c2202-5932-4bf7-b08c-ea52c502e8c6" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ShareWarrantsIssuedTransactionCosts_25157225-63df-4843-9a70-9b3494877384" xlink:href="oncyf-20241231.xsd#oncyf_ShareWarrantsIssuedTransactionCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6e045800-7923-4b53-a96a-dc99be153fd6" xlink:to="loc_oncyf_ShareWarrantsIssuedTransactionCosts_25157225-63df-4843-9a70-9b3494877384" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees_7ca750a1-e6a7-4c56-b2f4-8834cf420923" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6e045800-7923-4b53-a96a-dc99be153fd6" xlink:to="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees_7ca750a1-e6a7-4c56-b2f4-8834cf420923" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ShareWarrantsIssuedOperatingExpense_89b6ede9-3e87-46ee-af45-0cc4a768cf48" xlink:href="oncyf-20241231.xsd#oncyf_ShareWarrantsIssuedOperatingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6e045800-7923-4b53-a96a-dc99be153fd6" xlink:to="loc_oncyf_ShareWarrantsIssuedOperatingExpense_89b6ede9-3e87-46ee-af45-0cc4a768cf48" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_NumberOfWarrantsExercised_472c3465-4dd4-405f-a0f8-52328b63077d" xlink:href="oncyf-20241231.xsd#oncyf_NumberOfWarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6e045800-7923-4b53-a96a-dc99be153fd6" xlink:to="loc_oncyf_NumberOfWarrantsExercised_472c3465-4dd4-405f-a0f8-52328b63077d" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantsExercised_4cbad192-e370-4f04-b416-e4eeb0c3a2bf" xlink:href="oncyf-20241231.xsd#oncyf_WarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6e045800-7923-4b53-a96a-dc99be153fd6" xlink:to="loc_oncyf_WarrantsExercised_4cbad192-e370-4f04-b416-e4eeb0c3a2bf" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ProceedsfromWarrantExercises1_1c3331c7-2a76-4348-bd42-d021f6b4b4e5" xlink:href="oncyf-20241231.xsd#oncyf_ProceedsfromWarrantExercises1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6e045800-7923-4b53-a96a-dc99be153fd6" xlink:to="loc_oncyf_ProceedsfromWarrantExercises1_1c3331c7-2a76-4348-bd42-d021f6b4b4e5" xlink:type="arc" order="19"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="oncyf-20241231.xsd#ShareBasedCompensationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_e61bb7f7-be72-4dcc-abba-f9ca7a29d298" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_24411ed0-a660-4e95-b6df-1b155e29d01b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_e61bb7f7-be72-4dcc-abba-f9ca7a29d298" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_24411ed0-a660-4e95-b6df-1b155e29d01b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_26c8102e-4945-423c-8c01-82200f906796" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_24411ed0-a660-4e95-b6df-1b155e29d01b" xlink:to="loc_ifrs-full_RangeAxis_26c8102e-4945-423c-8c01-82200f906796" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeDomain_26c8102e-4945-423c-8c01-82200f906796_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RangeAxis_26c8102e-4945-423c-8c01-82200f906796" xlink:to="loc_ifrs-full_RangeDomain_26c8102e-4945-423c-8c01-82200f906796_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeDomain_5c3a82d0-bd5e-493b-b3f7-fab8dd4c1b22" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RangeAxis_26c8102e-4945-423c-8c01-82200f906796" xlink:to="loc_ifrs-full_RangeDomain_5c3a82d0-bd5e-493b-b3f7-fab8dd4c1b22" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BottomOfRangeMember_00675907-36f8-4156-a42c-9d40c1848699" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BottomOfRangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangeDomain_5c3a82d0-bd5e-493b-b3f7-fab8dd4c1b22" xlink:to="loc_ifrs-full_BottomOfRangeMember_00675907-36f8-4156-a42c-9d40c1848699" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember_813f0bf2-d3a2-43e8-915f-87c6df635c0b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TopOfRangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangeDomain_5c3a82d0-bd5e-493b-b3f7-fab8dd4c1b22" xlink:to="loc_ifrs-full_TopOfRangeMember_813f0bf2-d3a2-43e8-915f-87c6df635c0b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_dfab3b7e-0e01-4c59-9936-98b195c7ed21" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_24411ed0-a660-4e95-b6df-1b155e29d01b" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_dfab3b7e-0e01-4c59-9936-98b195c7ed21" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_dfab3b7e-0e01-4c59-9936-98b195c7ed21_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_dfab3b7e-0e01-4c59-9936-98b195c7ed21" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_dfab3b7e-0e01-4c59-9936-98b195c7ed21_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_831425f6-a3a5-4d4a-ae3b-5570c70dfa66" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_dfab3b7e-0e01-4c59-9936-98b195c7ed21" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_831425f6-a3a5-4d4a-ae3b-5570c70dfa66" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReserveOfSharebasedPaymentsMember_41f50c04-b0ff-41b4-9cef-d7550e27a952" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReserveOfSharebasedPaymentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_831425f6-a3a5-4d4a-ae3b-5570c70dfa66" xlink:to="loc_ifrs-full_ReserveOfSharebasedPaymentsMember_41f50c04-b0ff-41b4-9cef-d7550e27a952" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RestrictedShareUnitsMember_0147576f-df43-49d2-ad7d-ae704637a435" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RestrictedShareUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_831425f6-a3a5-4d4a-ae3b-5570c70dfa66" xlink:to="loc_ifrs-full_RestrictedShareUnitsMember_0147576f-df43-49d2-ad7d-ae704637a435" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CompensationWarrantsMember_b4bf9c18-651f-4fa5-b9cb-0b59b53c9dd4" xlink:href="oncyf-20241231.xsd#oncyf_CompensationWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_831425f6-a3a5-4d4a-ae3b-5570c70dfa66" xlink:to="loc_oncyf_CompensationWarrantsMember_b4bf9c18-651f-4fa5-b9cb-0b59b53c9dd4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_cfe1421d-2299-4bcd-bd20-2ad924a46e59" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_24411ed0-a660-4e95-b6df-1b155e29d01b" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_cfe1421d-2299-4bcd-bd20-2ad924a46e59" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityDomain_cfe1421d-2299-4bcd-bd20-2ad924a46e59_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_cfe1421d-2299-4bcd-bd20-2ad924a46e59" xlink:to="loc_ifrs-full_ComponentsOfEquityDomain_cfe1421d-2299-4bcd-bd20-2ad924a46e59_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityDomain_b694a3b0-9b98-47ef-838e-163537cc724b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_cfe1421d-2299-4bcd-bd20-2ad924a46e59" xlink:to="loc_ifrs-full_ComponentsOfEquityDomain_b694a3b0-9b98-47ef-838e-163537cc724b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember_7083bb93-13ad-40b8-ab20-2505f71ecab5" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_b694a3b0-9b98-47ef-838e-163537cc724b" xlink:to="loc_ifrs-full_IssuedCapitalMember_7083bb93-13ad-40b8-ab20-2505f71ecab5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharePremiumMember_9505466e-8a59-435b-99a4-b4752bbc03c8" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SharePremiumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_b694a3b0-9b98-47ef-838e-163537cc724b" xlink:to="loc_ifrs-full_SharePremiumMember_9505466e-8a59-435b-99a4-b4752bbc03c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_2eb26693-3b85-445a-b2c2-fcf79f3e82cc" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_24411ed0-a660-4e95-b6df-1b155e29d01b" xlink:to="loc_srt_TitleOfIndividualAxis_2eb26693-3b85-445a-b2c2-fcf79f3e82cc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_2eb26693-3b85-445a-b2c2-fcf79f3e82cc_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_2eb26693-3b85-445a-b2c2-fcf79f3e82cc" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_2eb26693-3b85-445a-b2c2-fcf79f3e82cc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_7870e041-dea6-4447-a485-34dcffa9ec52" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_2eb26693-3b85-445a-b2c2-fcf79f3e82cc" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_7870e041-dea6-4447-a485-34dcffa9ec52" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OfficerMember_91208d88-ca46-4ea7-9274-3ad14d68cb25" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OfficerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_7870e041-dea6-4447-a485-34dcffa9ec52" xlink:to="loc_srt_OfficerMember_91208d88-ca46-4ea7-9274-3ad14d68cb25" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_f3089dea-b88b-4780-b9d3-6d41c9c1f701" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_DirectorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_7870e041-dea6-4447-a485-34dcffa9ec52" xlink:to="loc_srt_DirectorMember_f3089dea-b88b-4780-b9d3-6d41c9c1f701" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_NumberOfSharesReservedForIssueUnderOptionsAndContractsForSaleOfSharesPercentageOfCommonSharesMaximum_0f7c73be-3867-495d-bca5-a5d528873c47" xlink:href="oncyf-20241231.xsd#oncyf_NumberOfSharesReservedForIssueUnderOptionsAndContractsForSaleOfSharesPercentageOfCommonSharesMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_e61bb7f7-be72-4dcc-abba-f9ca7a29d298" xlink:to="loc_oncyf_NumberOfSharesReservedForIssueUnderOptionsAndContractsForSaleOfSharesPercentageOfCommonSharesMaximum_0f7c73be-3867-495d-bca5-a5d528873c47" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares_0a20a334-5e05-496b-b9f5-c79c81eacddd" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_e61bb7f7-be72-4dcc-abba-f9ca7a29d298" xlink:to="loc_ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares_0a20a334-5e05-496b-b9f5-c79c81eacddd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_2ef3418d-dde9-4957-b69d-94c16848a43c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_e61bb7f7-be72-4dcc-abba-f9ca7a29d298" xlink:to="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_2ef3418d-dde9-4957-b69d-94c16848a43c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1_9185cac4-6347-40c2-a648-2a0b4fabeb1c" xlink:href="oncyf-20241231.xsd#oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_e61bb7f7-be72-4dcc-abba-f9ca7a29d298" xlink:to="loc_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1_9185cac4-6347-40c2-a648-2a0b4fabeb1c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_144e6bec-c763-4db4-903d-d1cd6148ef6c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_e61bb7f7-be72-4dcc-abba-f9ca7a29d298" xlink:to="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_144e6bec-c763-4db4-903d-d1cd6148ef6c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019_89483106-4cb2-4cb7-8281-9e0b748ea2c8" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_e61bb7f7-be72-4dcc-abba-f9ca7a29d298" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019_89483106-4cb2-4cb7-8281-9e0b748ea2c8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ExpirationPeriodOfOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement_47e91be7-961c-41c1-9889-ad4782680051" xlink:href="oncyf-20241231.xsd#oncyf_ExpirationPeriodOfOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_e61bb7f7-be72-4dcc-abba-f9ca7a29d298" xlink:to="loc_oncyf_ExpirationPeriodOfOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement_47e91be7-961c-41c1-9889-ad4782680051" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees_4b490fe5-23c8-415d-8093-a330382ad5bf" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_e61bb7f7-be72-4dcc-abba-f9ca7a29d298" xlink:to="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees_4b490fe5-23c8-415d-8093-a330382ad5bf" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails" xlink:type="simple" xlink:href="oncyf-20241231.xsd#ShareBasedCompensationScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_b95f3f85-bf8b-44a2-b1a7-b1b63be41278" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_9c0a3228-1b7a-4a1a-841a-d3c34b0520cd" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_b95f3f85-bf8b-44a2-b1a7-b1b63be41278" xlink:to="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_9c0a3228-1b7a-4a1a-841a-d3c34b0520cd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_72ea339f-cc95-4f4f-ac6a-aeb80b74dc07" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_9c0a3228-1b7a-4a1a-841a-d3c34b0520cd" xlink:to="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_72ea339f-cc95-4f4f-ac6a-aeb80b74dc07" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsDomain_72ea339f-cc95-4f4f-ac6a-aeb80b74dc07_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_72ea339f-cc95-4f4f-ac6a-aeb80b74dc07" xlink:to="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsDomain_72ea339f-cc95-4f4f-ac6a-aeb80b74dc07_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsDomain_772d6870-0467-461f-95f9-61dab044e86d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_72ea339f-cc95-4f4f-ac6a-aeb80b74dc07" xlink:to="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsDomain_772d6870-0467-461f-95f9-61dab044e86d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ExercisePriceRangeOneMember_28d221f7-899c-4af4-87ac-13f3be1d5836" xlink:href="oncyf-20241231.xsd#oncyf_ExercisePriceRangeOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsDomain_772d6870-0467-461f-95f9-61dab044e86d" xlink:to="loc_oncyf_ExercisePriceRangeOneMember_28d221f7-899c-4af4-87ac-13f3be1d5836" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ExercisePriceRangeTwoMember_e9211624-390f-4523-a29b-91c8b15cca89" xlink:href="oncyf-20241231.xsd#oncyf_ExercisePriceRangeTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsDomain_772d6870-0467-461f-95f9-61dab044e86d" xlink:to="loc_oncyf_ExercisePriceRangeTwoMember_e9211624-390f-4523-a29b-91c8b15cca89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ExercisePriceRangeThreeMember_9d7e8813-e625-4608-adeb-e9b8a1694d70" xlink:href="oncyf-20241231.xsd#oncyf_ExercisePriceRangeThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsDomain_772d6870-0467-461f-95f9-61dab044e86d" xlink:to="loc_oncyf_ExercisePriceRangeThreeMember_9d7e8813-e625-4608-adeb-e9b8a1694d70" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ExercisePriceRangeFourMember_eb55c80d-68d1-4c4e-8e5e-88ecbd5fb324" xlink:href="oncyf-20241231.xsd#oncyf_ExercisePriceRangeFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsDomain_772d6870-0467-461f-95f9-61dab044e86d" xlink:to="loc_oncyf_ExercisePriceRangeFourMember_eb55c80d-68d1-4c4e-8e5e-88ecbd5fb324" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ExercisePriceRangeFiveMember_e625fbf4-048a-4eed-9425-c63b6b41e197" xlink:href="oncyf-20241231.xsd#oncyf_ExercisePriceRangeFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsDomain_772d6870-0467-461f-95f9-61dab044e86d" xlink:to="loc_oncyf_ExercisePriceRangeFiveMember_e625fbf4-048a-4eed-9425-c63b6b41e197" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_9d871a75-a5c1-41d2-956a-41739381a9e6" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_9c0a3228-1b7a-4a1a-841a-d3c34b0520cd" xlink:to="loc_ifrs-full_RangeAxis_9d871a75-a5c1-41d2-956a-41739381a9e6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeDomain_9d871a75-a5c1-41d2-956a-41739381a9e6_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RangeAxis_9d871a75-a5c1-41d2-956a-41739381a9e6" xlink:to="loc_ifrs-full_RangeDomain_9d871a75-a5c1-41d2-956a-41739381a9e6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeDomain_d09051bb-fcf3-4e4a-8047-e4ad035df7a5" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RangeAxis_9d871a75-a5c1-41d2-956a-41739381a9e6" xlink:to="loc_ifrs-full_RangeDomain_d09051bb-fcf3-4e4a-8047-e4ad035df7a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BottomOfRangeMember_515d7b22-6288-46c4-9ea2-82f58f3fdd31" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BottomOfRangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangeDomain_d09051bb-fcf3-4e4a-8047-e4ad035df7a5" xlink:to="loc_ifrs-full_BottomOfRangeMember_515d7b22-6288-46c4-9ea2-82f58f3fdd31" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember_e23c5dab-3619-4178-9203-982401be382e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TopOfRangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangeDomain_d09051bb-fcf3-4e4a-8047-e4ad035df7a5" xlink:to="loc_ifrs-full_TopOfRangeMember_e23c5dab-3619-4178-9203-982401be382e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExercisePriceOfOutstandingShareOptions2019_a99b9640-f951-4976-8bc5-80a24ba002d4" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions2019"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_b95f3f85-bf8b-44a2-b1a7-b1b63be41278" xlink:to="loc_ifrs-full_ExercisePriceOfOutstandingShareOptions2019_a99b9640-f951-4976-8bc5-80a24ba002d4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions_4b2b99cb-3cdb-42b8-81b5-ae7aad4db4ca" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOutstandingShareOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_b95f3f85-bf8b-44a2-b1a7-b1b63be41278" xlink:to="loc_ifrs-full_NumberOfOutstandingShareOptions_4b2b99cb-3cdb-42b8-81b5-ae7aad4db4ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_332c2b36-0d31-4fea-8809-9244435b842b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_b95f3f85-bf8b-44a2-b1a7-b1b63be41278" xlink:to="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_332c2b36-0d31-4fea-8809-9244435b842b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_e5ceb5e0-9971-41a8-923a-0c394783c89d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_b95f3f85-bf8b-44a2-b1a7-b1b63be41278" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_e5ceb5e0-9971-41a8-923a-0c394783c89d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_84fbeed2-e5dd-4cd8-89dc-5ab38de30ba9" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_b95f3f85-bf8b-44a2-b1a7-b1b63be41278" xlink:to="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_84fbeed2-e5dd-4cd8-89dc-5ab38de30ba9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_79e86335-d05f-43e0-b550-7413ee1d024e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_b95f3f85-bf8b-44a2-b1a7-b1b63be41278" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_79e86335-d05f-43e0-b550-7413ee1d024e" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofNumberofOtherEquityInstrumentsDetails" xlink:type="simple" xlink:href="oncyf-20241231.xsd#ShareBasedCompensationScheduleofNumberofOtherEquityInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofNumberofOtherEquityInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_1988d87a-db9e-4c85-b865-f4d99c1a23e2" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_11b838a4-7df3-4f28-9be2-653651ffc521" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_1988d87a-db9e-4c85-b865-f4d99c1a23e2" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_11b838a4-7df3-4f28-9be2-653651ffc521" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_4687e02a-1792-45cd-949a-321afc305716" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_11b838a4-7df3-4f28-9be2-653651ffc521" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_4687e02a-1792-45cd-949a-321afc305716" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_4687e02a-1792-45cd-949a-321afc305716_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_4687e02a-1792-45cd-949a-321afc305716" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_4687e02a-1792-45cd-949a-321afc305716_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_5ad9dd9c-9ff6-428b-8684-77e1ef47edd1" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_4687e02a-1792-45cd-949a-321afc305716" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_5ad9dd9c-9ff6-428b-8684-77e1ef47edd1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RestrictedShareUnitsMember_41a7624d-4e65-4b4c-9245-eb068e5879e7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RestrictedShareUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_5ad9dd9c-9ff6-428b-8684-77e1ef47edd1" xlink:to="loc_ifrs-full_RestrictedShareUnitsMember_41a7624d-4e65-4b4c-9245-eb068e5879e7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_3f1d26b0-b00e-4da5-93f0-fd36ae98fb3d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_1988d87a-db9e-4c85-b865-f4d99c1a23e2" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_3f1d26b0-b00e-4da5-93f0-fd36ae98fb3d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_b4f3fa06-5e0d-4531-bc75-94234ef0bf15" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_1988d87a-db9e-4c85-b865-f4d99c1a23e2" xlink:to="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_b4f3fa06-5e0d-4531-bc75-94234ef0bf15" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_1f5c90f2-5ee3-4e59-b640-19193bb00a43" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_1988d87a-db9e-4c85-b865-f4d99c1a23e2" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_1f5c90f2-5ee3-4e59-b640-19193bb00a43" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_8d1bcb35-c443-40a2-98d6-8faf94c644de" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_1988d87a-db9e-4c85-b865-f4d99c1a23e2" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_8d1bcb35-c443-40a2-98d6-8faf94c644de" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_9deae02e-b042-4676-84ad-e7259b8c3ef9" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted_32dbcf24-1eb6-440e-bff3-4eab5fbda214" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_1988d87a-db9e-4c85-b865-f4d99c1a23e2" xlink:to="loc_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted_32dbcf24-1eb6-440e-bff3-4eab5fbda214" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="oncyf-20241231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_5c09c441-094a-4dd7-92c7-f90c1f435ab3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_91b0e1af-7a12-4521-b52d-2e7783b45089" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_5c09c441-094a-4dd7-92c7-f90c1f435ab3" xlink:to="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_91b0e1af-7a12-4521-b52d-2e7783b45089" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_dde21995-03eb-4b49-8d84-a93fe1894b4a" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_91b0e1af-7a12-4521-b52d-2e7783b45089" xlink:to="loc_srt_StatementGeographicalAxis_dde21995-03eb-4b49-8d84-a93fe1894b4a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_dde21995-03eb-4b49-8d84-a93fe1894b4a_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_dde21995-03eb-4b49-8d84-a93fe1894b4a" xlink:to="loc_srt_SegmentGeographicalDomain_dde21995-03eb-4b49-8d84-a93fe1894b4a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_10c3a093-28fb-438e-a400-bd2f393fd673" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_dde21995-03eb-4b49-8d84-a93fe1894b4a" xlink:to="loc_srt_SegmentGeographicalDomain_10c3a093-28fb-438e-a400-bd2f393fd673" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_dca50464-b947-4be3-b111-0b6ed16dd712" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_CA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_10c3a093-28fb-438e-a400-bd2f393fd673" xlink:to="loc_country_CA_dca50464-b947-4be3-b111-0b6ed16dd712" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_BB_fff7e135-458b-4acc-9074-b3435358ba11" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_BB"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_10c3a093-28fb-438e-a400-bd2f393fd673" xlink:to="loc_country_BB_fff7e135-458b-4acc-9074-b3435358ba11" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_ead4c287-57d4-4fdb-95de-b897c1a33410" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_10c3a093-28fb-438e-a400-bd2f393fd673" xlink:to="loc_country_US_ead4c287-57d4-4fdb-95de-b897c1a33410" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_24e58b30-e75b-4938-ab67-dc37376c3c7b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_91b0e1af-7a12-4521-b52d-2e7783b45089" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_24e58b30-e75b-4938-ab67-dc37376c3c7b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain_24e58b30-e75b-4938-ab67-dc37376c3c7b_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_24e58b30-e75b-4938-ab67-dc37376c3c7b" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain_24e58b30-e75b-4938-ab67-dc37376c3c7b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain_4b02aabb-da71-42ba-9888-83162082bd89" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_24e58b30-e75b-4938-ab67-dc37376c3c7b" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain_4b02aabb-da71-42ba-9888-83162082bd89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnusedTaxLossesMember_f3c92cb1-6714-4729-bdf0-229b42251634" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_UnusedTaxLossesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain_4b02aabb-da71-42ba-9888-83162082bd89" xlink:to="loc_ifrs-full_UnusedTaxLossesMember_f3c92cb1-6714-4729-bdf0-229b42251634" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnusedTaxCreditsMember_a6d38706-ed97-42c6-9f9d-46a90629fd66" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_UnusedTaxCreditsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain_4b02aabb-da71-42ba-9888-83162082bd89" xlink:to="loc_ifrs-full_UnusedTaxCreditsMember_a6d38706-ed97-42c6-9f9d-46a90629fd66" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember_70d2cb12-dd06-48a6-af96-2d99c217a3f8" xlink:href="oncyf-20241231.xsd#oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain_4b02aabb-da71-42ba-9888-83162082bd89" xlink:to="loc_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember_70d2cb12-dd06-48a6-af96-2d99c217a3f8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_1e0d2621-666a-48ab-af02-0bafb7ae5405" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_5c09c441-094a-4dd7-92c7-f90c1f435ab3" xlink:to="loc_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_1e0d2621-666a-48ab-af02-0bafb7ae5405" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised_44bc8594-985b-4a56-af79-466bb3527c73" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_5c09c441-094a-4dd7-92c7-f90c1f435ab3" xlink:to="loc_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised_44bc8594-985b-4a56-af79-466bb3527c73" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxesScheduleofUnrecognizedDeferredTaxAssetsDetails" xlink:type="simple" xlink:href="oncyf-20241231.xsd#IncomeTaxesScheduleofUnrecognizedDeferredTaxAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/IncomeTaxesScheduleofUnrecognizedDeferredTaxAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_c665e0f7-4ad5-412f-b013-4d32aaf73916" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_7e849eea-4ac8-4f14-aede-968e26df3ca3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_c665e0f7-4ad5-412f-b013-4d32aaf73916" xlink:to="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_7e849eea-4ac8-4f14-aede-968e26df3ca3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_8f8d24d7-f38e-48ba-a79c-581677fef1dc" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_7e849eea-4ac8-4f14-aede-968e26df3ca3" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_8f8d24d7-f38e-48ba-a79c-581677fef1dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain_8f8d24d7-f38e-48ba-a79c-581677fef1dc_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_8f8d24d7-f38e-48ba-a79c-581677fef1dc" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain_8f8d24d7-f38e-48ba-a79c-581677fef1dc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain_48bb43ad-fcf7-4109-97c9-2e93cbe63979" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_8f8d24d7-f38e-48ba-a79c-581677fef1dc" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain_48bb43ad-fcf7-4109-97c9-2e93cbe63979" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_UnusedNetOperatingLossCarryForwardsMember_db9382e4-489a-4053-912b-3d7723dc3388" xlink:href="oncyf-20241231.xsd#oncyf_UnusedNetOperatingLossCarryForwardsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain_48bb43ad-fcf7-4109-97c9-2e93cbe63979" xlink:to="loc_oncyf_UnusedNetOperatingLossCarryForwardsMember_db9382e4-489a-4053-912b-3d7723dc3388" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember_03b47d8f-ce2d-49c9-b7ab-5c07473a9376" xlink:href="oncyf-20241231.xsd#oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain_48bb43ad-fcf7-4109-97c9-2e93cbe63979" xlink:to="loc_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember_03b47d8f-ce2d-49c9-b7ab-5c07473a9376" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_InvestmentTaxCreditsMember_44bd9cc1-8c05-4b81-9b5f-7284ea5fcfc8" xlink:href="oncyf-20241231.xsd#oncyf_InvestmentTaxCreditsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain_48bb43ad-fcf7-4109-97c9-2e93cbe63979" xlink:to="loc_oncyf_InvestmentTaxCreditsMember_44bd9cc1-8c05-4b81-9b5f-7284ea5fcfc8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_PropertyPlantEquipmentRelatedTemporaryDifferencesMember_bf16e1f8-d7cb-489f-9f74-bee6c8826f31" xlink:href="oncyf-20241231.xsd#oncyf_PropertyPlantEquipmentRelatedTemporaryDifferencesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain_48bb43ad-fcf7-4109-97c9-2e93cbe63979" xlink:to="loc_oncyf_PropertyPlantEquipmentRelatedTemporaryDifferencesMember_bf16e1f8-d7cb-489f-9f74-bee6c8826f31" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ShareIssueCostsMember_cedefbe2-edf2-4ae9-9548-2f46bd0e3b83" xlink:href="oncyf-20241231.xsd#oncyf_ShareIssueCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain_48bb43ad-fcf7-4109-97c9-2e93cbe63979" xlink:to="loc_oncyf_ShareIssueCostsMember_cedefbe2-edf2-4ae9-9548-2f46bd0e3b83" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_UnusedCapitalLossCarryForwardNetMember_00e26e86-d4d9-4ac1-9420-d960efa99c8d" xlink:href="oncyf-20241231.xsd#oncyf_UnusedCapitalLossCarryForwardNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain_48bb43ad-fcf7-4109-97c9-2e93cbe63979" xlink:to="loc_oncyf_UnusedCapitalLossCarryForwardNetMember_00e26e86-d4d9-4ac1-9420-d960efa99c8d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised_bb6f869c-98a1-4326-94c2-d922ffede799" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_c665e0f7-4ad5-412f-b013-4d32aaf73916" xlink:to="loc_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised_bb6f869c-98a1-4326-94c2-d922ffede799" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="simple" xlink:href="oncyf-20241231.xsd#FinancialInstrumentsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_5590c2cd-3a80-4a37-997f-be067b6e0782" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_3bf5d10e-cc49-49ff-8a32-c0564cc0a1a6" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_5590c2cd-3a80-4a37-997f-be067b6e0782" xlink:to="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_3bf5d10e-cc49-49ff-8a32-c0564cc0a1a6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_ff58af63-f897-4989-bcc5-ec449924a581" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_3bf5d10e-cc49-49ff-8a32-c0564cc0a1a6" xlink:to="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_ff58af63-f897-4989-bcc5-ec449924a581" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LevelsOfFairValueHierarchyDomain_ff58af63-f897-4989-bcc5-ec449924a581_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LevelsOfFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_ff58af63-f897-4989-bcc5-ec449924a581" xlink:to="loc_ifrs-full_LevelsOfFairValueHierarchyDomain_ff58af63-f897-4989-bcc5-ec449924a581_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LevelsOfFairValueHierarchyDomain_cc2d4524-2e71-4a75-951c-b4cf2569b6f8" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LevelsOfFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_ff58af63-f897-4989-bcc5-ec449924a581" xlink:to="loc_ifrs-full_LevelsOfFairValueHierarchyDomain_cc2d4524-2e71-4a75-951c-b4cf2569b6f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Level2OfFairValueHierarchyMember_9d17ccfc-86f4-47e9-97e5-19fe846cfb5c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Level2OfFairValueHierarchyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LevelsOfFairValueHierarchyDomain_cc2d4524-2e71-4a75-951c-b4cf2569b6f8" xlink:to="loc_ifrs-full_Level2OfFairValueHierarchyMember_9d17ccfc-86f4-47e9-97e5-19fe846cfb5c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksAxis_78f28337-f47d-4b18-af2e-5e5b9efdf7bb" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfRisksAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_3bf5d10e-cc49-49ff-8a32-c0564cc0a1a6" xlink:to="loc_ifrs-full_TypesOfRisksAxis_78f28337-f47d-4b18-af2e-5e5b9efdf7bb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksDomain_78f28337-f47d-4b18-af2e-5e5b9efdf7bb_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfRisksDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfRisksAxis_78f28337-f47d-4b18-af2e-5e5b9efdf7bb" xlink:to="loc_ifrs-full_TypesOfRisksDomain_78f28337-f47d-4b18-af2e-5e5b9efdf7bb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksDomain_2d4b933e-723a-4a66-8bab-7eb74d50690a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfRisksDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfRisksAxis_78f28337-f47d-4b18-af2e-5e5b9efdf7bb" xlink:to="loc_ifrs-full_TypesOfRisksDomain_2d4b933e-723a-4a66-8bab-7eb74d50690a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrencyRiskMember_e7c3fba4-e5c6-45ea-b08a-dbccfa985f7e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrencyRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfRisksDomain_2d4b933e-723a-4a66-8bab-7eb74d50690a" xlink:to="loc_ifrs-full_CurrencyRiskMember_e7c3fba4-e5c6-45ea-b08a-dbccfa985f7e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis_4654343f-a0f2-418a-bedb-5161141c2b29" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CurrencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_3bf5d10e-cc49-49ff-8a32-c0564cc0a1a6" xlink:to="loc_srt_CurrencyAxis_4654343f-a0f2-418a-bedb-5161141c2b29" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_4654343f-a0f2-418a-bedb-5161141c2b29_default" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_AllCurrenciesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CurrencyAxis_4654343f-a0f2-418a-bedb-5161141c2b29" xlink:to="loc_currency_AllCurrenciesDomain_4654343f-a0f2-418a-bedb-5161141c2b29_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_679f8729-b60a-442e-adaa-4f8d0ebe378a" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_AllCurrenciesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CurrencyAxis_4654343f-a0f2-418a-bedb-5161141c2b29" xlink:to="loc_currency_AllCurrenciesDomain_679f8729-b60a-442e-adaa-4f8d0ebe378a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_USD_1da005dc-c08f-4733-9e74-6e1fe7f9046d" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_USD"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_679f8729-b60a-442e-adaa-4f8d0ebe378a" xlink:to="loc_currency_USD_1da005dc-c08f-4733-9e74-6e1fe7f9046d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_EUR_0425babd-b300-4cdb-9e51-21f9a7cc56af" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_EUR"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_679f8729-b60a-442e-adaa-4f8d0ebe378a" xlink:to="loc_currency_EUR_0425babd-b300-4cdb-9e51-21f9a7cc56af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentDerivativeFinancialAssets_90306d0c-b792-4806-a6fc-289190372911" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentDerivativeFinancialAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_5590c2cd-3a80-4a37-997f-be067b6e0782" xlink:to="loc_ifrs-full_CurrentDerivativeFinancialAssets_90306d0c-b792-4806-a6fc-289190372911" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentDerivativeFinancialLiabilities_51001136-82c3-4713-8ac0-c71d9dc835ec" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentDerivativeFinancialLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_5590c2cd-3a80-4a37-997f-be067b6e0782" xlink:to="loc_ifrs-full_CurrentDerivativeFinancialLiabilities_51001136-82c3-4713-8ac0-c71d9dc835ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount_546b4ebf-ab88-4464-a246-996dee48bf37" xlink:href="oncyf-20241231.xsd#oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_5590c2cd-3a80-4a37-997f-be067b6e0782" xlink:to="loc_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount_546b4ebf-ab88-4464-a246-996dee48bf37" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings_d176eda1-08a9-4b1a-a7fc-f5646f8827c5" xlink:href="oncyf-20241231.xsd#oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_5590c2cd-3a80-4a37-997f-be067b6e0782" xlink:to="loc_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings_d176eda1-08a9-4b1a-a7fc-f5646f8827c5" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/FinancialInstrumentsScheduleofBalancesinForeignCurrenciesDetails" xlink:type="simple" xlink:href="oncyf-20241231.xsd#FinancialInstrumentsScheduleofBalancesinForeignCurrenciesDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/FinancialInstrumentsScheduleofBalancesinForeignCurrenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_Currency1LineItems_ce7513aa-a685-4ba7-b12d-e480bf31976f" xlink:href="oncyf-20241231.xsd#oncyf_Currency1LineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_Currency1Table_b44df993-7511-472c-a016-b9a247997862" xlink:href="oncyf-20241231.xsd#oncyf_Currency1Table"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_oncyf_Currency1LineItems_ce7513aa-a685-4ba7-b12d-e480bf31976f" xlink:to="loc_oncyf_Currency1Table_b44df993-7511-472c-a016-b9a247997862" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis_fb39ba7d-9776-4040-b344-d25fc9e6786f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CurrencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_oncyf_Currency1Table_b44df993-7511-472c-a016-b9a247997862" xlink:to="loc_srt_CurrencyAxis_fb39ba7d-9776-4040-b344-d25fc9e6786f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_fb39ba7d-9776-4040-b344-d25fc9e6786f_default" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_AllCurrenciesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CurrencyAxis_fb39ba7d-9776-4040-b344-d25fc9e6786f" xlink:to="loc_currency_AllCurrenciesDomain_fb39ba7d-9776-4040-b344-d25fc9e6786f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_7fb29099-8c50-429d-b81f-308e019a0631" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_AllCurrenciesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CurrencyAxis_fb39ba7d-9776-4040-b344-d25fc9e6786f" xlink:to="loc_currency_AllCurrenciesDomain_7fb29099-8c50-429d-b81f-308e019a0631" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_USD_c810095c-21fa-4bac-a107-3e47ae64e613" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_USD"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_7fb29099-8c50-429d-b81f-308e019a0631" xlink:to="loc_currency_USD_c810095c-21fa-4bac-a107-3e47ae64e613" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_EUR_0a0127b1-2288-42a2-bc36-f93645dfef02" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_EUR"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_7fb29099-8c50-429d-b81f-308e019a0631" xlink:to="loc_currency_EUR_0a0127b1-2288-42a2-bc36-f93645dfef02" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_d16842e1-0e3a-4a67-81b9-a46eb8ef59f7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_Currency1LineItems_ce7513aa-a685-4ba7-b12d-e480bf31976f" xlink:to="loc_ifrs-full_CashAndCashEquivalents_d16842e1-0e3a-4a67-81b9-a46eb8ef59f7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayables_2aa1a4ba-b965-4680-afa6-d66097847a67" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_Currency1LineItems_ce7513aa-a685-4ba7-b12d-e480bf31976f" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayables_2aa1a4ba-b965-4680-afa6-d66097847a67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherLiabilities_e7851e79-e652-40b8-869a-0fa0b22c192e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_Currency1LineItems_ce7513aa-a685-4ba7-b12d-e480bf31976f" xlink:to="loc_ifrs-full_OtherLiabilities_e7851e79-e652-40b8-869a-0fa0b22c192e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_BalanceHeldInForeignCurrencyNet_65e3b36d-d67b-4e23-b6a6-c5558bae5ca6" xlink:href="oncyf-20241231.xsd#oncyf_BalanceHeldInForeignCurrencyNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_Currency1LineItems_ce7513aa-a685-4ba7-b12d-e480bf31976f" xlink:to="loc_oncyf_BalanceHeldInForeignCurrencyNet_65e3b36d-d67b-4e23-b6a6-c5558bae5ca6" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/EconomicDependenceDetails" xlink:type="simple" xlink:href="oncyf-20241231.xsd#EconomicDependenceDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/EconomicDependenceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ConcentrationRiskType1LineItems_23b51b3e-8fdc-4762-8766-772c239208e1" xlink:href="oncyf-20241231.xsd#oncyf_ConcentrationRiskType1LineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ConcentrationRisk1Table_4b105fdd-3d97-448e-8a7e-67c56385d22f" xlink:href="oncyf-20241231.xsd#oncyf_ConcentrationRisk1Table"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_oncyf_ConcentrationRiskType1LineItems_23b51b3e-8fdc-4762-8766-772c239208e1" xlink:to="loc_oncyf_ConcentrationRisk1Table_4b105fdd-3d97-448e-8a7e-67c56385d22f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ConcentrationRiskType1Axis_f3c9e268-7bb1-404f-8b28-3297a4b03b9d" xlink:href="oncyf-20241231.xsd#oncyf_ConcentrationRiskType1Axis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_oncyf_ConcentrationRisk1Table_4b105fdd-3d97-448e-8a7e-67c56385d22f" xlink:to="loc_oncyf_ConcentrationRiskType1Axis_f3c9e268-7bb1-404f-8b28-3297a4b03b9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ConcentrationRiskType1Domain_f3c9e268-7bb1-404f-8b28-3297a4b03b9d_default" xlink:href="oncyf-20241231.xsd#oncyf_ConcentrationRiskType1Domain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_oncyf_ConcentrationRiskType1Axis_f3c9e268-7bb1-404f-8b28-3297a4b03b9d" xlink:to="loc_oncyf_ConcentrationRiskType1Domain_f3c9e268-7bb1-404f-8b28-3297a4b03b9d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ConcentrationRiskType1Domain_ef686678-d8db-43b9-a637-c1399e54634e" xlink:href="oncyf-20241231.xsd#oncyf_ConcentrationRiskType1Domain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_oncyf_ConcentrationRiskType1Axis_f3c9e268-7bb1-404f-8b28-3297a4b03b9d" xlink:to="loc_oncyf_ConcentrationRiskType1Domain_ef686678-d8db-43b9-a637-c1399e54634e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SupplierConcentrationRisk1Member_bc84f8f6-603e-43e7-8c3f-bf7261d71c07" xlink:href="oncyf-20241231.xsd#oncyf_SupplierConcentrationRisk1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_ConcentrationRiskType1Domain_ef686678-d8db-43b9-a637-c1399e54634e" xlink:to="loc_oncyf_SupplierConcentrationRisk1Member_bc84f8f6-603e-43e7-8c3f-bf7261d71c07" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ConcentrationRiskNumber_9f43bec9-d1f9-42ad-8a83-7acb1b2fd04c" xlink:href="oncyf-20241231.xsd#oncyf_ConcentrationRiskNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_ConcentrationRiskType1LineItems_23b51b3e-8fdc-4762-8766-772c239208e1" xlink:to="loc_oncyf_ConcentrationRiskNumber_9f43bec9-d1f9-42ad-8a83-7acb1b2fd04c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ComponentsofExpensesDetails" xlink:type="simple" xlink:href="oncyf-20241231.xsd#ComponentsofExpensesDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/ComponentsofExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OtherExpensesAndAdjustmentsLineItems_fff24148-7a9b-4271-bd03-dfb8153e8945" xlink:href="oncyf-20241231.xsd#oncyf_OtherExpensesAndAdjustmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OtherExpensesAndAdjustmentsTable_10aaf894-a867-4647-89c0-94c1d815e3b5" xlink:href="oncyf-20241231.xsd#oncyf_OtherExpensesAndAdjustmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_oncyf_OtherExpensesAndAdjustmentsLineItems_fff24148-7a9b-4271-bd03-dfb8153e8945" xlink:to="loc_oncyf_OtherExpensesAndAdjustmentsTable_10aaf894-a867-4647-89c0-94c1d815e3b5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IncomeStatementLocation1Axis_383eab99-bd7d-43ed-a355-ca1a2142e70f" xlink:href="oncyf-20241231.xsd#oncyf_IncomeStatementLocation1Axis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_oncyf_OtherExpensesAndAdjustmentsTable_10aaf894-a867-4647-89c0-94c1d815e3b5" xlink:to="loc_oncyf_IncomeStatementLocation1Axis_383eab99-bd7d-43ed-a355-ca1a2142e70f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IncomeStatementLocation1Domain_383eab99-bd7d-43ed-a355-ca1a2142e70f_default" xlink:href="oncyf-20241231.xsd#oncyf_IncomeStatementLocation1Domain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_oncyf_IncomeStatementLocation1Axis_383eab99-bd7d-43ed-a355-ca1a2142e70f" xlink:to="loc_oncyf_IncomeStatementLocation1Domain_383eab99-bd7d-43ed-a355-ca1a2142e70f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IncomeStatementLocation1Domain_74591eff-14ba-4142-9c60-45fcdbf32934" xlink:href="oncyf-20241231.xsd#oncyf_IncomeStatementLocation1Domain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_oncyf_IncomeStatementLocation1Axis_383eab99-bd7d-43ed-a355-ca1a2142e70f" xlink:to="loc_oncyf_IncomeStatementLocation1Domain_74591eff-14ba-4142-9c60-45fcdbf32934" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ResearchAndDevelopmentExpense1Member_9c86cb0d-ba0d-40ed-9be4-6a667080e8cc" xlink:href="oncyf-20241231.xsd#oncyf_ResearchAndDevelopmentExpense1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_IncomeStatementLocation1Domain_74591eff-14ba-4142-9c60-45fcdbf32934" xlink:to="loc_oncyf_ResearchAndDevelopmentExpense1Member_9c86cb0d-ba0d-40ed-9be4-6a667080e8cc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_GeneralAndAdministrativeExpense1Member_303be746-8c33-4008-abe4-4b8d8f4892e7" xlink:href="oncyf-20241231.xsd#oncyf_GeneralAndAdministrativeExpense1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_IncomeStatementLocation1Domain_74591eff-14ba-4142-9c60-45fcdbf32934" xlink:to="loc_oncyf_GeneralAndAdministrativeExpense1Member_303be746-8c33-4008-abe4-4b8d8f4892e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ResearchAndDevelopmentExpense1Abstract_9437dc3c-e525-4971-9d5a-a516dbc63f7c" xlink:href="oncyf-20241231.xsd#oncyf_ResearchAndDevelopmentExpense1Abstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_OtherExpensesAndAdjustmentsLineItems_fff24148-7a9b-4271-bd03-dfb8153e8945" xlink:to="loc_oncyf_ResearchAndDevelopmentExpense1Abstract_9437dc3c-e525-4971-9d5a-a516dbc63f7c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ClinicalTrialExpense_23eac73c-9c87-4475-b741-dba8a9b864cc" xlink:href="oncyf-20241231.xsd#oncyf_ClinicalTrialExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_ResearchAndDevelopmentExpense1Abstract_9437dc3c-e525-4971-9d5a-a516dbc63f7c" xlink:to="loc_oncyf_ClinicalTrialExpense_23eac73c-9c87-4475-b741-dba8a9b864cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ManufacturingExpense_51b3e38e-a7c0-426b-bf51-43db1dc44bdb" xlink:href="oncyf-20241231.xsd#oncyf_ManufacturingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_ResearchAndDevelopmentExpense1Abstract_9437dc3c-e525-4971-9d5a-a516dbc63f7c" xlink:to="loc_oncyf_ManufacturingExpense_51b3e38e-a7c0-426b-bf51-43db1dc44bdb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IntellectualPropertyExpense_2e293b43-8124-4e00-af6a-6187b972a23b" xlink:href="oncyf-20241231.xsd#oncyf_IntellectualPropertyExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_ResearchAndDevelopmentExpense1Abstract_9437dc3c-e525-4971-9d5a-a516dbc63f7c" xlink:to="loc_oncyf_IntellectualPropertyExpense_2e293b43-8124-4e00-af6a-6187b972a23b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TranslationalScienceExpense_f25966f1-57cc-4ce5-b608-e0c4105c0032" xlink:href="oncyf-20241231.xsd#oncyf_TranslationalScienceExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_ResearchAndDevelopmentExpense1Abstract_9437dc3c-e525-4971-9d5a-a516dbc63f7c" xlink:to="loc_oncyf_TranslationalScienceExpense_f25966f1-57cc-4ce5-b608-e0c4105c0032" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherEmployeeExpense_e030288a-2818-4f0d-be4d-5d47abf9c47b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherEmployeeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_ResearchAndDevelopmentExpense1Abstract_9437dc3c-e525-4971-9d5a-a516dbc63f7c" xlink:to="loc_ifrs-full_OtherEmployeeExpense_e030288a-2818-4f0d-be4d-5d47abf9c47b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_364e179c-92fb-4d45-8a0d-1ed2003f179d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_ResearchAndDevelopmentExpense1Abstract_9437dc3c-e525-4971-9d5a-a516dbc63f7c" xlink:to="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_364e179c-92fb-4d45-8a0d-1ed2003f179d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MiscellaneousOtherOperatingExpense_bfb5cedd-c0a6-4cb6-9fea-ad7812087fd4" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MiscellaneousOtherOperatingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_ResearchAndDevelopmentExpense1Abstract_9437dc3c-e525-4971-9d5a-a516dbc63f7c" xlink:to="loc_ifrs-full_MiscellaneousOtherOperatingExpense_bfb5cedd-c0a6-4cb6-9fea-ad7812087fd4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense_82aab485-3a73-495a-82c6-9747f6c440cf" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_ResearchAndDevelopmentExpense1Abstract_9437dc3c-e525-4971-9d5a-a516dbc63f7c" xlink:to="loc_ifrs-full_ResearchAndDevelopmentExpense_82aab485-3a73-495a-82c6-9747f6c440cf" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_GeneralAndAdministrativeExpense1Abstract_6ea532c4-2a31-47ef-bf29-9ea52b67246b" xlink:href="oncyf-20241231.xsd#oncyf_GeneralAndAdministrativeExpense1Abstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_OtherExpensesAndAdjustmentsLineItems_fff24148-7a9b-4271-bd03-dfb8153e8945" xlink:to="loc_oncyf_GeneralAndAdministrativeExpense1Abstract_6ea532c4-2a31-47ef-bf29-9ea52b67246b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_PublicCompanyExpense_36bcf88f-3384-4cc8-9de0-814ade92d892" xlink:href="oncyf-20241231.xsd#oncyf_PublicCompanyExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_GeneralAndAdministrativeExpense1Abstract_6ea532c4-2a31-47ef-bf29-9ea52b67246b" xlink:to="loc_oncyf_PublicCompanyExpense_36bcf88f-3384-4cc8-9de0-814ade92d892" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OfficeExpenses_c45fdd4a-d777-473a-a842-bd654a3a4df7" xlink:href="oncyf-20241231.xsd#oncyf_OfficeExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_GeneralAndAdministrativeExpense1Abstract_6ea532c4-2a31-47ef-bf29-9ea52b67246b" xlink:to="loc_oncyf_OfficeExpenses_c45fdd4a-d777-473a-a842-bd654a3a4df7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmortisationExpense_a6acdcc6-ebf4-4beb-9b39-3e5df350253f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AmortisationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_GeneralAndAdministrativeExpense1Abstract_6ea532c4-2a31-47ef-bf29-9ea52b67246b" xlink:to="loc_ifrs-full_AmortisationExpense_a6acdcc6-ebf4-4beb-9b39-3e5df350253f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DepreciationRightofuseAssets_fdbe8601-532d-4dea-9f3b-b86e37b8bb70" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DepreciationRightofuseAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_GeneralAndAdministrativeExpense1Abstract_6ea532c4-2a31-47ef-bf29-9ea52b67246b" xlink:to="loc_ifrs-full_DepreciationRightofuseAssets_fdbe8601-532d-4dea-9f3b-b86e37b8bb70" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeneralAndAdministrativeExpense_f55a0ad3-fd22-4bab-bb84-280c52310583" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_GeneralAndAdministrativeExpense1Abstract_6ea532c4-2a31-47ef-bf29-9ea52b67246b" xlink:to="loc_ifrs-full_GeneralAndAdministrativeExpense_f55a0ad3-fd22-4bab-bb84-280c52310583" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EmployeeBenefitsExpense_63a5922c-b75e-44e7-ab88-4d5eb2c4409c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EmployeeBenefitsExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_OtherExpensesAndAdjustmentsLineItems_fff24148-7a9b-4271-bd03-dfb8153e8945" xlink:to="loc_ifrs-full_EmployeeBenefitsExpense_63a5922c-b75e-44e7-ab88-4d5eb2c4409c" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/SegmentDisclosuresDetails" xlink:type="simple" xlink:href="oncyf-20241231.xsd#SegmentDisclosuresDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/SegmentDisclosuresDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_cc3a6e9f-acc7-4758-ba6b-3cb2dbeaced2" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfGeographicalAreasLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfGeographicalAreasTable_5afb6a5a-bfab-4694-bd6a-e7d3107944d0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfGeographicalAreasTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_cc3a6e9f-acc7-4758-ba6b-3cb2dbeaced2" xlink:to="loc_ifrs-full_DisclosureOfGeographicalAreasTable_5afb6a5a-bfab-4694-bd6a-e7d3107944d0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasAxis_c922e06f-a3d5-448d-a0ae-30ee1b76b22d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeographicalAreasAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasTable_5afb6a5a-bfab-4694-bd6a-e7d3107944d0" xlink:to="loc_ifrs-full_GeographicalAreasAxis_c922e06f-a3d5-448d-a0ae-30ee1b76b22d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasDomain_c922e06f-a3d5-448d-a0ae-30ee1b76b22d_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeographicalAreasDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_GeographicalAreasAxis_c922e06f-a3d5-448d-a0ae-30ee1b76b22d" xlink:to="loc_ifrs-full_GeographicalAreasDomain_c922e06f-a3d5-448d-a0ae-30ee1b76b22d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasDomain_4b5c880f-9095-47cf-be02-d17124ebe3d9" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeographicalAreasDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_GeographicalAreasAxis_c922e06f-a3d5-448d-a0ae-30ee1b76b22d" xlink:to="loc_ifrs-full_GeographicalAreasDomain_4b5c880f-9095-47cf-be02-d17124ebe3d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_1a767b8d-accc-4682-8629-36f366f10330" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_CA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasDomain_4b5c880f-9095-47cf-be02-d17124ebe3d9" xlink:to="loc_country_CA_1a767b8d-accc-4682-8629-36f366f10330" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_RestOfWorldMember_8edbf904-6a0f-41b1-94c2-b3480c3c80fb" xlink:href="oncyf-20241231.xsd#oncyf_RestOfWorldMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_GeographicalAreasDomain_4b5c880f-9095-47cf-be02-d17124ebe3d9" xlink:to="loc_oncyf_RestOfWorldMember_8edbf904-6a0f-41b1-94c2-b3480c3c80fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_NumberOfReportableSegments1_39da2b3a-9e61-42b8-8b10-0082c6e7337f" xlink:href="oncyf-20241231.xsd#oncyf_NumberOfReportableSegments1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_cc3a6e9f-acc7-4758-ba6b-3cb2dbeaced2" xlink:to="loc_oncyf_NumberOfReportableSegments1_39da2b3a-9e61-42b8-8b10-0082c6e7337f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_1cfd6e4a-cc7f-40ae-b7b3-1909b77a1afc" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_cc3a6e9f-acc7-4758-ba6b-3cb2dbeaced2" xlink:to="loc_ifrs-full_PropertyPlantAndEquipment_1cfd6e4a-cc7f-40ae-b7b3-1909b77a1afc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RightofuseAssets_6c2a158e-a577-442e-a82f-994ee42ac173" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RightofuseAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_cc3a6e9f-acc7-4758-ba6b-3cb2dbeaced2" xlink:to="loc_ifrs-full_RightofuseAssets_6c2a158e-a577-442e-a82f-994ee42ac173" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="oncyf-20241231.xsd#SubsequentEventsDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_01089746-575e-48ed-9ed6-0bca660f2c9f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_b43cc972-7a64-4ff7-80d2-35c571850eba" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_01089746-575e-48ed-9ed6-0bca660f2c9f" xlink:to="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_b43cc972-7a64-4ff7-80d2-35c571850eba" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_61b4454c-521b-42f3-bcba-a34e936bc582" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_b43cc972-7a64-4ff7-80d2-35c571850eba" xlink:to="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_61b4454c-521b-42f3-bcba-a34e936bc582" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_61b4454c-521b-42f3-bcba-a34e936bc582_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_61b4454c-521b-42f3-bcba-a34e936bc582" xlink:to="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_61b4454c-521b-42f3-bcba-a34e936bc582_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_e949be60-834f-4cc2-8189-59c442968c80" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_61b4454c-521b-42f3-bcba-a34e936bc582" xlink:to="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_e949be60-834f-4cc2-8189-59c442968c80" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MajorOrdinaryShareTransactionsMember_54b74790-1131-4fe0-8430-17d1a3b32f2f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MajorOrdinaryShareTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_e949be60-834f-4cc2-8189-59c442968c80" xlink:to="loc_ifrs-full_MajorOrdinaryShareTransactionsMember_54b74790-1131-4fe0-8430-17d1a3b32f2f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IssueOfEquityShares_908af79e-e3ef-4ff6-9e18-4bf32c14ce50" xlink:href="oncyf-20241231.xsd#oncyf_IssueOfEquityShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_01089746-575e-48ed-9ed6-0bca660f2c9f" xlink:to="loc_oncyf_IssueOfEquityShares_908af79e-e3ef-4ff6-9e18-4bf32c14ce50" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ProceedsFromIssueOfOrdinarySharesGross_5bcdee1d-ff7a-49c0-bf13-08643c143942" xlink:href="oncyf-20241231.xsd#oncyf_ProceedsFromIssueOfOrdinarySharesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_01089746-575e-48ed-9ed6-0bca660f2c9f" xlink:to="loc_oncyf_ProceedsFromIssueOfOrdinarySharesGross_5bcdee1d-ff7a-49c0-bf13-08643c143942" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IssueOfOrdinarySharesPerShare_9e0a7e7e-ae09-4c7e-bfb5-b80c8c4b1c66" xlink:href="oncyf-20241231.xsd#oncyf_IssueOfOrdinarySharesPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_01089746-575e-48ed-9ed6-0bca660f2c9f" xlink:to="loc_oncyf_IssueOfOrdinarySharesPerShare_9e0a7e7e-ae09-4c7e-bfb5-b80c8c4b1c66" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromIssueOfOrdinaryShares_71bf8f6d-8e49-4c24-898d-258232663f91" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromIssueOfOrdinaryShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_01089746-575e-48ed-9ed6-0bca660f2c9f" xlink:to="loc_ifrs-full_ProceedsFromIssueOfOrdinaryShares_71bf8f6d-8e49-4c24-898d-258232663f91" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ShareIssueRelatedCostCommissions_7de526bc-b44b-4dd2-a2b0-13046fbda84c" xlink:href="oncyf-20241231.xsd#oncyf_ShareIssueRelatedCostCommissions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_01089746-575e-48ed-9ed6-0bca660f2c9f" xlink:to="loc_oncyf_ShareIssueRelatedCostCommissions_7de526bc-b44b-4dd2-a2b0-13046fbda84c" xlink:type="arc" order="4"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>13
<FILENAME>oncyf-20241231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:f2389c06-29ac-4823-bdfc-c1b39bddff80,g:9bb1793d-cf33-41ae-b11c-eb401ad874b8-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount_45adbfb9-6d3c-4350-9811-a47bdf3a4959_terseLabel_en-US" xlink:label="lab_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impact of increase in value of currency (cad per share)</link:label>
    <link:label id="lab_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount_label_en-US" xlink:label="lab_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Change In Risk Variable, Amount</link:label>
    <link:label id="lab_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount_documentation_en-US" xlink:label="lab_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">A reference variable for a specific type of market risk, defined in non-percentage terms. Positive value indicates an increase; negative value indicates a decrease.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount" xlink:href="oncyf-20241231.xsd#oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount" xlink:to="lab_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement_18dcbdc5-7887-4e34-ad76-5ee0a73ddced_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Expired during the year (shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement_label_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of share options expired in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AccumulatedDepreciationAndAmortisationMember_0f828138-474f-4f56-8ae2-07a8220e9866_terseLabel_en-US" xlink:label="lab_ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization</link:label>
    <link:label id="lab_ifrs-full_AccumulatedDepreciationAndAmortisationMember_label_en-US" xlink:label="lab_ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated depreciation and amortisation [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AccumulatedDepreciationAndAmortisationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:to="lab_ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_6f12da95-d715-43a6-88a9-7c183a089a94_terseLabel_en-US" xlink:label="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Types of share-based payment arrangements [axis]</link:label>
    <link:label id="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_label_en-US" xlink:label="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Types of share-based payment arrangements [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_f271f7b8-24ff-4f45-88e6-f7225703101d_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement_db2b30e3-7cb8-4c24-9b61-7a873fe5368b_terseLabel_en-US" xlink:label="lab_oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum option expiration term</link:label>
    <link:label id="lab_oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement_label_en-US" xlink:label="lab_oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum Term Of Options Granted For Share-based Payment Arrangement</link:label>
    <link:label id="lab_oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement_documentation_en-US" xlink:label="lab_oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Maximum Term Of Options Granted For Share-based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement" xlink:href="oncyf-20241231.xsd#oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement" xlink:to="lab_oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_c71dbced-4739-4061-b382-96d2785546ce_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issued pursuant to stock option plan (note 11)</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through exercise of options, equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory_b6224b76-60e6-4ccd-af75-d4b0dc581c8b_terseLabel_en-US" xlink:label="lab_ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Contract Liability</link:label>
    <link:label id="lab_ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory_label_en-US" xlink:label="lab_ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Explanation of significant changes in contract assets and contract liabilities [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory" xlink:to="lab_ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity_dec06b69-c17f-4605-bde0-e61918352bda_terseLabel_en-US" xlink:label="lab_oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issued pursuant to incentive share award plan (note 11)</link:label>
    <link:label id="lab_oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity_label_en-US" xlink:label="lab_oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Through Incentive Share Awards, Equity</link:label>
    <link:label id="lab_oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity_documentation_en-US" xlink:label="lab_oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Through Incentive Share Awards, Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity" xlink:href="oncyf-20241231.xsd#oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity" xlink:to="lab_oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProceedsFromIssueOfOrdinaryShares_daac3440-0bf4-4b65-bf92-b46a5ee200bd_terseLabel_en-US" xlink:label="lab_ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net proceeds from issue of ordinary shares</link:label>
    <link:label id="lab_ifrs-full_ProceedsFromIssueOfOrdinaryShares_label_en-US" xlink:label="lab_ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from issue of ordinary shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromIssueOfOrdinaryShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:to="lab_ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EarningsPerShareAbstract_de0e93c5-7047-451c-9bd2-7c057ca6d96a_terseLabel_en-US" xlink:label="lab_ifrs-full_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings per share [abstract]</link:label>
    <link:label id="lab_ifrs-full_EarningsPerShareAbstract_label_en-US" xlink:label="lab_ifrs-full_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings per share [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EarningsPerShareAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EarningsPerShareAbstract" xlink:to="lab_ifrs-full_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AccountingProfit_7014801f-af32-4c6f-874e-140f96769ec3_terseLabel_en-US" xlink:label="lab_ifrs-full_AccountingProfit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss before income taxes</link:label>
    <link:label id="lab_ifrs-full_AccountingProfit_label_en-US" xlink:label="lab_ifrs-full_AccountingProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting profit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccountingProfit" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AccountingProfit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AccountingProfit" xlink:to="lab_ifrs-full_AccountingProfit" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentLiabilities_a33b53a2-dff5-4bda-9a51-e2a0f62696b7_totalLabel_en-US" xlink:label="lab_ifrs-full_CurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_ifrs-full_CurrentLiabilities_label_en-US" xlink:label="lab_ifrs-full_CurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentLiabilities" xlink:to="lab_ifrs-full_CurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_DirectorMember_243c3676-f231-4480-bc25-f9049f199c43_terseLabel_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Director</link:label>
    <link:label id="lab_srt_DirectorMember_label_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Director [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_DirectorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_DirectorMember" xlink:to="lab_srt_DirectorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RestrictedShareUnitsMember_5dbf395c-68eb-4c5a-bab1-30084f1cff1c_terseLabel_en-US" xlink:label="lab_ifrs-full_RestrictedShareUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted share units</link:label>
    <link:label id="lab_ifrs-full_RestrictedShareUnitsMember_label_en-US" xlink:label="lab_ifrs-full_RestrictedShareUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted share units [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RestrictedShareUnitsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RestrictedShareUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RestrictedShareUnitsMember" xlink:to="lab_ifrs-full_RestrictedShareUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_7348a9e1-161f-4779-8017-064bf3231b88_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfEarningsPerShareExplanatory_7c0e9570-2448-4b28-86b0-cc4ffe35af16_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Per Share</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfEarningsPerShareExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of earnings per share [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfEarningsPerShareExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:to="lab_ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityAbstract_edd9382a-1f58-4cc8-8dc5-2ab59f59bf9c_terseLabel_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of changes in equity [abstract]</link:label>
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityAbstract_label_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of changes in equity [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfChangesInEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfChangesInEquityAbstract" xlink:to="lab_ifrs-full_StatementOfChangesInEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_SharesIssuedPricePerShare1_bd8679ec-af73-4dd3-9d5c-73a06c4b24b1_terseLabel_en-US" xlink:label="lab_oncyf_SharesIssuedPricePerShare1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase price (cad and usd per share)</link:label>
    <link:label id="lab_oncyf_SharesIssuedPricePerShare1_label_en-US" xlink:label="lab_oncyf_SharesIssuedPricePerShare1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued, Price Per Share1</link:label>
    <link:label id="lab_oncyf_SharesIssuedPricePerShare1_documentation_en-US" xlink:label="lab_oncyf_SharesIssuedPricePerShare1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Shares Issued, Price Per Share1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesIssuedPricePerShare1" xlink:href="oncyf-20241231.xsd#oncyf_SharesIssuedPricePerShare1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SharesIssuedPricePerShare1" xlink:to="lab_oncyf_SharesIssuedPricePerShare1" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfUncertaintiesOfEntitysAbilityToContinueAsGoingConcern_5adc815f-408d-42e9-804d-fa877f9bfb61_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfUncertaintiesOfEntitysAbilityToContinueAsGoingConcern" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Going concern</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfUncertaintiesOfEntitysAbilityToContinueAsGoingConcern_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfUncertaintiesOfEntitysAbilityToContinueAsGoingConcern" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of uncertainties of entity's ability to continue as going concern [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfUncertaintiesOfEntitysAbilityToContinueAsGoingConcern" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfUncertaintiesOfEntitysAbilityToContinueAsGoingConcern"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfUncertaintiesOfEntitysAbilityToContinueAsGoingConcern" xlink:to="lab_ifrs-full_DescriptionOfUncertaintiesOfEntitysAbilityToContinueAsGoingConcern" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory_f13a6e05-f3a4-42c8-b1b8-5de3c0a883d7_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant Derivative</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of financial liabilities [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_46b73ec3-b473-414c-91dc-8c72af4b0911_verboseLabel_en-US" xlink:label="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Foreign exchange gain (loss)</link:label>
    <link:label id="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_label_en-US" xlink:label="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign exchange gain (loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:to="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_InvestmentTaxCreditsMember_f277722c-9e56-46df-b68f-8259b2ee94da_terseLabel_en-US" xlink:label="lab_oncyf_InvestmentTaxCreditsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment tax credits</link:label>
    <link:label id="lab_oncyf_InvestmentTaxCreditsMember_label_en-US" xlink:label="lab_oncyf_InvestmentTaxCreditsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Tax Credits [Member]</link:label>
    <link:label id="lab_oncyf_InvestmentTaxCreditsMember_documentation_en-US" xlink:label="lab_oncyf_InvestmentTaxCreditsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Investment Tax Credits [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_InvestmentTaxCreditsMember" xlink:href="oncyf-20241231.xsd#oncyf_InvestmentTaxCreditsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_InvestmentTaxCreditsMember" xlink:to="lab_oncyf_InvestmentTaxCreditsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GeographicalAreasDomain_b120d185-49f8-4c5a-aeb5-a986171786af_terseLabel_en-US" xlink:label="lab_ifrs-full_GeographicalAreasDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical areas</link:label>
    <link:label id="lab_ifrs-full_GeographicalAreasDomain_label_en-US" xlink:label="lab_ifrs-full_GeographicalAreasDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical areas [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeographicalAreasDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GeographicalAreasDomain" xlink:to="lab_ifrs-full_GeographicalAreasDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_61938d6b-791c-4fd2-b9e3-3f5e4f6be0fc_terseLabel_en-US" xlink:label="lab_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unused tax losses</link:label>
    <link:label id="lab_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_label_en-US" xlink:label="lab_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unused tax losses for which no deferred tax asset recognised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" xlink:to="lab_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_6af1b13d-7fb5-4fc3-8c81-661534d4b2fd_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of stock options and weighted average exercise prices of share options</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of number and weighted average exercise prices of share options [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_WarrantsExercised_13ecb6ed-2d59-456d-858d-da9f2d0094d4_terseLabel_en-US" xlink:label="lab_oncyf_WarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants exercised, fair value</link:label>
    <link:label id="lab_oncyf_WarrantsExercised_label_en-US" xlink:label="lab_oncyf_WarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Exercised</link:label>
    <link:label id="lab_oncyf_WarrantsExercised_documentation_en-US" xlink:label="lab_oncyf_WarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantsExercised" xlink:href="oncyf-20241231.xsd#oncyf_WarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_WarrantsExercised" xlink:to="lab_oncyf_WarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_SharesPublicOfferingMember_672454c1-ef19-40c2-a447-e053f8428b1f_terseLabel_en-US" xlink:label="lab_oncyf_SharesPublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Public offering</link:label>
    <link:label id="lab_oncyf_SharesPublicOfferingMember_label_en-US" xlink:label="lab_oncyf_SharesPublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Public Offering [Member]</link:label>
    <link:label id="lab_oncyf_SharesPublicOfferingMember_documentation_en-US" xlink:label="lab_oncyf_SharesPublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Shares Public Offering [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesPublicOfferingMember" xlink:href="oncyf-20241231.xsd#oncyf_SharesPublicOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SharesPublicOfferingMember" xlink:to="lab_oncyf_SharesPublicOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OfficeEquipmentMember_9239a9c5-e5da-4003-a285-0aa071f22ed2_terseLabel_en-US" xlink:label="lab_ifrs-full_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Office equipment and furniture</link:label>
    <link:label id="lab_ifrs-full_OfficeEquipmentMember_label_en-US" xlink:label="lab_ifrs-full_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Office equipment [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OfficeEquipmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OfficeEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OfficeEquipmentMember" xlink:to="lab_ifrs-full_OfficeEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ProceedsFromIssueOfOrdinarySharesGross_920cd937-f832-4c8b-9c71-f82b9ec6846c_terseLabel_en-US" xlink:label="lab_oncyf_ProceedsFromIssueOfOrdinarySharesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross proceeds from shares</link:label>
    <link:label id="lab_oncyf_ProceedsFromIssueOfOrdinarySharesGross_label_en-US" xlink:label="lab_oncyf_ProceedsFromIssueOfOrdinarySharesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From Issue Of Ordinary Shares, Gross</link:label>
    <link:label id="lab_oncyf_ProceedsFromIssueOfOrdinarySharesGross_documentation_en-US" xlink:label="lab_oncyf_ProceedsFromIssueOfOrdinarySharesGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds From Issue Of Ordinary Shares, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ProceedsFromIssueOfOrdinarySharesGross" xlink:href="oncyf-20241231.xsd#oncyf_ProceedsFromIssueOfOrdinarySharesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ProceedsFromIssueOfOrdinarySharesGross" xlink:to="lab_oncyf_ProceedsFromIssueOfOrdinarySharesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ShareWarrantsIssuedTransactionCosts_4a2c97eb-a5e9-4f7d-8456-76a04426c40f_terseLabel_en-US" xlink:label="lab_oncyf_ShareWarrantsIssuedTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants issued, transaction costs</link:label>
    <link:label id="lab_oncyf_ShareWarrantsIssuedTransactionCosts_label_en-US" xlink:label="lab_oncyf_ShareWarrantsIssuedTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Warrants Issued, Transaction Costs</link:label>
    <link:label id="lab_oncyf_ShareWarrantsIssuedTransactionCosts_documentation_en-US" xlink:label="lab_oncyf_ShareWarrantsIssuedTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Warrants Issued, Transaction Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ShareWarrantsIssuedTransactionCosts" xlink:href="oncyf-20241231.xsd#oncyf_ShareWarrantsIssuedTransactionCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ShareWarrantsIssuedTransactionCosts" xlink:to="lab_oncyf_ShareWarrantsIssuedTransactionCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_a92f0685-6330-4345-b689-b11c2cd88635_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Released (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_label_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of other equity instruments exercised or vested in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressesAddressTypeAxis_cf1633f2-eb4e-49d7-bb29-f4ab7ede199a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressesAddressTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Addresses, Address Type [Axis]</link:label>
    <link:label id="lab_dei_EntityAddressesAddressTypeAxis_label_en-US" xlink:label="lab_dei_EntityAddressesAddressTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Addresses, Address Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressesAddressTypeAxis" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressesAddressTypeAxis" xlink:to="lab_dei_EntityAddressesAddressTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ShareCapitalAmountAbstract_a4d6ce48-eab8-4219-bc01-b09a2e783125_terseLabel_en-US" xlink:label="lab_oncyf_ShareCapitalAmountAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount</link:label>
    <link:label id="lab_oncyf_ShareCapitalAmountAbstract_label_en-US" xlink:label="lab_oncyf_ShareCapitalAmountAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Capital, Amount [Abstract]</link:label>
    <link:label id="lab_oncyf_ShareCapitalAmountAbstract_documentation_en-US" xlink:label="lab_oncyf_ShareCapitalAmountAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Capital, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ShareCapitalAmountAbstract" xlink:href="oncyf-20241231.xsd#oncyf_ShareCapitalAmountAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ShareCapitalAmountAbstract" xlink:to="lab_oncyf_ShareCapitalAmountAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TypesOfRisksDomain_f003644c-b3f3-4362-8c39-fa550e848dab_terseLabel_en-US" xlink:label="lab_ifrs-full_TypesOfRisksDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Types of risks</link:label>
    <link:label id="lab_ifrs-full_TypesOfRisksDomain_label_en-US" xlink:label="lab_ifrs-full_TypesOfRisksDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Types of risks [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfRisksDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfRisksDomain" xlink:to="lab_ifrs-full_TypesOfRisksDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_067f9b75-d021-4fd6-99f6-d4b698165fd3_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for increase (decrease) in trade and other payables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:to="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ComponentsOfEquityDomain_9bd6f91f-e6a5-440c-b86c-02de30c08c42_terseLabel_en-US" xlink:label="lab_ifrs-full_ComponentsOfEquityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Components of equity</link:label>
    <link:label id="lab_ifrs-full_ComponentsOfEquityDomain_label_en-US" xlink:label="lab_ifrs-full_ComponentsOfEquityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Components of equity [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain" xlink:to="lab_ifrs-full_ComponentsOfEquityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_40cbf610-a73f-4464-9cfa-2bf153b1136c_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">UNITED STATES</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_a1034dfd-40b8-4dfe-b717-5bff5dfbdfa8_verboseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of basis of preparation of financial statements [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_FairValueOfWarrantDerivativeExpired_532139f4-14ff-455b-86c8-dd382c6f96f9_negatedTerseLabel_en-US" xlink:label="lab_oncyf_FairValueOfWarrantDerivativeExpired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Expired</link:label>
    <link:label id="lab_oncyf_FairValueOfWarrantDerivativeExpired_label_en-US" xlink:label="lab_oncyf_FairValueOfWarrantDerivativeExpired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Of Warrant Derivative, Expired</link:label>
    <link:label id="lab_oncyf_FairValueOfWarrantDerivativeExpired_documentation_en-US" xlink:label="lab_oncyf_FairValueOfWarrantDerivativeExpired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair Value Of Warrant Derivative, Expired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_FairValueOfWarrantDerivativeExpired" xlink:href="oncyf-20241231.xsd#oncyf_FairValueOfWarrantDerivativeExpired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_FairValueOfWarrantDerivativeExpired" xlink:to="lab_oncyf_FairValueOfWarrantDerivativeExpired" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative_8386e589-b172-4ae9-b1b2-ab5d75e64b52_terseLabel_en-US" xlink:label="lab_oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of warrant derivative</link:label>
    <link:label id="lab_oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative_label_en-US" xlink:label="lab_oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Effect Of Change in Fair Value Of Warrant Derivative</link:label>
    <link:label id="lab_oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative_documentation_en-US" xlink:label="lab_oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tax Effect Of Change in Fair Value Of Warrant Derivative</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative" xlink:href="oncyf-20241231.xsd#oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative" xlink:to="lab_oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_f8a1ad00-e143-42d9-a842-ed549bac6595_terseLabel_en-US" xlink:label="lab_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Anticipated tax recovery</link:label>
    <link:label id="lab_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_label_en-US" xlink:label="lab_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax expense (income) at applicable tax rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TaxExpenseIncomeAtApplicableTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xlink:to="lab_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_OfficeExpenses_6c029db6-6ddf-497b-9cef-8eacdbb1b0de_terseLabel_en-US" xlink:label="lab_oncyf_OfficeExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Office expenses</link:label>
    <link:label id="lab_oncyf_OfficeExpenses_label_en-US" xlink:label="lab_oncyf_OfficeExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Office Expenses</link:label>
    <link:label id="lab_oncyf_OfficeExpenses_documentation_en-US" xlink:label="lab_oncyf_OfficeExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Office Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OfficeExpenses" xlink:href="oncyf-20241231.xsd#oncyf_OfficeExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_OfficeExpenses" xlink:to="lab_oncyf_OfficeExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DerivativeFinancialLiabilities_e94a03e0-e716-4a0d-87f6-a2e70ec4790d_periodStartLabel_en-US" xlink:label="lab_ifrs-full_DerivativeFinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance at beginning of period</link:label>
    <link:label id="lab_ifrs-full_DerivativeFinancialLiabilities_4a24421e-0bca-4f5e-858d-f1fd996ef615_periodEndLabel_en-US" xlink:label="lab_ifrs-full_DerivativeFinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance at end of period</link:label>
    <link:label id="lab_ifrs-full_DerivativeFinancialLiabilities_label_en-US" xlink:label="lab_ifrs-full_DerivativeFinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative financial liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DerivativeFinancialLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DerivativeFinancialLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DerivativeFinancialLiabilities" xlink:to="lab_ifrs-full_DerivativeFinancialLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_A2021SharesUnderAtTheMarketAgreementUnitedStatesMember_2182e6a3-0dda-40c0-95e7-662cb052bfe3_terseLabel_en-US" xlink:label="lab_oncyf_A2021SharesUnderAtTheMarketAgreementUnitedStatesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2021 United States ATM</link:label>
    <link:label id="lab_oncyf_A2021SharesUnderAtTheMarketAgreementUnitedStatesMember_label_en-US" xlink:label="lab_oncyf_A2021SharesUnderAtTheMarketAgreementUnitedStatesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2021 Shares Under At-the-market Agreement, United States [Member]</link:label>
    <link:label id="lab_oncyf_A2021SharesUnderAtTheMarketAgreementUnitedStatesMember_documentation_en-US" xlink:label="lab_oncyf_A2021SharesUnderAtTheMarketAgreementUnitedStatesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2021 Shares Under At-the-market Agreement, United States</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_A2021SharesUnderAtTheMarketAgreementUnitedStatesMember" xlink:href="oncyf-20241231.xsd#oncyf_A2021SharesUnderAtTheMarketAgreementUnitedStatesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_A2021SharesUnderAtTheMarketAgreementUnitedStatesMember" xlink:to="lab_oncyf_A2021SharesUnderAtTheMarketAgreementUnitedStatesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory_bfc7aa34-3810-46d0-8dfd-f32eeeb58750_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of change in fair value of warrant derivative</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of fair value measurement of liabilities [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_d2cb152a-af19-4a36-aa6f-2e34674a686e_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of fair value measurement of liabilities [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of fair value measurement of liabilities [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:to="lab_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForDerecognitionOfFinancialInstrumentsExplanatory_678c1b45-2057-43f8-85c7-a40b928cf23f_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForDerecognitionOfFinancialInstrumentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derecognition</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForDerecognitionOfFinancialInstrumentsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForDerecognitionOfFinancialInstrumentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for derecognition of financial instruments [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForDerecognitionOfFinancialInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForDerecognitionOfFinancialInstrumentsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForDerecognitionOfFinancialInstrumentsExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForDerecognitionOfFinancialInstrumentsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable_d5f48018-8246-400a-99df-19031f8d8802_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of maturity analysis of operating lease payments [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of maturity analysis of operating lease payments [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable" xlink:to="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherCurrentReceivables_807ed95c-17e1-430e-85b4-617dacef8fc7_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherCurrentReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_ifrs-full_OtherCurrentReceivables_label_en-US" xlink:label="lab_ifrs-full_OtherCurrentReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other current receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherCurrentReceivables" xlink:to="lab_ifrs-full_OtherCurrentReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_18b7c1d6-8b8b-4d02-866b-b479e13c3592_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ContractLiabilities_8d849ff2-039a-41c1-b41b-137b431287fb_periodStartLabel_en-US" xlink:label="lab_ifrs-full_ContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance, beginning of year</link:label>
    <link:label id="lab_ifrs-full_ContractLiabilities_f2821cac-aa03-4226-89ae-5102f6853d0d_periodEndLabel_en-US" xlink:label="lab_ifrs-full_ContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance, end of year</link:label>
    <link:label id="lab_ifrs-full_ContractLiabilities_label_en-US" xlink:label="lab_ifrs-full_ContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContractLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ContractLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ContractLiabilities" xlink:to="lab_ifrs-full_ContractLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract_3b032613-41f3-486a-b794-c5b701d88b37_terseLabel_en-US" xlink:label="lab_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of revenue from contracts with customers [Abstract]</link:label>
    <link:label id="lab_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract_label_en-US" xlink:label="lab_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of revenue from contracts with customers [Abstract]</link:label>
    <link:label id="lab_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract_documentation_en-US" xlink:label="lab_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of revenue from contracts with customers [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract" xlink:href="oncyf-20241231.xsd#oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract" xlink:to="lab_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_1f0e8540-89ef-4c4e-80c7-b47183a7a842_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Forfeited during the year (shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_label_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of share options forfeited in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TradeAndOtherCurrentPayables_1ca44cb8-ecad-4358-8638-fb4450aec6ee_terseLabel_en-US" xlink:label="lab_ifrs-full_TradeAndOtherCurrentPayables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued liabilities (note 7)</link:label>
    <link:label id="lab_ifrs-full_TradeAndOtherCurrentPayables_725243c1-b3c9-4dd7-a223-a96821b372fa_totalLabel_en-US" xlink:label="lab_ifrs-full_TradeAndOtherCurrentPayables" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:label id="lab_ifrs-full_TradeAndOtherCurrentPayables_1c4b9f4c-a1ea-4e63-96e1-7805d9190826_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_TradeAndOtherCurrentPayables" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:label id="lab_ifrs-full_TradeAndOtherCurrentPayables_label_en-US" xlink:label="lab_ifrs-full_TradeAndOtherCurrentPayables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade and other current payables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TradeAndOtherCurrentPayables" xlink:to="lab_ifrs-full_TradeAndOtherCurrentPayables" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_59dc6889-c2b2-44ea-8310-98e269df05df_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation - property and equipment (notes 6, 20)</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for depreciation and amortisation expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:to="lab_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_c6c51917-bf6e-4a5e-8d63-7c45cb722ea6_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected life</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Option life, share options granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfOptionLifeShareOptionsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:to="lab_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ClinicalTrialExpense_bfe275d7-fc4d-4949-9d6b-1141db574d7a_terseLabel_en-US" xlink:label="lab_oncyf_ClinicalTrialExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Clinical trial expenses</link:label>
    <link:label id="lab_oncyf_ClinicalTrialExpense_label_en-US" xlink:label="lab_oncyf_ClinicalTrialExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Clinical Trial Expense</link:label>
    <link:label id="lab_oncyf_ClinicalTrialExpense_documentation_en-US" xlink:label="lab_oncyf_ClinicalTrialExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Clinical Trial Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ClinicalTrialExpense" xlink:href="oncyf-20241231.xsd#oncyf_ClinicalTrialExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ClinicalTrialExpense" xlink:to="lab_oncyf_ClinicalTrialExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_8bb9e571-1247-41fa-8b8c-83974bde1034_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of number and weighted average remaining contractual life of outstanding share options [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of number and weighted average remaining contractual life of outstanding share options [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:to="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_c0b35741-6489-4efa-9c68-f86adfd4397d_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_69ba1ecf-f3a6-464f-b0ac-07d728702e70_verboseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Remaining Contractual Life (years)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average remaining contractual life of outstanding share options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:to="lab_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GrossLeaseLiabilities_8461b540-665a-4401-b893-739bcb9fc2b7_verboseLabel_en-US" xlink:label="lab_ifrs-full_GrossLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total undiscounted lease liabilities</link:label>
    <link:label id="lab_ifrs-full_GrossLeaseLiabilities_label_en-US" xlink:label="lab_ifrs-full_GrossLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GrossLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GrossLeaseLiabilities" xlink:to="lab_ifrs-full_GrossLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_UnusedTaxCreditsMember_8b79acb2-bfbb-442b-9de3-f5b65f020d4a_terseLabel_en-US" xlink:label="lab_ifrs-full_UnusedTaxCreditsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-refundable federal investment tax credits</link:label>
    <link:label id="lab_ifrs-full_UnusedTaxCreditsMember_label_en-US" xlink:label="lab_ifrs-full_UnusedTaxCreditsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unused tax credits [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnusedTaxCreditsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_UnusedTaxCreditsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_UnusedTaxCreditsMember" xlink:to="lab_ifrs-full_UnusedTaxCreditsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet_15f7d12c-f6a7-4f38-8180-905b343324ce_terseLabel_en-US" xlink:label="lab_oncyf_IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash impact of foreign exchange</link:label>
    <link:label id="lab_oncyf_IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet_label_en-US" xlink:label="lab_oncyf_IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Through Foreign Exchange, Financial Assets (Liabilities), Net</link:label>
    <link:label id="lab_oncyf_IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet_documentation_en-US" xlink:label="lab_oncyf_IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Through Foreign Exchange, Financial Assets (Liabilities), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet" xlink:href="oncyf-20241231.xsd#oncyf_IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet" xlink:to="lab_oncyf_IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DepreciationPropertyPlantAndEquipment_89796990-07c0-44cd-a777-997185fa4f60_terseLabel_en-US" xlink:label="lab_ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_ifrs-full_DepreciationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, property, plant and equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DepreciationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:to="lab_ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_SharesUnderAtthemarketAgreementMember_91d80327-7ae5-4c88-84c2-a9157a3e7db2_terseLabel_en-US" xlink:label="lab_oncyf_SharesUnderAtthemarketAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">At-the-market equity distribution agreement</link:label>
    <link:label id="lab_oncyf_SharesUnderAtthemarketAgreementMember_label_en-US" xlink:label="lab_oncyf_SharesUnderAtthemarketAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Under At-the-market Agreement [Member]</link:label>
    <link:label id="lab_oncyf_SharesUnderAtthemarketAgreementMember_documentation_en-US" xlink:label="lab_oncyf_SharesUnderAtthemarketAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Shares Under At-the-market Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesUnderAtthemarketAgreementMember" xlink:href="oncyf-20241231.xsd#oncyf_SharesUnderAtthemarketAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SharesUnderAtthemarketAgreementMember" xlink:to="lab_oncyf_SharesUnderAtthemarketAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_SaleOfStockAxis_c1e7ddaa-d8b5-4e80-ac4c-9e1b7ca0afb8_terseLabel_en-US" xlink:label="lab_oncyf_SaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale Of Stock [Axis]</link:label>
    <link:label id="lab_oncyf_SaleOfStockAxis_label_en-US" xlink:label="lab_oncyf_SaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Of Stock [Axis]</link:label>
    <link:label id="lab_oncyf_SaleOfStockAxis_documentation_en-US" xlink:label="lab_oncyf_SaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale Of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockAxis" xlink:href="oncyf-20241231.xsd#oncyf_SaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SaleOfStockAxis" xlink:to="lab_oncyf_SaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_Currency1Table_74baf1cd-7b95-4a8d-8072-147b57fd8435_terseLabel_en-US" xlink:label="lab_oncyf_Currency1Table" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency1 [Table]</link:label>
    <link:label id="lab_oncyf_Currency1Table_label_en-US" xlink:label="lab_oncyf_Currency1Table" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Currency1 [Table]</link:label>
    <link:label id="lab_oncyf_Currency1Table_documentation_en-US" xlink:label="lab_oncyf_Currency1Table" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Currency1 [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_Currency1Table" xlink:href="oncyf-20241231.xsd#oncyf_Currency1Table"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_Currency1Table" xlink:to="lab_oncyf_Currency1Table" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ComputerEquipmentMember_ed0a1993-7176-4745-a1ed-90867979a3ce_terseLabel_en-US" xlink:label="lab_ifrs-full_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computer equipment</link:label>
    <link:label id="lab_ifrs-full_ComputerEquipmentMember_ca436bbe-6da8-4a8d-9376-23c6bbf3f2db_verboseLabel_en-US" xlink:label="lab_ifrs-full_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Computer Equipment</link:label>
    <link:label id="lab_ifrs-full_ComputerEquipmentMember_label_en-US" xlink:label="lab_ifrs-full_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer equipment [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComputerEquipmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComputerEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComputerEquipmentMember" xlink:to="lab_ifrs-full_ComputerEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LossesOnDisposalsOfPropertyPlantAndEquipment_01cc8268-1d36-4150-8eec-e7cdcdd6c115_terseLabel_en-US" xlink:label="lab_ifrs-full_LossesOnDisposalsOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Losses on disposals of property, plant and equipment</link:label>
    <link:label id="lab_ifrs-full_LossesOnDisposalsOfPropertyPlantAndEquipment_label_en-US" xlink:label="lab_ifrs-full_LossesOnDisposalsOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Losses on disposals of property, plant and equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LossesOnDisposalsOfPropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LossesOnDisposalsOfPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LossesOnDisposalsOfPropertyPlantAndEquipment" xlink:to="lab_ifrs-full_LossesOnDisposalsOfPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfIncomeTaxExplanatory_800308f1-aa37-4d11-b1a9-c55b6fd7f9a1_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfIncomeTaxExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of income tax [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:to="lab_ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities_7477ec99-6b66-43d1-b68a-ac945eb89d7e_totalLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Cash (used in) provided by investing activities</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) investing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TypesOfRisksAxis_7d80af12-7373-49aa-817d-1418ea17d2f6_terseLabel_en-US" xlink:label="lab_ifrs-full_TypesOfRisksAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Types of risks [axis]</link:label>
    <link:label id="lab_ifrs-full_TypesOfRisksAxis_label_en-US" xlink:label="lab_ifrs-full_TypesOfRisksAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Types of risks [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfRisksAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfRisksAxis" xlink:to="lab_ifrs-full_TypesOfRisksAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_AdditionalCashFlowDisclosuresAbstract_label_en-US" xlink:label="lab_oncyf_AdditionalCashFlowDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Cash Flow Disclosures [Abstract]</link:label>
    <link:label id="lab_oncyf_AdditionalCashFlowDisclosuresAbstract_documentation_en-US" xlink:label="lab_oncyf_AdditionalCashFlowDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Additional Cash Flow Disclosures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_AdditionalCashFlowDisclosuresAbstract" xlink:href="oncyf-20241231.xsd#oncyf_AdditionalCashFlowDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_AdditionalCashFlowDisclosuresAbstract" xlink:to="lab_oncyf_AdditionalCashFlowDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LevelsOfFairValueHierarchyDomain_3736729c-981f-46b7-8192-a079d9292464_terseLabel_en-US" xlink:label="lab_ifrs-full_LevelsOfFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Levels of fair value hierarchy</link:label>
    <link:label id="lab_ifrs-full_LevelsOfFairValueHierarchyDomain_label_en-US" xlink:label="lab_ifrs-full_LevelsOfFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Levels of fair value hierarchy [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LevelsOfFairValueHierarchyDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LevelsOfFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LevelsOfFairValueHierarchyDomain" xlink:to="lab_ifrs-full_LevelsOfFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RangeAxis_6f75f107-367f-44a8-8ec0-470cdd1e34d9_terseLabel_en-US" xlink:label="lab_ifrs-full_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [axis]</link:label>
    <link:label id="lab_ifrs-full_RangeAxis_label_en-US" xlink:label="lab_ifrs-full_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RangeAxis" xlink:to="lab_ifrs-full_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_UnusedNetOperatingLossCarryForwardsMember_f298cba0-28eb-4bca-adfe-0b9db91a0b5d_terseLabel_en-US" xlink:label="lab_oncyf_UnusedNetOperatingLossCarryForwardsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-capital losses carried forward</link:label>
    <link:label id="lab_oncyf_UnusedNetOperatingLossCarryForwardsMember_label_en-US" xlink:label="lab_oncyf_UnusedNetOperatingLossCarryForwardsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unused Net Operating Loss Carry Forwards [Member]</link:label>
    <link:label id="lab_oncyf_UnusedNetOperatingLossCarryForwardsMember_documentation_en-US" xlink:label="lab_oncyf_UnusedNetOperatingLossCarryForwardsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Unused Net Operating Loss Carry Forwards [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_UnusedNetOperatingLossCarryForwardsMember" xlink:href="oncyf-20241231.xsd#oncyf_UnusedNetOperatingLossCarryForwardsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_UnusedNetOperatingLossCarryForwardsMember" xlink:to="lab_oncyf_UnusedNetOperatingLossCarryForwardsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfOtherProvisionsDomain_08e526be-8587-4681-8f90-7eab88714d2b_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfOtherProvisionsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of other provisions</link:label>
    <link:label id="lab_ifrs-full_ClassesOfOtherProvisionsDomain_label_en-US" xlink:label="lab_ifrs-full_ClassesOfOtherProvisionsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of other provisions [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfOtherProvisionsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfOtherProvisionsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfOtherProvisionsDomain" xlink:to="lab_ifrs-full_ClassesOfOtherProvisionsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_19735b5f-63eb-4111-a945-c0a7f2ae8785_periodStartLabel_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, beginning of the year (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_80049036-936a-46c8-8a88-91e2e7577338_periodEndLabel_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, end of the year (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_label_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of other equity instruments outstanding in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_9fbeb683-71d8-40ea-829c-0208103f2d94_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of terms and conditions of share-based payment arrangement [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of terms and conditions of share-based payment arrangement [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ProceedsfromWarrantExercises1_d8525058-b01d-4782-8e83-dc43d3acc17f_terseLabel_en-US" xlink:label="lab_oncyf_ProceedsfromWarrantExercises1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross proceeds from warrant exercises</link:label>
    <link:label id="lab_oncyf_ProceedsfromWarrantExercises1_label_en-US" xlink:label="lab_oncyf_ProceedsfromWarrantExercises1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Warrant Exercises1</link:label>
    <link:label id="lab_oncyf_ProceedsfromWarrantExercises1_documentation_en-US" xlink:label="lab_oncyf_ProceedsfromWarrantExercises1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds from Warrant Exercises1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ProceedsfromWarrantExercises1" xlink:href="oncyf-20241231.xsd#oncyf_ProceedsfromWarrantExercises1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ProceedsfromWarrantExercises1" xlink:to="lab_oncyf_ProceedsfromWarrantExercises1" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_7b4be935-d881-4a4d-baed-a95f02759049_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure weighted average assumptions and fair value of options</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of indirect measurement of fair value of goods or services received, share options granted during period [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:to="lab_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityLineItems_8f92d912-28ec-4010-a70d-ad3a6b76bfd5_terseLabel_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of changes in equity [line items]</link:label>
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityLineItems_label_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of changes in equity [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfChangesInEquityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="lab_ifrs-full_StatementOfChangesInEquityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfCashFlowStatementExplanatory_1c56beb4-1149-4396-b399-4ff99cefa842_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfCashFlowStatementExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Cash Flow Disclosures</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfCashFlowStatementExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfCashFlowStatementExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of cash flow statement [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfCashFlowStatementExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfCashFlowStatementExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfCashFlowStatementExplanatory" xlink:to="lab_ifrs-full_DisclosureOfCashFlowStatementExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_StockOptionsOutstandingAbstract_4e556f4c-110f-44d8-803f-23e2c68d1814_terseLabel_en-US" xlink:label="lab_oncyf_StockOptionsOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of options</link:label>
    <link:label id="lab_oncyf_StockOptionsOutstandingAbstract_label_en-US" xlink:label="lab_oncyf_StockOptionsOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Options, Outstanding [Abstract]</link:label>
    <link:label id="lab_oncyf_StockOptionsOutstandingAbstract_documentation_en-US" xlink:label="lab_oncyf_StockOptionsOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Options, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_StockOptionsOutstandingAbstract" xlink:href="oncyf-20241231.xsd#oncyf_StockOptionsOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_StockOptionsOutstandingAbstract" xlink:to="lab_oncyf_StockOptionsOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Level2OfFairValueHierarchyMember_c797a3e6-8f36-47c8-a543-741e778f5e73_terseLabel_en-US" xlink:label="lab_ifrs-full_Level2OfFairValueHierarchyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_ifrs-full_Level2OfFairValueHierarchyMember_label_en-US" xlink:label="lab_ifrs-full_Level2OfFairValueHierarchyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Level 2 of fair value hierarchy [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Level2OfFairValueHierarchyMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Level2OfFairValueHierarchyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Level2OfFairValueHierarchyMember" xlink:to="lab_ifrs-full_Level2OfFairValueHierarchyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfCashFlowsAbstract_935b6c0f-80d6-4faf-8bb7-6bca227a291e_terseLabel_en-US" xlink:label="lab_ifrs-full_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of cash flows [abstract]</link:label>
    <link:label id="lab_ifrs-full_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_ifrs-full_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of cash flows [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract" xlink:to="lab_ifrs-full_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentRegistrationStatement_189fc1a2-83a5-4080-883a-9a85a78a41cb_terseLabel_en-US" xlink:label="lab_dei_DocumentRegistrationStatement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Registration Statement</link:label>
    <link:label id="lab_dei_DocumentRegistrationStatement_label_en-US" xlink:label="lab_dei_DocumentRegistrationStatement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Registration Statement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentRegistrationStatement" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentRegistrationStatement" xlink:to="lab_dei_DocumentRegistrationStatement" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProceedsFromExerciseOfWarrants_2504d4c6-a1db-41d2-b0a6-c5db46f8a827_terseLabel_en-US" xlink:label="lab_ifrs-full_ProceedsFromExerciseOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from exercise of warrant derivative (note 9)</link:label>
    <link:label id="lab_ifrs-full_ProceedsFromExerciseOfWarrants_label_en-US" xlink:label="lab_ifrs-full_ProceedsFromExerciseOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from exercise of warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromExerciseOfWarrants" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromExerciseOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProceedsFromExerciseOfWarrants" xlink:to="lab_ifrs-full_ProceedsFromExerciseOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsDomain_11d1dc58-6ae8-4e42-a0f3-12c2dbab0098_terseLabel_en-US" xlink:label="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ranges of exercise prices for outstanding share options</link:label>
    <link:label id="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsDomain_label_en-US" xlink:label="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ranges of exercise prices for outstanding share options [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsDomain" xlink:to="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_38951f2e-d061-4726-bace-aa58564935ae_terseLabel_en-US" xlink:label="lab_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of Share Capital, Reserves And Other Equity Interest [Abstract]</link:label>
    <link:label id="lab_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_label_en-US" xlink:label="lab_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Share Capital, Reserves And Other Equity Interest [Abstract]</link:label>
    <link:label id="lab_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_documentation_en-US" xlink:label="lab_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of Share Capital, Reserves And Other Equity Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract" xlink:href="oncyf-20241231.xsd#oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract" xlink:to="lab_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_d38c09f6-bfdf-4ba4-b063-3d7f23559d22_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised_7b0d0b14-c79d-4b4f-8a30-966e7fb4beaa_terseLabel_en-US" xlink:label="lab_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unused tax credits</link:label>
    <link:label id="lab_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised_label_en-US" xlink:label="lab_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unused tax credits for which no deferred tax asset recognised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised" xlink:to="lab_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_ContactPersonnelEmailAddress_7955d91b-4c14-452b-bb50-4a16eec36987_terseLabel_en-US" xlink:label="lab_dei_ContactPersonnelEmailAddress" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contact Personnel Email Address</link:label>
    <link:label id="lab_dei_ContactPersonnelEmailAddress_label_en-US" xlink:label="lab_dei_ContactPersonnelEmailAddress" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contact Personnel Email Address</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ContactPersonnelEmailAddress" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_ContactPersonnelEmailAddress"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_ContactPersonnelEmailAddress" xlink:to="lab_dei_ContactPersonnelEmailAddress" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_0998541e-4d4e-494d-9251-96a01621aa50_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue recognition</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for recognition of revenue [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_RightOfUseAssetsAbstract_efd5cf37-c078-4c47-8a0b-fde96ce61888_terseLabel_en-US" xlink:label="lab_oncyf_RightOfUseAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right-Of-Use Assets [Abstract]</link:label>
    <link:label id="lab_oncyf_RightOfUseAssetsAbstract_label_en-US" xlink:label="lab_oncyf_RightOfUseAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-Of-Use Assets [Abstract]</link:label>
    <link:label id="lab_oncyf_RightOfUseAssetsAbstract_documentation_en-US" xlink:label="lab_oncyf_RightOfUseAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Right-Of-Use Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_RightOfUseAssetsAbstract" xlink:href="oncyf-20241231.xsd#oncyf_RightOfUseAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_RightOfUseAssetsAbstract" xlink:to="lab_oncyf_RightOfUseAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_fb11cd14-b0f8-4d0b-85f6-cd5b2b7a3b75_periodStartLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, beginning of the year (cad per share)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_58d4d8cf-0614-4f15-be4f-dedd75e36ddb_periodEndLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, beginning of the year (cad per share)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_13cc27a2-9ba2-4614-a383-dd2652b11c10_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price (cad per share)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average exercise price of share options outstanding in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AssetsAbstract_af83230e-8198-46ed-addb-f69a785e8d05_terseLabel_en-US" xlink:label="lab_ifrs-full_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_ifrs-full_AssetsAbstract_label_en-US" xlink:label="lab_ifrs-full_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AssetsAbstract" xlink:to="lab_ifrs-full_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_9195ad10-4148-4acf-b875-cc4f6e10421c_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LeaseLiabilities_01123f87-1e5c-46b4-9968-25d1017e34c8_periodStartLabel_en-US" xlink:label="lab_ifrs-full_LeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Lease liabilities, beginning balance</link:label>
    <link:label id="lab_ifrs-full_LeaseLiabilities_d414c488-e2be-47e4-ad35-792248f2e410_periodEndLabel_en-US" xlink:label="lab_ifrs-full_LeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Lease liabilities, ending balance</link:label>
    <link:label id="lab_ifrs-full_LeaseLiabilities_label_en-US" xlink:label="lab_ifrs-full_LeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LeaseLiabilities" xlink:to="lab_ifrs-full_LeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfFinancialPositionAbstract_72aa2955-a65a-4046-9385-2bc9da623a1b_terseLabel_en-US" xlink:label="lab_ifrs-full_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of financial position [abstract]</link:label>
    <link:label id="lab_ifrs-full_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_ifrs-full_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of financial position [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="lab_ifrs-full_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfGeographicalAreasTable_70b38a2c-4432-4860-a7e7-ed249963ab62_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfGeographicalAreasTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of geographical areas [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfGeographicalAreasTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfGeographicalAreasTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of geographical areas [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfGeographicalAreasTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfGeographicalAreasTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasTable" xlink:to="lab_ifrs-full_DisclosureOfGeographicalAreasTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ComponentsOfEquityAxis_70586ff9-c4f0-4e13-a637-c2edf0f07099_terseLabel_en-US" xlink:label="lab_ifrs-full_ComponentsOfEquityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Components of equity [axis]</link:label>
    <link:label id="lab_ifrs-full_ComponentsOfEquityAxis_label_en-US" xlink:label="lab_ifrs-full_ComponentsOfEquityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Components of equity [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis" xlink:to="lab_ifrs-full_ComponentsOfEquityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_GeneralAndAdministrativeExpense1Abstract_cbc4b7cb-43a6-4475-a586-07692d04d078_terseLabel_en-US" xlink:label="lab_oncyf_GeneralAndAdministrativeExpense1Abstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative expenses</link:label>
    <link:label id="lab_oncyf_GeneralAndAdministrativeExpense1Abstract_label_en-US" xlink:label="lab_oncyf_GeneralAndAdministrativeExpense1Abstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General And Administrative Expense 1 [Abstract]</link:label>
    <link:label id="lab_oncyf_GeneralAndAdministrativeExpense1Abstract_documentation_en-US" xlink:label="lab_oncyf_GeneralAndAdministrativeExpense1Abstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">General And Administrative Expense 1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_GeneralAndAdministrativeExpense1Abstract" xlink:href="oncyf-20241231.xsd#oncyf_GeneralAndAdministrativeExpense1Abstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_GeneralAndAdministrativeExpense1Abstract" xlink:to="lab_oncyf_GeneralAndAdministrativeExpense1Abstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TaxEffectOfForeignTaxRates_bc470f9f-1c47-4759-919b-117dc7dda580_terseLabel_en-US" xlink:label="lab_ifrs-full_TaxEffectOfForeignTaxRates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Difference in tax rates</link:label>
    <link:label id="lab_ifrs-full_TaxEffectOfForeignTaxRates_label_en-US" xlink:label="lab_ifrs-full_TaxEffectOfForeignTaxRates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax effect of foreign tax rates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TaxEffectOfForeignTaxRates" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TaxEffectOfForeignTaxRates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TaxEffectOfForeignTaxRates" xlink:to="lab_ifrs-full_TaxEffectOfForeignTaxRates" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTextBlock_3ff259a8-5535-444f-8dd2-e3f914397f45_terseLabel_en-US" xlink:label="lab_oncyf_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Lease liabilities</link:label>
    <link:label id="lab_oncyf_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTextBlock_label_en-US" xlink:label="lab_oncyf_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Quantitative Information About Lease Liabilities [Text Block]</link:label>
    <link:label id="lab_oncyf_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTextBlock_documentation_en-US" xlink:label="lab_oncyf_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Quantitative Information About Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTextBlock" xlink:href="oncyf-20241231.xsd#oncyf_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTextBlock" xlink:to="lab_oncyf_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock_eaccaf3b-5517-4ccc-8859-4b5bc7e77d30_terseLabel_en-US" xlink:label="lab_oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Other cash flow disclosures</link:label>
    <link:label id="lab_oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock_label_en-US" xlink:label="lab_oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Cash Flow, Supplemental Disclosures1 [Table Text Block]</link:label>
    <link:label id="lab_oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock_documentation_en-US" xlink:label="lab_oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule of Cash Flow, Supplemental Disclosures1 [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock" xlink:href="oncyf-20241231.xsd#oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock" xlink:to="lab_oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain_5ee7b838-27d8-4d0f-942d-c6a61ebe73de_terseLabel_en-US" xlink:label="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Temporary difference, unused tax losses and unused tax credits</link:label>
    <link:label id="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain_label_en-US" xlink:label="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary difference, unused tax losses and unused tax credits [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain" xlink:to="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AccrualsClassifiedAsCurrent_e88de376-3464-4e03-910c-5ef250c09250_terseLabel_en-US" xlink:label="lab_ifrs-full_AccrualsClassifiedAsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_ifrs-full_AccrualsClassifiedAsCurrent_label_en-US" xlink:label="lab_ifrs-full_AccrualsClassifiedAsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accruals classified as current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccrualsClassifiedAsCurrent" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AccrualsClassifiedAsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AccrualsClassifiedAsCurrent" xlink:to="lab_ifrs-full_AccrualsClassifiedAsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_SaleOfStockDomain_fed27aed-82a3-4400-aea0-91d4d1274faf_terseLabel_en-US" xlink:label="lab_oncyf_SaleOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale Of Stock [Domain]</link:label>
    <link:label id="lab_oncyf_SaleOfStockDomain_label_en-US" xlink:label="lab_oncyf_SaleOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Of Stock [Domain]</link:label>
    <link:label id="lab_oncyf_SaleOfStockDomain_documentation_en-US" xlink:label="lab_oncyf_SaleOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for Sale Of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockDomain" xlink:href="oncyf-20241231.xsd#oncyf_SaleOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SaleOfStockDomain" xlink:to="lab_oncyf_SaleOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementThresholdConsecutiveTradingDays_37cb95f4-8cfd-4120-9191-1f4db33283d0_terseLabel_en-US" xlink:label="lab_oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementThresholdConsecutiveTradingDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of warrant or right, threshold consecutive trading days</link:label>
    <link:label id="lab_oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementThresholdConsecutiveTradingDays_label_en-US" xlink:label="lab_oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementThresholdConsecutiveTradingDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Equity Instruments In Share-Based Payment Arrangement, Threshold Consecutive Trading Days</link:label>
    <link:label id="lab_oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementThresholdConsecutiveTradingDays_documentation_en-US" xlink:label="lab_oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementThresholdConsecutiveTradingDays" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Equity Instruments In Share-Based Payment Arrangement, Threshold Consecutive Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementThresholdConsecutiveTradingDays" xlink:href="oncyf-20241231.xsd#oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementThresholdConsecutiveTradingDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementThresholdConsecutiveTradingDays" xlink:to="lab_oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementThresholdConsecutiveTradingDays" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_61887554-0d49-4da6-8c82-96d1744ca88d_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted during the year (shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_label_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of share options granted in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_a26f434a-254e-4c2f-919a-0d055687c0cd_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense (note 11)</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through share-based payment transactions, equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_SegmentDisclosuresAbstract_label_en-US" xlink:label="lab_oncyf_SegmentDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Disclosures [Abstract]</link:label>
    <link:label id="lab_oncyf_SegmentDisclosuresAbstract_documentation_en-US" xlink:label="lab_oncyf_SegmentDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Segment Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SegmentDisclosuresAbstract" xlink:href="oncyf-20241231.xsd#oncyf_SegmentDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SegmentDisclosuresAbstract" xlink:to="lab_oncyf_SegmentDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ExercisePriceRangeThreeMember_c8b90df5-1f3c-46cf-9476-2353b144d90c_terseLabel_en-US" xlink:label="lab_oncyf_ExercisePriceRangeThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">$3.02 - $3.90</link:label>
    <link:label id="lab_oncyf_ExercisePriceRangeThreeMember_label_en-US" xlink:label="lab_oncyf_ExercisePriceRangeThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range Three [Member]</link:label>
    <link:label id="lab_oncyf_ExercisePriceRangeThreeMember_documentation_en-US" xlink:label="lab_oncyf_ExercisePriceRangeThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Exercise Price Range Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ExercisePriceRangeThreeMember" xlink:href="oncyf-20241231.xsd#oncyf_ExercisePriceRangeThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ExercisePriceRangeThreeMember" xlink:to="lab_oncyf_ExercisePriceRangeThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LeaseLiabilitiesAbstract_2a75f040-3913-4683-aae8-03d206e725bc_terseLabel_en-US" xlink:label="lab_ifrs-full_LeaseLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease Liabilities [Abstract]</link:label>
    <link:label id="lab_ifrs-full_LeaseLiabilitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_LeaseLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease liabilities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LeaseLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LeaseLiabilitiesAbstract" xlink:to="lab_ifrs-full_LeaseLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_OtherExpensesAndAdjustmentsLineItems_a00ed9b4-5692-4c37-a7f7-5633045fadc7_terseLabel_en-US" xlink:label="lab_oncyf_OtherExpensesAndAdjustmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Expenses And Adjustments [Line Items]</link:label>
    <link:label id="lab_oncyf_OtherExpensesAndAdjustmentsLineItems_label_en-US" xlink:label="lab_oncyf_OtherExpensesAndAdjustmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Expenses And Adjustments [Line Items]</link:label>
    <link:label id="lab_oncyf_OtherExpensesAndAdjustmentsLineItems_documentation_en-US" xlink:label="lab_oncyf_OtherExpensesAndAdjustmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Line Items] for Other Expenses And Adjustments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OtherExpensesAndAdjustmentsLineItems" xlink:href="oncyf-20241231.xsd#oncyf_OtherExpensesAndAdjustmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_OtherExpensesAndAdjustmentsLineItems" xlink:to="lab_oncyf_OtherExpensesAndAdjustmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory_8491dc71-086e-403f-9acb-adf5cdca975d_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Total undiscounted lease liability</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of maturity analysis of operating lease payments [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdditionalPaidinCapital_012fcd39-480d-44b9-a42e-6ad9cb32b70a_terseLabel_en-US" xlink:label="lab_ifrs-full_AdditionalPaidinCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contributed surplus (note 11)</link:label>
    <link:label id="lab_ifrs-full_AdditionalPaidinCapital_label_en-US" xlink:label="lab_ifrs-full_AdditionalPaidinCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionalPaidinCapital" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdditionalPaidinCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdditionalPaidinCapital" xlink:to="lab_ifrs-full_AdditionalPaidinCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_efa8809a-f9dc-4fa4-952e-764d71f8060c_terseLabel_en-US" xlink:label="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-adjusting events after reporting period [axis]</link:label>
    <link:label id="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_label_en-US" xlink:label="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-adjusting events after reporting period [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ShareIssueRelatedCost_1bb5fd3a-6377-44d6-b3ee-6dee9b8074ec_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_ShareIssueRelatedCost" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Share issue costs (note 10)</link:label>
    <link:label id="lab_ifrs-full_ShareIssueRelatedCost_8f6520ef-4fca-4651-9268-f467e01445eb_negatedLabel_en-US" xlink:label="lab_ifrs-full_ShareIssueRelatedCost" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Share issue costs</link:label>
    <link:label id="lab_ifrs-full_ShareIssueRelatedCost_acde5595-736a-4c9e-adde-967bf98ba595_terseLabel_en-US" xlink:label="lab_ifrs-full_ShareIssueRelatedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share issue related cost</link:label>
    <link:label id="lab_ifrs-full_ShareIssueRelatedCost_label_en-US" xlink:label="lab_ifrs-full_ShareIssueRelatedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share issue related cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareIssueRelatedCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShareIssueRelatedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ShareIssueRelatedCost" xlink:to="lab_ifrs-full_ShareIssueRelatedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WarrantLiability_dd47e105-4383-4414-bbba-a7f5c295b4f6_terseLabel_en-US" xlink:label="lab_ifrs-full_WarrantLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant liability</link:label>
    <link:label id="lab_ifrs-full_WarrantLiability_label_en-US" xlink:label="lab_ifrs-full_WarrantLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WarrantLiability" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WarrantLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WarrantLiability" xlink:to="lab_ifrs-full_WarrantLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_14ea9875-3f4e-439b-980e-6a07d9e28ca9_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected volatility, share options granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:to="lab_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalTable_69a30d7f-6a41-4904-b651-dfe2f30c54ca_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of classes of share capital [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of classes of share capital [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:to="lab_ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_IntellectualPropertyExpense_871ccda7-1591-4bd0-b475-079fdebfa34b_terseLabel_en-US" xlink:label="lab_oncyf_IntellectualPropertyExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intellectual property expenses</link:label>
    <link:label id="lab_oncyf_IntellectualPropertyExpense_label_en-US" xlink:label="lab_oncyf_IntellectualPropertyExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intellectual Property Expense</link:label>
    <link:label id="lab_oncyf_IntellectualPropertyExpense_documentation_en-US" xlink:label="lab_oncyf_IntellectualPropertyExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Intellectual Property Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IntellectualPropertyExpense" xlink:href="oncyf-20241231.xsd#oncyf_IntellectualPropertyExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_IntellectualPropertyExpense" xlink:to="lab_oncyf_IntellectualPropertyExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_37209d76-1111-4a01-bcd4-e1f6f27d51bd_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_ContactPersonnelName_def3b13d-6cc9-4f9b-943e-061074269634_terseLabel_en-US" xlink:label="lab_dei_ContactPersonnelName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contact Personnel Name</link:label>
    <link:label id="lab_dei_ContactPersonnelName_label_en-US" xlink:label="lab_dei_ContactPersonnelName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contact Personnel Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ContactPersonnelName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_ContactPersonnelName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_ContactPersonnelName" xlink:to="lab_dei_ContactPersonnelName" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RightofuseAssets_86a056ea-3fd6-46e1-8c5e-f782a0a5e2f4_terseLabel_en-US" xlink:label="lab_ifrs-full_RightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets (note 8)</link:label>
    <link:label id="lab_ifrs-full_RightofuseAssets_468f2bbe-60da-4275-85e1-dc067b98c30d_periodStartLabel_en-US" xlink:label="lab_ifrs-full_RightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets, beginning balance</link:label>
    <link:label id="lab_ifrs-full_RightofuseAssets_cbb27a84-9959-4dd4-8f00-bb5d685cdbca_periodEndLabel_en-US" xlink:label="lab_ifrs-full_RightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets, ending balance</link:label>
    <link:label id="lab_ifrs-full_RightofuseAssets_8660c1c7-e7f0-452d-be4a-6835617d502e_verboseLabel_en-US" xlink:label="lab_ifrs-full_RightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use-assets</link:label>
    <link:label id="lab_ifrs-full_RightofuseAssets_label_en-US" xlink:label="lab_ifrs-full_RightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-of-use assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RightofuseAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RightofuseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RightofuseAssets" xlink:to="lab_ifrs-full_RightofuseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities_1700d2ff-3e33-4394-a41f-2cc5bc8f2d63_verboseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Increase through new leases, liabilities arising from financing activities</link:label>
    <link:label id="lab_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities_d529e379-79fc-4aff-81c7-51a9e59e66bf_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities_label_en-US" xlink:label="lab_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase through new leases, liabilities arising from financing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" xlink:to="lab_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Liabilities_a09803f1-356f-403b-99d0-7fbe94c5164c_totalLabel_en-US" xlink:label="lab_ifrs-full_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_ifrs-full_Liabilities_label_en-US" xlink:label="lab_ifrs-full_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Liabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Liabilities" xlink:to="lab_ifrs-full_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_9af8de08-3cb8-45dd-b4fd-9909f0e668c8_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of financial instruments [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations_8064554f-fd0e-43e8-9687-4b102a78e2ec_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Standards and Interpretations Issued but Not Yet Effective</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of expected impact of initial application of new standards or interpretations [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xlink:to="lab_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory_417a86eb-b582-4bfe-bed1-8cb8af48174e_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital Disclosures</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of objectives, policies and processes for managing capital [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory" xlink:to="lab_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCountry_a6b0ab35-519f-4e14-a127-5563ddd29e5b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Country</link:label>
    <link:label id="lab_dei_EntityAddressCountry_label_en-US" xlink:label="lab_dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Country</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCountry" xlink:to="lab_dei_EntityAddressCountry" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16_5b268d7c-6339-4c37-b774-25e0315ca18e_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average rate</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average lessee's incremental borrowing rate applied to lease liabilities recognised at date of initial application of IFRS 16</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16" xlink:to="lab_ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfSharesIssued_abcbd95b-8872-4be0-bde2-191938414b17_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share capital issued (shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfSharesIssued_bfaa2080-ad9a-4873-9bd7-91f1be92e7a6_periodStartLabel_en-US" xlink:label="lab_ifrs-full_NumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Share capital issued, beginning (shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfSharesIssued_8d022bf1-4549-46d3-afea-ca1623e3dea7_periodEndLabel_en-US" xlink:label="lab_ifrs-full_NumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Share capital issued ending (shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfSharesIssued_label_en-US" xlink:label="lab_ifrs-full_NumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of shares issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfSharesIssued" xlink:to="lab_ifrs-full_NumberOfSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashOutflowForLeases_538780f0-3ad1-498d-9063-3e0a414c8efa_negatedLabel_en-US" xlink:label="lab_ifrs-full_CashOutflowForLeases" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payment of lease liabilities (note 8)</link:label>
    <link:label id="lab_ifrs-full_CashOutflowForLeases_bd37dae2-53f6-4d1f-a516-addcfe2460ab_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_CashOutflowForLeases" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payment of lease liabilities</link:label>
    <link:label id="lab_ifrs-full_CashOutflowForLeases_label_en-US" xlink:label="lab_ifrs-full_CashOutflowForLeases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash outflow for leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashOutflowForLeases" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashOutflowForLeases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashOutflowForLeases" xlink:to="lab_ifrs-full_CashOutflowForLeases" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_a117e00f-5979-4324-85be-30896f44075b_terseLabel_en-US" xlink:label="lab_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LaterThanFiveYearsMember_8c90f87f-89c9-48c9-95b1-5e58fa3a1603_terseLabel_en-US" xlink:label="lab_ifrs-full_LaterThanFiveYearsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">More than five years</link:label>
    <link:label id="lab_ifrs-full_LaterThanFiveYearsMember_label_en-US" xlink:label="lab_ifrs-full_LaterThanFiveYearsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than five years [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanFiveYearsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LaterThanFiveYearsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LaterThanFiveYearsMember" xlink:to="lab_ifrs-full_LaterThanFiveYearsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_dbc72c5a-854f-41ee-be6a-d1680a7180ec_terseLabel_en-US" xlink:label="lab_oncyf_SummaryOfSignificantAccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary Of Significant Accounting Policies [Abstract]</link:label>
    <link:label id="lab_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_label_en-US" xlink:label="lab_oncyf_SummaryOfSignificantAccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary Of Significant Accounting Policies [Abstract]</link:label>
    <link:label id="lab_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_documentation_en-US" xlink:label="lab_oncyf_SummaryOfSignificantAccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Summary Of Significant Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract" xlink:href="oncyf-20241231.xsd#oncyf_SummaryOfSignificantAccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract" xlink:to="lab_oncyf_SummaryOfSignificantAccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_IncomeStatementLocation1Domain_a72d8c72-250c-42d2-8a2e-48a55941a155_terseLabel_en-US" xlink:label="lab_oncyf_IncomeStatementLocation1Domain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location1 [Domain]</link:label>
    <link:label id="lab_oncyf_IncomeStatementLocation1Domain_label_en-US" xlink:label="lab_oncyf_IncomeStatementLocation1Domain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location1 [Domain]</link:label>
    <link:label id="lab_oncyf_IncomeStatementLocation1Domain_documentation_en-US" xlink:label="lab_oncyf_IncomeStatementLocation1Domain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for Income Statement Location1 [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IncomeStatementLocation1Domain" xlink:href="oncyf-20241231.xsd#oncyf_IncomeStatementLocation1Domain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_IncomeStatementLocation1Domain" xlink:to="lab_oncyf_IncomeStatementLocation1Domain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_258253d1-9f92-4d42-b50b-bc804543142a_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_UnusedCapitalLossCarryForwardNetMember_7a88fa21-10c6-4bf3-9175-8dda9cd86309_terseLabel_en-US" xlink:label="lab_oncyf_UnusedCapitalLossCarryForwardNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net capital losses carried forward</link:label>
    <link:label id="lab_oncyf_UnusedCapitalLossCarryForwardNetMember_label_en-US" xlink:label="lab_oncyf_UnusedCapitalLossCarryForwardNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unused Capital Loss Carry Forward, Net [Member]</link:label>
    <link:label id="lab_oncyf_UnusedCapitalLossCarryForwardNetMember_documentation_en-US" xlink:label="lab_oncyf_UnusedCapitalLossCarryForwardNetMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Unused Capital Loss Carry Forward, Net [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_UnusedCapitalLossCarryForwardNetMember" xlink:href="oncyf-20241231.xsd#oncyf_UnusedCapitalLossCarryForwardNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_UnusedCapitalLossCarryForwardNetMember" xlink:to="lab_oncyf_UnusedCapitalLossCarryForwardNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_8f2f8801-be26-46ed-9668-909e0d194a32_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development costs</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for research and development expense [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GrossCarryingAmountMember_87a2eeeb-4346-4632-9e5b-3489e51dcb0b_terseLabel_en-US" xlink:label="lab_ifrs-full_GrossCarryingAmountMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost</link:label>
    <link:label id="lab_ifrs-full_GrossCarryingAmountMember_label_en-US" xlink:label="lab_ifrs-full_GrossCarryingAmountMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross carrying amount [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossCarryingAmountMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GrossCarryingAmountMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GrossCarryingAmountMember" xlink:to="lab_ifrs-full_GrossCarryingAmountMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_IssueOfEquityShares_de26cb17-3103-4d87-b79d-2b6f752fa264_verboseLabel_en-US" xlink:label="lab_oncyf_IssueOfEquityShares" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Issued pursuant to public offering (in shares)</link:label>
    <link:label id="lab_oncyf_IssueOfEquityShares_36383d70-4a9a-47f0-9d4c-985ff8d8fadd_terseLabel_en-US" xlink:label="lab_oncyf_IssueOfEquityShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issued (in shares)</link:label>
    <link:label id="lab_oncyf_IssueOfEquityShares_label_en-US" xlink:label="lab_oncyf_IssueOfEquityShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issue Of Equity, Shares</link:label>
    <link:label id="lab_oncyf_IssueOfEquityShares_documentation_en-US" xlink:label="lab_oncyf_IssueOfEquityShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Issue Of Equity, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IssueOfEquityShares" xlink:href="oncyf-20241231.xsd#oncyf_IssueOfEquityShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_IssueOfEquityShares" xlink:to="lab_oncyf_IssueOfEquityShares" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_WarrantExercisePrice_0fc414cf-b0ae-4f80-87e2-7b723f773884_terseLabel_en-US" xlink:label="lab_oncyf_WarrantExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise price (usd per share)</link:label>
    <link:label id="lab_oncyf_WarrantExercisePrice_label_en-US" xlink:label="lab_oncyf_WarrantExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant Exercise Price</link:label>
    <link:label id="lab_oncyf_WarrantExercisePrice_documentation_en-US" xlink:label="lab_oncyf_WarrantExercisePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrant Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantExercisePrice" xlink:href="oncyf-20241231.xsd#oncyf_WarrantExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_WarrantExercisePrice" xlink:to="lab_oncyf_WarrantExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_ca6846fb-9c6d-45f9-b54f-fa456698c170_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Capital</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of share capital, reserves and other equity interest [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:to="lab_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_f3c619ed-6052-4851-82e2-9e5e01f09b51_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ConcentrationRiskType1Domain_9b49cc48-c193-40fe-bab8-98c0c8b662c8_terseLabel_en-US" xlink:label="lab_oncyf_ConcentrationRiskType1Domain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type1 [Domain]</link:label>
    <link:label id="lab_oncyf_ConcentrationRiskType1Domain_label_en-US" xlink:label="lab_oncyf_ConcentrationRiskType1Domain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type1 [Domain]</link:label>
    <link:label id="lab_oncyf_ConcentrationRiskType1Domain_documentation_en-US" xlink:label="lab_oncyf_ConcentrationRiskType1Domain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for Concentration Risk Type1 [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ConcentrationRiskType1Domain" xlink:href="oncyf-20241231.xsd#oncyf_ConcentrationRiskType1Domain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ConcentrationRiskType1Domain" xlink:to="lab_oncyf_ConcentrationRiskType1Domain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_fa02078e-2ec6-4d3f-a96d-fcc8a720d834_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:to="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_PurchaseObligationCommitmentProductionServiceAgreementPercentage_db9fefda-ec34-4b25-9932-5fa9d70ed38f_terseLabel_en-US" xlink:label="lab_oncyf_PurchaseObligationCommitmentProductionServiceAgreementPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Production service agreement, percentage</link:label>
    <link:label id="lab_oncyf_PurchaseObligationCommitmentProductionServiceAgreementPercentage_label_en-US" xlink:label="lab_oncyf_PurchaseObligationCommitmentProductionServiceAgreementPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Obligation, Commitment, Production Service Agreement, Percentage</link:label>
    <link:label id="lab_oncyf_PurchaseObligationCommitmentProductionServiceAgreementPercentage_documentation_en-US" xlink:label="lab_oncyf_PurchaseObligationCommitmentProductionServiceAgreementPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Purchase Obligation, Commitment, Production Service Agreement, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_PurchaseObligationCommitmentProductionServiceAgreementPercentage" xlink:href="oncyf-20241231.xsd#oncyf_PurchaseObligationCommitmentProductionServiceAgreementPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_PurchaseObligationCommitmentProductionServiceAgreementPercentage" xlink:to="lab_oncyf_PurchaseObligationCommitmentProductionServiceAgreementPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_a9c21e94-88c3-484e-80b2-ac82bbb04339_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashEquivalents_5524001b-9405-4c3f-ac48-d40223b7118e_terseLabel_en-US" xlink:label="lab_ifrs-full_CashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_ifrs-full_CashEquivalents_label_en-US" xlink:label="lab_ifrs-full_CashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashEquivalents" xlink:to="lab_ifrs-full_CashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_TaxEffectOfTaxPools_07c6dd33-d757-4dd5-857a-cc6a73beb75c_terseLabel_en-US" xlink:label="lab_oncyf_TaxEffectOfTaxPools" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revaluation of tax balances</link:label>
    <link:label id="lab_oncyf_TaxEffectOfTaxPools_label_en-US" xlink:label="lab_oncyf_TaxEffectOfTaxPools" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Effect Of Tax Pools</link:label>
    <link:label id="lab_oncyf_TaxEffectOfTaxPools_documentation_en-US" xlink:label="lab_oncyf_TaxEffectOfTaxPools" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tax Effect Of Tax Pools</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TaxEffectOfTaxPools" xlink:href="oncyf-20241231.xsd#oncyf_TaxEffectOfTaxPools"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_TaxEffectOfTaxPools" xlink:to="lab_oncyf_TaxEffectOfTaxPools" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight1_1d0aa667-8dba-450c-b221-55ec06ea69ce_terseLabel_en-US" xlink:label="lab_oncyf_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of common shares issuable per warrant (in shares)</link:label>
    <link:label id="lab_oncyf_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight1_label_en-US" xlink:label="lab_oncyf_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right, Number Of Securities Called By Each Warrant Or Right1</link:label>
    <link:label id="lab_oncyf_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight1_documentation_en-US" xlink:label="lab_oncyf_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right, Number Of Securities Called By Each Warrant Or Right1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight1" xlink:href="oncyf-20241231.xsd#oncyf_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight1" xlink:to="lab_oncyf_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight1" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ConcentrationRiskNumber_05b8a7dd-18d0-44fd-9244-ce75cc9c0fe6_terseLabel_en-US" xlink:label="lab_oncyf_ConcentrationRiskNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration, number</link:label>
    <link:label id="lab_oncyf_ConcentrationRiskNumber_label_en-US" xlink:label="lab_oncyf_ConcentrationRiskNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Number</link:label>
    <link:label id="lab_oncyf_ConcentrationRiskNumber_documentation_en-US" xlink:label="lab_oncyf_ConcentrationRiskNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Concentration Risk, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ConcentrationRiskNumber" xlink:href="oncyf-20241231.xsd#oncyf_ConcentrationRiskNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ConcentrationRiskNumber" xlink:to="lab_oncyf_ConcentrationRiskNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_56686aa6-aa5b-427f-93b9-48199e898d16_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract_789ec399-6d17-4270-b8e7-2ccce8a2d411_terseLabel_en-US" xlink:label="lab_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Share-based Payment Arrangements [Abstract]</link:label>
    <link:label id="lab_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract_label_en-US" xlink:label="lab_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Share-based Payment Arrangements [Abstract]</link:label>
    <link:label id="lab_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract_documentation_en-US" xlink:label="lab_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Share-based Payment Arrangements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract" xlink:href="oncyf-20241231.xsd#oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract" xlink:to="lab_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_60f126ca-9a94-40e1-aaac-54efc458e0a8_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:to="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_BottomOfRangeMember_88d28685-c417-413b-97c3-a3bb13e9296d_terseLabel_en-US" xlink:label="lab_ifrs-full_BottomOfRangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_ifrs-full_BottomOfRangeMember_label_en-US" xlink:label="lab_ifrs-full_BottomOfRangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bottom of range [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BottomOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BottomOfRangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BottomOfRangeMember" xlink:to="lab_ifrs-full_BottomOfRangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory_0e086167-6453-48aa-8aae-527fa210ab70_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract Liability</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of revenue from contracts with customers [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory" xlink:to="lab_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_926f031d-3f30-4dff-8114-c03884c183ee_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for property, plant and equipment [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_2880c07a-d5af-4560-add7-d3446bd4b6e1_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ShareIssueRelatedCostCommissions_e837ee53-9494-47ba-9f0f-15cb03485a25_terseLabel_en-US" xlink:label="lab_oncyf_ShareIssueRelatedCostCommissions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share issue related cost, commissions</link:label>
    <link:label id="lab_oncyf_ShareIssueRelatedCostCommissions_label_en-US" xlink:label="lab_oncyf_ShareIssueRelatedCostCommissions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Issue Related Cost, Commissions</link:label>
    <link:label id="lab_oncyf_ShareIssueRelatedCostCommissions_documentation_en-US" xlink:label="lab_oncyf_ShareIssueRelatedCostCommissions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Issue Related Cost, Commissions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ShareIssueRelatedCostCommissions" xlink:href="oncyf-20241231.xsd#oncyf_ShareIssueRelatedCostCommissions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ShareIssueRelatedCostCommissions" xlink:to="lab_oncyf_ShareIssueRelatedCostCommissions" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_a30f5336-c3d4-4ea2-854a-20e0d1d75c7d_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory_8c5e5cc7-642c-4f12-9cd3-91936a6ffc57_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Disclosures</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of entity's operating segments [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherReceivables_ddca23e6-0197-4c51-be57-455ed260220a_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_ifrs-full_OtherReceivables_label_en-US" xlink:label="lab_ifrs-full_OtherReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherReceivables" xlink:to="lab_ifrs-full_OtherReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock_762f0a78-ed85-4003-84c9-e52e93625e2e_terseLabel_en-US" xlink:label="lab_oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of balances in foreign currencies</link:label>
    <link:label id="lab_oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock_label_en-US" xlink:label="lab_oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Foreign Currency Held [Table Text Block]</link:label>
    <link:label id="lab_oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock_documentation_en-US" xlink:label="lab_oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule Of Foreign Currency Held [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock" xlink:href="oncyf-20241231.xsd#oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock" xlink:to="lab_oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_cdf235de-12da-4be5-b37f-62da68094238_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of non-adjusting events after reporting period [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of non-adjusting events after reporting period [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:to="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfLiabilitiesAxis_cb6ae777-68e6-42e5-a5a5-7ba22891f56f_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfLiabilitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of liabilities [axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfLiabilitiesAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfLiabilitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of liabilities [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfLiabilitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis" xlink:to="lab_ifrs-full_ClassesOfLiabilitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ExercisePriceRangeOneMember_89eceaaa-123e-4b54-b0bf-bb2c9b368b58_terseLabel_en-US" xlink:label="lab_oncyf_ExercisePriceRangeOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">$0.54 - $1.79</link:label>
    <link:label id="lab_oncyf_ExercisePriceRangeOneMember_label_en-US" xlink:label="lab_oncyf_ExercisePriceRangeOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range One [Member]</link:label>
    <link:label id="lab_oncyf_ExercisePriceRangeOneMember_documentation_en-US" xlink:label="lab_oncyf_ExercisePriceRangeOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Exercise Price Range One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ExercisePriceRangeOneMember" xlink:href="oncyf-20241231.xsd#oncyf_ExercisePriceRangeOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ExercisePriceRangeOneMember" xlink:to="lab_oncyf_ExercisePriceRangeOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_ae32a90d-7a3f-4a43-9b4d-f2e99be43285_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title and Position [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title and Position [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ExercisePriceRangeFiveMember_7f107f8d-ebcf-47ad-b203-8751bc1ef260_terseLabel_en-US" xlink:label="lab_oncyf_ExercisePriceRangeFiveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">$7.42 - $52.63</link:label>
    <link:label id="lab_oncyf_ExercisePriceRangeFiveMember_label_en-US" xlink:label="lab_oncyf_ExercisePriceRangeFiveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range Five [Member]</link:label>
    <link:label id="lab_oncyf_ExercisePriceRangeFiveMember_documentation_en-US" xlink:label="lab_oncyf_ExercisePriceRangeFiveMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Exercise Price Range Five [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ExercisePriceRangeFiveMember" xlink:href="oncyf-20241231.xsd#oncyf_ExercisePriceRangeFiveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ExercisePriceRangeFiveMember" xlink:to="lab_oncyf_ExercisePriceRangeFiveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_96f28b3a-bb90-48c0-a1c4-cf4e36e8a407_terseLabel_en-US" xlink:label="lab_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of warrant derivative (notes 9, 17)</link:label>
    <link:label id="lab_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_7e86bda6-03e0-4c40-b74c-25218a92684f_verboseLabel_en-US" xlink:label="lab_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value</link:label>
    <link:label id="lab_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_label_en-US" xlink:label="lab_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gains (losses) on change in fair value of derivatives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives" xlink:to="lab_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_InterestRevenueExpense_29eb47fb-6653-4ae2-b345-cc11e7f720cc_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_InterestRevenueExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest expense (income), net</link:label>
    <link:label id="lab_ifrs-full_InterestRevenueExpense_label_en-US" xlink:label="lab_ifrs-full_InterestRevenueExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest income (expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestRevenueExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InterestRevenueExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestRevenueExpense" xlink:to="lab_ifrs-full_InterestRevenueExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_NumberOfWarrantsExercised_f5ee32f4-3e05-4a14-a462-6b59683c90b3_negatedTerseLabel_en-US" xlink:label="lab_oncyf_NumberOfWarrantsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_oncyf_NumberOfWarrantsExercised_8ad0bfdb-47dc-4645-b973-a153639e698f_terseLabel_en-US" xlink:label="lab_oncyf_NumberOfWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_oncyf_NumberOfWarrantsExercised_label_en-US" xlink:label="lab_oncyf_NumberOfWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Warrants Exercised</link:label>
    <link:label id="lab_oncyf_NumberOfWarrantsExercised_documentation_en-US" xlink:label="lab_oncyf_NumberOfWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Warrants Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_NumberOfWarrantsExercised" xlink:href="oncyf-20241231.xsd#oncyf_NumberOfWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_NumberOfWarrantsExercised" xlink:to="lab_oncyf_NumberOfWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_95e713f7-946d-467d-860a-aadcf289fb61_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title and Position [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title and Position [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits_4fee0a66-3b9d-4919-bcfe-d04cd50ec070_terseLabel_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Termination benefits</link:label>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits_label_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Key management personnel compensation, termination benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits" xlink:to="lab_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities_1a5a8a06-703e-4280-bbf8-eac9f2f995c2_terseLabel_en-US" xlink:label="lab_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue recognized</link:label>
    <link:label id="lab_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities_label_en-US" xlink:label="lab_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Decrease through performance obligation being satisfied, contract liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities" xlink:to="lab_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_b405ef4f-5345-4837-9d65-a9ae3c336721_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RetainedEarnings_5ec7bad9-1159-4a1d-8811-02cf2feaf001_terseLabel_en-US" xlink:label="lab_ifrs-full_RetainedEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_ifrs-full_RetainedEarnings_label_en-US" xlink:label="lab_ifrs-full_RetainedEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetainedEarnings" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RetainedEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RetainedEarnings" xlink:to="lab_ifrs-full_RetainedEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted_66eca708-61b5-4cbf-8266-29b150081f5c_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average fair value of options (cad per share)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average fair value at measurement date, share options granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" xlink:to="lab_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_country_CA_7e9daf35-7c32-44d4-aa53-bea704624e17_terseLabel_en-US" xlink:label="lab_country_CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Canada</link:label>
    <link:label id="lab_country_CA_label_en-US" xlink:label="lab_country_CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CANADA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_CA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_CA" xlink:to="lab_country_CA" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_42fca12b-133e-4fd9-b28a-210fad6286ef_terseLabel_en-US" xlink:label="lab_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Corporate Information And Statement Of IFRS Compliance [Abstract]</link:label>
    <link:label id="lab_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_label_en-US" xlink:label="lab_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate information and statement of IFRS compliance [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract" xlink:to="lab_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_FairValueOfWarrantDerivativeExercised_cd058adb-bd17-4fbf-aa3f-225db11b5293_negatedTerseLabel_en-US" xlink:label="lab_oncyf_FairValueOfWarrantDerivativeExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Exercised</link:label>
    <link:label id="lab_oncyf_FairValueOfWarrantDerivativeExercised_label_en-US" xlink:label="lab_oncyf_FairValueOfWarrantDerivativeExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Of Warrant Derivative, Exercised</link:label>
    <link:label id="lab_oncyf_FairValueOfWarrantDerivativeExercised_documentation_en-US" xlink:label="lab_oncyf_FairValueOfWarrantDerivativeExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair Value Of Warrant Derivative, Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_FairValueOfWarrantDerivativeExercised" xlink:href="oncyf-20241231.xsd#oncyf_FairValueOfWarrantDerivativeExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_FairValueOfWarrantDerivativeExercised" xlink:to="lab_oncyf_FairValueOfWarrantDerivativeExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_3661faeb-2f0b-4eaf-b279-dc7d5ef38add_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of terms and conditions of share-based payment arrangement [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of terms and conditions of share-based payment arrangement [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CarryingAmountMember_9fa277d6-bbf0-41a9-b462-9cd8f28f90d9_terseLabel_en-US" xlink:label="lab_ifrs-full_CarryingAmountMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Carrying amount</link:label>
    <link:label id="lab_ifrs-full_CarryingAmountMember_label_en-US" xlink:label="lab_ifrs-full_CarryingAmountMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Carrying amount [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CarryingAmountMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CarryingAmountMember" xlink:to="lab_ifrs-full_CarryingAmountMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_NumberOfStockOptionPlans_5908148c-578f-4829-87a9-c75bd08e2ed6_terseLabel_en-US" xlink:label="lab_oncyf_NumberOfStockOptionPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of plans</link:label>
    <link:label id="lab_oncyf_NumberOfStockOptionPlans_label_en-US" xlink:label="lab_oncyf_NumberOfStockOptionPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Stock Option Plans</link:label>
    <link:label id="lab_oncyf_NumberOfStockOptionPlans_documentation_en-US" xlink:label="lab_oncyf_NumberOfStockOptionPlans" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Stock Option Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_NumberOfStockOptionPlans" xlink:href="oncyf-20241231.xsd#oncyf_NumberOfStockOptionPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_NumberOfStockOptionPlans" xlink:to="lab_oncyf_NumberOfStockOptionPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_DetailedDisclosureOfTradeAndOtherPayablesExplanatoryTableTextBlock_45dece2f-98c3-4fca-a748-b00816e520d8_terseLabel_en-US" xlink:label="lab_oncyf_DetailedDisclosureOfTradeAndOtherPayablesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of accounts payables and accrued liabilities</link:label>
    <link:label id="lab_oncyf_DetailedDisclosureOfTradeAndOtherPayablesExplanatoryTableTextBlock_label_en-US" xlink:label="lab_oncyf_DetailedDisclosureOfTradeAndOtherPayablesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Detailed Disclosure Of Trade And Other Payables Explanatory [Table Text Block]</link:label>
    <link:label id="lab_oncyf_DetailedDisclosureOfTradeAndOtherPayablesExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_oncyf_DetailedDisclosureOfTradeAndOtherPayablesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Detailed Disclosure Of Trade And Other Payables Explanatory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DetailedDisclosureOfTradeAndOtherPayablesExplanatoryTableTextBlock" xlink:href="oncyf-20241231.xsd#oncyf_DetailedDisclosureOfTradeAndOtherPayablesExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_DetailedDisclosureOfTradeAndOtherPayablesExplanatoryTableTextBlock" xlink:to="lab_oncyf_DetailedDisclosureOfTradeAndOtherPayablesExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_1cdf5b47-b927-4063-97f4-0e5e7be0d016_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercised during the year (cad per share)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average exercise price of share options exercised in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_A2022SharesUnderAtTheMarketAgreementUnitedStatesMember_82361c3c-660d-4e64-b0f8-9a73cda21ede_terseLabel_en-US" xlink:label="lab_oncyf_A2022SharesUnderAtTheMarketAgreementUnitedStatesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2022 United States ATM</link:label>
    <link:label id="lab_oncyf_A2022SharesUnderAtTheMarketAgreementUnitedStatesMember_label_en-US" xlink:label="lab_oncyf_A2022SharesUnderAtTheMarketAgreementUnitedStatesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2022 Shares Under At-the-market Agreement, United States [Member]</link:label>
    <link:label id="lab_oncyf_A2022SharesUnderAtTheMarketAgreementUnitedStatesMember_documentation_en-US" xlink:label="lab_oncyf_A2022SharesUnderAtTheMarketAgreementUnitedStatesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2022 Shares Under At-the-market Agreement, United States</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_A2022SharesUnderAtTheMarketAgreementUnitedStatesMember" xlink:href="oncyf-20241231.xsd#oncyf_A2022SharesUnderAtTheMarketAgreementUnitedStatesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_A2022SharesUnderAtTheMarketAgreementUnitedStatesMember" xlink:to="lab_oncyf_A2022SharesUnderAtTheMarketAgreementUnitedStatesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfShareCapitalAxis_eee5de12-7683-418f-926e-fce49d955af5_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfShareCapitalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of share capital [axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfShareCapitalAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfShareCapitalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of share capital [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis" xlink:to="lab_ifrs-full_ClassesOfShareCapitalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_69516cc5-e4ba-403e-bdc5-4767140a6817_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of quantitative information about right-of-use assets [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of quantitative information about right-of-use assets [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:to="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations_99ff8d58-7c84-4c47-a5d8-f5535b026a25_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adoption of New Accounting Standards</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of initial application of standards or interpretations [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations" xlink:to="lab_ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_4d086e19-5695-4f54-af03-a103e514ce3f_terseLabel_en-US" xlink:label="lab_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]</link:label>
    <link:label id="lab_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_label_en-US" xlink:label="lab_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="lab_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subclassifications of assets, liabilities and equities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract" xlink:to="lab_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_2c302226-0301-48fe-ae56-1c38ce0870db_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency translation</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for foreign currency translation [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_PropertyPlantEquipmentRelatedTemporaryDifferencesMember_d47ab820-5135-4d4e-bc70-58c648ea7929_terseLabel_en-US" xlink:label="lab_oncyf_PropertyPlantEquipmentRelatedTemporaryDifferencesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_oncyf_PropertyPlantEquipmentRelatedTemporaryDifferencesMember_label_en-US" xlink:label="lab_oncyf_PropertyPlantEquipmentRelatedTemporaryDifferencesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant, Equipment Related Temporary Differences [Member]</link:label>
    <link:label id="lab_oncyf_PropertyPlantEquipmentRelatedTemporaryDifferencesMember_documentation_en-US" xlink:label="lab_oncyf_PropertyPlantEquipmentRelatedTemporaryDifferencesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Property, Plant, Equipment And Intellectual Property Related Temporary Differences [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_PropertyPlantEquipmentRelatedTemporaryDifferencesMember" xlink:href="oncyf-20241231.xsd#oncyf_PropertyPlantEquipmentRelatedTemporaryDifferencesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_PropertyPlantEquipmentRelatedTemporaryDifferencesMember" xlink:to="lab_oncyf_PropertyPlantEquipmentRelatedTemporaryDifferencesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LevelsOfFairValueHierarchyAxis_dd573fc3-cf2d-4b27-a22a-917ba67c11dd_terseLabel_en-US" xlink:label="lab_ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Levels of fair value hierarchy [axis]</link:label>
    <link:label id="lab_ifrs-full_LevelsOfFairValueHierarchyAxis_label_en-US" xlink:label="lab_ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Levels of fair value hierarchy [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:to="lab_ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfGeographicalAreasLineItems_670fe0c9-ca67-4ff7-875b-9d1d74bc9eed_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfGeographicalAreasLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of geographical areas [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfGeographicalAreasLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfGeographicalAreasLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of geographical areas [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfGeographicalAreasLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems" xlink:to="lab_ifrs-full_DisclosureOfGeographicalAreasLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfLeasesExplanatory_66b0e220-a0a6-4b6c-abfd-d0f1abb8cf9e_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfLeasesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfLeasesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfLeasesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of leases [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfLeasesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfLeasesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfLeasesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfLeasesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_2e0a4e2c-2327-4ea0-9210-38d8f7295257_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of property, plant and equipment [domain]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_label_en-US" xlink:label="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of property, plant and equipment [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:to="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentLiabilitiesAbstract_139b433f-7190-4f8d-96ef-8c88339400e5_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities</link:label>
    <link:label id="lab_ifrs-full_CurrentLiabilitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_CurrentLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current liabilities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract" xlink:to="lab_ifrs-full_CurrentLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IssuedCapital_635bdbb1-1948-41ce-8eb5-55dbecd76021_terseLabel_en-US" xlink:label="lab_ifrs-full_IssuedCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share capital (note 10) &#160;&#160;Authorized: unlimited &#160;&#160;Issued: December&#160;31, 2024 &#8211; 80,020,131 December&#160;31, 2023 &#8211; 74,423,960</link:label>
    <link:label id="lab_ifrs-full_IssuedCapital_label_en-US" xlink:label="lab_ifrs-full_IssuedCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issued capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapital" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssuedCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IssuedCapital" xlink:to="lab_ifrs-full_IssuedCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ExercisePriceRangeTwoMember_b7387946-b4dd-45a6-b87d-c1b1cd6b8c97_terseLabel_en-US" xlink:label="lab_oncyf_ExercisePriceRangeTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">$1.80 - $3.01</link:label>
    <link:label id="lab_oncyf_ExercisePriceRangeTwoMember_label_en-US" xlink:label="lab_oncyf_ExercisePriceRangeTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range Two [Member]</link:label>
    <link:label id="lab_oncyf_ExercisePriceRangeTwoMember_documentation_en-US" xlink:label="lab_oncyf_ExercisePriceRangeTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Exercise Price Range Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ExercisePriceRangeTwoMember" xlink:href="oncyf-20241231.xsd#oncyf_ExercisePriceRangeTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ExercisePriceRangeTwoMember" xlink:to="lab_oncyf_ExercisePriceRangeTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_country_BB_5e210c6a-7c5b-461a-9c2b-546925eddd58_terseLabel_en-US" xlink:label="lab_country_BB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BARBADOS</link:label>
    <link:label id="lab_country_BB_label_en-US" xlink:label="lab_country_BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BARBADOS</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_BB" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_BB"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_BB" xlink:to="lab_country_BB" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_c6e3e8d4-36d4-4491-aa21-4b6bf106ac86_terseLabel_en-US" xlink:label="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Types of share-based payment arrangements</link:label>
    <link:label id="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_label_en-US" xlink:label="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Types of share-based payment arrangements [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" xlink:to="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ResearchAndDevelopmentExpense1Member_521d52be-ec8b-4cbc-afc0-ad3613bd8257_terseLabel_en-US" xlink:label="lab_oncyf_ResearchAndDevelopmentExpense1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_oncyf_ResearchAndDevelopmentExpense1Member_label_en-US" xlink:label="lab_oncyf_ResearchAndDevelopmentExpense1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development Expense 1 [Member]</link:label>
    <link:label id="lab_oncyf_ResearchAndDevelopmentExpense1Member_documentation_en-US" xlink:label="lab_oncyf_ResearchAndDevelopmentExpense1Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research And Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ResearchAndDevelopmentExpense1Member" xlink:href="oncyf-20241231.xsd#oncyf_ResearchAndDevelopmentExpense1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ResearchAndDevelopmentExpense1Member" xlink:to="lab_oncyf_ResearchAndDevelopmentExpense1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory_271b57c3-d6de-42a3-87c8-6114ebdfdd09_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of stock options outstanding and exercisable by range of exercise price</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of range of exercise prices of outstanding share options [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_NumberOfSharesReservedForIssueUnderOptionsAndContractsForSaleOfSharesPercentageOfCommonSharesMaximum_85565942-57f7-4fbd-80aa-bdb187e5592a_terseLabel_en-US" xlink:label="lab_oncyf_NumberOfSharesReservedForIssueUnderOptionsAndContractsForSaleOfSharesPercentageOfCommonSharesMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common shares reserved for issuance, maximum percentage</link:label>
    <link:label id="lab_oncyf_NumberOfSharesReservedForIssueUnderOptionsAndContractsForSaleOfSharesPercentageOfCommonSharesMaximum_label_en-US" xlink:label="lab_oncyf_NumberOfSharesReservedForIssueUnderOptionsAndContractsForSaleOfSharesPercentageOfCommonSharesMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Shares Reserved For Issue Under Options And Contracts For Sale Of Shares, Percentage Of Common Shares, Maximum</link:label>
    <link:label id="lab_oncyf_NumberOfSharesReservedForIssueUnderOptionsAndContractsForSaleOfSharesPercentageOfCommonSharesMaximum_documentation_en-US" xlink:label="lab_oncyf_NumberOfSharesReservedForIssueUnderOptionsAndContractsForSaleOfSharesPercentageOfCommonSharesMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Shares Reserved For Issue Under Options And Contracts For Sale Of Shares, Percentage Of Common Shares, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_NumberOfSharesReservedForIssueUnderOptionsAndContractsForSaleOfSharesPercentageOfCommonSharesMaximum" xlink:href="oncyf-20241231.xsd#oncyf_NumberOfSharesReservedForIssueUnderOptionsAndContractsForSaleOfSharesPercentageOfCommonSharesMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_NumberOfSharesReservedForIssueUnderOptionsAndContractsForSaleOfSharesPercentageOfCommonSharesMaximum" xlink:to="lab_oncyf_NumberOfSharesReservedForIssueUnderOptionsAndContractsForSaleOfSharesPercentageOfCommonSharesMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_A2024SharesUnderAtTheMarketAgreementUnitedStatesMember_35208f51-90e5-49bb-8be7-5249d91ef90f_terseLabel_en-US" xlink:label="lab_oncyf_A2024SharesUnderAtTheMarketAgreementUnitedStatesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2024 United States ATM</link:label>
    <link:label id="lab_oncyf_A2024SharesUnderAtTheMarketAgreementUnitedStatesMember_label_en-US" xlink:label="lab_oncyf_A2024SharesUnderAtTheMarketAgreementUnitedStatesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2024 Shares Under At-the-market Agreement, United States [Member]</link:label>
    <link:label id="lab_oncyf_A2024SharesUnderAtTheMarketAgreementUnitedStatesMember_documentation_en-US" xlink:label="lab_oncyf_A2024SharesUnderAtTheMarketAgreementUnitedStatesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2024 Shares Under At-the-market Agreement, United States</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_A2024SharesUnderAtTheMarketAgreementUnitedStatesMember" xlink:href="oncyf-20241231.xsd#oncyf_A2024SharesUnderAtTheMarketAgreementUnitedStatesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_A2024SharesUnderAtTheMarketAgreementUnitedStatesMember" xlink:to="lab_oncyf_A2024SharesUnderAtTheMarketAgreementUnitedStatesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_DisclosureofsharebasedpaymentarrangementAbstract_77a56d92-9cef-46d6-abf8-fab18deab3b0_terseLabel_en-US" xlink:label="lab_oncyf_DisclosureofsharebasedpaymentarrangementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of share-based payment arrangement [Abstract]</link:label>
    <link:label id="lab_oncyf_DisclosureofsharebasedpaymentarrangementAbstract_label_en-US" xlink:label="lab_oncyf_DisclosureofsharebasedpaymentarrangementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of share-based payment arrangement [Abstract]</link:label>
    <link:label id="lab_oncyf_DisclosureofsharebasedpaymentarrangementAbstract_documentation_en-US" xlink:label="lab_oncyf_DisclosureofsharebasedpaymentarrangementAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of share-based payment arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofsharebasedpaymentarrangementAbstract" xlink:href="oncyf-20241231.xsd#oncyf_DisclosureofsharebasedpaymentarrangementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_DisclosureofsharebasedpaymentarrangementAbstract" xlink:to="lab_oncyf_DisclosureofsharebasedpaymentarrangementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_6e0bce0f-c96c-47aa-bc93-bc4679778497_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other permanent differences</link:label>
    <link:label id="lab_ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_label_en-US" xlink:label="lab_ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other tax effects for reconciliation between accounting profit and tax expense (income)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:to="lab_ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract_ccf74b6b-3711-4123-b184-038557f72f30_terseLabel_en-US" xlink:label="lab_oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Notes And Other Explanatory Information [Abstract]</link:label>
    <link:label id="lab_oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract_label_en-US" xlink:label="lab_oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Notes And Other Explanatory Information [Abstract]</link:label>
    <link:label id="lab_oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract_documentation_en-US" xlink:label="lab_oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Notes And Other Explanatory Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract" xlink:href="oncyf-20241231.xsd#oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract" xlink:to="lab_oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustedWeightedAverageShares_0f7b0f49-6997-44bf-a0cf-60d7f5401f44_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustedWeightedAverageShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average number of shares (diluted) (shares)</link:label>
    <link:label id="lab_ifrs-full_AdjustedWeightedAverageShares_label_en-US" xlink:label="lab_ifrs-full_AdjustedWeightedAverageShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average number of ordinary shares used in calculating diluted earnings per share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustedWeightedAverageShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustedWeightedAverageShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustedWeightedAverageShares" xlink:to="lab_ifrs-full_AdjustedWeightedAverageShares" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_18cfc1d0-d511-4d7d-995c-ac47d9930c36_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about financial instruments [abstract]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about financial instruments [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="lab_ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_cd3b6ab2-fca4-4980-b247-80a3ab5eb2f5_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Assets_426e4eba-e973-4dfb-bb12-de62ce55fc84_totalLabel_en-US" xlink:label="lab_ifrs-full_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_ifrs-full_Assets_label_en-US" xlink:label="lab_ifrs-full_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Assets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Assets" xlink:to="lab_ifrs-full_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NotLaterThanOneYearMember_44d28af8-dbf6-4c67-817f-ad7d396a5e61_terseLabel_en-US" xlink:label="lab_ifrs-full_NotLaterThanOneYearMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Less than one year</link:label>
    <link:label id="lab_ifrs-full_NotLaterThanOneYearMember_label_en-US" xlink:label="lab_ifrs-full_NotLaterThanOneYearMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Not later than one year [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NotLaterThanOneYearMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NotLaterThanOneYearMember" xlink:to="lab_ifrs-full_NotLaterThanOneYearMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives_6480b235-c218-4851-a499-31e62def7286_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of warrant derivative (notes 9, 17)</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for gains (losses) on change in fair value of derivatives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives" xlink:to="lab_ifrs-full_AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_6a21a269-0119-41ca-b50f-d40ec3468e3b_terseLabel_en-US" xlink:label="lab_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation warrant expenses (note 11)</link:label>
    <link:label id="lab_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_label_en-US" xlink:label="lab_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expense from equity-settled share-based payment transactions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:to="lab_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProceedsFromIssuingShares_c6947975-cfec-4336-9462-baf6d83b5c7f_terseLabel_en-US" xlink:label="lab_ifrs-full_ProceedsFromIssuingShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from share issuance</link:label>
    <link:label id="lab_ifrs-full_ProceedsFromIssuingShares_label_en-US" xlink:label="lab_ifrs-full_ProceedsFromIssuingShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from issuing shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromIssuingShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromIssuingShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProceedsFromIssuingShares" xlink:to="lab_ifrs-full_ProceedsFromIssuingShares" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_ccf7fe5c-3d22-48cb-9df1-6386e1869bea_terseLabel_en-US" xlink:label="lab_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_label_en-US" xlink:label="lab_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected dividend as percentage, share options granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:to="lab_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ConcentrationRisk1Table_4d696137-ca49-447a-b1bb-39956c1cc550_terseLabel_en-US" xlink:label="lab_oncyf_ConcentrationRisk1Table" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk1 [Table]</link:label>
    <link:label id="lab_oncyf_ConcentrationRisk1Table_label_en-US" xlink:label="lab_oncyf_ConcentrationRisk1Table" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk1 [Table]</link:label>
    <link:label id="lab_oncyf_ConcentrationRisk1Table_documentation_en-US" xlink:label="lab_oncyf_ConcentrationRisk1Table" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Concentration Risk1 [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ConcentrationRisk1Table" xlink:href="oncyf-20241231.xsd#oncyf_ConcentrationRisk1Table"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ConcentrationRisk1Table" xlink:to="lab_oncyf_ConcentrationRisk1Table" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_IncreaseDecreaseThroughExpirationOfWarrantEquity_c03d8300-c95e-418f-bbf3-a61fc1e1c6b5_terseLabel_en-US" xlink:label="lab_oncyf_IncreaseDecreaseThroughExpirationOfWarrantEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiry of equity warrant agreement</link:label>
    <link:label id="lab_oncyf_IncreaseDecreaseThroughExpirationOfWarrantEquity_label_en-US" xlink:label="lab_oncyf_IncreaseDecreaseThroughExpirationOfWarrantEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Through Expiration Of Warrant, Equity</link:label>
    <link:label id="lab_oncyf_IncreaseDecreaseThroughExpirationOfWarrantEquity_documentation_en-US" xlink:label="lab_oncyf_IncreaseDecreaseThroughExpirationOfWarrantEquity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Through Expiration Of Warrant, Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IncreaseDecreaseThroughExpirationOfWarrantEquity" xlink:href="oncyf-20241231.xsd#oncyf_IncreaseDecreaseThroughExpirationOfWarrantEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_IncreaseDecreaseThroughExpirationOfWarrantEquity" xlink:to="lab_oncyf_IncreaseDecreaseThroughExpirationOfWarrantEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentShellCompanyReport_e539e0fa-1108-4b77-84f5-1962fd00561f_terseLabel_en-US" xlink:label="lab_dei_DocumentShellCompanyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Shell Company Report</link:label>
    <link:label id="lab_dei_DocumentShellCompanyReport_label_en-US" xlink:label="lab_dei_DocumentShellCompanyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Shell Company Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentShellCompanyReport" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentShellCompanyReport" xlink:to="lab_dei_DocumentShellCompanyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_IssueOfOrdinarySharesPerShare_37509c07-8756-4ac7-b784-9dca3d13611c_terseLabel_en-US" xlink:label="lab_oncyf_IssueOfOrdinarySharesPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of shares (in dollars per share)</link:label>
    <link:label id="lab_oncyf_IssueOfOrdinarySharesPerShare_label_en-US" xlink:label="lab_oncyf_IssueOfOrdinarySharesPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issue Of Ordinary Shares Per Share</link:label>
    <link:label id="lab_oncyf_IssueOfOrdinarySharesPerShare_documentation_en-US" xlink:label="lab_oncyf_IssueOfOrdinarySharesPerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Issue Of Ordinary Shares Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IssueOfOrdinarySharesPerShare" xlink:href="oncyf-20241231.xsd#oncyf_IssueOfOrdinarySharesPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_IssueOfOrdinarySharesPerShare" xlink:to="lab_oncyf_IssueOfOrdinarySharesPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ExpectedVolatilityOtherEquityInstrumentsGranted_06c5eac5-59ee-407f-abcb-6edd8d1152a8_terseLabel_en-US" xlink:label="lab_oncyf_ExpectedVolatilityOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_oncyf_ExpectedVolatilityOtherEquityInstrumentsGranted_label_en-US" xlink:label="lab_oncyf_ExpectedVolatilityOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected Volatility, Other Equity Instruments Granted</link:label>
    <link:label id="lab_oncyf_ExpectedVolatilityOtherEquityInstrumentsGranted_documentation_en-US" xlink:label="lab_oncyf_ExpectedVolatilityOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Expected Volatility, Other Equity Instruments Granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ExpectedVolatilityOtherEquityInstrumentsGranted" xlink:href="oncyf-20241231.xsd#oncyf_ExpectedVolatilityOtherEquityInstrumentsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ExpectedVolatilityOtherEquityInstrumentsGranted" xlink:to="lab_oncyf_ExpectedVolatilityOtherEquityInstrumentsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_MajorOrdinaryShareTransactionsMember_022f9a9f-81bc-475b-b968-66013c3743b0_terseLabel_en-US" xlink:label="lab_ifrs-full_MajorOrdinaryShareTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share transactions</link:label>
    <link:label id="lab_ifrs-full_MajorOrdinaryShareTransactionsMember_label_en-US" xlink:label="lab_ifrs-full_MajorOrdinaryShareTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Major ordinary share transactions [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MajorOrdinaryShareTransactionsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MajorOrdinaryShareTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MajorOrdinaryShareTransactionsMember" xlink:to="lab_ifrs-full_MajorOrdinaryShareTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_b5634fe0-8b0d-4993-a222-9214f629f781_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for share-based payment transactions [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherCurrentLiabilities_74ea6c19-0b88-4361-8ff3-3222bd9c2cb0_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other liabilities (note 5)</link:label>
    <link:label id="lab_ifrs-full_OtherCurrentLiabilities_f317fce9-36e7-4102-bdf1-352d74880608_verboseLabel_en-US" xlink:label="lab_ifrs-full_OtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_ifrs-full_OtherCurrentLiabilities_label_en-US" xlink:label="lab_ifrs-full_OtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other current liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherCurrentLiabilities" xlink:to="lab_ifrs-full_OtherCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_OtherExpensesAndAdjustmentsTableTextBlock_06ce78f3-06a5-4143-9b55-e8ed3a49fcbf_terseLabel_en-US" xlink:label="lab_oncyf_OtherExpensesAndAdjustmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Other expenses and adjustments</link:label>
    <link:label id="lab_oncyf_OtherExpensesAndAdjustmentsTableTextBlock_label_en-US" xlink:label="lab_oncyf_OtherExpensesAndAdjustmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Expenses And Adjustments [Table Text Block]</link:label>
    <link:label id="lab_oncyf_OtherExpensesAndAdjustmentsTableTextBlock_documentation_en-US" xlink:label="lab_oncyf_OtherExpensesAndAdjustmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Expenses And Adjustments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OtherExpensesAndAdjustmentsTableTextBlock" xlink:href="oncyf-20241231.xsd#oncyf_OtherExpensesAndAdjustmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_OtherExpensesAndAdjustmentsTableTextBlock" xlink:to="lab_oncyf_OtherExpensesAndAdjustmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_202f478e-c827-4ccc-b175-14969d8cc123_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_AdjustmentsForDepreciationRightOfUseAssets_ca31cee5-cc55-4de2-afb0-ac6516ca0b9b_terseLabel_en-US" xlink:label="lab_oncyf_AdjustmentsForDepreciationRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation - right-of-use assets (notes 8, 20)</link:label>
    <link:label id="lab_oncyf_AdjustmentsForDepreciationRightOfUseAssets_label_en-US" xlink:label="lab_oncyf_AdjustmentsForDepreciationRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments For Depreciation, Right-of Use Assets</link:label>
    <link:label id="lab_oncyf_AdjustmentsForDepreciationRightOfUseAssets_documentation_en-US" xlink:label="lab_oncyf_AdjustmentsForDepreciationRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adjustments For Depreciation, Right-of Use Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_AdjustmentsForDepreciationRightOfUseAssets" xlink:href="oncyf-20241231.xsd#oncyf_AdjustmentsForDepreciationRightOfUseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_AdjustmentsForDepreciationRightOfUseAssets" xlink:to="lab_oncyf_AdjustmentsForDepreciationRightOfUseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities_9f563418-e6a8-4641-8f62-f3260270f1a0_terseLabel_en-US" xlink:label="lab_ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maturities of marketable securities</link:label>
    <link:label id="lab_ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities_label_en-US" xlink:label="lab_ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from sales or maturity of financial instruments, classified as investing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:to="lab_ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_IssueOfEquitySharesNumberOfCommonShares_d7cf4cda-1d2d-4ae4-8825-f6c375ea7a4d_terseLabel_en-US" xlink:label="lab_oncyf_IssueOfEquitySharesNumberOfCommonShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of common shares (in shares)</link:label>
    <link:label id="lab_oncyf_IssueOfEquitySharesNumberOfCommonShares_label_en-US" xlink:label="lab_oncyf_IssueOfEquitySharesNumberOfCommonShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issue Of Equity, Shares, Number Of Common Shares</link:label>
    <link:label id="lab_oncyf_IssueOfEquitySharesNumberOfCommonShares_documentation_en-US" xlink:label="lab_oncyf_IssueOfEquitySharesNumberOfCommonShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Issue Of Equity, Shares, Number Of Common Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IssueOfEquitySharesNumberOfCommonShares" xlink:href="oncyf-20241231.xsd#oncyf_IssueOfEquitySharesNumberOfCommonShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_IssueOfEquitySharesNumberOfCommonShares" xlink:to="lab_oncyf_IssueOfEquitySharesNumberOfCommonShares" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensation_588511b7-2ed0-463c-852c-305e6e88fe23_totalLabel_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensation" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Compensation of key management personnel</link:label>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensation_label_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Key management personnel compensation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensation" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensation" xlink:to="lab_ifrs-full_KeyManagementPersonnelCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RangeDomain_545dc2a6-47ed-42de-bfbb-0f7048625856_terseLabel_en-US" xlink:label="lab_ifrs-full_RangeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range</link:label>
    <link:label id="lab_ifrs-full_RangeDomain_label_en-US" xlink:label="lab_ifrs-full_RangeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RangeDomain" xlink:to="lab_ifrs-full_RangeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_bf96066c-87c5-4044-89cb-666490a0ed99_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of quantitative information about right-of-use assets [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of quantitative information about right-of-use assets [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentDerivativeFinancialLiabilities_8fa55f68-77a6-4599-9174-6e5f68760aca_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentDerivativeFinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant derivative (notes 9, 17)</link:label>
    <link:label id="lab_ifrs-full_CurrentDerivativeFinancialLiabilities_8e88bd79-4990-499a-986a-eb9bd56f6191_verboseLabel_en-US" xlink:label="lab_ifrs-full_CurrentDerivativeFinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Warrant derivative liability</link:label>
    <link:label id="lab_ifrs-full_CurrentDerivativeFinancialLiabilities_label_en-US" xlink:label="lab_ifrs-full_CurrentDerivativeFinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current derivative financial liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentDerivativeFinancialLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentDerivativeFinancialLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentDerivativeFinancialLiabilities" xlink:to="lab_ifrs-full_CurrentDerivativeFinancialLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeAbstract_7ed8b818-97fd-42bb-9274-5e9d0244926f_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss) items that may be reclassified to net loss</link:label>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeAbstract" xlink:to="lab_ifrs-full_OtherComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_BasicEarningsLossPerShare_94a59e9d-5935-4b24-bdb3-10c51a2357be_terseLabel_en-US" xlink:label="lab_ifrs-full_BasicEarningsLossPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic loss per common share (cad per share)</link:label>
    <link:label id="lab_ifrs-full_BasicEarningsLossPerShare_label_en-US" xlink:label="lab_ifrs-full_BasicEarningsLossPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basic earnings (loss) per share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BasicEarningsLossPerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BasicEarningsLossPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BasicEarningsLossPerShare" xlink:to="lab_ifrs-full_BasicEarningsLossPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_75d795cb-c91f-4268-986e-f44411a6df52_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [abstract]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:to="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_fc8f9dd4-41e3-4f7e-9731-f00eb99e0a04_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issued pursuant to warrant derivative exercised (notes 9, 10)</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through exercise of warrants, equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ForeignExchangeImpactRightofUseAssets_40c8af50-b3b8-4be1-8c07-be77eba27fb0_terseLabel_en-US" xlink:label="lab_oncyf_ForeignExchangeImpactRightofUseAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign exchange impact</link:label>
    <link:label id="lab_oncyf_ForeignExchangeImpactRightofUseAssets_label_en-US" xlink:label="lab_oncyf_ForeignExchangeImpactRightofUseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Exchange Impact, Right-of-Use Assets</link:label>
    <link:label id="lab_oncyf_ForeignExchangeImpactRightofUseAssets_documentation_en-US" xlink:label="lab_oncyf_ForeignExchangeImpactRightofUseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Foreign Exchange Impact, Right-of-Use Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ForeignExchangeImpactRightofUseAssets" xlink:href="oncyf-20241231.xsd#oncyf_ForeignExchangeImpactRightofUseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ForeignExchangeImpactRightofUseAssets" xlink:to="lab_oncyf_ForeignExchangeImpactRightofUseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_183fea84-2a6e-4c57-891a-2cff11935c76_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nature of Operations and Going Concern</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of general information about financial statements [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ExpenseByNatureAbstract_129a8203-53ca-4220-b60d-6de68017a4fd_terseLabel_en-US" xlink:label="lab_ifrs-full_ExpenseByNatureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expenses</link:label>
    <link:label id="lab_ifrs-full_ExpenseByNatureAbstract_label_en-US" xlink:label="lab_ifrs-full_ExpenseByNatureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expenses by nature [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseByNatureAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpenseByNatureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExpenseByNatureAbstract" xlink:to="lab_ifrs-full_ExpenseByNatureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_34a028d1-0594-4fee-9192-e80151fd0ea8_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:to="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_444e2f82-a595-448d-ac3d-552f7f1eda8d_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_43a8b3dd-ec63-4783-8dc8-c83f07fa22b2_terseLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financing Activities</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) financing activities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_1c00a91c-8b5e-41d5-9227-f9385fb03ba2_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted during the year (cad per share)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average exercise price of share options granted in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_Statement1LineItems_c78d88d2-ddce-48fc-9d10-41a245471cb1_terseLabel_en-US" xlink:label="lab_oncyf_Statement1LineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement1 [Line Items]</link:label>
    <link:label id="lab_oncyf_Statement1LineItems_label_en-US" xlink:label="lab_oncyf_Statement1LineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement1 [Line Items]</link:label>
    <link:label id="lab_oncyf_Statement1LineItems_documentation_en-US" xlink:label="lab_oncyf_Statement1LineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Line Items] for Statement1 [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_Statement1LineItems" xlink:href="oncyf-20241231.xsd#oncyf_Statement1LineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_Statement1LineItems" xlink:to="lab_oncyf_Statement1LineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_GeneralAndAdministrativeExpense1Member_82d0079c-c2ac-4d5b-8056-dead4a139baf_terseLabel_en-US" xlink:label="lab_oncyf_GeneralAndAdministrativeExpense1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative expenses</link:label>
    <link:label id="lab_oncyf_GeneralAndAdministrativeExpense1Member_label_en-US" xlink:label="lab_oncyf_GeneralAndAdministrativeExpense1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General And Administrative Expense 1 [Member]</link:label>
    <link:label id="lab_oncyf_GeneralAndAdministrativeExpense1Member_documentation_en-US" xlink:label="lab_oncyf_GeneralAndAdministrativeExpense1Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">General And Administrative Expense 1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_GeneralAndAdministrativeExpense1Member" xlink:href="oncyf-20241231.xsd#oncyf_GeneralAndAdministrativeExpense1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_GeneralAndAdministrativeExpense1Member" xlink:to="lab_oncyf_GeneralAndAdministrativeExpense1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_3eb0ea3e-e6f3-45f6-a156-41c058f31f41_terseLabel_en-US" xlink:label="lab_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade payables</link:label>
    <link:label id="lab_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_label_en-US" xlink:label="lab_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current trade payables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:to="lab_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_8b6d2e42-0569-491d-8594-a850f0e1a89e_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of depreciation rates</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_a058be2a-d81c-432b-ac8f-71c7491d6d82_verboseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of property and equipment</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:to="lab_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_0405f830-3409-48c4-ba29-653f1dc629ce_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of number of other equity instruments</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of number and weighted average exercise prices of other equity instruments [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfOtherLiabilitiesExplanatory_9108f37b-1436-494b-9950-293c31a220e6_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfOtherLiabilitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Liabilities</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfOtherLiabilitiesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfOtherLiabilitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of other liabilities [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOtherLiabilitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOtherLiabilitiesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfOtherLiabilitiesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfOtherLiabilitiesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncomeTaxesPaidRefund_4f87e5e9-1bde-4102-8a9a-bca2b2c9bfa7_terseLabel_en-US" xlink:label="lab_ifrs-full_IncomeTaxesPaidRefund" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash taxes paid</link:label>
    <link:label id="lab_ifrs-full_IncomeTaxesPaidRefund_label_en-US" xlink:label="lab_ifrs-full_IncomeTaxesPaidRefund" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income taxes paid (refund)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxesPaidRefund" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeTaxesPaidRefund"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncomeTaxesPaidRefund" xlink:to="lab_ifrs-full_IncomeTaxesPaidRefund" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProfitLoss_435851ce-9a2e-475e-a467-177957c134a5_totalLabel_en-US" xlink:label="lab_ifrs-full_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_ifrs-full_ProfitLoss_ee4e638e-aaf2-4452-9c42-9dab0c3fda65_terseLabel_en-US" xlink:label="lab_ifrs-full_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss for the year</link:label>
    <link:label id="lab_ifrs-full_ProfitLoss_label_en-US" xlink:label="lab_ifrs-full_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit (loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLoss" xlink:to="lab_ifrs-full_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_OfficeEquipmentAndFurnitureMember_e709dbf9-0499-40d3-a53a-5441192edc82_terseLabel_en-US" xlink:label="lab_oncyf_OfficeEquipmentAndFurnitureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Office Equipment and Furniture</link:label>
    <link:label id="lab_oncyf_OfficeEquipmentAndFurnitureMember_label_en-US" xlink:label="lab_oncyf_OfficeEquipmentAndFurnitureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Office equipment and furniture [Member]</link:label>
    <link:label id="lab_oncyf_OfficeEquipmentAndFurnitureMember_documentation_en-US" xlink:label="lab_oncyf_OfficeEquipmentAndFurnitureMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Office equipment and furniture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OfficeEquipmentAndFurnitureMember" xlink:href="oncyf-20241231.xsd#oncyf_OfficeEquipmentAndFurnitureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_OfficeEquipmentAndFurnitureMember" xlink:to="lab_oncyf_OfficeEquipmentAndFurnitureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CurrencyAxis_806db6b2-b3e5-4818-b39c-1b50e81059de_terseLabel_en-US" xlink:label="lab_srt_CurrencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency [Axis]</link:label>
    <link:label id="lab_srt_CurrencyAxis_label_en-US" xlink:label="lab_srt_CurrencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Currency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CurrencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CurrencyAxis" xlink:to="lab_srt_CurrencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_5a11ca72-5364-4a1f-87b2-34a86bbac381_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of nature and extent of risks arising from financial instruments [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of nature and extent of risks arising from financial instruments [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xlink:to="lab_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_DisclosureOfCapitalComponentsTableTextBlock_af49e24b-b204-4f44-823c-9e9497d3bef1_verboseLabel_en-US" xlink:label="lab_oncyf_DisclosureOfCapitalComponentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of capital components</link:label>
    <link:label id="lab_oncyf_DisclosureOfCapitalComponentsTableTextBlock_label_en-US" xlink:label="lab_oncyf_DisclosureOfCapitalComponentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Capital Components [Table Text Block]</link:label>
    <link:label id="lab_oncyf_DisclosureOfCapitalComponentsTableTextBlock_documentation_en-US" xlink:label="lab_oncyf_DisclosureOfCapitalComponentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Capital Components [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureOfCapitalComponentsTableTextBlock" xlink:href="oncyf-20241231.xsd#oncyf_DisclosureOfCapitalComponentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_DisclosureOfCapitalComponentsTableTextBlock" xlink:to="lab_oncyf_DisclosureOfCapitalComponentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock_01f42291-3255-48cf-a1ad-03f7ee6c71ad_terseLabel_en-US" xlink:label="lab_oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Provision for income taxes</link:label>
    <link:label id="lab_oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock_label_en-US" xlink:label="lab_oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit)1 [Table Text Block]</link:label>
    <link:label id="lab_oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock_documentation_en-US" xlink:label="lab_oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit)1 [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock" xlink:href="oncyf-20241231.xsd#oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock" xlink:to="lab_oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ConcentrationRiskType1LineItems_12c3518d-bfa2-4b4f-a631-45dd1ad7f97e_terseLabel_en-US" xlink:label="lab_oncyf_ConcentrationRiskType1LineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type1 [Line Items]</link:label>
    <link:label id="lab_oncyf_ConcentrationRiskType1LineItems_label_en-US" xlink:label="lab_oncyf_ConcentrationRiskType1LineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type1 [Line Items]</link:label>
    <link:label id="lab_oncyf_ConcentrationRiskType1LineItems_documentation_en-US" xlink:label="lab_oncyf_ConcentrationRiskType1LineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Line Items] for Concentration Risk Type1 [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ConcentrationRiskType1LineItems" xlink:href="oncyf-20241231.xsd#oncyf_ConcentrationRiskType1LineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ConcentrationRiskType1LineItems" xlink:to="lab_oncyf_ConcentrationRiskType1LineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses_d375257b-012e-4f74-b90a-2df84b2c25da_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for decrease (increase) in prepaid expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses" xlink:to="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfShareCapitalDomain_38b51c40-9af8-46c6-8384-ff269a8376e6_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfShareCapitalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of share capital</link:label>
    <link:label id="lab_ifrs-full_ClassesOfShareCapitalDomain_label_en-US" xlink:label="lab_ifrs-full_ClassesOfShareCapitalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of share capital [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfShareCapitalDomain" xlink:to="lab_ifrs-full_ClassesOfShareCapitalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfLiabilitiesDomain_1ebec99e-16be-4c73-8d79-22989353bcce_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfLiabilitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of liabilities</link:label>
    <link:label id="lab_ifrs-full_ClassesOfLiabilitiesDomain_label_en-US" xlink:label="lab_ifrs-full_ClassesOfLiabilitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of liabilities [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfLiabilitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesDomain" xlink:to="lab_ifrs-full_ClassesOfLiabilitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ContingenciesAbstract_601bebb5-5149-4a5f-ba94-627072db7b99_terseLabel_en-US" xlink:label="lab_oncyf_ContingenciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingencies [Abstract]</link:label>
    <link:label id="lab_oncyf_ContingenciesAbstract_label_en-US" xlink:label="lab_oncyf_ContingenciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingencies [Abstract]</link:label>
    <link:label id="lab_oncyf_ContingenciesAbstract_documentation_en-US" xlink:label="lab_oncyf_ContingenciesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contingencies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ContingenciesAbstract" xlink:href="oncyf-20241231.xsd#oncyf_ContingenciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ContingenciesAbstract" xlink:to="lab_oncyf_ContingenciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_ef014ab2-524e-42ae-abbb-9cab664720a2_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Translation adjustment</link:label>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_label_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income, net of tax, exchange differences on translation of foreign operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:to="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_WarrantLiabilityUnamortizedDiscount_1db9f850-b19c-4046-af2a-39e386943896_negatedTerseLabel_en-US" xlink:label="lab_oncyf_WarrantLiabilityUnamortizedDiscount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Discount on warrants issued</link:label>
    <link:label id="lab_oncyf_WarrantLiabilityUnamortizedDiscount_181722d3-8c36-4c66-9797-da20853883e2_terseLabel_en-US" xlink:label="lab_oncyf_WarrantLiabilityUnamortizedDiscount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant liability, unamortized discount</link:label>
    <link:label id="lab_oncyf_WarrantLiabilityUnamortizedDiscount_label_en-US" xlink:label="lab_oncyf_WarrantLiabilityUnamortizedDiscount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant Liability, Unamortized Discount</link:label>
    <link:label id="lab_oncyf_WarrantLiabilityUnamortizedDiscount_documentation_en-US" xlink:label="lab_oncyf_WarrantLiabilityUnamortizedDiscount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrant Liability, Unamortized Discount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantLiabilityUnamortizedDiscount" xlink:href="oncyf-20241231.xsd#oncyf_WarrantLiabilityUnamortizedDiscount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_WarrantLiabilityUnamortizedDiscount" xlink:to="lab_oncyf_WarrantLiabilityUnamortizedDiscount" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_3220f080-d056-468c-b3a1-b2bea169b8ad_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options exercisable, end of the year (shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_5a868493-2454-4822-b91d-19b42614edc7_verboseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Number Exercisable (shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_label_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of share options exercisable in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted_90dcca99-b10f-42ee-8ffe-6ff74e7e7bf3_verboseLabel_en-US" xlink:label="lab_oncyf_WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fair value per warrant (usd per share)</link:label>
    <link:label id="lab_oncyf_WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted_label_en-US" xlink:label="lab_oncyf_WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Fair Value Price At Measurement Date, Other Equity Instruments Granted</link:label>
    <link:label id="lab_oncyf_WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted_documentation_en-US" xlink:label="lab_oncyf_WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted Average Fair Value Price At Measurement Date, Other Equity Instruments Granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted" xlink:href="oncyf-20241231.xsd#oncyf_WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted" xlink:to="lab_oncyf_WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_62ec6c86-179c-43d4-b91b-9e9575e1fe6e_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of commitments and contingent liabilities [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_SharePurchaseAgreementTerm_af8eeaa3-e1cd-4242-804c-65482b331ffd_terseLabel_en-US" xlink:label="lab_oncyf_SharePurchaseAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Agreement term</link:label>
    <link:label id="lab_oncyf_SharePurchaseAgreementTerm_label_en-US" xlink:label="lab_oncyf_SharePurchaseAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Purchase Agreement, Term</link:label>
    <link:label id="lab_oncyf_SharePurchaseAgreementTerm_documentation_en-US" xlink:label="lab_oncyf_SharePurchaseAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Purchase Agreement, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharePurchaseAgreementTerm" xlink:href="oncyf-20241231.xsd#oncyf_SharePurchaseAgreementTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SharePurchaseAgreementTerm" xlink:to="lab_oncyf_SharePurchaseAgreementTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WarrantsMember_da74c964-f020-4aa9-a8e3-666df21ef1a5_terseLabel_en-US" xlink:label="lab_ifrs-full_WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_ifrs-full_WarrantsMember_947fd101-0634-4f95-8685-8aa7c1dd148c_verboseLabel_en-US" xlink:label="lab_ifrs-full_WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_ifrs-full_WarrantsMember_label_en-US" xlink:label="lab_ifrs-full_WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WarrantsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WarrantsMember" xlink:to="lab_ifrs-full_WarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAccountingStandard_de79c413-21a3-40ba-bdf4-fa09ac415d8f_terseLabel_en-US" xlink:label="lab_dei_DocumentAccountingStandard" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Accounting Standard</link:label>
    <link:label id="lab_dei_DocumentAccountingStandard_label_en-US" xlink:label="lab_dei_DocumentAccountingStandard" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Accounting Standard</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAccountingStandard" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAccountingStandard" xlink:to="lab_dei_DocumentAccountingStandard" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember_60bbb2f4-ba48-4dd0-8c12-ae2d4f400998_terseLabel_en-US" xlink:label="lab_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unclaimed scientific research and experimental development expenditures</link:label>
    <link:label id="lab_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember_e77cdfd4-3700-4ca5-a750-b62c1fa3679d_verboseLabel_en-US" xlink:label="lab_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Scientific research and experimental development</link:label>
    <link:label id="lab_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember_label_en-US" xlink:label="lab_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unclaimed Scientific Research And Experimental Development Expenditures [Member]</link:label>
    <link:label id="lab_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember_documentation_en-US" xlink:label="lab_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Unclaimed Scientific Research And Experimental Development Expenditures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember" xlink:href="oncyf-20241231.xsd#oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember" xlink:to="lab_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_NumberOfWarrantsOutstandingRollForward_49f37e2d-34c2-4b0f-8e77-f55795becfc5_terseLabel_en-US" xlink:label="lab_oncyf_NumberOfWarrantsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Warrants Outstanding</link:label>
    <link:label id="lab_oncyf_NumberOfWarrantsOutstandingRollForward_label_en-US" xlink:label="lab_oncyf_NumberOfWarrantsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Warrants Outstanding [Roll Forward]</link:label>
    <link:label id="lab_oncyf_NumberOfWarrantsOutstandingRollForward_documentation_en-US" xlink:label="lab_oncyf_NumberOfWarrantsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Warrants Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_NumberOfWarrantsOutstandingRollForward" xlink:href="oncyf-20241231.xsd#oncyf_NumberOfWarrantsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_NumberOfWarrantsOutstandingRollForward" xlink:to="lab_oncyf_NumberOfWarrantsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory_f05c90ea-851c-4849-9933-e9fea9184cce_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial liabilities</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for financial liabilities [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentContractLiabilities_be6f4b2e-536c-4a70-a50b-b436fc9c438d_terseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract liability (note 13)</link:label>
    <link:label id="lab_ifrs-full_NoncurrentContractLiabilities_label_en-US" xlink:label="lab_ifrs-full_NoncurrentContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current contract liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentContractLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentContractLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentContractLiabilities" xlink:to="lab_ifrs-full_NoncurrentContractLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_b21aa0f8-8729-4fd8-963e-bd46f1a4482c_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_label_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of other equity instruments forfeited in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_EquityAuthorized_f6543c15-4ebf-4a38-b778-3e7220214ab8_terseLabel_en-US" xlink:label="lab_oncyf_EquityAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Base Shelf securities authorized</link:label>
    <link:label id="lab_oncyf_EquityAuthorized_label_en-US" xlink:label="lab_oncyf_EquityAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Authorized</link:label>
    <link:label id="lab_oncyf_EquityAuthorized_documentation_en-US" xlink:label="lab_oncyf_EquityAuthorized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_EquityAuthorized" xlink:href="oncyf-20241231.xsd#oncyf_EquityAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_EquityAuthorized" xlink:to="lab_oncyf_EquityAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_PropertyPlantandEquipmentAnnualDepreciationRate_e481812e-4547-4af2-b262-e44fa2e01a9d_terseLabel_en-US" xlink:label="lab_oncyf_PropertyPlantandEquipmentAnnualDepreciationRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual depreciation rate</link:label>
    <link:label id="lab_oncyf_PropertyPlantandEquipmentAnnualDepreciationRate_label_en-US" xlink:label="lab_oncyf_PropertyPlantandEquipmentAnnualDepreciationRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Annual Depreciation Rate</link:label>
    <link:label id="lab_oncyf_PropertyPlantandEquipmentAnnualDepreciationRate_documentation_en-US" xlink:label="lab_oncyf_PropertyPlantandEquipmentAnnualDepreciationRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Annual Depreciation Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_PropertyPlantandEquipmentAnnualDepreciationRate" xlink:href="oncyf-20241231.xsd#oncyf_PropertyPlantandEquipmentAnnualDepreciationRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_PropertyPlantandEquipmentAnnualDepreciationRate" xlink:to="lab_oncyf_PropertyPlantandEquipmentAnnualDepreciationRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SharePremiumMember_f7a82dbd-ae5a-4051-b91d-c53455113419_terseLabel_en-US" xlink:label="lab_ifrs-full_SharePremiumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contributed Surplus</link:label>
    <link:label id="lab_ifrs-full_SharePremiumMember_label_en-US" xlink:label="lab_ifrs-full_SharePremiumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share premium [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharePremiumMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SharePremiumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SharePremiumMember" xlink:to="lab_ifrs-full_SharePremiumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DilutedEarningsLossPerShare_7b148742-af3a-476b-b7e1-134625d23579_terseLabel_en-US" xlink:label="lab_ifrs-full_DilutedEarningsLossPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted loss per common share (cad per share)</link:label>
    <link:label id="lab_ifrs-full_DilutedEarningsLossPerShare_label_en-US" xlink:label="lab_ifrs-full_DilutedEarningsLossPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Diluted earnings (loss) per share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DilutedEarningsLossPerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DilutedEarningsLossPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DilutedEarningsLossPerShare" xlink:to="lab_ifrs-full_DilutedEarningsLossPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_UnusedTaxLossesMember_0851cab5-44cf-43f9-b2cf-a4228d9b16ea_terseLabel_en-US" xlink:label="lab_ifrs-full_UnusedTaxLossesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-capital losses</link:label>
    <link:label id="lab_ifrs-full_UnusedTaxLossesMember_label_en-US" xlink:label="lab_ifrs-full_UnusedTaxLossesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unused tax losses [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnusedTaxLossesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_UnusedTaxLossesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_UnusedTaxLossesMember" xlink:to="lab_ifrs-full_UnusedTaxLossesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory_87c794d6-fe41-41ff-b75b-06872a2dd727_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Material Accounting Policies</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of material accounting policy information [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory" xlink:to="lab_ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ConcentrationRiskType1Axis_a9fa4291-8118-4668-b9db-006799663f4b_terseLabel_en-US" xlink:label="lab_oncyf_ConcentrationRiskType1Axis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type1 [Axis]</link:label>
    <link:label id="lab_oncyf_ConcentrationRiskType1Axis_label_en-US" xlink:label="lab_oncyf_ConcentrationRiskType1Axis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type1 [Axis]</link:label>
    <link:label id="lab_oncyf_ConcentrationRiskType1Axis_documentation_en-US" xlink:label="lab_oncyf_ConcentrationRiskType1Axis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Concentration Risk Type1 [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ConcentrationRiskType1Axis" xlink:href="oncyf-20241231.xsd#oncyf_ConcentrationRiskType1Axis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ConcentrationRiskType1Axis" xlink:to="lab_oncyf_ConcentrationRiskType1Axis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AccumulatedOtherComprehensiveIncome_d97152cb-f141-44a9-ad92-42bd30c5408b_terseLabel_en-US" xlink:label="lab_ifrs-full_AccumulatedOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income</link:label>
    <link:label id="lab_ifrs-full_AccumulatedOtherComprehensiveIncome_label_en-US" xlink:label="lab_ifrs-full_AccumulatedOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedOtherComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AccumulatedOtherComprehensiveIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AccumulatedOtherComprehensiveIncome" xlink:to="lab_ifrs-full_AccumulatedOtherComprehensiveIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_8e9fb053-1f59-4458-8ac1-d1bdddaff675_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of temporary difference, unused tax losses and unused tax credits [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of temporary difference, unused tax losses and unused tax credits [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:to="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_5314f023-e0da-49c9-b77a-d1f00e8fac59_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_5e7d9a20-2979-4f5d-8c4f-dac7418c02a2_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of non-adjusting events after reporting period [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of non-adjusting events after reporting period [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="lab_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AddressTypeDomain_20e6cc83-5aa5-4b8b-b89a-e642aa47f930_terseLabel_en-US" xlink:label="lab_dei_AddressTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Address Type [Domain]</link:label>
    <link:label id="lab_dei_AddressTypeDomain_label_en-US" xlink:label="lab_dei_AddressTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Address Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AddressTypeDomain" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AddressTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AddressTypeDomain" xlink:to="lab_dei_AddressTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_SharesUnderPublicOfferingMember_9723628f-03fe-436c-876d-6cfff2e5c104_terseLabel_en-US" xlink:label="lab_oncyf_SharesUnderPublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Public offering</link:label>
    <link:label id="lab_oncyf_SharesUnderPublicOfferingMember_label_en-US" xlink:label="lab_oncyf_SharesUnderPublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Under Public Offering [Member]</link:label>
    <link:label id="lab_oncyf_SharesUnderPublicOfferingMember_documentation_en-US" xlink:label="lab_oncyf_SharesUnderPublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Shares Under Public Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesUnderPublicOfferingMember" xlink:href="oncyf-20241231.xsd#oncyf_SharesUnderPublicOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SharesUnderPublicOfferingMember" xlink:to="lab_oncyf_SharesUnderPublicOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019_ac379944-8535-4c8f-81b1-c5afab7bcbb4_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase price (cad and usd per share)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average exercise price of other equity instruments granted in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory_5225e4ee-1126-4542-bb31-3bc5f9ba2ecf_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for deferred income tax [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees_2bfc9287-0857-4901-a8df-46d237e6780e_terseLabel_en-US" xlink:label="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expense from share-based payment transactions with parties other than employees</link:label>
    <link:label id="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees_label_en-US" xlink:label="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expense from share-based payment transactions with parties other than employees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees" xlink:to="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares_152f5263-eaf6-45f7-a8f0-002e263c633b_terseLabel_en-US" xlink:label="lab_ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common shares reserved for issuance (in shares)</link:label>
    <link:label id="lab_ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares_label_en-US" xlink:label="lab_ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of shares reserved for issue under options and contracts for sale of shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares" xlink:to="lab_ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProfitLossFromOperatingActivities_ece5cbd0-3e90-4fc4-8227-6f412ae2b8a0_totalLabel_en-US" xlink:label="lab_ifrs-full_ProfitLossFromOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss before the following</link:label>
    <link:label id="lab_ifrs-full_ProfitLossFromOperatingActivities_label_en-US" xlink:label="lab_ifrs-full_ProfitLossFromOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit (loss) from operating activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossFromOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities" xlink:to="lab_ifrs-full_ProfitLossFromOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdditionsToRightofuseAssets_3812cb2b-ed3c-4078-86db-1a5cf04f55d7_verboseLabel_en-US" xlink:label="lab_ifrs-full_AdditionsToRightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Additions to right-of-use assets</link:label>
    <link:label id="lab_ifrs-full_AdditionsToRightofuseAssets_07a84066-3402-4838-9f2e-f37e759e30c4_terseLabel_en-US" xlink:label="lab_ifrs-full_AdditionsToRightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_ifrs-full_AdditionsToRightofuseAssets_label_en-US" xlink:label="lab_ifrs-full_AdditionsToRightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additions to right-of-use assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsToRightofuseAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdditionsToRightofuseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdditionsToRightofuseAssets" xlink:to="lab_ifrs-full_AdditionsToRightofuseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_6b1e8d00-ec25-49e8-9682-67ab2be56cca_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of property, plant and equipment [axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of property, plant and equipment [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_f77991b6-540c-44e9-a7b2-ed9424209439_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of related party transactions</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of transactions between related parties [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted_775ba134-7505-46f9-973b-744a2f2809aa_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average fair value at measurement date, other equity instruments granted</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average fair value at measurement date, other equity instruments granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted" xlink:to="lab_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_34515f9e-e1eb-447c-9ad3-e0e22084b5a0_terseLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investing Activities</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) investing activities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfProvisionsAxis_29e41793-b980-4bbb-a674-ec8ddc030b89_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfProvisionsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of other provisions [axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfProvisionsAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfProvisionsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of other provisions [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfProvisionsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfProvisionsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfProvisionsAxis" xlink:to="lab_ifrs-full_ClassesOfProvisionsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_8fc68bfa-a85d-4407-9b3d-2a68428d6e12_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted_f78fd485-9fe9-4983-97b9-70861f345413_terseLabel_en-US" xlink:label="lab_oncyf_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_oncyf_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted_label_en-US" xlink:label="lab_oncyf_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected Dividend As Percentage, Other Equity Instruments Granted</link:label>
    <link:label id="lab_oncyf_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted_documentation_en-US" xlink:label="lab_oncyf_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Expected Dividend As Percentage, Other Equity Instruments Granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted" xlink:href="oncyf-20241231.xsd#oncyf_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted" xlink:to="lab_oncyf_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_Currency1LineItems_d6e4907b-b9a9-47a9-8899-f6a6f28e9f80_terseLabel_en-US" xlink:label="lab_oncyf_Currency1LineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency1 [Line Items]</link:label>
    <link:label id="lab_oncyf_Currency1LineItems_label_en-US" xlink:label="lab_oncyf_Currency1LineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Currency1 [Line Items]</link:label>
    <link:label id="lab_oncyf_Currency1LineItems_documentation_en-US" xlink:label="lab_oncyf_Currency1LineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Line Items] for Currency1 [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_Currency1LineItems" xlink:href="oncyf-20241231.xsd#oncyf_Currency1LineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_Currency1LineItems" xlink:to="lab_oncyf_Currency1LineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities_8858d95b-4cfb-4889-95b9-4414f361afe1_totalLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Cash provided by financing activities</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) financing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentLeaseLiabilities_ccbc6e54-ccb3-4df4-b41c-c68d2901c980_terseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liabilities (note 8)</link:label>
    <link:label id="lab_ifrs-full_NoncurrentLeaseLiabilities_label_en-US" xlink:label="lab_ifrs-full_NoncurrentLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentLeaseLiabilities" xlink:to="lab_ifrs-full_NoncurrentLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_PublicCompanyExpense_63da585d-bf7a-45e4-811f-63b6ce116d9e_terseLabel_en-US" xlink:label="lab_oncyf_PublicCompanyExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Public company-related expenses</link:label>
    <link:label id="lab_oncyf_PublicCompanyExpense_label_en-US" xlink:label="lab_oncyf_PublicCompanyExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Public Company Expense</link:label>
    <link:label id="lab_oncyf_PublicCompanyExpense_documentation_en-US" xlink:label="lab_oncyf_PublicCompanyExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Public Company Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_PublicCompanyExpense" xlink:href="oncyf-20241231.xsd#oncyf_PublicCompanyExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_PublicCompanyExpense" xlink:to="lab_oncyf_PublicCompanyExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GeographicalAreasAxis_bdeb39a4-d6fe-4840-9347-882db640a477_terseLabel_en-US" xlink:label="lab_ifrs-full_GeographicalAreasAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical areas [axis]</link:label>
    <link:label id="lab_ifrs-full_GeographicalAreasAxis_label_en-US" xlink:label="lab_ifrs-full_GeographicalAreasAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical areas [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeographicalAreasAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GeographicalAreasAxis" xlink:to="lab_ifrs-full_GeographicalAreasAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_GainsLossesFromForeignExchangeImpact_60d685d9-a3a1-41e3-8a70-5d7afab62c82_terseLabel_en-US" xlink:label="lab_oncyf_GainsLossesFromForeignExchangeImpact" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign exchange impact</link:label>
    <link:label id="lab_oncyf_GainsLossesFromForeignExchangeImpact_label_en-US" xlink:label="lab_oncyf_GainsLossesFromForeignExchangeImpact" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gains (Losses) From Foreign Exchange Impact</link:label>
    <link:label id="lab_oncyf_GainsLossesFromForeignExchangeImpact_documentation_en-US" xlink:label="lab_oncyf_GainsLossesFromForeignExchangeImpact" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Gains (Losses) From Foreign Exchange Impact</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_GainsLossesFromForeignExchangeImpact" xlink:href="oncyf-20241231.xsd#oncyf_GainsLossesFromForeignExchangeImpact"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_GainsLossesFromForeignExchangeImpact" xlink:to="lab_oncyf_GainsLossesFromForeignExchangeImpact" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_1e7a2722-9bcb-4ffd-8d3a-2bfb8bffde21_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Liabilities</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of trade and other payables [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_da74fa55-1a20-4e54-aec7-1d1f03cfed73_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of share capital</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of classes of share capital [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:to="lab_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_936e78f2-b810-49b3-87e0-a4e8369aee39_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Right-of-use assets</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of quantitative information about right-of-use assets [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EquityAbstract_4c3877f4-75d5-44f0-96db-855590e40b33_terseLabel_en-US" xlink:label="lab_ifrs-full_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shareholders&#8217; equity</link:label>
    <link:label id="lab_ifrs-full_EquityAbstract_label_en-US" xlink:label="lab_ifrs-full_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EquityAbstract" xlink:to="lab_ifrs-full_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentAssets_6ad66205-2a24-458e-9d48-f4684f9113f3_totalLabel_en-US" xlink:label="lab_ifrs-full_CurrentAssets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_ifrs-full_CurrentAssets_label_en-US" xlink:label="lab_ifrs-full_CurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentAssets" xlink:to="lab_ifrs-full_CurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_NumberOfWarrantsOutstanding_6ff74159-9f92-4910-a5cf-e13855a366c8_periodStartLabel_en-US" xlink:label="lab_oncyf_NumberOfWarrantsOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance at beginning of period (in shares)</link:label>
    <link:label id="lab_oncyf_NumberOfWarrantsOutstanding_a23e811b-41f7-4254-be63-e3cf02102988_periodEndLabel_en-US" xlink:label="lab_oncyf_NumberOfWarrantsOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance at end of period (in shares)</link:label>
    <link:label id="lab_oncyf_NumberOfWarrantsOutstanding_fb65555f-a7d5-4bbc-972f-2f06f27c0321_terseLabel_en-US" xlink:label="lab_oncyf_NumberOfWarrantsOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Warrants Outstanding</link:label>
    <link:label id="lab_oncyf_NumberOfWarrantsOutstanding_label_en-US" xlink:label="lab_oncyf_NumberOfWarrantsOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Warrants Outstanding</link:label>
    <link:label id="lab_oncyf_NumberOfWarrantsOutstanding_documentation_en-US" xlink:label="lab_oncyf_NumberOfWarrantsOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Warrants Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_NumberOfWarrantsOutstanding" xlink:href="oncyf-20241231.xsd#oncyf_NumberOfWarrantsOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_NumberOfWarrantsOutstanding" xlink:to="lab_oncyf_NumberOfWarrantsOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ShareCapitalNumberSharesAbstract_57fc7759-9d71-45db-a54f-5ec794011d6f_terseLabel_en-US" xlink:label="lab_oncyf_ShareCapitalNumberSharesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number</link:label>
    <link:label id="lab_oncyf_ShareCapitalNumberSharesAbstract_label_en-US" xlink:label="lab_oncyf_ShareCapitalNumberSharesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Capital, Number, Shares [Abstract]</link:label>
    <link:label id="lab_oncyf_ShareCapitalNumberSharesAbstract_documentation_en-US" xlink:label="lab_oncyf_ShareCapitalNumberSharesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Capital, Number, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ShareCapitalNumberSharesAbstract" xlink:href="oncyf-20241231.xsd#oncyf_ShareCapitalNumberSharesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ShareCapitalNumberSharesAbstract" xlink:to="lab_oncyf_ShareCapitalNumberSharesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_df714195-79a0-439b-8d28-d98a66ceb056_terseLabel_en-US" xlink:label="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Temporary difference, unused tax losses and unused tax credits [axis]</link:label>
    <link:label id="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_label_en-US" xlink:label="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary difference, unused tax losses and unused tax credits [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:to="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_RestOfWorldMember_597da920-07f9-4ade-8113-d774e7ac8adc_terseLabel_en-US" xlink:label="lab_oncyf_RestOfWorldMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rest of world</link:label>
    <link:label id="lab_oncyf_RestOfWorldMember_label_en-US" xlink:label="lab_oncyf_RestOfWorldMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rest Of World [Member]</link:label>
    <link:label id="lab_oncyf_RestOfWorldMember_documentation_en-US" xlink:label="lab_oncyf_RestOfWorldMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Rest Of World</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_RestOfWorldMember" xlink:href="oncyf-20241231.xsd#oncyf_RestOfWorldMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_RestOfWorldMember" xlink:to="lab_oncyf_RestOfWorldMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ResearchAndDevelopmentExpense1Abstract_48b050c4-0b77-4b65-a585-f7e561088c55_terseLabel_en-US" xlink:label="lab_oncyf_ResearchAndDevelopmentExpense1Abstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_oncyf_ResearchAndDevelopmentExpense1Abstract_label_en-US" xlink:label="lab_oncyf_ResearchAndDevelopmentExpense1Abstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development Expense 1 [Abstract]</link:label>
    <link:label id="lab_oncyf_ResearchAndDevelopmentExpense1Abstract_documentation_en-US" xlink:label="lab_oncyf_ResearchAndDevelopmentExpense1Abstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research And Development Expense 1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ResearchAndDevelopmentExpense1Abstract" xlink:href="oncyf-20241231.xsd#oncyf_ResearchAndDevelopmentExpense1Abstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ResearchAndDevelopmentExpense1Abstract" xlink:to="lab_oncyf_ResearchAndDevelopmentExpense1Abstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_a07430f2-0e56-4fd0-8a24-225adbe3d9a0_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Exercised during the year (shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_label_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of share options exercised in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_CommonSharesPerUnit_6fd9b094-f0e3-4dea-b182-f6785a15da60_terseLabel_en-US" xlink:label="lab_oncyf_CommonSharesPerUnit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common shares per unit (in shares)</link:label>
    <link:label id="lab_oncyf_CommonSharesPerUnit_label_en-US" xlink:label="lab_oncyf_CommonSharesPerUnit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Shares Per Unit</link:label>
    <link:label id="lab_oncyf_CommonSharesPerUnit_documentation_en-US" xlink:label="lab_oncyf_CommonSharesPerUnit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common Shares Per Unit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CommonSharesPerUnit" xlink:href="oncyf-20241231.xsd#oncyf_CommonSharesPerUnit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_CommonSharesPerUnit" xlink:to="lab_oncyf_CommonSharesPerUnit" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_430075d5-8c4c-465e-8af2-529271886efb_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_label_en-US" xlink:label="lab_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of other equity instruments granted in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:to="lab_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_0e46a14b-0ae0-4b5f-a579-ae616e859992_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of events after reporting period [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:to="lab_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfExpensesByNatureExplanatory_5a1381f1-8d4f-4eb5-a4bc-b11fdf6f2bb8_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfExpensesByNatureExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Components of Expenses</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfExpensesByNatureExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfExpensesByNatureExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of expenses by nature [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfExpensesByNatureExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfExpensesByNatureExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfExpensesByNatureExplanatory" xlink:to="lab_ifrs-full_DisclosureOfExpensesByNatureExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherLiabilities_f09d888f-a58d-4ca0-8017-9f6dd87ca17e_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_OtherLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_ifrs-full_OtherLiabilities_label_en-US" xlink:label="lab_ifrs-full_OtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherLiabilities" xlink:to="lab_ifrs-full_OtherLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_e8154412-5963-4d5a-84c1-ce4ae7db14f6_terseLabel_en-US" xlink:label="lab_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of changes in property, plant and equipment [abstract]</link:label>
    <link:label id="lab_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reconciliation of changes in property, plant and equipment [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract" xlink:to="lab_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_b72431f3-6230-40be-926d-15a2487c729e_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OfficerMember_6eb3bde0-f1d7-4ab2-abd7-79f459e65e7e_terseLabel_en-US" xlink:label="lab_srt_OfficerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Officer</link:label>
    <link:label id="lab_srt_OfficerMember_label_en-US" xlink:label="lab_srt_OfficerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Officer [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OfficerMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OfficerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OfficerMember" xlink:to="lab_srt_OfficerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherEmployeeExpense_451fd95f-eafa-4ad7-9da4-91bcb5fa627c_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherEmployeeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Personnel-related expenses</link:label>
    <link:label id="lab_ifrs-full_OtherEmployeeExpense_label_en-US" xlink:label="lab_ifrs-full_OtherEmployeeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other employee expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherEmployeeExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherEmployeeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherEmployeeExpense" xlink:to="lab_ifrs-full_OtherEmployeeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EquityAndLiabilitiesAbstract_417f8618-b6ba-4326-9f61-360fd4a1424f_terseLabel_en-US" xlink:label="lab_ifrs-full_EquityAndLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities And Shareholders&#8217; Equity</link:label>
    <link:label id="lab_ifrs-full_EquityAndLiabilitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_EquityAndLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity and liabilities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAndLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAndLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract" xlink:to="lab_ifrs-full_EquityAndLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_88d0d589-6a51-48af-8581-1e812252c574_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_BusinessContactMember_d0201888-a67b-4617-9493-90ff89ee0e4d_terseLabel_en-US" xlink:label="lab_dei_BusinessContactMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Contact</link:label>
    <link:label id="lab_dei_BusinessContactMember_label_en-US" xlink:label="lab_dei_BusinessContactMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Contact [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_BusinessContactMember" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_BusinessContactMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_BusinessContactMember" xlink:to="lab_dei_BusinessContactMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisposalsPropertyPlantAndEquipment_0ca0293c-3020-4566-b83f-a0f154772299_terseLabel_en-US" xlink:label="lab_ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposals, net of foreign exchange impact</link:label>
    <link:label id="lab_ifrs-full_DisposalsPropertyPlantAndEquipment_label_en-US" xlink:label="lab_ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposals, property, plant and equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisposalsPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:to="lab_ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_37434593-138b-4725-9c96-04dc914f1cb5_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for leases [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_6df77064-474b-4e11-8c5e-9a0c191fd7d0_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of property, plant and equipment [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:to="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_USD_f6f0ca81-baa3-43b8-8380-ff9940c19663_terseLabel_en-US" xlink:label="lab_currency_USD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. dollars</link:label>
    <link:label id="lab_currency_USD_label_en-US" xlink:label="lab_currency_USD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">United States of America, Dollars</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_USD" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_USD"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_USD" xlink:to="lab_currency_USD" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems_31608954-4d75-4af9-b573-31c1495a7dc0_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of maturity analysis of operating lease payments [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of maturity analysis of operating lease payments [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems" xlink:to="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DepreciationRightofuseAssets_569eb330-1cc2-4f64-88fa-ae34e99808b9_negatedLabel_en-US" xlink:label="lab_ifrs-full_DepreciationRightofuseAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_ifrs-full_DepreciationRightofuseAssets_cce96136-742a-4fd6-8497-bb86be74ec3b_verboseLabel_en-US" xlink:label="lab_ifrs-full_DepreciationRightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Depreciation - right-of-use assets</link:label>
    <link:label id="lab_ifrs-full_DepreciationRightofuseAssets_label_en-US" xlink:label="lab_ifrs-full_DepreciationRightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, right-of-use assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DepreciationRightofuseAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DepreciationRightofuseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DepreciationRightofuseAssets" xlink:to="lab_ifrs-full_DepreciationRightofuseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LeaseholdImprovementsMember_7e773fbd-ac93-4e9d-880c-2276a0dbc8e1_terseLabel_en-US" xlink:label="lab_ifrs-full_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leasehold Improvements</link:label>
    <link:label id="lab_ifrs-full_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_ifrs-full_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold improvements [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseholdImprovementsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LeaseholdImprovementsMember" xlink:to="lab_ifrs-full_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_InterestIncomeOnCashAndCashEquivalents_c5423496-119c-468b-aa28-ce5da3c4a16a_terseLabel_en-US" xlink:label="lab_ifrs-full_InterestIncomeOnCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income, net</link:label>
    <link:label id="lab_ifrs-full_InterestIncomeOnCashAndCashEquivalents_label_en-US" xlink:label="lab_ifrs-full_InterestIncomeOnCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest income on cash and cash equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestIncomeOnCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InterestIncomeOnCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestIncomeOnCashAndCashEquivalents" xlink:to="lab_ifrs-full_InterestIncomeOnCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipment_9f9cffd0-fff0-4d25-8a3d-59de45d5f637_terseLabel_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment (note 6)</link:label>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipment_9d51f3e5-a708-45fe-ac45-eb4bceee48be_periodStartLabel_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, beginning balance</link:label>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipment_b6c53ba7-b055-41df-8852-2a759ef5dd2b_periodEndLabel_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, ending balance</link:label>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipment_cab4d31d-d92a-4ea2-a287-d9227bbcd9ae_verboseLabel_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipment_label_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, plant and equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PropertyPlantAndEquipment" xlink:to="lab_ifrs-full_PropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_DisclosureOfEconomicDependenceAbstract_cbc323e1-3c2f-49a0-bc5d-a0422c991849_terseLabel_en-US" xlink:label="lab_oncyf_DisclosureOfEconomicDependenceAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Economic Dependence [Abstract]</link:label>
    <link:label id="lab_oncyf_DisclosureOfEconomicDependenceAbstract_label_en-US" xlink:label="lab_oncyf_DisclosureOfEconomicDependenceAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Economic Dependence [Abstract]</link:label>
    <link:label id="lab_oncyf_DisclosureOfEconomicDependenceAbstract_documentation_en-US" xlink:label="lab_oncyf_DisclosureOfEconomicDependenceAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Economic Dependence [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureOfEconomicDependenceAbstract" xlink:href="oncyf-20241231.xsd#oncyf_DisclosureOfEconomicDependenceAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_DisclosureOfEconomicDependenceAbstract" xlink:to="lab_oncyf_DisclosureOfEconomicDependenceAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_WeightedAverageSharePriceOtherEquityInstrumentsGranted_6b940898-8347-4a9a-be97-7efe7347c4b0_terseLabel_en-US" xlink:label="lab_oncyf_WeightedAverageSharePriceOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying share price (usd per share)</link:label>
    <link:label id="lab_oncyf_WeightedAverageSharePriceOtherEquityInstrumentsGranted_label_en-US" xlink:label="lab_oncyf_WeightedAverageSharePriceOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Share Price, Other Equity Instruments Granted</link:label>
    <link:label id="lab_oncyf_WeightedAverageSharePriceOtherEquityInstrumentsGranted_documentation_en-US" xlink:label="lab_oncyf_WeightedAverageSharePriceOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted Average Share Price, Other Equity Instruments Granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WeightedAverageSharePriceOtherEquityInstrumentsGranted" xlink:href="oncyf-20241231.xsd#oncyf_WeightedAverageSharePriceOtherEquityInstrumentsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_WeightedAverageSharePriceOtherEquityInstrumentsGranted" xlink:to="lab_oncyf_WeightedAverageSharePriceOtherEquityInstrumentsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory_e37c165c-5fc6-4a3f-8d17-0cb00c6c5377_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurement</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for fair value measurement [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentAssetsAbstract_7955bbef-efb5-48ff-83b1-d74564e43bc5_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets</link:label>
    <link:label id="lab_ifrs-full_CurrentAssetsAbstract_label_en-US" xlink:label="lab_ifrs-full_CurrentAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current assets [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentAssetsAbstract" xlink:to="lab_ifrs-full_CurrentAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings_2e3336dd-9974-4ddd-98f4-55b1487a287b_terseLabel_en-US" xlink:label="lab_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (decrease) in net loss due to change in currency value</link:label>
    <link:label id="lab_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings_label_en-US" xlink:label="lab_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Change In Risk Variable, Impact On Pre-Tax Earnings</link:label>
    <link:label id="lab_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings_documentation_en-US" xlink:label="lab_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Change In Risk Variable, Impact On Pre-Tax Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings" xlink:href="oncyf-20241231.xsd#oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings" xlink:to="lab_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_d3764b2e-3e02-4a03-a9c8-74dd834db87e_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_b7121454-cd08-42c9-a631-8936e551e349_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_MedicalEquipmentMember_72b0eac1-0051-4f0d-bb03-e57b61ae7a4e_terseLabel_en-US" xlink:label="lab_oncyf_MedicalEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Medical equipment</link:label>
    <link:label id="lab_oncyf_MedicalEquipmentMember_92a1b61a-cd65-4adc-89cb-5616c8573998_verboseLabel_en-US" xlink:label="lab_oncyf_MedicalEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Medical Equipment</link:label>
    <link:label id="lab_oncyf_MedicalEquipmentMember_label_en-US" xlink:label="lab_oncyf_MedicalEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Medical Equipment [Member]</link:label>
    <link:label id="lab_oncyf_MedicalEquipmentMember_documentation_en-US" xlink:label="lab_oncyf_MedicalEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Medical Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_MedicalEquipmentMember" xlink:href="oncyf-20241231.xsd#oncyf_MedicalEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_MedicalEquipmentMember" xlink:to="lab_oncyf_MedicalEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_IssueOfEquitySharesNumberOfWarrants_5d956372-bfd0-4472-809c-78e4498539aa_terseLabel_en-US" xlink:label="lab_oncyf_IssueOfEquitySharesNumberOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of warrants (in shares)</link:label>
    <link:label id="lab_oncyf_IssueOfEquitySharesNumberOfWarrants_label_en-US" xlink:label="lab_oncyf_IssueOfEquitySharesNumberOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issue Of Equity, Shares, Number Of Warrants</link:label>
    <link:label id="lab_oncyf_IssueOfEquitySharesNumberOfWarrants_documentation_en-US" xlink:label="lab_oncyf_IssueOfEquitySharesNumberOfWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Issue Of Equity, Shares, Number Of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IssueOfEquitySharesNumberOfWarrants" xlink:href="oncyf-20241231.xsd#oncyf_IssueOfEquitySharesNumberOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_IssueOfEquitySharesNumberOfWarrants" xlink:to="lab_oncyf_IssueOfEquitySharesNumberOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_WarrantsTerm_28f0cbf1-fcc3-4f34-a6b2-47588dc5b72a_terseLabel_en-US" xlink:label="lab_oncyf_WarrantsTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants, term</link:label>
    <link:label id="lab_oncyf_WarrantsTerm_label_en-US" xlink:label="lab_oncyf_WarrantsTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants, Term</link:label>
    <link:label id="lab_oncyf_WarrantsTerm_documentation_en-US" xlink:label="lab_oncyf_WarrantsTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantsTerm" xlink:href="oncyf-20241231.xsd#oncyf_WarrantsTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_WarrantsTerm" xlink:to="lab_oncyf_WarrantsTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_OtherExpensesAndAdjustmentsTable_c4c5c140-4128-4656-bd95-00e69640a980_terseLabel_en-US" xlink:label="lab_oncyf_OtherExpensesAndAdjustmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Expenses And Adjustments [Table]</link:label>
    <link:label id="lab_oncyf_OtherExpensesAndAdjustmentsTable_label_en-US" xlink:label="lab_oncyf_OtherExpensesAndAdjustmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Expenses And Adjustments [Table]</link:label>
    <link:label id="lab_oncyf_OtherExpensesAndAdjustmentsTable_documentation_en-US" xlink:label="lab_oncyf_OtherExpensesAndAdjustmentsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Expenses And Adjustments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OtherExpensesAndAdjustmentsTable" xlink:href="oncyf-20241231.xsd#oncyf_OtherExpensesAndAdjustmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_OtherExpensesAndAdjustmentsTable" xlink:to="lab_oncyf_OtherExpensesAndAdjustmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_eaa38c60-2773-431c-a15f-7fc9f76a8077_terseLabel_en-US" xlink:label="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-adjusting events after reporting period</link:label>
    <link:label id="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_label_en-US" xlink:label="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-adjusting events after reporting period [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" xlink:to="lab_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_f2bd54da-9f90-4076-a0e8-1de56f12b177_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized foreign exchange (gain) loss</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for unrealised foreign exchange losses (gains)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:to="lab_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_MiscellaneousOtherOperatingExpense_dfcca91e-c4eb-43dc-8548-1b8975b614c0_terseLabel_en-US" xlink:label="lab_ifrs-full_MiscellaneousOtherOperatingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other expenses</link:label>
    <link:label id="lab_ifrs-full_MiscellaneousOtherOperatingExpense_label_en-US" xlink:label="lab_ifrs-full_MiscellaneousOtherOperatingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Miscellaneous other operating expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MiscellaneousOtherOperatingExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MiscellaneousOtherOperatingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MiscellaneousOtherOperatingExpense" xlink:to="lab_ifrs-full_MiscellaneousOtherOperatingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_f4978831-08db-4872-8b4a-d94e06404306_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_ea56e372-7b1f-471d-874f-e54fb35359a5_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_5782658f-05fe-44f3-a1fa-54b14ff15773_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options exercisable, end of the year (cad per share)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_801e8493-fbfa-44ad-8a9e-96ea2067d81f_verboseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price (cad per share)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average exercise price of share options exercisable in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_Statement1Table_48476b7b-a081-43cf-879a-5786a7f7a358_terseLabel_en-US" xlink:label="lab_oncyf_Statement1Table" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_oncyf_Statement1Table_label_en-US" xlink:label="lab_oncyf_Statement1Table" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement1 [Table]</link:label>
    <link:label id="lab_oncyf_Statement1Table_documentation_en-US" xlink:label="lab_oncyf_Statement1Table" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Statement1 [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_Statement1Table" xlink:href="oncyf-20241231.xsd#oncyf_Statement1Table"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_Statement1Table" xlink:to="lab_oncyf_Statement1Table" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityTable_86ddf7bd-8a05-46a1-8e08-327778f4ad7a_terseLabel_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of changes in equity [table]</link:label>
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityTable_label_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of changes in equity [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfChangesInEquityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable" xlink:to="lab_ifrs-full_StatementOfChangesInEquityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ContractLiabilityRecognitionPeriod_a54ae0d8-47c9-4ab6-8d73-8f2cc058cfbc_terseLabel_en-US" xlink:label="lab_oncyf_ContractLiabilityRecognitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected recognition period</link:label>
    <link:label id="lab_oncyf_ContractLiabilityRecognitionPeriod_label_en-US" xlink:label="lab_oncyf_ContractLiabilityRecognitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract Liability, Recognition Period</link:label>
    <link:label id="lab_oncyf_ContractLiabilityRecognitionPeriod_documentation_en-US" xlink:label="lab_oncyf_ContractLiabilityRecognitionPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract Liability, Recognition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ContractLiabilityRecognitionPeriod" xlink:href="oncyf-20241231.xsd#oncyf_ContractLiabilityRecognitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ContractLiabilityRecognitionPeriod" xlink:to="lab_oncyf_ContractLiabilityRecognitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_DisclosureofrelatedpartyAbstract_09f44f85-5fd6-4a04-a8cb-abc3fad5d001_terseLabel_en-US" xlink:label="lab_oncyf_DisclosureofrelatedpartyAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of related party [Abstract]</link:label>
    <link:label id="lab_oncyf_DisclosureofrelatedpartyAbstract_label_en-US" xlink:label="lab_oncyf_DisclosureofrelatedpartyAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of related party [Abstract]</link:label>
    <link:label id="lab_oncyf_DisclosureofrelatedpartyAbstract_documentation_en-US" xlink:label="lab_oncyf_DisclosureofrelatedpartyAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of related party [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofrelatedpartyAbstract" xlink:href="oncyf-20241231.xsd#oncyf_DisclosureofrelatedpartyAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_DisclosureofrelatedpartyAbstract" xlink:to="lab_oncyf_DisclosureofrelatedpartyAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashAndCashEquivalents_36785972-e89e-4000-b628-02029bb8a984_terseLabel_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_ifrs-full_CashAndCashEquivalents_bc5f830a-84df-470a-b4f3-d4eb83569455_periodStartLabel_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, beginning of year</link:label>
    <link:label id="lab_ifrs-full_CashAndCashEquivalents_9b4291aa-86ca-4067-9420-92f52389391a_periodEndLabel_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, end of year</link:label>
    <link:label id="lab_ifrs-full_CashAndCashEquivalents_5c34242f-7133-410c-b101-ca3d6e04a8d4_verboseLabel_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_ifrs-full_CashAndCashEquivalents_label_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashAndCashEquivalents" xlink:to="lab_ifrs-full_CashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationLineItems_5b6520f7-eaa8-46d3-8de9-6935173814bb_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:label id="lab_dei_DocumentInformationLineItems_label_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="lab_dei_DocumentInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_DescriptionOfAccountingPolicyForDeterminingComponentsOfCashAndCashEquivalentsPolicyTextBlock_03f74df7-e811-45e9-9631-ae1c613db12d_terseLabel_en-US" xlink:label="lab_oncyf_DescriptionOfAccountingPolicyForDeterminingComponentsOfCashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_oncyf_DescriptionOfAccountingPolicyForDeterminingComponentsOfCashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_oncyf_DescriptionOfAccountingPolicyForDeterminingComponentsOfCashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description Of Accounting Policy For Determining Components Of Cash And Cash Equivalents [Policy Text Block]</link:label>
    <link:label id="lab_oncyf_DescriptionOfAccountingPolicyForDeterminingComponentsOfCashAndCashEquivalentsPolicyTextBlock_documentation_en-US" xlink:label="lab_oncyf_DescriptionOfAccountingPolicyForDeterminingComponentsOfCashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Description Of Accounting Policy For Determining Components Of Cash And Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DescriptionOfAccountingPolicyForDeterminingComponentsOfCashAndCashEquivalentsPolicyTextBlock" xlink:href="oncyf-20241231.xsd#oncyf_DescriptionOfAccountingPolicyForDeterminingComponentsOfCashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_DescriptionOfAccountingPolicyForDeterminingComponentsOfCashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_oncyf_DescriptionOfAccountingPolicyForDeterminingComponentsOfCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_da182466-fe33-4893-aa58-0ee283d7d725_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_EUR_96c81fdc-5a41-4f94-8f23-115dc76acb6d_terseLabel_en-US" xlink:label="lab_currency_EUR" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Euro</link:label>
    <link:label id="lab_currency_EUR_label_en-US" xlink:label="lab_currency_EUR" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Euro Member Countries, Euro</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_EUR" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_EUR"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_EUR" xlink:to="lab_currency_EUR" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_CompensationWarrantsMember_607cd530-9a7e-4075-aa0f-018b761a930f_terseLabel_en-US" xlink:label="lab_oncyf_CompensationWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Warrants</link:label>
    <link:label id="lab_oncyf_CompensationWarrantsMember_label_en-US" xlink:label="lab_oncyf_CompensationWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Warrants [Member]</link:label>
    <link:label id="lab_oncyf_CompensationWarrantsMember_documentation_en-US" xlink:label="lab_oncyf_CompensationWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Compensation Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CompensationWarrantsMember" xlink:href="oncyf-20241231.xsd#oncyf_CompensationWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_CompensationWarrantsMember" xlink:to="lab_oncyf_CompensationWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1_df36363b-13e3-4cf0-8400-2ed0e9f79243_verboseLabel_en-US" xlink:label="lab_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Vesting period, if not immediately vested</link:label>
    <link:label id="lab_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period1</link:label>
    <link:label id="lab_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1_documentation_en-US" xlink:label="lab_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1" xlink:href="oncyf-20241231.xsd#oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_MaturityAxis_b659bf42-4555-4673-8c45-a7204a1f9959_terseLabel_en-US" xlink:label="lab_ifrs-full_MaturityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maturity [axis]</link:label>
    <link:label id="lab_ifrs-full_MaturityAxis_label_en-US" xlink:label="lab_ifrs-full_MaturityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maturity [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MaturityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MaturityAxis" xlink:to="lab_ifrs-full_MaturityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EquityAndLiabilities_fff5fe03-1efc-4c50-8782-0a4b81882741_totalLabel_en-US" xlink:label="lab_ifrs-full_EquityAndLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and shareholders' equity</link:label>
    <link:label id="lab_ifrs-full_EquityAndLiabilities_label_en-US" xlink:label="lab_ifrs-full_EquityAndLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity and liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAndLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAndLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EquityAndLiabilities" xlink:to="lab_ifrs-full_EquityAndLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_SignificantJudgmentsEstimatesAndAssumptionsAbstract_e83c1ede-387d-4d32-a6a6-8265ef8bd415_terseLabel_en-US" xlink:label="lab_oncyf_SignificantJudgmentsEstimatesAndAssumptionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant Judgments, Estimates And Assumptions [Abstract]</link:label>
    <link:label id="lab_oncyf_SignificantJudgmentsEstimatesAndAssumptionsAbstract_label_en-US" xlink:label="lab_oncyf_SignificantJudgmentsEstimatesAndAssumptionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Judgments, Estimates And Assumptions [Abstract]</link:label>
    <link:label id="lab_oncyf_SignificantJudgmentsEstimatesAndAssumptionsAbstract_documentation_en-US" xlink:label="lab_oncyf_SignificantJudgmentsEstimatesAndAssumptionsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Significant Judgments, Estimates And Assumptions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SignificantJudgmentsEstimatesAndAssumptionsAbstract" xlink:href="oncyf-20241231.xsd#oncyf_SignificantJudgmentsEstimatesAndAssumptionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SignificantJudgmentsEstimatesAndAssumptionsAbstract" xlink:to="lab_oncyf_SignificantJudgmentsEstimatesAndAssumptionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_TaxEffectOfExpirationOfTaxBenefits_568ff323-d9e1-4109-944b-75a6620a6039_terseLabel_en-US" xlink:label="lab_oncyf_TaxEffectOfExpirationOfTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiry of tax benefits</link:label>
    <link:label id="lab_oncyf_TaxEffectOfExpirationOfTaxBenefits_label_en-US" xlink:label="lab_oncyf_TaxEffectOfExpirationOfTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Effect Of Expiration Of Tax Benefits</link:label>
    <link:label id="lab_oncyf_TaxEffectOfExpirationOfTaxBenefits_documentation_en-US" xlink:label="lab_oncyf_TaxEffectOfExpirationOfTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tax Effect Of Expiration Of Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TaxEffectOfExpirationOfTaxBenefits" xlink:href="oncyf-20241231.xsd#oncyf_TaxEffectOfExpirationOfTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_TaxEffectOfExpirationOfTaxBenefits" xlink:to="lab_oncyf_TaxEffectOfExpirationOfTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ClinicalTrialMember_7e6a6159-ac51-446d-8794-bf1d7174bbe1_terseLabel_en-US" xlink:label="lab_oncyf_ClinicalTrialMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Clinical Trial</link:label>
    <link:label id="lab_oncyf_ClinicalTrialMember_label_en-US" xlink:label="lab_oncyf_ClinicalTrialMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Clinical Trial [Member]</link:label>
    <link:label id="lab_oncyf_ClinicalTrialMember_documentation_en-US" xlink:label="lab_oncyf_ClinicalTrialMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Clinical Trial</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ClinicalTrialMember" xlink:href="oncyf-20241231.xsd#oncyf_ClinicalTrialMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ClinicalTrialMember" xlink:to="lab_oncyf_ClinicalTrialMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_SharePurchaseAgreementAmount_e867c792-7aca-4ba7-ae14-878a8f05cc22_terseLabel_en-US" xlink:label="lab_oncyf_SharePurchaseAgreementAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Agreement</link:label>
    <link:label id="lab_oncyf_SharePurchaseAgreementAmount_label_en-US" xlink:label="lab_oncyf_SharePurchaseAgreementAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Purchase Agreement, Amount</link:label>
    <link:label id="lab_oncyf_SharePurchaseAgreementAmount_documentation_en-US" xlink:label="lab_oncyf_SharePurchaseAgreementAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Purchase Agreement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharePurchaseAgreementAmount" xlink:href="oncyf-20241231.xsd#oncyf_SharePurchaseAgreementAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SharePurchaseAgreementAmount" xlink:to="lab_oncyf_SharePurchaseAgreementAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ChangeInFairValueWarrantDerivativeRollForward_c0a5d4c1-b780-489b-a66c-22d132e9dd30_terseLabel_en-US" xlink:label="lab_oncyf_ChangeInFairValueWarrantDerivativeRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value of Warrant Derivative</link:label>
    <link:label id="lab_oncyf_ChangeInFairValueWarrantDerivativeRollForward_label_en-US" xlink:label="lab_oncyf_ChangeInFairValueWarrantDerivativeRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change In Fair Value Warrant Derivative [Roll Forward]</link:label>
    <link:label id="lab_oncyf_ChangeInFairValueWarrantDerivativeRollForward_documentation_en-US" xlink:label="lab_oncyf_ChangeInFairValueWarrantDerivativeRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Change In Fair Value Warrant Derivative</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ChangeInFairValueWarrantDerivativeRollForward" xlink:href="oncyf-20241231.xsd#oncyf_ChangeInFairValueWarrantDerivativeRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ChangeInFairValueWarrantDerivativeRollForward" xlink:to="lab_oncyf_ChangeInFairValueWarrantDerivativeRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_bcf5a9c9-e314-411c-b1c7-2a8c58465431_terseLabel_en-US" xlink:label="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impact of foreign exchange on cash and cash equivalents</link:label>
    <link:label id="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_label_en-US" xlink:label="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:to="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_790d1f6b-74d1-437c-abf8-58f4432c90e6_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_1c27d92b-35ed-4d7f-8bc5-6d5cf0763a2e_terseLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Activities</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) operating activities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_90dbce4e-d596-463e-93a6-894c082c1cf7_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_InterestExpenseOnLeaseLiabilities_773d296c-e4b4-4a97-94ca-bf575a70ecd8_verboseLabel_en-US" xlink:label="lab_ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Interest expense on lease liabilities</link:label>
    <link:label id="lab_ifrs-full_InterestExpenseOnLeaseLiabilities_label_en-US" xlink:label="lab_ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest expense on lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:to="lab_ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ReserveOfSharebasedPaymentsMember_aa0424a0-dd3b-4938-a6f0-05bc56cd5cc9_terseLabel_en-US" xlink:label="lab_ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reserve of share-based payments</link:label>
    <link:label id="lab_ifrs-full_ReserveOfSharebasedPaymentsMember_label_en-US" xlink:label="lab_ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reserve of share-based payments [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReserveOfSharebasedPaymentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:to="lab_ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementExpirationDays_bcd4364b-8713-4f96-b0d0-dd54dbbc7053_terseLabel_en-US" xlink:label="lab_oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementExpirationDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of warrant or right, expiration days</link:label>
    <link:label id="lab_oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementExpirationDays_label_en-US" xlink:label="lab_oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementExpirationDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Equity Instruments In Share-Based Payment Arrangement, Expiration Days</link:label>
    <link:label id="lab_oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementExpirationDays_documentation_en-US" xlink:label="lab_oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementExpirationDays" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Equity Instruments In Share-Based Payment Arrangement, Expiration Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementExpirationDays" xlink:href="oncyf-20241231.xsd#oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementExpirationDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementExpirationDays" xlink:to="lab_oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementExpirationDays" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EmployeeBenefitsExpense_0e5e8bae-fc38-45bf-891e-e08553a9432a_terseLabel_en-US" xlink:label="lab_ifrs-full_EmployeeBenefitsExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee compensation and benefits expense</link:label>
    <link:label id="lab_ifrs-full_EmployeeBenefitsExpense_label_en-US" xlink:label="lab_ifrs-full_EmployeeBenefitsExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee benefits expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EmployeeBenefitsExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EmployeeBenefitsExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EmployeeBenefitsExpense" xlink:to="lab_ifrs-full_EmployeeBenefitsExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_b93e4c52-49b2-4a69-b4db-5a23f6d96927_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_AuditorInformationAbstract_label_en-US" xlink:label="lab_oncyf_AuditorInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Information [Abstract]</link:label>
    <link:label id="lab_oncyf_AuditorInformationAbstract_documentation_en-US" xlink:label="lab_oncyf_AuditorInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Auditor Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_AuditorInformationAbstract" xlink:href="oncyf-20241231.xsd#oncyf_AuditorInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_AuditorInformationAbstract" xlink:to="lab_oncyf_AuditorInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_MaturityDomain_b8ceca38-a1bb-4603-a123-9ac040979f60_terseLabel_en-US" xlink:label="lab_ifrs-full_MaturityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maturity</link:label>
    <link:label id="lab_ifrs-full_MaturityDomain_label_en-US" xlink:label="lab_ifrs-full_MaturityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maturity [domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityDomain" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MaturityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MaturityDomain" xlink:to="lab_ifrs-full_MaturityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncomeTaxExpenseContinuingOperations_59233907-a6f3-4d69-b924-35401e7ad15d_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Income tax expense (note 15)</link:label>
    <link:label id="lab_ifrs-full_IncomeTaxExpenseContinuingOperations_a32f04ff-7189-494b-8155-2634e43b66c6_totalLabel_en-US" xlink:label="lab_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Current income taxes</link:label>
    <link:label id="lab_ifrs-full_IncomeTaxExpenseContinuingOperations_label_en-US" xlink:label="lab_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax expense (income)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="lab_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_eeccdd37-7797-4806-bde6-87d720db2d4d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities_eaf126d2-3d24-41da-a9f9-a02876771d3c_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Acquisition of marketable securities</link:label>
    <link:label id="lab_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities_label_en-US" xlink:label="lab_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase of financial instruments, classified as investing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:to="lab_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_ffa21c27-f874-4c82-a1b5-69f8610205fe_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of weighted average remaining contractual life and outstanding stock options by exercise price</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of number and weighted average remaining contractual life of outstanding share options [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_68650188-d916-4ed9-8b2a-1e2a5f09355e_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_48d5fe6e-6544-4ec9-a3d9-80a44009b564_terseLabel_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_label_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_c8046981-9c3b-4988-8203-6569177c8b1d_totalLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">(Decrease) increase in cash and cash equivalents</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) in cash and cash equivalents after effect of exchange rate changes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:to="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_7dafa6f2-5d53-4125-84cd-9975ed9dd17c_verboseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Risk free interest rate, share options granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:to="lab_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_9e2674e1-6fc5-4701-83b2-1d62c53c698e_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of fair value measurement of liabilities [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of fair value measurement of liabilities [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:to="lab_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_PurchaseObligation1_2fffd632-b4e0-4c8d-b12d-3f9e829e5983_terseLabel_en-US" xlink:label="lab_oncyf_PurchaseObligation1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitment for payment</link:label>
    <link:label id="lab_oncyf_PurchaseObligation1_label_en-US" xlink:label="lab_oncyf_PurchaseObligation1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Obligation1</link:label>
    <link:label id="lab_oncyf_PurchaseObligation1_documentation_en-US" xlink:label="lab_oncyf_PurchaseObligation1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Purchase Obligation1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_PurchaseObligation1" xlink:href="oncyf-20241231.xsd#oncyf_PurchaseObligation1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_PurchaseObligation1" xlink:to="lab_oncyf_PurchaseObligation1" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_d0e3ca92-a2bd-4131-b5e3-e118170aa377_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss per share</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for earnings per share [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_DisclosureofeventsafterreportingperiodAbstract_e63f988e-357c-41a2-9847-51777f1fa0ca_terseLabel_en-US" xlink:label="lab_oncyf_DisclosureofeventsafterreportingperiodAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of events after reporting period [Abstract]</link:label>
    <link:label id="lab_oncyf_DisclosureofeventsafterreportingperiodAbstract_label_en-US" xlink:label="lab_oncyf_DisclosureofeventsafterreportingperiodAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of events after reporting period [Abstract]</link:label>
    <link:label id="lab_oncyf_DisclosureofeventsafterreportingperiodAbstract_documentation_en-US" xlink:label="lab_oncyf_DisclosureofeventsafterreportingperiodAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of events after reporting period [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofeventsafterreportingperiodAbstract" xlink:href="oncyf-20241231.xsd#oncyf_DisclosureofeventsafterreportingperiodAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_DisclosureofeventsafterreportingperiodAbstract" xlink:to="lab_oncyf_DisclosureofeventsafterreportingperiodAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_TaxEffectOfStockBasedCompensation_3f4205c2-2ccc-4e26-a4ee-2c4846ea9e73_negatedTerseLabel_en-US" xlink:label="lab_oncyf_TaxEffectOfStockBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_oncyf_TaxEffectOfStockBasedCompensation_label_en-US" xlink:label="lab_oncyf_TaxEffectOfStockBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Effect Of Stock Based Compensation</link:label>
    <link:label id="lab_oncyf_TaxEffectOfStockBasedCompensation_documentation_en-US" xlink:label="lab_oncyf_TaxEffectOfStockBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tax Effect Of Stock Based Compensation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TaxEffectOfStockBasedCompensation" xlink:href="oncyf-20241231.xsd#oncyf_TaxEffectOfStockBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_TaxEffectOfStockBasedCompensation" xlink:to="lab_oncyf_TaxEffectOfStockBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfRelatedPartyExplanatory_40563cf0-520f-4735-8a75-a9ccb4190843_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transactions</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfRelatedPartyExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of related party [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfRelatedPartyExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:to="lab_ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_0ef4ef23-b5cb-418c-85b0-fb8953c2b406_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_14a0c065-1f59-41da-bb2f-fcf7c9ba716b_terseLabel_en-US" xlink:label="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions, net of foreign exchange impact</link:label>
    <link:label id="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_label_en-US" xlink:label="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additions other than through business combinations, property, plant and equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:to="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_50052af5-e247-4785-9027-6e427b3d2097_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_AllCurrenciesDomain_9a5c2b0f-85e3-4e06-a5fe-999bc152f5ba_terseLabel_en-US" xlink:label="lab_currency_AllCurrenciesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Currencies [Domain]</link:label>
    <link:label id="lab_currency_AllCurrenciesDomain_label_en-US" xlink:label="lab_currency_AllCurrenciesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Currencies [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_AllCurrenciesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_AllCurrenciesDomain" xlink:to="lab_currency_AllCurrenciesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInWorkingCapital_bf58b538-ba55-4003-8597-d1bdba33cfc0_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInWorkingCapital" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Net change in non-cash working capital (note 18)</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInWorkingCapital_8f8786d4-37fe-4e3d-abb2-3b1d9edd28fa_negatedTotalLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInWorkingCapital" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Change in non-cash working capital related to operating activities</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInWorkingCapital_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInWorkingCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) in working capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInWorkingCapital" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseInWorkingCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseInWorkingCapital" xlink:to="lab_ifrs-full_IncreaseDecreaseInWorkingCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_cfe89b9d-c6e9-4396-9565-6715e9a1f69a_terseLabel_en-US" xlink:label="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_label_en-US" xlink:label="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expense from share-based payment transactions with employees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:to="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ShareWarrantsIssuedOperatingExpense_27214598-e5ef-4243-ad9c-2df8c617c3f9_terseLabel_en-US" xlink:label="lab_oncyf_ShareWarrantsIssuedOperatingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share issue operating expense</link:label>
    <link:label id="lab_oncyf_ShareWarrantsIssuedOperatingExpense_label_en-US" xlink:label="lab_oncyf_ShareWarrantsIssuedOperatingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Warrants Issued, Operating Expense</link:label>
    <link:label id="lab_oncyf_ShareWarrantsIssuedOperatingExpense_documentation_en-US" xlink:label="lab_oncyf_ShareWarrantsIssuedOperatingExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Warrants Issued, Operating Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ShareWarrantsIssuedOperatingExpense" xlink:href="oncyf-20241231.xsd#oncyf_ShareWarrantsIssuedOperatingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ShareWarrantsIssuedOperatingExpense" xlink:to="lab_oncyf_ShareWarrantsIssuedOperatingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncomeStatementAbstract_a42e3e35-1ae9-4a49-9be8-600eac9d4cf5_terseLabel_en-US" xlink:label="lab_ifrs-full_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Profit or loss [abstract]</link:label>
    <link:label id="lab_ifrs-full_IncomeStatementAbstract_label_en-US" xlink:label="lab_ifrs-full_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit or loss [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeStatementAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncomeStatementAbstract" xlink:to="lab_ifrs-full_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019_e4d708fb-77e3-4d61-9a7e-2e12a7329780_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expired during the year (cad per share)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average exercise price of share options expired in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_CommitmentsAndContingencies1_64c321e8-58e2-4140-b36e-c287d73575f3_terseLabel_en-US" xlink:label="lab_oncyf_CommitmentsAndContingencies1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies (note 14)</link:label>
    <link:label id="lab_oncyf_CommitmentsAndContingencies1_label_en-US" xlink:label="lab_oncyf_CommitmentsAndContingencies1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments And Contingencies1</link:label>
    <link:label id="lab_oncyf_CommitmentsAndContingencies1_documentation_en-US" xlink:label="lab_oncyf_CommitmentsAndContingencies1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commitments And Contingencies1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CommitmentsAndContingencies1" xlink:href="oncyf-20241231.xsd#oncyf_CommitmentsAndContingencies1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_CommitmentsAndContingencies1" xlink:to="lab_oncyf_CommitmentsAndContingencies1" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_DisclosureOfEconomicDependenceTextBlock_356bdb6a-5752-4bb0-9bac-eefd15419134_terseLabel_en-US" xlink:label="lab_oncyf_DisclosureOfEconomicDependenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Economic Dependence</link:label>
    <link:label id="lab_oncyf_DisclosureOfEconomicDependenceTextBlock_label_en-US" xlink:label="lab_oncyf_DisclosureOfEconomicDependenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Economic Dependence [Text Block]</link:label>
    <link:label id="lab_oncyf_DisclosureOfEconomicDependenceTextBlock_documentation_en-US" xlink:label="lab_oncyf_DisclosureOfEconomicDependenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Economic Dependence [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureOfEconomicDependenceTextBlock" xlink:href="oncyf-20241231.xsd#oncyf_DisclosureOfEconomicDependenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_DisclosureOfEconomicDependenceTextBlock" xlink:to="lab_oncyf_DisclosureOfEconomicDependenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_c24a0d75-57ec-4f89-be2a-5fccce1dee78_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant Judgments, Estimates and Assumptions</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of accounting judgements and estimates [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_OperatingLeaseLeaseTerm_89b4b688-6e15-40f8-a3f7-14fa3b74d208_terseLabel_en-US" xlink:label="lab_oncyf_OperatingLeaseLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease term</link:label>
    <link:label id="lab_oncyf_OperatingLeaseLeaseTerm_label_en-US" xlink:label="lab_oncyf_OperatingLeaseLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Lease Term</link:label>
    <link:label id="lab_oncyf_OperatingLeaseLeaseTerm_documentation_en-US" xlink:label="lab_oncyf_OperatingLeaseLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Lease, Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OperatingLeaseLeaseTerm" xlink:href="oncyf-20241231.xsd#oncyf_OperatingLeaseLeaseTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_OperatingLeaseLeaseTerm" xlink:to="lab_oncyf_OperatingLeaseLeaseTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageShares_b0435b33-9285-49bf-8683-921b60c61ae6_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average number of shares (basic) (shares)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageShares_480bb75f-fa26-4840-a38e-9041ef28d704_verboseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageShares" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted average number of common shares outstanding (shares)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageShares_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average number of ordinary shares used in calculating basic earnings per share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageShares" xlink:to="lab_ifrs-full_WeightedAverageShares" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables_631e70db-d55c-4b96-af76-2e73c0d0a365_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for decrease (increase) in other operating receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" xlink:to="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ExercisePriceRangeFourMember_5566b834-de44-4963-b2ec-35a8f1599f2b_terseLabel_en-US" xlink:label="lab_oncyf_ExercisePriceRangeFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">$3.91 - $7.41</link:label>
    <link:label id="lab_oncyf_ExercisePriceRangeFourMember_label_en-US" xlink:label="lab_oncyf_ExercisePriceRangeFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range Four [Member]</link:label>
    <link:label id="lab_oncyf_ExercisePriceRangeFourMember_documentation_en-US" xlink:label="lab_oncyf_ExercisePriceRangeFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Exercise Price Range Four [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ExercisePriceRangeFourMember" xlink:href="oncyf-20241231.xsd#oncyf_ExercisePriceRangeFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ExercisePriceRangeFourMember" xlink:to="lab_oncyf_ExercisePriceRangeFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_249e8cc6-7ebf-49e4-b536-8e0c8338182d_terseLabel_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term employee compensation and benefits</link:label>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_label_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Key management personnel compensation, short-term employee benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:to="lab_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_SupplierConcentrationRisk1Member_86f2021e-259d-425b-9cb9-e81f18ae9355_terseLabel_en-US" xlink:label="lab_oncyf_SupplierConcentrationRisk1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Toll manufacturer</link:label>
    <link:label id="lab_oncyf_SupplierConcentrationRisk1Member_label_en-US" xlink:label="lab_oncyf_SupplierConcentrationRisk1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplier Concentration Risk1 [Member]</link:label>
    <link:label id="lab_oncyf_SupplierConcentrationRisk1Member_documentation_en-US" xlink:label="lab_oncyf_SupplierConcentrationRisk1Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Supplier Concentration Risk1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SupplierConcentrationRisk1Member" xlink:href="oncyf-20241231.xsd#oncyf_SupplierConcentrationRisk1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SupplierConcentrationRisk1Member" xlink:to="lab_oncyf_SupplierConcentrationRisk1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ExpirationPeriodOfOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement_20c59bf0-8209-4808-ba22-a27ab25d1364_terseLabel_en-US" xlink:label="lab_oncyf_ExpirationPeriodOfOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiration period, granted</link:label>
    <link:label id="lab_oncyf_ExpirationPeriodOfOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement_label_en-US" xlink:label="lab_oncyf_ExpirationPeriodOfOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expiration Period Of Other Equity Instruments Granted In Share-Based Payment Arrangement</link:label>
    <link:label id="lab_oncyf_ExpirationPeriodOfOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement_documentation_en-US" xlink:label="lab_oncyf_ExpirationPeriodOfOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Expiration Period Of Other Equity Instruments Granted In Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ExpirationPeriodOfOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement" xlink:href="oncyf-20241231.xsd#oncyf_ExpirationPeriodOfOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ExpirationPeriodOfOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement" xlink:to="lab_oncyf_ExpirationPeriodOfOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProceedsFromExerciseOfOptions_44f613e5-dc97-480a-b5a3-24e4c47b9847_terseLabel_en-US" xlink:label="lab_ifrs-full_ProceedsFromExerciseOfOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from exercise of stock options (note 11)</link:label>
    <link:label id="lab_ifrs-full_ProceedsFromExerciseOfOptions_label_en-US" xlink:label="lab_ifrs-full_ProceedsFromExerciseOfOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from exercise of options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromExerciseOfOptions" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromExerciseOfOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProceedsFromExerciseOfOptions" xlink:to="lab_ifrs-full_ProceedsFromExerciseOfOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TopOfRangeMember_97d22829-864e-44a2-b515-98fbfc61b437_terseLabel_en-US" xlink:label="lab_ifrs-full_TopOfRangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_ifrs-full_TopOfRangeMember_label_en-US" xlink:label="lab_ifrs-full_TopOfRangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Top of range [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TopOfRangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TopOfRangeMember" xlink:to="lab_ifrs-full_TopOfRangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_NumberOfWarrantsAndSharesOutstanding_05a4d4d3-d1e0-44e4-9fcf-1f9417317a88_terseLabel_en-US" xlink:label="lab_oncyf_NumberOfWarrantsAndSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of warrants and shares outstanding (in shares)</link:label>
    <link:label id="lab_oncyf_NumberOfWarrantsAndSharesOutstanding_label_en-US" xlink:label="lab_oncyf_NumberOfWarrantsAndSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Warrants And Shares Outstanding</link:label>
    <link:label id="lab_oncyf_NumberOfWarrantsAndSharesOutstanding_documentation_en-US" xlink:label="lab_oncyf_NumberOfWarrantsAndSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Warrants And Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_NumberOfWarrantsAndSharesOutstanding" xlink:href="oncyf-20241231.xsd#oncyf_NumberOfWarrantsAndSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_NumberOfWarrantsAndSharesOutstanding" xlink:to="lab_oncyf_NumberOfWarrantsAndSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PresentationOfLeasesForLesseeAbstract_ac77817b-dcc2-4605-87a4-aa6c29a6c547_terseLabel_en-US" xlink:label="lab_ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Presentation of leases for lessee [abstract]</link:label>
    <link:label id="lab_ifrs-full_PresentationOfLeasesForLesseeAbstract_label_en-US" xlink:label="lab_ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Presentation of leases for lessee [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:to="lab_ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_9b236986-066e-4247-b95a-8e268bb4a551_terseLabel_en-US" xlink:label="lab_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">One to five years</link:label>
    <link:label id="lab_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_label_en-US" xlink:label="lab_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than one year and not later than five years [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:to="lab_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentLeaseLiabilities_c779ae6e-3fc4-479b-a4e2-2f2182b9d808_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liabilities (note 8)</link:label>
    <link:label id="lab_ifrs-full_CurrentLeaseLiabilities_label_en-US" xlink:label="lab_ifrs-full_CurrentLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentLeaseLiabilities" xlink:to="lab_ifrs-full_CurrentLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperations_1ceb647c-34b4-457b-88f1-4d3507e4c838_totalLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Cash used in operating activities</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperations_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperations" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperations" xlink:to="lab_ifrs-full_CashFlowsFromUsedInOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_DisclosureofincometaxAbstract_a94511e2-a847-4ba1-8658-ca44b1bcf18c_terseLabel_en-US" xlink:label="lab_oncyf_DisclosureofincometaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of income tax [Abstract]</link:label>
    <link:label id="lab_oncyf_DisclosureofincometaxAbstract_label_en-US" xlink:label="lab_oncyf_DisclosureofincometaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of income tax [Abstract]</link:label>
    <link:label id="lab_oncyf_DisclosureofincometaxAbstract_documentation_en-US" xlink:label="lab_oncyf_DisclosureofincometaxAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of income tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofincometaxAbstract" xlink:href="oncyf-20241231.xsd#oncyf_DisclosureofincometaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_DisclosureofincometaxAbstract" xlink:to="lab_oncyf_DisclosureofincometaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_a186f477-e3e5-4684-8bc4-64cb8e700c4a_terseLabel_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_label_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Key management personnel compensation, share-based payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:to="lab_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrencyRiskMember_e8194025-b728-45fa-a9ed-ac6af0aefc02_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrencyRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency risk</link:label>
    <link:label id="lab_ifrs-full_CurrencyRiskMember_label_en-US" xlink:label="lab_ifrs-full_CurrencyRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Currency risk [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrencyRiskMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrencyRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrencyRiskMember" xlink:to="lab_ifrs-full_CurrencyRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ResearchAndDevelopmentExpense_db7ab2db-19aa-4cd1-bef7-20d0a730c278_terseLabel_en-US" xlink:label="lab_ifrs-full_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development (note 20)</link:label>
    <link:label id="lab_ifrs-full_ResearchAndDevelopmentExpense_cac7dfaa-361a-465e-b15d-88c16ca334fa_verboseLabel_en-US" xlink:label="lab_ifrs-full_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_ifrs-full_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_ifrs-full_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and development expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ResearchAndDevelopmentExpense" xlink:to="lab_ifrs-full_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_PurchaseObligationCommitmentTerm_0b2ad970-8447-46c4-be72-bdbdd01d37bd_terseLabel_en-US" xlink:label="lab_oncyf_PurchaseObligationCommitmentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitment term</link:label>
    <link:label id="lab_oncyf_PurchaseObligationCommitmentTerm_label_en-US" xlink:label="lab_oncyf_PurchaseObligationCommitmentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Obligation, Commitment Term</link:label>
    <link:label id="lab_oncyf_PurchaseObligationCommitmentTerm_documentation_en-US" xlink:label="lab_oncyf_PurchaseObligationCommitmentTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Purchase Obligation, Commitment Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_PurchaseObligationCommitmentTerm" xlink:href="oncyf-20241231.xsd#oncyf_PurchaseObligationCommitmentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_PurchaseObligationCommitmentTerm" xlink:to="lab_oncyf_PurchaseObligationCommitmentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_SharesUnderIncentiveAwardPlanMember_c71766cc-f265-444f-b12b-cc5087b7c9f9_terseLabel_en-US" xlink:label="lab_oncyf_SharesUnderIncentiveAwardPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Incentive share award plan</link:label>
    <link:label id="lab_oncyf_SharesUnderIncentiveAwardPlanMember_label_en-US" xlink:label="lab_oncyf_SharesUnderIncentiveAwardPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Under Incentive Award Plan [Member]</link:label>
    <link:label id="lab_oncyf_SharesUnderIncentiveAwardPlanMember_documentation_en-US" xlink:label="lab_oncyf_SharesUnderIncentiveAwardPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Shares Under Incentive Award Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesUnderIncentiveAwardPlanMember" xlink:href="oncyf-20241231.xsd#oncyf_SharesUnderIncentiveAwardPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SharesUnderIncentiveAwardPlanMember" xlink:to="lab_oncyf_SharesUnderIncentiveAwardPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_cce89c7a-fcd7-41f8-9de6-33339546a6c9_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProfitLossBeforeTax_9f05f1dd-4650-4357-afcf-e2519130bd25_totalLabel_en-US" xlink:label="lab_ifrs-full_ProfitLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss before income taxes</link:label>
    <link:label id="lab_ifrs-full_ProfitLossBeforeTax_label_en-US" xlink:label="lab_ifrs-full_ProfitLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit (loss) before tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossBeforeTax" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLossBeforeTax" xlink:to="lab_ifrs-full_ProfitLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_CashFlowOperatingCapital1TableTextBlock_5230a461-cbe0-4180-a9f9-a91e87053d80_terseLabel_en-US" xlink:label="lab_oncyf_CashFlowOperatingCapital1TableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Net change in non-cash working capital</link:label>
    <link:label id="lab_oncyf_CashFlowOperatingCapital1TableTextBlock_label_en-US" xlink:label="lab_oncyf_CashFlowOperatingCapital1TableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flow, Operating Capital1 [Table Text Block]</link:label>
    <link:label id="lab_oncyf_CashFlowOperatingCapital1TableTextBlock_documentation_en-US" xlink:label="lab_oncyf_CashFlowOperatingCapital1TableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash Flow, Operating Capital1 [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CashFlowOperatingCapital1TableTextBlock" xlink:href="oncyf-20241231.xsd#oncyf_CashFlowOperatingCapital1TableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_CashFlowOperatingCapital1TableTextBlock" xlink:to="lab_oncyf_CashFlowOperatingCapital1TableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GeneralAndAdministrativeExpense_6e904ffd-4b58-44f4-b4d2-1b4cec756850_verboseLabel_en-US" xlink:label="lab_ifrs-full_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">General and administrative (note 20)</link:label>
    <link:label id="lab_ifrs-full_GeneralAndAdministrativeExpense_69144f0b-72ad-4d3c-9d60-260217dbd1ee_terseLabel_en-US" xlink:label="lab_ifrs-full_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative expenses</link:label>
    <link:label id="lab_ifrs-full_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_ifrs-full_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and administrative expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GeneralAndAdministrativeExpense" xlink:to="lab_ifrs-full_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory_198da710-e339-4155-acc2-742b48e5bf2a_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial assets</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for financial assets [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ProceedsfromInterestReceived_240ab362-656c-40a6-87f0-c5a48c17c217_terseLabel_en-US" xlink:label="lab_oncyf_ProceedsfromInterestReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash interest received</link:label>
    <link:label id="lab_oncyf_ProceedsfromInterestReceived_label_en-US" xlink:label="lab_oncyf_ProceedsfromInterestReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Interest Received</link:label>
    <link:label id="lab_oncyf_ProceedsfromInterestReceived_documentation_en-US" xlink:label="lab_oncyf_ProceedsfromInterestReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds from Interest Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ProceedsfromInterestReceived" xlink:href="oncyf-20241231.xsd#oncyf_ProceedsfromInterestReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ProceedsfromInterestReceived" xlink:to="lab_oncyf_ProceedsfromInterestReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ApplicableTaxRate_01eec5f4-fb1e-45a9-828a-d1ffc8f185e2_terseLabel_en-US" xlink:label="lab_ifrs-full_ApplicableTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statutory Canadian corporate tax rate</link:label>
    <link:label id="lab_ifrs-full_ApplicableTaxRate_label_en-US" xlink:label="lab_ifrs-full_ApplicableTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Applicable tax rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ApplicableTaxRate" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ApplicableTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ApplicableTaxRate" xlink:to="lab_ifrs-full_ApplicableTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_65c5fb1f-7919-403c-be94-f702e235481b_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_WeightedAverageExercisePriceOutstandingAbstract_09642022-feed-4379-a344-f4cc9e6a6ab3_terseLabel_en-US" xlink:label="lab_oncyf_WeightedAverageExercisePriceOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price $</link:label>
    <link:label id="lab_oncyf_WeightedAverageExercisePriceOutstandingAbstract_label_en-US" xlink:label="lab_oncyf_WeightedAverageExercisePriceOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price, Outstanding [Abstract]</link:label>
    <link:label id="lab_oncyf_WeightedAverageExercisePriceOutstandingAbstract_documentation_en-US" xlink:label="lab_oncyf_WeightedAverageExercisePriceOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WeightedAverageExercisePriceOutstandingAbstract" xlink:href="oncyf-20241231.xsd#oncyf_WeightedAverageExercisePriceOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_WeightedAverageExercisePriceOutstandingAbstract" xlink:to="lab_oncyf_WeightedAverageExercisePriceOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IssuedCapitalMember_0810984c-b282-4df3-87f7-e8d5081fb3c6_terseLabel_en-US" xlink:label="lab_ifrs-full_IssuedCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Capital</link:label>
    <link:label id="lab_ifrs-full_IssuedCapitalMember_label_en-US" xlink:label="lab_ifrs-full_IssuedCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issued capital [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IssuedCapitalMember" xlink:to="lab_ifrs-full_IssuedCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_b878d69b-319d-4b1f-ac07-f7ba1851df49_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Acquisition of property and equipment (note 6)</link:label>
    <link:label id="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_label_en-US" xlink:label="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase of property, plant and equipment, classified as investing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:to="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_272c15e9-b262-41b5-a6f3-0af44bc14cc1_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_55b9509e-1318-4b79-ab12-bd4081a0135f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ExercisePriceOfOutstandingShareOptions2019_af1f212c-17aa-4557-a291-9bf3a4656f3d_terseLabel_en-US" xlink:label="lab_ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise price (cad per share)</link:label>
    <link:label id="lab_ifrs-full_ExercisePriceOfOutstandingShareOptions2019_label_en-US" xlink:label="lab_ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise price of outstanding share options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions2019"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:to="lab_ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_f92dda4e-badc-4589-ad55-3babb5c5611b_terseLabel_en-US" xlink:label="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ranges of exercise prices for outstanding share options [axis]</link:label>
    <link:label id="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_label_en-US" xlink:label="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ranges of exercise prices for outstanding share options [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:to="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_a1229dd8-cea4-443c-b1f5-5aaf677ae410_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_44fdb339-edbc-4da4-9f93-d523fbf34e49_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forfeited during the year (cad per share)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average exercise price of share options forfeited in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForSharebasedPayments_7c176d09-4b1f-4d20-8088-33c5af180e7c_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForSharebasedPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense (notes 11, 20, 22)</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForSharebasedPayments_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForSharebasedPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for share-based payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForSharebasedPayments" xlink:to="lab_ifrs-full_AdjustmentsForSharebasedPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_NumberOfWarrantsExpired_24941602-44ab-4d6a-8f77-ca780070e0ff_negatedTerseLabel_en-US" xlink:label="lab_oncyf_NumberOfWarrantsExpired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Expired (in shares)</link:label>
    <link:label id="lab_oncyf_NumberOfWarrantsExpired_label_en-US" xlink:label="lab_oncyf_NumberOfWarrantsExpired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Warrants Expired</link:label>
    <link:label id="lab_oncyf_NumberOfWarrantsExpired_documentation_en-US" xlink:label="lab_oncyf_NumberOfWarrantsExpired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Warrants Expired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_NumberOfWarrantsExpired" xlink:href="oncyf-20241231.xsd#oncyf_NumberOfWarrantsExpired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_NumberOfWarrantsExpired" xlink:to="lab_oncyf_NumberOfWarrantsExpired" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_TranslationalScienceExpense_8b54c3c0-cfe1-450e-9737-25ef56ab8591_terseLabel_en-US" xlink:label="lab_oncyf_TranslationalScienceExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Translational science expenses</link:label>
    <link:label id="lab_oncyf_TranslationalScienceExpense_label_en-US" xlink:label="lab_oncyf_TranslationalScienceExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Translational Science Expense</link:label>
    <link:label id="lab_oncyf_TranslationalScienceExpense_documentation_en-US" xlink:label="lab_oncyf_TranslationalScienceExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Translational Science Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TranslationalScienceExpense" xlink:href="oncyf-20241231.xsd#oncyf_TranslationalScienceExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_TranslationalScienceExpense" xlink:to="lab_oncyf_TranslationalScienceExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RetainedEarningsMember_300e4bbb-e12b-4ce5-87e8-fca9fe17d3f1_terseLabel_en-US" xlink:label="lab_ifrs-full_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_ifrs-full_RetainedEarningsMember_label_en-US" xlink:label="lab_ifrs-full_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained earnings [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetainedEarningsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RetainedEarningsMember" xlink:to="lab_ifrs-full_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementAcceleratedThresholdTradingDays_908a3259-5ae3-432b-9d6f-4e2e30d91fc0_terseLabel_en-US" xlink:label="lab_oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementAcceleratedThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of warrant or right, accelerated threshold trading days</link:label>
    <link:label id="lab_oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementAcceleratedThresholdTradingDays_label_en-US" xlink:label="lab_oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementAcceleratedThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Equity Instruments In Share-Based Payment Arrangement, Accelerated Threshold Trading Days</link:label>
    <link:label id="lab_oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementAcceleratedThresholdTradingDays_documentation_en-US" xlink:label="lab_oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementAcceleratedThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Equity Instruments In Share-Based Payment Arrangement, Accelerated Threshold Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementAcceleratedThresholdTradingDays" xlink:href="oncyf-20241231.xsd#oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementAcceleratedThresholdTradingDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementAcceleratedThresholdTradingDays" xlink:to="lab_oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementAcceleratedThresholdTradingDays" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TaxEffectFromChangeInTaxRate_df0b9a1f-1576-4b62-b002-ef2fe7d5baf9_terseLabel_en-US" xlink:label="lab_ifrs-full_TaxEffectFromChangeInTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impact of Barbados rate change</link:label>
    <link:label id="lab_ifrs-full_TaxEffectFromChangeInTaxRate_label_en-US" xlink:label="lab_ifrs-full_TaxEffectFromChangeInTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax effect from change in tax rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TaxEffectFromChangeInTaxRate" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TaxEffectFromChangeInTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TaxEffectFromChangeInTaxRate" xlink:to="lab_ifrs-full_TaxEffectFromChangeInTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_NumberOfReportableSegments1_b9dd672f-7d14-4fdf-8c21-a2148175bbee_terseLabel_en-US" xlink:label="lab_oncyf_NumberOfReportableSegments1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_oncyf_NumberOfReportableSegments1_label_en-US" xlink:label="lab_oncyf_NumberOfReportableSegments1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Reportable Segments1</link:label>
    <link:label id="lab_oncyf_NumberOfReportableSegments1_documentation_en-US" xlink:label="lab_oncyf_NumberOfReportableSegments1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Reportable Segments1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_NumberOfReportableSegments1" xlink:href="oncyf-20241231.xsd#oncyf_NumberOfReportableSegments1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_NumberOfReportableSegments1" xlink:to="lab_oncyf_NumberOfReportableSegments1" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentPrepayments_1fbbb1a9-ce5a-4ed9-a39b-ae1c44bf2ba8_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentPrepayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_ifrs-full_CurrentPrepayments_label_en-US" xlink:label="lab_ifrs-full_CurrentPrepayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current prepayments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentPrepayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentPrepayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentPrepayments" xlink:to="lab_ifrs-full_CurrentPrepayments" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IssueOfEquity_f6cac1f7-c349-4804-83da-c94c25830b81_terseLabel_en-US" xlink:label="lab_ifrs-full_IssueOfEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issue of equity</link:label>
    <link:label id="lab_ifrs-full_IssueOfEquity_76db122f-c1fa-48be-bff5-c35f42ef3a19_verboseLabel_en-US" xlink:label="lab_ifrs-full_IssueOfEquity" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Issued pursuant to public offering</link:label>
    <link:label id="lab_ifrs-full_IssueOfEquity_label_en-US" xlink:label="lab_ifrs-full_IssueOfEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issue of equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssueOfEquity" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssueOfEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IssueOfEquity" xlink:to="lab_ifrs-full_IssueOfEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_7b747cc4-409f-4e07-aadd-a69536499b70_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of classes of share capital [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of classes of share capital [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory_f8ffeecb-7e72-48ba-9f4a-ff48bcaa6e72_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for impairment of financial assets [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentDerivativeFinancialAssets_afbcf8ed-8d8d-4fe7-adaa-457633c73dd9_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentDerivativeFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant derivative (notes 9, 17)</link:label>
    <link:label id="lab_ifrs-full_CurrentDerivativeFinancialAssets_21a81305-e72b-4f7d-bb27-d98ed90bf2c2_verboseLabel_en-US" xlink:label="lab_ifrs-full_CurrentDerivativeFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Warrant derivative asset</link:label>
    <link:label id="lab_ifrs-full_CurrentDerivativeFinancialAssets_label_en-US" xlink:label="lab_ifrs-full_CurrentDerivativeFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current derivative financial assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentDerivativeFinancialAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentDerivativeFinancialAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentDerivativeFinancialAssets" xlink:to="lab_ifrs-full_CurrentDerivativeFinancialAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfOutstandingShareOptions_ac028141-eeed-4a08-83ba-e80341cdc530_periodStartLabel_en-US" xlink:label="lab_ifrs-full_NumberOfOutstandingShareOptions" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, beginning of the year (shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfOutstandingShareOptions_2911256a-0af3-46bc-8655-4d4595c26c85_periodEndLabel_en-US" xlink:label="lab_ifrs-full_NumberOfOutstandingShareOptions" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, end of the year (shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfOutstandingShareOptions_bbb1a5c8-8fa5-4fed-8a52-b0b83870ca94_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfOutstandingShareOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number Outstanding (shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfOutstandingShareOptions_label_en-US" xlink:label="lab_ifrs-full_NumberOfOutstandingShareOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of share options outstanding in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOutstandingShareOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfOutstandingShareOptions" xlink:to="lab_ifrs-full_NumberOfOutstandingShareOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ComprehensiveIncome_4ecb9f6d-1f0e-4b84-8aba-6318b157c3c1_totalLabel_en-US" xlink:label="lab_ifrs-full_ComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_ifrs-full_ComprehensiveIncome_d2c6a5dc-c241-416e-aabd-c3f486276cc7_terseLabel_en-US" xlink:label="lab_ifrs-full_ComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss and other comprehensive income (loss)</link:label>
    <link:label id="lab_ifrs-full_ComprehensiveIncome_label_en-US" xlink:label="lab_ifrs-full_ComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComprehensiveIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComprehensiveIncome" xlink:to="lab_ifrs-full_ComprehensiveIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Equity_62912158-81c4-4871-9ce1-c3d439580cb1_totalLabel_en-US" xlink:label="lab_ifrs-full_Equity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total shareholders&#8217; equity</link:label>
    <link:label id="lab_ifrs-full_Equity_0b5b4b4a-0c7f-4c1b-bacc-31a55a5e0a83_periodStartLabel_en-US" xlink:label="lab_ifrs-full_Equity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Equity balance at beginning of period</link:label>
    <link:label id="lab_ifrs-full_Equity_97fd40df-ff3b-4ee3-b234-70366e1f6eec_periodEndLabel_en-US" xlink:label="lab_ifrs-full_Equity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Equity balance at end of period</link:label>
    <link:label id="lab_ifrs-full_Equity_79101167-d6bc-4779-92db-d49ab163a522_terseLabel_en-US" xlink:label="lab_ifrs-full_Equity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shareholders' equity</link:label>
    <link:label id="lab_ifrs-full_Equity_label_en-US" xlink:label="lab_ifrs-full_Equity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Equity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Equity" xlink:to="lab_ifrs-full_Equity" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_BalanceHeldInForeignCurrencyNet_ce0b3480-7bc2-4b5e-a299-36b1156a21d1_terseLabel_en-US" xlink:label="lab_oncyf_BalanceHeldInForeignCurrencyNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balances in foreign currencies</link:label>
    <link:label id="lab_oncyf_BalanceHeldInForeignCurrencyNet_label_en-US" xlink:label="lab_oncyf_BalanceHeldInForeignCurrencyNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Held In Foreign Currency, Net</link:label>
    <link:label id="lab_oncyf_BalanceHeldInForeignCurrencyNet_documentation_en-US" xlink:label="lab_oncyf_BalanceHeldInForeignCurrencyNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Balance Held In Foreign Currency, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_BalanceHeldInForeignCurrencyNet" xlink:href="oncyf-20241231.xsd#oncyf_BalanceHeldInForeignCurrencyNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_BalanceHeldInForeignCurrencyNet" xlink:to="lab_oncyf_BalanceHeldInForeignCurrencyNet" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_RiskFreeInterestRateOtherEquityInstrumentsGranted_c6e5d1bf-ae93-4aba-b033-2e19993457d1_terseLabel_en-US" xlink:label="lab_oncyf_RiskFreeInterestRateOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_oncyf_RiskFreeInterestRateOtherEquityInstrumentsGranted_label_en-US" xlink:label="lab_oncyf_RiskFreeInterestRateOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Risk Free Interest Rate, Other Equity Instruments Granted</link:label>
    <link:label id="lab_oncyf_RiskFreeInterestRateOtherEquityInstrumentsGranted_documentation_en-US" xlink:label="lab_oncyf_RiskFreeInterestRateOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Risk Free Interest Rate, Other Equity Instruments Granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_RiskFreeInterestRateOtherEquityInstrumentsGranted" xlink:href="oncyf-20241231.xsd#oncyf_RiskFreeInterestRateOtherEquityInstrumentsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_RiskFreeInterestRateOtherEquityInstrumentsGranted" xlink:to="lab_oncyf_RiskFreeInterestRateOtherEquityInstrumentsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfGeographicalAreasExplanatory_c48fe808-b58f-40d0-9168-47c56cbed0e9_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfGeographicalAreasExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of geographical areas</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfGeographicalAreasExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfGeographicalAreasExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of geographical areas [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfGeographicalAreasExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfGeographicalAreasExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasExplanatory" xlink:to="lab_ifrs-full_DisclosureOfGeographicalAreasExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_1dccacf5-b662-4bbb-a6de-a977f4626b6e_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_ade243f9-8d28-4bb3-8bc9-18647b3377e2_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of nature and extent of risks arising from financial instruments [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of nature and extent of risks arising from financial instruments [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:to="lab_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementThresholdTradingPrice_3dea3186-cd73-4518-8b6c-08f0aa1970f3_terseLabel_en-US" xlink:label="lab_oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementThresholdTradingPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of warrant or right, threshold trading price (usd per share)</link:label>
    <link:label id="lab_oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementThresholdTradingPrice_label_en-US" xlink:label="lab_oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementThresholdTradingPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Equity Instruments In Share-Based Payment Arrangement, Threshold Trading Price</link:label>
    <link:label id="lab_oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementThresholdTradingPrice_documentation_en-US" xlink:label="lab_oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementThresholdTradingPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Equity Instruments In Share-Based Payment Arrangement, Threshold Trading Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementThresholdTradingPrice" xlink:href="oncyf-20241231.xsd#oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementThresholdTradingPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementThresholdTradingPrice" xlink:to="lab_oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementThresholdTradingPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory_98c4d1b1-d300-42b0-abd8-0494c2011ffa_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of unrecognized non-capital losses, non-refundable credits and deferred tax assets</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of temporary difference, unused tax losses and unused tax credits [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ManufacturingExpense_eb151ac2-ed08-4396-81b3-44be013afd74_terseLabel_en-US" xlink:label="lab_oncyf_ManufacturingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Manufacturing &amp; related process development expenses</link:label>
    <link:label id="lab_oncyf_ManufacturingExpense_label_en-US" xlink:label="lab_oncyf_ManufacturingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Manufacturing Expense</link:label>
    <link:label id="lab_oncyf_ManufacturingExpense_documentation_en-US" xlink:label="lab_oncyf_ManufacturingExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Manufacturing Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ManufacturingExpense" xlink:href="oncyf-20241231.xsd#oncyf_ManufacturingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ManufacturingExpense" xlink:to="lab_oncyf_ManufacturingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_99970c65-a077-47e8-bee2-62955f2dcb59_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_SharesPublicOfferingWarrantDerivativesMember_e2e0be83-c739-4716-9765-b9c33cb9d16d_terseLabel_en-US" xlink:label="lab_oncyf_SharesPublicOfferingWarrantDerivativesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares Under Warrant Derivative Agreement</link:label>
    <link:label id="lab_oncyf_SharesPublicOfferingWarrantDerivativesMember_2fb3e573-23c9-42e5-a9e7-757e96abb45e_verboseLabel_en-US" xlink:label="lab_oncyf_SharesPublicOfferingWarrantDerivativesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Warrant derivatives</link:label>
    <link:label id="lab_oncyf_SharesPublicOfferingWarrantDerivativesMember_label_en-US" xlink:label="lab_oncyf_SharesPublicOfferingWarrantDerivativesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Public Offering, Warrant Derivatives [Member]</link:label>
    <link:label id="lab_oncyf_SharesPublicOfferingWarrantDerivativesMember_documentation_en-US" xlink:label="lab_oncyf_SharesPublicOfferingWarrantDerivativesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Shares Public Offering, Warrant Derivatives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesPublicOfferingWarrantDerivativesMember" xlink:href="oncyf-20241231.xsd#oncyf_SharesPublicOfferingWarrantDerivativesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SharesPublicOfferingWarrantDerivativesMember" xlink:to="lab_oncyf_SharesPublicOfferingWarrantDerivativesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables_ca7adcb7-41b9-489a-ab11-78b36ec623bf_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for increase (decrease) in other operating payables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables" xlink:to="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_OtherEquityInstrumentsLifeOtherEquityInstrumentsGranted_53930aa4-280b-4331-93d0-c88b3347ac10_terseLabel_en-US" xlink:label="lab_oncyf_OtherEquityInstrumentsLifeOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected life</link:label>
    <link:label id="lab_oncyf_OtherEquityInstrumentsLifeOtherEquityInstrumentsGranted_label_en-US" xlink:label="lab_oncyf_OtherEquityInstrumentsLifeOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Equity Instruments Life, Other Equity Instruments Granted</link:label>
    <link:label id="lab_oncyf_OtherEquityInstrumentsLifeOtherEquityInstrumentsGranted_documentation_en-US" xlink:label="lab_oncyf_OtherEquityInstrumentsLifeOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Equity Instruments Life, Other Equity Instruments Granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OtherEquityInstrumentsLifeOtherEquityInstrumentsGranted" xlink:href="oncyf-20241231.xsd#oncyf_OtherEquityInstrumentsLifeOtherEquityInstrumentsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_OtherEquityInstrumentsLifeOtherEquityInstrumentsGranted" xlink:to="lab_oncyf_OtherEquityInstrumentsLifeOtherEquityInstrumentsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ShareIssueCostsMember_2b4c1a2e-3505-492f-bd24-bdcd30764001_terseLabel_en-US" xlink:label="lab_oncyf_ShareIssueCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share issue costs</link:label>
    <link:label id="lab_oncyf_ShareIssueCostsMember_label_en-US" xlink:label="lab_oncyf_ShareIssueCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Issue Costs [Member]</link:label>
    <link:label id="lab_oncyf_ShareIssueCostsMember_documentation_en-US" xlink:label="lab_oncyf_ShareIssueCostsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Issue Costs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ShareIssueCostsMember" xlink:href="oncyf-20241231.xsd#oncyf_ShareIssueCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ShareIssueCostsMember" xlink:to="lab_oncyf_ShareIssueCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_WarrantLiabilityAmortizedDiscount_eb2609fa-4862-4b84-852d-f6b44c29c9cb_terseLabel_en-US" xlink:label="lab_oncyf_WarrantLiabilityAmortizedDiscount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of discount on warrants issued</link:label>
    <link:label id="lab_oncyf_WarrantLiabilityAmortizedDiscount_label_en-US" xlink:label="lab_oncyf_WarrantLiabilityAmortizedDiscount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant Liability, Amortized Discount</link:label>
    <link:label id="lab_oncyf_WarrantLiabilityAmortizedDiscount_documentation_en-US" xlink:label="lab_oncyf_WarrantLiabilityAmortizedDiscount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrant Liability, Amortized Discount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantLiabilityAmortizedDiscount" xlink:href="oncyf-20241231.xsd#oncyf_WarrantLiabilityAmortizedDiscount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_WarrantLiabilityAmortizedDiscount" xlink:to="lab_oncyf_WarrantLiabilityAmortizedDiscount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationTable_f60492d5-463d-4d19-bd4a-044f2261b84b_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
    <link:label id="lab_dei_DocumentInformationTable_label_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationTable" xlink:to="lab_dei_DocumentInformationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised_29235f9a-f0c8-498f-b29d-07dd3ff2d8f1_terseLabel_en-US" xlink:label="lab_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized deferred tax asset</link:label>
    <link:label id="lab_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised_label_en-US" xlink:label="lab_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deductible temporary differences for which no deferred tax asset is recognised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" xlink:to="lab_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_e080eed2-bb78-4031-83d1-65e2b5239d81_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of share-based payment arrangements [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AmortisationExpense_ea50883a-7d7b-4451-872e-ec08eb09ea54_terseLabel_en-US" xlink:label="lab_ifrs-full_AmortisationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation - property and equipment</link:label>
    <link:label id="lab_ifrs-full_AmortisationExpense_label_en-US" xlink:label="lab_ifrs-full_AmortisationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortisation expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmortisationExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AmortisationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AmortisationExpense" xlink:to="lab_ifrs-full_AmortisationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_56bc6c91-1cfd-43a9-a809-9112dbc44a7f_terseLabel_en-US" xlink:label="lab_ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Analysis of income and expense [abstract]</link:label>
    <link:label id="lab_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_label_en-US" xlink:label="lab_ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Analysis of income and expense [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:to="lab_ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_20fa9a0b-4c93-4e7d-9c5a-8ea8c975919a_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_IncomeStatementLocation1Axis_e504de1b-6cca-48e8-9d70-db695cd80fc2_terseLabel_en-US" xlink:label="lab_oncyf_IncomeStatementLocation1Axis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location1 [Axis]</link:label>
    <link:label id="lab_oncyf_IncomeStatementLocation1Axis_label_en-US" xlink:label="lab_oncyf_IncomeStatementLocation1Axis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location1 [Axis]</link:label>
    <link:label id="lab_oncyf_IncomeStatementLocation1Axis_documentation_en-US" xlink:label="lab_oncyf_IncomeStatementLocation1Axis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income Statement Location1 [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IncomeStatementLocation1Axis" xlink:href="oncyf-20241231.xsd#oncyf_IncomeStatementLocation1Axis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_IncomeStatementLocation1Axis" xlink:to="lab_oncyf_IncomeStatementLocation1Axis" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1_b7b0312a-474d-4d22-b65e-3d91e5c6a2ec_negatedTerseLabel_en-US" xlink:label="lab_oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Provision to offset deferred tax asset</link:label>
    <link:label id="lab_oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1_label_en-US" xlink:label="lab_oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount1</link:label>
    <link:label id="lab_oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1_documentation_en-US" xlink:label="lab_oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1" xlink:href="oncyf-20241231.xsd#oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1" xlink:to="lab_oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_SharesUnderStockOptionPlanMember_8ebb43f9-d33c-4641-a53a-9bcd144b24fe_terseLabel_en-US" xlink:label="lab_oncyf_SharesUnderStockOptionPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock option plan</link:label>
    <link:label id="lab_oncyf_SharesUnderStockOptionPlanMember_label_en-US" xlink:label="lab_oncyf_SharesUnderStockOptionPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Under Stock Option Plan [Member]</link:label>
    <link:label id="lab_oncyf_SharesUnderStockOptionPlanMember_documentation_en-US" xlink:label="lab_oncyf_SharesUnderStockOptionPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Shares Under Stock Option Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesUnderStockOptionPlanMember" xlink:href="oncyf-20241231.xsd#oncyf_SharesUnderStockOptionPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SharesUnderStockOptionPlanMember" xlink:to="lab_oncyf_SharesUnderStockOptionPlanMember" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>14
<FILENAME>oncyf-20241231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:f2389c06-29ac-4823-bdfc-c1b39bddff80,g:9bb1793d-cf33-41ae-b11c-eb401ad874b8-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/Cover" xlink:type="simple" xlink:href="oncyf-20241231.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_81cac3d6-98ad-4e16-896f-e3824156ff9f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_9065b503-4370-4d21-99d3-804452f5c816" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_81cac3d6-98ad-4e16-896f-e3824156ff9f" xlink:to="loc_dei_DocumentInformationTable_9065b503-4370-4d21-99d3-804452f5c816" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressesAddressTypeAxis_4b664284-8f94-4b68-a848-f2a8821625dd" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_9065b503-4370-4d21-99d3-804452f5c816" xlink:to="loc_dei_EntityAddressesAddressTypeAxis_4b664284-8f94-4b68-a848-f2a8821625dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AddressTypeDomain_01eda1ea-4897-4c82-981d-e8a7f0f744c5" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AddressTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_4b664284-8f94-4b68-a848-f2a8821625dd" xlink:to="loc_dei_AddressTypeDomain_01eda1ea-4897-4c82-981d-e8a7f0f744c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_BusinessContactMember_f80e7397-ef72-491d-a784-008bc815c218" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_BusinessContactMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_AddressTypeDomain_01eda1ea-4897-4c82-981d-e8a7f0f744c5" xlink:to="loc_dei_BusinessContactMember_f80e7397-ef72-491d-a784-008bc815c218" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_42708aea-bd65-45df-830c-e698caebd2ed" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_9065b503-4370-4d21-99d3-804452f5c816" xlink:to="loc_dei_DocumentInformationLineItems_42708aea-bd65-45df-830c-e698caebd2ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_8f3990bf-93e3-457b-ac86-b3f534ad0fb8" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_42708aea-bd65-45df-830c-e698caebd2ed" xlink:to="loc_dei_DocumentType_8f3990bf-93e3-457b-ac86-b3f534ad0fb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentRegistrationStatement_08cf1535-07a4-444d-80a7-b3043b358a43" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_42708aea-bd65-45df-830c-e698caebd2ed" xlink:to="loc_dei_DocumentRegistrationStatement_08cf1535-07a4-444d-80a7-b3043b358a43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_ab90873d-5b4d-4bc5-8584-bf69262ccbda" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_42708aea-bd65-45df-830c-e698caebd2ed" xlink:to="loc_dei_DocumentAnnualReport_ab90873d-5b4d-4bc5-8584-bf69262ccbda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_84ae2929-41b9-40ae-9465-7748156a60b9" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_42708aea-bd65-45df-830c-e698caebd2ed" xlink:to="loc_dei_DocumentPeriodEndDate_84ae2929-41b9-40ae-9465-7748156a60b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_b82ccdf7-19d1-467d-b754-f2058ed33094" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_42708aea-bd65-45df-830c-e698caebd2ed" xlink:to="loc_dei_CurrentFiscalYearEndDate_b82ccdf7-19d1-467d-b754-f2058ed33094" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_9fa636ad-daee-45f0-9a84-09e9b16f68a6" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_42708aea-bd65-45df-830c-e698caebd2ed" xlink:to="loc_dei_DocumentTransitionReport_9fa636ad-daee-45f0-9a84-09e9b16f68a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentShellCompanyReport_8fb84a43-4c91-42d2-8795-b5d2d4d34e9d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_42708aea-bd65-45df-830c-e698caebd2ed" xlink:to="loc_dei_DocumentShellCompanyReport_8fb84a43-4c91-42d2-8795-b5d2d4d34e9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_ac8b1ebb-5d88-4173-8577-96f49f21e6ef" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_42708aea-bd65-45df-830c-e698caebd2ed" xlink:to="loc_dei_EntityFileNumber_ac8b1ebb-5d88-4173-8577-96f49f21e6ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_5c3d50c0-58fc-4a97-8ac9-10da9c75a409" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_42708aea-bd65-45df-830c-e698caebd2ed" xlink:to="loc_dei_EntityRegistrantName_5c3d50c0-58fc-4a97-8ac9-10da9c75a409" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_a3ea0c22-4640-4195-b511-1264c4204864" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_42708aea-bd65-45df-830c-e698caebd2ed" xlink:to="loc_dei_EntityIncorporationStateCountryCode_a3ea0c22-4640-4195-b511-1264c4204864" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_9eb06344-0c29-46a1-8391-327a84c04937" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_42708aea-bd65-45df-830c-e698caebd2ed" xlink:to="loc_dei_EntityAddressAddressLine1_9eb06344-0c29-46a1-8391-327a84c04937" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_940b7d4e-6c9c-4a65-9e9f-1d693c63700c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_42708aea-bd65-45df-830c-e698caebd2ed" xlink:to="loc_dei_EntityAddressCityOrTown_940b7d4e-6c9c-4a65-9e9f-1d693c63700c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_ecc5a0e2-7f3f-4094-98e2-5f24220133ad" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_42708aea-bd65-45df-830c-e698caebd2ed" xlink:to="loc_dei_EntityAddressStateOrProvince_ecc5a0e2-7f3f-4094-98e2-5f24220133ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry_109a97e1-af49-4b72-826e-7a3ae11c7054" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_42708aea-bd65-45df-830c-e698caebd2ed" xlink:to="loc_dei_EntityAddressCountry_109a97e1-af49-4b72-826e-7a3ae11c7054" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_4105b63e-1d6a-4b42-82a4-a9bc3137b5e1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_42708aea-bd65-45df-830c-e698caebd2ed" xlink:to="loc_dei_EntityAddressPostalZipCode_4105b63e-1d6a-4b42-82a4-a9bc3137b5e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ContactPersonnelName_7016a003-6fe6-468e-b48a-3a14046e36b0" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_ContactPersonnelName"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_42708aea-bd65-45df-830c-e698caebd2ed" xlink:to="loc_dei_ContactPersonnelName_7016a003-6fe6-468e-b48a-3a14046e36b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_ec46ab5a-4b12-418a-9c76-6980f482d526" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_42708aea-bd65-45df-830c-e698caebd2ed" xlink:to="loc_dei_CityAreaCode_ec46ab5a-4b12-418a-9c76-6980f482d526" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_e58861c1-6997-468c-85ba-1306b71218bb" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_42708aea-bd65-45df-830c-e698caebd2ed" xlink:to="loc_dei_LocalPhoneNumber_e58861c1-6997-468c-85ba-1306b71218bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ContactPersonnelEmailAddress_aa8a753d-c544-4367-bdce-80b68d926109" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_ContactPersonnelEmailAddress"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_42708aea-bd65-45df-830c-e698caebd2ed" xlink:to="loc_dei_ContactPersonnelEmailAddress_aa8a753d-c544-4367-bdce-80b68d926109" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_e693fdb1-a53b-4b60-8406-a898294b9251" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_42708aea-bd65-45df-830c-e698caebd2ed" xlink:to="loc_dei_Security12bTitle_e693fdb1-a53b-4b60-8406-a898294b9251" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_abf4500c-9acd-44d1-b229-759f72d2d836" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_42708aea-bd65-45df-830c-e698caebd2ed" xlink:to="loc_dei_TradingSymbol_abf4500c-9acd-44d1-b229-759f72d2d836" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_160aa766-7ce4-4a43-ad90-eb17ff7672fa" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_42708aea-bd65-45df-830c-e698caebd2ed" xlink:to="loc_dei_SecurityExchangeName_160aa766-7ce4-4a43-ad90-eb17ff7672fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_49d84196-bb05-4f8f-8872-583e4fa1c64d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_42708aea-bd65-45df-830c-e698caebd2ed" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_49d84196-bb05-4f8f-8872-583e4fa1c64d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_129ff5d7-8570-40bc-920a-4278c393ce5c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_42708aea-bd65-45df-830c-e698caebd2ed" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_129ff5d7-8570-40bc-920a-4278c393ce5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_f7d98cce-a8de-47ad-8770-f69a55afe182" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_42708aea-bd65-45df-830c-e698caebd2ed" xlink:to="loc_dei_EntityVoluntaryFilers_f7d98cce-a8de-47ad-8770-f69a55afe182" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_c948ce1d-76ba-485d-abc5-729034e2d5ee" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_42708aea-bd65-45df-830c-e698caebd2ed" xlink:to="loc_dei_EntityCurrentReportingStatus_c948ce1d-76ba-485d-abc5-729034e2d5ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_0a90a16f-83a2-444e-a7df-fddd07e599d0" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_42708aea-bd65-45df-830c-e698caebd2ed" xlink:to="loc_dei_EntityInteractiveDataCurrent_0a90a16f-83a2-444e-a7df-fddd07e599d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_34f3cf9e-2179-41db-89ef-708509ff2afb" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_42708aea-bd65-45df-830c-e698caebd2ed" xlink:to="loc_dei_EntityFilerCategory_34f3cf9e-2179-41db-89ef-708509ff2afb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_1574b965-ec0d-4395-a93a-67a767ab3661" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_42708aea-bd65-45df-830c-e698caebd2ed" xlink:to="loc_dei_EntityEmergingGrowthCompany_1574b965-ec0d-4395-a93a-67a767ab3661" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_e0ef2eba-1d7e-4603-8c0f-c920e5026605" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_42708aea-bd65-45df-830c-e698caebd2ed" xlink:to="loc_dei_IcfrAuditorAttestationFlag_e0ef2eba-1d7e-4603-8c0f-c920e5026605" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag_00446a2d-d73c-4232-9f2a-c4f89edd6837" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_42708aea-bd65-45df-830c-e698caebd2ed" xlink:to="loc_dei_DocumentFinStmtErrorCorrectionFlag_00446a2d-d73c-4232-9f2a-c4f89edd6837" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAccountingStandard_4a798e85-6518-4aa1-bc92-197bfecfa87c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_42708aea-bd65-45df-830c-e698caebd2ed" xlink:to="loc_dei_DocumentAccountingStandard_4a798e85-6518-4aa1-bc92-197bfecfa87c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_ce9fdf91-5bb0-4e34-a817-5d52c049bfb5" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_42708aea-bd65-45df-830c-e698caebd2ed" xlink:to="loc_dei_EntityShellCompany_ce9fdf91-5bb0-4e34-a817-5d52c049bfb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_ec92ed22-1e89-471b-8c6e-5e9c4d0fd62b" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_42708aea-bd65-45df-830c-e698caebd2ed" xlink:to="loc_dei_EntityCentralIndexKey_ec92ed22-1e89-471b-8c6e-5e9c4d0fd62b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_93ec7050-400d-4dea-b081-1eefb83f6b28" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_42708aea-bd65-45df-830c-e698caebd2ed" xlink:to="loc_dei_DocumentFiscalYearFocus_93ec7050-400d-4dea-b081-1eefb83f6b28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_0ecf8d3d-4dfc-496a-833a-e58af6e8952a" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_42708aea-bd65-45df-830c-e698caebd2ed" xlink:to="loc_dei_DocumentFiscalPeriodFocus_0ecf8d3d-4dfc-496a-833a-e58af6e8952a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_ca88c859-b304-4433-ac3e-a70e4ec604cf" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="37" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_42708aea-bd65-45df-830c-e698caebd2ed" xlink:to="loc_dei_AmendmentFlag_ca88c859-b304-4433-ac3e-a70e4ec604cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_9e71d5e6-cde4-4746-80df-218a2bfefebc" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="38" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_42708aea-bd65-45df-830c-e698caebd2ed" xlink:to="loc_dei_EntityPublicFloat_9e71d5e6-cde4-4746-80df-218a2bfefebc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/AuditInformation" xlink:type="simple" xlink:href="oncyf-20241231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_AuditorInformationAbstract_bedc698c-669b-4683-915f-3ff25a25ddeb" xlink:href="oncyf-20241231.xsd#oncyf_AuditorInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_80227b0a-dee9-4bda-a5f1-b27098a1a763" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_AuditorInformationAbstract_bedc698c-669b-4683-915f-3ff25a25ddeb" xlink:to="loc_dei_AuditorFirmId_80227b0a-dee9-4bda-a5f1-b27098a1a763" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_d2ce31d4-8fd8-4c1a-a147-f325d270f536" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_AuditorInformationAbstract_bedc698c-669b-4683-915f-3ff25a25ddeb" xlink:to="loc_dei_AuditorName_d2ce31d4-8fd8-4c1a-a147-f325d270f536" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_d65725c9-22de-46fd-9768-735bfd192a79" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_AuditorInformationAbstract_bedc698c-669b-4683-915f-3ff25a25ddeb" xlink:to="loc_dei_AuditorLocation_d65725c9-22de-46fd-9768-735bfd192a79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" xlink:type="simple" xlink:href="oncyf-20241231.xsd#CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfFinancialPositionAbstract_71646e0b-fb07-4416-8d89-34bdea25e8dc" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AssetsAbstract_69002765-4104-498d-a597-b846f6f3d852" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract_71646e0b-fb07-4416-8d89-34bdea25e8dc" xlink:to="loc_ifrs-full_AssetsAbstract_69002765-4104-498d-a597-b846f6f3d852" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssetsAbstract_daa8654a-79b3-4de8-bb8a-3221f65a184e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_69002765-4104-498d-a597-b846f6f3d852" xlink:to="loc_ifrs-full_CurrentAssetsAbstract_daa8654a-79b3-4de8-bb8a-3221f65a184e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_4e50dafa-574a-4f43-9abe-1cfee58bfd14" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_daa8654a-79b3-4de8-bb8a-3221f65a184e" xlink:to="loc_ifrs-full_CashAndCashEquivalents_4e50dafa-574a-4f43-9abe-1cfee58bfd14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentReceivables_971afd55-64df-44b1-afc5-ee0699067150" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentReceivables"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_daa8654a-79b3-4de8-bb8a-3221f65a184e" xlink:to="loc_ifrs-full_OtherCurrentReceivables_971afd55-64df-44b1-afc5-ee0699067150" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentPrepayments_0d3ec941-9086-43c7-937f-041c3558d0a0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentPrepayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_daa8654a-79b3-4de8-bb8a-3221f65a184e" xlink:to="loc_ifrs-full_CurrentPrepayments_0d3ec941-9086-43c7-937f-041c3558d0a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentDerivativeFinancialAssets_4c811220-bae1-4622-8e6f-29422b398c20" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentDerivativeFinancialAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_daa8654a-79b3-4de8-bb8a-3221f65a184e" xlink:to="loc_ifrs-full_CurrentDerivativeFinancialAssets_4c811220-bae1-4622-8e6f-29422b398c20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssets_1b15888a-fc76-412f-b936-96007d80fddd" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_daa8654a-79b3-4de8-bb8a-3221f65a184e" xlink:to="loc_ifrs-full_CurrentAssets_1b15888a-fc76-412f-b936-96007d80fddd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_c375e866-f1cb-4409-ac6d-a5f2229f3355" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_69002765-4104-498d-a597-b846f6f3d852" xlink:to="loc_ifrs-full_PropertyPlantAndEquipment_c375e866-f1cb-4409-ac6d-a5f2229f3355" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RightofuseAssets_b4ec2349-019a-478d-a419-e9d436b660ee" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RightofuseAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_69002765-4104-498d-a597-b846f6f3d852" xlink:to="loc_ifrs-full_RightofuseAssets_b4ec2349-019a-478d-a419-e9d436b660ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Assets_141d448e-c5e3-485d-ab7a-bc1b2e54bec9" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Assets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_69002765-4104-498d-a597-b846f6f3d852" xlink:to="loc_ifrs-full_Assets_141d448e-c5e3-485d-ab7a-bc1b2e54bec9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAndLiabilitiesAbstract_6a1d3fec-0d6b-4e0d-b966-b4dff6ee39d5" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAndLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract_71646e0b-fb07-4416-8d89-34bdea25e8dc" xlink:to="loc_ifrs-full_EquityAndLiabilitiesAbstract_6a1d3fec-0d6b-4e0d-b966-b4dff6ee39d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLiabilitiesAbstract_8a6fa76e-5e5e-4b54-8c23-1e967a3ee4e9" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLiabilitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_6a1d3fec-0d6b-4e0d-b966-b4dff6ee39d5" xlink:to="loc_ifrs-full_CurrentLiabilitiesAbstract_8a6fa76e-5e5e-4b54-8c23-1e967a3ee4e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayables_1a873c91-f3db-489f-af20-9fef361921e5" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_8a6fa76e-5e5e-4b54-8c23-1e967a3ee4e9" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayables_1a873c91-f3db-489f-af20-9fef361921e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentLiabilities_9da44532-29f9-4c93-afb1-152c467d13e1" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_8a6fa76e-5e5e-4b54-8c23-1e967a3ee4e9" xlink:to="loc_ifrs-full_OtherCurrentLiabilities_9da44532-29f9-4c93-afb1-152c467d13e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLeaseLiabilities_220e5551-0204-4343-80ca-6b90434e2afd" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLeaseLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_8a6fa76e-5e5e-4b54-8c23-1e967a3ee4e9" xlink:to="loc_ifrs-full_CurrentLeaseLiabilities_220e5551-0204-4343-80ca-6b90434e2afd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentDerivativeFinancialLiabilities_69344f26-08ef-47fd-9ced-ebc01a8945c5" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentDerivativeFinancialLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_8a6fa76e-5e5e-4b54-8c23-1e967a3ee4e9" xlink:to="loc_ifrs-full_CurrentDerivativeFinancialLiabilities_69344f26-08ef-47fd-9ced-ebc01a8945c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLiabilities_b3aff55a-0fc0-42d7-abc1-bcb5a927ff89" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_8a6fa76e-5e5e-4b54-8c23-1e967a3ee4e9" xlink:to="loc_ifrs-full_CurrentLiabilities_b3aff55a-0fc0-42d7-abc1-bcb5a927ff89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentContractLiabilities_feb61f87-d239-4b7c-a502-2aa22393be20" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentContractLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_6a1d3fec-0d6b-4e0d-b966-b4dff6ee39d5" xlink:to="loc_ifrs-full_NoncurrentContractLiabilities_feb61f87-d239-4b7c-a502-2aa22393be20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLeaseLiabilities_46d2688c-70dc-4eda-b366-91e1a2a4c910" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentLeaseLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_6a1d3fec-0d6b-4e0d-b966-b4dff6ee39d5" xlink:to="loc_ifrs-full_NoncurrentLeaseLiabilities_46d2688c-70dc-4eda-b366-91e1a2a4c910" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Liabilities_0e4be935-1b85-45e6-b96c-f07cc6aaa275" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Liabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_6a1d3fec-0d6b-4e0d-b966-b4dff6ee39d5" xlink:to="loc_ifrs-full_Liabilities_0e4be935-1b85-45e6-b96c-f07cc6aaa275" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CommitmentsAndContingencies1_45c11364-75ec-4b02-9d2a-8184dced53b5" xlink:href="oncyf-20241231.xsd#oncyf_CommitmentsAndContingencies1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_6a1d3fec-0d6b-4e0d-b966-b4dff6ee39d5" xlink:to="loc_oncyf_CommitmentsAndContingencies1_45c11364-75ec-4b02-9d2a-8184dced53b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAbstract_520612a1-4b7b-4ed9-8c14-6e0e0bd85836" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_6a1d3fec-0d6b-4e0d-b966-b4dff6ee39d5" xlink:to="loc_ifrs-full_EquityAbstract_520612a1-4b7b-4ed9-8c14-6e0e0bd85836" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapital_5aeead12-adad-4751-a029-8e20f214582f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssuedCapital"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_520612a1-4b7b-4ed9-8c14-6e0e0bd85836" xlink:to="loc_ifrs-full_IssuedCapital_5aeead12-adad-4751-a029-8e20f214582f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionalPaidinCapital_43314356-da2a-49f9-9068-fe8326e01afd" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdditionalPaidinCapital"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_520612a1-4b7b-4ed9-8c14-6e0e0bd85836" xlink:to="loc_ifrs-full_AdditionalPaidinCapital_43314356-da2a-49f9-9068-fe8326e01afd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedOtherComprehensiveIncome_d3652c78-a938-49a0-8f21-1f1755ed7bbd" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AccumulatedOtherComprehensiveIncome"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_520612a1-4b7b-4ed9-8c14-6e0e0bd85836" xlink:to="loc_ifrs-full_AccumulatedOtherComprehensiveIncome_d3652c78-a938-49a0-8f21-1f1755ed7bbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetainedEarnings_c67b7d81-9541-4260-8c12-f6995ae8dd56" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RetainedEarnings"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_520612a1-4b7b-4ed9-8c14-6e0e0bd85836" xlink:to="loc_ifrs-full_RetainedEarnings_c67b7d81-9541-4260-8c12-f6995ae8dd56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_72860c7a-5105-408d-96e3-dcfd22620de8" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Equity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_520612a1-4b7b-4ed9-8c14-6e0e0bd85836" xlink:to="loc_ifrs-full_Equity_72860c7a-5105-408d-96e3-dcfd22620de8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAndLiabilities_200b0ce7-0eb8-4dc9-aeaf-8050e44f9faf" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAndLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_6a1d3fec-0d6b-4e0d-b966-b4dff6ee39d5" xlink:to="loc_ifrs-full_EquityAndLiabilities_200b0ce7-0eb8-4dc9-aeaf-8050e44f9faf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITIONParenthetical" xlink:type="simple" xlink:href="oncyf-20241231.xsd#CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITIONParenthetical"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITIONParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfFinancialPositionAbstract_dd50cab9-ede4-4db3-b740-0a4ec86e9f9d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAbstract_d88d1252-3349-442e-baba-bad1692db698" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract_dd50cab9-ede4-4db3-b740-0a4ec86e9f9d" xlink:to="loc_ifrs-full_EquityAbstract_d88d1252-3349-442e-baba-bad1692db698" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesIssued_f3160cc9-a37e-406f-9ae2-03e7f8ba0774" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_d88d1252-3349-442e-baba-bad1692db698" xlink:to="loc_ifrs-full_NumberOfSharesIssued_f3160cc9-a37e-406f-9ae2-03e7f8ba0774" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="oncyf-20241231.xsd#CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeStatementAbstract_b059717c-7f8f-408b-b407-18f25d4125ce" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseByNatureAbstract_f61481ce-368f-45a8-bd06-6227cb05c341" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpenseByNatureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_b059717c-7f8f-408b-b407-18f25d4125ce" xlink:to="loc_ifrs-full_ExpenseByNatureAbstract_f61481ce-368f-45a8-bd06-6227cb05c341" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense_14c50155-487d-49d8-9f21-90500d8c0961" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ExpenseByNatureAbstract_f61481ce-368f-45a8-bd06-6227cb05c341" xlink:to="loc_ifrs-full_ResearchAndDevelopmentExpense_14c50155-487d-49d8-9f21-90500d8c0961" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeneralAndAdministrativeExpense_142a0782-d811-4790-b4c1-12e2172fb171" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ExpenseByNatureAbstract_f61481ce-368f-45a8-bd06-6227cb05c341" xlink:to="loc_ifrs-full_GeneralAndAdministrativeExpense_142a0782-d811-4790-b4c1-12e2172fb171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossFromOperatingActivities_c04eca87-5c3a-4f6f-82b0-a48a3495bd5c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_b059717c-7f8f-408b-b407-18f25d4125ce" xlink:to="loc_ifrs-full_ProfitLossFromOperatingActivities_c04eca87-5c3a-4f6f-82b0-a48a3495bd5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_340956d8-161a-4eb5-8244-6e78aa7a9908" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_b059717c-7f8f-408b-b407-18f25d4125ce" xlink:to="loc_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_340956d8-161a-4eb5-8244-6e78aa7a9908" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_fe97e462-3498-48b9-b88a-177b2b333a5a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_b059717c-7f8f-408b-b407-18f25d4125ce" xlink:to="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_fe97e462-3498-48b9-b88a-177b2b333a5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestIncomeOnCashAndCashEquivalents_f4fbc877-d842-47a1-9f73-73eb253c180c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InterestIncomeOnCashAndCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_b059717c-7f8f-408b-b407-18f25d4125ce" xlink:to="loc_ifrs-full_InterestIncomeOnCashAndCashEquivalents_f4fbc877-d842-47a1-9f73-73eb253c180c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossBeforeTax_ce2cae0f-b65b-43c3-b00b-2048d4f29944" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossBeforeTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_b059717c-7f8f-408b-b407-18f25d4125ce" xlink:to="loc_ifrs-full_ProfitLossBeforeTax_ce2cae0f-b65b-43c3-b00b-2048d4f29944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_cb591869-6d69-47c6-9bed-d2da5ece480e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_b059717c-7f8f-408b-b407-18f25d4125ce" xlink:to="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_cb591869-6d69-47c6-9bed-d2da5ece480e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_236a90e5-287f-4a1f-9c2b-972113830ce5" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_b059717c-7f8f-408b-b407-18f25d4125ce" xlink:to="loc_ifrs-full_ProfitLoss_236a90e5-287f-4a1f-9c2b-972113830ce5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeAbstract_71562a32-4b20-484e-8b9a-9c7eabb8a91b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherComprehensiveIncomeAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_b059717c-7f8f-408b-b407-18f25d4125ce" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeAbstract_71562a32-4b20-484e-8b9a-9c7eabb8a91b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_12e70869-74a8-405f-97d0-c9298d34fc0c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeAbstract_71562a32-4b20-484e-8b9a-9c7eabb8a91b" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_12e70869-74a8-405f-97d0-c9298d34fc0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncome_81d09c0f-e6a8-41f4-a8db-2078e4b543ad" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComprehensiveIncome"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_b059717c-7f8f-408b-b407-18f25d4125ce" xlink:to="loc_ifrs-full_ComprehensiveIncome_81d09c0f-e6a8-41f4-a8db-2078e4b543ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BasicEarningsLossPerShare_e91b7d34-15c0-4bf5-8472-180642ed5bc5" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BasicEarningsLossPerShare"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_b059717c-7f8f-408b-b407-18f25d4125ce" xlink:to="loc_ifrs-full_BasicEarningsLossPerShare_e91b7d34-15c0-4bf5-8472-180642ed5bc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DilutedEarningsLossPerShare_18dbbf95-d628-421f-81cf-052a8b7ccf4f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DilutedEarningsLossPerShare"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_b059717c-7f8f-408b-b407-18f25d4125ce" xlink:to="loc_ifrs-full_DilutedEarningsLossPerShare_18dbbf95-d628-421f-81cf-052a8b7ccf4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageShares_f43867f1-35f3-41bf-9d48-abe625c46dd3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageShares"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_b059717c-7f8f-408b-b407-18f25d4125ce" xlink:to="loc_ifrs-full_WeightedAverageShares_f43867f1-35f3-41bf-9d48-abe625c46dd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustedWeightedAverageShares_8ea0c0ea-38e9-4f8b-afe0-7c019951b5dc" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustedWeightedAverageShares"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_b059717c-7f8f-408b-b407-18f25d4125ce" xlink:to="loc_ifrs-full_AdjustedWeightedAverageShares_8ea0c0ea-38e9-4f8b-afe0-7c019951b5dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" xlink:type="simple" xlink:href="oncyf-20241231.xsd#CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityAbstract_7f6af757-2971-4039-8c36-8b16919b85da" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfChangesInEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityTable_05bc91ac-be2a-4dbf-ab0b-6961e7a911d9" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfChangesInEquityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityAbstract_7f6af757-2971-4039-8c36-8b16919b85da" xlink:to="loc_ifrs-full_StatementOfChangesInEquityTable_05bc91ac-be2a-4dbf-ab0b-6961e7a911d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_c5021a96-e0c1-4268-9c5e-58a558057605" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_05bc91ac-be2a-4dbf-ab0b-6961e7a911d9" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_c5021a96-e0c1-4268-9c5e-58a558057605" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityDomain_6d83655d-020c-4244-8bb0-ddb9721009b3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_c5021a96-e0c1-4268-9c5e-58a558057605" xlink:to="loc_ifrs-full_ComponentsOfEquityDomain_6d83655d-020c-4244-8bb0-ddb9721009b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember_04fdee9b-111f-48c8-9826-88cc6ac673f9" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_6d83655d-020c-4244-8bb0-ddb9721009b3" xlink:to="loc_ifrs-full_IssuedCapitalMember_04fdee9b-111f-48c8-9826-88cc6ac673f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WarrantsMember_bd44702f-5751-4e3f-8832-f4c3eece05fc" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WarrantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_6d83655d-020c-4244-8bb0-ddb9721009b3" xlink:to="loc_ifrs-full_WarrantsMember_bd44702f-5751-4e3f-8832-f4c3eece05fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharePremiumMember_e08dc1c3-82f0-45a5-9f93-5501085e9312" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SharePremiumMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_6d83655d-020c-4244-8bb0-ddb9721009b3" xlink:to="loc_ifrs-full_SharePremiumMember_e08dc1c3-82f0-45a5-9f93-5501085e9312" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_7e99e126-a0ba-4393-b72f-aa4fc7aec928" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_6d83655d-020c-4244-8bb0-ddb9721009b3" xlink:to="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_7e99e126-a0ba-4393-b72f-aa4fc7aec928" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetainedEarningsMember_66b23594-d86e-4f52-9938-19bbee3ed57c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RetainedEarningsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_6d83655d-020c-4244-8bb0-ddb9721009b3" xlink:to="loc_ifrs-full_RetainedEarningsMember_66b23594-d86e-4f52-9938-19bbee3ed57c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockAxis_b0065312-ed7a-4d3a-abf8-d3deebe6a50b" xlink:href="oncyf-20241231.xsd#oncyf_SaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_05bc91ac-be2a-4dbf-ab0b-6961e7a911d9" xlink:to="loc_oncyf_SaleOfStockAxis_b0065312-ed7a-4d3a-abf8-d3deebe6a50b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockDomain_017f7e0f-9099-439e-819b-2d2904e982bd" xlink:href="oncyf-20241231.xsd#oncyf_SaleOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockAxis_b0065312-ed7a-4d3a-abf8-d3deebe6a50b" xlink:to="loc_oncyf_SaleOfStockDomain_017f7e0f-9099-439e-819b-2d2904e982bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesUnderAtthemarketAgreementMember_62a3a456-ae4f-43a8-ac57-3258c97c9dd6" xlink:href="oncyf-20241231.xsd#oncyf_SharesUnderAtthemarketAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockDomain_017f7e0f-9099-439e-819b-2d2904e982bd" xlink:to="loc_oncyf_SharesUnderAtthemarketAgreementMember_62a3a456-ae4f-43a8-ac57-3258c97c9dd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesUnderPublicOfferingMember_80dec0b2-94e8-4581-bcc0-9ac6832109e4" xlink:href="oncyf-20241231.xsd#oncyf_SharesUnderPublicOfferingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockDomain_017f7e0f-9099-439e-819b-2d2904e982bd" xlink:to="loc_oncyf_SharesUnderPublicOfferingMember_80dec0b2-94e8-4581-bcc0-9ac6832109e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityLineItems_129db49e-c3f1-443d-8ae4-6449f4a9ab21" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfChangesInEquityLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_05bc91ac-be2a-4dbf-ab0b-6961e7a911d9" xlink:to="loc_ifrs-full_StatementOfChangesInEquityLineItems_129db49e-c3f1-443d-8ae4-6449f4a9ab21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_b7d6a9ea-de8b-4557-9d84-6e8091cdbf16" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Equity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_129db49e-c3f1-443d-8ae4-6449f4a9ab21" xlink:to="loc_ifrs-full_Equity_b7d6a9ea-de8b-4557-9d84-6e8091cdbf16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncome_e933a5c5-d5f2-418d-bea4-81075d1cb2cb" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComprehensiveIncome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_129db49e-c3f1-443d-8ae4-6449f4a9ab21" xlink:to="loc_ifrs-full_ComprehensiveIncome_e933a5c5-d5f2-418d-bea4-81075d1cb2cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_c4da153f-6ed2-41d4-91a4-f9d320679d4a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfOptions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_129db49e-c3f1-443d-8ae4-6449f4a9ab21" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_c4da153f-6ed2-41d4-91a4-f9d320679d4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity_e22ee65c-147b-486c-85fb-b00647470a47" xlink:href="oncyf-20241231.xsd#oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_129db49e-c3f1-443d-8ae4-6449f4a9ab21" xlink:to="loc_oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity_e22ee65c-147b-486c-85fb-b00647470a47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IncreaseDecreaseThroughExpirationOfWarrantEquity_dc872d0d-dfe6-4e5c-84ac-adf7cc3a4596" xlink:href="oncyf-20241231.xsd#oncyf_IncreaseDecreaseThroughExpirationOfWarrantEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_129db49e-c3f1-443d-8ae4-6449f4a9ab21" xlink:to="loc_oncyf_IncreaseDecreaseThroughExpirationOfWarrantEquity_dc872d0d-dfe6-4e5c-84ac-adf7cc3a4596" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_e6923413-f3eb-486e-91f7-5ff764c2887e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_129db49e-c3f1-443d-8ae4-6449f4a9ab21" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_e6923413-f3eb-486e-91f7-5ff764c2887e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssueOfEquity_46f0de32-309e-472e-a5ed-9e657a8d9d5c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssueOfEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_129db49e-c3f1-443d-8ae4-6449f4a9ab21" xlink:to="loc_ifrs-full_IssueOfEquity_46f0de32-309e-472e-a5ed-9e657a8d9d5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareIssueRelatedCost_926a6228-7ade-42dc-9db0-88537491348e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShareIssueRelatedCost"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_129db49e-c3f1-443d-8ae4-6449f4a9ab21" xlink:to="loc_ifrs-full_ShareIssueRelatedCost_926a6228-7ade-42dc-9db0-88537491348e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_792155f3-32f2-499f-851c-e179bb77a5ee" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_129db49e-c3f1-443d-8ae4-6449f4a9ab21" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_792155f3-32f2-499f-851c-e179bb77a5ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_4fafa1cc-b2cf-47db-89d8-dd56575e9692" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Equity"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_129db49e-c3f1-443d-8ae4-6449f4a9ab21" xlink:to="loc_ifrs-full_Equity_4fafa1cc-b2cf-47db-89d8-dd56575e9692" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="oncyf-20241231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfCashFlowsAbstract_b1936281-051b-463d-b864-6fde49bc724a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_Statement1Table_6fd615fb-244a-4f3e-b8e0-6129c942852e" xlink:href="oncyf-20241231.xsd#oncyf_Statement1Table"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_b1936281-051b-463d-b864-6fde49bc724a" xlink:to="loc_oncyf_Statement1Table_6fd615fb-244a-4f3e-b8e0-6129c942852e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockAxis_7dec98cd-724a-408e-b3c9-7b63dac198f7" xlink:href="oncyf-20241231.xsd#oncyf_SaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Statement1Table_6fd615fb-244a-4f3e-b8e0-6129c942852e" xlink:to="loc_oncyf_SaleOfStockAxis_7dec98cd-724a-408e-b3c9-7b63dac198f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockDomain_73107b11-7ab5-430f-873a-f2004f44daa3" xlink:href="oncyf-20241231.xsd#oncyf_SaleOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockAxis_7dec98cd-724a-408e-b3c9-7b63dac198f7" xlink:to="loc_oncyf_SaleOfStockDomain_73107b11-7ab5-430f-873a-f2004f44daa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesUnderAtthemarketAgreementMember_a563d0db-cb69-43cd-b454-682e7fb79602" xlink:href="oncyf-20241231.xsd#oncyf_SharesUnderAtthemarketAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockDomain_73107b11-7ab5-430f-873a-f2004f44daa3" xlink:to="loc_oncyf_SharesUnderAtthemarketAgreementMember_a563d0db-cb69-43cd-b454-682e7fb79602" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesPublicOfferingMember_35f5291d-f8d8-4078-93cc-5da3b153efbf" xlink:href="oncyf-20241231.xsd#oncyf_SharesPublicOfferingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockDomain_73107b11-7ab5-430f-873a-f2004f44daa3" xlink:to="loc_oncyf_SharesPublicOfferingMember_35f5291d-f8d8-4078-93cc-5da3b153efbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_Statement1LineItems_3b200002-44b9-436e-a6fe-a649bc7c1482" xlink:href="oncyf-20241231.xsd#oncyf_Statement1LineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Statement1Table_6fd615fb-244a-4f3e-b8e0-6129c942852e" xlink:to="loc_oncyf_Statement1LineItems_3b200002-44b9-436e-a6fe-a649bc7c1482" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_9b6957e8-bcd4-4f14-8c73-52a2a9e8bf72" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Statement1LineItems_3b200002-44b9-436e-a6fe-a649bc7c1482" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_9b6957e8-bcd4-4f14-8c73-52a2a9e8bf72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_7705e43e-b6d2-4b71-8a13-9b127a86ba81" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_9b6957e8-bcd4-4f14-8c73-52a2a9e8bf72" xlink:to="loc_ifrs-full_ProfitLoss_7705e43e-b6d2-4b71-8a13-9b127a86ba81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_f5241b7f-d325-4e1d-8349-bfb441f10d29" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_9b6957e8-bcd4-4f14-8c73-52a2a9e8bf72" xlink:to="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_f5241b7f-d325-4e1d-8349-bfb441f10d29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_AdjustmentsForDepreciationRightOfUseAssets_87517d66-6bfd-4cfc-b451-9f1dcbb96648" xlink:href="oncyf-20241231.xsd#oncyf_AdjustmentsForDepreciationRightOfUseAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_9b6957e8-bcd4-4f14-8c73-52a2a9e8bf72" xlink:to="loc_oncyf_AdjustmentsForDepreciationRightOfUseAssets_87517d66-6bfd-4cfc-b451-9f1dcbb96648" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForSharebasedPayments_a1a20e60-0ff5-487c-83fc-df57717a9bdd" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_9b6957e8-bcd4-4f14-8c73-52a2a9e8bf72" xlink:to="loc_ifrs-full_AdjustmentsForSharebasedPayments_a1a20e60-0ff5-487c-83fc-df57717a9bdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_c65f948c-6aae-4d69-a135-6833bda643c7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_9b6957e8-bcd4-4f14-8c73-52a2a9e8bf72" xlink:to="loc_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_c65f948c-6aae-4d69-a135-6833bda643c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestRevenueExpense_f0c27acc-8079-48ab-bcfc-4a6b7a9acdc2" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InterestRevenueExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_9b6957e8-bcd4-4f14-8c73-52a2a9e8bf72" xlink:to="loc_ifrs-full_InterestRevenueExpense_f0c27acc-8079-48ab-bcfc-4a6b7a9acdc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_27b2c4f0-7ea8-4023-b868-27cb521d00ef" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_9b6957e8-bcd4-4f14-8c73-52a2a9e8bf72" xlink:to="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_27b2c4f0-7ea8-4023-b868-27cb521d00ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives_ee0efc89-2032-4256-b5ef-f98919f40c23" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_9b6957e8-bcd4-4f14-8c73-52a2a9e8bf72" xlink:to="loc_ifrs-full_AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives_ee0efc89-2032-4256-b5ef-f98919f40c23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_713cd881-58e2-4c26-a43b-ccce4c8136a3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseInWorkingCapital"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_9b6957e8-bcd4-4f14-8c73-52a2a9e8bf72" xlink:to="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_713cd881-58e2-4c26-a43b-ccce4c8136a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperations_b4238d5d-740a-46ff-94a1-d42091f5a164" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperations"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_9b6957e8-bcd4-4f14-8c73-52a2a9e8bf72" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperations_b4238d5d-740a-46ff-94a1-d42091f5a164" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_232e60a6-8bb2-424f-b417-c3e79bcb8179" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Statement1LineItems_3b200002-44b9-436e-a6fe-a649bc7c1482" xlink:to="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_232e60a6-8bb2-424f-b417-c3e79bcb8179" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities_3341a953-addc-4bc8-b1d5-e3e9ecbcc4a1" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_232e60a6-8bb2-424f-b417-c3e79bcb8179" xlink:to="loc_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities_3341a953-addc-4bc8-b1d5-e3e9ecbcc4a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities_9d1e1e73-07f4-452c-b8f9-396ca3415c10" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_232e60a6-8bb2-424f-b417-c3e79bcb8179" xlink:to="loc_ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities_9d1e1e73-07f4-452c-b8f9-396ca3415c10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_f535ec7e-39a4-4e36-b210-08fba84f6764" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_232e60a6-8bb2-424f-b417-c3e79bcb8179" xlink:to="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_f535ec7e-39a4-4e36-b210-08fba84f6764" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_75ed489f-6137-4604-b969-9c88fe95292a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_232e60a6-8bb2-424f-b417-c3e79bcb8179" xlink:to="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_75ed489f-6137-4604-b969-9c88fe95292a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_2efc79cf-b409-4ef7-87ea-e3e3fceaf5db" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Statement1LineItems_3b200002-44b9-436e-a6fe-a649bc7c1482" xlink:to="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_2efc79cf-b409-4ef7-87ea-e3e3fceaf5db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromExerciseOfOptions_decb4891-aa49-41e1-becc-c7bba0c9f0b2" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromExerciseOfOptions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_2efc79cf-b409-4ef7-87ea-e3e3fceaf5db" xlink:to="loc_ifrs-full_ProceedsFromExerciseOfOptions_decb4891-aa49-41e1-becc-c7bba0c9f0b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromExerciseOfWarrants_40746820-d6c9-462e-a214-183d14c580a7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromExerciseOfWarrants"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_2efc79cf-b409-4ef7-87ea-e3e3fceaf5db" xlink:to="loc_ifrs-full_ProceedsFromExerciseOfWarrants_40746820-d6c9-462e-a214-183d14c580a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromIssuingShares_ae70d3fc-d32c-4db6-a513-b4338924f214" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromIssuingShares"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_2efc79cf-b409-4ef7-87ea-e3e3fceaf5db" xlink:to="loc_ifrs-full_ProceedsFromIssuingShares_ae70d3fc-d32c-4db6-a513-b4338924f214" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashOutflowForLeases_686bbf4f-b7e9-4995-80e7-84afd27df182" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashOutflowForLeases"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_2efc79cf-b409-4ef7-87ea-e3e3fceaf5db" xlink:to="loc_ifrs-full_CashOutflowForLeases_686bbf4f-b7e9-4995-80e7-84afd27df182" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_d757db46-4bc1-46f2-aa76-87878f1adbfd" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_2efc79cf-b409-4ef7-87ea-e3e3fceaf5db" xlink:to="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_d757db46-4bc1-46f2-aa76-87878f1adbfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_b24d8711-2b41-40f0-83be-1c6e9001ceaa" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Statement1LineItems_3b200002-44b9-436e-a6fe-a649bc7c1482" xlink:to="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_b24d8711-2b41-40f0-83be-1c6e9001ceaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_1e89a0d1-a62c-4abf-9b44-b3bc3b77ebef" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Statement1LineItems_3b200002-44b9-436e-a6fe-a649bc7c1482" xlink:to="loc_ifrs-full_CashAndCashEquivalents_1e89a0d1-a62c-4abf-9b44-b3bc3b77ebef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_884ad793-4465-4a83-abb8-286faead4d24" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Statement1LineItems_3b200002-44b9-436e-a6fe-a649bc7c1482" xlink:to="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_884ad793-4465-4a83-abb8-286faead4d24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_09ba697f-c9f4-4ac3-983d-59aee17b4a2b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Statement1LineItems_3b200002-44b9-436e-a6fe-a649bc7c1482" xlink:to="loc_ifrs-full_CashAndCashEquivalents_09ba697f-c9f4-4ac3-983d-59aee17b4a2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/NatureofOperationsandGoingConcern" xlink:type="simple" xlink:href="oncyf-20241231.xsd#NatureofOperationsandGoingConcern"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/NatureofOperationsandGoingConcern" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract_2a144d44-7475-4f41-ba6a-5311d445c6be" xlink:href="oncyf-20241231.xsd#oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_725db91b-966a-4390-ada3-d9fc01f35f3a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract_2a144d44-7475-4f41-ba6a-5311d445c6be" xlink:to="loc_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_725db91b-966a-4390-ada3-d9fc01f35f3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/BasisofPresentation" xlink:type="simple" xlink:href="oncyf-20241231.xsd#BasisofPresentation"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/BasisofPresentation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_8d7c12c8-a552-4d6f-9542-6060ec7e1d69" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_ec96a8c8-2d8c-4ed4-b1f3-d4ad5cd66e05" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_8d7c12c8-a552-4d6f-9542-6060ec7e1d69" xlink:to="loc_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_ec96a8c8-2d8c-4ed4-b1f3-d4ad5cd66e05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/SummaryofMaterialAccountingPolicies" xlink:type="simple" xlink:href="oncyf-20241231.xsd#SummaryofMaterialAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/SummaryofMaterialAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_313093b8-5259-4366-8376-66ea53492114" xlink:href="oncyf-20241231.xsd#oncyf_SummaryOfSignificantAccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory_f1de76f9-72b6-4e8e-aacc-7c41dd015d4a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_313093b8-5259-4366-8376-66ea53492114" xlink:to="loc_ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory_f1de76f9-72b6-4e8e-aacc-7c41dd015d4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/SignificantJudgmentsEstimatesandAssumptions" xlink:type="simple" xlink:href="oncyf-20241231.xsd#SignificantJudgmentsEstimatesandAssumptions"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/SignificantJudgmentsEstimatesandAssumptions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SignificantJudgmentsEstimatesAndAssumptionsAbstract_15036b87-d1f0-47fe-9a84-e356d93df69b" xlink:href="oncyf-20241231.xsd#oncyf_SignificantJudgmentsEstimatesAndAssumptionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_3df8eebd-e7ec-4553-aa3f-580d5e4ddf0a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SignificantJudgmentsEstimatesAndAssumptionsAbstract_15036b87-d1f0-47fe-9a84-e356d93df69b" xlink:to="loc_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_3df8eebd-e7ec-4553-aa3f-580d5e4ddf0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/OtherLiabilities" xlink:type="simple" xlink:href="oncyf-20241231.xsd#OtherLiabilities"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/OtherLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_bd86fc58-194a-41ac-bd3f-49f0021a7f55" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOtherLiabilitiesExplanatory_b5283aea-e2b2-44e9-aa4b-ef1f04ee66b3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOtherLiabilitiesExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_bd86fc58-194a-41ac-bd3f-49f0021a7f55" xlink:to="loc_ifrs-full_DisclosureOfOtherLiabilitiesExplanatory_b5283aea-e2b2-44e9-aa4b-ef1f04ee66b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/PropertyandEquipment" xlink:type="simple" xlink:href="oncyf-20241231.xsd#PropertyandEquipment"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/PropertyandEquipment" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_a75122a0-2595-4ccd-8860-113c631fc69f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_ac8de967-30c6-4e05-8072-057ef13e15df" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_a75122a0-2595-4ccd-8860-113c631fc69f" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_ac8de967-30c6-4e05-8072-057ef13e15df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/AccountsPayableandAccruedLiabilities" xlink:type="simple" xlink:href="oncyf-20241231.xsd#AccountsPayableandAccruedLiabilities"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/AccountsPayableandAccruedLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_3e44f23d-df52-4a14-bee7-cb468eaa7aa0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_e43fba8e-3de9-4d2d-9aa3-7c8d5433b97e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_3e44f23d-df52-4a14-bee7-cb468eaa7aa0" xlink:to="loc_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_e43fba8e-3de9-4d2d-9aa3-7c8d5433b97e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/Leases" xlink:type="simple" xlink:href="oncyf-20241231.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_eb463b85-990e-4cbd-b880-e548e64de20d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfLeasesExplanatory_187c4795-7596-4d26-90f2-eee10d1f9495" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfLeasesExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_eb463b85-990e-4cbd-b880-e548e64de20d" xlink:to="loc_ifrs-full_DisclosureOfLeasesExplanatory_187c4795-7596-4d26-90f2-eee10d1f9495" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/WarrantDerivative" xlink:type="simple" xlink:href="oncyf-20241231.xsd#WarrantDerivative"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/WarrantDerivative" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_f4e82127-a3f4-4ad0-9994-cf1869fb1202" xlink:href="oncyf-20241231.xsd#oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory_af6a15af-1319-421f-a9e4-c0a464e3d1b7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_f4e82127-a3f4-4ad0-9994-cf1869fb1202" xlink:to="loc_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory_af6a15af-1319-421f-a9e4-c0a464e3d1b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareCapital" xlink:type="simple" xlink:href="oncyf-20241231.xsd#ShareCapital"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareCapital" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_d0ce8e9d-1d53-42fb-8c51-5daa0b7a8550" xlink:href="oncyf-20241231.xsd#oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_3eb31a5c-a9e9-486f-9295-23980e95887e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_d0ce8e9d-1d53-42fb-8c51-5daa0b7a8550" xlink:to="loc_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_3eb31a5c-a9e9-486f-9295-23980e95887e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedCompensation" xlink:type="simple" xlink:href="oncyf-20241231.xsd#ShareBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract_78117e25-a161-4335-99bc-5223942deef6" xlink:href="oncyf-20241231.xsd#oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_374ac5b6-3e32-4863-804a-35b62b3f9fdc" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract_78117e25-a161-4335-99bc-5223942deef6" xlink:to="loc_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_374ac5b6-3e32-4863-804a-35b62b3f9fdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/LossPerShare" xlink:type="simple" xlink:href="oncyf-20241231.xsd#LossPerShare"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/LossPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EarningsPerShareAbstract_9eb2c59a-b825-4639-b8ee-102ee6528b3c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfEarningsPerShareExplanatory_e8ad4d6d-2a45-4018-9f8d-413f8d393dca" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfEarningsPerShareExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_9eb2c59a-b825-4639-b8ee-102ee6528b3c" xlink:to="loc_ifrs-full_DisclosureOfEarningsPerShareExplanatory_e8ad4d6d-2a45-4018-9f8d-413f8d393dca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ContractLiability" xlink:type="simple" xlink:href="oncyf-20241231.xsd#ContractLiability"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ContractLiability" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract_abd2062a-2282-47f4-a726-b44ab3901498" xlink:href="oncyf-20241231.xsd#oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory_fefc901a-b126-48cf-8d2b-597f3acad225" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract_abd2062a-2282-47f4-a726-b44ab3901498" xlink:to="loc_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory_fefc901a-b126-48cf-8d2b-597f3acad225" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="oncyf-20241231.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ContingenciesAbstract_7a1c6406-bc6c-4d20-81d4-7450db8bce42" xlink:href="oncyf-20241231.xsd#oncyf_ContingenciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_0604ab35-1d9f-4f40-b6e9-102d850a689c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ContingenciesAbstract_7a1c6406-bc6c-4d20-81d4-7450db8bce42" xlink:to="loc_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_0604ab35-1d9f-4f40-b6e9-102d850a689c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxes" xlink:type="simple" xlink:href="oncyf-20241231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofincometaxAbstract_820526eb-c861-43ca-a4a9-20d53633e646" xlink:href="oncyf-20241231.xsd#oncyf_DisclosureofincometaxAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIncomeTaxExplanatory_9e9ad675-8ecf-482f-8b14-2c22962c9c3f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_820526eb-c861-43ca-a4a9-20d53633e646" xlink:to="loc_ifrs-full_DisclosureOfIncomeTaxExplanatory_9e9ad675-8ecf-482f-8b14-2c22962c9c3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CapitalDisclosures" xlink:type="simple" xlink:href="oncyf-20241231.xsd#CapitalDisclosures"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/CapitalDisclosures" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityAbstract_990df5ef-f7cb-4b01-a18d-6cac06baae3c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfChangesInEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory_a211e4c4-bcff-4f3c-a292-dc3a702d1a47" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityAbstract_990df5ef-f7cb-4b01-a18d-6cac06baae3c" xlink:to="loc_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory_a211e4c4-bcff-4f3c-a292-dc3a702d1a47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/FinancialInstruments" xlink:type="simple" xlink:href="oncyf-20241231.xsd#FinancialInstruments"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/FinancialInstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_f43c56d0-469f-4a42-9361-5522e81ecc0a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_a9069403-f6c9-4bbd-8001-adfe65045ede" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_f43c56d0-469f-4a42-9361-5522e81ecc0a" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_a9069403-f6c9-4bbd-8001-adfe65045ede" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosures" xlink:type="simple" xlink:href="oncyf-20241231.xsd#AdditionalCashFlowDisclosures"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosures" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_AdditionalCashFlowDisclosuresAbstract_77386d52-81ab-4096-a5fb-0c88017a719a" xlink:href="oncyf-20241231.xsd#oncyf_AdditionalCashFlowDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfCashFlowStatementExplanatory_757b2f04-12d4-45d3-9202-83efddea9d3d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfCashFlowStatementExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_AdditionalCashFlowDisclosuresAbstract_77386d52-81ab-4096-a5fb-0c88017a719a" xlink:to="loc_ifrs-full_DisclosureOfCashFlowStatementExplanatory_757b2f04-12d4-45d3-9202-83efddea9d3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/EconomicDependence" xlink:type="simple" xlink:href="oncyf-20241231.xsd#EconomicDependence"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/EconomicDependence" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureOfEconomicDependenceAbstract_78f2066e-a81f-4f5a-897d-070562657a2a" xlink:href="oncyf-20241231.xsd#oncyf_DisclosureOfEconomicDependenceAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureOfEconomicDependenceTextBlock_9427f361-3008-4e2d-90cd-ec97d0cecbe9" xlink:href="oncyf-20241231.xsd#oncyf_DisclosureOfEconomicDependenceTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfEconomicDependenceAbstract_78f2066e-a81f-4f5a-897d-070562657a2a" xlink:to="loc_oncyf_DisclosureOfEconomicDependenceTextBlock_9427f361-3008-4e2d-90cd-ec97d0cecbe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ComponentsofExpenses" xlink:type="simple" xlink:href="oncyf-20241231.xsd#ComponentsofExpenses"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ComponentsofExpenses" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_afaa9e20-4335-47fc-9a3b-98af4bb821a0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfExpensesByNatureExplanatory_685e3bb4-88f7-4efd-bf5b-ea76162095f2" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfExpensesByNatureExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_afaa9e20-4335-47fc-9a3b-98af4bb821a0" xlink:to="loc_ifrs-full_DisclosureOfExpensesByNatureExplanatory_685e3bb4-88f7-4efd-bf5b-ea76162095f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/SegmentDisclosures" xlink:type="simple" xlink:href="oncyf-20241231.xsd#SegmentDisclosures"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/SegmentDisclosures" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SegmentDisclosuresAbstract_1f23b59a-a3ef-4cdd-a161-d7f674dd0070" xlink:href="oncyf-20241231.xsd#oncyf_SegmentDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory_be9f47fc-280b-4a3f-8add-8b2b490ac5e3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SegmentDisclosuresAbstract_1f23b59a-a3ef-4cdd-a161-d7f674dd0070" xlink:to="loc_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory_be9f47fc-280b-4a3f-8add-8b2b490ac5e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="oncyf-20241231.xsd#RelatedPartyTransactions"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/RelatedPartyTransactions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofrelatedpartyAbstract_00a91ccd-2b4e-4c66-b189-5193fec36bc6" xlink:href="oncyf-20241231.xsd#oncyf_DisclosureofrelatedpartyAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfRelatedPartyExplanatory_a9c53b07-c7c3-442a-adaf-a646e52b5a87" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfRelatedPartyExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofrelatedpartyAbstract_00a91ccd-2b4e-4c66-b189-5193fec36bc6" xlink:to="loc_ifrs-full_DisclosureOfRelatedPartyExplanatory_a9c53b07-c7c3-442a-adaf-a646e52b5a87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/SubsequentEvents" xlink:type="simple" xlink:href="oncyf-20241231.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofeventsafterreportingperiodAbstract_3d0873bf-9a15-4369-bd4c-556c75e8fb19" xlink:href="oncyf-20241231.xsd#oncyf_DisclosureofeventsafterreportingperiodAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_84488a3e-162b-4ca4-9f66-56b7ad273674" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofeventsafterreportingperiodAbstract_3d0873bf-9a15-4369-bd4c-556c75e8fb19" xlink:to="loc_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_84488a3e-162b-4ca4-9f66-56b7ad273674" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/SummaryofMaterialAccountingPoliciesPolicies" xlink:type="simple" xlink:href="oncyf-20241231.xsd#SummaryofMaterialAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/SummaryofMaterialAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_fe9224c9-60cd-41ad-8f16-4814e3242c7d" xlink:href="oncyf-20241231.xsd#oncyf_SummaryOfSignificantAccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfUncertaintiesOfEntitysAbilityToContinueAsGoingConcern_411ef2cd-381f-40e2-9e24-7f8526d3d63f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfUncertaintiesOfEntitysAbilityToContinueAsGoingConcern"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_fe9224c9-60cd-41ad-8f16-4814e3242c7d" xlink:to="loc_ifrs-full_DescriptionOfUncertaintiesOfEntitysAbilityToContinueAsGoingConcern_411ef2cd-381f-40e2-9e24-7f8526d3d63f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DescriptionOfAccountingPolicyForDeterminingComponentsOfCashAndCashEquivalentsPolicyTextBlock_1a947499-50bf-4ece-972b-ca046c8ff582" xlink:href="oncyf-20241231.xsd#oncyf_DescriptionOfAccountingPolicyForDeterminingComponentsOfCashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_fe9224c9-60cd-41ad-8f16-4814e3242c7d" xlink:to="loc_oncyf_DescriptionOfAccountingPolicyForDeterminingComponentsOfCashAndCashEquivalentsPolicyTextBlock_1a947499-50bf-4ece-972b-ca046c8ff582" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory_3f3bb832-2da0-4830-8fae-081a6808a7ab" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_fe9224c9-60cd-41ad-8f16-4814e3242c7d" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory_3f3bb832-2da0-4830-8fae-081a6808a7ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory_7755e53c-cb07-41e1-ad12-2897f4546ed5" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_fe9224c9-60cd-41ad-8f16-4814e3242c7d" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory_7755e53c-cb07-41e1-ad12-2897f4546ed5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory_ae92c257-1160-4ec2-9ff8-bf1dca0491d0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_fe9224c9-60cd-41ad-8f16-4814e3242c7d" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory_ae92c257-1160-4ec2-9ff8-bf1dca0491d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory_99f14485-ef29-4bf6-b5af-2e6561c3b973" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_fe9224c9-60cd-41ad-8f16-4814e3242c7d" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory_99f14485-ef29-4bf6-b5af-2e6561c3b973" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForDerecognitionOfFinancialInstrumentsExplanatory_10ef52be-de7b-41c9-881c-a26dd1f7415a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForDerecognitionOfFinancialInstrumentsExplanatory"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_fe9224c9-60cd-41ad-8f16-4814e3242c7d" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForDerecognitionOfFinancialInstrumentsExplanatory_10ef52be-de7b-41c9-881c-a26dd1f7415a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory_6c93ab5b-97b8-4da7-a146-a130243ef31d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_fe9224c9-60cd-41ad-8f16-4814e3242c7d" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory_6c93ab5b-97b8-4da7-a146-a130243ef31d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_ef8a54cb-8a73-4680-88d8-fdcaf29d5ffa" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_fe9224c9-60cd-41ad-8f16-4814e3242c7d" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_ef8a54cb-8a73-4680-88d8-fdcaf29d5ffa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_bbbf4175-a8eb-45c5-8425-5cdb5ac0c7ab" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_fe9224c9-60cd-41ad-8f16-4814e3242c7d" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_bbbf4175-a8eb-45c5-8425-5cdb5ac0c7ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_829bf35e-6149-48b2-9551-17c398045c58" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_fe9224c9-60cd-41ad-8f16-4814e3242c7d" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_829bf35e-6149-48b2-9551-17c398045c58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_03ce048c-5852-4d36-be98-d7f0079d18db" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_fe9224c9-60cd-41ad-8f16-4814e3242c7d" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_03ce048c-5852-4d36-be98-d7f0079d18db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_87150b76-5076-44a1-9bde-009ad220b786" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_fe9224c9-60cd-41ad-8f16-4814e3242c7d" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_87150b76-5076-44a1-9bde-009ad220b786" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_5fc7ec65-328b-4174-997a-ca0f2a08bd29" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_fe9224c9-60cd-41ad-8f16-4814e3242c7d" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_5fc7ec65-328b-4174-997a-ca0f2a08bd29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_238f9af1-ff44-4c33-bd8d-748e1b0ad3ba" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_fe9224c9-60cd-41ad-8f16-4814e3242c7d" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_238f9af1-ff44-4c33-bd8d-748e1b0ad3ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations_eb9ec2e0-1ff9-4ef3-845a-be4608c22849" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_fe9224c9-60cd-41ad-8f16-4814e3242c7d" xlink:to="loc_ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations_eb9ec2e0-1ff9-4ef3-845a-be4608c22849" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations_23d7b106-cfa2-4e30-9549-a48703287dea" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_fe9224c9-60cd-41ad-8f16-4814e3242c7d" xlink:to="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations_23d7b106-cfa2-4e30-9549-a48703287dea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/SummaryofMaterialAccountingPoliciesTables" xlink:type="simple" xlink:href="oncyf-20241231.xsd#SummaryofMaterialAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/SummaryofMaterialAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_29993835-b2db-4994-add5-cff8cc02302f" xlink:href="oncyf-20241231.xsd#oncyf_SummaryOfSignificantAccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_1356b319-b7b2-47a7-aa51-bff8420c28fb" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_29993835-b2db-4994-add5-cff8cc02302f" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_1356b319-b7b2-47a7-aa51-bff8420c28fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/PropertyandEquipmentTables" xlink:type="simple" xlink:href="oncyf-20241231.xsd#PropertyandEquipmentTables"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/PropertyandEquipmentTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_f382cb1a-a9c3-448f-8485-da6ed3e86c1f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_edeb541c-4d8e-4d28-8374-394e35e67dcf" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_f382cb1a-a9c3-448f-8485-da6ed3e86c1f" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_edeb541c-4d8e-4d28-8374-394e35e67dcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/AccountsPayableandAccruedLiabilitiesTables" xlink:type="simple" xlink:href="oncyf-20241231.xsd#AccountsPayableandAccruedLiabilitiesTables"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/AccountsPayableandAccruedLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_f840063d-0fc9-4afb-a2dd-2349ffbd4239" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DetailedDisclosureOfTradeAndOtherPayablesExplanatoryTableTextBlock_05c58af5-dd43-453a-8306-119478fe0bfd" xlink:href="oncyf-20241231.xsd#oncyf_DetailedDisclosureOfTradeAndOtherPayablesExplanatoryTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_f840063d-0fc9-4afb-a2dd-2349ffbd4239" xlink:to="loc_oncyf_DetailedDisclosureOfTradeAndOtherPayablesExplanatoryTableTextBlock_05c58af5-dd43-453a-8306-119478fe0bfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/LeasesTables" xlink:type="simple" xlink:href="oncyf-20241231.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_12b6b6a1-6e87-4e5e-a9b1-9dbd4162ab28" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_68c4dcba-a1e2-412b-8ad9-70ea768f848f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_12b6b6a1-6e87-4e5e-a9b1-9dbd4162ab28" xlink:to="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_68c4dcba-a1e2-412b-8ad9-70ea768f848f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTextBlock_f984ff91-ec01-4722-9b9c-5032d450cc48" xlink:href="oncyf-20241231.xsd#oncyf_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_12b6b6a1-6e87-4e5e-a9b1-9dbd4162ab28" xlink:to="loc_oncyf_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTextBlock_f984ff91-ec01-4722-9b9c-5032d450cc48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory_905bff85-8c48-4504-9edb-67bc59630082" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_12b6b6a1-6e87-4e5e-a9b1-9dbd4162ab28" xlink:to="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory_905bff85-8c48-4504-9edb-67bc59630082" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/WarrantDerivativeTables" xlink:type="simple" xlink:href="oncyf-20241231.xsd#WarrantDerivativeTables"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/WarrantDerivativeTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_151935e9-eeb4-4508-b25e-97ad0e8442ca" xlink:href="oncyf-20241231.xsd#oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory_bdcf37b2-b13a-4dc8-ae6b-d0f58d1b866b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_151935e9-eeb4-4508-b25e-97ad0e8442ca" xlink:to="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory_bdcf37b2-b13a-4dc8-ae6b-d0f58d1b866b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareCapitalTables" xlink:type="simple" xlink:href="oncyf-20241231.xsd#ShareCapitalTables"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareCapitalTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_08e5eecb-2ed6-4848-86b6-d7f13707a2ab" xlink:href="oncyf-20241231.xsd#oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_e4acea02-371e-4306-ad37-bd0c70ab735d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_08e5eecb-2ed6-4848-86b6-d7f13707a2ab" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_e4acea02-371e-4306-ad37-bd0c70ab735d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedCompensationTables" xlink:type="simple" xlink:href="oncyf-20241231.xsd#ShareBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofsharebasedpaymentarrangementAbstract_7dd8bffd-c167-45fc-b6ad-e55c1b9bd593" xlink:href="oncyf-20241231.xsd#oncyf_DisclosureofsharebasedpaymentarrangementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_77720db8-925f-43ad-ba40-32fd5aa1c9d8" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofsharebasedpaymentarrangementAbstract_7dd8bffd-c167-45fc-b6ad-e55c1b9bd593" xlink:to="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_77720db8-925f-43ad-ba40-32fd5aa1c9d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory_8821d3b0-d0bc-48cb-8167-8b4db3dc8bef" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofsharebasedpaymentarrangementAbstract_7dd8bffd-c167-45fc-b6ad-e55c1b9bd593" xlink:to="loc_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory_8821d3b0-d0bc-48cb-8167-8b4db3dc8bef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_0f4a4738-546f-467b-a7fa-22e21ffaaa2f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofsharebasedpaymentarrangementAbstract_7dd8bffd-c167-45fc-b6ad-e55c1b9bd593" xlink:to="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_0f4a4738-546f-467b-a7fa-22e21ffaaa2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_c9891b10-89c2-485c-81f3-59c0afcf9034" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofsharebasedpaymentarrangementAbstract_7dd8bffd-c167-45fc-b6ad-e55c1b9bd593" xlink:to="loc_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_c9891b10-89c2-485c-81f3-59c0afcf9034" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_127e5e93-0f44-4880-be3b-83c77de8c08b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofsharebasedpaymentarrangementAbstract_7dd8bffd-c167-45fc-b6ad-e55c1b9bd593" xlink:to="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_127e5e93-0f44-4880-be3b-83c77de8c08b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ContractLiabilityTables" xlink:type="simple" xlink:href="oncyf-20241231.xsd#ContractLiabilityTables"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ContractLiabilityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract_1e3d516c-bf43-439d-ac46-fce0dfca1215" xlink:href="oncyf-20241231.xsd#oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory_53979b38-a0ce-4ede-ae07-d5059a5bcd4d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract_1e3d516c-bf43-439d-ac46-fce0dfca1215" xlink:to="loc_ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory_53979b38-a0ce-4ede-ae07-d5059a5bcd4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="oncyf-20241231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofincometaxAbstract_9cac9562-fb57-42f3-9ca5-42f765d217d5" xlink:href="oncyf-20241231.xsd#oncyf_DisclosureofincometaxAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock_16fd232f-97fb-4c68-8c30-d8b48983e5ac" xlink:href="oncyf-20241231.xsd#oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_9cac9562-fb57-42f3-9ca5-42f765d217d5" xlink:to="loc_oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock_16fd232f-97fb-4c68-8c30-d8b48983e5ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory_a37e0f99-f80a-4dd4-b9e7-394e97082594" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_9cac9562-fb57-42f3-9ca5-42f765d217d5" xlink:to="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory_a37e0f99-f80a-4dd4-b9e7-394e97082594" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CapitalDisclosuresTables" xlink:type="simple" xlink:href="oncyf-20241231.xsd#CapitalDisclosuresTables"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/CapitalDisclosuresTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityAbstract_4c3d5f2a-3e86-45be-ae9a-56bdad712adc" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfChangesInEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureOfCapitalComponentsTableTextBlock_eefd55e5-87ef-4ff9-b19c-ad4386b9d406" xlink:href="oncyf-20241231.xsd#oncyf_DisclosureOfCapitalComponentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityAbstract_4c3d5f2a-3e86-45be-ae9a-56bdad712adc" xlink:to="loc_oncyf_DisclosureOfCapitalComponentsTableTextBlock_eefd55e5-87ef-4ff9-b19c-ad4386b9d406" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/FinancialInstrumentsTables" xlink:type="simple" xlink:href="oncyf-20241231.xsd#FinancialInstrumentsTables"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/FinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_0c9a991d-16c6-46b0-8c03-2610a71b9e48" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock_711c6767-94f8-4ce5-8b75-ce929c6a555e" xlink:href="oncyf-20241231.xsd#oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_0c9a991d-16c6-46b0-8c03-2610a71b9e48" xlink:to="loc_oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock_711c6767-94f8-4ce5-8b75-ce929c6a555e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresTables" xlink:type="simple" xlink:href="oncyf-20241231.xsd#AdditionalCashFlowDisclosuresTables"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_AdditionalCashFlowDisclosuresAbstract_268152af-0b8d-4bc1-9e55-cab93165c51c" xlink:href="oncyf-20241231.xsd#oncyf_AdditionalCashFlowDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CashFlowOperatingCapital1TableTextBlock_827f106f-b5ca-413d-9661-951daa58ac82" xlink:href="oncyf-20241231.xsd#oncyf_CashFlowOperatingCapital1TableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_AdditionalCashFlowDisclosuresAbstract_268152af-0b8d-4bc1-9e55-cab93165c51c" xlink:to="loc_oncyf_CashFlowOperatingCapital1TableTextBlock_827f106f-b5ca-413d-9661-951daa58ac82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock_36ac8c19-d54e-43d0-8cf3-0c17e1fe9264" xlink:href="oncyf-20241231.xsd#oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_AdditionalCashFlowDisclosuresAbstract_268152af-0b8d-4bc1-9e55-cab93165c51c" xlink:to="loc_oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock_36ac8c19-d54e-43d0-8cf3-0c17e1fe9264" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ComponentsofExpensesTables" xlink:type="simple" xlink:href="oncyf-20241231.xsd#ComponentsofExpensesTables"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ComponentsofExpensesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_0e525a13-9b7c-4bf8-9f90-a084995736e1" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OtherExpensesAndAdjustmentsTableTextBlock_f21359ae-ec0c-400c-ae50-2559dc90a07b" xlink:href="oncyf-20241231.xsd#oncyf_OtherExpensesAndAdjustmentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_0e525a13-9b7c-4bf8-9f90-a084995736e1" xlink:to="loc_oncyf_OtherExpensesAndAdjustmentsTableTextBlock_f21359ae-ec0c-400c-ae50-2559dc90a07b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/SegmentDisclosuresTables" xlink:type="simple" xlink:href="oncyf-20241231.xsd#SegmentDisclosuresTables"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/SegmentDisclosuresTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SegmentDisclosuresAbstract_ab08c560-6435-494f-9c38-b518b7ac0d42" xlink:href="oncyf-20241231.xsd#oncyf_SegmentDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfGeographicalAreasExplanatory_ead5e07a-d84f-4f8e-98a0-33773381dbf9" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfGeographicalAreasExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SegmentDisclosuresAbstract_ab08c560-6435-494f-9c38-b518b7ac0d42" xlink:to="loc_ifrs-full_DisclosureOfGeographicalAreasExplanatory_ead5e07a-d84f-4f8e-98a0-33773381dbf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsTables" xlink:type="simple" xlink:href="oncyf-20241231.xsd#RelatedPartyTransactionsTables"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofrelatedpartyAbstract_fedb657c-8483-44ff-b446-a3f64693c824" xlink:href="oncyf-20241231.xsd#oncyf_DisclosureofrelatedpartyAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_ae43f0ff-3f2f-4c9b-a823-1bd1a070ff19" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofrelatedpartyAbstract_fedb657c-8483-44ff-b446-a3f64693c824" xlink:to="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_ae43f0ff-3f2f-4c9b-a823-1bd1a070ff19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/NatureofOperationsandGoingConcernDetails" xlink:type="simple" xlink:href="oncyf-20241231.xsd#NatureofOperationsandGoingConcernDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/NatureofOperationsandGoingConcernDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract_d192ae2b-03a0-407c-a7c9-528ca4a1c580" xlink:href="oncyf-20241231.xsd#oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_ff0c2ff5-587b-44dc-8199-0aec99cdd993" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract_d192ae2b-03a0-407c-a7c9-528ca4a1c580" xlink:to="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_ff0c2ff5-587b-44dc-8199-0aec99cdd993" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_d906e5e7-907c-469f-987b-e41bd3241cea" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_ff0c2ff5-587b-44dc-8199-0aec99cdd993" xlink:to="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_d906e5e7-907c-469f-987b-e41bd3241cea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_32423a50-cccb-4c7b-aab8-8ccdceefaa46" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_d906e5e7-907c-469f-987b-e41bd3241cea" xlink:to="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_32423a50-cccb-4c7b-aab8-8ccdceefaa46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MajorOrdinaryShareTransactionsMember_329a8ee1-73f2-408e-a461-1b156a4f95e2" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MajorOrdinaryShareTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_32423a50-cccb-4c7b-aab8-8ccdceefaa46" xlink:to="loc_ifrs-full_MajorOrdinaryShareTransactionsMember_329a8ee1-73f2-408e-a461-1b156a4f95e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_ad691967-7677-46b9-95c1-580431b08033" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_ff0c2ff5-587b-44dc-8199-0aec99cdd993" xlink:to="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_ad691967-7677-46b9-95c1-580431b08033" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetainedEarnings_cd4a9d8a-9400-45d9-924d-c01ccba15b6e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RetainedEarnings"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_ad691967-7677-46b9-95c1-580431b08033" xlink:to="loc_ifrs-full_RetainedEarnings_cd4a9d8a-9400-45d9-924d-c01ccba15b6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_0bcf7909-7f2a-4f76-aedd-693d5be29217" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_ad691967-7677-46b9-95c1-580431b08033" xlink:to="loc_ifrs-full_CashAndCashEquivalents_0bcf7909-7f2a-4f76-aedd-693d5be29217" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromIssueOfOrdinaryShares_c21e41ee-98e0-4c25-b336-57b826a5d5ae" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromIssueOfOrdinaryShares"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_ad691967-7677-46b9-95c1-580431b08033" xlink:to="loc_ifrs-full_ProceedsFromIssueOfOrdinaryShares_c21e41ee-98e0-4c25-b336-57b826a5d5ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/SummaryofMaterialAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="oncyf-20241231.xsd#SummaryofMaterialAccountingPoliciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/SummaryofMaterialAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_9c614239-9fe1-4535-96d0-e7483bf622b2" xlink:href="oncyf-20241231.xsd#oncyf_SummaryOfSignificantAccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashEquivalents_00f6fe80-1622-4dfc-b3c0-e42a6ff23b6d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_9c614239-9fe1-4535-96d0-e7483bf622b2" xlink:to="loc_ifrs-full_CashEquivalents_00f6fe80-1622-4dfc-b3c0-e42a6ff23b6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_NumberOfStockOptionPlans_faaccda7-ec9d-44b4-9277-af256cb91fad" xlink:href="oncyf-20241231.xsd#oncyf_NumberOfStockOptionPlans"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_9c614239-9fe1-4535-96d0-e7483bf622b2" xlink:to="loc_oncyf_NumberOfStockOptionPlans_faaccda7-ec9d-44b4-9277-af256cb91fad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement_4bf6e385-4295-4851-84b6-ca986929bf8a" xlink:href="oncyf-20241231.xsd#oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_9c614239-9fe1-4535-96d0-e7483bf622b2" xlink:to="loc_oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement_4bf6e385-4295-4851-84b6-ca986929bf8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/SummaryofMaterialAccountingPoliciesScheduleofDepreciationRatesDetails" xlink:type="simple" xlink:href="oncyf-20241231.xsd#SummaryofMaterialAccountingPoliciesScheduleofDepreciationRatesDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/SummaryofMaterialAccountingPoliciesScheduleofDepreciationRatesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_a8c67b78-d54b-47cb-bb4c-c98719c552b9" xlink:href="oncyf-20241231.xsd#oncyf_SummaryOfSignificantAccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_67630b9c-e53f-42ca-88cc-cd187f4c4bf5" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_a8c67b78-d54b-47cb-bb4c-c98719c552b9" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_67630b9c-e53f-42ca-88cc-cd187f4c4bf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_8745e9af-d167-40d0-87bc-1233b4b0e06c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_67630b9c-e53f-42ca-88cc-cd187f4c4bf5" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_8745e9af-d167-40d0-87bc-1233b4b0e06c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_46de004d-143d-4ebb-86c6-21d7984fcb71" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_8745e9af-d167-40d0-87bc-1233b4b0e06c" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_46de004d-143d-4ebb-86c6-21d7984fcb71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OfficeEquipmentMember_4cb04fd0-0f2d-4dba-b86f-a90ebbe8bb7b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OfficeEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_46de004d-143d-4ebb-86c6-21d7984fcb71" xlink:to="loc_ifrs-full_OfficeEquipmentMember_4cb04fd0-0f2d-4dba-b86f-a90ebbe8bb7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_MedicalEquipmentMember_45cc275c-005a-4b74-8f9d-f7dc31470a2f" xlink:href="oncyf-20241231.xsd#oncyf_MedicalEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_46de004d-143d-4ebb-86c6-21d7984fcb71" xlink:to="loc_oncyf_MedicalEquipmentMember_45cc275c-005a-4b74-8f9d-f7dc31470a2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComputerEquipmentMember_db3d1386-d752-4c65-963c-d953a9c81b08" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComputerEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_46de004d-143d-4ebb-86c6-21d7984fcb71" xlink:to="loc_ifrs-full_ComputerEquipmentMember_db3d1386-d752-4c65-963c-d953a9c81b08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_3bc23387-5832-42f3-8d83-ec646bfba35e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_67630b9c-e53f-42ca-88cc-cd187f4c4bf5" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_3bc23387-5832-42f3-8d83-ec646bfba35e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_PropertyPlantandEquipmentAnnualDepreciationRate_24d191ab-2d08-448b-b16d-e5b2a4b182f2" xlink:href="oncyf-20241231.xsd#oncyf_PropertyPlantandEquipmentAnnualDepreciationRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_3bc23387-5832-42f3-8d83-ec646bfba35e" xlink:to="loc_oncyf_PropertyPlantandEquipmentAnnualDepreciationRate_24d191ab-2d08-448b-b16d-e5b2a4b182f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/OtherLiabilitiesDetails" xlink:type="simple" xlink:href="oncyf-20241231.xsd#OtherLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/OtherLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_a30c9d17-37f3-4276-bdd4-63585c05b57b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_Currency1Table_31fe1db2-031f-46a0-8af2-f39acaca1114" xlink:href="oncyf-20241231.xsd#oncyf_Currency1Table"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_a30c9d17-37f3-4276-bdd4-63585c05b57b" xlink:to="loc_oncyf_Currency1Table_31fe1db2-031f-46a0-8af2-f39acaca1114" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfProvisionsAxis_ce16c17a-d312-4a2c-80a8-512e8bc102b2" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfProvisionsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Currency1Table_31fe1db2-031f-46a0-8af2-f39acaca1114" xlink:to="loc_ifrs-full_ClassesOfProvisionsAxis_ce16c17a-d312-4a2c-80a8-512e8bc102b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfOtherProvisionsDomain_e7f288e5-688b-41c7-b647-ded4e4844c50" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfOtherProvisionsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfProvisionsAxis_ce16c17a-d312-4a2c-80a8-512e8bc102b2" xlink:to="loc_ifrs-full_ClassesOfOtherProvisionsDomain_e7f288e5-688b-41c7-b647-ded4e4844c50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ClinicalTrialMember_e29ade36-836f-4fda-a373-c3624f7e6ed2" xlink:href="oncyf-20241231.xsd#oncyf_ClinicalTrialMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfOtherProvisionsDomain_e7f288e5-688b-41c7-b647-ded4e4844c50" xlink:to="loc_oncyf_ClinicalTrialMember_e29ade36-836f-4fda-a373-c3624f7e6ed2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_Currency1LineItems_bd9956e0-2f2e-4d3b-acd2-a8581df35763" xlink:href="oncyf-20241231.xsd#oncyf_Currency1LineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Currency1Table_31fe1db2-031f-46a0-8af2-f39acaca1114" xlink:to="loc_oncyf_Currency1LineItems_bd9956e0-2f2e-4d3b-acd2-a8581df35763" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherReceivables_2dd59c03-bf51-4eb2-bba8-d79c58d104a7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherReceivables"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Currency1LineItems_bd9956e0-2f2e-4d3b-acd2-a8581df35763" xlink:to="loc_ifrs-full_OtherReceivables_2dd59c03-bf51-4eb2-bba8-d79c58d104a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentLiabilities_744cbb4f-2e51-45e3-ad7f-956369e0b8f9" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Currency1LineItems_bd9956e0-2f2e-4d3b-acd2-a8581df35763" xlink:to="loc_ifrs-full_OtherCurrentLiabilities_744cbb4f-2e51-45e3-ad7f-956369e0b8f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails" xlink:type="simple" xlink:href="oncyf-20241231.xsd#PropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_9c28b066-796e-4020-a4b3-528bcdbe0f8e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_10ee54c3-3fd0-443a-bbce-1c10e2b6bd11" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_9c28b066-796e-4020-a4b3-528bcdbe0f8e" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_10ee54c3-3fd0-443a-bbce-1c10e2b6bd11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_3c2781db-c855-46b5-aae7-9afbf5ede828" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_10ee54c3-3fd0-443a-bbce-1c10e2b6bd11" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_3c2781db-c855-46b5-aae7-9afbf5ede828" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_97949ae2-a2b8-4236-b6c0-5177b061036e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_3c2781db-c855-46b5-aae7-9afbf5ede828" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_97949ae2-a2b8-4236-b6c0-5177b061036e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_MedicalEquipmentMember_c8547435-f387-4a31-bc85-efe5eb0fdcb5" xlink:href="oncyf-20241231.xsd#oncyf_MedicalEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_97949ae2-a2b8-4236-b6c0-5177b061036e" xlink:to="loc_oncyf_MedicalEquipmentMember_c8547435-f387-4a31-bc85-efe5eb0fdcb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComputerEquipmentMember_8dd33f4f-bb62-4d20-be57-3734b5984c9f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComputerEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_97949ae2-a2b8-4236-b6c0-5177b061036e" xlink:to="loc_ifrs-full_ComputerEquipmentMember_8dd33f4f-bb62-4d20-be57-3734b5984c9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OfficeEquipmentAndFurnitureMember_ab0eb0ce-bb1c-4c91-a61e-e10ddfbed877" xlink:href="oncyf-20241231.xsd#oncyf_OfficeEquipmentAndFurnitureMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_97949ae2-a2b8-4236-b6c0-5177b061036e" xlink:to="loc_oncyf_OfficeEquipmentAndFurnitureMember_ab0eb0ce-bb1c-4c91-a61e-e10ddfbed877" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseholdImprovementsMember_1c0dcaaa-1d21-4592-bbcb-1cf967cd4bce" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LeaseholdImprovementsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain_97949ae2-a2b8-4236-b6c0-5177b061036e" xlink:to="loc_ifrs-full_LeaseholdImprovementsMember_1c0dcaaa-1d21-4592-bbcb-1cf967cd4bce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_5b1eef15-e79d-44ce-b848-1481aa8af886" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_10ee54c3-3fd0-443a-bbce-1c10e2b6bd11" xlink:to="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_5b1eef15-e79d-44ce-b848-1481aa8af886" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_31710b31-4b9e-4b30-a26a-b9809885b229" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CarryingAmountMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_5b1eef15-e79d-44ce-b848-1481aa8af886" xlink:to="loc_ifrs-full_CarryingAmountMember_31710b31-4b9e-4b30-a26a-b9809885b229" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossCarryingAmountMember_adc1c8f0-77b8-4320-a7ff-418d12f262d9" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GrossCarryingAmountMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_31710b31-4b9e-4b30-a26a-b9809885b229" xlink:to="loc_ifrs-full_GrossCarryingAmountMember_adc1c8f0-77b8-4320-a7ff-418d12f262d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember_071d3605-b065-41b1-a525-cfc15d6a8a39" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AccumulatedDepreciationAndAmortisationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_31710b31-4b9e-4b30-a26a-b9809885b229" xlink:to="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember_071d3605-b065-41b1-a525-cfc15d6a8a39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_edd63d4b-aea1-422f-814f-c338242475f3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_10ee54c3-3fd0-443a-bbce-1c10e2b6bd11" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_edd63d4b-aea1-422f-814f-c338242475f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_1d04d0ce-7685-48c8-a7cb-0931d792ce58" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_edd63d4b-aea1-422f-814f-c338242475f3" xlink:to="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_1d04d0ce-7685-48c8-a7cb-0931d792ce58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_7920ab6d-7ce2-4b6b-9ad9-4e43118a789c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_1d04d0ce-7685-48c8-a7cb-0931d792ce58" xlink:to="loc_ifrs-full_PropertyPlantAndEquipment_7920ab6d-7ce2-4b6b-9ad9-4e43118a789c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_5d88e1f6-8733-4ad6-b930-fd4a8f1d2b2a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_1d04d0ce-7685-48c8-a7cb-0931d792ce58" xlink:to="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_5d88e1f6-8733-4ad6-b930-fd4a8f1d2b2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DepreciationPropertyPlantAndEquipment_574b32fa-2443-4cca-9c8a-810e9c56b031" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DepreciationPropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_1d04d0ce-7685-48c8-a7cb-0931d792ce58" xlink:to="loc_ifrs-full_DepreciationPropertyPlantAndEquipment_574b32fa-2443-4cca-9c8a-810e9c56b031" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisposalsPropertyPlantAndEquipment_31b1bcbb-c358-465b-98f2-409edfeeffd1" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisposalsPropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_1d04d0ce-7685-48c8-a7cb-0931d792ce58" xlink:to="loc_ifrs-full_DisposalsPropertyPlantAndEquipment_31b1bcbb-c358-465b-98f2-409edfeeffd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_2ebe5726-8d60-4564-82c4-0e37a4a9aa29" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_1d04d0ce-7685-48c8-a7cb-0931d792ce58" xlink:to="loc_ifrs-full_PropertyPlantAndEquipment_2ebe5726-8d60-4564-82c4-0e37a4a9aa29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LossesOnDisposalsOfPropertyPlantAndEquipment_724bcc8f-808e-4659-8b2f-3e9900c62d7f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LossesOnDisposalsOfPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_edd63d4b-aea1-422f-814f-c338242475f3" xlink:to="loc_ifrs-full_LossesOnDisposalsOfPropertyPlantAndEquipment_724bcc8f-808e-4659-8b2f-3e9900c62d7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/AccountsPayableandAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="oncyf-20241231.xsd#AccountsPayableandAccruedLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/AccountsPayableandAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_6c1b047a-3dc1-4cda-8e70-0133e733852d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_98edf631-857b-4ef2-97ff-db84c1a9f742" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_6c1b047a-3dc1-4cda-8e70-0133e733852d" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_98edf631-857b-4ef2-97ff-db84c1a9f742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccrualsClassifiedAsCurrent_73bdd34f-1fa5-4aed-b2c1-441243ee012e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AccrualsClassifiedAsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_6c1b047a-3dc1-4cda-8e70-0133e733852d" xlink:to="loc_ifrs-full_AccrualsClassifiedAsCurrent_73bdd34f-1fa5-4aed-b2c1-441243ee012e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayables_61d562e4-2071-4c20-b6e0-5e15370ef9af" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_6c1b047a-3dc1-4cda-8e70-0133e733852d" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayables_61d562e4-2071-4c20-b6e0-5e15370ef9af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="oncyf-20241231.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_047fd463-eca0-4846-9d0a-d57b0c2a54a8" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_9af68229-b09e-456d-8b80-f794a7ecb85b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_047fd463-eca0-4846-9d0a-d57b0c2a54a8" xlink:to="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_9af68229-b09e-456d-8b80-f794a7ecb85b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0b4fa815-4a26-4ee4-83b9-b5373878b7ae" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_9af68229-b09e-456d-8b80-f794a7ecb85b" xlink:to="loc_srt_RangeAxis_0b4fa815-4a26-4ee4-83b9-b5373878b7ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_69218ddc-a5f6-4e7b-b692-4bd6af3f34e7" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_0b4fa815-4a26-4ee4-83b9-b5373878b7ae" xlink:to="loc_srt_RangeMember_69218ddc-a5f6-4e7b-b692-4bd6af3f34e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_fbd24d8b-210b-461e-9a77-a0ab4e860259" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_69218ddc-a5f6-4e7b-b692-4bd6af3f34e7" xlink:to="loc_srt_MinimumMember_fbd24d8b-210b-461e-9a77-a0ab4e860259" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c1990435-4929-4a73-a20e-b1f2af832cb1" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_69218ddc-a5f6-4e7b-b692-4bd6af3f34e7" xlink:to="loc_srt_MaximumMember_c1990435-4929-4a73-a20e-b1f2af832cb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_315940d2-3f86-4a8d-9b73-73616a682872" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_9af68229-b09e-456d-8b80-f794a7ecb85b" xlink:to="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_315940d2-3f86-4a8d-9b73-73616a682872" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OperatingLeaseLeaseTerm_aa9d3899-aa65-4f7f-9d4f-1933887d994c" xlink:href="oncyf-20241231.xsd#oncyf_OperatingLeaseLeaseTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_315940d2-3f86-4a8d-9b73-73616a682872" xlink:to="loc_oncyf_OperatingLeaseLeaseTerm_aa9d3899-aa65-4f7f-9d4f-1933887d994c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16_020a76d1-ee3c-46cf-85f3-73abf03355da" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_315940d2-3f86-4a8d-9b73-73616a682872" xlink:to="loc_ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16_020a76d1-ee3c-46cf-85f3-73abf03355da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsToRightofuseAssets_81cee3b4-65cf-48fa-a790-7113465f33ad" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdditionsToRightofuseAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_315940d2-3f86-4a8d-9b73-73616a682872" xlink:to="loc_ifrs-full_AdditionsToRightofuseAssets_81cee3b4-65cf-48fa-a790-7113465f33ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities_5dacd89d-a9ef-4261-b456-4f83b00cd1f7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_315940d2-3f86-4a8d-9b73-73616a682872" xlink:to="loc_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities_5dacd89d-a9ef-4261-b456-4f83b00cd1f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/LeasesRightofuseAssetsandLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="oncyf-20241231.xsd#LeasesRightofuseAssetsandLeaseLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/LeasesRightofuseAssetsandLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_8be57b9d-8970-4f00-b98f-8730ee7de97f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_RightOfUseAssetsAbstract_4a78c882-fcb2-4c33-a1bb-94624a22ce3f" xlink:href="oncyf-20241231.xsd#oncyf_RightOfUseAssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_8be57b9d-8970-4f00-b98f-8730ee7de97f" xlink:to="loc_oncyf_RightOfUseAssetsAbstract_4a78c882-fcb2-4c33-a1bb-94624a22ce3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RightofuseAssets_8f358276-05a9-4598-8a45-46ba59783fa7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RightofuseAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_RightOfUseAssetsAbstract_4a78c882-fcb2-4c33-a1bb-94624a22ce3f" xlink:to="loc_ifrs-full_RightofuseAssets_8f358276-05a9-4598-8a45-46ba59783fa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsToRightofuseAssets_bf02cfdb-c5b8-49bd-8ad3-df0c37b4f35f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdditionsToRightofuseAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_RightOfUseAssetsAbstract_4a78c882-fcb2-4c33-a1bb-94624a22ce3f" xlink:to="loc_ifrs-full_AdditionsToRightofuseAssets_bf02cfdb-c5b8-49bd-8ad3-df0c37b4f35f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DepreciationRightofuseAssets_f6c76c6a-6a7f-40f5-8b73-855d867a8d75" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DepreciationRightofuseAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_RightOfUseAssetsAbstract_4a78c882-fcb2-4c33-a1bb-94624a22ce3f" xlink:to="loc_ifrs-full_DepreciationRightofuseAssets_f6c76c6a-6a7f-40f5-8b73-855d867a8d75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ForeignExchangeImpactRightofUseAssets_90a44981-f5bc-44c1-96cf-348c782d0d5d" xlink:href="oncyf-20241231.xsd#oncyf_ForeignExchangeImpactRightofUseAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_RightOfUseAssetsAbstract_4a78c882-fcb2-4c33-a1bb-94624a22ce3f" xlink:to="loc_oncyf_ForeignExchangeImpactRightofUseAssets_90a44981-f5bc-44c1-96cf-348c782d0d5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RightofuseAssets_9e3e5b93-92f1-4ddd-9cd8-0c2b6d38a7e5" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RightofuseAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_RightOfUseAssetsAbstract_4a78c882-fcb2-4c33-a1bb-94624a22ce3f" xlink:to="loc_ifrs-full_RightofuseAssets_9e3e5b93-92f1-4ddd-9cd8-0c2b6d38a7e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilitiesAbstract_987e5862-aec0-4d25-8ca6-e9807650e3e9" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LeaseLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_8be57b9d-8970-4f00-b98f-8730ee7de97f" xlink:to="loc_ifrs-full_LeaseLiabilitiesAbstract_987e5862-aec0-4d25-8ca6-e9807650e3e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilities_1d75577c-5a2f-44ec-9fe2-34a3e11d9ae5" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LeaseLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LeaseLiabilitiesAbstract_987e5862-aec0-4d25-8ca6-e9807650e3e9" xlink:to="loc_ifrs-full_LeaseLiabilities_1d75577c-5a2f-44ec-9fe2-34a3e11d9ae5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities_675b7af9-3c75-475a-ba5c-6676467e5993" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LeaseLiabilitiesAbstract_987e5862-aec0-4d25-8ca6-e9807650e3e9" xlink:to="loc_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities_675b7af9-3c75-475a-ba5c-6676467e5993" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashOutflowForLeases_c435fa7a-4627-4ab8-a144-1f51a16450e4" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashOutflowForLeases"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LeaseLiabilitiesAbstract_987e5862-aec0-4d25-8ca6-e9807650e3e9" xlink:to="loc_ifrs-full_CashOutflowForLeases_c435fa7a-4627-4ab8-a144-1f51a16450e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseOnLeaseLiabilities_e78cd6dd-b19e-493e-b5cc-19f2bbaec504" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LeaseLiabilitiesAbstract_987e5862-aec0-4d25-8ca6-e9807650e3e9" xlink:to="loc_ifrs-full_InterestExpenseOnLeaseLiabilities_e78cd6dd-b19e-493e-b5cc-19f2bbaec504" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_GainsLossesFromForeignExchangeImpact_9b6833ae-5143-4d1c-a85d-34ce72a54cab" xlink:href="oncyf-20241231.xsd#oncyf_GainsLossesFromForeignExchangeImpact"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LeaseLiabilitiesAbstract_987e5862-aec0-4d25-8ca6-e9807650e3e9" xlink:to="loc_oncyf_GainsLossesFromForeignExchangeImpact_9b6833ae-5143-4d1c-a85d-34ce72a54cab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilities_8cef60ac-1898-4e84-aeb9-0f4936309f93" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LeaseLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LeaseLiabilitiesAbstract_987e5862-aec0-4d25-8ca6-e9807650e3e9" xlink:to="loc_ifrs-full_LeaseLiabilities_8cef60ac-1898-4e84-aeb9-0f4936309f93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/LeasesTotalUndiscountedLeaseLiabilityDetails" xlink:type="simple" xlink:href="oncyf-20241231.xsd#LeasesTotalUndiscountedLeaseLiabilityDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/LeasesTotalUndiscountedLeaseLiabilityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_626549be-a03c-4c26-ba06-3b6d231ae6ce" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable_2fab28b1-f1e9-4d9c-a19f-d1eb9a047183" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_626549be-a03c-4c26-ba06-3b6d231ae6ce" xlink:to="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable_2fab28b1-f1e9-4d9c-a19f-d1eb9a047183" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis_bd744922-943b-478f-ad8f-d63a1fcfff53" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MaturityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable_2fab28b1-f1e9-4d9c-a19f-d1eb9a047183" xlink:to="loc_ifrs-full_MaturityAxis_bd744922-943b-478f-ad8f-d63a1fcfff53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityDomain_956a361d-f41c-49fe-b944-66b84d39f1a3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MaturityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityAxis_bd744922-943b-478f-ad8f-d63a1fcfff53" xlink:to="loc_ifrs-full_MaturityDomain_956a361d-f41c-49fe-b944-66b84d39f1a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember_bd5659af-1183-43c7-a516-1ba84b2c63c5" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NotLaterThanOneYearMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityDomain_956a361d-f41c-49fe-b944-66b84d39f1a3" xlink:to="loc_ifrs-full_NotLaterThanOneYearMember_bd5659af-1183-43c7-a516-1ba84b2c63c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_fa567fb4-ca49-4ba1-9ac7-440e3e773601" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityDomain_956a361d-f41c-49fe-b944-66b84d39f1a3" xlink:to="loc_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_fa567fb4-ca49-4ba1-9ac7-440e3e773601" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanFiveYearsMember_27350e14-031f-4c39-b121-7917a28ebfa3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LaterThanFiveYearsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityDomain_956a361d-f41c-49fe-b944-66b84d39f1a3" xlink:to="loc_ifrs-full_LaterThanFiveYearsMember_27350e14-031f-4c39-b121-7917a28ebfa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems_3d3dc0dd-5048-4ff8-9a14-449a9f09a92d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable_2fab28b1-f1e9-4d9c-a19f-d1eb9a047183" xlink:to="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems_3d3dc0dd-5048-4ff8-9a14-449a9f09a92d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossLeaseLiabilities_bfa64410-fac5-4f20-a7dd-dd0bab9180f4" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GrossLeaseLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems_3d3dc0dd-5048-4ff8-9a14-449a9f09a92d" xlink:to="loc_ifrs-full_GrossLeaseLiabilities_bfa64410-fac5-4f20-a7dd-dd0bab9180f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/WarrantDerivativeReconciliationofChangeinFairValueofWarrantDerivativeDetails" xlink:type="simple" xlink:href="oncyf-20241231.xsd#WarrantDerivativeReconciliationofChangeinFairValueofWarrantDerivativeDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/WarrantDerivativeReconciliationofChangeinFairValueofWarrantDerivativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_72dd0573-fa6d-4e62-a49f-d1e4e85b955b" xlink:href="oncyf-20241231.xsd#oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_ebcf3929-eed5-49b7-921a-520ed50db3f1" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_72dd0573-fa6d-4e62-a49f-d1e4e85b955b" xlink:to="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_ebcf3929-eed5-49b7-921a-520ed50db3f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesAxis_9a078e6d-e774-4f32-b060-8607bb7f7cf7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfLiabilitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_ebcf3929-eed5-49b7-921a-520ed50db3f1" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesAxis_9a078e6d-e774-4f32-b060-8607bb7f7cf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesDomain_d22403a2-e174-49f3-a4fb-87804030b7ff" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfLiabilitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_9a078e6d-e774-4f32-b060-8607bb7f7cf7" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesDomain_d22403a2-e174-49f3-a4fb-87804030b7ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WarrantsMember_87f2329e-8f38-469c-9db5-52bc8f28e07a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesDomain_d22403a2-e174-49f3-a4fb-87804030b7ff" xlink:to="loc_ifrs-full_WarrantsMember_87f2329e-8f38-469c-9db5-52bc8f28e07a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_5f64db07-5a22-4871-8543-841ed3745768" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_ebcf3929-eed5-49b7-921a-520ed50db3f1" xlink:to="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_5f64db07-5a22-4871-8543-841ed3745768" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_NumberOfWarrantsOutstandingRollForward_b6414dbd-c1af-46f0-b74a-47a07edc1f22" xlink:href="oncyf-20241231.xsd#oncyf_NumberOfWarrantsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_5f64db07-5a22-4871-8543-841ed3745768" xlink:to="loc_oncyf_NumberOfWarrantsOutstandingRollForward_b6414dbd-c1af-46f0-b74a-47a07edc1f22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_NumberOfWarrantsOutstanding_5d8d5342-308a-4564-baaf-fecdccea4fcf" xlink:href="oncyf-20241231.xsd#oncyf_NumberOfWarrantsOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_NumberOfWarrantsOutstandingRollForward_b6414dbd-c1af-46f0-b74a-47a07edc1f22" xlink:to="loc_oncyf_NumberOfWarrantsOutstanding_5d8d5342-308a-4564-baaf-fecdccea4fcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IssueOfEquityShares_3b6d55c1-baaa-41f4-8417-a6b2b3a46940" xlink:href="oncyf-20241231.xsd#oncyf_IssueOfEquityShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_NumberOfWarrantsOutstandingRollForward_b6414dbd-c1af-46f0-b74a-47a07edc1f22" xlink:to="loc_oncyf_IssueOfEquityShares_3b6d55c1-baaa-41f4-8417-a6b2b3a46940" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_NumberOfWarrantsExercised_af869e0b-ba0b-4f10-9195-13dfd74b5c25" xlink:href="oncyf-20241231.xsd#oncyf_NumberOfWarrantsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_NumberOfWarrantsOutstandingRollForward_b6414dbd-c1af-46f0-b74a-47a07edc1f22" xlink:to="loc_oncyf_NumberOfWarrantsExercised_af869e0b-ba0b-4f10-9195-13dfd74b5c25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_NumberOfWarrantsExpired_69944826-ca81-4023-bab8-d3d48787e244" xlink:href="oncyf-20241231.xsd#oncyf_NumberOfWarrantsExpired"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_NumberOfWarrantsOutstandingRollForward_b6414dbd-c1af-46f0-b74a-47a07edc1f22" xlink:to="loc_oncyf_NumberOfWarrantsExpired_69944826-ca81-4023-bab8-d3d48787e244" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_NumberOfWarrantsOutstanding_2d0dca9b-98fb-4a06-a017-987f7775322e" xlink:href="oncyf-20241231.xsd#oncyf_NumberOfWarrantsOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_NumberOfWarrantsOutstandingRollForward_b6414dbd-c1af-46f0-b74a-47a07edc1f22" xlink:to="loc_oncyf_NumberOfWarrantsOutstanding_2d0dca9b-98fb-4a06-a017-987f7775322e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ChangeInFairValueWarrantDerivativeRollForward_004b1347-bd7b-4e08-a3e6-cb2826cd484a" xlink:href="oncyf-20241231.xsd#oncyf_ChangeInFairValueWarrantDerivativeRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_5f64db07-5a22-4871-8543-841ed3745768" xlink:to="loc_oncyf_ChangeInFairValueWarrantDerivativeRollForward_004b1347-bd7b-4e08-a3e6-cb2826cd484a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DerivativeFinancialLiabilities_4abd9745-c027-4f70-bc6a-cbd2b31f463f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DerivativeFinancialLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ChangeInFairValueWarrantDerivativeRollForward_004b1347-bd7b-4e08-a3e6-cb2826cd484a" xlink:to="loc_ifrs-full_DerivativeFinancialLiabilities_4abd9745-c027-4f70-bc6a-cbd2b31f463f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssueOfEquity_e00846af-fd61-4d1b-9698-3df20bdd02be" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssueOfEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ChangeInFairValueWarrantDerivativeRollForward_004b1347-bd7b-4e08-a3e6-cb2826cd484a" xlink:to="loc_ifrs-full_IssueOfEquity_e00846af-fd61-4d1b-9698-3df20bdd02be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantLiabilityUnamortizedDiscount_0f01ed16-6219-431b-ac07-2b87db09bd48" xlink:href="oncyf-20241231.xsd#oncyf_WarrantLiabilityUnamortizedDiscount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ChangeInFairValueWarrantDerivativeRollForward_004b1347-bd7b-4e08-a3e6-cb2826cd484a" xlink:to="loc_oncyf_WarrantLiabilityUnamortizedDiscount_0f01ed16-6219-431b-ac07-2b87db09bd48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_FairValueOfWarrantDerivativeExercised_11eca7d4-688f-409e-b73e-3afd07f6f65c" xlink:href="oncyf-20241231.xsd#oncyf_FairValueOfWarrantDerivativeExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ChangeInFairValueWarrantDerivativeRollForward_004b1347-bd7b-4e08-a3e6-cb2826cd484a" xlink:to="loc_oncyf_FairValueOfWarrantDerivativeExercised_11eca7d4-688f-409e-b73e-3afd07f6f65c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_FairValueOfWarrantDerivativeExpired_e6e484e8-2838-4166-967b-f467474e2b87" xlink:href="oncyf-20241231.xsd#oncyf_FairValueOfWarrantDerivativeExpired"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ChangeInFairValueWarrantDerivativeRollForward_004b1347-bd7b-4e08-a3e6-cb2826cd484a" xlink:to="loc_oncyf_FairValueOfWarrantDerivativeExpired_e6e484e8-2838-4166-967b-f467474e2b87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantLiabilityAmortizedDiscount_05b8f104-349a-44ff-b041-bb70cd84e48e" xlink:href="oncyf-20241231.xsd#oncyf_WarrantLiabilityAmortizedDiscount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ChangeInFairValueWarrantDerivativeRollForward_004b1347-bd7b-4e08-a3e6-cb2826cd484a" xlink:to="loc_oncyf_WarrantLiabilityAmortizedDiscount_05b8f104-349a-44ff-b041-bb70cd84e48e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_26499101-f287-49d2-9cdf-b02400d0cfc6" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ChangeInFairValueWarrantDerivativeRollForward_004b1347-bd7b-4e08-a3e6-cb2826cd484a" xlink:to="loc_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_26499101-f287-49d2-9cdf-b02400d0cfc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_GainsLossesFromForeignExchangeImpact_4fcf885d-9eb9-4bb4-9c45-890e20732bdf" xlink:href="oncyf-20241231.xsd#oncyf_GainsLossesFromForeignExchangeImpact"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ChangeInFairValueWarrantDerivativeRollForward_004b1347-bd7b-4e08-a3e6-cb2826cd484a" xlink:to="loc_oncyf_GainsLossesFromForeignExchangeImpact_4fcf885d-9eb9-4bb4-9c45-890e20732bdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DerivativeFinancialLiabilities_ae706b75-a855-4646-bbcc-8165f6ecf651" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DerivativeFinancialLiabilities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ChangeInFairValueWarrantDerivativeRollForward_004b1347-bd7b-4e08-a3e6-cb2826cd484a" xlink:to="loc_ifrs-full_DerivativeFinancialLiabilities_ae706b75-a855-4646-bbcc-8165f6ecf651" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/WarrantDerivativeWarrantDerivativeOutstandingDetails" xlink:type="simple" xlink:href="oncyf-20241231.xsd#WarrantDerivativeWarrantDerivativeOutstandingDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/WarrantDerivativeWarrantDerivativeOutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_423f0c63-6082-4f85-8402-a8d52f72b36f" xlink:href="oncyf-20241231.xsd#oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantExercisePrice_b7bce8a9-f6f8-4b86-b266-c41e49a8b6a8" xlink:href="oncyf-20241231.xsd#oncyf_WarrantExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_423f0c63-6082-4f85-8402-a8d52f72b36f" xlink:to="loc_oncyf_WarrantExercisePrice_b7bce8a9-f6f8-4b86-b266-c41e49a8b6a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_NumberOfWarrantsOutstanding_fa749f7f-7ea8-4530-bd49-ceabd43a47be" xlink:href="oncyf-20241231.xsd#oncyf_NumberOfWarrantsOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_423f0c63-6082-4f85-8402-a8d52f72b36f" xlink:to="loc_oncyf_NumberOfWarrantsOutstanding_fa749f7f-7ea8-4530-bd49-ceabd43a47be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails" xlink:type="simple" xlink:href="oncyf-20241231.xsd#WarrantDerivativeNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_e4d55bf0-2571-443b-b3ae-2507f6786db4" xlink:href="oncyf-20241231.xsd#oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_7ec3d1f7-be8d-4976-993f-63c22c9a5b09" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_e4d55bf0-2571-443b-b3ae-2507f6786db4" xlink:to="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_7ec3d1f7-be8d-4976-993f-63c22c9a5b09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_961ecf1c-2d2f-41c0-aa73-3e8afefa87e7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_7ec3d1f7-be8d-4976-993f-63c22c9a5b09" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_961ecf1c-2d2f-41c0-aa73-3e8afefa87e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_3ccffb74-96e6-4937-9fdc-0725ad322ea7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_961ecf1c-2d2f-41c0-aa73-3e8afefa87e7" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_3ccffb74-96e6-4937-9fdc-0725ad322ea7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesPublicOfferingWarrantDerivativesMember_20e5957c-7688-45fc-84fd-a76c27962c21" xlink:href="oncyf-20241231.xsd#oncyf_SharesPublicOfferingWarrantDerivativesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_3ccffb74-96e6-4937-9fdc-0725ad322ea7" xlink:to="loc_oncyf_SharesPublicOfferingWarrantDerivativesMember_20e5957c-7688-45fc-84fd-a76c27962c21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesPublicOfferingMember_4369404e-f33f-48ac-8853-c33ad8aa57cb" xlink:href="oncyf-20241231.xsd#oncyf_SharesPublicOfferingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_3ccffb74-96e6-4937-9fdc-0725ad322ea7" xlink:to="loc_oncyf_SharesPublicOfferingMember_4369404e-f33f-48ac-8853-c33ad8aa57cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_c7821665-82dc-41c2-ab4b-be7c26288bf2" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_7ec3d1f7-be8d-4976-993f-63c22c9a5b09" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_c7821665-82dc-41c2-ab4b-be7c26288bf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalDomain_0174ebb6-5416-4608-9e02-30f3f54d3e3f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_c7821665-82dc-41c2-ab4b-be7c26288bf2" xlink:to="loc_ifrs-full_ClassesOfShareCapitalDomain_0174ebb6-5416-4608-9e02-30f3f54d3e3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember_2ebb9fde-8c5d-434c-bd36-02b423e8ba70" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalDomain_0174ebb6-5416-4608-9e02-30f3f54d3e3f" xlink:to="loc_ifrs-full_IssuedCapitalMember_2ebb9fde-8c5d-434c-bd36-02b423e8ba70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesAxis_b55dac26-9c7f-498a-8d9d-3c463c66ac53" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfLiabilitiesAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_7ec3d1f7-be8d-4976-993f-63c22c9a5b09" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesAxis_b55dac26-9c7f-498a-8d9d-3c463c66ac53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesDomain_a3bdf26d-43c2-4f04-9600-3c3c7e51bfeb" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfLiabilitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_b55dac26-9c7f-498a-8d9d-3c463c66ac53" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesDomain_a3bdf26d-43c2-4f04-9600-3c3c7e51bfeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WarrantsMember_1159d38e-7538-4f86-b368-0dcc44f7f2b6" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesDomain_a3bdf26d-43c2-4f04-9600-3c3c7e51bfeb" xlink:to="loc_ifrs-full_WarrantsMember_1159d38e-7538-4f86-b368-0dcc44f7f2b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_75f8f8e3-7bd7-4ba9-9233-924d8cfc08a8" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_7ec3d1f7-be8d-4976-993f-63c22c9a5b09" xlink:to="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_75f8f8e3-7bd7-4ba9-9233-924d8cfc08a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LevelsOfFairValueHierarchyDomain_85357a87-4896-481b-b1ee-82523048c250" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LevelsOfFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_75f8f8e3-7bd7-4ba9-9233-924d8cfc08a8" xlink:to="loc_ifrs-full_LevelsOfFairValueHierarchyDomain_85357a87-4896-481b-b1ee-82523048c250" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Level2OfFairValueHierarchyMember_13185351-b8d1-4a3d-9bf4-51e251735e6e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Level2OfFairValueHierarchyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LevelsOfFairValueHierarchyDomain_85357a87-4896-481b-b1ee-82523048c250" xlink:to="loc_ifrs-full_Level2OfFairValueHierarchyMember_13185351-b8d1-4a3d-9bf4-51e251735e6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_8cef4b9d-5f34-461d-9174-cf76dd241979" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_7ec3d1f7-be8d-4976-993f-63c22c9a5b09" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_8cef4b9d-5f34-461d-9174-cf76dd241979" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityDomain_a50805e7-96ee-49a1-8270-c085fde7b611" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_8cef4b9d-5f34-461d-9174-cf76dd241979" xlink:to="loc_ifrs-full_ComponentsOfEquityDomain_a50805e7-96ee-49a1-8270-c085fde7b611" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember_9fe27aa8-95c7-4f8d-9cb9-6024ed9139ed" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_a50805e7-96ee-49a1-8270-c085fde7b611" xlink:to="loc_ifrs-full_IssuedCapitalMember_9fe27aa8-95c7-4f8d-9cb9-6024ed9139ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockAxis_6d1d893b-31f7-4a36-8100-bfd095b267e1" xlink:href="oncyf-20241231.xsd#oncyf_SaleOfStockAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_7ec3d1f7-be8d-4976-993f-63c22c9a5b09" xlink:to="loc_oncyf_SaleOfStockAxis_6d1d893b-31f7-4a36-8100-bfd095b267e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockDomain_26ec3a56-9ff5-49d5-80c2-bb7414e682c7" xlink:href="oncyf-20241231.xsd#oncyf_SaleOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockAxis_6d1d893b-31f7-4a36-8100-bfd095b267e1" xlink:to="loc_oncyf_SaleOfStockDomain_26ec3a56-9ff5-49d5-80c2-bb7414e682c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesPublicOfferingWarrantDerivativesMember_ccd2e716-b105-48fd-94e6-2034d7dcedeb" xlink:href="oncyf-20241231.xsd#oncyf_SharesPublicOfferingWarrantDerivativesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockDomain_26ec3a56-9ff5-49d5-80c2-bb7414e682c7" xlink:to="loc_oncyf_SharesPublicOfferingWarrantDerivativesMember_ccd2e716-b105-48fd-94e6-2034d7dcedeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_9458dace-7945-4b5a-9452-759c0ee33544" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_7ec3d1f7-be8d-4976-993f-63c22c9a5b09" xlink:to="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_9458dace-7945-4b5a-9452-759c0ee33544" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_NumberOfWarrantsAndSharesOutstanding_cde85d38-f163-4a46-9740-f20df67ba3c3" xlink:href="oncyf-20241231.xsd#oncyf_NumberOfWarrantsAndSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_9458dace-7945-4b5a-9452-759c0ee33544" xlink:to="loc_oncyf_NumberOfWarrantsAndSharesOutstanding_cde85d38-f163-4a46-9740-f20df67ba3c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ProceedsFromIssueOfOrdinarySharesGross_0d99c964-1fb1-487e-9f30-745ff7d07a34" xlink:href="oncyf-20241231.xsd#oncyf_ProceedsFromIssueOfOrdinarySharesGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_9458dace-7945-4b5a-9452-759c0ee33544" xlink:to="loc_oncyf_ProceedsFromIssueOfOrdinarySharesGross_0d99c964-1fb1-487e-9f30-745ff7d07a34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesIssuedPricePerShare1_51828fd5-fd52-4c3c-ba77-1a885f9f8b3a" xlink:href="oncyf-20241231.xsd#oncyf_SharesIssuedPricePerShare1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_9458dace-7945-4b5a-9452-759c0ee33544" xlink:to="loc_oncyf_SharesIssuedPricePerShare1_51828fd5-fd52-4c3c-ba77-1a885f9f8b3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CommonSharesPerUnit_2eba0443-6427-4cfa-93b9-5d75d48cd972" xlink:href="oncyf-20241231.xsd#oncyf_CommonSharesPerUnit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_9458dace-7945-4b5a-9452-759c0ee33544" xlink:to="loc_oncyf_CommonSharesPerUnit_2eba0443-6427-4cfa-93b9-5d75d48cd972" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight1_1681a959-1b9b-4099-ab4d-8bad381efb4a" xlink:href="oncyf-20241231.xsd#oncyf_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_9458dace-7945-4b5a-9452-759c0ee33544" xlink:to="loc_oncyf_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight1_1681a959-1b9b-4099-ab4d-8bad381efb4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantExercisePrice_69c942d7-7881-41b1-92a4-d96fdc243d29" xlink:href="oncyf-20241231.xsd#oncyf_WarrantExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_9458dace-7945-4b5a-9452-759c0ee33544" xlink:to="loc_oncyf_WarrantExercisePrice_69c942d7-7881-41b1-92a4-d96fdc243d29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ExpirationPeriodOfOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement_8489ca19-9616-4eaf-abb2-5d9d9e436e8c" xlink:href="oncyf-20241231.xsd#oncyf_ExpirationPeriodOfOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_9458dace-7945-4b5a-9452-759c0ee33544" xlink:to="loc_oncyf_ExpirationPeriodOfOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement_8489ca19-9616-4eaf-abb2-5d9d9e436e8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementThresholdTradingPrice_b4c647ed-83fb-4979-bbe6-3e03a0d40435" xlink:href="oncyf-20241231.xsd#oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementThresholdTradingPrice"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_9458dace-7945-4b5a-9452-759c0ee33544" xlink:to="loc_oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementThresholdTradingPrice_b4c647ed-83fb-4979-bbe6-3e03a0d40435" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementThresholdConsecutiveTradingDays_0bb95f9e-77ab-45fa-a181-9b282fe1119d" xlink:href="oncyf-20241231.xsd#oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementThresholdConsecutiveTradingDays"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_9458dace-7945-4b5a-9452-759c0ee33544" xlink:to="loc_oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementThresholdConsecutiveTradingDays_0bb95f9e-77ab-45fa-a181-9b282fe1119d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementAcceleratedThresholdTradingDays_2ba12abc-cbc3-436c-a8cc-9b2ceb2813b0" xlink:href="oncyf-20241231.xsd#oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementAcceleratedThresholdTradingDays"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_9458dace-7945-4b5a-9452-759c0ee33544" xlink:to="loc_oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementAcceleratedThresholdTradingDays_2ba12abc-cbc3-436c-a8cc-9b2ceb2813b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementExpirationDays_e00c7d72-2413-4dc4-8d87-369ad69197f2" xlink:href="oncyf-20241231.xsd#oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementExpirationDays"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_9458dace-7945-4b5a-9452-759c0ee33544" xlink:to="loc_oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementExpirationDays_e00c7d72-2413-4dc4-8d87-369ad69197f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssueOfEquity_47a243ff-5725-47b3-b5e0-fae7f6b166bf" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssueOfEquity"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_9458dace-7945-4b5a-9452-759c0ee33544" xlink:to="loc_ifrs-full_IssueOfEquity_47a243ff-5725-47b3-b5e0-fae7f6b166bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WarrantLiability_5da6a6fc-f42b-41ec-88ea-5d3247b59f11" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WarrantLiability"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_9458dace-7945-4b5a-9452-759c0ee33544" xlink:to="loc_ifrs-full_WarrantLiability_5da6a6fc-f42b-41ec-88ea-5d3247b59f11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantLiabilityUnamortizedDiscount_b087d9e1-2424-4615-9a75-1f9f1eba094f" xlink:href="oncyf-20241231.xsd#oncyf_WarrantLiabilityUnamortizedDiscount"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_9458dace-7945-4b5a-9452-759c0ee33544" xlink:to="loc_oncyf_WarrantLiabilityUnamortizedDiscount_b087d9e1-2424-4615-9a75-1f9f1eba094f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantsTerm_229d463c-5995-4ea3-ab8e-5c847f3a3777" xlink:href="oncyf-20241231.xsd#oncyf_WarrantsTerm"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_9458dace-7945-4b5a-9452-759c0ee33544" xlink:to="loc_oncyf_WarrantsTerm_229d463c-5995-4ea3-ab8e-5c847f3a3777" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/WarrantDerivativeSummaryofAssumptionsUsedintheBlackScholesOptionPricingModelforWarrantsDetails" xlink:type="simple" xlink:href="oncyf-20241231.xsd#WarrantDerivativeSummaryofAssumptionsUsedintheBlackScholesOptionPricingModelforWarrantsDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/WarrantDerivativeSummaryofAssumptionsUsedintheBlackScholesOptionPricingModelforWarrantsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_1dfe8964-9e16-4d7c-aafb-6bf11010a24e" xlink:href="oncyf-20241231.xsd#oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_6a28a068-17cd-4330-bd2f-f91362034600" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_1dfe8964-9e16-4d7c-aafb-6bf11010a24e" xlink:to="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_6a28a068-17cd-4330-bd2f-f91362034600" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesAxis_0a47d6ba-795a-4bf4-952f-c323d37596d5" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfLiabilitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_6a28a068-17cd-4330-bd2f-f91362034600" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesAxis_0a47d6ba-795a-4bf4-952f-c323d37596d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesDomain_2131f597-813c-47cc-933e-f49cf2cb26d3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfLiabilitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_0a47d6ba-795a-4bf4-952f-c323d37596d5" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesDomain_2131f597-813c-47cc-933e-f49cf2cb26d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WarrantsMember_5fb203eb-b2c2-43f2-b008-e766f835f1b7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesDomain_2131f597-813c-47cc-933e-f49cf2cb26d3" xlink:to="loc_ifrs-full_WarrantsMember_5fb203eb-b2c2-43f2-b008-e766f835f1b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_153113ce-24b6-4f26-8f9d-5375ea6033fa" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_6a28a068-17cd-4330-bd2f-f91362034600" xlink:to="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_153113ce-24b6-4f26-8f9d-5375ea6033fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WeightedAverageSharePriceOtherEquityInstrumentsGranted_4ac20eb6-8261-4e92-bb00-ee81241e43cf" xlink:href="oncyf-20241231.xsd#oncyf_WeightedAverageSharePriceOtherEquityInstrumentsGranted"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_153113ce-24b6-4f26-8f9d-5375ea6033fa" xlink:to="loc_oncyf_WeightedAverageSharePriceOtherEquityInstrumentsGranted_4ac20eb6-8261-4e92-bb00-ee81241e43cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_RiskFreeInterestRateOtherEquityInstrumentsGranted_cbac7794-3221-4335-9a62-f1eb817d4067" xlink:href="oncyf-20241231.xsd#oncyf_RiskFreeInterestRateOtherEquityInstrumentsGranted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_153113ce-24b6-4f26-8f9d-5375ea6033fa" xlink:to="loc_oncyf_RiskFreeInterestRateOtherEquityInstrumentsGranted_cbac7794-3221-4335-9a62-f1eb817d4067" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OtherEquityInstrumentsLifeOtherEquityInstrumentsGranted_4941f384-b6c6-4a86-a43d-6e88e1daf40e" xlink:href="oncyf-20241231.xsd#oncyf_OtherEquityInstrumentsLifeOtherEquityInstrumentsGranted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_153113ce-24b6-4f26-8f9d-5375ea6033fa" xlink:to="loc_oncyf_OtherEquityInstrumentsLifeOtherEquityInstrumentsGranted_4941f384-b6c6-4a86-a43d-6e88e1daf40e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ExpectedVolatilityOtherEquityInstrumentsGranted_cf7ac625-40fa-40d7-8aee-0702aae90291" xlink:href="oncyf-20241231.xsd#oncyf_ExpectedVolatilityOtherEquityInstrumentsGranted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_153113ce-24b6-4f26-8f9d-5375ea6033fa" xlink:to="loc_oncyf_ExpectedVolatilityOtherEquityInstrumentsGranted_cf7ac625-40fa-40d7-8aee-0702aae90291" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted_aa199a42-8817-4471-96d4-5c07d6f28be8" xlink:href="oncyf-20241231.xsd#oncyf_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_153113ce-24b6-4f26-8f9d-5375ea6033fa" xlink:to="loc_oncyf_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted_aa199a42-8817-4471-96d4-5c07d6f28be8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted_2c581523-804e-4f2c-83f2-96c87ee0e57d" xlink:href="oncyf-20241231.xsd#oncyf_WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_153113ce-24b6-4f26-8f9d-5375ea6033fa" xlink:to="loc_oncyf_WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted_2c581523-804e-4f2c-83f2-96c87ee0e57d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails" xlink:type="simple" xlink:href="oncyf-20241231.xsd#ShareCapitalScheduleofShareCapitalDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_31d3a12d-014b-47f8-a0cd-67151ee3357b" xlink:href="oncyf-20241231.xsd#oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_e92a8ee5-eb02-4b93-b44a-a10beeb94814" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_31d3a12d-014b-47f8-a0cd-67151ee3357b" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_e92a8ee5-eb02-4b93-b44a-a10beeb94814" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_c1acdbc7-cf1f-4e74-9a6b-06134eb6f82d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_e92a8ee5-eb02-4b93-b44a-a10beeb94814" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_c1acdbc7-cf1f-4e74-9a6b-06134eb6f82d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_b420cc40-f631-4301-be1d-8d11d4bc817d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_c1acdbc7-cf1f-4e74-9a6b-06134eb6f82d" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_b420cc40-f631-4301-be1d-8d11d4bc817d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesUnderStockOptionPlanMember_2b66803d-d3e1-499c-bb0e-2cc6c1f583f2" xlink:href="oncyf-20241231.xsd#oncyf_SharesUnderStockOptionPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_b420cc40-f631-4301-be1d-8d11d4bc817d" xlink:to="loc_oncyf_SharesUnderStockOptionPlanMember_2b66803d-d3e1-499c-bb0e-2cc6c1f583f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesUnderIncentiveAwardPlanMember_1ed32200-3010-4787-9328-413b0bde62f1" xlink:href="oncyf-20241231.xsd#oncyf_SharesUnderIncentiveAwardPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_b420cc40-f631-4301-be1d-8d11d4bc817d" xlink:to="loc_oncyf_SharesUnderIncentiveAwardPlanMember_1ed32200-3010-4787-9328-413b0bde62f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesPublicOfferingMember_9703667b-bccb-448a-b82b-de847d26f7e7" xlink:href="oncyf-20241231.xsd#oncyf_SharesPublicOfferingMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_b420cc40-f631-4301-be1d-8d11d4bc817d" xlink:to="loc_oncyf_SharesPublicOfferingMember_9703667b-bccb-448a-b82b-de847d26f7e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesPublicOfferingWarrantDerivativesMember_9b884cb0-8273-444c-a375-8b2ad6199329" xlink:href="oncyf-20241231.xsd#oncyf_SharesPublicOfferingWarrantDerivativesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_b420cc40-f631-4301-be1d-8d11d4bc817d" xlink:to="loc_oncyf_SharesPublicOfferingWarrantDerivativesMember_9b884cb0-8273-444c-a375-8b2ad6199329" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_6a259025-6dfa-419e-acf7-a9f3dd29adef" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_e92a8ee5-eb02-4b93-b44a-a10beeb94814" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_6a259025-6dfa-419e-acf7-a9f3dd29adef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityDomain_4e525b1f-232f-4207-a6b8-fc6f43126f02" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_6a259025-6dfa-419e-acf7-a9f3dd29adef" xlink:to="loc_ifrs-full_ComponentsOfEquityDomain_4e525b1f-232f-4207-a6b8-fc6f43126f02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember_fd1c4432-f5ea-4660-b297-99a1fe4fd09a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_4e525b1f-232f-4207-a6b8-fc6f43126f02" xlink:to="loc_ifrs-full_IssuedCapitalMember_fd1c4432-f5ea-4660-b297-99a1fe4fd09a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockAxis_de1c4325-6b21-4e62-ae91-83bfe3834c4a" xlink:href="oncyf-20241231.xsd#oncyf_SaleOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_e92a8ee5-eb02-4b93-b44a-a10beeb94814" xlink:to="loc_oncyf_SaleOfStockAxis_de1c4325-6b21-4e62-ae91-83bfe3834c4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockDomain_531cef6a-184d-475b-a29a-ff75470eb3e0" xlink:href="oncyf-20241231.xsd#oncyf_SaleOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockAxis_de1c4325-6b21-4e62-ae91-83bfe3834c4a" xlink:to="loc_oncyf_SaleOfStockDomain_531cef6a-184d-475b-a29a-ff75470eb3e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesUnderAtthemarketAgreementMember_4d378817-d018-4b5f-bfbe-05d83374da02" xlink:href="oncyf-20241231.xsd#oncyf_SharesUnderAtthemarketAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockDomain_531cef6a-184d-475b-a29a-ff75470eb3e0" xlink:to="loc_oncyf_SharesUnderAtthemarketAgreementMember_4d378817-d018-4b5f-bfbe-05d83374da02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesPublicOfferingWarrantDerivativesMember_34bcb33e-efbc-414c-a2ec-5b667e7442a2" xlink:href="oncyf-20241231.xsd#oncyf_SharesPublicOfferingWarrantDerivativesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockDomain_531cef6a-184d-475b-a29a-ff75470eb3e0" xlink:to="loc_oncyf_SharesPublicOfferingWarrantDerivativesMember_34bcb33e-efbc-414c-a2ec-5b667e7442a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesPublicOfferingMember_0d867ab1-8613-43ab-b86e-2d66bd321834" xlink:href="oncyf-20241231.xsd#oncyf_SharesPublicOfferingMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockDomain_531cef6a-184d-475b-a29a-ff75470eb3e0" xlink:to="loc_oncyf_SharesPublicOfferingMember_0d867ab1-8613-43ab-b86e-2d66bd321834" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_5d935d0c-44e8-4d52-96aa-37a3025ff305" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_e92a8ee5-eb02-4b93-b44a-a10beeb94814" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_5d935d0c-44e8-4d52-96aa-37a3025ff305" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ShareCapitalNumberSharesAbstract_6fbc3ae9-fb16-4a98-903f-c260befd2856" xlink:href="oncyf-20241231.xsd#oncyf_ShareCapitalNumberSharesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_5d935d0c-44e8-4d52-96aa-37a3025ff305" xlink:to="loc_oncyf_ShareCapitalNumberSharesAbstract_6fbc3ae9-fb16-4a98-903f-c260befd2856" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesIssued_f3cf7167-9c74-4dfa-845f-2c986414e7fb" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ShareCapitalNumberSharesAbstract_6fbc3ae9-fb16-4a98-903f-c260befd2856" xlink:to="loc_ifrs-full_NumberOfSharesIssued_f3cf7167-9c74-4dfa-845f-2c986414e7fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IssueOfEquityShares_93205b5b-4143-4fee-9eb1-7220a9564fb8" xlink:href="oncyf-20241231.xsd#oncyf_IssueOfEquityShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ShareCapitalNumberSharesAbstract_6fbc3ae9-fb16-4a98-903f-c260befd2856" xlink:to="loc_oncyf_IssueOfEquityShares_93205b5b-4143-4fee-9eb1-7220a9564fb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesIssued_9da19cfc-5965-4127-9d57-bc23b062eb62" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ShareCapitalNumberSharesAbstract_6fbc3ae9-fb16-4a98-903f-c260befd2856" xlink:to="loc_ifrs-full_NumberOfSharesIssued_9da19cfc-5965-4127-9d57-bc23b062eb62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ShareCapitalAmountAbstract_f7e575a4-0f80-4cf3-b897-9a8cdfd85f63" xlink:href="oncyf-20241231.xsd#oncyf_ShareCapitalAmountAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_5d935d0c-44e8-4d52-96aa-37a3025ff305" xlink:to="loc_oncyf_ShareCapitalAmountAbstract_f7e575a4-0f80-4cf3-b897-9a8cdfd85f63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_9518798f-b59b-4ce2-83b0-f0d644115347" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Equity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ShareCapitalAmountAbstract_f7e575a4-0f80-4cf3-b897-9a8cdfd85f63" xlink:to="loc_ifrs-full_Equity_9518798f-b59b-4ce2-83b0-f0d644115347" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssueOfEquity_10d2536b-1cf6-4294-b98d-0bc1e1aafb13" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssueOfEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ShareCapitalAmountAbstract_f7e575a4-0f80-4cf3-b897-9a8cdfd85f63" xlink:to="loc_ifrs-full_IssueOfEquity_10d2536b-1cf6-4294-b98d-0bc1e1aafb13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareIssueRelatedCost_85a8115a-08d5-4146-b5be-8d6dd414e9e6" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShareIssueRelatedCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ShareCapitalAmountAbstract_f7e575a4-0f80-4cf3-b897-9a8cdfd85f63" xlink:to="loc_ifrs-full_ShareIssueRelatedCost_85a8115a-08d5-4146-b5be-8d6dd414e9e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_95d827cb-bd55-41de-ae75-0f38c8fb9f84" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Equity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ShareCapitalAmountAbstract_f7e575a4-0f80-4cf3-b897-9a8cdfd85f63" xlink:to="loc_ifrs-full_Equity_95d827cb-bd55-41de-ae75-0f38c8fb9f84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails" xlink:type="simple" xlink:href="oncyf-20241231.xsd#ShareCapitalScheduleofShareCapitalFootnotesDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_360f0306-e5e7-4074-a373-15c3ecea3753" xlink:href="oncyf-20241231.xsd#oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_1e751f8c-c2cc-45e3-a5c9-4dfe36c0c0af" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_360f0306-e5e7-4074-a373-15c3ecea3753" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_1e751f8c-c2cc-45e3-a5c9-4dfe36c0c0af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockAxis_29b271c0-6611-4e48-a67d-f44101334988" xlink:href="oncyf-20241231.xsd#oncyf_SaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_1e751f8c-c2cc-45e3-a5c9-4dfe36c0c0af" xlink:to="loc_oncyf_SaleOfStockAxis_29b271c0-6611-4e48-a67d-f44101334988" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockDomain_eb76200b-dffe-42d6-99d8-1e14489518a8" xlink:href="oncyf-20241231.xsd#oncyf_SaleOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockAxis_29b271c0-6611-4e48-a67d-f44101334988" xlink:to="loc_oncyf_SaleOfStockDomain_eb76200b-dffe-42d6-99d8-1e14489518a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_A2021SharesUnderAtTheMarketAgreementUnitedStatesMember_1170b158-0f3f-4914-83d5-3cf7485ab3f7" xlink:href="oncyf-20241231.xsd#oncyf_A2021SharesUnderAtTheMarketAgreementUnitedStatesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockDomain_eb76200b-dffe-42d6-99d8-1e14489518a8" xlink:to="loc_oncyf_A2021SharesUnderAtTheMarketAgreementUnitedStatesMember_1170b158-0f3f-4914-83d5-3cf7485ab3f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_A2022SharesUnderAtTheMarketAgreementUnitedStatesMember_e4034eea-9452-4403-9772-038948601a8a" xlink:href="oncyf-20241231.xsd#oncyf_A2022SharesUnderAtTheMarketAgreementUnitedStatesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockDomain_eb76200b-dffe-42d6-99d8-1e14489518a8" xlink:to="loc_oncyf_A2022SharesUnderAtTheMarketAgreementUnitedStatesMember_e4034eea-9452-4403-9772-038948601a8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesPublicOfferingMember_4f49afc3-7c8b-421f-912b-444dad4610f5" xlink:href="oncyf-20241231.xsd#oncyf_SharesPublicOfferingMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockDomain_eb76200b-dffe-42d6-99d8-1e14489518a8" xlink:to="loc_oncyf_SharesPublicOfferingMember_4f49afc3-7c8b-421f-912b-444dad4610f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_A2024SharesUnderAtTheMarketAgreementUnitedStatesMember_1455b0d5-330a-43b2-9d08-33b7a208a670" xlink:href="oncyf-20241231.xsd#oncyf_A2024SharesUnderAtTheMarketAgreementUnitedStatesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockDomain_eb76200b-dffe-42d6-99d8-1e14489518a8" xlink:to="loc_oncyf_A2024SharesUnderAtTheMarketAgreementUnitedStatesMember_1455b0d5-330a-43b2-9d08-33b7a208a670" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesAxis_f332b20b-9848-4c4d-aa74-4dcc37621ebd" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfLiabilitiesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_1e751f8c-c2cc-45e3-a5c9-4dfe36c0c0af" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesAxis_f332b20b-9848-4c4d-aa74-4dcc37621ebd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesDomain_dc39673d-ee3d-47cc-ab71-588a8a0d63c2" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfLiabilitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_f332b20b-9848-4c4d-aa74-4dcc37621ebd" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesDomain_dc39673d-ee3d-47cc-ab71-588a8a0d63c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WarrantsMember_6790771d-cc42-4aa2-8658-06607cfc1609" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesDomain_dc39673d-ee3d-47cc-ab71-588a8a0d63c2" xlink:to="loc_ifrs-full_WarrantsMember_6790771d-cc42-4aa2-8658-06607cfc1609" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_0f3db73a-3ef4-4ec0-9e8f-586a42160370" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_1e751f8c-c2cc-45e3-a5c9-4dfe36c0c0af" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_0f3db73a-3ef4-4ec0-9e8f-586a42160370" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_6ade69a2-a41f-4780-9ef1-8cdabe894a44" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_0f3db73a-3ef4-4ec0-9e8f-586a42160370" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_6ade69a2-a41f-4780-9ef1-8cdabe894a44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CompensationWarrantsMember_b43480bb-b302-4935-8108-bd0d4989365a" xlink:href="oncyf-20241231.xsd#oncyf_CompensationWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_6ade69a2-a41f-4780-9ef1-8cdabe894a44" xlink:to="loc_oncyf_CompensationWarrantsMember_b43480bb-b302-4935-8108-bd0d4989365a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_6056e39c-5f4a-4225-9724-aff0d8cd0101" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_1e751f8c-c2cc-45e3-a5c9-4dfe36c0c0af" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_6056e39c-5f4a-4225-9724-aff0d8cd0101" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityDomain_e69b0ff7-fbbc-4769-b051-99ae25c5e3f3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_6056e39c-5f4a-4225-9724-aff0d8cd0101" xlink:to="loc_ifrs-full_ComponentsOfEquityDomain_e69b0ff7-fbbc-4769-b051-99ae25c5e3f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharePremiumMember_8861108d-25f4-467f-bc13-b40498738f5e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SharePremiumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_e69b0ff7-fbbc-4769-b051-99ae25c5e3f3" xlink:to="loc_ifrs-full_SharePremiumMember_8861108d-25f4-467f-bc13-b40498738f5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6e045800-7923-4b53-a96a-dc99be153fd6" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_1e751f8c-c2cc-45e3-a5c9-4dfe36c0c0af" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6e045800-7923-4b53-a96a-dc99be153fd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharePurchaseAgreementAmount_bb80b48c-dc8a-45ee-a89d-ddd53f4885c9" xlink:href="oncyf-20241231.xsd#oncyf_SharePurchaseAgreementAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6e045800-7923-4b53-a96a-dc99be153fd6" xlink:to="loc_oncyf_SharePurchaseAgreementAmount_bb80b48c-dc8a-45ee-a89d-ddd53f4885c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharePurchaseAgreementTerm_7004ddd5-a1da-4a35-88d7-993cc9859afb" xlink:href="oncyf-20241231.xsd#oncyf_SharePurchaseAgreementTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6e045800-7923-4b53-a96a-dc99be153fd6" xlink:to="loc_oncyf_SharePurchaseAgreementTerm_7004ddd5-a1da-4a35-88d7-993cc9859afb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IssueOfEquityShares_e2f16619-2be1-4aaf-aad3-d8a46b0a406e" xlink:href="oncyf-20241231.xsd#oncyf_IssueOfEquityShares"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6e045800-7923-4b53-a96a-dc99be153fd6" xlink:to="loc_oncyf_IssueOfEquityShares_e2f16619-2be1-4aaf-aad3-d8a46b0a406e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ProceedsFromIssueOfOrdinarySharesGross_4d054e5c-6ff0-40b1-85b3-6b6036300cc5" xlink:href="oncyf-20241231.xsd#oncyf_ProceedsFromIssueOfOrdinarySharesGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6e045800-7923-4b53-a96a-dc99be153fd6" xlink:to="loc_oncyf_ProceedsFromIssueOfOrdinarySharesGross_4d054e5c-6ff0-40b1-85b3-6b6036300cc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesIssuedPricePerShare1_361e719a-d24a-48dc-aacb-684e0f8f0c06" xlink:href="oncyf-20241231.xsd#oncyf_SharesIssuedPricePerShare1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6e045800-7923-4b53-a96a-dc99be153fd6" xlink:to="loc_oncyf_SharesIssuedPricePerShare1_361e719a-d24a-48dc-aacb-684e0f8f0c06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromIssueOfOrdinaryShares_eca6fe0b-febd-4587-9359-8fc222c81d8b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromIssueOfOrdinaryShares"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6e045800-7923-4b53-a96a-dc99be153fd6" xlink:to="loc_ifrs-full_ProceedsFromIssueOfOrdinaryShares_eca6fe0b-febd-4587-9359-8fc222c81d8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ShareIssueRelatedCostCommissions_5db29b5b-0a3a-4fff-90e3-2953077cfed0" xlink:href="oncyf-20241231.xsd#oncyf_ShareIssueRelatedCostCommissions"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6e045800-7923-4b53-a96a-dc99be153fd6" xlink:to="loc_oncyf_ShareIssueRelatedCostCommissions_5db29b5b-0a3a-4fff-90e3-2953077cfed0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareIssueRelatedCost_b5d0e328-16bb-40ed-aae8-b2a74bfdb145" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShareIssueRelatedCost"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6e045800-7923-4b53-a96a-dc99be153fd6" xlink:to="loc_ifrs-full_ShareIssueRelatedCost_b5d0e328-16bb-40ed-aae8-b2a74bfdb145" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_NumberOfWarrantsAndSharesOutstanding_15dad989-cc5c-4cfe-a799-9cb151b1aa87" xlink:href="oncyf-20241231.xsd#oncyf_NumberOfWarrantsAndSharesOutstanding"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6e045800-7923-4b53-a96a-dc99be153fd6" xlink:to="loc_oncyf_NumberOfWarrantsAndSharesOutstanding_15dad989-cc5c-4cfe-a799-9cb151b1aa87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IssueOfEquitySharesNumberOfCommonShares_bd985b8d-b1ce-47f9-96dd-218a22e30645" xlink:href="oncyf-20241231.xsd#oncyf_IssueOfEquitySharesNumberOfCommonShares"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6e045800-7923-4b53-a96a-dc99be153fd6" xlink:to="loc_oncyf_IssueOfEquitySharesNumberOfCommonShares_bd985b8d-b1ce-47f9-96dd-218a22e30645" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IssueOfEquitySharesNumberOfWarrants_8c149078-d9ed-4b70-b834-b6a5261f3bc1" xlink:href="oncyf-20241231.xsd#oncyf_IssueOfEquitySharesNumberOfWarrants"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6e045800-7923-4b53-a96a-dc99be153fd6" xlink:to="loc_oncyf_IssueOfEquitySharesNumberOfWarrants_8c149078-d9ed-4b70-b834-b6a5261f3bc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssueOfEquity_a1af974a-3700-41ab-8b49-8275950c460d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssueOfEquity"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6e045800-7923-4b53-a96a-dc99be153fd6" xlink:to="loc_ifrs-full_IssueOfEquity_a1af974a-3700-41ab-8b49-8275950c460d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WarrantLiability_5e9ce00f-e394-4631-88fa-42d8876185a8" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WarrantLiability"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6e045800-7923-4b53-a96a-dc99be153fd6" xlink:to="loc_ifrs-full_WarrantLiability_5e9ce00f-e394-4631-88fa-42d8876185a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_832c2202-5932-4bf7-b08c-ea52c502e8c6" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6e045800-7923-4b53-a96a-dc99be153fd6" xlink:to="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_832c2202-5932-4bf7-b08c-ea52c502e8c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ShareWarrantsIssuedTransactionCosts_25157225-63df-4843-9a70-9b3494877384" xlink:href="oncyf-20241231.xsd#oncyf_ShareWarrantsIssuedTransactionCosts"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6e045800-7923-4b53-a96a-dc99be153fd6" xlink:to="loc_oncyf_ShareWarrantsIssuedTransactionCosts_25157225-63df-4843-9a70-9b3494877384" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees_7ca750a1-e6a7-4c56-b2f4-8834cf420923" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6e045800-7923-4b53-a96a-dc99be153fd6" xlink:to="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees_7ca750a1-e6a7-4c56-b2f4-8834cf420923" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ShareWarrantsIssuedOperatingExpense_89b6ede9-3e87-46ee-af45-0cc4a768cf48" xlink:href="oncyf-20241231.xsd#oncyf_ShareWarrantsIssuedOperatingExpense"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6e045800-7923-4b53-a96a-dc99be153fd6" xlink:to="loc_oncyf_ShareWarrantsIssuedOperatingExpense_89b6ede9-3e87-46ee-af45-0cc4a768cf48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_NumberOfWarrantsExercised_472c3465-4dd4-405f-a0f8-52328b63077d" xlink:href="oncyf-20241231.xsd#oncyf_NumberOfWarrantsExercised"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6e045800-7923-4b53-a96a-dc99be153fd6" xlink:to="loc_oncyf_NumberOfWarrantsExercised_472c3465-4dd4-405f-a0f8-52328b63077d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantsExercised_4cbad192-e370-4f04-b416-e4eeb0c3a2bf" xlink:href="oncyf-20241231.xsd#oncyf_WarrantsExercised"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6e045800-7923-4b53-a96a-dc99be153fd6" xlink:to="loc_oncyf_WarrantsExercised_4cbad192-e370-4f04-b416-e4eeb0c3a2bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ProceedsfromWarrantExercises1_1c3331c7-2a76-4348-bd42-d021f6b4b4e5" xlink:href="oncyf-20241231.xsd#oncyf_ProceedsfromWarrantExercises1"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_6e045800-7923-4b53-a96a-dc99be153fd6" xlink:to="loc_oncyf_ProceedsfromWarrantExercises1_1c3331c7-2a76-4348-bd42-d021f6b4b4e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="oncyf-20241231.xsd#ShareBasedCompensationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract_a514b82a-51bc-4a83-84ae-22409b6c63cc" xlink:href="oncyf-20241231.xsd#oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_24411ed0-a660-4e95-b6df-1b155e29d01b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract_a514b82a-51bc-4a83-84ae-22409b6c63cc" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_24411ed0-a660-4e95-b6df-1b155e29d01b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_26c8102e-4945-423c-8c01-82200f906796" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_24411ed0-a660-4e95-b6df-1b155e29d01b" xlink:to="loc_ifrs-full_RangeAxis_26c8102e-4945-423c-8c01-82200f906796" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeDomain_5c3a82d0-bd5e-493b-b3f7-fab8dd4c1b22" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeAxis_26c8102e-4945-423c-8c01-82200f906796" xlink:to="loc_ifrs-full_RangeDomain_5c3a82d0-bd5e-493b-b3f7-fab8dd4c1b22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BottomOfRangeMember_00675907-36f8-4156-a42c-9d40c1848699" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BottomOfRangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeDomain_5c3a82d0-bd5e-493b-b3f7-fab8dd4c1b22" xlink:to="loc_ifrs-full_BottomOfRangeMember_00675907-36f8-4156-a42c-9d40c1848699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember_813f0bf2-d3a2-43e8-915f-87c6df635c0b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TopOfRangeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeDomain_5c3a82d0-bd5e-493b-b3f7-fab8dd4c1b22" xlink:to="loc_ifrs-full_TopOfRangeMember_813f0bf2-d3a2-43e8-915f-87c6df635c0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_dfab3b7e-0e01-4c59-9936-98b195c7ed21" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_24411ed0-a660-4e95-b6df-1b155e29d01b" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_dfab3b7e-0e01-4c59-9936-98b195c7ed21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_831425f6-a3a5-4d4a-ae3b-5570c70dfa66" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_dfab3b7e-0e01-4c59-9936-98b195c7ed21" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_831425f6-a3a5-4d4a-ae3b-5570c70dfa66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReserveOfSharebasedPaymentsMember_41f50c04-b0ff-41b4-9cef-d7550e27a952" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReserveOfSharebasedPaymentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_831425f6-a3a5-4d4a-ae3b-5570c70dfa66" xlink:to="loc_ifrs-full_ReserveOfSharebasedPaymentsMember_41f50c04-b0ff-41b4-9cef-d7550e27a952" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RestrictedShareUnitsMember_0147576f-df43-49d2-ad7d-ae704637a435" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RestrictedShareUnitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_831425f6-a3a5-4d4a-ae3b-5570c70dfa66" xlink:to="loc_ifrs-full_RestrictedShareUnitsMember_0147576f-df43-49d2-ad7d-ae704637a435" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CompensationWarrantsMember_b4bf9c18-651f-4fa5-b9cb-0b59b53c9dd4" xlink:href="oncyf-20241231.xsd#oncyf_CompensationWarrantsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_831425f6-a3a5-4d4a-ae3b-5570c70dfa66" xlink:to="loc_oncyf_CompensationWarrantsMember_b4bf9c18-651f-4fa5-b9cb-0b59b53c9dd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_cfe1421d-2299-4bcd-bd20-2ad924a46e59" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_24411ed0-a660-4e95-b6df-1b155e29d01b" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_cfe1421d-2299-4bcd-bd20-2ad924a46e59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityDomain_b694a3b0-9b98-47ef-838e-163537cc724b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_cfe1421d-2299-4bcd-bd20-2ad924a46e59" xlink:to="loc_ifrs-full_ComponentsOfEquityDomain_b694a3b0-9b98-47ef-838e-163537cc724b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember_7083bb93-13ad-40b8-ab20-2505f71ecab5" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_b694a3b0-9b98-47ef-838e-163537cc724b" xlink:to="loc_ifrs-full_IssuedCapitalMember_7083bb93-13ad-40b8-ab20-2505f71ecab5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharePremiumMember_9505466e-8a59-435b-99a4-b4752bbc03c8" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SharePremiumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityDomain_b694a3b0-9b98-47ef-838e-163537cc724b" xlink:to="loc_ifrs-full_SharePremiumMember_9505466e-8a59-435b-99a4-b4752bbc03c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_2eb26693-3b85-445a-b2c2-fcf79f3e82cc" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_24411ed0-a660-4e95-b6df-1b155e29d01b" xlink:to="loc_srt_TitleOfIndividualAxis_2eb26693-3b85-445a-b2c2-fcf79f3e82cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_7870e041-dea6-4447-a485-34dcffa9ec52" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_2eb26693-3b85-445a-b2c2-fcf79f3e82cc" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_7870e041-dea6-4447-a485-34dcffa9ec52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OfficerMember_91208d88-ca46-4ea7-9274-3ad14d68cb25" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OfficerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_7870e041-dea6-4447-a485-34dcffa9ec52" xlink:to="loc_srt_OfficerMember_91208d88-ca46-4ea7-9274-3ad14d68cb25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_f3089dea-b88b-4780-b9d3-6d41c9c1f701" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_DirectorMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_7870e041-dea6-4447-a485-34dcffa9ec52" xlink:to="loc_srt_DirectorMember_f3089dea-b88b-4780-b9d3-6d41c9c1f701" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_e61bb7f7-be72-4dcc-abba-f9ca7a29d298" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_24411ed0-a660-4e95-b6df-1b155e29d01b" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_e61bb7f7-be72-4dcc-abba-f9ca7a29d298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_NumberOfSharesReservedForIssueUnderOptionsAndContractsForSaleOfSharesPercentageOfCommonSharesMaximum_0f7c73be-3867-495d-bca5-a5d528873c47" xlink:href="oncyf-20241231.xsd#oncyf_NumberOfSharesReservedForIssueUnderOptionsAndContractsForSaleOfSharesPercentageOfCommonSharesMaximum"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_e61bb7f7-be72-4dcc-abba-f9ca7a29d298" xlink:to="loc_oncyf_NumberOfSharesReservedForIssueUnderOptionsAndContractsForSaleOfSharesPercentageOfCommonSharesMaximum_0f7c73be-3867-495d-bca5-a5d528873c47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares_0a20a334-5e05-496b-b9f5-c79c81eacddd" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_e61bb7f7-be72-4dcc-abba-f9ca7a29d298" xlink:to="loc_ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares_0a20a334-5e05-496b-b9f5-c79c81eacddd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_2ef3418d-dde9-4957-b69d-94c16848a43c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_e61bb7f7-be72-4dcc-abba-f9ca7a29d298" xlink:to="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_2ef3418d-dde9-4957-b69d-94c16848a43c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1_9185cac4-6347-40c2-a648-2a0b4fabeb1c" xlink:href="oncyf-20241231.xsd#oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_e61bb7f7-be72-4dcc-abba-f9ca7a29d298" xlink:to="loc_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1_9185cac4-6347-40c2-a648-2a0b4fabeb1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_144e6bec-c763-4db4-903d-d1cd6148ef6c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_e61bb7f7-be72-4dcc-abba-f9ca7a29d298" xlink:to="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_144e6bec-c763-4db4-903d-d1cd6148ef6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019_89483106-4cb2-4cb7-8281-9e0b748ea2c8" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_e61bb7f7-be72-4dcc-abba-f9ca7a29d298" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019_89483106-4cb2-4cb7-8281-9e0b748ea2c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ExpirationPeriodOfOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement_47e91be7-961c-41c1-9889-ad4782680051" xlink:href="oncyf-20241231.xsd#oncyf_ExpirationPeriodOfOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_e61bb7f7-be72-4dcc-abba-f9ca7a29d298" xlink:to="loc_oncyf_ExpirationPeriodOfOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement_47e91be7-961c-41c1-9889-ad4782680051" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees_4b490fe5-23c8-415d-8093-a330382ad5bf" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_e61bb7f7-be72-4dcc-abba-f9ca7a29d298" xlink:to="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees_4b490fe5-23c8-415d-8093-a330382ad5bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsandWeightedAverageExercisePricesDetails" xlink:type="simple" xlink:href="oncyf-20241231.xsd#ShareBasedCompensationScheduleofStockOptionsandWeightedAverageExercisePricesDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsandWeightedAverageExercisePricesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract_2eb3d71d-0649-450a-a9b7-088ce1edbf95" xlink:href="oncyf-20241231.xsd#oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_StockOptionsOutstandingAbstract_c8a5f046-fb50-4fbb-bc2a-1555b1dfa0cb" xlink:href="oncyf-20241231.xsd#oncyf_StockOptionsOutstandingAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract_2eb3d71d-0649-450a-a9b7-088ce1edbf95" xlink:to="loc_oncyf_StockOptionsOutstandingAbstract_c8a5f046-fb50-4fbb-bc2a-1555b1dfa0cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions_e281a8ed-accf-4234-a1e1-441639a2c4d7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOutstandingShareOptions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_StockOptionsOutstandingAbstract_c8a5f046-fb50-4fbb-bc2a-1555b1dfa0cb" xlink:to="loc_ifrs-full_NumberOfOutstandingShareOptions_e281a8ed-accf-4234-a1e1-441639a2c4d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_75f86a48-070f-4902-9029-aba8278e5579" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_StockOptionsOutstandingAbstract_c8a5f046-fb50-4fbb-bc2a-1555b1dfa0cb" xlink:to="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_75f86a48-070f-4902-9029-aba8278e5579" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_f22001ba-763d-4967-b049-6a2184a7b95d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_StockOptionsOutstandingAbstract_c8a5f046-fb50-4fbb-bc2a-1555b1dfa0cb" xlink:to="loc_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_f22001ba-763d-4967-b049-6a2184a7b95d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement_bfd3be67-5b88-4e0c-af02-85c0760ead23" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_StockOptionsOutstandingAbstract_c8a5f046-fb50-4fbb-bc2a-1555b1dfa0cb" xlink:to="loc_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement_bfd3be67-5b88-4e0c-af02-85c0760ead23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_8d25f396-5e98-4ea8-877a-9d1add34ac3d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_StockOptionsOutstandingAbstract_c8a5f046-fb50-4fbb-bc2a-1555b1dfa0cb" xlink:to="loc_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_8d25f396-5e98-4ea8-877a-9d1add34ac3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions_b3a19225-0575-4e43-8a56-ec72780c3f61" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOutstandingShareOptions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_StockOptionsOutstandingAbstract_c8a5f046-fb50-4fbb-bc2a-1555b1dfa0cb" xlink:to="loc_ifrs-full_NumberOfOutstandingShareOptions_b3a19225-0575-4e43-8a56-ec72780c3f61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_f89cc24e-9b1f-4c3b-88cc-6882b436dfe4" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract_2eb3d71d-0649-450a-a9b7-088ce1edbf95" xlink:to="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_f89cc24e-9b1f-4c3b-88cc-6882b436dfe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WeightedAverageExercisePriceOutstandingAbstract_24e83d7c-28ff-486d-a9d7-e27a5fa2b117" xlink:href="oncyf-20241231.xsd#oncyf_WeightedAverageExercisePriceOutstandingAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract_2eb3d71d-0649-450a-a9b7-088ce1edbf95" xlink:to="loc_oncyf_WeightedAverageExercisePriceOutstandingAbstract_24e83d7c-28ff-486d-a9d7-e27a5fa2b117" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_a338a9d1-6bc8-4883-9194-e35a19c90f69" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_WeightedAverageExercisePriceOutstandingAbstract_24e83d7c-28ff-486d-a9d7-e27a5fa2b117" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_a338a9d1-6bc8-4883-9194-e35a19c90f69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_4568d39f-9646-408f-be34-e3a9bc5ac4be" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_WeightedAverageExercisePriceOutstandingAbstract_24e83d7c-28ff-486d-a9d7-e27a5fa2b117" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_4568d39f-9646-408f-be34-e3a9bc5ac4be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_d1f2d7d0-2b7a-4352-9161-5ad24edef16f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_WeightedAverageExercisePriceOutstandingAbstract_24e83d7c-28ff-486d-a9d7-e27a5fa2b117" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_d1f2d7d0-2b7a-4352-9161-5ad24edef16f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019_d422e564-9b94-493b-b6fa-d6041c6de75d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_WeightedAverageExercisePriceOutstandingAbstract_24e83d7c-28ff-486d-a9d7-e27a5fa2b117" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019_d422e564-9b94-493b-b6fa-d6041c6de75d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_2ecc2e39-e447-4088-947a-40d71889aa6b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_WeightedAverageExercisePriceOutstandingAbstract_24e83d7c-28ff-486d-a9d7-e27a5fa2b117" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_2ecc2e39-e447-4088-947a-40d71889aa6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_0447929a-e641-4da6-a082-3a62cb792af4" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_WeightedAverageExercisePriceOutstandingAbstract_24e83d7c-28ff-486d-a9d7-e27a5fa2b117" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_0447929a-e641-4da6-a082-3a62cb792af4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_4c3733ba-3591-43a9-9fa1-6a687ca6420d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract_2eb3d71d-0649-450a-a9b7-088ce1edbf95" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_4c3733ba-3591-43a9-9fa1-6a687ca6420d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails" xlink:type="simple" xlink:href="oncyf-20241231.xsd#ShareBasedCompensationScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract_1caa6837-b8ec-440e-bb6e-f3dfae7233e6" xlink:href="oncyf-20241231.xsd#oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_9c0a3228-1b7a-4a1a-841a-d3c34b0520cd" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract_1caa6837-b8ec-440e-bb6e-f3dfae7233e6" xlink:to="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_9c0a3228-1b7a-4a1a-841a-d3c34b0520cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_72ea339f-cc95-4f4f-ac6a-aeb80b74dc07" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_9c0a3228-1b7a-4a1a-841a-d3c34b0520cd" xlink:to="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_72ea339f-cc95-4f4f-ac6a-aeb80b74dc07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsDomain_772d6870-0467-461f-95f9-61dab044e86d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_72ea339f-cc95-4f4f-ac6a-aeb80b74dc07" xlink:to="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsDomain_772d6870-0467-461f-95f9-61dab044e86d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ExercisePriceRangeOneMember_28d221f7-899c-4af4-87ac-13f3be1d5836" xlink:href="oncyf-20241231.xsd#oncyf_ExercisePriceRangeOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsDomain_772d6870-0467-461f-95f9-61dab044e86d" xlink:to="loc_oncyf_ExercisePriceRangeOneMember_28d221f7-899c-4af4-87ac-13f3be1d5836" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ExercisePriceRangeTwoMember_e9211624-390f-4523-a29b-91c8b15cca89" xlink:href="oncyf-20241231.xsd#oncyf_ExercisePriceRangeTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsDomain_772d6870-0467-461f-95f9-61dab044e86d" xlink:to="loc_oncyf_ExercisePriceRangeTwoMember_e9211624-390f-4523-a29b-91c8b15cca89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ExercisePriceRangeThreeMember_9d7e8813-e625-4608-adeb-e9b8a1694d70" xlink:href="oncyf-20241231.xsd#oncyf_ExercisePriceRangeThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsDomain_772d6870-0467-461f-95f9-61dab044e86d" xlink:to="loc_oncyf_ExercisePriceRangeThreeMember_9d7e8813-e625-4608-adeb-e9b8a1694d70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ExercisePriceRangeFourMember_eb55c80d-68d1-4c4e-8e5e-88ecbd5fb324" xlink:href="oncyf-20241231.xsd#oncyf_ExercisePriceRangeFourMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsDomain_772d6870-0467-461f-95f9-61dab044e86d" xlink:to="loc_oncyf_ExercisePriceRangeFourMember_eb55c80d-68d1-4c4e-8e5e-88ecbd5fb324" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ExercisePriceRangeFiveMember_e625fbf4-048a-4eed-9425-c63b6b41e197" xlink:href="oncyf-20241231.xsd#oncyf_ExercisePriceRangeFiveMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsDomain_772d6870-0467-461f-95f9-61dab044e86d" xlink:to="loc_oncyf_ExercisePriceRangeFiveMember_e625fbf4-048a-4eed-9425-c63b6b41e197" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_9d871a75-a5c1-41d2-956a-41739381a9e6" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_9c0a3228-1b7a-4a1a-841a-d3c34b0520cd" xlink:to="loc_ifrs-full_RangeAxis_9d871a75-a5c1-41d2-956a-41739381a9e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeDomain_d09051bb-fcf3-4e4a-8047-e4ad035df7a5" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeAxis_9d871a75-a5c1-41d2-956a-41739381a9e6" xlink:to="loc_ifrs-full_RangeDomain_d09051bb-fcf3-4e4a-8047-e4ad035df7a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BottomOfRangeMember_515d7b22-6288-46c4-9ea2-82f58f3fdd31" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BottomOfRangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeDomain_d09051bb-fcf3-4e4a-8047-e4ad035df7a5" xlink:to="loc_ifrs-full_BottomOfRangeMember_515d7b22-6288-46c4-9ea2-82f58f3fdd31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember_e23c5dab-3619-4178-9203-982401be382e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TopOfRangeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeDomain_d09051bb-fcf3-4e4a-8047-e4ad035df7a5" xlink:to="loc_ifrs-full_TopOfRangeMember_e23c5dab-3619-4178-9203-982401be382e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_b95f3f85-bf8b-44a2-b1a7-b1b63be41278" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_9c0a3228-1b7a-4a1a-841a-d3c34b0520cd" xlink:to="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_b95f3f85-bf8b-44a2-b1a7-b1b63be41278" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExercisePriceOfOutstandingShareOptions2019_a99b9640-f951-4976-8bc5-80a24ba002d4" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions2019"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_b95f3f85-bf8b-44a2-b1a7-b1b63be41278" xlink:to="loc_ifrs-full_ExercisePriceOfOutstandingShareOptions2019_a99b9640-f951-4976-8bc5-80a24ba002d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions_4b2b99cb-3cdb-42b8-81b5-ae7aad4db4ca" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOutstandingShareOptions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_b95f3f85-bf8b-44a2-b1a7-b1b63be41278" xlink:to="loc_ifrs-full_NumberOfOutstandingShareOptions_4b2b99cb-3cdb-42b8-81b5-ae7aad4db4ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_332c2b36-0d31-4fea-8809-9244435b842b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_b95f3f85-bf8b-44a2-b1a7-b1b63be41278" xlink:to="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_332c2b36-0d31-4fea-8809-9244435b842b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_e5ceb5e0-9971-41a8-923a-0c394783c89d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_b95f3f85-bf8b-44a2-b1a7-b1b63be41278" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_e5ceb5e0-9971-41a8-923a-0c394783c89d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_84fbeed2-e5dd-4cd8-89dc-5ab38de30ba9" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_b95f3f85-bf8b-44a2-b1a7-b1b63be41278" xlink:to="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_84fbeed2-e5dd-4cd8-89dc-5ab38de30ba9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_79e86335-d05f-43e0-b550-7413ee1d024e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_b95f3f85-bf8b-44a2-b1a7-b1b63be41278" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_79e86335-d05f-43e0-b550-7413ee1d024e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedCompensationDisclosureWeightedAverageAssumptionsandFairValueofOptionsDetails" xlink:type="simple" xlink:href="oncyf-20241231.xsd#ShareBasedCompensationDisclosureWeightedAverageAssumptionsandFairValueofOptionsDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareBasedCompensationDisclosureWeightedAverageAssumptionsandFairValueofOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract_62daaac3-a532-414d-8448-0a0bfe4142a2" xlink:href="oncyf-20241231.xsd#oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_01f74db6-cca4-4f7d-a6cc-7f639ae395ef" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract_62daaac3-a532-414d-8448-0a0bfe4142a2" xlink:to="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_01f74db6-cca4-4f7d-a6cc-7f639ae395ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_bbba255c-8469-42f4-8ca9-3ec8436e9fa7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfOptionLifeShareOptionsGranted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract_62daaac3-a532-414d-8448-0a0bfe4142a2" xlink:to="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_bbba255c-8469-42f4-8ca9-3ec8436e9fa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_30c35374-f191-4e24-9b7b-cba7f5ccc1e7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract_62daaac3-a532-414d-8448-0a0bfe4142a2" xlink:to="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_30c35374-f191-4e24-9b7b-cba7f5ccc1e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_c4ea6b08-9026-48d2-865d-ca1723b4f95a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract_62daaac3-a532-414d-8448-0a0bfe4142a2" xlink:to="loc_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_c4ea6b08-9026-48d2-865d-ca1723b4f95a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted_11673f62-e495-45f4-aecb-d0b3fa701fcb" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract_62daaac3-a532-414d-8448-0a0bfe4142a2" xlink:to="loc_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted_11673f62-e495-45f4-aecb-d0b3fa701fcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofNumberofOtherEquityInstrumentsDetails" xlink:type="simple" xlink:href="oncyf-20241231.xsd#ShareBasedCompensationScheduleofNumberofOtherEquityInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofNumberofOtherEquityInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract_02c68d77-04c0-41bb-894e-7d8ede0d380f" xlink:href="oncyf-20241231.xsd#oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_11b838a4-7df3-4f28-9be2-653651ffc521" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract_02c68d77-04c0-41bb-894e-7d8ede0d380f" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_11b838a4-7df3-4f28-9be2-653651ffc521" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_4687e02a-1792-45cd-949a-321afc305716" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_11b838a4-7df3-4f28-9be2-653651ffc521" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_4687e02a-1792-45cd-949a-321afc305716" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_5ad9dd9c-9ff6-428b-8684-77e1ef47edd1" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_4687e02a-1792-45cd-949a-321afc305716" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_5ad9dd9c-9ff6-428b-8684-77e1ef47edd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RestrictedShareUnitsMember_41a7624d-4e65-4b4c-9245-eb068e5879e7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RestrictedShareUnitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_5ad9dd9c-9ff6-428b-8684-77e1ef47edd1" xlink:to="loc_ifrs-full_RestrictedShareUnitsMember_41a7624d-4e65-4b4c-9245-eb068e5879e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_1988d87a-db9e-4c85-b865-f4d99c1a23e2" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_11b838a4-7df3-4f28-9be2-653651ffc521" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_1988d87a-db9e-4c85-b865-f4d99c1a23e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_3f1d26b0-b00e-4da5-93f0-fd36ae98fb3d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_1988d87a-db9e-4c85-b865-f4d99c1a23e2" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_3f1d26b0-b00e-4da5-93f0-fd36ae98fb3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_b4f3fa06-5e0d-4531-bc75-94234ef0bf15" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_1988d87a-db9e-4c85-b865-f4d99c1a23e2" xlink:to="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_b4f3fa06-5e0d-4531-bc75-94234ef0bf15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_1f5c90f2-5ee3-4e59-b640-19193bb00a43" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_1988d87a-db9e-4c85-b865-f4d99c1a23e2" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_1f5c90f2-5ee3-4e59-b640-19193bb00a43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_8d1bcb35-c443-40a2-98d6-8faf94c644de" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_1988d87a-db9e-4c85-b865-f4d99c1a23e2" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_8d1bcb35-c443-40a2-98d6-8faf94c644de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_9deae02e-b042-4676-84ad-e7259b8c3ef9" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_1988d87a-db9e-4c85-b865-f4d99c1a23e2" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_9deae02e-b042-4676-84ad-e7259b8c3ef9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted_32dbcf24-1eb6-440e-bff3-4eab5fbda214" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_1988d87a-db9e-4c85-b865-f4d99c1a23e2" xlink:to="loc_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted_32dbcf24-1eb6-440e-bff3-4eab5fbda214" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/LossPerShareDetails" xlink:type="simple" xlink:href="oncyf-20241231.xsd#LossPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/LossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EarningsPerShareAbstract_c719b6f3-33f5-4b78-9ac5-6a56586cd0d0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageShares_3f07f302-9f48-4611-8805-76afa3a68708" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_c719b6f3-33f5-4b78-9ac5-6a56586cd0d0" xlink:to="loc_ifrs-full_WeightedAverageShares_3f07f302-9f48-4611-8805-76afa3a68708" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ContractLiabilityNarrativeDetails" xlink:type="simple" xlink:href="oncyf-20241231.xsd#ContractLiabilityNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ContractLiabilityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract_f3e520e9-a45a-46fe-9b53-402a090005d8" xlink:href="oncyf-20241231.xsd#oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ContractLiabilityRecognitionPeriod_37f08169-83a8-4537-80fb-1793616be286" xlink:href="oncyf-20241231.xsd#oncyf_ContractLiabilityRecognitionPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract_f3e520e9-a45a-46fe-9b53-402a090005d8" xlink:to="loc_oncyf_ContractLiabilityRecognitionPeriod_37f08169-83a8-4537-80fb-1793616be286" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ContractLiabilityScheduleofContractRevenuesandLiabilitiesDetails" xlink:type="simple" xlink:href="oncyf-20241231.xsd#ContractLiabilityScheduleofContractRevenuesandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ContractLiabilityScheduleofContractRevenuesandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract_eed67d7b-3425-4365-975d-233f394ad07f" xlink:href="oncyf-20241231.xsd#oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContractLiabilities_b758d1da-89d0-4d7d-8f1d-daa5c93da7e2" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ContractLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract_eed67d7b-3425-4365-975d-233f394ad07f" xlink:to="loc_ifrs-full_ContractLiabilities_b758d1da-89d0-4d7d-8f1d-daa5c93da7e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities_8071228e-cab6-45e2-b75b-6990fa2d3a75" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract_eed67d7b-3425-4365-975d-233f394ad07f" xlink:to="loc_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities_8071228e-cab6-45e2-b75b-6990fa2d3a75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContractLiabilities_5514de7e-25ea-4265-b0a8-54bd917f5920" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ContractLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract_eed67d7b-3425-4365-975d-233f394ad07f" xlink:to="loc_ifrs-full_ContractLiabilities_5514de7e-25ea-4265-b0a8-54bd917f5920" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="oncyf-20241231.xsd#CommitmentsandContingenciesDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ContingenciesAbstract_4f66e22a-ffba-49d0-b2ee-b32246a0f8ac" xlink:href="oncyf-20241231.xsd#oncyf_ContingenciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_PurchaseObligation1_9321a80d-a279-4888-9b49-2c7f32e62bf6" xlink:href="oncyf-20241231.xsd#oncyf_PurchaseObligation1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ContingenciesAbstract_4f66e22a-ffba-49d0-b2ee-b32246a0f8ac" xlink:to="loc_oncyf_PurchaseObligation1_9321a80d-a279-4888-9b49-2c7f32e62bf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_PurchaseObligationCommitmentTerm_90f0e838-b72b-49a8-b0c6-9c1af50fce7b" xlink:href="oncyf-20241231.xsd#oncyf_PurchaseObligationCommitmentTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ContingenciesAbstract_4f66e22a-ffba-49d0-b2ee-b32246a0f8ac" xlink:to="loc_oncyf_PurchaseObligationCommitmentTerm_90f0e838-b72b-49a8-b0c6-9c1af50fce7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_PurchaseObligationCommitmentProductionServiceAgreementPercentage_ae3b04c2-fd23-4b1f-afe7-9ae9bd923b8a" xlink:href="oncyf-20241231.xsd#oncyf_PurchaseObligationCommitmentProductionServiceAgreementPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ContingenciesAbstract_4f66e22a-ffba-49d0-b2ee-b32246a0f8ac" xlink:to="loc_oncyf_PurchaseObligationCommitmentProductionServiceAgreementPercentage_ae3b04c2-fd23-4b1f-afe7-9ae9bd923b8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails" xlink:type="simple" xlink:href="oncyf-20241231.xsd#IncomeTaxesProvisionforIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofincometaxAbstract_026f8ea7-8a25-4527-b0ae-bfa77d7ebc4d" xlink:href="oncyf-20241231.xsd#oncyf_DisclosureofincometaxAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccountingProfit_af43c47f-b5a6-4b86-bbaf-c8dcab6f8277" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AccountingProfit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_026f8ea7-8a25-4527-b0ae-bfa77d7ebc4d" xlink:to="loc_ifrs-full_AccountingProfit_af43c47f-b5a6-4b86-bbaf-c8dcab6f8277" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ApplicableTaxRate_12592f3b-de13-4c8c-afd9-4fbd6e0aeffc" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ApplicableTaxRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_026f8ea7-8a25-4527-b0ae-bfa77d7ebc4d" xlink:to="loc_ifrs-full_ApplicableTaxRate_12592f3b-de13-4c8c-afd9-4fbd6e0aeffc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_58634cff-a612-4354-85a9-fcf104ae2bd8" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TaxExpenseIncomeAtApplicableTaxRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_026f8ea7-8a25-4527-b0ae-bfa77d7ebc4d" xlink:to="loc_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_58634cff-a612-4354-85a9-fcf104ae2bd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TaxEffectOfForeignTaxRates_fa2ef108-026a-4dd4-a644-d27febac97b7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TaxEffectOfForeignTaxRates"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_026f8ea7-8a25-4527-b0ae-bfa77d7ebc4d" xlink:to="loc_ifrs-full_TaxEffectOfForeignTaxRates_fa2ef108-026a-4dd4-a644-d27febac97b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TaxEffectOfStockBasedCompensation_40aad80a-36db-4f52-8530-2c25f8931425" xlink:href="oncyf-20241231.xsd#oncyf_TaxEffectOfStockBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_026f8ea7-8a25-4527-b0ae-bfa77d7ebc4d" xlink:to="loc_oncyf_TaxEffectOfStockBasedCompensation_40aad80a-36db-4f52-8530-2c25f8931425" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TaxEffectOfTaxPools_7559fa60-8a1f-4deb-819d-8d7f3e065154" xlink:href="oncyf-20241231.xsd#oncyf_TaxEffectOfTaxPools"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_026f8ea7-8a25-4527-b0ae-bfa77d7ebc4d" xlink:to="loc_oncyf_TaxEffectOfTaxPools_7559fa60-8a1f-4deb-819d-8d7f3e065154" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TaxEffectFromChangeInTaxRate_1e81fa1a-2bca-4c22-ba73-b9f3b8e6efdf" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TaxEffectFromChangeInTaxRate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_026f8ea7-8a25-4527-b0ae-bfa77d7ebc4d" xlink:to="loc_ifrs-full_TaxEffectFromChangeInTaxRate_1e81fa1a-2bca-4c22-ba73-b9f3b8e6efdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_f54477c3-903f-4539-bfc4-91c302189e2d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_026f8ea7-8a25-4527-b0ae-bfa77d7ebc4d" xlink:to="loc_ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_f54477c3-903f-4539-bfc4-91c302189e2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TaxEffectOfExpirationOfTaxBenefits_eb48a8b8-4d90-4db3-83ca-d2bb74bc7c74" xlink:href="oncyf-20241231.xsd#oncyf_TaxEffectOfExpirationOfTaxBenefits"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_026f8ea7-8a25-4527-b0ae-bfa77d7ebc4d" xlink:to="loc_oncyf_TaxEffectOfExpirationOfTaxBenefits_eb48a8b8-4d90-4db3-83ca-d2bb74bc7c74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative_4d20b010-60a2-402e-a1cd-8801c8234214" xlink:href="oncyf-20241231.xsd#oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_026f8ea7-8a25-4527-b0ae-bfa77d7ebc4d" xlink:to="loc_oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative_4d20b010-60a2-402e-a1cd-8801c8234214" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1_fd809300-91fa-4043-8800-bb4e4409e418" xlink:href="oncyf-20241231.xsd#oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_026f8ea7-8a25-4527-b0ae-bfa77d7ebc4d" xlink:to="loc_oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1_fd809300-91fa-4043-8800-bb4e4409e418" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_575ccbe0-5f82-49d3-97c0-5d6d00dbb143" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_026f8ea7-8a25-4527-b0ae-bfa77d7ebc4d" xlink:to="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_575ccbe0-5f82-49d3-97c0-5d6d00dbb143" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="oncyf-20241231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_91b0e1af-7a12-4521-b52d-2e7783b45089" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_dde21995-03eb-4b49-8d84-a93fe1894b4a" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_91b0e1af-7a12-4521-b52d-2e7783b45089" xlink:to="loc_srt_StatementGeographicalAxis_dde21995-03eb-4b49-8d84-a93fe1894b4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_10c3a093-28fb-438e-a400-bd2f393fd673" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_dde21995-03eb-4b49-8d84-a93fe1894b4a" xlink:to="loc_srt_SegmentGeographicalDomain_10c3a093-28fb-438e-a400-bd2f393fd673" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_dca50464-b947-4be3-b111-0b6ed16dd712" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_CA"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_10c3a093-28fb-438e-a400-bd2f393fd673" xlink:to="loc_country_CA_dca50464-b947-4be3-b111-0b6ed16dd712" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_BB_fff7e135-458b-4acc-9074-b3435358ba11" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_BB"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_10c3a093-28fb-438e-a400-bd2f393fd673" xlink:to="loc_country_BB_fff7e135-458b-4acc-9074-b3435358ba11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_ead4c287-57d4-4fdb-95de-b897c1a33410" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_10c3a093-28fb-438e-a400-bd2f393fd673" xlink:to="loc_country_US_ead4c287-57d4-4fdb-95de-b897c1a33410" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_24e58b30-e75b-4938-ab67-dc37376c3c7b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_91b0e1af-7a12-4521-b52d-2e7783b45089" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_24e58b30-e75b-4938-ab67-dc37376c3c7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain_4b02aabb-da71-42ba-9888-83162082bd89" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_24e58b30-e75b-4938-ab67-dc37376c3c7b" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain_4b02aabb-da71-42ba-9888-83162082bd89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnusedTaxLossesMember_f3c92cb1-6714-4729-bdf0-229b42251634" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_UnusedTaxLossesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain_4b02aabb-da71-42ba-9888-83162082bd89" xlink:to="loc_ifrs-full_UnusedTaxLossesMember_f3c92cb1-6714-4729-bdf0-229b42251634" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnusedTaxCreditsMember_a6d38706-ed97-42c6-9f9d-46a90629fd66" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_UnusedTaxCreditsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain_4b02aabb-da71-42ba-9888-83162082bd89" xlink:to="loc_ifrs-full_UnusedTaxCreditsMember_a6d38706-ed97-42c6-9f9d-46a90629fd66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember_70d2cb12-dd06-48a6-af96-2d99c217a3f8" xlink:href="oncyf-20241231.xsd#oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain_4b02aabb-da71-42ba-9888-83162082bd89" xlink:to="loc_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember_70d2cb12-dd06-48a6-af96-2d99c217a3f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_5c09c441-094a-4dd7-92c7-f90c1f435ab3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_91b0e1af-7a12-4521-b52d-2e7783b45089" xlink:to="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_5c09c441-094a-4dd7-92c7-f90c1f435ab3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_1e0d2621-666a-48ab-af02-0bafb7ae5405" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_5c09c441-094a-4dd7-92c7-f90c1f435ab3" xlink:to="loc_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_1e0d2621-666a-48ab-af02-0bafb7ae5405" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised_44bc8594-985b-4a56-af79-466bb3527c73" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_5c09c441-094a-4dd7-92c7-f90c1f435ab3" xlink:to="loc_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised_44bc8594-985b-4a56-af79-466bb3527c73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxesScheduleofUnrecognizedDeferredTaxAssetsDetails" xlink:type="simple" xlink:href="oncyf-20241231.xsd#IncomeTaxesScheduleofUnrecognizedDeferredTaxAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/IncomeTaxesScheduleofUnrecognizedDeferredTaxAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofincometaxAbstract_47840ec3-69e8-4dea-ab6f-c4a4d47db91e" xlink:href="oncyf-20241231.xsd#oncyf_DisclosureofincometaxAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_7e849eea-4ac8-4f14-aede-968e26df3ca3" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_47840ec3-69e8-4dea-ab6f-c4a4d47db91e" xlink:to="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_7e849eea-4ac8-4f14-aede-968e26df3ca3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_8f8d24d7-f38e-48ba-a79c-581677fef1dc" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_7e849eea-4ac8-4f14-aede-968e26df3ca3" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_8f8d24d7-f38e-48ba-a79c-581677fef1dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain_48bb43ad-fcf7-4109-97c9-2e93cbe63979" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_8f8d24d7-f38e-48ba-a79c-581677fef1dc" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain_48bb43ad-fcf7-4109-97c9-2e93cbe63979" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_UnusedNetOperatingLossCarryForwardsMember_db9382e4-489a-4053-912b-3d7723dc3388" xlink:href="oncyf-20241231.xsd#oncyf_UnusedNetOperatingLossCarryForwardsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain_48bb43ad-fcf7-4109-97c9-2e93cbe63979" xlink:to="loc_oncyf_UnusedNetOperatingLossCarryForwardsMember_db9382e4-489a-4053-912b-3d7723dc3388" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember_03b47d8f-ce2d-49c9-b7ab-5c07473a9376" xlink:href="oncyf-20241231.xsd#oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain_48bb43ad-fcf7-4109-97c9-2e93cbe63979" xlink:to="loc_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember_03b47d8f-ce2d-49c9-b7ab-5c07473a9376" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_InvestmentTaxCreditsMember_44bd9cc1-8c05-4b81-9b5f-7284ea5fcfc8" xlink:href="oncyf-20241231.xsd#oncyf_InvestmentTaxCreditsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain_48bb43ad-fcf7-4109-97c9-2e93cbe63979" xlink:to="loc_oncyf_InvestmentTaxCreditsMember_44bd9cc1-8c05-4b81-9b5f-7284ea5fcfc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_PropertyPlantEquipmentRelatedTemporaryDifferencesMember_bf16e1f8-d7cb-489f-9f74-bee6c8826f31" xlink:href="oncyf-20241231.xsd#oncyf_PropertyPlantEquipmentRelatedTemporaryDifferencesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain_48bb43ad-fcf7-4109-97c9-2e93cbe63979" xlink:to="loc_oncyf_PropertyPlantEquipmentRelatedTemporaryDifferencesMember_bf16e1f8-d7cb-489f-9f74-bee6c8826f31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ShareIssueCostsMember_cedefbe2-edf2-4ae9-9548-2f46bd0e3b83" xlink:href="oncyf-20241231.xsd#oncyf_ShareIssueCostsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain_48bb43ad-fcf7-4109-97c9-2e93cbe63979" xlink:to="loc_oncyf_ShareIssueCostsMember_cedefbe2-edf2-4ae9-9548-2f46bd0e3b83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_UnusedCapitalLossCarryForwardNetMember_00e26e86-d4d9-4ac1-9420-d960efa99c8d" xlink:href="oncyf-20241231.xsd#oncyf_UnusedCapitalLossCarryForwardNetMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain_48bb43ad-fcf7-4109-97c9-2e93cbe63979" xlink:to="loc_oncyf_UnusedCapitalLossCarryForwardNetMember_00e26e86-d4d9-4ac1-9420-d960efa99c8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_c665e0f7-4ad5-412f-b013-4d32aaf73916" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_7e849eea-4ac8-4f14-aede-968e26df3ca3" xlink:to="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_c665e0f7-4ad5-412f-b013-4d32aaf73916" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised_bb6f869c-98a1-4326-94c2-d922ffede799" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_c665e0f7-4ad5-412f-b013-4d32aaf73916" xlink:to="loc_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised_bb6f869c-98a1-4326-94c2-d922ffede799" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CapitalDisclosuresDetails" xlink:type="simple" xlink:href="oncyf-20241231.xsd#CapitalDisclosuresDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/CapitalDisclosuresDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityAbstract_4a83426f-6ee6-41df-acfd-f3ff7672d346" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfChangesInEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_c1b22c0f-2a5f-4c9d-89a7-4b9f491aa5f8" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityAbstract_4a83426f-6ee6-41df-acfd-f3ff7672d346" xlink:to="loc_ifrs-full_CashAndCashEquivalents_c1b22c0f-2a5f-4c9d-89a7-4b9f491aa5f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_38432d3c-04e5-44b3-9c3a-10095b366ab4" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Equity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityAbstract_4a83426f-6ee6-41df-acfd-f3ff7672d346" xlink:to="loc_ifrs-full_Equity_38432d3c-04e5-44b3-9c3a-10095b366ab4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_EquityAuthorized_cdf987cd-c7fd-4a7e-ae25-218fce852de2" xlink:href="oncyf-20241231.xsd#oncyf_EquityAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityAbstract_4a83426f-6ee6-41df-acfd-f3ff7672d346" xlink:to="loc_oncyf_EquityAuthorized_cdf987cd-c7fd-4a7e-ae25-218fce852de2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="simple" xlink:href="oncyf-20241231.xsd#FinancialInstrumentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_e90abf6e-1e8b-4ceb-be19-cc8854131aaa" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_3bf5d10e-cc49-49ff-8a32-c0564cc0a1a6" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_e90abf6e-1e8b-4ceb-be19-cc8854131aaa" xlink:to="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_3bf5d10e-cc49-49ff-8a32-c0564cc0a1a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_ff58af63-f897-4989-bcc5-ec449924a581" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_3bf5d10e-cc49-49ff-8a32-c0564cc0a1a6" xlink:to="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_ff58af63-f897-4989-bcc5-ec449924a581" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LevelsOfFairValueHierarchyDomain_cc2d4524-2e71-4a75-951c-b4cf2569b6f8" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LevelsOfFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_ff58af63-f897-4989-bcc5-ec449924a581" xlink:to="loc_ifrs-full_LevelsOfFairValueHierarchyDomain_cc2d4524-2e71-4a75-951c-b4cf2569b6f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Level2OfFairValueHierarchyMember_9d17ccfc-86f4-47e9-97e5-19fe846cfb5c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Level2OfFairValueHierarchyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LevelsOfFairValueHierarchyDomain_cc2d4524-2e71-4a75-951c-b4cf2569b6f8" xlink:to="loc_ifrs-full_Level2OfFairValueHierarchyMember_9d17ccfc-86f4-47e9-97e5-19fe846cfb5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksAxis_78f28337-f47d-4b18-af2e-5e5b9efdf7bb" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfRisksAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_3bf5d10e-cc49-49ff-8a32-c0564cc0a1a6" xlink:to="loc_ifrs-full_TypesOfRisksAxis_78f28337-f47d-4b18-af2e-5e5b9efdf7bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksDomain_2d4b933e-723a-4a66-8bab-7eb74d50690a" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfRisksDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksAxis_78f28337-f47d-4b18-af2e-5e5b9efdf7bb" xlink:to="loc_ifrs-full_TypesOfRisksDomain_2d4b933e-723a-4a66-8bab-7eb74d50690a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrencyRiskMember_e7c3fba4-e5c6-45ea-b08a-dbccfa985f7e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrencyRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksDomain_2d4b933e-723a-4a66-8bab-7eb74d50690a" xlink:to="loc_ifrs-full_CurrencyRiskMember_e7c3fba4-e5c6-45ea-b08a-dbccfa985f7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis_4654343f-a0f2-418a-bedb-5161141c2b29" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CurrencyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_3bf5d10e-cc49-49ff-8a32-c0564cc0a1a6" xlink:to="loc_srt_CurrencyAxis_4654343f-a0f2-418a-bedb-5161141c2b29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_679f8729-b60a-442e-adaa-4f8d0ebe378a" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_AllCurrenciesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CurrencyAxis_4654343f-a0f2-418a-bedb-5161141c2b29" xlink:to="loc_currency_AllCurrenciesDomain_679f8729-b60a-442e-adaa-4f8d0ebe378a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_USD_1da005dc-c08f-4733-9e74-6e1fe7f9046d" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_USD"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_679f8729-b60a-442e-adaa-4f8d0ebe378a" xlink:to="loc_currency_USD_1da005dc-c08f-4733-9e74-6e1fe7f9046d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_EUR_0425babd-b300-4cdb-9e51-21f9a7cc56af" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_EUR"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_679f8729-b60a-442e-adaa-4f8d0ebe378a" xlink:to="loc_currency_EUR_0425babd-b300-4cdb-9e51-21f9a7cc56af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_5590c2cd-3a80-4a37-997f-be067b6e0782" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_3bf5d10e-cc49-49ff-8a32-c0564cc0a1a6" xlink:to="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_5590c2cd-3a80-4a37-997f-be067b6e0782" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentDerivativeFinancialAssets_90306d0c-b792-4806-a6fc-289190372911" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentDerivativeFinancialAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_5590c2cd-3a80-4a37-997f-be067b6e0782" xlink:to="loc_ifrs-full_CurrentDerivativeFinancialAssets_90306d0c-b792-4806-a6fc-289190372911" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentDerivativeFinancialLiabilities_51001136-82c3-4713-8ac0-c71d9dc835ec" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentDerivativeFinancialLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_5590c2cd-3a80-4a37-997f-be067b6e0782" xlink:to="loc_ifrs-full_CurrentDerivativeFinancialLiabilities_51001136-82c3-4713-8ac0-c71d9dc835ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount_546b4ebf-ab88-4464-a246-996dee48bf37" xlink:href="oncyf-20241231.xsd#oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_5590c2cd-3a80-4a37-997f-be067b6e0782" xlink:to="loc_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount_546b4ebf-ab88-4464-a246-996dee48bf37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings_d176eda1-08a9-4b1a-a7fc-f5646f8827c5" xlink:href="oncyf-20241231.xsd#oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_5590c2cd-3a80-4a37-997f-be067b6e0782" xlink:to="loc_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings_d176eda1-08a9-4b1a-a7fc-f5646f8827c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/FinancialInstrumentsScheduleofBalancesinForeignCurrenciesDetails" xlink:type="simple" xlink:href="oncyf-20241231.xsd#FinancialInstrumentsScheduleofBalancesinForeignCurrenciesDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/FinancialInstrumentsScheduleofBalancesinForeignCurrenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_1d4d135b-9d0d-4b27-9f7c-1614e8a5a4f5" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_Currency1Table_b44df993-7511-472c-a016-b9a247997862" xlink:href="oncyf-20241231.xsd#oncyf_Currency1Table"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_1d4d135b-9d0d-4b27-9f7c-1614e8a5a4f5" xlink:to="loc_oncyf_Currency1Table_b44df993-7511-472c-a016-b9a247997862" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis_fb39ba7d-9776-4040-b344-d25fc9e6786f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CurrencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Currency1Table_b44df993-7511-472c-a016-b9a247997862" xlink:to="loc_srt_CurrencyAxis_fb39ba7d-9776-4040-b344-d25fc9e6786f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_7fb29099-8c50-429d-b81f-308e019a0631" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_AllCurrenciesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CurrencyAxis_fb39ba7d-9776-4040-b344-d25fc9e6786f" xlink:to="loc_currency_AllCurrenciesDomain_7fb29099-8c50-429d-b81f-308e019a0631" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_USD_c810095c-21fa-4bac-a107-3e47ae64e613" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_USD"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_7fb29099-8c50-429d-b81f-308e019a0631" xlink:to="loc_currency_USD_c810095c-21fa-4bac-a107-3e47ae64e613" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_EUR_0a0127b1-2288-42a2-bc36-f93645dfef02" xlink:href="https://xbrl.sec.gov/currency/2024/currency-2024.xsd#currency_EUR"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_7fb29099-8c50-429d-b81f-308e019a0631" xlink:to="loc_currency_EUR_0a0127b1-2288-42a2-bc36-f93645dfef02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_Currency1LineItems_ce7513aa-a685-4ba7-b12d-e480bf31976f" xlink:href="oncyf-20241231.xsd#oncyf_Currency1LineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Currency1Table_b44df993-7511-472c-a016-b9a247997862" xlink:to="loc_oncyf_Currency1LineItems_ce7513aa-a685-4ba7-b12d-e480bf31976f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_d16842e1-0e3a-4a67-81b9-a46eb8ef59f7" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Currency1LineItems_ce7513aa-a685-4ba7-b12d-e480bf31976f" xlink:to="loc_ifrs-full_CashAndCashEquivalents_d16842e1-0e3a-4a67-81b9-a46eb8ef59f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayables_2aa1a4ba-b965-4680-afa6-d66097847a67" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Currency1LineItems_ce7513aa-a685-4ba7-b12d-e480bf31976f" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayables_2aa1a4ba-b965-4680-afa6-d66097847a67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherLiabilities_e7851e79-e652-40b8-869a-0fa0b22c192e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Currency1LineItems_ce7513aa-a685-4ba7-b12d-e480bf31976f" xlink:to="loc_ifrs-full_OtherLiabilities_e7851e79-e652-40b8-869a-0fa0b22c192e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_BalanceHeldInForeignCurrencyNet_65e3b36d-d67b-4e23-b6a6-c5558bae5ca6" xlink:href="oncyf-20241231.xsd#oncyf_BalanceHeldInForeignCurrencyNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Currency1LineItems_ce7513aa-a685-4ba7-b12d-e480bf31976f" xlink:to="loc_oncyf_BalanceHeldInForeignCurrencyNet_65e3b36d-d67b-4e23-b6a6-c5558bae5ca6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails" xlink:type="simple" xlink:href="oncyf-20241231.xsd#AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_AdditionalCashFlowDisclosuresAbstract_61fb4c8c-39f8-4826-88e1-4c5e8456f47f" xlink:href="oncyf-20241231.xsd#oncyf_AdditionalCashFlowDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables_27734ee1-411b-411a-abf8-267820260d53" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_AdditionalCashFlowDisclosuresAbstract_61fb4c8c-39f8-4826-88e1-4c5e8456f47f" xlink:to="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables_27734ee1-411b-411a-abf8-267820260d53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses_5e484bfd-588a-4781-adc1-6d65797b198c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_AdditionalCashFlowDisclosuresAbstract_61fb4c8c-39f8-4826-88e1-4c5e8456f47f" xlink:to="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses_5e484bfd-588a-4781-adc1-6d65797b198c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_6b082d5d-e9c0-41ad-ade2-4648d50c7cc6" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_AdditionalCashFlowDisclosuresAbstract_61fb4c8c-39f8-4826-88e1-4c5e8456f47f" xlink:to="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_6b082d5d-e9c0-41ad-ade2-4648d50c7cc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables_962f5c76-cd31-4c0e-9bea-1cd3abe7dd85" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_AdditionalCashFlowDisclosuresAbstract_61fb4c8c-39f8-4826-88e1-4c5e8456f47f" xlink:to="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables_962f5c76-cd31-4c0e-9bea-1cd3abe7dd85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet_22fbb1f4-d412-4016-959f-b79ba3cd8a6d" xlink:href="oncyf-20241231.xsd#oncyf_IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_AdditionalCashFlowDisclosuresAbstract_61fb4c8c-39f8-4826-88e1-4c5e8456f47f" xlink:to="loc_oncyf_IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet_22fbb1f4-d412-4016-959f-b79ba3cd8a6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_d10ad9ef-7ee5-41c7-b586-23ddf8716cbf" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseInWorkingCapital"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_AdditionalCashFlowDisclosuresAbstract_61fb4c8c-39f8-4826-88e1-4c5e8456f47f" xlink:to="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_d10ad9ef-7ee5-41c7-b586-23ddf8716cbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresOtherCashFlowDisclosuresDetails" xlink:type="simple" xlink:href="oncyf-20241231.xsd#AdditionalCashFlowDisclosuresOtherCashFlowDisclosuresDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresOtherCashFlowDisclosuresDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_AdditionalCashFlowDisclosuresAbstract_c890a9c3-ee43-462f-812d-25975b435a0c" xlink:href="oncyf-20241231.xsd#oncyf_AdditionalCashFlowDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ProceedsfromInterestReceived_d5aa9849-4868-49cc-9319-31d9253d7f01" xlink:href="oncyf-20241231.xsd#oncyf_ProceedsfromInterestReceived"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_AdditionalCashFlowDisclosuresAbstract_c890a9c3-ee43-462f-812d-25975b435a0c" xlink:to="loc_oncyf_ProceedsfromInterestReceived_d5aa9849-4868-49cc-9319-31d9253d7f01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxesPaidRefund_6d934079-686c-4b3c-a519-ed6998a2889b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeTaxesPaidRefund"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_AdditionalCashFlowDisclosuresAbstract_c890a9c3-ee43-462f-812d-25975b435a0c" xlink:to="loc_ifrs-full_IncomeTaxesPaidRefund_6d934079-686c-4b3c-a519-ed6998a2889b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/EconomicDependenceDetails" xlink:type="simple" xlink:href="oncyf-20241231.xsd#EconomicDependenceDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/EconomicDependenceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureOfEconomicDependenceAbstract_99fc4755-8d5d-4d4f-a943-f907bea18c53" xlink:href="oncyf-20241231.xsd#oncyf_DisclosureOfEconomicDependenceAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ConcentrationRisk1Table_4b105fdd-3d97-448e-8a7e-67c56385d22f" xlink:href="oncyf-20241231.xsd#oncyf_ConcentrationRisk1Table"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfEconomicDependenceAbstract_99fc4755-8d5d-4d4f-a943-f907bea18c53" xlink:to="loc_oncyf_ConcentrationRisk1Table_4b105fdd-3d97-448e-8a7e-67c56385d22f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ConcentrationRiskType1Axis_f3c9e268-7bb1-404f-8b28-3297a4b03b9d" xlink:href="oncyf-20241231.xsd#oncyf_ConcentrationRiskType1Axis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ConcentrationRisk1Table_4b105fdd-3d97-448e-8a7e-67c56385d22f" xlink:to="loc_oncyf_ConcentrationRiskType1Axis_f3c9e268-7bb1-404f-8b28-3297a4b03b9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ConcentrationRiskType1Domain_ef686678-d8db-43b9-a637-c1399e54634e" xlink:href="oncyf-20241231.xsd#oncyf_ConcentrationRiskType1Domain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ConcentrationRiskType1Axis_f3c9e268-7bb1-404f-8b28-3297a4b03b9d" xlink:to="loc_oncyf_ConcentrationRiskType1Domain_ef686678-d8db-43b9-a637-c1399e54634e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SupplierConcentrationRisk1Member_bc84f8f6-603e-43e7-8c3f-bf7261d71c07" xlink:href="oncyf-20241231.xsd#oncyf_SupplierConcentrationRisk1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ConcentrationRiskType1Domain_ef686678-d8db-43b9-a637-c1399e54634e" xlink:to="loc_oncyf_SupplierConcentrationRisk1Member_bc84f8f6-603e-43e7-8c3f-bf7261d71c07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ConcentrationRiskType1LineItems_23b51b3e-8fdc-4762-8766-772c239208e1" xlink:href="oncyf-20241231.xsd#oncyf_ConcentrationRiskType1LineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ConcentrationRisk1Table_4b105fdd-3d97-448e-8a7e-67c56385d22f" xlink:to="loc_oncyf_ConcentrationRiskType1LineItems_23b51b3e-8fdc-4762-8766-772c239208e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ConcentrationRiskNumber_9f43bec9-d1f9-42ad-8a83-7acb1b2fd04c" xlink:href="oncyf-20241231.xsd#oncyf_ConcentrationRiskNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ConcentrationRiskType1LineItems_23b51b3e-8fdc-4762-8766-772c239208e1" xlink:to="loc_oncyf_ConcentrationRiskNumber_9f43bec9-d1f9-42ad-8a83-7acb1b2fd04c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ComponentsofExpensesDetails" xlink:type="simple" xlink:href="oncyf-20241231.xsd#ComponentsofExpensesDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ComponentsofExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_f0c9b684-cf8a-4506-a8f4-30b3828759f1" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OtherExpensesAndAdjustmentsTable_10aaf894-a867-4647-89c0-94c1d815e3b5" xlink:href="oncyf-20241231.xsd#oncyf_OtherExpensesAndAdjustmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_f0c9b684-cf8a-4506-a8f4-30b3828759f1" xlink:to="loc_oncyf_OtherExpensesAndAdjustmentsTable_10aaf894-a867-4647-89c0-94c1d815e3b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IncomeStatementLocation1Axis_383eab99-bd7d-43ed-a355-ca1a2142e70f" xlink:href="oncyf-20241231.xsd#oncyf_IncomeStatementLocation1Axis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_OtherExpensesAndAdjustmentsTable_10aaf894-a867-4647-89c0-94c1d815e3b5" xlink:to="loc_oncyf_IncomeStatementLocation1Axis_383eab99-bd7d-43ed-a355-ca1a2142e70f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IncomeStatementLocation1Domain_74591eff-14ba-4142-9c60-45fcdbf32934" xlink:href="oncyf-20241231.xsd#oncyf_IncomeStatementLocation1Domain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_IncomeStatementLocation1Axis_383eab99-bd7d-43ed-a355-ca1a2142e70f" xlink:to="loc_oncyf_IncomeStatementLocation1Domain_74591eff-14ba-4142-9c60-45fcdbf32934" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ResearchAndDevelopmentExpense1Member_9c86cb0d-ba0d-40ed-9be4-6a667080e8cc" xlink:href="oncyf-20241231.xsd#oncyf_ResearchAndDevelopmentExpense1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_IncomeStatementLocation1Domain_74591eff-14ba-4142-9c60-45fcdbf32934" xlink:to="loc_oncyf_ResearchAndDevelopmentExpense1Member_9c86cb0d-ba0d-40ed-9be4-6a667080e8cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_GeneralAndAdministrativeExpense1Member_303be746-8c33-4008-abe4-4b8d8f4892e7" xlink:href="oncyf-20241231.xsd#oncyf_GeneralAndAdministrativeExpense1Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_IncomeStatementLocation1Domain_74591eff-14ba-4142-9c60-45fcdbf32934" xlink:to="loc_oncyf_GeneralAndAdministrativeExpense1Member_303be746-8c33-4008-abe4-4b8d8f4892e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OtherExpensesAndAdjustmentsLineItems_fff24148-7a9b-4271-bd03-dfb8153e8945" xlink:href="oncyf-20241231.xsd#oncyf_OtherExpensesAndAdjustmentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_OtherExpensesAndAdjustmentsTable_10aaf894-a867-4647-89c0-94c1d815e3b5" xlink:to="loc_oncyf_OtherExpensesAndAdjustmentsLineItems_fff24148-7a9b-4271-bd03-dfb8153e8945" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ResearchAndDevelopmentExpense1Abstract_9437dc3c-e525-4971-9d5a-a516dbc63f7c" xlink:href="oncyf-20241231.xsd#oncyf_ResearchAndDevelopmentExpense1Abstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_OtherExpensesAndAdjustmentsLineItems_fff24148-7a9b-4271-bd03-dfb8153e8945" xlink:to="loc_oncyf_ResearchAndDevelopmentExpense1Abstract_9437dc3c-e525-4971-9d5a-a516dbc63f7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ClinicalTrialExpense_23eac73c-9c87-4475-b741-dba8a9b864cc" xlink:href="oncyf-20241231.xsd#oncyf_ClinicalTrialExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ResearchAndDevelopmentExpense1Abstract_9437dc3c-e525-4971-9d5a-a516dbc63f7c" xlink:to="loc_oncyf_ClinicalTrialExpense_23eac73c-9c87-4475-b741-dba8a9b864cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ManufacturingExpense_51b3e38e-a7c0-426b-bf51-43db1dc44bdb" xlink:href="oncyf-20241231.xsd#oncyf_ManufacturingExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ResearchAndDevelopmentExpense1Abstract_9437dc3c-e525-4971-9d5a-a516dbc63f7c" xlink:to="loc_oncyf_ManufacturingExpense_51b3e38e-a7c0-426b-bf51-43db1dc44bdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IntellectualPropertyExpense_2e293b43-8124-4e00-af6a-6187b972a23b" xlink:href="oncyf-20241231.xsd#oncyf_IntellectualPropertyExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ResearchAndDevelopmentExpense1Abstract_9437dc3c-e525-4971-9d5a-a516dbc63f7c" xlink:to="loc_oncyf_IntellectualPropertyExpense_2e293b43-8124-4e00-af6a-6187b972a23b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TranslationalScienceExpense_f25966f1-57cc-4ce5-b608-e0c4105c0032" xlink:href="oncyf-20241231.xsd#oncyf_TranslationalScienceExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ResearchAndDevelopmentExpense1Abstract_9437dc3c-e525-4971-9d5a-a516dbc63f7c" xlink:to="loc_oncyf_TranslationalScienceExpense_f25966f1-57cc-4ce5-b608-e0c4105c0032" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherEmployeeExpense_e030288a-2818-4f0d-be4d-5d47abf9c47b" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherEmployeeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ResearchAndDevelopmentExpense1Abstract_9437dc3c-e525-4971-9d5a-a516dbc63f7c" xlink:to="loc_ifrs-full_OtherEmployeeExpense_e030288a-2818-4f0d-be4d-5d47abf9c47b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_364e179c-92fb-4d45-8a0d-1ed2003f179d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ResearchAndDevelopmentExpense1Abstract_9437dc3c-e525-4971-9d5a-a516dbc63f7c" xlink:to="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_364e179c-92fb-4d45-8a0d-1ed2003f179d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MiscellaneousOtherOperatingExpense_bfb5cedd-c0a6-4cb6-9fea-ad7812087fd4" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MiscellaneousOtherOperatingExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ResearchAndDevelopmentExpense1Abstract_9437dc3c-e525-4971-9d5a-a516dbc63f7c" xlink:to="loc_ifrs-full_MiscellaneousOtherOperatingExpense_bfb5cedd-c0a6-4cb6-9fea-ad7812087fd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense_82aab485-3a73-495a-82c6-9747f6c440cf" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ResearchAndDevelopmentExpense1Abstract_9437dc3c-e525-4971-9d5a-a516dbc63f7c" xlink:to="loc_ifrs-full_ResearchAndDevelopmentExpense_82aab485-3a73-495a-82c6-9747f6c440cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_GeneralAndAdministrativeExpense1Abstract_6ea532c4-2a31-47ef-bf29-9ea52b67246b" xlink:href="oncyf-20241231.xsd#oncyf_GeneralAndAdministrativeExpense1Abstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_OtherExpensesAndAdjustmentsLineItems_fff24148-7a9b-4271-bd03-dfb8153e8945" xlink:to="loc_oncyf_GeneralAndAdministrativeExpense1Abstract_6ea532c4-2a31-47ef-bf29-9ea52b67246b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_PublicCompanyExpense_36bcf88f-3384-4cc8-9de0-814ade92d892" xlink:href="oncyf-20241231.xsd#oncyf_PublicCompanyExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_GeneralAndAdministrativeExpense1Abstract_6ea532c4-2a31-47ef-bf29-9ea52b67246b" xlink:to="loc_oncyf_PublicCompanyExpense_36bcf88f-3384-4cc8-9de0-814ade92d892" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OfficeExpenses_c45fdd4a-d777-473a-a842-bd654a3a4df7" xlink:href="oncyf-20241231.xsd#oncyf_OfficeExpenses"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_GeneralAndAdministrativeExpense1Abstract_6ea532c4-2a31-47ef-bf29-9ea52b67246b" xlink:to="loc_oncyf_OfficeExpenses_c45fdd4a-d777-473a-a842-bd654a3a4df7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmortisationExpense_a6acdcc6-ebf4-4beb-9b39-3e5df350253f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AmortisationExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_GeneralAndAdministrativeExpense1Abstract_6ea532c4-2a31-47ef-bf29-9ea52b67246b" xlink:to="loc_ifrs-full_AmortisationExpense_a6acdcc6-ebf4-4beb-9b39-3e5df350253f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DepreciationRightofuseAssets_fdbe8601-532d-4dea-9f3b-b86e37b8bb70" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DepreciationRightofuseAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_GeneralAndAdministrativeExpense1Abstract_6ea532c4-2a31-47ef-bf29-9ea52b67246b" xlink:to="loc_ifrs-full_DepreciationRightofuseAssets_fdbe8601-532d-4dea-9f3b-b86e37b8bb70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeneralAndAdministrativeExpense_f55a0ad3-fd22-4bab-bb84-280c52310583" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_GeneralAndAdministrativeExpense1Abstract_6ea532c4-2a31-47ef-bf29-9ea52b67246b" xlink:to="loc_ifrs-full_GeneralAndAdministrativeExpense_f55a0ad3-fd22-4bab-bb84-280c52310583" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EmployeeBenefitsExpense_63a5922c-b75e-44e7-ab88-4d5eb2c4409c" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EmployeeBenefitsExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_OtherExpensesAndAdjustmentsLineItems_fff24148-7a9b-4271-bd03-dfb8153e8945" xlink:to="loc_ifrs-full_EmployeeBenefitsExpense_63a5922c-b75e-44e7-ab88-4d5eb2c4409c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/SegmentDisclosuresDetails" xlink:type="simple" xlink:href="oncyf-20241231.xsd#SegmentDisclosuresDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/SegmentDisclosuresDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SegmentDisclosuresAbstract_99c85e9f-e98f-40cb-8021-ee600b33199e" xlink:href="oncyf-20241231.xsd#oncyf_SegmentDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfGeographicalAreasTable_5afb6a5a-bfab-4694-bd6a-e7d3107944d0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfGeographicalAreasTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SegmentDisclosuresAbstract_99c85e9f-e98f-40cb-8021-ee600b33199e" xlink:to="loc_ifrs-full_DisclosureOfGeographicalAreasTable_5afb6a5a-bfab-4694-bd6a-e7d3107944d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasAxis_c922e06f-a3d5-448d-a0ae-30ee1b76b22d" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeographicalAreasAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasTable_5afb6a5a-bfab-4694-bd6a-e7d3107944d0" xlink:to="loc_ifrs-full_GeographicalAreasAxis_c922e06f-a3d5-448d-a0ae-30ee1b76b22d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeographicalAreasDomain_4b5c880f-9095-47cf-be02-d17124ebe3d9" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeographicalAreasDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasAxis_c922e06f-a3d5-448d-a0ae-30ee1b76b22d" xlink:to="loc_ifrs-full_GeographicalAreasDomain_4b5c880f-9095-47cf-be02-d17124ebe3d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_1a767b8d-accc-4682-8629-36f366f10330" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_CA"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasDomain_4b5c880f-9095-47cf-be02-d17124ebe3d9" xlink:to="loc_country_CA_1a767b8d-accc-4682-8629-36f366f10330" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_RestOfWorldMember_8edbf904-6a0f-41b1-94c2-b3480c3c80fb" xlink:href="oncyf-20241231.xsd#oncyf_RestOfWorldMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_GeographicalAreasDomain_4b5c880f-9095-47cf-be02-d17124ebe3d9" xlink:to="loc_oncyf_RestOfWorldMember_8edbf904-6a0f-41b1-94c2-b3480c3c80fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_cc3a6e9f-acc7-4758-ba6b-3cb2dbeaced2" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfGeographicalAreasLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasTable_5afb6a5a-bfab-4694-bd6a-e7d3107944d0" xlink:to="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_cc3a6e9f-acc7-4758-ba6b-3cb2dbeaced2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_NumberOfReportableSegments1_39da2b3a-9e61-42b8-8b10-0082c6e7337f" xlink:href="oncyf-20241231.xsd#oncyf_NumberOfReportableSegments1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_cc3a6e9f-acc7-4758-ba6b-3cb2dbeaced2" xlink:to="loc_oncyf_NumberOfReportableSegments1_39da2b3a-9e61-42b8-8b10-0082c6e7337f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_1cfd6e4a-cc7f-40ae-b7b3-1909b77a1afc" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_cc3a6e9f-acc7-4758-ba6b-3cb2dbeaced2" xlink:to="loc_ifrs-full_PropertyPlantAndEquipment_1cfd6e4a-cc7f-40ae-b7b3-1909b77a1afc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RightofuseAssets_6c2a158e-a577-442e-a82f-994ee42ac173" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RightofuseAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfGeographicalAreasLineItems_cc3a6e9f-acc7-4758-ba6b-3cb2dbeaced2" xlink:to="loc_ifrs-full_RightofuseAssets_6c2a158e-a577-442e-a82f-994ee42ac173" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="oncyf-20241231.xsd#RelatedPartyTransactionsDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofrelatedpartyAbstract_508a9b85-ac84-4803-bced-120ad4c81af4" xlink:href="oncyf-20241231.xsd#oncyf_DisclosureofrelatedpartyAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_62eddc3a-1895-48c2-9ebf-9734b62a82b0" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofrelatedpartyAbstract_508a9b85-ac84-4803-bced-120ad4c81af4" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_62eddc3a-1895-48c2-9ebf-9734b62a82b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits_4a67dbfa-e3fc-4bb2-8a89-b309ff06992e" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofrelatedpartyAbstract_508a9b85-ac84-4803-bced-120ad4c81af4" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits_4a67dbfa-e3fc-4bb2-8a89-b309ff06992e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_5567e88d-e8b1-4e00-adbf-10a4dcccdc75" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofrelatedpartyAbstract_508a9b85-ac84-4803-bced-120ad4c81af4" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_5567e88d-e8b1-4e00-adbf-10a4dcccdc75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensation_6ffcd565-6e90-428e-ad4d-6e7b5b9445a5" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofrelatedpartyAbstract_508a9b85-ac84-4803-bced-120ad4c81af4" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensation_6ffcd565-6e90-428e-ad4d-6e7b5b9445a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="oncyf-20241231.xsd#SubsequentEventsDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofeventsafterreportingperiodAbstract_853f4351-ae35-4714-951f-40279b72a97e" xlink:href="oncyf-20241231.xsd#oncyf_DisclosureofeventsafterreportingperiodAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_b43cc972-7a64-4ff7-80d2-35c571850eba" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofeventsafterreportingperiodAbstract_853f4351-ae35-4714-951f-40279b72a97e" xlink:to="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_b43cc972-7a64-4ff7-80d2-35c571850eba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_61b4454c-521b-42f3-bcba-a34e936bc582" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_b43cc972-7a64-4ff7-80d2-35c571850eba" xlink:to="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_61b4454c-521b-42f3-bcba-a34e936bc582" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_e949be60-834f-4cc2-8189-59c442968c80" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_61b4454c-521b-42f3-bcba-a34e936bc582" xlink:to="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_e949be60-834f-4cc2-8189-59c442968c80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MajorOrdinaryShareTransactionsMember_54b74790-1131-4fe0-8430-17d1a3b32f2f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MajorOrdinaryShareTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_e949be60-834f-4cc2-8189-59c442968c80" xlink:to="loc_ifrs-full_MajorOrdinaryShareTransactionsMember_54b74790-1131-4fe0-8430-17d1a3b32f2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_01089746-575e-48ed-9ed6-0bca660f2c9f" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_b43cc972-7a64-4ff7-80d2-35c571850eba" xlink:to="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_01089746-575e-48ed-9ed6-0bca660f2c9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IssueOfEquityShares_908af79e-e3ef-4ff6-9e18-4bf32c14ce50" xlink:href="oncyf-20241231.xsd#oncyf_IssueOfEquityShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_01089746-575e-48ed-9ed6-0bca660f2c9f" xlink:to="loc_oncyf_IssueOfEquityShares_908af79e-e3ef-4ff6-9e18-4bf32c14ce50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ProceedsFromIssueOfOrdinarySharesGross_5bcdee1d-ff7a-49c0-bf13-08643c143942" xlink:href="oncyf-20241231.xsd#oncyf_ProceedsFromIssueOfOrdinarySharesGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_01089746-575e-48ed-9ed6-0bca660f2c9f" xlink:to="loc_oncyf_ProceedsFromIssueOfOrdinarySharesGross_5bcdee1d-ff7a-49c0-bf13-08643c143942" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IssueOfOrdinarySharesPerShare_9e0a7e7e-ae09-4c7e-bfb5-b80c8c4b1c66" xlink:href="oncyf-20241231.xsd#oncyf_IssueOfOrdinarySharesPerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_01089746-575e-48ed-9ed6-0bca660f2c9f" xlink:to="loc_oncyf_IssueOfOrdinarySharesPerShare_9e0a7e7e-ae09-4c7e-bfb5-b80c8c4b1c66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromIssueOfOrdinaryShares_71bf8f6d-8e49-4c24-898d-258232663f91" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromIssueOfOrdinaryShares"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_01089746-575e-48ed-9ed6-0bca660f2c9f" xlink:to="loc_ifrs-full_ProceedsFromIssueOfOrdinaryShares_71bf8f6d-8e49-4c24-898d-258232663f91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ShareIssueRelatedCostCommissions_7de526bc-b44b-4dd2-a2b0-13046fbda84c" xlink:href="oncyf-20241231.xsd#oncyf_ShareIssueRelatedCostCommissions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_01089746-575e-48ed-9ed6-0bca660f2c9f" xlink:to="loc_oncyf_ShareIssueRelatedCostCommissions_7de526bc-b44b-4dd2-a2b0-13046fbda84c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>oncolyticslogotaglineblueaa.jpg
<TEXT>
begin 644 oncolyticslogotaglineblueaa.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP"$  $! 0(" @(" @(" @(" @(" @("
M @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(!
M 0$! @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M @(" @(" @(" @(" @(" @(" O_  !$(!H\/  ,!(@ "$0$#$0'_Q  ?  $
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M9(2CU'7BI/_:  P# 0 "$0,1 #\ W^
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                       "&H!$
M$JN0EVP"H"GTGF*:J 7!*KD*( *NV@VT*.HU0 J;9#:4I[:$-M +%7:4;2E+
M;\RD-I>SX 9M^+HJ[2D"GM+V? -I>SX +?BZ*@)-5[$([_,!;\71,"7?YB&_
MS 6_%T3D=5*6TO8-I>SX +?BZ*VTHVE*.TO9\!';[4 M^+HJ[2D=M2CMH-M
M+?BZ+C;&VA1VD&H,%='H3:EN "X!;DZ/\P!5!3Z3S$R/0 F!#4B
M
M
M
M
M
M
M
M
M
M
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MXR*A%'*4MI4XH11X%BNCR9'(40#!< H:J3(\ J@E1R*3
M
M
M
M
M
M
M
M
M
M
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M@JC4IZ*GG(H_M L5D>5$<A0U !< I(]2='H 3
M
M
M
M
M
M
M
M
M
M
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M)HOF([T\Z ^D8JW J(I51Y;H]"<'R+C4%!%)VO[0"H""*1
M
M
M
M
M
M
M
M
M
M
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MB]@,W_%BJC]2<I:HO'B-I?2@/I*ULK%9':%5':ENCM28'R+@%)'E1% (@
M
M
M
M
M
M
M
M
M
M
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M"HCNW>#-RMJ"DB=B^HF1W;N L5T?VE0MR9KM 8*P)4=J3
M
M
M
M
M
M
M
M
M
M                                             IN?U $SG:>DI*I
M@JZ $2FKM=R#37CU$JJG4#EDN_LX$>'G)5<2JY$)->M?8##9-M;]$)51$\ZD
MBN]2%!SM08*KI>_44574E5="@YX!55_847/*3G:E%S^P JN>45D*+I"B]_6
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M1:XK(H
M
M
M
M
M
M
M
M
M                                                          (*
MN@5="BJZ@$5=J2@DUUX !7=A*FB;U]@543@4U4').W F52GKKP]I*N_CN)7/
MW>8'$F5=.'K4HN>2N=J4G.T )E7M*2O*;W^TH.D *BO["BKBDYY0<_7U %1[
MRBY^[>4EDW*6SY._6 5W2E!TGJ+=TNA;.F +E9>_66SIBW?(45> 5W2%!9"@
M^3]9;OE[_0 73GH4'S%D^8H/E +QTQ068LUD[J4G2=T +MTI0VRT6?0H.FU]
M'?OP +YTGH*#IT+%TB]NA363UJO5U\43AQZ_1VZ!?B[2^5F5;F]WJR;3]!?+
M-WW_ #%-9%7BB>E2TZ14X)ZTWI[4W?"?S&*\9VBQ4<EROMVMEEM\>O25]WN%
M);**/1-5VZNNF@IVZ)OWR:Z><YTZ;F]V,92;X**;^9._>LCYU*L8QWI2C%?I
M24?EE8_K%D7K4D<].M3RTS;YYKDY8.Z1M3F+;[Y51:HZDPK3U>(9-4W-^O4,
M2T;F.5-$?'5/;IO541%/,7-;PFW!M&LL."\M<17][55(ZF_72@PY0RZ[VO9X
MM#>K@Q$7559+0L<NFRUR(NVFR8#4W26)_)X2K9NR<TJ4?VJCC$U?2.O&B<+=
M5<=0WEQA3;JS7?""<OD-H3I=.!)TBKNXK[?@-%W,KPCO/J[NE9A^UX P?3.1
M>B?362OOMUC5=R+)67JZRVN;83[%$P_$FJN5Z2:M2/X-S$YUKE%8HZ5MTS:Q
M1'#/KTM-:)**Q4KD54W)!9Z6B8B-5-6HU&HB>3H;7A=DVD)I.I5P]'K3E*<E
M^PG'_N-*QNVC1=-M4J>)KM<&H1A%]OAR4DOU3I 7.]TE$B.K*NFHVKO1:JHB
MIFJG:BS/8BIYT4^>L>\L_*/"ZO;B/,[ ED<Q51S;EBFSTKD5KD8K=F2K15=M
MJC$:U%<KE1J(JJ<SC%6:6)[ZKG7O$N(+QM*JN2Z7JYW!N]=5:C*JJD8UJJNN
MB-T;P\H_/HJ:./<R.-B)PV6(WJ_ZNRB=2::::[S8L-L<INW38V3[*=-17IE*
M5_0K=O+5\5MTFG[!@(VZYU7+Z$8KY?\ 7HJXPYZKDPV17)4YK6RL5JJB-L=E
MQ1B/:5."-?8;'<8415W(]94CX[3T;J?.F(O")^3C1(J4E1CR][+7*BVS!TM/
MM[.RJ-:E]N-DT=(KG)'M]&UJL59'1MV-=#L'N4=D^C5X\\1.V7C1@GYHQ^TU
M^OMITH_R=+"T_P!2=2W[4T;JU[\)DRDB<[W.P)F+6HU9$8ZKBPY;E=L[HG*V
M.\W%&+(B;3VH]Z1.54;TR;S\TKO"?<*-72FR@Q-,BM5=J?%5H@T>NJ(FPRVU
M&TQ-$77I&NU<OD:&GH#T8;,]$+^IJOOK2^Q)9]QY=3:WIJ3OTU&/O*$%\[D;
M:%5X3]'T;N@R@FZ73ZVLV*8EB1R)N5Z,MB2*G#7>BJG!4/Y_ZI[N7X)*+_.2
M;\Q-4\'8CLZT0O\ TS??5J_Q'4>U'3?]K_\ U4_X3:Q^J>[E^"2A_P Y)_S$
MR]O\)\5&+XWE"KI-M=E:7%#61]'LMT1R36YS]O:V]51=G9V41-=34W!E[.]$
M/_TO_P"RI]LF<EM3TW_:_P#]5/[(HV_K9X3_ (<5L25F3V(&O_\ 724N*[6]
MC5\K18HIK2QRHK=$=M3(NNNBZ:'Z+9/":LKY$;[H9=8]H]SMKQ6?#]PV7(Y4
MC:Q7UMO54<S>YWD]$J[&DFG2+I> Z\MF>B'_ %$U[VK)?8S[T]K6FXN_3TY=
MDZ46OD:-ZO#_ (1QR>:Q6I54V8]H7K?7X3HIV(NRCM46SX@NDJMVE5F^-%7B
MK&IJJ?0.%.?-Y+UV<V-N92VZ9VNL=ZPGC.U-:B(J^565-@;;]51JZ(VM>KG*
MUKM-I%.>F#SZNR?1C\26)I]U12^246CTJ&V?2L7>I#"U/^5*.75>,[G37P7S
MA&1N(GMCLN;F7U?,_32FAQ3:6U2:KHW;I9*ED\:KHNB/C:JZ:Z'U#9\8VJX[
M"V^Z6ZNVT1S/$ZZEJMM':;*M2"5ZJBZIINWZIVG*$DC:]-'M:Y..CDUU]NNG
ML^ _H,.8HNEF=MV:Z7*T/UU1]JKZJW.1VJ.VMJCEIW;6TFNNK=%1':JNFGBX
MG8]2=^AQLT^JI3A+T[CB_D-APNW.M?V;1].2_P"%6<7_ /L4D_2=7]7*FY4T
M7SIH.EZCF99><XMGMA5&-L6:^-:6)FB)3SWB:X4SD:W1B207'QILB-151=O7
M:5=K=O1?N_+GPA+E'6)86W&X8-Q?#'LM<S$>%64\SH^"IXUA:NPW+TNF]LTS
M:G1Z(^1DS=J-^O8S9'CX?D:U"MW[]+N7A1:7G:76T;/@]M6CI_E\/BJ#Y^#3
MJI=?BU%)KNA?J3-^':3T$Z2+U+P-2_*OPGB%>CCQQE140Z:)+6X1Q!#5](O^
M&VVWNFH5IVM7BSW6K%<F]';2[)Z:Y2\_#R<L3]'%5XJK<)5#D3:CQ19ZZBIX
MW+IHQ:ZFCJZ5SE775S51F[553B:GC=2-*8>^_A*LTO;4DJD>_>@Y+TV-QT=M
M!T/BDNCQU*+?M:V]1EW6J*-_-='L^V1>Q%7TE1)5\_?T'XUE;GK@O&U,E5@[
M%F',3P*SI%6Q7FWW22)G6L\%'42STRM_A-GBB<WK0_5E?HNB\>.G7V)N_0:S
M.A.#W9PG"7Z4-WY&U+SV9MU&O3J+>IU*<U^C-/Y4G'Y491LY69+ZC#H].ZHI
M4;)V*?(^M_Q_L9KI/056RF%24KLJ._?](!F6S%=LQATE3T%9) #-,F*[9$4P
MC92NV8 S22>LK-D_48ALO?K+EL@!EFS=I<-EW=1B4?ZRJR0 S+7\/B*[93#M
ME+IDH!E62%=KS%-D["Z9)N ,DUY6:_V&-:_1-2NU_8 9)KRLCM3'-D[]17:\
M OT>5FN]A8H_M*K7: %WKIYT*B*6['E1.U "ON7TD4=IQX%%%]I41>T&;E8B
MBZ%+AZ"=% :\Y<([4B4$70JM=J#!,
M
M
M
M
M
M
M
M
M
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M$UZW5TE1M*_5&^ZO,D01$ZD3NNOQD0#TSR0 !Z?2/,O1\P  ]'H08
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MJM<BDQ23?O3BA.UVH,M?[%9KRH6Y4:_J!Q*@
M
M
M
M
M
M
M
M
M
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M[S;\[\Q#>E-.8S&U.DQ6(K5IO-=)*Z7<E:*[-V*RXL=_1NTW=F[< #T;GDV
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MW4 5
M
M
M
M
M
M
M
M
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M7:[4 N44J<?26R=O=2HUVH!7:[J4G*6NOI[29KNI0+%=KNTJ%N5&OZ@"H
M
M
M
M
M
M
M
M
M
M                        2N71"*KH454 @JDKG:$570I^=?4G &4/.O'J
M0D<[K"KVE)5]@,,CKUKPZOTE-[_T(0<[0H:@!5[2@Y^X.=["V<X BYY;/?\
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MT7=Y_F*B* 5FN)REQ37K0G:[4&;<RNUQ.6Z*5FNU!@F
M
M
M
M
M
M
M
M
M
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M% :\Y<(NI$HM70K P
M
M
M
M
M
M
M
M
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M=="DU>KK0JHNNY?4#*?H*I.UW446KU$X#5BX!(QVI.#
M
M
M
M
M
M
M
M
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MFE!SD_,F8LR@2Y8PP/)6XSRWB<^IE1(>DQ-A6E<[>R[PP)I=;?3JYJ>[5)'
MZ.!46X4,2Q2U,U@M4MH]#&[M#%)8?$^*I7?1U9=E\HR?N>%^#M8K-KKLKQ&
M4L1A+XG"YRM'.M0CU2CQJ17*5FTK;T>+/"X$$<CD1R*BHNBHJ;T5%WIHJ;E1
M4WIIQ3>A$DXB(     )@+O3MX[E7=OUU3?N375=>'G/>7FE^>+NN3]938&S!
MK*V\985<L45%4RK+5U^!'J[8?/0)L/FJ+ _:9XY:4VG4"M\9ML<:/J:>?P:'
M?V>WT>@\O2^A\/CJ$J&(@I0EDG9;T)<I0=LI1X]3X/(]C06G<3H[$0Q&%FX3
MC;*[W9QYPFDUO1DLK/AQ3BU<ZO6$<76N^6V@O5DN-%=K3=*6&NMUSMM5#64%
M?1U#$?#54E5 ^2&>GE:Y%CEC>YCT7<O%$_JHWZ;TW]J?/W]AH$<TSSM5TR,N
ME-A#%;JB[94W6O5*F)KG25V#JFLE7I+Y:8%VTJ*%9WI+>K1')#TD2SU] Y]:
MQ:6NWRL'8PME]ME!>K+7TUSM-TI8:VWU]%*R:EJZ6H8DD4\$K'/:^-[5U3RM
M6[VN1KFJU*OZU:IUM%UMV5YT)M]%6]TEPNN4N4EUEOM3]<L/I>AOTVH8BG%=
M/0;RB^'@OG!^UEQ?9P/[R-Z%W&\PL;]/G0OXWZ_,:FF;D9F.3SF08_4P+'F0
MBD[]^L S#)#(12&':[4NXG^< S+'%ZQYAXI"]8\ RK7ERUWL,:QY=L> 9)KB
MLUWL+%CBY:NH!>HNOIZBHU=4+:-WM*VO6GL +A-Z>="9JZE%%)^Q4]8%RLBE
M9%+=%U)VJ 5@
M
M
M
M
M
M
M
M
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MW %9NY="H4DW[NOJ)VNU!GM*[%)R@BZ%9%!@B
M
M
M
M
M
M
M
M
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M6KV>;U&<?%UH63X@#"/B3J+&1O:9Q\99R1:]0!A7L+9[._?>99T:IWX%H^,
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MTLT4N&._2 7"*5.&_M*#=V[V%5%Z@$5B=CNHHM7J)P&7 )6KJA,
M
M
M
M
M
M
M
M
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M9?A?ZD-$[2&J)Y^_H)T:A,#-UU7^0I:^;X"._L0J "ZZOE*>B]B#1>Q/@*@
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MT(U*34J4XJ4))W3B^:*D8O#5*-6=*K%PJ4Y.$X25I1E')J2^;K68 !]CK@
M']+@[&-UP]=[9?[)73VR]6>NIKE:[C32.CJ*.NI9&RT\\;V^4BM>U-I/L7L5
MS'HK'.1>AOS6G.)VO/\ P&RMJ%AH<=8<Z&W8RLS5:W2H5G][7RW,1=9+3=HV
M](Q=&NHZUM502-V8(9ZGG1GT]R/>5GBG)7'=HQWA63;J*)Z076TR2/918ALL
MSV>/V>M1J.V4J(V[5+4I'(ZBK&0521RMCDIYM+UTU4AI+#6BDL32O*A/FV_&
MA)Y>#+CGDI9Y9F^Z@ZYST1BO";>$K6CB*>;2:RC5BL\X<TLW&Z=[1MU F/\
M;U&1ADU/G[D\9^X;S.P=8L<82K$K+)?J1M33;6RE333-\BKMU;&U7+%<*"='
MTU7#KJR5FJ)LN:J_ND3NOON*L5Z,J<Y0FG&492C*+R:E%V::>:S+C8>O"K3A
M5IR4H3C&49+-.,E=-/FFN#,W$XR$4AA(WZH7T4A\CZF=8[<BEY&\Q$3^'?U%
M\QWL ,Q&\OHWF'B=O+Z-WP &6C?J7;'&,C=V%ZQW6 9)CBNU=Y8,7J+MJ@%Z
MG#T%1%+9B]G$K\%UZE *RKNU3B5$4I,7>3-W+H#EQ\R*S5WE8MRLUVH.),
M
M
M
M
M
M
M
M
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MS#R]FKPOB)Q?Y*BWE!_I5,T^:CWHQ"K\&G'T(GMT1$U[$X(0 + _)W%9>_,
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M1T O^+(EV4(DZ,]1,C$!@I$^PI5 !31A'80G !+L)V#83L)@ 2["=@V$["8
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M*7+'?  7#7:E7BGG0H*O65F*#*94:NI4:NA23<NG:3@P7 )6KN)@
M
M
M
M
M
M
M
M
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MW[# (LC_ %E]''W[!%&7S&:( 1C9YB[C9^D@QA?1Q $8HR]9'YA&SS%VQOM
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M7109Y>C[2LQ2L6Y7:NX&"(
M
M
M
M
M
M
M
M
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MD)MG7C["9&^TF!EV\_6"9&ZD485$30'$@C="8
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M$JHI48I19UH3HH,%P B@
M
M
M
M
M
M
M
M
M         $KEW$Q2>O4 2%-=Z^@G5=Q3ZE7M!E?CSHE<N\I=JDSE^$I.=N]'
MT P47J6[U^ JJO6I:2.^$ HO<6DCBL]=Y82.W]^P HRN,?*XN9'=_,8^5P!;
M2*6,KMQ<O=UF,E> 6TK^)CY7%>1WZ3'3/U^+T!A%L]_6>='.B<LN'(_*&_XI
MA?&N)+EIAS!U*]6JL^(KI')'!4R1*YCGTEGIFU%WK4:]BNBI&T\4B5-3 CO1
M&1>_Q(OF7K-"#GVN6>W,S-R?"MGJUGPMEE)6V"G='(JP5V)>E2/$E8Q&N5KV
MTM3$EF:_K?156RLD#XGNW+4;0'J_'THR6]1HM5:W5NKA!^_:M;L-%VA:R?R;
MHZK.+2KU[T*"OGO33WIKG[&EO)]=EU)^)U?<)ZN>>KJIY:JJJIIJFJJIW])-
M4U-1(Z:>>5^[:DFE>^21=-5D<]RHFNB6@[]^_P .JJ+6J*2LDDEP2X6Y6\Q3
M)R;=W>[XW=W?G=]=^( !DP "#G(B*JKHB)JOH3CY_,FB*JJJ;A^/QW\!^.KS
M^;B?9'(*Y(=SSOS.P_@2A26&WU$BW'$]TC:JLL^&:!S'W.L<Y?)2>9'1VZW,
M7[9<*VFU3HFRR1=)?+_ EIPQ9;5AZQ4<5!9K)0TUMME%"B-CIZ2DA9!$Q-E&
MHKD8Q%>_9;MOU>J;>KCR7YE'D)?W(,K::]7NA\6QUF##17R_-EC1M5:K6YCY
MK#8)7*NVR6BI:CQNX0.1B4]QJZJFT>Z)SY/9QK?9WT^DK%M$UE]7XN5*$KX?
M#MPIV>4Y)^'4:3X-I1CV0OS+=;+M4OY.P2K55;&8M1G4DUG2I\84HWX-)[T^
MMSZDBI&TO&1[D)(F>WOWT+Z&/OV$>7?-W^SL).Z_QER_U*T3-"_B84HHS)11
M@%6&,OF-^ D8TNXF %:-OZ2_8SOV%.-FA>1L )V-X%XQOFWDC6%VQOM )F,+
MF-I!C2X:WJ (M34KL9N\P8SV%5$U]'4@!!$U]'8540@3::\.P&4B;S)P[2=$
MT((W0G1-09;ZN! JM;H3(FA$'$
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M#%+MJ[@"]3>GH*B*4(W%5J[] "NJ[T7M*A23@OM)V+N!FV5RNQ2<H-7>5P8
M
M
M
M
M
M
M
M
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M^9.'6H!%%1?5U%5K=?02HA/YD]8,I#CN0J(F@1-"9$ ;_'6$34K(F@1-"(,
M
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MT4NV;TT *S2=NY="BU=4*SEX*#**A71=2AJ5&+U P5
M
M
M
M
M
M
M
M
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MQO)=,;["_B9P+>)O?SF3A8@!<1M+V)G?SE&-/T&0B8 5HVE]&THQL[]I?QM
M*C&?H+MC/TDC$ZRZC8 5&)UE=J:DK4WZ<"Z:W=Z.H ::>GXBHU-$")UE5$TW
M_  .&[K)VIH2L3K*B RWR";]Q71-"#6Z$P,
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MHW%TQ=X!=)N70JIU^TH:\%[-Q78N\ J,7<5&KO*2;E5"<&6N'<7 ((NJ$08
M
M
M
M
M
M
M
M
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M$: %Q&W]!D8VEM&W]!?QH 5XFE\UO44(4W:EZQ "K&WX"[:FGK*;&^PN6)J
M3QL[^8K:;].I"")HGIW%1J:( 3-0GTU] TZNOK)T30&5^/E(E1C>LE:F\K P
M
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MB>8:-=WH,E"[=H5V+1&8B4R<;OI0PL;OA,I"[AWX@&6B7YC(QNU0P\;C)1.
M,HQ>_M+^->'G,9"[M+]B[@"_C7XR[12Q8I>,7< 7K=Z*A4:O MXW%9O6@!5<
MO7U[_@*Q1ZE\Q5:NX&?]/M*S%W$Y28N\J@P
M
M
M
M
M
M
M
M
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M$T?AJ/!JFI3Y7G+PIO\ :;*/:Y:6]6Z3Q>(O>,JLH0[*='V*"7ZL4^]OAP
M-@-9   /V/D[Y*W',?'F$,!VIKW5F+,0VZRI(U$<E)1U,[%NER>W<YT%JMC*
MRXSHGE]#12+%J](]>H3@_"E!8K5;;):H&TMLL]OH[7;J9FFD-'04[*2F9NW.
M<VGB:CW_ &3WZO?Y;C3;\&[Y.;;WF!BO,FLAVJ7!=JCLMJ>K46/W:Q"U75$J
M:M56S4UJIY6,=&Y-&U4S951LR--TAC>HKMM7TPZN,IX56Z/#4VIVYUJGA?\
M;#<3[;WX%HMBVA%0P-3&27AXR=H/JH4KJ+[I3WVGP:W2XB;P]I>1-U4H1IW\
MQD(&? I%!,Q=QM,E"TM(FF2B: 7D:;B^8W@6T;?@,A"T NHF[B]C9])1C3X"
M_C3X@"LQI>1H4&(7L;4]@!4:FXNHV_2I28F\N--$](!.F]=?456]I(B=1/IU
M=@,I$S6]?P$X*C$ZP)/,G1-"( ,
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M)%+K7=Z "X9Q(L7J*;5X%37?Z087WE5%WE<MRNBZ@R1
M
M
M
M
M
M
M
M
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M1-2LA(Q.LJ P
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M  $47JZS%_QWF+_C\=Q, #)D $BN7L,-@G!+KV_J)C*8
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MKH 1!(JJGSD6KJ84D"8 &0 "&H%R(((I$        $NJZ[N!AL$P(:]A$R
M  "!$           $ "(                  !*J^P F!+KN)D,7  !D
M        E<J]0N"8$NUWWDPN    "57>TCK^@Q<$0 9
M                 !+M(-3%_,$R8$NTA%%,@B"55[]_H)=OCU>I?H[[MQCS
M"Y4!+M=]4^D;7?=])DQ=$P*>VOF^'KX=7H3T^8F:NH,DP)5=H05W9\0!."3:
MW?H(HNH!,"":]9$                             E7J&O?NOT@$P)&JN
MOFZB;4Q<(B"15Z^/?OU!'=_4G?=N,W!."7:[ZI](VN_Z@8NB8$B.[[^^J#5>
MZ*8O^+,S<G!(CEZR"/X_ 9N"H"1'$=KUBX)@
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MT@RE<G:G63D$X%5@,-DZ$0
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M5->W?UG):JXT?%(U>#F.;V<6JG'J.HQR0\V?V=96Y?8O67II;_A&Q5U7*O\
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MZ(TA4I3G3J0H2E"=.3A.+33O&2S75D:PG[=ORK_PVXD_HC!W^[1+^W;<J_\
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M'A:]:G*E6JN,TJ-.+LJ<Y9-)-9Q1OP_#P]>[C["J2IW]JDQ *998  R
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MO>/9)Y$:[3M8\7HS!T:^$G&%2>(5.3E",UNNG)VM*ZXQZC98^JQLN/P28_\
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MX),?_P!)X9_/31T ]:[0_P"9J?OZGWCUW--_GZ7_ $]+^$WB_JL;+C\$F/\
M^D\,_GH^JQLN/P28_P#Z3PS^>FCH!ZUVA_S-3]_4^\>NYIO\_2_Z>E_";Q?U
M6-EQ^"3'_P#2>&?ST?58V7'X),?_ -)X9_/31T ]:[0_YFI^_J?>/7<TW^?I
M?]/2_A-XOZK&RX_!)C_^D\,_GH^JQLN/P28__I/#/YZ:.@'K7:'_ #-3]_4^
M\>NYIO\ /TO^GI?PF\7]5C9<?@DQ_P#TGAG\]'U6-EQ^"3'_ /2>&?STT= /
M6NT/^9J?OZGWCUW--_GZ7_3TOX3>+^JQLN/P28__ *3PS^>CZK&RX_!)C_\
MI/#/YZ:.@'K7:'_,U/W]3[QZ[FF_S]+_ *>E_";Q?U6-EQ^"3'_])X9_/1]5
MC9<?@DQ__2>&?STT= /6NT/^9J?OZGWCUW--_GZ7_3TOX3>+^JQLN/P28_\
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M._$Q\2?$92%O#OP +^-"^B3>6K$X>8OXD^D OHT^$OF-UTT]9;1MWIYC(1H
M7$:%[&G M&)N+YB %=J;RX37VE&-/H+GKT[ "HU."%3BOH)&]O83,3K!E,J%
M9J;BFWB5@8
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M/B^YOM/[2$474I,<BKU\._L[>!50A-/EZ?N+ )D0 9,@
M    &J?X6%]RS*K\9-3^2=[-%\WH/"PON695?C)J?R3O9HOEF]EWDFG\+6^F
MRI.V#RU5^ P_T&  2*1:#9J\%B^[GC'\6]7\O6@UE39J\%B^[GC'\6]7\O6@
MU+7OR1CO@E].!NNSGRWH[X:7U50WY$[^U28E3O[5)BI:^_YRZ8 !D
M            E5VA,2N (ZH05R%)7:>GON3OZ#X6Y=?.)Y9\GS#K;WCN\,9<
M*UD_['\+4#HY\18BGIVMZ1MNM^TCVTL#Y(FUESJ>BH*%)8O&)T?+!%+]\)A:
MM>I&C1A*K5D[1A"+<I/J[,LV^2XV5SJXW&TL-2G6KU(4J--7E4F[02[^>>22
MS;R69]L7W$%#:Z.JN%RK*:@H**"2IK*VLGCIJ2EIXF[4DU143.9%#&QJ:N>]
MS6HG%35LYP?PF#"6$9J["N2%L@QW?H$DIZG&EQ<Z#!EMG^N,5MK@CV:[$U7
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M*#\9?\2VZGPWF1KKEM)PFC-ZA3W<3C+/V&,TH0R_K9K*+7%T_&:ZD;%_+_\
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M!TM#V&?1UXI;^'J-*:X7<>52-VEO0O;@[/(_? 2)P[Z_#\_L)S5S<0
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M"V&R?6OU=@_4E:7\YP:4&F_"G0RC2GQN]VVY)VY1OQ/VG4B2H3$;(E@
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MZ_?)^_>'@?WH8;^1:(A/;)XFC_?8KYJ!8#83XVD^["_XQ^P  @LL0
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MM-^[KX\/5\7J*Q%-^/83.F  9,@
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M#A^BT3A%;QX3J/M<ZLFGYU<IEM*QO3:9QDKW49TZ2[%3I137FD_3<  W$T0
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MX%JQ.LO "O'U=^LK,[21C=WHX%5J: %3J])41-"14X(5 9ZB=B=95)&<"<&
M
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M!KOO5,,>^O'OY57$]["G^M?E+'?&:OTF7CU,\E:/^*TOH@ &OFS
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MYVE\$\3A<1AU)1=:C4I;S5TNDA*-VN=KWM=''FU0:H=6M.;%Y-G_ $>\D/\
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MA_8JO[RG]P]8RO\ V^E^YE_&<I3:3M0(O?CU[^"*NY/-Z51-YU;$YL7DV?\
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M?\.I'>7:X>.EV-$:Z2T)B\')QQ6'J8=_\:$XQ?O:ENCEW)F. !WUZ>Z_VGF
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MTTO8J/ZL7O37NVT[V1#9)@#022P
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M G3[(J$C.LJ-XH#+XLK(1 !@
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M  -?-F                           !*Y-RZ:=_9\9,04-@\(.?GYN?\
MNV95SXCP]0NJ<P\N:>OO5B93QH^KO=G9&L][PW&C6]+45%5! E5:8&O3;N5/
M# B.=4'.+AE:]C'M5'->U'-<U45'([>BHJ<45%UU3<NNO'4[)ZMW::)V>;37
M?JG7JB\/B.=GX05S=ZY/YH-QQAZAZ' 69]777"G2GCTI;+BYKO&KW9W(U5;
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M/\7B#Y'J#I?)P0KEM;\HTOBL/K*I:;8IY,K_ !RI]"F1 !%A,0
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M5^/BQ648*_*$;)=?>2_H'0U+1^$HX2DK1HP2;]U-YSF^-W.6;SR[BH #S3V
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M35"LA(C?-U$Z$2+S][_'^Y-=_F5^_L["( ,F0
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M?67+ "LG%._G*[>OT%%$W^@K)P7OQ )V<"JSB4V<"JP&7Q95  ,
M
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M3;S;;>;=RV5"A3I0C3I0C"G!*,(12C&,5DDDK))  ' ^H
M                        +6>9K&*][VL8Q%>][U1K6M:BN<Y[ET:UK6HK
ME<JZ-1%551$+ER[CP+\(.Y>K\H<G%PO8JI:?&^:,E5AVUK$_2HM6'HX$=B>^
M;GM<QT=--!9Z)S5VO=&[P3M;+!252-]#1.C)XS$T<-3\>K-175%<92?9%+>?
M8FN9Y>F]*TL%A:^*K?DZ,')I63D^$8QO[:4K)=YJD<^'SB=1GMFU7VZSU:OR
MYP!4U5BPG%&Z3H;O6Q*V"^8HGC5VP]]?6,GH[4NB+%9J:FE79EKJJ)/%Q5]/
MKTU]:HB:^Q"5K41$1$T1$T1---R</_V=$7L5%3CJ1+@:+T93P>'I8:DDJ=*"
MBDE9RE[:<G[IW;?:4=TQI6KCL35Q5=WG6FYSSNE'VE.'5&*M%=UP #T'\AYH
M'?J]6NO#Z=W%40=T[^;CQ37335-=3U1YIKFS[SRD<P&VV7QFWX PW)35F.;[
M$KHY&TLCE=!8;;-L.;[L7=K'L16K_>%"D]:YR2M@8_I:2Q]+"4:E>O)0A26]
M*_&ZX1MSDW9)<VTN9Z&B]&UL77I8>A!SJ5I*,;>+VN3Y12SD^4<SZ*YFGF<K
MGRA;LS%^+VU5JRALU:Z"LJ89'4U?B^XTST2:PV>5OEP4<;O(N]T9L/IM])2.
M6L>]]-T.\O<NK'A.R6O#6&K50V2PV6B@M]JM-NIV4U'04=.Q&1001,1&M:U$
M35=[GN5SWN>][E&767=CPE8;3AG#=LI+-8+%0T]LM5KH8VPTM%14L:100Q1I
MQT:FT][E=)+(KY97OE>][O[A&H54UKUJKZ4KN<VXT(M]#13\&*]U/@I5)9;S
MM^BK122N-J=J;A]$8=0@E/$S2>(Q%DI3EQW8<7&G#A&*>?C.\FV2HN_LU*A+
ML_K)C5S<5W)=B  !D               $%(@ \U><GYLK O*/P>^T7Z)MIQ5
M:XY)L(8UHXV^Z=BK=4<D%0BZ-N5EK=$@N=KJE<Q\3UJ:-]'<H:2NI^:QRHN3
M/BW)_'-[R^QM;UM]]LDK%56H_P 3N=OJ.D6@O-IFE:U:JUU\<3U@F8KT;-#4
M4TJI54]1%%US]GOP^(\D^=SYL"R\H[ 4D%-'24.8^'*:KJ<#W^5$B_OA[4EE
ML%SG:BO6RWB2*.*='(]*.H6*OB8KHGMDDC437:> J1PV(FY8.<LG)O\ F\I/
MQT_S?NXY)7<UG=.)]HVSZGI&D\5AH*..IQN]VR]412\22R]DMXDN+LH/*S7,
M=!_3XUP5=\-WBYX?Q!;:NSWRRUU1;;M:J^)8:RWU]*]8ZBFGC77>QZ+LO:KH
MY8U9-"^2&2.1W\P66C.,DG%III----._--<5]Y5*=-P<HR34HNS3333S33ZF
MGDT\TTT  <C@0<U%145$5%3147>BHN[14ZTW\-VO:= /P<SG$GYE9=R958HN
M'C.,\LJ*F@MTM3*KJN[X(:K:2U3N?(NU53V-W1VBKGVG/\7]SI:E$DFZ2;G^
MGU5R).51=LE<T\'9E6ATKG8=N:+=*-CW(RZX?KXWT5^M<[6JB2LJ;=-,^!DC
M7MBKX:*KC:V>EBD9JFN6KL=(X&I22731]DP\K9JI"+>[?W,XW@^]/DC<]1=9
MY:+TA2JMOH*CZ/$1ODZ4VEO6X;T)6G%]C7,ZTK5U34B?PV6^8=JQ9A^RXFL=
M2RML]_ME'=K951N:YL]%701U,#]6.<W:6.1$>C7.1KT<W:734_M]?C^8J7*+
MBVFK--IKFFLFGW%TH5%)*2=U)*2:S33X-/F3  P<P            07J[]2D
M2"]7?J4 AU>KYCER<\S]]/G?[\(_D"RG4;ZO5\QRY.>9^^GSO]^$?R!926-C
M_P#3L1\5_P 2!#&V[R;AOC<?JJAYF  L05>  #X+O^XP^7XY,Z,G@UWWJF&/
M?7CW\JKB>]AX)^#7?>J88]]>/?RJN)[V%/\ 6ORECOC-7Z3+QZF>2M'_ !6E
M]$  U\V8                              @I\@<NKD@6#//++$N7-_:V
M-EWI5EM-Q1NU-9;]2:RVF[T^Y=)*.J5NVFCFRT[YH)&OCE<QWV 2.0^V'Q$Z
M4X5:<G"I3DIPE'C&47=-><Z^+PM.O3G1JQ4Z=2+A.$E=2C)6DGWHX_.<&4]\
MP)BK$6"\344MOQ!A:\5UDNM+*Q[%;544KF]+#MHBS4M7#T5;15+$6&JHJBGJ
MX'R4\T<COS@W9?"8N;H]UK1!R@L*T*.N=@IZ2U9AQ4[/KM98&/;!:L0S-9']
M=DLLKHZ&NJ))6.9:98G2/=3T#>@TFN_?@6WU6T_#26#IXB-HRRA6BGE"LDE)
M=D9>-#]%]=RD^M^K=31>.JX:6\X+PZ$VGX=&3>Z[^V<<XSL\I+JL  ;&C5P?
M5G(GY7&(,C<R\-9DX>UFDLE6UEWM>TK8K[AZJ<V.\V:5VTUC'UE&C_$IW;24
M=PCI:QS)60.AD^4R*+HNOS)WU[.SJ/ABL-"M2G1J14H5(N%12S4H-6LER>;L
M^MI\CL83%5*%6G6I2<:E*<9TY1=G&:?C7YI632YNZX,[ 646;%CQUA>P8QPS
M6QW&PXCME)=[75Q*U4FI*R)LK$>C7.2.:)56&HB5=J*:.2)WE,<?I::_ :4?
M@RO.)+07.MY/F*JQWB=R2LOV7%742-Z.GN$>DM[PMM.\O2OB>^\VA-[&RTMU
MHU>DD]N@?NMM[H5#UGT#/1^,J8:5]Q/?HR?]91DWNN_6O%E^DFN1=K5+6*GI
M/!4L5&RFUNUH)_DZT4E)6>:4O&C^C)$X /"-F    !3<[=WXF&P3.<B&H]X3
M;SA+K-8J#(+"]?T5QQ+%!>,P)J=^DL&&XWJ^V8>5[=\7NW60MK;BC5:LEMH$
MH9.DIKG41+L>\LGE5X?R7RXQ/F-B14?18?H))J:A9(R.HO%UEUAMEGI%D7]T
M7"L=%!JC7K#&LL^S(V)6KRHLY\X<0Y@XMQ#CG%=9X]B3%-SJ+O=ZEJ*V-:F=
M41E/3-<^1T=#0P,AHJ"G621(**FIX=IRQ[1*>S#5EXK%>K*B]BPLEN1DKQJ5
MWXN7522WW^ENKKM#NUS6OU+A5@:4ETV,@W4:DKT\/%K>[I5?%CEXN^[\#\S7
MO]/7QZR []_F!8U%6;]?$ #OWZO;ZM5T1<C_ 'RXY9EW06^HJZBGHZ."2JJZ
MN>&EI*:%NW/45,\C8X((6<7232.;&QNBHYSD:NFITVN9TYN^DY/>4U%;*Z&-
MV.L5NI\08\KOLI$N4E.UE%8X)/LFT&'Z5WBD,6NR^MDN-<K6RUTIK0>#<\W$
MN-<8KGCBJBZ3"V!*UT&#:>HC7H[MC2-NCKJK5=L.IL,,D;-2_;D]V9H)OK4M
ML:LV^.U-WT$ [5-9^EJ1T=2E>%*TL3*+MOU/:TI+_A+.7)S?7%EDMCVJ/1TW
MI3$1]DJK=PB:\2B_&JQ[:CRB^4(]4B"*NXJ$$0B0XE;TW)V0 !D
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M\X_DT_ZRJGXTGQIJW@Y2:WK;LC45J+W[^O\ 054(;),0PO23TE;(  R9
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M4*5MMW;=VVVV^-V[E^8P44HI622274EDD  #D
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MX)W[0"=G K1]92;P0JQ]8#94
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M?T3HRE@\-1PU".[2HP4(\+NW&4NN4I7E)OC)M@ '2/1
M                       !3<OPAL$SUT157@B;_1UG,,YY_EF.SJSYQ3=J
M*K\:PMA6:7!F$^C>CZ9]OL]3-%7W"!S7R1N9=;JE74QS1O6*II$I)F(C7;][
MCG@^55)E#R?<P,2T-6ZCO]QM;\+88GC>K)X;[B-KK;2UE.]N]D]MAFJ+C!(K
M7,9/21=(FPKCET0Q-C8R-B;,<;&L8W@C6M391$UWHB(U$T[$3>39LCT*MZOI
M"<?$]@I-K*^3JOOLXQ75>765]VV:>=L-HZG*V\U7KJ_%>$J2?9=2F[KW/4RH
M "=/]_3F5YOW>;AED ""]]> &?+CR[S]*R<RDON/<68=P5ABCDK[_BBZTMGM
M=+&USE=453E1\TNRBJREI(&S5E9,J;%-203SRJV*)[DZE?-_\B7#.0665ER_
MP[#&^:!/=+$EW5B-JL0XFJX8672\5;_LGK)T,5)1QN78I+;2T='"C8:>-J:Y
M'@PO(&B@I+MR@<0T>M75^.X8R_9/%^YK>U4@Q#?H-I=T]=,UUFIYFM56T<-<
MUDFE=4,;N'1^CUZ:=NOPZ^K1"NFU'6=XC$+ TI/H<,_97?\ *8A<8RMQC27@
MK]+>ZD6BV1:HQPN&>D*L?9\4KT+_ -5AW:THWX2JM[TN%XJ"ZQIINX=GT^?=
MUJ5$7<-")%*1,WX0 !D                      D?U$Y(X,&H#X2SS:T=9
M;&<H7!EK5;C:_%;=F92444CW5=F5%@M^+701ZHLMHF6"@O$L<;52V3Q7&J=T
M%KGD;I8KW[\%]*;EXIN.Q/B_"EOOMKN-FNU)#76N[T55;KA1SL22&IHZR%]/
M402L<BHYDD<BM7=U^9#E=\X[R/*W(G./%^7=0R5;91U3+KA:LE:J)<L*7GI*
MFSU3%5561:9K:BTU6SKLW&V5T.T[HFROL!LKUF=:C+ 5I7G0AOT&^,J-TG#_
M );DL[^(^J!67;#JDL/6AI*A!1I8B;A7C'*,:]FXS?)=*HR?+P\LW,^&P-03
M!]R]/->;KYD(]?8[>@#3YT]2\?: +_)P'X?6;XO@PW+*DQ7EG?\ *2\UCI[S
MEI61UF'VRO1TLV";XYSJ>GCU^N/;8[RRNH]5^MP4-;9Z:)=F-6LVAV[TX\=Z
M*GG^;>AR^^9IY4[LI>4+@.\SS+%9<0U[<%8@17;,24&)9(:*FJ)456QHE%=7
M4%0Z65R-B@\8D\GH]7]05JIV]G="KNTK0BPFD9U*:M2Q25:-EDIIVK17ZWA=
MBDBW6RC3SQFBX4YRWJN$DZ$[\=SC1D_U/!_5)P :"2<            ""]7?
MJ4B07J[]2@$.KU?,<N3GF?OI\[_?A'\@64ZC?5ZOF.7)SS/WT^=_OPC^0+*2
MQL?_ *=B/BO^) AC;=Y-PWQN/U50\S  6(*O  !\%W_<8?+\<F=&3P:[[U3#
M'OKQ[^55Q/>P\$_!KOO5,,>^O'OY57$]["G^M?E+'?&:OTF7CU,\E:/^*TOH
M@ &OFS                               E<I, #^7Q=A:VWVUW*R7BCI
M[C:;Q0U=LN5!5PLGI:V@KX)*6KI:B*1',E@J()7Q2QN:YKF.<CDT5=.73SH?
M(1K>3WFW>L%;%3)AFL;[NX(N,[G2NKL-5DTK(87SNU=/5VB>.2V5BN59G2PQ
MSRJY*B-TG4]T0\=>>JYNZ+E 93U4%II8W8_P4E7?\$5.SI-/.L4?NMA]9$5-
M*>_TE/%!L+ML2NI[?4]&Z2FC5-[U UE_D_&*%65L+B&H5E[6+_JZK77!OPG[
MF3ZD1QM+U2_E/ N=.+>+PMZE%KQI)9U*2?Z<5E'AO1CULYG0*U13RPR20S12
M0S0R20S0RM5DL,T+ECEAE8[1S)(I&NCD8Y$5CFJU414*):1.^?7Z.]=CXE/W
M&UU:UFW;FKYV?=P  ,F#^LP'CN[X7O=IQ)8*Z6VWRP7&DN]IKX51'TE=0S-G
MIY=_DNC25K$EB?\ 6IXG202;22'4NYMKEM6O/[*3#.8%#T5/=)XG6O%=ICD8
M]]EQ3;=F&ZT3D1$5*>I7H[I;7JUJSVJOHJA6L5[HV<J7]?K/<WF&N<53)+->
M##V(:QT67V9%30V.]/EE5M-8[Z]Z4UAQ#(FBM;3-J9DMETF<C4AHJMM;+,R"
MWRMFCO:/JWZNP:K4X[V)PJE4A99RI7:J4W;C[N"Y2NO;,D_9=K;_ "=CE0JR
MMAL7*-.HGPIU%^2JWY<Z<N'@N[\2)T@P6['*J;]51?7U:[NKYN.BE9./H30K
M%?E^/QD6X3X/D^#_ !Z>XF !DR"D[AU:]785%X+Z#QYYZ7G"F9 Y07"KM,\?
M[/L8K+AO!5.KFJ^EJ9XE]T\12L56N\6L% LE1'Y.S/=9+;1N6..HEFB[FC]'
MU,57HX>E'>J5JD807*[?%]22NV^25SS]*Z2I8/#UL37ENTJ-.4YOG9<$NN4I
M6C%<VT:O/A&7.(/S)S'CRHPS<-O ^6T[VW5]-(UT%_QTYJLK9G2,U26DPW3*
MVVT;62*Q;A476:5LBQ4+XM;SOW^?K4K5-3+/))/42RU%1/))//43R.EFGFF>
MZ2:::5ZJ^6::9TDLLDBJ^21[WKQVGT2W^A-$T\!A:6%I);M-1WI6LYU$O#FW
MUN5^Y9<BD&L&FZFD<77Q=;QJLGNI7M"FLH0C?E%)<LW=V5P #U3Q[]8/HWDD
M\F'$6<F8>&<NL+Q*MRQ#7,BFJUC=+!:;7"J2W6\5;6__ #-;J-))E1RM;+-T
M,"O8LJ.3YQ<Y$157@G'JX=6O5\:=2*NXZ ?@Z?-N.RPP'/FMBNCV,<9DT5))
M;::HAV9L.8,8KIZ"E8DB=)%77Z1[;K<W(D>E.RU46PBTDLM3JNN.L<=&X*=9
M-.M/V/#Q:XU6LW;FJ:\*7+@N:ON.H^JT]*XZG0L^@A[)B)K@J*=K7RLZK6Y'
MGQ?)GNSR;>3[AS*S N&,OL*4BTUBPK:::UT>TJ.J*I\3-:NXUTK6L2IN-SJW
M35]PJ58BU%74S2*UB.V$_=$&A$J95JRG.4YMRE.3E*3=Y2E)W;;YMMMMET:-
M&-.$:<(J,(14(05DHQBK122X)))+L0 !P/J
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M^HIU^^3]^\/ _O0PW\BT1">V3Q-'^^Q7S4"P&PGQM)]V%_QC]@ !!98@
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M)/<
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M-Z_2I57[%._:4F\5*J_8IW[0"HG!"K'UE)."%6/K *@
M
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M]18'8AH6[Q6D)K-6H4F[9-VE4MS\7<2[')9IA$T7ON*@!!J5BPX !D
M                                  IK\7=2H2*NG?M,/\?<8-*3PK'E
M'.FOV6N4M'4+T5!;:K'M]@9JC5EKYZFQX>21S4T?HRAOLKHGN78<VEFV$VHG
MKJ&GIUSRV=+L><IK-J\MFZ:BM]_BPK:MF3I(8[=A2WTEB;XO_@Q5-91UMQ<Q
M%T2HK9W(B*]4;YBEN=3=&K"Z,P=*UFZ2JS[9U?9)7R3=MZW<DBDNO>DWC-+8
MZK>\8UIT:=N5.B^CBEFTO%OWN^0 !M!J0/UG(?)>]9C8UPM@/#S-N\XMOE!8
MZ)VSTC:9:R9&U%PE8BHKZ>V4C:BX5+475T%)*UJ.?HU?R8V<O!=N30S$V;>*
MLQJVG;)19=6&"CM[Y&->SW?Q4ZH@@<S:1%;+36RW7%VTS5\2S1[6B3ZKXFL>
ME5@<%B<2[7I4WN7YU)VC27;X<E?L3-@U5T.\?I#"X2SM5JK?:RM3A>=5WSMX
M$79];1O!9$9,V3+O!N&,#X;IDI;'A2QVZQ6V%-[EI[?3,@2HF=_ZZJJGM?55
ME0_66IJIIIY7.DD<Y?UM"5J+KW^+AY_@X(3E/:E24Y2G)N4I2<I2>;E*3NV^
MMMN]R\E&E&G"-."480BHQBE9*,59))<DLDN  !P/H
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M\&N^]4PQ[Z\>_E5<3WL*?ZU^4L=\9J_29>/4SR5H_P"*TOH@ &OFS
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M\U14U$TBMCB@@BC?)+*]S6,8QSG*B(IR\N=>Y?-;RA,V[SBB&:H;@ZS/FL.
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MNHJ,>1<K9[JI'16 A"27JFONU<3+FI6\&E?JI)[MN#EO2MFR8 &GF^
M                            U:O"L/N/9>?C#;\@W(VE35J\*P^X]EY^
M,-OR#<C:M1O*^"^%_N3-+VB>1=(? KZR!HBK]'Q$"*_1\1 MJN"*5+[_ )P
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MZCT30;5JF+OBJE^-JBBJ<?U::CE[J[RX$Z*1 -))&
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MM545-%1="LU=33S>T[DP !D
M                    %)Y5*<G4 47\"FO!"H_@4UX(#E?+\=I23[)>_86T
MA<_PBW?P!Q+=_ L)$^ OW\"QDZ^_6 63DT5OI3X=3'2IQ+^3J]/SJ6,OS &,
MF[^PQ[^LR,R=_@,=)U@&,F^DQ<R=_@,M-Q[^8Q4W?V@&-DX^K3YSYQY6E)+4
M959H00,66:;+G'4,,2(BK)++A:ZLCCT7<NV]S6[*[EUT7<I]'2\?:?FF:UE6
MY87Q-;D255N&'KW0HD&G3ZUELJJ9.AU1R=+K+];16JFWLZIIJ=G!3W:U*754
M@_1)'5QT-ZA6C[JE->F+1RG:?[7'HJJG1LT5=^ODIOU]A6+*VO1::G<FB:P1
MNT3AHZ-J[N"Z)P3<7I==-/-=I0.2LVN<;)]?/[D  #B10M:UNU#,G;%(GM:J
M=_@U71%N2G,W5CT3K8Y/:BIZ.OBNY.)GD_-^/F,KBO/Z7:WRG5 R,NGCN"L(
M5>QT?C&&+!+L:JNSM6JET35415]:(O:B'ZW$I\G\AJ^)<LFLK+@U55M;@+"]
M2BJ_I55);12.1>D_AZHJ+M=:Z]6B)]81=12G'PW:]:/55FO^YE_,!54Z%&:X
M2I4Y+SP3,C%Q4R<2_-\!BX^/K3X>)DH3J';,M O?V&29Q3OU&,AX]^PR3%X>
MH R47S&1B7>GG,9"IDHNKT &0CW;B^C7AW\QCXT^!2_CZN_6 7S.!<Q?.6L?
M67,?S@%RG%?45-=W?SE).*E5."^H J-7<A6CZRBS@5F*#+*@ !@
M
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M^Y9E5^,FI_).]FB^;T'A87W+,JOQDU/Y)WLT7RS>R[R33^%K?394G;!Y:J_
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MZ[OQ?22;B^+]HHV[+$0 :6;^
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MG$-?D,.DGU3K3W?3N4WZ>&=SZ= !7LLZ
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ME19<LJ6KB:J22KK%>\7-C57*U&(CK/99'M:JHMTJVM<Q;=.FN9S>G(FO6?\
MFGA_+VUNFI+?4RMN&*KS$Q'>X>%Z.6);K6LVVK$ZMEB<E':X9%5LU?4P[;?%
MHJAS.I[EQEW9L)V"SX8P]0PVRQV&W4EJM5# FD5+144+(((VJOE/=L,19)'J
MLDLBODD<Y[W.6(]J.M'04?4%*2Z7$1O6:;O3HJUH]2=65[_H)]:9-6R#5'U3
M7_E&O'V'"S]@3652NT[RSXJC'ARWVE[1I_VB,T[[N&GM\Y.A$%>RSP
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M5E]\-15*G3IQ5HTX1A%=D(J*^1  'S/N
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MHU'WQBU;G<DO1&U30^*<8NO+"S=ENXI*$;]E5.5+LSDG?E;,VA]2&UOX>L_
M\C.4_E]F;;DNF <8X?Q91;#9)'6:XT]544S7*K4\;HT<E92*KD5J)500[2M<
MB<#]Y:NO7KJF[=NX<4WKN7J\W6:/4I3@]V<7&2XJ2<6N]/-><D*C7A4CO4YQ
MG%\)1:DFNQK)KM*B*1((FA$X'V
M              !3DZBH4Y.H HNX%+J*RE+J]8,\O1]I37BGK+9_ N'<4])1
MDZ^_6#!:OX%D_K]9>OX%G)U]^H L9$X>LQ\W%>_:7\K=?A^8L9>(!C)N_M,=
M+UF2F,?(G'SH 8V7K]7S&*E3YS*S&+E3YP#%2IO3SZ_"8NL9M1RMTUUC>FGI
M:OZ]VJ]B*NXRTO5Z2R<W5R)VJB>G5=-$]/5IOUX;]#E!V:?4T_E.,UX+[G\Q
MR>;_ &%;5<+A:G(B+:[A76U6M5SFIXA52T:HUSFHYR(L&B*_9<J:+L_9:8D^
MA^5YAQUHS9S1MJMV&TN8>,TA9H_5M/-B.Y3TJ.5_E.5*:2'REW*NTK=474^>
M"Z^%GOTJ<_=0A++AX<(S*!XZCT=>K#G"I4IY\? G*.=^>6?;D  ?<ZH'?OU^
MC37?HBZ)JJ"*=O9\'5KZD77S\%W*H_W]%W\_XX&4[?-Z6CH]<TIB'W3Y-V3D
M^NJ4V"K;:MR-31;,LMJ<GDJJ:HM&J<=I41%>C7J]C?1N/YSQ?Y@K%*7'DRX/
MIM5=)8[YC6S3*KMI=4Q1<;O U4V&;"QT5WI(D;Y7D1L>BM1Z1M]GV<"G6LM'
MH](8V'N<562OU*I*WR%Y]5*_2Z,P%3+P\)0;MPOT<;_*9&-=%]1DXEX>@Q<7
M$R,2\/2>(; 9>%>'J^<R4?5WZS%0_J[^LRD:\/2 9&'YS)1]1BXN/L,E%U &
M2C7CH7C.!8QKP])>Q]8!D(^LN(^LM(UX%TSB 7"<?5\Q7;U^@MT3AWZRY9Q
M)F<"LSB4&=95:N] 9?%E<  P
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MU7IJ&C<!%</4>&?IHP8 !XY[P
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MSLDB[FAM%4<#AJ.%H1M3HP48O*\G;PIRLEG)W;=EFRH #I'J
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MI71T%SQ=%_LS3_NG1^9P[]_,3$D?#OV)\Y.4_+Q@
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MC4IRC.$U>,HR4HR76G%M/S,F!#:0(NI\S[D0
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M"\8N\LF%X@!=IP]"E5O%"BU=RE1J\% *J+O4J%->*+VE0&65T4B2M7<3 P
M
M                       ""J 454I/ZBH2+Q0'*/$E>N\H=:^@JN7>4>KT
M@XE"3B6DB\?07+EWEI([B 6DG463UT]I>/+!_;J 64B\3&RK\9?2*8^5?B +
M*1>)BYE^(R,KC%RKQ]@!CY>LQLCM_P !?RK\.IC'KQ +21?A4\N^>7QBEEY,
M^:\R/5DEQLE!8HD17-61+[?;5;*F/5J+HCJ"IJW*U^C9&-=&NYV_U"?U&O\
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ML?L,JKH-(0Y]-1DEV.$U?_M+\ $,$\@
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MVC454\[3$]S"8J;Y8:N_-&G*_GR9ZFA*6_C<)#W6)PR7>ZU-(ZK " I@7T
M          !!>KOU*1(+U=^I0"'5ZOF.7)SS/WT^=_OPC^0+*=1OJ]7S'+DY
MYG[Z?._WX1_(%E)8V/\ ].Q'Q7_$@0QMN\FX;XW'ZJH>9@ +$%7@  ^"[_N,
M/E^.3.C)X-=]ZIACWUX]_*JXGO8>"?@UWWJF&/?7CW\JKB>]A3_6ORECOC-7
MZ3+QZF>2M'_%:7T0 #7S9@
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MM%^J,7&.Y?C2H+.-N:=7*4OT=Q=8;P)@"+R80
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M$K_M$W\5)_44Z_?)^_>'@?WH8;^1:(A/;)XFC_?8KYJ!8#83XVD^["_XQ^P
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M--W?3LW>;L)R1B]G:OZOU>CJ)RGI>4
M                        %.3V=^_T%0@8!_ 9C978<QA:*JP8JL=IQ'9*
MU$2JM=YH*>XT,RIO8]U/51R,;+$[RX9FHV:%Z))"]CT14UV>5KX,;E)C!U5<
MLM;S<LK[M-MO9011NQ!A-TKG*NCK35U--7TD6S];2.WW2GB;OE?#,[R5V940
M*AZ^B].XS!2WL-B*E*_%*5X2]]!WA+SKSGAZ8U<P6/AN8O#4ZMN$MU1G'+VL
MU:4?,T<TCE+\PARD\M4FJ?V(T>.;/"CG>ZV7]?)>FMA;J[:J+364EJOE.YD:
M(LVEMEIV.U9%55"-VU\?\18>N%GKI;9=Z"NM-R@^WV^Z4=3;ZZ'CITM)5Q0U
M#-=%TVHTUV5ZD.QHL::Z]?;U]]Q^!9V\E/+;,BB?08]P-A;%M*Y5<C+[9*&O
MDC>J;*2PU$L*U,$[$^UU$$L<\:HCHY&N1%),T7M<KQM'&8:G57.I1\"??N3<
MH-VZG#/F1-IG8CAYWE@L54H/\U6M4I]V_%1G%+NGW'(QT[_HX^;LUZ]Z:P[^
ME.TZ".?'@Q')^Q(LU3@VLQ=EQ5R+JV"VW>;$5E8JZJ]4H,2OKKBQ7/5'-C@O
M4%/$U7LBIVM<FQXOY[>"X9Q619JC F+<)XUI6NE='1U[JK#5U6)J^0Q'2MKZ
M"HJ7<$:LU-$F]%EW)K(&CMI.BJ^732P\GDXXBGN6_6AO0],K$9:3V5:8PS;6
M'CB(+A/#5%4O^I)0J>B/R&L<#Z[Y0'($SKRL=*N/LK\8X?I(OLKPMHGNF'51
M%ZL1V9+C8VN<FCF0R7".H5J^5"QR.:WY#1R+KHJ+IJBZ;]-.U$U7S:\-===$
M34W;#XNE6BI4JD*L7FI4Y1G&W?%M&AXK!5J$G"M2J4IK+=J1<)=7"23?F(@=
M^^FJ>P':W7U/T'4N  <3-P  #Z-Y+'*QQ[DQBRCQGE[?:BRW>!T,=9"BK+;+
MY01S)(ZTWRWN7H;A;Y5VVHQR-GI5FDFH9Z:I5)CHL<UISLN">4E8)64K6X=S
M!L=+3R8HP=4S-<^-K]6>Z]AG5?\ A2QS2L<U)6(E302.;3W""!TE/)4<QKV^
MK<OM/U3)3.W%.7.*;1C3!EWJ+)B.QU3:NAKJ=55JZ*WI:2K@VD;5V^JC:L-=
M1O7HZFG<YB[+D:]NCZXZET=)TMZ,8T\7"/@5HJR=N$*J]M'J>;CRRNB0-2-?
M<3HFLE*4JV#DTJM"3O;_ (M)OQ9+BTK;]K/@F=??:[.KOW])413S3YKSG%\/
M\HS+BCQ-1LAMN*K6V"V8WPVV1'NM%\;"FW/2:N<^6S7+1:NU5+_*6G?T$Z-J
MH96GI6U=W#0J_B\'5P]6="M%QJTI.,XOK3]#36::R:S61;S 8^EBJ-*O1FIT
MJL(SA)<U+DUQ33NFGFGD^HF !USN
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M"HBE)%XH3L7<#/V?>7#%)RBSB5@8
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M0<\/)9-Q<)-Q3_4E#+_<B #1B1
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MV)Z05/2&(P[?](H7@NN5'P[_ +$Y&PZ "O):
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M[XS5^DR\>IGDK1_Q6E]$  U\V8
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MJ(9<E30F*LW;S>;?'O+BI)*R5DLDEDDN278N0  ,@
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M4N-.<X2[XMK["_&!Q*K4:56.<:E.G43ZU.*E]I.""$3X':
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M]15*Z*4"JQ0<2<
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MM)/M3R9>>A6C4A"I"2E"I%3A*+NI1DKQ:?4UFNPF !P/J
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M][#P3\&N^]4PQ[Z\>_E5<3WL*?ZU^4L=\9J_29>/4SR5H_XK2^B  :^;,
M                                       04_@\T/WM8BX_\17?T?\
M%]0?WI_"YH?O9Q%_,5W^3Z@^V'_*4_?P^DCK8Q>Q5?@Y_19QV+1^Y*7^3P?V
M33(F/LW[DI?Y-#_9-,@76I>+%=27T44$K>//WTOG8 !]#YEI7K]8G_B9/ZCC
MKY<G1O\ YOL"+_\ @;A?Y#H4.0;7_:)OXJ3^HIU]N3G]SW GO-PO\B4)"FV1
M7IX%?IUOHP)\V%KV72/P>'^E4?V'[&U-._?L)B1.*^CZ"<@E?/F6,  ,@
M                                    &K5X5A]Q[+S\8;?D&Y&TJ:M7
MA6'W'LO/QAM^0;D;5J-Y7P7PO]R9I>T3R+I#X%?60-$5?H^(@17Z/B(%M5P1
M2I??\X !DR>R/,#_ 'U.7/\ %X@^1Z@Z7R<$.:#S _WU.7/\7B#Y'J#I?)P0
MKEM;\HTOBL/K*I:;8IY+K_'*GT($0 183$
M #\\S=_>IB?WOWGY.J3]#/SS-W]ZF)_>_>?DZI/I1\>/OH_.CXXC\G/WDOHL
MX^]1]LE_C9?[1Q2*M1]LE_C9?[1Q2+LT_%1^?\_&E[Y@ ',XEI7_ &B;^*D_
MJ*=?OD_?O#P/[T,-_(M$<@2O^T3?Q4G]13K]\G[]X>!_>AAOY%HB$]LGB:/]
M]BOFH%@-A/C:3[L+_C'[  ""RQ             )57S:DQ!0P?F^;N7-%C'"
MF)L)7'7W.Q3A^\X=K=G17>*7JW5-MJ5:B[MM(JEZM[%1%ZCD'X@PO<+'<+A8
M[O#XO=[)7UMFNU/O^L72U54M!<8-Z(OUFLIYH]Z(OD[T1=43L9::Z+V?H7XS
MFB<_)R<UR[Y2N-N@IT@M6-5I<<6W88K8727IBMN[6*J)M2>[%/65-0[['IJM
M4VE528-D&D=S$XO"R=NEIQK03]U2WE)+MW)7\S[B"MN&C'/#83%J-^@JRHU&
MN4:RBXOAPWXVX\7PZO'$ %@>KM2?F>:*V+[6O.N((IW_ $=GI[-2 ,7,6-ZK
MP6GE*MO66V,,L*J;6NP1?4O-MB>]7/=8L2H]^K=I=T<-TI*UB1L:J0MD:KE^
MNM1=J%%[/C]7?YCF \S/RN_[C7*"P7?JVK6EPSB&6;!6+M5=T*VC$'1PTE9*
MUJ.3_@B^QVBY])T;Y$I8*VGC5J53]>GU',QS4<UR.:Y$5KF^4BM5$5JHJ:ZH
MJ:*BIJBIO*P;3-#/#:2G4C%JGBUTT6EEO-VJQ[U);R[)HMSLFTZL7HJ%)RO5
MP<G0DGQW$DZ4NNVYX-^N$N1<@ CXE
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M@)VKHI11=%])5!E_<7 )6KN)@8
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MPR:W9UE*O-9IJ563:7["@^K/@4VVFZ46*TQBG%[T*#CAH-<&J44I/]XZB\R
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MR'XN_P Y>QI\):QIUE[&G  NXT^ N&%%A=1)\(!5TWHG9O*["DG%?456[D4
MF8G7VFL%X5']QG _XP(OD>O-GYO!#6!\*C^XS@?\8$7R/7FUZD>5<#\8I_::
M=M#\BZ2^+5#0W !;7J[E\R*4]7XYL  &#:*\%5^[!F)[P*7Y:C-\7K]GSFAU
MX*K]V#,3W@4ORU&;XO7[/G*O;3?*];X.E]!%N=D7D6A\-B/ILB #0"3P
M     04B0=P,,'YWFGEA8,9X>N^%<46NEO-@OU%-;;I;:R-LE/54D[5:YCFK
M]B]NY\4K%;+%*ULD3FR-:Y.9[SK?-F7[DVX]EMVE5<LO\03U55@;$<K%<LM(
MSZX^Q7:9K&Q-OMJ8Y(I516)<J5C;E!%&CIZ>GZ@:IJN_X%X'S!RPN27A'.O
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M-2U[\D8[X)?3@;KLY\MZ.^&E]54-^1._M4F)4[^U28J6OO\ G+I@ &0
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M*-G\G%,N_H#35'2&%I8JB_!J1SC?.$UE*$NIQE=?Z  'EGL@
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M.[(-;EB,/_)M>2Z?#QOA[V\/#>Y3YRI/)KW#C;Q6>A()$>G=%3X.HG(F)K
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MOZWT8$^["ORND?>8?Z50_8D^R7OV$Y(GV2]^PG((7!%BP #(
M                           !JU>%8?<>R\_&&WY!N1M*FK5X5A]Q[+S\
M8;?D&Y&U:C>5\%\+_<F:7M$\BZ0^!7UD#1%7Z/B($5^CXB!;5<$4J7W_ #@
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MSC*+X-/_ %L3  'T
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MCBY5>"@%9$U0G:NXIM7>3)N4 K-712L6Y68NX F
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M:'7@JOW8,Q/>!2_+49OB]?L^<J]M-\KUO@Z7T$6YV1>1:'PV(^FR( - )/
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MUDUFLBW6 Q]'$TH5J%2-2E-7A*+337V-<&GFGDR8$-4"*=8[A$
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M[5[N$O;0EU.+NL^J_!E'M.Z&JX#%UL)634Z4GG9VG!YQJ1ZXR6=UDG=<4T
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M^'TO05G&&+A%=/0OG=9.=.]MZFWFFK[M]V6?']F!#:3M0B:@;R
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MG@??UOHP)]V%?E=(^\P_TJA^Q)]DO?L)R1/LE[]A.00N"+%@ &0
M                              #5J\*P^X]EY^,-OR#<C:5-6KPK#[CV
M7GXPV_(-R-JU&\KX+X7^Y,TO:)Y%TA\"OK(&B*OT?$0(K]'Q$"VJX(I4OO\
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MJ.8]CE:Y%1454T,BBD$O)M/EQOR+&QDFDUFFKIKJ9$$-I"(,@
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M]' M]KK]6A61= +E5JZH3HNA1X+KU+W^ J@S+B7 *;'=14!@
M
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M]V#,3W@4ORU&;XO7[/G*O;3?*];X.E]!%N=D7D6A\-B/ILB #0"3P
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M[BYVIVJU/1.#AAXN,JLFJF(JI6Z2I;.WZ,?%BK\,^;(M4B :Z;8
M      ""]7?J4B07J[]2@$.KU?,<N3GF?OI\[_?A'\@64ZC?5ZOF.7)SS/WT
M^=_OPC^0+*2QL?\ Z=B/BO\ B0(8VW>3<-\;C]54/,P %B"KP  ?#N:^5HP^
MOJX^A_C(Z,G@UWWJF&/?7CW\JKB>]AX)>#7K_P"BIACWUX^_*JXGO9M(4_UK
M\I8[XS5^DR\>IGDK1_Q6E]$B"&T@VD-?-F(@AM(-I "((;2#:0 B"&T@VD (
M@AM(-I "((;2#:0 B"&T@VD (@AM(05WK%P3 EVMY,
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M"%<MK?E&E\5A]95+3;%/)=?XY4^A B "+"8@
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MZZN#NFDU8F'5O3M/2."HXNG9=)%;\4[]'55ND@^=T_2FFFT3  \@]T
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M\9I?#MQ;I89O$U';+P%[&G[ZHX6YV3MP9L1MZNO=W\WL*I+IP7S$Q5<N(E8
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M@!7!!%(@
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MRZFN*+B-N]/09*)-VA:1LU7X/5V>PR,:=9!Q80O(6]_092)-Q8Q-[^@R<:<
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M5M"JM2>!(G122V<U.UWH:3@J<FJ6+BO"HWRG[J=%OBN?1\8*_%+>*D:\;/\
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M"<D3[)>_83D$+@BQ8 !D
MU:O"L/N/9>?C#;\@W(VE35J\*P^X]EY^,-OR#<C:M1O*^"^%_N3-+VB>1=(?
M KZR!HBK]'Q$"*_1\1 MJN"*5+[_ )P #)D]D>8'^^IRY_B\0?(]0=+Y."'-
M!Y@?[ZG+G^+Q!\CU!TODX(5RVM^4:7Q6'UE4M-L4\EU_CE3Z$"( (L)B
M                       !^>9N_O4Q/[W[S\G5)^AGYYF[^]3$_O?O/R=4
MGTH^/'WT?G1\<1^3G[R7T6<?>H^V2_QLO]HXI%6H^V2_QLO]HXI%V:?BH_/^
M?C2]\P #F<2TK_M$W\5)_44Z_?)^_>'@?WH8;^1:(Y E?]HF_BI/ZBG7[Y/W
M[P\#^]##?R+1$)[9/$T?[[%?-0+ ;"?&TGW87_&/V  $%EB
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MJ&,>ZKW:IXB*2@^SI%:#[=SJ-[8%!J]JK^DJM77>5O[&OQYLD6JO]W-<.\F
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M#LWU2_DK!>RJV+Q.[5K\]S+P*2?5!-WMEO-D0 :,2(
M                           47IO*;N!7?P*0"915=40I.XHI61.*%-R
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M47V$Z+IZ.H'*W^Q68N\K%N3-=H#B5@
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M?R]:#4M>_)&.^"7TX&Z[.?+>COAI?55#?D3O[5)B5._M4F*EK[_G+I@ &0
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MV$":1T9B,)4=+$T:E"I')QJ1S[U;*2[8MJW,F [[]WP*#N'0
M     'XR  (/<C4555$1$55<JIHB)O55771-.WJ,-K@G?KR>7??GW,S9^Y:\
MZ:?=8B%73?Y]$XKO541$W;U555$1$WJJHB;U0]+>1+S2^=>>\M+4X6PQ-:,+
M3[$BXUQ/'46K#SJ9ZM5)[<^2)U7>VJQ5=&ZTP3T\FPYOC+9&JB;GG-[<P)E+
MDNM%B#$J?W3L?PJDR7N^T4,5AM$^BM1F',-JZIAI]AJHUU?=*FZ7&27I98)J
M"FG;0PZ7K#KY@-'QE%U%7KK)8>EG)2Y;\K.--)\;O?ZHF]ZL[.M(Z3<91INA
MAV\\36\%)<'T<,I596>5EN=<T['P-X,KR;L]<%1XJON)[5+AW*3%]N@J[7:;
M^LU+>Z_$U++31TN(+/9E8CZ"UU-J=54=PJZ]M))<UIK5)1TTL%/XPNW 46MW
MIKQ_7YN&_AU=7FK%:].Z9EC\55Q4Z4*4JC7@4U:-HI)9^V=DDY<6UR+8:MZ"
MAHW!T<)3J5*L::?AU7>3<G>5O<QWKN,<]V]KNP !Y![@              !2
MXZ\>/L[_  !6[N'LU^(J@,'Q?RT^0;EOGYA=V&LP;%'6+!M36:^TNS3XAP]6
M.31:FT71&NFA1^YM51R=)0UK&HRJIY=B-T>@ASD7,J9IY U=9=Z>BJ\<9:H]
M7TN,K/2++/;(U5=FFQ5:X5DJ;5/&U$9[IQ,EL]2B,7QNEJ)&T4?2_+2NI(JB
M*2">*.>":-\4T,T;98I8I&JR2*2-Z*R2-[55KV.:YKFJJ.313;M6==,7HR5H
M-U<.WX6'FWNJ_%TW[1\W9-/G%NS-%UMU P6EH[TUT.)2M'$TXK?:7"-19=)%
M<KYKE)(XW+51=--%1>&SHJ+NU\G3=IIO31$\G?IQ(G0%YP/P</+;,N2LQ+EA
M5Q97XPF=)45%!3TK:G!%[ED\N3QJTQ=%462LEET=[HVF1:?5TKZJSULCVR0Z
M:?+ YN_-[(RMF@S"PC74%K;.V&EQ30L=<<*URR.1L/0WFG:L%-+,]>CBI+@E
M'5O>CFQPO1$<MA= :ZX#2$8JG55.NUX5"J]R=^:C?*:YIP;R\91>167674'2
M.BY-UJ?2T+^#B:*<Z5N6];PJ<NM3LO<RES^)@/9U]>[=QW\ ;;R[?1\CS7GX
M\LC2_N_'X^<                   $NTGDIQ5SFL:WK>][D:QC4357/>Y4:
MQK45SE5$:U55$#M_KP2\_P"$<HQ;X*_8GG]OW]A'4RUBL5==*VFMMKHJVY7*
MNE93T5NMM--6U]9/(Y&LAI*2F;)/43/<J(QD;'+M*B[M-3VUY#7,"YW9OK17
M:^T2Y8X/J%CE=>,4T<R7RKI7;+NDM>&'.@K7/DC5>C=<GVR)%:BN5S'-VMU3
MD'\T_E!R?:.-<(V1USQ.^-&5^-\1+#<,2UKU8C)$AF;#%36FD>B+LT%HIZ.E
M:CG*]DLLDTLD?:Q[1L%@5*%*2Q.(5TJ=)WA%_IS2W5;FHN4ES2XDD:K;+](:
M0<:E6+PF&=GTE56G)=5.G???OFHQZFV:Y_-@^#<W"Y/MV-N4/3NMUN^MUE#E
ME35&S<:I-(Y8/V75M+)I0P/U7IK#1RK5(W9BKJFGD6:DAW.L&8.M.'[5;[)8
MK90V:SVJDAH;;:K920T-OH**GC2*"DI*2G9'#!!#&UK(XXV,:UJ(B(A_0HS3
M]"?!Z$^+SE9J[BONGM9<5I*KTF(G>*ON4HW5*G[V/NG[:3NWS99G5O5/!:+I
M='A:5I.W25YVE6JOCX4[7W5[6*M&/)7S)--/@[\"H >$;*
M       ""]7?J4B07J[]2@$.KU?,<N3GF?OI\[_?A'\@64ZC?5ZOF.7)SS/W
MT^=_OPC^0+*2QL?_ *=B/BO^) AC;=Y-PWQN/U50\S  6(*O
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M"0KMC_)X'W];Z,"?=A7Y72/O,/\ 2J'[$GV2]^PG)$^R7OV$Y!"X(L6  9
M                                      -6KPK#[CV7GXPV_(-R-I4U
M:O"L/N/9>?C#;\@W(VK4;RO@OA?[DS2]HGD72'P*^L@:(J_1\1 BOT?$0+:K
M@BE2^_YP #)D]D>8'^^IRY_B\0?(]0=+Y."'-!Y@?[ZG+G^+Q!\CU!TODX(5
MRVM^4:7Q6'UE4M-L4\EU_CE3Z$"( (L)B
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MLM3]&:B]9."NLG>3EDKW=EDLW?)<K<$N2+2PCNI1NWNI)-N[LDEF^;=KM\V
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MLZ>'OV/*=5<IK*.:C?BX-1=.SOW[->S30J-UZR8$7DP
M                               $%*!<%%Z;P"DNY=21W$J.3<2<4U[-
MP,E#M3V%L]"Z=NT4I2)Q]H,%D]"S>GP&0=P+-Z=8!CY$+"1/,91[>KV%A+O]
M0!BIF=_B,>]#,2-^@QTK._?M ,3,TQ<K3-R-,9,WOZ ##3LU34QKVZF;D;Q,
M9*WJ%_O]!E?A&NQX0YR/UQGEK;\R;32=+?\ +:65:]T4>U/4X/NDD;;E')LK
MM/9:ZQE+=(=4DZ"-:]D36K63.-(!.'?ONW:Z:IOW*IU?L4X:H;S;KA:+I2QU
MEMNE%56^OI)->CJ:*MA?3U4#]-Z-EA>YNJ>4U?*8K7;SF4<M;DNW')K,[%67
MU>LLL-HKGS6.OE:UKKKAJM<Z:Q7%48UD?2RT:-@K$B:D3*^FJXXDZ-C7.L!L
MIT\JM&>!G+PZ3Z2BGQ=-OPXWY[LL^M*74LJT;9]6^BKT])4X^!771UVLDJL5
M[&VN3E!-763W.N1\L  F @T   =_H]:+O3L5$7J-JSP<KEL)3U-ZR.Q#6KT-
M4LV)< OG>Y6QU"(KL1X=AUU1C)U6.^6^/5K5G6\,U5\]-&FJF?W&6>9-ZP=B
M&RXJPY5NH;[8+C37.UU2;2HRJII$>UDL;7,6:GF36&I@VF]-3OEBU1'*IX6L
M>A(:0P=7#2\::O3D_:U4[P?I\%_HMFQZIZ?GHS'4,5&[C"6[5A?QJ4E::[TO
M"77)*YU6&OX+Z/BW^=.S?OZ^&A=QN/E#D9\J*SYQY;X8S!LZ-A;>J*-MTMR3
M)-)9K[3(D-XM$TB-C1SJ&M;(R*161K/2NIZKHF=/L)]3QKVE0\3AIT:DZ51.
M,Z<G"<6K;LHMQ<>U75T^:LR[^%Q5.O2IUJ34J=6$9PFGE*,DI1?9D^'+GF9:
M%YDHW&$8[KZS(Q2:[CX'V,W"XR,;S!1/,E"_> 9B-Y?QN,.Q_L+Z)P!F(W_,
M7K'?H,3&\O&/ ,JQW674;S&L=\!=,?[ #(-=H7+7:II\/86#7=17:[0 O$["
MHCNI>!;IO^8J(O;Q 3*Z+HNA.447J7@3HNFY?4#D\^'G*K7:%8MR=KM <2J!
MJ
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M)63]XENI<%=OF4KUZUE>E,?5KQ;Z&F^CH)\%265[<+U))RD^-E%/@  ;4::
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M3CNSLI)Q23X.2^4G3470%71FCX82O*$ZD*E6=Z>]NVG-N/C)/)9$P -9-Q
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MDB"1Z:+KP^C3OZ5)]GAYB8&JV-R(:;@B$09
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MFVW6?,S ]S8FUT<=707JW3.T:]6[2HRJA9M.2-BKMJC5<KOL6GSW>_!D>4G
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MS!:.AT>$H0I)^-*UZD[>[J.\I>=V)=-Y%$(@\BQ[@ !D
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M$VNGG0')YY\.PK-=H544H:A%!Q+@$J.)@
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M"(                               (;*#0B  2JU%)@ 05"(
M                           (:$0 0V4&RA$ $-!HA$ $$1.'4-"( (:$
M-E.SOP]7I)@8L"&R@V4(@R"&R@T(@ AHA$
M         $$30B ""H1  (:(-"( (:!$(@ AH@1J=U]1$&+ @J$%:BDP,@AH
MA$  AH@1J$0                                  0T"(1
M                        !#0B                             ""(
M1                                              !!4"(1
M!#0B $@                                   $@     +
M                        $--^I$  @J:D08L"&R@V4[._'XR(,@EV$&PG
M'3>3 "Y#0:$08LNH$NPG8-E"8&1<ALIV)["&PA,#%@01"(!D$$30B
M                   "&A$ $- J:\2( (:#93L(@ AH$:B=^PB "&A#93AH
MFG9Z>/MZ^TF L"&B!$(@PU?B@0V4(@&0
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M7]I11VG$G 2+C4%!%*K7:@P3
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MIGQ%)B=97TW(G: 3M[>TJ\$])*B=1.G'T RB9J:(5&)O)2JQ-P,$X
M
M
M
M
M
M
M
M
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M279ZN^A51.H F;N15]1.U/A)535=$X(5 9N10KE-B=94!@
M
M
M
M
M
M
M
M
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MJ"EMJ2ZJ 5R&J%  %57D-LID%5 ";:4@2*_L&_T Y;K)]217DN[MU\PV^Q-
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MY8WV%)B%QYD]8!%O:56KHBD&IU$Z[UTZD!E*Y,U"=$(%1C>L&"H
M
M
M
M
M
M
M
M
M                                                   47(5B5R:@
M%!4U0IIO30JDCDZP<HJY1<FI35-=_7UE=W:4G;EU[>(.):.0MWM+U[?T%NJ
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M
M
M
M
M
M
M
M
M
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M:>PCJWL+1%([2@%WJG4NGJ(;7G^#]!;;2DVWY@"Y_P#>3X"&_M0M^D\PZ3S
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MI,U.L&5UDR)H3M3524K-3<#!,          0U (@               AJ1
M               !#4 B   "&I$7                      !#4B  -0
M!J  "&H!$                :@ #4
M                                               #4  $-2(  &H
M!#4B              !J     "&H!$             :@     AJ 1
M                               &H  U               (:@$00U(@
M              AJ 1    &H                    (:@$00U0B  "&H!$
M$-2(
M
M
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MX^U]_P",[<D51UWVB8G2TG3@Y4,'%^!1CDZG+?KN]I99QAXL6^;28 !O9'0
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M.NX CL]7M*B)U$&IH5.&[K4&5;F1TUW=2%0@U-"9$U ;^0F8G652")HA$&
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M+&$E9O)9R=^LE+9=KICM*U<9#%RIR5"%&4.CI*GG4<U)/-MVW4?48 (L)C
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M)::**-8-1<?H^]2=-5:"O[-1O**7Z<7:</UENWX29,VK.T;1VD[0A4="N_\
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MV(HTI[M%1ENSJ1B[.^63.FFUJ>TJDBKN]&A%O KNOQ\I: F !D
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MK#4+]%2FHPWI.3LX1EQ?'-LL=J9I:KCM&83%UW%U:T)2GNQW8W52<5:/+)(
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M
M
M
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M:SY#Q7O\/]?3-54 %I2GY2G^UR?Y#_ZJG6RY$/W',K?>#A3Y$HSDFS_:Y/\
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M;?-2#P33]YN<WOKPQ\AU9MOE3-?/*^-^$A]53+G;-/(>C_@I?6U  #43>@
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M;$? 5?JY')QI_M<?^0W^JA6*-/\ :X_\AO\ 50K%TEP104&XCX);^[<\OXG
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MYYO/F\_LX=R+I15E;JY=0 !R,@
M
M
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MV7(A^XYE;[P<*?(E&0YME_(8#X2M]"F3SL*_+Z2]Y0^G5/J, $!%CP
M   ?(O+FY8&',B\L\29C8D=TD%GI>BM=LC<B55]O]7]9LUEI$7_UE=6*QLTV
MBLHZ)M573:04TKD^M7;MWLU.?7X1_P O"7,+-A<K+)5J_"65<KZ.XI$[2&YX
MXGC;[L/?HY=N.PPN;98]6)LUZ7>-VG10R&TZG:O/26-A1=U2A[)7DN5.-KI/
MKFVH)\KWY&G:\ZS+16CZM=6Z>?L6'B^=62=I6YQII.;[DN9X8<H?E 8HS2QG
M?L>XRN$ERQ!B*M?5U4CGR.@I(==FEMEOC>JI36RVP-CI*&GCT8V&)KW;4KY'
MN_%QWZD^!.'TZZ;M 6SHT8TX1ITXJ,(QC&,5P2BMV*2Y)+(I96K3J3E4J2<Z
MDY2G4G)MRG*3NVV^W\(#OV>K7J]/4._?<OQ+Z%/3?FO.;&Q9RE<:+:J!T]FP
M38Y*>;&N,>C1S+?!*JOBM=I25BP5N(;C&CG4U.C'PT42I<;CI"ZGAJNOC](4
ML+1J5Z\U3I4XW<GPO[GK<GPBDFY.R2S.UH[1U;%UJ>'P].52K5ENPC%<^;D^
M$8I9N3R23;:1\[<D?D1YG9Y8@3#F6F&9[U41/C]T[I42LM^'[#3R+&U:R]7B
MI3H:6.-CTG2DIXZVZ5,:*EOMU;,YL#]T/D7^#1Y2X,@I+IFI/-F?B)&-?/;Y
M5GMF#J695:Y8H;9!(VMN,<:M;LNN52^.96/6:E2-Z0M]V^3+R7\$90X4M^"L
M V*FL5BM\::1Q)MU5=4JB=-<+I6.3IZ^XU3T62HJJASWO<Y=G99LL;]"%=-9
MMI.+QDI4\+)X7#7:6YX-:I'A[)-/*_N862X-RR9:+5+93@L%"%3%QCB\4TG+
M?\*A2EU4X62E;G*=VVKI1X'YOEGE'A7!EKIK)A##-@PM9J1%2EM6';/;[+;H
M-K[)8:.W4]-3L5ZIJ]S8]IZ^4Y55=3]&5O?1/1\1,".*DW.3E)N4GQ<FVWVM
MOGVDJTZ48+=C%175%;J\R7!=A(C>_#3NI97"@@J8GPU,,-1"]KFR13L;-$]C
MD5KFOC>CFN:Y%5KFJBHJ*J&0!Q3L[KCUW9F44U9JZYK*S74>+_*XYB'D]9J0
MUE33X0H\O\25*OD;B' =/3V+:JGZ[51766GB98Z]TCMJ2>22@94SRKTLE0]Z
MZKI><XIS-6;')YFFNEPI$Q?E\Z14IL<V"!ZT](BZ;-/B2U[4E78*C?HVIE=4
M6FH1$Z"X^,/=11=.,PM]L5'<Z2IH+C24]=0UD+Z>JHZN&.HI:F"1JMDAG@E:
MZ.2-[5T<U[7([@Y-$0WC5W7['8"44ZDL103SI56Y67_#F[R@[<,W'LX-1]K/
MLVT?I",I0IK"XJW@5Z*4/"SMTE..[&:N\\E++)\GQR=>S>GJW]?5NWIOW;NS
M<#9>Y\/F469/NK\VLK:65^6=;6L7$.'(V/F?@*KKIMEE10JGE?L1J:MS(F-E
MVW6*:H93;?N6ZG;1:T7Q=6N[K5/C14]**G461T)IJACZ$*^'FY4YNS3SG2FU
M=TYQXQ:\Z:::;31573V@,1H[$RPV)CNSCP:X58_G*;X2C+S----7(#T*K535
M4<U7-5BIY6TCFZ*Q47RD=M,5%35'M7> >MQ5GYTNOMZ[<N_,\6+LU).ZXKM7
MV<#HF\P?SFS\[L 2X+Q;<7U.9>7='107*>K?M5>)<-RJM+:\1HY^CJNJB?%[
MGWV5$?-%6K1U56Y%NU.Z;W]1VFB+QZUTXG)^Y 7*[N61N;&$\QK>^5::UUJ4
M>(:.-7+[I87KW,CO=$YC=\J^+M;601Z:K64E,K%1VCF]6+".*J"^6FV7NU5,
M59;+O04=TMU7"]KXJFAKZ>.JI*B-[%5KV302LD:YJJU6N14712L&T;5I8#&=
M)2C;#XJ\Z:]K"HG[)!>:2FN&4K+Q2V^RW6MZ1P/159;V)PEJ<WSJ4FK4JCZV
MFI0>=VXW?C']* "/R4    4UT3=IV>LJ PT"GIV;N.NF[AHB?!IZB;9\Z^TF
M M^,@2[/G7V_H&SYU]OZ"8"W;\WW DV?.OM_0%33M[^HG MV@\@.?K5?_DDY
MQ:<?<W#'Y<X73T<%.9>ITT>?M^])SB_F[#/Y<88.9<O%2Q.R#R?B.OU9+ZF@
M5=VWK_S/#?$(=_\ 2,20 !*]_ER^W["&&_N\UU<WB?!.T_\ -WFWU?\ E];O
MR9MQMB[/G7V_H-3SP3O[G>;?O_MWY,VXVQ2IVON>E\;R]DCEE^;AV%S]FOD3
M ?!R^MF2[/G7V_H(;/G7V_H)P:A;M^;[C>B79\Z^W]!!4]/M)P+ DT[]^LBU
M"8!(  &0      ?R^-O^)KO_ #77_P"JS''&L_[DI?Y/!_9-.QSC;_B:[_S7
M7_ZK,<<:S_N2E_D\']DTG+8UPTCWX3YL25YV[_\ TSOQ/^"9$ $W%?38=\&$
M^^<J_P 4V,_E_!&OQ(=#!&^=?:<]#P83[YRL_%-C+Y?P2=#%."%:-JJ_\UMD
MOYO2X*U_"J9\RVFQWR-'-O\ G-?C;]!]7(AL^=?;^@AL^=?;^@G!&MNWYON)
M4)=GSK[1L^=?:3 6[?F^X$NSYU]I#9\Z^W]!.!;M^;[@2[/G7V_H)53Y^)4
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M?OEPC\CW0CW:?Y(J_"T/IDE;)/+>&^!K_0D;>( *P%OP
M           07Z/C(D%^CXP#RKY[3[UG.3WK2?ZU2G,%7BIT^N>T^]9SD]ZT
MG^M4IS!5XJ6'V0?T'$_&?\.)6+;AY0PGQ7_%F0 !+2^_YB%'P_:^B;N/@FG[
MS<YO?7ACY#JS;?-2#P33]YN<WOKPQ\AU9MOE3-?/*^-^$A]53+G;-/(>C_@I
M?6U  #43>@        #Q%\(L^]#S-_G++;_O2P6<VI>KOUJ=)7PBS[T/,W^<
MLMO^]+!9S:EZN_6I8K9%Y/K_ !N7U5(JUMK\IT?BL/IS(  E=\60X J:HJ+O
M145%3_*\GX-=5T5%5$5$U7R5 XV7'-7XYY>@<^[AE=I=5^)NN\P3SS#KY%:\
MB<U[NY]\@C919=XJN,CG2WJEA8O186O%6K5:^Z44#-+3<*B1)+E21I2U$DE?
M$V6JV[XUW>?KX<?5K\:^DXW-/4RPR1SP2RP3P2QSP3P2/AG@FA>V2&>":-S)
M89X96LDAEC>R2.1K9&.:]C5.@!S%O/&1YQ6FERMS'N4+<U+)0N2V7*=R0NQY
M9Z")NW6-1R-C?B&AA17W2GA59:RGB?=&QZ)5JV!-HNHSI.>/PD+4F][$T8K\
ME)_UD$L^C?&2MX,G?Q6]VR.RW: JL:>C<;4O62W<+6E+.M"/BTZC?];%.T'?
MPDK/-+>V2@46OX)WTX=]?I*Q#9.X  !#K]GSGQQSAGW#,V?>#B7Y-G/L?K]G
MSGQQSAGW#,V?>#B7Y-G.[HW^D8?X:E].)T=)_P!&Q'P%7ZN1R<:?[7'_ )#?
MZJ%8HT_VN/\ R&_U4*Q=)<$4%!N(^"6_NW/+^)P%_7Q0:=QN(^"6_NW/+^)P
M%_7Q0:-M(\D8GOI?61)!V7>6\'_S?JIFYVG%._4A4*:<4[]2%0JPOO\ G+C@
M &0   4N''X/6:M7A'7.9S8%PRW(_!=TDI<6XTMZ3XOKZ&5\578L'5#UB6@C
MGC5KJ>LQ0L<U&]S?KD=G;7;*PR5$$S=C?/G..SY>8-Q-CB_2-BM&%[+<;U6N
M<](]N.A@?,V!KU1R-DJ9$93Q*K51LDC55%3<<GKE%9\7_-#'6*LPL3U"U%ZQ
M9>*N[56NJ,I897)'06VG;M.2.CM5NCI;;1PHNL5-2Q-<Z21'2ODO9GJTL9BW
MB:L;T<+NR2:O&=5N\(M/BE9RDNR*=TV1'M:ULE@<''"4)..(QB<')>-2HQ_*
M-/DYI[D7E:\GQ2O^+(B)N1-$1$1$1-$1$1-$V4W-T14].]&JNRJD0"RM_F5^
M?#A;S9%4Y/B^]I+YK?BV?$!51-ZZ(B;U5>"(G%5\R=9!RHB*J[D1%557AHG%
M?0G6;>W,?\Q92WVGLN=&=-M=-:Y6Q7/!& JR)J4]QAD;#-;L38D8YZOEI'(J
MSVJR/8D50BTU?6N?!LT+_"U@U@P^CL.ZV(?93IKQZLK748]7:WE%9OD;!JUJ
MYB=)XE8?#1O:W25'XE&+\:4W]%*[D^'-KR=YO;F0\X,^DI;ZZC_8'E],J/\
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M5J;]2JXJ,I12M3A:[M&"X9YMN7,E3C\/K12< U8W,
M
M
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MJ<7G"2>3BT5;TQH;%8"LZ&*HRHU%=V?BRC?*4)\))]:_T40 >B>8[<@  8
M Y6ZP9?#V(+A:*ZENEIKZZTW2AE;/0W*UUE1;KC1S-WMFI*ZCD@J::5/X,L,
MC)&IJB.T4Q .,HIJTDI+FFKIKJ[NSAV&8R::DFTUP:;35N%FN%N5N!L/\D'P
MAS,;"*4MIS0MS,Q;'"UD*W:%T%KQ?%&B)&U\M1LMMEUD:Q&M5]3%1U$K6(DU
M6Z61]0;/O)2YRG)S..&-N#<74K+NK&NGPO?FI8\24SET16K;:M^S6L:[1JU5
MJJ+A1*YS6MJ5<Y&G-C]/T?I]FGLW%>EJI8)HJB"62"H@D26"H@D=#/#*W162
MPS1*R6&1JIJDD3V/3=HY-END?:<V:Z/QF].DO4M67MJ?Y._;2R2_5W23M6]K
M.D<$HTZ\HXNE'+=K.U6V64*JO)RMPWU/O.L.CNW<O7KU+O\ H*B/7TG/CY+?
M/<9[99K24,]\@Q[ARGZ.-]CQFR2LJ&4[$V5CMV(*9T-XH9=C=$ZHEN5'&[1\
MEOG3::[8YY,/A F2V-&P4F+UK\M+U)L,D;>T\=L,DNB;:P7N@C<D<6TNRSQ^
MDHI5^V/ACC\HA[3.SG26#NU26)IJ[Z2C=MKK=+QXY<\UVDYZ"VHZ)QN[&566
M$K.RZ+$)15WU5<X/NNGV'O2V3J0K)+U*A_%X0QG:,0V^GNU@NMMOEJJDVJ:Y
M6>OI;G03IQ7H:NBEG@D5J?9M9(JL7<]$4_IDE\_J75/C3]!HLHN+<7%*2XQD
MVI+]7BWV$BP<9)2C+>3S3C9Q?GNTC(H[L4JI(J=AC>D\Q5;(<?QPM\CX&?QQ
MO\JR9DVS^<JME[\#%)(5$>G4 9;IO.5$E]!AVO\ .5>D7]6@!ETE)DF,2DOF
M4J)+Z0#*I,3I*IBNF)DE3S@&5Z8BD_?>8KI$\Y-TGG4 RG2^@CTR]OPF+Z8=
M* 93IE[?A(=+Z#&]+Y_@(=-WW &3Z?S_ !DO3]^ZF-67TDJRIU@&2Z9>_P"H
ME6;OJ8[I4[J2K-WW@%^LW?\ 62]+Z3'+-V]_B)%E\R@&163T(4W2]6ICEE4E
M63K5?@ +U9BDZ;]/="R67UDBR %XLBKYBBYW:I:NE["GT@!<+(4G2]T+=7)U
MK[?G[#%7B]T=OI9Z^OJZ6@H:6-TM36UU3!24E/$W>Z2HJ:A\<$$;&JCGR22-
M8UKD55TWF5%MI*S;X+VS[O\ 1,2DDG*645QEDDN^YF5D]7?X=.Q$5>Q"DY_K
M7Y^ST^CAJBKHBZGC%RG.?4R)R^2JH[3>9LPK[ CV-H,(MCJ;>V=JJU&5%]J'
M16MK6O1'/?3RU3%C571+,Y-A=<CE2<_=G=CY:B@PU/0998?DVV)2X;1U3B">
M)ZZ*E=B:M9T[7JSR52ST=H9LJK)?&=$>;MH74#2.,:?1.A3?]96\#+]&%G.?
M?9+M- T_M+T5@$UTWJFLG;H:%I6[)5+]'#SRNO<FY!RF^7-E7E!0OK,?XPMM
MGE1J]!:(5?<L05\B*C4AHK';VU%QF<KG-:^5T$=+3H[IJNHIZ=LDS-9+E>>$
M<XFO3*FTY.X>_8K12-=&W%&)&TU?B!VJO9T]%:8WU%JM[^C2-\/C,UPDB<BJ
M]KFNZ-NM-?+Y77.LGN-SK:NXW"J?MU-?7U,U965#]ZZS5%0^263[)?LG*J)H
MB*B:ZXOV^W7OKUZZ^K0E[06S# 86TL0GBZV3O4CNTUW0SX?I/,@_6#:]I#%;
MT,*U@J#NET34ZSO?QZO%75K='%;K]MU?W&8^9N(\87>IQ!BR^W;$E\K'*ZHN
MEZKZFX5;D555(8Y)Y')3TL*N<VFHZ5M/24T.S#3P11-:QO\ #]]>M?.Y>M>I
M%7^"B)U $D4Z48*,8145%622R2Y)+@DNRQ%52K*;<IMSE)[SE+-N3XMMYW?6
MV  <[_C[3YV7&ROS?-@      =^^NX=_-U[O3PW<=%U/0KD'\VIF-GY=&-P[
M1+:,)T\ZQ7?&]UAD99:-8UUDIJ#39?>+ELZJVDHU6.'95:NHIU6)DW3QND*.
M&IRK5ZD:5."O*<GEUI6XW[%S.[@-&U\76AA\/1G6JU/$A%<<U?N6=G)M12SN
M?%&7N75_Q;>:'#V%[/<+_?;G+T-!:K73255942+Y.K8V;.S&Q519)9'1Q1)O
ME>Q-YN8\V3S$]DR_=;\;YN16_$V-H^CJ[?AMJLK<.86J$<V6*2=VB0WZ\T[D
MWU"HZUT\R:T;9UC952>GO(6YN3+C(2RK184H'5U_KHV+?L7W=(ZF_7B1$1%B
M2;92.V6N/1OBUJMS8:1CEDGE\:K)JJKG^_&Q_-^O]":(G4B(A 6M^TJIBM[#
M8'>I8=74JOBSJI]6>47PR\*SLRRVI&RFE@]S$X_=KXFRE&DO"HX=K-)-J\YQ
M?&645)+=7,ILC[$[$W:<$X;MR<-VY$]!=L9KNZN_ JLBUZMW4GSEZR/3@11?
M\?;WDR))<$EW</Q^$4HX]/07C(]29D?K+V*(&26.,OHXR9D1=,C_ % $&,]A
M=QQD8XR]9& 0C9H73&>TF8SVETQGZP"#(RZ:SV!C-Q=,9I]  8SAZM"Y:W0@
MUO65V-U (L:5TW>D)N^@G;\8 1OM*J)IO]@:G63(FN]?8#DEUAJ=:DX*C&]8
M,-D6(3@ P               #5[\*D^XQ@?\8$/R/7&T(:O?A4GW&,#_ (P(
M?D>N-IU)\K8#XQ#[33=H7D72/Q:?V&AF "V_5W+YD4J?+\<V#I\<R']ZEDM[
MVJKY>O!S!SI\<R']ZEDM[VJKY>O!$6V#^AX7XS_A5":]AO\ 3\;\47UU(]6
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M^VG^2*OPM#Z9).R3RWAO@:_T)&WB "L!;\
M $%^CXR)!?H^, \J^>T^]9SD]ZTG^M4IS!5XJ=/KGM/O6<Y/>M)_K5*<P5>*
MEA]D']!Q/QG_  XE8MN'E#"?%?\ %F0 !+2^_P"8A1\/VOHF[CX)I^\W.;WU
MX8^0ZLVWS4@\$T_>;G-[Z\,?(=6;;Y4S7SROC?A(?54RYVS3R'H_X*7UM0
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M15;$2MX6]*\H0[%3C+=MU[SYDFG G -.2-^
M
M
M
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M.U4Z*K](Z.E8UF(XH6(J*^VPLKY&L1S;=*][T;/VK&TK"XS<I8FV%Q#LK/\
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MW_6[\F;<;8IJ=>"=_<[S;]_UN_)FW&V*5.U[\K8WX2/U<"Y^S7R)@/@Y_6S
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M:-;2VCZ<E=/$TW;D]SP\^SP?/P-_EJ=_0I,2\-WI)BH1=\  R
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M+T*P  ,@
M
M
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M5'35E9+)5UDSDW(Z6IG5\\BHFY%?(_<FNC2D >NDEDE9=AX<IR><G=L  R8
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M!PI\B49#FV7\A@/A*WT*9/.PK\OI+WE#Z=4^HP 0$6/      !!2)!>'=?@
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ML;\)'ZN!<_9KY$P'P<_K9@ &HF]               '\OC;_ (FN_P#-=?\
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M47>+G=6DD^:+!;-M!XG1VC5AL7!0K=/5G92C);LMW=SBVN7R$P -*-^
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M>'J-)<7N+?LN_=-GU+Q2HZ6T?4?!8FG']N\/[QT\T0B2M7OZU)BH*+P@ &0
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M&Z_X)A^]?.OWRX1^1[H1[M/\D5?A:'TR2MDGEO#? U_H2-O$ %8"WX
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M14U3RHY&KN54[%,X4O::;3XIM6ZK9%]8M-)KFD[]C28  .0
M
M
M
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M3G!KS22?GX+F1 !V%^.5^ZYU5^,U?OM>]@
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MU+PYVY[J@FG[Y+F27LHT.\5IBE-Q;IX2,L5)YVWX^QTT^5]Z2DD^.Z^H]YD
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M23K02IXB'MHUH*TG;CNS:WHOFGV%8$J.)C5S<        0U (@E1Q,
M    "5>KOUH3$J]7?K0 U6_"P/N296_C1=^1N)C15-ZKPL#[DF5OXT7?D;B8
MT52SNRWR/1^%K_3*C[8/+=7X##_0!%.OOUH0(IU]^M"0R+UQ7>=(GP<K[T?+
MO^>,Q_\ O)Q8>XQX<^#E?>CY=_SQF/\ ]Y.+#W&*=:R^4<=\;Q'ULR\^J7DS
M ?%:/T$  >(;"      #R9Y\C[U?-WWO1?*5">LQY,\^1]ZOF[[WHOE*A/7T
M!_3L'\9H?61/$UE\GXWXM6^KD<Q4 %RGQ91%<$#=?\$P_>OG7[Y<(_(]T-*
MW7_!,/WKYU^^7"/R/="/=I_DBK\+0^F25LD\MX;X&O\ 0D;>( *P%OP
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MF[M2@E>7NU+L/Z($B.4G-%)&       !  B"5%\Q,@
M
M
M
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MR:=CG&W_ !-=_P":Z_\ U68XXUG_ ')2_P G@_LFDY;&N&D>_"?-B2O.W?\
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M$=JJZZ:(F_4;KZGZ']PZ2/NH^E&0!1:N_=W^,JIYSBG_ *=QR3[NVV=GU$0
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MR<6'N,>'/@Y7WH^7?\\9C_\ >3BP]QBG6LOE''?&\1];,O/JEY,P'Q6C]!
M'B&P@      \F>?(^]7S=][T7RE0GK,>3//D?>KYN^]Z+Y2H3U] ?T[!_&:'
MUD3Q-9?)^-^+5OJY',5 !<I\6417! W7_!,/WKYU^^7"/R/=#2@-U_P3#]Z^
M=?OEPC\CW0CW:?Y(J_"T/IDE;)/+>&^!K_0D;>( *P%OP
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M!?U\4&B[2/)&)[Z7UD20=EWEO!_\WZJ9N=IQ3OU(5"FG%._4A4*L+[_G+C@
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M$G&<)*SC)9--$NX/%TZ].%:E)3IU(J<)Q=U)/A;\73R:31, #XG9
M
M
M
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M[@@ :G9Q[>I"9&^TBB:$^B=OJ (:$WHX=9%$U]'85 9_'XR)6MT)B*(54;H
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MT;Y5*BS3J+C&+\3B_"MNS(S<-%T[]^!.A$AU>GO)U_#((1 ,@
M    \@>?M^])SB_F[#/Y<88.9<O%3IH\_;]Z3G%_-V&?RXPP<RY>*EB-D'D_
M$?')?4T"KVW#RGA?B,/_ )&((  E=\OQR9"[^[YS>+\$[^YWFW[_ *W?DS;C
M;%-3KP3O[G>;?O\ K=^3-N-L4J=KWY6QOPD?JX%S]FOD3 ?!S^MF  :B;T
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M+>_SX_.0/4M+\W#]B/W#U;6_/5?WL_XC]&_NQXQ_QPQ9_G+>_P ^']V/&/\
MCABS_.6]_GQ^<@>I:7YN'[$?N'JVM^>J_O9_Q'Z-_=CQC_CABS_.6]_GQ]Z<
MUKFIBFJY1^2-+5XGQ)5TM1F/AV*>FJK]=ZFGFB6H55CF@FK'Q2QN5$U9(QS5
MW+IN/,4^_>:H^^6R,_&3AW_6''DZ?PM+U#C?8X?T3$>TCDU1G9K+BGFNT]K5
MS&5GI# IU:K7JS#73J3::Z:&36]FGS1U36,W:>O5-.OU)\14;P#?F3YPS@4[
M77YOE+RDP ,@      D5/,8J^6.CN5%56ZX4E/74%?3S4E=1U<3)Z6JI*B-T
M513U$$J.CFAFB>Z.2.1KF/8YS7(J+H9@E=P"=LU>ZLU9YW7-=IAQ3332::LT
MUDUU/K78<Z7GI>9MN&0-UGQS@BEK;ED_>:_1'Z.JI< U]=,_Q:R7.9%69UCE
MD5M)8[K4MT8YU+:KA5R7&:DEK_ M$W=6Y-?0G:O8U$_A+HFB:ZG8LQ1A>W7N
MW5UHN]#27.U7.DFHKC;JZGCJJ.LHZF-T5135-/,UT4T$T;W,DC>U6JU32'YU
M7P=:_88J;GCW(6EEO^%7=+773+[:=)?L/KKTDLN&E<CDO5I:FU(MMD>VZT*)
ML4ZW&F>D=#/NH^T:G4C'"8^:C65HT\3.5HU4LE&K)JT*BRM)NTTG>TK;U:MH
M&RZI2G/&:.@YT7=U,+"&].B\VYTTLZE-OVL5O0;LDX^+JE@N*REEIYIJ:HAF
MIJBFED@J*:HBDAJ:>>)=F2">"5K9H9XG^1+'*QKHU31^BJB+;DQK@FN?"2X-
M?H]G @Z2L[-9KBGQ3[> '?L]/;YM%T\E=Z;P [=2[S"RX9=WW\?->PA1(Y63
MQZQ3L75D\:[$S':ZHYDK4:]CDZE8K571%54755_3K9G=C:B;L46-,843=EK$
M;28HOE*U&MUT;LP5[6[+$55C:K7,155=-Y^8@^4Z$)>-",O?14OI7/O2Q-2'
MB3G'WLI1?IBT?I-VSFQE7II78QQ;7:M:U4K,2WNJ39:YST;_ 'Q72ZL1SE<U
MNB(UZN5K4U/S)86*]TJHBRNT5\BM1TCUTTU>]4VW+IHW>Y55$^SZEJ S"C"/
MBPC'WJ4?HV,5,14GX]2<O?2<OEDV15>_S>A.KK[54@ ?19</L=^^]^\^#65O
MQ]U^TG:]S5:K'/8]JHYCV.V7L>UR.8^-R(NPYK_*1VCEU3=IY*ITO.9)Y?;,
M]\G*":Z5<<F.L#^*X8QE"KTZ>::.G_X(ORQ.<Z5*>^T<+WMF=M))<*6Y0I(Z
M2EGTYH.GPZ^;AKV[^I.&JZ+JB*A[F^#UYI9@8;Y0=MBP9AZ\8EL6(*+W#S I
M+9&UU+;[%+(Z>AOMPGFE@H*9]HK8W3TJU-3%4RP/N,%$R=TTL,FA;1-!PQFC
MZM1N,:N%4J]*4G&,<MWI*;D[*U2*\%7SFHVOP)(V8:PSP6DZ5-*4J.,:H580
MC=YWZ.HHQ5[TY-7=G:GO7ZSH_M7AZ/A)RFUR*JZ=^K]!4*MQ[K=G&Q<!  &3
M(   )5ZN_6A,2KU=^M #5;\+ ^Y)E;^-%WY&XF-%4WJO"P/N296_C1=^1N)C
M15+.[+?(]'X6O],J/M@\MU?@,/\ 0!%.OOUH0(IU]^M"0R+UQ7>=(GP<K[T?
M+O\ GC,?_O)Q8>XQX<^#E?>CY=_SQF/_ -Y.+#W&*=:R^4<=\;Q'ULR\^J7D
MS ?%:/T$  >(;"      #R9Y\C[U?-WWO1?*5">LQY,\^1]ZOF[[WHOE*A/7
MT!_3L'\9H?61/$UE\GXWXM6^KD<Q4 %RGQ91%<$#=?\ !,/WKYU^^7"/R/=#
M2@-U_P $P_>OG7[Y<(_(]T(]VG^2*OPM#Z9)6R3RWAO@:_T)&WB "L!;\
M                        $%^CXR)!?H^, \J^>T^]9SD]ZTG^M4IS!5XJ
M=/KGM/O6<Y/>M)_K5*<P5>*EA]D']!Q/QG_#B5BVX>4,)\5_Q9D  2TOO^8A
M1\/VOHF[CX)I^\W.;WUX8^0ZLVWS4@\$T_>;G-[Z\,?(=6;;Y4S7SROC?A(?
M54RYVS3R'H_X*7UM0  U$WH         \1?"+/O0\S?YRRV_[TL%G-J7J[]:
MG25\(L^]#S-_G++;_O2P6<VI>KOUJ6*V1>3Z_P ;E]52*M;:_*='XK#Z<R
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MGQLLRT.Q+%59Z/Q%.;;ITL0NBO[53IJ4HK]:[:7-LF !%),X
M
M
M
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MXN5]U2G%Q3=L\F^1R#".[NGZ3I<LY@KDK]66<*?_ %8O"?\ V:I/^T$\E?\
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M>?.3;RO8LMJMJY1T5@Z>$I/>M>=2H^-2I*V]-]5\E&/",4DB( /#-C
M
M
M
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M2= G:9/HR78[[_H ,=T/?>.A[[S)=&.B3N@!C>A[[QT/?>9+HD[H.C[ #&]
MG:3=%WT+_8[[_H(I& 6/1+W0BD/?@7R1DW1^90"Q2'O^HF2)"^Z+S?"12+S
M%DD9/T?F+U(NZ(3I%Y@"R2/U$_1=]"];%YOG*J0^;X@"P;%YB=(B_2)"HV).
MI "Q;#VE5L)=I%YBJV/]0!:I%H56Q^;UERD:%5L0!:HPK)%H7+8RJUG8@!:I
M'YO@^<JI&7",[2HC>Q "@C.K3VE5(^Z%=K.TK-9Z@"W1JE5L>G:5T:B$Z-4
MIHPJ:$[6?J*VSIQW %%L?ZBMLHG'=YB9J=F[SDR-]8!+HJ\-R=A.UNA-LJ3)
MYMZ@RD$;V[B.O8GK&SKQ*@&7G)$83@J-9V@-DK6ZE5$T(@&
M                                         "&A$  AH1
M
M                (:$0
M                                  0T(@    AH1
M
M
M                 (:$0
M
M
M
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M
M
M
M
M
M
M
M
M
M
M                    05-2( *:L["F7!!4 *!)L=FXKJSL*>@,IE)=>O>1
MV47@5"16:@Q<IJFA)LIZ"MHH73KW* 6ZHO7O[^8EW>@N%;Y]2&@!;K'KYRFL
M?J+A6$-%\R@%LK%*:M0O=W6BD-CSH 6*L3J).C]!>NC\Q(C/. 63H^Z$BL+W
M0@ 6*Q^@D6/S>PR"IJ2='YP"PV$)5C,AT9*L?F +#H^^JDO1^;XB^Z+TD.B[
MZ %AL?\ 54AL(7_1^<AL %@K._="7H_1W]1D=A1L* 6'1IWT)=A.Q?8A?]'Y
MAT?F^( L-A.Q?8A%(T[/B+[H_-\0Z/S?$ 6'1>@BC.^OZ#(;"C84 L>C]'M_
M01V/,I>[!'H_. 621^;3V?.3]'WX?%N+OHN^A%(_-\8!9]'Z"?8+SH_,3; !
M9MC\VI.D?J+KH_.3-;H 6J,)D8GI+HCH 44C]!,C"OL$S8_6 4$30G1JEPC/
M0A,B)YU +=&%1L?FT*FB^A"*, )51$[H11%ZDT*B(3(WMW %-&]N\F0G33TD
M=%7NB+W]8,VZ\O,01O;N&O8A%&$^@#L2HWM7U$R)H1)T8 V2$Z,*B)H1!@E1
MJ(3
M
M
M
M
M
M
M
M
M
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M(!D2;UX)IY]Q'8[5)P!?L((FA$F1BE1&Z P4D34F1G:50 01$0B
M
M
M
M
M
M
M
M
M
M
M                                      "56HI, "FK.PDV5["N "W(
M:%PK44E5B %#93L&SZ4*NPI!6J#-RBNO4-I>SX"H +]GSE+5.Q0B)YRJ05$
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MC.TCLH#!21J]A,C.TJ@ E1J(3
M
M
M
M
M
M
M
M
M
M
M                                 $-!HG81 !3Z/SCHRH "BK%(:+V*
M5P 4-%[!H5P 6X*RM0AL( 4@5=A!L( 4B&B=A6V$&P@!1T3L(E780;" %(%7
M80;" %(%780BC4 *)'1>PK@ H:+V*1V%*P *6P1Z/SE0 $J-0CHG81
M
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M.CL?5='"8N%>JH.;A&-2+4$TG+PJ<4[-I//*Z/N9%(D$(GA(V8  R
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M.K!/H5&$J<7&,\E-WG>\4XY/,]GT74F)6IYNLF-9CP^<VX  R
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MM'XO'>H,+5=>HH3G*<%>DE#=36^_&=Y>UNNT][D!+KV$QK!N(
M                )4ZR8IJOQ]2[^)QD_P 9_,N(_'X?(BKM.KX25RZ>8\).
M7_S]&7F0.8D^6URPKB+%-XH+-:[K=:FR5=L@IK;-=TGJ*6UU#:R1DJUR6YM'
M<I%1B1>*W*B5KW/61L?Q--X5YEFC7.3*O';E:U7;+;C8=7*B:HU/K^B*NY$7
MAJNBFSX;4S2E:G&K2P=6=.<54A)2IK>@UE))S3L^2M=FH8O7W1%"K.C6QU*G
M5IR<)P<:C<9K)Q=H-73YWL;7#5(GYQE#F=:,:X5PYC&P5"55DQ58[7B&T5*?
M^OMUVHH:^CDTTW*Z"=FTU=[7:HJ)IH?HNTG?SFN3@XMQDK2BW%I\4T[-._-/
M)]IM=*K&<8SBTXS2E%K@U)737>LUV$P .)]             04B6-SN-/24T
M]5530TU+30R3U%142,B@@@B8KY9II9%;''%$QKGR2/<C&-:KG*B(H1ANRN\D
MN+ZNTNM?4B><@B[U77S:&NMRTO"0<ELO?'+1E\]^;.)(6.:V:Q3I#@ZGJ4VD
M2.?$[F/AN+6JB.D=8HKC3[+MCQI)V/A9\9<RKSJ.<7*%Y3.(*3'%\@I\*TF4
M6+;K:<$62ECHL/6ZN@QGES24MPDVFR5]TND%%7UE)X]<*N5K&5=4E#344=5-
M$NT1U-Q_J6KC*M%T:%*._>K>$IJZ2W8/PN-G>2BFN!IT]?=&^K*. I5UB,15
MGN6HK?IT\FVYU/%Y-6BY._&QM\*OGX?$3E!K>&O??H5D\YJR_'G-R_U(@ R
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M6I&K1DVHSBFDW%V=KI/)IIY<28 '3.^
M
M
M
M
M
M
M
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MY4C)FVN7_DRG?^V4[6ZNCKV((V+6_E:LU_8*J:XYJI0OZ38$ !6\M4
M "&\ B""*1       !KH>%!(B\FNBU373,W":IZ?<_$7L[-?CX+L7FNEX4!]
M[71_C-PG\GXA-BU12>E-'W5UZKH9=?LD35]=G_Y1I+XEB.'P<CGN]^_I75?7
MVZZ[\W@M'W"\4_C N'^H4!H,&_/X+/\ <+Q3^,"X?ZA0$Z[5%;1+7+U31\WC
ME==CC7\M*RM_-<1QS;_)YW-F5O'V?$I4*;>/L^)2H5G7/\<D6Q7!  &3(
M                     /YW$^)J.SVVX7:X2I!0VRCJKA63.5K6Q4U'"^HG
M>JO5K4V8XW+O<B:Z)JFI_1'A)X1!RJ/[F_)UOEHHJE8+_F;7T^!+6D:Z31V^
MLBGKL3U::*U\<<5@HJNA94L7^]Z^YV]=ZO:B^AHG1TL7BL/AH\:U6$.Y-J\N
MZ*O)]B9Y>FM)1P>$Q&*GXM"E.IRS<8MJ*OSE*T8];:1H*<KK/NJS2S0Q[F'5
MJJR8MQ-<;I"BN>Y([=MI2VBG9TFKTCI;534=-$QR_68HF1)N1I\Z]_F]/7IN
M5%\_4I$3J3S)YDW?0FOHU(([7AZ_-P7?_@KIOT=H[S;E+DT,-&E3A2IQM&G"
M,(1ZE"T8I>9?*42Q.)G6JU*LWO5*LYU)M<Y3E*4I>F7V'05\&9Y3RXNR)FP)
M75#IKIEA>ZNU4Z2.:Z5V'+S++>;2B:NZ1[**:HK[<Q>C;'#3T])3LU6-438X
MU3L]?H.<-X/'RIFY=<HBS6&OJ?%['FC2/P75K(_9@;?'=)6X4DE7_#J+HR2R
M4B(U5=67N#54:CG-Z/#4T\^_?ZRKNT;1#PNDZVZMVGB;8BF^5YOV1?MJ3MU-
M=9;S9?IOU9HF@I.]3"_S>I?C:FET<NW>A97[.?$J)P0B$!I!(B  !D
M @NHW@$3YKY97W(\SO>#BWBFO_L*NZCZ40^;.63]R/,[W@XM^0JX[6!_+T?A
M:?TT=+27]'K_  -7A[R1R.:-$Z&)$X)''IV(B,:B(B:*N[?_  M-Z^2BFR/X
M+.G_ *2V(U__ $(XP^''65WT&MS2?:HOXMG]5#9%\%H^^6Q'^)'&'Y=96EI]
M>$OY(QMLET$<N2\4ISL]\M:/XWZ9MW=V\JAT#^OO_A%0I]??_"*A4XNF
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M."$;[3?+&(^#H?5(EC9+Y#PWPF(^NF1 !H))0
M
M
M
M
M
M
M
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M>>1JQKS@]+3JPPL*WL,%*<JD%&"WK[L;J3SDDVNQ'U."DS7K]7GW%4U4W0
M     $%4,$3GZ^$U<J!<79UVW+^CJ5DMF6=E9%50L?K&W$6(XX;E6](Q=4;/
M!;&6MB.1J(L4K%5'<4WP\W,SK7@O#&(<77N98+/ABS7*^7*1%9MI1VRDEJYF
MQ)(YC'SRLB6.GB5[5EG?'&U45Z*<C7-?-*ZXZQ3B/&M^<C[UBV^W3$5R1KWO
MCBJKQ62UTM+ ]ZJ]M)1=*VEHHW:]'2P01ILHQ$26=DNB>EQ=;%R7@X6&[%VN
MNDK)K+M4+KODGR(3VV:<='!4<%"7AXN;G-)V?1T6I*_8ZEG^K;F?Q%)0SU4T
M-+2QNEJ:J:*FIHF(KGR5%1(V&"-K6^4YSY7L:UK=[E5&IO4]F^>IY L>0^)\
MLJ&AITAMU^RSLL52Z-$=!)BG#K&4>)W-F:QC)99JJLIZMRM1=(:BGU75=_\
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M=D;/ZJ&R-X+/]\MB/\2.,/RZRM)KUX\D8WMH)^AQ1 .S[RW@.RLUW^#-_:=
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MM7LE\AX;X3$?73(@ T$DH
M
M
M
M
M
M
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MJJ="'9(Z=>Y/1V$/8W:MCJ]&K0G0PNY5ISINT:EXJ<7%N-ZC5TG=732?(G#
M;&]'X:O1Q$,3B]ZC5A5BM^FHR<)QFE*U--IN*3SX97YD6KN0F((1(O)>/SO-
M3-"Q8*PW?,6XFN-/:</X=MM7=[M<*E^S%345#$Z:9^G&21R-Z.&"-'2U$SXX
M(8Y)9&,=S-.=)YSC%7*0QM/7U,]9;, 6:HEBP9A+I5;2TE,U71^[5RB;LMJ;
M]<H]9*B>7;=10O914BQQQJLFP-X4ARU):*@POD19ZE6.O44.,<:-AE<W6V4M
M6^+#MKJ6M1$DAK+E2U5P=$Y[F+[EPNDBUZ%YI<HNF_AIJO'M1-=Z\-R:*O\
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MU#9L*XJ2*-'>(X?Q-&ET>Y'2*K88+O1VNDD1K4:J:5T;G*[HVQ.5%5_B5CS
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MB #022@
M
M
M
M
M
M
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M &BDC@
M
M
M
M
M
M
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M,86IH/3DMRZ6&Q,*]*%K;U"<G-1NN3IWA+-VNUF=D!R_-Z34K\*AY5WN7A+
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MU$1$1$1$1$3@B(FY$3J1.!. +$-!H1 !!41>*!$(@
M
M
M
M
M
M
M
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M6.U0F-7-S!KI>% ?>UT?XS,)_)^(C8M-=+PH#[VNC_&9A/Y/Q$;'JAY5T?\
M&Z'UD35]=O)&DOB6(^KD<]PWY_!9_N%XI_&!</\ 4* T&#?G\%G^X7BG\8%P
M_P!0H"=-JODI_&*/]\KIL;\M+XKB/GIFS*WC[/B4J%-O'V?$I4*SKG^.2+9+
M@@ #)D\[N=8Y*;LY<ALP\%TE*RKOSK'47O"<3ME'.Q386/N5FIV/<YK8EN4\
M*VE\SE5L4-?+(K7;.B\K]'*J:JCFN_A->U6O:[K:YKD16N1=45JZ*U4T5$4[
M)KFZKOX+NTZNZ\.^AS#^>KY*+<H^4+C6UT=.ZGL.*:C]G%@U1R1+38AFGJ+A
M3PN5&M<VFO+;C%L1-;% Q60,1&QIK->R'3-IXC S>4ET])?I*T:B7>E!\O%D
MROVV_0=X8;2$(YQ<L/7?Z+O*E)]B;J1[Y1/M#FQN<UJLK.3#RB\(LN'B]]MM
M'35^7>U-T<\5VQX_]C-5+;VZ(^26S5#?V1S,16-:RG<UNBR*IKHQL:QC6-W-
M8U&IKO31-&[]?,B:N75RZ;U554JH]416HJHBZ:HBZ([373:1-$<J:KHJ\-VF
M]-]"65(V.>Y=&L:YRKOW(U-57T:)OX;NM.)+V!T-2PU;%5X+P\54C4J<,G&"
MCYU=.>=_#G)\"$=)::KXJC@\/4E>.#HRI4O>RGO6?7*UH*V6[&"XIFU[X+5R
M2O=C'.+\XKE2(^CP?;GX5PQ/-&QR)?K[$V2]5M/MIMQST=D:RW,J(M6+#>;C
M3;6BO1V\JU-/T<.!YD\T%R579/\ )]R_PS64JTM_K[3#BC%,+V;$T.(,21LN
M=913)_\ 3;5'-!:G[U17T;WHNCSTW:A5[7/3#QVDL16O>$9=%2MPW*?@IKWS
MWI]\BWNH.@UH_1>&HVM.<.GK=?2U4I-/MA'=AUVCV$0 :N;D      "#N U)
M)96L:Y[U1K6(KG.541&M:FJN55W(B(FJJNY$0!LT^?"J^5*E-;,O<F;?4*D]
MUFJ,>8GBCD5-FV6^22UX:I9XT54DBK[I[JUR;6RZ*6Q0N;KTB[.ERJ^;CQWH
MB?#HFY-W4JHFNFNIZ+\['RFW9MY_YB8KBGZ>U4UW?ABP*B:,99<,J^V4VQHY
MS7-FGCJJSI&+L3+5+,U/KBJOR#D+E!79@8WPE@:V[?CN+<16BP0+&J(]BW*L
MBIY9F[2*U%@@=-,U7:-1S&[2[.T6SU0T=#1VBZ$9^#*-#U16;]U43J2O:WBQ
M>Z^%E%=12S772DM)Z7Q$H^$I5_4^'BK9QIRZ&#C>^4Y7DNMNZR-]GP;/DKNP
M5R?8\67.D8R[YJ7RHQ6U9F-6:/#=)"RT89A5=%:L51!3UU]IW-<J]%?D:Y4<
MBL9L(^(0_P#TF'_X;/\ PG\AEAE_;L)X<L6&+3%'!;,/VBWV:@AC8D;(Z6W4
ML5+"C6-\EFK(D79;N371-VA_=Z%7M,Z2EB\7B,0[KIJLII>YBV]V/'VL;+S%
MN- :'A@L%AL+%*70TH0<FE>4DKSEPXRFY2\Y9^(0_P#TB'_X;?\ PCQ"'_Z1
M#_\ #;_X2\T[_ -._?T'F[S[?3_J>OT:]S'T+[BS\0@ZX(?5&S_PEG76*DJ8
MIJ>>DIIJ>>)\$T,D,;HYH96.CECD:K=',D8Y6.:J:*U7(O$RZH-GOO&]*Z:=
MK9\0Z46FG&.>3R7W')MY??)OJ,H\Y\R,O9HWLI[#BBX/LSWINJ,-W5WNSAJH
M1^RV-[Y+-743:I(5V(JQE53NT= Y"WY"G*:ER>S=P'F*DLT=%AZ_TC[XV';5
MTV&ZQ?$;\Q8HM'5&Q;)YZJ*EX2U5+ BKPTV/O"J.2\E+?,O\X*&!=FZ4LV",
M02,8JMZ>@6:YV&:5Z-V6:PS72F;MN<Z9R1MW-@1%U#%35%14U1475/-IO^#]
M2\"VFKN-AI/15)U%O=+0="LOTHITY_*E+N92W6C 5-$Z8K1IO=E2Q$<11GEG
M3<NFIKS-VN_<M'9"MM?!500U--)'-3U$4<\$T3FOCEAE8CXI(WM56O8^-S7-
M>U5:YJHJ;E+UIXU<PURG4S+Y.."TJ:E)[U@:G_8%=T<]'3Z8>9'3VB:9%U>B
MU%D\05'2.5\JL?*NBO5$]E4XKV%5])8"6&Q-?#S\:A5G2?;N2:WNZ7%=Y<71
M&D(XO"X?$PMNUZ5.JK<M^-W']5NS[B8TU/"N>3Q,]<K\U:2GUBIVW3 M\F;&
MYRM942>[.'W3/TV(88IVWJ!CGKI)47")C/*71VY6?&7+^Y)=OSORFQCES6NC
MAJ+S;9)+'72(BI;<142+562N7R7+T45='%'5(Q$D?12U+(WLD>R1OK:IZ8]0
MZ0PV(?B1GN5>KHJBW)MV]RGO=Z7,\?730?\ *.C<5ADKU'#?H]?2T_#A;AQ:
MW>-L\\CD^&[IX+[RX**OPI>,AKS6,CNV&ZJXXFP9!,Y4=66&[5CJZ_4-+M+H
MYUNO=7/<GQ-U=L7=\NKHT332WQY@2\X6O=WPUB.WU%IOU@N-5:+Q;:ENS+1W
M&BF=!4P.7[%[-IJ/AG8KH:F!\=13ODAFBD?E\I,U\0X%Q-8\883N=19\28=N
M$-SM%RIOME/50[6J/9HK:BGJHWR4M92SI)!5TLTU-*QT<KFK9G6?0<-*8&5!
M2CX5JM"I>ZZ2/B-/G&49.,K<8O+.Q4K5/6"IH?2$<3NMJG>EB:5[-TI-=+"2
MY3C**E&_"<;.R.P4Q4WZ$YKT<W;X0=E7FA;*&T9CW&W9:X_CBAIZV.[3I285
MO54U$8^LLEYJ'K!21S/VGOM]TE@J*16R-26I@;'42>[=HS2PU<*5E=08AL5;
M1/8Y[*RDN]OJ:5S&IJYS:B&H?"K6IO<Y'JU.*J58TAH7%82HZ5>A5A-/G!M/
MMC)*S74T[%Q-%ZPX+&4E6P^)I5(2S\9*2[)1=I1DN::^0_NE/AKG)LYL.X%R
M+S1OV)[@RWV[]B%YM4#G)MS5EVO=%+:;1;*.'5%FK+A<:RFI8(]6L1TBS3/B
MIXY9F?PG*CYV?(3*6WU%3B/,&QW"X1QO?!A[#5;38AOE7*Q-U.RDMLLS*9ZK
MHBNKI::.-J](]R,U<:%G.C\Z]C3E*XAB\;IW8:R_L=7)+A7!L50LSXW;"PMO
M.(:ENS#7WV>)9=EL$;*.U02NH*-U4K*BY5VT:G:EXO&XBG5E"5'#4IQG.K-.
M*ENR34:5[;TG:S:\%)YO@GJ.O6O6$P&&JTH3A7Q56$J=.C3DI.._%QWZMGX,
M$FVEXTFK)-7:\GX(U9&QBZ:M8UJ^E$1.Q.S7T=ALA^"S_?+8C_$CC#\NLK37
M"U_3V>G3M]9L>^"S_?+8C_$CC#\NLKB>->8K^2,;V4/[T2N>SWRU@'S==W_8
MF= [K[_X1%4[^PAU]_\ ")]"I37X[BZAX!^$JV::KY+UWDA:KFT.,L'UL^B:
M[,#*^>![UX:)M3LW]BIVG.L[]_.=6OG)N3E/FQD5F=@*B8C[K><*W"2PM56M
M1^(;6C;M8H'2.U2*.JNM#2TL\J;V4T\VB+O1>4JK'M56R1R0RL<Z.6*5CHY8
M98U5LL,L;T:^.6)Z*R2)[6R1O16N:BHI8?9#BXRP-:C=;U/$N;5\[5*44GW7
MA9=J?85@VW82<=(8:M9[E7"JG&26473J3?IM//L\YT#?!?\ ,"W5_)XN-B@F
M1;CAS'M_;<(-=7Q176&AKJ&5W8V:-)=GMZ)7:KM&Q\KMW6AR^N:CYRZ]<FO'
M_NPE-)>,$8B\5MV-[!&[2IEHHI'>+WFSN<YL3+S:%D?-%%*G07*F6>VS/IG3
M4U=0=%7DO\N#*S.*UP7/+[&=FOJRQ-FFM<=7%!?J#5K7.9<+).^.Y4KHE=L.
M?)3]"KVN1DK]ERI'>T'5S$8;'5\3T=2=#$U'556,6U&4\YQE;Q=V5[72NN!)
MFS'6K#8G1V'P?20IXK"THT>BE))SA3\&$X7?A;T4K[K;4LFED?6:!2FUZ\-%
M]>I\-\JKG),E\FJ.IFQUCJRT5PA8_8P]0545UQ+42M15;##9:%T]8R231=A:
MF.")=ER;?DJAHE#"U*LNCI4YU)OA&$7)Y]R9).*QM&C!U*U6G3II-N<Y*,4E
MVR:1]9Y@8QM5AL5WO5[N%):K1;+;5UMQN5=,RGHZ*DA@>^:HGGD5&1QL:FJJ
MJZJNB-155->0SF1=J:OQ'B.OHY4GHZ_$5]KJ2=&R,2:EK+K5U%/,C)6,D8DD
M,C'[$C&2-UT>QJ[CU^YU/GJL:<HN23#-KI9<&Y64U2R:GPVV=)+MB&6"1SZ>
MX8JJXGOII48J,DI++1I)0T4C5EGJ;A.V&:+Q-U[IW7AU>EVNNNZQ^SK52MHZ
ME6J8AQC5Q'1^Q)I]&H7=IR63J-.[2NH\&[Y*JNU#76AI2M1I817P^&5273NZ
MZ:<\FH)YJ$;>"VE*3ODHK/WZ\&C^^CH/Q?8U_K64Z*C.!SJ_!H_OHZ#\7V-?
MZUE.BHS@1IM6\J?_ (]#YZA+VQSR/_\ E5_[A,8J^_N&L_DM1_8O,J8J^_N&
ML_DM1_8O(VAQ7>OG)2J^)+WLOF9QU+O^[*W^6UG^LRGHQS.^<>'< <IS)_%N
M++C':</6Z]7^BK[E,CEIZ.3$N!\4X5MDU4YJ+T-)[KWR@;5U3](:.E6:KJ',
M@A>Y/.>[_NRM_EM9_K,ICG-145%35%TU3=HJ=BHNJ+ZT7T%S\9@UB<-4P\FU
M"K2E2G)<5&I#=;74^_*Q0S1^/EA<72Q,-USHU8U5&5]V;ISWDLK<5=99G9&@
MJHY8V2Q/;+'*ULD<D:H^-['IM,>Q[=6N:YNCFJU516JBHNBH7.UN- [FG_"!
M[WE12T.7V;\=?BO+^G;%3V7$=-MU6*<)0-T9XI41OD5<06*&-$6EA:D=VMR-
MDCBEN-*Z"DH=T#(GET9/YE4<-;@K,7"E[25FJ4<5YHH+I%HC5<V>U54L%QA<
MQ5V7J^F1J.1S4<NBE5M8-4,;HZJXU:4YTF_8Z\(N5.:Y>$KJ,K<8NS7:LW<;
M5C7C :3HQE2JPIUK7J8>I-1JP?/P7;>5^#C=/KO='UF4Y.'I/QW,'E$X"PG1
MNK\38TPK8*-C'2+/=K_:Z%CFL15<D25%2QTS]$71D+7O<NYK57<:K7.N^$7V
M22R7++_D^UK[C<KFR6BO&9'0RPV^U4$C594085BGCC?7W6K8Y8VW>5J4=LBZ
M1]/#55KXI:+IZ'U<QF.JJG0HSXI2J2@U3IJ^<IR:227I?),[NG]:<%H^A*KB
M*T+[LG"E&:=6H[91A%7=V^;LEQ;23/);PA7EH4V:^>\UCLE4VKPIE90282MT
M\3VR4]=B"HJ&U>+KE3O;]G#XU#06-BHKHI?<)]7!(Z.K15\(7R(UJO<J-:QJ
MN<JKN1&IJY57S)O55X)H5I)7R.<^1[GO>YSY))'.?)(][E<^21[M7OD>Y5?(
M]SE5RJYRGJUS,W(7J,]LZ[);*NDEEP=@]U-BO&U3L:TK:"EJ&NM5HED<QT2S
MWZY0I!#3O1ZU-#2721&.BI9UCM)2A0T3HY1;2I8.CW.4MV\FUSE4FVUQ\)M<
M"G]:I7TUI.4[.5?&UUNJ/"$;I16=DE2II1;ZH7YF]GS-O)OJLK>3?EAANXP.
MIKU5V:3%-]@E;LU$%UQ;6U.(9:*I1$1$GM5/<*:T/V=6_P#!Z:.DWR/]/RW@
MB2-C(XV-8R-C6,8U-&L:U$:UC43<C6M1$1.I$+@J3CL9+$5ZU>?C5JDZC_7D
MY6[E>R+KZ-P4,-AZ&'AXE"E"E'NA%1OY^-^T@O5WZE)?T_UD)E)-?C7YE.H^
M7XY,[C.1_P L;[L6;_XV,RORVOI]'\T+6Q4_*=R3EF>D<:8UACVG:Z;<]LN<
M$+=R*OUR:1D:+IHCG(BJFNI^$<N:R3VW/#.F@J6*R>ES=S,B>BHK4<W]FU\?
M%*Q'(BK%/"Z.>%RHFU%(QVF\_)LF,TJ_ V,,*8UM<:37'".)+)B6CIGR.ABK
M);)<::X>(32M1SV05R4[J.H<UKE2"HE5&N71I<B5!U]'.G#C5P?1KM=2BE#N
M3;X\%S*,>J%0TMTTEX-''NH\LFH8EREFN=DW;B^1V!1J?)_)HY;F66;6'+?B
M7!>+K+<*>MHH*N>WON5'#>;4^1C%EH[O;'S)54-52RNZ"9LL?1+(U5AEEC5C
MW?G_ "F.<RR/REH:BJQEF'AZGJJ=CW>XELKX+UB"=[$1>AAL]L?4UB2O1?(Z
M=D+':.V7KLKI4:.C,0ZG0JA6=6^[T:IR<K]5DKY%UY:8PD:73RQ-"-%K>Z1U
M8*-K7O=M'W<CM28^#.;RY<-+R@L#UF85JP[78>L$F([M9;'%<ZB*6XU]':'Q
MTTUPK(:=JT]$^:M\98RDBJ*OHX8V.DG25SX8OO)JZGPQ6&G1J3I58N%2G)QG
M%VO&4<FG:ZNGQ.Q@\73KTJ=:C)3I58J=.:O:49*\6K\FLT1.:AX0A]]MF=_)
M,#?D/83I7G-0\(0^^VS._DF!OR'L))>R3RE6^)U/K\.1)MN\E4/CL/\ X^(/
M$B_?N&M_DE3_ &+SLH6+]Q4?\E@_LV'&OOW[AK?Y)4_V+SLH6+]Q4?\ )8/[
M-A[>V3CH_P#_ "O\$\'89_\ 4/\ D?-(RC>OTJ3$K>OTJ3$)%@@05-Q$@J '
M.#\(=Y*S\NN45>K]24_18?S1HH,:6US6Z0QW?8BMV*Z-':(JS>ZE.R]S:ZM:
MV_PLC5=AS&>17)_SEN&7F.,(X[M:S>.X2Q!:[Y&R!=)9XZ*I8^JI6+JB(^LH
MO&J-%54TZ=RZIU[Y/A*G)9;C7(C]FU) C[QE==8;XLC43I'6"XNCMEZCVMES
MW11=-25SXT1&IXKTSU1L2J<]G=^E/.G'?VHO'35==VF[2T>H>DHZ0T53A4M*
M5*#PE6+YJ*M!RZU*FXE/=HNBGH[352=*\%6G'&T6K*SE)R:3X7A54EV)IOCG
MZJ<\[RP:7.G/W%&([/<&W#"EEHK1A7"DL+G.II*"V4,<]UJH-5Z.1E;B.LO+
MX:IC=*F@;1+K(QD;D_%^;/Y+#LY<\, 8%EI_&;357B*ZXDC5B/B7#=D5MPN\
M4[%W/@K8J=EOD;KJC*M7(NNA\)=_I[^U57>;E?@JG)8<V+,3.:Y0;II:7 6%
M72,3:V*9&7;%%='M-^PEEFLEM@FC5CMJCND+T5KD.WK#B:>B-#U%1\'H:4</
M03XN<UT4)*V6^DW5D_=1;.KJQA)Z:TU2E6\+IJ[Q.(ZMRFW4FG?VMXQI1Y)2
MC%<D;CE/3MB;'&QJ-CC8UC&IN1K6M1K6HGF1-$[$0N21-=Q.507V_P"_RERT
MK)+@EP75V>8  R9/@7G.^36[-S(C,K D,22W"Y6"6NLJ+NV;_8IX+[8W(J:*
MB)=+=3(]$5KI&*Z-%T>J+RJY89(WR131/AFB>^&>&5JLEAFC=L2PRL7RF2Q2
M(Z.1BHCF/:Y%1--_9(5$75>SX>_ZSG+\_P <WI4Y.YLU>,K+2*W+W,VNJKQ:
MY(VHV&R8EE9XS?\ #TJM9'&ULT_C%YM.FNU05$U*JN?;99I9EV2:>C3J5L!4
MDHJM:K1O^=7@SBNV<+2[=RW&Q VVK5V52E0TC3@Y="^AKI?FI>%";[(3NF^6
M_P!1B/!_^7#19.9V^YN(JY*+"&9UOI<*W:HD<K::BO=/6.GPI=:E=4:C(JFK
MN%J?([=%%>II55=A#H_P.14U:NJ+HJ*F]%33BBIN5%[ZG&U?'JFRY-SD5%33
M<O;HJIO375$7S+P-N_FC?"'Z;#5IM>6>?=3.^W6R&FMV&\QV1U%7/!0Q*D,%
MOQE&CIIYO%(UCBIK_31ZK20HRZ0NGC6MJ/6VDZEU<1-8[!P<Y[JA7HQ5YS4?
M%J4UQ;2RFE>Z2:YGB[*M?*.%B]'8R>Y2WM_#5G?<C*?C4IODF\X/@KM.V1NP
M@_)LJ<]\&8ZM[+I@S%-@Q10/8R1*FQ76CN36->BJU)VTLLDE,]=%UCJ&1R-5
M%1S45%/Z7&N8M@PU1/N6([W:,/V^+[977NY4=JHV?Y=57300-];T((=&:>ZX
M34EENN+4K^]M?EU%C%BJ3CO*I!Q]TIQ<?VKV^4_LG+N[Z$C':[]Z>9=W;WUX
M+Q153136IYPKPCW+? -OK;'D_)19D8VD9+!#<F=/^PRQSHO1I4U]<Q8)+S+$
M[;<RW6N1K9',9XQ74L,K)'^?_,R<_7B&?&,N7F?6(O=2BQC=JBIPSC:OZ&F]
MP[Y<JCI&8?N*11QT\-AKYY5BM$OD,M%5T="_6CJ(74NU4M1-)3P=3&>IW&--
M)JG--5:D/;2C"U]V"SS2;5]VYIM?:+HJ&-I8+U0ISJMQ=6+3H4I^UC.?#>F\
ME:Z3M>QNLIQ)BE&NO!=?TIJB_"5343>$P  9
M
M
M
M
M
M
M
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MJ8:IJTD]=07.EC>LD#$<Z6BF385R(U':.3PN^I7N3SK^^[.3S?\ E)@Y?_X
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M+@3#J-LJ6CZT,9BZW2XBF[TJ=)RC2@[6WIR=I5&N"64.;3Y0CX)W^GA[.PG
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MSY+)<BR%"C&G"%."M&$5"*NW:,59*[S>2Y@ 'S/J
M
M
M
M
M
M
M
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M1T[]T(@IZEDB[Q)KYE[^A""MWK]!4!RL"GO[./Q$S4)@82M_NW\YBP !DR
M 0(*3  IJWNI'3A[-Q. P4U[=^[J)F<"8  I-3J*H!AHIJW<15.Z(A.##5S)
M*U-/C)@#(2!!5(@ $JH3 Q;F"DJ*A43@1!DPE^.0  ,@   E=PW;B8 %-.W?
M\_ FZ^!,##0*:-[[R;90F L/QED0T(@"P  ,@
M
M
M
M
M
M
M
M
M
M             $KG:$Q!4U_1N[^K> :B_A4'*O;08<P1DW;Y]*O$-6[&.(8V
M/8KHK+:)'T=HBF8UW2,2ONCZB6%7,?%,RUUC4U?$U%TF/5\7H[3J[Y[\W+D=
MF;?W8JQ_EIAK%>(7T5+;5NUXIIJFK\0HEE6EI&NZ=K&00.GGDCC8QK4EFEE^
MV2/<OXVO,Q\EA4T_N'X&T7=_Q?.GFT_=782_JKM"P.C<%3PWJ;$2J*4IU)Q=
M/=E.3S><KM6LE=)V2ZD0;KCLQQ^E,?5Q:Q>&C"2C&E":J;T*<%E'*+5[W;MS
M;?%GQ_X.7R6?V \GRU8GKJ?H[WFE628QE<YBMD;87(E'AACE<KMIE1:X67:%
M6;+'0W*+5NVUSW>_3>.FG?J,%AK#%!9[?06FU4=/;[9:J.EMUNH*2-L%+14%
M% RFI*2FA8B,BIZ:GCCBAB:B,9&QK431J:9YI%^EM(RQ6*K8B7&M4E.SXQ3\
M2'ZL;+S$NZ$T7'!83#X6%K4*4(-KVTU'PY?K2;?G)@ = ]4
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M@
M
M
M
M
M
M
M
M
M
M                                     @J#93L(@   6
M                                                        (:$0
M 0T0:$0+
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
D                                             __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>pipelinea.jpg
<TEXT>
begin 644 pipelinea.jpg
M_]C_X  02D9)1@ ! 0$!2@%*  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 7[#68# 2(  A$! Q$!_\0
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M10!ZY_PU)X\_Y^[7_OS_ /7H_P"&I/'G_/W:_P#?G_Z]>1T4 >N?\-2>//\
MG[M?^_/_ ->C_AJ3QY_S]VO_ 'Y_^O7D=% 'KG_#4GCS_G[M?^_/_P!>C_AJ
M3QY_S]VO_?G_ .O7D=% 'KG_  U)X\_Y^[7_ +\__7H_X:D\>?\ /W:_]^?_
M *]>1T4 >N?\-2>//^?NU_[\_P#UZ/\ AJ3QY_S]VO\ WY_^O7D=% 'KG_#4
MGCS_ )^[7_OS_P#7H_X:D\>?\_=K_P!^?_KUY'10!ZY_PU)X\_Y^[7_OS_\
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MX:D\>?\ /W:_]^?_ *]>1T4 >N?\-2>//^?NU_[\_P#UZ/\ AJ3QY_S]VO\
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M'G_/W:_]^?\ Z]>1T4 >N?\ #4GCS_G[M?\ OS_]>C_AJ3QY_P _=K_WY_\
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M;T <1_PU)X\_Y^[7_OS_ /7H_P"&I/'G_/W:_P#?G_Z]>1T4 >N?\-2>//\
MG[M?^_/_ ->C_AJ3QY_S]VO_ 'Y_^O7D=% 'KG_#4GCS_G[M?^_/_P!>C_AJ
M3QY_S]VO_?G_ .O7D=% 'KG_  U)X\_Y^[7_ +\__7H_X:D\>?\ /W:_]^?_
M *]>1T4 >N?\-2>//^?NU_[\_P#UZ/\ AJ3QY_S]VO\ WY_^O7D=% 'KG_#4
MGCS_ )^[7_OS_P#7H_X:D\>?\_=K_P!^?_KUY'10!ZY_PU)X\_Y^[7_OS_\
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MX:D\>?\ /W:_]^?_ *]>1T4 >N?\-2>//^?NU_[\_P#UZ/\ AJ3QY_S]VO\
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M?\-2>//^?NU_[\__ %Z/^&I/'G_/W:_]^?\ Z]>1T4 >N?\ #4GCS_G[M?\
MOS_]>C_AJ3QY_P _=K_WY_\ KUY'10!ZY_PU)X\_Y^[7_OS_ /7H_P"&I/'G
M_/W:_P#?G_Z]>1T4 >N?\-2>//\ G[M?^_/_ ->C_AJ3QY_S]VO_ 'Y_^O7D
M=% 'KG_#4GCS_G[M?^_/_P!>C_AJ3QY_S]VO_?G_ .O7D=% 'KG_  U)X\_Y
M^[7_ +\__7H_X:D\>?\ /W:_]^?_ *]>1T4 >N?\-2>//^?NU_[\_P#UZ/\
MAJ3QY_S]VO\ WY_^O7D=% 'KG_#4GCS_ )^[7_OS_P#7H_X:D\>?\_=K_P!^
M?_KUY'10!ZY_PU)X\_Y^[7_OS_\ 7H_X:D\>?\_=K_WY_P#KUY'10!ZY_P -
M2>//^?NU_P"_/_UZ/^&I/'G_ #]VO_?G_P"O7D=% 'KG_#4GCS_G[M?^_/\
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M/_UZ\CHH ]<_X:D\>?\ /W:_]^?_ *]'_#4GCS_G[M?^_/\ ]>O(Z* /7/\
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MNU_[\_\ UZ\CHH ]<_X:D\>?\_=K_P!^?_KT?\-2>//^?NU_[\__ %Z\CHH
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M'G_/W:_]^?\ Z]'_  U)X\_Y^[7_ +\__7KR.B@#US_AJ3QY_P _=K_WY_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 >W?L>_P#)8H_^O"?_ -EKS;XF?\E(\5_]A:[_ /1SUZ3^Q[_R
M6*/_ *\)_P#V6O-OB9_R4CQ7_P!A:[_]'/0!S5%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %?2?A3_ ),N\5?]?W_M:WKYLKZ3\*?\F7>*O^O[_P!K6] 'S91110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% 'TGK'_)DNA?]?S?^E4U?-E?2>L?
M\F2Z%_U_-_Z535\V4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'TG\ _P#DWGXJ
M?]>\_P#Z3&OFROI/X!_\F\_%3_KWG_\ 28U\V4 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MDC KZV_:(_:>MOV=_$$_AKP=X?L+G7;QCJ>HW5YN,0DE).&5"K.Y ')8!1M
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MW6K^3<1^9+'MCA0^1'PTCD(#[$Y-?27_  3Y_P"2&W'_ &%[C_T".LK]I/\
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M"BBBK)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH ]N_8]_Y+%'_ ->$_P#[+7FWQ,_Y*1XK_P"PM=_^CGKTG]CW_DL4
M?_7A/_[+7FWQ,_Y*1XK_ .PM=_\ HYZ .:HHHH **** "BBB@ HHHH ****
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M/X!_\F\_%3_KWG_])C7S90 4444 %%%% !1110 4444 %%%% !1110 4444
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MU45O_$#_ )'SQ)_V$KG_ -&M6!40E[2,9=U<UE'EDUV"BBBK("BBB@ HHHH
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M0 5])_M=?\BQ\,/^O&;_ - MJ^;*^D_VNO\ D6/AA_UXS?\ H%M0!\V4444
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M'R@22N&.,8Z8&*^9/V/_ (SV_P $_B5>Z?XB9K#1=646EX\JD&UG1CY;N.H
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M2?\ BO\ ["B?^BEKRW]I2:&W_;7T.6XP($O-):3/3:&3->I?\$X?^2?^*_\
ML*)_Z*6O!?VZ':/]HC4G0E66TM2&'4'RQS4U)6K4Y/I;\A45S4II>?YGV?\
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M&3^TKQMKK&Q4X,V#@@=:YW_@G3_R2'7O^PV__HB&OSRK]#?^"=/_ "2'7O\
ML-O_ .B(:VA%VG*_1?FB)6M%6ZO\C@/VL/VE/B/\,_C-?Z'X;\1?V;I<5M;R
M);_8;:7#,@+'<\;-R?>O(/\ AM3XS?\ 0Y?^4NR_^,U]I_%C]CWP9\8O&=QX
MEUK4]=MK^:..)H["XA2(!%P,!H6.<>]<C_P[K^&__0;\5?\ @7;?_(]84[I6
MEYER:>WD?#?Q'^+GBSXN7EE=>+=6_M:>SC:*!_LT,.Q2<D8C10>?6OMW_@G3
M_P DAU[_ +#;_P#HB&O,/VEOV0/!WP9^%UUXDT74M=NKZ*XAA6._N(7BVNV"
M2$A4Y_&O3_\ @G3_ ,DAU[_L-O\ ^B(:VI./+.,>G^:,YIWB^Y\Q?MI,6_:0
M\5Y).!:@9_Z]HJ^E_P#@G*Q_X5;XE&>!K)Q_WXBKYG_;2_Y.0\5_]NW_ *31
M5]+_ /!./_DE_B;_ +#)_P#1$=9T?X;]/U1=?^)'Y?D>"_M6^%[SQI^UQJ&@
M6"@WFI2V%K%N^Z&>"(9/L,Y/L*^J=)^ /P>_9V\#OK/B+3[*_%JB&[UC68/M
M3/)G \N(A@I+' "+GIDG&:^;?C]XRB^'O[;I\13J7MM/N;"695&3Y?V>,/@>
MNTG'O7VC\1/ ^@?M#?"Z32AJ7F:3J:1W%KJ-BROM92&1QV89&"/3(X/(2YHT
M5R]RZMG6M+:R_(X#X<_M?>$/B/\ $+2_!?A;1=2*W!E'VR>..WAC2.-GW*@8
ML0=H&"%Z_A7#?\%'I&'P_P#":9^1M3<GZB(X_F:ZCX._LY>"OV9=:M-5U?Q.
MNI>)-3D&G6$MTBVZEI& V0PAF)8\ MN.!Z#.<3_@HIH]Q=_"O0+^*-GALM5
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M^2&VO_8OK_Z3BOS^_8>_Y.*T'_KWNO\ T2]:T_\ >I^C_4YO^8:/R_0^B?\
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M_P""=/\ R5+Q%_V"#_Z.CKZL_:<^,,_P3^&$^MV,4<VK3SI9V2S@F,2,"2S
M=0%5CCN0*VJ24%%VZ?B94TYRDO/_ "/+_C9^R1\(O"?PM\0:U:Z5=:)<:;9R
M7$=U;W\KL\BK\B%96=2&;:. #SP17@'[+_[),OQLM9=?UZ\N-*\,12&&/[,
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MZ3^Q[_R6*/\ Z\)__9:\V^)G_)2/%?\ V%KO_P!'/0!S5%%% !1110 4444
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M/FIW:U/U&\(KGPEI'_7G#_Z *^<O ?["/A&WEO-2\;/-X@U*\FDF-G#.\%M
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MA4;B?N@Y[U[%\.OV\M=T7P_IOAFW\!VFHS6ULEE91Z;<2QGY4"I^[*R%CP.
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MZ\/Z/&OB2*Z\5:DR@RSR7,EM$K=Q&D3*0/\ >+'Z=*P_B_\ L$^$]2T&YNO
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M:44U3;>]PE+]XDMK/]#\P_BYX0L_ /Q,\1^'=/EGFL=.O7MX9+IE:1E'0L5
M!/T KU7]F_\ 9&U3XV0#7=6NY-%\**Y1)HU#3W; X81 \ #D%SGD8 /..9^-
M6@R^*?VH/$.BPMLFU#7_ +(C8S@R2*H/ZU^F4_\ 9?PG^&\SV\'DZ1H&G,ZQ
M)VBAC)Q]2%_,U%*2C14Y:Z?\.743E4Y(GENF_L0_!^QM(X9_#5QJ$BJ ;BYU
M*Y#N?4B.15S]% KS[XK_ /!/WPYJNGSW?@.\GT34D7*:?>3--:RX'W0S9="3
M_$2P]N]?&7Q&^+'B;XI>)YM;U[5+B><RF2"%9&$5J,\+$N<(!@=.3C))/-?:
MW["7QNUOQ]H^L^&/$%[)J5YI"QSVMY<.7F>%B5*,3RVU@,$G.'QV%6HN:;V8
M2?LVNJ/@GQ!H&H^%=:O=(U:TDL-2LY3#/;S##(PZCW]B.",$5]4?LQ_LC^#_
M (T?#-?$6MZEK=K??:YK?R]/GA2+:FW!P\3'//K6A_P46\ VNGZYX;\7VT*Q
MS:@DEE>,HQO:,!HV/J=I89]%'I7KW[ G_)!U_P"PE<?^RT4GS0ES;HBK>,H<
MNS_R//O"_P#P3ZTN;X@:U)JVH:A'X.M)D33K=I4-W=C8C.TCA0%3<6484,<=
ML GUJ^_8A^#]W8R6\/ANXLY64J+J#4KDR(?[P#R,N?JI'M7@_P"W_P#%C7K?
MQE8^"=/U":RT:.Q2ZNXK>0I]ID=F 63'50JC"GC+9.>,2?\ !._Q]JDWB+7_
M  C<7LL^EK9?;[:VD8LL+K(JML_N@^8,CU /K13_ 'JTZ?H5/]V[O6]OQ/$_
MVDOV?KOX!^++:U6Z;4=#U!6EL+R10'PI :-P.-RY7D<$$'CD#R"OT"_X*-6:
M/\-/#%T5'F1ZQY8;OAH9"1_XX/RK\_:RIMZI]'_P325M'W"BBBM2 HHHH **
M** "BBB@#Z3UC_DR70O^OYO_ $JFKYLKZ3UC_DR70O\ K^;_ -*IJ^;* "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ K]C?A-_R2_P (?]@BT_\ 1*5^
M.5?L;\)?^27^$/\ L$6G_HE*T7P/U_S,9?Q(^C_-'Y4_'+_DLWCK_L-WG_HY
MZZ3]E+5-=TWX]>%$T-Y@]S=+#=1QL0LEL>90X[@*"W/=0>HK[\US]D?X3^)-
M:OM6U+PI]JU"^G>YN)O[1NUWR.Q9FPLH R2>  *ZSP'\&?!/PP+OX7\-V6DS
M2+L:X12\S+UVF1R6QD#C..*SI?NTK]#:M^\;MU)?B]';R_"OQBMV=MJVCW8D
M/HODODU\#?L"?\E\C_[!=S_[)7M_[:?[26D:5X1O_ ?AZ_CU#6M1!@U"2V<.
MEG#GYXV8<;VP5V]0,YQQGQ#]@7_DOD?_ &"[G_V2E2]ZI*2VM;\!5M*<4][K
M\T?:/[1OPEOOC3X&MO#=G=1Z>)-0AEFNI5WB*)0VY@N1N/( &1R>H'-<IX?_
M &&?A-I&G1VU[HMUKEPH^:\O-0F1V/\ NQ,B@?A^=='^U;\2-0^%_P %]8U3
M1YOL^JRM'9VUP.L32-@N/<*&Q[XK\WOAO\2/$'A7XF:5XBM]7O#J#7D1N9GG
M9FN4+C>DA)^<$=<YHI>]-PCU?XV_R'4]V/.^G0^D/VG?V*],\$^%[WQ=X&DN
M$L[(>;>Z1<.9=D7>2)S\V%ZE6)XR<\8/R!I^GW.K:A;65G"]S=W,BPPPQC+.
M[$!5 ]22!7[)^.+"/5_!>N6<BJR7%A-$RMT(:-A@_G7Y$?#GQS<_#;QMI7B6
MSLK74+K3Y3+%!>*S1%MI )"D'(SD<]0*FFU[1P>V_P#7W%2^!-;_ /#'V_\
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MBGPWY^'_ (;_ .P;;?\ HI:_)#XE>/+WXF^/-:\3Z@HCN=2N#+Y2G(C0 *B
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M5FQC)",,GBN?HHVV!Z[FKJ'BS7-6UJ+6+[6=0O-7B97CO[BZDDG1E.5(D)W
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M/V)/^2C:W_V"F_\ 1T5% &G^W)_R,WAK_KVF_P#0UKYDKZ;_ &Y/^1F\-?\
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MLCC<L1]"4'_ J]>T3P_\/_V9_ ,X@:U\.:+"3+/<W4I:2>3'4L?FD<XP%'T
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M8V6BVLT\TV#M5I$,2+GU.]B!Z*?2OJO]N;_DW;6_^OFU_P#1R5M>#?&GPS\
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M&(,^H:G#&B]\(KNQ_0#_ (%7J7AWPIX!_9H\"W)MS;>']&C/FW-Y>39DF?&
M68\NQZ!1ZX K\]OVG_CW+\=/'2SVJ26_AW35:#3H).&8$C=*P[,V!QV 4=<U
M-9^TY8+I;\!TH\O--]3Z9_X)P_\ )/\ Q7_V%$_]%+7G7_!1K_DH7A;_ +!C
M_P#HUJ]%_P""</\ R3[Q7_V%$_\ 12UYU_P4:_Y*%X6_[!C_ /HUJ5?XX?+\
MA8?X7\_S/6O^"=?_ "1G6?\ L.3?^B(*\)_X*%?\ETL?^P);_P#HV>O=O^"=
M?_)&=9_[#DW_ *(@KPG_ (*%?\ETL?\ L"6__HV>M:_\2/R_(=/X9?,^K?V8
M?@7HGPH^'^DWHL8I?$FH6J7%]J$B!I074-Y2L?NHN0,#J1DUYQ\0O^"A7ASP
MWJUSI_AWPY=>(3;RM"UY/<K:PL0<;DPKLPSZA:];_9M^+FE?%KX8Z3/:74?]
MK6-M';:C9Y DAE5=N[;_ '6QN4],''4$#E/$?[%/PKU3Q5=>)K^&^M8)':YN
M;".\$5D2269C\N]1G)PK@#M@4ZE_::O0BE;V>N_]7/1O@7\0K[XJ?"W1O%6H
MV<>GW.H><WV>+=M55F=$P6Y.54'/?-?F_P#M73&;]H;QNQ&,7BK^42#^E?I1
M\*_''A'QCHMS;>"YH)M&T6X_LQ?LR;80413B/U3# !NAP<9'-?GC^VIX9N/#
MO[0FOS31[8-32&^MVQPRF-48_P#?:./PK&=O;*25DT[?@:1NX-/<_2WPCSX1
MT?\ Z\XO_0%K\?/'6@W'A7QIKVD72,D]C?36[!Q@_*Y&?Q'/XU^O>@W7V'P)
MI]P5W"+3XY-O3.(P<?I7B.K?!_X1?M>:?;>,;2>XBOI51+FZTJ=(KD$#_53H
MRLH8#C)7) &"1BJE%NJY+IO\R:4N6DHOK;\#Q7_@G)HMQ-XT\5ZL$86D%C':
ME\<%WDW ?E&?TKM/^"C^K11^#_!VF%AYTU_-<!>^U(PI/YR"OHGPIX1\&_L_
M> Y;:P%OH6@VF9[FZNI>78X!DD<_>8X _( =!7YP_M0?&P?&[XE2:A9>8F@V
M,?V33DD^4L@)+2$=BYY^@4'D45I*;C!=+?@.E'EO)]?\K'Z.? ;68]>^"W@J
M]B96#Z1;(VWH'6,(P_!E(_"OR_\ CMX?N_"_QD\9Z?>1M'*NJW$J[A]Z.1RZ
M-]"K*?QKZ"_8O_:@TWP/9'P-XMO%L=*:5I-.U*8XCMV8Y:*0_P *DDL&/ ).
M>#Q]0_%C]G7P'\>H[6_U>&1;Q8PL.K:3,J2M%G(7<0R.OID'&3C&:NK%NISK
M9W_$FDU&/(]U^A\!_LB^&[GQ)^T!X42W1F2SF:]GD4<(D:$Y/L6VK_P(5]Y?
MM>:]#H/[/7BYI2"UU EI&I[M)(J\?0$G\*TOAS\&_ 7[.N@7UUIJK81F/-YK
M&JW"F1D7GYY#A57V4 >U?$_[7_[24'QCUBVT'P_(S>%=+D,BSL"IO)\$>9@\
MA5!(7//))ZC&59J<537S_4NE'EFZDCTC_@FS_P ?OCS_ '++^<U3_P#!29CM
M\ KD[<WIQ_WXJ#_@FS_Q^^//]RR_G-4W_!2;_F0/K>_^T*UQ&\?E^0Z'Q2^?
MY'Q39VLM]=P6T*[YIG6-%]6)P!^9K]9OA+\(O#'P%\$+!:6T$5Q#;^;J6JN@
M\V=E7+,S==HYPO0#\2?R;T^]DTV^MKN+'FV\JRIN&1N4@C^5?KU\+_B3H7QF
M\$6NM:5/%=07$02[M20S6\A WQ2+V(SWZC!&0:N5_9^[O_5C#_EXK[?U<^;?
M%W_!1K1K&YE@\-^$[K58E)47>H7(M@<'A@BJY(/7DJ?85]2?#?Q)<^,? 'AW
M7;V%;:ZU+3X+N6&,$*C.@8@9YQSWKQ2X_8K^#WA?6+OQ1J:74.E6^;B2RO[\
M+80 <Y)P&V^S.1VQCBO9OAQXYT/XB>%;?6?#<OG:0TDEO"VSR_\ 5N4X7L/E
MR!QP1P*R7P-=31WYK]#\O-2D,W[2EU(1@MXM=L?6\-?IU\9%+?"/QH ,DZ+>
M8'_;!Z_,[XS:?<_#7]H[Q#)<1'-KKAU*-<</&\HG3'_ 6%?J)INI:1\1O!Z7
M-G/'J.C:M:D"2)^'C=2",CD'!(/<&I46\.DOZV'?DQ%_3\#\9J_8WX5ZU%XC
M^&?A?4X<%+K3+>7Y>Q,:Y'X'(_"OB#]K3]F+PG\#_A[H^J>'FU&XN;G5/L\T
MU_.)"$:)V"@*JJ "G7&?>N@_8O\ VH]*\+Z/'X#\7WR:?:Q.S:7J5PVV) QR
MT,C'[HR258\<D$C SI&2E&45O_P")IJ2F]M?S/EKXJ>'[KPM\2O$^DWD;1W%
MKJ,Z$.,$KO)5OH5((]B*],_8J\.W6N?M">'YX(V:'34GO+AQT1!$R _BSJ/Q
MK[E^+7[,W@/XY30ZGJT%Q;:EL4+JFDS+'+)&.@;*LCCT)4G'0UH^ ?A7X!_9
MO\+WTVG^5I5H0KWNK:E./,EV]-\AP /15 &2<#)J*5J4;2Z&E7]XW;J<E^VY
MK4&D_L\:_#*ZK)?2VUK"K'EF\Y'('_ 48_A7E7_!-O\ Y _CG_KXM?\ T&2O
M%OVMOVC4^-OB6WT[1C(GA727;[.S@JUW*>#,5/08X4'D DG&[ ]I_P"";?\
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MXKZ\^+'[3G@/X2Z?<F\U>WU36(\K'H^GS++.S]@^"1&.<Y?''0$\5^9WQ/\
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M$Y/YU]H_LJ_M4:1\0/#>G^&?$FHPV'BRTC6W5KIPBZ@H&%9&/!DQC*]2>1W
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MC$3D+DAE=><C(.,G&,FM'P!\.?!7[.O@N[BT]TTK2XSY]YJ.I3C=(P&-TCG
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MQ59QXD,UOJEJ#PLT9C"2*3Z$K(I^M?;_ (%^(G@O]H;P+-]BD@U*QO(/*O\
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M,U8:05UY'0O?=O+_ ()^=M%%%:&84444 %%%% !1110 4444 %%%% !1110
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M7W'^W@W_ !CY??\ 7]:_^AU-27LX*?=V_&PHOFFX=C\T****H84444 %%%%
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MGJ2:SJ7GRQ>R_1FD+0;EU9SE%%%62%7M%U[4_#=^E]I.HW>EWJ@A;FRG:&0
M]0&4@U1HH Z/Q!\2O%WBRS%IKGBG6M9M P80:AJ,TZ9'0[78C-<Y110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 >W?L>_\EBC_ .O"?_V6O-OB9_R4CQ7_ -A:[_\
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MV2XV_3>QQ6)11ON&VP4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% 'TG\ _\ DWGXJ?\ 7O/_ .DQKYLKZ3^ ?_)O/Q4_Z]Y_
M_28U\V4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %7='US4?#M^E]I6H76F7L?W+FSF:*1?H
MRD$52HH Z37_ (F>+_%5C]CUOQ7K>L6>0WV?4-1FGCR.AVNQ%<W110 59TW5
M+S1[V*\L+N>QNXCF.XMI&CD0^H8$$56HH [7_A=WQ&*;#X_\4%/[O]LW./\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110![=^Q[_P EBC_Z\)__ &6O-OB9_P E(\5_]A:[_P#1SUZ3
M^Q[_ ,EBC_Z\)_\ V6O-OB9_R4CQ7_V%KO\ ]'/0!S5%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %?2?A3_DR[Q5_U_?\ M:WKYLKZ3\*?\F7>*O\ K^_]K6] 'S91
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% 'TGK'_ "9+H7_7\W_I5-7S
M97TGK'_)DNA?]?S?^E4U?-E !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!])_ /_
M )-Y^*G_ %[S_P#I,:^;*^D_@'_R;S\5/^O>?_TF-?-E !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?2?[77_
M "+'PP_Z\9O_ $"VKYLKZ3_:Z_Y%CX8?]>,W_H%M0!\V4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% 'MW['O\ R6*/_KPG_P#9:\V^)G_)2/%?_86N_P#T<]>D_L>_\EBC
M_P"O"?\ ]EKS;XF?\E(\5_\ 86N__1ST <U1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !7TGX4_P"3+O%7_7]_[6MZ^;*^D_"G_)EWBK_K^_\ :UO0!\V4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110!])ZQ_R9+H7_7\W_I5-7S97TGK'_)D
MNA?]?S?^E4U?-E !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!])_ /\ Y-Y^*G_7
MO/\ ^DQKYLKZ3^ ?_)O/Q4_Z]Y__ $F-?-E !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?2?[77_(L?##_KQF
M_P#0+:OFROI/]KK_ )%CX8?]>,W_ *!;4 ?-E%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 ?7O[-/[8GA3X/_"^U\,Z_IFM75U;W,TB
M2Z=#"\>QVW '?*ISDMV]*I_M _MQO\1_#%YX:\):5=:3I]\GEW=]?.HN)(S]
MZ-40D*#T)W'()&!UKY.HHE[^X1]S8**** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^B/V)/^2C:W
M_P!@IO\ T=%11^Q)_P E&UO_ +!3?^CHJ* /</CM^SU=_&C5-,NX=6_LL6,<
MD15K0R[MS YR&&.E>7_\,'ZC_P!#4O\ X+6_^.5^B=% 'YV?\,'ZC_T-2_\
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M $-2_P#@M;_XY7Z)T4 ?G9_PP?J/_0U+_P""UO\ XY1_PP?J/_0U+_X+6_\
MCE?HG10!^=G_  P?J/\ T-2_^"UO_CE'_#!^H_\ 0U+_ ."UO_CE?HG10!^=
MG_#!^H_]#4O_ (+6_P#CE'_#!^H_]#4O_@M;_P".5^B=% 'YV?\ #!^H_P#0
MU+_X+6_^.4?\,'ZC_P!#4O\ X+6_^.5^B=% 'YV?\,'ZC_T-2_\ @M;_ ..4
M?\,'ZC_T-2_^"UO_ (Y7Z)T4 ?G9_P ,'ZC_ -#4O_@M;_XY1_PP?J/_ $-2
M_P#@M;_XY7Z)T4 ?G9_PP?J/_0U+_P""UO\ XY1_PP?J/_0U+_X+6_\ CE?H
MG10!^=G_  P?J/\ T-2_^"UO_CE'_#!^H_\ 0U+_ ."UO_CE?HG10!^=G_#!
M^H_]#4O_ (+6_P#CE'_#!^H_]#4O_@M;_P".5^B=% 'YV?\ #!^H_P#0U+_X
M+6_^.4?\,'ZC_P!#4O\ X+6_^.5^B=% 'YV?\,'ZC_T-2_\ @M;_ ..4?\,'
MZC_T-2_^"UO_ (Y7Z)T4 ?G9_P ,'ZC_ -#4O_@M;_XY1_PP?J/_ $-2_P#@
MM;_XY7Z)T4 ?G9_PP?J/_0U+_P""UO\ XY1_PP?J/_0U+_X+6_\ CE?HG10!
M^=G_  P?J/\ T-2_^"UO_CE'_#!^H_\ 0U+_ ."UO_CE?HG10!^=G_#!^H_]
M#4O_ (+6_P#CE'_#!^H_]#4O_@M;_P".5^B=% 'YV?\ #!^H_P#0U+_X+6_^
M.4?\,'ZC_P!#4O\ X+6_^.5^B=% 'YV?\,'ZC_T-2_\ @M;_ ..4?\,'ZC_T
M-2_^"UO_ (Y7Z)T4 ?G9_P ,'ZC_ -#4O_@M;_XY1_PP?J/_ $-2_P#@M;_X
MY7Z)T4 ?G9_PP?J/_0U+_P""UO\ XY1_PP?J/_0U+_X+6_\ CE?HG10!^=G_
M  P?J/\ T-2_^"UO_CE'_#!^H_\ 0U+_ ."UO_CE?HG10!^=G_#!^H_]#4O_
M (+6_P#CE'_#!^H_]#4O_@M;_P".5^B=% 'YV?\ #!^H_P#0U+_X+6_^.4?\
M,'ZC_P!#4O\ X+6_^.5^B=% 'YV?\,'ZC_T-2_\ @M;_ ..4?\,'ZC_T-2_^
M"UO_ (Y7Z)T4 ?G9_P ,'ZC_ -#4O_@M;_XY1_PP?J/_ $-2_P#@M;_XY7Z)
MT4 ?G9_PP?J/_0U+_P""UO\ XY1_PP?J/_0U+_X+6_\ CE?HG10!^=G_  P?
MJ/\ T-2_^"UO_CE'_#!^H_\ 0U+_ ."UO_CE?HG10!^=G_#!^H_]#4O_ (+6
M_P#CE'_#!^H_]#4O_@M;_P".5^B=% 'YV?\ #!^H_P#0U+_X+6_^.4?\,'ZC
M_P!#4O\ X+6_^.5^B=% 'YV?\,'ZC_T-2_\ @M;_ ..4?\,'ZC_T-2_^"UO_
M (Y7Z)T4 ?G9_P ,'ZC_ -#4O_@M;_XY1_PP?J/_ $-2_P#@M;_XY7Z)T4 ?
MG9_PP?J/_0U+_P""UO\ XY1_PP?J/_0U+_X+6_\ CE?HG10!\2?!O]EN]^$_
MC)=>EUP:BBV\D'DK9-%]['.XN?3TKFO%'[%.H>(_$NK:LOB58%O[N:Z$7]G,
MVS>Y;;GS.<9ZU^@%% 'YV?\ #!^H_P#0U+_X+6_^.4?\,'ZC_P!#4O\ X+6_
M^.5^B=% 'YV?\,'ZC_T-2_\ @M;_ ..4?\,'ZC_T-2_^"UO_ (Y7Z)T4 ?G9
M_P ,'ZC_ -#4O_@M;_XY1_PP?J/_ $-2_P#@M;_XY7Z)T4 ?G9_PP?J/_0U+
M_P""UO\ XY1_PP?J/_0U+_X+6_\ CE?HG10!^=G_  P?J/\ T-2_^"UO_CE'
M_#!^H_\ 0U+_ ."UO_CE?HG10!^=G_#!^H_]#4O_ (+6_P#CE'_#!^H_]#4O
M_@M;_P".5^B=% 'YV?\ #!^H_P#0U+_X+6_^.4?\,'ZC_P!#4O\ X+6_^.5^
MB=% 'YV?\,'ZC_T-2_\ @M;_ ..4?\,'ZC_T-2_^"UO_ (Y7Z)T4 ?G9_P ,
M'ZC_ -#4O_@M;_XY1_PP?J/_ $-2_P#@M;_XY7Z)T4 ?G9_PP?J/_0U+_P""
MUO\ XY1_PP?J/_0U+_X+6_\ CE?HG10!^=G_  P?J/\ T-2_^"UO_CE'_#!^
MH_\ 0U+_ ."UO_CE?HG10!^=G_#!^H_]#4O_ (+6_P#CE'_#!^H_]#4O_@M;
M_P".5^B=% 'YV?\ #!^H_P#0U+_X+6_^.4?\,'ZC_P!#4O\ X+6_^.5^B=%
M'YV?\,'ZC_T-2_\ @M;_ ..4?\,'ZC_T-2_^"UO_ (Y7Z)T4 ?G9_P ,'ZC_
M -#4O_@M;_XY1_PP?J/_ $-2_P#@M;_XY7Z)T4 ?G9_PP?J/_0U+_P""UO\
MXY1_PP?J/_0U+_X+6_\ CE?HG10!^=G_  P?J/\ T-2_^"UO_CE'_#!^H_\
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M?HG10!^=G_#!^H_]#4O_ (+6_P#CE'_#!^H_]#4O_@M;_P".5^B=% 'YV?\
M#!^H_P#0U+_X+6_^.4?\,'ZC_P!#4O\ X+6_^.5^B=% 'YV?\,'ZC_T-2_\
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MAJ7_ ,%K?_'*_1.B@#\[/^&#]1_Z&I?_  6M_P#'*/\ A@_4?^AJ7_P6M_\
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M_P"AJ7_P6M_\<H_X8/U'_H:E_P#!:W_QROT3HH _.S_A@_4?^AJ7_P %K?\
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M (8/U'_H:E_\%K?_ !RC_A@_4?\ H:E_\%K?_'*_1.B@#\[/^&#]1_Z&I?\
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M (8/U'_H:E_\%K?_ !ROT3HH _.S_A@_4?\ H:E_\%K?_'*/^&#]1_Z&I?\
MP6M_\<K]$Z* /SL_X8/U'_H:E_\ !:W_ ,<H_P"&#]1_Z&I?_!:W_P <K]$Z
M* /SL_X8/U'_ *&I?_!:W_QRC_A@_4?^AJ7_ ,%K?_'*_1.B@#\[/^&#]1_Z
M&I?_  6M_P#'*/\ A@_4?^AJ7_P6M_\ '*_1.B@#\[/^&#]1_P"AJ7_P6M_\
M<H_X8/U'_H:E_P#!:W_QROT3HH _.S_A@_4?^AJ7_P %K?\ QRC_ (8/U'_H
M:E_\%K?_ !ROT3HH _.S_A@_4?\ H:E_\%K?_'*/^&#]1_Z&I?\ P6M_\<K]
M$Z* /SL_X8/U'_H:E_\ !:W_ ,<H_P"&#]1_Z&I?_!:W_P <K]$Z* /SL_X8
M/U'_ *&I?_!:W_QRC_A@_4?^AJ7_ ,%K?_'*_1.B@#\[/^&#]1_Z&I?_  6M
M_P#'*/\ A@_4?^AJ7_P6M_\ '*_1.B@#\[/^&#]1_P"AJ7_P6M_\<H_X8/U'
M_H:E_P#!:W_QROT3HH _.S_A@_4?^AJ7_P %K?\ QRC_ (8/U'_H:E_\%K?_
M !ROT3HH _.S_A@_4?\ H:E_\%K?_'*/^&#]1_Z&I?\ P6M_\<K]$Z* /SL_
MX8/U'_H:E_\ !:W_ ,<H_P"&#]1_Z&I?_!:W_P <K]$Z* /SL_X8/U'_ *&I
M?_!:W_QRC_A@_4?^AJ7_ ,%K?_'*_1.B@#\[/^&#]1_Z&I?_  6M_P#'*/\
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M%K?_ !ROT3HH _.S_A@_4?\ H:E_\%K?_'*/^&#]1_Z&I?\ P6M_\<K]$Z*
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M_A@_4?\ H:E_\%K?_'*/^&#]1_Z&I?\ P6M_\<K]$Z* /SL_X8/U'_H:E_\
M!:W_ ,<H_P"&#]1_Z&I?_!:W_P <K]$Z* /SL_X8/U'_ *&I?_!:W_QRC_A@
M_4?^AJ7_ ,%K?_'*_1.B@#\[/^&#]1_Z&I?_  6M_P#'*/\ A@_4?^AJ7_P6
MM_\ '*_1.B@#\[/^&#]1_P"AJ7_P6M_\<H_X8/U'_H:E_P#!:W_QROT3HH _
M.S_A@_4?^AJ7_P %K?\ QRC_ (8/U'_H:E_\%K?_ !ROT3HH _.S_A@_4?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M #]7G_?\ULT4 8W_  BMO_S]7G_?\T?\(K;_ //U>?\ ?\ULT4 8W_"*V_\
MS]7G_?\ -'_"*V__ #]7G_?\ULT4 8W_  BMO_S]7G_?\T?\(K;_ //U>?\
M?\ULT4 8W_"*V_\ S]7G_?\ -'_"*V__ #]7G_?\ULT4 8W_  BMO_S]7G_?
M\T?\(K;_ //U>?\ ?\ULT4 8W_"*V_\ S]7G_?\ -'_"*V__ #]7G_?\ULT4
M 8W_  BMO_S]7G_?\T?\(K;_ //U>?\ ?\ULT4 8W_"*V_\ S]7G_?\ -'_"
M*V__ #]7G_?\ULT4 8W_  BMO_S]7G_?\T?\(K;_ //U>?\ ?\ULT4 8W_"*
MV_\ S]7G_?\ -'_"*V__ #]7G_?\ULT4 8W_  BMO_S]7G_?\T?\(K;_ //U
M>?\ ?\ULT4 8W_"*V_\ S]7G_?\ -'_"*V__ #]7G_?\ULT4 8W_  BMO_S]
M7G_?\T?\(K;_ //U>?\ ?\ULT4 8W_"*V_\ S]7G_?\ -'_"*V__ #]7G_?\
MULT4 8W_  BMO_S]7G_?\T?\(K;_ //U>?\ ?\ULT4 8W_"*V_\ S]7G_?\
M-'_"*V__ #]7G_?\ULT4 8W_  BMO_S]7G_?\T?\(K;_ //U>?\ ?\ULT4 8
MW_"*V_\ S]7G_?\ -'_"*V__ #]7G_?\ULT4 8W_  BMO_S]7G_?\T?\(K;_
M //U>?\ ?\ULT4 8W_"*V_\ S]7G_?\ -'_"*V__ #]7G_?\ULT4 8W_  BM
MO_S]7G_?\T?\(K;_ //U>?\ ?\ULT4 8W_"*V_\ S]7G_?\ -'_"*V__ #]7
MG_?\ULT4 8W_  BMO_S]7G_?\T?\(K;_ //U>?\ ?\ULT4 8W_"*V_\ S]7G
M_?\ -'_"*V__ #]7G_?\ULT4 8W_  BMO_S]7G_?\T?\(K;_ //U>?\ ?\UL
MT4 8W_"*V_\ S]7G_?\ -'_"*V__ #]7G_?\ULT4 8W_  BMO_S]7G_?\T?\
M(K;_ //U>?\ ?\ULT4 8W_"*V_\ S]7G_?\ -'_"*V__ #]7G_?\ULT4 8W_
M  BMO_S]7G_?\T?\(K;_ //U>?\ ?\ULT4 8W_"*V_\ S]7G_?\ -'_"*V__
M #]7G_?\ULT4 8W_  BMO_S]7G_?\T?\(K;_ //U>?\ ?\ULT4 8W_"*V_\
MS]7G_?\ -'_"*V__ #]7G_?\ULT4 8W_  BMO_S]7G_?\T?\(K;_ //U>?\
M?\ULT4 8W_"*V_\ S]7G_?\ -'_"*V__ #]7G_?\ULT4 8W_  BMO_S]7G_?
M\T?\(K;_ //U>?\ ?\ULT4 8W_"*V_\ S]7G_?\ -'_"*V__ #]7G_?\ULT4
M 8W_  BMO_S]7G_?\T?\(K;_ //U>?\ ?\ULT4 8W_"*V_\ S]7G_?\ -'_"
M*V__ #]7G_?\ULT4 8W_  BMO_S]7G_?\T?\(K;_ //U>?\ ?\ULT4 8W_"*
MV_\ S]7G_?\ -'_"*V__ #]7G_?\ULT4 8W_  BMO_S]7G_?\T?\(K;_ //U
M>?\ ?\ULT4 8W_"*V_\ S]7G_?\ -'_"*V__ #]7G_?\ULT4 8W_  BMO_S]
M7G_?\T?\(K;_ //U>?\ ?\ULT4 8W_"*V_\ S]7G_?\ -'_"*V__ #]7G_?\
MULT4 8W_  BMO_S]7G_?\T?\(K;_ //U>?\ ?\ULT4 8W_"*V_\ S]7G_?\
M-'_"*V__ #]7G_?\ULT4 8W_  BMO_S]7G_?\T?\(K;_ //U>?\ ?\ULT4 8
MW_"*V_\ S]7G_?\ -'_"*V__ #]7G_?\ULT4 8W_  BMO_S]7G_?\T?\(K;_
M //U>?\ ?\ULT4 8W_"*V_\ S]7G_?\ -'_"*V__ #]7G_?\ULT4 8W_  BM
MO_S]7G_?\T?\(K;_ //U>?\ ?\ULT4 8W_"*V_\ S]7G_?\ -'_"*V__ #]7
MG_?\ULT4 8W_  BMO_S]7G_?\T?\(K;_ //U>?\ ?\ULT4 8W_"*V_\ S]7G
M_?\ -'_"*V__ #]7G_?\ULT4 8W_  BMO_S]7G_?\T?\(K;_ //U>?\ ?\UL
MT4 8W_"*V_\ S]7G_?\ -'_"*V__ #]7G_?\ULT4 8W_  BMO_S]7G_?\T?\
M(K;_ //U>?\ ?\ULT4 8W_"*V_\ S]7G_?\ -'_"*V__ #]7G_?\ULT4 8W_
M  BMO_S]7G_?\T?\(K;_ //U>?\ ?\ULT4 8W_"*V_\ S]7G_?\ -'_"*V__
M #]7G_?\ULT4 8W_  BMO_S]7G_?\T?\(K;_ //U>?\ ?\ULT4 8W_"*V_\
MS]7G_?\ -'_"*V__ #]7G_?\ULT4 8W_  BMO_S]7G_?\T?\(K;_ //U>?\
M?\ULT4 8W_"*V_\ S]7G_?\ -'_"*V__ #]7G_?\ULT4 8W_  BMO_S]7G_?
M\T?\(K;_ //U>?\ ?\ULT4 8W_"*V_\ S]7G_?\ -'_"*V__ #]7G_?\ULT4
M 8W_  BMO_S]7G_?\T?\(K;_ //U>?\ ?\ULT4 8W_"*V_\ S]7G_?\ -'_"
M*V__ #]7G_?\ULT4 8W_  BMO_S]7G_?\T?\(K;_ //U>?\ ?\ULT4 8W_"*
MV_\ S]7G_?\ -'_"*V__ #]7G_?\ULT4 8W_  BMO_S]7G_?\T?\(K;_ //U
M>?\ ?\ULT4 8W_"*V_\ S]7G_?\ -'_"*V__ #]7G_?\ULT4 8W_  BMO_S]
M7G_?\T?\(K;_ //U>?\ ?\ULT4 8W_"*V_\ S]7G_?\ -'_"*V__ #]7G_?\
MULT4 8W_  BMO_S]7G_?\T?\(K;_ //U>?\ ?\ULT4 8W_"*V_\ S]7G_?\
M-'_"*V__ #]7G_?\ULT4 8W_  BMO_S]7G_?\T?\(K;_ //U>?\ ?\ULT4 8
MW_"*V_\ S]7G_?\ -'_"*V__ #]7G_?\ULT4 8W_  BMO_S]7G_?\T?\(K;_
M //U>?\ ?\ULT4 8W_"*V_\ S]7G_?\ -'_"*V__ #]7G_?\ULT4 8W_  BM
MO_S]7G_?\T?\(K;_ //U>?\ ?\ULT4 8W_"*V_\ S]7G_?\ -'_"*V__ #]7
MG_?\ULT4 8W_  BMO_S]7G_?\T?\(K;_ //U>?\ ?\ULT4 8W_"*V_\ S]7G
M_?\ -'_"*V__ #]7G_?\ULT4 8W_  BMO_S]7G_?\T?\(K;_ //U>?\ ?\UL
MT4 8W_"*V_\ S]7G_?\ -'_"*V__ #]7G_?\ULT4 8W_  BMO_S]7G_?\T?\
M(K;_ //U>?\ ?\ULT4 8W_"*V_\ S]7G_?\ -'_"*V__ #]7G_?\ULT4 8W_
M  BMO_S]7G_?\T?\(K;_ //U>?\ ?\ULT4 8W_"*V_\ S]7G_?\ -'_"*V__
M #]7G_?\ULT4 8W_  BMO_S]7G_?\T?\(K;_ //U>?\ ?\ULT4 8W_"*V_\
MS]7G_?\ -'_"*V__ #]7G_?\ULT4 8W_  BMO_S]7G_?\T?\(K;_ //U>?\
M?\ULT4 8W_"*V_\ S]7G_?\ -'_"*V__ #]7G_?\ULT4 8W_  BMO_S]7G_?
M\T?\(K;_ //U>?\ ?\ULT4 8W_"*V_\ S]7G_?\ -'_"*V__ #]7G_?\ULT4
M 8W_  BMO_S]7G_?\T?\(K;_ //U>?\ ?\ULT4 8W_"*V_\ S]7G_?\ -'_"
M*V__ #]7G_?\ULT4 8W_  BMO_S]7G_?\T?\(K;_ //U>?\ ?\ULT4 8W_"*
MV_\ S]7G_?\ -'_"*V__ #]7G_?\ULT4 8W_  BMO_S]7G_?\T?\(K;_ //U
M>?\ ?\ULT4 8W_"*V_\ S]7G_?\ -'_"*V__ #]7G_?\ULT4 8W_  BMO_S]
M7G_?\T?\(K;_ //U>?\ ?\ULT4 8W_"*V_\ S]7G_?\ -'_"*V__ #]7G_?\
MULT4 8W_  BMO_S]7G_?\T?\(K;_ //U>?\ ?\ULT4 8W_"*V_\ S]7G_?\
M-'_"*V__ #]7G_?\ULT4 8W_  BMO_S]7G_?\T?\(K;_ //U>?\ ?\ULT4 8
MW_"*V_\ S]7G_?\ -'_"*V__ #]7G_?\ULT4 8W_  BMO_S]7G_?\T?\(K;_
M //U>?\ ?\ULT4 8W_"*V_\ S]7G_?\ -'_"*V__ #]7G_?\ULT4 8W_  BM
MO_S]7G_?\T?\(K;_ //U>?\ ?\ULT4 8W_"*V_\ S]7G_?\ -'_"*V__ #]7
MG_?\ULT4 8W_  BMO_S]7G_?\T?\(K;_ //U>?\ ?\ULT4 8W_"*V_\ S]7G
M_?\ -'_"*V__ #]7G_?\ULT4 8W_  BMO_S]7G_?\T?\(K;_ //U>?\ ?\UL
MT4 8W_"*V_\ S]7G_?\ -'_"*V__ #]7G_?\ULT4 8W_  BMO_S]7G_?\T?\
M(K;_ //U>?\ ?\ULT4 8W_"*V_\ S]7G_?\ -'_"*V__ #]7G_?\ULT4 8W_
M  BMO_S]7G_?\T?\(K;_ //U>?\ ?\ULT4 8W_"*V_\ S]7G_?\ -'_"*V__
M #]7G_?\ULT4 8W_  BMO_S]7G_?\T?\(K;_ //U>?\ ?\ULT4 8W_"*V_\
MS]7G_?\ -'_"*V__ #]7G_?\ULT4 8W_  BMO_S]7G_?\T?\(K;_ //U>?\
M?\ULT4 8W_"*V_\ S]7G_?\ -'_"*V__ #]7G_?\ULT4 8W_  BMO_S]7G_?
M\T?\(K;_ //U>?\ ?\ULT4 8W_"*V_\ S]7G_?\ -'_"*V__ #]7G_?\ULT4
M 8W_  BMO_S]7G_?\T?\(K;_ //U>?\ ?\ULT4 8W_"*V_\ S]7G_?\ -'_"
M*V__ #]7G_?\ULT4 8W_  BMO_S]7G_?\T?\(K;_ //U>?\ ?\ULT4 8W_"*
MV_\ S]7G_?\ -'_"*V__ #]7G_?\ULT4 8W_  BMO_S]7G_?\T?\(K;_ //U
M>?\ ?\ULT4 8W_"*V_\ S]7G_?\ -'_"*V__ #]7G_?\ULT4 8W_  BMO_S]
M7G_?\T?\(K;_ //U>?\ ?\ULT4 8W_"*V_\ S]7G_?\ -'_"*V__ #]7G_?\
MULT4 8W_  BMO_S]7G_?\T?\(K;_ //U>?\ ?\ULT4 8W_"*V_\ S]7G_?\
M-'_"*V__ #]7G_?\ULT4 8W_  BMO_S]7G_?\T?\(K;_ //U>?\ ?\ULT4 8
MW_"*V_\ S]7G_?\ -'_"*V__ #]7G_?\ULT4 8W_  BMO_S]7G_?\T?\(K;_
M //U>?\ ?\ULT4 8W_"*V_\ S]7G_?\ -'_"*V__ #]7G_?\ULT4 8W_  BM
MO_S]7G_?\T?\(K;_ //U>?\ ?\ULT4 8W_"*V_\ S]7G_?\ -'_"*V__ #]7
MG_?\ULT4 8W_  BMO_S]7G_?\T?\(K;_ //U>?\ ?\ULT4 8W_"*V_\ S]7G
M_?\ -'_"*V__ #]7G_?\ULT4 8W_  BMO_S]7G_?\T?\(K;_ //U>?\ ?\UL
MT4 8W_"*V_\ S]7G_?\ -'_"*V__ #]7G_?\ULT4 8W_  BMO_S]7G_?\T?\
M(K;_ //U>?\ ?\ULT4 8W_"*V_\ S]7G_?\ -'_"*V__ #]7G_?\ULT4 8W_
M  BMO_S]7G_?\T?\(K;_ //U>?\ ?\ULT4 8W_"*V_\ S]7G_?\ -'_"*V__
M #]7G_?\ULT4 8W_  BMO_S]7G_?\T?\(K;_ //U>?\ ?\ULT4 8W_"*V_\
MS]7G_?\ -'_"*V__ #]7G_?\ULT4 8W_  BMO_S]7G_?\T?\(K;_ //U>?\
M?\ULT4 8W_"*V_\ S]7G_?\ -'_"*V__ #]7G_?\ULT4 8W_  BMO_S]7G_?
M\T?\(K;_ //U>?\ ?\ULT4 8W_"*V_\ S]7G_?\ -'_"*V__ #]7G_?\ULT4
M 8W_  BMO_S]7G_?\T?\(K;_ //U>?\ ?\ULT4 8W_"*V_\ S]7G_?\ -'_"
M*V__ #]7G_?\ULT4 8W_  BMO_S]7G_?\T?\(K;_ //U>?\ ?\ULT4 8W_"*
MV_\ S]7G_?\ -'_"*V__ #]7G_?\ULT4 8W_  BMO_S]7G_?\T?\(K;_ //U
M>?\ ?\ULT4 8W_"*V_\ S]7G_?\ -'_"*V__ #]7G_?\ULT4 8W_  BMO_S]
M7G_?\T?\(K;_ //U>?\ ?\ULT4 8W_"*V_\ S]7G_?\ -'_"*V__ #]7G_?\
MULT4 8W_  BMO_S]7G_?\T?\(K;_ //U>?\ ?\ULT4 8W_"*V_\ S]7G_?\
M-'_"*V__ #]7G_?\ULT4 8W_  BMO_S]7G_?\T?\(K;_ //U>?\ ?\ULT4 8
MW_"*V_\ S]7G_?\ -'_"*V__ #]7G_?\ULT4 8W_  BMO_S]7G_?\T?\(K;_
M //U>?\ ?\ULT4 8W_"*V_\ S]7G_?\ -'_"*V__ #]7G_?\ULT4 8W_  BM
MO_S]7G_?\T?\(K;_ //U>?\ ?\ULT4 8W_"*V_\ S]7G_?\ -'_"*V__ #]7
MG_?\ULT4 8W_  BMO_S]7G_?\T?\(K;_ //U>?\ ?\ULT4 8W_"*V_\ S]7G
M_?\ -'_"*V__ #]7G_?\ULT4 8W_  BMO_S]7G_?\T?\(K;_ //U>?\ ?\UL
MT4 8W_"*V_\ S]7G_?\ -'_"*V__ #]7G_?\ULT4 8W_  BMO_S]7G_?\T?\
M(K;_ //U>?\ ?\ULT4 8W_"*V_\ S]7G_?\ -'_"*V__ #]7G_?\ULT4 8W_
M  BMO_S]7G_?\T?\(K;_ //U>?\ ?\ULT4 8W_"*V_\ S]7G_?\ -'_"*V__
M #]7G_?\ULT4 8W_  BMO_S]7G_?\T?\(K;_ //U>?\ ?\ULT4 8W_"*V_\
MS]7G_?\ -'_"*V__ #]7G_?\ULT4 8W_  BMO_S]7G_?\T?\(K;_ //U>?\
M?\ULT4 8W_"*V_\ S]7G_?\ -'_"*V__ #]7G_?\ULT4 8W_  BMO_S]7G_?
M\T?\(K;_ //U>?\ ?\ULT4 8W_"*V_\ S]7G_?\ -'_"*V__ #]7G_?\ULT4
M 8W_  BMO_S]7G_?\T?\(K;_ //U>?\ ?\ULT4 8W_"*V_\ S]7G_?\ -'_"
M*V__ #]7G_?\ULT4 8W_  BMO_S]7G_?\T?\(K;_ //U>?\ ?\ULT4 8W_"*
MV_\ S]7G_?\ -'_"*V__ #]7G_?\ULT4 8W_  BMO_S]7G_?\T?\(K;_ //U
M>?\ ?\ULT4 8W_"*V_\ S]7G_?\ -'_"*V__ #]7G_?\ULT4 8W_  BMO_S]
M7G_?\T?\(K;_ //U>?\ ?\ULT4 8W_"*V_\ S]7G_?\ -'_"*V__ #]7G_?\
MULT4 8W_  BMO_S]7G_?\T?\(K;_ //U>?\ ?\ULT4 8W_"*V_\ S]7G_?\
M-'_"*V__ #]7G_?\ULT4 8W_  BMO_S]7G_?\T?\(K;_ //U>?\ ?\ULT4 8
MW_"*V_\ S]7G_?\ -'_"*V__ #]7G_?\ULT4 8W_  BMO_S]7G_?\T?\(K;_
M //U>?\ ?\ULT4 8W_"*V_\ S]7G_?\ -'_"*V__ #]7G_?\ULT4 8W_  BM
MO_S]7G_?\T5LT4 9.@_Z[6/^PA-_,5K5DZ#_ *[6/^PA-_,5K4 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M[LQNI/#'@G'-?28&C0>'E5JQO9O]#YC,:U>.)A1I3M=+[V['0_\ #R;XF_\
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MECSRL=O<H?S,Y_E7TEX+_8M^#6K>#=!OKOP=YMU=6%O-+)_:EZ-SM&K,<";
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!DZ#_KM8_["$W\Q6M63H/^NUC_ +"$W\Q6M0 4444 %%%% 'R!
M_P %+/\ DE'A?_L-C_T1+7QA\#_CQK_P!\07^L>'K/3;RYO+7[)(FIQ2.@3>
MKY 1T.<J.]?9_P#P4L_Y)1X7_P"PV/\ T1+7SO\ L._"/PG\8/B#KVF>+M*_
MM>RM=+-S#%]IFAVR>;&N[,;J3PQX)QS7U>7RC'!S<U=7=_P/D,TC*6,@H.SL
MK>MSH3_P4F^)K C^P_"8]_L=S_\ )%>)_$KXO>*?V@/&%C=^*M6M82"+>W#*
M8;2S1B,G !(&>2QW'CO@5^C;?L._!-E('@LJ?4:K>\?^1J^:?VQOV0?#/PH\
M&IXQ\'O<V=I'<I;W>FW$QE0!\A7C9OFZX!!)ZYXQRL/BL%[6*A"S>B=NY6(P
M>.=*7/.Z6K5WT^1]9_LP_"O0_A/\)M.T_1-4MM>%X3>W.K6;AXKJ5@ 2A!/R
M@ */]W)Y)KP#_@IM_P BWX%_Z^[K_P! CKS_ /X)U_%+4M)^)%UX(EG>71M6
MMY+B&!B2(;B,;BR^FY P/KA?2O0/^"FW_(M^!?\ K[NO_0(ZY*E&=+,(<SO=
MWN==&M"ME\N56Y4U8^5?@5^T5XD_9]NM7N/#MEI5Z^J)'',-4BED"A"Q&W9(
MF/O'.<UZXW_!27XFLI T3PHI_O"SN<C\[BJW["OP5\&?&35/%T/C#1O[7CL(
M;9[9?M4T&PNT@8_NG7.=HZYZ5TG[7'[%NF_#CPV_C'P)'<C2;4C^T=+ED:8P
M(>!+&Q^8J#]X,3C.<XSCU<34POMU3K1]YVUZ>1Y.&I8SV#JT9^ZKZ=?,^>OB
M=\7/&W[0_BJRFUIVU.^'^CV.FZ?;D)'N(RL<:Y))..3DG YX%?H#^Q+^S_J'
MP7\"WVH:_%]G\1:Z\<DUKP3;0H#Y<;?[669CZ9 ZBOCS]DO]I@_ [Q.EAJUG
M;7'AG4) ES<+;H+FU)./,60#<RCNA)X&1@]?U.M;J&^M8;FWE2>WF021RQL&
M5U(R&!'4$5QYC4GAZ:H4XV@^OXV\M3MRNG#$577J3YIKH_S/@O\ X*<?\ASP
M!_U[7G_H4-> ? G]ISQ3^S[:ZO;^';#2+U-4>*28ZI#+(5*!@-NR1,??.<Y[
M5[__ ,%./^0YX _Z]KS_ -"AKGOV%?@-X&^,FD^+YO&&A_VO)8S6R6S?:YX-
M@=9"P_=.N<[1USTK7!RIPR[FJJ\5>Z_[>,<=&I/,^6D[2=K/_MTI_P##R;XF
M_P#0"\)_^ EU_P#)%:WA'_@HA\1]>\5Z+IEQHOA9(+V]AMI&CM+D,%>15)!-
MP1G!]*^FO^&'?@G_ -"5_P"56^_^/59TW]B_X-Z/J-K?VG@[RKNUE2>&3^U+
MUMKJ0RG!FP<$#K7)]:P'6F_N1V+"YC_S\7WL]MKYI_;X^)W_  @WP5ET6VEV
M:CXDE^Q*%/(@&&F;Z$;4_P"!U]+5^67[='Q._P"%@_'"]L+:;S-,\/)_9T..
MAE!S,W_??R_\ %>9@:/UC$*/1:OT1ZN-K_5\-*779>K_ ,C6_P""?GPU_P"$
MR^,S:_<Q;[#PW;FYRPR/M#Y2(?@-[#W057_;Z^&?_"$_&R36K>+9I_B.$7JD
M#@3K\LH^N=K?\#KD/@?^U9XH^ .@W^E^'='T&Z2^N/M,]QJ-O,\S$*%"Y29!
MM&#@8ZL:;\<?VJ/$_P ?]%T[3O$>D:%:K83F>"XTV"9)02NUER\KC:>,C'51
M7U%2G7>,C5C\*5OD]SY.E6P_U.5*7QMWVZK8^U/V ?BC_P )O\&_[ N9-^H^
M&I?LIR>6MWRT)_##I]$%?3,T*7$,D4JAXY%*LIZ$$8(K\J?V)?BA_P *W^.6
MEP7$_E:5KH_LRYW'Y0SG]RWX2!1GL&:OU(U_Q%I7A72IM3UK4;72=.AQYEW>
MS+%$F2 ,LQ &20/QKP<TH>SK\R6DM?GU/H<HQ'M*'*WK'3Y=#\I/VF/V<-<^
M!OC"\=;*:X\)74S/I^I(A:,*QR(I#_"Z],'KC(]L/X=_M+?$KX6PQVN@>*KR
M/3X\!;"[VW-NJC^%4D#!!_N8K]/-$^/7PP^(WB!?".F^)-.U_4+R-_\ 04B:
M6.5%4LP+%=AX!.">U<AXZ_8?^$OC9II4T&3P[=R<FXT.8P ?2(AHA^"5UTL?
MRP5/%POYVW^3..MEW/4E5PD[/M?9^J/ OAW_ ,%+-0AFBM_''A>"Z@) >^T1
MS'(H]?)D)#'Z.OTK[3^'OQ&\/?%+PS!KWAG4H]3TZ4E=Z95HW'5'4\JPR.".
MX/0@U^=?[2G[$]]\$?#DOBG2-;&N>'XI5CGCN(?*N;?>P52<$JXR0"1MQD<=
MZM_\$\/'E[H/QGE\-B9CINNV<@>$GY1-$ID1_KM#K_P+VJZN&PV*H2K8?1QO
M^&K5C.EBL5A:\:.)U4K?B[)W/TNKR7]K#_DW/QY_V#C_ .AK7K5>2_M8?\FY
M^//^P<?_ $-:^;A\:/J9_"S\X/V1_P#DX_P)_P!?Q_\ 1;U^O-?D-^R/_P G
M'^!/^OX_^BWK]>:^@SC>!\YDOPS]0HHHKYP^E/D+_@I5J$L'PI\-6B'$5QK&
MY_?;"^/_ $*O'/\ @FS817'QCU^Y=0TMOHC^62.FZ:($C\/YU[O_ ,%%_#,V
ML?!&QU.%2PTG5(I9<#I&ZM'G_OID_.OFK_@GWXPMO#/Q[6QNI1$FM:?-8Q%C
M@&4,LBC\?+8#W(KZ; ^]@:BCOK^2/E<Q]W'TG+;3\S]/J**YCXF^/;+X7^ =
M<\4WZ^9;Z9;--Y._897Z)&#@X+,0O0]:^:UV/J?,Z>BOG#X2?MT>!?BIK^FZ
M =/U?1=<OY!###- )H7D/\(>,DX]V50.]>O_ !>^(%O\+OAKXA\3W!7_ (E]
MH[Q*W\<I^6-?Q<J/QK:K1JTGRSC9_F84:U*LKP::_(_.G]O+XG?\)Y\;;C2K
M:7?IOAR/[!'M.5,Q.Z9OKNPO_;.OIG]F']G^VN/V2[[1]2A$=WXTMY+N5V'*
M*RXMC^ 59![L:_."^U&?5-2N+^[?[1<W$S3S._\ &[,68GZDFOI^P_X*,?$;
M2[&VL[7P]X1AMK>-88HUL[K"HH 4#_2.P KZJIA*L<)&A1WZO\3Y&EC*3QLL
M16VZ?E^1X+X1\0:K\&_BCI^J>4T6J:!J/[Z \9,;E9(S[$;E_&OV8T#7+3Q-
MH>G:O82>=8W]O'=02?WD=0RG\B*_%SXC>.KOXE>--5\3W]E96%[J4OG3PZ>C
MI#OP 6 9F(R1D\]2:_0G_@GK\4/^$N^$MQX8NY]^H>')_+C5C\QM9,M&?P;S
M%]@%K+,:,JF&C4:]Z._ZFN68B%/%2IQ?NRV^6Q4_X*2?\D9T+_L-Q_\ HF6O
ME#]GGX&K\</!/Q&M;2,'Q#I=O:WFF/W9P9=T7T<#'U"GM7U?_P %)/\ DC.A
M?]AN/_T3+7G7_!,?_D.>/O\ KVL__0I:PP4I0P%2479I_P"1UXZ,9X^E&2NF
MOU9\W? 3XMZA\!OBI8:X$E%M&YM-3LL$-) 2!(I!_B4C<,_Q**^R?^"AFL6?
MB#X!^%M4TZX2[L+S58;B">,Y62-H)2K#Z@UY%^WY\!/^$*\7)X[T>VV:+K<F
MV]2-?E@N\9+>PD&3_O!O45XG>_&2[UGX"VOP\U$R3#3-62^TZ8\[(2D@DB/L
M&8,/]YAV%=?+''1IXF'Q1:O]^OW''&4LOG5PU1^[).S_ "/I'_@F/_R'/'W_
M %[6?_H4M8G_  4MU"27XG^%;(_ZJ'2#*O/=YG!_] %;?_!,?_D.>/O^O:S_
M /0I:@_X*9>&9H?%/@WQ (R;>>SEL6D[!D?>!^(D/Y&L*S2S.%_ZT-Z*;RJ:
M7]:H[C_@F?I\4?P[\77H4>?-JJ0LV.=J1*5'YNWYU]D5\,_\$S?&%M]D\9>%
MI)0MWYD6I01D\NF/+D('L1'_ -]"ON:O,S1-8J3?6WY(]/*9)X2*72_YA17F
M'[07QWTW]G_P;;:[?V3:G)<W:6L-E',(W?()9@2#]U03[\#(S6/\$?VKO!?Q
MXU2;2M#BU2RU:& W#VE_:XQ&" 6#H67&6 Y()STKAC1JR@ZD8W2/0GB*4*BI
MR=I/8^=_^"G7_'Q\/_\ =O/YPU\Y? G]I;Q/^SW'K*>';#2;T:H8C-_:D,LF
MWR]VW;LD3'WSG.>U?1O_  4Z_P"/CX?_ .[>?SAKC/V$_@9X(^,EOXQ;QAHG
M]L-I[6HMO]+G@\O>)=W^J=<YVKUSTKZ3 RA#+W*JKQ5[KY_YGR^81G/,8QIN
MTFE9_(C_ .'DWQ-_Z 7A/_P$NO\ Y(K0\/\ _!1?XDZMKVFV,VB>%5BN;F*%
MV2TN0P5G )&;CK@U]0?\,._!/_H2O_*K??\ QZI[+]BGX,:?>075OX-\NX@D
M66-_[4O3M93D'!FP>17+]:P'6F_N1U?5,Q_Y^K[W_D>WU^)OQ*_Y*-XJ_P"P
MM=_^CGK]LJ_$WXE?\E&\5?\ 86N__1SUGE'\>7I^IIG7^[Q]?T/H#1?^"B7Q
M'T'1[#3;?1/"SP6=O';QM):7)8JBA03BX S@>E5/$W_!0KXJ>(M)N+*!=$T,
MS)L-UIMI()E!Z[3)(X!]\9';%?3VD?L._"7Q9\.](E70[G2]3O=.@E;4+74)
MV=9&C4E@LCLG4]-N*^"/BM\--<^ ?Q,N-#O_ "Y+FRD6XM+IHE>*YBSF.0(P
M((.,%3D9!!S7I4OJ5>K*')[WGU[GF5%CL/0C4Y_=TVZ=NAL_ ']G[Q)\>O&%
MM#;6MQ'H*3AM2UB13Y429!8!CPTA'11SSDX&37Z[6-E#IMC;VEM&(K>WC6*.
M->BJH  _(5\_?L?_ +2EI\;/"[Z/?06VF^*-(C7SK:U41Q7$/031H/N\X#*.
M 2,<, /HBO(S*M4J5/93CRJ/]7/9RNC3C!UH2YG+?_(****\8]P**** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M26$Z7+'&6+@ [M\;Y'RCIBN&IC%6Q<*TE:,?R.^E@70PDZ,7>4K_ 'M'RO\
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MV'N&_M.^56_@7*Q*1[MO;_@(K[>55C4*H"JHP% P *^?OBI^Q/X+^,'C>_\
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MI?U^1\(?\%.O^/CX?_[MY_.&O$/V8OVH_P#AG&+Q"G_",_\ "0_VLT!S]O\
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MT(/6:M<^@?AS_P D]\+_ /8+M?\ T2M>0?MD?L_CXU?#PWNF0!O%.B*\]EM
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110!DZ#_KM8_["$W\Q6M63H/^NUC_ +"$
MW\Q6M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 9.@_Z[6/^PA-_,5K5DZ9H/B&2XU9M/ALY8?M\P9I)"#N#8('3CBM
M#_A'_%__ #Z:?_W]/^- $U%0_P#"/^+_ /GTT_\ [^G_ !H_X1_Q?_SZ:?\
M]_3_ (T 345#_P (_P"+_P#GTT__ +^G_&C_ (1_Q?\ \^FG_P#?T_XT 345
M#_PC_B__ )]-/_[^G_&C_A'_ !?_ ,^FG_\ ?T_XT 345#_PC_B__GTT_P#[
M^G_&C_A'_%__ #Z:?_W]/^- $U%0_P#"/^+_ /GTT_\ [^G_ !H_X1_Q?_SZ
M:?\ ]_3_ (T 345#_P (_P"+_P#GTT__ +^G_&C_ (1_Q?\ \^FG_P#?T_XT
M 345#_PC_B__ )]-/_[^G_&C_A'_ !?_ ,^FG_\ ?T_XT 345#_PC_B__GTT
M_P#[^G_&C_A'_%__ #Z:?_W]/^- $U%0_P#"/^+_ /GTT_\ [^G_ !H_X1_Q
M?_SZ:?\ ]_3_ (T 345#_P (_P"+_P#GTT__ +^G_&C_ (1_Q?\ \^FG_P#?
MT_XT 345#_PC_B__ )]-/_[^G_&C_A'_ !?_ ,^FG_\ ?T_XT 345#_PC_B_
M_GTT_P#[^G_&C_A'_%__ #Z:?_W]/^- $U%0_P#"/^+_ /GTT_\ [^G_ !H_
MX1_Q?_SZ:?\ ]_3_ (T 345#_P (_P"+_P#GTT__ +^G_&C_ (1_Q?\ \^FG
M_P#?T_XT 345#_PC_B__ )]-/_[^G_&C_A'_ !?_ ,^FG_\ ?T_XT 345#_P
MC_B__GTT_P#[^G_&C_A'_%__ #Z:?_W]/^- $U%0_P#"/^+_ /GTT_\ [^G_
M !H_X1_Q?_SZ:?\ ]_3_ (T 345#_P (_P"+_P#GTT__ +^G_&C_ (1_Q?\
M\^FG_P#?T_XT 345#_PC_B__ )]-/_[^G_&C_A'_ !?_ ,^FG_\ ?T_XT 34
M5#_PC_B__GTT_P#[^G_&C_A'_%__ #Z:?_W]/^- $U%0_P#"/^+_ /GTT_\
M[^G_ !H_X1_Q?_SZ:?\ ]_3_ (T 345#_P (_P"+_P#GTT__ +^G_&C_ (1_
MQ?\ \^FG_P#?T_XT 345#_PC_B__ )]-/_[^G_&C_A'_ !?_ ,^FG_\ ?T_X
MT 345#_PC_B__GTT_P#[^G_&C_A'_%__ #Z:?_W]/^- $U%0_P#"/^+_ /GT
MT_\ [^G_ !H_X1_Q?_SZ:?\ ]_3_ (T 345#_P (_P"+_P#GTT__ +^G_&C_
M (1_Q?\ \^FG_P#?T_XT 345#_PC_B__ )]-/_[^G_&C_A'_ !?_ ,^FG_\
M?T_XT 345#_PC_B__GTT_P#[^G_&C_A'_%__ #Z:?_W]/^- $U%0_P#"/^+_
M /GTT_\ [^G_ !H_X1_Q?_SZ:?\ ]_3_ (T 345#_P (_P"+_P#GTT__ +^G
M_&C_ (1_Q?\ \^FG_P#?T_XT 345#_PC_B__ )]-/_[^G_&C_A'_ !?_ ,^F
MG_\ ?T_XT 345#_PC_B__GTT_P#[^G_&C_A'_%__ #Z:?_W]/^- $U%0_P#"
M/^+_ /GTT_\ [^G_ !H_X1_Q?_SZ:?\ ]_3_ (T 345#_P (_P"+_P#GTT__
M +^G_&C_ (1_Q?\ \^FG_P#?T_XT 345#_PC_B__ )]-/_[^G_&C_A'_ !?_
M ,^FG_\ ?T_XT 345#_PC_B__GTT_P#[^G_&C_A'_%__ #Z:?_W]/^- $U%0
M_P#"/^+_ /GTT_\ [^G_ !H_X1_Q?_SZ:?\ ]_3_ (T 345#_P (_P"+_P#G
MTT__ +^G_&C_ (1_Q?\ \^FG_P#?T_XT 345#_PC_B__ )]-/_[^G_&C_A'_
M !?_ ,^FG_\ ?T_XT 345G:M9>*-(T^>]N+6P$,*[F*N2>N.F:M_\(_XO_Y]
M-/\ ^_I_QH FHJ'_ (1_Q?\ \^FG_P#?T_XT?\(_XO\ ^?33_P#OZ?\ &@":
MBH?^$?\ %_\ SZ:?_P!_3_C1_P (_P"+_P#GTT__ +^G_&@":BH?^$?\7_\
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M^$?\7_\ /II__?T_XT?\(_XO_P"?33_^_I_QH FHJ'_A'_%__/II_P#W]/\
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M FHJ'_A'_%__ #Z:?_W]/^-'_"/^+_\ GTT__OZ?\: )J*A_X1_Q?_SZ:?\
M]_3_ (T?\(_XO_Y]-/\ ^_I_QH FHJ'_ (1_Q?\ \^FG_P#?T_XT?\(_XO\
M^?33_P#OZ?\ &@":BH?^$?\ %_\ SZ:?_P!_3_C1_P (_P"+_P#GTT__ +^G
M_&@":BH?^$?\7_\ /II__?T_XT?\(_XO_P"?33_^_I_QH FHJ'_A'_%__/II
M_P#W]/\ C1_PC_B__GTT_P#[^G_&@":BH?\ A'_%_P#SZ:?_ -_3_C1_PC_B
M_P#Y]-/_ ._I_P : )J*A_X1_P 7_P#/II__ ']/^-'_  C_ (O_ .?33_\
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M^$?\7_\ /II__?T_XT?\(_XO_P"?33_^_I_QH FHJ'_A'_%__/II_P#W]/\
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M FHJ'_A'_%__ #Z:?_W]/^-'_"/^+_\ GTT__OZ?\: )J*A_X1_Q?_SZ:?\
M]_3_ (T?\(_XO_Y]-/\ ^_I_QH FHJ'_ (1_Q?\ \^FG_P#?T_XT?\(_XO\
M^?33_P#OZ?\ &@":BH?^$?\ %_\ SZ:?_P!_3_C1_P (_P"+_P#GTT__ +^G
M_&@":BH?^$?\7_\ /II__?T_XT?\(_XO_P"?33_^_I_QH FHJ'_A'_%__/II
M_P#W]/\ C1_PC_B__GTT_P#[^G_&@":BH?\ A'_%_P#SZ:?_ -_3_C1_PC_B
M_P#Y]-/_ ._I_P : )J*A_X1_P 7_P#/II__ ']/^-'_  C_ (O_ .?33_\
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M@:=%9GV7Q/\ \^MC_P!]G_&C[+XG_P"?6Q_[[/\ C19@:=%9GV7Q/_SZV/\
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M[/\ C19@:=%9GV7Q/_SZV/\ WV?\:/LOB?\ Y];'_OL_XT68&G169]E\3_\
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M (T?9?$__/K8_P#?9_QHLP-.BLS[+XG_ .?6Q_[[/^-'V7Q/_P ^MC_WV?\
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M .?6Q_[[/^-'V7Q/_P ^MC_WV?\ &BS TZ*S/LOB?_GUL?\ OL_XT?9?$_\
MSZV/_?9_QHLP-.BLS[+XG_Y];'_OL_XT?9?$_P#SZV/_ 'V?\:+,#3HK,^R^
M)_\ GUL?^^S_ (T?9?$__/K8_P#?9_QHLP-.BLS[+XG_ .?6Q_[[/^-'V7Q/
M_P ^MC_WV?\ &BS TZ*S/LOB?_GUL?\ OL_XT?9?$_\ SZV/_?9_QHLP-.BL
MS[+XG_Y];'_OL_XT?9?$_P#SZV/_ 'V?\:+,#3HK,^R^)_\ GUL?^^S_ (T?
M9?$__/K8_P#?9_QHLP-.BLS[+XG_ .?6Q_[[/^-'V7Q/_P ^MC_WV?\ &BS
MTZ*S/LOB?_GUL?\ OL_XT?9?$_\ SZV/_?9_QHLP-.BLPVWB=?\ EUL1_P "
M8]O3<**0'<^#/]3K'_84N?\ T.NBKG?!G^IUC_L*7/\ Z'714 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 <Y\0O^1-U7_KD/_0A71USGQ"_Y$W5?^N0_]"%='0 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 5SES_ ,E"TS_L%W?_ *.MZZ.N<N?^2A:9
M_P!@N[_]'6] '1T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Q6J?\
M)0)O^P9%_P"C9:NU2U3_ )*!-_V#(O\ T;+5VM%L2PHHHIB"BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** ,+6O^1B\/?]=9O_135NUA:U_R,7A[_KK-_P"BFK=H **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MK"\,_P#'UKW_ &$6_P#1<=;M87AG_CZU[_L(M_Z+CH W:*** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M &MVHH;M12>X%CP9_J=8_P"PI<_^AUT5<[X,_P!3K'_84N?_ $.NBK,L****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH YSXA?\B;JO\ UR'_ *$*Z.N<^(7_ ")NJ_\
M7(?^A"NCH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH *YRY_Y*%IG_8+N_P#T=;UT
M=<Y<_P#)0M,_[!=W_P"CK>@#HZ*** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH XK5/^2@3?\ 8,B_]&RU=JEJG_)0)O\ L&1?^C9:NUHMB6%%%%,04444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110!A:U_R,7A[_KK-_Z*:MVL+6O^1B\/?]=9O_135NT
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 5A>&?^/K7O^PBW_HN.MVL+PS_ ,?6O?\ 81;_ -%QT ;M%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% #6[44-VHI/<"QX,_U.L?]A2Y_P#0ZZ*N=\&?ZG6/^PI<_P#H==%6
M984444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110!SGQ"_Y$W5?^N0_]"%='7.?$+_D3=5_
MZY#_ -"%='0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 5SES_P E"TS_ +!=W_Z.
MMZZ.N<N?^2A:9_V"[O\ ]'6] '1T444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110!Q6J?\E F_[!D7_HV6KM4M4_Y*!-_V#(O_ $;+5VM%L2PHHHIB"BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** ,+6O^1B\/?\ 76;_ -%-6[6%K7_(Q>'O^NLW_HIJ
MW: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH *PO#/_ !]:]_V$6_\ 1<=;M87AG_CZU[_L(M_Z+CH W:*** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** &MVHH;M12>X%CP9_J=8_["ES_Z'715SO@S_4ZQ_P!A2Y_]#KHJ
MS+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** .<^(7_ ")NJ_\ 7(?^A"NCKG/B%_R)
MNJ_]<A_Z$*Z.@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0_YYZ;_X#S?_ !=%P/HVBOG'_AI[4/\ GGIO_@/-_P#%T?\ #3VH?\\]-_\
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M'45\X_\ #4%__P \]-_\!YO_ (NC_AJ#4/\ GGIO_@/-_P#%T7 ^CJ*^<?\
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MQTW_ ,!YO_BZ7_AI?5/^>.F_^ \W_P 71<#Z)HKYV_X:7U3_ )XZ;_X#S?\
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MEKO:WLED4X8+&^/_ $*M)?BAJ;?\L+/_ +X?_P"*HYD%CTZL+PS_ ,?6O?\
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M4U%*@C8 >E #**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** &MVHH;M12>X%CP9_J=8_P"PI<_^AUT5<[X,_P!3K'_84N?_ $.NBK,L
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH YSXA?\B;JO\ UR'_ *$*Z.N<^(7_ ")N
MJ_\ 7(?^A"NCH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *YRY_Y*%IG_8+N_P#T
M=;UT=<Y<_P#)0M,_[!=W_P"CK>@#HZ*** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH \9^.7^KUS_L%VO_ *5-7SK7T5\<O]7KG_8+M?\ TJ:OG6@!C+2-
M3VIK*: &,M-J6F[: (MHII2IMM)M- $!7VII6K&VFE: *YCIOEU9\ND\L^E
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MJ0'TO^%)2_X4 )2_X4E*M4 M._PIM._PH 6J]Q_K!]*L57N/]8/I0!%1110
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M5BL+/"S4)M7:OH1A<5#%P<X)I)VU^0ZBBBN4[0HI*6@ HHHH **** "BBB@
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M7]:_/C^T/VYO2?\ [\:+_P#$UD2?M=?M$_ 75K,_%'PW_:6F7$FTF^LH[8R
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MUVG@;X3:OX_T^XO-.N;*&*&7R6%T[JQ. >-J'CFN+KZ-_9G_ .13U7_K]_\
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M)FMWMY7BE1HY$.UD<8(/H10!6\ND\OVJQMK0TWPWJNM*S:?IEY?*IP6MH'D
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M %JO<?ZP?2K%5[C_ %@^E $5%%% !1110 4444 %%%% !1110 4444 %%%%
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MO[#)(APPMU7?*!_O?*I]F-<>*P+HUH0INZGM_7D=N#Q_MJ4Y5%9PW,GXN?\
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MU?7[YGN;Z?+D9S)-,WKA0[8[XQ4X#"+$RE*;M&.Y6/QCPL(J"O*6Q]W>#O\
M@JYX<U+6$M_$G@6^T+3W;:;VROUOBF3U:,QQG [X)/H#7RU^W?XJTCQM^T-?
MZ[H>H0ZGI-]IUE+;W=NV4D4PK^1'0@\@@@X(K[M'_!-OX,?\(F-*.EZE_:GE
M;/[<_M&7[3OQ]_9GR>O;R\5^7WQ@^&E]\'OB7K_@[4)!/<:7<F(3JNT31D!H
MY .VY64X[9Q7JX)82>)3H732?S/'QKQD,.U7LXRMMNG]Q^G?[,/Q&L_A+^PI
MX<\6ZAI^H:EI^EV]S-<0Z7&DD_E_;)06"NZ A<Y//0&KOPI_X*$_#CXN>/\
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M-/LT6X9.CSM\\S?C(S'\:]!KBKJ"J25/9/0[<.YRI1=3XFM1U%%%9'0%%%%
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M%% !1110 4444 %%%% '.?$+_D3=5_ZY#_T(5T=<Y\0O^1-U7_KD/_0A71T
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M_P#V +G_ -!K&K\$C6G\<?4^>O\ @CGXZT[7/V:=2\.1S(-5T/69C-;[AO\
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M>(9K9_,B=&QYCHG7&3STK]7?V;_V>/#/[,?PQL?!OAE7DBC<SWM_,!YM[<,
M'E?'3@  #@*H';->1?MR?L%:-^UM86>L6&H1^'/'FF0F"TU.2,O#<Q9+""<#
MYL!B2KKDKN;ALXJ)-0G!Q5XI6_X)<;U%.[LY._IV+0_X)=_LQG_FF?\ Y7]4
M_P#DFOG_ /:1^#?[#G[+/B#0-%\9?#?4Y[[6(GGCCTG5M0G-O$K!0\H-ZI 8
MDA<!B=C>E9&D>%_^"BGPMTP^%]*GT_Q9IMN@@MM7FO--N&C4< K)<LDS]?\
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MAXCO[VQN+6YM[J=I@TTA1UW')##';/8]J\9K;C\;>(X8Q%'K^J)&HP$6\D
M],;JJ7O-/J2M+H]Q^&OP]L/AKK%O+K&J6TNO7V8+:VB)(4'DD9&3D#K@ =.]
M<%^T3;O#\0%=@=LMG&RG'H6']*\Y&I78OA>BZF%X'\P7'F'S P_BW9SGWJ75
M-<U+6VC;4=0NK]HP0C74S2%0>N-Q.*F7O6;Z#^&]NI[_ .)/^3<K;_KRM?\
MT-*^<JTI/$FKS::+"35;V2P"A1:M<.8@!T&S.,# [5FT_M-]QKX5'L?1'A7_
M )-SN_\ KTNO_0WKA?V>?^2B+_UZ2_\ LM<%%XDU:#33I\>J7L>GL"IM5N'$
M1!ZC9G&#GTJ#3M4O='N/M%A=SV4^"OFV\K1M@]1D'.*J_O-]R7\-O,[+XX?\
ME.UC_ME_Z*2HO@G_ ,E-T7_>D_\ 13UR%]J%UJET]S>7,UW</C=-.Y=VP,#)
M/)XI+&^N=-NDN;.XEM+B/[DT#E'7(P<$<CBE#W;%2U/2OVBO^2@)_P!>4?\
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M_P!"%='7.?$+_D3=5_ZY#_T(5T= !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M)2T4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<Y
M<_\ )0M,_P"P7=_^CK>NCKG+G_DH6F?]@N[_ /1UO0!T=%%% !1110 VO"_V
MX_\ DT7XKG_J7[G_ -!KW0&@K^59R7-%HJ+Y9)GP=_P1KY_95U4_]3-=?^B+
M>OO''6DX7..M.%;3ES/FL8PCR*WFW][N%+114F@4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110!SGQ"_P"1-U7_ *Y#_P!"%='7.?$+
M_D3=5_ZY#_T(5T= !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7.7/_)0M,_[!=W_
M .CK>NCKG+G_ )*%IG_8+N__ $=;T ='1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% 'E?Q-T.X\3:KJFF6KQQSSZ7;[6F)"C%P['. 3T![5Y;_PH?Q!
M_P _FF_]_9/_ (W7M^J_\C_+_P!@R+_T;+5IAVJTKHD\$_X43X@_Y^]-_P"_
MLG_QNF_\*+U\?\O6F_\ ?V3_ .-U[TRTQEJN5"NSP;_A2&O_ //UIO\ W]D_
M^-TG_"D=?_Y^=-_[_2?_ !NO=V6F%?:CE079X5_PI/7_ /GYTW_O])_\;IO_
M  I77_\ GXTW_O\ 2?\ QNO==E-:.ERH+L\*/P7U\?\ +QIO_?Z3_P"-TT_!
MK7Q_RWT[_O\ 2?\ QNO=#'3&C]J?*A79X9_PIW7Q_P M]._[_2?_ !ND_P"%
M/Z]_SWT[_O\ 2?\ QNO<?*%,:&CE079X?_PJ/7O^>VG?]_I/_C=)_P *CU[_
M )ZZ=_W_ )/_ (W7M[0^U,\CVI\J"[/$?^%2Z]_SUT[_ +_R?_&Z0_"?7O\
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M_@0__P ;KV7[%_LTGV$>E'*@YF>-?\*_UW_J'_\ @0__ ,;I/^%?Z[_=T_\
M\"'_ /C=>R_81Z&D^PC^[2Y4',SQK_A7^N^EA_X$/_\ &Z/^$!USTT__ ,")
M/_C=>R?V>OI1_9Z>E/E0<TCQK_A ]=_NZ?\ ^!#_ /QND_X0/7?[NG_^!+__
M !NO9?[/7T--_L]?2CE0<TCQO_A!==_NZ?\ ^!+_ /QNE_X077?[MA_X$O\
M_&Z]D_L]?[M']G*>U'*A<TCQG_A!]=_N6'_@2_\ \;H_X0?7?[EA_P"!+_\
MQNO9?[-7T-']FCT-'*A\TCQG_A!]=_YYV/\ X$O_ /&Z/^$(UW_GG8?^!+__
M !NO9?[-7TH_LP>E'*A<TCQK_A"-=_YYV'_@2_\ \;H_X0?7?^>=C_X$O_\
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M[:-M $'DGTI1$:GVFC:: (A&:<(S4BJ:7:: (_+]Z=MIVVC;0 T#%+2[:-M
M#J*** "BBB@ HHHH **** "BBB@ HHHH **** "L+PS_ ,?6O?\ 81;_ -%Q
MUNUA>&?^/K7O^PBW_HN.@#=HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH :W:BANU%)[@6/!G^IUC_
M +"ES_Z'715SO@S_ %.L?]A2Y_\ 0ZZ*LRPHHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@#G/B%_R)NJ_P#7(?\ H0KHZYSXA?\ (FZK_P!<A_Z$*Z.@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ KG+G_DH6F?]@N[_ /1UO71USES_ ,E"TS_L%W?_ *.M
MZ .CHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#B=5&?B!-_P!@R+_T
M;+5W;5/5/^2@3?\ 8,B_]&RU=K1;$L3;1MI:*8A-M&VEHH 3;1MI:* $VT;:
M6B@!-M&VEHH 3;1MI:* $VT;:6B@!NT4;13J* &[11M%.HH ;M%&T4ZB@!NT
M4;13J* &[11M%.HH ;M%&T4ZB@!NT4;13J* &[11M%.HH ;M%&T4ZB@!NT4;
M13J* &[11M%.HH ;M%&T4ZB@!NT4;13J* &[11M%.HH ;M%&T4ZB@!NT4;13
MJ* &[11M%.HH ;M%&T4ZB@!NT4;13J* &[11M%.HH ;M%&T4ZB@#!UI1_P )
M'X>_ZZS?^BFK<VBL36O^1B\/?]=9O_135NT -VBC:*=10 W:*-HIU% #=HHV
MBG44 -VBC:*=10 W:*-HIU% #=HHVBG44 -VBC:*=10 W:*-HIU% #=HHVBG
M44 -VBC:*=10 W:*-HIU% #=HHVBG44 -VBC:*=10 W:*-HIU% #=HHVBG44
M -VBEVBEHH 3;1MI:* $VT;:6B@!-M&VEHH 3;1MI:* $VT;:6B@!-M&T4M%
M ";12T44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %87AG_CZU[_ +"+?^BXZW:PO#/_ !]:]_V$6_\ 1<= &[11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 UNU%#=J*3W L>#/\ 4ZQ_V%+G_P!#KHJYWP9_J=8_["ES
M_P"AUT59EA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% '.?$+_D3=5_ZY#_ -"%='7.
M?$+_ )$W5?\ KD/_ $(5T= !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7.7/_)0M
M,_[!=W_Z.MZZ.N<N?^2A:9_V"[O_ -'6] '1T444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110!Q6J?\E F_P"P9%_Z-EJ[5+5/^2@3?]@R+_T;+5VM%L2P
MHHHIB"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** ,+6O^1B\/?]=9O_ $4U;M86M?\ (Q>'
MO^NLW_HIJW: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH *PO#/_'UKW_81;_T7'6[6%X9_X^M>_P"PBW_HN.@#
M=HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH :W:BANU%)[@6/!G^IUC_L*7/\ Z'715R%Q\,M'N;RY
MN6:[26XE:9PDY W,<G IG_"J]&_YZ7W_ ($FLRSLJ*XW_A5>C?\ /2^_\"31
M_P *KT;_ )Z7W_@2: .RHKC?^%5Z-_STOO\ P)-'_"J]&_YZ7W_@2: .RHKC
M?^%5Z-_STOO_  )-'_"J]&_YZ7W_ ($F@#LJ*XW_ (57HW_/2^_\"31_PJO1
MO^>E]_X$F@#LJ*XW_A5>C?\ /2^_\"31_P *KT;_ )Z7W_@2: .RHKC?^%5Z
M-_STOO\ P)-'_"J]&_YZ7W_@2: .RHKC?^%5Z-_STOO_  )-'_"J]&_YZ7W_
M ($F@#LJ*XW_ (57HW_/2^_\"31_PJO1O^>E]_X$F@#LJ*XW_A5>C?\ /2^_
M\"31_P *KT;_ )Z7W_@2: .RHKC?^%5Z-_STOO\ P)-'_"J]&_YZ7W_@2: .
MRHKC?^%5Z-_STOO_  )-'_"J]&_YZ7W_ ($F@#LJ*XW_ (57HW_/2^_\"31_
MPJO1O^>E]_X$F@#LJ*XW_A5>C?\ /2^_\"31_P *KT;_ )Z7W_@2: .RHKC?
M^%5Z-_STOO\ P)-'_"J]&_YZ7W_@2: .RHKC?^%5Z-_STOO_  )-'_"J]&_Y
MZ7W_ ($F@#LJ*XW_ (57HW_/2^_\"31_PJO1O^>E]_X$F@#LJ*XW_A5>C?\
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MQO\ PJO1O^>E]_X$FC_A5>C?\]+[_P "30!V5%<;_P *KT;_ )Z7W_@2:/\
MA5>C?\]+[_P)- '945QO_"J]&_YZ7W_@2:/^%5Z-_P ]+[_P)- '945QO_"J
M]&_YZ7W_ ($FC_A5>C?\]+[_ ,"30!V5%<;_ ,*KT;_GI??^!)H_X57HW_/2
M^_\  DT =E17&_\ "J]&_P">E]_X$FC_ (57HW_/2^_\"30!V5%<;_PJO1O^
M>E]_X$FC_A5>C?\ /2^_\"30!V5%<;_PJO1O^>E]_P"!)H_X57HW_/2^_P#
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M ($FC_A5>C?\]+[_ ,"30!V5%<;_ ,*KT;_GI??^!)H_X57HW_/2^_\  DT
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MX$&CF"Q;HJI_PJG1/[]Y_P"!!H_X53HG]^\_\"#1S!8MT54_X53HG]^\_P#
M@T?\*IT3^_>?^!!HY@L6Z*J?\*IT3^_>?^!!H_X53HG]^\_\"#1S!8MT54_X
M53HG]^\_\"#1_P *IT3^_>?^!!HY@L9NM?\ (Q>'O^NLW_HIJW:I-\)]#9E)
M:\RO3]^?\*=_PJG1/[]Y_P"!!HY@L6Z*J?\ "J=$_OWG_@0:/^%4Z)_?O/\
MP(-',%BW153_ (53HG]^\_\  @T?\*IT3^_>?^!!HY@L6Z*J?\*IT3^_>?\
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M!HY@L6Z*J?\ "J=$_OWG_@0:/^%4Z)_?O/\ P(-',%BW153_ (53HG]^\_\
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M<P6+=%5/^%4Z)_?O/_ @T?\ "J=$_OWG_@0:.8+%NBJG_"J=$_OWG_@0:/\
MA5.B?W[S_P "#1S!8MT54_X53HG]^\_\"#1_PJG1/[]Y_P"!!HY@L6Z*J?\
M"J=$_OWG_@0:/^%4Z)_?O/\ P(-',%BW153_ (53HG]^\_\  @T?\*IT3^_>
M?^!!HY@L6Z*J?\*IT3^_>?\ @0:/^%4Z)_?O/_ @T<P6+=%5/^%4Z)_?O/\
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M:.8+%NBJG_"J=$_OWG_@0:/^%4Z)_?O/_ @T<P6+=%5/^%4Z)_?O/_ @T?\
M"J=$_OWG_@0:.8+%ENU%5O\ A56B?W[S_O\ G_"BES#.SHHHJ0"BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .=
MA\9V4TUU&(KC=;SO ^57!93@D?-TJ;_A++3^Y/\ ]\K_ (UP]E_R$-;_ .PE
M<?\ H57* .L_X2RT_N3_ /?*_P"-'_"66G]R?_OE?\:Y.B@#K/\ A++3^Y/_
M -\K_C1_PEEI_<G_ .^5_P :Y.B@#K/^$LM/[D__ 'RO^-'_  EEI_<G_P"^
M5_QKDZ* .L_X2RT_N3_]\K_C1_PEEI_<G_[Y7_&N3HH ZS_A++3^Y/\ ]\K_
M (T?\)9:?W)_^^5_QKDZ* .L_P"$LM/[D_\ WRO^-'_"66G]R?\ [Y7_ !KD
MZ* .L_X2RT_N3_\ ?*_XT?\ "66G]R?_ +Y7_&N3HH ZS_A++3^Y/_WRO^-'
M_"66G]R?_OE?\:Y.B@#K/^$LM/[D_P#WRO\ C1_PEEI_<G_[Y7_&N3HH ZS_
M (2RT_N3_P#?*_XT?\)9:?W)_P#OE?\ &N3HH ZS_A++3^Y/_P!\K_C1_P )
M9:?W)_\ OE?\:Y.B@#K/^$LM/[D__?*_XT?\)9:?W)_^^5_QKDZ* .L_X2RT
M_N3_ /?*_P"-'_"66G]R?_OE?\:Y.B@#K/\ A++3^Y/_ -\K_C1_PEEI_<G_
M .^5_P :Y.B@#K/^$LM/[D__ 'RO^-'_  EEI_<G_P"^5_QKDZ* .L_X2RT_
MN3_]\K_C1_PEEI_<G_[Y7_&N3HH ZS_A++3^Y/\ ]\K_ (T?\)9:?W)_^^5_
MQKDZ* .L_P"$LM/[D_\ WRO^-'_"66G]R?\ [Y7_ !KDZ* .L_X2RT_N3_\
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MRO\ C1_PEEI_<G_[Y7_&N3HH ZS_ (2RT_N3_P#?*_XT?\)9:?W)_P#OE?\
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M7_&N3HH ZS_A++3^Y/\ ]\K_ (T?\)9:?W)_^^5_QKDZ* .L_P"$LM/[D_\
MWRO^-'_"66G]R?\ [Y7_ !KDZ* .L_X2RT_N3_\ ?*_XT?\ "66G]R?_ +Y7
M_&N3HH ZS_A++3^Y/_WRO^-'_"66G]R?_OE?\:Y.B@#K/^$LM/[D_P#WRO\
MC1_PEEI_<G_[Y7_&N3HH ZS_ (2RT_N3_P#?*_XT?\)9:?W)_P#OE?\ &N3H
MH ZS_A++3^Y/_P!\K_C1_P )9:?W)_\ OE?\:Y.B@#K/^$LM/[D__?*_XT?\
M)9:?W)_^^5_QKDZ* .L_X2RT_N3_ /?*_P"-'_"66G]R?_OE?\:Y.B@#K/\
MA++3^Y/_ -\K_C1_PEEI_<G_ .^5_P :Y.B@#K/^$LM/[D__ 'RO^-'_  EE
MI_<G_P"^5_QKDZ* .L_X2RT_N3_]\K_C1_PEEI_<G_[Y7_&N3HH ZS_A++3^
MY/\ ]\K_ (T?\)9:?W)_^^5_QKDZ* .L_P"$LM/[D_\ WRO^-'_"66G]R?\
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MPEEI_<G_ .^5_P :Y.B@#K/^$LM/[D__ 'RO^-'_  EEI_<G_P"^5_QKDZ*
M.L_X2RT_N3_]\K_C1_PEEI_<G_[Y7_&N3HH ZS_A++3^Y/\ ]\K_ (T?\)9:
M?W)_^^5_QKDZ* .L_P"$LM/[D_\ WRO^-'_"66G]R?\ [Y7_ !KDZ* .L_X2
MRT_N3_\ ?*_XT?\ "66G]R?_ +Y7_&N3HH ZS_A++3^Y/_WRO^-'_"66G]R?
M_OE?\:Y.B@#K/^$LM/[D_P#WRO\ C1_PEEI_<G_[Y7_&N3HH ZS_ (2RT_N3
M_P#?*_XT?\)9:?W)_P#OE?\ &N3HH ZS_A++3^Y/_P!\K_C1_P )9:?W)_\
MOE?\:Y.B@#K/^$LM/[D__?*_XT?\)9:?W)_^^5_QKDZ* .L_X2RT_N3_ /?*
M_P"-'_"66G]R?_OE?\:Y.B@#K/\ A++3^Y/_ -\K_C1_PEEI_<G_ .^5_P :
MY.B@#K/^$LM/[D__ 'RO^-'_  EEI_<G_P"^5_QKDZ* .L_X2RT_N3_]\K_C
M1_PEEI_<G_[Y7_&N3HH ZS_A++3^Y/\ ]\K_ (T?\)9:?W)_^^5_QKDZ* .L
M_P"$LM/[D_\ WRO^-'_"66G]R?\ [Y7_ !KDZ* .L_X2RT_N3_\ ?*_XT?\
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M_P"^5_QKDZ* .L_X2RT_N3_]\K_C1_PEEI_<G_[Y7_&N3HH ZS_A++3^Y/\
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M^-'_  EEI_<G_P"^5_QKDZ* .L_X2RT_N3_]\K_C1_PEEI_<G_[Y7_&N3HH
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MQKDZ* .L_P"$LM/[D_\ WRO^-'_"66G]R?\ [Y7_ !KDZ* .L_X2RT_N3_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MZ5-6BF=62XFIBL!3K5G>4EJ]NOD<U\1/&]O\//"5[K=Q%]I\C:L=OOV&5V(
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M &$[;_T:M;?P=^)#^ =:NHIW;^R=2@:VN5[*2"$DQ_LD_D36)\-/^2B>&/\
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MD.>U\1B98+&PM47E;;=/SZGJ=%%%?)GZ %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MGZ9=Q77B/4SJNP[OL5NACB)_VF)W,/8!:]^@ACM88X88UBAC4(D: !54#
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MZNNCC<OJX&&&Q$]M]'_D<&,RW-Z.:U,=@J=[[-M;62V;.F_X:\\'?] W7/\
MOQ#_ /':TO#?[3OA;Q3K]AI%I8:Q'<WLRP1M-#$$#$X!)$A./PKA_P#AC/\
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M"6F:) =ZVD(1I ,;W/+M^+$G\:S/A_\ "?PY\-87&D6C&ZD7;)>W#;YG'IG
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M2IY+ROEF[_/_ "/6IUN)^=<]-6_[=_S.S_::_P"2/ZM_UUM__1JU\[_LT_\
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M#K?_ $,%K_X+3_\ 'J *=%7/^$!UO_H8+7_P6G_X]1_P@.M_]#!:_P#@M/\
M\>H IT5<_P"$!UO_ *&"U_\ !:?_ (]1_P (#K?_ $,%K_X+3_\ 'J *=%7/
M^$!UO_H8+7_P6G_X]1_P@.M_]#!:_P#@M/\ \>H IT5<_P"$!UO_ *&"U_\
M!:?_ (]1_P (#K?_ $,%K_X+3_\ 'J *=%7/^$!UO_H8+7_P6G_X]1_P@.M_
M]#!:_P#@M/\ \>H IT5<_P"$!UO_ *&"U_\ !:?_ (]1_P (#K?_ $,%K_X+
M3_\ 'J *=%7/^$!UO_H8+7_P6G_X]1_P@.M_]#!:_P#@M/\ \>H IT5<_P"$
M!UO_ *&"U_\ !:?_ (]1_P (#K?_ $,%K_X+3_\ 'J *=%7/^$!UO_H8+7_P
M6G_X]1_P@.M_]#!:_P#@M/\ \>H IT5<_P"$!UO_ *&"U_\ !:?_ (]1_P (
M#K?_ $,%K_X+3_\ 'J *=%7/^$!UO_H8+7_P6G_X]1_P@.M_]#!:_P#@M/\
M\>H IT5<_P"$!UO_ *&"U_\ !:?_ (]1_P (#K?_ $,%K_X+3_\ 'J *=%7/
M^$!UO_H8+7_P6G_X]1_P@.M_]#!:_P#@M/\ \>H IT5<_P"$!UO_ *&"U_\
M!:?_ (]1_P (#K?_ $,%K_X+3_\ 'J *=%7/^$!UO_H8+7_P6G_X]1_P@.M_
M]#!:_P#@M/\ \>H IT5<_P"$!UO_ *&"U_\ !:?_ (]1_P (#K?_ $,%K_X+
M3_\ 'J *=%7/^$!UO_H8+7_P6G_X]1_P@.M_]#!:_P#@M/\ \>H IT5<_P"$
M!UO_ *&"U_\ !:?_ (]1_P (#K?_ $,%K_X+3_\ 'J *=%7/^$!UO_H8+7_P
M6G_X]1_P@.M_]#!:_P#@M/\ \>H IT5<_P"$!UO_ *&"U_\ !:?_ (]1_P (
M#K?_ $,%K_X+3_\ 'J *=%7/^$!UO_H8+7_P6G_X]1_P@.M_]#!:_P#@M/\
M\>H IT5<_P"$!UO_ *&"U_\ !:?_ (]1_P (#K?_ $,%K_X+3_\ 'J *=%7/
M^$!UO_H8+7_P6G_X]1_P@.M_]#!:_P#@M/\ \>H IT5<_P"$!UO_ *&"U_\
M!:?_ (]1_P (#K?_ $,%K_X+3_\ 'J *=%7/^$!UO_H8+7_P6G_X]1_P@.M_
M]#!:_P#@M/\ \>H IT5<_P"$!UO_ *&"U_\ !:?_ (]1_P (#K?_ $,%K_X+
M3_\ 'J *=%7/^$!UO_H8+7_P6G_X]1_P@.M_]#!:_P#@M/\ \>H IT5<_P"$
M!UO_ *&"U_\ !:?_ (]1_P (#K?_ $,%K_X+3_\ 'J *=%7/^$!UO_H8+7_P
M6G_X]1_P@.M_]#!:_P#@M/\ \>H IT5<_P"$!UO_ *&"U_\ !:?_ (]1_P (
M#K?_ $,%K_X+3_\ 'J *=%7/^$!UO_H8+7_P6G_X]1_P@.M_]#!:_P#@M/\
M\>H IT5<_P"$!UO_ *&"U_\ !:?_ (]1_P (#K?_ $,%K_X+3_\ 'J *=%7/
M^$!UO_H8+7_P6G_X]1_P@.M_]#!:_P#@M/\ \>H IT5<_P"$!UO_ *&"U_\
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M .@U:_\ ?C_ZU'_"!>(_^@U:_P#?C_ZU #**?_P@7B/_ *#5K_WX_P#K4?\
M"!>(_P#H-6O_ 'X_^M0 RBG_ /"!>(_^@U:_]^/_ *U'_"!>(_\ H-6O_?C_
M .M0 RBG_P#"!>(_^@U:_P#?C_ZU'_"!>(_^@U:_]^/_ *U #**?_P (%XC_
M .@U:_\ ?C_ZU'_"!>(_^@U:_P#?C_ZU #**?_P@7B/_ *#5K_WX_P#K4?\
M"!>(_P#H-6O_ 'X_^M0 RBG_ /"!>(_^@U:_]^/_ *U'_"!>(_\ H-6O_?C_
M .M0 RBG_P#"!>(_^@U:_P#?C_ZU'_"!>(_^@U:_]^/_ *U #**?_P (%XC_
M .@U:_\ ?C_ZU'_"!>(_^@U:_P#?C_ZU #**?_P@7B/_ *#5K_WX_P#K4?\
M"!>(_P#H-6O_ 'X_^M0 RBG_ /"!>(_^@U:_]^/_ *U'_"!>(_\ H-6O_?C_
M .M0 RBG_P#"!>(_^@U:_P#?C_ZU'_"!>(_^@U:_]^/_ *U #**?_P (%XC_
M .@U:_\ ?C_ZU'_"!>(_^@U:_P#?C_ZU #**?_P@7B/_ *#5K_WX_P#K4?\
M"!>(_P#H-6O_ 'X_^M0 RBG_ /"!>(_^@U:_]^/_ *U'_"!>(_\ H-6O_?C_
M .M0 RBG_P#"!>(_^@U:_P#?C_ZU'_"!>(_^@U:_]^/_ *U #**?_P (%XC_
M .@U:_\ ?C_ZU'_"!>(_^@U:_P#?C_ZU #**?_P@7B/_ *#5K_WX_P#K4?\
M"!>(_P#H-6O_ 'X_^M0 RBG_ /"!>(_^@U:_]^/_ *U'_"!>(_\ H-6O_?C_
M .M0 RBG_P#"!>(_^@U:_P#?C_ZU'_"!>(_^@U:_]^/_ *U #**?_P (%XC_
M .@U:_\ ?C_ZU'_"!>(_^@U:_P#?C_ZU #**?_P@7B/_ *#5K_WX_P#K4?\
M"!>(_P#H-6O_ 'X_^M0 RBG_ /"!>(_^@U:_]^/_ *U'_"!>(_\ H-6O_?C_
M .M0 RBG_P#"!>(_^@U:_P#?C_ZU'_"!>(_^@U:_]^/_ *U #**?_P (%XC_
M .@U:_\ ?C_ZU'_"!>(_^@U:_P#?C_ZU #**?_P@7B/_ *#5K_WX_P#K4?\
M"!>(_P#H-6O_ 'X_^M0 RBG_ /"!>(_^@U:_]^/_ *U'_"!>(_\ H-6O_?C_
M .M0 RBG_P#"!>(_^@U:_P#?C_ZU'_"!>(_^@U:_]^/_ *U #**?_P (%XC_
M .@U:_\ ?C_ZU'_"!>(_^@U:_P#?C_ZU #**?_P@7B/_ *#5K_WX_P#K4?\
M"!>(_P#H-6O_ 'X_^M0 RBG_ /"!>(_^@U:_]^/_ *U'_"!>(_\ H-6O_?C_
M .M0 RBG_P#"!>(_^@U:_P#?C_ZU'_"!>(_^@U:_]^/_ *U #**?_P (%XC_
M .@U:_\ ?C_ZU'_"!>(_^@U:_P#?C_ZU #**?_P@7B/_ *#5K_WX_P#K4?\
M"!>(_P#H-6O_ 'X_^M0 RBG_ /"!>(_^@U:_]^/_ *U'_"!>(_\ H-6O_?C_
M .M0 RBG_P#"!>(_^@U:_P#?C_ZU'_"!>(_^@U:_]^/_ *U #**?_P (%XC_
M .@U:_\ ?C_ZU'_"!>(_^@U:_P#?C_ZU #**?_P@7B/_ *#5K_WX_P#K4?\
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MN7:*I?\ "-^(/^@M;_\ ?C_ZU'_"-^(/^@M;_P#?C_ZU'LY=@]K#N7:*I?\
M"-^(/^@M;_\ ?C_ZU'_"-^(/^@M;_P#?C_ZU'LY=@]K#N7:*I?\ "-^(/^@M
M;_\ ?C_ZU'_"-^(/^@M;_P#?C_ZU'LY=@]K#N7:*I?\ "-^(/^@M;_\ ?C_Z
MU'_"-^(/^@M;_P#?C_ZU'LY=@]K#N7:*I?\ "-^(/^@M;_\ ?C_ZU'_"-^(/
M^@M;_P#?C_ZU'LY=@]K#N7:*I?\ "-^(/^@M;_\ ?C_ZU'_"-^(/^@M;_P#?
MC_ZU'LY=@]K#N7:*I?\ "-^(/^@M;_\ ?C_ZU'_"-^(/^@M;_P#?C_ZU'LY=
M@]K#N7:*I?\ "-^(/^@M;_\ ?C_ZU'_"-^(/^@M;_P#?C_ZU'LY=@]K#N7:*
MI?\ "-^(/^@M;_\ ?C_ZU'_"-^(/^@M;_P#?C_ZU'LY=@]K#N7:*I?\ "-^(
M/^@M;_\ ?C_ZU'_"-^(/^@M;_P#?C_ZU'LY=@]K#N7:*I?\ "-^(/^@M;_\
M?C_ZU'_"-^(/^@M;_P#?C_ZU'LY=@]K#N7:*I?\ "-^(/^@M;_\ ?C_ZU'_"
M-^(/^@M;_P#?C_ZU'LY=@]K#N7:*I?\ "-^(/^@M;_\ ?C_ZU'_"-^(/^@M;
M_P#?C_ZU'LY=@]K#N7:*I?\ "-^(/^@M;_\ ?C_ZU'_"-^(/^@M;_P#?C_ZU
M'LY=@]K#N7:*I?\ "-^(/^@M;_\ ?C_ZU'_"-^(/^@M;_P#?C_ZU'LY=@]K#
MN7:*I?\ "-^(/^@M;_\ ?C_ZU'_"-^(/^@M;_P#?C_ZU'LY=@]K#N7:*I?\
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M&?\ QZZ[_P!A:?\ DM=E4F@4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!R?Q2_Y$34
M_P#ME_Z-2NEL_P#CT@_ZYK_*N:^*7_(B:G_VR_\ 1J5TMG_QZ0?]<U_E0!/1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !7':A_R5+2O^O"3^;5V-<=J'_)4M*_Z\)/
MYM0!V-%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >?WG_)3KO\ [!R_
M^ABMJL6\_P"2G7?_ &#E_P#0Q6U773^$\VM\84445J8A1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% ',^)/^1I\-?[\W_H*UTU<SXD_Y&GPU_OS?^@K735"W9I+:/\ 74**
M**LS"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ KF?!W_ !_>(/\ K_>NFKF?!W_']X@_Z_WJ.J+A\+.FHHHJR HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@##\9?\ (+B_Z[#_ -!-%'C+_D%Q?]=A_P"@FBN>>YU0^%&A\,_^/77?
M^PM/_):[*N-^&?\ QZZ[_P!A:?\ DM=E7.=P4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 VD8A>3Q[TGW<5XQ^UIKF
MI>'_ (03WNE:A=Z9=_;($^T6<S0N%).1N4@X-:T:3K58TD[<SL<V*KK#4)UF
MKJ*;^X]HW#U%+N'J*_+G_A;'CG_H<O$'_@TN/_BZ7_A;?CG@_P#"9>(/_!G/
M_P#%U]6^&ZRWFOQ/@%QK0>U&7X'ZB>_44=:_.7P9^TY\0?"%]%(VN3:S:!LO
M:ZDWG!QZ;S\Z_4'\^E?=OPQ^(6G?$_P?8Z]II*1S B6!B"T,@^\C>X/Y@@]Z
M\?'957R]*<[.+ZH^BRK/L+FTG3IW4ET9UI8#OBD7';I7PE^U%\0O%.A?&?6;
M+3?$VKZ?91QVY2VM+^:*-<PH3A58 9))KZ?_ &:]4OM<^"OAR]U&\GO[R59M
M]Q<RM)(^)I ,LQ)/  Y]*BOEM3#X6&+<KJ=M/57-,+G-/%9A4P$8M.";OT=F
ME^IZE1117E'T04444 %%%% !1124 +1110 44E+0 4444 %%%% !1124 (>*
M16SG!R:^;_VTO%&M>%_#/AR31M7OM)>:[D61[&Y>!G 0$ E",BL;]B;Q?KOB
MB\\7#6=:U#5O)6U,0O[J2;R\F7.W>3C.!G'H*]6.75)81XSFT73YV/G:F<TZ
M68QRYQ?-+KTVN?5E%%%>4?1!1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% ')_%+_D1-3_[9?^C4KI;/_CT@_P"N:_RK
MFOBE_P B)J?_ &R_]&I72V?_ !Z0?]<U_E0!/1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 452U/5K/1;-[O4+RWL;2,9>>YE
M6-%^K,0!7/V_Q8\$WD\<-OXQT">>0[4CCU2!F8^@ ?DT =;12*0P!!R*6@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ KCM0_Y*EI7_7A)_-J[&N.U#_DJ6E?]>$G\VH [&BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** //[S_DIUW_V#E_]#%;58MY_
MR4Z[_P"P<O\ Z&*VJZZ?PGFUOC"BBBM3$**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH YGQ
M)_R-/AK_ 'YO_05KIJYGQ)_R-/AK_?F_]!6NFJ%NS26T?ZZA1115F84444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<SX.
M_P"/[Q!_U_O735S/@[_C^\0?]?[U'5%P^%G344459 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!A^,O\
MD%Q?]=A_Z":*/&7_ ""XO^NP_P#0317//<ZH?"C0^&?_ !ZZ[_V%I_Y+795Q
MOPS_ ./77?\ L+3_ ,EKLJYSN"BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** &5X9^V;_P D4G_Z_K?^9KW.O#/VSO\
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MR"0VJR>7'"IZ&1L'D]0H&?IQ7@=Q^W)XYDF)BTG0HXL\*T,S-CZ^:/Y5UWQ
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MS[#HHHK\]/V,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110!Y_>?\E.N_P#L'+_Z&*VJQ;S_ )*==_\ 8.7_ -#%
M;5==/X3S:WQA1116IB%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 <SXD_Y&GPU_OS?^@K7
M35S/B3_D:?#7^_-_Z"M=-4+=FDMH_P!=0HHHJS,**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N9\'?\ ']X@_P"O]ZZ:
MN9\'?\?WB#_K_>HZHN'PLZ:BBBK("BBB@ HHHH **** "BBB@ HHHH ****
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MG[37_)=/%?\ UVC_ /1,=?;/[.G_ "1/PC_UY+_,U\3?M-?\ET\5_P#7:/\
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M-^T5_P!!>Z_\%=I_\9H_X:&_:*_Z"]U_X*[3_P",U^B?_".Z9_T#K7_OTO\
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MM/\ XS1_PT1^T1_T&+K_ ,%=I_\ &:_13_A'=+_Z!UK_ -^5_P */^$=TO\
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M.[,K<YQ@#CU<?>O;H$M$F^KL?4E+124@%HHHH **** "BDI: "BBB@ HHHH
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ML?\ /OIO_?B7_P"+H_X:0U?_ )]],_[\2_\ Q=>.^7^%)Y-',^XO9Q['L?\
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M[$*3[&/2CFEW#ECV/<?^&HK_ /YYZ;_X#3?_ !=)_P -17__ #STS_P'F_\
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MF_\ BJ/^&I+[^YIG_@/-_P#%UX;_ &>*/[/%/FEW%R1['N7_  U)??W-,_\
M >;_ .+H_P"&I+[^YIO_ (#3_P#Q5>&_V>*/[/%'-+N')'L>Y?\ #4E]_<TS
M_P !IO\ XNC_ (:DOO[FF?\ @--_\57AO]GBC^SQ1S2[ARQ['N7_  U)??W-
M,_\  :;_ .+H_P"&I+[^YIO_ (#3?_%5X=_9])_9XHYI=PY8]CW+_AJ2^_N:
M9_X#S?\ Q=+_ ,-27W]S3?\ P&F_^+KPS^SQ1_9XHYI=PY(]CW+_ (:EOO\
MGGIO_@-/_P#%4O\ PU)?_P#//3?_  &F_P#BZ\,_L\4OV(4<TNX<L>Q[E_PU
M)?\ _//3?_ :;_XNC_AJ*_\ [FF?^ \W_P 77AOV(4OV$4<TNX<L>Q[C_P -
M17__ #STW_P&G_\ BJ/^&HK_ /YYZ;_X#3__ !5>'?811]B'I1S2[AR1['N/
M_#45_P#\\]-_\!I__BJ/^&HK_P#YYZ;_ . T_P#\57A_V,>E'V,>E'-+N/DC
MV/</^&HK_P#YYZ;_ . TW_Q='_#45_\ \\]-_P# :;_XNO#_ +&/2C[&/2CF
MEW%R1['N'_#45_\ \\]-_P# :;_XNC_AJ*__ +FF?^ \W_Q=>'_8QZ4?8QZ4
M<TNX<L>Q[A_PU%?_ ///3?\ P&F_^+I?^&HK_P#YYZ;_ . \W_Q=>&_8AW%'
MV-?2CFEW#DCV/<O^&H=1_P">>F_^ \W_ ,71_P -0:A_SSTW_P !YO\ XNO#
M_L0I?L8HYI=PY(]CV_\ X:@U#_GGIG_@/-_\71_PU!J'_//3/_ >;_XNO$?L
MHH^RKZ4<TNX^2/8]O_X:>U'_ )Y:9_X#S?\ Q='_  T[J/\ SSTW_P !YO\
MXNO$/LJ^E.^RC^[1S2[AR1['MO\ PT[J/_//3?\ P'F_^+H_X:=U'_GGIO\
MX#S?_%UXE]G'I2_9QZ4<TNX<D>Q[;_PT]J/_ #RTW_P'F_\ BZ/^&G-2_P">
M6F_^ \W_ ,77B7V<>E*+<?W:.:7<.2/8]L_X:<U+_GEIO_@/-_\ %TO_  TY
MJ7_/+3?_  'F_P#BZ\3\CVH\CVHYI=PY(]CVS_AIK4_^>.F_^ \W_P 71_PT
MUJ?_ #QTW_P'F_\ BZ\3\CVH\CVHYI=PY(]CVS_AIK4_^>.F_P#@/-_\72_\
M--:G_P \=-_\!YO_ (NO$O(]J/(]J.:7<.2/8]M_X:8U3_GEIO\ X#S?_%TO
M_#3.J?\ /'3?_ >;_P"+KQ/R?SIWDT<TNX<D>Q[5_P -+:K_ ,\--_\  >;_
M .+H_P"&EM5_YXZ;_P!^)O\ XNO%O)I?)]J.:7<?)'L>T_\ #2VJ_P#/#3?^
M_$W_ ,72_P##2NK?\\--_P"_$W_Q=>*^32^3[4<TNX<D>Q[1_P -*:M_SPTS
M_OQ-_P#%TO\ PTIJW_/#3?\ OQ-_\77B_DT[R?:CFEW#V<>Q[-_PTIJW_/#3
M?^_$O_Q='_#26K_\\--_[\2__%UXUY-+Y='-+N'LX]CV7_AI+5_^??3?^_$O
M_P 71_PTEJ__ #[Z;_WXE_\ BZ\;\H4X1T<TNX_9Q['L7_#2&L?\^^F_]^)?
M_BZ7_AI#6/\ GAIO_?B7_P"+KQSR_;]:7R_:ES/N'LX=CTK_ (7EXE_Z#7_D
MI'_\12_\+R\3?]!G_P E(_\ XBO-=E.\O\:7,^X^6/8])_X7EXF_Z# _\!8_
M_B*7_A>7B;_H++_X"Q__ !%>;B.G;!2YGW#ECV/1_P#A>/B;_H*J?^W6/_XF
ME_X7EXF_Z"B_^ L?_P 37G*I[4[91S2[CY8]CT7_ (7AXG_Z":?^ J?_ !-.
M_P"%X^)_^@DG_@,G_P 37G07VIVVCFEW#DCV/1/^%X>)_P#H(Q_^ R?_ !-+
M_P +P\3_ /00B_\  9/\*\[V^U/5:.:7<.2/8]"_X7?XG_Y_XO\ P&3_  IW
M_"[?%'_/]%_X#I_A7GH&*<!1S2[CY(]CT'_A=WBG_G]A_P# =?\ "E_X7;XH
M_P"?N'_P'7_"O/UI5HYI=PY(]CU?0OBQK^J+()+Y5E0CA8$P1_WS6POC[7#_
M ,O_ /Y!C_\ B:\?T6\^PZA&Y/R'Y6^AKO8^U/F?<GDCV.G7QWKA_P"7[_R"
MG_Q-4]-\5:I937C0W6QIIC)(?+0Y8]^166G6DM_OR_[YHYGW#EC;8Z9?&^MX
M_P"/W_R$G_Q-2+XUUG_G\_\ (2?_ !-<\M2K3YGW(Y8]C?7QGK/_ #^?^0D_
MPIZ^,=8_Y^__ "$G^%8*5(OWJ.9]PY8]C='B[5O^?O\ \AI_A3_^$MU7_G[_
M /(:?X5B+4E',^X<L>QM?\)7JO\ S]?^0T_PI_\ PE.J8_X^O_(:_P"%8RU(
MOW:.9]Q.,>QK#Q1J?_/S_P"0U_PIZ^)M3Q_Q\_\ D-?\*QUJ1>E7S/N/ECV-
M?_A)-2_Y^?\ QQ?\*?\ \)'J/_/Q_P".+_A62/NFI%Z4<S[B<8]C5'B'4/\
MGX_\<7_"G?\ "07_ !^__P#'%_PK+7M4@[4<S[BY8]C3_MZ__P">_P#XXO\
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M!A^,O^07%_UV'_H)HH\9?\@N+_KL/_0317//<ZH?"C0^&?\ QZZ[_P!A:?\
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M72V?_'I!_P!<U_E7-?%+_D1-3_[9?^C4KI;/_CT@_P"N:_RH GHHHH ****
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M47UTO_F'*Y)M;K6W<_27]N(_\8B_%C_L 7/_ *#7SC_P1;_Y-E\4?]C9<?\
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M.^S>U'V;VKW+X8_ BW\5:"-;UN_FL;&3<8HX-JL5!P79F! &0>WOFKMU\'_
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M X=J>M,':GK4DLDIU-IU A].6FTY: 'TJTE%4@'KVI],7M3Z8#J<.]-IP[T
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MM"(P.&9CG+'OZ5W2P-:-!8EKW&>/'-<-+&/ IOG7EIWW/6Z*2EKA/8"BBB@
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M9XF#A333=]W;HE^9>,S2E&#5*5Y=+;+SN;"\*!2T45^_+30^)"BBBF 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7':A_R
M5+2O^O"3^;5V-<=J'_)4M*_Z\)/YM0!V-%%% !1110 G<5X9^W%_R:+\5_\
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MEUCQ';W$$,61@R(+D0J".N"9.F-K5E"WLXV5Y=;[W-)WYWKH?)WQ$^!G@_\
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M^T%:MX.\'6(7R]' \B0PYW-;V]ON9XMQ'SR2G?R,;L +^A_Q\\,O-^S?\0-
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MF"%V'W%"AG8?7('X'UH2LW?9:CZ*V[.2TO\ 9W\6:C:K-+]AT\M_RRNICO\
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M?PU)Z5'-_#36Y,MB&BBBM#$**** "BBB@ HHHH **** "BBB@ HHHH ****
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M110 4444 %%%% !1110 4444 <G\4O\ D1-3_P"V7_HU*Z6S_P"/2#_KFO\
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MK?Q=^TUJ6A?#>\F\%6NH78M+I=+ >TE"#,TDENW[MP"KD*0!P*^\OB?XUA\
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MD"OH#1]:T_Q!I\5_I=];ZC8S+NBN;2598W'J&4D&E9K<9?HHHH **** "BO
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MFQ\//C%J7C[QDFG#3;>ST]8'E?:S/(,8 ^;@8R1VKS;X_P#_ "4B[_ZX1?\
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MN?+D0?=RPY5EXYZ<#FM+:.VY'57V+FC_ +2UG,HCUC1I(@1AI+202 ^OR-C
M_$TGQ;\$^']4\$CQ7HL$=J^V.7? GEK-&[ <KV;+9SC/7-5E^%_PT2;SF\7H
MT0.[RO[0@R1Z<#/]:S?BK\4-(O?#L/ACPTN=/0(LDP4JFU,;44'D\@$D^G?-
M1*UO,N.^NQO?LUKYF@Z^G=I4'_CAKP:ZM9+*ZFMYE*2PNT;J>S X(KWS]F7_
M ) ^N?\ 7>/_ -!-5M0TWX<_$VX;59M6_L'4&.+F%YTA+-TR0XP3QU7KWYJI
M7Y].R,Z?P/U?YG+?L[V,EUX\-PJMY5O:R,[8X&<*!^I_*M_4=8A/[25NY91'
M'(MMNS_$8=N/^^FQ6G-XX\&_"30;BQ\,/'JNIS#)D5_,#-C :20<$#^ZOZ9S
M7@TFI7,VI-?M,QO&E\\S9^;?G.[ZYYHYDY)]$/EM%]V?1GQ>^)VN_#[5K**R
MM+&>RN82PDN8W9MX)##*N.Q7MWK@_P#AI7Q/_P ^.D_]^9?_ (Y74Z;\2?"?
MQ-\/QZ3XL*6%XN/G<E$+@??1_P"$^S>N.:K:?\/_ (8Z'="]N/$T.HI =XMY
M;V%U./54&YOIW]#0M'9CO=72,OQQXN\?:MX%GDU?0[&UT6[2-C<Q API92O!
ME)&3CJ.]=/\ "%1K'P;U&P@.9\74!'^TRY'_ *$*X+XO?%>'QEY6EZ4'3287
MWM(PVF=AP#CLH[ _IBLSX4?$QOA]JDJW"--I=U@3QI]Y".CJ/7DY'?\ "DO>
M4EM<;NK>6IPA!4D$8-=/X'^'>J?$"6\336MX_LJJSM<,R@Y)P!A3SP?RKU75
MO"?PR\:7CZK#XBBTQYSNDC6YCA#-GEMD@R"?;CVHU+Q]X5^%OAN;2?"<BZAJ
M$G)N%?S%#$8WNXX8CLJ\?2B]EKN+=Z&'\ M/DTGXD:Q93%&FMK26%S&<KN65
M <'TR*XOXL?\E'U[_KO_ .RBNB^ >M6>F>-+ZYU._@LTDLG'G7<RQAF,B'&6
M/)X)KF/B;>0:AX\UJXMIX[FWDGRDL+AT88'((X-#OS1OV#2TK=SV#7O^3;X/
M^O2W_P#1JUY=\$_^2FZ+_O2?^BGKO]:\2:3+\ H-.35+)]0%M IM%N$,N1(I
M(V9SD#VKSGX1WUMIOQ#TFYO+B*UMXVDWS3.$1<QL!DG@<UI'^)(7_+I'0_M%
M?\E 3_KRC_\ 0GKO/C<O]K?"K3;VV_>0+)!.6']QD(!_-A^=><?'C5;+6/'"
M7%A>6]]!]DC7S;:59%R"V1D$C-;OPQ^+&EP^'V\,^*$W6&TQQ7#*778?X' Y
MX[$=/;&:QBKP:ZW*;Y9J72QXY796/PKUG4/!DGB9)+5-/2.24I)(PD*H2"0-
MN.QQS7HG_"L_AC]J^T_\)5&+?=O^S?VC#C'7;TW8[>OO6-\5/BIINH:''X9\
M-)MTN,*LDZJ45E7&$0'G&0,D]<53>FFX+?R/(J***:$?07QHLY;CX2Z#,B[E
MMW@>3V!B*Y_,C\Z^?:^L=:U[2="\ Z3_ &Y 9M,NXXK2;"[@H:/.X@<X&WMS
MW%<)!\.?A?%<"^;Q0DMMGS/LCW\0XZ[2  ^/;K2?QOM<4?@CZ&K\/E.A? F^
MNK@;!)!<3*'XR""J_G@?G7/?LR_\A?7/^N,?_H1K,^+7Q8M/$.GQ^'] 3R](
MBV[Y=NP2!?NJJ]E''7J0.F.9?V>=<T_1=4UA]0U"UL%DAC"-=3+&&(8Y W$9
MII\TF_(4ERQ4?.YPGQ#_ .1Z\0?]?TW_ *&:]9_9END:UUZUZ2!XI/J"&']/
MUKR+QU<Q7GC/7)X94G@DO)722-@RLI<X((ZBI? ?C2Z\"^((M1MT\Z/'ES09
MP)(SU&>QX!!]11#X;/JBJFLKKHRCXHL9=-\2:I:SJ5EBN9%.1C^(\_CUJQX'
ML9=2\9:);PJS.UY$?EZ@!@2?P )_"O:-87X;_%0)J4^K+I&H;0)&DE2WD/'
M8.-K8]1Z=:-(F^'/PE6:]M=4_MC464JC12K/)CNJ[ %7ZGGW[40_=VOT"7OW
M\S-_:<ND,WA^V!!D59I".X!V ?R/Y5K>%?\ DW*\_P"O2Z_]#>O%?&WC"[\<
M:_/J=THCW )%"IR(HQT7/?J23ZDUZY\)?&/AV^^'TOAG6;Z&Q<"6-Q<2B)9(
MW).5<\9Y/OQ22;A)=6-RUCV1Q7P"O$M?B-:(YP9X98E^NW=_[+4G[0&GRV?Q
M$N)W!\NZ@BD0XXP%V$?FOZU1\<:3I'@'Q!I5UX4UI=1"CSO,6YCF:.16Z$H
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MJ,DG % '2>#K'=)+=L.%^1/KWKI[?[\O^^:ATNS%C8Q0CJH^;W/>IK?[\O\
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH P_&7_(+B_Z[#_T$T4>,O\
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MP^LM(U%U>YBZE1@=!7V^98JA4RFC2A-.2M='P&5X.O1S>O6J0:B[V?S/C/\
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M?@?H#1110 4444 -R <4O6ORH_X+A<W7PB'^SJ@_6UK \#?\$8;CQMX)T#Q
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MOL??/O2GI44))A0GK@?RJ6J$G=7%HHHI#"BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M5L>H-?0R95%7H<4[M[UX/]IXSV?L?:/E_KKN?4_V'ETJJQ#HKF_#[MA-H4
M8%>+?&C]F70OBYJ0U9;Z;1M:V"-[F)!)'*HZ;T)&2!QD,..N>*]K-)^-<-&M
M4H352G*S1ZF)PM'%TG1KQYHOH?-7PY_8SM? _BO3]=NO%,^H2V$RSQ0P6:P
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M?XS9B.5,=-YR@)&2>A^Z?V4OVGO#W[5GPMM_%NBP/IUY%)]EU+29I \EG<
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M_$ _Y>=-_P"_TG_QNCDEV%[2'<\]HKT#_A2/B#_GYTW_ +_2?_&Z3_A2>O\
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M!]>_YYV/_@2__P :HY)=@]M#N8M%;7_"#Z]_SSL?_ E__C5'_"#Z[_SRL/\
MP)?_ .-4<DNP>VAW,6BMO_A!]>_YYV'_ ($O_P#&Z3_A!M>_YYV'_@2__P ;
MHY)=@]M#N8M%;?\ P@NO_P#/.P_\"7_^-TO_  @NO_W+#_P)?_XW1R2[![:'
M<PZ*W?\ A ]>_N6'_@2__P ;I?\ A =>_N6'_@2__P ;HY)=@]M#N8-%;_\
MP@.O?W=/_P# A_\ XW1_P@.O>EA_X$2?_&Z.278/;0[F!16__P *_P!=_NZ?
M_P"!,G_QNE_X5_KWII__ ($2?_&Z.278/:P[G/T5T/\ PK[7O33_ /P(?_XW
M2_\ "O=>_P"H?_X$O_\ &Z.278/;0[G.T5T7_"O->]-/_P# A_\ XW1_PKO7
M?^H?_P"!$G_QNCDEV#VL.YSM%='_ ,*\UW_J'_\ @0__ ,;H_P"%=:[_ -0_
M_P ")/\ XW1R2[#]K#N<Y172?\*YU[_J'_\ @1)_\;I?^%<Z]_U#_P#P(?\
M^-T<DNP>UAW.:HKIO^%;Z]ZZ?_X$2?\ QNE_X5KKWKI__@1)_P#&Z.278/:P
M[G,45U/_  K/7O[^G_\ @0__ ,;I?^%8Z]ZZ?_W_ )/_ (W1R2[![6'<Y6BN
MK_X5?KW][3__  (?_P"-TO\ PJ[7O^>FG_\ ?^3_ .-T<DNP>UAW.3HKK?\
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M_P#C=._X4KX@_P"?C3?^_P!)_P#&Z.278/:P[G!45WW_  I77_\ GXTW_O\
M2?\ QNE'P3\0'_EYTW_O])_\;HY)=A>TAW. HKT$? _Q!_S\Z;_W^D_^-TX?
M WQ ?^7K3?\ O[)_\;HY)=A^TAW//**]%_X43X@/_+UIO_?V3_XW3O\ A1'B
M#_G[TW_O[)_\;HY)=@]I#N><45Z0/@-X@/\ R]Z;_P!_9/\ XW3O^%!^(?\
MG\TS_O[)_P#&Z.278/:0[GFM%>E_\*!\0_\ /YIG_?V3_P"-T?\ "@?$/_/Y
MIG_?V3_XW1R2[![2'<\THKTO_A0/B'_G\TS_ +^R?_&Z/^% ^(?^?S3/^_LG
M_P ;HY)=@]I#N>:45Z7_ ,*!\0_\_FF?]_9/_C='_"@?$/\ S^:9_P!_9/\
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M]/O_ )"_^RIW_"$[?^7W_P A?_957*Q^TAW.;'W34B]*Z+_A"_\ I]_\A?\
MUZ7_ (0W_I\_\A?_ %Z.5B=2/<Y]>U2#M6^/"'_3W_Y#_P#KT[_A$_\ IZ_\
MA_\ UZ.5B]I'N85*M;W_  BO_3U_Y#_^O1_PBO\ T]?^0_\ Z]'*P]I'N8BT
M]:VO^$8_Z>?_ "'_ /7I1X:_Z>?_ !S_ .O1RL/:1[F.M2_XUJCP[C_EX_\
M'/\ Z]._X1__ *;_ /CG_P!>FHL/:1[F4.U*.]:O]@_]-_\ QS_Z]+_87_3?
M_P <_P#KT.+#VD>YECM3UK2_L/\ Z;_^.?\ UZ7^Q3_SV_\ '?\ Z]+E8G4C
MW,]>]/J^-'_Z;?\ CO\ ]>E_LG_IK_X[_P#7HY6+GB4J<M7?[+_Z:?\ CO\
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MXXQ32=Q2DK#****LR"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M"O7/$MI-+N-+F5T?:U%<%\$/BQIGQQ^%'AGQSI"B*SUJS6Y\CS Y@D^[)"6
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M)X>_X2O4]:O'@ATS^T/L9$2)NDEW^5)D M&N-O\ 'UXI-V+2<MCZ5I17SO\
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MBBB@ HHHH **** "BBB@#S?]H;X6I\9O@YXF\)Y5;J\MBUG(W1+A"'B/TW*
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MXV?\$I/ OCC3?!-I\/=6A^%S>'/.+W$6F'4)K]G9&5Y9&FC8NK(<%BW#8
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M_P"T=\4#)J<\UY)<:+]LP3=7>XB2\*XP$C.5C'0,"0 $7/O7[2'_  3GU/\
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M1(SZB0CO7V1W%<Q\1/A[X?\ BMX,U7PGXHTR+6-!U.+R;JTFR PR""",%6!
M8,""" 0<BL:D7*-EY?U\S:$E&2;/@S_@FS^R-\#?&7[/NB^-=4T#2?'?BJ]D
MG346U91=1V3K(RK;_9V)12$"-EEW-OSG:0![!^VGXY^%W[+G[,OC+0].T_0/
M#.I>(M*N=+TS0='M(;:2Y>:,Q%Q%&!\B!BS,1@8 SD@'QNX_X([KX9\13W_P
MY^.'B3P1:S#:8A9&:XV_W3-#/!D?5:]1^$7_  2U^%G@'4[C7?%EUJ7Q0\33
MQLKWWB-@\",5*F1(><M@\&1I,$ C!&:VK?O$[:+M^A-/]W)/=W/*/^")K)_P
MJOXBH#E_[8MV*YYP83C^1_*N"_X+.2K:_%;X/3S'9"EO=,TAZ ":$G\A7UK^
MQ-^Q'>?L<7/BQ(O'O_"6:3KPA<6;Z/\ 8VMY(B^U]_GR;LJY!&T= ?:NH_:^
M_8U\*_M?>&M,LM<OKK0]8TAI'T[5[-5=HO, #H\;<.A*H<94Y488<YNI+]["
MM'6UM/E8BG&RG"76YZAX[\-VGQ5^$^OZ!'<Q26/B'1Y[)+F)@Z%)X60.".",
M,""*_+S_ ()<_&ZR_9U^*GCGX-?$6XC\,WFH7RBVDOF$<4=_"6CD@9R< R+M
MV$\$I@'++GZT_8G_ ."?]U^QQXN\1:LGQ$_X2VTUFR2UDLO[&^Q;'1]R2;_M
M$F< N,8'WNM=1^U!^P!\,/VI+T:SK-M=:!XK5 G]NZ*RI+,JC"K.C*5E XYP
M'PH 8#BH^";FM4UJ$?>I^SEI9Z,^BM:US3O#>CW>JZI?6^G:9:QM-<7EU*L4
M,48&2[.Q   [DU\-? 7_ (*&>*OVB_VM-2\ >#O#&EW_ ,-K=YI!KS+/'=1V
ML28\]LOM/F2X"KM4XD7/(-<#:_\ !& W#6EAJ_QQU?4/#MN^4TN+1_+V#T1F
MNG13UY\OOTK[7_9U_9?\ _LO^$VT3P1ILD)N"KWNI7CB6\OG48#2R8 P,G"J
M%49. ,G+BDI<TGI;1>82;MRI:OJ>6_M[?ML:;^RCX%%EI9AU#XAZQ$PTNQ8@
MK:IR#=3#^XIX5?XV&.@8CQK_ ()S_L3ZEI%\?CG\6X+B_P#'NL2/>Z;::GDS
M6@DR6NI@W_+=]Q(!^XIS]XX7IOVK?^"8,G[3OQIU'X@#XFMX9-U!;PKIXT+[
M48_*C"9$GVF/J1G[HQGO7EEU_P $6]8OKAY[G]H"^N)Y#EY9?#KLS'U)-]DU
M-)N-YR7O/3T]"ZB32C%Z:7\V?J!BO@3_ (+$?":_\;? 31?%NFVK73^$[]I;
MO:,LEK.H1W^@=(<^@R>U>;#_ ((H:CG_ )+U='_N6F_^3J_0GX7_  R@\ ?!
M[PWX"U"YC\1V^EZ1#I-Q/<VP5+Q4C$;%HBS@!@#E26ZXR:4XJ4;IZIZ#A-PE
MY?TCQ_\ 8#_:4\.?'SX"^&K6VU2%_%>@Z?!I^KZ6[@7$;Q((Q-MZE) H8,,C
M)*YR"*WOVS_VDO#O[.7P6U[4M1U"%/$%]:2VVC:8)!Y]S<,I52$SG8A(9FZ
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M[RCZ5;$-.\F@"JL1IRQ&K0AH\DT 0".GK'4XB/I3O*- $*K3U6I!&:<(SZT
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MH?AI)X)_94LM;NT8:CXLU"XU>5I/O>7N\F+GT*Q;Q_OTJ?\ $E/HEIZR_P"
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MHFG'6=VH'^T?LD?VC(OKE?\ 68W?=XZ].**'P5&]KJ_Z#K;0MYV/?_C-\?O
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M;_E+A\*?^X3_ .C):ZI:U81?5_H<>U*I)=$_ON?JC(PC0L<!0,DFOD3XL_\
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MQHHHH **** "BBB@ HHHH **** $I:** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!*
M*6B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \^OO\ DIUU_P!@Y?\
MT,5LUC7W_)3;O_L'+_Z&*VMM==/X3S:WQC=HI-HI^VC;6IB,V"F[1Z5+MHVT
M 1;1Z4;14NVC;0!#L%'ECTJ;;1MH @V>U&SVJ?;1MH @\OVI!$%X P*L;:-M
M %?RQZ4>75C;1M% %?RZ;Y0JUM%&T4 5O*'I1Y0]*L[11M% %;RAZ4>7[59V
MBC:* *WE^U'E^U6=HHVB@"KY-'DU:VBC:* *ODT>2/2K6T4;10!5\D>E'DCT
MJUM%&T4 5?)'I1Y(]*M;11M% %7R1Z4>2/2K6T4;10!5\D>E'DCTJUM%&T4
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MBX?"SIJ***L@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M  JTO29OM?BKXCRV^FW5O$W[QWM65;G _P!JX6(8])*^L?B%\,[7X-_\$_\
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M&O//V#_V%M-_9*\.W6HZM<V^M?$'58Q'?:A;@^3;0@@_9X"P!*[@"S$ L0.
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!7':A_R5+2O^O"3^;5V-<=J'_)4M*_Z\)/YM0!V-%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 >?WG_ "4Z[_[!R_\ H8K:K%O/^2G7?_8.7_T,5M5U
MT_A/-K?&%%%%:F(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110!S/B3_ )&GPU_OS?\ H*UT
MU<SXD_Y&GPU_OS?^@K735"W9I+:/]=0HHHJS,**** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "N9\'?\?WB#_K_ 'KIJYGP
M=_Q_>(/^O]ZCJBX?"SIJ***L@**** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH P_&7_(+B_Z[#_T$T4>,O^07
M%_UV'_H)HKGGN=4/A1H?#/\ X]==_P"PM/\ R6NRKC?AG_QZZ[_V%I_Y+795
MSG<%%%% !1110 4444 %)2T4 %)2T4 %%%% !1110 4444 %)2T4 %)2T4 )
M2T44 %%%% "4M%% "4M%% "4M%% !1110 E+110 4E+10 4444 )12T4 %%%
M% !24M% "4M%% "4M%% !24M% !1110 E+110 4E+10 4444 %)2T4 %)2T4
M %)2T4 )2T44 %%%% !1110 4444 %%%% !1110 4444 <G\4O\ D1-3_P"V
M7_HU*Z6S_P"/2#_KFO\ *N:^*7_(B:G_ -LO_1J5TMG_ ,>D'_7-?Y4 3T44
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 5QVH?\ )4M*_P"O"3^;5V-<=J'_ "5+2O\
MKPD_FU '8T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Y_>?\E.N_\
ML'+_ .ABMJL6\_Y*==_]@Y?_ $,5M5UT_A/-K?&%%%%:F(4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110!S/B3_D:?#7^_-_Z"M=-7,^)/\ D:?#7^_-_P"@K735"W9I+:/]
M=0HHHJS,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "N9\'?\?WB#_K_>NFKF?!W_ !_>(/\ K_>HZHN'PLZ:BBBK("BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?_@4:/\ A7<W_0SZW_X%&@#LJ*XW_A7<W_0SZW_X%&C_ (5W-_T,^M_^!1H
M[*BN-_X5W-_T,^M_^!1H_P"%=S?]#/K?_@4: .RHKC?^%=S?]#/K?_@4:/\
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MI+1Y/M+3GS5P3\H/I0!ZK17&_P#"NYO^AGUO_P "C1_PKN;_ *&?6_\ P*-
M'945QO\ PKN;_H9];_\  HT?\*[F_P"AGUO_ ,"C0!V5%<;_ ,*[F_Z&?6__
M  *-'_"NYO\ H9];_P# HT =E17&_P#"NYO^AGUO_P "C1_PKN;_ *&?6_\
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MT?\ "%2?]![5?_ @T:]@Y8]SIJ*YG_A"I/\ H/:K_P"!!H_X0J3_ *#VJ_\
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M:BN9_P"$*D_Z#VJ_^!!H_P"$*D_Z#VJ_^!!HU[!RQ[G345S/_"%2?]![5?\
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MKF?^$*D_Z#VJ_P#@0:/^$*D_Z#VJ_P#@0:->P<L>YTU%<S_PA4G_ $'M5_\
M @T?\(5)_P!![5?_  (-&O8.6/<Z:BN9_P"$*D_Z#VJ_^!!H_P"$*D_Z#VJ_
M^!!HU[!RQ[G345S/_"%2?]![5?\ P(-'_"%2?]![5?\ P(-&O8.6/<Z:BN9_
MX0J3_H/:K_X$&C_A"I/^@]JO_@0:->P<L>YTU%<S_P (5)_T'M5_\"#1_P (
M5)_T'M5_\"#1KV#ECW.FHKF?^$*D_P"@]JO_ ($&C_A"I/\ H/:K_P"!!HU[
M!RQ[G345S/\ PA4G_0>U7_P(-'_"%2?]![5?_ @T:]@Y8]RUXR_Y!<7_ %V'
M_H)HK \1>%WL;&-SJ^H7'[S;MEEW <$Y^M%8RW-X\MCK_AG_ ,>NN_\ 86G_
M )+795QOPS_X]==_["T_\EKLJYSM"BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** .9\2?\C3X:_P!^;_T%:Z:N9\2?\C3X:_WY
MO_05KIJA;LTEM'^NH44459F%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !7,^#O\ C^\0?]?[UTU<SX._X_O$'_7^]1U1
M</A9TU%%%60%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 8?C+_ )!<7_78?^@FBCQE_P @N+_KL/\ T$T5
MSSW.J'PHT/AG_P >NN_]A:?^2UV5<;\,_P#CUUW_ +"T_P#):[*N<[@HHHH
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M&_[N._TIDMPD! D8*?0FCW;Z,"2BF13++N 8;NPSUI9IHX/OL$STW'%'N+J
MZBHH[J*5MJ2(6/3YJ>9E3[[*G^\<9/I4*SUOH ZBD>18U4NRKD]S3?M$.QF\
MY<C'&>M/W.Y=XCZ*;O\ FV\%CR #VH\Q-Y!;Z>I_"J7+:]Q/0=1387\[<5^Z
MO&:DV^]3=MZ;#&U]K?\ !*7_ )+YKO\ V 9O_1T-?%>VOM7_ ()2C'QZUW_L
M R_^CH:\[-/]SJ>APXS^!(_5^BBBORL^2"BBB@ HHHH **** "BBB@ HHHH
M*X[4/^2I:5_UX2?S:NQKCM0_Y*EI7_7A)_-J .QHHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@#S^\_Y*==_]@Y?_0Q6U6+>?\E.N_\ L'+_ .ABMJNN
MG\)YM;XPHHHK4Q"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** .9\2?\C3X:_P!^;_T%:Z:N
M9\2?\C3X:_WYO_05KIJA;LTEM'^NH44459F%%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !7,^#O\ C^\0?]?[UTU<SX._
MX_O$'_7^]1U1</A9TU%%%60%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 8?C+_ )!<7_78?^@FBCQE_P @
MN+_KL/\ T$T5SSW.J'PHT/AG_P >NN_]A:?^2UV5<;\,_P#CUUW_ +"T_P#)
M:[*N<[@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **2EH **** "BBB@
M HHI* %HI*6@ HHHH **** "BBB@ HHI* %HHI* %HHI* %HHHH ***2@!:*
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** .3^*7_(B:G_VR_P#1J5TM
MG_QZ0?\ 7-?Y5S7Q2_Y$34_^V7_HU*Z6S_X](/\ KFO\J )Z*** "BBB@ HH
MHH **** "BBB@ HHI* %HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!C=&^E?SF5_1FW1OI7\YE
M?8\.[U?E^I[F6?;^04V;_4R?[I_E3J9<?\>\G^Z?Y5]H]CW#]/==^)GA7]G?
M]E'X1^([CX=Z'XFEU+2X$N&GM8A+Q$K%\["6)SWKPS]N?X:^#&\ ^!/BSX0T
MV/11XFA,UW9PG]V,HK !>@(+'.!VKZ'\5?L]R_M$?L<_!W2DUZ#0(K/2X)99
MYR!E3$H.,^F*\5_:\\0>$Y?#/PA^"WA?5[?Q'-I=Q#8WMW;L",L40=.Y(.1V
MKX7#24:G-%N_,[]K:GBT9.Z:>MW<])T/]FW3%_X)]S++I%H^KR6LFN)>-$OG
M^7CS?]9C=C Z9KP7_@F=H>E^)OC@T&IZ?:ZE;-I\TGDWD"RH#M!!PP(S7VI;
M^,H;#XU:-\#VD/E_\(DT#V^/D*_9\5\M?\$]=#/AO]KKQ=I7EB,6+7UNJ^@5
MB!CVXJJ=>3P]=2EJ]5\Q4ZC=*IJ:5Y\#]-^'/_!0:RTS^SK>;P]J@^U003VZ
MO"2V&=0A&, G%5X/@GX?^*'_  49U_PU=6$-MHNGP)J#6-M&(HF$:K\NU< 9
MW5]0V=NGQ]\1>#?B%96ZMJ/AK7;S2;B*,?,D2W&PNWX)G\:\F^$G_*43QV>W
M]AMC\HZF&+FX-M^\HO[[@JLO9MWU2-K3OBK\&/B_\1/%'P@O?!VDZ3IMK:2)
M%JWDI"S%<*55@H(;.>A[5Y_^Q/X/\/\ @S0/C+)>Z3I?BDZ#?EK=KVWCE!0(
M"JAF!QQCI7Q3\89I[/XP>+#!))!)_:$V&C8J?OGN*^S_ /@FOIMKKWPJ^+%C
MJ^H&QM;J4+<7DA!\I?+&7)/I[UW5\++#85S4G9VN:SC*G2<D]SH_ >O_  ]_
M;D\!^+=!D\!Z=X2\1:3%)+;OIT:J!M.-VY57/T-<I^P';:)I?P+^(^OZGX=T
MKQ#/I.H2-#'J%NCLP50-NYE)45WWA7P;X"_8E^"_BKXB^&?$MQX\?Q!OBL;Z
M.)/+R<Y4;3@J"IY]17)_\$Y;'3]>^ ?Q-L]8O%TW2[S4)/M%V^ L(95)))^M
M<*E^YGRM\EU:][^9@IRY&H_">&?&3]MC2?BA\/=>\)VOP@\.^'9M018EU6Q9
M#+ 5<-E<1CD[<=>]>H?\$O?A+IWC.X\;^(-;TNSU*QFMULK=;R!91%)N.X@,
M#@X(KS']HCX&_!7X=> Y=2\$?$ZS\3:RLA'V"WEC=V![X!->T_!OQ%+^SY^Q
M5H>H"8P:AXEUZ"2"6/@E'DBSD^F,UV5I4XX3EH7C=];_ *G1*4/8VIMZGB?A
M7XE67[+?[1GQ%T:^\#Z9XMM+S5!IUO'J855MU67[\8*MG.[MCI7U'^UY\:O#
M?P1\(^&$M?A7X;U"3Q182;G:"*(VS-'U0A/F(S[=*^?/^"AG@V+0?VHM,U2W
M 2RU:*TN 0.'D,A+$?I77?\ !2Q4_P"$(^#Y/7[$W/\ VR6CV<,1.C4D_BWU
M[(A?O)0EW(_B5X?TA?\ @FZFN1Z38VVIOJ<)^U1VZ"8*91\N_&ZNV\"Z1X(_
M9%_91T?X@:QX6L_%.LZP\32M>1*YVR'*@9!V[0>W6N8^(FS_ (=<0$YQ_:$'
M_HP5TG[74 _X8 \  CDK8G!^@K&/-/\ <MNTIM?<@E)R]UO>3/.?VW_#/P^\
M5?#_ ,+_ !.\%I8Z7<WZI'>:=:[4)9@,'8.!MYY'6OBZG-=7,D(ADN)GA7[L
M3R$J/H,XIBU]7A:#H4^3FNCUJ<'3C9NXM?:?_!*7_DOFN_\ 8!E_]'0U\65]
MI_\ !*7_ )+YKO\ V 9O_1T-<^:?[G4]#FQG\"1^L%%%%?E9\D%%%% !1110
M 4444 %%%% !1110 5QVH?\ )4M*_P"O"3^;5V-<=J'_ "5+2O\ KPD_FU '
M8T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110!Y_=_P#)3;O_ +!R_P#H
M8K:KP7]JCQYKOP\OHM2T"^_LZ]E:&W>3R8Y<QE)&(PZD=57G&>*^??\ AJ+X
ME_\ 0R_^2-K_ /&J^DP.4U\92]I3:2\[_P"1\1FN?X;+L2Z%6,F[)Z)6U]6?
M?E%? ?\ PU)\3/\ H9?_ "0M?_C=)_PU-\3!_P S*?\ P M?_C=>A_8.*[Q^
M]_Y'C_ZVX+^27W+_ #/OVBO@#_AJ;XE_]#,?_ "U_P#C=)_PU1\2_P#H93_X
M 6O_ ,;I_P!@XGO'[W_D'^MN"_DE]R_S/T HK\__ /AJKXE?]#*W_@!:_P#Q
MND_X:J^)7_0R-_X 6O\ \;I?V%B?YH_>_P#(K_6S!?RR^Y?YGZ T5^?G_#5G
MQ*_Z&1O_   M?_C='_#5GQ*_Z&1O_ "U_P#C=+^PL3_-'[W_ )"_UKP?\DON
M7^9^@=%?GW_PU=\2?^ACD_\  "U_^-TG_#67Q)_Z&23_ , +7_XW1_86)_FC
M][_R'_K7@_Y)?<O\S]!:*_/K_AK+XC_]#&__ ( 6O_QND_X:S^)'_0QR?^ %
MK_\ &Z7]AXC^:/WO_(/]:\'_ "2^Y?YGZ#45^?/_  UG\2/^ACD_\%]K_P#&
MZ3_AK;XD?]#')_X+[7_XW1_8>(_FC][_ ,@_UKP?\DON7^9^@]%?GQ_PUI\1
M_P#H8Y/_  7VO_QND_X:W^(__0Q2?^"^U_\ C=']AXC^:/WO_(?^M6$_DE]R
M_P S]"**_/7_ (:X^(__ $,<G_@OM?\ XW2_\-<?$?\ Z&*3_P %]K_\;H_L
M3$?S1^]_Y!_K5A/Y)?<O\S]":*_/3_AKKXC?]#')_P""^U_^-T?\-<_$;_H8
MY?\ P M/_C=']B8C^:/WO_(/]:L)_)+[E_F?H717YZ?\-=?$;_H8I/\ P7VG
M_P ;H_X:\^(__0Q3?^"^T_\ C=+^P\1_-'[W_D'^M.$_DE]R_P S]"Z*_/3_
M (:\^(W_ $,4O_@OM?\ XW1_PUY\1O\ H8I?_!?:?_&Z/[#Q'\T?O?\ D'^M
M.$_DE]R_S/T+HK\\_P#AKWXC?]#%+_X 6G_QNC_AKWXC?]#%+_X 6G_QNC^P
M\1_-'[W_ )!_K3A/Y)?<O\S]#**_//\ X:]^(O\ T,,O_@OM/_C='_#7WQ%_
MZ&*7_P %]I_\;H_L/$?S1^]_Y#_UIPG\DON7^9^AE%?GE_PU]\1?^ABE_P#
M"T_^-T?\-?\ Q$_Z&*7_ , +3_XW3_L3$?S1^]_Y!_K3A/Y)?<O\S]#:*_/+
M_AK[XC?]#'-_X+K3_P"-TG_#8'Q%_P"ABF_\%]I_\;H_L3$?S1^]_P"0?ZTX
M3^27W+_,_0ZBOSQ_X:_^(W_0PS_^"^T_^-T[_AK[XC?]##-_X+K3_P"-T?V)
MB/YH_>_\@_UIPG\DON7^9^AE%?GG_P -??$;_H89O_!=:?\ QND_X:^^(G_0
MQ3?^"ZT_^-T?V)B/YH_>_P#(/]:<)_)+[E_F?H;17YY_\-??$;_H89O_  76
MG_QNF_\ #8'Q%_Z&*;_P7VG_ ,;H_L3$?S1^]_Y!_K3A/Y)?<O\ ,_0ZBOSS
M_P"&O_B+_P!#%+_X 6G_ ,;H_P"&O?B-_P!#%-_X+[3_ .-TO[#Q'\T?O?\
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MO_QNJ_L+$_S1^]_Y$?ZUX/\ DE]R_P S]!:*_/K_ (:P^)/_ $,<G_@OM?\
MXW2C]J_XDG_F8Y/_   M?_C=']A8G^:/WO\ R#_6O!_R2^Y?YGZ"45^?G_#5
MOQ*_Z&1O_ "U_P#C=._X:L^)7_0RM_X+[7_XW1_86)[Q^]_Y"_ULP?\ )+[E
M_F?H#17Y_P#_  U7\2O^AC;_ , +7_XW2_\ #5/Q+/\ S,C?^ %K_P#&Z?\
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M_P#^$JU3_GZ_\AK_ (4[_A*-3_Y^?_(:_P"%'U>0_KE/LSOJ*X7_ (2;4O\
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M;HU6YK9:?/H>[EN9YUB:\%B:"C3ENU?;[V>_T4E+7S1]V%%%)N'J* %HHHH
M*2C</6C(H 9[UPC_ !N\&IXW_P"$0;6"/$/FB VGV6;_ %A&<;]FWIWSBN[X
M[U\.W?\ R>Q_W%U_]$BO4R_"PQ<IJ;:Y8MZ>1X.;8ZI@:=*5-)\TU%W[,^Y:
M6FY 49.*7->6>Z+1110,**3</44M !129HR* $]*K7%[!:O&LTT<1D;RT#L
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M#-_Z.AK#,_\ <ZGH<^,_@2/U@HHHK\K/D@HHHH **** "BBB@ HHHH ****
M"N.U#_DJ6E?]>$G\VKL:X[4/^2I:5_UX2?S:@#L:*** "BBB@ HHHH ****
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M>E'V<>E:7D^U'D^U'('M#-^SCTI?L_M6CY-'DT<@>T,WR13OL]7_ "*/(HY
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^RWXM^)?A.S\0:5>Z1%971D5$NIY5D&QRAR!&PZJ>]=)_P ,.^/O^@EX?_\
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M>W;O)6277OKT/G<[P>,QE3#_ %5*T97;?1JUG;J<>_[>UO\ ;"J^#)3:[O\
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M:[_V 9O_ $=#7FYG_NE3T./%?P)'ZP4445^6'R84444 %%%% !1110 4444
M%%%% !7':A_R5+2O^O"3^;5V-<=J'_)4M*_Z\)/YM0!V-%%% !1110 WWKS7
M]H[XAZG\(O@3XW\9Z-#:W.J:'I<U[;0WR,\#N@R X5E8CZ,#[UZ4>HKPW]N+
M_DT/XK_]@"Y_]!K*H[0;1=-*4TGW/C[PA_P5F\1^(OA?H%GIO@:V\;?&C6KJ
MXCCT#P];W"6MK"C8C=U+2R.S $[%8?*"Q*#&37?^"B7[2?P(N[/4?C/\";&Q
M\,7+JGVK2XY[;86Z*9VEGCWX!(1MI..W6MW_ ((V_!_1]'^#^N?$62TBD\0:
MSJ,NGQ71 +Q6D03Y%/\ #ND+%L==J>@K[R^(7@?1_B7X+UKPMK]E'J&CZK;/
M;7-O(N058=1Z,#@@CD$ CD5M47L]8ZZ+\C*G)3T>BNU?KN8?P/\ C9X5_:"^
M'>F^-/!]ZUWI-X"K1S+LFMY5^_#*N3M=2>1D@Y!!(()X7]J_]L#P5^R5X4@U
M'Q&9=2UN^W#3-!LV GNBN,L2>(XUR,N?7 #'BOAS_@D'XDU'P/\ &SXK_"FZ
MN&FM8(GO53^!9K6X%O(P'8L)4S_N+Z5XW\?OC!X/\5?\%)]4UOXKFYOO /A?
M5&TYK&. S_N[1&5(O+R,HUP"S#H0[=C4R2G.$8Z*2O\ )%).*GSZN+MZGT'9
M?\% ?VMO'UF_B/P/^SS;OX3D036[7&DW]W)-&1D&.598A-D=TC->W?LH_P#!
M2/0_CMXR;X?>-?#MQ\._B$KM#'I]T[-#=2*/FC4NJO%*,-^[<=N&)XJLO_!7
M3]GJ-55+SQ JJ,!5T=@![?>KX/\ ^"@W[3'PK^.'C[P5X^^%,NH6/C#3BRZA
M>36/V5G\MD>UDW9^9T(<9ZXVC. *:=II-:/\/,+.47T:/U7_ &XC_P 8B_%C
M_L 7/_H-?./_  1;_P"39?%'_8V7'_I):U[)^TEXJ;QU_P $_?%OB.1/+?5_
M!@OBG]TRP(^/S:O&_P#@BW_R;'XH_P"QLN/_ $DM*NG'E=6/9+\R7+GI4Y=&
M_P!#UW]L3]O;PC^R2MEI,NG3^*O&FH1>?;:':S"()&6VB2:4AMBDA@H"L6*G
M@#FOFVY_;@_;1U*U?6M)_9TMX-#/SI#<Z'J,UT4SV G1FX/41^^*]K\<_L8^
M"-#_ &IU_:,\=_$2"WT^UN%N#IGB!(8+.&5(?*@Q</(H41E5< J<LO6O0/%G
M_!0G]G?P;\M]\4]'NF[?V2LVH _C;HX_6L8_"I-ZOIV\C1[V2T[GD/[(?_!3
M.R^/'Q B^'/CCPJW@GQO*9(K?RI&:VN)HP3)"R. \$@"MA6W [2-P. ?N>OQ
M!^(GQO\ !GQO_P""E/P[\:_#V.YBTRZ\0:+!-<7-L+=KF9;A(WE"YS@IM&6P
M>.17[?+]T5KO3C.UF_T,W[M1Q3NK)_>+]**/6OCK]MW]G?X__&?Q5X:O/@]\
M29/ ^F65E)#?6Z^(;[3?/E,F5?;;HP;"\9;FL7)II6W+2\SC/^"S1/\ PR[H
M0/3_ (2FU/\ Y+75?2O[' Q^RI\(\=/^$8L/_1"U^2/[8W[-/[1OP?\ A?8Z
MS\6OBG)XU\-S:K%:PZ>WB34-1"7+1RLLGEW"*@PJ2#<#D;L=S7I/P?\ V-?V
MOO%WPK\)ZWX3^-TFB^&=0TRWN=-T[_A,=5MQ;V[H#''Y4<91,*0-JG QQ6U-
M6IS2UNT_338*FO)TLG\]3]B**^>_V*OA)\5/@[\,=5T?XN>,&\:^(;C5Y+NW
MOVU6YU$I;&&%5C\RX56&'20[0,?-GJ37T)2E%1=D[DIW.$^.'C:_^&OP<\;^
M+M+BMYM2T/1;O4;:*\5FA>2*)G4.%925)49P0<=Q7P;X&_X*W:CJ7P>TR:\\
M(6WC#XOZQJ4]I8^%?"T4\<2P($V22 M-)N8E\(N2VW^$<U]I_M:?\FO?%CU_
MX1;4O_2:2OAO_@BI\,M+_P"$9\>>/YK6.76#>IHUO.Z@M!$L:RR!#U&\R)GU
M\L5--.4IW>B2?XES]VG"26K;7X(RK[_@J)^T)\)]8LKOXL_ ^#1/#=U)LC5M
M-O\ 2YG[D)-.[HS <[=HS[5[E\6O^"G7A^UTOPUIWP<\+ZA\5/&_B&P6_BT>
MQB=SI\;+G;<+$'8R@YS$O0 DL 5W>@_\%)]#LM<_8Q^(?VR%9C9PVUU"S8S'
M(ES%AAZ'!(^C$=Z\5_X(T_#[1])^ FO>+XK:,Z[JVLRVDUV4'F"WB2/9$&Z[
M=SNQ]21Z"G#]YS1>G+;YW)G[BC):W=K'G$/_  55^-?PE\6Z?;_&WX,1:'H]
MXV52WT^\TRZ,8(W/%]I=TF*@CY1MYX++7Z9^"_&&E^/_  EH_B31+H7NCZK:
M1WMI<+D;XI%#*<'D'!Y!Y!XKY&_X*Y:+9ZA^R#J-Y<6Z2W%AJME-;2LH+1,T
MGEL0>V5=A^-=G_P3-U*;4OV)_AU).VYXX[V(<G[J7MPJCGV IP_>4IRMK%V^
M]7)E[DH]F?$>A_\ *::8?]1F?_TUM7Z_KT K\,OCQ\&6_:#_ ."FWBSX?+JP
MT$ZUJK1C4&MO/\G99"7/E[UW9V8^\.N:]U_X<;W1'_)98?\ PF3_ /)=12O]
M6I)KH5-+VTG?4_5CM6-XR\36G@KPEK7B"_;;8Z5937L[>D<:,[?HIK\Z?A3_
M ,$<;CX9_$[PEXN;XL1:BN@ZM::H;-?#QB,_DS+)LW_:3MSMQG!QGH:^V_VJ
MK6:\_9F^*D-NC2SMX8U((B=2?LTG J:WNTG*+UL_D72CS5%%[.Q^97_!-3P&
MW[4O[57C?XO>.8DU:71Y!J217"[X_MUP[^2<'C;$D;[1_"1&1]T5^Q6.:_,3
M_@B+<6S>%_BK "INEN]/=E_BV%)P#],AOUK].UZUTU$J?+!;)+\5<PBW*4IO
M=L/PK\9O^"@_@63]C_\ ;$\(_%;P-"NF6^K2_P!KK;P?NX_M<3A;J/ Z)*KJ
M2._FOVK]F-U?EM_P6\O;7[!\)+0J#>>9J<@.XY5,6P/'?)QS_L^]<S;A5A-=
MSI@E.,H/9H^WOVDM<M?%'['OQ%UBR;S+/4/!M[=0-ZQO:,ZG\B*^2?\ @B7_
M ,DI^(O_ &&8/_1->^:]9W.F_P#!-.YM+W/VN'X8^7+NZ[AIH!_6O O^")O'
MPI^(O_88@_\ 1-=$4HU:T5V7YG/?FP]%O=M_DC]):*2EK,L**** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH ^0?VX/]7:_P#7Q!_Z+FKY'KZY
M_;?_ -7:_P#7Q!_Z+FKY'VU^GY!_N2]6?A/%W_(SEZ(2C;NI=M+S7TA\4,VT
M;:=MHVT -VBDVT_;1MHL!'Y8W9QSTI=M/VT;:+!<CVBC:*DVT;: N1[11Y0J
M3;1MHL%R/RA1Y0J3;1MHL%R/RA2;!4NVC;18+D7ECUHV"I=M&VBP7(M@HV"I
M=M&VBP7(O+'K1Y8]:EVT;:+!<B\L>M'ECUJ7;1MHL%R+RQZTOE"I-M&VBP7(
M_*%'E"I-M&VBP7(_*%'E"I-M&VBP7(_*%'E"I-M&VBP7(MHHVBI=M&VBP7(M
MHH\L>M2[:-M%@N1>6/6CRQZU+MHVT6"Y%Y8]:7RA4FVC;18+D?E"CRA4FVC;
M18+D?E"CRA4FVC;18+D?E"CRA4FVC;18+D?E"DV"I=M&VBP7(M@HV"I=M&VB
MP7(M@H\L>M2[:-M%@N1>6/6C8*EVT;:+!<C\H4>4*DVT;:+!<CV"C:*DVT;:
M+!<CVTNT>M/VT;:+ ,VCUHVCUI^VC;18!FWVHVU)MHVT6"XS;2T[;2T["N,H
MI]%%@N-ZT;33J*+!<;MIU%%,04444 %%%% !1110 5ZA\"?$G]GZ[/I,KXAO
M5W1@]!(H_J,_D*\OJQI]]-I=_;W<#%)H)%D1@>X.:PKTE6IN+ZG7A:[P]:-1
M=#[$6I5K+T'5HM>T>SU"'_5W$0<>Q[C\#D?A6HM?$23B[,_3Z<E)*2V9)'WJ
M5.M11]ZE3K64C=$JU(GW34:U(GW34FB)8^U2KTJ*/M4J]*AFJ'+4B]JC6I%[
M5):):?3*?4&B'5*M15*M)FA(OWA4J]:B7[PJ5>M9EH>M/6F+3UJ6421]ZD6H
MX^]2+4LU0]:>M,6GK4EDJ_=%/7[HIB_=%/7[HJ2QQ[5)49[5)4LT0^GTRGTA
MCJ?3*?4%CUZT]:8O6GK4E(>M/6F+3UJ#1#UI:1:6@M#EIZ]*8M/7I290Y:DJ
M-:DJ2D.I6I*5JD:'54JW52JB3,****LS"BBB@ KF?!W_ !_>(/\ K_>NFKF?
M!W_']X@_Z_WJ.J+A\+.FHHHJR HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@##\9?\ (+B_Z[#_ -!-%'C+
M_D%Q?]=A_P"@FBN>>YU0^%&A\,_^/77?^PM/_):[*N-^&?\ QZZ[_P!A:?\
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MQF-/%<M"A\$?SV^X];AO)ZV"Y\7B_P")/[TM]?-L_+'XD?\ )1/%'_85NO\
MT<U?>GPS^+'@K3_AWX9M;KQ=H=O<0Z;;QRPS:C"K(PB4%6!;((/!!KY;\;?L
MQ_$S5O&6O7UIX9:6UNK^XGAD^VVR[D:1F4X,N1D$=:Q_^&4_BIC/_"*M_P"!
M]K_\=KZ#$QP>/P]*$Z\8\J75=O4^2PM3,LJQU>M2PTI\S?1VM??8^V;_ ..G
MP_TVUEN9O&.C.D8R5M[R.9S]$0EB?H*_/?XJ^*K7QO\ $77]<LHFAM+ZZ:6)
M6&&V] 2/4XS^-=E'^RA\4F.#X8">[7UM_26O4OA1^Q;J$.L6NH^-;BU%I"PD
M&EVKF1I"#PLCX "^H7.1QD5CA%E^4N595N9M6T:?X'1F$\XS]0PTL,X13O=I
MK7;=]+'N_P"SMI=SHGP3\+6UV"L_V7SL-U"R.SJ/^^6%?G?XN_Y&O6O^OV;_
M -&-7ZK)&L<81  JC '08]*_/WQ%^R[\3[[Q!J=S!X8+P374LD;?;K894N2#
M@R^AKBR3&4OK-:K6DH\W=VW=SU>)<OK_ %'#T,/!SY++1-[*U]#Z]\)_%SP/
M:^&M+AE\8Z%%+':Q*ZR:E""I" $$;^#6Q_PN;P%_T.GA_P#\&<'_ ,77PW_P
MRG\5/^A4;_P/M?\ X[1_PRG\5/\ H5&_\#[7_P".T3RO+Y2<OK*U]/\ ,SIY
M]FU."A]2EIY2_P C[X\/^-O#WBUYDT37-.U>2$ RK8W<<Q0'H6"L<9]Z^$/V
MN,_\+WUS/_/*V_\ 1"5[G^R3\(/%OPUU;Q!-XDT@Z;'=10I"QN(9-Y4N2/D=
ML=1UKC?VBO@!X]\=?%C5=9T/03?:=/' L<_VN"/<5B53\KR CD'M6>6K#X',
MFO:)QMO=6N['1G$L9F>3*3HM3;7NI.]EU/0OV8OB5X3\-_!?0['5/$VD:=>Q
MM<%[>ZOHHY%S.Y&59@1D$'\:]6'QF\!<?\5IH'_@S@_^+KX=_P"&4_BI_P!"
MHW_@?:__ !VC_AE+XJ?]"HW_ ('VO_QVNG$9?@,16G5>)2YFWNNOS//P><9M
M@\/3H+!2:BDMGT^1]Q_\+F\!?]#IX?\ _!G!_P#%UV*L&4%3D'G-?G7_ ,,I
M?%3_ *%1O_ ^U_\ CM?H=9HT5K$KC#JH!_*O S#"8?"J+H55.^_D?7Y/F.,Q
MSG]:H.G;:Z>I8;H:_*KQU_R.OB'_ +"-Q_Z-:OU4;.VOS]\5_LO_ !-U+Q5K
M-W;>&#)!/>32Q/\ ;;8;E9R0<&7(X/>O2X?KTJ%6HZLE&ZZNQY'%V%K8K#TH
MT8.34NB;_(^W_AQ_R('AW_L'V_\ Z+6NCK$\$Z?/I/A#1;*Z3RKJWLH8I4R#
MM=4 89'!Y!Z5M]SZ5\U5:=237<^UPR<:$$UK9?D.Z5Q'QI\.S>*_A7XHTRU&
M^YFLI#$@ZLZC<!^)7%=M[T$YJ(2Y)*:W6IK4@JD'![/0^0?V&?%UK;OX@\,W
M$BPW4KK>01L<%\#;(![C"''H3Z5]>?C7R_\ %K]DV^NO$C^*/A]J"Z5J+2F=
M[-I6BVR9R7AD7[I)_A.!R>1TKF[KPM^TOX@M?[(O;R6WLI/W;S_:;2,[>G+Q
M'S"/UKZ7%4:&95/K-.K&-[74G9I[:=SXC XC%9+2^IUJ$IJ+?*XJZ:;OKV.Y
MD_:9U?4/CTG@G1-.L=3T@W:VIN5W^:,#,S[@Q4A</V_AKQWXQ,_PM_:HB\07
M*,+*2\M]1#A?O1$!9,>I&'%>_P#[/_[-]I\(?,U;4KF/5/$<\>QIHU(CMU/5
M8\\DD]6(!(XP.<]/\:/@II'QET%+:\=K+4K8EK._C7<T1/56'\2' R,]N"*5
M+%X3"8I1I*\.7ED^]]V.ME^89A@93KNU3FYHQTTMLK^AWNGW\&JV,%Y:31W-
MM/&LD<D;;E=2,A@>X(KSK]HOQM9^"OA+KKSS)'<W]N]C:Q-]YWD4J<#O@$D_
M2O ])^%'Q^^$^_3O"M^+W3B3M%M<0/"N23E4N<;">IVCKZU-I_[,?Q*^*VNP
M:E\2-<-M APT;3+-.%SRL:I^[0'U!]]IK*G@<-3J*K.O%P6OF_*QM4S;&U:+
MH0PLE5:MJERI][W-W]A/P]-;:#XGUF1=L-Y/#;Q,?XO+5F8_3]X!^!KA;O\
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M_*@">BBB@ HHHH **** &;L<G@5\D_M;?M-0^'[6?PGX?FWW\OR3SQG[G.,
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M?3J?=M%?/OP'_:UT7XN7$>F7:)INM/P+<$D,?K7O=Q=1V5O)/*P2*-2S,>@
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M\#UK]IO0=%_;H_X65H&I_:O"LS003WRQ.N;<@";Y2-V1CTK0_::_:@\-:O\
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MH?'+P3??$KX-^./"6ERP0ZEKFBW>GVTMVS+"DDL3(I<JK$*"PS@$X[&O$O\
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M+)Y=Q$J#"JXW9R-WN:I)/=F;;1]QT444B@HHHH **** "BBB@ HHHH ****
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MHHHH **** "DI:* "DVCTI:* $I:** "BBB@!, ]11@>E+10 4444 %)2T4
M)2T44 %%%% !24M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M(_'2SAT>YVPM<K/%Y;?=7?\ =-?IAX'UB3Q!X5TV_EP9)H@S8'>OS(NO@?\
M$[7M6M+[4;.[OIUD7]],&8@9]<5^DWPIT^ZTGX?:+:7J>7<Q0!77T.:\3B-P
ME0HWFISCHVCWN&%..(K6@X0EJDSKZJ:IIEOJUC/:74:S03(4=&&<@C%7*2O@
M4W%W1^C2BI*S/SF_:*^!.I? GQ:GBKPV7&D/(9!Y><P?[Q]S7U/^S;^T)I_Q
M;\/16L\BP:U;(%DA9AE@, -^-0_M9?$W0?!?P]N]/U&.*[O;Y"L%NP#<^I%?
M,'['OPGUSQ-XT@\1PSS:=IEG<QW!:,E5E"RJQC]P0,8K]#TS+*76QONRA\,N
M_D?F.N59RJ.!]Z,_BCV\_(_1BBD'2EK\\/T\**** "BBB@ HHHH **** &-T
M;Z5_.97]&;=&^E?SF5]CP[O5^7ZGN99]OY!1117VI[@QF1&W.5'8%CBIO,.P
M M\N>.:^T_\ @FG\&]$^)6L^,KSQ-HUGK-C;VT<-LMY;B1%=F*L1GN!CFOG+
MXE?#U-&_:0U/P6B"VM&\0G3K=2,@1O*$5L?C7G+&0E7G1?V3D]K%3<>J/-&F
MB5L%U#>F1FFR21QLN]E4'E=QQ^5?J'KUA\!/V;?$'A/X6:WX*L]:U75/+@N-
M6NK59)$DEP%;>5S@DGO\M>;WDGPE_9;^/WB3PMJ?@RR\:Z1KTEF^G/=".?["
MQ#>8BY4\$L.F.E</]J7OR4VUNO-$K$*WNQ_X)\"+/"N<2QAB<_>%/6;]YC?\
MWIGFOTX_:Z\8?!WX*:):Z0?A5HDE_P"(]*EDL[N"RA1H&*C!^[G(+#TZ5XYX
M\\!^&H_^"=_AGQ7!H&GVVOS:H%;48[=1.5\R4;2^,D8 X]JTHYFI1C.4&N9V
M0XXKFY=+79\432*F#(P7/3=Q21LK<H0<\Y%?H;\/_"/PK_9;_9G\/>.?'/A:
M'QKK6N3!/+NHED0,Q;;L#*0HP!7"?MN?";P3_P *Q\%_&'P'ID>B6&NW<5I+
MI\:!(P6+<A0  /D(IPS2,JO*XNST3\R)8R[Y7$^+%D1F.&4D=<&A9(Y'.&5G
M'7!R17Z5_MF?LV^'I/V6](\7^&?#VG:1J.DQ17M[-86JQ--%LP0V.OS$&O*?
MBUX!\-:;_P $^OA7XBLM T^TUV]53<:A%:JEQ+]_.]P,MT'7TIT\TA4Y5%:N
M7*.GC%)12ZNQ\6\K[4G3@4YLECP0!TR<YI-IKVT>B.HHHILE!1112*"BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@_Z_WKIJYGP=_P ?WB#_ *_WJ.J+A\+.FHHHJR HHHH **** "BBB@ HHHH
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M>'(BN+Q[VWN( 0&DLKB0!XW3_GDVT<_,@W*U?KMX'\9:3\0O".C^)=!O%O\
M1M5M8[RTN5! >-U!!P>0>>0>000:.5.//%W0KM/EDK&_G&:7TKXA^(/[$OCG
MQ5^WUHGQOLM4\/Q^%+&:UDELYKB<7Y$5OY;;4$)CY/3,@X]*^W!Q@'J!41]Z
M*;W'+25EJK+7]"2BBBJ&%%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%)0 F1S0O:OR?_ ."V_/BSX0?]>^I?^AVU?JOIYS9P_P"X/Y41
MCS4E4\VON%)\LU'RN6J3/3--<]/I7QQ_P5HY_8Q\1#_J(V'_ *4+64Y\BOYI
M?>TBXKF=C[+I*_$;]E/_ ()>R_M/_!G3?'T?Q(3PVMY<7$']GMHAN2GE2%,^
M9]H3.<9^[Q7KK?\ !#[4K53+:?&6$7"\IGPZR<_[PNB1^5;./*[,A-/8_5OC
MKFC@<FOQ?T'XS_';_@FW\=],\)?$37[SQ9X'NO+D>WFNI+NUN+,MM,UF\HW1
M2)SE!M!(PP(*M7ZS?$[4+?5?@SXIO;259[:YT*ZEBD4_*Z-;L5(]B"*SJR]G
M2=:.JU_ J*;FH/J=WUHK^?G]B7]B>3]LB^\6V\?C!?"?]@I;2%FTTWGG^<9!
MC_6Q[<>7[YSVQ7U5)_P0]U&%=]O\9(#.O*;O#C(,_471Q^5:./+:_4E--M=C
M]6Z/6OQ@\7:;^U'_ ,$SM;TO6)/%$GBSP%)*(57[5->:5)R3Y,L4F&MY"!D,
MF,XP';!%?J?^SG\>] _:2^$^D>-O#Y,<-XICNK.0YDM+A>)(7]2#T/=2I[T6
M4ES1=^XFW%I2TOL>H<<4F1@=J/2OS?\ ^"PGQ4NKC0/ _P &]#<RZMXGO4O+
MJWB(+-$CA+>,CKAYF)'O#6;;O&*U;=C2,;W;=DC](,C(]:7BORH_X)A>+M1_
M9_\ VD/B+^SWXEN<-+=32V.[Y5>ZMLAR@_Z:P /](17ZKUJUHFG=/4R4GS.+
M6P>E&:H:QJUEX?TF[U+4;F.SL+.%[BXN)F"I%&BEF=B>@ !)/M7Y4?$']LSX
MY?MP?%2\^'7[.XNO#7A6$E9=:A8VUP\.['VF>YQNMHS_  I'B0]/F)VC/5OE
M2U-+*W,WH?K+QMI>U?E9_P .7_%GBU%U7Q=\<?/\1RC?<-_8\M\-_M/)<H[#
MW* ^U<%XPM_VG/\ @F-K^EZFWBJ3QQ\-9IQ;K'-/+<:?(!DB%XI,M:2%02#&
M<''WGP5JM$TF[?D+5J\=3]D:.M><? #XW>'_ -H;X6:)XY\..XL=1C/FVTQ'
MFVLZG$D+X_B5LC/0C!'!%>C8ZT.+B[,F,N97'4444%!1110!R?Q2_P"1$U/_
M +9?^C4KI;/_ (](/^N:_P JYKXI?\B)J?\ VR_]&I72V?\ QZ0?]<U_E0!/
M1110 4444 )P:HZQI%IKNFSV-["L]K,NR2-NA%7N,4=J:;B[HF45)6>Q^<WQ
MV^#>N_L\^.8?%?AQY#I;3"19%X"MG/E_2OK;]G;X^:?\9O#,;LZPZS;J%N8"
M>=V.M>B>,O"&G^./#]WI.HPK+#,A4%AG:2.HK\\O%7AGQ3^R7\5(]5LO,?36
MD)20 E'0G&#[XK[JC4IY]AO85G:M!>Z^Z['YW7IU>'<5]8HJ^'F_>79]S]*N
M.*=7!?"3XLZ1\6_#,&J:9(HD*_O;<L"\9]_;-=Y7Q-6E.C-TZBLT??T:T,13
M56F[I['F'[2&%^#^NYZ>6/YU\*?L;_\ )9XO^NH_G7Z"?&+PE=^./A_JFC63
MK'<W" *S#BOES]G3]ECQ=\.?B0FL:G/"UJK@X5""1FOLLIQ5"CEE>E4FE)[+
MY'P^<8.O6S2A5IP;BK7?S/J#XT:3'K'PUUR*1=P2V>0?4*:^"_V(;B.W^-%M
M$YPS%PH_ U^B7C+2Y=:\*ZM80$":YMI(D)]2I KXM^!G[*'C?X?_ !2TO7+R
MXB^R0.S2;4()!K/)\31AE^)HU9)-K3[B\ZPM>IF.&K4H.2B]?O.(_;P\-S:;
M\6I=5RS174*(O' .,U]:_LV_$30+OX-Z2([^,MI]JJ7"L0"K <BM;X_? FP^
M-GAE;28K!J$'SP3],-CO[5\9W'['/Q+T.XEL[+4&^SL<$P%@AKNI5L)FN7T\
M-6J\DH=SSZM#&Y1F-3%4*7/&?;SU_,XOXXZK;?$WX_:E-IQ\RWNKA50J,YQB
MOL?]H3PJ;?\ 9QM+.*$S_9;96/'W?D'-<K^SG^QG)X+UZ+Q#XKGCO+R$[[>)
M,_*>^X'K7U5KFAV?B#1KK2[N(26=S$8G3_9(QQ6&9YI0C6H4L.^:%*VO<Z<J
MR>O.AB*N(7+*K?3MU_,^#/V!OB1I_AG6;[0;^1(&OF,JRN<8(&,5Z=^VA\>K
MWP;:Z5I_A77/L]^SM]H$&#A<<5YK\3/V'?$>B>(KB^\(W@^P2.7BCCW>8@],
MBLKPC^Q/XW\7:Q#+XBOC%;%OWOVC=OP/0U[$XY7B,4LRG55K:Q?>QXT)9MA\
M*\LA2=[Z27:Y[G^R3XN\5^-OA9K>H>);V6^7$J1RS#!Z5\S?"?\ Y.LD_P"O
MB2OT/\.^ ;+P;X&_L#2T$:+;F,'^\VW&:^4? 7[*_B[0_CN_B>YFB_L\RL_"
M'.#7EX''X:4L7.Z@I+1'KX[+L5&.$A9R<7[SW/IOXY9_X4WXFS_SXM_2OS\_
M9&.WXY1'V_\ 9A7Z*_%#PW=>*OAWK6C6C*MS=6IB1FZ9XKY,^ /[*?C#X??$
MY-9U&:%K11CY4()YK#)\51HY?B(3FE)[+OH;9U@Z];,</4IP;C'=_,P_^"@W
MAAK'Q5HFJJS-'.C9XX'->X?L:^.-%N/@W863W\*WEH7,T;':5!/!KTKXT?"'
M3?C%X1N-)O559L?N9NZ'K7PWJ7['GQ)\,ZA);:9>2-;R,5WVQ8#;VSBNC"UL
M-F>6PP=:KR2@^IRXK#XO*\SGC:%+GC-=.FQV_P 7/VNO%'_"U8M'\+7'EZ?'
M<"W98U!WG=C-?:WA&XO;OPY83:B-MXT8,@/K7R9^S]^Q;=Z!XBB\0>+[E+IX
MFW1P+D-N'()S7V8%   Z5X^<U,%'DP^#2?*M9+JSW,CIXZ7M,1C6US/2/9"G
MI[UP7QB^+&F?"/PC<ZM?R+YF-L,6>68CC]:W/''C;3/ 'AVZU?5)EBMX$+8+
M8+D=A[U^>WBCQ#XF_:\^*4=I9)(FE1.5BCP=J1@YR<=3BL<HRSZY-UJVE*&K
M?Z&V=9K]1@J-#6K/1+]1O@WPSXH_:V^)[:AJ;R1Z6LFZ1LY$"^GXU^AG@GP;
MIG@/P_;:1I<"PVT*C[H^\V.6/UK$^$7PITSX3^%;?2[%%,H7]]-W<_6N[HSC
M,_KDU2H^[2CHE^H9+E7U*#K5WS59ZM_H.HHHKYX^G"BBB@ HHHH **** "BB
MB@!C=&^E?SF5_1FW1OI7\YE?8\.[U?E^I[F6?;^04,=N313X;=KRXAME'S7$
MBPKCU9@H_G7VDM%<]P_0K]GW7KSX#_L8VVOPD6^J:UXCM1'-C:3;O/$#]?E+
M5P'[:7A2/1OVVO!NIVL.VQU:\TNYCD"X#N9@6/\ *O?_ (G?$+P'^SO\"?A9
MX<\=:&VN/'8QD6\3$>7(B!B[@#N1QGN*Y/\ ;$N=,^(6F?L^_$?1E-MIG]K6
MLDS.N?)B+Q;58]L<U\+&4HUG6L_>NK_D>%+X^:W<\G_X*>74D/[05J8W:-X[
M*%ED4X96QP0:^7O"^J7NK>.O#DU]=SWLBZA /,N'+M]X=S7WQ^VG^S?XM^,W
M[1/A34-*TI[[PMJ(MH;C4("2(H@0)&.!QP>/6OFCX_\ P?\ #WP-_:/T?PKX
M>O7O+>&YM9G,C99"Q!P>3TKU<#B:7L8TE\5CJHU8NFH=4CU/_@J W_$^^&.!
M_P PB3_T%*U?B!)M_P""77A,_P#444?^19:QO^"H3%M?^&&!E?[(?G_@*5K?
M$92W_!+GPB!\I_M5/Q_>S5S-/ZO07]XS^S3]2S^V =O[$?PM][R'^35%^TU\
MW_!._P"$/_89M_YS5TGQP\!:Y\;OV(_AO_PA%DVN&UN(I)(X!N=0NX-@#K@U
MA?MC:3=>!_V(_A3X0UIH[3Q%;ZI!+)8ALMM!ER?PW"L%*+=.%]5)W_$REJHV
MW3/M2\U#1]3^'/AWP7K<2-#XCTU;6-6(P[^7D+C_ (#FOD']J[P=J'P__8/^
M'/A[4X_+O]/N/)D3TYD(_0BNP_;(\;7GPQ^'_P #O$UDV)]-U*WD^8\$&(@@
M_@35[_@I%KEMXH_9K\-:I93+-:75ZLL<BG@@Q'^N:YL/3E'$4Y+X92?WZF-*
M+4X/NS\L^>XQ24\KCJ<TFT5^@GTHVBG$4VK("BBB@ HHHH *^UO^"4O_ "7O
M7?\ L S?^CH:^*:^UO\ @E+_ ,E[UW_L S?^CH:\K-/]SJ>AQXK^!(_6"BBB
MORD^3"BBB@ HHHH **** "BBB@ HHHH *X[4/^2I:5_UX2?S:NQKCM0_Y*EI
M7_7A)_-J .QHHHH **** "BBB@!HQ1UJGJE]_9^FW5V%W^1$TNW.-V 3C/;I
M7S1^Q#^VT?VRK+Q;<_\ "&?\(A_8,EM'M_M7[=Y_FB0YSY,6W'E^^<]L417.
MVH]%=B;Y4F^I]2T4E-=@JDDX YI#/-KS]HCX?V/QFLOA1+K_ /Q<"[@^U1:/
M'97$G[O8TFYI5C,2?*C'#.#T]1GTK.*_.']A"-OCS^VS\=OC7*WGZ=9S?V-I
M4O5'C9@B,I]1!;)_W]K]'>YH7P1;W:NQ/2<H]G8?1113&%%%% !1124 -=E4
M98X Y-5K"^MM4LX+NSN(KJUG0213PN'212,AE8<$$=Q7PE_P6,\7:UX9_9T\
M/0:1J][ID&J:\ME?K9SM$+J VT[&*3:1N0E5)4\' KZ?_9-_Y-=^$G_8IZ7_
M .DD=$%S1<NS"7NM+NCUJBBDH 6BBB@ HHHH **3-% "T4E+0 4444 %%%%
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M^%MS;,K+%I7V1MO9X9'B8?7*&BBK0J26]TOP'5_Y=KIJ_F?0M<1\8OA+X?\
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M:9X\T"VU;2YUGMYD#?*<E21T-<)^T+\$[#XO>$I8O)4ZK;JS6T@'.[TKX[^
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M^2<^;]X\L>/>O=KC_@F#\9+.UDGEN_#(2-2Y_P!-?H/^ 5Y7\4OV4_&_P?\
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MA(.?.?(#$?<4X^\<I[E^P;^QCIW[*/P[\S45AO?'^LQK)K&H)\PA'5;:(_\
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M\_X(7^KV6_\ /K\7_F?,G_#*=S_T-,?_ (+#_P#'J;_PRK=?]#3'_P""P_\
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MKZ?_ ++'I^E)_9H]/TH_M?&_S_@@_P!7LM_Y]?BSYA_X9?OO^AFB_P#!:?\
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M15H_M?&_\_/P7^0O]6\L_P"?7XO_ #/EX?L/D_\ ,Z_^4K_[=3A^P[_U.O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110!A^,O^07%_UV'_ *":*/&7_(+B_P"NP_\ 0317//<ZH?"C
M0^&?_'KKO_86G_DM=E7&_#/_ (]==_["T_\ ):[*N<[@HHHH **** /G#_@H
ME_R9E\3A_P!.4/\ Z415Y1_P1[/_ !B8X_ZC]Y_Z#%7TW^T5\'S\?/@QXG\
MC5QH7]MP+#_:'V;[3Y.V1'SY>]-WW,?>'6N5_8]_9E'[)_PE;P3_ ,))_P )
M5G4)K[[?]A^Q_P"L"#9Y?F2=-G7=SGI4T_=E._5*PJOO1@ET;;^ZQZ'\5OAA
MH/QF^'NN^#/$EJ+O1]6MVMYEXW(>JR(>SHP#*>Q45^#/Q/\ ^$]_9$_X6O\
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M7,2N??RQ]*]0\$_\$K?A)X1\'^)[*ZDOO%/BG7M/N+(^)M>VW$EF\L94S01
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M .UUX_\ %T-_X0TK2O!6D(TD.IVOG+-N>3%O ^YV5G\L.S%<#Y>@R*\QTO\
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MY9>,O!O@C^Q/$5H9?)NX]5OI%3S$9''E/.T9!5B,%<#J,$"BF^52A+9N_P"
MZGO*+6ZT_$_//XO:?XH_X)P_MR7'Q/M='GU+X>>)KF>3=",)-#<-YD]KNZ++
M&XWHIZA$[;L?<>D_\%,/V<]2\,+K+_$**P 0-)876GW(NXV('R>6L9+$9QE-
MR^^.:^CO$GA/1?&FBW.C^(-(L=:TFZ7;/8ZA;I/!*,YPR."#SSR*^>KW_@FM
M^S7J&J/J$OPOM5G9MY2#4KZ*'/M$DX0#V"XJ(WY%!]-GY#E:4N?J]SXX\/\
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M%%AJ'BGXW^-+:>UOO$D;0Z9]J39+<QRRB:>Z*GHKLJ!3W 8C@@GZE\ _L"_
M#X::PFJ:#\,M*2^C8/%-J4D^H^6P.0R"YDD"L",@@ BOH%>.*J-H-R6K:MZ$
MRO**B]%>_KV)****104444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% 'GU]_P E.NO^P<O_ *&*UVK(OO\
MDIUU_P!@Y?\ T,5L;1773^$\VM\9&U,J?:*:RCTK4Q("*:5]JL;11M% %7R_
M:FF+VJV5HV4 4-F9"@'(&>G%'V>K^RD\N@#/:WH\CVK0\L4>4* ,YK<^E-^S
M^U:?E^U'EGTH S/L_M2&U/\ =Q6IY9]*/+/I0!E?8SZ4?9?]FM7RSZ4GD^U
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M.:4/<ES+?\O0;=X\@B(L:JJ@!5&  , "I***8@I*6B@ HHHH **** "BBB@
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M>KVZBC^TL;_S^E_X$_\ ,/[)R_\ Y\1_\!7^1XC_ ,,5_!S_ *%!O_!G=_\
MQZC_ (8K^#G_ $*#?^#.[_\ CU>W44?VEC?^?TO_  )_YA_9.7_\^(_^ K_(
M\1_X8K^#G_0H-_X,[O\ ^/4?\,5_!S_H4&_\&=W_ /'J]NHH_M+&_P#/Z7_@
M3_S#^R<O_P"?$?\ P%?Y'B/_  Q7\'/^A0;_ ,&=W_\ 'J/^&*_@Y_T*#?\
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MT4;1110 ;11M%%% !M%&T444 &T4;1110 ;11M%%% !M%&T444 &T4;1110
M;11M%%% !M%&T444 &T4;1110 ;11M%%% !M%&T444 &T4;1110 ;11M%%%
M!M%&T444 &T4;1110 ;11M%%% !M%&T444 &T4;1110 ;11M%%% ',>)%'_"
M4^&O]^;_ -!6NGVBN9\2?\C3X:_WYO\ T%:Z:H6[-);1_KJ&T4;1115F8;11
MM%%% !M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %<SX._P"/[Q!_U_O735S/@[_C^\0?]?[U'5%P^%G344459 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0!A^,O\ D%Q?]=A_Z":*/&7_ ""XO^NP_P#0317//<ZH?"C0^&?_ !ZZ[_V%
MI_Y+795QOPS_ ./77?\ L+3_ ,EKLJYSN"BBB@ HHHH **** "BBB@ HHHH
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M "14_7L+_P _8_>O\P^L4?YU]Z/G.BOHS_AWG^T%_P!$_/\ X.+#_P"2*/\
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MBBBL#(**** "BBB@ HHHH **** "N.U#_DJ6E?\ 7A)_-J[&N.U#_DJ6E?\
M7A)_-J .QHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#S^\_P"2G7?_
M &#E_P#0Q6U6+>?\E.N_^P<O_H8K:KKI_">;6^,****U,0HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@#F?$G_(T^&O]^;_ -!6NFKF?$G_ "-/AK_?F_\ 05KIJA;LTEM'
M^NH44459F%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !7,^#O^/[Q!_U_O735S/@[_C^\0?\ 7^]1U1</A9TU%%%60%%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MM0_Y*EI7_7A)_-J .QHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MXOCT-=8@?3-2NR^I32;[6 .HS@8)R.>/U%=!_P +,A_Z .M_^ @_^*H^&?\
MQZZ[_P!A:?\ DM=E7.=QQO\ PLR'_H ZW_X"#_XJC_A9D/\ T =;_P# 0?\
MQ5=E10!QO_"S(?\ H ZW_P" @_\ BJ/^%F0_] '6_P#P$'_Q5=E10!QO_"S(
M?^@#K?\ X"#_ .*H_P"%F0_] '6__ 0?_%5V5% '&_\ "S(?^@#K?_@(/_BJ
M/^%F0_\ 0!UO_P !!_\ %5V5% '&_P#"S(?^@#K?_@(/_BJ/^%F0_P#0!UO_
M ,!!_P#%5V5% '&_\+,A_P"@#K?_ ("#_P"*H_X69#_T =;_ / 0?_%5V5%
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MF0_] '6__ 0?_%5V5% '&_\ "S(?^@#K?_@(/_BJ/^%F0_\ 0!UO_P !!_\
M%5V5% '&_P#"S(?^@#K?_@(/_BJ/^%F0_P#0!UO_ ,!!_P#%5V5% '&_\+,A
M_P"@#K?_ ("#_P"*H_X69#_T =;_ / 0?_%5V5% '&_\+,A_Z .M_P#@(/\
MXJC_ (69#_T =;_\!!_\57944 <;_P +,A_Z .M_^ @_^*H_X69#_P! '6__
M  $'_P 57944 <;_ ,+,A_Z .M_^ @_^*H_X69#_ - '6_\ P$'_ ,57944
M<;_PLR'_ * .M_\ @(/_ (JC_A9D/_0!UO\ \!!_\57944 <;_PLR'_H ZW_
M . @_P#BJ/\ A9D/_0!UO_P$'_Q5=E10!QO_  LR'_H ZW_X"#_XJC_A9D/_
M $ =;_\  0?_ !5=E10!QO\ PLR'_H ZW_X"#_XJC_A9D/\ T =;_P# 0?\
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M  $'_P 51_PLR'_H ZW_ . @_P#BJ[*B@#C?^%F0_P#0!UO_ ,!!_P#%4?\
M"S(?^@#K?_@(/_BJ[*B@#C?^%F0_] '6_P#P$'_Q5'_"S(?^@#K?_@(/_BJ[
M*B@#C?\ A9D/_0!UO_P$'_Q5'_"S(?\ H ZW_P" @_\ BJ[*B@#C?^%F0_\
M0!UO_P !!_\ %4?\+,A_Z .M_P#@(/\ XJNRHH XW_A9D/\ T =;_P# 0?\
MQ5'_  LR'_H ZW_X"#_XJNRHH XW_A9D/_0!UO\ \!!_\51_PLR'_H ZW_X"
M#_XJNRHH XW_ (69#_T =;_\!!_\51_PLR'_ * .M_\ @(/_ (JNRHH XW_A
M9D/_ $ =;_\  0?_ !5'_"S(?^@#K?\ X"#_ .*KLJ* .-_X69#_ - '6_\
MP$'_ ,51_P +,A_Z .M_^ @_^*KLJ* .-_X69#_T =;_ / 0?_%4?\+,A_Z
M.M_^ @_^*KLJ* .-_P"%F0_] '6__ 0?_%4?\+,A_P"@#K?_ ("#_P"*KLJ*
M .-_X69#_P! '6__  $'_P 51_PLR'_H ZW_ . @_P#BJ[*B@#C?^%F0_P#0
M!UO_ ,!!_P#%4?\ "S(?^@#K?_@(/_BJ[*B@#C?^%F0_] '6_P#P$'_Q5'_"
MS(?^@#K?_@(/_BJ[*B@#C?\ A9D/_0!UO_P$'_Q5'_"S(?\ H ZW_P" @_\
MBJ[*B@#C?^%F0_\ 0!UO_P !!_\ %4?\+,A_Z .M_P#@(/\ XJNRHH XW_A9
MD/\ T =;_P# 0?\ Q5'_  LR'_H ZW_X"#_XJNRHH XW_A9D/_0!UO\ \!!_
M\51_PLR'_H ZW_X"#_XJNRHH XW_ (69#_T =;_\!!_\51_PLR'_ * .M_\
M@(/_ (JNRHH XW_A9D/_ $ =;_\  0?_ !5'_"S(?^@#K?\ X"#_ .*KLJ*
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M5J:K':/'Y#6X$K9)Y"YY%>JUQVH?\E2TK_KPD_FU "?\+,A_Z .M_P#@(/\
MXJC_ (69#_T =;_\!!_\57944 <;_P +,A_Z .M_^ @_^*H_X69#_P! '6__
M  $'_P 57944 <;_ ,+,A_Z .M_^ @_^*H_X69#_ - '6_\ P$'_ ,57944
M<;_PLR'_ * .M_\ @(/_ (JC_A9D/_0!UO\ \!!_\57944 <;_PLR'_H ZW_
M . @_P#BJ/\ A9D/_0!UO_P$'_Q5=E10!QO_  LR'_H ZW_X"#_XJC_A9D/_
M $ =;_\  0?_ !5=E10!QO\ PLR'_H ZW_X"#_XJC_A9D/\ T =;_P# 0?\
MQ5=E10!QO_"S(?\ H ZW_P" @_\ BJ/^%F0_] '6_P#P$'_Q5=E10!QO_"S(
M?^@#K?\ X"#_ .*H_P"%F0_] '6__ 0?_%5V5% '&_\ "S(?^@#K?_@(/_BJ
M/^%F0_\ 0!UO_P !!_\ %5V5% '&_P#"S(?^@#K?_@(/_BJ/^%F0_P#0!UO_
M ,!!_P#%5V5% '&_\+,A_P"@#K?_ ("#_P"*H_X69#_T =;_ / 0?_%5V5%
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M_P#@./\ &C_A.H_^@1JO_@./\:Z:BC7N'-'L<S_PG4?_ $"-5_\  <?XT?\
M"=1_] C5?_ <?XUTU%&O<.:/8YG_ (3J/_H$:K_X#C_&C_A.H_\ H$:K_P"
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MZC_Z!&J_^ X_QH_X3J/_ *!&J_\ @./\:Z:BC7N'-'L<S_PG4?\ T"-5_P#
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M (3J/_H$:K_X#C_&NFHHU[AS1[',_P#"=1_] C5?_ <?XT?\)U'_ - C5?\
MP''^-=-11KW#FCV//=:\5)=:]HEP-.OXQ;M(3')#AWR!]T9YQBMS_A.H_P#H
M$:K_ . X_P :/$G_ "-/AK_?F_\ 05KIJE)W>I<G&RT.9_X3J/\ Z!&J_P#@
M./\ &C_A.H_^@1JO_@./\:Z:BJU[D<T>QS/_  G4?_0(U7_P''^-'_"=1_\
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M'L<S_P )U'_T"-5_\!Q_C1_PG4?_ $"-5_\  <?XUTU%&O<.:/8YG_A.H_\
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MH_X3J/\ Z!&J_P#@./\ &NFHHU[AS1[',_\ "=1_] C5?_ <?XT?\)U'_P!
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M'L<S_P )U'_T"-5_\!Q_C1_PG4?_ $"-5_\  <?XUTU%&O<.:/8YG_A.H_\
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MH_X3J/\ Z!&J_P#@./\ &NFHHU[AS1[',_\ "=1_] C5?_ <?XT?\)U'_P!
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M !E_R"XO^NP_]!-%8RW-X\MC0^&?_'KKO_86G_DM=E7&_#/_ (]==_["T_\
M):[*N<[0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBDH 6BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** .3^*7_(B:G_VR_\ 1J5TMG_Q
MZ0?]<U_E7-?%+_D1-3_[9?\ HU*Z6S_X](/^N:_RH GHHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ KCM0_Y*EI7_7A)_-J[&N.U#_DJ6E?]>$G\VH [&BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** //[S_DIUW_V#E_]#%;58MY_R4Z[_P"P
M<O\ Z&*VJZZ?PGFUOC"BBBM3$**** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH YGQ)_R-/AK_
M 'YO_05KIJYGQ)_R-/AK_?F_]!6NFJ%NS26T?ZZA1115F84444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<SX._P"/[Q!_
MU_O735S/@[_C^\0?]?[U'5%P^%G344459 4444 %%%% !1110 4444 %%%%
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MGIN7/Z@D>]=PWKBORV\&>+M9^%?C6WU2RWVM_8S&.>W?@.H.'B<>AP0?3KU
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M%_B=\-]+\0ZCJ6L6UY<M,KQVLL0C&R5D& T;'HH[UWO_  POX)_Z#/B#_O\
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M;5V-<=J'_)4M*_Z\)/YM0!V-%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 >?WG_ "4Z[_[!R_\ H8K:K%O/^2G7?_8.7_T,5M5UT_A/-K?&%%%%:F(4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110!S/B3_ )&GPU_OS?\ H*UTU<SXD_Y&GPU_OS?^
M@K735"W9I+:/]=0HHHJS,**** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "N9\'?\?WB#_K_ 'KIJYGP=_Q_>(/^O]ZCJBX?
M"SIJ***L@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M#PV/"PU06K2M]I.H>5OWR,_W?*;&-V.O:NP_X;Z?/_(C#'_86_\ M-9WP/\
MV5_"_P 3OAOI?B'4=2U>VN[EIE>.UEB$8V2L@P&C8]%'>N^_X87\$?\ 09\0
M?]_X/_C->GBJF3JO-58/FN[[[]>I\_E]'B*6%IO#U$H65MMNFZ)/A+^UPWQ1
M\>:?X;/A4:9]K$A^TC4/.V[(V?[OE+G.W'7O7T5G\:\5^'?[*?A?X9^+K/Q#
MINI:O<W=J'"1WDL31_,C*<A8U/1CWKVI1P.:^6QTL+*HGA%:-OQU[W/O<ICF
M$:,EF,DYWTM;:R[)=;BMT;Z5^57CK_D=?$/_ &$;C_T:U?JJW1OI7Y5>.O\
MD=?$/_81N/\ T:U?0\-?Q:GHOS/D^-O]VH_XC],OAQ_R('AS_L'P?^BUKI/X
MJYOX;_\ (@>'/^P?!_Z+6ND/6ODJW\27JS[["?[O3]%^054U+48-)T^ZOKIQ
M%;6T332N?X54$D_D*M?=KS;]HJZDL_@CXN>([7-GLS[,RJ?T)I4H>TJ1AW:1
M=:I[*E*IV3?W'RJUYXO_ &O/B-<6<=[)I_AZV)D6-LF"TASA24!&^5O?KSR
M./4M2_84\/MH[K8>(=3CU0)\LMR(WA+8[HJA@/\ @1Q[TW]A&SB7PCXFNPG[
M^2]2)F]56,$#\W;\Z^H:^DS#&U<'7^K89\L86VZZ7N^Y\3E&64,RPRQN.7/.
M=WK?17:278^-OV9_B1K_ ,/_ (E2_#7Q',\ELTLEM"DSEOLTR D*A/\  X!X
MZ9*D8R<]7^UA\=M4\,WEOX,\,W$EOJ5U&KWEU#GS45N$BC(Z,W4D<X(QUKZ(
MC\*Z-#K$FJ)I-BNJ2D%[U;=!,Q P"7QD\ #K7Q7K48UO]M#R[LF1%UJ,*&](
MT4J/I\HJL+.CC\6Z\J=N6-VNC:ZD8ZGB<IP'U:G4;YYJ*?6,7TN=KX#_ &)(
MM2TA+[QGK-['J=POFO:Z>R Q$\X>1U;<WK@ 9SR>M<E\5O@'KW[/<D/C#P=K
MEY-802!9)>$GMLD ;\?+(A/!X Y (Q7W$HXZ_A7(_%RQAU+X6^++>==\3:9<
M-CW$;,/U KCIYOB763F[Q>ZMI;L>C5X=P4<,XTU::6DKN]^]S#^ OQ67XN>!
M8-3E18=3MV-M?0I]T2@ [E_V6!!'IDCG%?'7Q@U/5-%_:5URZT3<=734%6TV
MJ&;S&C55P#U.3Q[UZK^P7-)YWC.'=^[46C!?^_PS^E<GJ4,=Q^VMLD0.HUE&
MV^XB4@_@0#7MX6C'!YAB(Q7NJ+=O6SL?,XW$5<QR;"RG*TG42OYJZOZG=^'_
M -B@:U:-J/C/Q-?3ZY=#S9A:[2$8]0TCAC(??C^M>1>-_"GB+]E/XE:?=:7J
MK7$$J^?!,H*+<1!L/%*F2#VS]01@]/T'Z=^E?(O[>8'G>#R!SBYS^<=<.6YA
M6Q.*5&L[PE=6LK;=#U,YR?"X/ 2Q-!-3A9J5W>]U>Y]0Q>*[%O"(\1/+Y6G?
M8_MID;M'LWY_*OBAKWQE^UY\0Y[&&[?3_#ULWF^6V3#:0YPI*@C?*??J<\@#
MCW;Q_=26G['X>+AFT&SB)_V6$2G]":P/V%-/AC\"^(+U5Q<3:EY+MZJD2%1^
M;M^=9X6,,)0K8J*O)/EC?IYFV.J3S#$87 SDU"<>:5M+Z7L)<?L)^&GTMEM_
M$.K1ZCL^6:41/"&]?+"@X]M_XUYK\/\ QYXI_9F^)H\(^)+EI] :54=&<M''
M&Y^6>(G[H[E>^"",@$?<I_.OC;]O*UC7Q%X3N0N)9+:>,MZA70@?^/'\ZO+L
M94QM;ZKBGS1G??H[7NB<XRVAEF&^O8)<DZ=MKZJZ5GW/?/VE&$GP+\5D'(^R
MK_Z,2OD3X _"_4OC:9-!N=4FT_PKI4OVN=(,;GEE 4!0>-Q6,_,0<#/'-?2W
MQ)O)=0_9)GN9VW3S:):R.WJQ\HD_F:YG]A.T1? >OW(_UDFI&,\=EB0C_P!#
M-&%J/"X"O*'Q*5D_/0RQ])9AFF%C4^&46VN_6QIZ/^Q;X2TFXU '4]3NK2\M
M?LVV5H_,A.]6+JX0#)"[?N]":^;KCX4Z/'^T1_P@JS7?]D?;EMO,\Q?/VE V
M=VW&<_[-?HQTKX;O/^3V#_V%U_\ 1(K3*<9B*TZO/-NT&_FA9]EF$P]&@J5-
M*]2*^3W1]4?"GX0Z/\'])O-/T:>\GANIO/<WDBNP;:%XVJO&!7=T>E!]J^5J
M5)U).<W=L^[HT:>'IJG25HK9(1FV_2OE7]IOXE:CXZ\2VOPI\(9N;NXF5-0D
MB;@MU$1(Z*H&YSVQ[&O5?VC?BQ)\)_ $EW9H6U6^<VEFV,K&Y4DR'_= ) [G
M%?/O[-/CKX;_  [MKWQ!XF\1,_BR_9@P:TN)3!&6R1N6,@LY^8D$\8'KGW,N
MPLHP>,<'+E^%)-W??3HCY;.LP@ZL<N510<E>3;2M'LK]6=_\:/AM8?"O]EF]
MT.Q&]DEMI+BXQAIIC*FYS^6 .P %;7[%)'_"GY!T;^T9OY)7)?M&?M > _'W
MPHU31M"UPWNI32P,D)LYX]P656;YGC Z ]ZS_P!E_P"./@GX>_#EM*U_6OL&
MHO>R2"'[)-)\K!0#E$(['O7<Z&*J9;/GC)R<[VL[[;V/*6*P-#.:/LJD53C3
MM>ZMN]+WW/K^BFJP90PY!&13J^1/T8**** "BBB@ HHHH **** "BBB@#D_B
ME_R(FI_]LO\ T:E=+9_\>D'_ %S7^5<U\4O^1$U/_ME_Z-2NEL_^/2#_ *YK
M_*@">BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH ;24<5\P_M<?M#6_@O1I_#>D7"/JMRA6;&#A".E=N#
MP=7'UHT:2U?X>9YV.QU++Z$J]5Z+\7V/IWS4_OK^='FJ?XU/XU^6G@W]F'QU
M\1M+&L064D%M/\\;.GWP>XK>_P"&)?'W_/(_]^Z^GED.#IR<)XQ)KR_X)\G3
MXBQM2*G#!-I^?_ /TM\Q?[R_G1YB_P!Y?SK\TO\ AB7Q]_SR;_OW1_PQ+X^_
MYY-_W[J/[$P/_08ON_X)?]OX_P#Z I??_P  _2WS%_O+^='F+_>7\Z_-$_L3
M^/E_Y8,?^V='_#$_C_\ YX'_ +]T_P"P\#_T&K[O^"']OX__ * I??\ \ _2
M[S$_O+^='F)_>7\Z_-'_ (8G\?\ _/ _]^Z/^&)_'_\ SP/_ '[H_L/ _P#0
M:ON_X(?ZP8__ * G]_\ P#]+O,3^\OYT>8G]Y?SK\T?^&)_'_P#SP/\ W[H_
MX8G\?_\ / _]^Z/[#P/_ $&K[O\ @A_K!C_^@)_?_P  _2[S%_O+^='F+_>7
M\Z_-+_AB7Q]_SQ;_ +]T?\,2^/O^>3?]^Z7]B8+_ *#%]W_!#^W\?_T!2^__
M (!^EWFI_?7\Z/-3^^/SK\T?^&)?'W_/(_\ ?NC_ (8E\??\\F_[]T?V)@?^
M@Q?=_P $/[?Q_P#T!/[_ /@'Z7>8G3</SI?2ORI\;? ?QM\%UMM<O+*0VL+J
MWV@)\J-GC-?;_P"R_P#'ZW^*WAN.SO9T&M6J 2+TWCH"!7+CLC^K4%B</552
M'5I6M^+.S+\_^M8AX7$TG2GT3=[_ ((]YHHHKY@^N"BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "N.U#_DJ6E?]>$G\VKL:X[4/^2I:5_UX2?S:@#L:*** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH \S\0:K:Z%XXU;4;Z7R+*ST@W$\FTMLC0[F. "3@
M\ 9KDO\ AJ#X9?\ 0S?^2%U_\:J]\9.8?'?_ &*UU_Z+:OSUR:^LR;+:6.IR
M=1M6?2W^3/SOB3.<1E=:$*44U)7U3_0^^_\ AJ#X9?\ 0R_^2%U_\:H_X:@^
M&7_0R_\ DA=?_&J^ LGGFDW'UKZ#^P,-_-+[U_D?'_ZVX[^2/W/_ #/O[_AJ
M#X9?]#+_ .2%U_\ &J/^&H/AE_T,O_DA=?\ QJOS_P!S>II-S?WC^=']@X;^
M:7WK_(K_ %NQW\D?N?\ F?H#_P -0?#+_H9?_)"Z_P#C5'_#4'PR_P"AE_\
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M_P"2%U_\:K\[O,E_YZO_ -]&D\R;_GJ__?1H_L/#?S2^]?Y!_K3COY8_<_\
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M/_,_1K_AJ#X9?]#+_P"2%U_\:H_X:@^&7_0R_P#DA=?_ !JOSD\VX_Y[2?\
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M^9^C_P#PU!\,O^AE_P#)"Z_^-4?\-0?#+_H9?_)"Z_\ C5?G!YUS_P ]Y?\
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MG!YEU_SWF_[[/^-+YEQ_SWE_[[/^-']B8;O+[U_D#XIQS27+'[G_ )GZ/?\
M#4'PR_Z&7_R0NO\ XU1_PU!\,O\ H9?_ "0NO_C5?G#YES_SWF_[[-'F7/\
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M--/_ "PNO^^%_P#BJ7_A86G9QY-U_P!\+_\ %5YVGWJ>/O5/U>F4L;5/0_\
MA/K#_GC=?]\K_P#%4O\ PGEA_P \+G_OE?\ XJO/UJ1>E'U>!?URJ=[_ ,)Y
M8M_RQN?^^5_^*H_X3JP_YXW/_?*__%5PBTM3]7@/ZY4.[_X3JQ_YXW'_ 'RO
M_P 56#X6\66EO>:VS1S$27KN,*.GOS6+6=H?^OU+_KX:I="%T:1Q=2S/3/\
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M9Y3!X:A256";Y7=)I/6SOOJ9/@[XH^*_B]^TEGP_K.I6WA:.X$KVPD80BUB
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N.U#_DJ6E?\
M7A)_-J[&N.U#_DJ6E?\ 7A)_-J .QHHHH **** "BBB@ HHHH **** "BBB@
M HHI* %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MN=6MGNX&T2VMY45%?80YEGC(.?0&E+W6D]V*/O*ZU/I.BOS_ /\ A]5\$/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M9TW#=O5D-^TDG;1;'Y#?L5_\I5/B/_V$/$'_ */:OU\K\@_V*_\ E*I\1_\
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MIX-_;6_9OTGXS_VQJFG)H?A6_P!:TZUM/**R,T E,4VY2<J\(0[2/XJ^0/\
M@G1^PMX6_:<\)ZOXPUSQ!K&E7^A:TEO!!I_E>5(%CCE!;>A.<G'!'%?JI^TE
MI]KI'[,/Q/M+*VAM+2+PKJ:QPV\81$'V67@*!@"OD#_@BB/^+(>.S_U,0_\
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MFENFU?RZ"<5"M%);JY^57PWL?C?_ ,%3/&GBO5+WX@7GP^^&&FS?9A86 D:
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M3\11ZQ\-?%5U#9JD=TMPFV=-UL2RDCS(I6\O=U*DYZU^LVN>"?#WBB:*;6M
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M.%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MIC\.6UPNIZY>R_;-7U0)M^T3[0 J \B-!\J@^YZL:\2_;_\ V!-4^/VK:?\
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M_CI_PI/[6M/^>O\ XZ?\*7M(=P]E/^4N453_ +6M/^>O_CI_PH_M:T_YZ_\
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M2_VE;_\ /3_QT_X4<\.X>SG_ "EFBJ_]H6__ #T_\=/^%']H6_\ ST_\=/\
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M^P=3_P"@==_]^&_PJ7.'<OV<^Q46GK5M=!U/_H'77_?AO\*>-#U+'_(/NO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?\UKU7X!?\%!/@U^T;K4&A^'=>N-*\23@M#HNNV_V:XFQR1&P+1NV,G:KEL
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MB:)__':B^MNI5G:Y]R4E>)_L^_M@?"W]IJ*9/!'B)9]5MX_-N-&OHS;WL*\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M<G\4O^1$U/\ [9?^C4KI;/\ X](/^N:_RKFOBE_R(FI_]LO_ $:E=+9_\>D'
M_7-?Y4 3T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %)2T4 (:\#_ &H/@#!\5/#DM]8P*NM6ZEE*)N:4 ?=
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MC[O>N7&9S5Q=%8>,5""Z+J=> R*E@Z[Q,YN<GU?0?1117SY].%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %<=J'_)4M*_Z\)/YM78UQVH?\E2TK_KPD_FU '8T444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110!Y_>?\E.N_P#L'+_Z&*V*Q[S_ )*==_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MF%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !7,^#O^/[Q!_U_O735S/@[_C^\0?\ 7^]1U1</A9TU%%%60%%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KCM0_Y*EI7_7A)_-J
M[&N.U#_DJ6E?]>$G\VH [&BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M //[S_DIUW_V#E_]#%;58MY_R4Z[_P"P<O\ Z&*VJZZ?PGFUOC"BBBM3$***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH YGQ)_R-/AK_ 'YO_05KIJYGQ)_R-/AK_?F_]!6N
MFJ%NS26T?ZZA1115F84444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %<SX._P"/[Q!_U_O735S/@[_C^\0?]?[U'5%P^%G3
M44459 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110!A^,O\ D%Q?]=A_Z":*/&7_ ""XO^NP_P#0317//<ZH
M?"C0^&?_ !ZZ[_V%I_Y+795QOPS_ ./77?\ L+3_ ,EKLJYSN"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** .3^*7_(B:G_ -LO_1J5TMG_ ,>D'_7-?Y5S7Q2_Y$34
M_P#ME_Z-2NEL_P#CT@_ZYK_*@">BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N.U#_
M )*EI7_7A)_-J[&N.U#_ )*EI7_7A)_-J .QHHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@#S^\_Y*==_P#8.7_T,5M5BWG_ "4Z[_[!R_\ H8K:KKI_
M">=6^,****U, HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@#F?$G_(T^&O]^;_T%:Z:N9\2
M?\C3X:_WYO\ T%:Z:H6[-);1_KJ%%%%69A1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 5S/@[_C^\0?\ 7^]=-7,^#O\
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M% '&_P#"NYO^AGUO_P "C1_PKN;_ *&?6_\ P*-=E10!QO\ PKN;_H9];_\
M HT?\*[F_P"AGUO_ ,"C7944 <;_ ,*[F_Z&?6__  *-'_"NYO\ H9];_P#
MHUV5% '&_P#"NYO^AGUO_P "C1_PKN;_ *&?6_\ P*-=E10!QO\ PKN;_H9]
M;_\  HT?\*[F_P"AGUO_ ,"C7944 <;_ ,*[F_Z&?6__  *-'_"NYO\ H9];
M_P# HUV5% '&_P#"NYO^AGUO_P "C1_PKN;_ *&?6_\ P*-=E10!QO\ PKN;
M_H9];_\  HT?\*[F_P"AGUO_ ,"C7944 <;_ ,*[F_Z&?6__  *-'_"NYO\
MH9];_P# HUV5% '&_P#"NYO^AGUO_P "C1_PKN;_ *&?6_\ P*-=E10!QO\
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M  *-'_"NYO\ H9];_P# HUV5% '&_P#"NYO^AGUO_P "C1_PKN;_ *&?6_\
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M"C7944 <;_PKN;_H9];_ / HT?\ "NYO^AGUO_P*-=E10!QO_"NYO^AGUO\
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M?\*U_P"IAUC_ ,"*[;(HR*+L.5=CB?\ A6O_ %,.L?\ @11_PK7_ *F'6/\
MP(KMLBC(HNPY5V.)_P"%:_\ 4PZQ_P"!%'_"M?\ J8=8_P# BNVR*,BB[#E7
M8XG_ (5K_P!3#K'_ ($4?\*U_P"IAUC_ ,"*[;(HR*+L.5=CB?\ A6O_ %,.
ML?\ @11_PK7_ *F'6/\ P(KMLBC(HNPY5V.)_P"%:_\ 4PZQ_P"!%'_"M?\
MJ8=8_P# BNVR*,BB[#E78XG_ (5K_P!3#K'_ ($4?\*U_P"IAUC_ ,"*[;(H
MR*+L.5=CB?\ A6O_ %,.L?\ @11_PK7_ *F'6/\ P(KMLBC(HNPY5V.)_P"%
M:_\ 4PZQ_P"!%'_"M?\ J8=8_P# BNVR*,BB[#E78XG_ (5K_P!3#K'_ ($4
M?\*U_P"IAUC_ ,"*[;(HR*+L.5=CB?\ A6O_ %,.L?\ @11_PK7_ *F'6/\
MP(KMLBC(HNPY5V.)_P"%:_\ 4PZQ_P"!%'_"M?\ J8=8_P# BNVR*,BB[#E7
M8XG_ (5K_P!3#K'_ ($4?\*U_P"IAUC_ ,"*[;(HR*+L.5=CB?\ A6O_ %,.
ML?\ @11_PK7_ *F'6/\ P(KMLBC(HNPY5V.)_P"%:_\ 4PZQ_P"!%'_"M?\
MJ8=8_P# BNVR*,BB[#E78XG_ (5K_P!3#K'_ ($4?\*U_P"IAUC_ ,"*[;(H
MR*+L.5=CB?\ A6O_ %,.L?\ @11_PK7_ *F'6/\ P(KMLBC(HNPY5V.)_P"%
M:_\ 4PZQ_P"!%'_"M?\ J8=8_P# BNVR*,BB[#E78XG_ (5K_P!3#K'_ ($4
M?\*U_P"IAUC_ ,"*[;(HR*+L.5=CB?\ A6O_ %,.L?\ @11_PK7_ *F'6/\
MP(KMLBC(HNPY5V.)_P"%:_\ 4PZQ_P"!%'_"M?\ J8=8_P# BNVR*,BB[#E7
M8XG_ (5K_P!3#K'_ ($4?\*U_P"IAUC_ ,"*[;(HR*+L.5=CB?\ A6O_ %,.
ML?\ @11_PK7_ *F'6/\ P(KMLBC(HNPY5V.)_P"%:_\ 4PZQ_P"!%'_"M?\
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M,XZ\CK17=T4AA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1124 +1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%)2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%)0 M%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 -H_AKC/B]\4=+^"
M_P -=?\ &VMV]Y=:3HEL;JYAL$1YW4$#"!V52>>["OC7_A]1\$0>?"WC_P#\
M%]C_ /)E1=7:[#L[7/OZBO@2W_X+2? ^:9$?PYX\@5C@R2:=9E5]SMNR?R%?
M3WP'_:J^&7[2EG=2^ O$T.J7-HH:ZTZ:-[>[@!Q\S1. Q7) WKE<\9S6G*WJ
M2VEN>NBEKQ7]J#]JCPI^R;X0TKQ)XNT[6=1L=1OQI\4>BP0RRK(8WDRPEEC
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M%%% !1110 4444 ,Q2]Z3(YKP3PK^V1X,\6?M*ZS\$;/2]=3Q7I2223WDT$
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MG+PVD4C ><YERTC   %L[<JM73B_;1?1;^@3:]E)/JM/4]T_X+5_\F^^"?\
ML9D_]);BO=?V8?V??A=K7[-_PNU#4/AMX1O[ZZ\,:;/<75UH-K)+-(UK&6=V
M:,EF))))Y)->%?\ !:O_ )-]\$_]C,G_ *2W%?6W[)G_ ":[\)/^Q4TO_P!)
M(Z=/^'/_ !+\@J;T_1_F8WCO]BKX'?$+0;K2]0^%_AFT2=-GVS2=,AL;J+T9
M)H55@0><9QZ@CBOSP^ -]XA_X)X_MVM\)M1U6:^^'_BFYAAA:; 65)R5L[K
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M=X<K>S=OG:Y[SX-_:F^%?C[6?&FF:-XOMY+KP:S+K[7D$UG#8;7=&+RSHD9
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M%;:V\C].?C5^T+\/_P!G;1=/U;XA:_\ \(_8:A<&TMIOL5Q<[Y I;;B&-R.
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M1O?2)%$J X+(JESMQR"5/Z!?L=_LVVO[+/P3TWP:MTE_JC2-?:I?1 A)[N0
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M]O?"Y5(Y+5Y&MI'!.XQRH"-WS#:N3G)-1LYJ#Z[$ROR.:Z:M>1Z]_P %MO\
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M!.%!X%:G[6A_XQ=^+'I_PBVI?^DTE?G'_P %1/V9/A+\"M#\,^,/ATMKX/\
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MHYFB0-RC#Y2>E?$?_!93X6^$/"WAOPAXGTCPYIVF^(-8U>X_M'4[:!4GN\1
MCS''+<^M??'P.^"?@+X7>%[6_P#"'A'2/#=[J6GVXO)]-M5A>XP@8;R!\W+$
M\^IKE@[4IM_T[&U3XX6[:>E]3RK]BO\ X9C_ +8\9_\ #/O_ !_XMO[<_P"0
MGTW2^3_Q^\=?-_U?X]J^EO$OBK1?!>AW.LZ_J]EHFDVJYGOM0N$@@B&<99W(
M YXY-?F#_P $63M\9?&;/]S3O_0[JLW]H"37?V_/V^!\&5UFYT[X>>$Y9$NX
M[5QUA4?:I]IX,ID;R5)!"C!QRP.[O*4(1W:OZ+J.249U&]D[>;/LV3_@I+^S
M;'K/]EM\3[0W/F>5YBZ=>F#.<9\X0^7C_:W8]Z]_\)^,-$\=:';:UX=U>QUS
M1[D$P7VG7"3P2X.#M="0<'(/H17@\?\ P3K_ &>(_!Y\/#X9::UN5V_;&EF-
M[G^]]IW^8#GGAL>V.*^)/A"NM_\ !//]OJT^%4.L76H?#CQE+ EO!<L#\MP3
M';RD<*)8Y5\MF &Y03CD $;.2I]7MV]")74746RW7D?I#\4OVC?AW\&?$OAC
MP_XR\0_V/JWB6;[/I-O]BN9_M$F^-"-T4;*GS2H,N5'S>QKG?BU^V?\ !7X&
M:P='\:?$#3M,U96Q+I]O'->W$)P"!)';I(T>001O R#7PQ_P6@O[[2_'WP5O
M-+EDM]3MQ?S6TT1PR2K):E&'N& -?3WP1_X)O_"#P1X-M_\ A+O"]MX]\87T
M0FUC6]>9[EY[A_FD**QVH-S-@@;B,%F)YJ(7E3YWIJU]PY6C/E[JY[G\(_V@
M?AU\>--EO? /B[3?$L<(#3PVLA6X@!) ,D+A9(P<'&Y1G!Q7HHK\>_'_ ,,M
M-_8D_P""E?PSM?AU+/I7A[Q%-8[]/DN'=(H+JX:UG@+,2SIE-XW$X./[H-?L
M&OW15Z2@IK9W^];B=XSY'V3^\QO%OBS2_ OA?5O$6N77V+1]*M9+V\N?*>3R
MH8U+.VU 6; !.%!)["OQG_:#^/7P;^-G_!03PIXRU;7(]=^$UI#:QWEU<:==
M>5MB21S&T#1>8RF4C(V$$,>V:_:#7=#T_P 4:+?:1JUG#J&EWT+VUU:SH&CF
MB<%61@>H()!'O7Y+?%#X'^ -)_X*I>"_ ]GX/T>V\'W4,#3Z&EHHM)";69B6
MCQ@Y90?J*A?QH>NGXFFGLI^FOIIMYGZ'_LR^)_@C\0/#NH^)/@GIN@P:5]I_
MLZ]N]&T(Z67EC57$;JT,3,%64$<$#><=Z?\ %C]LCX+_  1U-].\9?$'2]+U
M2-MDNGP"2\N820"/,B@1W3@@_,!UKQO]M7QEHG[#W[*NKI\+=&T_P;J'B'4%
ML;,:3;K"L4\L9\VX '\8BA(#=B$]*\Y_85_X)V_#^\^%6B?$/XGZ,OC;Q7XE
M@75%BU21Y+>VAE&] 8\XDD96#,TF[!.!C!)OXVW'9::]S/2"CS;O:W9=3ZT^
M$/[6GPA^/%Y]C\#>/-+UK4<$KIS%[6[8 9++!,J2, .I"D"O2_$.O6/A?0]0
MUG4Y_LVG:?;R75S,$9_+B12SMM4$G"@G !/I7YR?\% /V O!_@/X;WOQ;^$E
MA)X)\1^&94U"YM=)FD2*6,.H,L2[OW,D?#@Q[1A6XS@CV[X)_'B\_:*_X)^Z
M[XHU9P^OP^']3T[5)% 'F7$,$BF3 X!==CD#@%R!64YI4ISCO'HRXQ]^,7M+
M3_@'H\/[<?P-N/AF_P 0C\0+2+PD+UM/6\N+2YBDEN$56:..!XA-(0KJ3L0C
M!^M=C\&?VA?AY^T%I5WJ/P^\4VGB2WM&5;E84DBF@+9V^9%(JNH.UL$J,[3C
MI7Y>_P#!*O\ 97\+?'FV\1>)_B#8MXDT'P]<K::5HMW*YLUN9%#SRM$#ACM6
M$8/!SR#M7'ZF?"GX&^!/@?9ZM:> _#=KX:M=4N_MMW#:;MKR[0@(#$[5 7A5
MPHR2!R<]#BHZ/LOT,;WVZ-GH"]Z,X&:/2O-OVBOBU:? SX)^+_&]TR?\2BPD
MEMXY#@2W!&R&/_@4C(OXUSSER1;-HIR:2/SV^*"6W[:W_!3O2_!<\*ZGX&\!
MPR1WT+$-$_DC=<$C_:N'BA([A*O?\$S_ !->_L_?M(_%']G?7[DA/M<EWI?F
MX DFAX8J/66W,<GTBKM?^"/_ ,)[NT^'/BSXM:YOGUKQAJ#QP74W+O;Q.QDD
MS_MS-)GU\L5P'_!3[PWJ7P"_:-^&/[0GAN'9(UQ';7VP[1)/!RJL?^FL!>,^
MT=;17L90IMZ-6EZO6Y$OWRFX[JUOE_F?J;7+>/OB7X5^%>@2:WXP\0:?X;TF
M-MGVK4KA849L$A%R?F8X.%7)..E7O!OBS3_'7A#1O$FE2B?2]6LXKZVD'\4<
MB!U/Y$5^4_\ PCD__!1[_@H!XET?Q-J%V/AKX':XCBLK:3:KPPRK#L1A]UIY
M<NSCYM@P"-JD1RRY_9K1]?1#3C[-U&]-/Q/NSP-^WY^S_P#$SQ)%H&@_$K3Y
M=4F<1PQ7UO<V*R.3@*DEQ$B,Q/  ))SQFOB[]@7_ )2;?'?_ '-;_P#3I#7U
M?\1?^":OP%\<>!9- L?!-GX7NXX2EEK&E,Z74$F,*[L6/G>XDW9]CS7Q)_P2
MI\+:IX'_ &X/B/X=UJ8SZOI6BZA97DQ8MYDL=];(S9/)R03D^M:4>7VWFHO\
M@G?V+[-Q^1^N'B+Q-I/@_1;G5]>U2RT;2K5=\]]J%PD$$2^K.Y"J/J:^=M4_
MX*5?LV:-JDEC<?%"TDG1MI:UTV^N(L^TL<#(1[AL5Y3^W!^RW\6?VJOCOX"T
M-$:U^"UBT<FHW-O?PK(LI+&:4PLP9GV;8T(5MI9CC!->SV?_  3]_9WTOPNV
MD-\+M#>T$95[BX,CW.,<L;AG\P'W##';%91UCS/OMZ?YCE9-16NE[]#U?X9_
M&#P5\9-$.K^"/$VF^)K $"233YP[0L1D+(GWHVQSM8 ^U8OQ@_:0^'GP#NO#
M]OX[\0_V%-KTLD.G)]BN+GSG0H&&88WVX,B<M@<^QK\SOV>=&T?]G3_@J6O@
MCX;Z\NH>"M4$UK)#!>BY41M9M/Y#NI(9HIDP,Y8!<$Y)->@?\%KKJ>S7X,W%
MJQ2ZAN-3DA9>2''V,@C\<4Y-6IRBG:3^8XQ;G*#Z*_X7/M/XO?MF_!?X$ZXN
MC>-O'MCI6L=7T^"&>]GBR 1YD=O'(T>001O R#Q77?"GX[> /CEI<FH^ _%F
MF^);:+;YRV<O[Z#=G;YL38>/.#C<HS@U\Y?LZ_\ !.7X<^&_!<.L?$[0HOB%
M\1=<3[;K6I:X6N%2>7YWCC0G:-K$_O"-[')R 0H^3?VM/@[_ ,.X_C_X%^+'
MPH>ZT[POJ=P\-SHQF:2-"A4S6Q9B6:*6,D@-DJR$@\+BK*,E";WTOTN1\<7*
M'3IW/J__ (*;?'SP-X.^ 7B[X=:OKGV/QCX@TR.;3--^R3O]H07"9/FJAC7[
MC_>8=*X'_@ES^U%\,K'X)^!?A)-XFV?$*:XO]FC?8+HYS--,/WPB\K_5_-]_
MVZ\5Z/\ \%#O ?@CX@_LF^*_B!<>'].U'7+;1[>32]:G@5[BWBDGC8"-^J@A
MST_O&N5_X):?!/P'<?LW^!_'LOA'29/&D=Q?E->:U7[6N+F:,8DQG[GR_3BI
MH^ZZG/TW_3_@E5))TZ;CLV[>ME^!Z"H_9B_X;=^7_DX?<<?\A/K]A.?^G7_C
MVS_^U7JNJ?M2?"_0_C/;?"B_\3?8_'MT46#2I;"Z59"\?F+MG\KR3E>GS]?E
MZ\5\ Q_\IM/^VK_^F(UU7_!7#X?W_@S7?AG\>/#@\K5M!OH[&ZF4$X*.9[5V
MQV#K*I]=ZBFFE"C*3LI;^6MARB_:3BM6DFONN?I=]*\F^)?[47PR^$/CS0/!
M7BKQ,=-\4Z]Y?]G:;'875S)/YDOE1\PQ.%W."HW$=#Z5V'PS\>6'Q-^'?AWQ
M=I9SI^M6$.H0[CRJR(&VGW&2#[@U^;?[/,?_  V!_P %,/&?Q*G'VSPIX'W)
MIS?>C)3=;VN/]XB:<>XIJ+]K[-]+M_+]3/FO2=1>5O5GZA:AJ%MI5E/>7ES%
M:6L"&26XG<)'&H&2S,>  .YKYTUS_@H[^S?X=UE]+N_BCI\MS&VTR6-E=W<&
M?::&%HR/<-BOE#_@HY\0M>^.7[2G@O\ 9MT/7ET'0KA[>36IVDVHTLG[P&49
M&Y8H0) A(!9QW"D?2G@_]A/]E_PGX1707\+Z!K9:(1W&I:M>B:\E;&"_F;P8
MR>O[O8!V J(^]'GZ7T[ERM%J'6UW\SZ+\"_$;PO\4- CUSPCK^G^)-(D8H+S
M3+E9XPPP2C%3\K#(RIP1GD5TM?D3K&GVW_!.7]M_PE_P@&O277PO\9F..^TI
M[OSUAB>;RW1CD[C"662-S\V"5).6+?KLK9Q5Z."G'9W_  W(UC)Q>X'[IK\A
MY_#>D>,/^"S=_I6O:78ZWI=Q=2>=8ZC;I/!)MT3<NY'!4X8 C(Z@&OUX;IBO
MQ*^/GQJ?]GC_ (*D>*?'\6A-XEDTFZ7_ (E:7)MS/YFE)#_K-C[<>9N^Z<[<
M<=:5%I8A-_RR_0J=W2DEOH?K;_PS7\(=O_)*O!/_ (3MG_\ &Z\9_:H_8;^$
M'Q$^$'B7[#X)T'PIK]E83WEAK&C6,5B\4T<99?,,8421G&"KY&"2,$ CYDN/
M^"W%W:KOF^!4T*9QND\3E1G\;&N>\;?MQ?'W]N#P9J/@OX1?!^[T?2]55]/U
M'5;:X>\ 1E&^'[6\<,,&Y3@[N2&X(K.I&4X-0W+BU%IR>AZ7_P $6OB)JFN?
M"WQOX/O)))M/\/W\%S9%R2(EN5D+QKV W1%L>LC'O7Z%>(_$VC^#]%NM8U_5
M+/1M)M4WSWVH3I!!$OJSL0 /J:^?OV$?V3V_9,^$#:-J5U#?^*M6G^WZM<6^
M3$C[0J0QD@$JBYY(Y9F/ (%?%_[1VL7W[<G[>$?P;O/$K:%\-/"4L@O%CG5%
M>2%1]IDPQVF8NWDJ3G8,D#E@>BK+GJJ,-VOR6K,:<>6$IRT29]GG_@I%^S=_
M;7]E?\+0LOM7F>5YGV"\^SYSC/G^3Y>/]K=CWKZ!\,^*='\::+:ZUH&JV>M:
M1=+OM[[3YTG@E7.,JZD@\@C@]J^;E_8=_9:C\(GP]_PAOALVVS:;PW[&]S_>
M^T^9YF<\_>Q[8XKY)_9IU6[_ &)OV];GX+:?XBDUWX:>*V4V2R3B01221%X)
M/E^42AE,+%<;Q@D<*!$;2ER/?OT]!RNHN?1;^G<_3OQMX^\-?#?P_-K?BO7=
M/\.Z1"0KWVI7*01!CT7<Q&6/8#D]J\'L?^"DW[-NH:LNFQ?%"S2Y9M@>?3KV
M&'/O,\ C ]]V*^-O^"E&N:7K7[;7PR\-?%&^OK+X26]E;W,Z6^\(1)+*)I/E
MR<DI&C%?F"CCFOJW1/V0OV3/C1X%FT[PEX:\(:S8+'Y?]H^&K]9;J!L<,9XY
M"^X9!PY.>X/2LXW<'.VEWIZ%RM&2AULG?IJ?47AWQ)I'B_1[75]"U6SUG2KI
M/,@OM/G2>"5?574D$?0TOB#Q%I7A/1[K5]<U*ST?2K1#+<7U].L$$*C^)W8A
M5'N37RO^P9^R)XY_9)/C/2M;\6Z?KGA34[D3Z98VAE+P,K,/-;<JA6="@95R
M,H.37RU^U7XAU']M3]NNP^!LOB5_#_P[\-R$7S),J+)+'%YEQ+ACM:3)\E-V
M0O)QRP-/WIJ%/=J^O1+<4=$Y3V7;KZ'V3-_P4B_9N@UK^RF^*%C]J\SR_,6P
MO&M\YQGSQ#Y>/]K=CWKW[PKXNT7QUH5MK7A[5K+6]'N@6@O]/N$G@E .#M=2
M0<$$'T(KYOM?V'/V6[;P?_PCP\&>&YK<IM:\FOV:])[M]I\SS <\\,!Z#'%?
M(WP$U"?]A?\ ;X3X1Z3XBDUKX9^,FB^S0R3B41O,I$$AV_*)5D3RF88W*02.
M!BHVE+DZ]^A,G:+GT6Z\C]5=6U:QT'3;G4=2O+?3]/M4,D]U=2K'%$@&2S.Q
M 4 =R:^=O$7_  4@_9O\,ZD]A>?%&PFG3@OIUC>7L7X2P0NA_!J\W_X*'?L_
M_&+]I;6O ?A#PA&L7PX^TI-KUTM]%$P=I0OF/$[*9%AC#.%&<LW3(%>F^%?^
M">O[/OA7PS'H_P#PK;2=3C$6R6^U0-<74IQRYE9LJ3U^3:!V %1&[BY/36UO
M3J6[)I+72]SU+X4_'KX>_'+39+[P'XNTSQ+%$ 9H[.;]_ #G'F0MB2/.#C<H
MSBH?C5^T%X"_9X\/V.N?$'7?^$?TN\NA9P7'V.XN=\Q1GV[88W8?*C') ''6
MORVNO!OA?]E/_@IUX!TGX3:NI\/ZI<6MO=:?;ZA]I%J+EVAFM)&W,Q  60+(
M2P)0]@:^@?\ @M9_R;WX*Q_T,Z_^DMQ3D[PC./5V"*?M'3ET5_OV/I;XE?MO
M? [X2Z]:Z)XK^(-CINJW$4<PM([>XN7C5U#(91%&_E$JRL!)M."#TKV+P[XH
MTCQ;X>LM=T74;;4]&O81<6U]:RAX98R,AE8<$5\7_LF_L#?"K6/V?= UWX@>
M%X?&OB[Q;I\>J:IJNL2R2S@SKYBI&^[,957 +*0Q())Z8\\_X*C?$C4O _A+
MX;_L_?#H?V-!X@1;66WM',?^AH4@M[7(Y\MV)W>HC .03EU%R2]FM9-V7ZD4
MWSKFO:-KW/IWQG_P4)_9X\!ZPVEZK\3]+>[4E6_LR"XU"-2#@@R6T4B @]B:
M]7^&/QC\$?&C0VU?P/XHTWQ-8H0LKV$X9X6(R%D3[T;$=F -?/\ \%?^":/P
M2^&?@>UTS6_"-CXTUZ2W5-0U?65:4RR$?,8D)VQ*"2%V@-@#+$\UX[HO["WC
MS]F[]LK0/&'P.LQ#\,KQ(UUFROM44+#"S[9[<!V,D@"A94)#88 %N*:2YU%]
M>O0).\7)=.AQW_!1KG]OK]GC/_/?3O\ TY5]G_%#]N+X%?!K7I-#\6?$33[+
M5X6*36=G#/?R0,.JR"WCD\MO9L&O@3_@KE8ZKJW[4GPILM#GDM-:N=-ABLKB
M*0QO'.UXZQLK#E2&(.1R*^R/A;_P36^!G@'P;'I>K^#[3QEK$T074-:UHO-/
M<2$?,Z#=B$9)QLP<8R2>:BC?ZNO*4OGJ:5+>T\[(]Q^%?QN\"?&[1VU3P+XI
MTWQ+9Q[?-^Q39D@+#*B6,X>,G!X=0>*E^+7Q@\)? WP?/XK\;:K_ &+H,$B1
M2WGV:6?:SMM0;(D=CDGL*_+SPW\/[?\ 8N_X*D>&?"W@N[N[7PGXC$:?V?+*
MSC[-<HZ^2S')=4F0,I.3\JY)()/Z4_M"? /P_P#M+?#*\\#>)[W4K#2KJ6&>
M2;2)8X[C=&X=0&DC=<9'/R_E3EK",X=>_KJ0O=J.$^U_OV.B^%_Q3\,_&?P/
MIOC#P?J7]L>'-0,@M;S[/+#YGER-&_R2JKC#HPY4=,]*Z^O.O@+\%=#_ &>?
MA7HO@'PY=:A>Z-I7G>1/JDD<EPWFS/*VYD1%/S2$#"C@#KUKT6KE:_N["C>V
MIQ/Q;^+WA+X&^#I_%GC;5O[%T"WD2&6\^SS3[6=@J#9$CL<D]A7'>,OVO?@]
M\/?!&@>+?$7CFPTO1-?M([[2VEBF-S=0. 5D2V5#-MP1D[.,\XKQS_@K1G_A
MC/Q%_P!A"P_]*%KQW]@']ACPS\3/A?H7Q2^,-F_C;5-0M8[?1=+U21FM;#3X
M 881Y8(#EE4D!LJ%*G&XDUG3O-3;TLTOPN5)J/+YGV=\'_VL/A)\?+A[7P+X
MYTW6[]0S?V>WF6UV5'5A!,J2%1W8+@>M>NU^6W_!1+]BGPY\"_"EG\:_@];2
M>"M4T&_@>^M=.E985#R!8[B$$GRV60H"JX4ALX&#N^B]4_;.N+7_ ()[1?&]
M4B_X2&?25@2/9^[_ +3,OV4MMS]P3!GV_P!T8I<T>251+9V:\WM]X^5\RB]G
ML>S_ !>_:C^%7P%F2'QWXWTS0KQD$BV+,T]T5.</Y$2M)M.#\VW'!K)^%'[9
MOP5^-^K1Z5X-^(6FZEJDC;(M/N$ELKB8X)(CBN$1I. 3\H/2OA[]@?\ 9"^'
MWQ>\'M\9/C5J-OXT\2>(KN:>WLM7U#Y(U61D,LR[P9'=E;Y7RH7;\N>G<?ML
M?L-_!N;X2:_XW^&\6E^"?&?ANT;4X/[%O!'#<I"-[1F(-M5]JDJZ!6W 9)%7
M+]U_$^?D*/[QVAZ>I^B,QW1R>PK\O?\ @BO_ ,AKXU_[^E_SO*^GO^"=7[0>
MI_M#?LTV&IZ_<->^)-%N'T;4+I_O7+1HK1RMZLT<B;CW8,:^8?\ @BOQK?QK
M_P"NFE_SO*TIQ<*M1?W?U0.7-A[_ -Y?J?I1XP\;>'_A[H,^M^)];T_P]I$)
M DOM4N4MX5)Z#<Y R3T'4U\_3?\ !3#]FJTU![*3XG6YF5MA:/2K]XL^TBP%
M"/<'%>-_M,?LA?$[]JO]K_0&\7P&#X$Z3&HC:TU*,.V(]\F8MV]9)9<1EPIP
M@'((KW?4OV _V=(_"KZ7<_#'0K;3XX\-=;I([A% ^\;G?YF?<O6"OR\TNO3J
M-V3Y5Y:]#V7P'\2/"OQ2T&+6_"'B'3O$FDR-M%YIMRLR!L E6VGY6&1E3@CN
M*P?C5^T#X"_9W\/V6M_$#7?^$?TN\N19P7'V.XN=\I1GV[88W8?*C') ''6O
MS9_X)\PVOP<_X*"?$#X<^$/$ USP/<6UU'%)#<K-%*L122%RR?*\D89XRP]7
MZ=*_0/\ :@_97\*?M9>$-+\->+M1UG3;'3[X:A%)HLT,4K2"-X\,98I 5Q(>
M@!R!S5R7NQE#JDR8_'*,NG8]*\#>-M&^(_A'2?$_AV\_M#0]6MDN[*Z\IXO-
MB895MCJK+D=F -=#7(_"SX;Z=\(_ASX>\%Z/<75SI>AV4=C;37SJ\[1H, N5
M55+?10/:NNH=KNPHWMJ>;_&K]H+P%^SQX?LM;^(.N_\ "/Z7>70LX+C['<7.
M^8HS[=L,;L/E1CD@#CK6!\5OVOO@[\$4L1XS\=V&C3WL23P6:Q37-R8W&5<P
M0H\BJ1T+*!7RO_P6J^;]GWP7C_H9U_\ 26XK;_9!_8#\%ZO\/=,^(OQ?TM?B
M%X_\4VT>HW#ZXS30VD4B QQ+%G:6$>S)8':1M7:!RHIR3>UG8J5HN*[IO\3Z
ME^$'[2'PR^/5O++X"\9:=XB>)?,EM87:.ZB7.-SP2!9%7/&2H%>FU^2?[>G[
M,ME^Q/XL\'?'#X+M+X7BCU,6USIL4KR0P3E6=2NXD^5(J2(\9.WD 8!P/J/]
ML']L"X\!_L2Z5\0_"\IL-<\:6MG#I4B\M:O<Q>:[C_:2-9,'LVVE*2]GSQ[V
M^8U%\Z@]FKK]3V'XM?MB_!GX&ZH=,\:>/],TK4T($FGPB2\N8L@$>9% CNF0
M01N S5SX/_M6?"7X]7#6_@7QSINNWP4M_9_SVUWM'5A!,J2%1GE@N*^.?V'_
M -AKX1S?"O1?B!\43IOC;QAXEA753'K%[OAM8YAO13&7Q)(P(9FD!.3@8P2>
M>_;X_9#^''PR^'\GQ@^#=];>"O%?ARZANY;71+[$<R-(J"2) Y\J1&96_=X4
M@-E<X(J5J3M4]/04?WB]SY7ZGWG^U%_R;7\4_P#L5M4_])):^4/^"+?_ ";+
MXH_[&RX_])+2O1O#GQKN/VA/^"<?B/QK?*B:M=^#M6@U 1KM4W,,$T4C =@Q
M3<!V#8KSC_@BW_R;+XI_[&RX_P#22TJX1<)U4^B7YA)\U*#\W^1]J?$#XH^$
M/A/HO]K^,O$FE^&=-+;$N-4ND@$C8SL3<<NV ?E7)XZ5X7;?\%,/V:KG4%LD
M^)UN)F;9NDTJ_2+/O(T 0#WSBO"_%G[#_C_]IK]M+6/%/QIL6;X3:>DB:-:6
MNJ(5GB1E6&#;&XDBWY:5R #D;=W3'O?CS]@C]G#4/!MS9:E\/]"T"RAB/_$T
MM7-E-!@<.9PP)(Z_.2#CD$5A%OD4Y==;=BM.9Q73J>_>%?&&A^.M#MM:\.ZO
M8Z[H]R"T%_IUPD\$N#@[70D'!R#Z$5QGB#]I+X<^%?B]I'PPU7Q%]C\<ZM +
MFRTMK*X82QD2$-YRQF)>(I/O./N^XS^?7_!(G6KGPK\:/C#\.K#6/[9\,6I:
MYM9XY0\,K0W!@$\>"5_>(RDL.H5>N!7(?\%*/"U_XX_X*"^ _#.EWLVFW>N:
M3IVE"[@<JT:7%S<0R'((XV.P([@D=ZV:O."CM+N9Q:M4YMX?=T/T!TW]O/X!
MZUX\7P=9?$W2I]<><6\8$<PMI)"<!4NC'Y#$DX&'.3P*]I\3^+-&\$Z'<:SX
M@U:RT32+89GOM0N$@@B&< L[D <X'7O7BO@O]@_X%^ O^$:GTKX>Z<NI^'[B
M.\LM4E:1[HSH<K)))NS(=WS8;*@XP!@8^%?CAJ5U^WI^WI/\*-4\2OH?PQ\&
MR3+/'',L8=H,+<2#=\IF>5O*5CG:@R!]X-&\E3COKKY(I;.;V5O7T/M2/_@I
M%^S=)K7]E#XH60NO,\KS&L+Q;?.<9\\P^7C_ &MV/>OH/P]XDTKQ=HMKJ^A:
MI9ZSI5TGF6]]8SK/#,O]Y74D,/H:^:W_ &'/V6F\('P^?!OAM;;;M%XM^PO
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M_8%_; \&_LC^-?'^H>,--UW4H=:B@AMUT.WAE96C>1F+^;-'@8<8QGO65/\
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M^%2PGX\?\B/_ &A#C_C]_P"/K:_E_P#'G^\Z;_\ 9]>U?%G[:_\ RE*^ _\
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M\_V)/!?Q(^#NB?$_XJZ8?'&MZG%]GTNUUB1Y+:QL8"8(4$6=K9$9(W @#;@
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MO&OSE_8Q^"NC?MR>/O&/QG^.^M)K-O'J'V*ST.6^-O$SA1)MX8,L$2NBJBD
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MCT&J/)%:2?8;FY\UD +#$$;D8##KCK70^-OBCX8^'7P_O?'/B'4_[/\ "]G
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MQSI>O7RH9#8!F@N]@QEO(E5)-HR,MMP,UY1_P5$;_C"?Q]_O6!_\GH*^$/\
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MFO;;^S[JW\I0X0G=+$BM\Q ^4G\JSOV,_C9/^T)^SCX.\8ZAC^V+FW:VU#:
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M/%?5?[%/["?AO]D;1[J]-[_PD?CC4H_+OM::+RUCBR#Y$"9.U,@$DG+D G
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MCDE%RPDZ:W7-\[[6-=JT9]'9'CG_  1./_%J/B*.N-8@_P#1-<3_ ,$];A/
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M'DVI+N_X+:6N0#\JGD?]0$U^I?\ RS_"O@:\_9E^)4W_  5*A^+B^&L_#Q%
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M&G_$?]J'Q3;ZO]B"-!X9LY%D!"G(AD\M5ABB!Y*Q;B^3E@<DS*,:C2O97O\
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M&B:MJ>B?';3POA>UTJ.+2+HSZ;(ZS(RJ$8VSF1LH?O.#]SDY//.HMPJ1ZO\
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M-V, ^I%?JEVI,9!HJ-M/E=F3'W;7Z'P%_P $A?CL?'GP-U'P!J5R7U;P?/\
MZ.K_ 'FLIBS)UZ[)!(OL-@KRG_@FC<Q^ /VUOCAX*U?;;ZQ</<B 3</(8+MB
MP7URL@?W"Y[5U/P;_9'^+W[-W[>NK>+/"GA#[=\)M8O)[>>\AU&SC$=G<8DX
MA:99/W,NW@)DK&<9S7I/[8W[ FM_$KXB6/Q=^#OB&/P?\3[,H\H=VABO&0;5
MD$B@E)=GR'(*N  V.2='-.<*S6ZL^Z9/)[LZ*?5-/Y['V^YPI/3BORS_ &$_
M$5EXL_X*;?''5=-F6>PN;356@F4@K(HO[90P(Z@XR/8UT=QX7_X*"?&'11X)
M\0S:'X$TB=/(OO$D-Q9K<7$9X;FV>1U)&3^[2//3(!J[^P3^Q'\0OV8_VKO&
M>J:MI$C>!?['N=-TS7I;NU9KUC<6[(QACE:1-RQNV&48Q@G/6:<>6JY-]))%
M2?[IQ6]U^90_:N_:6^+OQF_:LC_9R^#FN_\ "&",B&_UI',,\D@@\^5O.4%X
MXT3 'E@,S \X(%:\/_!(^[\97"3?%'X]>+?&@ZF-8V5U/?$EQ+/GGOM%6_VO
MOV#OB1JGQWB^.7P)UR#3_&.4FN;">=8)#.D8B\R%W!C8.@"O')A3SR0Q J65
MG_P4(^)]FN@ZFWA?X:6SIY<^N>9:/.ZD88KY#SE6QD@HJ<]"O:::7LU_-UOW
M*G\=[^[H?/OPG^%O@_X)_P#!5SPMX(\$7%U=Z+HLS6YGO+A9Y7G.ER-+N954
M9#L00  "","O8/\ @M!?QZ7?? ^\EC\V*VO=1F=,?>539DC\A67X4_X)X_$K
M]GG]KSX9^,_"UO??$;P[:M'<^(/$%U?6MM,+F4RQ73B*299&4(XD RY.2,D\
M59_X+<*&LO@^IZ-)J@_2SIIRM12=VI?C<J"4JL^W*_R9^F/A_6K/Q)HFGZMI
ML\=UIU];QW-O-&<K)&ZAE8'T((-?G/\ \%I_$UI-X#^&_A"(K<:U?:O+?10(
MNZ7RTB,7&.S-, !W*^U36/P=_;,_99MW\+_"'5-+^)_@#!_LF'69+9;G3HSR
M%(GDBQCH KNG&0JY(&U^S[^P)\1/%WQIM/C-^TEXEA\0^)K)XY]/T*WD66.*
M1#F/S2JB-$C;++%$"I;YBW4-7(I372-]>_H8PDX0ONVCU3]K[0+GPK_P3F\1
MZ+>?\?6G>'=/M)<?WHWMT;]0:;_P2M_Y,K\&#_IXU#_TLFKV_P#:,^$Y^.7P
M1\8>!$NUL9M:L6@@N74E(I@0\;,!R5WJN<=LU\*_L=?!_P#;$_9U\>^&/!6I
MZ;!-\'K34Y#??9[S3)HQ#)N+21LS"Y"[R'VX!Z_+R12C+FG43TYK XJ%&"6O
M*W^1S4?_ "FT'KYC?^F(U^A'[2WPAM_CO\#/&/@F=$,NJ6#K:-(.([E/G@?\
M)%0_3-?)D?[+OQ.7_@J5_P +>_X1G_BW>]C_ &Q]OM>ATDV_^I\WS?\ 6_+]
MSWZ<U^@;+G^5*2Y\/3AUM]VIHY<M=S7D?DC^S;^UM<_"_P#X)W_%+P]?SR6?
MBWP?</HVG0.VV:,WS,L9 /.Z*3[2V.PC%?4O_!+#X)_\*J_9=TW6+NW\K6/&
M$IUB9B/F%N1MMESZ>6-X]Y37S)^TM_P35^(OCK]K/4KWPEI+?\*N\3ZI:ZEJ
ME]'J%O"EHSL?M+&!I [LI:9UVH?];@=Z_5?1])M="TNSTVQA6VLK2%+>"%!A
M8XT4*J@>@  JXRO%U)?%*R:[67ZLSG%1DJ<=4FW]Y^.'[7WPET#Q=_P5 3P[
M\0;^^TGPKXL>QVWUA*D4RJ]HL,15Y$=0//CVDE3QGIV^GO\ ARQ\$N/^*I^(
M'_@QL?\ Y#KUO]N#]B#2/VO/#-C-!?KH'C;1U<:;JK1EXG5CDP3@<E"1D,.4
M)) .2I^=-"T[_@HA\+=)/A33['0_&ME;HMO:Z]=7EC+(B 8!#S2Q2/CKF6-F
M/?-94_=I\G5?B:U+RGS)Z67WK_,QO&G[ ?[(_P &?B/H/A;Q-\5/&FD^*=0\
MNXL-/FN;>0R@R%4R4L"J[G4J 2"2.*_455$:A1V&*^ /V9/^"?/C1?C,OQG_
M &@_$T'BOQI#,MU9:=#)YT<4P V22OM508_X(HUV*0I!XQ7Z [1Q[5J_@2;U
M_ QWFVOQW%;O7Y,:*?\ C=K<_P#7W+_Z8FK]9B>M?GCIG[*OQ1M_^"I$WQ=D
M\+X^'37$CC6/[0M3\ITHP ^3YOF_ZWY?N>_3FB@^7$*3VY9?C8JIK2DEN?H#
MJVE66N:;<:?J-I#?6-RABGM;F-9(Y4(P596!!!'8U^1?[4OPQ\5?\$W?V@-,
M^*WPF>2S\ Z[/Y<VE;V-JDG+26,RYYC8;GC)Y7#8P4!/[!5P7QM^$.@_'?X7
MZ[X(\10[].U6 Q^8H&^WD',<R9Z,C!6'TP>":QE>,E..Z_%%QLUR3V8GP3^,
M&@?'CX7Z'XW\.S>9INJ0"0Q,09+>0<20OCHZ,"I^F1P17Y!:3^SCX1^+W_!1
M_P")7PY^)>JZKHL.I:IJ5WI\NE3Q0S2S/(+B%298Y!AH68XQDG&#Z_4/_!/C
MX$_M"?LI_$W7O"7B3PI]N^%NJ3R'^U;?5+-D@G3(CNDA\[S0LBJ%9=F[[A(^
M4UZ5^V__ ,$_S^T=KNG^/O NN)X0^)NFK&L=W([QP78C;,1:2,%XI4/W9%!.
M  1P"NLN6-6-6.J:?JK_ .1,7+DE2;L[[]['(_\ #E?X(XS_ ,)3\0,?]A&Q
M_P#D.N2\ _L;?LI_!_\ :=\.>'+#XG^+)?B?HM_;7UKH-Y/#(DDHVRQH[)9!
M3E<,5#@A>>.M$5U_P4:T_2F\-)I>@WA!\E?%+S:89@O0/@RC/'=H2WKS7I_[
M%7_!/_4/@IXXO_BC\4=?C\8?$Z^\PI-'(\T5H9,B23S9 &DE93M+8 4%@,YS
M3A?FYKZ(B=N1Q:O?3R.__:%T_P#9V_:*\=:=\&?B#?66H^/%\Q]/L;=IH[ZS
M8P^:Q69%VIF,!]CG:VU?E; KY?\ ''_!&'^Q;[^V?A;\5=0T>_M?WEI#K4'[
MQ9!T/VNW*%/J(B:]G_;?_81UKXY>,-$^)OPQ\00^%OB;HXC59;B1X8[I8VW1
M.)$!,<J9(!VD,, X S7F$.L?\%&WTW^P7T#PZKD^5_PDK2Z7YH'3S-HFV_\
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M#7I_C7_@DC^SQ\./">K>)_$?CCQWI>A:5 UU>7DE]9L(HU')VK9%F/H%!))
M )KFA^P[^T?^R%XWU;6/V<?%-KXA\,:A('?0=2EACE=03M25)\0N5! $JNCG
MGA1U;XV_9W_;2_;#:W\/_%;4M%^'7@E9HWN;&TF@D27:<[Q';O(TS X(2255
MR 1@C-:RE[1WAI?N1%<C]YW2[=O\SZ>_8+^'/P?^'_PKUP_!?Q=JGC'PUJ&I
M&6XO=592\=PL2*8QB"'&%V$@J3SUKY<_X(L?\AKXV?[^E_SO:_03X(_!?P]\
M ?A?HO@7PQ$Z:;IL1!EE(,MQ*Q)DFD(ZLS$D]AP!@ "ODK_@F'^S'\2OV>=3
M^*$WQ!\-?\(]'K+6!L#]NMKGSA&;DO\ ZF5]N/,3[V,YXZ&KB_WM1IZ<ME?K
MJA+^ TUK=.WWGF/Q>^/_ ,:/VO/VLM;^!OPD\6-\/?#F@RSQ7VK6LKP7#BW9
M4GF:5/WF/,.Q(XRH;(+'!RO9V_\ P2!M?%5X+KXG?&[Q?XV8<@QH(7![_//)
M<?R%9G[0W[!_QB\!_M#:E\:_V==:M4U749I+NZT>:>.&832_ZY5\X>3+%(<L
M5D*[2>,X!&I'X6_;Z^-UJ=!\2:EX<^$6BS+Y-YJ-@]N]W)&>&,9@DF8/CIM>
M+_>%80_AI+XNOJ:3?OMW]WH>)?L0>#_#/P__ ."FWBCPSX.EDG\.:/!J%C:R
M33><[>6BHY+@ $[P_08]*_7[/>OS+_9^_8+^(?[+7[;>AZ[X>TNZ\4_#-+0V
M]UXBN+^TBF5I;4K*S0&59"!/R%"M\I'+$9KZ+_X*%>!?C3\0/A=X>LO@A<ZU
M:^(HM96:\;1-;72I3:^1*"&D::+<N\I\N3S@XXS6DG:G35[M*S];F:7[R71/
M5?<?57U%+7FW[.NC^*_#OP,\$:;XX>ZF\86NE01:J]]>"[G:X"_.7F#,)&S_
M !;CGUKTGVI-6;5[@G=7/SP_X+5*%_9^\%_]C.G_ *2W%?:7P,\4Z?XV^#O@
MG7M*=)-/O]'M9H?+QA08EROL5.5([$$5\7?\%JL_\,^^"QV_X2=/_26XKBOA
MG\%?VLOV;? OA^?X%ZQIWQ \":WI\&I1>'];D@273IIXEDD"^<\8"[F)'ER
M,224SR2G\$[]U^05%[U.SUL_NN>D_P#!9#Q78:3^S3I&B320G4=7UR$VT+<O
MLBCD:1U]AE%)_P"F@'>O&/V[/A_K&A_\$WO@/%<P21R:,=/%_#M.83+9R#YO
M3#$+]6KOOAI^P7\7?CU\6M,^)/[4/B&VO8]-97M/"MK)'*ORMN$3B,>3'%D
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M/GB/_@B_\#IHTDC\6>/GC8!E9=1L2"#T(/V/I7G'Q@_X)W_LC_ .YT:W\?\
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M'4AE9?#]H"".A!\NN\T_3;72;..TL;6&SM8QA(;>,1HH] H&!5RBK)&UY?\
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M?(\ 7AN?(U?[=;-OW68C7]R)3*,N".4]^E?=VO6\EYHM_!"-\LD#HBY'+%2
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M/B)KOC36([ V&HV^J.IC@C,JL'&+6$DEH\!MQ!&[&>HM?\%#/VW+KX,6-O\
M#+X<EM1^*?B + OV53+)IL<ORHRJ.L[D@1KV^\1]T-Z+^S?^R1'^R#\"/$>D
M>#9EU_Q_J%I)<RZG-&L0N[Q8F%O$JLV%B5C@!F_B8DC/'P!\*OV7?VQ?A1\5
MM0^),7PHTGQ/XUO&DD&J>(]7T^Z>"61LO+&!>J Y&5W$' )"XS2E:<E3;NDM
M?/R)A[L93ZMZ?YL^X_V ?V+;;]F7P5)KWB..._\ B9K\8DU2]9O,-HC'=]E1
M^^#R[#[S#J0JU[G^T1X=O/%WP%^(FB:<K2:AJ'AZ_M;=%ZM(]NZJOXD@?C7Q
M>/B1_P %%A_S2KPB!_U]6'_RPKWW]DSQ-^TKX@U;Q$OQY\):/X;L8H83I;:7
M+;N99"S>:&\JXE.  F,@=3UHJIU4XK32R\ATW[%J>[NG\SY[_P""*_BO3[KX
M/^.O#(E0:M9:[_:$D'1_*FACC5OIN@<>WXU^B\TBPQN[L%11DL3@ =S7YU?&
M;_@GK\2?AK\8KWXL?LS>*8?#VK7KRS7>@74JQ)N<[G2(LK121,W/E2@!2 0>
M%"X?BKP/^WY^T-HLG@WQ-%H'P\\/741@O[RWO+6/[5&>&5VMY)Y<$9RJ! P)
M!X-5*3JI-*SLE9_<"BHR>NE[G,?\$[9D^(/_  4.^-OC72#]I\/LNJ2I=K\R
M,+B_1H<'_:5&8>RUM?!/YO\ @L=\1/3R+K_TE@K[(_9#_9)\.?LD_#F30=)N
M'U;6;]UGU;6IHQ&]W*!@!5R=D:@G:N3C))))->"_"_\ 9G^)/AW_ (*4>-/B
MIJ'AO[-X"U"&=;75OMULWF%H(D4>2LAE&64CE!THC[M6$5M&#5R*DG.,Y6W:
MT/(_^"VW_(3^#_\ NZG_ #M:_3NYU>S\/^'YM1U*[BL=/L[<SW%U<.$CBC5<
ML[,>   22:^%?^"I'[+_ ,3OVC+SX;R?#SPS_P )"FD"^^VG[?:VWD^8;?9_
MKY4W9\MONYQCGM74_P#!2KX3_&SXS?#;PMX.^%6E/JNDW4LLGB&WCO[:T+^6
M(C;HS32IN3<9&*KGE%)Z"I4N7#J,5KS/\;:FSBIU8W>B6O\ D?-?CKQ=XK_X
M*J?M"Q^"/"TUUHWP3\+W GO-05"IG7E?/<'@RR898D(^52S$?> _4?X?^ M"
M^&'@W2/"WAO3HM*T32X%M[:UA'"J.Y/5F)R2QY)))Y-?F?\  _PE^W%^SSX#
MM?"7@CX*^$--TV$F269[RQDN+N8_>FFD-_\ .YX'8      5W_\ PLC_ (*+
M?]$J\(_^!5A_\L*O2,>2.W5]V9.\I<TODNQO_P#!9A?^,6]#(' \4VI/M_HU
MU7TQ^R-=17?[+?PEDBD$B_\ "*Z:I8>JVT:D?@01^%<U\3O@3JO[5'[*EIX-
M^)"Q^'O&.H:=;7%W):*DJ:?J: ,2H5V5D#[E(#G*D@-SFOCOX8_"?]N_]F/2
MSX$\&6WA_P 7^$X2RV5W<7EK)!9AF))B\Z2*8#)SL*LH.<#DYB/N\]-]7=/I
MM8N7O*$ETNAW_!;K6K3^R?A7I/FYOC-?W/E#J(P(%W'ZD\?0U],_MK?-_P $
M^_%_;_B1V0_\BP5\@?M&_P#!.;X[?$;P;:^,]>U8_%+XQZCJ44=Y#:WEO:66
MFZ<D4N(XO.:%"?,*$A%4 DX!RS'[H_:B^%WB;XB?L>^)/!/A[3/[0\3W>DVM
MK!8>?'%OD22(LOF.RH,!6Y+8XK&<'&A..[O?0TC).O2?1+]4</\ \$JXU3]B
MOP857:6N=0)XZG[9,,_I7B7_  6V_P"28_#?_L+W/_HD5]-_L _"GQ5\%?V7
M_#'A+QGI?]C>(;*:\:>S^T13[!)<R.AWQ.R'*L#P>]>6?\%1_P!G+XB?M%>!
M?!.G?#SP]_PD-YI^H3SW4?VVWM?+1H@JG,\B \]@2:VQ.LE;NOT,\/[M[Z;_
M *GUI\)1_P 6O\)?]@FT_P#1*5^<_P"T5_RE^^%GI]GL?_0;BOT@^'FE7.@^
M _#NG7T?DWEII]O!-'N#;)%C56&02#@@\@XKXN^,_P"S/\2_%W_!1[P#\4-)
M\-_:O NEP6B7FK?;K9/**"8./*:02MC>O1#UJY/_ &B,O,PIJV&E%K7EM;S-
M'_@I3^V+XL_9[TOPMX.^'OEVWC#Q1YC?VE)$LAM(5*H!&K_+YCNV 6!"A3QD
M@CS[2O\ @F#\4_B7IEM/\6?VB_$FH2W #WFC6[W%W%&QY*K++.%XSVBQZ<5[
M/_P4 _8CN?VL/#NA:EX;U2VT?QIX?,@M&O2RP743E2T;NH+(P90RL >201SD
M>+>$Y/\ @HII>D0^%7TKP\\<8^SQ^*-5N=/FE1!@*Y*2DO@#JT+,>IR:RIVY
M7=>]=_=T-Y7]VSTL?*W_  4(_9-^'/[)5U\/]%\':GJVJ:SJBW=UJ,FKW4<D
M@C4PK#A(XT"*6\[!().#R<5^C7_!38;OV&?&^?\ J'C_ ,G8*^1?VC/^"8_Q
MJ\5^&++QI=>)IOBS\7-1U #58$NH+6UM;7RV*B%IVC#!7 &!L #@+&,$G[0_
M:[^&/COXX?L5ZEX6T;P[(WCC4K/37?19+RW5HYDFADFC,S2>4=NU^0Y!QP3F
MG.[P_(]6I?G;\$5&WM82Z6'_ /!-WQ38^*/V-OAXUG)&SV-O-87$<>!Y<L<\
M@(8=B05;WW ]Z7_@I!XNT_PC^QQ\0?M\P1]1MXM.MH\X:2625 %7UP S'V4U
M\I?"G]D']J;]EGP+HGB'X1ZG:G5M2MP_B7P!K5U;2Q_:E=E5XG+>208PA)65
M&&,;F' OO^QC^TA^V)XYTG4_VCM>M/#'A'2YRZ>'M+GA>3!QE8D@+QJ6&099
M)'<#H"*NLO;2DEI=Z_\  ,Z+]BE)ZVV/?/\ @E;X:O?#O[&WA:6]C:+^TKJ\
MOHE88(C:=E4_0A-P]B*^O:S/#OAW3O"?AW3]#T>UCL-+TZV2UM+6$82*)%"H
MH]@ *_/S]@>\^,GAW]K+XG>#?BMXC\17\UII OK;3-7UUM1A@22X4QN@$LB(
M2AZ#! .#BG*2J5.5:*WY&:BZ=+G>]_S?Z'Z,T445)J%%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 )2T44 %%%% !1110 4444 %%%% !24
MM)0 E>&_MM>']4\5?LJ_$C2-$TV\UC5;K2V2VL;"!YYYFWJ=J1H"S'CH!7N-
M+UJ)0YHM%1ERR4ET/E+_ ()E^#=?\!_LE^'M'\3:%J7AW5HKV]>33]6LY+6X
M16N'*DQR , 001QR*^K$IPZFEK23YG<SC'E_'\0HHHI%!1110 E+110 4E+1
M0 4444 %%%% "4M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 E+24M !1110 E+110 4444 %%%% "4M%% !1110 4444 %%%
M% !1110 4444 )2T44 %%%% !24M% !1110 E+110 4E+10 4444 )2T44 %
M%%% "4M%% !1110 E%+10 4E+10 4444 >2_M-?#'Q7\9/A'J?@SPGXG@\)7
M&L,EIJ&H36QG;["YVW$<8!&'9"0#]1E<[AV/PU\!Z9\+? 6@>$-%5DTG1;**
MQM_,.7*1J%W,>['&2?4FNGHI+1.W4'JUY#J***8!1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M24M% !1110 E+110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4E+10 E+110 4444 %%%% !1110 4E+10 4444 %%%% !1110 4444
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MBBBJ&%)2T4 %%%% !1110 E%+10 4444 %%%% !1110 4444 %%%% "4M%%
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M%?._[;?[:3?L<Z1X7O\ _A#AXO&N3SP^7_:?V+R/+5#G/DR;L[_;&.]?'?\
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ML>(K#^U?#]AX$BNM1L/)2;[3;)9[I8O+<A7W(&&UB <X/%87[./[3'P:UKX
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M!-[YK.=X3)'XG/S;6*[L"R.,XK]/I/\ 5M]*_*+_ ()"_P#)PGQF_P"N"_\
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M<,,J=IP3@UVOC/QKH7P\\-WWB#Q-JUIH>BV*>;<7U]*(XHQG R3W)(  Y)(
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MI\AM^W;N^^N<XXZUQ%]_P6)^ EKXB.G10^++RS\P)_;$.EQBUQ_?VO,LV/\
MMGGVKYD_:H^)_A7XP?\ !0K]GKQ1X-UNVU_0[QM#,5W;$\$:I+E'4@,CCNK
M$=Q5TX\U6":T;U*T4)M[I77K='[ ,.AH7C-<!\<OC)HW[/\ \*]<\>^(;:_O
M-(T=8FG@TR-)+AO,F2)=BNZ*?FD!.6' /TK-_9U_:$\/?M,_#:#QOX7LM3L-
M)FN)K98=7BCCGW1MAB1'(ZX]/FJ5[U[="'HDWU/5***:[;5)I7LKC*&L:O9>
M'M+N]2U&[AL=/M(FGN+JXD"1Q1J,L[,>   22:^<?V6?VX=&_:J^)'Q \/\
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M'P@_9IOWTKQ1K\E]XB50[:%HT/VJ[0$ CS.0D9((($CJ2#D BO./AG_P5D^
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M7LRQ0PJ.[,QP/3ZFOC+Q1_P6(^ GAW6&LK*+Q9XD@7C^T-+TN-8#]!/-$_\
MXY4WUMU'9VN?<O-%>/\ P!_:L^&G[2VFSW'@3Q%'J%U:J&N],N(V@O+<''+1
M-R5R<;UW+GC=FO8*MIK<E-,6BBBD,**** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MQ2]?T/.?B]H]A%_P6%\"6<=C;I9M;VQ:W6%1&?\ 0YNJXQ7U/_P4@TVSTO\
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MI?XJ_P"19U3_ *]I/_037Y?_ /!#S_6?&#_N$_\ M[7Z@>*O^19U3_KVD_\
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MWX/N@4'FJ4N5WL0US*Q\H_\ !43_ ),G\??[^G_^ET%'_!,'_DQ_P!_W$?\
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M $HAKG/^"5?_ "93X*_Z^-0_]+)JJ&E2J_0P_P"7%)>;_)'E/_!6SX">"G^
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M)+2>\,?W3<7$K1B1E_B$42LP'^VU?5O[7W[<6D?LGZYX.T5O#D_B_6?$3O\
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MK'7JG<]1_8W\5:+X'_8C^&NL^(=7L="T>UT:(SZAJEREO;P[I"J[Y'(5<LP
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M<2?\$OOCU\)[B2T^#7Q\ETS1)9&D:UN-0OM*QGIN2W\U)&Q_%A<XZ"KVA_\
M!*'XB_$[6;+4/CS\;-0\31VK'%I8W5Q?R;3U6.XNL>4"0.D1Z=J_3BBFM-]1
M/7R.*^%/PE\*?!/P79>$_!FC0Z'HEIRD$669W/WI)')+.Y[LQ)X'8"OF[_@H
MI^Q]XS_:XT'P98^#]2T+3IM&N;F:X;7+B:)6614"A/*ADR<H<YQVK[$]J*4E
MS?$$'[/X?ZN?EK9_L)?MMZ?:6]I:_M!V=M;01K%%#'XLU951%&%4 6W   %3
M?\,-_MR?]'$6O_A7:O\ _(U?J-157Z@?/_QD^!_B_P"*/['MY\,FU:QN/&M[
MHEG87&IW]Q*;>6ZC,1ED:3RVD(8HQW%,G(R!6-^P+^S7XG_96^"]YX/\67VD
MZCJ<VL3Z@LNBS2R0B-XXE )DCC;=F,_PXY'-?2X.:6GK>4E]HGE7+&/1;?D)
M[UY;^TY\+]5^-'P%\:>"=$GL[75=:L#:V\VH.Z0(Q93ERBLP''937JG%%92B
MI1LS12Y6FNAX#^Q)\!/$/[-G[/ND^!O$UYIM]K%G<W4SS:5+));E99F=0&DC
M1LX(S\O7UKBO^"AG[*/B[]K/X>^&-"\'ZCHNG7FF:HU[,^MSS11LAB9,*8HI
M"3EAU &.]?65 JY>_:Y,?<V\_P 3E_AEX:N/!?P[\,:!>O$]YI>F6ME,]N28
MV>.%48J2 2N5.,@''85\L?'#]C/QM\2OVWOA_P#&/3-3T&'POX>CLDN[6\N)
MUO7,,TKOY:+"R'(D7&7'(/2OL\49IN3<U4Z[D*"C3=-;-6//_C9\$_"G[0'P
M]U#P;XPL6O=(O &#1OLF@E7[DL3_ ,+J>G4')!!!(/PCH_\ P3U_:4^!,USI
MWP3^/-I:>&)F9EL=::>W$6XYR(A%<1[^F74(3Z#I7Z7YI/TJ4K-M:7W-+Z)=
MMCX'^!__  3#FL_B/;?$?XY^.KCXH^*X)$GCLY#)):+*ARADDE.^95."J;44
M8P0PXK[<\7>$-)\=^%]3\.Z[I\6IZ-J4#VMU:3#Y)8V&"#Z?4<@\BMS/XT>A
MIRM*/*UH2M'S7U/S8F_X)K_&;X&^++^^_9T^,J^'M#U!R\FEZ]-+$(^, -Y<
M4L<Y'.':-2!QSU.%X_\ ^"3_ ,1OB1X1U/7?%?Q2M_&GQ<O985ANM6N+A-.L
M[=6)D0/L>1SSA0(T103\O0C]1/>BEV\BK]>YX?I/P1UVP_8WC^$\MUI[>(U\
M&MX=-TDDAM/M!M#"'W;-_E[CG.S./X>U</\ \$]?V6_%G[*'PKU_PUXNO]'U
M&^U#6&U&*319YI8A&88H\,9(HSNS&>@(P1S7U/N[4M:<S<I3ZRW_ #)^S&'1
M'QGX\_8W\:^*/V_?#/QPM=3T&+PGID42364MQ.+]BEO)&=J"$QGEQUD'&:]E
M_:]^#NM_'W]G;Q;X#\/75C9ZQJZVRP3:G(Z6Z^7<Q2MO*([#Y8R!A3R1]:]H
M- Q6/*G#D>Q:DXS51;_Y'A/[%OP-U[]G/]GGP]X#\2W>G7VL:?+=/+-I4DDE
MN1+</(NUI$1CPPSE1SGK7AW[37_!,^S^)WQ&D^)?PO\ %]Q\,_'LDK7,TEN'
M6WGN"#F97C99()&S\S+N#==N2Q/W-2]JTFW*7.]^Y,?=32V9^9VN?L'_ +6O
MQ<T]/#?Q)_: TUO"+#9-'IT]S</,OI+%Y, EZ#AW/-?:7[-'[,OA#]EKX?+X
M7\*1RSF:3S[_ %.ZP;B]FQC>Y    X51P!ZDDGU^BA-I-+KN2U>U^A\A_MA?
M\$^="_:6UJT\9Z#K<W@;XC6*H(]8MD+QW'EG,?FJI5@ZX 653N QD-A0/%?^
M&"?VHOBA8VWA3XK?M PS^!$PL]OI-S<7-S=Q@CY)=\,._([R/)@X.#BOTEVT
M;>]3%<NG3L6Y-Z]>Y\,?L8_L$^(OV5_VAO'7BIM1T>X\$ZE:7%CHUK;74\U]
M'$;F.2+SP\*KD(F&*LWS=..:^YS3>G%.J^9M)/H1RJ[:ZB2+N1AZBOB/]A/]
MB7QS^S#\4OB!XE\5ZIX?U"Q\01A+2/2+B>65")F?]X)(8P.".A/-?;U)Q41T
MESK>UBI>]'D>UT_N'44450%#5M)M-<TZZT_4+6&]L;N)H)[:XC$D<L; AD93
MP5()!!ZYK\]_BQ_P21@M_%DGB[X&^/[[X:ZKN:2+3Y))O*A<]H;F)A+$G7@B
M3KP0.*_1:C%397NMQ\SM8_+;_AW7^UCXXB.C^./VB/,\.3J8KB.'7M4O_,0C
M!#02)$K\=F;UKZK_ &4?V _AW^REG5--$WB7QC)$8I?$&I(H>-2,,D$8^6%3
MWY9B"06(XKZ?I*M-QO;J2US;G)_%#PS=>-/AQXIT"R>&.]U32[FRADN"1&LD
MD3(I8@$A<L,X!..QK\N_ 7_!,K]K#X5V=W:>#/B]X?\ "MM=R"6XAT?Q#J=L
MDK@8#,$M!DXXR:_6_I1VK-12DY+=V7W%7=DNQ^77_##O[<G_ $<3:_\ A7:O
M_P#(U?4W[%'P3^-?P;LO%D7QC^($?CR>_DMCILD>K7=_]F5!)Y@S<1IMW%D^
M[G.WGI7U#2"M$[)KN2U>WD?#O[/_ .Q%XZ^%/[;'COXP:MJOAZ?PQKTNIO;6
MEE<SM>H+FX62/>C0J@P!SASSTS7W#2]J,5*TBHKHK(;UDY/=B?PU\_\ [;WP
M#\1?M*?L_P"J>!O#%WIEAJ]W=VLZS:M+)';A8Y0[ M'&[9P./E_*OH#K2^E1
M**E^#^X:;1XW^R/\']9^ O[//A'P)X@N;&[U?2(IH[B;39'>W8O/)(-C.B,>
M''51SFO O"?[$GCG0_\ @H)J?QUGU3P^WA&ZFN'2RCN)S?@/9F 90PB/[W)_
M>=/?BON >M%;.3]I[5[ZK[]R.7W/9] ]*Y7XF?#G1/BUX#UOPAXCM%O=&U>W
M:VN(FX.#T93V92 RGL5!KJZ6LI14DT]BXOE::/@G]A_]BOXR_LA_%#6A-XE\
M+ZY\-=79UN+2*[N5NP4SY%PL1M]@DQA67S,88_,=JUJ_MS?L1^.OVF/BOX \
M4>%M5\/V%AX?A,=U'J]S/'*Y\\2?NQ'#(#P.Y'-?;]%7=\T)=8[$65I+^8Y7
MXH>&[GQG\-O%.@63PI>:II=U8PR7!(C626)D4L0"0N6&< G'8U\\_P#!//\
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M]F?'O[8/_!/31?VBO$EKXZ\+Z]/X#^)-H$*ZM;(QBN3'_JC(%*LDBX 65#D
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 E+110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4E+10 4444 %%%% "4M
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 )2T44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %)2T4 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
44 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>oncyf-20241231_g1.jpg
<TEXT>
begin 644 oncyf-20241231_g1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!817AI9@  34T *@    @ ! $Q  (
M   1    /E$0  $    ! 0   %$1  0    !     %$2  0    !
M  !!9&]B92!);6%G95)E861Y  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" (; I\# 2(  A$! Q$!_\0
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M%ZS.0*N^<95(]:I2V+>9\O/-!!>TFY9E^:K5U<;!4>E6+ #=UJQJ%IN@/;%
MRG#=DO\ -TS5SRO,3@=*R8CLD"FMRVD40X]J 16BBQ(?2M%0I@_"LNZE,4GR
MU8M[LO'MH'$S?$)\H9%8JW#/+6QKYW]:R[: /.JT$/<MVN3]*NQQLX]JF@LT
MBBILEVMN,4QF/JB$2D4NES&VE_&K=R%NF]ZA2T9'I ;<%Z)EI"<FJ=J-KBK@
M8541^HV08%1JU2N-XIBPX-#U$1W#;!FHX)<G^E+J1POX5!8NS3;?>I U%@\Q
M:;]DVC-6(2 *?< &/BJN5RF9+>>5)MI)'-U$:@O(2):L:9%A?F[TEV)*#61#
MUIV2[(E%3-9 ]*$BV4#LR>,\5'-TI4YI)CA:13V(LYK.U%L2\5:,N'J"[AW'
M/;%4V0/T>3]Y6M(ZYK'L8O+D&*T=V:DJ(XS9--D7:M1,X4<TJ2[ZK8.8C\S]
MY5J ;EJ$V^6R:L0?(M((C9T\NH8I5#T[4Y\15CB[;S/QHN#W.@:0&/;565=Y
MI;>0RQ4DGRFF@8U8Q$O%9E]=%)2,U?DNE"-UZ5@ZF[/*:'Y$FQI%WYK5I,N%
MKG]#!5A6Z[92B(T]!E!.*JS7)5ZCFNFD&*.81-/J"Q*<=:IM=^8:AE)<TZ*$
MLU2!:@B+KTJU''LC]ZBBG\E,5)#=+(*:&[CU&#DU,DO%0N<BFJQXSQ38AT['
MM4,<^#4Q.[Y:C-ODU-P([^<+;-ZUDQ2X>KNIHRQ\]*RH/FFS0!U^B'$"U+J,
M7F+5+2YRMN*?/J"XQF@J^A3*^5)5ZWG5QBJ-U(&%1QS^7("":"369:JRL/,Y
M-*E[YB5G75RS2GVH*;+DUO\ :5Z5"+0I_#5C1Y?.&VKTUL"GW: 2*\+%0!3B
M^:D$.3]*;/\ (#0%M MUS6A%%E:RXI]AX-7H[L"+WH")#J4$8%<GJ,.VX;;7
M37KLY^Z:R9[/>_3K0*11LHN:O"V+U<T[25C3)6K@L=C?=H#E(=/TX@<U]._\
M$C8@G_!0CX?_ /<1_P#3;=U\X(/)6OHS_@DA-N_X*'_#T?\ 82_]-MW0S#&:
M8>?H_P CYC^U[WJ9+7S@:SDC^<5LV(R@S0=%C+O=)7JM5[6P_>BMN\AST[U4
MV>6U F6K6#Y.*69BG>HDOQ"M,DO5D'WJ!^@R>3>*=;)DTBQ[ZFBCV'F@%N2R
MDI'7.ZG*QNB:Z1YU9,;>U8>I6F;@T!(-)/G\GM6DEJI8&LVR'V4=.*L)J>']
MJ!(V8(,5!J8_<G%.M+O?UZ5'?OE3[B@HY^6,NV?>M33Y?W ]:I&/,OM[U?M=
ML<?6@@;<0;B>]$"^6*GQG)S^50.I5^^:!E75XO-3-9L46V1?K6X(6FCY_E4?
M]DKOW>E K#8N8:SM3<H>:VHX]IQ4&J6*SQ\#\J!F/:3-YHK:C4-%67!9%)!6
MD8S''BF(>J*HJ!YCGBD\XI46_>V*0]F7K5O,3FI"%%0I^XBJ,3YDJ@"]CW&H
M;>(HX:M%(?-6E^R;1TH8K,JO<[&ZU)%>YZTVXLFQP*@,++VJ2B>7;(W_ ->I
M+=0O3I5/IUJU!\PJMP+<<@(YZTK'(JG*_EFH5U!NE2-,T W-1WC*L)/?%107
M.Y:+H^9%UH$Y&8]UF7\:OV_[Z'FJ!MB)>_6M*PM6V4$@D82I&;*T^2#;4>,-
M@U6C'L5KL_-3K$9<#L:L-:^;3X8! *D:'/\ =J%Y<&I99%)IH@\WI0#U*TZM
M,OUJDMD4E]JUF@VBHV4 U6XK$EDFU*;?<+BA7*4KGS%^M#'T,R1#BH)+ OVK
M3%M\U2)$*5NY)5TS3_*'-:9A'EE:A4[:>)\BD4M"G/:G?TJ%;+ZUI?*]2>4"
M* Y3-AL%7[U/-L,U//B-<U46[RU5H207_P"X&:JPR,9QSUK2ND^T1U5CL#Y@
MQ_\ JJ0+EJ-XJ9X=J]:=;1;%I\VT)S57*MU*R-AL5=M8=RUE-<!9?QK5L)MR
M^U2"W(M4L ]NU8+6?ERCCO73WTV(^?2L.0;I<^] 2W+<+F*VQ[=:I2?/*:O0
M@F*F1VH:3G\:"1]K8^?%R.U5KW3C;GVK<LE58Z;J5NKI05RF';K\V*6XLSGY
M:?\ ZJ7ITIXO,"@&2:7;>4*TQ)B.J=G(LBCG'-7&C 3Y><T%#DD7:6JG=OY@
M.VJ^H7+0_*.*AL;C?)M-!-]2P+=L9J5'*=:NB-%A!]JS;J3$O^% 6[%J.+S1
M49MEW=.14EDS,*F<A*"AUK%LCI;EPHJM+J*Q';44UV9AQ0*Y%J.I^2,5]%_\
M$?+CS_\ @HG\/?\ N)?^FR[KY@U/<9N:^F/^"-R,?^"B7P_)_A_M+_TV7='0
MY<8_W$_1_D?/:QJ&JS$^P564\U*K8H.E$[R?+BJ\O(HDGR,5&&S0!3O"54U3
MCE*MUK6FMO,7FJ,EF87H)-#39PZ?-4TT^35&VW(O2DDE):@"Z)LU%+AS\U%N
M?-6DGA)[T# 0*T=0/;\>E2PR%5]ZCGD/UH$6() B 5),WF(5JBDQ'-6HWSS0
M,A>VP::9?+%6I "/PJG(* +%K+D]>M6EB\Q:HPIL6K=K)S0-#L;34%S>+&N*
MT)8 8ZP=:CP_% ,D6]W2#%6BZLM9-F"\E6KBY\GB@DM1Q*SYJ9X,I6=9:@#)
MMK26<,E S.NQL-1P<FG:AN+T:;#N:@1)<2Y2JJ,<UH2V>X4U+)5% $UK/\GI
M4PG^7-5POEK4<TFU*!EAKD,::?G%9,UPRO5W39BX^:@=PE&#[U/:G"T3Q\TV
M%MIZYIBZCKE<BJJPX>KDWS"HXXZ0R,ILIT;'=S4S1;A3=H4TR1PC7TJ2-U45
M$3Q4,TI%(I%R6?-5&<[Z;!-\U6A;;A0&XZVFPM-N;DA: FS--:+?UH#4IB9F
MD^:M"TD^2JYM]IJ6-MHH)'7<N!5:*XPU6)5WI5*1=KT%,T8E$@J.4;:+60JG
MO1-\XH&1M)\U&[GI31%D\U($VB@5Q6EVBHFDW5#<S[7J.WN-ST[V N12&G27
M)3BA#D5'*F^@"&YN#(M5T4ENAJY]F#"DC11)2))88\Q4NU8S3V98T^9E4>I.
M*I7UQY:AE.1ZCO5 61(!T-)/+N2LN._._K5N*^68':RMMZX/2I @>%FR:O6$
MS0I@U+I=M)JEP(8+>:XF;I'%&9&;Z #-22VWE$[E*LIP01@@T $K>:-M5GL_
M+-(UX$?!JP)Q+'0,:G'RT!-OK4UO8SW4<LL,$\T5NH>9XXV98E/&6(&%'N:C
MD.*8B:WGQ3KHL5ZU5MI<&K;HURJJJLS.0%"C+,3T %(JYC7%Q^\-$*;LXJ/5
MK.:PU&6&XAFMYXFVO'*A1T/H5/(-6=)CPO-!)+;0LK5I1MMCJLG#5/-(H3K0
M4BAJF)#[U6M(3'/NJ2:X5I,58MX]X!H)ZD_G,$Q5:9?G)JQ(<"JLMQAJ"F3P
MR>6*BGO6)(H+[DJJS8?F@5QWEM(<\U8@0QCFIK+;Y>6J"\OE0[: &7=N)AFO
MI7_@CQ!Y/_!0OP![_P!H_P#IMNZ^:K>;SACK7T]_P2(BV?\ !0GX?'_L(_\
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M%^R1^V3\+=+N_%GB6]^*FJ>';C6I[06,9T<Q2V\J-$L@(D1UPY!.X,(SG:6
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MB7-U<16)9,>J.W^KQV\K9S[U\NZ-XSUZ[^)]D_B-;(6<*E8RKMY0)^Z_))8
MXXYQWKWCP/XZ^R:5=WVH:_IJQV4F0#,T:.",@#&'VYSSSVZU;I-'-[2K'[3O
MZLY#]HC_ ()<>)_"=Q+K?@EHM2T6X821Z=<S".ZM W.P.QVR<\#)#= <GFOG
MCQ'X.UKP#J+:?KNDZEH]ZA*F&]MVA8XZXW#D#U&17WU\-OVU_#.F^9#+"9+6
MXB\IRJ&:VF8]1N/3&<#CMZU@_$SXPV?BX77ASQ3IUGXR\,74FRR+?N[BWW<Q
MRQ2?>#@';D=2"#D5&J/1PV<5(6C55UWZ_P#!/@BZN&#;34MA+O.W\J[[]I?X
M$+\'];L[C3Y[R\T'5%)M9KJ+RYX)%QO@E XWKD$,.&4@@#D#SO29@):9]%2J
M1J14X;,O7,&!S_%4M@1&U)<R^9%5&*=DE_3%!J:6H89/PKDM1E99V"UTL\AD
MA_"N=OEW2-ZYH%+R&V(+BM*")N!4>B0)L^:M":181E:!%6_MB(*QO);S-U:T
MNH;R5:HOL?GC*_I0(GTN^:--IK1\WS%S67#:-&*O0?(F#30R2H9#\U3>9NIC
M0[FS38#<[DJHTGSXKJ_AG\.+_P"+/CC3_#NF2V<%]J9D"2W<AC@C"1O*S.P!
M( 5&/ )XZ5'X[^#U]X,\,6'B"UU;P_XDT#4;MK!+_1KIYHXKE4$A@D5T21'*
M,&7*X89P3@XDGG2?*8MI^\05.;7=76?#7X):UXK^)FB^%+^UO/#E]K2O)"VI
M64L.$6)Y-^Q@&92$(!'&36/HN@:EKVA7.I6>EZE=6%BH>ZN8+626&T!&?WCJ
M"J?\"(H*4HF%>R?9Q@5%!=><=N:U+SPAJEYX?FU:/2]2DTFWD$4M\EK(UK$Y
MZ*TH&P'D<$]ZKVO@W5H=#CUA]+U-='DD\I+]K206KO\ W1+C86]LYH"Z,VXL
M-S$U/I\/DUN7_A#4],TBSU"\TO4K.PU#FTNI[22."ZQ_SS=@%?\ X"33-#\+
M:AXFU5+'2]/OM3O) 2EO9V[SS.!U(5 20/I0'2Y5C;'6B3D5WWP=_9\U7XK/
MXDFD74M,T[PG:_:-1FCT>XOID<RI"L"PQC<92T@)4D;55F/ K@YEV%E_NDCD
M8H",DWRHKDX-5=2.5%23RX:HY$\^/CM3 JV$NV8?6MU9OW:BLB&WPX^M:"<)
M2&A[3<TA.X5&\@C!--CFWGBF%QLC$.*L6_--,.X<U)%B.D-#IH]B[JJ_:%5^
MM37T^8.*Q)96:7K0)F^L^4^M02#=3+!B\0J25=M,8U5"BLG4[GRY3S5][O%8
MNJ*TSG%(DOZ/>>9)C-:Y&!7/Z+$P85O8)CH!#,\T.^Q>:JSRL'J&25I..:KF
M DN=1VCY:J_:6=N::R,[5)#;'<-U2!8MX&<?UJTD>Q,57%P8UQVJ2TO8Y)U6
M63RX]P#N!G8N>3CO@<T :7AGQ+J/@O7K;5-)OKK3=2LWWP7-O(8Y(C[$=CW!
MX(X((KZJ\$_M]^'_ (I:5;6?Q(L&T/Q!;+Y<?B71[-9(+L'@_:K4$,K$9S)"
MPZGY17S'\1_ MU\._$\NGW#+-$0);2Z0?N[R%AN213Z%2.YQ6"N<C.*\?,,I
MP&:T8RKQ4EO%]5Z/IZ?>C3WZ<NS1]=ZS^S_=>(_#\VM6MEX=^*OAN1^-0TN4
MO<0+S@22)MFA;'>0,N>IKS#QY^R#>7/A&\\4>!X]4U+2]-!;4=*O$#:CI@'W
MB"H G1<<D*K <E2.:\V^%_Q7\1?!GQ;#KGA75[O1M2A()DA;Y)Q_<D3[LB'N
MK CZ5]S_  .\50^._!6D^+-#ADT]=:66>_MT<LEK?+(5F16/)3.'7)R%D4<X
MS7QN<_VAD"CB<+/GI72<7LO\KVT:MKNNAW0J/%U.6IOWZ_\ !^9^=>I7:M;?
M*<[NA'>LVVG_ '@'O7U/^V9^RJM\^H>,/!^FR6Y4-<:OI4<>%&.7N+< ?=_B
M=!TY8<9 ^4[%=TBM^(]Z^VR?.,/F6'6(P[]5U3[/^M>ARXO"5</4]G47_!7=
M'7Z=,(K;)Z 9-?4'QQ\!S?"K]BOP1X-T^SFN/$7CS55GN;>",O/<.L:3N@4<
MG#26J ?],C7RI&S?8VYY*XYK]-=6^)F@>-_V6O!GB[0U@\W7"Z7-P0OVC2I(
MX@+N!'(RA)4C@C*L#R,5Y/%&,J854*ZCS1C*[5[:V:C?R3=_5(*,8SO%O6VG
MYO\  ^7/A#_P3AUCQ%=2?\)!)JQN+=5:YT_0[=;B2TSVFN&_=(W^RH;'KFK/
M[07[$%O\)_"5]JD-GXBT>&S4LDFK:E9.L^!G&Q=K@GH  22>AK6_;C_:)U30
M?A7\/]"\%:M=:+H^IV<MWK1T^5H9KJ^^0&-W4[MB*VT $9QGFOD.?5);RZ\Z
MXGGN9<_?FD:1OS;)KGRFAF>,4,=5Q5HO[,8JUD[6UUZ6U;?F7[2-.\735[=6
M[^NC-.0C%5&F57YK<\0^&H_#&A1M?731ZQ<A9([%(]WEQ'.7D;/RDX. ,DX/
M0<GD7D;?GGK7UU*M&I'GAJOZV[KSV?0PJ4Y0?++<TGM?. ;VKNOV?_V<M6^/
MVM:M::;>V.GMI5GYXDN]P2ZN';9;V:8'^NG?*IGCY23P*XS23OB&ZO8/A_\
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M3TMMIYH-K!;VBQ**^D_^"2+@?\%"_A\O_81_]-MW7S=)/Y5?1/\ P2*DW_\
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MM@L6%<3\.?V4?^%@^'O!<[>,=$TK6/B))<V^@:7<6MP[3S0S-"5FE12D",P
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M-TO28E2)HN6VJN /K[^I-?F7'/%=+&91'#X;2<VN:Z?NVZ;:MO:W1:V/;R_
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M7P/^V-=?#H:;'IG@_0%M=!U:?5M+MGOK_P FU:?;YBR(LP%P?EPCS!FCW''
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MK;\;EO%.A72,TGEVL[S0D _.VT\'U')Y[5\Z-:"&:XFU76ETIKI\1G.UH6.
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MH^#^B1PR^/(;R\3QU\3]/O-,MUDTU]-UJXCT\6SB5(?[1S#+Y4@AAE:+<55
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MKN%^8G)SJ^)?VIM4U_Q%KE]J?A[PAJMKXJC@;6M-N+.4V>IW$))2\(64/'<
MLWS1.@PS#;@D4S'EK6NWK_PW_!L=7X9_8T:_^*VL>$KK6M4FO-/N+2&!M&\/
M3:EF*YC61+FYPZK;1H&575G:0/N 5MI-0>$OV09=>T'Q!<:AK%]%-H.M7>AW
M":/HLFKK8O;CYKF[$;B6&V<Y"NL<A.US@;<'E?!G[4>L:!%?6R:!X,FL;S5H
MM=MK)M+*6FF7D48CCDABC=5(5 !LE$BDC<06))W=._:GU30_&UYXEM_#/@M-
M=FU276K2]^P2B?3+N0AG>)A*"ZEQO$<WF(K$X !(I!:OK9_D6_AE^Q#JGQ&^
M'NAZPVHWEC=>*;6>\TO;IGFZ;%'&\B+]KNC(ODF1HG"[8W"C:6(!X\U^$7PW
MD^*WB^/3/MT.DVT=I<:A?7L\;2+96MO"TTTFQ>7(1#A1]YB!D9S6UIOQSOH?
M"]GI.H:#X2\02:3'/#I>H:KIWVB[TR.=WDD1#N$;KYDCNHE1PC.2N*P_A_XZ
MU'X7^)K;6=):W^U6J21-'<PB>"YADC:.6&5&X>-XV96!Z@]0<&J-(JI[UWZ?
MU]QZQ\"O@#X/UOXT_#"^DUJ\\0>!_%.MR:<R7.C^1<_:[?RW:TN(?.*B-TEC
M;S$D;*D@KD$5Y)\4=;L_$OCS4+W3YXKJSN&4I)'H\.D(<* 0+6%F2/!&."<X
MR>2:Z#_AI36M.\6>$]0T?2_#N@6O@F[>_P!)TNPM76RCN)"IDED#R-)([[4!
M+.<*B@8 Q7#VL6>?6@*<9<W-+^M7_P  @:(LM=)\*/BO>?!OQ8NI6\(O+6:,
MV][:%S&+N$D$KN'W6! *MS@CD$$@Y$L>U*S[H;UQ6-:C"M3E1JJ\9*S3ZIG0
MI.+YH[H^Z/#GA7P%^VEX46U\*ZM9Z]>6\!E/AS7"+/6=/8#YC!*/O#/="RGN
MO:O"O&G[&WB'2(+Z?P]:ZAJ T]REWI=U$(]2M"/1>%F7T9,-_LUX7I#W&E:K
M;WEG//:75JXD@G@D,<L3CHRLI!4^XKZL^&'[9.H?&LZ=X>\<3(WBBWC\K0_$
MT;"WDFD496WO0N ZL!M67@J2-P()-?&U,GQF3Q=7*I<U-:N$M=-W;7\FGWN=
M'UAU)?OU>_79K_/YGRU?L\%W)!-')#-"Q62.12KQGN"#R#[&D@MOXB?Q-?7D
M7A^'Q_XCMY/%GAG3/$P8EY)C$?,>,],.I5P1]<<5U&F?#CPGX*FCUC0? NGV
M-O;L-M[/$\Q#]1M\PMCZBN>IQ]1II1G0ESM7233C]]T__)3HIY?&I.T)JW=J
MWX?\$^<O!G[(GB+5M"L]:UR&;P_H]\1]E:YC*SW@Z[D0\A,?Q-^ /6OO']CW
MQ#X#^"?P_P!:T?3XUTF9K5UBN]H+7$Y7 );JSGJ,]@0*\E\4WNK>.M!AGOKQ
MI(Y'+&,R'RX<<9VYZG/:O09_AEX^\ ?!*XOKC3_#<NAWTD5M=6=\X6:%2=R2
MN"N!CG&UO,4-VZ#XW$9IB\\Q%.&)]VG?6"^&U_M=_7YI(]"O@Z%*@Z5[M]>K
M\EH_NZ[,Y76?&&H:;J]PDD<TMT^U8I98_E50>'4GL16K\./VA9M%\0R+J%_]
M^*2-7E7=SM)!QG/)!K@_'/Q)U&]U$6=G#)#:K$4@G7]_O')X.2W_ .NN9U'P
MO:^'[73?,M[P3.ZO))<KY1N&W$G+-PH/.!FOU3)LIE4K24XII+3OT_0Y\54H
M3I<LU9VZ:]#Z$\/^,)M5E$=Y<7$PNH9)RSI@1\9!&.G &/PKL_ =W'XS\*6-
M^TFY9+<2/*KD;CRO Z9)KY^3QU;^);&WC;4[:&.X/DR"VFWNASC&>!DCC'45
MWGBS7;UO 4^F^&I)+:.WB2-FCYV1*,D*?7@ GUS7U%;VU"_+'2VR/DY454E&
M#TN]7T/0_%OC'3M-N(=)TS_3-0N ROL)Q&.^X]AVS7GOB[1=,TC4;.74+_PY
M,(Y 'L[]!LN-YQA<\MSCGVKSBS^.D?@?1?L-O'#'=76'N+QGW,Z@99<>N2,5
MY/K'QGFDU*>XCBTYK6:<7#W5W )IHL=USVW< =*\/*,%+$8E>U333NK[*_7S
M/6G@Y4DITW[OXO\ R\NI]R?"OPQ\._%-];S7G@'PO+JEQ)Y(E@.XN!@Y /
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M?LCW5C9W#:U,NB:I!;&^US49E#1^&[$9+1 GC[0R@[AV.%Z*^?F;XL^(]/\
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M[CPE+;Z=! VM7(L[9XWA=<>?(,,$))(.57GBOF,1M/(L:*TDDC!551EF)X
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M>I\X_"">\N_A_INE^'9O MI8ZA+=0^.'U@6YO6A,B&!0L[*K6;1@API)#*>
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M!LM/'9'V_*V/^>:80=RU9_B/X^R>/=$NM)\26[76CRNDD=K"Y@6 IG:$V\*
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MDS0L L4(^9BX[#MGKD@5[5JNL>#[SQ3<:+?W^GRR>&XT/]D6TJ.--! *RSQ
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M0K<Z)/M$LMM-;D,L9)'W&^8 'HW/%>OZ#^UK)X3M9KR9K>Y5GPT:JWES*/\
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M[ U\=I936S-'*C1RH2KHPP4(Z@UUG@;]HF3X52M%?:6TUY<I:V%C>6]P85A
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MJ1_,*DNAF(LOI3KCPYJNF^'+/6)M-OHM'U">2VM;YX66WN98\&1$?&&9=RY
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MIF>2,.[/R>%$6 !C.:\M^)]Q#?Q^'+W3+A6OK56T\J[*[,5!SYB8P 5QM4C
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MTKFIU2*?Y8UX.1QTHW+J4.:5V_Z_R_4CTR&2:[FFD6-7N)&D8)&(T!)).%4
M*.> !@#@<5Z[^SW^T9XJ_9B\8+K'AF\55F 2^T^XR]GJ<0_Y9RIW[X889>Q[
M'S*P=63++C%:",)8NOM3\C7V<91Y9;'ZN_LX_M&>$?VLO#;WGA=S8:]9Q^9J
M?AVXD!NK/U>(_P#+:'/1EY'0@'BNA_X2B\C^)L?A_P#X1G7&TU]*;43X@'E?
MV:DPE\L69^;S/.(^?IC&/<C\?]#\8:M\/?%-EK6AZA>:3J^FR"6VO+60QS0,
M.X(]>X/!'!R*_0K]D#_@IOH/QX-KX<^(TEAX7\:2;8K?6 !#IFLMT E[6\Q]
M?N,>A7[M95(RE;E=M?O\OG]YY%3"1H.<^3VD6FE=M.+>TE9J]NB=UW3/I,A8
M59G9(XT!9W=@JH!R22> !ZGI5RT+02+)&Q1EPRLIZ>A!%97Q(^&UCXT\+:QX
M7\3::M[I.M6K6=]:2,RK<PMC(#(0<' (*D=*TO#&@0V=OI^DV,<=K:VZ165M
M&"=D,:A41><G 4 <\\5/O\]K+EM\[^EMOG\CS+4/8*2D_:7=U9<O+96?->][
MW37+9))W=[(US7H=*TZ^U74[S[-9Z7:RWUW<L&?[/!"AD=\+DG:JDX SQQ7S
M#^U7\"?!O[7/PAUKXP>$%\3?\5'HDVD>(SI5H]EJ]W:0SQL]W#'E7+A8O+E"
M,#+!(<'<N#[%\"/VE]$_:$?Q1-X;TWQ)IL7A2_%C)/JMNL/VQB71BJ?>0AD8
M%''*D$$@D#M-/U*31Y[=[,0V8L^(([>)88HADDA44!0"220!SDUQ)QQD+TY7
MI--.UT[WZ/R]#W*U*KD=9T<52E'%PE"2NXN*BX\UI1L[N5XOXM%=-7/RE^-'
M@_4/'?@+PSKOAS3;I_"?AW0!;VUU?748U*^MDE<FY^SM(\PMT+A5+$X4 \+C
M'FO@?6['2O$D%QJ4+3VJI(ORPI.89&1ECE\IR$EV.5?8Q ;;@D9K]#/^"AGP
M"O--^'NK^.OAKX7T0-<Z8=,\3+;P/]OT^S.<R0(#L,.TLK87=&"2.,[?SC6R
M4JK)R&'!'>C X>I"A+#U4E%74;-WY?-]_2WR/H,5FE'%UXX^A)RG*TI\T8V]
MHW>24=4X^JL^UC<\1ZQ9ZYXFNKJQMUM;60KL01+%DA5#/L7Y4WL"^U>%W8'
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M<JG*HSE?FIV=WR:V7-LW:]O)N_#^/+3PWXIT^WLM4TS3_#]NO""&R2T:!B,
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MO$$D>1UW]Z]NNOVB;GQ1\&]4\;:'XCUKQ)8:WJD&GVVC7D'EQ^%!%ES%L P
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MJ:UN$\GQ=25/!8A-QWM9V?9V>C\MSZM^%G[./_":Z:)M2O%M8MH(AA(,G/\
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M59$FG6\JPJ?:M?Q=\1)-;\.^%=+G@CMT\*VLUK!+&QWS"6YDN"S>A#2$#'8
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MB_M=.B\CWLRR'+,(U"CC%.,X*<>6-WS-V]G47-[CNI-N\M$G;73P?]G>XNO
M_A?&GZAJUPUU(98XIU7Y3RO'/!XZGUKMM)N+NYN;6^6XNHX)[D_:K>5%/F]
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M5IQ_9]Q$A93;1*(D)49*DA-V" ><TGBK7]"?P;))</Y&L!&:21Y"TDDA*[5
MR<KC<<@#@>HYXGPQK+:VBVLEPODR/\JNP!&?3=W]J^<Q<<3@Z,5)QDIVE:-]
M-+?+^O1?6Y=3PV8U:F*IJ5.='FIWE%*ZNI-KHUHM;K[FFZ/P%\0O\1/&-KX?
MTG[5;7EYF&?RV,1=.K;SQP/?H*]6\4>*-/\ $FKN\WF?\*W^'@QR<)JUT?\
MXX1^$2^K58U3P-;^%=!_L_PS:S3>)O$1%@+JY BE6&27:3%T;:RX#-SM7?ZY
MKD/VCO%']@>&K;P%X>M;?5-(T]&%V\>5DO;D_P"LF/&/O#"C/"@"OTW*\+0R
M;!+%8V?+B*B:IW?PQZR5]F]E>W5G\Z9M4?&N>/+<MCS8*@U.M)1Y74FM8P:W
M=GK*S?1:&3XU_;)OO'A-C=;9H[J92%CCW;%7.Q>3MP-QZ '@'/ I^K?$>QT2
M]7?:10[P)%N8S@L2/NN!_,BN5_9K_91\>?%77H-+T[19K#SB[&\OK=MJ!4W]
M!_LD=^XKK_\ A@K6/'?C:;1]=\::3X=EMU>-)RGF0B9>%##<& ;UQ7YMCN?&
M8E5*TV^E[W6A^SY/D>&RZ#AEU)0BDYN*TW>]MWY;[:'J/[*FKVMYXUT_5FE9
M-/NKB2VN[6/YO-&S._'KP0<=>*]N\'^(?!?@ 7-OI]M;V#V88M<7[A[M^3R"
MW3V"@5X#X ^"_BK]F+3UMV^S^++J&ZB>&;2YDF55 D#%UR&12-O49!;![5[%
M_P ,U_\ #8WQ/T:Q@OKW3=4ALS+J-E8P+-*4WKAGESY<:C..I))P 36F'@W/
MV<6[7LFNO8^=XFA[&3KTXK1)MNUDG;KM\_U.^^&6D:M^TMXMNH="U".2PTJ%
M9+^]OSY=O:JQ.P%A]YF(.% R<$\ 9K7/PXM?#FKRQ75\NO75K\PCMU/V:+!&
M""3N)SQS@>QKKI_V,X/@)X#_ .$;L/%&I:?IUY/]KD2)S=37DJH%^>3("(JK
M]T#')YJS\(_A#8^)M>TW1K>>2SBN$DN+NX)'VJ:).K ?P[B0!Z#)Y-?HV"R'
M!1@JU1.5EM)+\4M'^)_./$?&F95\1+#8&7)#1)I^])OMU7X:(Q+?5&TWPTR6
M<,=O<S3%A;0_)L]7DP ,]_I7IGPA^!^B>(OAP->\3:G=7;:DADBA2Y.V)23@
MDG)+$Y..@KG/C'X)T#P?J7]FZ!I>M74_E$SM:S_P=WD+'&!GV)/%>7^,?VC)
M=*TA;.&&ZM=,@18(TWB-G50 9 ,<\X ''/7BOHJ.%]K'EH+E/AZ,92KR5;WY
M)6W;NWN]M2'XGZ%>?#?Q-]ECN(=6M+JZ;R6MK/!$7&TOC^,#@@X''&>WI \&
M7T/A.>\6ZL[JW@A\V1K=3)/#'CEFAYX7OL)./X:\1TKXCW&JZY<70BACAP##
M+*V&=!P PR?F'X]ZC\:_M/W'PETRUU#2W\R660K-Y,A^1"<*P!Y"GOZ<5CCL
MFH8K2K!2?>UG]^Z%@>(,?D]1QP]648K513;2[^Z[I^>E_/J9?C7XTMH=]=6J
MF7[3"V-T)+;@>001U4@@@]P:IZ1!J7[07B'2?#MWI-]=2:E<+;I/- V+;NS[
ML94*N6].*M>#_'\NJ> ];U6PMX=-M88_MKKL"^2-Q#J&_N$?,O. >!UKW+]D
MF2\@^'EQXRNE:.;6MUEI88_,(%/[V;G^\PVCV4^M?!YADL,-BU2HQ:MK>]W;
MRLM.V[/W')>+J>:94L9?W_A:_O>7>/5>6FYZYX1\"^"O#NA:?H]M;32:?H5L
MME:H[_*47J^!CYF;))/4FMY-'\*PVZ>3I\4<T,QGMW#%WMY"A0O'G.UBI(R/
M4UQNG^((Y)O,O(0T.=A(^4G/N*W(_$,.DHL-G#'&L@S&P/,GXFJE4JWOS,YE
M3A*.J,W6_A9:W&Z6Q_M"%Y#D>:ID1L^^,_SKC[SP-JRWCPBPNG>,X)1"R^O4
M<5VOQ#^,6B_"?P]::EK=]J#6MX_E*UI;B18Y ,E&8L K>@/7M7E&N?\ !0_1
MM-E6;3_#NIW4,I*I+>WJQH^/]B,'^=7]<J4-*ORO?]#6EEM6LN:E!V[_ /#V
M.LM/ACK%S!N^R;?]EG56/X9J&_\ AMK&EPM<7EBUA:1C<]S=.L,*#U+L0!7+
M^(_VZ-2'AQ;ZS_LO1[>3"[H(@70D<#>V3^5<"?B_<?%%99+SQ1]ND<9,%Q<B
M12.X\MB=WY5C_;4UK&#:7R7WZ_D>I0X9J5=YJ/X_Y?FSIO%WQ\^''@=)$O?$
MZZY=1\&UT.+[4<^AE.(Q^9KYU^+7_!1;5;&YDMO!/A?2]!7.T:AJ1_M"\'N%
M.(T/X-7>-\-_#/BGQ TMQI=O-):R>9/%9O\ 9OM*$\Y"\?CQ777?[,_PA\2Z
M6MPVCVICN -HAEF6=&'\).[J#UXI?ZR8=).47^'^9<>&G>V[\[_E;\SY)7XB
M>*/B_>B^\3:UJ>M7&>/M4Q:./_=3A5_ "M>.$QJ%KW>S_8^\,Z.MS-:WFM1V
MW)C0,C^1]<KENW4UQ/Q#^!E]X;1KC2YO[9@R,1+$8[H D ?)SN_"NFAGF%K3
MY(RU\U8Z997B*,?AT7;H>7Z]:%HOZ5Q=WI$EQ<,N<'->J1_"[Q?KTWEP^%?$
M'W_+RUC(B[O]Y@!^/2EUC]G_ ,6>%X_M&H>&]5@A[OY!=1]2N:]/V]-/XE]Z
M./V;:NT<%I?A^2*W7Y<UJ0+]GCPRX_"MZU2-4V%=K#@CTJCJL4<:M^E:<W4+
M=CE_$4NZ;:<[<4NI>/=<\50S6NI:_KNH6LT<<,D5SJ$TT<B(<QJRLQ!53R >
M >E3WVF2:B#L4^V*S[3PA<?;.5(Y[]J%+HS-QUU-K4=0U;Q7':MJ6J:IJ@L8
MQ%:_;+R2X^S(/X4WD[!P.!@<"M+4-6UCQ(9IM2U35=0DF""5[J[DF:0)G8&+
M$[MN3MSTR<8S5_1-'$-FJL.0.]6_LR_=Q4R>I<8I(XFXU34K/5[>[74+Y+FQ
M"K:S+.XEM@GW1&V<H%[!2,=JN76O^(?$4\5Q=:]KEU+!<F\B>:_FD>*<XS*I
M+960[5^88/RCG@5M:IX66X.Y5]^*;8:8UDWSK\O2AU+D\B,N[U'5M7N':]U#
M4;Z2:;[1+)<W+S/)+@#S&+$DO@ ;CS@ 9XK<O_$6M>(-0M[R^UG5KR]LU"V]
MQ<7LLLT '0([,2N/8BHY+7SCN5?RIKV[1C&TT[Z#]FALTC1Z<UL)96A9_-,9
M<["^,;MO3=@D9ZXKV?\ X)@!HOV[/ JXPK?;\_\ @ON:\@BTXN-U>Y_\$U;,
M1_MQ>"6_B7[?_P"D%S0GV.?&_P"[U/\ "_R/ES7(C:P"L73M8/V[8P^7UKM#
MX"USQ-!YEKHVJ3QMT=+9RI_'%<GJO@;4M,OUCFL[J&1CC;)&5/UYI\\=CHDF
MM3:LHEO8N&[U)K/AK[?IQ55RV.U-T;29K.V16^]WP#71Z1I%VT32&VN/+7J3
M&=HSTYQ4\PXZ[GBFI>$KBSO-I5MH;@FNH\+:%'-"-^&]0:[;Q)X=^WLW[M@P
MZC;6/I>A2V]RL<*-)(QPJJ,D_A57N+V=F26WA6%Y-W<>@JQJ-BUG:[8ZZ2Q\
M":XFFFY_L?4OLXX,GV9]N<XZXJ!M!OI%=VLKHQQ_>/DM\I_*IYE?1FEM#B$\
M.2:A/\R\=3[UOZ5I8M&5=OUK<\*^#M9\7WK0Z1I-]?RJ<,(H2=OU/0?C7;?\
M,M^.K 1R7'AVZ19#@?,N?KUZ5C4Q%.+M.23]4*G3E+9'GMWX>ANX-V,'%>=?
M$/0Y+:XW*O&<')Z"OJ;3/V0O'&LQ+LTR&W5C@F:X1-H]377:=^Q'X=T\)_PE
M"WVM31@-+#:W"1(/IC+,/?BN6IFF'I:RE?R6IO3P56J^6"U\[+\SX9\+3-&W
M/KQ7;6 DD53FOKW1?V6_A2->@CLO#4K7<*_\>TUW(WF9Z$CN177^(_@=X"TB
MT5;[1-#T^5U $(!W*?<@\5Q_ZQ8>^D7^'^9U+)L1'W9V3_KL?"^K>']0U.W
ML;&[O)&X AA9\G\!6Y\-/V4_B)XP9;AM'?2[64_(]^WDEA[*?F_2OO6VN=+\
M/> [>STF&PL[5?E M@J>8?KW_$UP-K<:EXR\3M$LW]EPK*(A/.K*SMQ@(O\
M%]>E<57B*LXMT867=Z_E_F;4\I@O>K2^2/GKQ%^QQXD\+K"]]=::L4CA699"
M2/H,9-=%X>_9Z\*6,4<EU'?:VRN 58^7$Y^@YQ7K'Q@\1V.@:O#9SBZO+BT3
M8WFOLW<<G '6O.]'U&+6KQ;?1]9U;2;A5+>9&Z2QHO<MD9 QQQ6%/,L3B$HS
MGRKO9K[[)O[CLIX3#0>BOY-Z_=L>@^'=:T71(;;2[&QM--8MLB%JB[D/;C&3
M750^.[WP5"]O#--?94F:8I\XY'W%],>G)KB/@MI-C92RM9-]NUJZC>--2N%+
MS23@$[5!.$! ./I7!ZC\<K[1/$4EO?74BS*V=T<_H<=C7FU,/=R]G>:6\N_Z
MKYG54Q$5&TMET7X?TCJ/B1\>])T#5V8W\S7'F@.JHS2)^/MFJ.AS>*/$%]<:
MM)'-#9H,6:3R>6LY(^^P/\('/N:T(O',+:*MQK5G:WU],XEM5GA4R6T?9B2,
M[VZ_3D\FL'X@^.X]8T:(I-]GO+63RV3S&DDN%;!5AZ <Y[#UKKI8>E/DI8&G
M)U'H[V=W_=22?YV_$R6(BXZ_+_@N_7^MS+UC0?&=I<S36-QI<4UP") U^J^:
M/Q&"#R"#P0:X'6?AKK,NHK<ZU]NFFN'\R8JXDC8=2"ZD\GU/2KWB'Q/J%M=V
M\<*S212N$!<_/NZ8 !)/->[>"-,L/#FFQKJ8AN+B1!YZR?,L7JI'0M^@]S7<
MJD\N<Z&+H1YVK:I\RTTM9VZWV.3F4FHU%HG?R_IGR/K?C?QAXT\6_8++0]2N
M4A(MH4M;1VA@0?=0$# _R:ZSX-W?B71/BK--XC\+>(-*T>'3Y[>6Y-HR"0^6
M5W%SQR&V[>^ .]>[^/?',GCGQ!)I_@_1]2O9K2)B5MU 3 X+8& JC@9:O*KG
MQMJ6E>,%T/7X]0TNYDD\BZCN(BIMP_R[B/09SGTYK3+:U6F_;^Q3C:UW?2^E
M^U^U^IYV;4(SA4A=NZ=MM^AYQX>ED\+ZZL*K(+&,@*4VR"W$N#N';@D-CL<C
M->W_ !,^&USH,6GZTNL6^OPK&$EGB40O)&<Y/S %B&8+G)Z>@J/QK^SO8_#K
MX-V\NJL9O%.I7L0M/L>)H;BT?R]V]>/F0'.%);/0'(JQX?\ !'BR^\,W6D7%
MNNJV-M*N=T@,:Q@#&&5<A\?-SG!.#W _0<OQ$HQM'6SV^_YGY=3K.$=K^1=L
M_ABU[H%Q=6\L$=RH93#(-LENXP N.F3D<8 (-<I!\(?%EAJ37VK0R<RKBW67
M?Y:JN688& ,#@"O8OA)X);P1XCAU35O#>M7[_9(U73;:]CEN4B+'RY7B#[HT
M.?O%0.1TKU?Q]J=SXJT71[W2/"UY:QP;9W^T6^X!,.".@+*23R3DYKT)5H8N
M%X-:-IV>E_/S1W2IU&H\\7%O756T>S].SZH\(\0Z/:^(M0T\6UQ>+:JG[RVW
M9DA"C( _N]N#_6O1O#_PFO/#OAZ.\CM;BUL\+-.\LVWS!ZY/+#&.E=/X=\+:
M_;:,S6NF6.DV-[$JB,0[O)&?E=L@D@@8X^8YR3WKVOP/^S[):Q6EQKGB".[N
MM@\Z"$Y17QRR]N@ ]  ?K7/BZW(DHO7J]_\ @#G4=*FH\UWU?]:'S+83S:U?
M7%Q=0R?9[+Y"&SN52>"!V'&?>N/_ ."B'[$DG_!0?]D":3P0T*_%+X53C4='
M@=MD.L0R@+-;8/ =T1=C$<.B@X#$U] ?$3P%X?U;Q^NF:1J$6G_:7*74TC8B
M#*O ^9@/X0,#C/>NB^$_PXU[PIX&UZ/4KK2="NM+ABO%U.&5741+(LCM)V&V
M-&R<D<C%?/XB,:T7&KJGN<F&QE:CB(UZ3]^+T_KSV/PL_9V_:2\6Z;X8AL6N
MKJ&'?Y-S:2 J00=K(R]B""".Q%?0?P[FO-.\;Q:E';1+IL.Z6]$H+>4NTX4Y
MZ[_NX]SZ&O+M'\-+X@^.?B36-2TBTL=$U[7M0U6S07**R)/<22QJ5!XX8'MB
MNC^*?CW4/#\,.F-"\"Y>5I ,K=.^%9L]"%"JBX/ W?WJ_#\PRFG4Q<_812MO
M9II]G='][933GB<MI3JQY)-6DFK-NV]EO;N>E:Q'J&K2KJ$ETNVS B",=RA3
MTP!P!CG Z=*]0^"NNVGC6W>WN&DU!=-0>7;V5O&\[DNJGRU8J,*&W-SD*C'G
M&*^.[7XE:TMG-&K736MQ(D4BI \GFLQX VJ<$<'J#C.,\U]!?LL:/;0W]G-J
M5Y:Z:MWJ$&F1IJ!\OS[N7=Y=LO!/F-M;C@#:<D5I_8^(H8=5<4K0EI%VT^_U
M^[YH\+,,9@JTZF"H55.M2LY07Q*Z3U2U5T]'UUML[=Q\1-$M?AU\8=-UJ:/4
M-6AT]Y=KPD3^0I1U$\2M\K&,D2!2,$J*V_#7Q$T_]H[X?^*?A]:W.K:Q+=:)
M<SPZKJ<8CENKN.4W,("Y)VIM" DY^<XP,"N]^*?AZ*6__L]K6\99(X99C8W$
MEO< QRJZ*KQ_-M8K\ZC[R^F,U@^&M$3PMXSM=4M?L-@;J)KZSGLY%;SPY8EU
M"YRJL,=_2OM^"<EQ%'$4\QC>U-IQDKV6O732VGKVT/R+C+.LOQV25,EQDXNI
M6A**@W%2DN5V<;N[WDNB3M>[:MSNC?$#Q)>_L?>#[B&QA;7?"<K:;.FI6#2-
M;+&RF"9#D [HQ'P2RL8 <';6#^S3X UV#Q/XBUF2\9KR2PNIIYI$WFY:4%6S
MQP27SQT[8P*]A^$.G6]E\1_%'PQUL:]J7B#3?#D>I06]E)'(NH)%''*MO;1N
MH&620D,".C#&16QX?MK'2O%_BOP3X=U*STOQC%INGW8BU.T^UG3HIGC=Q/"K
M*&9,B,[7(5G4D8(!]SQ RFE1S:I6H+2JE45NM]='M:^Q\IX&\7UZ_"]/ XEI
M3H-T9<W3E:3YDKO1-.7NN[VN]#PK2O@)9Z?H:K;V?[Z2247&ZV:2:7,6(1%(
M'41;9<LVY6RO ]]:Z^'=]XBTF\DN(;Z.&\9A;6<4"Q0P$+$K2D9)='VDA@0!
MP<=17M7B;1M-UJZ\'ZPOASQW:HWBBXL(K8VQM!:D+/"+F]C+\V?!96).2R'%
M>0_"/Q O[0G[9_CH^$-%U[POI^@VMN?%=[<VK >(+B$26T-NZ2?\>X1090(^
M6"*QV9P?%R7,'@:%2-.FI*JK-RW6C5UWU:T>A];Q=EU'/,;1Q>)K3I2PSYDH
MVM*7/&\9ZII64ES1O+X8_#K'Q'XL_ EM7U:.'SHX[6/<'D&6E"XX(4<%N"%!
MX)-7M ^$GA?2M U'4I-+ODT7PY<2275S.Z+<%P4:) #@;W#%<;<#=QTS7K/Q
M2\(+HNJQS2Z;J6KV/VY%NELT8+&A."VX<*?3)&3BHOBA\"+?QQX>\-Z+:ZA]
METVQ8C4[=(IO.N7A1&DV!V81Q@%BJO(Q5F8?3Z;@##T\=.I1Q%*Z3?O632CU
M5MT_Y7KKKHE9_%>+O$&-RVC1Q6#Q3@M%&"<HRE4OHW*[37\Z=O=5E=N\? ]=
M^(5YX3\&ZEXXU*:2'7/%6^#2(""8]/M3\K2*/X=VT1J1C*JQ[UXWX4^)=Y!K
M"KNCOH6S+<EP2;8?Q,2.<>U=5^U)XO@\>>(KJZ\J6STVPC^S6<,;;5BB0 (@
M'L !7&? 'QSI_P 'M7O-0\1QQJ)X46WD:+SI(@[;O,V$%2N% )^4X;@UP<38
M?^TL?^^DH1VBG\,8I:)/II^/J?H_!N'APIPWRPIO$5?CGRKWZDY/WGW>ODVE
MTT*WC/XIZW=:Y:6MOK&HMHS6[M;VJ,PCB!<[@%SA<Y!/>N@^$_PVUKXKV6HW
M%DMO:6>EH'N;R\Q%:Q+M=N7Y(8[#C@YZ9R1GF_BEXCTGQD=2U?28IK".UN%,
MT9)9GCPJ< =\\]2,8KJ_AS\>G^&^CQZ?JUNL>EW2>0BR$^=;H5.95;HH!"_*
M01]*^=RJAA/KGL<5\%VKK35+1]]='I?7H?>9[F&>PR5XW)*2]O)0GRR=TN9K
MF79]5=N*W=[JSLZE\,O%NH^)_#W@VSCET_5_%&J6^E6SW+D0Q-,ZH'8C^ ;M
MW'. :_4#X":?X,_X)O?#W_A%=,FU+4-;O$#ZEKMY$S-JTB GY NX0KR=D8&!
MG+,S$M7YQ^.?VP[?P[K6G^(M,L-+$^CW4.HV8BR(S+%@@'G^+&"1W)QCBOM[
MQ9XQL?CE\%+'XC:?-#)I>J6\-UI\D<VX21M$&97STD4Y0@=61N!7UG#>4TH8
MBJZD?M/E;[>6K^_M]Q_-/C1Q-G\LOPLJSY%./OJ+;3DDG:6BMW2VNGO9,]6T
M3Q=<_M'^+91:W-QI:O'F(7"L3+"N=V8U."2V %4X('7BNZ@O/#OPQ:./3)/M
MFI[@;R\GD_?L2,8)Q@+C[J+P/U/'VWB#P;:?#SP_JFC^9HEK>VJ1P70^_$5
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M#[_PW\(-=\O1+6'2]-,C"6Z<AYF/7!D;D*., '%9?C;]HR_2_P#,BN)&M6)
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M+O?M^GZC;[5+RIG*G+@@JN,@D$ \'V3X2_%^+5]?ACDL+.X\/JF(?(TW;]F
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M$?M?_'WQ%\3I(]8^#$GA[QQI5[:M(IT9H]3U**=2"8Y[(LLD< 3HP4G=P=@
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MOX<+-X=UQ6DP[07MQ"^1Z88Y!X[\USE_\-/%VF7;+J7AS4-,CP&#R0G:I(Z
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MI.T5TZWLTON=V[>1X1+^S#\5--U;^T;&WT:YE"^7Y1U) SJ>#UP/UKH_@/\
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M%23YBOL.X]ZU/A39W&N:M&MHUPUQNQY.TACCGI7+?\,X>-O"PGELM8;6-/\
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MJX^7(Z"O(?V+OA[X9\#_  _;P[JW@K3UD^(9<:AIVI6SQIJ2VK?N;6=)%)5
MH9]KX4GGBO2?@CX\75Q"6CGM6C22,[UC:Y5B7P[A8TCWIN  *8Q&H;/)/H>A
M^,M(NK::WWOJLMG<+H^J74XMX)'/D?Z1=2#Y5;)"AT@&2TF ,*:^LRK,(8*$
MX5:5[]>J>UM-_P"M3\;XNX6GFE>$\-7<4NB>C6]UHK/1:MWZ<M]ORH_X*J^%
M? _[//[;FK-X(O+'29M6@M=1E\-Z59>1:^&V:)0R;PQ4^9M\P1J!M#Y/4"O#
ME^,&N>,@\EN^I74%N<F.T!6-#[D=_:OU"O?V"/A!^T#^TOXB^(FN^ ;#7-'N
M+-EN-2E\23+:7NN12)!]E>UC<%!%"A=VQ@D*,=<Z%KK,GBW]B'7M,L?!]MX!
MU*6SOELM%TFS6UE18)Y/LZ!5VMF6..,,-P)$AYY%>36K4YR\SZC*J>*HP]A!
M<RC97;O^6[77_,\]_P"">WASQEX,\6_ ?XI:9HUF]W>>'M>T/5_,A$SR6T<-
MQ-8R%2<[\H(BR\[8T'(8U\*_ '5Y_CU^TAX<\-7VG>;J/B?6T-W9FW\GYGDW
MR@ICY$'S9&,*OTK]+?\ @G%^T;J%[\:/A;X#UNSNKCQ(OA2]O]8N[O\ T6XL
M'$#/##Y).YOW3(K.5&=J=3NQW?Q+^)L>@Z2MUI.FV\VL74L4*SP1(L^68*VY
M@ V"I(SN!R1U (KTJ6$I8ZM0PF'>LG;6R5]/PM\_(^<QN88G*J6.S#,HKEIQ
M4KP3<N1.;7SO>W1*UVCA_B#\!T\,_'&3XV^*[3PK:^&_%&AS>!?'^C6<,XAT
MQG0V3/9RK&KNX"PP?NU#-NRA()([&P\4^%_%'P.\/SZ#>VIT^QA6"RGTNXG>
MSB6W9XDB3[1F6)U4(CDGS%9#VXKBOCWXHG^(_P )C?:]8M]EU*S)U?6'U.1C
MX7TS!N!+;Q1R%9)X)4BPH7<VUP0=QQ#X6^'^@_ 7]D7P]HND7]CJVB6VEI>V
M^I+YD5UJ=W/*TLLK0'*I$4<,/F+9P#WQ.(K8K)\5*-USQ=KK5-]?U_K0K+\O
MRKB;*J52<9>RJI-1E[K2^SL]6M&NZV5E<\K_ &@O &IW]J^IR6>VTC*)(]O*
MTZQ_)P2QRV#C&YL9)YZUX9\%+6'7]8UR[:)KE88BA,B A 3@8/;ZBO0_B-\<
M=3ENY3I]NNGS%EP]O*_F2 <EC)O(P3SLZ+@8J.UTBZU_X07_ (KT?0?[0UC2
MR\^HQ(QC.K6P^9\JN#O7DY7J.<9%<E3-L'1QWM9R4O:]=ES2W]/QUZM'Z#PY
ME..PF6QI5TX1IOEC%ZOE2]UW3=^R>G1<JLSR7Q7X93PC=QZU8M]GA67#@9.X
M_P!T'\N:M^ /'&K^.HKRPL=+M=0^V*4NHW19/,1><E21MP#UZ9Z<UR?Q<^+6
MCZY8V_\ 8.GZU86]V?.D34YA(J]&VQLH!//&6 Z5TGP9TB[U;PK?-I&N:'I,
MFH.L,\=Q=1I.RJPD5HE9/DVNH.2XW<C&#1F&79;C\QBJDN2+5G+SZ;7\EY;W
MT.C.,VQ6'RFKB,/05:I&S4=M.KNVME=Z7O:R6IZ?\'?VBO$'[-?B&7P[)-J%
MMX<OH_+O=+DCVK)&W.P@@@AN@;TKV?\ ;S^+/B#]I[PCH>I6-Q]D\.6,(_LZ
MTM(S#!:J%VA"F3RN-O)/0U\S)I$WB_Q+IUM'8K-'HR^5(S@[]0E8EI9G.XCE
ML 8., <5]@?LS^'/M7AFX\-ZYI\EYI\D9E@6([7B<+V.#P>,\?PUXU;+X4<0
MX82?-!VU[]?U^>]B<DS*4J5/&8Z@H5XJ2?=-Z-IOK9+T3:NS\^_AI\%=1\0?
M&BQ20^9=-YC;I"""> >>G>O5/B)^RW<6]G<W%U:1OE0-B+R!_>/I7TIXC_9C
MGN?$-O=64EKI4UG+B%PIPV3R&'^T._4<5M^*_".CWWAZ='O;K3=4L0$>">?#
M;O[Q!ZJ<#GO7T6#SI4N6C'=;KY[_ *>1X-7&*ABKU+ROU/S2NOA=?>!?&<<P
MFGM8X^('7G#$CC:>N>F/\:]J^$_QV\*P?&CP[<?$KPU>7G@/[3Y>O6VFN1/J
M$8B9$8+N!!W[&9 V<!@I&:V/B7<6'B_4CI][;QW5I;S*\GE.(@Q!!QGC&<'/
M/(],YKA?C=JNB>,K6W-C&5<RE+>6.W\@6\2HBK$PR2>0_7)X!W'-=694)QH3
MKTZBC&33<&M[=OUM\[(ERH8G-L/1GAYR=I)5(NW(FK:N_JXWV:O&\MO2OC]\
M)+7PAJTGQ"^%-PVI?!?6;S;:75O(\LWAUF )L+^-_P!Y!*,D OE7 &UFKV+X
M!?%VR@\%VNZ^;=LVG:^.*\D_9C\6W7[+GP*\:>,I)9OW-G*MSILENMQ9ZW%Y
M986MS"_R21.Y12&Y ;*D'!KJ?@)X*\(_'WP WB/X16YL]42+[7JW@62X>XFL
M2HS*^FNWSW%N.3Y+?OXAQ^\4;J\#!X.%>$ZM%6=[.W7KIY:_\.:>(V.G@GAL
M#5ES**;4G>[3LDI]&U;XD]=VH]?3O&7CJ\\2.;>T:299@?WKL24 !))_#]<"
MO+/'?A^+0EDN;F[?IMWMS@]B .^>,?SZUSUW^T>N@Z]Y<"-,PS%<1(<,!D9
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MI:='=G3=.O"+568.ZIYC(4B=/+9I2/NAV0#<<']OX7G0KY31JT=K:[_%K?\
M%WZG\W\<4Z^&SS$8?$+7FTV^%VY?P5NG6YYKX=^(6N^%/"$=]X?_ +*T?7-0
MU9DTFW6*&XDC:.>+<B-*A0$EGDX 7RUZC^+[*_8_\/ZU=^*/!'C_ %+0]35Q
M=--<C6%=5N%\MH[:97=B7F*+)M?!VDAR6W*YYO\ 8[^'&B_M ^&M2CFTSPOK
MFC1VN;G[7:1*UO Q>-(5\[*0LYE8 *XF.Q2R,&&?;O#?B_3;7XF>%O"^G::O
MA_0[>[NM'B35HVC^U&*Y=08I9)R4D=5<>5M\UPH8KAE4].,J1M.B[-<OO7M\
M/*[]5:Z_"QPY;&:J4ZRNI<R<;7OS<RY;:.^N]^MSV#XD7<<WB6[T^ZOI&DC+
M;YYI,L<$XY)_&O)?C/\ #/1?C+\.KSPOJ%TL"^8ESIUR(=TEE>(C 33%@VZ,
M[BNR,+\K$G<RK1XY^(=OJ'BK6M0OEGMUN+EIA$T9$JIGCY.N,8]!63XPUO4=
M?T_[5I/EV\<2[FP5>Y9!C(_NJ<9P.3Q7X5P?E-6$)8[#RM.+]VZ3?1WUZO:_
MKW/ZZXDPM3.*;P$(.:M[R3M':S3>B\TK[I-+0\=^('[,GQ&_X6YX)NO#NA3&
M[:?=>O%<"[TVX194>5$/ 57B+8 Y!C<@ * /HW]HW28OAWXEOM2M5O+/7M0@
M,;JD9N[/2(C L)$R+@.'VYVPE&0,2KCD-Y_X&N-\OVJT=;N^\U;F)KE?-DAE
M"LBNIS]\+(XYR &-?1GCBU\1:KX,\*W\4.GQ2?9Y;;41<1DM.JA?+^;[HQR#
MN!SD8Z5WYMXC8G&1C1P\53E9\S:W5U=6;:LUO?S5[,^1X=\'Z&7S>(Q$G4]Y
M<J3M9V=G=13NGM;K9VNCY&O/%UQXAU>Y@M=0FM])5@+=))A I';C/KD_,3CC
M)S5'P]IVKMK2V6GW#7<>I#R'6RD\QV]5('/M^->]7GP[\-K<K<S>%[2ZG;[[
MVMFK*&[C[P'7VJ]<_%*Q^'>A3-I>CR6MQ#&V%2SCCDB[9SSD?3/TKX/%XO$8
MMKVM?F\N;1>BV^X_4J>6^R7-&A)=VX_FWK]YX_XE^&-_\-7L;.\39>:E,JPV
M,<X:1!W=AR%P,DD]/2N/US]IZZ^']YJ=KX7O+CPYI.J2B2YCTJ589M195V!Y
MI,EY<@8R<+@_*H%<KK/Q9^V6/C#4KF6:3Q=X@M_*DF>Z,R:?8Y7]W$QQAI/F
MW$8X?'7IY#HFFW7CCQ6+&.Z5-R>8T@7AB1PB]L?X5\U0]IB,8Z<6]-$MO5M]
MC]NX<P^$P&$^L8B"G+I=7MYI.^O9]->Y[3X/_:(NK75X]6F^W7'V"0$$7K(Z
ML>F60#:/0]Z^J?"6I_"']J&PMY?B)\/=2\&ZCKP!CUM)99X]1==N'D+ .2P4
M'J<@]"#FOG7X:^)V^&/PE;0M6TEKZ!/M%T5T^PC,FHR21B-5F:3A555^90"&
M!!&&7G%C^(_BSXA#6AX,^'\=SXBU%[*]O[?=*O\ :;0QF)'224F&,1INRL>!
MGKV%>OF^4U,N5&O3J1J*HO>72-ME?O\ -->AYN6\63SW%8K#X[#U,-[!\M.H
MI6YTVKM*Z7+:[5XS3:4;)W<?MG7?^"0_A&;5+/Q5HBWPL%C$D45G<&>)XB>4
M"2*65<<X7H21@5Y-XZ_X)=Z$UVVH6MQXBTJ\27,%M=V.Z-!DX[\I_NG(]*WO
MAO\ \%%[W]A_P3I^G^)-(O-6U[4;;SF\-:=<@I9#)S*\KC"?/N POS8/&!FN
M5U;_ (.2=?@UJ80_"K1UT]6P%N=:=Y2/<K&%S]!7+]7I5FIRDX]U:_W.YX#S
M3B+ XF5*A:K!;2O&+:Z)IWNUUW\GN.\$_L!>*;CQ-<2-IMJRVFT"<RJL-P#T
MV9_B]<XQWKU#X>?L7MXCM5O?LJC['=SVY%MISQ2N\#F-XRTJH<%E(5U#*P^8
M$CFO/;W_ (.1TDT1O+^$=K%?R)P9-7+Q$_00@X_&OE/]I3_@L)\:/VB9YK4^
M*+KPIH,H*_V;H!-@C*>SRJ3,_'&"^/:N>IE&#4O:N7-Y6_X/^8EF>>XZI^^H
M1@_YFT].NB3NWTU27Y?IG:?#R'X3VS:AX@_X1KPG9HNY+<RQ),3T :64C+'C
MH,Y]J\Z^)6HP_%;Q%IMQ\/\ Q7X*\10^$TND\:0PWAN]2@B.U;0Q!<(R[VD5
MY!E5VJ.XK\?7\9W=]=M)/<SSO(?FDED+NWU8G->I?LS_ ![U3X"?$73_ !+H
M,P2ZLPT<UN^?)O;=AB6WD'>-UX/H<$8(!K:6#PM2'(HV7Y>=C:5#&X>:Q/,F
MXO9*R:ZIW;Z=>]F]K/ZZ\>_#^\UJWECDC29%8S;67.?8^U<'\1?$2GX>:U9Z
MC;:MJUY>65M86EB8HS;:<L$S2;C*%!"%6.U4PX)(+$5]L>#?"'AKXV_#[2_&
M'A.\BN=*\1?-;VSL/.@< F6V?_II&?E/KE2!AA7E?QT^"\BZ-=(MKMC\LS*K
MKM;CC_(J<%G>*R6E7PM"$>6LK.Z3[[-I[WV=U;IK<TS7+\FXFQ^!QV,<U+"3
MYX<LY07-=/WDFG=<N\;23^U9-/\ -WQ+X@NM,62Q5;FUC888!C'N'OCK^-=U
M^R_\;V^%7BBZL-/NKVZ76H/(N(DV(PC."P$AR5+;0IXQMR>#@C)^(7P'U#Q?
M\0K?2['S)+W4F,5LFY8P'_AWEB %]3UQT!/%4?#_ .RWXR\'>/O#]MINF_VY
M<>(&F^P7EI+NLKH18#[6(!!4YSN &,8KJR+Z]@J']J86_LX/5M7BF[*S3TUO
ML?8<98OA[.:CX7S-P=2O'FY.:TY15Y<R:M)6Y6[I]'TN?<'@#XSVD.KS2/<6
M<#7CF1HVE::6/T!DQEB.['D]ZY_3_&'A?X3:AJ"V,K7%AJ&JSZE/ EQ)(;V[
MF;?*%9S\B9QG' !X'-8O@K]B;XS3:>K)::7%]H7GS;I(TB_WQU./09KG/B+^
MSC?Z-/J"VNN:=K">'4$5U';. RG"L[\GYMS%AQDC"@XQ7S..SBKB,1.I?1MM
MO:[>NAU<+Y+E5.<</3J+EA%144[V2LE=ZVMHE=^AZ+IWQ:AU<><JVN@V6IWC
MR-'9VZQPAW.9)-@P"[8 ))R3C)-9&K_$^#P3\3;'3]0OI+BPN"DY4$^=Y9=@
M$(7^+Y>>G7CL3XI\=_'9T7PE:Z;8M-YEBF+@M$5".>J8/H#]:\KT/QCJ%A(]
MW?-)N\O]Q+(VY@W4$D\G'O75D&:48X;WZ/-44T[M_9T]VWGZGI9IP/CL16J8
MC#XKV6'=*4%325U-WM44G>UE:RM^6OZ'_#Q['P=^V)X<OK6WLY9-2M]4M8KM
M8RT\$:65Q+Y!D;YB -A. %.5/S;LUX!X%^+%]\3!;W*M-!8PC+3*X:25QQP.
M-H'J.3S7(_L1_$"Y\5?MB^!;:>]NIO)M-5@B!D)38=+NR?RP/R'I65H.OP_#
MCX8:?:6WF27ABWDJ<*@QW[]S[U]]4IX7,,5]=H4^2+?NQ\^6-WIIT/S7A?)<
M9D^&_LK,JZKU8PC>>NJYZK2UN]$UJVSZ/\.^/;6#PI<:;:1R6J^7.J)'/LAF
MWJJDR1C/F,FW*$D;23UK#\=?$:R;P*MCJFUKRU,YO;VXNTA%G;"-3$55G&]B
MP8@*#D @\X!\+\&_$F;4]3MYI)/)<R$+O8A .>I![\_I[UF^.?C'I.M_$^S.
MIWEI#I]G/$C2M&)+=D .XLQ#<CC VG)QTKU(4<-AL3RUX1DZCM[ST3>G,[]E
MTNK^IYG&668BM@.; 5)T_8>^E33YI*%Y<B2_F>SL[.VEKH\?U[QS_;'B#=<W
M VL^5>)MT<BY(R/;K7W1^P3>Z'82M#J94V5U;2)&OS.CDIR71?FV[<_=Y'6O
MC?X[0Z3JGAW1&M[C1]4UMIY#/-IR1I#!; $1AW3#-.#RP90"3G KT3]E^_\
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MNZT3Q,9!IZ(BM,DL(59]Q[ 2' '?K7*^'OV*O!-M-]ML--#3<95Y0R(?H?\
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MHN1MD"GJ" PP#V(_2+2/^+K^'K.ZMY%\5>'=:3SM-O+><&50>-B,V3D'AHI
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MC'!#O@@<< FO#SS/*N*K1JQU?2RT7Z?B>R\CQF'A[.A23EUYGT]%K;[CY&\
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M,U[BO\D>;3PJY^6K)KU;_P _R*O[.EC\.=0NM3UU_AC-HS>'D:57;Q7=S*7
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MA/9RM:W#8^Q/?2Q*;3R\Y\@."4X+BOC?PI^QQKEG$LWVRTE7@22$-N"_3O\
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M]$UI:U^BO\KZ9;0ZSX;\(MJUWIVM:MX\N?*U:););B2UBCN$*Q,1(H:0,%9
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MI6-Y*$@EB#*;*1%1'C)R&R=V3U5F[5T&K^#)/#NIW%O<Q/#.&)96'6M7X?\
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M57AECC2>#@2H1E&!X(^A&>/>LZD*N%G['$Q^_P#X!RU(4ZDO9MV?1GSK>_M
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MXLM[Y>HMY[00D>P;D'\<5Z%:FOBN_DO^">!!Q<O=:^;_ $2?XG7_  F_9_\
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M"M9N_$?DP6-Q-'(0,%2=O_ZA7U6*XPC+%U*\E4JQ:CRJ5E9I:[:*[VT;L<7
MV1X?*<.HU:--54WK&[T;TUEK>VYWMW:OK'B!9+$,T2((XW5<;ADG. 3^'3BO
M?/V;/AK'(#K'B6001VHS&)1M50.XK=_9^_93;2K:&;6%^SPA0Y#$$Y],=JTO
MVB)([2P&E::A\BW3;N ^^YY/Y#'XFOS/,,17Q>*GB:D;.6OW:)+\C[B..IU:
MGL:;]Z75=%U."^)7@/X?^/\ XB:SK%UI=OK%YK&Q-UX-T=O%& JJB#CL#SDY
MKRCQYX9M?"NHM#I\T>BJ%Q$\$:,K>@"D'/XXK2@T2]TBZ3(D9PQ;=SP.M1^+
MO!FN>-)6O%N#;PHN%79\TG?(/;O@8QFMLKRW,,=4<*<G]]HI?UMH>@H82FU3
MII25NJ3?EJSQWQ5XL\>>'KE?)C\.^(+!FY\S3TBF]_EQU^AKJOB)$;CPCH]U
M:[(_M"@2)$O"$8S@=L9Z5/+X$FT74S#>77FX^;('W2?I7IWP)^%4WBJ2XMXU
M+  O&\B[HXSCY@WL1U^E1C*=:C5>&Q+UB[=]?Z]":=.E34YP26C[+^N_R/G3
M_A-6T_4/L<TWE^00R,$!#%2"#^.*] \$:^/'%Q;QE1;QKPL8._<>F3ZGL.XR
M13[GP3X%^+7C:\TG2]4M[36K.9XY[9@3N*]2OJ/>O9OV=OV6O#O@76+>^OM2
M>ZFM6\U$W852#GIWKMCB<9A\)/!PNH3U>GZ]$[*_<\>.+A%.+E\NIZ-\+?V9
M]*\)V4.K:UY"W\@\P*P^6U4<ECGN/TK$^/.D>'OB8;674[2&1;/<MC*_$MDA
MZNG97;J3UQQZYC^-'QG_ +2U^ZTZQN&*V,8>Z^;N?N1?U->8:WXS>ZM3',LI
M6,>9NW=#_P#6KYOZS*G#EI-IM[];=EZ]?N/4P6#D[5\3*Z6RZ7[_ "Z?>>7_
M !MT'XH?#AUNO"?B^:]M9%++:7,:K,@[8?H>/[P%>'7O[6FN^+[EO#7Q2TNW
MUK2Y&"R)<VP6:U/3S(VZJP]1UKWSXD?%#4K>-;J2PEDL=BJ)5884X^Z5(^4^
MV:\KU_PG:_%^&X^T6\;_ #92;(#1],8/]*^BJ4\;A;?68N-]M?Z^XSQ%+E2;
M46^S2_RO]QZYX%LOLVK2SV#--HU]9H]O(/FRHP!SZ_X5M:!;PQZLWVVYA@V-
MYL<KD\$<C''7C@>M<+^R[#K'P4U8Z7JUQ]IT"Z.V-Q^\6'/JO]W/4#IUKW?Q
M3X)L]6E;[%$L%]L#QQ8#)*/6-CP0?3K7GRH\TW.._4Y<56<M5=*V_:W1_P!6
MZZ&S\-/"$4/@_5?%6N6%[!X?T2.XU'[+I&G%KJ\+NTTGE01C+R2.S,<<EF_)
MO[8/@[PEXV_9?\1V>OZEX[M_#=E=)XN\1Z3IUZ+O4($C1)?[)" $QQ\)B%""
MK<AAUKUCX6W=_I'A2V;40QDMXUV0QL/F8#IZ5\>?%7QQHG@/PSX@\"_#/3]2
MM8[75)]2UF\ EDCO+JXD+S,L[DM*58[2V<#  X%=5.B_9V5[17R7IZ_D3@L1
M4E5=6<VY.2MKN]V[O6ZWOK=M?/%_X)Z7>L?&#XT^,OBYXHT.;0]/;2+3PSX1
M@^SF""WT],/Y2!@'=81'%'O(P[M(PSQCW7PY\?;?6?B!=^'Y[?SH(Y6M+R&Y
M18TDBD"*'7<WSJ0Y!QD9*_[2CE?"7Q9L_#?@ZQ^U7MO:6K>5;+)+D^6S849Z
MGKCISZ9/!;8>(-2U;4&NH[&Q@\DJ'>1VW$$ KU'0Y&/7M7L</X'$UJ53$_5O
M:P:<4^:RC+OYV/+XDQ4<;F%/+\'B?958VG*"7,Y4UI;7:[Z^IC?L"_L>^&X/
M@9JEOXPM;6Q\4ZIXHU"RL999!'>/%"H$4,9;#282)Y-J@_*"W(&:^;K[X7ZI
M;?'#Q!H?PJ\*>)?'?A>SOYX5U'2[-I+%7."Z))_J_P#6,YP&QWP,U]5?LJ_#
MC6/V?==\8WGB3QD=2T[QYXJ-WI41LOW.C32PRN?.GY$>]1Y?FG&<(G)8BNUT
M7Q1\5/$W[/-_K>@ZAX)\-^,-*@DL9?#Z1#5M+TZZCOLO*\EKOF\QK; \G!V-
M)EAQQY%2C*$W1DM4[-+IZ_\  /K*>)J4<0\3=/F6CE>S;>T4DWI:SOHFG=ZI
M'YZ?''X9?V4ZQ^+/#VN>%]8L(RSI?V_E/CKW^^/=<BLK]GO]K/Q-^SQK*V?@
MM;?Q#X9\<7-OH^N:/.!]DUB.0M']FF &^-FCDD"NI##=U."*^_\ P/\ %G6W
M^(WQ8?Q)K-YK\,=_;W4/A2W U.X\/%XQF")F")*D@9)5"<(@(.6#$^5_M3>"
M_!/Q<U>.WA(T'Q+I-ROV37-*2..:%HWW)P!MD57&X!NAY!Y.9E/DERTWJCLE
MB85:=\;!.,M--KV3VWTNM?FFS%\:_P#!-?PW\._A5K.L:/=I'I>I37.MVU[J
MS.=1TN:/9<&&9T<1B2WCCF3 0F0>4RLHR!YS^P[X%USQ%\(_B VK1WVK>'?#
M]_#XB\.MH]V;2\N]7@$:SQPN'3=&\;J&1OE<@"OKG2=0;0'U;5K6]D\9:;X@
MDCTC4/#UQ<6\$.K7$4GDO+:M(WEB0*#)'@@2;&& K$5QW[77PGO/V=?@'H<_
MPKO=!NM#6PDN].TW1K6*'3M2E:0,T\$X9BC,I<-&6=,D<@ 5UXS#X65.-3#3
M<E)7E>^C=M%Y>EUMWLOG\@S3%TJL\-F%-4^6:C%JUY1BV[R:^T[[RMU6T4WY
M3\=W\2>.?A38^/(--6'1-:!O]1MA:BUOM-N@/*=+J/.YG0*%R,^O?)^/OB'K
MT'BS3[J2TCGN_LJEF9 _EQGIEC@  5] ZC^UIXAOM"N+C3?-MYI'D76]'DCC
MGAB;:N'$; @[AN!(Q]WK6'??"'PYX@\&R7FK:;-X3UBX+7=C>Z?92/I^HQA
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MO,&[#IW/O7UF<\1SS' 0P:A^\33<NEDFO76_^6YS8C'*5-*70\B^%GP=BO\
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MG=7=O\V[]&K)>:;-[Q'+IOAO]G'7(M#N/#>DZI,/L^BW5[,BP+>W'EI',,Q
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MB\5CJLY5Y.\E:W1*][)=OZW/CW1? 7]I6ICDC#$]B.M>\_LX^#HOV,O#-O\
M%_4(4/B+4/,M_ FBR']W<RCY)=5N$[VT&2L:G_6S?[*$UU'[-_P"TJ\TR_\
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MN[--07[1:J/,GB896;:1@$<YQG=@\$@"O8_V(OB=:>/OVUO![*L?VD&]&YF
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MT_7(98V$N=J72!@3$Y_A##C=V[\4Z=.G=*LVH]U_P>A,7@Y*])-2[/\ *_\
MPQT?Q3_:0\JRN([660W$VZ*1Q\KS ]47NB>IZGVZ5XQJ7PQC^(C#4M>O%6'J
MD4? 0=@*].UGX _V)\5]3TN\811K.65I#]Q'R0?H.?RK7\6?#*+P1:C['<1W
MD<:;F5H\DJ0,''IZ^QJL%AH3Q,:,Y<MW9M]/Z[G5B<S51+#TDHP\NOFV>!^*
M/A]X5T;3WCMH;[[0P^0JV"??KTKB[?P3XJ12VA:Q?0QQY;RS)R,5ZAJ$TK:I
MM%FIWL=KE=HBSG&?IQG@\]/6MEM)L_!&GR:D;B-V$9W*#RXY->YFV#P&$AR4
M:G--O;1KY]OS.+VCA_#FUZ-K\CCO@-\2=>MO&%C:>)/+U6U,NPF9=S+V/_UC
MVKJ8/A(VB?&;7M"TEO+M[Z475H_\)B<9Y/MS7GOA?Q1%KGC=9[-=J^:) /QY
M!KZ%O-/FT#3])\6VJS7?V(FWD$8RXC<'&>_!'X9-?-UOBY%U.A5:E;#R]I)M
MQLU?MM^I9^&UMJ'P]=+"_@^Z['<.0V.OZT_Q3XPO/'$]U*]U<6Z6KO';PJQ5
M$"\;L \D\\\_SKS_ %OXQW&IZC_I)NI'5LKD?=/I3/"W@O7M=GNX[))6749Q
M("V1M!Z\CD#V'6OH.%OJ]/&MXFWPZ-[7NN_D<U&M%:2(?$GBW4=:NI-+8),T
M?S"X'!<?X]OPKIO"VF6MI\-_$%IJD;)9W5H!+N;;@GA6!Z<$@BK5W\)8/ 2*
MLTWVW5$ $OR_NU/]P <LQS^&:\\^.GQ#DUOPM=>$[>[9A"ZMJSQ@>7!MP5M4
M;NV<%\< A5[&O/S*5!XZ<L)\'-=?K\K[>1U9=A^9R;>FIQ?PB\>MH^J*UQKU
MO'-@)_KMLAQV9AE6Q_M U[AI?CV^L+=KZSB^W,5+!X98I3GT W=Z^6+/P[IU
MSI,B&V82*Y",H.X=/2LRVM-6\-72QZ?<W?F2L%6-6.XD]!BM*D9\OM)0T]&E
M]^Q4L1AEI*+]=&_Q7ZGU'XC^)^J:G\/;FY^Q7ME<70E%QYIS<+&C@$ C[NY>
M3CJ.]+X,^&5YXD\/C5+.U-PFT/\ *?\ 5@#( 'ICTKQOX5_&+Q'X7UAK2\C>
MZCW^5<P70^\IZ@YZ?A7T5\8+.3X?>!=!\1>'-T>CW<"JZ*?]7GJK8QR&[_2N
M&M#F7N*WD9XRK"5%.G)VO9W5O-?K_P #KZ=!XP:*\1I(QMU"U1DSSY;(,L!Z
M97/UP:\H^(FHLES/=QWD<<"-^\C/1@ 2.!T(XKBKGXP7E];PPV\EU<760T95
M\G=V_*L&_P#AMX[^*>H&&=1903/YDLI4JN3Z <GUP*]S+<RP\<MGA,2KM)I:
M;]G\G^7<YY9@G#D>YG)\89?&.JW-M]Z!24!QUQ5OXO>);OP!X \/W2LD,C7;
MV\>X[3(I0,V/4#CC!ZUW'A?]G.R^&MQ;QK.=3N,@R!X@J[R>%X->._M;:JOQ
M:\=6MCI9$FE>%\VT$D9_=M*2#*X]<L H]EKYVFH*JK;&V#YH4YU+]/Z1O?#V
MT\-^+;B.]6[\)M>R'+AYFMFSW!!!7/N*]\\&>$=8\+VL4^G:5I6H0D;A]DUF
M!VY]$)!_K7SK\)OV8+;Q=J$,FJ+)Y"CS&$?RDCW-=QXU_9BC2V,V@WEPLD8P
MJM(0P-=52:9/L</-<ZIM?._X:?F>M?$:^O-;\+7*7VFW:76/W<3H?]']2S=
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M0?&:PMO[8\/W&GWT2!M\J;89F]48\\]:^BM3\90:/8*6BMH_+^9U27S&(Z]
M*_.7X;>-=6LYO,COKA79L$AJ[K4O&NK7^F_O=0N6W'GYL9_*O1J5KR=H_C_P
M#GCE>'DTW)WZZ?\ VUOP/I7XG_MF:I>Z/?:/I_AE?[(FADMYM36?YXCL.,Q
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'[/\ %'__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>oncyf-20241231_g2.jpg
<TEXT>
begin 644 oncyf-20241231_g2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!817AI9@  34T *@    @ ! $Q  (
M   1    /E$0  $    ! 0   %$1  0    !     %$2  0    !
M  !!9&]B92!);6%G95)E861Y  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" 00!@0# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HKXZ_P""R?[17C+]G;X,^ IO
M"=QJ&EP>(_&5II.JZE93+#):PM',ZIO;A1)(B*3D9&5S\U;O_!*_]HKQ/^TM
M\*?$.N:]J,VL6*ZJ\.G7DD:J2H+!XP5 !"E5^A)'6O8ADM666O,E)<JERM=>
MGEYGB3SRE',UE;B^9QYD]+=?GT['U11117CGMA1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MD;\>?A]X7^&_AOX;:WI_BS0)=5NY/$NGWMS-'*EPT0$9M[N !=H!P03GOVH
M_6VBOY^/VL/^#S?Q1X+^'_P]TWX6>!_ >N^-KKPSI6I^,=6U1;N31;;4[BSB
MFNK*SMHITEQ#*[(7DG8JRLF&*[S^A_[=?_!<GP[_ ,$Q_P!@WX7^.OBEI=OK
MWQ<^(GARSO;3PCH;M9PWE\;6&2[8/(96MK2.27;O?S7^90 YW$ 'WQ17\U5_
M_P 'H_[2%UXC?7;'X._"B+P%;ZA!;S12VFJ37*!E+FW-\MRL*S2+',4)@X"D
M['"'/Z\?\$7_ /@N#X"_X+#?#W6?[+TFZ\&_$+PBD+Z]X;NIQ<!8Y,A+JUF
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M'X>F[GM['4/&,%[=W>LI&4RZ_9YX(X6 ;+)F8KYB9/K^JG_!$_\ X++>&?\
M@L5\!];URRT&3P?XR\&745EXBT)[M;I(/.5F@N89 %+0R[)0-ZJRO#(N" '8
M ^TJ**^0_P#@L+_P6%\!_P#!('X$V'B3Q)I]QXF\5^)I9;;PUX:M;A;>75)(
ME4R222D-Y5O'OC#R!'(,B *2U 'UY17\T^I_\'H?[2ESK;Z]8?!_X2P>!8]0
MBMF2:RU2:=<C>;<WJW21><R+(5/D< 9V,%.?U@_X(C_\%Y/!O_!8?PYKNE_\
M(_+X$^)GA.!;O4] >\%Y!<VC/Y8N[6;:C.@<JKJR QM(@RX8,0#[XHK\0_\
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M/IOQ<M;S0_@CX%TOX=WB_:+2QUI[Z35]1MO,D02I=I)'"H8ICBWD561QN;L
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MS]D#XB^%?$FK6D-OJ$7A7X6Z[9VM_)$"!<2K,LSM.RE59]_(C3C@D^W>#?\
M@G[_ ,%&_P#@@O\ 'GQ!J'P=\*^*O$6DZM<P6<^H^$-%3Q1IGBBVC9Y(C-9J
MDL\( \U2SQQ/&9&"R 2*S^V_L1_LW?\ !5']O[]L;0?B)X\\=_%OX+Z'A;;5
M=9U4)X?BALHW=6@BT,(BRRL"Y0RVNS=MD9\[6(!SO_!W7XS\8:C\/?V/-+\4
M+J5E=-X&FU'4[.Y9E9=3>.Q6X$B, ?-0KM)8 C<PP.17ZD?\&O/PO\,>%?\
M@B5\*[C2;.QDE\6G5;_6YQ$NZ_N?[2NH&$O'S;(XDBP?X8P*TO\ @OQ_P1I/
M_!6[]E[1['P_J=EIGQ0^'\TMYX<OM0 6WOEE15N+2=T0E%E\N-@RC"O&O&TF
MOQ/^!4__  54_P""4OP]U7X0^!?AW\8=-\/W0DN(;?2O!$7BNUTR:293)-:W
M<$%S&CMY3J4$A7$S2! [)( #Y]T6QB_9Y_X.%!IO@&/^Q['PI^T ^F:);V!,
M20VL?B%H(X$"_P#+,Q 1E>A4E3D$BON3_@]S_P"3P?@O_P!B=<_^EKUW/_!
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M6EOI7Q&\?VD.G6NC1S1SR:'IRN)66:1,KYTL@C9D5B%$*9.XD+^LU 'X;_\
M![__ ,FY_ ?_ +&34O\ TEBKTG_@S"^&7A?0_P#@FKXM\5:='9S^*->\<7=I
MJ]T(U^T0QP6UKY%J6 W;%60RA2>MPQ[UYM_P>_\ _)N?P'_[&34O_26*OB'_
M ()9> ?VYOV9_P#@GE-\:?V2-8U'Q%X;\7:KJ.F^*/"EEHUKJMYIUU:QA8;^
M"VF5VF8I( !"I;=$@=)4(  /GS_@X"\&Z/\ !'_@M3\<++P5'#HME8Z]:ZE;
M#3@+=;2ZFLK6ZF,>S&QA<22'*XPW-?J;_P 'I&H7&K?L@?LX75XOEW=SJ]Y+
M.I.=KM90%A^9-?)G_!,+_@@=^TK_ ,%"/VZ+'XI_M$>%?&'A/PFNOCQ%XJU'
MQE9M8ZIXBE6;S&MHK291+B5EVEFC6-(R=I/R*?O_ /X/#_V8?B5^TW\!?@M9
M_#;X>>.?B%>:5K^H37L'AK0;K5I+-&MXPKR+;QN44D$ M@$B@";_ (,T?V9O
M"?A/_@GQXA^)Z:797'C3Q=XJN[&;5)(%-Q;V=M%"D=LC\E4WO*YQC<9,'.U:
M^9_^#WG6[ZP^(_[/?A^#=:^'X=+UF^CMXFV0-</-;*[;!QN"A>?]L^IS^@7_
M  :N_ WQM^SU_P $J;7P[X_\'^*? _B!?%>J7)TSQ!I,^F7@B?R=DGE3(K[6
MP<-C!P<5U'_!P!_P1N_X>Z_LRZ3:>';_ $_1_B=X!N)K[PW=WORVUVLJJ)[*
M9PI9$E\N-@P!VO$N1@F@#+_X->?A?X8\*_\ !$KX5W&DV=C)+XM.JW^MSB)=
MU_<_VE=0,)>/FV1Q)%@_PQ@5_._HMC%^SS_P<*#3? ,?]CV/A3]H!],T2WL"
M8DAM8_$+01P(%_Y9F(",KT*DJ<@D5]!? J?_ (*J?\$I?A[JOPA\"_#OXPZ;
MX?NA)<0V^E>"(O%=KIDTDRF2:UNX(+F-';RG4H)"N)FD"!V20?3?_! G_@VW
M^+7A[]KK2OCY^TKI4OAR/P?J;:SHVA:C>0WVJ:YJ@;?'>W)5I!'''*3*-["5
MY8U; 3#. <-_P>Y_\G@_!?\ [$ZY_P#2UZ_3#_@@C^SKX/T'_@@%X)TM-#T^
M:T^('AK5-0\0K) K?VO+<R7"2&;(^?\ =!(AGHD:CM7PQ_P>"_L:_&#]IG]J
MGX2:C\-_A3\2?B#I^F^%)[:[N?#7AF]U:&UE-X[".1[>-PK%2#M)!QS7Z=_\
M$:?ACXD^%_\ P1A^$OA;Q-X>USP[XFTWPE/;7>D:G82V=_:RF2<B.2"11(K$
M$?*0#R/6@#^9W_@W6^&6A_%[_@M%\"=%\1:;:ZMI?]JWFH-;7,8DB>:TTV[N
MX&*G@[9H8VY[J*_3;_@^*\'::/#G[._B!;6)=8^TZYIS7*KAY(-ME(J,>I"M
MN*@]-[X^\:^2/^#=K_@GE\?_ ()?\%DO@QXH\:? WXP^$?#.ES:J;W5]:\&:
MCI]C9A]'OHT\R:6%43<[HHW$99E Y(%?H+_P>,_LM?$[]IWX:? >W^&OPY\>
M?$*?1]3UB2_C\,Z!=ZL]DKQ681I1;QN4#%6 +8SM..AH YG_ ()J^*-4\&?\
M&>'Q.U#1IKBWU"'0O%B)+!(8Y(E>XF1V5AR"$9CD<\<5\?\ _!F3\.?#OC3_
M (*?>+-4UBWM+S5O"_@*[O\ 1DG0,UO,][90/<)GHZQRNF1VG:OUC_X-X_V1
MM6LO^"'%E\)_C!X'\1>&V\13:_INL:#XATN;3KQK2[N)D.Z&=%=0\;DJ2O((
M(K\C?C#_ ,$3_P!M[_@BE^UE??$#]G73_%7C'2=/66+1?$_A+3X=8O9K2=@A
MMKO3"DCM( 4+CR'BR ZM\AV 'O/_  ?#_#S0='^)_P"SSXHM-/LX?$FO:=KN
MGZE=QQA9[JWM9-/>V5VZL$:ZN=N>F]J]V_X)Y^*]5\5?\&<WC[^U+BXNO[-\
M"^,[&SDF<NWV=);W8H)YVIDHHZ*J #  %? /BC_@G%_P4/\ ^"\?[3.D^(/C
M%X1\5>%[&UE?31JOB_1QX:TSPQ9;_.98+%UCGF'[P*K)'))*0H>0B-G3^A'0
MO^"9_A/X?_\ !*[4/V6?#-U-8^';GP1?>$8]2>)!,TUW!*LM\ZJ ID>>9YF
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M:UI/B">70]6NS\*T0W]NX6 V[7\=H+?[/N4O]I1@3O9C.R8P ?J9_P &Z?\
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MYR<'TH ^+O\ @K_X5M_'7_!>+XO:'>%Q::Q\2/L,Y0X8)+-$C8/KAC7[U?\
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M&;XE_#/X@_#M=:A\/#3CXF\.WFDB_,3:GYGE?:(T\S9YD>[;G;O7.,BOD?\
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M/#.I?#WPOHGB&'QQ>R:R(K75M?OUF^V)$EDGSP;I]C2>:D052RJ"P*K]3?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M8(K["H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M6UA<:UXDNVTK1O$D.GKIMW!J0RJV=[;H%CS(ZE%9$0K(55E(;*>O_P#!H?\
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MQQ3P3QQJL9=3+&RNBKD;PP) )_8^348(6VO/"C=PS@$5_+-_P9O_ /*7*_\
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MJG_!8*X*J%+^#-)+$#[QS.,_D /PK]C_ /@H?_RJ]ZQ_V1W1/_2:RH _GO\
M^"._Q7_;"^'7C3QM:_LAP:Y=:UJ5E;2^(XM,T>QU%OL\3R"%F%U&X4!I7 *X
M))YS@8^TO^#EO7?BMXH_X)P_L57_ ,<8;ZW^+-S%XB;Q)'=VL-K.EP'LP-T4
M(6-28PAPH QSUS6S_P &17_)W7QJ_P"Q0M?_ $M6O6_^#XU<^#/V<6QQ]MU\
M9_X!I] 'U-_P;.?$S3_@K_P;\:#XQU:.\ETOPJWB35[N.T@,]Q)%!>W,K+&B
M\NY"D*HY)('>OS=G_P""Y?\ P4._X*P_'[Q)I/[-NDWWAK2=#S=?V'X>TNRD
MDTZV+%8S=WMXI_>L0> R!B&VI@''WU_P;F_M:>"/V8?^#>ZU\8>)-8M&M?A_
M_P )'J^IV-M.CWVR&ZGG\M8MP.]E*[0< [U.0#FOC_\ 9>_X*X_MC_\ !:K]
MKSQ?X4_9M/PC_9_AGL?[5U346T^"34)+&*41QFYNI(9I+F93/@>7$@7<WW02
M2 8/[ ?_  <S?M-?LO\ [:^F?"7]J15\2:1_;D?AW7EU'2H-/UOPW*\JQ><'
M@5$D6,L&975BZ9*L."?T+_X.C_\ @H9\7O\ @G3^RO\ #GQ)\'?%G_"(ZUKW
MBMM-O[C^S;2^\^W%I-($VW$4BCYD4Y !XQG&17\[?[=WAWQ)X)_X*@>*-+\;
M?$JQ^+GBG2_$EG;ZOXNMGS!JEPBP!\$GI$1Y)Z &$\ #%?MS_P 'LSB3]AKX
M/D$,#XX8@@Y!_P")?<4 ?+_P8_X+??\ !0W]OG]D>S\/_ WP[KGBCQ7X-CNK
MGQUXZLM!L&N)VDFE>VM;>(QK;H5MU4$)&T[G) &,OQO_  3Z_P"#LS]HSX3:
MQK7AGXG6$GQNO-6LY;/PU;_V?%::G!K#$+;1/]G1#-"TAVNFPR\C8P(VG]%/
M^#-/3;>U_P""4&N3QPQI-=?$+4FF=5PTA%I8J"3WP  /:OQ9_P""7MG#<_\
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MI2QYEGFMLK MPK[5$C!8,.-REL!OT#_;ITRWTS_@U9O+:WABAMX?@QH(2-%
M5<6UB> ..O/UYK\Z/^#(^TC;]L+XSS-&AFC\&VZ*Y'S*K7J%@#V!*J<=\#TH
M \U^"_\ P<C?MF?L"_MGR>&OVA=3OO$UCH^J1VGBSPMKFCVEK>6<3%2[VTMO
M&A601L'C.6B<%3@JP-?LO_P73_X+9Z9_P2>_9G\.ZQX>TVQ\4?$+XC&1/"UC
M=.RVD4*(C2WLX4AVC021 ("I=I%&0 Q'X-?\'6R*G_!;;XEE57YM,T0G ZG^
MS+8<_E7T%_P>">"]8M_$'[+OB"2.8^'[OX?G3K>3!\L743122C/0,4FA..I
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MC]S[.BB0?ZOYGRW3GFO[%*_G*_X/>U/_  TA\"6YP?#6H@''<74?^- '-_\
M!%OXP_\ !2'2],_9^T7P=IOBR3]F?^W-/@,T7AW2I+3^QFU$?;#]H>+S]H#3
MY;=N'.T\"M'_ (*7_P#!>W]J[]G_ /X+!^/?A;X1^*7]E>!]%\8VVE6>F_\
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M=_P5A^/WB32?V;=)OO#6DZ'FZ_L/P]I=E))IUL6*QF[O;Q3^]8@\!D#$-M3
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M#P7JNK7&J_8X(?,N86NQ$_E1HL0V^6G 0 XY!R<_EO\ \&[O_!<7]I_]N?\
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M1NFAEA!*QW")F0&/".BO\J%1O^3_ /@IC_P<(?M&?L:_\%I?&'@>W^(D]O\
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M_P &7'PS\:> _"%I\*?B1K/@K7=!L?L>L7FM6 U6/Q'(79S<LJ21>1(-Q4!
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MQ!^)7C>Z^+.N>&[A+[3-+&EKIVD6]RA#1RRH9)'N"C ,JED3(&Y6 Q7Z_44
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MPYTW_A8W_"O?^$!N;^X\S^PO[4^V_:5@7&//AV;?)SG)SNZ#'/WE10!\S_\
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M4-GI.O\ ]@A-/\,;;F&:26*T\_=-,Z1M%O:50JROA<G-?9W_  1"_P"",/\
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MCU_PO/\ MC^P?%<GB;^Q/^$1\CS]\DC^3Y_VQL8WXW>6<XZ#/'TI_P %P_\
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M_P OY_YGV@__  6X\9#IX#\-_P#@?/\ _$T1_P#!;GQDQY\!^&@/^O\ G_\
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M4N4/[/P_\OYGVF?^"VWBX?\ ,B^'/_ Z?_XFF_\ #[SQ9NQ_P@OAW_P.G_\
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M/&)/_(B>&_\ P.G_ /B:^+XTW4]XPE%D"R^@_L_G_F?:(_X+7^+O^A%\._\
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M%+,0: ^*?*@^HX?^7\S[7_X?8>+O^A%\._\ @=/_ /$TI_X+7^+O^A%\._\
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M[\*_AJ5Q_P#$U?@_X+[>,Y?^:>^%Q_W$;C_XFOS8TO4\@'=6[8:EC%'*=?\
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M(OAO_P #Y_\ XFD?_@MKXO7_ )D7PW_X'S__ !-?&14-]*0Q\9HY4']GX?\
ME_,^R#_P6^\8*?\ D0O#?_@?/_\ $TG_  ^_\8?]"'X;_P# ^?\ ^)KXSE@#
M=JB^RY[4<J#^S\/_ "_G_F?:/_#\#QA_T(?AO_P/G_\ B:>G_!;KQ>R_\B+X
M;_\  ^?_ .)KXGDAP>G%.@7;1RH/J&'_ )?S/MK_ (?;>+?^A%\._P#@=/\
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MI_\ XFFG_@MEXO"_\B+X=_\  Z;_ .)KXSV?+[U#(<*U&@?V?A_Y?S/M,?\
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M#O\ X'3_ /Q-*/\ @M=XN/\ S(OAW_P.G_\ B:^)U;FIHJ.5 LOP_P#+^?\
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M /B:^+P=RXQ2[03CY=U%D-9?A_Y?S/LF3_@MQXQ3_F0_#?\ X'S_ /Q--/\
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M13U.10-(S]0M]@!JHGWJU[E-T1K,:':YH"2Z%VP&8\>E1WL=2V)VQTMQ%YE
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M[,'Q*^&W[5OQ=L?AC=?"'PKX9T'Q$D]OI&JZ;),=9TV58GDBDEG9\3$A,,"
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MO;^MA_B3P7X;^.G[27@[PWX9\,ZI\.[SQ!);V6N:7=*PBT^Z9CYKVZO\XCV
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M<DDU]!_LLWTG@S]C#X\>)M-9X=;:/3-$6YC)62VM;B8B;!Z@.#@GV'I7AGQ
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M[MG(6:)QT*NA((/?!Z@&O-SK(*&,IR<5:??OY-=;]_\ AAT\3.GL]#U;XH?
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MB=FU7Q1)-'@LJ6ECL<@''5F(!^@-<9X_T#P_\,K0?8_#5UJ,JXW3:E=.1R<
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MMH-@JPHP*6)0BDU!)+M(]ZH)#IDW#'K55[5E]ZL*^ZI%7=B@-BHELS8[5.L
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M./+(];_:J_95D^!=U8^(O#MZOB3X;^),2Z/K,3>8$#9(@F(& X&0&(&[!X#
M@>40KN45ZM^R/^U<OP?AOO"/C"S_ .$B^&?B1C'J>ER#S#9EL SP#/##@D C
M. 00P!K0_:A_96;X(267B#P[>_\ "1?#KQ$!+H^KQ'>$#9(AE(& X&0"0-V#
MP&! 9C1J.,O9U=^C[_\ !/'U7!IU.04UV IG40S_ #53F! J^/F-13VNYLU/
M,2S+>-LD@9J&2-A6@\! /'%,>+*]*-@D4X+;(J[%%M44V&&K$A"1>YJ@6HT\
MBJ\\/F_44&7YCS3U;<*6Y)5^SLIZ9J2.V^;YNE6X4#M5@VX8#M2-$4?+Q5>Y
MDV$5H2P[,\UG7"AW-439C4NCGK45Q(6'%.2,C[WS42INXH)*L1PU7(^@]:@B
MMMQXYJR(&&.*5P%5=YJ3[$&-.@AP/>IPNWK3*D4Y=-7!QU%9SP;'K<?YA69>
MIMY]#022:62)<5TFF#=@^E<QILO[WZUTFD-@]:-T(ZG1V) KI-+;.*Y;3)PN
M.U=%IMR,+S1L82.CMI< <U/YFXUFVTNX"K<<F:EIF$CH]0\-CXC?LV?$[PSM
MWO?Z)/)$O^VL;%<>^Y%K\E-,GRB'U S7[#? :[1?&QM9/FAO[:2%P>A&,X/X
M U^2/Q)\+R> _BGXDT.0,K:1JMS:8/4!)64?H!1$UPK]Z2]&-LR3(#ZUUWAQ
M,LM<CI?++FNR\.<,#5'4=II,6(ZV( % ]:R])?*K6LG"T&A<ADPHJ]:_,M8H
MN=K5J:/+Y^*-D9FM'%B/W--8;0M6H8MT=0W2[5S4[ ,W?+3*@DNPAZU+'.'2
MJ =OVB@2\]:9*X]:9&^^@-22?D<5 +;)JT%R*0CGTH %^5<4XOD5&[[!1$=P
MH 9>IYD)K(:+8:Z-K3='5"\TPELXH KZ4QC:MRWD\R.L6*/[.1GI5^&YPORG
MK0!-=Q$G-0B/;]:LQR^8/>@PJ?K216Y7?I1&A)J9XN<5)''2YA#K>'*@8JQ]
MEPN13K6+:*L,<"ES,:B9_DX:E*%:D<[G)IRQ!ZO8'J5B=L@]ZMVZ;U^E,-IF
M0$_PU8BCQ4\P1(Y>!38D^;VJ6XCWO2+'BCF*+$47%7/#OB?4O VO0:KI%]<:
M=J%H=T4\+E6'J#V(/<'(/<55CXXJ.].;<^]$HIIIK0#Z7\&_%S0_VI3;W%RE
MOHGQ8TI";983Y-MXC4 [HQSCS6'\#=>1D@Y7S#Q_X"T/Q/(UWH\:^']8,C"Z
MTB8XB##[Q3C*8/!&,#T7%>.M(]K?Q2QR/%)"1(CHQ5HR#D,#U!!Y!'0U[QXI
M\.7_ (TU,:UJ5G+I^KRVUM-<W@)"3S-$H=FYP"QY8=F#'@DBOS_-\!/*\1'&
M8"7*I.TENM/+M^*Z-7.W!UHN+IUES1Z=&O1_TO(\UU'P'K6C!?M.E:A&C\H_
MV=F20>JL 5(/L36MX(^#/B3X@WZ6^GZ9,BL<-/<_Z/!'GN7; _+)KU[P5K^J
M:)I]OH-AK-@P*;XI'N2JQAB<CK@D&H]0O]:BUN#3;B\DC$CG?,2=LZC(!0]Q
MGOZUXU3Q"QO).-.A'FB[7YFU]UKW\KGHX?*J%36<VO*WZG%W7P4LO OBV/3]
M:N_M,UOA[E$&V(\9"*2"2/5NA';O7U9\+OB=X>TG]GK5K729(=+UC8L%O&?E
M)#?W1V'!&1WQ[5\\Z1\.M8\2^,%CTNT>^NX\%(\[L+G&]V8A54=R2 !Q7=?$
M"+7O!FI:;H/BSPNNG3:-&UY;ZM8LC1K&XR%5U^656;.4(R#R" *\C#_6LXQL
M)8V;E%='\.S>RT7K8Z,70H0I*C3M>Z>CU=FNCWUZ?<<Y/\15OY)7NA]NN&*I
M#&P($8'4$?AW%=_\'OBQ;ZSXHMX;JUA7RDDC"0@ 8"$D!<X & ..M>+^+/BG
M;^*+J]FTG3UN;F9O*5@P4[NG(XP<]<_6L.RL]:\/:W8_Z=&)Y2!*T8"QQ$J=
MQW9YP"?8XY.:_2<JRGVTY.K#9;KSZ_UL9XR-&I3LGRRMHKOHO(^H(/'L.O/<
MVMO:2V<-TXCCE(7YU Y [@8. /QK:\'ZW';:+&UO;2%;4M#*(CEBR?*<EB,@
MGG%>-6WB>R\,R6ERLDTHLE#A$<,9"1U/)&2:]#^$E_\ V3X3%UX@:.U>226^
MD5\)Y:L<JK<XR !GW-?9TZT</+DZ6ZGQ.(H1<4TM;Z(ZB[>XURYA9E?R+<DD
M%2S$].#TZ^U>1?'?P<VN^(HS,CS0)"!-';L<DX+$GW QDYSFNWN/CS_PE$;Z
M?X9M?MEW* /M!&V- "223TP!^)[5@^*M7T'2K;_B?:YY%S+\K,) OE ]=JXR
M0.YKYVIB:U?$N>'6M[;JUM-7WVV.ZC0>%:E46KTMJW;O;H>+ZEHWA7Q^WEW&
MH7GA^[TUE#/*#&)48  ,2""02#D'N:ZKX9^#--\%^*8I+36&UIA%(YDSYC0J
M$(&&7@C.#@@8KT;X0>.=(UK3[73&_P"$=\7:&P:,K?6X+;06 SR<\CN,C%>Z
M>"_A#X!U3P_<W^E^&+'09UB98WM%\M)%P0Q(7 (ZX)&<]*^3XTP,:F(<H02E
M.*=]5KM=;K;[ST*-9TG%SYN2,EV>CUZV9\T_M5?%72?A)X073]-NUO?&?B2T
M5V99-QTBUD48=CG D<'"#J 2QQQGX]GQ&G':OI[6=%\)S?&/5=->VM]4TR>4
MKNN$+&*0]B?O1MG/ (&,=ZXCQY^S?8:M;7%UX9O([>XA=E.G74V0Y!QA)#C!
M/8-D'^\.E<?"^?Y3@(?4IQ=.;LY2EJI-K?F6R[:67>^_H8[#5L1)U(U/:6Z:
MII=DO\F>'>?@TLDVY:LZUH-YX>U)[6^M;BRNHS\T4R%&^N#U'N.#VJNPVK7Z
M=&49+FCJCPG%IV93D_UG6K%L<TUH=SY[U/%:D+5"%SGZU,EN&'O38H,&K21;
M:2=RN8@:S0CI6?J%GL;CH*U]P]*IWZ[J9)DJNTUHVPR![UG,VV7:*T+,[P.:
M +D:;>@J4KBFJV%IK7 /?I2*8YCL'I5::;>*=+-N!Q5:0X-,-A?,VT4U&^6B
M@FYJ:HF8F]JYFY.9FKJM1(\EO>N7O8MLQH*EN6-'D*R&MR)MJ&L71(LOG%;6
MW$>:!)V*&KS^3'FL5IO,;K5OQ!,7;;629-K!?[U F;%CEXZ+I]@_WJ=I2?N1
M3[V#"GCD4 5K6Y^< UH1-N6L:13&VZI[?4&7'<4!U-%CDU!*^\^U2QOO4'UI
M&A/.%XH 6W_U@K5A@W)6?9P$$>U:$4VQ1Z4#7F1W5MQTXK+N;?FMB6;S!5"Y
M4%\&@>Y3C.WBK,+%C4?E?/TXJ1#L;TH)ZD[/LQ3(V+R=:<G[T].*<(-LFX?E
M4FA8A !'>K:'FJD8Y4]JF1QGK5$Q)9>151OE>KA3(XJ%E^>IV&T26BYJPMOD
M]*CBX JW&25Z4;C(GCV=L5$!AO6K%RVU.:I27H4T/4"95W-]VI8XMS57M[K<
M*M13JAYH>FP#;N ;*Q9XMLY_*MRYF#CBLRZB,DE2 ZT.S'O5O=Q5:U@*@5;"
M9%: 12R[:A$^YZGF0E354IY<E3+<"RDF:-NZH8W^:I%)+4BAS0 ]JIS+L?I6
MI%#YBU7O;78U/K<F2N45.[BJ]Q'OD'^S6A#;?-3KBRP.E',3RF2K;)#5B"7#
M5'=1[3Z8J.)RL@Q1$HTEN,5#<WVUL5'O^6J-Q(<YZYJB+EO>LII&M<MUJO:N
M6F'I6G'!OCS0.]RA-'M?VIT,&6J2>V9G],4V#Y.#4R"1-Y&:"FR@38%0O= U
M5A)7)C/\AJ$7&\U'O8@CUI886\SD<=:5[#V&7&YE-41#B6MAX-R53DMMLO3F
MDR2QI>[%;=C,5'/!K'M&\O&.];5HOF$9HD3T-G2Y,$5TNEOG%<Q91!170:3-
MG%-7ZF,SI+(9%78%VUGZ=SCFM2T&]A29BUU.I\/^'%\??"GQ]X9D7<-:T2>)
M5QGYC&ZC ]<E:_(S12T)5&&'3Y6'H1P1^=?L+\$KX6/Q MHV^Y<QO$P_O9&0
M/TK\I/CGX1_X5O\ M!^--!9?+&EZW=0H,8^7S25P/3:1CVII6-,*[3:]"72)
M,J*UPVV/.:P-&F! YK;5P\8%,[9;&CILG(KM/#,Q:):X;33AJ[?PR-J+[T$(
MZN!\Q 52U*[V/MW5H:%I4VNZO9V$+0I/?SQV\32OY<89V"@LQX503R3P!R:]
MHM/^"7_Q0\1ZB8;&\\ WD^TOY<'B6&1\#J< $X'KVI7,ZE6$/C=CP&*7+ UJ
M1#,(->A?$G]B+QG\(/!5YX@U;4?!,^GZ?L\U+#Q!#=7!WNJ#;&O+8+#..@R>
M@-<#;Q[HL>U+F",XS5XE.YDVM4UG<AQ[BH[Z'%4U<POUJC0VU/RTR1^*IVU^
M78*:N;=U V[D .Z3G\*NV R:] _9+^ EM^TC\>=(\'WVH76EV^HQ7,C7-NBO
M(ABA>0 !N#DK@Y[5%^SE\(;?XQ_'C0?"%U>W%A;:Q>/:M<PH&DC"H[ @-QDE
M .?6E<R=2*;3Z*[_ !_R.4^S[A5.]@P#Q6[XNTQ?#'B[6-,C=IDTV^GM%=@
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M KA<-2JNX_PU6EO<$XZTZVN\_6B(7+D46YZOV'AB\U[*VL#.J\,[$+&GU8D
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MI2+J<_V+?/\ X!G^!OV<_$'C7XZ:%X"OK"^\/ZMK5U'"Z7]LT4MK$P+-*48
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MB.F06^UJD(P_I210YI@HH,F[%9NHWWES<&M+P7IEQXRUZUTRT7=<7;[5ST0
M$LQ]E )^@I.:BG*6R!:NR-;PIX"OO'=Y)#9JBPPKNN+F4[8;93QECZGL!DD\
M 5[-/#<_$/7=!CO&;[.EO%HT<DXVRSF,!%=AU&<=_7VK>\ ?#?4-&M8[+3;&
MX989 L5L @DG8K\T[DD!<8R6) 48 /3-'6]&T?0_B!%'J'C32[&\B<.8DBDF
M^SR \AF^7GVQ^-?CO$F88K-,1R4HVIPNUIJ^EY=E^"ZZ[?48&-/#1<5K-]=[
M>2_S/$?VI/ACJTWCF[AF7_4_*'7DHJ@ 9]CCKVK@9%NM0\)65I:PN(]$$C,0
M> [D$X/7HHX_&OM:_P#A5<^/-6U/5&2;[$9V33[Z:,QFXCWC&5.<9#9ZFO&_
MBG\ H]-\82V5LLVGV<A#SSP-E'/0LPY ]A@5IPSQE5P]18?%+WH]5JOG\MFC
M3'8>$Z"E3:OU78^>5\$ZAXTT:9HT9BXP^]MN>G.>_ K8^#WP#DUFYN8[B/R(
MK-RSHYQO(!YQDYZD@9]*]VNOV;;J%;>Q\.OJ&H2WJA1%:P#S",X +<@#U)KW
M#]G_ /8HTWP'KD</Q&N+>:SN4WII<4[_ &@R$C!(3YFZ8.[@@]!7ZYA..,MJ
M>_>7W6U\V[?D?)XJEB%"24UY);V/EWPI\ /LWAEM0BFAC>XE41.J$M;*00$4
M9.21R.Y) %5?B5?PZ%%#I=]I4B1_9R(YI8L+'@X(P>21C&>!G/:OU>TNV\%_
M#S3;:VT?1]+2UA=0(X[96F1QG!)8@Y&.#DD'I7#_ !/\!Z?\<O .N:/JGAS2
M6DNK=X]*U)[1$:.8@[4;C,9S@9!(YQGI7A\2<;U<5+ZK@IQC%;Z7DU;2SO;7
MYZ]F<.'KS@^:I![[O=?@?EM\%?ACI][XM'G,K6\DN5=B<ACT![@<]?RKZ!U3
MX+:%\"K9_%FN:K)H^GPNICECP;R_D*Y$4 ;&2<_>) 4<D] ?*]9^&OB'X=^,
M4@U+39K.[L9"ET.500KG)D..&3!P3U XR<5QO[0_Q1N_BC^T9_9_BC4)G\*P
MV^D_V='$F94A*!9$B7IEV=F8GDE0.P ^/R/(UF^9*C.HU!)R=MW:RM\[]?\
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MW(:I3V.Z7TP<UJ!&#<CBAK<$]*-B[%6PAV=JOKTJ!1L(JU"FZF,@E4AJB,@
MZU:N(O2J,\!5Z7,!<MI<D5:F3S<5E03^61DYS6K;2>9'23T HZHGEK]*S8Y]
MY&.]:FJ'.[O67:6KRW'2B7<3U-&VM_-')YJ[;60':FZ=9-&.E7TCV#WJ2T5I
M[-0F>A%86HR&&4\5T]TJB'W-<_J%H6E/>@F6I!IURQD'''2MJW@WC<1@5F:=
M!Y<@R.*W(,,M 1*%ZNP-M["N2U*\(F*Y[\UV>I($@;UQ7#:I'MN2?6JOJ3(U
M- N/,DK?MC\W-<YX:BWG.:Z9$VQBA;#CL-NAG/I6:9MLGO5J^OO(7:!UJJ L
MISW-#0P,Y?I1]GWC=U]JE:U8Q_*.:6*'R8_FZFET#4K_ &'< >F.E6+>W*KG
MO4MNRS#;Z5<BL\)2!(@A; J0OO6GO:\<5$,JV*I 5IH QSBHTMMW;%7_ "Q(
M#3?+"+1L!7%ID8JK=V'/RU<DN=@-0I<&3K2 JQ1-&>G2K3M\OM4@3<N=O-0W
M+;(\'J:=[ 4;UMR&L&ZC*2FNB\H,#FJ\FF^=SCBFB'J9NE0DSY[=*ZBQ.U,>
ME9=G8>0W2M"U.P'-&XXE?7;@K ?:N7GNV+'UKHM:_>JP%<V8\3$>E"=R9&EH
MD_F+@_6M9&Y-8^DV_P"\&!Q6Y%#SZFB^M@W+VF7'EL@KKM NV9UYKE-/@RPX
MKH-)S&PHNC&1W.GW.Y16BISMK!T24N,5OV@WBEN8R+%N=_6O/O\ @J%X:_X2
MW]B3PSK(&Z7PUK:1,?1)5DC/Z[*]#B0(U1_'WP]_PL+]A?XFZ2%WS6%K_:4(
MZG=$5ER/P1JDSVDI>:/R[TV#* BNAT>U)92!BL30F$BJ>QKI]-F6)151/3Y3
M?TR+RP*WM/N]A7!KFX+S$8-6K*^)/6J)?8]"TJ[R@YYK6*I=0X958>A%<?X?
MO3+&,FNDLK@B,#/%)["-."W#"M.RCPOTK+L)N .]:D#87-0-JQ+/( ".]<YJ
M]HLA+;5))R>.M;EQ)N%9]Q'YK'BK0FS(C@+R#BK<,81<,JXSGIW]:MQ6X0]*
M;<Q;.U, CEW#'4&I8TWG;C[W7_Z]0PJ6/M5Z"#9S05$=!;+#^.!_A4AB"4AS
M2T$CHES^-23P;HNE.MX\"IDC)&"*2=RDCU3]DS]J5O@F]_X7\467_"2?#/Q)
MF+5=(E'F?9]V 9X1GAAP2H(S@$$, :O_ +4'[*0^"OV+Q-X7O?\ A(OAOXBQ
M+I.J1G?Y&[I!,<<,.0&(&<$$!@17CC6^*]D_92_:G_X4T;SPOXGLO^$B^''B
M+,6JZ5*-_D;L S0C/##@E01G ((8 U*.>=*4)>TI;]5W_P"#^9Y">15=QM/-
M>X?M1?LKCX-BS\3>&;W_ (2+X<^(,2Z5JL9W^1NSB"8XX8<@$@9P00&!%>)W
M$);(I\QO3J1G'FB0K)\_TJ]:OEJRRGE-UJQ9W6V3;GFB)5R\\.]B>PK)U-_)
M?UW'M6T'5X<@J>*QM44L#@9HW&T16SEGZUHV]GNQWJAI=DTHK>M+5HXQGBI!
M#8;-2O2H=0MA'&2*T45<CTJOJB!T(':@J1S$LYCD;BM#2Y6D&,57GLR9.F:T
M-*3RQTYH(1<6W"1_-WK*ULF*V8KP*W0N]*Q?$R 6I5>]5?0J6ARK7VZ?/9>*
M]2\$_"Z^AT<:CK&FZ@MC*A,"H3&T[9  SM(& <D$@D# YQ1\ _ %GINE7/BO
M6M+N+M890FD)(,6SNN=\[#&76,[0 .,DDYQBO5/"G@Z3]H;QRDFM7FJZ9H^F
M0F>2;3X@+0*HPL:G[J,V0!@$DYR#U"LWHCPL=F#A+V5/?J_\B]X0T'_A8.M6
M&@^#;2V9[>V^T_ZQ +.;9M^8!P26.,DAB"N,$9%?4'[/GQ-TG]D'X=-HOC+4
MK^^DN;F2=+BUM9;B!'. 85"@X.1G/<DYP0,_.WA[2='_ &>_$ULND:?Y6%DF
ME66Y!O+E0"R"=^&56/!"X'ID\CB/%'QR\7>+;NX^U:A-%;B0R0P#/DVX)!*H
M !A3^///7K[>&R.M4]YK^NU^_D>-"E*H[K7_ (/GW/KV<67C'Q9<M<?#W3;K
M1-0>2?3XKZ%MD[.Q)F;:K!<JV"#DYST"@#.\%_LF>%[FZU2QL[*YTB:2".YN
M+>WE$D$$A8LJY7<QC<(5R&) XV@@D_+>K_''7-9C@N+B?4(;&WB$:.C>8L4:
M_=*#'"C'3/..<=3VVD?'36H]5T^#2[S5+72K:'?$AD$4T[L5+.[1\;F/08(
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MS)N6)., @' "CJ?K4,^;S2NY5>1;(]A\9_&K6O[2FO6MKFZM0,&:(C,6<Y+
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MDKJCH@X"M'Y9 ' ' Z5U/Q@\4PV7BM=!O]1ALAI%XP6X#GRTCX#!MIR",+@
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M2"W?S4U.%W!C=" 0'C PP)! Y!.37,>&M+32ET;4-3V2V]Y@B$Y& I*D$<9
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M\?1D[\BZGD/BK2=<\!ZE-8VY1Y-*NS P+X\L/AE=1W#*,8QUQCO7*Z]K]_\
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MQ"V"'@%G0$DG/T(QGTKL/"7Q2\-W-_\ 9[J&V.GV<(BAEDMXWFGWJRJZ'Y2
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M,=J?I\JRS 'L:J0M"U8Z=MCZ5>M5:,[3TJY:K&(_E&:)$52#C%+F(DC6T1\
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MS_9IE9"RNC!E8'!4@\$'J"#7T[\*/VN])^(&L6^G^*F;0I)(]D=[&H-L\IP
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M+9P,<Y/ )XKP_P")'AEOBY\4-2\)Z'JWA[5(O#,1\_1H]0#ZA;C(#3318"#
MP"H)(''7-=IKVDZAXY\5:<8;G[?(DD4MM!;J8TC=""H9> 2#U)R>N,5V_P -
M_P!ESX=?LX_$GQA\2AI"Z/XS\71RG4I+C4?,A\R;#3>3$PW+YC 9))"C(  K
MYO-LRQE3V=#!I<E_?;W?I^B._*?[(J8;$QS"513Y+TN5)\U2ZLIWVCZ6:WUV
M?SYH[CX9>,-66QT]+%M.E1+1R@VSSHX9I5'(,8(P 1SCI@U0\0>(+[Q/K-QJ
M&HW,UY>W3;Y9I3EG/\@ . !P!P*ZSXF:M:^+/&D]Q9+_ **JB-'P1YI!)+@=
M0"2<9[ 5S]WIRA<X4FN:4E<Z\OP<:-)-_$]_\CGM0N6V[1^-5[1"\^*V9]($
MBLRCA>3[?4]J9!IGD'<5P*;DFCNL.N(%CA'K67J<FP5J7AS&*R=5@+MTX(H\
MV!!9'SG7M5^:WS%R,\51T]?WRUO1VJRP=<M1;J),Y\G!P*L+'OCSWJ/Q5JFG
M>$X$DU&\M[,2'"!V^9S[#DG\J=INO:7) DC7T:PO@E]I. >^.,G';-;4\/4J
M*\(L\W&9U@,++DQ-:,7V;5_NW'.HC />F,RS&O2?AWXK^"Y1M/UIKS4=2D!W
M2W-XUD(^,@(JG:#CGYB2?3%4-5^!T-Y<-/X5UFQU:Q*[O+GN8HYXR205SG:P
M P<Y!]LUK+!U8J[1YN%XNRO$3Y(5+>;T3_KSL<!+9AP?:LVYM_*E/>NVUOX?
M:WX9L6N+[2KZVA"AO->(F/'0'<,C!/?-<G>0;VS7-9K<^@C4A47-!IKR=R"V
MCRPQ3[R$,/I2PMY,9;O59KW+MFJZ#)K:Q\QAWK8MK(H@*C&*JZ$T;MEJZ"/:
MT?3BINR7$;IV=PW<UU.D-O4?[-<U;@1S#M6]I=YY3JN.M5N82.DLCD[:TH6R
M,8[5FZ>AD(-:]M"H(8FC8QEN==\*-'C\0-K>BS!3#K>FRVS ]&W*5/Z.:_&I
M[:;P]K=[ITH99M.N9+60'J&1RI!_$5^R'PQU8:5X[TU\XWR&/_OH$#^E?EM^
MVGX&_P"%>_MD_$73%C\N(ZS+=0C&!LFQ,,?]_*2=AX?2HUY&#H5X7C'-=/8,
MSQ"N.T7G Z5UVCNQPO6K.XUBA:T&[C%2Z: P&:<T>^V^@IEK%A#C@T&<M#M_
M!C[MOH*[JT(^RUY[X0E\I .]=[IC[K0_2@NGL-GG9*FMW$D:FJ6H7&P_2C3+
MS(Z\&INA]3IO#WAL:^E]/->6.E:=I5LUY?W][(8[>SB! +N<$\D@  $DG%'B
MCPX?"MW#']KL=0MKRWCO+6[LY?,@NX7Y1T/!P1Z@$4>%_%\GA47:K;6&H6>I
M0&UO;&^@$]M>19!V.AZ@$ C!!!'6J_BCQ#>>+[LWT\,<4,$:6T26UOY5M:1(
M,)$@4;551P!G]37+^_\ K&MO9V\[W_*QV?[+]5TYO;<WER\MNV_-?K>UC-NX
MT$1;')K-6V\VYQV')_'@5=EN!Y6,U4CF_>MC@C%=+W.'=FUI>GJJ;FJXB!#C
M'RU3T^Y+QK5U5):D:1)?*68\*O'M_6JLNE[FSCY:M1RD$<XJV%W**"B#2K46
M[AF7<!CCU]1^->K>'?!^C?$7XW>+-8N/B+J$NC^*O#[:18^$[F P6=H[1!-I
M=OW86,@LI +ECQ[^9+!G_"K,=L6'S+E3ZBN'%8&EB90E5O[CNM;:^?<]#!9I
MBL)2KTL,TO;0=.3<8R]UM-VYD[/3=6?9GT1^SYX9/P@T/4_"/V'4-9U62));
M>RU%DEL1$I"S3"90#&G&0Y) .T$9R:E^('P-M5TV\NM CTK6-/UM'59(+J.8
M^?'N0!)5)7*%BKC.<XR,]?+_ (:_$VR\.>&]=\,^(M/GU7POXET^73;H6THB
MO+)'(+- Y& 20"5. V!GH*])\*^&?"5U\%K+0_!%W=-;MJ<UW=QN4LK][N4@
M+F%5>-H@J* "2"%^8DCCHHX[&4<4HTXITFM;_P"1\U4RG T,LJ5JM67M^=*,
M5'W7!K5N5]'?2WI:]W9? WP(T27PNMC)<:O?II]PLLES.0CH&*HT6 3A8]V0
M<'!0@G!KV6\\+ZI)=+INGM;>'='TJY6W@@M25EO0J>60SX#*N,GY0 2H()R2
M..TKX.MI:V;2:;<6%I:Q$>1NQ*)-KO(^Y01M! ('3+  ]AW,WA?Q?!H>EWFB
MV=CXONSJEE%=1WNK&RBT^T;)DN0Y'SLJX*Q\9R>/7W\1GE.%)R4&GY*_9:6Z
MGFY?)UIQP\+1E+K*48K;=R=DOGU\R#_A4>CZ%K5^UOJ.H6[Z_8S6DM]!=_O[
M)I(C'YL+L %D4L2I)/(R.14_PU^&NE_L<?LY>'-!U;QK>:AI_A\M$_B7Q=J2
MQRR^:Y*^9,YYP7(5<G &<UVS?!:SLF%JEG;>7+-+YSV[-+D Y641@#:,\$9/
M.3G!KRG]I#1_A'XU\'WG@GXA_8_$&@7-U!<K;?;G>]MI(P=KCR22N0S C(.&
M(KP\<TU[:@KU$FES.RUUUM?[SMRG&4*DX8#&2FL-*<95'",93M&ZO&]KM*3L
MG))];V1[EJ<^F>!/"?\ PE6K:I'9V5E;F62Z"I*,$@HT9P1A@>,<G(QS7#^&
M_P!OGX9Z-HRV.CW%]=W[[A;K>0M )Y2"5WRL J!C@%CT)Z&O#_VLOVN(OB7X
M5M_!/@Z#[!X/M[>*&9Y(/+DN1&1L10Q)2-0B]>21S@<'YS&D.>BL1ZU,IMJU
M]2<+D\)+GJWWT76W2_F=%X7?XG?M3P:7J'Q%\!Z?X ^*7B[Q#<69TBWO_M22
M6H($4[L&8 * 1N& R+D  8K[B^'W[,O@KX#> I-/L[&VU+Q$8OL5YJ0 2<N<
M,Q+9!5,X( / "CKFO"O^";/@2/4_CG=ZW=*[1^'=,DG1CR!(^(UR?789,5]I
MZ-XMT>YLO,C6*.XOI60(^ \DF2".>_'Y4\'3<()-N7G\[_@8\38SVU94::4%
M9:+;9+;SW:VNW9)62^9X- UKP+=7K:AJ<-Y#-/O79.7PF3L09).2>O/.*FTO
MQ4NL^,M(C:6VT_5+6Z3RG.&,CLXQN/0 9^F/PJ]^T+I<=I=7$MK)]D2WD0B(
M*")22  #Q@ECZ_TKC]*73_,:2_=K]XP5P(R-C [BX/7(.>2>,<<U];AZ<)4N
M=[[:+R^[J?(X>G"BO=UL[+J^[\OG_D?,O[%>B_#>^_X*,_&JZ\'>!_&>BCPQ
MJNJ74%UJ\<#0:IJ,$TC32;MIGC@642F+DD@!6(!"GO/&,-W:1NUS<3))<R%H
M5,($A_B)/.!CKP2<<>U>U^%_C_I>HZAJ=S#H^GV^HZFI@N=06PB@O+V%3P))
ME&YP".YP<=S7EWQX^+T/P^^%OCWQPWA7_A*?^$%CMGM-(20LT[37$<;3R(6X
M$8?=CA0,%L#->#E6#GD="O5KQ6[D[+IT7]>A]MQ/G>)XNS; X#!N7-RPI+VD
MD_>ZMM**2;>[N]-7<X?QO^T5\/\ ]FWX$:9XO\=1ZEJ,FH:G/HVB6ED'5[F:
M*(S.)FC5FV@%5&!U))X!KS7X@:;;_#N[\+?&CPC9WWASPYKR2PZEH.I#S/[,
MN4>-7R^ #;R*RN'P,;LX&2!ZC\$/BM#^TS^S5X@O/B=\._#4=GI>L0W5C;VT
MHM)K=Y#+"R%K=AY=RB+C<F!(CG(P,G$^-7B.S^(/A"WT.UT]-/T'P[;-:P65
MI(\BQV<@"LS,Y+R.Q;)+$D[3V%1DV(QV8XMYA2E_LS3M%VO?_A^M[6*\0N'\
MBR3*'PW7HMYK3DINHFW'D>NCOV:4H\J<6KWZ+AO@=)??%K4]2M-,O/[?DGO)
M9=//RK*82C2-'V!*D$+W;TY%;T^E9+QS(RNI*LI!!!!P01U!!X->;?LJ[?"?
MQ8TO2(F2VN+J<Z?$R$)F526CD!_O$@?-R<'TKW'XVZC8W?Q0U*XTV99K2Y9)
M#*%*+))@+(P'8,ZL1[&NS-L.H3]I'J?&^'>>5:]-X"MKR7Y6][)I6^5].VW8
M\\_:-_9SO?CI\19M4O/C9JNC> 8A:3:5X:TNUE$EA)$B@H47:O4,0Y8DEAGU
MIWBK3(_&GQ.U+5XEN1!=2+Y?V@@RE514#.>A9MN3[FN@:?$63SFM;0/!UOJ.
MO:5ILVNZ#8ZUK5N;^RTB6Z"WUW:J?GE1,$  !B 2"=IKX_#X#"X"<J][.>C;
M>^MTC]TS+/LUSG"T<#47-3P\6XQA!+E22YI-Q5WI%-MO3?34QS8+!;!1_"*L
M^!X/-\1"SW,$U)?LY YWL2"H(]R,?C70_9M8N[GX@V/B#X?V_@W2?#=[';^%
M]66\::7Q"A<ABP)PP* /D !<XKEA:RPRK)&S1R1L&1U."C Y!![$'D5I&=/,
M,+.&J4KQU5O*_P#D>/C\OJX"O["JXMVC+W9*2M)*2U3:O9V:Z,L>*_AXVA:=
M;0Y4L'9B-FPX("Y(_P!Y&'Y5SUYX2BO-%O\ 3+S:^GZM$8;E,9'^S(!_>0\@
M]>HS@FO9/'6K1^/_  H?%,D\<US+BWU& J!)93X!+J0,E)"GF*#D9\Q>H&?-
MM1F4KCY1C_/6O)X>M6PE3+L1K*FW&2M;1ZI^G9_,\Z,I/WGTT^X\_P#AGX5U
MKP-X471=<D6>YTV>2&WG63S%GMB0T3!NXP2!W X.",5T$D3%3D<'K6G'!]H[
M+72VVG7MM\4/ /AFV^'5]X@\->*[%[G6/&$=VZPZ)+F0&(*N5!C"*S>9U#<5
M[#JT\OPT85&Y).U[=WI_D>G@,MK9A6E3H6YE&4M9*.D5=ZR:N[)V6[.F^'?Q
M);XM:##X4U[19/$^H6<+MI[&]>&6Y5 "D&%QED +(V<C'.0*U?[5\,>+/VD;
M_P" NK?"'Q-X@\)Z_P"'X;S6-:U=BNGEEB^TIE$4#,;*JEPX</T'->4:='=:
M5XG@FTF:87]I<AK2:V!\PNK?*R@<Y.,X_"OJWPY\>_#_ ,0;"QBUS5+_ ,'^
M)-/?]_93R-;VSN,?,6<892 2$(!0]"1S7I8CVF(I1PZJ<JNF]+\T>L;/N?&T
M\+ALJQU3-HX7VTG!J%I2@Z57[-6+CJW'=+:Z[,Q;.^T^+P-HWA/0_!36D.E1
M+::0/#[">)+4N2Q9)"V\$Y+/G=DY.,&L'Q/HA@UB^\/Z\]CH&J*9$@TUE4@N
MJ[ER790ZL&)R,@]!SBO1_%-IHFO16_\ PCNL6UWK]M$JB.":..2/!!(C\MMS
M.0P '0[B21@5R7QC;Q+X?\)Z%:7F[6H+Z8B>PUBW29;29 "I!;$B\Y(P0!M!
M!).*^LR_'2H05*C;EM9+M;MY>6Q^9YAFF/<ZE7'2E4E+5N6K=W=MO25VW=N[
M\TP^%GA33_#OB6XCU[19KNXN[(W4_B&:0"/R$ *(8L$H"#@ 9  4 DG P[OX
M+Z5\3O&<>JS>+[C^Q[R1DM+;3K)XXQ$N-P89P6'&6)!QSCL.T\+^,/'C1:EH
M^O:;<:E96C+;^=8Z5YC*SD[04;RVP1RKQAB#@D\@GJOA1\4K6TMH+?\ X1^X
MU&ZL92REM/,,@E4E<@.I6,E< D#DCJ.M9RQ4XR<XK7R>GXG!'V%1I-63ONG?
MLUH]>N][]SE]0_9"U+3+B^OM)T5KBX=FE^TWX2!;>)5#85<Y.<\Y !/8UD_$
MCX26/AZ^LQ?7=UKFOSVD<D<&DKM>)APLID55VJV\CA23GG(&1]-0?%2:'21]
MMM=41KA2#!)Y4C3-C)X5<@$<<DYX'H#Y#\1[W1?"<<'B/7=9N/!$=U.RF!(#
M]NO548 'EG(&W!"X'."Q7@'E>.K3=ZK_ *_KL=^(P'MK4Z-Y-VT[6[+1?><Y
MH'BC0OV5_"4I\0SV^FZM*H-C:(!+. 5!=S& 274E1\YR2<D@"OC[XE?$"?XD
M>.-1UBY++)?2Y16.2B !5!/<@ 9/<Y-=5^T3\5].^(.H6EKHMG=6^DZ:TK1S
M7C[[N\D<C=+)U R$4!03CN23QY9&C/-U[UYM:I[23['Z-P[DZP-",IJTVM5>
M]M=M$O*_H7?*$@XJGJ-FL:UJ6=ONCS5?4(][D-7.?2&/&F#5LQ[8/<TQ8]LH
M[U#?W;(W'2JB9D+6>YS[FK%MI7!P*AM+I7F :N@MG4Q#;Z5.H'.W-JUNQ]*+
M<%2.,9K5U.'AB1S6:\GE*6 Y%,"4VV3138+II(]Q%%/E0$D5HPDZ5#JEB'0C
M%:$.HQR>YJ'4WWQ_+UH XN_T]HISQ\OI5O2H"A6K<]HTCG=4UE8LK;JDGE-2
M*;9;A167JD)=V]^E:D$)V<BFM:B5^15-E&390[$6KT9:53FK262ABN*<UNL/
M?KVH H^1Q4,EOGC.<5I>1Q[TR&P\R7VHL!0M[%G?[O6MS2M/)4;N*LV>G)QV
MK4M+=4(P*CFL5RE86*HO^-59P(7-:TT>6K+NK)GF^II%%BRG\Q<=Q6C"(U0?
M=S65%9R6_:I%$IEZX%&X;&HUTB#UJ&2[W'V-0P6[R-C!-6H](E4Y9<#WH>C*
MC*Y>T>QFU>YCM[6&2YN)B%2.)"SN3V ZDU9U[PI?>&[Q;?4+*YL9RH8)-&48
MJ>A (Y_"K?P]OK?1M5N!>37]M;7UE<6+W%B^RZMA+$4\V-N,,N[(((/I5S2_
M#6G^#OASX?\ "^EZCK6MVF@+/_Q,M6;-Q=M+)O/RY8JJ] ,G\*XJE:LL0J:A
M[EKN5]GT5CT(8?#/!RKRJVJJ22ARO6+3;ES7LN5I+EM=WNMF9-B)K>)U662-
M9!AE5R X]QG!_&FM9Y;VJ>\'DOCN*MZ58&]8 ;F)., 5OS6U./0KVNVW7A:/
M.6:;!KM-)^!NM:^RA+;[-&W.^8[1C/8=3726'[)4KP;IM;MXYNNSRSC\#7'6
MQ^'AI*2N;1PM6:YHQT/,&VI%TJD;_#%?2O3-:_9LUZQ8+9JNJ*S!%$)^<DGC
MCK^(KBM>\ 2:>HDM[S2]447+6,K:==I="WNE +0/M)VR ')!_/K6E/%8>HER
MS5WYZD_5:O*Y.+M&UW;17VN_/H8C7 D;UJ]IX3OMKUGX=_LH226/VKQ ZV[-
MC;;B0 _B<X_*NZLOV<O"AL2UW;1Q6]JAFEG>Z\N.)%&2[N2 % YR2 *XZN<8
M>F^57EZ&U/!5)1NCYWFMDDC^ZM94]OY<AQQ7TYXH_9W\.WNGQMI\RV^^-7CE
MBE$L4JL,JX8$@J1R"#@BO)_$GP*UW3I_W5LM\C/A6@.XX[$CJ*,+F5"J[1=G
MV>AG+"U(+F:.%ACVQ=,TZWM#<O\ *K/CT&:]O\'_ +,5MHVA?;_$DC&0D$6\
M;X '7#'N?:M2W_L72;25EBM;&W7Y5"* <#W/)-8XC/*,)<D$Y6^XZZ&7SJ0Y
MWHCP.XM5@3YD93[C%8NHP[S\M>T^(O'W@NTC99I(;N3G:),?)GCCZUP.H:/X
M?\1R22:+?K%(3GR)6XSZ ]:K#9S2J2M-.)%;+YPUCJ<A\3OC)IO[+OPK\+ZP
MW@6;QQK?CB_O+&UDE!.GZ1]F6,GSAO3E@[-USM0X!P:['XC^'+?^QO#^K0Z<
MNAOXBTQ;Z?3%G^T)92[V1@DF3NC8IN0GJI%=)\(=*UR6VNM+,&FS:+-*)+FW
MU2SBN[4NHP'$<@(W ="!G%>S0?"S3=9D^V:BJ:A?2JH:>X48VJ!M"H,!5&
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M7W3:MJ<Y9^'=)L?!]UX@\1>(+;P[H5I=Q:?]IDMY+F26XE!*HL<8R1@$DG@
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M.^-\ICC49?! SR<9QUJJFEZ]H7B2)KC1;^,/;3O:-<6LL<5X[ (%5L '@D@
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M955:T')VC?1;:>FM[KS:6IW=YX8T_P )WR;=7U6&XN<QP*=5(DR 6(4E3D@
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MK,FX&53R&7N!G/;@UU1JTJT_91EK\]#:MEN)AA(XVK3]QR<5+HY*S:];._\
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M@SW,2X@LA!$H3  !=N69B.I/YUXO\3/$$U_IS7EK-=/J$TPW77EGRHMWMR,
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M-?:M<"8J/+7Y0D2] %7& !TKYW%X_$X=\E2SZIH^TP-3!XJG[6+:MHXO=/\
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MM;Q;R19KB7;.67?A<9Z8/)^GY5Z?\ _#?AS6]"_LJ\L;;5'UA60R&("X1N>
MR@$>@(P0>]>;7@E[JU.*5K66K74\A^"FIW6EZ)YC2-)!O/\ HTBB2.1,<YXX
M)_GWKV+P?\*]'\>^)],AN;*ZM=/OIA++<B0A4C# ,".<$?W<@C.1Q7J%U^SK
MX8\/^!I+2U1M$DO8A!!NQ))DGDA<EB#R,GL<@UY?J-SJGPW\;S>&S);.M],\
M<<,4Q8(L:J4D!QU8%@0<$ ?0GQ<=AY3@ZE-VDEWW\F>KD^92H5%0EK"3^YO2
MZ_7HRQ\*=0\5:EXI\96/BKPAHO@[PWH]F?LCVNGR6\]M<"X98XQ<,BK<"2(
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M. Q<Z"E&7*WMJM]M.O<^MX;SQYME=+'6<542?+)./1.Z3;T?1]5]Q]U_L^_
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M:7*K6?5WM'Q._CN-%TXS6DTGS_,L>XDGG!&.E7/!_P 9]?\ A_JT:R-,UNS
M <HZ9]&''Y@US.K?&6*RNXT\Q)>0H8H 7![$<@<UZ%8^"_$'Q(\#7&LR:%%;
MZ;8R+$9Y9DA,CGA416(8LQX4 8)R 217DX7"YA5J>QI4G4>M^6[^ZV_EW/1Q
M^?4\%2C7S.4%"76=H[V_FM;?79KK:Q]%Z#\5O'GQ5^#/A^/P-XZ'AV;3KB9M
M>19((;^1S/$T4OF22(HA2$2 D!P2,%2#D=[IWCKX1>)?V@?^$VT^W76/%=G.
MLMSJ%KY"VFJ7@ABB:=CL\TH#$I"*X3*AL DY^*XCI^F7"[KZYL+NX0;5&-A8
M<%64C@YKH_!+Z;HWACQ-XN;3=6UV_P#"=M%<II6B-Y=YJ#/*$&< YC3.6."0
M.E8T*T(2DZEVE^#7]6T9I6H5,5AZ<<K:IWYHZ147)56KQE.ZNKZ+FM9;O2Z_
M1UOCO! RK,ZEIAO,F  2>3C\>O>K4/Q5L[VP:=GA6/H9'.0._)KY_P#!7AZZ
M^,OP+TS4K6"Z\-7M[;1:@MGJLF9; ERKHS8RRL!N4D D8R :Z;PS\/M%T6T:
M.:\NM;F4[F,DACMRW;Y%(R![DU]%AZ>%JJ-6I?E?WV\EH?FF,P=7"XF>'G%)
MP;B]59-.S5U=/5=+KL>A:YKNE^)],>:VO+:Y ."89 VP^XSD8->6^*='M]8D
M>WN&28=5D7&\#Z^E:7B/Q'_85LD=OI]K9P\Y%NJ[3GJ3C! ^M3:')KU_X9UW
M_A%(]'7QC)9+_8DNNP'^STD\U#)N8@*&,>\(6(7=CD"NBI3C1ESX5.W1;O\
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MW81H2RE04/ 9>Y!((SGIFN\\2:I#!X&DAMFLX#?1 I/>LS7+J7.0J[F0$@'
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M8,"",]P02*ZOX0_LO:+<>.M+U+XJ>/-'FMKU)+F4WM^\\LL87$3.B[I KG!
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M\(R+/<+IOB:!"^FWD0"DD=(I1W1B,,#T'(YZ^$Q^)K6W>W^SB219?G$C2B/
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M ?,@SG(YX))'8YY%>8^)=)O;S3+NWGF2SF6[DN5O)&8B=F0!E<LQ5%&T;0
M#G&,U[AX:\.WU]\)="U"^\-W'A+4KJT!N--D;8MH2<G"!BJ GD+@$ X(!S7C
M/[1?B.'1-*&FV_S7-S\J*O)1<X+D?7C-<^.QV(H5*N5Y9-JE.6VEWKNVNEEK
MLK:6._+\KHXAX?,\TI1E7IQ6NK2TU23;ZO1ZN^J>K/)?&/B77O"MLXCB>ZC0
MC$EMATS_ +P) Q5;PE\7[_[1#%"]O;ZR]S$8Y]08+&%(977."" &SSCD#TKJ
MM)TB;PYH:*B3,[(5WQH6W\@9'7C<0.1UX//%<7XRTJ37;R6-[54E1-CK)&$<
MC()R,=>GOQ7IY7E3P%:.(J4^:W7O=/;I^?Z'7G-/^T\//#4:O+WM;2S6_7\K
M]]F=GX6\=-\/M2MM5TVY29H[>2UO8Y[2+:2Q*R(5Y5E(&1@8((KMM+^-4FJZ
M;_;"36QBTVV<VUJ+1%@MDC4LH2%1M4J1D8'4YKY;BOG\.ZN+-_.CC)#  %@@
MSR,<?A7OG@&PTBY\'6S6K))?W;1QS2><SK 2'9XWB7'EEE "EC@YYQ7DXC):
MN:8VK.DE&VKVVNOGUWMY7.?^VJ&0X*C0Q$I2U45:^K2=M&[;*UKZ7T/,_ 7[
M;/B'Q9>W6H1.EI+/*7C"H)&&>I+N&8D]3@@>@'%>CZ+^T+XJ\9S_ .G:UKCF
M)=W%U*=B@@ X4\#)XXZD#O7S9X3\"?\ "J]3U5M0=1%'JLEO9JH)S#@.A(Z
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MPD0(C07!FCCSQD#)  ]/SJA,MS9W.A^'X;C^S;+5KN*.YN-O5F8*">0/ES@
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M2NT#!(SG SR.O%?/XRI&NG&?O7Z6T^1PQQ]:G65>C-QFG=-:6?=/OYG@>O\
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MT^%E56(CV!4()7D?,<\8KR[Q1+<^#]5AUSPQJ5S%,ETZ+<VLA2:W#,0H# #
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MZ)N^SZ7I=FK  B*T1<@=,G';)Z^M0W?Q%TW6K-(;ZUTV_MAD^7<6J-LR,<'
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M,2"1>0#A6Z'KU[U\W_"'XR-/J4LECX6L]2;S8$9;F 3#R(E**)%)P=JC).<
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MQ8[,*6+K/$1BHWMHOZW)JTZW*KK\;G%_M&Z_')X=T+76G^S"9Y+)U7@R,H#
M@Y'0&LWX?>'?B%XLC#:'X;FNM/D4;Y]0 LT<C. &?!8$@C(YZ<CBOH34]#T?
MX>>$/#^FZAI=C?ZY#YE[%)-$)&L/, 7*YR Q5>N,C/!%0V?B6:ZDROF-$#W)
MXQVS_C583-*V#=\-I*W7L];?D'*IOFF[>GEIOZW.;\+?!;QII-I+<;?#\.I"
M$B*!;W=M8C)&[9R?X1S@#J><UGR?!CXD1K"U]I:W$* DO;3QSX!.>0ISG)/
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M)I?NT[ZI)-ZM[O7?J:NBZ;I?Q5NH/%*Z>NCZ=J5VTS*#O1"K!5!W''!R,@$
M,23WKZ"_8N\/1:T\&K6<%Y,-/O;NW:W8@I<^:Q82D\D@ #D<= .F#P7@[X'R
M:9X>BUCQM?75G"%:&UTNV !OVC#NX5>5.], J1SR0.,CU3X>>.-=\ :1''8Z
M1-X8T^[D_>/=.EQ,F 2HV* $4#H "1W//'H9ABYN+A'5=/ZZOT^1Y=2I)1Y8
M;6MV_I^2-C]K_P#:!\?? /X9Z;>>#_#]EK%U?7<\,L]S#)/;Z2J1[XD:./+L
M96RJC(Z8!!(KHM?\97VH^&M*O-7TI;:ZDL89-4L+=R?LEQ+'\\08@$;22%)
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ME0R#-PDH9$&>2>X&/6NN\5>*='A\5ZB=(TZUM2\@2:[BB"S7C(H169NI "#
MS@>E>?3K1@_:+^G_ , TI\UE"6G7:^B_S9X_X%^$_P 3M>2#[5H>EV%BK81K
MZZ2"6-,9SY:@D'/!!'X#K7H%U\%?'$&@06NE3Z).[R"2<K=>6=PY&-R@;1@
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M"9('!&"986.5R><CCGH*O_#TV_C#6]2US2]<TFU\,-(+5K,VKI<229&)1D<
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M-6G2551;AP1;Q>=^\V(!G)P,Y(')%>(_"SX,Z7XVM_$6OZUJL<6G6"QPBWC
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M;B*=K>X4E) CAL J0RMQP0<#]#E_$#XL:QK-Q!_I<D:/*\-C;RN76VA9BWE
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M%]>J]&S]+-%^)WPU\-_!AM<LU:S^'NA2O"L=I;,HO9%?84PV&8%V_P"!'/.
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MC. <#GVQ751RO,:,/KBIR4>_^:O>WJK'F8B4*T.2K35OR\UV.\M/#%SX8O\
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M#X3FT&37+BXM4O)9Y9GMX(YQ%(Q:.U5855?+A7*H6R2#DXR /A_5O#NDZO\
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MU;F18T^=O[V<_P"<U6-]A.TJ4>5]>QQ2Q5]$=]=3KXO\+2*H_P!,M%+PL.I
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MG QJ5YJ%2F[OFT=_+I)6T_%I,\V^ GPFL_BQX_T[1[K;I-O*QDDNKV%V@>
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M?H[GH?CNYD^'"K-$[RZ7<G$4H/*9Z(Q]>P/?ZUS.F>*]/U==[S2-=*,D,^<
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MW_71GU+S/ZS5EB'&*=EI!**TBDK)62O:_F[MN]S5N?&^K2:=%;QR_9X5)9Y
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M6/$7CV"\O+_4+1+BVB%I.D$8B,WF2-.AB3Y8Q*-KEP5)/!&:](_:5_X)X/\
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MQ)9FTCDC.PJ<Y5NX8,IR<Y!(&#QT7A+XSMX3^'5H+6WCNF2=7E+,2X0%64J
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M23(&YL'/%:WPR^&5EJ_AG6]:\5);Q>$M-MA/JLLF2MP.%6)!U,SL0%P1@G/
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MKK/BBPLI 64SKN&>P.<@^V*^2?VSO'<OB7]L7Q8H?SK;3Y8M.7'(Q%& 0/\
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M&K76E_&2;7TM6M$NI(TN?XHI;H1 NP'/$BD.![D=J^2J8-XCE=[2CI>U]/\
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MUY3A9"^ N"PR, $$9!\C\<?#;X?V5[YVG0MJ2Z;;0:?ID=XI^R1+&@1,Y"C
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M@#D#!/4 _'WP]_8"^*7CKPQ'K']E6UG;WJF>4W,QBD2$_<+A5+#(Q@$@XZ@
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M3[_6O=E3A&-FU?\ KL?*RITX1LWK_78@M/VE8==O(H;VPMA82Y^X"< <$$$
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MVR,'$L(C=0VW!P0ZY!< XX/@G[3,%_9?%"]O=?D;4-2U>7[3,ZVS6N<\ A6
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MU4$R*6?YMI&-I(SSGZV_9G^"EOX<@6]CO6UBXA9HVO5^2%&4D.$!^9B#D$G
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MP)2($J22KR%!QDG.!SQ7BP4^3VC6G?IW_(^C]FI5O8P?O/TOV_,^)?\ @O\
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M3WL[O5K3?6I6PTL<\,W&$M9:_9BE>4VNLFEU^%67Q;<O^U?^T]X6_9S\'?\
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M \$@>^>?I^/2O+5UY8KL*S(I<Y;)_+COQ70^$_$46KWLD4D4<LB$($+''?D
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MI)&X)Y+;"R[B1G)P>V,5K>%OVS;?X??$9=4T^+4+J.YD6YN$D=(8)I@"IDV
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M"BG['5A^P5^U+J7@C2?$5]XDT-K&WU6PN+RW$5S'#,6 BD( 5W0HP+* "-O
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MI5_J"A+NYU)A CP)<AC*ETH#;UC4@QC'W2#U)#O!/QSTJZ\1EKJ^U;3+*>W
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M^Z_AO^SY\-/V>K"QUZX$>D-:JSA+VZDGN+"<K@J48 LQP "JC)  '0U]0_\
M!,G]C";P3H(^-'Q&MVDO-;U'[;HVE706.XFB+@17#J_<!C(D8Y)*DD' KVLR
MS:MG>9^WH149223MI964=7U[*[VT/-X=RG+.".'%A\7*=2-%OEYKMRDY2FE%
M6LN[LK+?6R9=_9#_ ."??AG_ ()X?LJKXH^(EQ:P^,M2MA=:C)(P L69/EMH
MB>K@8#-SDY X'/YQ_MD?&W3_ (K>.;JWL[G[+92%C&74D'!/);'/L#UKZG_X
M*T_M;>//%?BB&'3K*]&@ZDSBRELY$E^R0J2K2RCDQNK Y# #@@$D&OD#XF?L
MK6^E^"Y-07Q3;:GK8TV*YU25K==J2,X954<D22@X!) ) !&#FO1ED><592HT
M*3C"GO?1MM7N[]_ST?0^6P?%O#^ 5/-LPQ,*^)Q6JY7S0IP3Y>5<M[./Y:KJ
MSYE\'>'(M.^*EI'=6#:]9W5R4:WB<K-=ALC",N2&).1P>0,@CBOTAU2+X7^*
MO@580:5H?A?0-*\/:3!':W37"QZF^HHS"2Y@B"%C<H7"RDL3(.1@#)_/#2Y/
M[*UJ1;BT>-DD(W3+MGB(^Z3M. P&,X/TKTCX7>([;2KME01^5-\K X)4YSD
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MI2HQI+EBFH7LW%6<K-NSEN[65^AP7_"8<>OU-%<;JVM>7?R(K+ 8V*,D@Y#
MD'MTHKV?JYX#Q6I^D.D>#],\,V ;3[.."V,;*9E^Z,C'7L:\(^+%Z]QK$EM\
MT<</&/4^M?0'P^UB/6-.N-)U2)'@NEV-@?*3V..W->/_ !RT".T\0S:>HV7D
M2%H2W_+PHZX/<KW'I@UY-.E[:/M.J>Q[];$<D_9OX6E9^?F>>W>D27FF1_NU
M= 00W.X'U![4[3-5U![673YI%E21AABN)$4<8ST(_"H9/$&H^'+9+>XLVA@<
M;E=T)!!]#@C-;?PZ\%77CK5HI+/SE6-\R7!0B)%'7J!FNNCBL31@Z=.32?\
M7]6.;VS3['>?"#PN2'EU!)/LXPH4=93UQ[?6O6=.TO3M4TR2W:VMX8%4@(JC
MH>",]37,7:1>&[&&"$YD1 BY/KR6/N>3[5G#Q*L\Z1;G2./C>I($GN*^=JJ4
MI>ZSW8\E&C9;_P!;'&^./V/M-229M&EFLP69U2-R$0L03A,[020,X'/>OF'X
MC?LR0?#C4)AK&GS?9YG+Q:M91C[99.23O'(#C."5)&1T(.*^[;CQ]#>CRTCC
M$T0 WD_,1CC(SCZ\<BN,UO4[/Q1/=6M_&DL1X(8 J"?3US3C3E!_U<\^6,;C
MRUHW78^?=$TSXF>-?#9L8+Y/&6D_V:K6M]86HVSQ18#)(NT,)$( 8.-PRI/!
MS6U\*O&&EOX7*ZUOM)D.R1=X1T8#C(ZY]1TQS6Q?^ M6^"FHS:QX2DN3I]PZ
MRW=C!<-;L[*<K)$Z\QRK_"P!'8@J2#U4_P )M,_;-TI->L=0L])\1R$Q3W[0
M)!:WL@P/)O(U(%M=#NX!BDR&&TG%=&$QSPDVJK]R3_'_ #=OG;[L(T'3E[?#
M:KKW7_ 5WZ?B</XO^%LWCWPT=0TVRO+F*(2,[K&&\Q$(5B@R"P4NH8KG&03C
M-6?V)/C#XT^ 6MC4=/L]8NO##2M'=S06[O$B YRW! 93SG.!T)P35&*VU3P0
M\G@S5VM[V#1;F:Y@TUS+"'F8!'@E"DEHV(!*J5R0#DU] ?!;]B_7_B'=_#3Q
M;?ZUXB\"Z7X/\V2YT028AU=G=W+Y)7"N'"MY@.50 #'7WN+LRP+P6'CETW4G
M?FE?3D[:NWX)^O0X.%,3C,;C\3'/%'#T(J7LY-.?.TFU%QBGK)VC=V2O>UDV
M?7NH_'"'6/A_;Z]'!'/&Z@R1K\RAB 0X[A7!!!]R#R#7FVO_ +4,.N>$?M'A
MVTDU"\+BW,+ [+>3.#N(.2!U!.!CN*MZ#H&A^%M&U&S\/:A-+8V,;W#V\K>=
M$ZY+/$N[!*%OND'Y-S%3CBO%_P!H+6+71O&=W8Z*T.EPVVU9(H8PH64(/,8L
M.6;<2"3SQQ@<5^?5\=5JS=>4KIZ6\UNUY/?R;MYGOX'+<)'W.1IWOK?;32SZ
MZZ>6_GB_%6=[MI9/$/B>YDFN3F;2K4E8?49.<CGM\N,#!->?:O\ %.WT.-;B
MWU"VCQ&MM9V-C$!=B=W"1!SMW>6^'W/N)!3 '.:YSQYXHL[ JDTS3R3G!;OD
M]"33M$L],N8+>V>]N%FD>.[MUCE= DL+AUDRI!W!F&,$9!(.037T/"-;*:6,
M=3.X2G2<6K1^6K2UT5W=235NNQY7&T<ZGET5P_4C3K*2UEV[)[*[LK.,D[K;
M<]$\&:UJ'B'2(Y;&Y;5A(H\RZ+!3*>A8C.1D@X!'2KFHZ8KLOVZ>&W?!R5(;
M\.M<WK'C'4/ ?AJ6XF#/>7;$*\R&))7QDL>.!W 'L :XGP_J"_$"0W6L7MY<
M#)S!'E8\$] H(S@="<]SGT\O#Y+/,:]6MA/=I)NU]7;Y)?DO0]##XRNX0I5Y
M<U2*2;5TKVUW;_-^IV&]-2UHV=AJL=LJNJF:XF2"! 6 &2QR3D\ <GH.:\A^
M/NN:QX/U)[6]OOM,%Q),D,IWQK+L;:=H/.#U!Z$'KG('>2^!5T^X\[P]YEO.
M65&CU "YLY$#ABK)P<DJ-K DJ0#R.*Y7XUZ/J/Q(TJ2-;6ZTZ+0Y)K>&TDE\
MURLQ5V ?J8R1\JD#;SU))/VU7AO*,+D;KSGS5VTMM4N9=+VZ6NW?5]+(^1EF
MW$4>(%1Y>7"VWOI*7*W:^^C?16NDKMW.!^&7[9'Q>^&<JV>@>.-2L=(A8XM+
MG9>0X)Z!)0P_+&.U?57[/O[8_P 1/CQXCTO2]4LM/U43R"%GAC:%GS@E_F+;
M0H!)*D*!N)!S7Q]X>\#/:[H;I/W[$;0@SWQ@5]U_L^_"63X'?"R2^DCC@US5
M(!'*I^5K.!@"8_:1^"W<#"GDD5\3BL4J5/D6W;I]VQ]YAL/S5/:O?H_U[_U;
M=F/\</V@_P"R]:&V\O\ 49-*C-H+(6Q1KFYD<1Q3CY=BH78Y7)?8L8 .2:B^
M'7CO^T-,43S7$UU;L8[B2Y0QS%PQ#97 P P8 8' 'U//>+]%A\=ZI=OJ 7[/
M-A/))(50KAU)&0"0RJ02#@C(ZFKEO$WV0-/>7%Q,/ORN1F0^IZ#)]J]C-,VR
M2>44,/@Z+CB(M<\KZ-6]-=6UJDUHDY)7/FLKRW/J&=XG$8W$*>%E_#@E9Q;:
MOI>T;V3TNI7;:@]"Q\4/B7XFL/$5B^DK<FQGBFL1/%"&DLYW 96"YRRN!Y>[
ML2<X&<ZGAS2_#OC_ ,.2Z;XC@AU'P]KEG#,VEZII:11H@V#RV?)8D3)Y@&01
MD' QFL"QUQ+S7X]-@$9DA*R27!^8P$@[2HP1G!Z]L\<FO1=.T/0](TH1I%')
M, 0\KG<7[\?CT Q7L8//*M3*H8"=-13ZI:M7\]-];K773N^2/"T5G;S6%23?
M:[LGMTL[6TL[J]M]E8T7P)8M_8O@GPII/PYLOA3>I=#Q7HKZ?NEU$,%V+$BD
M)\S#]X\@+8"XR>D7_!6Z;33_ ,$LOB;8K86[V>D:9:26%N(QLLGBN8%B>,=%
M*#@$=!Q7/:EJLGA;4(+ZW15^SN&RA Y]^YR*]2^(_@+3?VC?@CXG\"ZW)(FE
M>+]+ET^66/!> 2+\LBCH2C;6 /!*UP8C"RP\E9W3/H:R<JD93WBT_P ;W]3\
MP?\ @@K_ ,$^M-_;.^,'B;Q=XVT6PU3P)X5M9+.S6\DW0R:RQB>$/$K!F6.,
MLY#?(V0#GD#B_P#@H;_P2[\??\$O-,\,>+]<\:Z9XFC\4ZO<6SW&FVKVJ6,^
M#*GWC@AQOP   5(P1BOTU_X)A_!WPG_P3M_93@T6\U[1[?7-6U&XO-<O[F1+
M5[NX#M&B%2YR(XT55QU!SCFN"_X.%?VV;[X&?L@:%X9M;&RN=5\=ZN8;;4+Z
MPBNH]'CMT#R2(9595G8.JHP 8 N001754PTJ2]G6@UOKWM^#]4<V#SRO6S!5
M\'44H.VE^CZ]UU=FDW:SV/S&\/\ Q7TS4F:\UBU2VU:# F;81YI'7CLWJ#6O
M=_M3S7BR6]C9,D+1LBS,P#(2" P]Q7D/[.G[/?Q2_:HUY=.\!>#O$7B:=\O+
M/#;N+6,=2\L[#RU'<DMR:^@_C/\ \$EOBA^S[X!T_6O'.K^%]#CU.X6SMX#K
M$.YY2I8H!G!PJEF.<  DD"O*EA5?1'Z33SK"1:A4E[W9:_@KE?\ :*\5:UX*
MC\+^(M%OK@>&OB!H\>JV83&;:5/W%S; XS^ZEC('?8T9/6O*[;QA>7MV9I+V
M0R.IW.[%G)/J37ZG?$S_ ((_+\</V!?A5X'L_$6FZ'XF\&(^HQ:@,W=G<-=@
M//&'0Y9,B/:XR#MR 0<U\<?$O_@A#^T/X/UOR=!3POXNLF&5N;;5TM2,#.&6
M;:0>PZCWK.OAW)MP.3!\28:=/EG+EDFTNFB>FO>UKZ[W-#]C;]@VY_::_9K^
M,7C%M6M8M8TG1Y8/#EG(X\S4;J,"YG"KD%B($*+@'!E!QP*]>_X)!^'-8\%_
MLUW7Q1^'L?@N[\>6_BZVT?7KKQ+,L$/A7PXJ"2]GC9F4++(&W%R<[$P <$5]
M-?\ !/K]B2U_9+^ 7@_4/&FEV-]\3O#OVZX,UM>%UTP7?EI+$I!V.1#$F6P3
MPX4X))\M_;=_:7T#]BSQUJ7B#X?:#X)CM_B-X=6X\01:EI4D]CK"I+)Y<26\
M92-I)5DE,SODA!&<<G/91PE2G3CB$M%HWY[_ "?3\MCY>OFLL=B9X!SYG)W2
M=K66C7=II7]=&K/7[R^)5K<^)M-^U6M\VIVMT@D@F24,LJ'E6&#@@@@Y'!!S
M7R;\9=)D@GFDRK2PDY0C#<=L>M>D?#?]HJ?Q]^S_ .#O%2Z>WA%O$6CVM\--
M0[X; /&"(@I ^4#&, <8XKDO'/C&Q\63%?$ME'!9E08]5LF9DW=]Q4$Q^OSC
M%>?BI4YU//SZ_,G+XUL-!TVM%II:Z^6S^1X)<S6M[J=YIJV&JZSJ=[IBO;16
M>1)%<O=B(;2Q5&41Y8@DG(.0!C/'>-?AO-I=M=0275\=0L[AX9(IHO),>TD$
M8(P2",'WSZBNU_:+^ 'B;PAYNL>%;M-8T>^M0+I5C4R! X92.""PQD.,'G K
MDM:\;V&L>&+6W:[DFNO++RF7(D#YRS9QR3[YSU)[U^D2_L?%X&A3P])*HE%2
M;ZM12U?5:/=)KHVGK\?PS@,YHYMBL1CL1ST9.3@NR<I/;[/39M/JDT<%X=NK
M=]2_LS7+>.YC<GRY<8.?3V/TXKT&V6^L]*,6@ZPJPLI(LKP">UNUQ@QNC95@
M1ZC/O7FWBSQ#9SQ0SV\JF[D< LT7&#DG!YP1CISGUY%.^'M]>:OK-G8NR?Z<
MQ$):=(@"!D@%B%W$#(!//:O@<RR-O'1P^&WELNE]DOF_1>:6WUF/Q2PU*>*E
M)J,%=OR6[\[+5[M]$W9'H7PHUC3_  ]XF^U0FX\)7B2!9[&+,]A<8YV@'YT4
MGD [P.Q P*^Z/@5X8D^*%CI^HZC,UG$ZI?ZBTDV8[.%2?LZ(XP"S$-*W/!\L
M'E1CX .L>'/'(MI- FU2[NKN,W&SRQ*;9$49\YAC9ZC([\XQ7IOA3XX^+K'X
M0WVAZ;?W"6UO$TSP!@6$1QYN.OW.'&.V^N',\DQ&7U8U*L4W;J_D[=='=7^:
M.')>)(9A3=.C.R3WL].S[7:LTM+.U]CZ-_;M_:\T7P9X+L]%\+3W5O-IDR&V
M2*8I:R%75@\RKRZY7@9Y!;.<U^:GQJ^)J^/%T[3+:PDMX97,4\\EW(;BX=B&
M!9E*KLBP0B   '!SBO=/']I<?$_PG#)*VZ[L\>8HXWXZX]<GFN'\/?L]:MKO
MB71Y]/T]=0G6Y5I+17"RO$<AG )&2!T SSV/-?5\+9UFBIQRY5/=E)-I)65K
M62LKJ*M>VW5GS?$/#.1QQ7]J5:>L(M<TF[N][MW=KN]KZ/HF5X;.^E\$2Z1,
M-/N!?Q1+<SO:#S_.3*^>K9RLA10">N2QZ'%>5^-OA[+X1NWF*,]N225.27R3
MR/0D#-?9&HZ%X;GU:6PLY4NKJU=D<Q(SQV[J"&1G VA@>-I.<\=0:X/XA_#*
M'45E1"MQ"X.<8#')Z<XX'^1VKZ_,JE;'3]GF$+2[-6:[:;E\+Y?E>'P?+E,D
MXWW4N:[6^MVOZML>&?"4VMP(+A5?8[@^6Y.-RGHP )QG@XYQTSTKUN[GD\2-
M-#;O;SO:K&L BW<P[ Q*L0"V&)#9YR,'D8KQV]T:Z\(^.ETFW6X5;ECL$"EW
M# %B0%YX Y(Z#GM730Z+J/P[\0(TBR1S0NJLRN&0Y&X*2#UP>0>1WYKXO%TY
MX/#U<.J2DGM/LM-'WO=VV>NE]BZM'VN94INLXM+X._FNVVNZ[VW??>$O$#6L
MAT^XWH\A"%1_&I/'Y5V7P1MK/P]\4/%'R+(T%_)$F[&$*A0>.YS6+;Z2_BO3
M;?7$MV6:VQ)* /X00#D]\'!K@= ^,DG@WXW>*].NE9+J;4Y+G8<[@)0K#-?+
M8&+J5K+MM]Q]M6C['"SK-ZNR/N?3/BG>#1D@:"&1(P1@C#;>HP>E<9XT\?J8
M9),[,9^7/(^M>?\ A7QWJ?B6XBMK.&:>:? 1(U+NY(Z #DFKNH:)+_;KQ:K#
M-9S6R"66"YC*LX/ )# 9 )!/&,"O9P.7RQ>*CAHV3?Z:O\#P:56">BW./\4:
MW>ZI.)A'(J2'F3:<#MG\._7BI/"7Q0F\-7WE7&U@A R#P<]"/4$=#6QXF>)+
M5VW)YH4 !B&,H P"0.N"3@]@<=J\\32;W7;S[3,J(L+$(%Z;0>A/4^N?P]*^
MHSSA^A@:<)QDW=VUM]_]7)Q$XWMU/5M9T#P_XU\1Z1JFI^7!:03*U^SDI')"
M 3\Y7D '&2.V17D_C3QRP\#Z5%XDN/ \WB;^U+EF_P"$2 $$=@0!$'8?*6!Y
M&><#FO2O#4$FM^$=;M5D2"=M.FC5IA\@)7;GW//%> M^ROK]K.K1O'.@.=R-
MC./:O%R_VE.O'$TYM<MU;H[]UU*J8NI1PL\/"E&7M'%\S5Y1Y>D7TO?WN]D=
M9K.K+KN@1QI&T:,=Q;<&+,0 3Z9/?M3_ (;^$IU?;Y;2(2,9&2<UVOP/_9WN
M[R"237)7M;. @HB ,TI[X[ #UKV#PI\,K07:_9XOL=M"0SR.<R8[?3-=F88V
MKB:O/4WL>13IU)^_/8S_ (8?#.\'AO4[Y;?<T=LZ+&QQO8C&/PJY\,_V:M)C
MTQ=4UJ/9,[$"VC/&0>23_A74>)/B1;^%?#=T\3)%90 I"G&9'[N3WJ]X)\8V
M][H\'VF58_W*E=Q&,D9/XDUA4O"'+%ZLWBT[U''1:+NW_P  O:=X4TO2T7['
M8PP[1P<\_G5V:!9HRL8V[A@;":K1:G$\OF>8I0'@#'SCID>^:EU#5E:(+"RC
M=W-<UZBZB<DM3AOVVKFS\)_L1:S:3;FD\2ZC;V8#G@KY@9A[\1FO@M["/3=&
M=%A6)0=R(,?. .WJ*^L/^"J_B>;2?AM\.O#\<B^9---J,J^H5 HS^+M7S3HE
MO%XH\/KYB;;FT!>-O08Y_ ]ZZOB:IR['9@IVH.K'=N_RO_P#S>W+7NI[V9LE
MNF>/I740Z5<13K-'^YF51M=>OXCH:R[K3&OKTM9QYECD*2P]XV_P/8]Q6SI^
MN73M]GO(7A*\8\LELC\,'-)>THRO'1HJ52^L=;G9^&OMFO\ V97*N\ " JN,
M^Y'/-?1'PK\/P:=I,+WMOYUP<,$D'RQYZ$^I/I7E_P #?AK-+=+J-PDT-GP5
M24$&=O7U ]:]:?55LYMJGY4.]C_?;L!7FYC6J59\TY-MGIX",7>K/4[3Q3\.
M=%^)OA&2QU.WMYX;E2&1HPR],<C&,=J\-^*/[$UOJOA:[TW3;BX@LIP"UNDI
M\M\8QE<]L  8Z#'2O5O#'BI8+_[4VY67)$9/RC@X!'<5L:AXWCO+-YK=(8D*
MYVJ<]OQ_ ^E>9&C.W,5+,*M.;=/1>6GR]#\]OB+X,UCX)M:P0W6H>%]0M;A"
M=8L+?Y"BG(%RBC=@#I)&"4(Y4@DCTWQ#XJ^+U]X8TWQ1K>H:IK%I%=M)'?6L
M:M!DD8EB,?RJ"%4Y&,C!YKZ&\2^'M'^)>C^1?PI))(/E9A\W7@CN*\<U+3?$
M_P"RUJT%UH=S-'HL>^,^6OF)%%(?G26$G9-"<DM&0",DJ01S.(I5).-2F[2B
M_O75?=<Z(8R&,:A4LI:6OLVK;]N][;[^5W5OC8GCK3K-=7UJZO[B),P*\@8!
MB,ME!@9..O)([]*\M_:F^"NI>"M,&N7>BZK;Z>\HB5E59?L\N =L@SO0G<IP
M0"0017K1_9EL_BQ:7_B;0[O3]*F@A-[/I!Q/%.  6GLWX\R,8),; .G^T #6
M!K/B77OC#?VD,.D3>*M8GO+6VEN8&E!\N#RP/*!RJ%U4+([$Y P<"OL,ESS*
ME@ZSQ,W&I%/EC;23=[+MNNZMW=SCS?$<0TLPPV$P.&4J;E^];=N6.FJ]4^BE
M?HEN>E_\$P_VG_'WP \31:)XETC7E\+ZVA^S1WT+K;.Q&0$+#@E><<?0C-?7
M/[47BZ+P1JUGJD,#+INIQQRPWT,0D/EL/NLW]Y>0,DC(]>*\.\ _LTVOPLUO
MQYKOB+7M6U63Q:\,\.F7THDBTHAC*FP*^6=2 JD;0%7KCFO;-%\:V>E_"^R^
MV1V>M:9.P:2"ZA$PL$V2/+*IR"0K1'*=&#8Z\G\]P>85)T7AZWNK5K^[KL_)
M_@S[_-<'@Z680Q^%7M5I&347%3O%/2]_>@[QN]))7VL?.O[17[0&O0>(!HFB
MW+:=I;P+)/>VL9FGD!) PW"J& X4'=CDD XKR'Q#\01_;</V>ZDU01JOV:YN
MY=DQ?')"1N$7DX!9W/H 367XY\4P^*/%5X;J6Z:S><RM&?W3."<[3C   XP.
M .E>:ZUXDTZZUP0"1556PH4G;$H/ !ZX'3]:XXXA5I)M/EW=M[>MG8^W^KTL
M+3]A0MS6WMI=]TFG+SU5]M#UKQQ:*ELR6/B!)]0E+7]ZUK"4LI$+"*-=X57$
MS290@C QP3G-0:!I^M6D8GO87:UC[R2CR\^PSS]:J>'/$\_B")K>PU&ZN)A;
M&QE(F=Y#;EQ*8FYP4#8()!(SP0#BCXV:K-;:?I^DQO\ 9GB5%N6#$OAN<J.0
M,#]3P,U[G&F,RO,L=0PG#])PNO>YM->]K+I9W3UO\*=[_D?!-;B;+L'5H<48
MJ-1RF^3DZ1M\-[]'=6:NFOCDK6U)KGPG:I+/+=/:W##_ %" 2;V]CG R>PJ?
M2?!DGQ+\"7=U9:O:V/V>&2:VAN"'NKDJRJ0D2X;&6QD]^ #D5PFB_#'09+5K
MAX-2OVD)>-FD(DBP000V3CV.!R,^P]"\":/J'@_1Y8K.RFU/35AF<V4TQ6\2
M5B")(;D ,@RH)7&"54@C%>UPKP3@HXE_VS7?(EMLKW6EUKW[/N[7)X^SWB##
M9="7#<7*IS+5N[2LVW9^[;1;WWT3DT?,'QDN]2\*>+M1L3=;=0TZY:-""RS1
M.""'#*1@]"/8\C-=7\.OV[OC!X.U&WN+KQI<ZM-;Q[$2<9<1D8V--&5E..PW
MD"H_VH/ ?B3Q/XMEUJ67+ZY(=0DR?+BBD=0& 7HIP "1U(SDDYKG_AO\*IO%
M^M6%G8I)/>.R[HPN <<DD]L8SUP!R:\BM*A"I.6&?N\SMTMKMO\ <?59+/%Y
MCA:*QLN:3BKZWN[:MW2WZGVA^S]^TAXP^*W@O7M3\3Z38"SL0LK:A JQRP*Q
MPT9X =F7 #-E@23N)K"\8^)H;N_=K"35)IW5]0EN([1Q':6<15!!M92QQ,Q'
MF*-FSD$G)I?BA&WP[^%ECX9TU]UC;PEY,##7ER_65A_=4<*#T'/4UPWAXS,8
MV-Y)'Y:E(_F^>-'"F5 <G".5&5!P<#OFNWAOB+)\/#$/-:7M')6@ULI:N^UU
MK;WD[J_PR6WC\><-Y_B7A9\.8I8>$)7J*UW*'NII7;NVKOD:47;649*[]-T;
MXA2:7 9%"+)(N<QCV_(_UJGX;^+6K77BF6QU@WW]FG41-NM(!*+A)@%BD(9A
MAH2,$$CH".,DX%U%"S K)E0,Y=N" .?>M_X1Z1:^+[GS[E6M[$8*!209U!XR
M<9Z]!GCZUQ<(\1U,%7J5*5-2BUKS7]W7356U^6K['!QYP[2SO#TZ%2I*,HN_
MNZ7TUNG?\[I=6=[8Z3X1\=+HLGB<>'=<L=#L+BTDL-4\/V[SW=Z9/EO!(5;8
MA(#;0P' &""37HOPGTN\\3^/[W6O$[^$M7L-$O0?!HL[#_2M$A:()*7E8G$C
M'C$8 "@?AP^M3Z'80K%8V]K%C[JA>W<$^A]ZO?#"?4-)\1[E^QQP7EL]V(1=
MQ"XDA1]GGK#NWF,,-I<# )QFO0J4HU(3Q3E9R=[.RU?1?HD=?U:M##TZ'+I&
M*BM-;+JWU?>3NVMWH?*7_!R;JD,.H_"&^^SH;N2QU2"2[V#S'B1[9EC+8R0K
M,Q /0L<=379_LA?\$-+CXU?\$N]M\VB^#?BU\0;V+58=<OK<WCP:&S1216J8
M8",R!%D8CYAO*M@$@>N_\%!OV+-/_;W^&/@^QN-3;1]7T'78VL95>+S;R*78
M+J"-)&4R,(E$H"Y(\KI@U] _#?Q7:^!_CG<:3X7U7PO#X?UNTEU34=/^WR7.
MJMJ21Q1*\:,Y6* 1K'E44( 3D;B*O#PK<JJ1AS+52MK;9W=MEKN[+UU/G<75
MC&E]5594IQ]Z-]%-W?NIMZMZV24FVDG:]S\/?VBO@IXH_P""=G[6OB'X9WVI
MKK<FEV\-R+@0F*+4[22(2!RA)V@98'DX*G!KZ _9]^%7A&\^$UGXX\0:W=^'
MX-:$K:=86-F+JZD6.40R3$,RC:)&P%7+L 2!Q6%_P<#?MG:U\4_VSI/AW:V7
MV#3?!=C;6L["Q1;K6[B11/N\T)YCPH'540,5R&.,UTW_  3B^'/[0/Q"^#EO
MH,WPCN-2\$65QYFGZMK6I3^'3'F5;CR <;[B'S560*%X/(;%>?G&'JRIWPJU
M^6UO/3>V_0^TX;SC"QC2EG;:A]KE:YFO*Z^=K>29S'B'Q#<?#S]IZT\!^*[B
MWM]+N+N.U_M6S8@?9KV I!=J",@H)ED(/((8>]>-_%;Q-XP^'OCW6O!_B"[N
MH;WP]>RZ==1HQ50T;%3TP2"!D9Z@@]Z^DM9_8<\6_$S_ (*5Z/9_$;Q3X/;7
M-1O;6^U"PL]0 CMK94WQ6\0*C,GDQ_)'DN1\QXR:]]_X*"_\$;KK]J?]H'6/
MB#X3\8:?X=O==CC>]L+VW=HWG1 F]73) 8(N01P<G)S13P[]C&-2W-U[;*XW
MG]"-=)7Y''>SWOI;39J]VEV/S.BUJXNK-HENF!D; 53P<\8^IKZ._; _88_X
M4!^PI\*?B!8ZC#JFHW5Y(?%%O$5=M/ENXHY[16VDLJB%%&U@,EP1G<*J^&O^
M"'_[0%M\0M/M[V/PI'H@O(UN=2CUE6$<.X%I%CQO/&<# ).![U^I&I^%_ W[
M.GA;Q=J4FCZ5<>!=;@M#J^FVVBM?WVHZD2(3/.S.8VA:&.-1'M4*R$]3R4\/
MRQDZFWX+JW^AR8K,JU?$4J6#GS-O2*NW)OW5'O=W;6FZU,/]B[2+CX#W'@GP
MCI%[\/8O@KXD\'VEYIE[*\1UKQ3XG?$]Q-M<Y<"$%@ "45$ (VD#TSXW^&=2
MO([FX9EN@ 2S%LD@]2!U^M?#NC_MJZG^SE^U)X6^"NE^&_#.H>%M-\47&BZ5
MILFF2MJFC032,?MAN'8A'(>1O+2, 194L-M?3_CSXY7&B7\ENERD#I_RSE.8
MR/?/(^H-=&)JQ=-1G_PQX.'RVO3K*M"WO*_KKN_-]>E_(^>OB[H.[4@)"BP3
M.%9UQP"0#QZXZ9KA=;^&UC\0/"UVVBZ3K%O)I+:C->ZK O[OR(K@QPJ\;'=N
M91R0 ,@G.,5Z]XLU"U^(LKG5+)+>[G)"-IQ(>? )!56S&YP,X+*3T!->5Z;^
MSSX^U;Q'!)I<=YJ_A2UFDVR(8K:2R#N"892Q&"Q0#RRQP>B\\_2<(XS*:.'K
MTL?34G*SC)[:*6]]MUJGZIV/$XPR_B#$YA@ZN7XATJ<'[\=KIR@].DE:+?+*
MR>R:=CQ7XD?#-M"N5FT^>0A K;V^_NQDY'4>G'YU-X(72_$EZMU>;].UB(F-
MI(VPC$]"1WSCFNZ^(VB75GKURTEGJ%L;&Y-G>"6$F2$D E''; Z$XSG(R,5X
MQXZO9H=:FAM4:.*-?-V%-AY)&2<<GC.1UY[5Y/$.2T9815J/NO2UOU[GZ+&3
MJ."<G?NM->_6QZ;JMCJGAZWD-X]MXO\ #]P'6YLKI]\MDYX+H^"RY'<9!Z$8
MKTOX&:Y-HEX;?298=3M?+CDBCO9]UW9<@-$&S\T(&3R6P-PP.M>(_#+7+--(
MFU/6KEEM;%X;6=DNT64R3'".5)W&(8;) Q\I!(/73.HGPKJJ:]X9FU0:=%,+
M9;EXPL<DBH&)A?.&3'? //3%>3'A_-88#ZQ-IP:NNS5[-ZVLT[*W7=76K^=I
M\:86GF_U.<N:I%N+TUO:Z6ET[QN[N]EH[.Z/T4L-#\-Z-%#KVK7/D^'[4Q?8
M[)1LFU41 B- O181(TDF,8RQ.#7R_P#MI?MDG4/&MZMNM]<:1<+&MS;17KQA
M1'('2.W/.P*0=S8!(=@,=:R==\<^(O'":)KD\DDMG$QE?RR=FX !EQG@$ ,,
M<?> Z5ROQ1^&2^(M2CN[6/S8;T!-AR "3DY]L]ZZ,GSG&8+%1Q&#?(TO77;K
M?;=+H]3NXJX;RG-,M=#'KVR=M'>*BM'I9IW=K2E>[3:VL?//ASQC=?$GX\76
MK?9+738X7,J6T(E-M'"P"FU$18J(]H()'))R3C@]G\5=/N/B196=C<16OEZ7
M;M%;O#;B)W0N2J2D %M@X!Z EB.N*]%^ 7[/5SX1\3ZUK&K6-J/#=O"&N=1>
MY58[-Q\N'&<@$Y )'48SGBN[U[PGX?UC1YVL=\$<B@>?);O&93M!#@,!N4YZ
MC@G(!R#7Z8LRQ_U*,<0G[.6KDU]IO:[7SMOU/S7*<!PY#-^:@XJO37+936BC
M;7E3Z*T;OHN6UM#X*\2>&AX2O8XY%D??(HRO&Q2>I/IBO:O@/J%G;W#O)L@N
MD@*I+<LWEY&2F,#:K%MH ;((SG'2NB^(?P4BO#+'((7= 9(B9% P,^^2?H*\
MW\$>"M4\7G4;6T$@.EX+L[%+? #. SGY00%. ?H.:^7Q6%5"O'%X>FIK6\?E
MNNWR_P" ?59Y+GPLL/.LZ<7;WETU6CZ-/;7\-UT/C?P]-;:C;W\(\ZW:-996
MC7&6ZNKKV8=#@5VVB^#=0^(O@Y)K7P[XDO%%E)<6MQ%;,T,D:@@D$ YP<CW/
M2O(-%\1W'@^_:QE6Y7[0J@Q2Y!16&00,D8YX]1@U[Q\4+[5OC;HW@;3;?X@G
MX<76@W >:QMXY88M6M@8UB964,?,0HPV$ '.> #7Y_G52M[24N76[T73RT^X
M_2.%<KIUJ6'A4KVA97FTW;31V6MF^G2_4]Z_9WU?_A%?"=FEO$JW<. Y<?-N
M'7(ZC![5ZM\2_P!H7PC\,O#&EWWC[Q';Z$_B%W32;6VM3<75RJ.B/($R"55G
M (&21N(!Q7S_ *#\??#_ ,5/'/Q'L]%MO%FGZYX'F4W\NI6:16FJ$,L#O"5.
MX889!;[_ "0,5WW@WQ"WQ+\-V]KJO@J7Q3#H;,UM<6\LT$]HKNDK1,\8R8VD
MB1RG!RN<UV3K.M0YZ%O/U/A7@Z."S2$,_IS4':34;*;BU>+CS)JST>O3S)/C
M9J\WA+6I;!9TNV=$EAEAR4N(70.CJ.N"K C/K7CVH7NH0WSOM>$Q_,H;^/'4
M?4=LCD>XKTWQ)XBD\8>(+O7KTPK>7D@18D4(MLL>4$*@YQ@!>"1D<$=:\_\
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M8'\ZW/"?A>U\+P'4+A8Q& /)MT/#GL2>_-.\4?%'RM>TNQDE66XF??(!@!%
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M%SI?PT7Q/K*QFTM9YWE.CW#LI+&56()>/Y0$8A3P02>3]AD,O90=)='IZ/\
MR9^-^(&%]I6CC%IS))[Z./R>ZV]&>(? OP;%XW6]T^X:VVV]N9)>2T\>X8&!
MT*XYR 2._'7T[P3J%UIGPZTQ8SJJ16JO;QNTQ5, G:<8QLSG&2>O  XKS/\
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M\PWL2!P!@\_J?[*7AOXE?&#4]#\,65]_9=I>%+AIOGMX%Y#[FR05C((WDY.
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MP1@$XR"#DUL_M%_!C0?VD["W\(F/5;>72+E;.TG60R&PO!"98I-V/F4 E6!
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MQAR078# !)XQ7*^+O'4WC_0(-WG+&$&0\A<Q\DDJS9(//(Z9Y&*V7TWPW8^
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MMW0G#  @$[F!(X' Q]>:L>!?A-=ZEK6I:]XHO?#-A\2M<\0QZGI5_!91:F-
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M_B;:=LWP7T*\LLB>N,X/4=0:Z#P9\,=0\:7,2Z=:75U*2"6C0_NQ[GH!]:]
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M;\PR.#'G##L2!5GQK\:]4\3:E?#^U4N[VXNHD18CNDC5PQ=G&,878<8R3GH
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MQ['#G"A0<DCVS@"JOPRGC,37$ENCQE@(PV2,=SCTKG?&'Q G^)^JP1L/*M
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M:YDDF.Q"-C1H1&> "%3DG-9WC_X\^'_A?'J6@^ UTNSGU*8W6K:K#&J&[NF
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M-K))!"5,C2R@D \#L" >W6OLG]E#]I#PYI,3>']2^&MKXBL2IGFE@GE>:V4
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MG:>AS7E_BKQIKGB.U;4M>6.*\OG)2$$DQA1R"['D#@#@9)QUXK*_:'\9ZOX
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MX<^ ^@V))OI-5O"Y!;=,=KG/<<"N@U;PMI]KHU_K&N:TN@Z5IJ*]W?7%W)%
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MLK,&*/6-0MC))<+D$F* D*B\<%\D]2!TKB_A/_P6Q^)'@6Y6/Q%H/A'Q59G
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M9!(R",$')W]5^ GAWXNZ#;GPYJEKK=YYKW-O9ZE"6M(V,3IEP&5@"'. #@G
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M^BMHD[:I:I^3_%:GAZP7W[0/QNT/PIYKZ?=:K?+:_:@04B4Y+E1P"0H) [G
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M8*&$6) >A)*'! ST_P"S;\</#?A#X=Z+#_PE,?AJYLM7EO/$%L^E&[?Q#:G
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MC!JFJ:[XS.K7L]Y<F9%C"RRM*+= #M1,\JBYX'0<]\U<\$:LUQ"_*@0J&.6
M)!. 0.IY]/?TKM-:BA\6^+M/L]/U"UTZ1 ;B_>:Z-NC6P(5D+;2 7#E2"" ,
MG!'7ZW^)W@CP;XS\%7FCZ%X<T32?#+^';?4H;R[5(K7PXT Q,D=P@#&1U).&
M#?.1W8@S_JO5SBO6Q\)*#2;=[).6KWZ=6W;I9:[>+Q)QUE_##PV30I.46XQB
MHMMQBK*R3W=K**YNMWMKP'_!/?\ X*$:Q^Q+\1%%P;C4_ FM2!=8TL$MY?\
MT\PC.!(HZC@..#S@C]AO#?BCPK\7O =CXJ\)W%KK6@ZM$)K>XMOFC<=P1U#
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M 2H',@(&TD$<X R":POBE\,19Z4FH_V7)HTFI*MQ)!)$QCGD()!A<LQV\,&
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M@# Y.!DU[0^H"QTJUN$5A:RA$CF?&!D<@OT!R.<D?3O7#^,=4TOQAKMAIO\
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M<9.,U][_ +&%]HVI?!_0-)\$PZ'!HBZW;7'B3[>PCU*./>48WLRA5DMP69B
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MYT]!<0O;S)("TB8VCD$D-@G)(P?4<5Y-8_#M?$LL^O>?#<6LLQ5 P#>4F2%
M'8#&3W)KZ>CF6'S+"TL)3I*G*G\4NLF[6TMUU=KZ._?7XC*\MQ6%S"O7KUG.
M$]HN]HJ_KOLKVU5CYFBTAO&DYT/P_'J32ZB(X&L+!)$:\(Z JN W3))]SZUQ
MNJ_!5([V2.-9+:9&.Y3"0(R&(*^^T@CC.,=>#7V%XV^&,R:1<2Z=*PFU"![<
M)&#$D^1E"74,R@,@)8<@%NY )K/@/3;=+>V26^N4M+>,;KCRV\LL@+1HRJI:
M,-NP7&[YCDXQC[9\/X.KE2Q/UF4JE_A>MK/7=>:\M':[/'HYCC5GTLOI811H
M6O[165W;3;KI+3XM4W9'/_L%_M;>,/V,]058[YM6\+S'-YIDCG;_ +RCJK>X
M'L<U^EWP3_;J^%/[5D/]F6.LV=KK$ZY;3;YEC:4^@S\K_0<U^6/Q+^&<EW:?
MZ 'BD+'8_"DXYP?8<\'C'6N>^'?A&SU5VA6%+>>V<B7;D$..I!Z@'J*^%QF#
MK8"+G?FI2WBU=7].E^ZZ[GUE7 T\3-1FK3Z23L_GT:7GKV:/T^_:"_93\-^(
M99UL[S3]/OH(_.:"6-)5"'C)'W@N>,@D \9KYA\<?!K1? MVTE_K.DPW(((@
MBP#*.Q&!DYKT+2OAM!\2/A?\%KS7+RZ2\LO%]KH9NTF=)[FSF;)MVD4ABK$
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M  !_9CT'X77/A?2-/UGP_P"#[OQQI\^NZMHE\HN/$&L&5%D)CED82+#!EQ@
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M R\Y^AKN_A3%9?"[2_)+Y3.21DLY]AS6]<SO\4-1A$VS3-)A):2:4@2.HY(
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M.=LJQN5=5/7!/5\ X.1DXQEV7Q[F^%.JZ!-I-C;_ /"1:Q=VL%C>W:B5[(J
MA.QE(8  ,"",'ICG/1^,O@]#IOA6XU6:"%IM166X=TCP&=R79CUY+$FOT7,,
M\RZC&$L-'FEKK]V]T[_YWW/RKAO*LZQ&*JK,Y>Y%1T_\"LE9JW?57M;OI]4_
ML_\ BW3/BK\%++2?#NF2?V/I\&_7-.M]'>YGN%6"1K5YUW9N TV\*8B"05R#
MC(^)_ '@/5/C=\<[[PYX?L6B>UT&;6]0_M*X2W33-KA0ID<@*JDXPQ).<'D$
MU]$?L,:/9+\"='A\1:C?:6VI^+C+X>^RW#I)J=Q%%&OE2%5;RXE8  GIEL
M<^&R?&77O"7QL\8>(H](T.?4M?>ZL=1T^\C::TGC:X,I@8JRL560<,"#^!Q7
MQ_$'&F(SE/!0HPC&BK*SW;TN[;6UT6A]?POX=T>'I?VHL35F\7-SFI)V48R=
MU3;=IMW=V[--<K>IT6M_#_Q)H>MR>#[YH]#F:SM;C[-;7AEM-415)CG#ABK;
MB6(P< \ # Q-X?\ #=S]HE^V)B=F)?( R3WP, ?A7*_%7XV:GX@\>R>(=4AM
MX+.VCBLVM-/@Q#IEJ@ 58E!SMB/)Y)(W9R37UO<?!V.]^%=O?3:IHK>)[/1[
M?6[[28"[3+83[1#<;\;"6#H2H.0&&>XKQ:6)JM1^MSU=EOI==$O+I;N?5UL+
M12G' 4_A3D_=][E;5Y2:N][*3;WM=[&]_P $L?AG<ZI\9/&&M00M(- \-RHG
MS;%,L\BHJ%L'&51^<' R<8KT_P 83^)]+DMM7U[3=/T#Q%;7 N8H+*\-[%&$
M?,3&0JN3A02,8KTS_@G5\-8_!/['-WX@-O<277B:_N]1D2UB,MS=0VJ&..*-
M>-S$I+M&0"7Z\UB?M$6*Z_/9SPQWEI]LT^"Y%I?1^1=VGF('\J9,D+(N[:PR
M<'BO/S:7).S['?PAB(U:LG4^%NWW:?YGA7B;XEZ5+8^);'PQX.L?#>I>,R1K
M-U;W!>.0,Y>4Q1;1M,C,2Q)8X.!P!AWA[X+^"X?#MQ;ZCX?L-4UC4HD2W-S!
MYYM]SJN]?,8(1C>6!(()4C@5E:=8?V5XBDEF^SQF%LA9&VYY['&*]K\'>--
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MO"9  0#SDYP>,GFOH'X:ZWI_AZ^T;18;G5-5N-0(1G>':\9V@CGJ03E5..N
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M!]C73P_6IX3&PJU/AU3^:W.NIB)0K:G9>(O#']HZ4[2?NY3.%0%B3Q@Y'3C
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MI)IL @LN % &/4GDG-=5\??VB;K0=372M.O([^.ZM8KFVN;7_CWE@E4-&Z#
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M& "2,8_/->::7XIU#P>PTG6TV/L*K*#NBN%/0@X_2KNHZX\%H_EW6^.50N6
M8HO8*?7W_.O:R>6'H-NNM>CM<\ZGC5)>\=5J\EC(Q^SK(L0!(#'' [@]>>O]
M:YO4/%RZ==-&HWQG'S$Y./Y5A0>)+ED:,*SQMP QX/;@5OZ+\,]6\1P"[:U=
M85&[<W''L.IK;,<71JJT(_/_ "_KY'+6Q"EHCT3X5>(?[+\/>(_$#(S)HNE2
MW"CN2$+  ^IV8_&OSK@^.?BP2230^'VMWN"9&>5M^&8DG..#R:^ZOCC$WPW_
M &$OB)<+</;7.J0KIT3J?F#2LL?RD]2 S<5^:.D+XFT34(@FHM<VVX9QD,%S
MSD<]O0UYL*JIKEL=> HRDI3\[?A_P3V;2O$]X^FI<7AS=2C?(0, L3Z=JZ#1
M=3;44P#ENN?2N=U"U%UX:M[A&W2%<$C^,X'^-.LIVTFWCY;:ZC<,\@]Z\NM'
MFFY?,]ZM)TZ<4NGZ'J/P]L9HM,N%):20R,H4YYQR3G')_3'XUT\O@X2ZE 8]
MI<1 .,^I! )]0!G\1^/">#?%(L;A&MU60S$%_,/W3C&0/7I_DU[3\)]'/B*_
MBBC+R7%PXP$ ^9FZDCID]S7TV:9U1EEJHT]9M)-=K6O\VU]QG*MST[%+0?"]
MY>W7V=+7S6X"[0<YS_.O=/$_@+4O"'[.NN:A<2_9K^SM1+;[0'+R* 57'<DX
M''//%>E?#CX/6'@S38FFV37\^ 7QA8QWQ_4U:\3>([>[)2VV&TL\K#N (D<=
M9,>W0?G7Q]&K&+]K66D?Q?1&<<9*HEAJ.KEOZ+K_ %\CYH^&^K'XT>&([CQ9
MH":1J:@*RR2JKOD=0,G'N" 0:ZS2?V<O"CA9/ED<'(#3#\NM6OB-\*-%^(L;
M,QDL[[#/)<VC^6X/8L> ?Q!]Z^8/B;\)_&/@6ZE?2]7O-1MX2?XRLP /IT;\
M/RK>%>E57-R\M_/_ ( 2POLVXJ>W]W_[9?@?6?CKXPZ/^S3X-CN&LKHVHRN=
M-M#.1C'+-PJ^Q-</>?%B3XG_ ! T/4(1)#ITD23!)7R^,$@,>A.>3BOF7P!^
MTCXB\*ZDUGJEQ<7MC,=EQ;W!+*X/!!!'Z5[U9V]OK,VC:OHX1;!MH"Q#B+ P
M1[8J\13INERQ6OF[Z&V'O=SYE)=DK._GOY];'H'C+Q=-?$JLC..0%)QS7-QZ
MHVE1W^O7-U-I]CH-H;V]>*WEN7,2LJG;%&"[MEEQ@9'4D &K.N6C/.LG>/!8
M?U'K6SI-XMK8Q26-[(NI,=D26Y*RC.,DD=!VX-<6#J5<.N>B^62V?_ Z^A"Q
M485%*LG*-U=)V;5]4G9V;76SMV>QZ'8^*9EU.2WU2X:::)5"L[O]T@,,;AD9
MW<@@$'@C-='H6AV>[6-2!T2S%I$HU>^40_:8X88RZ)<LN9/DC)*K(<@'( S6
M#:#2O@;\(]5\>>,K?5+VSTB+[0UK96CW=W<,6"J%B4%F9F8 #ISDD#-:GBWX
M;^$_B?\ #[Q'H-UX:MM%OOBW9+<^*;*UD-O?W EB$8,[H=PD5#@D8 (;KSGV
M<9F53$TXPG%:.]_.UM.USDHU(U%*+YE?2ZM9V<6U+5:):Z)KFY4[;KX7_:7G
M^"_[5/[4^G:'K6I_%U-<U#3K,W\&E70>ST:PN8E:.6*,H48.C!I #O!9R VT
MU]Q^#?AWX+^$?PPL?!7@70]-TGPK:QB(K%$/]-4#EI6QNE+'EBY))Z^E?G3X
MW_:LNOB7\=M ^&7P.\&V:V?@F[A\(0:O>:.;C7K:")S'=W[7+9\F.-2RQF8D
MD[GP"0H_0_4-0L]/TJSLK,M##8Q+;PAV+,40!5+-U)(&23U/->!@Y8BE4G[5
MIWMK^?H?7\14<++#82GAH2@XQ?,G*Z;OI*W33ITVZ-OY!_;J_P""?6D_#CP_
MK/Q&\"^;;:5(1/XDT&"$-;)$?O7<"@Y0J2"Z#(V[F &"#^>WB+X0>+O&_C.]
ML?!UE;WJ08C>[E4K;6V?XY)%!(&.@'+'@=R/VU\2Z@GB[X9>)M!VK/)JVDW=
M@(R<;VD@= #]2PKP3_@DK\&-+T/]D3Q"GC#[+IDVO>+9H8Y+N46Z[PL4,,2-
M(5+,SAU52,E@P .,UVRLY*2T1Q87,ZD,'.G.\I)I1ZO7MZ=#\O/V1/@GJWP>
M^)?B73O$B*FN6UW%/.Z2;X[R)U8QRQ\ E<K(#QD'@@=*]@_:$^#'_"<S#4=-
ME\N^MPLT:J<988(93Z@BOIC_ (*'^#OAC^SQ\6_ NEZBGB;5?$GBV2XM;9-&
MMXBFGH7B4-*S G<23B,$$@YQR*\[\5?#'QU\/-6OEU3P'XNFTC096MVUA=)G
MCM'1>!)NVD!3D=> <\UQRQ2J8B4(_$K7/ILMP,Z.4T:]=<M.KS<C;2YK/7K>
MZ;5[VOHUHSY<^)GQ[\=?$O0Y] U^>S6WFFCEO6@T^*WEOY(QA&F=0"Y'49P,
M\XKBK7PV86^8ILXW'/Z8[U[I\3X/#]S"^J2*UL&;!9")02>GW2:\K\>6<F@V
MT=U:JEU8WI6""Y!RD<K$ AO0J.<&J]G"G'D@DO):&E/GJ2Y[\WG>^QE>$/$G
MBKP3^T1X4U#P7=6MEJ?ARVEU5O/ \MT?,+1N,$$2H67!&""2:^I_!/[3Z^+/
M%_POUJ[M[#18=)U:W2WMH+5+>WLC%=HTJ-&O"G<Q))ZYR#BOKCX>?"V?3[^T
M^#^D^';C1;:ST:*\7Q;#86]U=2+"(9FD(D0H(YR[Q#HP'() 85\2?MR_L_77
M@[XOZCI.GW,*ZSJDL$@T>TCVM;S7<S20Q*,C<1&4&< 98#Z8X7&*M[RIV<=$
MWUUU\_/\#EJ9;5HU_9UZJ<<0N?E3O:/*E"3M>.OO*U^96=U&ZO\ J3\??BEH
M?Q#^*<_AK0_$>GW6I682WU/3HK@FXLB?G!DA'S%6# J<$'H"2:^4_C0_V[0]
M.U319[O^S=6:Z2%Y[=K6:'[/($E+H2<(68 '/))! (($>E>+[?\ 9T\4Z'+\
M3/ >M^,_'^N:+#H5YXAT&WCGO]+;* M)M(:18PB@LN2"I(.!717_ ,%M>\:2
M^+EM[^^UGQ!'9V^GRWFH:G*I$(=G1U/*E6 (9<?>W9)')]3"9=@ZU:<\QJ<M
MHMJ*W<K::[>JZ[(^;Q&89C@:%&AE5'GO.$7-M<L8W]]N*5VW=6=URVU3NCY;
M\06\MC?-=:AJEP5C.[Y6../J:?K?QRL?B!HDFF6,MU;2PQ8C8YP[+@C SC.0
M#VK(^(>JW&E>*IO#UQ930:G YA>.1D + X(#,2#GUKD8/AE<'QC-<:UKEGX;
M2UNTMBSCSE@!0ME@,+MVALG/!& ,UY^ X=J9C7C3P\.:2>ENENNMOQ]-SZ[B
MCB7!99@I5\QDHQMU[[6T3UUZ7[[)GHFB_MCZK96EK!XB9_.@!R(\E)% V@C@
MCH.N"<UI3?MBVD=@K0HKP1J578YWQY)W#!'&0V,X)]\5Y-XTCF^'ETUK)"]U
MIER"]C<36Q1;N,#&\*PR 3P,$@]1Q@GE(/#\WB2XCD:W2S@?C=%&1D]<9R!F
MO8GBJF!K/#8^CRRCO9K]&_S^X^1RR<,PI1Q>#DI4Y_"];-7M?5(]HL/VPK19
MW6SMFDED(4;\DQ[B%!'&!DD=?85)XL^/9GD2Q\06=U',^2?M$6UXSDKSG&.1
M@#'(YZ$5U'[&G[(B:M:7?C19D:;290NGP22L6N9D*NX*@Y (&%P"0S X &:]
MX\6_L_Z;\6O#?]L>-)O[/73M0DEO)7DBD^9]KDDJNXR.KA2JGY2O()YKVJ>9
M9=/+JF)YDIQVCHGZ_/\ R[Z*>.S&AG-' >PO2DKN>KMY)?UOY:^4?L;>!(_B
MKXWALI6;[#8H;IUVY*H' "8[9) ]A7N/_!23QUJ'PQ_8QU;^QXTM[SQOK<6B
MWTXP)4TY(GD\H'&2'DR",XP#71_LR_"KPIX(\<:K=^#_ .TEM[JP1$2]1@VX
MRKN";L,1@ Y(R-V,UQO_  4WT36/%^I^%/"6GPS:AH^F1R:@D5K"))+F8LT?
MF.!C$>5E"GIUYZ9_/\MBZCE4I[R=M//]-S[O-,93=2G2F[0@N9WTM97;VW3Y
M;>A^?7PM^$>J>+/$UE:M;R+!=J96.Y5.P=QD\9/?'2OI;P/X 7X%ZV+[0YHT
MO'C6VN%ED62.;#@@ L"0P8*5< $$9Y&0<K1?#&K:1J,5];:8\=U:H4O(\@J$
M/) ;."!CH#7$?$#XU7VK7/VM-*O!<V[MY?F1-&+A < @L ",G&>?KS7TV1XV
M&%KQJIJ%2%[W6M^FCZ6/F<WIX;-<+5P==>TI5%9I/=>4D_Q3OV/8-3^S?%SP
M?+-?6]Y-<:!;&TMXY[CSS/('8O*&^526)!*J ,@<#DGQ.Q^$VF1:ZUQ?JUB&
MG$Z1D+*Z1@X("YVL0<_*3[5VGP5\:>)/'_A",6NGZA=6MC="+4?+MFDM+)6(
M+%VP2&')&W)'<8KVS6_!&B?M.V\6C^'WLX!8PI''<VEHD/EW3.2TC* 6+"-1
M&P:15/49))//@\'4S3'8K.<;67NRYK-\O,MTKV26B23O=:+31KX:M*?#=##Y
M+@:,DJJ<4XKF4-$G)IMMO5R:LT]7K9I^73>$=,\%P/KNEZ1JFD6_AYX[.6Z8
M-<0ZG,K#S':7@0LZ/$R0G!() R017TGXJ\,Z1XA^"5CXLT^_VRZM%C:D?W'
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MO$.LB>1?5(U9OKC<Z?C7Q)X6TV2Z*LQPV/Y>W6OI[_@K#\08?^$Q\$>&K/;
M=(TN60H<L=TCA<D^N(^I_"OGGP/H4M]*OS9R01USSUYZUOCJ=*%*G?XW>_IT
M/?R^FHT5;K=GH7PJ\-MJ$PMVVM@[X0P^7<!T(]"/\:[74?A/:ZO<&)@MK>@9
M\E\<GU!]/>NE^!7P_M]-LTU"[9=D9!W,>G;I[],5B_&#X7ZMXN\?W&L6UY(H
MMV"V\5I/L?: <@G&,G]*\ZG*+3531=#?$.56?)3W2U[$?AO]G+5KF\B6%/+&
M1R3E:^J/V:/@5_P@4Z:I=77FSQ*3C'RQDC&!ZU\OZ/\ M(ZM\/VCTN\T:X2:
MU 1C<3'>?0DXP<^HXKUSX>_M93>)M*DMXH5L[OCR_M),D1;/?;@@$<?6LZM.
M+7N2^^YY_P"]?N6];6O^+/=OB%\1)+;419V\K-<2H6D"_P#+*/OGT)Z5R">,
MQY3;I=JN-H'H/:O//"OB^\UF34+ZZ<>??S%3D\(HX 'MUK;M+B.^)3KM.%KP
MZRDERO\ KNSW:/L\/3_O/\NQI7?C&/0;:X^9Y-ZY!"EGZC(VC.1GOVK@=3^)
M%EJI<+(LC,#@,I4G'7CVK;U*1M/\50B:)]LT9";"5D('!V] <94D$\]@:P_&
M?PY7Q?,EUH\?E3*-SQ)'NRPQT';W[>_:OMLLX56*P,<0I^\[^B_KJ*RG'GCN
M><^+? EEX[MVD\D)=DDB:->>O0CC(JY\"O$&M?"/Q/'9W8D.F/(&P061&'&]
M?Y'VX-=3X:TFZL;;R]L<C G<5YY!(.#W&:[+1_#LFOH(F"<>J L/K]:^:J5/
M93=.>Z=O1H\NZY[Q_P" _4]1N-!T_P 2:=',##!-=(&C=3^YESU /8^H_G6)
MHVE/X*\;61$"$L^!D9/(QD>H]Z<FG77PP^%FN7E]"LMA9V,MW#'(V%#A25 /
M4 G KG/V:?VHH?B+I=O-?Z-J&FF*/B2:-7C=NX1S@D>F1^-=-+#.M'GBO)_T
MSDQ-J.C=UNO\K_U^A]3>'=:9M-2[NI&AAB^8@_*3CU^M?,>F>$M-_9)T'QE.
MOB?5O%'C+QOJ,NMWEUJ]P'OO*8E8H@H.$AC7A0 !U.!G ](\5?M-:%X>LL3W
M5K$4&0CL&P>QV@XS]37ROXU^+/@.?Q]?ZZL=[J>N7Y/F7-S,7!!&-H' "@=
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M>H_%2X36O$^DW'B+1;=I;?4B+.*]O8RJ';N.!,JDD8DR>._!%>=>,OA1X/\
M"/BB/5H+2ZUS08+=W-K,9(Y[978;!(>,E"&^900"R[B<C-G2/BA>?"+XEW&D
M^+(=4\)ZOI,C6]PUDVV:.0'(.[.UE[C!&00<BK$/Q>L[[5Y7AU5+BS1S)',8
MBL^[DDD*202>,@X.>>,U>49QC<LKK$8=6>SZZ.VU[K6W^0\\P. XBPOU+&7<
M;WM=JS2T>EGI?:YY)^T7\:(_B'XDL+6U6_ETGPYIL>DZ1]LO1-+;*C%V,K8
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MN)%BW$;B2Q ! ]>>E?*,'QST&^U.*3[))IZ ;8KB(%_+ & '7J1[CGV->M>
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M+2:VE6.4&*0LLT3*[OYA(8L&# './,]&_:\G\0^$Y/%?AO45MKRVM+4W,"Q
MKJ$3&12=C @A2%.#@C>PR,5[/XK_ ."@.K?'']I+X:_#.Q\(Z?J+ZKHMOJWC
M6^U&%S;V<,ML)I!:.NU0$R2SD#+$#'6O!-?_ &?=2^(7Q7N)/!\VGZ;:V"R2
MW4]\XM[*"R5\9E*@X'*@  G)  Y-<?MH5Z<N65^3K:R?7\CZ:I]8RJ=*.(I6
MCB4Y0CSJ<E%R<5S62][F3ULKK=7O;EO$_P 1=#^/?B:TD\2^&M#NYYIX[:2X
MMY9-/= Q RQRR9 .<G''4XK$^-?[--G\/=.N-5TO5+?Q'X8U M;0,+@2RZ>
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M!1[Y)["OCO6-&\5?%F"WCOK^YN/#VBA+6!O,"V VX BC7),S@<$G'O@5[G\
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M[J?<?K5[0OA5;V%Y"LZQRK&0W(!Y'2L>?XA+XA\;:A>:AJ#6\$LA$;VK[&8
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M;CPW=()PN^2U#9$RGH\9[@^W2O-=<O?$&GHUO);S(R'T.,CV]:;X,^,FB>
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MPCI;L9#&K'!);IGM@9ZUC4BYR<GL>]2E*$(Q6^AZ/8>)%U)VCM9%%AI[>3&
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MS;KWP^O-;OWO%3;@D!6.#MSQV[U]-F>5X?!TE%/79+R/+Q4G3GSQD[O4\O\
MAQ\4OB%\(];CN([R^DCX5WMWV.5]#MVDC\:]4UK]KJ\\(_"F&'P?X8N!?6(D
M8O+(XD+.26(8DL!DDD@Y/ X ->@:'^Q;XIN-.L%FNO#UMJNJ0FXL]%N-01-1
MNXPH<[(\8)"D-MSNQSBL'7OA+_8>BF6ZBC81R RH#\I4$9!QR 0"#7ROL<%5
MGS*SMTO^9[^#XCS3"P5!II35TVG=K;1OIOT>I]%_L6>$--L_"&@>+-8T/1/[
M1U+3X-2BU/7#+_9T4L@SBVL4):\F0J6:9R A9%!4@DY/[9__  507X:^-8M/
MTGQ=X3^V:<FU[_5=-_M"\E8')\JTC#16R G"AR9&P"3C%?$'[4G[7GQ3\9^(
M[);[QM>>3J^EP)##:I'%%90L 4MU"JI 48!/;DX/.>3\?_L566EI#-:^(VUJ
MY@@5KTQ1E([B1\_O%9FR2LF8V4C)55<$@G'5EN48G,>=X7W:<=6]%;7KT_!N
MR>MCT<^S[+\!7H0S']YB*JY4FFXW:Z/?79J\8W:?+?4^KH?VO/&W[3OC/1O$
MB>)=/^PPVP%_J=Y>RVUN]VTH6*)+=6"PJ%Y.T#/()R.>]L?C=IOQ4\5S6NK7
M5G!KEN1#;ZJ)"\%_P<!V!.0#]U^WN*^1?@'\(]/G^(NCP^(M3O\ 0=.O;BWA
MG^S8MHKR,$*T8."J, ,@D'!YQD@UZ'^T-\/(/AZFE>)O MMJEOIEUJ4L9_M:
MWEA6_M8YF"3P[V+B11M60$9(8. %.#]5Q+PS/&Y4L7A::BJ5^9WNY62U5KV[
MM/5)IW:39^?\&<7T^'>)Y97F-:4GB.7D222A=O2[T:V2:T;BXM)N*/MCXA?'
M/Q5X _98U#[3;:+J5YHD;-I]I?6[7*)E2>><'.,C!ROL#BOAWQ!^U/\ $3Q#
M/!]NT#PFTRJ'(@BGMP<\[#LD!(]>?QKZU^(]\WC#_@G5'XHMW1FBN5L[S9(2
ML:L5 *GJ2&4 GJ<^U?,GAOP?_:]_$\:;@J9/&:_-^&9PQE"<JRYK/E5[-JUE
M8^VX@S:="M*67R=/WI<W*VDW?MYWOU>NK9AG]K3Q!!F&Z\&+*A 7RXKP20<=
M<"1-P!/;<3[]ZX?6='UKXO7T)U2"/3M)MF,D5C H4.S<EI&ZL23W)KZ,\-?!
MN/5]0/VF/9&F2Y"Y( ]!WXY/I7<:%^SQI^H>)]*T]5CBEU2>.$2$DK'O<*&(
MR!D @\\'G K[+#<+TX1>(II1?S?^9XU;/LTQ%'V52J^5_P!;_GW/#?AEX.LW
M\*:IX7U3PUIOB#PWK1@>ZM;LO&$DA8M%(CH0RLI)QBO<O$WAZU\1_LYZSI]M
MI]MI6G:+IL<&G65MG9;HC@@;F.YB2222<DFNB\*>%?"?CF3Q5:^'='\5:;+X
M-7<UYJ9C6'4]MP8' B #1-N0LN<A@#W!K4U+P^]A\)O$^Z+&+(Y7IQD8KYV-
M:C6J?6*2][:_70Z\1A\TP-LHQLI1BFI\G->*<HZ2LFUS<K]5L^J/C&Q\*+!+
M&K#+8W-726WA0368++R!Z=:Z"T\,K=7H=AM7:,#Z=:U;^PC@B"+MZ=NM>M[2
MZ/G*U'DJ.)YU_8GV*Z)"JV.WK7(OX9CM?',5DEDTUIKLKQR!9 G)1CWXR& (
MQW)('6O5I;!9)RKKMS6?XH^'G]O:<WDEHI4P\4J<-&_4,#UR#7/B*?M*;B]S
MLR?,'A,3&;VOJ>#_ !-^!>F>$M-AUN-;G5M.NKK[/<(%$<MLXR<@X(*NH(!(
MP2&'4&O<OAA\*]'^)/@GP_X<T;3M*.CJ\FZ6X9Y)I+N"(,J"9E)MRQ)#!?E)
M4<] .=\*^&+CQ)%]OO;&YU)=#O5AU/3DNO*6Z7!90<G Y+.IP<C(X.36I<^)
M=3\1Z<-,\3WEC\-? _AFXVVFE6:,^JZH48< GY@,KS(V%)Y ;&:UR;/GEJJ-
MP4W)6UZ>?9ZVT:U[KK]+QIPQ'-Y4'2K2IQC)3]WJK;>6EUS7T[/IJ?LG7 L?
MBWXI\77D$=VOA6VFO&\N%809U5EBB ^Z H5R/<9Y.#7F_A/3]3^(6LWNLWY:
M>ZOKA[N[=L_O)G)8@>PSC'H*] T?X^KXQ\+ZMX:\*^$[6RM-=FCM9KN!0(X+
M4/@[EP2S["P,A))+$DYXKVCP#^SBT2W<=K;XL[.0B=AC*$\CCK@BO.RV-2"G
M7J*SEMZ+_AR^+*\*L:5.D[J.K]7MY76OWG.^$O#^DZOXGM_'I\,H_CC2M 70
MX]1^WNUO'"L;1JY@QPZJQ'!P2<D'C%72?AM'+]D:XVI\A17*G8@P<,.,D$<C
MDD?C7M7PV\"::?'^E:3<Z>MS:RW!?!(59Y0A*1LV1A68*,9P<\US'[.'C_XN
M_&[XIZIHOQ$LM!L-%71&N;W0X%WMHCA)=DN=@^S3I,JJ8BV&5A@$\U[V'XHP
M66)4L/AGS3=W9Z-[7\_0K+\OQV>8&MB9UURX2FDE.3OR^\U&"L]+WMLKM*^I
MS'AG;H'F><B1J!M4*,!L>G?'I7/ZW:R:IJCR^6PB=MHP.YKWKPI^S%_PD-B;
MO5M2960;A'$@V@^A)Z\^U9NJ?#ZUT*^>)=TP0;5 7+.QZ8]3GI7FU\3*M6E6
MGNSXWFYVHKH1_#W2M-U?X4W$.I-"6M;F.)%D.UI5<$*JG^\"./RKB?&'PUU/
M2(S>Z)<MJ&G$G"\^9 >ZL.H(Z57^.M_'9Z7'I*RM;QQNMS?"!@I#+RBEN@(Z
MG'>LKP;^TOX<:58[B[O+.Z50C3HW^MQ_?!!#'WZU-DXZ/5'I8C+JU1>TEI>U
MKORMW\D<UK\^O7V8_)F!.%Q@GV%:&A?!36-5L+;SG2/)# #((XP./7_/%>B0
M?$72/$$16#5M*9W V/*/*;)ZY(R.*V=)GU81AK&Y\,W##HTM\0?RVUU8'%5J
M#O1>_P SSY8'$TNEOP_,PO"'P6;28@UT%N9% W&3Z 8 P!C\S797WA.QL/#R
M*+>W3;T( !P>E<I\0OB'X@\+6&;J?2XE;@FRC><H.YS@<5R5Q\=VL$L8UCDO
M)+O+QR3+MC&#C<5ZDGL"0/6M,5BL37]ZJ[V^X<<+4E\;7_ /6?#NE_9[+[1>
ME8;7:3%$.'N>>B^@SW/%<YXJOYO$VL",-\_$<<<6=D"]E4?S/4GDU3AUVZUZ
MS$UQ<2$S#!<GYG^G8#T &*[[X<>"HK007#+ELALGDDCI7'%]6;5L1"A'V>'W
M>[_R.5C^%MQ9JLC2212@9VEB/S/K43PZKX?EW0R287J-QYKWM_#D-[8C<JYQ
MS7$^(O"JM>>7"%.]@N/<\5<:R;LSR*DYK529\^?\%-/%UX/V9_ &@LS"?4-0
M;4)4/4A(SC/XR5\;:)=SRE56.16! 8KGL?2OK+_@J;XTTN+X[^&?",[K'+IF
MB+,BMPKF1R"![@(O'7D5XOX.^'MG=:A%(EWL#$%E88R/2NQRE3ES1TL=N"C.
M5-3W;+'@'X5W6H".=4D=6^8\YSTKZ1^"OP6GU-TDD=;< @#<O7W%9?P_L+/1
M+*-45E7'WF7"_FV!7:Z;^T=X4\"W=O9S:QIYO+A@D<,+>?*['@#"Y"Y/<G@5
MY5:-2M*^K_KN=TJDH1LM/4] O=0C\)W$?A^UE:.[N5+W,JMAHK<<G/N_ '<#
MGO3K?4(9;A&:55(X51P$ Z8%>1_#'QA=>-M=\0:M=;U>XG\M.A.T9)X[ <8K
MO]+OK73$CFF&\%@HR>2S'"C\2:X9J522IP]$EU9Z5&*IPO+XI;_Y>GYF[XKM
M[76+)H<(ZR*4E5AD2 ]<UX%\0/A]-X*U7[1II:6S;ENK&#Z^H]#V[U[)XODN
MM%MY)UB22% 0WEOO8XP#M'!..<CT&?:N0\*^((=9U.7YTF@9@"#V^H[9]#7=
M4RW&8-7KP:7WK[U=''BJ=U=FI\$9X=>%O!<,R2KD>;@LIR.C#Z]"*[[Q-X(D
M@MVD@XY&TH<CGW]*RM&\*6/AZ83:>4C5@2RYZ<<CT]_;M72Z#XVCTZY\N9FD
M7&YB!G'J0/7U'?J.>O#*TGJ1[&I4I<\=6MU^IYGX@\8WGA^3[',/+!.%W='!
MX^AJ/P_XKM=#FMK6-O/ARKAF^[&1G@]"<>N:]"^*?@RW\77$5U%!&Z*H=@O\
M8/0BLWP%\*;&YO4N%A=ER 5^AY^F*]3*\TJX"?/27JNC.2-:=-Z&YX6\-2>,
M-2BD41E5B55"KCDY8D]\Y//TKKI/AM)I+KYMK(LC8*LZG'OS["NV\ >%=)T9
M8I(X660$<Y/![5U'BO6[--(:&5U\RY!CC7(SD]\5QYA4K8NM/&XC2^OW:)?<
MB:>(=2NDE?N<MH=W9>#_  9J=])(OV?3X3B3IOD(. /<5\CV?PLOOC7]NU*S
MU*71]/-RWD*B9:[.3N=CD$Y/2O;_ -MGQO;^"/ASI7A7364W6J8\W9UR>"3^
M'\ZP=(@MO!FBV5G:#;%'"(P#U! Y)]R>M34J>SIJ%-ZO5_Y'11IJI4=1]]/U
M?S=_N/#?%'[+7BJ*+<+N._0?=!F*,>?0\?K7-W/[-'BK.V;2GDCQD;)$8?B<
M\5]*>(_'_P#9MK%$L:R3R?=W9"C'=CUQGTJ"WU#5M1MCYUS'%(1^[0!0F #G
MZG/;(-=67Y?C\9'FI))=WI?TM<TE1<GH?)WB7X0:UX6@9FTZZCC&2<+N ]>5
MSBJ'P^\6:G\/O$)FM;J:Q=N&4Y*28[,O3/OUKZ9\817N'\Y4F4_=E@!("D9!
M8=C]..#VK8UWX8_VQX@U>QU#PAX5A^&UCHBW.E>)(YM^I7M\8HVR6R"&\XNA
MB(.5&>.,Y8V.)P,E3Q<'[VS6J^\ZL%AZLN=<T4H1<FI-*Z5M(WWD[Z):O4Z;
M]G[XGW6NV5M=;;;[0P!?< ZN?4-C//H?SKZ*T+X@1W%N8)BMO<LFT>6P!!(X
M(&3@]QUKY$^#-O\ \(?=Q_95V(6&Y>H/_P!?'>M?]J6-;/QKX1N+6>2TEUH+
M%)L8J#@C!.#U[4\+)5*G(V>?BJ=&LN>,;'T'\-_"OA;]FGX6:396]W?:Y<:-
MY_V/4=9O#J6I&29V>9S/)E@SLQR%(4#    %>2_MC?L6>#_V^_"7AAO%U])I
MNM>$KJXO=,O#;"[@47"*LD<D.Y2P!2-E(8%67/()!YS7_&5QJNIK#$DAM;%A
M&$'3 /)/N:[D>/?)N8DN&\F.0#;NX&/K]*,9*-2'L8KW?S)R_'8G+\9''X>?
M+5B[J5D[?)IIIW::::=W=&==ZEX?^!GPRTOP7I,\VI'30[SW,=F(S=W#X#R&
M*,;8\[5&,D\9))))\O\ 'OB36(['5[*RN+:[DTR>.SU2SMY4DNM*DN8A*L3_
M "Y3S(T!(C<@@ -R,5U7Q"\?6&CRII\!COE<LWVE"?+D)R27SR,'UZGDGTQ+
M;Q%JGQ%FATVUN'O [@K&B'*!0 "1PS?+P"QR  !QQ7TV'X=P'LJ=6-12BOB^
M[1+71I][GH?7%B)5,1B).52=W>Z7O-W;:MJFFU9<J3:Z*SYKX5^%;OQE;7EJ
M_AN'7-.D,,EU:7EH9X2T4@EB?&1RKJ",'G!!!&14G[0GACPS\=O&NE>#_B+X
M2TO1_A!):7?B#6?%EI<C1AIFINX0*TB%5S/N".) Q?S5  P2/<?"W[+D^KZ5
MI\>K6=G-'I6JV^N6$9FFC:VO(0PBD)C90P&XY1@0>XKH!\'UT>&[AUBWM;ZT
MEB>22"X@6:&?!R R,"IYP1D<$ ]17SN+IT5BY^QLXZ6>[?EMLGMY=2J>/C3I
MQITJLG;F;C>RBW9<T;2=VTE=N*M9)W. O](M=%CL_"NDPV^G:)8VJZ;;00Q+
MNBM$'RPB3!?9CL6.<DG))K"\1?"SP_K?@[Q%X9UK3/M'ACQ18-I^HP6SB&3R
MPRNKHW0%613@Y!Q@Y!K/^/O[0G@7]F:VTGQ!XZU+4([GQ)//::)IEB +C4'B
M\L/AF!4$&1  < D\D#FNG\:7$.O^ ]'U726NKC2->MX+V$SP&*X2%R04E3.5
M8,"K#. 0>HKAC"&*Q"PD'K)I/YG1+ YAA84\T<91@Y6A/^]%WT>]TTWYM.U[
M.WRC^T_\*]!L_@KHO@CP7IFH2:)HU])?SW$\,4$L\A0HA58PJJD:D@$9)&,G
M@"OD7QA\-/$W@NX::&22XA? V3.QX/3)SC/OBOTR\1W.DOH863Y<1B%U8!I4
M.<$@\@@ C))SST%?-/Q-\#S:I?"SCVM;D!Q)R>"<J#QU'>OM,3P[@\!A;-VM
MM?J^QCF.:8FK7>,JU'*<M6WO?]/EH?.GP[^.&J?#'4 UYX:M[^T9#'-!<(9X
M74]2,$,I'4$$$'H>M>H>$?B)\+_'7BW3-3U?4K;PCI=B"=0LH3=SW5ZN"6B0
M$D#=T&,GG'/2NU^'_P"RA=>+=)U#5;_5-#\/:#I?R3ZCJ4I6+=M+%%5069@J
MDD < 9-9WQE_9&D\$:''>>?I=]'/;K?Z??Z?*)8+R,\I+$^.02/3((P17Q\J
M>%=1J+][=GMY7Q1F.'@JSI/EE[JFT[7MT>UUOJ?<_@3X5_#_ .'>GV6O?$:+
M3O"37%L+BQ\/27:)J-G!C</.5"WV=0FTB.,ELDEGR"*^0_\ @H[_ ,%;?AIX
MLL#X)\#Z'JFMZ1ILA4V\%X^FZ2[CK)*8SYERW;)(  ..237P[^USXY\3^-_C
M;KVJZQK5]J=WJ;>9-,\I.?, 8A3GA<$#%:WP!_9;\/\ Q9^&6H:E>ZW?17UQ
M<BSM;2WM#+/ %"EIB%R&'F%5*\'R_,;.1BO2R_!5,QG]5PJ6OI>R[M_\->QT
M\0YU1R6G'-<PK2E*-DF[N,6]/<@KV>^K;=KV70Z/X-_'^[^*VF>(?"OAA=/\
M+7>L11I;:=9WEQ;V]W,6"^;+*TFZ0J"Q"DXSQ@YKWB'XGM\#_#]EX=F\3Z;J
M[2&26&6V=X&T]D8(RN&Y)8@D8 R.HXR?G#0?@$=#,EG")&M;>=9IOLY1Y7*C
M8SHX )Q\Q4 8 (.,\U]-67[/?PT\:_ 6Q2UMM<UC5;/1[O4-5UZ8ADTXI*IB
ME8R2*JA%#>;  <I\Q8$#/W>%X;^MY9+ 8>$5..O._5OU5]D]NCM='Y/G'%^(
MX>X@HY]C*TY4ZON^S6J?NI+NM-W&U[:INS1ZYX'_ &I[;XV>'K/P5XFA35OM
M#I;Z?<";][&SD*H5N>3D=B".",@5]G>#_P!D3X/_ +..DV[67@_P]>ZY;JIN
MM<O[&*XO99.C,'8'9@]E  'J<FOR&_X)N_LJ_&JS_:5T#Q1>Z9)I_@'1]=CO
M+F^U,""TN4C?S"+-" TH8@;#&-G(Y %?KQXP\7V>E^%]8U#4/MAN;=-PM;M?
M*;)!P-O)QP3T]CFO"RO+Y*3=6.J=D[6?S]/P/9XGS2EB:J6 ;C3G[THJ5X\S
MW:L[6Z].CL97Q=_8]^&'Q^O&OO$7@OPSX@D:+:)+[3(F?;VPVT,,=N:^5_B7
M_P $RO@C\.;V:9OAGH<MI)O:,0RW#-; C^&/>4.3U../2OIK0?C-$^A6T-J)
M&5(U>9ILK' I. #UZ]AZ=JS?CAXNLV\'3M&/ME](Q5%"':% XP.203R>AZ5Z
MU3"3ISC"I'5]#Y#GJTYJ%_Q/ECPE'H?@GP^NE:"8[3RYFBM[2*W3,"@#)"J
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M>/)X[?6FN;/S'@Y1(W;< N<[2,>O.?6O>Y?BA%XDTYH]4TRWN(V_B@;:2/4
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M";X.MH]K,;>Z^T8?S8P5P0>X!SR#7*^.O%]G<: ]C?63QSP9V2<A@XR 0<8
M /3D5#X._:*DGA\FSN[:5<_+#<K^\0>F,C(^AK<UWQAI?BBW7^UM*RV/]9;O
MR/P;!Q[9-.G)TY*<&XR1R5J-=/WM5W1\[W=[+I-[+&D;7"2$M\Y+$D]2#ZGO
M6EH7PCU+QYF2QTN9\'+;%R >N2>E>P:=X>\*B96M6C=F;[EPA7'XX(_6O8O
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M"2<D\]ZJZOX7QX@>V:-E123NQQ@>]<.48)8&DZ47=MMM^9YF:M5;58*R>O\
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M8O\ 9M/F@BMI81YCQ>7$JLH';)W9]ZY7X8>)=/\ AD1#&VJ2S*</]IN7./\
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M2B\7-25&FJ4=$K15VEHE?5O5W=NIY;\??&6I1:?_ &4MLEW=BWD@\Z3 D.<
MDGH"""#[\9JQ\+;;7/!'PO\  ]C9^(?"N@:<-9GN_&%IJFGF[NM<LVC0QI <
M'@#<#@@Y(YP,'<G\,)X^^*]Q'Y#"QTORQ()$$SQQJ26^4Y!/)/.<D9.353]H
MR[CU+QK!)8V?V6RAMUMHDV[6&UB<D=L@\#TKY_-*+JX>4=5ML['G\/XN6&QJ
MKQC&32:M**DM5:]GI=;KL]>AXI\0/ ^H^'?&9\0^%T&^*Y\Y;=A\DBJ6V@CK
MPK$<<C/'-<EJ^I>*]#\(72Z;X$:R>VMWAL]8GN0][&)9"[E954$ $G !!&23
MUQ7O7AF8JZK<)MYXR*]?O-!M=?\ V>;G%O&&MI&&['/(SQ7@0I\TN5^9^B9?
MGE:C05*2NDTEY)M+]3\W-)^ E_KA&I:U--<3-SAY68*/3))))ZDGDGDU[_\
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MJJ=WLU:UO4XZ$:%*K>I[R2OH]]B;X@_$J_\ %NJ/!#,MS<L/*\T\+$H_A4=
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M*O?8_P"R?B;8ZS-$%CO@4GR./, X./<>G/7%:GBSXBQ7\TT*Q0ID@;QP#M
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MCQK7@^T#+=[GXP6&['M7"XRY5S:L]_%4Z<I2M*W;S7Z'WYIWQ#^P'$ENT(3
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M2KRJ8:'+%]//KZ>AG[-1]]:(YWX1-<V;*GS%<C+<_J*ZSQSX*.ML)[&94NE
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ME;L<7XUTK_A((MT;K'*X.[:WRGWQD$'L3W&0<YKSW4O!$D-WYDK/@-G!/R<
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MS_+%=<*BO?J<M;+:\7IJNZU.HT'PQ9>']/>Y\L23MC;N Y;USUP/3IQ7BO\
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M!,06 #8/" 9!W9YY%</JGPZN/'FMS76G1.T:$-)YXV_OBHWJO^RI! / .,@
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M4X\"^*HGSDYMXV'ORKFG:]\*/'TL6VQ^'WBAGQSFW1 3]=_%?H)11_9\>[_
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M5"'_ )-_F?G?-^SO\1VMEAO_  #JUT@_BMGC/Z,PY_&M33_@]XRTV$*OP_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MABI5@H4DDLYR .!DBA1?E_7X@ETT-2STGQ=>:<UQ;WVDPQ:@#-<;XR\AR/\
MEFP8*H XR5)[\&G7'Q*L?$.A)I<$DBZTS+%]BV-YB,I!W8QS&<<.,@],YXJF
M-7\2:]I)L81%/8AU\K5M)NSO*#D*5VL&##@D-@CL#5:5K*UMR(/%_D:GL DL
M/M$4C6T62&VQLK. 0>>#@9(QQ1R]_P  WW_ 2"^UW6=9.UO"_P#:%VYBR-/E
MF@V@$D;U8$MU!=CCL!ZZFEZ1XKL6EATI?#MB5(6X>X$MR0< A%"LORX.02<]
MB.]9MI<S6$B26NL6%VQ4K9ROJ$'V>T4C:"#GE5!R%P6)P#QTDT31[N8S7&E^
M*+J/4K$&262^9I+>[B.<R21\ C(/(VD# ! XIRB5+;H51X8NFN[NZ72- N!%
MNCNKR.9[:YC/4AE*-YBGJH)!QP3WJI>:3>6UE"MQIWB*Z29@MH(M<A6:-!QF
M)UVA5(. N[/8FM&ZN%NK5+BY\91VKWK&5-.A:* :BWJ%<F7:PZ+GD =2:FEL
M?#=II:267B*Y9KM@1 ^H^:+8#[S+'N(BV#.<8 /!IZ_U<.9]?U*L#:EHL37"
MZ;XFN9X<>3'XAO(F6 YP'+1EFV#H!DDGTY-6+)?$6OVEU,TNDS19$M[ EJRY
M9>5,9W''3!SN)Z@"I/"OA.QU>]\G3_%5YJB2QM*)H;UKV.4 X*.[,V!GG (Y
MI;O1KC3I[J%?$D.F^3A9[:/RF^V#'*C>I;@''RD$4M-NHN9?/YEF[U+Q9K>G
MK)=6_AO3M*G9<-'=2328)&T$[0I!/4C! Z$&JE[H.MW>L+:7LG@RYU*6,^6@
MTQS&8^N)5+DL.#MY !R<&HM6UMK-Y='_ .$N\+ZU:3J$^QRE!>P#J%3RR=PQ
MW8 @<DTZ/3M<U#4I9--N8[/49@K$VABO4\M0%4!I%Y7CG !!)&1UI*-D*.P:
MCHNO+=26<BZ?J']GQ^9:L(V4VX88*%5(#IQP1@CH2:N6_P 1EUS18]'ATY[?
M69\P-9)*&$$8Y,H8 C81TS@D\=C393KD=O=:E<>*]#TI[)Q:W%\]@%MFP1E,
M2.0"&X)!P3P!573M>NM+N!)8ZGH%[<*Q9K6ZF%LSJW65I.2%;^$D$#)'.<@Y
M;K^O^&'>ZUZ>I>U#3O%^D)',=0\.B6.016S+9RIG=QB4"0!^.>, $9P: _BU
MK]B='T5]25/+.;P_8T4G_6A=N_)(P5)YP"&'-5;'Q#J'CW5H[74M6T?3K1G*
M0#3M[&6;G 6:0 ,5YP4&"02">E6-=\%ZEX0U"V?3=3UB^U15,TCW<F\7(! "
MRA -R <=,CU[4<O1VO\ UV)\I6N8YTK6+Z&?;:^&]<,$W^GV]U9.LJ2?[)!^
M50.@VL/4]:AO?AW<#2%G;P[X7^Q+M>!\2+<2L3PCA<<'/&#G@$@\BNBN/!$]
MWHR:EK'B2YL+BY7=.L,J6MM<]2JL,9P!P #G'<G-49/"UK9>'8=4FN=<,UVY
MC6W34I9;6+D_-L)"J  2, 8/0GK19/L6JFOS_KL<[8>'M$DG5M#AU;4+Z$D7
M-A%/+:/ >@7)8 $'G/(QS[5K:?X%\=/:R?V?XKN-%GCE*R1F[N9XH^ 0BDN-
MQ&>3T)Z 5.==6RC9='^(-CJ+L#&\ET8+N6 $95 4*_,3PID#<\$'I4#>#O#G
MCC29F75F\0WVF@/=PWDQ=48_><Q, H;/&X#M@$<"CE6_]?H3)1DO>7WJ_P"E
MC0TK5/BE#;?;;/Q\9;&W5A,+J,NX91R5X((/'!P0.Y-6I_CE\7O"IMVEO+;6
M;*X162>VTU9'W'G!0E#@^QS_ +..:JS_  \"Z,NH3:E?Z9MROV5[MXK>X Y
M$>=I)QZ9..N*;<:E=>((5@U!M*M++3X&,+66K!KBX8* !NPHC8]@<D'G/'+U
MZ/\ ,YY83#3WA%_)'3:-^TS\4[;Y=0T7PHLWEF86\D[K<&,=3M4D ^PS]36I
MI7[8GBN_L1=6_@S3]>M]_EM)I6K(WEGN&#8(([@X(]*\]\'>&M0N5A>SFO\
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M@YJ2J,@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_B7_ (.8_A%8JW]D^!_B-JV.[VD%J#^+2&N6IG&"A\56/WGN8;P[XFK_ ,/
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M/#>O:?J/V.*#P>]XL>TK;PO;Q6L9))*Q[F D);.20".>:D3Q+XTL$DMX]/\
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M./%LC?VQXZ\<ZFK\N+C7KEE/U&\#]*Y'6;*+4YMUP]S=D]3<7$DN?KN8UO7
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MK7':W_P7S^#MLQ72]!^(^M<<&'0C$I_&1U_E7)4S?!0^*K'[T>[A^!.(Z_\
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M;&%FEB8]%157YE[8 !'4Y'-,U6]U#65N[F+28;>WDV"4:CM$L '1@@# N<Y
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MA8[AMZF<GC,Q4$@YX&,CZ5M?\(U)JVI0V]WJEQ>+YS&0+;HL<DB@8<X)QC(
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M5 "@'IUZ>QIUYX)U#3IHXX==U*4R(Q=[LI(95'5"=O YSD8(/>C38GVD=O\
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MN);HQ"WVSPF)3(#]YN!P!TQ@'IG-"01E\S,,/AJ73/*#Z:-65?+V,$6XXX*
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MV$L.E0LL<$*-C *H!C]*XY<=5;VC32]6W_D>M1\%<#%?O<1.7I9?HSZ:OO\
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MTQX)DN%L[4< B=G+L3U&!T7T)ZD5)%<R)<"XN9MI#;G9<A5'< <G&*M>7<+
MI^V*O3RXTC&1DXSUY_04LZ7EFQ+-;2L@RLC1[!@]<@$Y/TJB>8HW%TMW*LTT
M.F*F=JE_F"J>A!QRV?8?UJX^M&73UAC$<D[?NY$#[2@QC<!@Y[8[>]$=O<[2
MTE[Y,C=&V* ?]G'3'U.?>FO"T>V2.X!E9<EE5,H??C/.>A./I3W%HQMW->V:
M+]H_L]$7Y$+R$9' Y.,!O3'>ELIXK"9)I;O8H!+F23@>B\]O0?E4LEQ-=JJS
M+8$CD.)CC.,\KC(![\FHUM&8YWVZL 7/V90^<=B3SG'< $4O42VU"/5?*CF6
MU621[E\QL00H!ZG."..PZGCBBX34%M3'(MJ+=,;621O,!'0D8QU[5);V<=X\
MJ_:[AT _U3XV$8[<<CWJ.&5K>T%K'';B(8*,LBKL&<X*_P!10'42YU-;ORI(
M(8YIE!$B.P7GIAN"0>XXZ54NM#:XG._3-/=@N_)F,3(O<$J#N _#CM5[=)).
MS-=:?%<'D83<I4>ISDGW!IQAN+Q)&>XMCQL=E0JI7K@'<?SS^%%QIVV*Z_;+
M>SC:&.U\A?FC 9L$^XQT'8]:FDFU.Y\M9EL$#$,@21LN1R.W ]::TMU)'M:Z
MC5 =AA2+:<#WR3CWJ6;2'CMPZW5TS-C8&8?NR?3CBD+KJ0RPZA<3_O+?3&F
MW*I)*=>I.,DCM2"*^ D;R[/'(E&XG:<<[>,\CUJ::2[D.YE6S90$:1F#$#U
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M?_$4_P"SL5_(_N#_ %TR/_H*A_X$C!HK=_X9,_:&_P"B>^%?_"H3_P"(I/\
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M5D^8.DJ5"E)+Y?YG'A^..'E4<ZV+IM^IYVQW'ZU);V<EP_R(S9]*[^+]@_\
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M4B?_ !-7+/\ 8%_:"@_UO@3PK)Z >)4 _P#0*I<-YDW_  G^ ?\ $1>&TO\
M?(?>>8:19M+,JMW//TKM;:^MK2%8]Z]*WKO]A#]H:1<0^!?"<([_ /%2IG_T
M"J3?\$_OVC&/_(E^$O\ PI%_^)KLP^2YGAV^2BVWU.>MQYPW6MS8V"^9QOB>
MQ6\F\R.16SP1FN=FTI8/F ;(KU4?\$_OVBQ_S)GA/_PI$_\ B:=_PP#^T0WW
M_!/A-A_V,B?_ !-<U7A_,YS<E1:N=%/Q"X;A%1>-@_F>0+>SK)MV\9J2\LFO
M$!)QZUZW_P .^OV@MV?^$'\+_P#A2Q__ !%7;7]@[X^VJX_X5_X5;W/B6/\
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M[-^5?O5SC>-V,F/.7->N:Q_P3D_:*U:1V_X0_P )KNX_Y&)/_B:P_P#AU?\
MM%?:-_\ PBOA+KG_ )&!/_B:FMDF:U)M^SDET_JY='Q$X5C%7QE._77_ (!Y
MSJ=_->QE]VYL<5RVH6%UJ+G<OXU]!P?\$U?VB(HPI\(^$3C_ *F%/_B:D/\
MP37_ &@MO'@WPON]?^$B3_XFN6/#N:IW]B[_ ".M^)G"MK?78?>_\CYOM=%N
M+6<-C:/6KVL79GM5C63YN_->\7__  3*_:*NHBJ^$_"2?]S A_\ 9:R8O^"4
M?[1*3[W\,^$V[X_X2!/_ (FJ_P!7<SEK*D_P#_B)G"R5EC8?>_\ (\1TK09O
M,#L[ ?6MJ9&$!53\V*]J3_@F1^T1%"%7PCX3X_ZF%/\ XFJ[?\$P/VD"^?\
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M_'_(^<O$.KR6(_=C-<O?7UQJ<BJV[FOIR_\ ^"17[1U[(6_X1_PF!Z?VZO\
MA5<?\$>/VC W_(O^$O\ P>I_A712X<S"*_@LSGXH<+2?^_0^]_Y'SSHWAIH9
M!+)T'-;#:Q;VQV[E&*]_M/\ @DK^T5;P&-O#?A-\]_[>3_"L^Y_X(Z_M"3S%
MO^$=\*C/_4>7_"LWPWF4W[])_@:+Q1X5BO=QL/O?^1X!KUK'>V_FAL@>E9^A
MZFEI-LPQS7TI%_P2'_:,AB\L>'?")7WUU?\ "IH?^"0W[041#?\ "+^$RWJ-
M>3_"C_5W,E'E]BW]P_\ B*'"E[_7H?>_\CP1=)75<?NU8X]*L6OA,Q-\J*E?
M0-K_ ,$I_P!HJS!\OPQX2&?^H^O^%3?\.MOVCS_S+/A'_P 'R?X4Z?#6.M[]
M*7X?YCEXJ<+7]W'4_P ?\CYGUW1!-F%_TKGY_#-O8-OD;@5]4:A_P27_ &C;
MS<5\.^$D9NYUY#_2L>]_X(X?M(7RD-H?A''_ &'$_P *4.'<S3TI-(J7BEPF
MU_OL&_G_ )'@.FZC;[0L;+\M&H>)HM^V23)%>[6__!%W]HRV?<NB^$O_  >+
M_A1+_P $6OVB+E]S:#X2_P#!XG^%5_JSC[_PY6#_ (BMPM;_ 'VG][_R/G.3
M2X]9F+QR5L:'HOE;4SD#J37T%I?_  1M_:&TO[OA[PFWUUU/\*O)_P $C_VC
M(^GAWPFOTUY/\*F7#N9WM[%M?(J/BEPG:_UZ%_G_ )'SSK4,8(1...<5S<WA
MCSY]QDR,]*^HK[_@D#^T9=J=F@^$U)[G74/]*KV?_!'7]H^W?+Z'X3=?3^W%
M_P */]7<TNY*BU]P_P#B*?"5DGCH/YO_ "/G2'1HX(@VQ=H[^M0:S/\ 9K)M
MA (%?3TO_!(7]HF2';_PCOA,?]QU/\*P[[_@BU^T?>N?^)/X3"GM_;B?X5,.
M&LR<KRI,<O%;A-+W<;#[W_D?)IUJX\_[[=:ZK1Y_/L@9#R1WKZ$M/^")?[0U
MKG=H7A%R?^HVO^%22_\ !%G]I!S\NC^$47T&MI_A6]7AW'RT5)HQI>*?"T=7
MCH/YO_(^>GTV&5MVU2:N6*Q6RGG# <5[Y!_P1C_:3@7 TCPB?^XVO^%3V_\
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M*'##=UCH?>_\CX3V[C392!VK[M7_ (-V?VBB?^/?PC_X-5I6_P"#=;]HD_\
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MY(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%?'.C*P1[S0]4AOXHG(SL<QLVUL?PM@^U5[C]J?X9VGQBG^'<OQ"\$Q>/K:
MW4WAM];MEU:*(1><9&MM_F!1%^\)*X"?-TYH [ZBOGC4O^"JO[.K^#O%6K:;
M\<?A+>1^$R+>]D_X2FS$$-RZ2M#"TF_;ND,,@4 DG8V,X-? W_!$#_@Y!7]M
MO7OBWJ'[17C?X-_">QT632T\+:;-J,6D+,L@NS<D27<Y>X(V09(("Y' W4 ?
ML!15#P[XBL/%WA^QU;2;ZTU/2]4MTN[.\M95F@NX9%#)(CJ2&1E((()!!!'!
MJ_0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !17Y:_\'2O_!13XQ?\$YOV=/AAKWP=\7?\(CJGB+Q'
M<6&H3?V;:7WVB%;8NJ;;B*15PPSE0#[XK[>^#_[4.B>$?V'/AK\2?BMXR\.^
M&H=:\+:->ZKK>MWMOIEF]W=6D+L2[%(D+R.<*,#)P!T% 'ME%>*_$[_@HS\
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M4@XP:\X^&W_!3_\ 9S^,?Q!3PIX5^.7PKU[Q'+)Y,.GV7B:TEGN7SC9$H?\
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M^"3GBCX"^/OV?],U'X>ZIJ5U>I*MMJ=S<>7<V/V26WNXWF=W24&1MQ#8)"G
M.2?MOXU_\$M/CIXN_P"#H?PO^T3I_@GSO@_ITUB]QKW]K62^6(]&-LY^SM,)
MSB;Y>(SGJ,CFM_\ X.I?^"9_QK_X*/\ @?X,6?P;\&_\)A<>$[[5IM53^U+.
MQ^S+-':+$?\ 2)8PV3&_W22,<XR* /%O^#R;7IO%?_!/_P#9UU2YV_:=2UTW
M4N!@;I--#-C\37W!^UN/^.;+Q/Z?\*%C_P#3-'7#_P#!>G_@DGXZ_P""E'_!
M-[P#X7\#FPC^(GPWFM-1M],O;E88M3 M#!/;"8G8DF2K*S$(3&02 VX?).A_
M K_@J!^V+^P=+^S;XQ\"^"?AGX&T7PU_8UYXAN)[8ZWXDMK2 ?9M.01W3Q[I
MC%'$\NR)"K$LX^8. )_P;TC/_!LU^U1_UT\7Y_\ ">MJ\:_X-<?^"1OPH_X*
M-? ;QUXJ^-5CJOC70O!^O-H_A_PX^JW-IIUA--;12W5V5A=&,LBFW4'< !#D
M@D*5^W?^".'_  3/^-?[*O\ P0U^/_P>\=^#/[#^(GC5_$9T;2O[4L[C[8+O
M1H+:#]]%*T2;ID9?F<8QDX!!KL?^#7/_ ()\?%[_ ()U_LD_$+PQ\8/"?_"(
MZWKGB\ZI96_]I6E]YUO]CMXM^ZWED4?.C#!(/&<8(- 'P9_P0>\ #]B#_@Y=
M^,_P5\%ZEJ4?@.WAUS2_L=S,9#-;VTJ36OF'^*2+.T.1G#/TW$'YM_;'_;2^
M%?[1'_!=KXL>)/VLM-^(WC?X7^ =7U/PYH/A?PVR[E2RN?LT$3;IX3% P26:
M0QN'>5@#PQK]-/V*?^"6GQU^$O\ P<F?%+X^>(/!'V#X3^(Y];?3];_M:RE^
MT"X5!#^X28SKN(/6,8[XKGOVYO\ @D1^TY^Q7_P4_P!?_:O_ &.;/P]XQ;QL
M;BX\1>$=4EBC8RW&U[J,I*\2S032HLPV2I*DG ! !(!^96M?MG_ OX(?\%1O
M@W\5OV+_  K\4/AGIUOJEO:^)- UW!MKI)+E$EBA*W,[M#/"SJ\;OA2J,@!Z
M?UP5^2_[(EI_P4V_:N_;2\+>+OBA;^#_ -G?X1Z"X&K>'K&WL[[^W80X9XEA
M:2YD\Z3:$\YI(Q&I+("<AOUHH _$?_@]5_:4\2> ?V<?A#\,M'O[JQT;XB:K
MJ%]K2PN4%['8K;"&"0CK'YEUO*G@M$AZJ*U_VK/^#:GX!_L]_P#!)#Q3XD\'
MVNM:-\8/ 7@>Z\1GQI#K5R)]3N(;%I;J&2+?Y MYXUEBV*@VI)U/S%OIK_@X
MD_X)":Q_P5D_93T6U\%W5C:_$CX>W\NI:''?2>5;ZE%,@2XM&DQ^[9]D3*YX
M#1 ' 8L/CSPE\)/^"HG[97[(=Y^SA\1O"/@WX<^#+?17T?5_&5Q/;3:YK]G#
M#M2QC\JZ>)GGV+$\WEH"KDLX.=X!Y+_P0#_:-US]DC_@W;_:Z^(GAF3R/$7A
MO6[N32Y]N[[-=2:=8PQ38Z'RVD5\'@[>>*^*?^"='Q\_8;\+?"7Q%J'[4WPT
M^-7Q>^*7BC4;F:;4M/G_ -#LX&V[71Q?P227#OO=Y) >2 .A+?L5_P $$?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M<6^N>(M0N=5U9_#6F64EU<.9)94MO$4%M$68\L1'"@R22<9Y-?3G_!J(,?\
M!$KX:_\ 83UO_P!.=S5#X+?\$IO'GQ)_X-NK']EWQE!;>"_B)<>'KBV:*XN8
M[J"RO4U62^MA)) SJ8V*Q!BA8@,>"1BOC3_@G'\"_P#@J5^Q5\$+K]FOPG\,
M_ ?AWPO)?W/V/QQK5];7 \-QW+EIIX&ANCYH#,TB*8'<,QRI'"@&/_P9Z_\
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M(EBD=,JH*L22!S?@_6O^"L7[:WQL\&V^I^'? O[+_A+0KM9=9U2T@L[M=07
M$F^VEGNGN/EW%(P$0,06<$!@ >4_\'3G@;XU_M6_L]?LV_$S1_"_B;Q)\(QH
M46N>*='T196&GWUS';S"2X1 S*IA9XTF*,(CO!(+@-\X^#K_ /X)8_MKV?@_
MP_I%K\3/V1_'EC?VO_$]N;J>^M92DBEXWN6GF2-FY"W#I#Y;[6;*KL/[%?\
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MQGRH$=@9&Z#"@\LHZL 6M^T9X!C^.2?#-O&7AD?$.33SJJ^&_P"T8O[3-J"
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MU\&Z3:>*[/1%MR#"EG'J]LL*H>Z! H4CJ #7T[\.?^#3OQK\ ?B!KVF_#/\
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M,;LY.,$ _'7X*>*O$>C_ /!E%XPDT.6X\X7EW8SM&3NCL9?$,:W(_P!UHY)
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M!_P7?_:(U3QEX?TWQ(W@:;7-4TBWU"W2XM[>[?6%A$Y1@5+I&\@4D'!;<,$
MC]@O^"17_!&'X;_\$AOAMJ^G^%;S4/%/B[Q2T;:]XFU*-8[B]$>2D,4:Y$,*
MEF8)EB2Q+,V%"^>_\$M_^"%G_#MG]MSXN?&+_A9O_"8_\+2CO(_[)_L#[!_9
MOGWXO/\ 7?:)/,V[=GW%SUXZ4 ?=^D^!=#T+3C9V.CZ79V9N?MA@@M(XXC/N
M#^;M  W[@#NQG(!SD5>FTRWN;V&XDMX9+BU#"&5D!>(-C=M;J,X ..N*LT4
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 QXUDQN56VG(R,X/K08E9U;:NY<X..
M1FGT4 ?SM_\ !TQX'TWXG?\ !<S]F/PWK$*W6D>(=*T/3+Z$])8)M>N8Y%]>
M58BOK3_@[T^$_A?1_P#@D%HK6?A_1['_ (13Q?IEOHWV:SCA&F1-%<1M%"%
M"1LH *+@':O&0,>T?\%+/^"%/_#PW_@H-\(_CK_PL[_A$_\ A5J::G]B_P!@
M?;?[1^R:C)>Y\_[1'Y>[?L^XV,9YSBO8/^"P?_!-3_AZY^Q\_P *?^$Q_P"$
M&W:U::Q_:?\ 9?\ :/\ J!(/+\KS8OO;_O;N,=#F@#\O_P!N'Q1X@TO_ (,U
M_A2-+N+I;>_L="LM5=&.?L0O'(5C_<\Q(%QT(P.AQ7W)_P &ZWP9^'$O_!$3
MX6V>GZ)X?U#2_%VE7<WB=9;:.9-4NWN9H[E;H,,2;=OEX?.$15Z 5[=\#/\
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M_9O_  C$&G0_\)1_87F_:?LD_FY^R^>NW?TQYIQUYZ4 ><?\$+?V;O ^F_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
<% !1110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45622344940736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">20-F<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentRegistrationStatement', window );">Document Registration Statement</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentShellCompanyReport', window );">Document Shell Company Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38512<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ONCOLYTICS BIOTECH INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">A0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">804, 322 11th Avenue SW<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Calgary<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">AB<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">T2R 0C5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">no<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ONCY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="nump">80,020,131<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAccountingStandard', window );">Document Accounting Standard</a></td>
<td class="text">International Financial Reporting Standards<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001129928<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember', window );">Business Contact</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">804, 322 11th Avenue SW<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Calgary<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">AB<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">T2R 0C5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_ContactPersonnelName', window );">Contact Personnel Name</a></td>
<td class="text">Kirk Look<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">403<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">670-7377<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_ContactPersonnelEmailAddress', window );">Contact Personnel Email Address</a></td>
<td class="text">info@oncolytics.ca<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelEmailAddress">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Email address of contact personnel.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelEmailAddress</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of contact personnel</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAccountingStandard">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAccountingStandard</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:accountingStandardItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentRegistrationStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a registration statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentRegistrationStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentShellCompanyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentShellCompanyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45622344993824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_AuditorInformationAbstract', window );"><strong>Auditor Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">1263<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst & Young LLP<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Calgary, Canada<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_AuditorInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Auditor Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_AuditorInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45622344822976">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF FINANCIAL POSITION - CAD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssetsAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 15,942<span></span>
</td>
<td class="nump">$ 34,912<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentReceivables', window );">Other receivables</a></td>
<td class="nump">68<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentPrepayments', window );">Prepaid expenses</a></td>
<td class="nump">1,885<span></span>
</td>
<td class="nump">3,246<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentDerivativeFinancialAssets', window );">Warrant derivative (notes 9, 17)</a></td>
<td class="nump">980<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssets', window );">Total current assets</a></td>
<td class="nump">18,875<span></span>
</td>
<td class="nump">38,173<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment (note 6)</a></td>
<td class="nump">411<span></span>
</td>
<td class="nump">282<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets (note 8)</a></td>
<td class="nump">901<span></span>
</td>
<td class="nump">365<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Assets', window );">Total assets</a></td>
<td class="nump">20,187<span></span>
</td>
<td class="nump">38,820<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLiabilitiesAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayables', window );">Accounts payable and accrued liabilities (note 7)</a></td>
<td class="nump">4,792<span></span>
</td>
<td class="nump">3,572<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentLiabilities', window );">Other liabilities (note 5)</a></td>
<td class="nump">1,618<span></span>
</td>
<td class="nump">332<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLeaseLiabilities', window );">Lease liabilities (note 8)</a></td>
<td class="nump">277<span></span>
</td>
<td class="nump">133<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentDerivativeFinancialLiabilities', window );">Warrant derivative (notes 9, 17)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLiabilities', window );">Total current liabilities</a></td>
<td class="nump">6,687<span></span>
</td>
<td class="nump">4,237<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentContractLiabilities', window );">Contract liability (note 13)</a></td>
<td class="nump">6,730<span></span>
</td>
<td class="nump">6,730<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLeaseLiabilities', window );">Lease liabilities (note 8)</a></td>
<td class="nump">787<span></span>
</td>
<td class="nump">290<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Liabilities', window );">Total liabilities</a></td>
<td class="nump">14,204<span></span>
</td>
<td class="nump">11,257<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_CommitmentsAndContingencies1', window );">Commitments and contingencies (note 14)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAbstract', window );"><strong>Shareholders&#8217; equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssuedCapital', window );">Share capital (note 10) &#160;&#160;Authorized: unlimited &#160;&#160;Issued: December&#160;31, 2024 &#8211; 80,020,131 December&#160;31, 2023 &#8211; 74,423,960</a></td>
<td class="nump">438,193<span></span>
</td>
<td class="nump">430,906<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionalPaidinCapital', window );">Contributed surplus (note 11)</a></td>
<td class="nump">44,542<span></span>
</td>
<td class="nump">42,116<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AccumulatedOtherComprehensiveIncome', window );">Accumulated other comprehensive income</a></td>
<td class="nump">961<span></span>
</td>
<td class="nump">544<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RetainedEarnings', window );">Accumulated deficit</a></td>
<td class="num">(477,713)<span></span>
</td>
<td class="num">(446,003)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Total shareholders&#8217; equity</a></td>
<td class="nump">5,983<span></span>
</td>
<td class="nump">27,563<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAndLiabilities', window );">Total liabilities and shareholders' equity</a></td>
<td class="nump">$ 20,187<span></span>
</td>
<td class="nump">$ 38,820<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AccumulatedOtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of accumulated items of income and expense (including reclassification adjustments) that are not recognised in profit or loss as required or permitted by other IFRSs. [Refer: IFRSs [member]; Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AccumulatedOtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionalPaidinCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount received or receivable from the issuance of the entity's shares in excess of nominal value and amounts received from other transactions involving the entity's stock or stockholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionalPaidinCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B12_b_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentDerivativeFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current derivative financial assets. [Refer: Derivative financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentDerivativeFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentDerivativeFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current derivative financial liabilities. [Refer: Derivative financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentDerivativeFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B12_b_iii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 69<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentPrepayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current prepayments. [Refer: Prepayments]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentPrepayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssuedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value of capital issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssuedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current contract liabilities. [Refer: Contract liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2024-01-01<br> -Paragraph 105<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current other receivables. [Refer: Other receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period. Note that right-of-use assets are not included. [Contrast: Property, plant and equipment including right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetainedEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing the entity's cumulative undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph IG6<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_IG6&amp;doctype=Implementation%20Guidance<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetainedEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that represent a lessee's right to use an underlying asset for the lease term that do not meet the definition of investment property. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 53<br> -Subparagraph j<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_53_j&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph k<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_k&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_CommitmentsAndContingencies1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commitments And Contingencies1</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_CommitmentsAndContingencies1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45622342698224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF LOSS AND COMPREHENSIVE LOSS - CAD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseByNatureAbstract', window );"><strong>Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development (note 20)</a></td>
<td class="nump">$ 21,647<span></span>
</td>
<td class="nump">$ 17,709<span></span>
</td>
<td class="nump">$ 15,432<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative (note 20)</a></td>
<td class="nump">13,335<span></span>
</td>
<td class="nump">16,082<span></span>
</td>
<td class="nump">11,492<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossFromOperatingActivities', window );">Loss before the following</a></td>
<td class="num">(34,982)<span></span>
</td>
<td class="num">(33,791)<span></span>
</td>
<td class="num">(26,924)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives', window );">Change in fair value of warrant derivative (notes 9, 17)</a></td>
<td class="nump">1,242<span></span>
</td>
<td class="nump">5,285<span></span>
</td>
<td class="num">(20)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss', window );">Foreign exchange gain (loss)</a></td>
<td class="nump">961<span></span>
</td>
<td class="num">(475)<span></span>
</td>
<td class="nump">1,665<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestIncomeOnCashAndCashEquivalents', window );">Interest income, net</a></td>
<td class="nump">1,199<span></span>
</td>
<td class="nump">1,326<span></span>
</td>
<td class="nump">528<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossBeforeTax', window );">Loss before income taxes</a></td>
<td class="num">(31,580)<span></span>
</td>
<td class="num">(27,655)<span></span>
</td>
<td class="num">(24,751)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Income tax expense (note 15)</a></td>
<td class="num">(130)<span></span>
</td>
<td class="num">(97)<span></span>
</td>
<td class="num">(84)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net loss</a></td>
<td class="num">(31,710)<span></span>
</td>
<td class="num">(27,752)<span></span>
</td>
<td class="num">(24,835)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeAbstract', window );"><strong>Other comprehensive income (loss) items that may be reclassified to net loss</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation', window );">Translation adjustment</a></td>
<td class="nump">417<span></span>
</td>
<td class="num">(118)<span></span>
</td>
<td class="nump">274<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Comprehensive loss</a></td>
<td class="num">$ (31,293)<span></span>
</td>
<td class="num">$ (27,870)<span></span>
</td>
<td class="num">$ (24,561)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BasicEarningsLossPerShare', window );">Basic loss per common share (cad per share)</a></td>
<td class="num">$ (0.41)<span></span>
</td>
<td class="num">$ (0.41)<span></span>
</td>
<td class="num">$ (0.43)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DilutedEarningsLossPerShare', window );">Diluted loss per common share (cad per share)</a></td>
<td class="num">$ (0.41)<span></span>
</td>
<td class="num">$ (0.41)<span></span>
</td>
<td class="num">$ (0.43)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageShares', window );">Weighted average number of shares (basic) (shares)</a></td>
<td class="nump">76,482,914<span></span>
</td>
<td class="nump">67,624,036<span></span>
</td>
<td class="nump">58,029,745<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustedWeightedAverageShares', window );">Weighted average number of shares (diluted) (shares)</a></td>
<td class="nump">76,482,914<span></span>
</td>
<td class="nump">67,624,036<span></span>
</td>
<td class="nump">58,029,745<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustedWeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2024-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustedWeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2024-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2024-01-01<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ix<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B12_b_ix&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 81A<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81A_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutedEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2024-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2024-01-01<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutedEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseByNatureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseByNatureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) resulting from change in the fair value of derivatives recognised in profit or loss. [Refer: Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of exchange differences recognised in profit or loss that arise from foreign currency transactions, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: At fair value [member]; Classes of financial instruments [domain]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 21<br> -IssueDate 2024-01-01<br> -Paragraph 52<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=21&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_52_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 35<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to general and administrative activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2024-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 79<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B13<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 82<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestIncomeOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest income on cash and cash equivalents. [Refer: Interest income; Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestIncomeOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income, net of tax, after reclassification adjustments, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 91<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2024-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) before tax expense or income. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2024-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 32<br> -IssueDate 2024-01-01<br> -Paragraph IE33<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=32&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_IE33&amp;doctype=Illustrative%20Examples<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2024-01-01<br> -Paragraph 126<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_126&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2024-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45622345162784">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY - CAD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>At-the-market equity distribution agreement</div></th>
<th class="th"><div>Public offering</div></th>
<th class="th"><div>Share Capital</div></th>
<th class="th">
<div>Share Capital </div>
<div>At-the-market equity distribution agreement</div>
</th>
<th class="th">
<div>Share Capital </div>
<div>Public offering</div>
</th>
<th class="th"><div>Warrants</div></th>
<th class="th"><div>Contributed Surplus</div></th>
<th class="th">
<div>Contributed Surplus </div>
<div>Public offering</div>
</th>
<th class="th"><div>Accumulated Other Comprehensive Income</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity balance at beginning of period at Dec. 31, 2021</a></td>
<td class="nump">$ 36,099<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 391,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,618<span></span>
</td>
<td class="nump">$ 34,161<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 388<span></span>
</td>
<td class="num">$ (393,416)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Net loss and other comprehensive income (loss)</a></td>
<td class="num">(24,561)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">274<span></span>
</td>
<td class="num">(24,835)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions', window );">Issued pursuant to stock option plan (note 11)</a></td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity', window );">Issued pursuant to incentive share award plan (note 11)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(98)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_IncreaseDecreaseThroughExpirationOfWarrantEquity', window );">Expiry of equity warrant agreement</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,618)<span></span>
</td>
<td class="nump">3,618<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issue of equity</a></td>
<td class="nump">13,338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,338<span></span>
</td>
<td class="nump">$ 13,338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue costs (note 10)</a></td>
<td class="num">(764)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(764)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Share-based compensation expense (note 11)</a></td>
<td class="nump">2,378<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,378<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity balance at end of period at Dec. 31, 2022</a></td>
<td class="nump">26,502<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">404,040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">40,051<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">662<span></span>
</td>
<td class="num">(418,251)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Net loss and other comprehensive income (loss)</a></td>
<td class="num">(27,870)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(118)<span></span>
</td>
<td class="num">(27,752)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions', window );">Issued pursuant to stock option plan (note 11)</a></td>
<td class="nump">781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,271<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(490)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issue of equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,676<span></span>
</td>
<td class="nump">$ 18,362<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,676<span></span>
</td>
<td class="nump">$ 17,724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 638<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue costs (note 10)</a></td>
<td class="num">(2,805)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,805)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Share-based compensation expense (note 11)</a></td>
<td class="nump">1,917<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,917<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity balance at end of period at Dec. 31, 2023</a></td>
<td class="nump">27,563<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">430,906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">42,116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">544<span></span>
</td>
<td class="num">(446,003)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Net loss and other comprehensive income (loss)</a></td>
<td class="num">(31,293)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">417<span></span>
</td>
<td class="num">(31,710)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity', window );">Issued pursuant to incentive share award plan (note 11)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(297)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity', window );">Issued pursuant to warrant derivative exercised (notes 9, 10)</a></td>
<td class="nump">71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issue of equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue costs (note 10)</a></td>
<td class="num">(751)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(751)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Share-based compensation expense (note 11)</a></td>
<td class="nump">2,723<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,723<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity balance at end of period at Dec. 31, 2024</a></td>
<td class="nump">$ 5,983<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 438,193<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 44,542<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 961<span></span>
</td>
<td class="num">$ (477,713)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ix<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B12_b_ix&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 81A<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81A_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from the exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughExerciseOfOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssueOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase in equity through the issue of equity instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssueOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareIssueRelatedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cost related to the issuance of shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareIssueRelatedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_IncreaseDecreaseThroughExpirationOfWarrantEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) Through Expiration Of Warrant, Equity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_IncreaseDecreaseThroughExpirationOfWarrantEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) Through Incentive Share Awards, Equity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45622345129888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - CAD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract', window );"><strong>Operating Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net loss for the year</a></td>
<td class="num">$ (31,710)<span></span>
</td>
<td class="num">$ (27,752)<span></span>
</td>
<td class="num">$ (24,835)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense', window );">Depreciation - property and equipment (notes 6, 20)</a></td>
<td class="nump">120<span></span>
</td>
<td class="nump">81<span></span>
</td>
<td class="nump">93<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_AdjustmentsForDepreciationRightOfUseAssets', window );">Depreciation - right-of-use assets (notes 8, 20)</a></td>
<td class="nump">304<span></span>
</td>
<td class="nump">322<span></span>
</td>
<td class="nump">299<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForSharebasedPayments', window );">Share-based compensation expense (notes 11, 20, 22)</a></td>
<td class="nump">2,723<span></span>
</td>
<td class="nump">1,917<span></span>
</td>
<td class="nump">2,378<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Compensation warrant expenses (note 11)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">151<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestRevenueExpense', window );">Interest expense (income), net</a></td>
<td class="nump">139<span></span>
</td>
<td class="nump">71<span></span>
</td>
<td class="num">(76)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains', window );">Unrealized foreign exchange (gain) loss</a></td>
<td class="num">(838)<span></span>
</td>
<td class="nump">282<span></span>
</td>
<td class="num">(1,625)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives', window );">Change in fair value of warrant derivative (notes 9, 17)</a></td>
<td class="num">(1,242)<span></span>
</td>
<td class="num">(5,285)<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInWorkingCapital', window );">Net change in non-cash working capital (note 18)</a></td>
<td class="nump">3,538<span></span>
</td>
<td class="nump">1,765<span></span>
</td>
<td class="nump">391<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperations', window );">Cash used in operating activities</a></td>
<td class="num">(26,966)<span></span>
</td>
<td class="num">(28,448)<span></span>
</td>
<td class="num">(23,355)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract', window );"><strong>Investing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities', window );">Acquisition of marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(20,348)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities', window );">Maturities of marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">20,230<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities', window );">Acquisition of property and equipment (note 6)</a></td>
<td class="num">(239)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="num">(55)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivities', window );">Cash (used in) provided by investing activities</a></td>
<td class="num">(239)<span></span>
</td>
<td class="nump">20,222<span></span>
</td>
<td class="num">(20,403)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract', window );"><strong>Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromExerciseOfOptions', window );">Proceeds from exercise of stock options (note 11)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">781<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromExerciseOfWarrants', window );">Proceeds from exercise of warrant derivative (note 9)</a></td>
<td class="nump">65<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashOutflowForLeases', window );">Payment of lease liabilities (note 8)</a></td>
<td class="num">(348)<span></span>
</td>
<td class="num">(407)<span></span>
</td>
<td class="num">(381)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivities', window );">Cash provided by financing activities</a></td>
<td class="nump">6,636<span></span>
</td>
<td class="nump">31,994<span></span>
</td>
<td class="nump">12,205<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents', window );">(Decrease) increase in cash and cash equivalents</a></td>
<td class="num">(20,569)<span></span>
</td>
<td class="nump">23,768<span></span>
</td>
<td class="num">(31,553)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents, beginning of year</a></td>
<td class="nump">34,912<span></span>
</td>
<td class="nump">11,666<span></span>
</td>
<td class="nump">41,262<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents', window );">Impact of foreign exchange on cash and cash equivalents</a></td>
<td class="nump">1,599<span></span>
</td>
<td class="num">(522)<span></span>
</td>
<td class="nump">1,957<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents, end of year</a></td>
<td class="nump">15,942<span></span>
</td>
<td class="nump">34,912<span></span>
</td>
<td class="nump">11,666<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_SaleOfStockAxis=oncyf_SharesUnderAtthemarketAgreementMember', window );">At-the-market equity distribution agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract', window );"><strong>Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Proceeds from share issuance</a></td>
<td class="nump">6,919<span></span>
</td>
<td class="nump">10,261<span></span>
</td>
<td class="nump">12,574<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_SaleOfStockAxis=oncyf_SharesPublicOfferingMember', window );">Public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract', window );"><strong>Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Proceeds from share issuance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 21,359<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for depreciation and amortisation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Depreciation and amortisation expense; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for gains (losses) on changes in the fair value of derivatives to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: At fair value [member]; Derivatives [member]; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForSharebasedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForSharebasedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for unrealised foreign exchange losses (gains) to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Section A Statement of cash flows for an entity other than a financial institution<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;doctype=Illustrative%20Examples&amp;dita_xref=IAS07_IE_A_TI<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity, from continuing and discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents, from continuing and discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash from (used in) the entity's operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Section A Statement of cash flows for an entity other than a financial institution<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;doctype=Illustrative%20Examples&amp;dita_xref=IAS07_IE_A_TI<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashOutflowForLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 53<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_53_g&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashOutflowForLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense arising from equity-settled share-based payment transactions in which the goods or services received did not qualify for recognition as assets. [Refer: Expense from share-based payment transactions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 51<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_51_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in cash and cash equivalents after the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInWorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in working capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInWorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestRevenueExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income or expense arising from interest. [Refer: Interest expense; Interest income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestRevenueExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromExerciseOfOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromExerciseOfOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the exercise of share purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssuingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuing shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssuingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales or maturity of financial instruments, classified as investing activities. [Refer: Classes of financial instruments [domain]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 16<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_16&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2024-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchase of financial instruments. [Refer: Classes of financial instruments [domain]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 16<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_16&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 16<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_16_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_AdjustmentsForDepreciationRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments For Depreciation, Right-of Use Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_AdjustmentsForDepreciationRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SaleOfStockAxis=oncyf_SharesUnderAtthemarketAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SaleOfStockAxis=oncyf_SharesUnderAtthemarketAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SaleOfStockAxis=oncyf_SharesPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SaleOfStockAxis=oncyf_SharesPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45622345994800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Operations and Going Concern<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract', window );"><strong>Disclosure Of Notes And Other Explanatory Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory', window );">Nature of Operations and Going Concern</a></td>
<td class="text">Nature of Operations and Going Concern<div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Oncolytics Biotech Inc. was incorporated on April 2, 1998, under the Business Corporations Act (Alberta) as 779738 Alberta Ltd. On April 8, 1998, we changed our name to Oncolytics Biotech Inc. We are a limited company incorporated and domiciled in Canada. Our shares are publicly traded on the Nasdaq Capital Market and the Toronto Stock Exchange. Our principal place of business is located at 804, 322 11</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Avenue S.W., Calgary, Alberta, Canada.   </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage biopharmaceutical company developing pelareorep, a well-tolerated intravenously delivered</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. Our primary focus is to advance our programs in hormone receptor-positive / human epidermal growth factor 2-negative (HR+/HER2-) advanced and metastatic breast cancer and metastatic pancreatic ductal adenocarcinoma to registration-enabled clinical studies. In addition, we are exploring opportunities for registrational programs in other gastrointestinal cancers through our GOBLET platform study. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not been profitable since our inception and expect to continue to incur substantial losses as we continue our research and development efforts. As at December&#160;31, 2024, we had an accumulated deficit of $477,713. We do not expect to generate significant revenues until and unless pelareorep becomes commercially viable. To date, we have funded our operations mainly through issuing additional capital via public offerings, equity distribution arrangements, and the exercise of warrants and stock options. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Going concern</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management assesses our ability to continue as a going concern when preparing our consolidated financial statements. In assessing whether the going concern assumption is appropriate, management takes into account all available information about the future, which is at least, but not limited to, twelve months from the end of the reporting period. As at December&#160;31, 2024, we had cash and cash equivalents of $15,942. Subsequent to December&#160;31, 2024, we further raised net proceeds of $6,041 (see note 23). Without raising additional funding or reducing or eliminating our planned expenditures, we estimated our cash and cash equivalents to fund our operations into the third quarter of 2025. Factors that will affect our anticipated cash needs for the next twelve months include, but are not limited to, expansion of our clinical trial program, the timing of patient enrollment in our clinical trials, the actual costs incurred to support each clinical trial, the number of treatments each patient will receive, the timing of activity with our clinical trial research collaborations, the number, timing and costs of manufacturing runs required to conclude the validation process and supply product to our clinical trial program, and the level of collaborative activity undertaken. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to continue as a going concern is dependent upon raising additional financing through equity or strategic collaborations and transactions. We plan on raising additional funds through the sale of our common shares or other capital resources, such as collaborations and debt, to fund our ongoing operations. However, given the difficulty for micro-cap market capitalization companies to raise significant capital and the matter in note 23(b), there can be no assurance that additional liquidity will be available under acceptable terms or at all. Furthermore, if we are unable to obtain additional financing when required, there can be no assurance that we will be able to sufficiently reduce or eliminate our planned expenditures to extend our operating runway. These material uncertainties raise substantial doubt on our ability to continue as a going concern and meet our obligations as they come due and, accordingly, the appropriateness of the use of accounting principles applicable to a going concern.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These consolidated financial statements were prepared in accordance with International Financial Reporting Standards ("IFRS") applicable to a going concern. However, the use of the going concern assumption on which these consolidated financial statements are prepared may not be appropriate based on the factors described above.</span></div>These consolidated financial statements do not reflect the adjustments to the carrying values of assets and liabilities and the reported expenses and statements of financial position classifications that would be necessary if we were unable to realize our assets and settle our liabilities as a going concern in the normal course of operations. Such adjustments could be material.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for general information about financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 51<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_51&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Notes And Other Explanatory Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45622345745824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract', window );"><strong>Corporate information and statement of IFRS compliance [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory', window );">Basis of Presentation</a></td>
<td class="text">Basis of Presentation<div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Statement of compliance</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These consolidated financial statements have been prepared in accordance with IFRS as issued by the International Accounting Standards Board ("IASB"). </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated financial statements for the year ended December&#160;31, 2024, were authorized for issue in accordance with a resolution of the Board of Directors (the "Board") on March&#160;6, 2025. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of presentation</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated financial statements include our financial statements and the financial statements of our subsidiaries, Oncolytics Biotech (Barbados) Inc. and Oncolytics Biotech (U.S.) Inc., and are presented in Canadian dollars, our functional currency. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsidiaries are entities over which we have control which is achieved when we are exposed, or have the rights, to variable returns from our involvement with the investee and have the ability to affect those returns through our power to govern. The accounting policies of our subsidiaries are consistent with our accounting policies, and all intercompany transactions, balances, income, and expenses are eliminated on consolidation. </span></div>Our accounts are prepared on the historical cost basis, except for certain assets and liabilities, which are measured at fair value as explained in the notes to these financial statements.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the basis used for the preparation of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45622344877264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Material Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_SummaryOfSignificantAccountingPoliciesAbstract', window );"><strong>Summary Of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory', window );">Summary of Material Accounting Policies</a></td>
<td class="text">Summary of Material Accounting Policies<div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements have, in management's opinion, been properly prepared within reasonable limits of materiality and within the framework of the material accounting policies summarized below.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and cash equivalents </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents include interest-bearing deposits with our bank totaling $12,312 as at December&#160;31, 2024 (December&#160;31, 2023 - $31,534). </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Deferred income taxes</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We follow the liability method of accounting for income taxes. Under the liability method, deferred income taxes are recognized for the difference between the financial statement carrying values and the respective income tax basis of assets and liabilities (temporary differences). Deferred income tax assets and liabilities are measured using substantively enacted income tax rates and laws expected to apply in the years in which temporary differences are expected to be recovered or settled. The effect on deferred income tax assets and liabilities of a change in tax rates is charged or credited to income, except when it is related to items charged or credited to either other comprehensive income or directly to equity.  </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial instruments </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Classification and measurement</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial assets</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets are initially measured at fair value. In the case of a financial asset not at fair value through profit or loss, the financial asset is initially measured at fair value plus or minus transaction costs. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets are subsequently measured at amortised cost, fair value through profit or loss (FVPL), or fair value through other comprehensive income (FVOCI). The classification is based on two criteria: the Company&#8217;s business model for managing the assets; and whether the financial asset&#8217;s contractual cash flows represent 'solely payments of principal and interest' on the principal amount outstanding (the 'SPPI criterion'). </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The classification and measurement of our cash and cash equivalents and other receivables are financial assets at amortized cost, as these assets are held within our business model with the objective to hold the financial assets in order to collect contractual cash flows that meet the SPPI criterion. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial liabilities</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial liabilities are initially measured at fair value and are subsequently measured at amortised cost or FVPL. The classification and measurement of our accounts payable and accrued liabilities and other liabilities are financial liabilities at amortized cost. The classification and measurement of the warrant derivative is financial liabilities at FVPL.  </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounting for impairment losses for financial assets uses a forward-looking expected credit loss (ECL) approach. We are required to record a loss allowance for ECLs on all financial assets not held at FVPL. ECLs are based on the difference between the contractual cash flows due in accordance with the contract and all the cash flows that the Company expects to receive. The shortfall is then discounted at an approximation to the asset&#8217;s original effective interest rate.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derecognition</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A financial asset is derecognized when the contractual rights to the cash flows from the financial asset expire, or we transfer the financial asset and substantially all the risks and rewards of ownership of the financial asset to another entity. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A financial liability is derecognized when our obligations specified in the contract are discharged or canceled, or expired. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurement</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is the price that would be received to sell an asset, or paid to transfer a liability in an orderly transaction between market participants, at the measurement date. In determining the fair value measurement of our financial instruments, we prioritize the related inputs used in measuring fair value into the following hierarchy: </span></div><div style="margin-top:10pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities;</span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 - Inputs other than quoted prices included within Level 1 that are either directly or indirectly observable;</span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 - Unobservable inputs in which little or no market activity exists, therefore requiring an entity to develop its own assumptions about the assumptions that market participants would use in pricing.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign currency translation</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial statements for each of our subsidiaries are prepared using their functional currency. Our functional and presentation currency is the Canadian dollar. Foreign currency transactions are translated into the functional currency using exchange rates prevailing at the dates of the transactions. Exchange differences resulting from the settlement of such transactions and from the translation at exchange rates ruling at the statement of financial position date of monetary assets and liabilities denominated in currencies other than the functional currency are recognized directly in the consolidated statement of loss and comprehensive loss.  </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exceptions to this are where the monetary items form part of the net investment in a foreign operation, and the foreign operation's functional currency is the local currency. These exchange differences are initially recognized in equity. The statement of financial position of foreign operations is translated into Canadian dollars using the exchange rate at the statement of financial position date and the income statements are translated into Canadian dollars using the average exchange rate for the period. Where this average is not a reasonable approximation of the cumulative effect of the rates prevailing on the transaction dates, the exchange rate on the transaction date is used. Exchange differences on translation into Canadian dollars are recognized as a separate component of equity. On disposal of a foreign operation, any cumulative exchange differences held in equity are transferred to the consolidated statement of loss and comprehensive loss.  </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of a contract, we assess whether a contract is, or contains, a lease by determining whether the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. To assess whether a contract conveys the right to control the use of an identified asset, we assess whether:</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the contract involves the use of an identified asset;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we have the right to obtain substantially all of the economic benefits from the use of the identified asset throughout the period of use; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we have the right to direct the use of the identified asset. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A right-of-use asset and corresponding lease liability are recognized on the lease commencement date. The right-of-use asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, plus any initial direct costs incurred and an estimate of costs to dismantle and remove the underlying asset or to restore the underlying asset or the site on which it is located, less any lease incentives received. The right-of-use asset is subsequently depreciated using the straight-line method from the commencement date to the end of the lease term. In addition, the right-of-use asset is reduced by impairment losses and adjusted for certain remeasurements of the lease liabilities, if any. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date. The lease payments are discounted using the implicit interest rate in the lease. If the rate cannot be readily determined, our incremental rate of borrowing is used. The lease liability is subsequently measured at amortized cost using the effective interest method. The lease liability is remeasured when there is a change in future lease payments arising from a change in an index or rate, if there is a change in our estimate of the amount expected to be payable under a residual value guarantee, if we change our assessment of whether we will exercise a purchase, extension or termination option, or if the underlying lease contract is amended.  </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have elected not to separate fixed non-lease components from lease components and instead account for each lease component and associated fixed non-lease components as a single lease component.  </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have elected not to recognize right-of-use assets and lease liabilities for short-term leases that have a lease term of 12 months or less. We recognize the lease payments associated with these leases as an expense on a straight-line basis over the lease term. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Loss per share</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic loss per share is calculated by dividing the loss attributable to common shareholders by the weighted average number of common shares outstanding during the year. Diluted loss per share is computed in a manner consistent with basic loss per share except that the weighted average common shares outstanding are adjusted to include the effects of all dilutive potential common shares, which comprise stock options, share awards, and warrants. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property and equipment </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are recorded at cost. Depreciation is provided on bases and at rates designed to amortize the cost of the assets over their estimated useful lives. Depreciation is recorded using the declining balance method at the following annual rates:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.192%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.608%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment and furniture</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Straight-line over the term of the lease</span></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and development costs</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred, net of recoveries. We record accruals for the estimated costs of our research and development activities performed by third parties. Advance payments for goods or services that will be used or rendered for future research and development activities are capitalized as prepaid expenses and recognized as an expense as the related goods are delivered or the related services are performed. Development costs that meet specific criteria related to technical, market, and financial feasibility will be capitalized. To date, all development costs have been expensed. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue recognition</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue relates to a long-term contract associated with a regional licensing agreement (the "Licensing Agreement") with Adlai Nortye Biopharma Co., Ltd. ("Adlai"). The pricing for the contract was based on the specific negotiations with Adlai and included non-refundable upfront license fees, development and regulatory milestone payments, royalties, and sales-based milestone payments. We account for a contract with a customer when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance, and the collectability of consideration is probable.</span></div><div style="margin-bottom:8pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Licensing Agreement, we have granted a regional license to our intellectual property. The granting of this license is accounted for as one performance obligation. We have determined that we provide Adlai with a right to access our intellectual property and, therefore, recognize revenue related to the upfront license fee over time. Revenue is recognized based on the extent of progress toward completion of the performance obligation using the input method. Under the input method, the extent of progress toward completion is measured based on the ratio of costs incurred to date to the total estimated costs at completion of the performance obligation. We use this method because Adlai receives and consumes the benefit of our intellectual property as we undertake activities that impact the intellectual property. Management must use judgment in making assumptions and estimates regarding total estimated costs, the complexity of the work to be performed, and the length of time to complete the performance obligation, among other variables.</span></div><div style="margin-bottom:8pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contract also provides for development and regulatory milestone payments, royalties, and sales-based milestone payments. These amounts are contingent on the occurrence of a future event and, therefore, give rise to variable consideration. We estimate variable consideration at the most likely amount to which we expect to be entitled. We include estimated amounts in the transaction price when it becomes highly probable that the amount will not be subject to significant reversal when the uncertainty associated with the variable consideration is resolved. Our estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of our anticipated performance and all information (historical, current, and forecasted) that is reasonably available to us. Based on this information and related analysis, any quarterly adjustments to revenue are recognized as necessary in the period they become known.</span></div><div style="margin-bottom:8pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The upfront license fee is not considered a significant financing component because it is used to meet working capital demands that can be higher in the early stages of a contract and to protect us from the other party failing to adequately complete some or all of its obligations under the contract. </span></div><div style="margin-bottom:8pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from sales-based royalties and the achievement of annual sales volumes will be recognized when the subsequent sale occurs, as the license of the intellectual property is the predominant item to which the royalty relates. We consider payments associated with the achievement of annual sales volumes to be, in substance, royalty payments, and we will recognize such sales-based payments upon achievement of such sales volumes, provided that collection is reasonably assured.</span></div><div style="margin-bottom:8pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contract liability</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Our contract liability includes upfront license fees and billings in excess of the revenue recognized. Contract liabilities are recognized as revenue as or when we perform under the contract. We classify our contract liability as current or non-current based on the timing of when we expect to recognize revenue.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Share-based compensation </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock option plan</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have one stock option plan (the "Stock Option Plan") available to directors, officers, employees, and consultants with grants under the Stock Option Plan approved from time to time by our Board of Directors (the "Board"). Under the Stock Option Plan, no option shall be granted with an exercise price at a discount to the closing price of our stock on the Toronto Stock Exchange </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on the last trading date prior to the date of the grant. Vesting is provided at the discretion of the Board, and the expiration of options is to be no greater than ten years from the date of grant. Exercised stock options are settled with common shares issued from treasury. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the fair value-based method of accounting for stock option awards granted under the Stock Option Plan. We recognize compensation expense and a corresponding adjustment to contributed surplus equal to the fair value of the stock options granted using the Black-Scholes valuation model over the vesting periods of the respective options. Compensation expense is adjusted for subsequent changes in management&#8217;s estimate of the number of options that are expected to vest.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options awarded to non-employees are accounted for at the fair value of the goods received or the services rendered. The fair value is measured at the date the Company obtains the goods or the date the counterparty renders the service. If the fair value of the goods or services cannot be reliably measured, the fair value of the options granted will be used.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share award plan</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our share award plan (the "Share Award Plan") is available to directors, officers, employees, and consultants. Under our Share Award Plan, performance and restricted share awards may be approved from time to time by the Board. Performance share awards  ("PSAs") can be awarded to certain officers and employees to which common shares shall be issued based upon achieving the applicable performance criteria. Restricted share awards ("RSAs") can be awarded to certain officers, employees, non-employee directors, and consultants to which common shares shall be issued in accordance with the Share Award Plan.  </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize compensation expense and a corresponding adjustment to contributed surplus equal to the market value of our common shares at the grant date based on the number of PSAs/RSAs expected to vest, recognized over the vesting period. Compensation expense is adjusted for subsequent changes in management&#8217;s estimate of the number of PSAs/RSAs that are expected to vest. The effect of these changes is recognized in the period of the change. </span></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adoption of New Accounting Standards</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IAS 1 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Classification of Liabilities as Current or Non-Current</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2022, the IASB issued amendments to clarify how conditions with which an entity must comply within 12 months after the reporting period affect the classification of a liability. This is in addition to the amendment from January 2020 where the IASB issued amendments to IAS 1 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Presentation of Financial Statements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to provide a more general approach to the presentation of liabilities as current or non-current based on contractual arrangements in place at the reporting date. These amendments specify that the rights and conditions existing at the end of the reporting period are relevant in determining whether the Company has a right to defer settlement of a liability by at least 12 months, provided that management's expectations are not a relevant consideration as to whether the Company will exercise its rights to defer settlement of a liability and clarify when a liability is considered settled. The amendments became effective on January 1, 2024. Adopting the amendments did not have a material impact on our consolidated financial statements.   </span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounting Standards and Interpretations Issued but Not Yet Effective</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IFRS 18 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Presentation and Disclosure in Financial Statements</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2024, the IASB issued IFRS 18 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Presentation and Disclosure in Financial Statements </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which replaces IAS 1 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Presentation of Financial Statements. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IFRS 18 introduces new requirements on presentation within the statement of profit or loss, including specified totals and subtotals. It also requires disclosure of management-defined performance measures and includes new requirements for aggregation and disaggregation of financial information based on the identified roles of the primary financial statements and the notes. Narrow scope amendments have been made to IAS 7 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Statement of Cash Flows</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and some requirements previously included within IAS 1 have been moved to IAS 8 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting Policies, Changes in Accounting Estimates and Errors, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which has also been renamed IAS 8 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Preparation of Financial Statements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. IAS 34 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interim Financial Reporting </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">has also been amended to require disclosure of management-defined performance measures. IFRS 18 and the amendments to the other standards are effective for annual periods beginning on or after January 1, 2027, with early application permitted. IFRS 18 applies retrospectively to both annual and interim financial statements. We are assessing the impact of adopting this standard on our consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of material accounting policy information applied by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SummaryOfSignificantAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary Of Significant Accounting Policies [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SummaryOfSignificantAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45622348975456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Judgments, Estimates and Assumptions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_SignificantJudgmentsEstimatesAndAssumptionsAbstract', window );"><strong>Significant Judgments, Estimates And Assumptions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory', window );">Significant Judgments, Estimates and Assumptions</a></td>
<td class="text">Significant Judgments, Estimates, and Assumptions<div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The preparation of our consolidated financial statements in conformity with IFRS requires us to make judgments, estimates, and assumptions that affect the application of accounting policies, the reported amount, and disclosures in our consolidated financial statements and accompanying notes. Management makes estimates based on our best knowledge of current events and actions that the Company may undertake in the future. We consider the potential impact of certain external factors outside of our control, including global political conflicts, supply chain disruptions, inflation, fluctuating interest rates, and liquidity, when making certain estimates and judgments relating to the preparation of these consolidated financial statements. Estimates and underlying assumptions are reviewed on an ongoing basis. Actual results could differ from these estimates, and such differences could be material. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant estimates made by management affecting our consolidated financial statements include:</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue recognition</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We entered into a Licensing Agreement which provides, among other payments, upfront license fees in exchange for a regional license to our intellectual property. Management uses its judgment in applying the input method when determining the extent of progress toward completion of the performance obligation. Revenue recognition requires assumptions and estimates regarding total estimated costs, the complexity of the work to be performed, and the length of time to complete the performance obligation, among other variables.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clinical trial and manufacturing expenses</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trial and manufacturing expenses represent significant components of our research and development expenses, and we outsource a significant portion of these activities to third-party contract research/manufacturing organizations. The financial terms of these agreements are subject to negotiation, vary from contract to contract, and may result in uneven payment flows to these organizations. Payments under the contracts depend on factors such as achieving certain milestones. As part of preparing the consolidated financial statements, we estimate the expense to recognize based on services that the contract research/manufacturing organizations have performed. When making these estimates, we use operational and contractual information from third-party service providers, operational data from internal personnel, and considerable judgment. We base our estimates on the best information available at the time. However, additional information may become available to us which may allow us to make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain. Such increases or decreases in cost are generally considered to be changes in estimates and will be reflected in research and development expenses in the period identified.   </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Valuation of share-based compensation </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimating the fair value of share-based compensation requires determining the most appropriate valuation model, which is dependent on the terms and conditions of the grant. This estimate also requires determining the most appropriate inputs to the valuation model, including the expected life, volatility, and dividend yield, and making assumptions about them. The assumptions and inputs used for estimating fair value of share-based compensation are disclosed in note 11. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Valuation of warrant derivative </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimating the fair value of the warrant derivative at initial measurement, at each exercise date and at each reporting period requires determining the most appropriate valuation model. This estimate also requires determining the most appropriate inputs to the valuation model, including the expected life, volatility, and dividend yield, and making assumptions about them. The assumptions and inputs used for estimating fair value for warrant derivative issued are disclosed in note 9.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income taxes</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Uncertainties exist with respect to the interpretation of complex tax regulations and the amount and timing of future taxable income. Currently, we are accumulating tax loss carry-forward balances in various tax jurisdictions creating a deferred tax asset. Deferred tax assets are recognized for all unused tax losses to the extent that it is probable that taxable profit will be available against which the losses can be utilized. Management's judgment is required to determine the amount of deferred tax assets that can be recognized based on the likely timing and the level of future taxable profits together with future tax planning strategies.  </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have determined that none of our deferred tax assets should be recognized. Our deferred tax assets are mainly comprised of our net operating losses from prior years, prior year research and development expenses, and non-refundable </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">investment tax credits. These tax pools relate to entities that have a history of losses, have varying expiry dates, and may not be used to offset taxable income within our other subsidiaries. There are also no taxable temporary differences or any tax planning opportunities available that could partly support the recognition of these losses as deferred tax assets.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Functional currency</span></div>We assess the relevant factors related to the primary economic environment in which our entities operate to determine the functional currency. Where the assessment of primary indicators are mixed, we assess the secondary indicators, including the relationship between the foreign operations and reporting entity.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of judgements that management has made in the process of applying the entity's accounting policies that have the most significant effect on amounts recognised in the financial statements along with information about the assumptions that the entity makes about the future, and other major sources of estimation uncertainty at the end of the reporting period, that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next year. [Refer: Carrying amount [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SignificantJudgmentsEstimatesAndAssumptionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Significant Judgments, Estimates And Assumptions [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SignificantJudgmentsEstimatesAndAssumptionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45622346012928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract', window );"><strong>Subclassifications of assets, liabilities and equities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherLiabilitiesExplanatory', window );">Other Liabilities</a></td>
<td class="text">Other Liabilities In 2023, we were selected by the Pancreatic Cancer Action Network (PanCAN) as the recipient of its Therapeutic Accelerator Award to conduct a clinical trial with pelareorep in combination with modified FOLFIRINOX chemotherapy with or without an immune checkpoint inhibitor in pancreatic cancer patients. Under the terms of the award agreement, we are entitled to receive up to US$5&#160;million in funding for eligible research expenses, and we must comply with the conditions set out with the award agreement, including providing periodic performance progress reports. As at December&#160;31, 2024, we recorded US$1,125 ($1,618) (December&#160;31, 2023 - US$225 ($298)) in other liabilities representing unapplied funding received from PanCAN.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOtherLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of other liabilities. [Refer: Other liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOtherLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45622345416896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract', window );"><strong>Disclosure of detailed information about property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory', window );">Property and Equipment</a></td>
<td class="text">Property and Equipment<div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.328%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.042%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.371%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.042%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.371%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.471%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.371%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.471%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.371%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.762%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Medical Equipment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Computer Equipment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Office Equipment and Furniture</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Leasehold Improvements</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2022</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">429&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">970&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions, net of foreign exchange impact</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2023</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">436&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">977&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disposals, net of foreign exchange impact</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(173)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at December 31, 2024</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">464&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">392&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,043&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2022</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">614&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2023</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">351&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">695&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disposals, net of foreign exchange impact</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(165)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at December 31, 2024</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">632&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net book value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2023</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at December 31, 2024</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">119</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">250</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">41</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">411</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>For the year ended December&#160;31, 2024, we incurred losses on disposal of property and equipment of $18, which was included in depreciation expense on our consolidated statement of cash flows.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;doctype=Standard&amp;dita_xref=IAS16_g73-79_TI<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45622342419824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable and Accrued Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract', window );"><strong>Subclassifications of assets, liabilities and equities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory', window );">Accounts Payable and Accrued Liabilities</a></td>
<td class="text">Accounts payable and accrued liabilities<div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.861%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade payables</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,087</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,082&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,705</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,490&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,792</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,572&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of trade and other payables. [Refer: Trade and other payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45622345656480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PresentationOfLeasesForLesseeAbstract', window );"><strong>Presentation of leases for lessee [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfLeasesExplanatory', window );">Leases</a></td>
<td class="text">Leases<div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have office space leases with initial lease terms generally between 3 to 6 years. We currently do not have leases with residual value guarantees or leases not yet commenced to which we have committed. We have variable lease payments related to office space lease operating costs that are not material. Lease liabilities have been measured by discounting future lease payments using our incremental borrowing rate as rates implicit in the leases were not readily determinable. The weighted-average rate applied was 15%. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2024, we recorded an addition of $794 to the right-of-use asset and $785 to the lease liabilities relating to one of our subsidiaries' office leases. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our right-of-use assets activity for the years ended December&#160;31:      </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">         </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.274%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at beginning of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">365</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">794</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">392&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(304)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(322)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange impact</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">46</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at end of year</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">901</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our lease liabilities activity for the years ended December&#160;31:    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">              </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.274%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at beginning of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">423</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">785</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">392&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment of lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(348)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(407)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense on lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">139</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange impact</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">65</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at end of year</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,064</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">423&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our total undiscounted lease liabilities as at December&#160;31, 2024 was as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:81.252%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.548%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than one year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">418&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">One to five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">995&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">More than five years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total undiscounted lease liabilities </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,413&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfLeasesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Section Presentation<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;doctype=Standard&amp;dita_xref=IFRS16_g47-50_TI<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;doctype=Standard&amp;dita_xref=IFRS16_g51-60_TI<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfLeasesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PresentationOfLeasesForLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PresentationOfLeasesForLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45622346021888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrant Derivative<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract', window );"><strong>Disclosure of Share Capital, Reserves And Other Equity Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory', window );">Warrant Derivative</a></td>
<td class="text">Warrant Derivative<div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common share purchase warrants ("warrants") with a U.S. dollar exercise price, which differs from our functional currency, are treated as a derivative measured at fair value, and revalued each period end at fair value through profit and loss. There is no cash flow impact as a result of the accounting treatment for changes in the fair value of the warrant derivative or when warrants expire unexercised. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the value of our warrant derivative were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:64.098%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.080%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.935%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Warrants Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value of Warrant Derivative</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,035&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to public offering</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,667,050&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,360&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount on warrants issued</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,822)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of discount on warrants issued</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,431)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange impact</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(132)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,731,085&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52,456)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,579)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of discount on warrants issued</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,605)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange impact</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at December 31, 2024</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,667,050</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(980)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our outstanding warrant derivative as at December&#160;31, 2024:</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.291%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.291%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.542%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercise price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Issuance date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expiry date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Warrants Outstanding</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US$2.81</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 8, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 8, 2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,667,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US$2.81</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 7, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 8, 2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000,050&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,667,050&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 8, 2023, pursuant to an underwritten public offering, we issued 6,667,000 units for gross proceeds of $20,185 (US$15,001) at a price of US$2.25 per unit. On September 7, 2023, pursuant to the over-allotment option exercised by the underwriter, we issued an additional 1,000,050 units for gross proceeds of $3,077 (US$2,250) at a price of US$2.25 per unit. Each unit consisted of one common share and one warrant, which were immediately separable and issued separately in this offering. Each warrant entitles the holder to purchase one common share at an exercise price of US$2.81 up to 60 months from the date of issuance. The expiry of the warrants may be accelerated by the Company at any time prior to the expiry date if the volume weighted average price (if applicable, as converted to U.S. dollars at the Bank of Canada posted rate for the respective trading day) of the issued and outstanding common shares on the Toronto Stock Exchange or such other principal stock exchange on which the common shares are listed and posted for trading is greater than US$6.50 for any 20 consecutive trading days, at which time the Company may, within 10 business days, accelerate the expiry date by issuing a press release announcing the reduced warrant term whereupon the warrants will expire on or after the 75th calendar day after the date of such press release.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proceeds were allocated amongst common shares and warrants by applying a relative fair value approach, which resulted in $17,724 recorded in share capital and an initial warrant derivative liability of $7,360. The difference between the fair value of the warrants and their allocated proceeds was a discount of $1,822, which is amortized on a straight-line basis over the five-year </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expected life of the warrants and recorded under change in fair value of warrant derivative on our consolidated statement of loss and comprehensive loss.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2024, as the unamortized discount balance was greater than the fair value of the warrant derivative liability, the net balance was presented as an asset on our consolidated statement of financial position. </span></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the Black-Scholes valuation model to estimate fair value. The expected volatility is based on the Company's common share historical volatility less an estimated market participant risk adjustment. The risk-free interest rate is based on the Government of Canada benchmark bond yield rates with an approximate equivalent remaining term in effect at the time of valuation, and the expected life represents the estimated length of time the warrants are expected to remain outstanding. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of the warrant derivative with an exercise price of US$2.81 was determined using the following assumptions: </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.104%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.007%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Underlying share price</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">US$0.92</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US$1.35</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.9%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.6 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">36.5%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.5%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value per warrant</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">US$0.03</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US$0.18</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of financial liabilities. [Refer: Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of Share Capital, Reserves And Other Equity Interest [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45622345480320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract', window );"><strong>Disclosure of Share Capital, Reserves And Other Equity Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory', window );">Share Capital</a></td>
<td class="text">Share Capital<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Authorized:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unlimited number of no par value common shares</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.104%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.007%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,043,789&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">391,348&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to stock option plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,333&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to incentive share award plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,560&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to "At the Market" (ATM) equity distribution agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)(b)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,235,232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,338&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share issue costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(764)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2022</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,327,914&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">404,040&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to stock option plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450,391&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,271&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to "At the Market" (ATM) equity distribution agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,978,605&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,676&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to public offering</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,667,050&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,724&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share issue costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,805)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,423,960&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">430,906&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to incentive share award plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133,572&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to "At the Market" (ATM) equity distribution agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)(d)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,410,143&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,670&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to warrant derivative exercised</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(e)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,456&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share issue costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(751)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at December 31, 2024</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">80,020,131</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">438,193</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">On March 5, 2021, we entered into an ATM equity distribution agreement with Canaccord Genuity Inc. The ATM allowed us to issue common shares, at prevailing market prices, with an aggregate offering value of up to US$80,000 over a 16-month period through the facilities of the Nasdaq Capital Market in the United States. This sales agreement was terminated on June 16, 2022. During the year ended December&#160;31, 2022, we sold 2,719,770 common shares for gross proceeds of </span></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$5,744 (US$4,560) at an average price of $2.11 (US$1.68). We received proceeds of $5,572 (US$4,423) after commissions of $172 (US$137). In total, we incurred share issue costs (including commissions) of $209. </span></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">On June 17, 2022, we entered into an ATM equity distribution agreement with Canaccord Genuity Inc. The ATM allowed us to issue common shares, at prevailing market prices, with an aggregate offering value of up to US$65,000 over a 25-month period through the facilities of the Nasdaq Capital Market in the United States. This sales agreement was terminated on July 17, 2024. During the year ended December&#160;31, 2024, we sold 2,560,933 (2023 - 4,978,605; 2022 - 3,515,462) common shares for gross proceeds of $4,016 (US$2,964) (2023 - $10,676 (US$7,904); 2022 - $7,594 (US$5,632)) at an average price of $1.57 (US$1.16) (2023 - $2.14 (US$1.59); 2022 - $2.16 (US$1.60)). We received proceeds of $3,895 (US$2,875) (2023 - $10,356 (US$7,667); 2022 - $7,366 (US$5,463)) after commissions of $121 (US$89) (2023 - $320 (US$237); 2022 - $228 (US$169)). In total, we incurred share issue costs (including commissions) of $187 (2023 - $415; 2022 - $555).</span></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">On August 8, 2023, pursuant to an underwritten public offering, we issued 6,667,000 units for gross proceeds of $20,185 (US$15,001) at a price of US$2.25 per unit. On September 7, 2023, pursuant to the over-allotment option exercised by the underwriter, we issued an additional 1,000,050 units for gross proceeds of $3,077 (US$2,250) at a price of US$2.25 per unit. Each unit consisted of one common share and one warrant, which were immediately separable and issued separately in this offering. These warrants were classified as a financial liability (see note 9). Proceeds were allocated amongst common shares and warrants by applying a relative fair value approach, which resulted in $17,724 recorded in share capital and an initial warrant derivative liability of $7,360. In consideration of the services rendered by the underwriter, we issued 536,693 compensation warrants (see note 11). In total, we incurred transaction costs of $3,130 (including a fair value of $638 (US$473) for the compensation warrants), of which $2,390 were allocated to share issue costs and $740 were allocated to operating expenses, based on the relative fair values of the common share and warrant of each unit.</span></div><div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">On August 2, 2024, we entered into an ATM equity distribution agreement with Cantor Fitzgerald &amp; Co. The ATM allows us to issue common shares, at prevailing market prices, with an aggregate offering value of up to US$50,000 over a 25-month period through the facilities of the Nasdaq Capital Market in the United States. During the year ended December&#160;31, 2024, we sold 2,849,210 common shares for gross proceeds of $3,654 (US$2,562) at an average price of $1.28 (US$0.90). We received proceeds of $3,544 (US$2,485) after commissions of $110 (US$77). In total, we incurred share issue costs (including commissions) of $564. </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(e)</span>On August 16, 2019, pursuant to an underwritten public offering, we issued units consisting of common shares and warrants. During the year ended December&#160;31, 2024, 52,456 warrants with a fair value of $6 were exercised for gross proceeds of $65 (US$47). During the years ended December&#160;31, 2023 and 2022, no warrants were exercised.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share capital, reserves and other equity interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 79<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of Share Capital, Reserves And Other Equity Interest [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45622345466672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract', window );"><strong>Disclosure of Share-based Payment Arrangements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory', window );">Share-Based Compensation</a></td>
<td class="text">Share-Based Compensation<div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock options and share awards</span></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Our amended and restated Stock Option Plan and Share Award Plan (collectively, the "Equity Incentive Plans") were approved by our shareholders at the annual general meeting of shareholders on May 9, 2023. Pursuant to our Equity Incentive Plans, we may grant stock options, restricted share awards, and performance share awards. The number of common shares reserved for issuance under our Equity Incentive Plans in aggregate shall not exceed 14% of the total number of issued and outstanding common shares from time to time. As at December&#160;31, 2024, we reserved 11,202,818 common shares for issuance relating to our Equity Incentive Plans. Our share-based compensation expense for the year ended December&#160;31, 2024, was $2,723 (2023 - $1,917; 2022 - $2,378). </span></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Our stock option activity for the years ended December&#160;31 was as follows:</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.039%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of options</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price<br/>$</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of options</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price<br/>$</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of options</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price<br/>$</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, beginning of year</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,063,333</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.72</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,963,185&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.91</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,334,420&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.53</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,016,800</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.22</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,145,400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.23</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,005,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.04</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(175,534)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.46</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(280,288)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.86</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62,962)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.83</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,028,254)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.22</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(314,573)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.17</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(304,940)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.80</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(450,391)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.74</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,333)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.45</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, end of year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,876,345</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.14</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,063,333&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.72</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,963,185&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.91</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable, end of year</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,718,058</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.43</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,039,604&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.85</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,420,482&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.01</span></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information about the stock options outstanding and exercisable at December&#160;31, 2024:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.208%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.456%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.456%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.456%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.456%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.458%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Range of Exercise Prices</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Life (years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price<br/>$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number Exercisable</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price<br/>$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.13 - $1.50</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,799,300&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.14</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">637,257&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.13</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.51 - $2.20</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,232,850&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.88</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,434,792&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.94</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$2.21 - $2.70</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">699,689&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.36</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">699,689&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.36</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$2.71 - $3.11</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">940,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.78</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">742,614&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.78</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3.12 - $7.60</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,203,706&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.51</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,203,706&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.51</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,876,345&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.14</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,718,058&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.43</span></td></tr></table></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Option grants vest either immediately or annually over periods ranging from <span style="-sec-ix-hidden:f-735">one</span> to three years.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the Black-Scholes valuation model to estimate fair value. We use historical data to estimate the expected dividend yield</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and expected volatility of our stock in determining the fair value of the stock options. The risk-free interest rate is based on the</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government of Canada benchmark bond yield rates in effect at the time of grant. The expected life of the options represents the</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">estimated length of time the options are expected to remain outstanding. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of stock options granted during the years ended December&#160;31 were determined using the following weighted average assumptions: </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.642%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.1%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.0 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">66.4%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96.0%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average fair value of options</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$0.57</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.12</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.24</span></td></tr></table></div><div style="margin-top:5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Our share award activity for the years ended December&#160;31 was as follows:</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.642%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, beginning of year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">398,440</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,560&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">853,642</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">403,200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,760)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Released</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(133,572)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,560)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, end of year</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,118,510</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398,440&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> (1) The weighted average fair value of the RSAs granted was $1.15 in 2024 (2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$2.23).</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2024 and 2023, we granted restricted share awards to officers and a board of director member in his capacity as interim chief executive officer of the Company. Restricted share award granted to officers vest immediately or over a three-year period. Restricted share award granted to the board of director member vest on the second anniversary from the grant date. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Compensation warrants </span></div>In consideration of the services rendered by the underwriter as part of a public offering in 2023 (see note 10(c)), we issued 536,693 compensation warrants. Each compensation warrant is exercisable into one common share at an exercise price of US$2.25 up to 60 months from the date of issuance. At issuance date, we used the Black-Scholes valuation model to estimate the fair value of the services rendered. As at December&#160;31, 2024 and 2023, there were 536,693 compensation warrants outstanding.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 44<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_44&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Share-based Payment Arrangements [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45622345771248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EarningsPerShareAbstract', window );"><strong>Earnings per share [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfEarningsPerShareExplanatory', window );">Loss Per Share</a></td>
<td class="text">Loss Per Share<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss per common share is calculated by dividing net loss for the year by the weighted average number of common shares outstanding for the year ended December&#160;31, 2024, of 76,482,914 (2023 - 67,624,036; 2022 - 58,029,745). The effect of any potential exercise of our stock options, share awards, and warrants outstanding during the year has been excluded from the calculation of diluted loss per common share, as it would be anti-dilutive.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEarningsPerShareExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2024-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2024-en-r&amp;doctype=Standard&amp;dita_xref=IAS33_g70-73A_TI<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEarningsPerShareExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45622345978128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contract Liability<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract', window );"><strong>Disclosure of revenue from contracts with customers [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory', window );">Contract Liability</a></td>
<td class="text">Contract Liability<div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We entered into a regional licensing agreement (the "Licensing Agreement") with Adlai Nortye Biopharma Co., Ltd. ("Adlai") in November 2017. Under the terms of the Licensing Agreement, Adlai will have exclusive development and commercialization rights to pelareorep in China, Hong Kong, Macau, Singapore, South Korea, and Taiwan. We are entitled to receive upfront license fees, development and regulatory milestone payments, royalties, and sales-based milestone payments. </span></div><div><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contract liability balance at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31</span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which w</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e expect to record in revenue over the next five years, is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.104%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.007%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, beginning of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,730</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,730&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue recognized </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, end of year</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,730</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,730&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for revenue from contracts with customers.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2024-01-01<br> -Section Presentation<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2024-en-r&amp;doctype=Standard&amp;dita_xref=IFRS15_g105-109_TI<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2024-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2024-en-r&amp;doctype=Standard&amp;dita_xref=IFRS15_g110-129_TI<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of revenue from contracts with customers [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45622345496464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ContingenciesAbstract', window );"><strong>Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are committed to payments of approximately $7,793 for activities mainly related to our clinical trial and manufacturing programs, which are expected to occur over the next two years. Approximately one-third of the committed payments relate to a</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">production service agreement with our primary toll manufacturer, which cannot be canceled without a significant penalty. We</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are able to cancel most of the remaining agreements with notice. </span></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Indemnification of Officers and Directors</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our corporate by-laws require that, except to the extent expressly prohibited by law, we will indemnify our officers and directors against all costs, charges, and expenses, including an amount paid to settle an action or satisfy a judgment reasonably incurred in respect of any civil, criminal, or administrative action or proceeding as it relates to their services to the Company.&#160;The by-laws provide no limit to the amount of the indemnification.&#160;We have purchased directors&#8217; and officers&#8217; insurance coverage to cover claims made against the directors and officers during the applicable policy periods.&#160;The amounts and types of coverage have varied from period to period as dictated by market conditions.&#160;We believe that we have adequate insurance coverage; however, there is no guarantee that all indemnification payments will be covered under our existing insurance policies.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is no pending litigation or proceeding involving any of our officers or directors as to which indemnification is being sought, nor are we aware of any threatened litigation that may result in claims for indemnification.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of commitments and contingent liabilities. [Refer: Classes of contingent liabilities [domain]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ContingenciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingencies [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ContingenciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45622345474560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_DisclosureofincometaxAbstract', window );"><strong>Disclosure of income tax [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIncomeTaxExplanatory', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes recorded in the consolidated financial statements differs from the amount which would be obtained by applying the statutory income tax rate to the loss before income taxes as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.353%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(31,580)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,655)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,751)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Statutory Canadian corporate tax rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">23.00%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.00%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.00%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anticipated tax recovery</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(7,263)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,361)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,693)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Difference in tax rates</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,323</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,841</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,552</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">668</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">441</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">547</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revaluation of tax balances</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(639)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(338)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of Barbados rate change</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,088)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other permanent differences</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">94</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(368)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expiry of tax benefits</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,804</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,382</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,614</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of warrant derivative</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(286)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,215)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision to offset deferred tax asset</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,429</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,770</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">765</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current income taxes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">130</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2024, we have non-capital losses of $117,096 and $145,104 in Canada and Barbados, respectively (December&#160;31, 2023 - $110,450 and $129,884, respectively). These losses are expected to expire between 2025 and 2044, if not utilized. At December&#160;31, 2024, we have Canadian investment tax credits of $3,839 (December&#160;31, 2023 - $4,056) that are expected to expire between 2025 and 2044, if not utilized. As well, we have unclaimed Canadian scientific research and experimental development expenditures available to reduce future years' taxable income of $28,470 (December&#160;31, 2023 - $28,376).&#160;We also have unclaimed U.S. credits for research activities available to reduce future years' taxable income of $1,313 (December&#160;31, 2023 - $1,232) expiring between 2031 and 2044. We have not recorded the potential benefits of these tax pools in these consolidated financial statements. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets are recognized, to the extent that it is probable that taxable income will be available to utilize the deductible temporary differences. The components of our unrecognized deferred tax asset are as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.353%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-capital losses carried forward</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">40,078</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,174&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,726&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Scientific research and experimental development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,861</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,742&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,648&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment tax credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,956</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,123&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,363&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">453</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">382&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">366&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share issue costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">666</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">833&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">518&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net capital losses carried forward</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized deferred tax asset</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">52,020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,260&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,627&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>The Company currently files income tax returns in the various jurisdictions in which it operates. These tax returns are subject to periodic examinations in the normal course by the applicable tax authorities. Management is not aware of any material income tax examinations currently in progress by any taxing jurisdiction.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIncomeTaxExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;doctype=Standard&amp;dita_xref=IAS12_g79-88_TI<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIncomeTaxExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureofincometaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of income tax [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureofincometaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45622345962848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capital Disclosures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_StatementOfChangesInEquityAbstract', window );"><strong>Statement of changes in equity [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory', window );">Capital Disclosures</a></td>
<td class="text">Capital Disclosures<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our objective when managing capital is to maintain adequate cash resources to support planned activities, including our clinical trial program, product manufacturing, administrative costs, and intellectual property expansion and protection.&#160;See note 1 for the discussion on our ability to continue as a going concern. We include shareholders' equity and cash and cash equivalents in the definition of capital.    </span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.104%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.007%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15,942</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,912&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shareholders' equity</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,983</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,563&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no debt other than accounts payable and accrued liabilities and lease liabilities. We also have commitments and potential contingent obligations relating to the completion of our research and development of pelareorep.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In managing our capital, we estimate our future cash requirements by preparing a budget and a multi-year plan annually for review and approval by our Board. The budget establishes the approved activities for the upcoming year and estimates the associated costs. The multi-year plan estimates future activity along with the potential cash requirements and is based on our assessment of our current clinical trial progress along with the expected results from the coming year&#8217;s activity.&#160;Budget to actual variances are prepared and reviewed by management and are presented quarterly to the Board.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, funding for our plan is primarily managed through the issuance of additional common shares and common share purchase warrants that upon exercise are converted to common shares.&#160;Management regularly monitors the capital markets attempting to balance the timing of issuing additional equity with our progress through our clinical trial program, general market conditions, and the availability of capital.&#160;There are no assurances that funds will be made available to us when required.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 19, 2024, we renewed our short form base shelf prospectus (the "Base Shelf") that qualifies for distribution of up to $150 million of common shares, subscription receipts, warrants, or units (the "Securities") in either Canada, the U.S. or both. The Base Shelf will be effective until August 19, 2026. Under the Base Shelf, we may sell Securities to or through underwriters, dealers, placement agents, or other intermediaries. We may also sell Securities directly to purchasers or through agents, subject to obtaining any applicable exemption from registration requirements. The distribution of Securities may be performed from time to time in one or more transactions at a fixed price or prices, which may be subject to change, at market prices prevailing at the time of sale, or at prices related to such prevailing market prices to be negotiated with purchasers and as set forth in an accompanying Prospectus Supplement.  </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Renewing our Base Shelf provides additional flexibility when managing our cash resources as, under certain circumstances, it shortens the time required to close a financing and is expected to increase the number of potential investors that may be </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">prepared to invest in the Company. Funds received from using our Base Shelf would be used in line with our Board approved budget and multi-year plan.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Base Shelf allowed us to enter into our ATM equity distribution agreement (see note 10). We plan on using this equity arrangement to assist us in achieving our capital objectives. This arrangement provided us with the opportunity to raise capital and better manage our cash resources.   </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not subject to externally imposed capital requirements, and there have been no changes in how we define or manage our capital in 2024.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of information that enables users of financial statements to evaluate the entity's objectives, policies and processes for managing capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 134<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_134&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_StatementOfChangesInEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_StatementOfChangesInEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45622344600208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract', window );"><strong>Disclosure of detailed information about financial instruments [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory', window );">Financial Instruments</a></td>
<td class="text">Financial Instruments<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair value of financial instruments</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As at December&#160;31, 2024, and December&#160;31, 2023, the carrying amount of our cash and cash equivalents, other receivables, accounts payable and accrued liabilities, and other liabilities approximated their fair value due to their short-term maturity. The warrant derivative is a recurring Level 2 fair value measurement as these warrants have not been listed on an exchange and, therefore, do not trade on an active market. As at December&#160;31, 2024, the fair value of our warrant derivative was presented as an asset of $980 (December&#160;31, 2023 - liability of $200) (see note 9). </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial risk management</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit risk</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Credit risk is the risk of a financial loss if a counterparty to a financial instrument fails to meet its contractual obligations.&#160;As at December&#160;31, 2024, we were exposed to credit risk on our cash and cash equivalents in the event of non-performance by counterparties, but we do not anticipate such non-performance. Our maximum exposure to credit risk at the end of the period is the carrying value of our cash and cash equivalents. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We mitigate our exposure to credit risk connected to our cash and cash equivalents by maintaining our primary operating and investment bank accounts with Schedule I banks in Canada.&#160;For our foreign-domiciled bank accounts, we use referrals or recommendations from our Canadian banks to open foreign bank accounts. Our foreign-domiciled bank accounts are used solely for the purpose of settling accounts payable and accrued liabilities or payroll.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest rate risk </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates.&#160;We hold our cash and cash equivalents in bank accounts or high-interest investment accounts with variable interest rates. We mitigate interest rate risk through our investment policy that only allows the investment of excess cash resources in investment-grade vehicles while matching maturities with our operational requirements.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fluctuations in market interest rates do not significantly impact our results of operations due to the short-term maturity of the investments held.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign exchange risk</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign exchange risk arises from changes in foreign exchange rates that may affect the fair value or future cash flows of our financial assets or liabilities. For the year ended December&#160;31, 2024, we were primarily exposed to the risk of changes in the Canadian dollar relative to the U.S. dollar and Euro as a portion of our financial assets and liabilities were denominated in such currencies. The impact of a $0.01 increase in the value of the U.S. dollar against the Canadian dollar would have increased our comprehensive loss for the year ended December&#160;31, 2024, by approximately $34 (December&#160;31, 2023 - decreased by approximately $139). The impact of a $0.01 increase in the value of the Euro against the Canadian dollar would have increased our comprehensive loss for the year ended December&#160;31, 2024, by approximately $30 (December&#160;31, 2023 - $15). </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant balances denominated in U.S. dollars were as follows:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.104%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.007%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,534</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,294&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,722)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,476)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,125)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(251)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,687</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,567&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant balances denominated in Euros were as follows:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.104%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.007%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,114)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(673)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We mitigate our foreign exchange risk by maintaining sufficient foreign currencies by purchasing foreign currencies or receiving foreign currencies from financing activities to settle our foreign accounts payable and accrued liabilities.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity risk</span></div>Liquidity risk is the risk that we will encounter difficulty in meeting obligations associated with financial liabilities. See note 1 for the discussion on our ability to continue as a going concern.&#160;We manage liquidity risk by managing our capital structure as outlined in note 16. Accounts payable and accrued liabilities are all due within the current operating period. Other liabilities associated with funding received from PanCAN (see note 5) are expected to be applied within the current operating period. See note 8 for a maturity analysis of our lease liabilities.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Section Scope<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;doctype=Standard&amp;dita_xref=IFRS07_g3-5A_TI<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45622345802480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Additional Cash Flow Disclosures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_AdditionalCashFlowDisclosuresAbstract', window );"><strong>Additional Cash Flow Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfCashFlowStatementExplanatory', window );">Additional Cash Flow Disclosures</a></td>
<td class="text">Additional Cash Flow Disclosures<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Change In Non-Cash Working Capital</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.353%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Change in:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(53)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">506&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,361</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">777&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,247)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,220</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,662&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,286</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">332&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(352)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash impact of foreign exchange</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(276)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in non-cash working capital related to operating activities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,538</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,765&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">391&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Cash Flow Disclosures</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.353%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash interest received</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,339</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,554&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">452&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash taxes paid</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">184</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfCashFlowStatementExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a statement of cash flows.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Section Presentation of a statement of cash flows<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;doctype=Standard&amp;dita_xref=IAS07_g10-17_TI<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfCashFlowStatementExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_AdditionalCashFlowDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional Cash Flow Disclosures</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_AdditionalCashFlowDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45622345735472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Economic Dependence<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_DisclosureOfEconomicDependenceAbstract', window );"><strong>Disclosure Of Economic Dependence [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_DisclosureOfEconomicDependenceTextBlock', window );">Economic Dependence</a></td>
<td class="text">Economic Dependence<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are economically dependent on our toll manufacturers. We primarily use one toll manufacturer in the U.S. to produce the clinical-grade pelareorep active ingredient and a second toll manufacturer to formulate finished product required for our clinical trial program.&#160;Any significant disruption of the services provided by our primary toll manufacturers has the potential to delay the progress of our clinical trial program.&#160;We have attempted to mitigate this risk by identifying an alternative toll manufacturer, establishing stability profiles for long-term storage of pelareorep, and producing sufficient pelareorep in advance of patient enrollment in a particular clinical trial.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureOfEconomicDependenceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Economic Dependence [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureOfEconomicDependenceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureOfEconomicDependenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Economic Dependence [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureOfEconomicDependenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45622345778304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Components of Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract', window );"><strong>Analysis of income and expense [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfExpensesByNatureExplanatory', window );">Components of Expenses</a></td>
<td class="text">Components of Expenses<div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.353%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Research and development expenses</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trial expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,463</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,675&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,970&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing &amp; related process development expenses</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,267</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,789&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,148&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intellectual property expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">433</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">397&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">544&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Translational science expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">101</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Personnel-related expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,451</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,324&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,023&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,717</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,305&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,371&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">215</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21,647</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,709&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,432&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">General and administrative expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Public company-related expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,565</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,278&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,790&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Personnel-related expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,848</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,332&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,870&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">492</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">457&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">433&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,006</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">612&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,007&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation - property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">120</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation - right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">304</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13,335</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,082&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,492&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2024, our research and development personnel-related expenses included employee compensation and benefits of $5,328 (2023 - $6,324; 2022 - $5,983).</span></div>For the year ended December&#160;31, 2024, our general and administrative office expenses included employee compensation and benefits of $2,650 (2023 - $3,332; 2022 - $2,870).<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AnalysisOfIncomeAndExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfExpensesByNatureExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of expenses by nature. [Refer: Expenses, by nature]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfExpensesByNatureExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45622345442528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Disclosures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_SegmentDisclosuresAbstract', window );"><strong>Segment Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory', window );">Segment Disclosures</a></td>
<td class="text">Segment Disclosures<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations have one reportable segment engaged in the research and development and commercialization of oncology</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">treatments, which is consistent with the way we report information to our chief decision maker and Board of Directors.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following geographic information reflects non-current assets by location:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.104%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.007%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Property and equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">203</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of world</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">208</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">411</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.104%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.007%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Right-of-use-assets</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">74</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of world</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">827</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">901</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;doctype=Standard&amp;dita_xref=IFRS08_g20-24_TI<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SegmentDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Segment Disclosures [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SegmentDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45622345736912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_DisclosureofrelatedpartyAbstract', window );"><strong>Disclosure of related party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfRelatedPartyExplanatory', window );">Related Party Transactions</a></td>
<td class="text">Related Party Transactions<div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Compensation of Key Management Personnel</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Key management personnel are those persons having authority and responsibility for planning, directing, and controlling our activities as a whole. We have determined that key management personnel comprise the Board of Directors, Executive Officers, President, and Vice Presidents. </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.353%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term employee compensation and benefits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,267</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,870&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,308&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Termination benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,349</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,496&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,615&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,616</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,685&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,923&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfRelatedPartyExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2024-01-01<br> -Section Disclosures<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2024-en-r&amp;doctype=Standard&amp;dita_xref=IAS24_g13-24_TI<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfRelatedPartyExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureofrelatedpartyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of related party [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureofrelatedpartyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45622345753328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_DisclosureofeventsafterreportingperiodAbstract', window );"><strong>Disclosure of events after reporting period [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory', window );">Subsequent Events</a></td>
<td class="text">Subsequent Events<div style="margin-bottom:3pt;margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">From January 1, 2025, to March&#160;6, 2025, we sold 5,302,950 shares for gross proceeds of $6,228 (US$4,327) at an average price of $1.17 (US$0.82). We received proceeds of $6,041 (US$4,197), after commissions of $187 (US$130). </span></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">On February 13, 2025, we received a delinquency notification letter (the "Notice") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") indicating that, for the prior 30 consecutive business days, the closing bid price for our ordinary shares listed on the Nasdaq Capital Market was below the minimum $1.00 per share required for continued listing on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2). The Notice provides that we have a period of 180 calendar days from the date of the Notice, or until August 12, 2025, to regain compliance with the minimum bid price requirement. The receipt of the Notice has no immediate effect on our business operations or the listing of our ordinary shares, which will continue to trade uninterrupted on the Nasdaq under the ticker "ONCY." If at any time before August 12, 2025, the bid price of our ordinary shares closes at or above $1.00 per share for a minimum of 10 consecutive business days, Nasdaq will provide written confirmation of compliance to us. In the event that we do not regain compliance by August 12, 2025, we may be eligible for additional time to regain compliance. To qualify, we would be required to meet the continued listing requirement for the market value of publicly held shares and all other initial listing standards for the Nasdaq Capital Market, except for the minimum bid price requirement. In addition, we would be required to notify Nasdaq of its intent to cure the deficiency during the second compliance period.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</span>In early 2025, the President of the United States issued executive orders directing the United States to impose new tariffs on imports originating from Canada, Mexico, and China. The impacts of these tariffs on our operations remain uncertain. New or increased tariffs, export controls, or other measures discouraging contracts with Chinese companies could materially impact our supply chain and manufacturing costs and our licensing agreement with Adlai. We are assessing the direct and indirect impacts of such trade protectionist measures to our operations as this situation develops.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for events after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 10<br> -IssueDate 2024-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=10&amp;code=ifrs-tx-2024-en-r&amp;doctype=Standard&amp;dita_xref=IAS10_g17-22_TI<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureofeventsafterreportingperiodAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of events after reporting period [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureofeventsafterreportingperiodAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45622345454112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Policies and Procedures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingPoliciesProcLineItems', window );"><strong>Insider Trading Policies and Procedures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTrdPoliciesProcAdoptedFlag', window );">Insider Trading Policies and Procedures Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingPoliciesProcLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingPoliciesProcLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTrdPoliciesProcAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTrdPoliciesProcAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45622342444048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity Risk Management and Strategy Disclosure<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text"><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a cybersecurity program, which uses technology and Governance, Risk, and Compliance processes to help mitigate cybersecurity risks, with our management team working to monitor, assess, identify, and respond to potential cybersecurity incidents that threaten the Company. The program also focuses on security awareness and training for employees and contractors with access to Company facilities or systems. Cybersecurity risks for the Company include financial loss, loss of data, and business interruption. The Company maintains technology and non-technology based system controls, cybersecurity insurance, a robust backup program, and disaster recovery testing to mitigate these risks.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company has implemented a comprehensive cybersecurity risk management program to identify, assess, and manage material risks from cybersecurity threats. This program is integrated into our overall enterprise risk management framework and includes the following key components:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">Risk Assessment Process: We conduct regular cybersecurity risk assessments using industry-standard frameworks such as NIST CSF and CIS. These assessments help us identify potential vulnerabilities and prioritize our mitigation efforts.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">Threat Detection and Response: We have deployed advanced threat detection technologies and maintain an incident response plan that is regularly tested and updated.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">Third-Party Risk Management: We assess and monitor the cybersecurity practices of our key vendors and partners to mitigate supply chain risks.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">Employee Training and Awareness: We provide ongoing cybersecurity awareness training to all employees and conduct simulated phishing exercises to reinforce best practices.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cybersecurity program also follows defense in depth principles, which aim to implement various layered access control, detection, prevention, and response measures. We also engage with independent third parties to assess our vulnerabilities and help us mitigate cybersecurity-related risks. Our security posture is also tested by internal personnel and independent third parties to gauge its effectiveness from time to time. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Management&#8217;s Role in Assessing and Managing Cybersecurity Risks </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s cybersecurity risk management and strategy processes for assessing, identifying, and managing material risks from cybersecurity threats are managed by members of the Company&#8217;s management team, primarily the Chief Executive Officer and the Chief Financial Officer. Per the Company&#8217;s policies, cybersecurity incidents are to be immediately reported to the management team for resolution with outsourced IT support team. Information technology general controls, including controls to mitigate cybersecurity risks, are included with management&#8217;s testing of internal control over financial reporting. A virtual Chief Information Security Officer is in place to help lead the Company's cybersecurity program. This individual, who </span></div>reports directly to the Chief Financial Officer, is well positioned, with over 25 years of experience in the field. He holds various industry-leading certifications along with a Master of Laws in cybersecurity and privacy law.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag', window );">Cybersecurity Risk Management Processes Integrated [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock', window );">Cybersecurity Risk Management Processes Integrated [Text Block]</a></td>
<td class="text"><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a cybersecurity program, which uses technology and Governance, Risk, and Compliance processes to help mitigate cybersecurity risks, with our management team working to monitor, assess, identify, and respond to potential cybersecurity incidents that threaten the Company. The program also focuses on security awareness and training for employees and contractors with access to Company facilities or systems. Cybersecurity risks for the Company include financial loss, loss of data, and business interruption. The Company maintains technology and non-technology based system controls, cybersecurity insurance, a robust backup program, and disaster recovery testing to mitigate these risks.</span></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company has implemented a comprehensive cybersecurity risk management program to identify, assess, and manage material risks from cybersecurity threats. This program is integrated into our overall enterprise risk management framework and includes the following key components:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">Risk Assessment Process: We conduct regular cybersecurity risk assessments using industry-standard frameworks such as NIST CSF and CIS. These assessments help us identify potential vulnerabilities and prioritize our mitigation efforts.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">Threat Detection and Response: We have deployed advanced threat detection technologies and maintain an incident response plan that is regularly tested and updated.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">Third-Party Risk Management: We assess and monitor the cybersecurity practices of our key vendors and partners to mitigate supply chain risks.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">Employee Training and Awareness: We provide ongoing cybersecurity awareness training to all employees and conduct simulated phishing exercises to reinforce best practices.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag', window );">Cybersecurity Risk Management Third Party Engaged [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag', window );">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock', window );">Cybersecurity Risk Board of Directors Oversight [Text Block]</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cybersecurity risks are included in an overall risk management assessment, which is reviewed annually by the Company&#8217;s audit committee. The Company engages third-party specialists on a periodic basis to review key information technology systems and provide recommendations for system updates and improvements. Results of these reviews are used to update information technology systems within the Company&#8217;s information system governance policies. The Company's management regularly discusses cyber trends and, should they arise, any material incidents with audit committee. The Company&#8217;s management will also review the Company&#8217;s cybersecurity program with the Board once every year.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cybersecurity risks are included in an overall risk management assessment, which is reviewed annually by the Company&#8217;s audit committee. The Company engages third-party specialists on a periodic basis to review key information technology systems and provide recommendations for system updates and improvements. Results of these reviews are used to update information technology systems within the Company&#8217;s information system governance policies. The Company's management regularly discusses cyber trends and, should they arise, any material incidents with audit committee. The Company&#8217;s management will also review the Company&#8217;s cybersecurity program with the Board once every year.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s cybersecurity risk management and strategy processes for assessing, identifying, and managing material risks from cybersecurity threats are managed by members of the Company&#8217;s management team, primarily the Chief Executive Officer and the Chief Financial Officer. Per the Company&#8217;s policies, cybersecurity incidents are to be immediately reported to the management team for resolution with outsourced IT support team. Information technology general controls, including controls to mitigate cybersecurity risks, are included with management&#8217;s testing of internal control over financial reporting. A virtual Chief Information Security Officer is in place to help lead the Company's cybersecurity program. This individual, who </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reports directly to the Chief Financial Officer, is well positioned, with over 25 years of experience in the field. He holds various industry-leading certifications along with a Master of Laws in cybersecurity and privacy law.  </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Board of Director&#8217;s Oversight of Risks from Cybersecurity</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cybersecurity risks are included in an overall risk management assessment, which is reviewed annually by the Company&#8217;s audit committee. The Company engages third-party specialists on a periodic basis to review key information technology systems and provide recommendations for system updates and improvements. Results of these reviews are used to update information technology systems within the Company&#8217;s information system governance policies. The Company's management regularly discusses cyber trends and, should they arise, any material incidents with audit committee. The Company&#8217;s management will also review the Company&#8217;s cybersecurity program with the Board once every year.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskRoleOfManagementTextBlock', window );">Cybersecurity Risk Role of Management [Text Block]</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s cybersecurity risk management and strategy processes for assessing, identifying, and managing material risks from cybersecurity threats are managed by members of the Company&#8217;s management team, primarily the Chief Executive Officer and the Chief Financial Officer. Per the Company&#8217;s policies, cybersecurity incidents are to be immediately reported to the management team for resolution with outsourced IT support team. Information technology general controls, including controls to mitigate cybersecurity risks, are included with management&#8217;s testing of internal control over financial reporting. A virtual Chief Information Security Officer is in place to help lead the Company's cybersecurity program. This individual, who </span></div>reports directly to the Chief Financial Officer, is well positioned, with over 25 years of experience in the field. He holds various industry-leading certifications along with a Master of Laws in cybersecurity and privacy law.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cybersecurity risks are included in an overall risk management assessment, which is reviewed annually by the Company&#8217;s audit committee. The Company engages third-party specialists on a periodic basis to review key information technology systems and provide recommendations for system updates and improvements. Results of these reviews are used to update information technology systems within the Company&#8217;s information system governance policies. The Company's management regularly discusses cyber trends and, should they arise, any material incidents with audit committee. The Company&#8217;s management will also review the Company&#8217;s cybersecurity program with the Board once every year.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock', window );">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</a></td>
<td class="text">A virtual Chief Information Security Officer is in place to help lead the Company's cybersecurity program. This individual, who reports directly to the Chief Financial Officer, is well positioned, with over 25 years of experience in the field. He holds various industry-leading certifications along with a Master of Laws in cybersecurity and privacy law.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</a></td>
<td class="text">The Company's management regularly discusses cyber trends and, should they arise, any material incidents with audit committee. The Company&#8217;s management will also review the Company&#8217;s cybersecurity program with the Board once every year.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementThirdPartyEngagedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskRoleOfManagementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskRoleOfManagementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45622356398688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Material Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_SummaryOfSignificantAccountingPoliciesAbstract', window );"><strong>Summary Of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfUncertaintiesOfEntitysAbilityToContinueAsGoingConcern', window );">Going concern</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Going concern</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management assesses our ability to continue as a going concern when preparing our consolidated financial statements. In assessing whether the going concern assumption is appropriate, management takes into account all available information about the future, which is at least, but not limited to, twelve months from the end of the reporting period. As at December&#160;31, 2024, we had cash and cash equivalents of $15,942. Subsequent to December&#160;31, 2024, we further raised net proceeds of $6,041 (see note 23). Without raising additional funding or reducing or eliminating our planned expenditures, we estimated our cash and cash equivalents to fund our operations into the third quarter of 2025. Factors that will affect our anticipated cash needs for the next twelve months include, but are not limited to, expansion of our clinical trial program, the timing of patient enrollment in our clinical trials, the actual costs incurred to support each clinical trial, the number of treatments each patient will receive, the timing of activity with our clinical trial research collaborations, the number, timing and costs of manufacturing runs required to conclude the validation process and supply product to our clinical trial program, and the level of collaborative activity undertaken. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to continue as a going concern is dependent upon raising additional financing through equity or strategic collaborations and transactions. We plan on raising additional funds through the sale of our common shares or other capital resources, such as collaborations and debt, to fund our ongoing operations. However, given the difficulty for micro-cap market capitalization companies to raise significant capital and the matter in note 23(b), there can be no assurance that additional liquidity will be available under acceptable terms or at all. Furthermore, if we are unable to obtain additional financing when required, there can be no assurance that we will be able to sufficiently reduce or eliminate our planned expenditures to extend our operating runway. These material uncertainties raise substantial doubt on our ability to continue as a going concern and meet our obligations as they come due and, accordingly, the appropriateness of the use of accounting principles applicable to a going concern.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These consolidated financial statements were prepared in accordance with International Financial Reporting Standards ("IFRS") applicable to a going concern. However, the use of the going concern assumption on which these consolidated financial statements are prepared may not be appropriate based on the factors described above.</span></div>These consolidated financial statements do not reflect the adjustments to the carrying values of assets and liabilities and the reported expenses and statements of financial position classifications that would be necessary if we were unable to realize our assets and settle our liabilities as a going concern in the normal course of operations. Such adjustments could be material.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_DescriptionOfAccountingPolicyForDeterminingComponentsOfCashAndCashEquivalentsPolicyTextBlock', window );">Cash and cash equivalents</a></td>
<td class="text">Cash equivalents include interest-bearing deposits with our bank<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory', window );">Deferred income taxes</a></td>
<td class="text">We follow the liability method of accounting for income taxes. Under the liability method, deferred income taxes are recognized for the difference between the financial statement carrying values and the respective income tax basis of assets and liabilities (temporary differences). Deferred income tax assets and liabilities are measured using substantively enacted income tax rates and laws expected to apply in the years in which temporary differences are expected to be recovered or settled. The effect on deferred income tax assets and liabilities of a change in tax rates is charged or credited to income, except when it is related to items charged or credited to either other comprehensive income or directly to equity.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory', window );">Financial assets</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets are initially measured at fair value. In the case of a financial asset not at fair value through profit or loss, the financial asset is initially measured at fair value plus or minus transaction costs. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets are subsequently measured at amortised cost, fair value through profit or loss (FVPL), or fair value through other comprehensive income (FVOCI). The classification is based on two criteria: the Company&#8217;s business model for managing the assets; and whether the financial asset&#8217;s contractual cash flows represent 'solely payments of principal and interest' on the principal amount outstanding (the 'SPPI criterion'). </span></div>The classification and measurement of our cash and cash equivalents and other receivables are financial assets at amortized cost, as these assets are held within our business model with the objective to hold the financial assets in order to collect contractual cash flows that meet the SPPI criterion.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory', window );">Financial liabilities</a></td>
<td class="text">Financial liabilities are initially measured at fair value and are subsequently measured at amortised cost or FVPL. The classification and measurement of our accounts payable and accrued liabilities and other liabilities are financial liabilities at amortized cost. The classification and measurement of the warrant derivative is financial liabilities at FVPL.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory', window );">Impairment</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounting for impairment losses for financial assets uses a forward-looking expected credit loss (ECL) approach. We are required to record a loss allowance for ECLs on all financial assets not held at FVPL. ECLs are based on the difference between the contractual cash flows due in accordance with the contract and all the cash flows that the Company expects to receive. The shortfall is then discounted at an approximation to the asset&#8217;s original effective interest rate.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForDerecognitionOfFinancialInstrumentsExplanatory', window );">Derecognition</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A financial asset is derecognized when the contractual rights to the cash flows from the financial asset expire, or we transfer the financial asset and substantially all the risks and rewards of ownership of the financial asset to another entity. </span></div>A financial liability is derecognized when our obligations specified in the contract are discharged or canceled, or expired.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory', window );">Fair Value Measurement</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is the price that would be received to sell an asset, or paid to transfer a liability in an orderly transaction between market participants, at the measurement date. In determining the fair value measurement of our financial instruments, we prioritize the related inputs used in measuring fair value into the following hierarchy: </span></div><div style="margin-top:10pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities;</span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 - Inputs other than quoted prices included within Level 1 that are either directly or indirectly observable;</span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 - Unobservable inputs in which little or no market activity exists, therefore requiring an entity to develop its own assumptions about the assumptions that market participants would use in pricing.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory', window );">Foreign currency translation</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial statements for each of our subsidiaries are prepared using their functional currency. Our functional and presentation currency is the Canadian dollar. Foreign currency transactions are translated into the functional currency using exchange rates prevailing at the dates of the transactions. Exchange differences resulting from the settlement of such transactions and from the translation at exchange rates ruling at the statement of financial position date of monetary assets and liabilities denominated in currencies other than the functional currency are recognized directly in the consolidated statement of loss and comprehensive loss.  </span></div>Exceptions to this are where the monetary items form part of the net investment in a foreign operation, and the foreign operation's functional currency is the local currency. These exchange differences are initially recognized in equity. The statement of financial position of foreign operations is translated into Canadian dollars using the exchange rate at the statement of financial position date and the income statements are translated into Canadian dollars using the average exchange rate for the period. Where this average is not a reasonable approximation of the cumulative effect of the rates prevailing on the transaction dates, the exchange rate on the transaction date is used. Exchange differences on translation into Canadian dollars are recognized as a separate component of equity. On disposal of a foreign operation, any cumulative exchange differences held in equity are transferred to the consolidated statement of loss and comprehensive loss.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory', window );">Leases</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of a contract, we assess whether a contract is, or contains, a lease by determining whether the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. To assess whether a contract conveys the right to control the use of an identified asset, we assess whether:</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the contract involves the use of an identified asset;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we have the right to obtain substantially all of the economic benefits from the use of the identified asset throughout the period of use; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we have the right to direct the use of the identified asset. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A right-of-use asset and corresponding lease liability are recognized on the lease commencement date. The right-of-use asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, plus any initial direct costs incurred and an estimate of costs to dismantle and remove the underlying asset or to restore the underlying asset or the site on which it is located, less any lease incentives received. The right-of-use asset is subsequently depreciated using the straight-line method from the commencement date to the end of the lease term. In addition, the right-of-use asset is reduced by impairment losses and adjusted for certain remeasurements of the lease liabilities, if any. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date. The lease payments are discounted using the implicit interest rate in the lease. If the rate cannot be readily determined, our incremental rate of borrowing is used. The lease liability is subsequently measured at amortized cost using the effective interest method. The lease liability is remeasured when there is a change in future lease payments arising from a change in an index or rate, if there is a change in our estimate of the amount expected to be payable under a residual value guarantee, if we change our assessment of whether we will exercise a purchase, extension or termination option, or if the underlying lease contract is amended.  </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have elected not to separate fixed non-lease components from lease components and instead account for each lease component and associated fixed non-lease components as a single lease component.  </span></div>We have elected not to recognize right-of-use assets and lease liabilities for short-term leases that have a lease term of 12 months or less. We recognize the lease payments associated with these leases as an expense on a straight-line basis over the lease term.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory', window );">Loss per share</a></td>
<td class="text">Basic loss per share is calculated by dividing the loss attributable to common shareholders by the weighted average number of common shares outstanding during the year. Diluted loss per share is computed in a manner consistent with basic loss per share except that the weighted average common shares outstanding are adjusted to include the effects of all dilutive potential common shares, which comprise stock options, share awards, and warrants.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory', window );">Property and equipment</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are recorded at cost. Depreciation is provided on bases and at rates designed to amortize the cost of the assets over their estimated useful lives. Depreciation is recorded using the declining balance method at the following annual rates:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.192%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.608%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment and furniture</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Straight-line over the term of the lease</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory', window );">Research and development costs</a></td>
<td class="text">Research and development costs are expensed as incurred, net of recoveries. We record accruals for the estimated costs of our research and development activities performed by third parties. Advance payments for goods or services that will be used or rendered for future research and development activities are capitalized as prepaid expenses and recognized as an expense as the related goods are delivered or the related services are performed. Development costs that meet specific criteria related to technical, market, and financial feasibility will be capitalized. To date, all development costs have been expensed.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue', window );">Revenue recognition</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue relates to a long-term contract associated with a regional licensing agreement (the "Licensing Agreement") with Adlai Nortye Biopharma Co., Ltd. ("Adlai"). The pricing for the contract was based on the specific negotiations with Adlai and included non-refundable upfront license fees, development and regulatory milestone payments, royalties, and sales-based milestone payments. We account for a contract with a customer when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance, and the collectability of consideration is probable.</span></div><div style="margin-bottom:8pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Licensing Agreement, we have granted a regional license to our intellectual property. The granting of this license is accounted for as one performance obligation. We have determined that we provide Adlai with a right to access our intellectual property and, therefore, recognize revenue related to the upfront license fee over time. Revenue is recognized based on the extent of progress toward completion of the performance obligation using the input method. Under the input method, the extent of progress toward completion is measured based on the ratio of costs incurred to date to the total estimated costs at completion of the performance obligation. We use this method because Adlai receives and consumes the benefit of our intellectual property as we undertake activities that impact the intellectual property. Management must use judgment in making assumptions and estimates regarding total estimated costs, the complexity of the work to be performed, and the length of time to complete the performance obligation, among other variables.</span></div><div style="margin-bottom:8pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contract also provides for development and regulatory milestone payments, royalties, and sales-based milestone payments. These amounts are contingent on the occurrence of a future event and, therefore, give rise to variable consideration. We estimate variable consideration at the most likely amount to which we expect to be entitled. We include estimated amounts in the transaction price when it becomes highly probable that the amount will not be subject to significant reversal when the uncertainty associated with the variable consideration is resolved. Our estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of our anticipated performance and all information (historical, current, and forecasted) that is reasonably available to us. Based on this information and related analysis, any quarterly adjustments to revenue are recognized as necessary in the period they become known.</span></div><div style="margin-bottom:8pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The upfront license fee is not considered a significant financing component because it is used to meet working capital demands that can be higher in the early stages of a contract and to protect us from the other party failing to adequately complete some or all of its obligations under the contract. </span></div><div style="margin-bottom:8pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from sales-based royalties and the achievement of annual sales volumes will be recognized when the subsequent sale occurs, as the license of the intellectual property is the predominant item to which the royalty relates. We consider payments associated with the achievement of annual sales volumes to be, in substance, royalty payments, and we will recognize such sales-based payments upon achievement of such sales volumes, provided that collection is reasonably assured.</span></div><div style="margin-bottom:8pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contract liability</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Our contract liability includes upfront license fees and billings in excess of the revenue recognized. Contract liabilities are recognized as revenue as or when we perform under the contract. We classify our contract liability as current or non-current based on the timing of when we expect to recognize revenue.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory', window );">Share-based compensation</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock option plan</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have one stock option plan (the "Stock Option Plan") available to directors, officers, employees, and consultants with grants under the Stock Option Plan approved from time to time by our Board of Directors (the "Board"). Under the Stock Option Plan, no option shall be granted with an exercise price at a discount to the closing price of our stock on the Toronto Stock Exchange </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on the last trading date prior to the date of the grant. Vesting is provided at the discretion of the Board, and the expiration of options is to be no greater than ten years from the date of grant. Exercised stock options are settled with common shares issued from treasury. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the fair value-based method of accounting for stock option awards granted under the Stock Option Plan. We recognize compensation expense and a corresponding adjustment to contributed surplus equal to the fair value of the stock options granted using the Black-Scholes valuation model over the vesting periods of the respective options. Compensation expense is adjusted for subsequent changes in management&#8217;s estimate of the number of options that are expected to vest.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options awarded to non-employees are accounted for at the fair value of the goods received or the services rendered. The fair value is measured at the date the Company obtains the goods or the date the counterparty renders the service. If the fair value of the goods or services cannot be reliably measured, the fair value of the options granted will be used.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share award plan</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our share award plan (the "Share Award Plan") is available to directors, officers, employees, and consultants. Under our Share Award Plan, performance and restricted share awards may be approved from time to time by the Board. Performance share awards  ("PSAs") can be awarded to certain officers and employees to which common shares shall be issued based upon achieving the applicable performance criteria. Restricted share awards ("RSAs") can be awarded to certain officers, employees, non-employee directors, and consultants to which common shares shall be issued in accordance with the Share Award Plan.  </span></div>We recognize compensation expense and a corresponding adjustment to contributed surplus equal to the market value of our common shares at the grant date based on the number of PSAs/RSAs expected to vest, recognized over the vesting period. Compensation expense is adjusted for subsequent changes in management&#8217;s estimate of the number of PSAs/RSAs that are expected to vest. The effect of these changes is recognized in the period of the change.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations', window );">Adoption of New Accounting Standards</a></td>
<td class="text"><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adoption of New Accounting Standards</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IAS 1 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Classification of Liabilities as Current or Non-Current</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2022, the IASB issued amendments to clarify how conditions with which an entity must comply within 12 months after the reporting period affect the classification of a liability. This is in addition to the amendment from January 2020 where the IASB issued amendments to IAS 1 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Presentation of Financial Statements</span>, to provide a more general approach to the presentation of liabilities as current or non-current based on contractual arrangements in place at the reporting date. These amendments specify that the rights and conditions existing at the end of the reporting period are relevant in determining whether the Company has a right to defer settlement of a liability by at least 12 months, provided that management's expectations are not a relevant consideration as to whether the Company will exercise its rights to defer settlement of a liability and clarify when a liability is considered settled. The amendments became effective on January 1, 2024. Adopting the amendments did not have a material impact on our consolidated financial statements.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations', window );">Accounting Standards and Interpretations Issued but Not Yet Effective</a></td>
<td class="text"><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounting Standards and Interpretations Issued but Not Yet Effective</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IFRS 18 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Presentation and Disclosure in Financial Statements</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2024, the IASB issued IFRS 18 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Presentation and Disclosure in Financial Statements </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which replaces IAS 1 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Presentation of Financial Statements. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IFRS 18 introduces new requirements on presentation within the statement of profit or loss, including specified totals and subtotals. It also requires disclosure of management-defined performance measures and includes new requirements for aggregation and disaggregation of financial information based on the identified roles of the primary financial statements and the notes. Narrow scope amendments have been made to IAS 7 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Statement of Cash Flows</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and some requirements previously included within IAS 1 have been moved to IAS 8 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting Policies, Changes in Accounting Estimates and Errors, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which has also been renamed IAS 8 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Preparation of Financial Statements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. IAS 34 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interim Financial Reporting </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">has also been amended to require disclosure of management-defined performance measures. IFRS 18 and the amendments to the other standards are effective for annual periods beginning on or after January 1, 2027, with early application permitted. IFRS 18 applies retrospectively to both annual and interim financial statements. We are assessing the impact of adopting this standard on our consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for deferred income tax. [Refer: Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForDerecognitionOfFinancialInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for the derecognition of financial instruments. [Refer: Classes of financial instruments [domain]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForDerecognitionOfFinancialInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for fair value measurement. [Refer: At fair value [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for financial assets. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for financial liabilities. [Refer: Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for foreign currency translation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for the impairment of financial assets. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for leases. A lease is an agreement whereby the lessor conveys to the lessee in return for a payment or series of payments the right to use an asset for an agreed period of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for recognising revenue. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for research and development expense. [Refer: Research and development expense]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Types of share-based payment arrangements [domain]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the known or reasonably estimable information relevant to assessing the possible impact that the application of a new IFRS, that has been issued but is not yet effective, will have.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 30<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_30_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the initial application of an IFRS. [Refer: IFRSs [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfUncertaintiesOfEntitysAbilityToContinueAsGoingConcern">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of material uncertainties related to events or conditions that may cast significant doubt upon the entity's ability to continue as a going concern.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfUncertaintiesOfEntitysAbilityToContinueAsGoingConcern</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DescriptionOfAccountingPolicyForDeterminingComponentsOfCashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description Of Accounting Policy For Determining Components Of Cash And Cash Equivalents</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DescriptionOfAccountingPolicyForDeterminingComponentsOfCashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SummaryOfSignificantAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary Of Significant Accounting Policies [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SummaryOfSignificantAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45622345652784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Material Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_SummaryOfSignificantAccountingPoliciesAbstract', window );"><strong>Summary Of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory', window );">Schedule of depreciation rates</a></td>
<td class="text">Depreciation is recorded using the declining balance method at the following annual rates:<div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.192%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.608%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment and furniture</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Straight-line over the term of the lease</span></td></tr></table></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.328%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.042%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.371%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.042%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.371%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.471%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.371%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.471%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.371%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.762%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Medical Equipment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Computer Equipment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Office Equipment and Furniture</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Leasehold Improvements</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2022</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">429&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">970&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions, net of foreign exchange impact</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2023</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">436&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">977&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disposals, net of foreign exchange impact</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(173)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at December 31, 2024</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">464&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">392&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,043&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2022</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">614&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2023</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">351&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">695&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disposals, net of foreign exchange impact</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(165)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at December 31, 2024</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">632&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net book value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2023</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at December 31, 2024</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">119</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">250</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">41</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">411</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>For the year ended December&#160;31, 2024, we incurred losses on disposal of property and equipment of $18, which was included in depreciation expense on our consolidated statement of cash flows.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 73<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_73&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SummaryOfSignificantAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary Of Significant Accounting Policies [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SummaryOfSignificantAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45622345414080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract', window );"><strong>Disclosure of detailed information about property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory', window );">Schedule of property and equipment</a></td>
<td class="text">Depreciation is recorded using the declining balance method at the following annual rates:<div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.192%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.608%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment and furniture</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Straight-line over the term of the lease</span></td></tr></table></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.328%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.042%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.371%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.042%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.371%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.471%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.371%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.471%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.371%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.762%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Medical Equipment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Computer Equipment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Office Equipment and Furniture</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Leasehold Improvements</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2022</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">429&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">970&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions, net of foreign exchange impact</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2023</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">436&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">977&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disposals, net of foreign exchange impact</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(173)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at December 31, 2024</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">464&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">392&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,043&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2022</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">614&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2023</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">351&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">695&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disposals, net of foreign exchange impact</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(165)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at December 31, 2024</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">632&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net book value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2023</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at December 31, 2024</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">119</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">250</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">41</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">411</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>For the year ended December&#160;31, 2024, we incurred losses on disposal of property and equipment of $18, which was included in depreciation expense on our consolidated statement of cash flows.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 73<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_73&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45622345485488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable and Accrued Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract', window );"><strong>Subclassifications of assets, liabilities and equities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_DetailedDisclosureOfTradeAndOtherPayablesExplanatoryTableTextBlock', window );">Schedule of accounts payables and accrued liabilities</a></td>
<td class="text"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.861%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade payables</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,087</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,082&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,705</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,490&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,792</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,572&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DetailedDisclosureOfTradeAndOtherPayablesExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detailed Disclosure Of Trade And Other Payables Explanatory</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DetailedDisclosureOfTradeAndOtherPayablesExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45622345421424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PresentationOfLeasesForLesseeAbstract', window );"><strong>Presentation of leases for lessee [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory', window );">Schedule of Right-of-use assets</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our right-of-use assets activity for the years ended December&#160;31:      </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">         </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.274%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at beginning of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">365</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">794</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">392&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(304)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(322)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange impact</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">46</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at end of year</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">901</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTextBlock', window );">Schedule of Lease liabilities</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our lease liabilities activity for the years ended December&#160;31:    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">              </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.274%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at beginning of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">423</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">785</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">392&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment of lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(348)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(407)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense on lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">139</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange impact</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">65</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at end of year</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,064</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">423&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory', window );">Schedule of Total undiscounted lease liability</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our total undiscounted lease liabilities as at December&#160;31, 2024 was as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:81.252%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.548%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than one year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">418&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">One to five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">995&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">More than five years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total undiscounted lease liabilities </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,413&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of a maturity analysis of operating lease payments. Operating lease is a lease that does not transfer substantially all the risks and rewards incidental to ownership of an underlying asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 97<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_97&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of quantitative information about right-of-use assets. [Refer: Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 53<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_53&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PresentationOfLeasesForLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PresentationOfLeasesForLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Quantitative Information About Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45622345804096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrant Derivative (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract', window );"><strong>Disclosure of Share Capital, Reserves And Other Equity Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory', window );">Schedule of change in fair value of warrant derivative</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the value of our warrant derivative were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:64.098%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.080%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.935%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Warrants Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value of Warrant Derivative</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,035&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to public offering</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,667,050&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,360&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount on warrants issued</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,822)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of discount on warrants issued</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,431)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange impact</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(132)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,731,085&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52,456)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,579)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of discount on warrants issued</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,605)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange impact</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at December 31, 2024</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,667,050</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(980)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our outstanding warrant derivative as at December&#160;31, 2024:</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.291%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.291%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.542%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercise price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Issuance date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expiry date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Warrants Outstanding</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US$2.81</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 8, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 8, 2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,667,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US$2.81</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 7, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 8, 2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000,050&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,667,050&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of the warrant derivative with an exercise price of US$2.81 was determined using the following assumptions: </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.104%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.007%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Underlying share price</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">US$0.92</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US$1.35</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.9%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.6 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">36.5%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.5%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value per warrant</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">US$0.03</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US$0.18</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the fair value measurement of liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of Share Capital, Reserves And Other Equity Interest [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45622345410432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract', window );"><strong>Disclosure of Share Capital, Reserves And Other Equity Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory', window );">Schedule of share capital</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unlimited number of no par value common shares</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.104%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.007%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,043,789&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">391,348&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to stock option plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,333&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to incentive share award plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,560&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to "At the Market" (ATM) equity distribution agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)(b)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,235,232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,338&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share issue costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(764)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2022</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,327,914&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">404,040&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to stock option plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450,391&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,271&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to "At the Market" (ATM) equity distribution agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,978,605&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,676&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to public offering</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,667,050&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,724&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share issue costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,805)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,423,960&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">430,906&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to incentive share award plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133,572&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to "At the Market" (ATM) equity distribution agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)(d)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,410,143&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,670&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to warrant derivative exercised</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(e)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,456&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share issue costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(751)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at December 31, 2024</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">80,020,131</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">438,193</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">On March 5, 2021, we entered into an ATM equity distribution agreement with Canaccord Genuity Inc. The ATM allowed us to issue common shares, at prevailing market prices, with an aggregate offering value of up to US$80,000 over a 16-month period through the facilities of the Nasdaq Capital Market in the United States. This sales agreement was terminated on June 16, 2022. During the year ended December&#160;31, 2022, we sold 2,719,770 common shares for gross proceeds of </span></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$5,744 (US$4,560) at an average price of $2.11 (US$1.68). We received proceeds of $5,572 (US$4,423) after commissions of $172 (US$137). In total, we incurred share issue costs (including commissions) of $209. </span></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">On June 17, 2022, we entered into an ATM equity distribution agreement with Canaccord Genuity Inc. The ATM allowed us to issue common shares, at prevailing market prices, with an aggregate offering value of up to US$65,000 over a 25-month period through the facilities of the Nasdaq Capital Market in the United States. This sales agreement was terminated on July 17, 2024. During the year ended December&#160;31, 2024, we sold 2,560,933 (2023 - 4,978,605; 2022 - 3,515,462) common shares for gross proceeds of $4,016 (US$2,964) (2023 - $10,676 (US$7,904); 2022 - $7,594 (US$5,632)) at an average price of $1.57 (US$1.16) (2023 - $2.14 (US$1.59); 2022 - $2.16 (US$1.60)). We received proceeds of $3,895 (US$2,875) (2023 - $10,356 (US$7,667); 2022 - $7,366 (US$5,463)) after commissions of $121 (US$89) (2023 - $320 (US$237); 2022 - $228 (US$169)). In total, we incurred share issue costs (including commissions) of $187 (2023 - $415; 2022 - $555).</span></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">On August 8, 2023, pursuant to an underwritten public offering, we issued 6,667,000 units for gross proceeds of $20,185 (US$15,001) at a price of US$2.25 per unit. On September 7, 2023, pursuant to the over-allotment option exercised by the underwriter, we issued an additional 1,000,050 units for gross proceeds of $3,077 (US$2,250) at a price of US$2.25 per unit. Each unit consisted of one common share and one warrant, which were immediately separable and issued separately in this offering. These warrants were classified as a financial liability (see note 9). Proceeds were allocated amongst common shares and warrants by applying a relative fair value approach, which resulted in $17,724 recorded in share capital and an initial warrant derivative liability of $7,360. In consideration of the services rendered by the underwriter, we issued 536,693 compensation warrants (see note 11). In total, we incurred transaction costs of $3,130 (including a fair value of $638 (US$473) for the compensation warrants), of which $2,390 were allocated to share issue costs and $740 were allocated to operating expenses, based on the relative fair values of the common share and warrant of each unit.</span></div><div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">On August 2, 2024, we entered into an ATM equity distribution agreement with Cantor Fitzgerald &amp; Co. The ATM allows us to issue common shares, at prevailing market prices, with an aggregate offering value of up to US$50,000 over a 25-month period through the facilities of the Nasdaq Capital Market in the United States. During the year ended December&#160;31, 2024, we sold 2,849,210 common shares for gross proceeds of $3,654 (US$2,562) at an average price of $1.28 (US$0.90). We received proceeds of $3,544 (US$2,485) after commissions of $110 (US$77). In total, we incurred share issue costs (including commissions) of $564. </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(e)</span>On August 16, 2019, pursuant to an underwritten public offering, we issued units consisting of common shares and warrants. During the year ended December&#160;31, 2024, 52,456 warrants with a fair value of $6 were exercised for gross proceeds of $65 (US$47). During the years ended December&#160;31, 2023 and 2022, no warrants were exercised.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of classes of share capital. [Refer: Classes of share capital [domain]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_79_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of Share Capital, Reserves And Other Equity Interest [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45622344911760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_DisclosureofsharebasedpaymentarrangementAbstract', window );"><strong>Disclosure of share-based payment arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory', window );">Schedule of stock options and weighted average exercise prices of share options</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Our stock option activity for the years ended December&#160;31 was as follows:</span><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.039%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of options</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price<br/>$</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of options</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price<br/>$</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of options</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price<br/>$</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, beginning of year</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,063,333</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.72</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,963,185&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.91</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,334,420&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.53</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,016,800</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.22</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,145,400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.23</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,005,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.04</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(175,534)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.46</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(280,288)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.86</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62,962)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.83</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,028,254)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.22</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(314,573)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.17</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(304,940)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.80</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(450,391)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.74</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,333)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.45</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, end of year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,876,345</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.14</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,063,333&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.72</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,963,185&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.91</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable, end of year</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,718,058</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.43</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,039,604&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.85</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,420,482&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.01</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory', window );">Schedule of stock options outstanding and exercisable by range of exercise price</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information about the stock options outstanding and exercisable at December&#160;31, 2024:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.208%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.456%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.456%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.456%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.456%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.458%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Range of Exercise Prices</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Life (years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price<br/>$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number Exercisable</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price<br/>$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.13 - $1.50</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,799,300&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.14</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">637,257&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.13</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.51 - $2.20</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,232,850&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.88</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,434,792&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.94</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$2.21 - $2.70</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">699,689&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.36</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">699,689&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.36</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$2.71 - $3.11</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">940,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.78</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">742,614&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.78</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3.12 - $7.60</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,203,706&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.51</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,203,706&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.51</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,876,345&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.14</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,718,058&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.43</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory', window );">Schedule of weighted average remaining contractual life and outstanding stock options by exercise price</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information about the stock options outstanding and exercisable at December&#160;31, 2024:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.208%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.456%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.456%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.456%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.456%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.458%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Range of Exercise Prices</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Life (years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price<br/>$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number Exercisable</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price<br/>$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.13 - $1.50</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,799,300&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.14</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">637,257&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.13</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.51 - $2.20</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,232,850&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.88</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,434,792&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.94</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$2.21 - $2.70</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">699,689&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.36</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">699,689&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.36</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$2.71 - $3.11</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">940,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.78</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">742,614&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.78</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3.12 - $7.60</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,203,706&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.51</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,203,706&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.51</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,876,345&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.14</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,718,058&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.43</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory', window );">Disclosure weighted average assumptions and fair value of options</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of stock options granted during the years ended December&#160;31 were determined using the following weighted average assumptions: </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.642%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.1%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.0 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">66.4%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96.0%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average fair value of options</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$0.57</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.12</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.24</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory', window );">Schedule of number of other equity instruments</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Our share award activity for the years ended December&#160;31 was as follows:</span><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.642%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, beginning of year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">398,440</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,560&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">853,642</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">403,200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,760)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Released</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(133,572)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,560)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, end of year</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,118,510</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398,440&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> (1) The weighted average fair value of the RSAs granted was $1.15 in 2024 (2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$2.23).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of information about indirect, by reference to the fair value of the equity instruments granted, measurement of the fair value of goods or services received as consideration for the entity's share options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the number and weighted average exercise prices of other equity instruments (ie other than share options).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the number and weighted average exercise prices of share options. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the number and weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the range of exercise prices for outstanding share options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureofsharebasedpaymentarrangementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of share-based payment arrangement [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureofsharebasedpaymentarrangementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45622346496368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contract Liability (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract', window );"><strong>Disclosure of revenue from contracts with customers [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory', window );">Schedule of Contract Liability</a></td>
<td class="text"><div><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contract liability balance at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31</span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which w</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e expect to record in revenue over the next five years, is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.104%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.007%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, beginning of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,730</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,730&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue recognized </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, end of year</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,730</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,730&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The explanation of the significant changes in the contract assets and the contract liabilities. [Refer: Contract assets; Contract liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2024-01-01<br> -Paragraph 118<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_118&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of revenue from contracts with customers [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45622345457232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_DisclosureofincometaxAbstract', window );"><strong>Disclosure of income tax [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock', window );">Schedule of Provision for income taxes</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes recorded in the consolidated financial statements differs from the amount which would be obtained by applying the statutory income tax rate to the loss before income taxes as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.353%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(31,580)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,655)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,751)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Statutory Canadian corporate tax rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">23.00%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.00%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.00%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anticipated tax recovery</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(7,263)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,361)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,693)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Difference in tax rates</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,323</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,841</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,552</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">668</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">441</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">547</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revaluation of tax balances</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(639)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(338)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of Barbados rate change</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,088)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other permanent differences</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">94</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(368)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expiry of tax benefits</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,804</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,382</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,614</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of warrant derivative</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(286)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,215)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision to offset deferred tax asset</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,429</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,770</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">765</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current income taxes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">130</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory', window );">Schedule of unrecognized non-capital losses, non-refundable credits and deferred tax assets</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets are recognized, to the extent that it is probable that taxable income will be available to utilize the deductible temporary differences. The components of our unrecognized deferred tax asset are as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.353%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-capital losses carried forward</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">40,078</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,174&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,726&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Scientific research and experimental development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,861</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,742&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,648&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment tax credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,956</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,123&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,363&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">453</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">382&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">366&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share issue costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">666</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">833&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">518&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net capital losses carried forward</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized deferred tax asset</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">52,020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,260&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,627&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of types of temporary differences, unused tax losses and unused tax credits. [Refer: Unused tax credits [member]; Unused tax losses [member]; Temporary differences [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81_g&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureofincometaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of income tax [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureofincometaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Components of Income Tax Expense (Benefit)1 [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45622346021632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capital Disclosures (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_StatementOfChangesInEquityAbstract', window );"><strong>Statement of changes in equity [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_DisclosureOfCapitalComponentsTableTextBlock', window );">Schedule of capital components</a></td>
<td class="text"><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.104%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.007%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15,942</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,912&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shareholders' equity</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,983</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,563&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_StatementOfChangesInEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_StatementOfChangesInEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureOfCapitalComponentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Capital Components [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureOfCapitalComponentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45622345454912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract', window );"><strong>Disclosure of detailed information about financial instruments [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock', window );">Schedule of balances in foreign currencies</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant balances denominated in U.S. dollars were as follows:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.104%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.007%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,534</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,294&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,722)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,476)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,125)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(251)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,687</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,567&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant balances denominated in Euros were as follows:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.104%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.007%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,114)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(673)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Foreign Currency Held [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45622345989088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Additional Cash Flow Disclosures (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_AdditionalCashFlowDisclosuresAbstract', window );"><strong>Additional Cash Flow Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_CashFlowOperatingCapital1TableTextBlock', window );">Schedule of Net change in non-cash working capital</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Change In Non-Cash Working Capital</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.353%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Change in:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(53)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">506&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,361</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">777&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,247)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,220</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,662&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,286</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">332&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(352)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash impact of foreign exchange</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(276)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in non-cash working capital related to operating activities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,538</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,765&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">391&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock', window );">Schedule of Other cash flow disclosures</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Cash Flow Disclosures</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.353%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash interest received</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,339</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,554&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">452&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash taxes paid</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">184</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_AdditionalCashFlowDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional Cash Flow Disclosures</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_AdditionalCashFlowDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_CashFlowOperatingCapital1TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash Flow, Operating Capital1 [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_CashFlowOperatingCapital1TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Cash Flow, Supplemental Disclosures1 [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45622345410432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Components of Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract', window );"><strong>Analysis of income and expense [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_OtherExpensesAndAdjustmentsTableTextBlock', window );">Schedule of Other expenses and adjustments</a></td>
<td class="text"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.353%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Research and development expenses</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trial expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,463</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,675&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,970&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing &amp; related process development expenses</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,267</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,789&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,148&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intellectual property expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">433</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">397&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">544&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Translational science expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">101</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Personnel-related expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,451</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,324&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,023&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,717</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,305&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,371&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">215</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21,647</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,709&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,432&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">General and administrative expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Public company-related expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,565</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,278&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,790&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Personnel-related expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,848</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,332&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,870&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">492</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">457&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">433&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,006</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">612&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,007&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation - property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">120</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation - right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">304</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13,335</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,082&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,492&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AnalysisOfIncomeAndExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_OtherExpensesAndAdjustmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Expenses And Adjustments [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_OtherExpensesAndAdjustmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45622345785072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Disclosures (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_SegmentDisclosuresAbstract', window );"><strong>Segment Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasExplanatory', window );">Schedule of geographical areas</a></td>
<td class="text"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following geographic information reflects non-current assets by location:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.104%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.007%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Property and equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">203</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of world</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">208</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">411</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.104%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.007%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Right-of-use-assets</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">74</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of world</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">827</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">901</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfGeographicalAreasExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of geographical information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 33<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_33&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfGeographicalAreasExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SegmentDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Segment Disclosures [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SegmentDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45622345747952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_DisclosureofrelatedpartyAbstract', window );"><strong>Disclosure of related party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory', window );">Schedule of related party transactions</a></td>
<td class="text">We have determined that key management personnel comprise the Board of Directors, Executive Officers, President, and Vice Presidents. <div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.353%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term employee compensation and benefits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,267</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,870&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,308&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Termination benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,349</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,496&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,615&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,616</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,685&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,923&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of transactions between the entity and its related parties. [Refer: Total for all related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2024-01-01<br> -Paragraph 18<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_18&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureofrelatedpartyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of related party [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureofrelatedpartyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45622342841936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Operations and Going Concern (Details)<br> $ in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">2 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 06, 2025 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Mar. 06, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>CAD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Disclosure of non-adjusting events after reporting period [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RetainedEarnings', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (477,713)<span></span>
</td>
<td class="num">$ (446,003)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,942<span></span>
</td>
<td class="nump">$ 34,912<span></span>
</td>
<td class="nump">$ 11,666<span></span>
</td>
<td class="nump">$ 41,262<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=ifrs-full_MajorOrdinaryShareTransactionsMember', window );">Share transactions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Disclosure of non-adjusting events after reporting period [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssueOfOrdinaryShares', window );">Net proceeds from issue of ordinary shares</a></td>
<td class="nump">$ 6,041<span></span>
</td>
<td class="nump">$ 4,197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssueOfOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuing of ordinary shares. [Refer: Ordinary shares [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssueOfOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetainedEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing the entity's cumulative undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph IG6<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_IG6&amp;doctype=Implementation%20Guidance<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetainedEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=ifrs-full_MajorOrdinaryShareTransactionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=ifrs-full_MajorOrdinaryShareTransactionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45622345656480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Material Accounting Policies - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>CAD ($) </div>
<div>plan</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>CAD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_SummaryOfSignificantAccountingPoliciesAbstract', window );"><strong>Summary Of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashEquivalents', window );">Cash equivalents | $</a></td>
<td class="nump">$ 12,312<span></span>
</td>
<td class="nump">$ 31,534<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_NumberOfStockOptionPlans', window );">Number of plans | plan</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement', window );">Maximum option expiration term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum Term Of Options Granted For Share-based Payment Arrangement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_NumberOfStockOptionPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Stock Option Plans</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_NumberOfStockOptionPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SummaryOfSignificantAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary Of Significant Accounting Policies [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SummaryOfSignificantAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45622356714816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Material Accounting Policies - Schedule of Depreciation Rates (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OfficeEquipmentMember', window );">Office equipment and furniture</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_PropertyPlantandEquipmentAnnualDepreciationRate', window );">Annual depreciation rate</a></td>
<td class="nump">20.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=oncyf_MedicalEquipmentMember', window );">Medical equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_PropertyPlantandEquipmentAnnualDepreciationRate', window );">Annual depreciation rate</a></td>
<td class="nump">20.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember', window );">Computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_PropertyPlantandEquipmentAnnualDepreciationRate', window );">Annual depreciation rate</a></td>
<td class="nump">30.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_PropertyPlantandEquipmentAnnualDepreciationRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Property, Plant and Equipment, Annual Depreciation Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_PropertyPlantandEquipmentAnnualDepreciationRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=oncyf_MedicalEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=oncyf_MedicalEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45622344877760">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Liabilities (Details)<br> $ in Thousands, $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_Currency1LineItems', window );"><strong>Currency1 [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentLiabilities', window );">Other liabilities</a></td>
<td class="nump">$ 1,618<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfProvisionsAxis=oncyf_ClinicalTrialMember', window );">Clinical Trial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_Currency1LineItems', window );"><strong>Currency1 [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherReceivables', window );">Other receivables</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentLiabilities', window );">Other liabilities</a></td>
<td class="nump">$ 1,618<span></span>
</td>
<td class="nump">$ 1,125<span></span>
</td>
<td class="nump">$ 298<span></span>
</td>
<td class="nump">$ 225<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount receivable by the entity that it does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_Currency1LineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>[Line Items] for Currency1 [Table]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_Currency1LineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfProvisionsAxis=oncyf_ClinicalTrialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfProvisionsAxis=oncyf_ClinicalTrialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45622342209184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Details) - CAD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, beginning balance</a></td>
<td class="nump">$ 282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, ending balance</a></td>
<td class="nump">411<span></span>
</td>
<td class="nump">$ 282<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LossesOnDisposalsOfPropertyPlantAndEquipment', window );">Losses on disposals of property, plant and equipment</a></td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, beginning balance</a></td>
<td class="nump">977<span></span>
</td>
<td class="nump">970<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions, net of foreign exchange impact</a></td>
<td class="nump">239<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals, net of foreign exchange impact</a></td>
<td class="nump">173<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, ending balance</a></td>
<td class="nump">1,043<span></span>
</td>
<td class="nump">977<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember', window );">Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, beginning balance</a></td>
<td class="num">(695)<span></span>
</td>
<td class="num">(614)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation expense</a></td>
<td class="nump">102<span></span>
</td>
<td class="nump">81<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals, net of foreign exchange impact</a></td>
<td class="num">(165)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, ending balance</a></td>
<td class="num">(632)<span></span>
</td>
<td class="num">(695)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=oncyf_MedicalEquipmentMember', window );">Medical Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, beginning balance</a></td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, ending balance</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=oncyf_MedicalEquipmentMember', window );">Medical Equipment | Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, beginning balance</a></td>
<td class="nump">62<span></span>
</td>
<td class="nump">62<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions, net of foreign exchange impact</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals, net of foreign exchange impact</a></td>
<td class="nump">59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, ending balance</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">62<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=oncyf_MedicalEquipmentMember', window );">Medical Equipment | Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, beginning balance</a></td>
<td class="num">(55)<span></span>
</td>
<td class="num">(53)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation expense</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals, net of foreign exchange impact</a></td>
<td class="num">(54)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, ending balance</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(55)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember', window );">Computer Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, beginning balance</a></td>
<td class="nump">85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, ending balance</a></td>
<td class="nump">119<span></span>
</td>
<td class="nump">85<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember', window );">Computer Equipment | Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, beginning balance</a></td>
<td class="nump">436<span></span>
</td>
<td class="nump">429<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions, net of foreign exchange impact</a></td>
<td class="nump">71<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals, net of foreign exchange impact</a></td>
<td class="nump">43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, ending balance</a></td>
<td class="nump">464<span></span>
</td>
<td class="nump">436<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember', window );">Computer Equipment | Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, beginning balance</a></td>
<td class="num">(351)<span></span>
</td>
<td class="num">(321)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation expense</a></td>
<td class="nump">35<span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals, net of foreign exchange impact</a></td>
<td class="num">(41)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, ending balance</a></td>
<td class="num">(345)<span></span>
</td>
<td class="num">(351)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=oncyf_OfficeEquipmentAndFurnitureMember', window );">Office Equipment and Furniture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, beginning balance</a></td>
<td class="nump">128<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, ending balance</a></td>
<td class="nump">250<span></span>
</td>
<td class="nump">128<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=oncyf_OfficeEquipmentAndFurnitureMember', window );">Office Equipment and Furniture | Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, beginning balance</a></td>
<td class="nump">248<span></span>
</td>
<td class="nump">248<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions, net of foreign exchange impact</a></td>
<td class="nump">168<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals, net of foreign exchange impact</a></td>
<td class="nump">24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, ending balance</a></td>
<td class="nump">392<span></span>
</td>
<td class="nump">248<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=oncyf_OfficeEquipmentAndFurnitureMember', window );">Office Equipment and Furniture | Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, beginning balance</a></td>
<td class="num">(120)<span></span>
</td>
<td class="num">(92)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation expense</a></td>
<td class="nump">45<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals, net of foreign exchange impact</a></td>
<td class="num">(23)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, ending balance</a></td>
<td class="num">(142)<span></span>
</td>
<td class="num">(120)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, beginning balance</a></td>
<td class="nump">62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, ending balance</a></td>
<td class="nump">41<span></span>
</td>
<td class="nump">62<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LeaseholdImprovementsMember', window );">Leasehold Improvements | Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, beginning balance</a></td>
<td class="nump">231<span></span>
</td>
<td class="nump">231<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions, net of foreign exchange impact</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals, net of foreign exchange impact</a></td>
<td class="nump">47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, ending balance</a></td>
<td class="nump">184<span></span>
</td>
<td class="nump">231<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LeaseholdImprovementsMember', window );">Leasehold Improvements | Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, beginning balance</a></td>
<td class="num">(169)<span></span>
</td>
<td class="num">(148)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation expense</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisposalsPropertyPlantAndEquipment', window );">Disposals, net of foreign exchange impact</a></td>
<td class="num">(47)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, ending balance</a></td>
<td class="num">$ (143)<span></span>
</td>
<td class="num">$ (169)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to property, plant and equipment other than those acquired through business combinations. [Refer: Total for all business combinations [member]; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_73_e_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation of property, plant and equipment. [Refer: Depreciation and amortisation expense; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_73_e_vii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 75<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_75_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisposalsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease in property, plant and equipment resulting from disposals. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_73_e_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisposalsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LossesOnDisposalsOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The losses on the disposal of property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 98<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_98_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LossesOnDisposalsOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period. Note that right-of-use assets are not included. [Contrast: Property, plant and equipment including right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=oncyf_MedicalEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=oncyf_MedicalEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=oncyf_OfficeEquipmentAndFurnitureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=oncyf_OfficeEquipmentAndFurnitureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45622342288240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accounts Payable and Accrued Liabilities (Details) - CAD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract', window );"><strong>Subclassifications of assets, liabilities and equities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers', window );">Trade payables</a></td>
<td class="nump">$ 1,087<span></span>
</td>
<td class="nump">$ 1,082<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AccrualsClassifiedAsCurrent', window );">Accrued liabilities</a></td>
<td class="nump">3,705<span></span>
</td>
<td class="nump">2,490<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayables', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">$ 4,792<span></span>
</td>
<td class="nump">$ 3,572<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AccrualsClassifiedAsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of accruals classified as current. [Refer: Accruals]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AccrualsClassifiedAsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph k<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_k&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current amount of payment due to suppliers for goods and services used in entity's business. [Refer: Current liabilities; Trade payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 70<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_70&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45622345420896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Narrative (Details) - CAD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure of quantitative information about right-of-use assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16', window );">Weighted average rate</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsToRightofuseAssets', window );">Additions to right-of-use assets</a></td>
<td class="nump">$ 794<span></span>
</td>
<td class="nump">$ 392<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities', window );">Increase through new leases, liabilities arising from financing activities</a></td>
<td class="nump">$ 785<span></span>
</td>
<td class="nump">$ 392<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure of quantitative information about right-of-use assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_OperatingLeaseLeaseTerm', window );">Lease term</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure of quantitative information about right-of-use assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_OperatingLeaseLeaseTerm', window );">Lease term</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsToRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to right-of-use assets. [Refer: Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 53<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_53_h&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsToRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase in liabilities arising from financing activities resulting from new leases. [Refer: Liabilities arising from financing activities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Section A Statement of cash flows for an entity other than a financial institution<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;doctype=Illustrative%20Examples&amp;dita_xref=IAS07_IE_A_TI<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 44B<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_44B&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average lessee's incremental borrowing rate applied to lease liabilities recognised in the statement of financial position at the date of initial application of IFRS 16. The incremental borrowing rate is the rate of interest that a lessee would have to pay to borrow over a similar term, and with a similar security, the funds necessary to obtain an asset of a similar value to the right-of-use asset in a similar economic environment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph C12<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_C12_a&amp;doctype=Appendix&amp;subtype=C<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_OperatingLeaseLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Lease Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_OperatingLeaseLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45622346069296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Right-of-use Assets and Lease Liabilities (Details) - CAD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_RightOfUseAssetsAbstract', window );"><strong>Right-Of-Use Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets, beginning balance</a></td>
<td class="nump">$ 365<span></span>
</td>
<td class="nump">$ 296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsToRightofuseAssets', window );">Additions</a></td>
<td class="nump">794<span></span>
</td>
<td class="nump">392<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationRightofuseAssets', window );">Depreciation expense</a></td>
<td class="num">(304)<span></span>
</td>
<td class="num">(322)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ForeignExchangeImpactRightofUseAssets', window );">Foreign exchange impact</a></td>
<td class="nump">46<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets, ending balance</a></td>
<td class="nump">901<span></span>
</td>
<td class="nump">365<span></span>
</td>
<td class="nump">$ 296<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilitiesAbstract', window );"><strong>Lease Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liabilities, beginning balance</a></td>
<td class="nump">423<span></span>
</td>
<td class="nump">373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities', window );">Additions</a></td>
<td class="nump">785<span></span>
</td>
<td class="nump">392<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashOutflowForLeases', window );">Payment of lease liabilities</a></td>
<td class="num">(348)<span></span>
</td>
<td class="num">(407)<span></span>
</td>
<td class="num">(381)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpenseOnLeaseLiabilities', window );">Interest expense on lease liabilities</a></td>
<td class="nump">139<span></span>
</td>
<td class="nump">71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_GainsLossesFromForeignExchangeImpact', window );">Foreign exchange impact</a></td>
<td class="nump">65<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liabilities, ending balance</a></td>
<td class="nump">$ 1,064<span></span>
</td>
<td class="nump">$ 423<span></span>
</td>
<td class="nump">$ 373<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsToRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to right-of-use assets. [Refer: Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 53<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_53_h&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsToRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashOutflowForLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 53<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_53_g&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashOutflowForLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation of right-of-use assets. [Refer: Depreciation and amortisation expense; Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 53<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_53_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase in liabilities arising from financing activities resulting from new leases. [Refer: Liabilities arising from financing activities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Section A Statement of cash flows for an entity other than a financial institution<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;doctype=Illustrative%20Examples&amp;dita_xref=IAS07_IE_A_TI<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 44B<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_44B&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpenseOnLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest expense on lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 53<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_53_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpenseOnLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LeaseLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LeaseLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that represent a lessee's right to use an underlying asset for the lease term that do not meet the definition of investment property. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 53<br> -Subparagraph j<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_53_j&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ForeignExchangeImpactRightofUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Foreign Exchange Impact, Right-of-Use Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ForeignExchangeImpactRightofUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_GainsLossesFromForeignExchangeImpact">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gains (Losses) From Foreign Exchange Impact</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_GainsLossesFromForeignExchangeImpact</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_RightOfUseAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Right-Of-Use Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_RightOfUseAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45622356387136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Total Undiscounted Lease Liability (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>CAD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems', window );"><strong>Disclosure of maturity analysis of operating lease payments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GrossLeaseLiabilities', window );">Total undiscounted lease liabilities</a></td>
<td class="nump">$ 1,413<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember', window );">Less than one year</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems', window );"><strong>Disclosure of maturity analysis of operating lease payments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GrossLeaseLiabilities', window );">Total undiscounted lease liabilities</a></td>
<td class="nump">418<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember', window );">One to five years</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems', window );"><strong>Disclosure of maturity analysis of operating lease payments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GrossLeaseLiabilities', window );">Total undiscounted lease liabilities</a></td>
<td class="nump">995<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember', window );">More than five years</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems', window );"><strong>Disclosure of maturity analysis of operating lease payments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GrossLeaseLiabilities', window );">Total undiscounted lease liabilities</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GrossLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of contractual undiscounted cash flows in relation to lease liabilities before deducting finance charges. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 58<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_58&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph B11D<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B11D_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GrossLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45622342225440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrant Derivative - Reconciliation of Change in Fair Value of Warrant Derivative (Details) - CAD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 07, 2023</div></th>
<th class="th"><div>Aug. 08, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_NumberOfWarrantsOutstandingRollForward', window );"><strong>Number of Warrants Outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_NumberOfWarrantsOutstanding', window );">Balance at beginning of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,731,085<span></span>
</td>
<td class="nump">64,035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_NumberOfWarrantsOutstanding', window );">Balance at end of period (in shares)</a></td>
<td class="nump">1,000,050<span></span>
</td>
<td class="nump">6,667,000<span></span>
</td>
<td class="nump">7,667,050<span></span>
</td>
<td class="nump">7,731,085<span></span>
</td>
<td class="nump">64,035<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ChangeInFairValueWarrantDerivativeRollForward', window );"><strong>Fair Value of Warrant Derivative</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Balance at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issued pursuant to public offering</a></td>
<td class="nump">$ 17,724<span></span>
</td>
<td class="nump">$ 17,724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,338<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_WarrantLiabilityUnamortizedDiscount', window );">Discount on warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,822)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives', window );">Change in fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,242<span></span>
</td>
<td class="nump">5,285<span></span>
</td>
<td class="num">(20)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_GainsLossesFromForeignExchangeImpact', window );">Foreign exchange impact</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Balance at end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (980)<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 79<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfLiabilitiesAxis=ifrs-full_WarrantsMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_NumberOfWarrantsOutstandingRollForward', window );"><strong>Number of Warrants Outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued pursuant to public offering (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,667,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_NumberOfWarrantsExercised', window );">Exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(52,456)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_NumberOfWarrantsExpired', window );">Expired (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,579)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ChangeInFairValueWarrantDerivativeRollForward', window );"><strong>Fair Value of Warrant Derivative</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issued pursuant to public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_WarrantLiabilityUnamortizedDiscount', window );">Discount on warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,822)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_FairValueOfWarrantDerivativeExercised', window );">Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_FairValueOfWarrantDerivativeExpired', window );">Expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_WarrantLiabilityAmortizedDiscount', window );">Amortization of discount on warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">365<span></span>
</td>
<td class="nump">146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives', window );">Change in fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,605)<span></span>
</td>
<td class="num">(5,431)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_GainsLossesFromForeignExchangeImpact', window );">Foreign exchange impact</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 67<span></span>
</td>
<td class="num">$ (132)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DerivativeFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of financial liabilities classified as derivative instruments. [Refer: Financial assets; Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DerivativeFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) resulting from change in the fair value of derivatives recognised in profit or loss. [Refer: Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssueOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase in equity through the issue of equity instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssueOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ChangeInFairValueWarrantDerivativeRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change In Fair Value Warrant Derivative</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ChangeInFairValueWarrantDerivativeRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_FairValueOfWarrantDerivativeExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value Of Warrant Derivative, Exercised</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_FairValueOfWarrantDerivativeExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_FairValueOfWarrantDerivativeExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value Of Warrant Derivative, Expired</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_FairValueOfWarrantDerivativeExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_GainsLossesFromForeignExchangeImpact">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gains (Losses) From Foreign Exchange Impact</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_GainsLossesFromForeignExchangeImpact</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_IssueOfEquityShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issue Of Equity, Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_IssueOfEquityShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_NumberOfWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_NumberOfWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_NumberOfWarrantsExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Warrants Expired</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_NumberOfWarrantsExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_NumberOfWarrantsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Warrants Outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_NumberOfWarrantsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_NumberOfWarrantsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Warrants Outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_NumberOfWarrantsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_WarrantLiabilityAmortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant Liability, Amortized Discount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_WarrantLiabilityAmortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_WarrantLiabilityUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant Liability, Unamortized Discount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_WarrantLiabilityUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfLiabilitiesAxis=ifrs-full_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfLiabilitiesAxis=ifrs-full_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45622321882672">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Warrant Derivative - Warrant Derivative Outstanding (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Sep. 07, 2023</div></th>
<th class="th"><div>Aug. 08, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract', window );"><strong>Disclosure of Share Capital, Reserves And Other Equity Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_WarrantExercisePrice', window );">Exercise price (usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.81<span></span>
</td>
<td class="nump">$ 2.81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_NumberOfWarrantsOutstanding', window );">Number of Warrants Outstanding</a></td>
<td class="nump">7,667,050<span></span>
</td>
<td class="nump">7,731,085<span></span>
</td>
<td class="nump">1,000,050<span></span>
</td>
<td class="nump">6,667,000<span></span>
</td>
<td class="nump">64,035<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of Share Capital, Reserves And Other Equity Interest [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_NumberOfWarrantsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Warrants Outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_NumberOfWarrantsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_WarrantExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant Exercise Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_WarrantExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45622321714688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrant Derivative - Narrative (Details)<br> $ / shares in Units, $ in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 07, 2023 </div>
<div>CAD ($) </div>
<div>d </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 07, 2023 </div>
<div>USD ($) </div>
<div>d</div>
</th>
<th class="th">
<div>Aug. 08, 2023 </div>
<div>CAD ($) </div>
<div>d </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 08, 2023 </div>
<div>USD ($) </div>
<div>d</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Sep. 07, 2023 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Aug. 08, 2023 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems', window );"><strong>Disclosure of fair value measurement of liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_NumberOfWarrantsAndSharesOutstanding', window );">Number of warrants and shares outstanding (in shares) | shares</a></td>
<td class="nump">1,000,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,667,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ProceedsFromIssueOfOrdinarySharesGross', window );">Gross proceeds from shares</a></td>
<td class="nump">$ 3,077<span></span>
</td>
<td class="nump">$ 2,250<span></span>
</td>
<td class="nump">$ 20,185<span></span>
</td>
<td class="nump">$ 15,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_SharesIssuedPricePerShare1', window );">Purchase price (cad and usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.25<span></span>
</td>
<td class="nump">$ 2.25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_WarrantExercisePrice', window );">Exercise price (usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.81<span></span>
</td>
<td class="nump">2.81<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ExpirationPeriodOfOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement', window );">Expiration period, granted</a></td>
<td class="text">60 months<span></span>
</td>
<td class="text">60 months<span></span>
</td>
<td class="text">60 months<span></span>
</td>
<td class="text">60 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementThresholdTradingPrice', window );">Class of warrant or right, threshold trading price (usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50<span></span>
</td>
<td class="nump">6.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementThresholdConsecutiveTradingDays', window );">Class of warrant or right, threshold consecutive trading days | d</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementAcceleratedThresholdTradingDays', window );">Class of warrant or right, accelerated threshold trading days | d</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementExpirationDays', window );">Class of warrant or right, expiration days | d</a></td>
<td class="nump">75<span></span>
</td>
<td class="nump">75<span></span>
</td>
<td class="nump">75<span></span>
</td>
<td class="nump">75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issued pursuant to public offering</a></td>
<td class="nump">$ 17,724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WarrantLiability', window );">Warrant liability</a></td>
<td class="nump">$ 7,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_WarrantLiabilityUnamortizedDiscount', window );">Warrant liability, unamortized discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,822<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_WarrantsTerm', window );">Warrants, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_SaleOfStockAxis=oncyf_SharesPublicOfferingWarrantDerivativesMember', window );">Shares Under Warrant Derivative Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems', window );"><strong>Disclosure of fair value measurement of liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_SharesIssuedPricePerShare1', window );">Purchase price (cad and usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.25<span></span>
</td>
<td class="nump">2.25<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember', window );">Share Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems', window );"><strong>Disclosure of fair value measurement of liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issued pursuant to public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember', window );">Share Capital | Shares Under Warrant Derivative Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems', window );"><strong>Disclosure of fair value measurement of liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issued pursuant to public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level2OfFairValueHierarchyMember', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems', window );"><strong>Disclosure of fair value measurement of liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_WarrantExercisePrice', window );">Exercise price (usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.81<span></span>
</td>
<td class="nump">$ 2.81<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfLiabilitiesAxis=ifrs-full_WarrantsMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems', window );"><strong>Disclosure of fair value measurement of liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issued pursuant to public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_WarrantLiabilityUnamortizedDiscount', window );">Warrant liability, unamortized discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,822<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=oncyf_SharesPublicOfferingWarrantDerivativesMember', window );">Shares Under Warrant Derivative Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems', window );"><strong>Disclosure of fair value measurement of liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight1', window );">Number of common shares issuable per warrant (in shares) | shares</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=oncyf_SharesPublicOfferingWarrantDerivativesMember', window );">Shares Under Warrant Derivative Agreement | Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems', window );"><strong>Disclosure of fair value measurement of liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_CommonSharesPerUnit', window );">Common shares per unit (in shares) | shares</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=oncyf_SharesPublicOfferingWarrantDerivativesMember', window );">Shares Under Warrant Derivative Agreement | Share Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems', window );"><strong>Disclosure of fair value measurement of liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_CommonSharesPerUnit', window );">Common shares per unit (in shares) | shares</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssueOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase in equity through the issue of equity instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssueOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of warrant liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Number Of Securities Called By Each Warrant Or Right1</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_CommonSharesPerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Shares Per Unit</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_CommonSharesPerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ExpirationPeriodOfOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiration Period Of Other Equity Instruments Granted In Share-Based Payment Arrangement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ExpirationPeriodOfOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_NumberOfWarrantsAndSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Warrants And Shares Outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_NumberOfWarrantsAndSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementAcceleratedThresholdTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Equity Instruments In Share-Based Payment Arrangement, Accelerated Threshold Trading Days</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementAcceleratedThresholdTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementExpirationDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Equity Instruments In Share-Based Payment Arrangement, Expiration Days</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementExpirationDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementThresholdConsecutiveTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Equity Instruments In Share-Based Payment Arrangement, Threshold Consecutive Trading Days</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementThresholdConsecutiveTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementThresholdTradingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Equity Instruments In Share-Based Payment Arrangement, Threshold Trading Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementThresholdTradingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ProceedsFromIssueOfOrdinarySharesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Issue Of Ordinary Shares, Gross</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ProceedsFromIssueOfOrdinarySharesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SharesIssuedPricePerShare1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares Issued, Price Per Share1</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SharesIssuedPricePerShare1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_WarrantExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant Exercise Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_WarrantExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_WarrantLiabilityUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant Liability, Unamortized Discount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_WarrantLiabilityUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_WarrantsTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants, Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_WarrantsTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SaleOfStockAxis=oncyf_SharesPublicOfferingWarrantDerivativesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SaleOfStockAxis=oncyf_SharesPublicOfferingWarrantDerivativesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level2OfFairValueHierarchyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level2OfFairValueHierarchyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfLiabilitiesAxis=ifrs-full_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfLiabilitiesAxis=ifrs-full_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=oncyf_SharesPublicOfferingWarrantDerivativesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=oncyf_SharesPublicOfferingWarrantDerivativesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_IssuedCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_IssuedCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45622341973456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrant Derivative - Summary of Assumptions Used in the Black Scholes Option Pricing Model for Warrants (Details) - Warrants<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>year </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>year </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems', window );"><strong>Disclosure of fair value measurement of liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_WeightedAverageSharePriceOtherEquityInstrumentsGranted', window );">Underlying share price (usd per share)</a></td>
<td class="nump">$ 0.92<span></span>
</td>
<td class="nump">$ 1.35<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_RiskFreeInterestRateOtherEquityInstrumentsGranted', window );">Risk-free interest rate</a></td>
<td class="nump">0.029<span></span>
</td>
<td class="nump">0.032<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_OtherEquityInstrumentsLifeOtherEquityInstrumentsGranted', window );">Expected life | year</a></td>
<td class="nump">3.6<span></span>
</td>
<td class="nump">4.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ExpectedVolatilityOtherEquityInstrumentsGranted', window );">Expected volatility</a></td>
<td class="nump">0.365<span></span>
</td>
<td class="nump">0.365<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted', window );">Expected dividend yield</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted', window );">Fair value per warrant (usd per share)</a></td>
<td class="nump">$ 0.03<span></span>
</td>
<td class="nump">$ 0.18<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected Dividend As Percentage, Other Equity Instruments Granted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ExpectedVolatilityOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected Volatility, Other Equity Instruments Granted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ExpectedVolatilityOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_OtherEquityInstrumentsLifeOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Equity Instruments Life, Other Equity Instruments Granted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_OtherEquityInstrumentsLifeOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_RiskFreeInterestRateOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Risk Free Interest Rate, Other Equity Instruments Granted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_RiskFreeInterestRateOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Fair Value Price At Measurement Date, Other Equity Instruments Granted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_WeightedAverageSharePriceOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Share Price, Other Equity Instruments Granted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_WeightedAverageSharePriceOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfLiabilitiesAxis=ifrs-full_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfLiabilitiesAxis=ifrs-full_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45622345217648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital - Schedule of Share Capital (Details) - CAD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 07, 2023</div></th>
<th class="th"><div>Aug. 08, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ShareCapitalAmountAbstract', window );"><strong>Amount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity balance at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,563<span></span>
</td>
<td class="nump">$ 26,502<span></span>
</td>
<td class="nump">$ 36,099<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issued pursuant to public offering</a></td>
<td class="nump">$ 17,724<span></span>
</td>
<td class="nump">$ 17,724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,338<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(751)<span></span>
</td>
<td class="num">(2,805)<span></span>
</td>
<td class="num">(764)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity balance at end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,983<span></span>
</td>
<td class="nump">27,563<span></span>
</td>
<td class="nump">$ 26,502<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_SaleOfStockAxis=oncyf_SharesUnderAtthemarketAgreementMember', window );">At-the-market equity distribution agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ShareCapitalAmountAbstract', window );"><strong>Amount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issued pursuant to public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,670<span></span>
</td>
<td class="nump">$ 10,676<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember', window );">Share Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ShareCapitalNumberSharesAbstract', window );"><strong>Number</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Share capital issued, beginning (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74,423,960<span></span>
</td>
<td class="nump">61,327,914<span></span>
</td>
<td class="nump">55,043,789<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Share capital issued ending (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,020,131<span></span>
</td>
<td class="nump">74,423,960<span></span>
</td>
<td class="nump">61,327,914<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ShareCapitalAmountAbstract', window );"><strong>Amount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity balance at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 430,906<span></span>
</td>
<td class="nump">$ 404,040<span></span>
</td>
<td class="nump">$ 391,348<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issued pursuant to public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,338<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(751)<span></span>
</td>
<td class="num">(2,805)<span></span>
</td>
<td class="num">(764)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity balance at end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 438,193<span></span>
</td>
<td class="nump">$ 430,906<span></span>
</td>
<td class="nump">$ 404,040<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember', window );">Share Capital | At-the-market equity distribution agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ShareCapitalNumberSharesAbstract', window );"><strong>Number</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,410,143<span></span>
</td>
<td class="nump">4,978,605<span></span>
</td>
<td class="nump">6,235,232<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ShareCapitalAmountAbstract', window );"><strong>Amount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issued pursuant to public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,670<span></span>
</td>
<td class="nump">$ 10,676<span></span>
</td>
<td class="nump">$ 13,338<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember', window );">Share Capital | Warrant derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ShareCapitalNumberSharesAbstract', window );"><strong>Number</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,456<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ShareCapitalAmountAbstract', window );"><strong>Amount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issued pursuant to public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember', window );">Share Capital | Public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ShareCapitalNumberSharesAbstract', window );"><strong>Number</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,667,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ShareCapitalAmountAbstract', window );"><strong>Amount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issued pursuant to public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=oncyf_SharesUnderStockOptionPlanMember', window );">Stock option plan | Share Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ShareCapitalNumberSharesAbstract', window );"><strong>Number</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">450,391<span></span>
</td>
<td class="nump">8,333<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ShareCapitalAmountAbstract', window );"><strong>Amount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issued pursuant to public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,271<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=oncyf_SharesUnderIncentiveAwardPlanMember', window );">Incentive share award plan | Share Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ShareCapitalNumberSharesAbstract', window );"><strong>Number</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">133,572<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,560<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ShareCapitalAmountAbstract', window );"><strong>Amount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issued pursuant to public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 98<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssueOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase in equity through the issue of equity instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssueOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareIssueRelatedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cost related to the issuance of shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareIssueRelatedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_IssueOfEquityShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issue Of Equity, Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_IssueOfEquityShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ShareCapitalAmountAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Capital, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ShareCapitalAmountAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ShareCapitalNumberSharesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Capital, Number, Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ShareCapitalNumberSharesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SaleOfStockAxis=oncyf_SharesUnderAtthemarketAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SaleOfStockAxis=oncyf_SharesUnderAtthemarketAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SaleOfStockAxis=oncyf_SharesPublicOfferingWarrantDerivativesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SaleOfStockAxis=oncyf_SharesPublicOfferingWarrantDerivativesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SaleOfStockAxis=oncyf_SharesPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SaleOfStockAxis=oncyf_SharesPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=oncyf_SharesUnderStockOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=oncyf_SharesUnderStockOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=oncyf_SharesUnderIncentiveAwardPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=oncyf_SharesUnderIncentiveAwardPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45622318838928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital - Schedule of Share Capital Footnotes (Details)<br> $ / shares in Units, $ / shares in Units, $ in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="6">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 02, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 07, 2023 </div>
<div>CAD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 07, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 08, 2023 </div>
<div>CAD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 08, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 17, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 05, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>CAD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>CAD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>CAD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 07, 2023 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Aug. 08, 2023 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ProceedsFromIssueOfOrdinarySharesGross', window );">Gross proceeds from shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,077<span></span>
</td>
<td class="nump">$ 2,250<span></span>
</td>
<td class="nump">$ 20,185<span></span>
</td>
<td class="nump">$ 15,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_SharesIssuedPricePerShare1', window );">Purchase price (cad and usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.25<span></span>
</td>
<td class="nump">$ 2.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue related cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 751<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,805<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 764<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_NumberOfWarrantsAndSharesOutstanding', window );">Number of warrants and shares outstanding (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,667,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_IssueOfEquitySharesNumberOfCommonShares', window );">Number of common shares (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_IssueOfEquitySharesNumberOfWarrants', window );">Number of warrants (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issued pursuant to public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WarrantLiability', window );">Warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ProceedsfromWarrantExercises1', window );">Gross proceeds from warrant exercises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65<span></span>
</td>
<td class="nump">$ 47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_SharePremiumMember', window );">Contributed Surplus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees', window );">Expense from share-based payment transactions with parties other than employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 638<span></span>
</td>
<td class="nump">$ 473<span></span>
</td>
<td class="nump">$ 638<span></span>
</td>
<td class="nump">$ 473<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=oncyf_CompensationWarrantsMember', window );">Compensation Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_IssueOfEquitySharesNumberOfCommonShares', window );">Number of common shares (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Granted (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">536,693<span></span>
</td>
<td class="nump">536,693<span></span>
</td>
<td class="nump">536,693<span></span>
</td>
<td class="nump">536,693<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">536,693<span></span>
</td>
<td class="nump">536,693<span></span>
</td>
<td class="nump">536,693<span></span>
</td>
<td class="nump">536,693<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfLiabilitiesAxis=ifrs-full_WarrantsMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,667,050<span></span>
</td>
<td class="nump">7,667,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issued pursuant to public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_NumberOfWarrantsExercised', window );">Exercised (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,456<span></span>
</td>
<td class="nump">52,456<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_WarrantsExercised', window );">Warrants exercised, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_SaleOfStockAxis=oncyf_A2021SharesUnderAtTheMarketAgreementUnitedStatesMember', window );">2021 United States ATM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_SharePurchaseAgreementAmount', window );">Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_SharePurchaseAgreementTerm', window );">Agreement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">16 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,719,770<span></span>
</td>
<td class="nump">2,719,770<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ProceedsFromIssueOfOrdinarySharesGross', window );">Gross proceeds from shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,744<span></span>
</td>
<td class="nump">$ 4,560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_SharesIssuedPricePerShare1', window );">Purchase price (cad and usd per share) | (per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssueOfOrdinaryShares', window );">Net proceeds from issue of ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,572<span></span>
</td>
<td class="nump">$ 4,423<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ShareIssueRelatedCostCommissions', window );">Share issue related cost, commissions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">172<span></span>
</td>
<td class="nump">$ 137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue related cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_SaleOfStockAxis=oncyf_A2022SharesUnderAtTheMarketAgreementUnitedStatesMember', window );">2022 United States ATM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_SharePurchaseAgreementAmount', window );">Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_SharePurchaseAgreementTerm', window );">Agreement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">25 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,560,933<span></span>
</td>
<td class="nump">2,560,933<span></span>
</td>
<td class="nump">4,978,605<span></span>
</td>
<td class="nump">4,978,605<span></span>
</td>
<td class="nump">3,515,462<span></span>
</td>
<td class="nump">3,515,462<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ProceedsFromIssueOfOrdinarySharesGross', window );">Gross proceeds from shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,016<span></span>
</td>
<td class="nump">$ 2,964<span></span>
</td>
<td class="nump">$ 10,676<span></span>
</td>
<td class="nump">$ 7,904<span></span>
</td>
<td class="nump">$ 7,594<span></span>
</td>
<td class="nump">$ 5,632<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_SharesIssuedPricePerShare1', window );">Purchase price (cad and usd per share) | (per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.60<span></span>
</td>
<td class="nump">$ 1.57<span></span>
</td>
<td class="nump">$ 2.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssueOfOrdinaryShares', window );">Net proceeds from issue of ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,895<span></span>
</td>
<td class="nump">$ 2,875<span></span>
</td>
<td class="nump">10,356<span></span>
</td>
<td class="nump">$ 7,667<span></span>
</td>
<td class="nump">7,366<span></span>
</td>
<td class="nump">$ 5,463<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ShareIssueRelatedCostCommissions', window );">Share issue related cost, commissions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">121<span></span>
</td>
<td class="nump">$ 89<span></span>
</td>
<td class="nump">320<span></span>
</td>
<td class="nump">$ 237<span></span>
</td>
<td class="nump">228<span></span>
</td>
<td class="nump">$ 169<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue related cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 187<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_SaleOfStockAxis=oncyf_SharesPublicOfferingMember', window );">Public offering | Compensation Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue related cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ShareWarrantsIssuedTransactionCosts', window );">Warrants issued, transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ShareWarrantsIssuedOperatingExpense', window );">Share issue operating expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_SaleOfStockAxis=oncyf_A2024SharesUnderAtTheMarketAgreementUnitedStatesMember', window );">2024 United States ATM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_SharePurchaseAgreementAmount', window );">Agreement</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_SharePurchaseAgreementTerm', window );">Agreement term</a></td>
<td class="text">25 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,849,210<span></span>
</td>
<td class="nump">2,849,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ProceedsFromIssueOfOrdinarySharesGross', window );">Gross proceeds from shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,654<span></span>
</td>
<td class="nump">$ 2,562<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_SharesIssuedPricePerShare1', window );">Purchase price (cad and usd per share) | (per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssueOfOrdinaryShares', window );">Net proceeds from issue of ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,544<span></span>
</td>
<td class="nump">$ 2,485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ShareIssueRelatedCostCommissions', window );">Share issue related cost, commissions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110<span></span>
</td>
<td class="nump">$ 77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue related cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 564<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense from share-based payment transactions with parties other than employees. [Refer: Expense from share-based payment transactions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssueOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase in equity through the issue of equity instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssueOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssueOfOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuing of ordinary shares. [Refer: Ordinary shares [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssueOfOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareIssueRelatedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cost related to the issuance of shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareIssueRelatedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of warrant liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_IssueOfEquityShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issue Of Equity, Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_IssueOfEquityShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_IssueOfEquitySharesNumberOfCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issue Of Equity, Shares, Number Of Common Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_IssueOfEquitySharesNumberOfCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_IssueOfEquitySharesNumberOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issue Of Equity, Shares, Number Of Warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_IssueOfEquitySharesNumberOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_NumberOfWarrantsAndSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Warrants And Shares Outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_NumberOfWarrantsAndSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_NumberOfWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_NumberOfWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ProceedsFromIssueOfOrdinarySharesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Issue Of Ordinary Shares, Gross</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ProceedsFromIssueOfOrdinarySharesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ProceedsfromWarrantExercises1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Warrant Exercises1</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ProceedsfromWarrantExercises1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ShareIssueRelatedCostCommissions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Issue Related Cost, Commissions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ShareIssueRelatedCostCommissions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SharePurchaseAgreementAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Purchase Agreement, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SharePurchaseAgreementAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SharePurchaseAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Purchase Agreement, Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SharePurchaseAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ShareWarrantsIssuedOperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Warrants Issued, Operating Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ShareWarrantsIssuedOperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ShareWarrantsIssuedTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Warrants Issued, Transaction Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ShareWarrantsIssuedTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SharesIssuedPricePerShare1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares Issued, Price Per Share1</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SharesIssuedPricePerShare1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_WarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_WarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_SharePremiumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=ifrs-full_SharePremiumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=oncyf_CompensationWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=oncyf_CompensationWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfLiabilitiesAxis=ifrs-full_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfLiabilitiesAxis=ifrs-full_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SaleOfStockAxis=oncyf_A2021SharesUnderAtTheMarketAgreementUnitedStatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SaleOfStockAxis=oncyf_A2021SharesUnderAtTheMarketAgreementUnitedStatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SaleOfStockAxis=oncyf_A2022SharesUnderAtTheMarketAgreementUnitedStatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SaleOfStockAxis=oncyf_A2022SharesUnderAtTheMarketAgreementUnitedStatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SaleOfStockAxis=oncyf_SharesPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SaleOfStockAxis=oncyf_SharesPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SaleOfStockAxis=oncyf_A2024SharesUnderAtTheMarketAgreementUnitedStatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SaleOfStockAxis=oncyf_A2024SharesUnderAtTheMarketAgreementUnitedStatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45622320185920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Narrative (Details)<br> $ / shares in Units, $ in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 07, 2023 </div>
<div>CAD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 07, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 08, 2023 </div>
<div>CAD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 08, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>CAD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>CAD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>CAD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_NumberOfSharesReservedForIssueUnderOptionsAndContractsForSaleOfSharesPercentageOfCommonSharesMaximum', window );">Common shares reserved for issuance, maximum percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Share-based compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,723<span></span>
</td>
<td class="nump">$ 1,917<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,378<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ExpirationPeriodOfOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement', window );">Expiration period, granted</a></td>
<td class="text">60 months<span></span>
</td>
<td class="text">60 months<span></span>
</td>
<td class="text">60 months<span></span>
</td>
<td class="text">60 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_SharePremiumMember', window );">Contributed Surplus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees', window );">Expense from share-based payment transactions with parties other than employees</a></td>
<td class="nump">$ 638<span></span>
</td>
<td class="nump">$ 473<span></span>
</td>
<td class="nump">$ 638<span></span>
</td>
<td class="nump">$ 473<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=ifrs-full_ReserveOfSharebasedPaymentsMember', window );">Reserve of share-based payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares', window );">Common shares reserved for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,202,818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=ifrs-full_RestrictedShareUnitsMember', window );">Restricted share units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">853,642<span></span>
</td>
<td class="nump">403,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=ifrs-full_RestrictedShareUnitsMember', window );">Restricted share units | Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1', window );">Vesting period, if not immediately vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=ifrs-full_RestrictedShareUnitsMember', window );">Restricted share units | Director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1', window );">Vesting period, if not immediately vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=oncyf_CompensationWarrantsMember', window );">Compensation Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Granted (in shares)</a></td>
<td class="nump">536,693<span></span>
</td>
<td class="nump">536,693<span></span>
</td>
<td class="nump">536,693<span></span>
</td>
<td class="nump">536,693<span></span>
</td>
<td class="nump">536,693<span></span>
</td>
<td class="nump">536,693<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019', window );">Purchase price (cad and usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ExpirationPeriodOfOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement', window );">Expiration period, granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1', window );">Vesting period, if not immediately vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1', window );">Vesting period, if not immediately vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense from share-based payment transactions with employees. [Refer: Expense from share-based payment transactions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense from share-based payment transactions with parties other than employees. [Refer: Expense from share-based payment transactions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issue under options and contracts for the sale of shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_79_a_vii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of other equity instruments (ie other than share options) granted in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ExpirationPeriodOfOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiration Period Of Other Equity Instruments Granted In Share-Based Payment Arrangement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ExpirationPeriodOfOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_NumberOfSharesReservedForIssueUnderOptionsAndContractsForSaleOfSharesPercentageOfCommonSharesMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Shares Reserved For Issue Under Options And Contracts For Sale Of Shares, Percentage Of Common Shares, Maximum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_NumberOfSharesReservedForIssueUnderOptionsAndContractsForSaleOfSharesPercentageOfCommonSharesMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period1</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_SharePremiumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=ifrs-full_SharePremiumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=ifrs-full_ReserveOfSharebasedPaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=ifrs-full_ReserveOfSharebasedPaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=ifrs-full_RestrictedShareUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=ifrs-full_RestrictedShareUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_OfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_OfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=oncyf_CompensationWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=oncyf_CompensationWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45622388098784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Schedule of Stock Options and Weighted Average Exercise Prices (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>shares </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_StockOptionsOutstandingAbstract', window );"><strong>Number of options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Outstanding, beginning of the year (shares) | shares</a></td>
<td class="nump">7,063,333<span></span>
</td>
<td class="nump">5,963,185<span></span>
</td>
<td class="nump">5,334,420<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Granted during the year (shares) | shares</a></td>
<td class="nump">2,016,800<span></span>
</td>
<td class="nump">2,145,400<span></span>
</td>
<td class="nump">1,005,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement', window );">Forfeited during the year (shares) | shares</a></td>
<td class="num">(175,534)<span></span>
</td>
<td class="num">(280,288)<span></span>
</td>
<td class="num">(62,962)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement', window );">Expired during the year (shares) | shares</a></td>
<td class="num">(2,028,254)<span></span>
</td>
<td class="num">(314,573)<span></span>
</td>
<td class="num">(304,940)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement', window );">Exercised during the year (shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(450,391)<span></span>
</td>
<td class="num">(8,333)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Outstanding, end of the year (shares) | shares</a></td>
<td class="nump">6,876,345<span></span>
</td>
<td class="nump">7,063,333<span></span>
</td>
<td class="nump">5,963,185<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Options exercisable, end of the year (shares) | shares</a></td>
<td class="nump">4,718,058<span></span>
</td>
<td class="nump">5,039,604<span></span>
</td>
<td class="nump">4,420,482<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_WeightedAverageExercisePriceOutstandingAbstract', window );"><strong>Weighted Average Exercise Price $</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Outstanding, beginning of the year (cad per share) | $ / shares</a></td>
<td class="nump">$ 2.72<span></span>
</td>
<td class="nump">$ 2.91<span></span>
</td>
<td class="nump">$ 3.53<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019', window );">Granted during the year (cad per share) | $ / shares</a></td>
<td class="nump">1.22<span></span>
</td>
<td class="nump">2.23<span></span>
</td>
<td class="nump">2.04<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019', window );">Forfeited during the year (cad per share) | $ / shares</a></td>
<td class="nump">2.46<span></span>
</td>
<td class="nump">2.86<span></span>
</td>
<td class="nump">3.83<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019', window );">Expired during the year (cad per share) | $ / shares</a></td>
<td class="nump">3.22<span></span>
</td>
<td class="nump">4.17<span></span>
</td>
<td class="nump">10.80<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019', window );">Exercised during the year (cad per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1.74<span></span>
</td>
<td class="nump">1.45<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Outstanding, beginning of the year (cad per share) | $ / shares</a></td>
<td class="nump">2.14<span></span>
</td>
<td class="nump">2.72<span></span>
</td>
<td class="nump">2.91<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019', window );">Options exercisable, end of the year (cad per share) | $ / shares</a></td>
<td class="nump">$ 2.43<span></span>
</td>
<td class="nump">$ 2.85<span></span>
</td>
<td class="nump">$ 3.01<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOutstandingShareOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOutstandingShareOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options exercisable in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_b_vii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options exercised in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_b_iv&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options expired in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_b_v&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options forfeited in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_b_iii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_b_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options exercisable in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_b_vii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options exercised in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_b_iv&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options expired in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_b_v&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options forfeited in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_b_iii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options granted in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_b_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_StockOptionsOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Options, Outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_StockOptionsOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_WeightedAverageExercisePriceOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Exercise Price, Outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_WeightedAverageExercisePriceOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45622345366496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Schedule of Stock Options Outstanding and Exercisable by Range of Exercise Price (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>shares </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number Outstanding (shares) | shares</a></td>
<td class="nump">6,876,345<span></span>
</td>
<td class="nump">7,063,333<span></span>
</td>
<td class="nump">5,963,185<span></span>
</td>
<td class="nump">5,334,420<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted Average Remaining Contractual Life (years)</a></td>
<td class="text">3 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted Average Exercise Price (cad per share)</a></td>
<td class="nump">$ 2.14<span></span>
</td>
<td class="nump">$ 2.72<span></span>
</td>
<td class="nump">$ 2.91<span></span>
</td>
<td class="nump">$ 3.53<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Number Exercisable (shares) | shares</a></td>
<td class="nump">4,718,058<span></span>
</td>
<td class="nump">5,039,604<span></span>
</td>
<td class="nump">4,420,482<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019', window );">Weighted Average Exercise Price (cad per share)</a></td>
<td class="nump">$ 2.43<span></span>
</td>
<td class="nump">$ 2.85<span></span>
</td>
<td class="nump">$ 3.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeOneMember', window );">$0.54 - $1.79</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number Outstanding (shares) | shares</a></td>
<td class="nump">1,799,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted Average Remaining Contractual Life (years)</a></td>
<td class="text">4 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted Average Exercise Price (cad per share)</a></td>
<td class="nump">$ 1.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Number Exercisable (shares) | shares</a></td>
<td class="nump">637,257<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019', window );">Weighted Average Exercise Price (cad per share)</a></td>
<td class="nump">$ 1.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeOneMember', window );">$0.54 - $1.79 | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price (cad per share)</a></td>
<td class="nump">1.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeOneMember', window );">$0.54 - $1.79 | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price (cad per share)</a></td>
<td class="nump">$ 1.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeTwoMember', window );">$1.80 - $3.01</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number Outstanding (shares) | shares</a></td>
<td class="nump">2,232,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted Average Remaining Contractual Life (years)</a></td>
<td class="text">3 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted Average Exercise Price (cad per share)</a></td>
<td class="nump">$ 1.88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Number Exercisable (shares) | shares</a></td>
<td class="nump">1,434,792<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019', window );">Weighted Average Exercise Price (cad per share)</a></td>
<td class="nump">$ 1.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeTwoMember', window );">$1.80 - $3.01 | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price (cad per share)</a></td>
<td class="nump">1.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeTwoMember', window );">$1.80 - $3.01 | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price (cad per share)</a></td>
<td class="nump">$ 2.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeThreeMember', window );">$3.02 - $3.90</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number Outstanding (shares) | shares</a></td>
<td class="nump">699,689<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted Average Remaining Contractual Life (years)</a></td>
<td class="text">1 year 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted Average Exercise Price (cad per share)</a></td>
<td class="nump">$ 2.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Number Exercisable (shares) | shares</a></td>
<td class="nump">699,689<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019', window );">Weighted Average Exercise Price (cad per share)</a></td>
<td class="nump">$ 2.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeThreeMember', window );">$3.02 - $3.90 | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price (cad per share)</a></td>
<td class="nump">2.21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeThreeMember', window );">$3.02 - $3.90 | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price (cad per share)</a></td>
<td class="nump">$ 2.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeFourMember', window );">$3.91 - $7.41</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number Outstanding (shares) | shares</a></td>
<td class="nump">940,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted Average Remaining Contractual Life (years)</a></td>
<td class="text">3 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted Average Exercise Price (cad per share)</a></td>
<td class="nump">$ 2.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Number Exercisable (shares) | shares</a></td>
<td class="nump">742,614<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019', window );">Weighted Average Exercise Price (cad per share)</a></td>
<td class="nump">$ 2.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeFourMember', window );">$3.91 - $7.41 | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price (cad per share)</a></td>
<td class="nump">2.71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeFourMember', window );">$3.91 - $7.41 | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price (cad per share)</a></td>
<td class="nump">$ 3.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeFiveMember', window );">$7.42 - $52.63</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number Outstanding (shares) | shares</a></td>
<td class="nump">1,203,706<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted Average Remaining Contractual Life (years)</a></td>
<td class="text">1 year 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted Average Exercise Price (cad per share)</a></td>
<td class="nump">$ 3.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Number Exercisable (shares) | shares</a></td>
<td class="nump">1,203,706<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019', window );">Weighted Average Exercise Price (cad per share)</a></td>
<td class="nump">$ 3.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeFiveMember', window );">$7.42 - $52.63 | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price (cad per share)</a></td>
<td class="nump">3.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeFiveMember', window );">$7.42 - $52.63 | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price (cad per share)</a></td>
<td class="nump">$ 7.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exercise price of outstanding share options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExercisePriceOfOutstandingShareOptions2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOutstandingShareOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOutstandingShareOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options exercisable in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_b_vii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options exercisable in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_b_vii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45622342255760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Disclosure Weighted Average Assumptions and Fair Value of Options (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>CAD ($) </div>
<div>year</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>CAD ($) </div>
<div>year</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>CAD ($) </div>
<div>year</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract', window );"><strong>Disclosure of Share-based Payment Arrangements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free interest rate</a></td>
<td class="nump">3.10%<span></span>
</td>
<td class="nump">4.10%<span></span>
</td>
<td class="nump">3.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Expected life | year</a></td>
<td class="nump">3.0<span></span>
</td>
<td class="nump">3.0<span></span>
</td>
<td class="nump">3.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected volatility</a></td>
<td class="nump">66.40%<span></span>
</td>
<td class="nump">72.00%<span></span>
</td>
<td class="nump">96.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted', window );">Weighted average fair value of options (cad per share) | $</a></td>
<td class="nump">$ 0.57<span></span>
</td>
<td class="nump">$ 1.12<span></span>
</td>
<td class="nump">$ 1.24<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The option life of share options granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfOptionLifeShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of an expected dividend used to calculate the fair value of share options granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value of share options granted during the period at the measurement date. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Share-based Payment Arrangements [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45622353119216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Schedule of Number of Other Equity Instruments (Details) - Restricted share units<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>CAD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>CAD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, beginning of the year (in shares)</a></td>
<td class="nump">398,440<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">40,560<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Granted (in shares)</a></td>
<td class="nump">853,642<span></span>
</td>
<td class="nump">403,200<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Forfeited (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(4,760)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Released (in shares)</a></td>
<td class="num">(133,572)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(40,560)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, end of the year (in shares)</a></td>
<td class="nump">1,118,510<span></span>
</td>
<td class="nump">398,440<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted', window );">Weighted average fair value at measurement date, other equity instruments granted | $</a></td>
<td class="nump">$ 1.15<span></span>
</td>
<td class="nump">$ 2.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) forfeited in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at the measurement date of granted equity instruments other than share options. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=ifrs-full_RestrictedShareUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=ifrs-full_RestrictedShareUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45622345992656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EarningsPerShareAbstract', window );"><strong>Earnings per share [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageShares', window );">Weighted average number of common shares outstanding (shares)</a></td>
<td class="nump">76,482,914<span></span>
</td>
<td class="nump">67,624,036<span></span>
</td>
<td class="nump">58,029,745<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2024-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45622353212160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contract Liability - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract', window );"><strong>Disclosure of revenue from contracts with customers [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ContractLiabilityRecognitionPeriod', window );">Expected recognition period</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ContractLiabilityRecognitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract Liability, Recognition Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ContractLiabilityRecognitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of revenue from contracts with customers [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45622342838288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contract Liability - Schedule of Contract Revenues and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract', window );"><strong>Disclosure of revenue from contracts with customers [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContractLiabilities', window );">Balance, beginning of year</a></td>
<td class="nump">$ 6,730<span></span>
</td>
<td class="nump">$ 6,730<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities', window );">Revenue recognized</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContractLiabilities', window );">Balance, end of year</a></td>
<td class="nump">$ 6,730<span></span>
</td>
<td class="nump">$ 6,730<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of an entity&#8217;s obligation to transfer goods or services to a customer for which the entity has received consideration (or the amount is due) from the customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2024-01-01<br> -Paragraph 105<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2024-01-01<br> -Paragraph 116<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_116_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease in contract liabilities resulting from the performance obligation being satisfied. [Refer: Contract liabilities; Performance obligations [domain]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2024-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_118_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of revenue from contracts with customers [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45622388087616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>CAD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ContingenciesAbstract', window );"><strong>Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_PurchaseObligation1', window );">Commitment for payment</a></td>
<td class="nump">$ 7,793<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_PurchaseObligationCommitmentTerm', window );">Commitment term</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_PurchaseObligationCommitmentProductionServiceAgreementPercentage', window );">Production service agreement, percentage</a></td>
<td class="nump">33.33%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ContingenciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingencies [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ContingenciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_PurchaseObligation1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase Obligation1</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_PurchaseObligation1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_PurchaseObligationCommitmentProductionServiceAgreementPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase Obligation, Commitment, Production Service Agreement, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_PurchaseObligationCommitmentProductionServiceAgreementPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_PurchaseObligationCommitmentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase Obligation, Commitment Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_PurchaseObligationCommitmentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45622341865904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Provision for Income Taxes (Details) - CAD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_DisclosureofincometaxAbstract', window );"><strong>Disclosure of income tax [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AccountingProfit', window );">Loss before income taxes</a></td>
<td class="num">$ (31,580)<span></span>
</td>
<td class="num">$ (27,655)<span></span>
</td>
<td class="num">$ (24,751)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ApplicableTaxRate', window );">Statutory Canadian corporate tax rate</a></td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate', window );">Anticipated tax recovery</a></td>
<td class="num">$ (7,263)<span></span>
</td>
<td class="num">$ (6,361)<span></span>
</td>
<td class="num">$ (5,693)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TaxEffectOfForeignTaxRates', window );">Difference in tax rates</a></td>
<td class="nump">3,323<span></span>
</td>
<td class="nump">2,841<span></span>
</td>
<td class="nump">3,552<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_TaxEffectOfStockBasedCompensation', window );">Share-based compensation expense</a></td>
<td class="nump">668<span></span>
</td>
<td class="nump">441<span></span>
</td>
<td class="nump">547<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_TaxEffectOfTaxPools', window );">Revaluation of tax balances</a></td>
<td class="num">(639)<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="num">(338)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TaxEffectFromChangeInTaxRate', window );">Impact of Barbados rate change</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(9,088)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome', window );">Other permanent differences</a></td>
<td class="nump">94<span></span>
</td>
<td class="nump">325<span></span>
</td>
<td class="num">(368)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_TaxEffectOfExpirationOfTaxBenefits', window );">Expiry of tax benefits</a></td>
<td class="nump">1,804<span></span>
</td>
<td class="nump">3,382<span></span>
</td>
<td class="nump">1,614<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative', window );">Change in fair value of warrant derivative</a></td>
<td class="num">(286)<span></span>
</td>
<td class="num">(1,215)<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1', window );">Provision to offset deferred tax asset</a></td>
<td class="nump">2,429<span></span>
</td>
<td class="nump">9,770<span></span>
</td>
<td class="nump">765<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Current income taxes</a></td>
<td class="nump">$ 130<span></span>
</td>
<td class="nump">$ 97<span></span>
</td>
<td class="nump">$ 84<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AccountingProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) for a period before deducting tax expense. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AccountingProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ApplicableTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The applicable income tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ApplicableTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2024-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 79<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B13<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 82<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that the entity does not separately disclose in the same statement or note. [Refer: Accounting profit; Applicable tax rate]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxEffectFromChangeInTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to changes in the tax rate. [Refer: Accounting profit]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxEffectFromChangeInTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxEffectOfForeignTaxRates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to foreign tax rates. [Refer: Accounting profit]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxEffectOfForeignTaxRates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The product of the accounting profit multiplied by the applicable tax rate(s). [Refer: Accounting profit; Applicable tax rate]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxExpenseIncomeAtApplicableTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureofincometaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of income tax [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureofincometaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Effect Of Change in Fair Value Of Warrant Derivative</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_TaxEffectOfExpirationOfTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Effect Of Expiration Of Tax Benefits</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_TaxEffectOfExpirationOfTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_TaxEffectOfStockBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Effect Of Stock Based Compensation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_TaxEffectOfStockBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_TaxEffectOfTaxPools">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Effect Of Tax Pools</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_TaxEffectOfTaxPools</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount1</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45622353227664">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Narrative (Details) - CAD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CA', window );">Canada | Non-capital losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Unused tax losses</a></td>
<td class="nump">$ 117,096<span></span>
</td>
<td class="nump">$ 110,450<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CA', window );">Canada | Non-refundable federal investment tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised', window );">Unused tax credits</a></td>
<td class="nump">3,839<span></span>
</td>
<td class="nump">4,056<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CA', window );">Canada | Unclaimed scientific research and experimental development expenditures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised', window );">Unused tax credits</a></td>
<td class="nump">28,470<span></span>
</td>
<td class="nump">28,376<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_BB', window );">BARBADOS | Non-capital losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Unused tax losses</a></td>
<td class="nump">145,104<span></span>
</td>
<td class="nump">129,884<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">UNITED STATES | Unclaimed scientific research and experimental development expenditures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised', window );">Unused tax credits</a></td>
<td class="nump">$ 1,313<span></span>
</td>
<td class="nump">$ 1,232<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of unused tax credits for which no deferred tax asset is recognised in the statement of financial position. [Refer: Unused tax credits [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 81<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of unused tax losses for which no deferred tax asset is recognised in the statement of financial position. [Refer: Unused tax losses [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 81<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_UnusedTaxLossesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_UnusedTaxLossesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_UnusedTaxCreditsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_UnusedTaxCreditsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_BB">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_BB</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45622353044688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Unrecognized Deferred Tax Assets (Details) - CAD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised', window );">Unrecognized deferred tax asset</a></td>
<td class="nump">$ 52,020<span></span>
</td>
<td class="nump">$ 49,260<span></span>
</td>
<td class="nump">$ 38,627<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_UnusedNetOperatingLossCarryForwardsMember', window );">Non-capital losses carried forward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised', window );">Unrecognized deferred tax asset</a></td>
<td class="nump">40,078<span></span>
</td>
<td class="nump">37,174<span></span>
</td>
<td class="nump">26,726<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember', window );">Scientific research and experimental development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised', window );">Unrecognized deferred tax asset</a></td>
<td class="nump">7,861<span></span>
</td>
<td class="nump">7,742<span></span>
</td>
<td class="nump">7,648<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_InvestmentTaxCreditsMember', window );">Investment tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised', window );">Unrecognized deferred tax asset</a></td>
<td class="nump">2,956<span></span>
</td>
<td class="nump">3,123<span></span>
</td>
<td class="nump">3,363<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_PropertyPlantEquipmentRelatedTemporaryDifferencesMember', window );">Property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised', window );">Unrecognized deferred tax asset</a></td>
<td class="nump">453<span></span>
</td>
<td class="nump">382<span></span>
</td>
<td class="nump">366<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_ShareIssueCostsMember', window );">Share issue costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised', window );">Unrecognized deferred tax asset</a></td>
<td class="nump">666<span></span>
</td>
<td class="nump">833<span></span>
</td>
<td class="nump">518<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_UnusedCapitalLossCarryForwardNetMember', window );">Net capital losses carried forward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised', window );">Unrecognized deferred tax asset</a></td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of deductible temporary differences for which no deferred tax asset is recognised in the statement of financial position. [Refer: Temporary differences [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 81<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_UnusedNetOperatingLossCarryForwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_UnusedNetOperatingLossCarryForwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_InvestmentTaxCreditsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_InvestmentTaxCreditsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_PropertyPlantEquipmentRelatedTemporaryDifferencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_PropertyPlantEquipmentRelatedTemporaryDifferencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_ShareIssueCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_ShareIssueCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_UnusedCapitalLossCarryForwardNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_UnusedCapitalLossCarryForwardNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45622353176256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Capital Disclosures (Details) - CAD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Jun. 19, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_StatementOfChangesInEquityAbstract', window );"><strong>Statement of changes in equity [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 15,942<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,912<span></span>
</td>
<td class="nump">$ 11,666<span></span>
</td>
<td class="nump">$ 41,262<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Shareholders' equity</a></td>
<td class="nump">$ 5,983<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,563<span></span>
</td>
<td class="nump">$ 26,502<span></span>
</td>
<td class="nump">$ 36,099<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_EquityAuthorized', window );">Base Shelf securities authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_StatementOfChangesInEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_StatementOfChangesInEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_EquityAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Authorized</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_EquityAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45622387952256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Narrative (Details) - CAD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of nature and extent of risks arising from financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentDerivativeFinancialAssets', window );">Warrant derivative asset</a></td>
<td class="nump">$ 980,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentDerivativeFinancialLiabilities', window );">Warrant derivative liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember', window );">Currency risk | U.S. dollars</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of nature and extent of risks arising from financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount', window );">Impact of increase in value of currency (cad per share)</a></td>
<td class="nump">0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings', window );">Increase (decrease) in net loss due to change in currency value</a></td>
<td class="nump">34,000<span></span>
</td>
<td class="num">(139,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember', window );">Currency risk | Euro</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of nature and extent of risks arising from financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount', window );">Impact of increase in value of currency (cad per share)</a></td>
<td class="nump">0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings', window );">Increase (decrease) in net loss due to change in currency value</a></td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentDerivativeFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current derivative financial assets. [Refer: Derivative financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentDerivativeFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentDerivativeFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current derivative financial liabilities. [Refer: Derivative financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentDerivativeFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A reference variable for a specific type of market risk, defined in non-percentage terms. Positive value indicates an increase; negative value indicates a decrease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Change In Risk Variable, Impact On Pre-Tax Earnings</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_USD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_USD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_EUR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_EUR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45622342895952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Schedule of Balances in Foreign Currencies (Details)<br> &#8364; in Thousands, $ in Thousands, $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>CAD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_Currency1LineItems', window );"><strong>Currency1 [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 15,942<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,666<span></span>
</td>
<td class="nump">$ 41,262<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayables', window );">Accounts payable and accrued liabilities</a></td>
<td class="num">$ (4,792)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3,572)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_USD', window );">U.S. dollars</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_Currency1LineItems', window );"><strong>Currency1 [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayables', window );">Accounts payable and accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,722)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,476)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherLiabilities', window );">Other liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,125)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(251)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_BalanceHeldInForeignCurrencyNet', window );">Balances in foreign currencies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,687<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,567<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_EUR', window );">Euro</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_Currency1LineItems', window );"><strong>Currency1 [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayables', window );">Accounts payable and accrued liabilities | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">&#8364; (1,114)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">&#8364; (673)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph k<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_k&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_BalanceHeldInForeignCurrencyNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Balance Held In Foreign Currency, Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_BalanceHeldInForeignCurrencyNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_Currency1LineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>[Line Items] for Currency1 [Table]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_Currency1LineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_USD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_USD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_EUR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_EUR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45622341864464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Additional Cash Flow Disclosures - Net Change In Non-Cash Working Capital (Details) - CAD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_AdditionalCashFlowDisclosuresAbstract', window );"><strong>Additional Cash Flow Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables', window );">Other receivables</a></td>
<td class="num">$ (53)<span></span>
</td>
<td class="nump">$ 506<span></span>
</td>
<td class="nump">$ 345<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses', window );">Prepaid expenses</a></td>
<td class="nump">1,361<span></span>
</td>
<td class="nump">777<span></span>
</td>
<td class="num">(1,247)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">1,220<span></span>
</td>
<td class="num">(78)<span></span>
</td>
<td class="nump">1,662<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables', window );">Other liabilities</a></td>
<td class="nump">1,286<span></span>
</td>
<td class="nump">332<span></span>
</td>
<td class="num">(352)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet', window );">Non-cash impact of foreign exchange</a></td>
<td class="num">(276)<span></span>
</td>
<td class="nump">228<span></span>
</td>
<td class="num">(17)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInWorkingCapital', window );">Change in non-cash working capital related to operating activities</a></td>
<td class="nump">$ 3,538<span></span>
</td>
<td class="nump">$ 1,765<span></span>
</td>
<td class="nump">$ 391<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in other operating receivables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for the decrease (increase) in prepaid expenses to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Current prepaid expenses; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in other operating payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in trade and other payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other payables; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInWorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in working capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInWorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_AdditionalCashFlowDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional Cash Flow Disclosures</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_AdditionalCashFlowDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) Through Foreign Exchange, Financial Assets (Liabilities), Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45622344687168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Additional Cash Flow Disclosures - Other Cash Flow Disclosures (Details) - CAD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_AdditionalCashFlowDisclosuresAbstract', window );"><strong>Additional Cash Flow Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ProceedsfromInterestReceived', window );">Cash interest received</a></td>
<td class="nump">$ 1,339<span></span>
</td>
<td class="nump">$ 1,554<span></span>
</td>
<td class="nump">$ 452<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxesPaidRefund', window );">Cash taxes paid</a></td>
<td class="nump">$ 184<span></span>
</td>
<td class="nump">$ 120<span></span>
</td>
<td class="nump">$ 46<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxesPaidRefund">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from income taxes paid or refunded.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 35<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxesPaidRefund</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_AdditionalCashFlowDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional Cash Flow Disclosures</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_AdditionalCashFlowDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ProceedsfromInterestReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Interest Received</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ProceedsfromInterestReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45622344860720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Economic Dependence (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>manufacturer</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ConcentrationRiskType1Axis=oncyf_SupplierConcentrationRisk1Member', window );">Toll manufacturer</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ConcentrationRiskType1LineItems', window );"><strong>Concentration Risk Type1 [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ConcentrationRiskNumber', window );">Concentration, number</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ConcentrationRiskNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Concentration Risk, Number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ConcentrationRiskNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ConcentrationRiskType1LineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>[Line Items] for Concentration Risk Type1 [Table]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ConcentrationRiskType1LineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ConcentrationRiskType1Axis=oncyf_SupplierConcentrationRisk1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ConcentrationRiskType1Axis=oncyf_SupplierConcentrationRisk1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45622344951088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Components of Expenses (Details) - CAD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ResearchAndDevelopmentExpense1Abstract', window );"><strong>Research and development expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Share-based compensation expense</a></td>
<td class="nump">$ 2,723<span></span>
</td>
<td class="nump">$ 1,917<span></span>
</td>
<td class="nump">$ 2,378<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">21,647<span></span>
</td>
<td class="nump">17,709<span></span>
</td>
<td class="nump">15,432<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_GeneralAndAdministrativeExpense1Abstract', window );"><strong>General and administrative expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationRightofuseAssets', window );">Depreciation - right-of-use assets</a></td>
<td class="nump">304<span></span>
</td>
<td class="nump">322<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">13,335<span></span>
</td>
<td class="nump">16,082<span></span>
</td>
<td class="nump">11,492<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_IncomeStatementLocation1Axis=oncyf_ResearchAndDevelopmentExpense1Member', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ResearchAndDevelopmentExpense1Abstract', window );"><strong>Research and development expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ClinicalTrialExpense', window );">Clinical trial expenses</a></td>
<td class="nump">5,463<span></span>
</td>
<td class="nump">3,675<span></span>
</td>
<td class="nump">4,970<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ManufacturingExpense', window );">Manufacturing &amp; related process development expenses</a></td>
<td class="nump">8,267<span></span>
</td>
<td class="nump">5,789<span></span>
</td>
<td class="nump">2,148<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_IntellectualPropertyExpense', window );">Intellectual property expenses</a></td>
<td class="nump">433<span></span>
</td>
<td class="nump">397<span></span>
</td>
<td class="nump">544<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_TranslationalScienceExpense', window );">Translational science expenses</a></td>
<td class="nump">101<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">264<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherEmployeeExpense', window );">Personnel-related expenses</a></td>
<td class="nump">5,451<span></span>
</td>
<td class="nump">6,324<span></span>
</td>
<td class="nump">6,023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Share-based compensation expense</a></td>
<td class="nump">1,717<span></span>
</td>
<td class="nump">1,305<span></span>
</td>
<td class="nump">1,371<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MiscellaneousOtherOperatingExpense', window );">Other expenses</a></td>
<td class="nump">215<span></span>
</td>
<td class="nump">219<span></span>
</td>
<td class="nump">112<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_GeneralAndAdministrativeExpense1Abstract', window );"><strong>General and administrative expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EmployeeBenefitsExpense', window );">Employee compensation and benefits expense</a></td>
<td class="nump">5,328<span></span>
</td>
<td class="nump">6,324<span></span>
</td>
<td class="nump">5,983<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_IncomeStatementLocation1Axis=oncyf_GeneralAndAdministrativeExpense1Member', window );">General and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ResearchAndDevelopmentExpense1Abstract', window );"><strong>Research and development expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherEmployeeExpense', window );">Personnel-related expenses</a></td>
<td class="nump">2,848<span></span>
</td>
<td class="nump">3,332<span></span>
</td>
<td class="nump">2,870<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Share-based compensation expense</a></td>
<td class="nump">1,006<span></span>
</td>
<td class="nump">612<span></span>
</td>
<td class="nump">1,007<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_GeneralAndAdministrativeExpense1Abstract', window );"><strong>General and administrative expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_PublicCompanyExpense', window );">Public company-related expenses</a></td>
<td class="nump">8,565<span></span>
</td>
<td class="nump">11,278<span></span>
</td>
<td class="nump">6,790<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_OfficeExpenses', window );">Office expenses</a></td>
<td class="nump">492<span></span>
</td>
<td class="nump">457<span></span>
</td>
<td class="nump">433<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmortisationExpense', window );">Depreciation - property and equipment</a></td>
<td class="nump">120<span></span>
</td>
<td class="nump">81<span></span>
</td>
<td class="nump">93<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationRightofuseAssets', window );">Depreciation - right-of-use assets</a></td>
<td class="nump">304<span></span>
</td>
<td class="nump">322<span></span>
</td>
<td class="nump">299<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EmployeeBenefitsExpense', window );">Employee compensation and benefits expense</a></td>
<td class="nump">$ 2,650<span></span>
</td>
<td class="nump">$ 3,332<span></span>
</td>
<td class="nump">$ 2,870<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AmortisationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of amortisation expense. Amortisation is the systematic allocation of depreciable amounts of intangible assets over their useful lives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AmortisationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation of right-of-use assets. [Refer: Depreciation and amortisation expense; Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 53<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_53_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EmployeeBenefitsExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expense of all forms of consideration given by an entity in exchange for a service rendered by employees or for the termination of employment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 104<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_104&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EmployeeBenefitsExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense from share-based payment transactions with employees. [Refer: Expense from share-based payment transactions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to general and administrative activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MiscellaneousOtherOperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of miscellaneous other operating expenses. [Refer: Other operating income (expense)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MiscellaneousOtherOperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherEmployeeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of employee expenses that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2024-01-01<br> -Paragraph 5<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_5&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherEmployeeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2024-01-01<br> -Paragraph 126<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_126&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ClinicalTrialExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Clinical Trial Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ClinicalTrialExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_GeneralAndAdministrativeExpense1Abstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>General And Administrative Expense 1</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_GeneralAndAdministrativeExpense1Abstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_IntellectualPropertyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intellectual Property Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_IntellectualPropertyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ManufacturingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Manufacturing Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ManufacturingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_OfficeExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Office Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_OfficeExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_PublicCompanyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Public Company Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_PublicCompanyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ResearchAndDevelopmentExpense1Abstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development Expense 1</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ResearchAndDevelopmentExpense1Abstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_TranslationalScienceExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Translational Science Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_TranslationalScienceExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_IncomeStatementLocation1Axis=oncyf_ResearchAndDevelopmentExpense1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_IncomeStatementLocation1Axis=oncyf_ResearchAndDevelopmentExpense1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_IncomeStatementLocation1Axis=oncyf_GeneralAndAdministrativeExpense1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_IncomeStatementLocation1Axis=oncyf_GeneralAndAdministrativeExpense1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45622342201680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Segment Disclosures (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>CAD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>CAD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_NumberOfReportableSegments1', window );">Number of reportable segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">$ 411<span></span>
</td>
<td class="nump">$ 282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use-assets</a></td>
<td class="nump">901<span></span>
</td>
<td class="nump">365<span></span>
</td>
<td class="nump">$ 296<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_CA', window );">Canada</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">203<span></span>
</td>
<td class="nump">246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use-assets</a></td>
<td class="nump">74<span></span>
</td>
<td class="nump">111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=oncyf_RestOfWorldMember', window );">Rest of world</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasLineItems', window );"><strong>Disclosure of geographical areas [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">208<span></span>
</td>
<td class="nump">36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use-assets</a></td>
<td class="nump">$ 827<span></span>
</td>
<td class="nump">$ 254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfGeographicalAreasLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfGeographicalAreasLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period. Note that right-of-use assets are not included. [Contrast: Property, plant and equipment including right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that represent a lessee's right to use an underlying asset for the lease term that do not meet the definition of investment property. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 53<br> -Subparagraph j<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_53_j&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_NumberOfReportableSegments1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Reportable Segments1</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_NumberOfReportableSegments1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=oncyf_RestOfWorldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=oncyf_RestOfWorldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45622345454912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details) - CAD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_DisclosureofrelatedpartyAbstract', window );"><strong>Disclosure of related party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits', window );">Short-term employee compensation and benefits</a></td>
<td class="nump">$ 4,267<span></span>
</td>
<td class="nump">$ 4,870<span></span>
</td>
<td class="nump">$ 4,308<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits', window );">Termination benefits</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">319<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment', window );">Share-based compensation expense</a></td>
<td class="nump">2,349<span></span>
</td>
<td class="nump">1,496<span></span>
</td>
<td class="nump">1,615<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensation', window );">Compensation of key management personnel</a></td>
<td class="nump">$ 6,616<span></span>
</td>
<td class="nump">$ 6,685<span></span>
</td>
<td class="nump">$ 5,923<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel in the form of share-based payments. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel in the form of short-term employee benefits. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel in the form of termination benefits. [Refer: Termination benefits expense; Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureofrelatedpartyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of related party [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureofrelatedpartyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45622347198336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details)<br> $ / shares in Units, $ / shares in Units, $ in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2">2 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 07, 2023 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Sep. 07, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 08, 2023 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Aug. 08, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 06, 2025 </div>
<div>CAD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 06, 2025 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Disclosure of non-adjusting events after reporting period [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ProceedsFromIssueOfOrdinarySharesGross', window );">Gross proceeds from shares</a></td>
<td class="nump">$ 3,077<span></span>
</td>
<td class="nump">$ 2,250<span></span>
</td>
<td class="nump">$ 20,185<span></span>
</td>
<td class="nump">$ 15,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=ifrs-full_MajorOrdinaryShareTransactionsMember', window );">Share transactions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Disclosure of non-adjusting events after reporting period [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,302,950<span></span>
</td>
<td class="nump">5,302,950<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ProceedsFromIssueOfOrdinarySharesGross', window );">Gross proceeds from shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,228<span></span>
</td>
<td class="nump">$ 4,327<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_IssueOfOrdinarySharesPerShare', window );">Issuance of shares (in dollars per share) | (per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.17<span></span>
</td>
<td class="nump">$ 0.82<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssueOfOrdinaryShares', window );">Net proceeds from issue of ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,041<span></span>
</td>
<td class="nump">$ 4,197<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ShareIssueRelatedCostCommissions', window );">Share issue related cost, commissions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 187<span></span>
</td>
<td class="nump">$ 130<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssueOfOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuing of ordinary shares. [Refer: Ordinary shares [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssueOfOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_IssueOfEquityShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issue Of Equity, Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_IssueOfEquityShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_IssueOfOrdinarySharesPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issue Of Ordinary Shares Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_IssueOfOrdinarySharesPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ProceedsFromIssueOfOrdinarySharesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Issue Of Ordinary Shares, Gross</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ProceedsFromIssueOfOrdinarySharesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ShareIssueRelatedCostCommissions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Issue Related Cost, Commissions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ShareIssueRelatedCostCommissions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=ifrs-full_MajorOrdinaryShareTransactionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=ifrs-full_MajorOrdinaryShareTransactionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>104
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M0=5 Y3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%
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M:;\N.,NX,A? _^^EU.L#\P/MN^B3?P%02P,$%     @ &F9G6I=!< <Z @
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M[@K2)IC]O1#Z&-@#AGZ=_P502P,$%     @ &F9G6MW4P!!Y!0  @18  !@
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ME#:#T@(H+431VO^[]%!XH,H+#\[(=,L)?3/=#>TXQVH:_!GN#=2G#:4Y9_7
MA?KTH#0?2IM!:0&4%J)H;74=BAY4>=%#S_2Z*C@C-OFRD*G<9]]=#$JSS^J!
M _7I0FD>E.9#:3,H+8#20A2MK;1#%80JKX+XL>2ZVCTP5TV5SWW(0^@M/.S3
M$9 T!TISH30/2O//FOD9U&< I84H6EMXAU()55XJT3.YK@OEUSUW'UN3COR@
M#W& TFQ!#W1M0OGTJ0/UZD)IGJ /?&Y=U$U]K*N\7*#/5! XM?@'?(2"1D/=
M-$W*Y]9'1X_4JAY']UN4/<5)3E;LL;14/IKE5T&V>\+;[DV1;NJG;#VD19&N
MZY=+%BU85C4H__Z8EAM+\Z9Z<-?^.7M7_P)02P,$%     @ &F9G6M'U<V\Q
M!P  /2(  !@   !X;"]W;W)K<VAE971S+W-H965T-BYX;6RMFFUOFSH8AO^*
ME3,=K=*R8/,6>MI(7=BT2MM:K=O99X<X"2J!##OM>G[]>0PI!-NXC<2'-D >
MW_CVR^/+@8O'HKSG&\8$^K/-<GXYV@BQ.Y],>+)A6\K?%SN6PS>KHMQ2 :?E
M>L)W):/+JM VFQ#'"29;FN:CV45U[;:<711[D:4YNRT1WV^WM'SZP++B\7*$
M1\\7OJ?KC9 7)K.+'5VS.R9^[FY+.)LT*LMTRW*>%CDJV>IR=(7/8]>5!:J(
M?U/VR(^.D;2R*(I[>7*]O!PYLD8L8XF0$A0^'MB<99E4@GK\/HB.FGO*@L?'
MS^J?*O-@9D$YFQ?9KW0I-I>CZ0@MV8KN,_&]>/S,#H9\J9<4&:_^H\<Z-G!'
M*-ES46P/A:$&VS2O/^F?0T,<%<!!3P%R*$#4 EY/ ?=0P'UM >]0P*M:IK92
MM4-,!9U=E,4C*F4TJ,F#JC&KTF _S66_WXD2ODVAG)C-;[[=W7RYCJ]^?(S1
MW0_X^/KQVX\[=/,)S:_N/J-/7VY^W:$QG,3H[9LS] :E.?JQ*?:<YDM^,1%0
M!ZDT20[W^U#?C_3<#Q/TM<C%AJ./^9(MNP(3J'SC@#P[^$"LBC%+WB,7OT/$
M(9ZA0O/7%W<-Q>/7%R<6-V[3'VZEY_;HW>Q8246:K]&5G!&I2)FQE6L5SZPB
MD\4YW]&$78X@&W!6/K#1[.^_<.#\8VJA(<7B@<0ZK><UK>?9U&??(%%F!><(
M$B(2&X:>&"U-S5?+!)6,3(T/L[&+0^Q<3!Z.&\801L+0)]VPV!3F35V_">N8
M\1LSOM5,S*"%DI16^7&,=B4D^U(\(9AXB/W>ISM(OP*]S0O!. KD"#PS6:UO
MXA]5#A/5IQXSQ8I'/21RS?Z"QE]PBK]29NAQL1KO.4.4<R;XL[EIK[E JY7K
M>(HY0PQ1>U"/(5%DMA<V]D*KO;L-+=E8KDE+E!1;6*AY;97]D<?LV1RND@?\
M$:/#4*]92%S%HAZ$(QPJ'@U*;C@UFYPV)J=6D_-C8X^T+"D,R8/!0_>!0:.Q
MJ58==53J$=A7AZ5-I>,H:AQ%5D?7N6"0F$3;36D.W<?.WJ&<"9.12*^F&RE6
M])A0=:*'C,/ [ 4[[>KN6-W\S $&L_0_&(.0$@&"Y/!+-C1?@[$U8.%9E2^-
MZ[BC5VCJ3A5CAB@R56>720H'I"<_XB-VP?;15QL!(EG1M$0/--LS5*R:@;AD
M9?I )5@^3[;H'<*A<3@>;M6M(_&(ZM<0YI.IKSK6PTC/P,2DM4M>7-V2QG)>
MY..$\DT%UA(8$KI+!<V>9]W4;)/HV=#7>U6/PF&@F31H1;C'90M V$H(L[GT
MM)=9$TP6#0Y1*PX=-#O=0H(H"%1CIKBIYTU5:Z8XU_7[AFP+*-BS\MUU_@#)
MY66^PU;0.17P!E6+AU+K-F&+1=C.15<)P ]/JR4')CML5^^9H(N,(<Z2?=G?
MI#K"J"O.RR&Q(61,'-?K64AQ2T/8CD-?J3A4_C17.KIHK@QT YL=S9E-J6NJ
M92!LAR"EKVP,BP)SPM*Q!6:BNKZ:HK0Y;8CIG= M .$7"$BFJ[>'?'4F'3ZD
ML+%%BR<X?Y[K+R0O'6),%O4HN>?4UEJ3F.,Y/;".6R["D35S?4ISFB>OR%Q6
MOCHY<PVI%@^EUOVAHJ4Q8J>QV[)(&%O"]K0LM@!BK$Q27A$+%T5R#ZN=G"@O
M<#/184J=\(:04-O0&8(P,0\2TA(9L1-9O\,^)D.1V:4.4"I_S TQ:DZSAG0]
MMAA&[!AV2Y^JK 6F,@;;.Y2E=)%F=>JN/9G9B^B\-'95])B;HCQ'W<P9M:8]
M\$5:^"*O@*_C'+9J9KT]AQ$=F(+ 5?'+$.7B*/)4<WH8)L3IR=6DA2]B_WGH
M;<R24G;9&>3F^DA"9D71<D6J#N2R!#L)Z&&S4<^47_U 3=>&.-AN!^JB9))S
ML>_WI&O24A*Q4]*\S]0[M&#K-,]EG\(0[ON%C.B<XWH15O=#AC", Y6[8T.8
MATG0EV]::")V:+K>0KJNIJ*VO2U.[5@=?[ ?:=VJ1\'^3UV$35J1'_:X;6F*
MV&G*TJ<,KMIZT_ +D1]INUM#F*'38Y-:I].[_EJ6(G:6NA)CL6'CFGTK?X"*
MRY2+,EWLZ\=$ZY(QF7V-)JWJIY+'H&KQ4&K=EFWAC0P#;V10>!M4+1Y*K?M<
MIH4W]Q1XX_+7791ROH=V9<8G-#I?!1%6\XDA"CLD4&'-%$;\T#//.+?E-?<%
M7MLOLC2!S+$"+,O71A]6A9,?-0VI%@^EUFV]E@1=,LBL<JU >7(3#JD6#Z76
M;<*CQYUVX#QY5KG:LS9U]V,((=CU(W5*V91J-Y.CY^I;5JZK]Q,X2HI]+NH'
MU,W5YAV(J^K)OW+] SZ/ZS<96IGZQ8JOM 08X["36(&D\SZ$*5[6[RK4)Z+8
M54_O%X40Q;8ZW# *NR@9 -^O"MAP'$[D#9HW1F;_ U!+ P04    "  :9F=:
M+5>]^8$)   1%@  &    'AL+W=O<FMS:&5E=',O<VAE970W+GAM;*U8:V_;
MRA']*PNU*!)4EFS9B9W4-F#G)C<!;AZPT^9#T0\K<B0NO-QE]F%%_?4],TM*
MLJ_MW*+]8E/D[NP\SCDSY.G*AYO8$"7UH[4NGHV:E+K7TVFL&FIUG/B.')XL
M?&AUPL^PG,8ND*YE4VNGL_W]E]-6&S<Z/Y5[7\+YJ<_)&D=?@HJY;7587Y+U
MJ[/1P6BX<6663>(;T_/33B_IFM+?NR\!OZ8;*[5IR47CG0JT.!M='+R^/.+U
MLN ?AE9QYUIQ)'/O;_C'A_ILM,\.D:4JL06-?[?TAJQE0W#C>V]SM#F2-^Y>
M#];?2>R(9:XCO?'VFZE3<S8Z&:F:%CK;=.57[ZF/YP7;J[R-\E>MRMJ7+T:J
MRC'YMM\,#UKCRG_]H\_#SH:3_4<VS/H-,_&['"1>_J*3/C\-?J4"KX8UOI!0
M93><,XZ+<IT"GAKL2^>?=,J!E%^HSQT%S9F*2KM:_>J-6ZHWWE44W.DTX2S>
M,:UZNY?%[NP1NP<S]=&[U$3UUM54WS4PA9,;3V>#IY>S)RW^0M5$'1Z,U6Q_
M=O2$O<--Y(=B[_ Q>R96UD>._O-"??*)HKI X)]30T&]_=%9[73R8:T^N )^
M1M$_+^8Q!6#I7P_EI)QX]/")S*_7L=,5G8U H$CAED;G?_G3P<O]OST1S]$F
MGJ.GK/\/E?Q_V%6?':"X3J:*ZM(@F56#O*%B*QV5P;/0>6RF6B&)%UTP5LW&
MZN#5JY.QRD!(4$B[NLP1I\<(JV6]''91)?7LPLXI)/U<P=[Q\:OCPQ/5WU*_
MI7J"\WNS)X/9%:FJT6[)9^:@G&Y))?^HH]](:<2IE36M84<KWW;:K>]ZSX'7
MOC65L?AEG'H#E-0:Y^.(V,!"%#-=GEM3V;4"6.H2-0?X2<=:?\>FSB1MU4<=
M;B"\;)2??O4!G/'J.OGJ!A L[A?;B,U5IL,F +.2>LR';)FHK*^*?TF=[!^-
MU>%LI@X.8%5=W)++I*XGWR9C'&R7T-[QD+OQQO]-^!4 8"IM]V*"*JNY\1W"
M:G%F3GQ_DY>:;J'I'8.@(XO-/E WAH45-'8O>4LE9<8A!W#"YVAYEX4,![[?
MMMEY9IONQ+;">2[!9P0A:JV9DYP8XT!%DCS!V8Z%O&PG%=<Q45L0N2)]@WZA
M4FY]8&W&#U(M<1Y-;.-$?6V0*]-VP=_VIO7<6)/6G$\Y:=<JPV7!LJXJS2@?
M0WEO.%XY("K\P=(<*X)+<ROPTFH>O*Y5X-*Q5<]X\TM& NF$?H8F.E24^Z!:
M>.@\UY!WU[=\D@ 63BZ#;ID^JH$ >?@5B,_R8:_ST4@:IJK)K7:*.@,6M:C/
M$L*!NB^00F1AMN=HJ67IL_=7?YV^?WLUVWL^'%0 W5+2J#:78 XGXQ#O_8<H
M>\5!X++.%0,8V'9 7JB,\ZWF" (M#2LD4W>/G)XS3P9,J9AR;0@)^("&7->&
M5PE3&7L$S?6!\^L[\"UEA^<H$]3WCEGFP$YN!$)J"2<#% F028:7E!"XR,'G
M92,I_?7SY6]OOS*#$DNZN+,6[#= J (:U9S(L?D%",HE!<7Z>O!%5T8)I 7.
M8K#@B"MPUC#%<(TUK ,934+C+MQ BXFL"5'T:%C*]K@%('--T91")H:'H@6<
M8Y1<1.8S&A^U8.NF^4G"&LVU T^JW&8K1 /@H4N)0??GH^/C\?'!H<16>XEL
MZS%H)MQ$<$MGL F^PAT1B@@Y3I!1=BH[R_*R93>R _9C#?ZVA*IK"TK?&LX4
MR.55#:N]>\CG@I6]J*_?]@X>%5D8^[J8&#/7?("#E*[((PSW0HJ8%L30B&-%
MWS,3MF8\F'DN%0G"-V'7>*.G](-]C$+#E2Q)12BB"*R7:B+/I9-5?2?["$4L
MIE UU([+QR$,2K%;<I15J^6=[:M& $2=+E#&3CR*WII:JK0 .AUG3C&KJ!<$
MYH,<QGM@0C#-,=PUCC6Y+2"$8.@.0(6,2-+;K=L),LC48$&I*I\Y$HN2WFIC
M!=1F9Z+1<\SJ<M0B<Z='^1I3-6(_*<MR,$:K28*AH3<F/U8).H\BMV7,6P3?
MEJ0CO[V8(@D <FD0P?CZYXBN="Q\D NN]*VVG"$!]<&+\:NCV41=@U]X)J'Z
M1ZPM<I <!@T U,JAS2)9%5%=;+T<[Q\=J&>1A/:D9H?/01:3&LX&;[J'2<:R
MU).)"_7KKXDS@N8TE)JG1D=%'K"!$QK%'Y:EM@Q C(A'X^26D]WO2"/%Y)RF
MQH1:?<\Z)$2'2!#QBXEZ)VH?2_-<&:XV& .Z"W*!5IX=9*KA YVD@76533KZ
MD>Y5$SIF<TVE\*S-]XN/^'1Y,^,6QQ$-$@]2;@5Z7'SF'"UY)7PP(G$N>&L%
MK*S@O]L?RT8$E67BB"D6;0UR/A16.H0B#:3>W5IVNBR08"!NVFY9/;@@2>)^
MBM9XWTV9/ICK*P#BH? VVHW>#DH-H^KNV>/!GI19(H!EL#1S9\XB#B&CM('+
MW\?%/.?$BQU @C6#DRS0C;UX(7;H)VYQ$^9=3^5_T$++#88]V/'XEK:1RA#.
MPN'*=/('U0XJ41-#G5.:.WY3?X [1?)X<.I%O]=P %":.II[=2^5Q7%(=M15
M+]-H94PO]<@AB&#;[3GD"$IMX(F&A7W]A(YSR]0P=!K<Q*J*N1HSM^3XD#LU
MS:&%=QCJ2CJV3)VH]WZ%7*/^2R2XC/VU6:#+9IO60CJ\/@2_A[,!!WD!Z-TP
M_R[5+A,VCSX\4+& W>G4@]-#:2$KK 4@4J]DS^;/!8G@+3:@:>.!M(X@PV49
ML+>9LP;5J O<P0DLWW:*\FZ&+H+11V[@I%82J*6I0'F*T/(L/%9F,0QSV>E^
M(O;SA([_,!ZD60X$^*G/,+WQL#<>,V>6"0U*B##3KBS3HZ+,FZ%[=%=J"R=7
M>LVO"A0EMR2$RHQW#D1&TKXH.W->[?,\,33_BU&AC-=41-ICSED.8)-WDS4#
M >#)\N8SEEX>N G9=2^/V_XO[X%]V\UEXNE;O[3?\O)H268&S%-Z\[9RQZ,A
MZI\.+"@%O^3*E%/>@XMS4BL1S0^8Q(,;YO5W&QM7FYG@&JFK=0!IGXT^O+NZ
M'CW_F7,;9NU$^>2,Y%T_S*0_&);>C:K5Z_Z58#?3\A%P\T*_Z/MN3;'"-,HO
M5'.\6TX>^J SW?E,A^EY*1\C66A0I?+%;G-W\[WSHGSFVRXO'TL_ZK T (JE
M!;;N3XY?C%0H'R#+C^0[^>@W]RGY5BX;PMM:X 5XOO"0BOX''[#Y"GS^'U!+
M P04    "  :9F=:7F1'&?<#   ;"0  &    'AL+W=O<FMS:&5E=',O<VAE
M970X+GAM;(U676_K-@S]*X0'#"U0V$F:=A==$J!I=[$^7-RBV=T>ACW(-A,+
M5Y8\2HZ;_?J1<N)F6!KT)=$'>7A('DF>=8Z^^PHQP&MMK)\G50C-79;YHL):
M^=0U:'EG[:A6@:>TR7Q#J,KH5)ML,AK=9K72-EG,XMHS+6:N#49;?";P;5TK
MVBW1N&Z>C)/#PHO>5$$6LL6L41M<8?C6/!//L@&EU#5:KYT%PO4\N1_?+:=B
M'PU^U]CYHS%()KESWV7R5,Z3D1!"@T40!,5_6WQ 8P2(:?R]QTR&D.)X/#Z@
M?XZY<RZY\OC@S!^Z#-4\^91 B6O5FO#BNE]QG\^-X!7.^/@+76][>YM T?K@
MZKTS,ZBU[?_5Z[X.1PZ?1N\X3/8.D\B[#Q19/JJ@%C-R'9!8,YH,8JK1F\EI
M*TU9!>)=S7YAL51>>W!K>";T:(.26LVRP-!BD!5[F&4/,WD'9CR!+\Z&RL,O
MML3ROP 9<QJ(30[$EI.SB(]8I' ]OH+):#(]@W<])'H=\:[?P7MPU#A2 4';
M7LM1%+8$STDCZRQ(&9X^OZR@<'5CM+(%PI\J]X%8.W^=*DH?<GHZI)RG.]^H
M N=)(]6E+2:+'W\8WXY^/I/0=$AH>@[]XYT["W.:Y$EL6!T7ZJA&OU5LQ O6
M.Z-+MBEAK2UO:67>JNNA4EN$'-$"1VH4L9V6<UDX*B-0IT/5=T!YT-ZW;)'O
M(%0(3S8@V<B#0>_9I[5!VXV0LJ6BTL/2\1]<)$_WJV5RF<+7ECY BK40 ^Q0
M$:"(%UAZ6.=(@_RNH$-"4&VH'.E_!(J](L%3&2B^K3AJ&XO&I1+XGAQ/'C7Q
MA>3(PX6L)W$CN00V_:*HJ. VQKQ)86A"<]R$CV6E;6':$L&Q]4D#$;[$/[G)
M,<71M[G7I5:DT5_!5\MWS2[H@BNM74"F>K%4E*O2^4ON#Q]7 3UE]BU=I;W)
M5;3AUA^2ZC7PH*SB0!9*9XPBCA:)M[;8-[QHB= 6NQ161Z0B$(/H(!.WY99U
ME>:('?9BXT(%DCLUKG(U55%IW'+0KF(9LEE$>&V<QY*#4N\FA2&YSIE(<+#E
M8"HWO(:A)<N:(5='AMING=GV9R*V7CQY$7U C*D.>"K71H>=X*GUFB7 JQQU
MP P5N7931=C&L=[$<B,YV51.6%397O,--[^(*?^_43$C$8AF#@=:8G3"?]\-
M8Y@S'R\YTLHR15+6JUAZ-LF5$6GSB$7E:NR=N&;\,A]:8#0_35&-K- W=3)
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MLOW2N[9<-J9H[-9B.A"U5:)L?RC*-C[;@YQ55VX-@0$]1Q?"L\" N(%=V(#
MD?T#ZRT)H\Z+UZ7?\)P5_6%^'^Q-V? V7D\OV+9JAMK@?ZQ@?']_:3 7IJ_-
MSGDBE>@JW$#8T7XL>M>#9-S_^Z.+Q6/82.F+LB^@VF:[-%U4[^+N]-+CXG[Q
M=_S]U>,G]\XQ8&4Z8A$(<%M3].4G;.57[-TUV /ONK'ETC)_MJ;?N)JXD3$
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MJ"154V$2_JW/H]6"SB1Y+!W>A5.>J-1'7 S :-IZ+"\")$[4RKJV L/]2;K
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M<Y(N\KM^I1 X)Y1:BK8WPCG-!;!-WB;/M.%M![DZ!Z_U7_EB@G;H5^F=")3
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MY9R Z@= ;QC9^J;+I+$M[+>5G9FH7( ]+Z4T!\,E&*=P^@=02P,$%     @
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MG$P3\'VIM6L?:(/NAO;ROU!+ P04    "  :9F=: ,SG-,0'   0%@  &0
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MKS@ZX0/%_2@:% \B?W8RUSR;NDDZXNMCZ#'R_#%+STNLPE$Z^T%YR9/X7FK
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M[HV' >AV>+6&5;4?&$ME:?SX94GS'K4+('^AZ)IWACN@^P>9_P%02P,$%
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MSM*[6&E?,FD^_AA1'TXFR-"2G9=M'@^</ZV@P]H3\4DT8JQ2#(W7/+!@8LR
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M9G>5+S2/Q_.U\!.&!'05AE8PG8S.WA?"YZM6WD37I.O-TD5<EM*RPNV4/!_
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M,XM4J+2GRMF2?/A'#R@^7+PT//#$7EM 4( GQ],6M@DY,2JSTV<*V*=Z0W[
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ME,\?3_)+=*U\L$"YB:Z6QXI0ECTOP/S6(?;="Q\P?,&Z_1]02P,$%     @
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M*FM"='5[&1K4QJ9?_:6U0^_"Z\F1"[/VPDST3H)$R^]UU+?7WJV59VIPXX5
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M,W7L \DE)O$8(HHM_FP(Y(!;A,^S^YGLBHNO!@FK:Z7PTX@OFF J04,K3'S
M?KJFXML$K$B)&%>!@:@TJQ-1!%E[TV -(]0"*Y>AFH*Q](VO PF2VJ1\GB(#
M!Y*OV F%;@;7;@^1&D>U[$K4BF(8^M0Y?)TX:UVIQ*@^CR3G'+;[!#EJL3\A
M%;0F)M_>LZ2B 85N)=GNQV6-CC%JB'/D1/#6B"J&&;N>4760;L#4:-+<4H1
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MG#;^_0$3$OS^06MW#$*!Z44K?P%02P,$%     @ &F9G6FY]$5[R"0  V38
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ME4Y5PL1!Q7IGX1[#U.Y1*;*@V L"%C%#P-"&-L2K QF*+"3 ;5@..H -WG3
M'=I!E;EZ0N5.ZV4'!U8VS'QA^V.Z,'U3Q4XGK>^,*LW:YS;U6+KANY\VQN.V
MB8 0@6YR"7O,!<+"8F]97]BYKC(_8 &#F3<P2UFU]*3EMX%J=H1NUXR^5,@>
M3WEC@':9NOMFE)?'RV,=L-GDZ=R*I.G"\=':X\/1UU7=16TAX\E--6DLKLF
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MOEOKIH ];I7#KW$D_.2!B15(654L3:.:$H7-M_ %KN/GQ:=&%L,Q,$6[UJZ
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MC4W& #M"-$+H*DMJB8]=(-_SYK41H9G%M,V*PH#J4/QTZ!7'R(C6[;A3G
MRQ -EBYXL)X^#D4H7X:(D<X Z\W1OI!=32VL">ZG>+ (/;R"&D34@JJ$1!/V
M&GM_G$[NA8T%DEFRG/!7KJA5R!.,"*PX7K,!M@;U%D0A1KBG+Q0,M=S-8H'C
M'HT 8CO"?[4.B55)K(TP) ^RL2 4@])TJ/GWL_LO"V3'^+5'-(E0RASEUR?R
M+$IK,30?>ER"?/?;&ITUIE9(7@1O+72I\#L^8\D3A<1YX[N-I-\DAQD\_)$3
MQW[C=$,A=Z\D4YB_*4.>>U2TLSM=FX[R!;KX5U>MP@V4C;J1G%BJHB$>%JZ@
M9*R4XVAJC%]!\9%C7T63*3BQ[B:$[\$1YW<RFE6[COEMCLB0YWJ"W3.$TJB@
M%,/?*O#58!V\-.!$7U1[&Q2-<<[_K8'^B1JL.7$AH(<:WU<DP"R0MI3R2V@*
M9!2%ZM<>:#5>GB@HL@*VA%T.4_Z_)JAXY)E8(\>(HS8WV)TFZ168EV.X76A&
ME9.B*FLM.8L0(Z8##YN4K%A>K>>V@.""0 <LROD:3!M?V%EPY!U"5R&$$).D
MT<!'_$LHR:]\H&5S< :IVR/=1]@?  _\_0@[R,AYK%)47-=,(@YG<HR'!&][
M2:"41<KBZ#_ H]1[5&,K+9;2F] PD3)5P\MKN4:$UJ+\+N,#L$ @T0Q56=@"
M5@6A*A4W%;#-0$8H;_&:RCZ[\ +;Z4">WR9+2MG:[+XDZ0X[&+ J]=X;TI%]
MN)17AW+!)ESH"WYI4.0 L]9H='98Y!1.25FFQ=L?+#_%36-W?#-CU),9[N\*
M)T:./Q>==-DF9<."=>9$/X4X0"8% FBQZ&&Y9%1I8'<EAE9NYJ! \X4C\E(*
MMPS(9A7[KO/VKY;L4(M"W66E*C9?"++VV#-2LVD%SD$8#;RM]\D6>NF<EAH8
MM3QDEV6ZZ$'#NLFGTW*Y[8IF+1IA5:Z-OHWU7<D+T)CBUM;DJ4),,]9VE5+4
M<N$,K1Q*!#NX<%2A8#;JX&)7D:ZHI(U.J=6;9*+(GQ/I^Q"&D'4*IYZEI$=L
MP7VV2*9O5J3"(\+4L&1R"Y3)TO'RI  OZ@[(V1S)H2N!@_73TV'U6<HDL9PQ
M+(X&*^FI)Z SAR!(1"RE\D_)GI6'/XAY\J.1"^T('D0!]%)BSNY2N7X$^?OH
MVB%,Z.MVU'K*+I"\[*)3'Y7:7V,'[3[<&Q_N!2,*MFO<0=2<AH\][)>NLH9U
MDX<[P,N3L7;JISZ?[H2^QHRG'#^J+G#X>*//Y%3CC0S768*5[X&&$ .1B#_X
ME<-K'O4C?W\%W^,ML]S8<_W5HL9:2@+B7QHLC]WK 'X(L=8M=TNA4E&4E%N>
M@V4D]M2ACBGXCOY=\.F^M8CDX8C>!Q*$9OH!@_J?C\\_P^XQV:Y?*S9/(?+C
MD*I)A1WQN6"08]TO]H;6ULL5P3+>EA5NLBS]9%%IK- 0VX="B1Z<*OIW+@ @
M$*..P3!]E96UB+QY\0O"!*[]1:T/;4M G.N%',2+A)BI2S5"$,FVD_FT<F5T
MA=>]8_</R#Y?2(I^)Q DQ'P0%E7]!#XWYO,M)&9GOZI@P [%LW44?NVS."AO
MMPR@^=@%M9[D<L$@'N2$@,7\*:MRKG$I=8@0:=!XD:!)[(#!DA RH'/4G8 .
MN [GE[5SRHGT^10IC>'MVUJ5-Z?7Y=J2@8>A3!3?08D)[UN1 @8\F;V-E^)D
MB3EEV _VAOF(O$"?N6$64,]Q78C[8C/XL-B:"ELV[Y0<7E%#>N?%=5](\+3X
M9[3$T6IPH:F?+6F/L)/SN;%W./1CA!1N2#LS_EOV&I&'G0,<U:]35SUW$OEL
MG7![,3S))#J&8;R6SPF(U?YCA.=Y\[P9 #U65K*?'9ED*$9YUAVXG8IH;-/1
MP?OAEV+HZ>M+^EKL/(K(7S#UP?ZB01S./CL(1;#3 $PH*5)6^Z-+Q.$"\5%W
M$"W=O+C*YNU-].#DZOK2P[8$A&?"%YI3PJXX=Q&E,:+(O@V+;D.,&=NI#+#%
M:V+I5G:^ZU I0+0]OO<')U_N2W+O(')ERD]MZ(OON;$CEU2&9SI=W4^WC,[O
MN"I4V=AH^8/>Y6]2BC?>1S'17Y^V^'1Y79P7[_JWL&# YQRH^N)=0I _ *O#
MQT^@8,!IM(879Q<7K+,PY=O 2.KEB%$M0%6'2'4-'"K1NV15!#Z6U+%.23<*
MZ/:AT_[\(KQL1BU;'2I8_1<&A9?8,% 9[BJ[08'FT7ANK(K=7_$R4"";E>\_
M%(0_$''#'L\0'DMKW/&-,E>O\HYO6#W=_+N.3>=3[_=*]X@NIN\1C9XLBCZ]
M4@$ <2N![R?1VZZ%8VR+_X+H_4/H?AJ3L/^/=0M\DT-Q_J+/+ISE/6 [P)H=
M78T<Y1X*X"6@QUK>XC0\E;\R-0LDR!>@$^W_P)'.X[(&FX6Q9Q#3-KMP,T_Z
M )O^C0"1<<9+6??X\'8SAZ9T 9]+<F0=6ZR%RRTK_@142$Y7EO6$E673_%XA
M 3JGE5Y2N26WU>*'0].4Q,,'VR"DLEIALCLE_HS/O^KU[.=YL5[\F?4%.\*!
MH8+@#+UM;OSE&P+R\2TVL.,?%'8)%A"N;'6ND:E83%VWHJ#/TYGA8O3&BX]T
MY8T8B2FDWE;QSH2QG:_WQ? .$ M'MHR56UWXPXNQ5^/-BG<)<V:_?XC)523B
M ^S'Q<XA*E#BB=(:8( 5-BWP$F_#2R"N'+?'30AH,:=!CY^PGIK-Z,M6^JM)
M4QYG X@I?TZ<DG+$;%K/<J9$GT\6Q>5-FMQ/3?FH$ DL],HTU,/#S8?L'H+5
MYG>\/9^QG^'<HP 4COTQ2]VV"!\C;?@S86E0X!!>\ L8J @LZ\?KZ<#"\9?T
MR9W<]**^EGMF,46#_HA<-'V-K:NRX_!.H+M? CCF/1YE[[?<:+>BMWAZQNW\
MJLOX;7Q3Z"6_'S,]SJ\9_5ZY%48#M5["T+/Y\Z<G7'4-'UJ[I;=E E-:NZ$_
MUQI4S.$#\/O2@F+*!UP@OC_US?\"4$L#!!0    ( !IF9UI"P*^ VP,  !4)
M   9    >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;)56;6_;-A#^*P=U*U(@
MBTSJQ79J&W!>BA5HMJ#IM@_#/M#2V28JB2Y)Q5E__>XH1W8 Q\6^4'R[Y[E[
M>.1ILC7VJULC>GBJJ\9-H[7WF\LX=L4::^4NS 8;6ED:6RM/0[N*W<:B*H-1
M7<5R,,CC6NDFFDW"W+V=34SK*]W@O077UK6R_UYA9;;32$3/$Y_U:NUY(IY-
M-FJ%#^C_V-Q;&L4]2JEK;)PV#5A<3J.YN+Q*>7_8\*?&K3OH T>R,.8K#SZ6
MTVC #F&%A6<$19]'O,:J8B!RX]L.,^HIV?"P_XS^(<1.L2R4PVM3_:5+OYY&
MHPA*7*JV\I_-]E?<Q9,Q7F$J%UK8=GNS-(*B==[4.V/RH-9-]U5/.QT.#$:#
M5PSDSD &OSNBX.6-\FHVL68+EG<3&G="J,&:G-,-'\J#M[2JR<[/'KK# +.$
M.^71:E7!O"A,VWC=K.#>5+K0Z.#LBUI4Z-Y-8D^L;!L7.X:KCD&^PB DW)G&
MKQW<-B66+P%B<K?W63[[?"5/(MY@<0&). <YD.D)O*37( EXR0\T^'T)#WK5
MZ*4N5../RO#W?.&\I53ZYY@0'4UZG(:OUZ7;J *G$=T?A_81H]G;-R(?O#\1
M1-H'D9Y"GSW0=2W;"ODD2R2"0JN0]Y:.U1WS]B3><6]O#H&UHUM9&$N'"JUC
MF?P:B;L@*!XM5*6: J%&OS8E*!_6EZ:BAX#75=.TE&W!OTL2GV1'P&^MWM"E
M][1<PK*UC?:M13IJ^!GNL*2CJ0XVA>EK4V]:RMV#^83G/R%=U[6I2M#UQII'
MY"4'%*7BN_H+APPT;8-C!%"S>-ROV+*GN^UA>Z;]U,[OVQ=^?^C]WOOP\="'
M+\83\+5QE&:.I:&<QGI!R+N\EO 3Y-RD<DRM3$?<)H+:\7  \[+4? CN'!IZ
MN<EM>I_I!6H GXJU:E;(,5.>PMLW(RGD>QCVO?W,<>J$B=,D#Z1,.1X.]X1[
M<P$B'_5#F8SA1KN-<:KZL5=GV?@=G*4)-3+EWI :,:3Q<9]2BCMA-?+0&[,R
M8L1]<3Y($YC7QGK]O4O,UQ7-&".10<4 $63-10HO,AN?J.91 DC.(TDB"!B)
M5]7*,D@R$H-R4>1CR,?9<31!VR#-&$T,Y/\2*T@D6*RD%RO/3HG%T25$QC%V
MD7+H>2+A-R+C*@F/JFKQU:B&,,HHIA$G@QS)$U2LIA A2[,!GY$(C8!CKUI\
M4*IJM*M0D!V$E[:K6OUL7_/G7:G;;^]^&.Z476E*R J79#JX&&81V*X(=P-O
M-J'P+8RG,AJZ:_IO0<L;:'UIC'\>,$'_)S3[#U!+ P04    "  :9F=:;Q7
MD]\#   D"0  &0   'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6R55FUOVS80
M_BL'=2M2((M%2O)+:AO(6]$"RQ8TW?9AV =:.MM$)5$EJ3C=K]\=Y<@.8'O;
M%XH\\IY[[N&1U'1C[%>W1O3P7)6UFT5K[YO+P<#E:ZR4NS -UC2S-+92GH9V
M-7"-154$IZH<R#@>#BJEZV@^#;8'.Y^:UI>ZQ@<+KJTJ9;]?8VDVLTA$+X;/
M>K7V;!C,IXU:X2/ZWYH'2Z-!CU+H"FNG30T6E[/H2EQ>I[P^+/A=X\;M]8$S
M61CSE0>?BED4,R$L,?>,H.CSA#=8E@Q$-+YM,:,^)#ON]U_0/X3<*9>%<GAC
MRC]TX=>S:!Q!@4O5EOZSV7S$;3X9X^6F=*&%S79M'$'>.F^JK3,QJ'3=?=7S
M5H?_XB"W#C+P[@(%EK?*J_G4F@U87DUHW FI!F\BIVO>E$=O:5:3GY\_6-I?
MZ[^#J@NX^];JAA3W</9%+4IT[Z8#3T%XZ2#? EYW@/((H)!P;VJ_=G!7%UB\
M!A@0NYZB?*%X+4\BWF)^ 8DX!QG+] 1>TJ><!+SD&)YV>6E<:Q',DG;0*UUB
M ;KN2CS4RH+J%YJM-N?0E(I$88FPE^A/M7#>4E7]=4BDCD)ZF *?M$O7J!QG
M$1TEA_8)H_G;-V(8OS^18-HGF)Y"GS_2R2W:,J37[.]O3_X0XY.8AQG?(O5S
MW6FF'1W2W%C:=&B=KE?@UTCRY@3%HX4B$7.$"OW:%*!\F%^:DNX%GE=UW:H2
MK/+H+N'7Y5+3XIW<S'_9VEI[WC@9PX]PCX7.R66W*)AO3-6T'NV>/6'[STBG
M=VU*VNJ*9'E"GG) 62H^NC]QRD!F&X@10,4"<K]DSS[<[I3TD7:F+>^[5[P_
M]+QW'#[M<_AB/ '?&.?ARK$T5/-8+0AY6_<2?H A-ZF<4"O3,;>)H'8RBN&J
M*#1O@CN'FBYRHDVU3!=2#?B<KU6]0LZ9:A7>OAE+(=_#J._M+(=#)QPX388A
M*(><C$:[@#MW 6(X[H<RF0 =M,8X5?X[J[-L\@[.TH0:F7)O1(T8T?@PIY3R
M3EB-8>A-6!DQYKXXC],$KBICO?Z[*\SCBF:,D<B@8H (L@Y%"J\J&Y_I":0"
MD%Q'DD00,!9'U<HR2#(2@VI1#"<PG&2'T00M@S1C-!'+_R56D$BP6$DOUC [
M)19GEU PSK'+E%,?)A)^H6#\:,*3*EL\FM4(QAGE-.9BD&-Y(A2K*42HTBSF
M/1*A$7#H9AOLO5P5VE5XGQWDIJU]]XCUUOX7X*I[^7;+N_^'>V57F@JRQ"6Y
MQA>C+ +;O<G=P)LFO(,+X^E5#=TU_<:@Y04TOS3&OPPX0/]C-/\'4$L#!!0
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MGQ\Q#&CZK33_64-]=,8GLNZ>LY?M5W.&_FO&C,C[:\:,/S$PI&'&??&#HVW
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MH *,SZK*;06<H/W",_X74$L#!!0    ( !IF9UHN^FFIH (  -<%   9
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M^#^2PH+;"K@JB049OF]/7'H.< +CR>@R2\A(L]$E789EQ0U66I9H[+M=CT^
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MY&I&L3%=T^\V3K>AT6ZUH[8=EC7]DVB\ -WOM':GC3<P_+RK?P!02P,$%
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M5):&OA<W],JB=@KT_THIN]\X!\.[O?@'4$L#!!0    ( !IF9UH4['NYF (
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M*DMCH=V6-(=1NP ZSY6R>\,5&"9[\A=02P,$%     @ &F9G6@NQ="'9 @
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MNZ'KAACFA=+VPA$"+"NAMH@^+W4)5JN<0!8H,>?6P!=(6G'_TL^#R\C/W6@
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M>-6[Y@8?5Z#L!/R>26GV'9N@>:[%?P%02P,$%     @ &F9G6C%"7Q[* @
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MEP@  '-)   9    >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;,6<;8^C1A*
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MQTQ?=E 8 _T^Y5P]#HR#^OH4_0%02P,$%     @ &F9G6G$EH-#Y P  -1$
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M>58=[AA=LZ(,4+]O.)?/)V4#S3;;Y7]02P,$%     @ &F9G6I:7TU79 @
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M(,$EJ3)YSS;?L%E/5^O%+!/F'S9U;+]K05P)R?(&5C/(:5%?R7.S#SN &QP
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MMGDT]N9%D:ZJAR _I461QM7BDOMBF%<V$.\_IVFQ?5$FV#V@?/H_4$L#!!0
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M_M?L;TG74Z6>:$U+'(WKG]?DM&"'#R*M1U43FXXGD_KY7]/:_ZU;+Y:A3UF
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MH/S[?9H6+V^J"@Y/D[WY/U!+ P04    "  :9F=:^4.Q'TT#   Q"@  &0
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M VD ^#T30N\G9H.F2XS^ %!+ P04    "  :9F=:]7:FGZ4#  "*"P  &0
M 'AL+W=O<FMS:&5E=',O<VAE970V-RYX;6RM5FUOVS@,_BN";SBT0!N_YZ67
M!&B2[6X?MA4M=OMPN ^*S<3";"F3Y&0%[L<?);M>8B=I!NQ+0LGD(SZD1'*\
M$_*KR@ T^5[D7$V<3.O-G>NJ)(."JI[8 ,<O*R$+JG$IUZ[:2*"I-2IR-_"\
MOEM0QIWIV.X]R.E8E#IG'!XD46514/D\@USL)H[OO&P\LG6FS88['6_H&IY
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M4B8F#:D";3Q,>W"3:Q,1VYGMMNS?[VRG68$6\<!+8Y_O^WSW-?=EM)'J05<
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M6J>):FS%):XUF$8(IE\66*G]+!@&QX,'7I36'81I4K,"']%^K=>:O+!#R;E
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MHG8!=+]5RAX=1] M\/0W4$L#!!0    ( !IF9UJ:.4VU< 0  )\/   9
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M@@IRJ26P^MO# JI**ZDX_FM%G6Y,[7A^_:K^V< KF!46L&#5WZ20FYF3.:B
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M$F0S534++6H[9VR%QJG%/A8XB((T!OA^)X0^+\P'NM%V^0]02P,$%     @
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M\W=:EFAK?3M1O+;5;\Z5KJ5V6.KV",($Z/T%YVH[,0?T#3?] U!+ P04
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M_WZV$S((@?6A+V [YQS?<R_<F_&&\6>1 TCT4A943*Q<RNK6MD6:0XG%-:N
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M)M6@,\M<O;L UP#U?,&8W&WT!>W;4/074$L#!!0    ( !IF9UI3"KH+6P0
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MBP^7+7'=GX-Y6IS"!-V8NV(M,:,WHPG/P9R.)NK&/& F,0.-\5^BV=>YO+6
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M5 B:Z<<-X!B8,I"_KR@5+P750/V_PO0_4$L#!!0    ( !IF9UIV>7T(50,
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MH %#PM"\!W?>1\'F/14T_YT<_P%02P,$%     @ &F9G6I>*NQS     $P(
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MCKX.9QYDA$!&QX,<+K]ZD#$"&=-"SKBMM&!JS>9;H7?'&2\S]D5!(&$>9()
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M)R]+"/16U%L)]%;46PGT5M1;"?16U%L)]%;46PGT5M1;"?1.J'<BT#NAWHE
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M5X&;7U!+ 0(4 Q0    ( !IF9UH'04UB@0   +$    0              "
M 0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ &F9G6B7A20[P
M*P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#
M%     @ &F9G6IE<G",0!@  G"<  !,              ( !S@$  'AL+W1H
M96UE+W1H96UE,2YX;6Q02P$"% ,4    "  :9F=:FU$G86D&  "7'@  &
M            @($/"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#
M%     @ &F9G6I=!< <Z @  NP4  !@              ("!K@X  'AL+W=O
M<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( !IF9UK=U, 0>04  ($6
M   8              " @1X1  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q0
M2P$"% ,4    "  :9F=:MC-L0#P%  #X$P  &               @('-%@
M>&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ &F9G6O!GO56/
M"   <T\  !@              ("!/QP  'AL+W=O<FMS:&5E=',O<VAE970U
M+GAM;%!+ 0(4 Q0    ( !IF9UK1]7-O,0<  #TB   8              "
M@00E  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    "  :9F=:
M+5>]^8$)   1%@  &               @(%K+   >&PO=V]R:W-H965T<R]S
M:&5E=#<N>&UL4$L! A0#%     @ &F9G6EYD1QGW P  &PD  !@
M     ("!(C8  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    (
M !IF9UK3^;E$B!D  ')/   8              " @4\Z  !X;"]W;W)K<VAE
M971S+W-H965T.2YX;6Q02P$"% ,4    "  :9F=:SLP]78@)  #5&0  &0
M            @($-5   >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4
M Q0    ( !IF9UIF0-49G@,  *P'   9              " @<Q=  !X;"]W
M;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ &F9G6O+G9<IJ P
M. @  !D              ("!H6$  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX
M;6Q02P$"% ,4    "  :9F=:)W=PO6 "  "1!0  &0              @(%"
M90  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( !IF9UI+
M2GVY<P0  '4*   9              " @=EG  !X;"]W;W)K<VAE971S+W-H
M965T,30N>&UL4$L! A0#%     @ &F9G6L*! NK""   K14  !D
M     ("!@VP  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( !IF9UH(%DD_X@0  /L*   9              "
M@7^,  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ &F9G
M6GK#Q@_J!0  E0T  !D              ("!F)$  'AL+W=O<FMS:&5E=',O
M<VAE970R,2YX;6Q02P$"% ,4    "  :9F=:'52()RD(  #-$@  &0
M        @(&YEP  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0
M   ( !IF9UHBRI<C^ 8  &83   9              " @1F@  !X;"]W;W)K
M<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ &F9G6DR)&GX' P  V@8
M !D              ("!2*<  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q0
M2P$"% ,4    "  :9F=:OM#3LD0#  !A!P  &0              @(&&J@
M>&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( !IF9UJD?E/'
MRP,  %L(   9              " @0&N  !X;"]W;W)K<VAE971S+W-H965T
M,C8N>&UL4$L! A0#%     @ &F9G6GTVT'4( P  T08  !D
M ("! [(  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    "  :
M9F=:E'.>Y!P#  #D!@  &0              @(%"M0  >&PO=V]R:W-H965T
M<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( !IF9UIVTUZI(04  *<+   9
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M  !X;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ &F9G6D+
MKX#; P  %0D  !D              ("!I^4  'AL+W=O<FMS:&5E=',O<VAE
M970S,RYX;6Q02P$"% ,4    "  :9F=:;Q7 D]\#   D"0  &0
M    @(&YZ0  >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    (
M !IF9UH8V!CF<@(  'X%   9              " @<_M  !X;"]W;W)K<VAE
M971S+W-H965T,S4N>&UL4$L! A0#%     @ &F9G6GX@/-QQ P  + D  !D
M             ("!>/   'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"
M% ,4    "  :9F=:5W[>DSX$  #X"0  &0              @($@]   >&PO
M=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( !IF9UH9Z>E%R@<
M  L6   9              " @97X  !X;"]W;W)K<VAE971S+W-H965T,S@N
M>&UL4$L! A0#%     @ &F9G6HZV&DG@!0  [1$  !D              ("!
ME@ ! 'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"% ,4    "  :9F=:
M+OIIJ: "  #7!0  &0              @(&M!@$ >&PO=V]R:W-H965T<R]S
M:&5E=#0P+GAM;%!+ 0(4 Q0    ( !IF9UH0X-:(_ 0  /\*   9
M      " @80) 0!X;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%
M  @ &F9G6O'W.&UD @  /04  !D              ("!MPX! 'AL+W=O<FMS
M:&5E=',O<VAE970T,BYX;6Q02P$"% ,4    "  :9F=:3W#A:]D"  !T!@
M&0              @(%2$0$ >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+
M 0(4 Q0    ( !IF9UKJ&S>+. ,  (4'   9              " @6(4 0!X
M;"]W;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @ &F9G6M\0"9B9
M P  PP<  !D              ("!T1<! 'AL+W=O<FMS:&5E=',O<VAE970T
M-2YX;6Q02P$"% ,4    "  :9F=:%.Q[N9@"  #E!0  &0
M@(&A&P$ >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    ( !IF
M9UH+L70AV0(  "(&   9              " @7 > 0!X;"]W;W)K<VAE971S
M+W-H965T-#<N>&UL4$L! A0#%     @ &F9G6LHA&+&U P  -!(  !D
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M=#4R+GAM;%!+ 0(4 Q0    ( !IF9UKNL34H@ (  (8&   9
M  " @4$W 0!X;"]W;W)K<VAE971S+W-H965T-3,N>&UL4$L! A0#%     @
M&F9G6IP&+(5; P  2@T  !D              ("!^#D! 'AL+W=O<FMS:&5E
M=',O<VAE970U-"YX;6Q02P$"% ,4    "  :9F=:<26@T/D#   U$0  &0
M            @(&*/0$ >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4
M Q0    ( !IF9UI*,!(2T (  (4*   9              " @;I! 0!X;"]W
M;W)K<VAE971S+W-H965T-38N>&UL4$L! A0#%     @ &F9G6A-/@"OQ!0
M<BL  !D              ("!P40! 'AL+W=O<FMS:&5E=',O<VAE970U-RYX
M;6Q02P$"% ,4    "  :9F=:EI?35=D"  "."0  &0              @('I
M2@$ >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4 Q0    ( !IF9UJ6
M!AI>)0H  *Q\   9              " @?E- 0!X;"]W;W)K<VAE971S+W-H
M965T-3DN>&UL4$L! A0#%     @ &F9G6LT98K54 P  ? D  !D
M     ("!55@! 'AL+W=O<FMS:&5E=',O<VAE970V,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( !IF9UJ60/HQ7 H  %EV   9              "
M@9&% 0!X;"]W;W)K<VAE971S+W-H965T-C4N>&UL4$L! A0#%     @ &F9G
M6OE#L1]- P  ,0H  !D              ("!)) ! 'AL+W=O<FMS:&5E=',O
M<VAE970V-BYX;6Q02P$"% ,4    "  :9F=:]7:FGZ4#  "*"P  &0
M        @(&HDP$ >&PO=V]R:W-H965T<R]S:&5E=#8W+GAM;%!+ 0(4 Q0
M   ( !IF9UJ'P%\]A@(  *4&   9              " @827 0!X;"]W;W)K
M<VAE971S+W-H965T-C@N>&UL4$L! A0#%     @ &F9G6IJX9N8V @  UP0
M !D              ("!09H! 'AL+W=O<FMS:&5E=',O<VAE970V.2YX;6Q0
M2P$"% ,4    "  :9F=:T0V;RK4"   S!P  &0              @(&NG $
M>&PO=V]R:W-H965T<R]S:&5E=#<P+GAM;%!+ 0(4 Q0    ( !IF9UKZT_@L
M;0(  ,P%   9              " @9J? 0!X;"]W;W)K<VAE971S+W-H965T
M-S$N>&UL4$L! A0#%     @ &F9G6IHY3;5P!   GP\  !D
M ("!/J(! 'AL+W=O<FMS:&5E=',O<VAE970W,BYX;6Q02P$"% ,4    "  :
M9F=:'NY@^[P#   <$@  &0              @('EI@$ >&PO=V]R:W-H965T
M<R]S:&5E=#<S+GAM;%!+ 0(4 Q0    ( !IF9UJJ/<Q7?P0  "@<   9
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M970W."YX;6Q02P$"% ,4    "  :9F=:V4E<PIL"  !\!P  &0
M    @($FOP$ >&PO=V]R:W-H965T<R]S:&5E=#<Y+GAM;%!+ 0(4 Q0    (
M !IF9UI9R@GK. (  $0%   9              " @?C! 0!X;"]W;W)K<VAE
M971S+W-H965T.# N>&UL4$L! A0#%     @ &F9G6B,!)P:L!0  Z!X  !D
M             ("!9\0! 'AL+W=O<FMS:&5E=',O<VAE970X,2YX;6Q02P$"
M% ,4    "  :9F=:'>$:EVX#  #P$   &0              @(%*R@$ >&PO
M=V]R:W-H965T<R]S:&5E=#@R+GAM;%!+ 0(4 Q0    ( !IF9UKQO[UM$ ,
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M<F5L<R\N<F5L<U!+ 0(4 Q0    ( !IF9UI<B9[H108   (W   /
M      "  3': 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    "  :9F=:DS&\
M_8 "  "3,0  &@              @ &CX $ >&PO7W)E;',O=V]R:V)O;VLN
M>&UL+G)E;'-02P$"% ,4    "  :9F=:]S F!B<"   R,   $P
M    @ %;XP$ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     7 !< #L9  "S
%Y0$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>252</ContextCount>
  <ElementCount>322</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>64</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>12</UnitCount>
  <MyReports>
    <Report instance="oncyf-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="oncyf-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="oncyf-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>9952151 - Statement - CONSOLIDATED STATEMENTS OF FINANCIAL POSITION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF FINANCIAL POSITION</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="oncyf-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>9952153 - Statement - CONSOLIDATED STATEMENTS OF LOSS AND COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF LOSS AND COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="oncyf-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>9952154 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="oncyf-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>9952155 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="oncyf-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>9952156 - Disclosure - Nature of Operations and Going Concern</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/NatureofOperationsandGoingConcern</Role>
      <ShortName>Nature of Operations and Going Concern</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="oncyf-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>9952157 - Disclosure - Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/BasisofPresentation</Role>
      <ShortName>Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="oncyf-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>9952158 - Disclosure - Summary of Material Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/SummaryofMaterialAccountingPolicies</Role>
      <ShortName>Summary of Material Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="oncyf-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>9952159 - Disclosure - Significant Judgments, Estimates and Assumptions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/SignificantJudgmentsEstimatesandAssumptions</Role>
      <ShortName>Significant Judgments, Estimates and Assumptions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="oncyf-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>9952160 - Disclosure - Other Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/OtherLiabilities</Role>
      <ShortName>Other Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="oncyf-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>9952161 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/PropertyandEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="oncyf-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>9952162 - Disclosure - Accounts Payable and Accrued Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/AccountsPayableandAccruedLiabilities</Role>
      <ShortName>Accounts Payable and Accrued Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="oncyf-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>9952163 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="oncyf-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>9952164 - Disclosure - Warrant Derivative</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/WarrantDerivative</Role>
      <ShortName>Warrant Derivative</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="oncyf-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>9952165 - Disclosure - Share Capital</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ShareCapital</Role>
      <ShortName>Share Capital</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="oncyf-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>9952166 - Disclosure - Share-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ShareBasedCompensation</Role>
      <ShortName>Share-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="oncyf-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>9952167 - Disclosure - Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/LossPerShare</Role>
      <ShortName>Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="oncyf-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>9952168 - Disclosure - Contract Liability</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ContractLiability</Role>
      <ShortName>Contract Liability</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="oncyf-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>9952169 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="oncyf-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>9952170 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="oncyf-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>9952171 - Disclosure - Capital Disclosures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/CapitalDisclosures</Role>
      <ShortName>Capital Disclosures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="oncyf-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>9952172 - Disclosure - Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/FinancialInstruments</Role>
      <ShortName>Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="oncyf-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>9952173 - Disclosure - Additional Cash Flow Disclosures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosures</Role>
      <ShortName>Additional Cash Flow Disclosures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="oncyf-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>9952174 - Disclosure - Economic Dependence</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/EconomicDependence</Role>
      <ShortName>Economic Dependence</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="oncyf-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>9952175 - Disclosure - Components of Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ComponentsofExpenses</Role>
      <ShortName>Components of Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="oncyf-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>9952176 - Disclosure - Segment Disclosures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/SegmentDisclosures</Role>
      <ShortName>Segment Disclosures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="oncyf-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9952177 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="oncyf-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9952178 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="oncyf-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>995447 - Disclosure - Insider Trading Policies and Procedures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc</Role>
      <ShortName>Insider Trading Policies and Procedures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="oncyf-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure</Role>
      <ShortName>Cybersecurity Risk Management and Strategy Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="oncyf-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9955511 - Disclosure - Summary of Material Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/SummaryofMaterialAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Material Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/SummaryofMaterialAccountingPolicies</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="oncyf-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9955512 - Disclosure - Summary of Material Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/SummaryofMaterialAccountingPoliciesTables</Role>
      <ShortName>Summary of Material Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/SummaryofMaterialAccountingPolicies</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="oncyf-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9955513 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/PropertyandEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/PropertyandEquipment</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="oncyf-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9955514 - Disclosure - Accounts Payable and Accrued Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/AccountsPayableandAccruedLiabilitiesTables</Role>
      <ShortName>Accounts Payable and Accrued Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/AccountsPayableandAccruedLiabilities</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="oncyf-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9955515 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/Leases</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="oncyf-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9955516 - Disclosure - Warrant Derivative (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/WarrantDerivativeTables</Role>
      <ShortName>Warrant Derivative (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/WarrantDerivative</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="oncyf-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9955517 - Disclosure - Share Capital (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ShareCapitalTables</Role>
      <ShortName>Share Capital (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/ShareCapital</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="oncyf-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9955518 - Disclosure - Share-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ShareBasedCompensationTables</Role>
      <ShortName>Share-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/ShareBasedCompensation</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="oncyf-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9955519 - Disclosure - Contract Liability (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ContractLiabilityTables</Role>
      <ShortName>Contract Liability (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/ContractLiability</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="oncyf-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9955520 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/IncomeTaxes</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="oncyf-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9955521 - Disclosure - Capital Disclosures (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/CapitalDisclosuresTables</Role>
      <ShortName>Capital Disclosures (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/CapitalDisclosures</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="oncyf-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9955522 - Disclosure - Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/FinancialInstrumentsTables</Role>
      <ShortName>Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/FinancialInstruments</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="oncyf-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9955523 - Disclosure - Additional Cash Flow Disclosures (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresTables</Role>
      <ShortName>Additional Cash Flow Disclosures (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosures</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="oncyf-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9955524 - Disclosure - Components of Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ComponentsofExpensesTables</Role>
      <ShortName>Components of Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/ComponentsofExpenses</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="oncyf-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9955525 - Disclosure - Segment Disclosures (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/SegmentDisclosuresTables</Role>
      <ShortName>Segment Disclosures (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/SegmentDisclosures</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="oncyf-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9955526 - Disclosure - Related Party Transactions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsTables</Role>
      <ShortName>Related Party Transactions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/RelatedPartyTransactions</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="oncyf-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9955527 - Disclosure - Nature of Operations and Going Concern (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/NatureofOperationsandGoingConcernDetails</Role>
      <ShortName>Nature of Operations and Going Concern (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/NatureofOperationsandGoingConcern</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="oncyf-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9955528 - Disclosure - Summary of Material Accounting Policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/SummaryofMaterialAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Summary of Material Accounting Policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="oncyf-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>9955529 - Disclosure - Summary of Material Accounting Policies - Schedule of Depreciation Rates (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/SummaryofMaterialAccountingPoliciesScheduleofDepreciationRatesDetails</Role>
      <ShortName>Summary of Material Accounting Policies - Schedule of Depreciation Rates (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="oncyf-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>9955530 - Disclosure - Other Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/OtherLiabilitiesDetails</Role>
      <ShortName>Other Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/OtherLiabilities</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="oncyf-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>9955531 - Disclosure - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails</Role>
      <ShortName>Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/PropertyandEquipmentTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="oncyf-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>9955532 - Disclosure - Accounts Payable and Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/AccountsPayableandAccruedLiabilitiesDetails</Role>
      <ShortName>Accounts Payable and Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/AccountsPayableandAccruedLiabilitiesTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="oncyf-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>9955533 - Disclosure - Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="oncyf-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>9955534 - Disclosure - Leases - Right-of-use Assets and Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/LeasesRightofuseAssetsandLeaseLiabilitiesDetails</Role>
      <ShortName>Leases - Right-of-use Assets and Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="oncyf-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>9955535 - Disclosure - Leases - Total Undiscounted Lease Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/LeasesTotalUndiscountedLeaseLiabilityDetails</Role>
      <ShortName>Leases - Total Undiscounted Lease Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="oncyf-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>9955536 - Disclosure - Warrant Derivative - Reconciliation of Change in Fair Value of Warrant Derivative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/WarrantDerivativeReconciliationofChangeinFairValueofWarrantDerivativeDetails</Role>
      <ShortName>Warrant Derivative - Reconciliation of Change in Fair Value of Warrant Derivative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="oncyf-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>9955537 - Disclosure - Warrant Derivative - Warrant Derivative Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/WarrantDerivativeWarrantDerivativeOutstandingDetails</Role>
      <ShortName>Warrant Derivative - Warrant Derivative Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="oncyf-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>9955538 - Disclosure - Warrant Derivative - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails</Role>
      <ShortName>Warrant Derivative - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="oncyf-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>9955539 - Disclosure - Warrant Derivative - Summary of Assumptions Used in the Black Scholes Option Pricing Model for Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/WarrantDerivativeSummaryofAssumptionsUsedintheBlackScholesOptionPricingModelforWarrantsDetails</Role>
      <ShortName>Warrant Derivative - Summary of Assumptions Used in the Black Scholes Option Pricing Model for Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="oncyf-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>9955540 - Disclosure - Share Capital - Schedule of Share Capital (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails</Role>
      <ShortName>Share Capital - Schedule of Share Capital (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="oncyf-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>9955541 - Disclosure - Share Capital - Schedule of Share Capital Footnotes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails</Role>
      <ShortName>Share Capital - Schedule of Share Capital Footnotes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="oncyf-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>9955542 - Disclosure - Share-Based Compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ShareBasedCompensationNarrativeDetails</Role>
      <ShortName>Share-Based Compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="oncyf-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>9955543 - Disclosure - Share-Based Compensation - Schedule of Stock Options and Weighted Average Exercise Prices (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsandWeightedAverageExercisePricesDetails</Role>
      <ShortName>Share-Based Compensation - Schedule of Stock Options and Weighted Average Exercise Prices (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="oncyf-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>9955544 - Disclosure - Share-Based Compensation - Schedule of Stock Options Outstanding and Exercisable by Range of Exercise Price (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails</Role>
      <ShortName>Share-Based Compensation - Schedule of Stock Options Outstanding and Exercisable by Range of Exercise Price (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="oncyf-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>9955545 - Disclosure - Share-Based Compensation - Disclosure Weighted Average Assumptions and Fair Value of Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ShareBasedCompensationDisclosureWeightedAverageAssumptionsandFairValueofOptionsDetails</Role>
      <ShortName>Share-Based Compensation - Disclosure Weighted Average Assumptions and Fair Value of Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="oncyf-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>9955546 - Disclosure - Share-Based Compensation - Schedule of Number of Other Equity Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofNumberofOtherEquityInstrumentsDetails</Role>
      <ShortName>Share-Based Compensation - Schedule of Number of Other Equity Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="oncyf-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>9955547 - Disclosure - Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/LossPerShareDetails</Role>
      <ShortName>Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/LossPerShare</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="oncyf-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>9955548 - Disclosure - Contract Liability - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ContractLiabilityNarrativeDetails</Role>
      <ShortName>Contract Liability - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="oncyf-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>9955549 - Disclosure - Contract Liability - Schedule of Contract Revenues and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ContractLiabilityScheduleofContractRevenuesandLiabilitiesDetails</Role>
      <ShortName>Contract Liability - Schedule of Contract Revenues and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="oncyf-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>9955550 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/CommitmentsandContingencies</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="oncyf-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>9955551 - Disclosure - Income Taxes - Provision for Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Provision for Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="oncyf-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>9955552 - Disclosure - Income Taxes - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/IncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="oncyf-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>9955553 - Disclosure - Income Taxes - Schedule of Unrecognized Deferred Tax Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/IncomeTaxesScheduleofUnrecognizedDeferredTaxAssetsDetails</Role>
      <ShortName>Income Taxes - Schedule of Unrecognized Deferred Tax Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="oncyf-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>9955554 - Disclosure - Capital Disclosures (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/CapitalDisclosuresDetails</Role>
      <ShortName>Capital Disclosures (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/CapitalDisclosuresTables</ParentRole>
      <Position>75</Position>
    </Report>
    <Report instance="oncyf-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>9955555 - Disclosure - Financial Instruments - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails</Role>
      <ShortName>Financial Instruments - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="oncyf-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>9955556 - Disclosure - Financial Instruments - Schedule of Balances in Foreign Currencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/FinancialInstrumentsScheduleofBalancesinForeignCurrenciesDetails</Role>
      <ShortName>Financial Instruments - Schedule of Balances in Foreign Currencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="oncyf-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>9955557 - Disclosure - Additional Cash Flow Disclosures - Net Change In Non-Cash Working Capital (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails</Role>
      <ShortName>Additional Cash Flow Disclosures - Net Change In Non-Cash Working Capital (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="oncyf-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>9955558 - Disclosure - Additional Cash Flow Disclosures - Other Cash Flow Disclosures (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresOtherCashFlowDisclosuresDetails</Role>
      <ShortName>Additional Cash Flow Disclosures - Other Cash Flow Disclosures (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="oncyf-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>9955559 - Disclosure - Economic Dependence (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/EconomicDependenceDetails</Role>
      <ShortName>Economic Dependence (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/EconomicDependence</ParentRole>
      <Position>80</Position>
    </Report>
    <Report instance="oncyf-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>9955560 - Disclosure - Components of Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ComponentsofExpensesDetails</Role>
      <ShortName>Components of Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/ComponentsofExpensesTables</ParentRole>
      <Position>81</Position>
    </Report>
    <Report instance="oncyf-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>9955561 - Disclosure - Segment Disclosures (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/SegmentDisclosuresDetails</Role>
      <ShortName>Segment Disclosures (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/SegmentDisclosuresTables</ParentRole>
      <Position>82</Position>
    </Report>
    <Report instance="oncyf-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>9955562 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsTables</ParentRole>
      <Position>83</Position>
    </Report>
    <Report instance="oncyf-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>9955563 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/SubsequentEvents</ParentRole>
      <Position>84</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="20-F" isDefinitelyFs="true" isIfrs="true" isUsgaap="true" original="oncyf-20241231.htm">oncyf-20241231.htm</File>
    <File>oncyf-20241231.xsd</File>
    <File>oncyf-20241231_cal.xml</File>
    <File>oncyf-20241231_def.xml</File>
    <File>oncyf-20241231_lab.xml</File>
    <File>oncyf-20241231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>oncyf-20241231_g1.jpg</File>
    <File>oncyf-20241231_g2.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="15">http://xbrl.sec.gov/cyd/2024</BaseTaxonomy>
    <BaseTaxonomy items="45">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="1">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
    <BaseTaxonomy items="720">https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>111
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "oncyf-20241231.htm": {
   "nsprefix": "oncyf",
   "nsuri": "http://www.oncolyticsbiotech.com/20241231",
   "dts": {
    "inline": {
     "local": [
      "oncyf-20241231.htm"
     ]
    },
    "schema": {
     "local": [
      "oncyf-20241231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/dimensions/rol_full_ifrs-dim_2024-03-27.xsd",
      "https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd",
      "https://xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/currency/2024/currency-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-af-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-af-sub-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "oncyf-20241231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "oncyf-20241231_def.xml"
     ],
     "remote": [
      "https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/dimensions/dim_full_ifrs_2024-03-27_role-995000.xml"
     ]
    },
    "labelLink": {
     "local": [
      "oncyf-20241231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "oncyf-20241231_pre.xml"
     ]
    }
   },
   "keyStandard": 241,
   "keyCustom": 81,
   "axisStandard": 20,
   "axisCustom": 3,
   "memberStandard": 32,
   "memberCustom": 28,
   "hidden": {
    "total": 10,
    "http://xbrl.sec.gov/dei/2024": 6,
    "http://www.oncolyticsbiotech.com/20241231": 4
   },
   "contextCount": 252,
   "entityCount": 1,
   "segmentCount": 64,
   "elementCount": 623,
   "unitCount": 12,
   "baseTaxonomies": {
    "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full": 720,
    "http://xbrl.sec.gov/dei/2024": 45,
    "http://xbrl.sec.gov/cyd/2024": 15,
    "http://xbrl.sec.gov/ecd/2024": 1
   },
   "report": {
    "R1": {
     "role": "http://www.oncolyticsbiotech.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.oncolyticsbiotech.com/role/AuditInformation",
     "longName": "0000002 - Document - Audit Information",
     "shortName": "Audit Information",
     "isDefault": "false",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorFirmId",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorFirmId",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION",
     "longName": "9952151 - Statement - CONSOLIDATED STATEMENTS OF FINANCIAL POSITION",
     "shortName": "CONSOLIDATED STATEMENTS OF FINANCIAL POSITION",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "ifrs-full:CashAndCashEquivalents",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "ifrs-full:OtherCurrentReceivables",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS",
     "longName": "9952153 - Statement - CONSOLIDATED STATEMENTS OF LOSS AND COMPREHENSIVE LOSS",
     "shortName": "CONSOLIDATED STATEMENTS OF LOSS AND COMPREHENSIVE LOSS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:ResearchAndDevelopmentExpense",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:ProfitLossFromOperatingActivities",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY",
     "longName": "9952154 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY",
     "shortName": "CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-14",
      "name": "ifrs-full:Equity",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-10",
      "name": "ifrs-full:Equity",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "longName": "9952155 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:ProfitLoss",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.oncolyticsbiotech.com/role/NatureofOperationsandGoingConcern",
     "longName": "9952156 - Disclosure - Nature of Operations and Going Concern",
     "shortName": "Nature of Operations and Going Concern",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.oncolyticsbiotech.com/role/BasisofPresentation",
     "longName": "9952157 - Disclosure - Basis of Presentation",
     "shortName": "Basis of Presentation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.oncolyticsbiotech.com/role/SummaryofMaterialAccountingPolicies",
     "longName": "9952158 - Disclosure - Summary of Material Accounting Policies",
     "shortName": "Summary of Material Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.oncolyticsbiotech.com/role/SignificantJudgmentsEstimatesandAssumptions",
     "longName": "9952159 - Disclosure - Significant Judgments, Estimates and Assumptions",
     "shortName": "Significant Judgments, Estimates and Assumptions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.oncolyticsbiotech.com/role/OtherLiabilities",
     "longName": "9952160 - Disclosure - Other Liabilities",
     "shortName": "Other Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfOtherLiabilitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfOtherLiabilitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.oncolyticsbiotech.com/role/PropertyandEquipment",
     "longName": "9952161 - Disclosure - Property and Equipment",
     "shortName": "Property and Equipment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.oncolyticsbiotech.com/role/AccountsPayableandAccruedLiabilities",
     "longName": "9952162 - Disclosure - Accounts Payable and Accrued Liabilities",
     "shortName": "Accounts Payable and Accrued Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.oncolyticsbiotech.com/role/Leases",
     "longName": "9952163 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfLeasesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfLeasesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.oncolyticsbiotech.com/role/WarrantDerivative",
     "longName": "9952164 - Disclosure - Warrant Derivative",
     "shortName": "Warrant Derivative",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.oncolyticsbiotech.com/role/ShareCapital",
     "longName": "9952165 - Disclosure - Share Capital",
     "shortName": "Share Capital",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.oncolyticsbiotech.com/role/ShareBasedCompensation",
     "longName": "9952166 - Disclosure - Share-Based Compensation",
     "shortName": "Share-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.oncolyticsbiotech.com/role/LossPerShare",
     "longName": "9952167 - Disclosure - Loss Per Share",
     "shortName": "Loss Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.oncolyticsbiotech.com/role/ContractLiability",
     "longName": "9952168 - Disclosure - Contract Liability",
     "shortName": "Contract Liability",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.oncolyticsbiotech.com/role/CommitmentsandContingencies",
     "longName": "9952169 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.oncolyticsbiotech.com/role/IncomeTaxes",
     "longName": "9952170 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.oncolyticsbiotech.com/role/CapitalDisclosures",
     "longName": "9952171 - Disclosure - Capital Disclosures",
     "shortName": "Capital Disclosures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.oncolyticsbiotech.com/role/FinancialInstruments",
     "longName": "9952172 - Disclosure - Financial Instruments",
     "shortName": "Financial Instruments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosures",
     "longName": "9952173 - Disclosure - Additional Cash Flow Disclosures",
     "shortName": "Additional Cash Flow Disclosures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfCashFlowStatementExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfCashFlowStatementExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.oncolyticsbiotech.com/role/EconomicDependence",
     "longName": "9952174 - Disclosure - Economic Dependence",
     "shortName": "Economic Dependence",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "oncyf:DisclosureOfEconomicDependenceTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "oncyf:DisclosureOfEconomicDependenceTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.oncolyticsbiotech.com/role/ComponentsofExpenses",
     "longName": "9952175 - Disclosure - Components of Expenses",
     "shortName": "Components of Expenses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfExpensesByNatureExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfExpensesByNatureExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.oncolyticsbiotech.com/role/SegmentDisclosures",
     "longName": "9952176 - Disclosure - Segment Disclosures",
     "shortName": "Segment Disclosures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.oncolyticsbiotech.com/role/RelatedPartyTransactions",
     "longName": "9952177 - Disclosure - Related Party Transactions",
     "shortName": "Related Party Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.oncolyticsbiotech.com/role/SubsequentEvents",
     "longName": "9952178 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc",
     "longName": "995447 - Disclosure - Insider Trading Policies and Procedures",
     "shortName": "Insider Trading Policies and Procedures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure",
     "longName": "995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure",
     "shortName": "Cybersecurity Risk Management and Strategy Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.oncolyticsbiotech.com/role/SummaryofMaterialAccountingPoliciesPolicies",
     "longName": "9955511 - Disclosure - Summary of Material Accounting Policies (Policies)",
     "shortName": "Summary of Material Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DescriptionOfUncertaintiesOfEntitysAbilityToContinueAsGoingConcern",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DescriptionOfUncertaintiesOfEntitysAbilityToContinueAsGoingConcern",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.oncolyticsbiotech.com/role/SummaryofMaterialAccountingPoliciesTables",
     "longName": "9955512 - Disclosure - Summary of Material Accounting Policies (Tables)",
     "shortName": "Summary of Material Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R34": {
     "role": "http://www.oncolyticsbiotech.com/role/PropertyandEquipmentTables",
     "longName": "9955513 - Disclosure - Property and Equipment (Tables)",
     "shortName": "Property and Equipment (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R35": {
     "role": "http://www.oncolyticsbiotech.com/role/AccountsPayableandAccruedLiabilitiesTables",
     "longName": "9955514 - Disclosure - Accounts Payable and Accrued Liabilities (Tables)",
     "shortName": "Accounts Payable and Accrued Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "oncyf:DetailedDisclosureOfTradeAndOtherPayablesExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "oncyf:DetailedDisclosureOfTradeAndOtherPayablesExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.oncolyticsbiotech.com/role/LeasesTables",
     "longName": "9955515 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.oncolyticsbiotech.com/role/WarrantDerivativeTables",
     "longName": "9955516 - Disclosure - Warrant Derivative (Tables)",
     "shortName": "Warrant Derivative (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.oncolyticsbiotech.com/role/ShareCapitalTables",
     "longName": "9955517 - Disclosure - Share Capital (Tables)",
     "shortName": "Share Capital (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationTables",
     "longName": "9955518 - Disclosure - Share-Based Compensation (Tables)",
     "shortName": "Share-Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.oncolyticsbiotech.com/role/ContractLiabilityTables",
     "longName": "9955519 - Disclosure - Contract Liability (Tables)",
     "shortName": "Contract Liability (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.oncolyticsbiotech.com/role/IncomeTaxesTables",
     "longName": "9955520 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "oncyf:ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "oncyf:ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.oncolyticsbiotech.com/role/CapitalDisclosuresTables",
     "longName": "9955521 - Disclosure - Capital Disclosures (Tables)",
     "shortName": "Capital Disclosures (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "oncyf:DisclosureOfCapitalComponentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "oncyf:DisclosureOfCapitalComponentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsTables",
     "longName": "9955522 - Disclosure - Financial Instruments (Tables)",
     "shortName": "Financial Instruments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "oncyf:ScheduleOfForeignCurrencyHeldTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "oncyf:ScheduleOfForeignCurrencyHeldTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresTables",
     "longName": "9955523 - Disclosure - Additional Cash Flow Disclosures (Tables)",
     "shortName": "Additional Cash Flow Disclosures (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "oncyf:CashFlowOperatingCapital1TableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "oncyf:CashFlowOperatingCapital1TableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.oncolyticsbiotech.com/role/ComponentsofExpensesTables",
     "longName": "9955524 - Disclosure - Components of Expenses (Tables)",
     "shortName": "Components of Expenses (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "oncyf:OtherExpensesAndAdjustmentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "oncyf:OtherExpensesAndAdjustmentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.oncolyticsbiotech.com/role/SegmentDisclosuresTables",
     "longName": "9955525 - Disclosure - Segment Disclosures (Tables)",
     "shortName": "Segment Disclosures (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfGeographicalAreasExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfGeographicalAreasExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsTables",
     "longName": "9955526 - Disclosure - Related Party Transactions (Tables)",
     "shortName": "Related Party Transactions (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.oncolyticsbiotech.com/role/NatureofOperationsandGoingConcernDetails",
     "longName": "9955527 - Disclosure - Nature of Operations and Going Concern (Details)",
     "shortName": "Nature of Operations and Going Concern (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "ifrs-full:RetainedEarnings",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R49": {
     "role": "http://www.oncolyticsbiotech.com/role/SummaryofMaterialAccountingPoliciesNarrativeDetails",
     "longName": "9955528 - Disclosure - Summary of Material Accounting Policies - Narrative (Details)",
     "shortName": "Summary of Material Accounting Policies - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "ifrs-full:CashEquivalents",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "ifrs-full:CashEquivalents",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.oncolyticsbiotech.com/role/SummaryofMaterialAccountingPoliciesScheduleofDepreciationRatesDetails",
     "longName": "9955529 - Disclosure - Summary of Material Accounting Policies - Schedule of Depreciation Rates (Details)",
     "shortName": "Summary of Material Accounting Policies - Schedule of Depreciation Rates (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c-54",
      "name": "oncyf:PropertyPlantandEquipmentAnnualDepreciationRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-54",
      "name": "oncyf:PropertyPlantandEquipmentAnnualDepreciationRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.oncolyticsbiotech.com/role/OtherLiabilitiesDetails",
     "longName": "9955530 - Disclosure - Other Liabilities (Details)",
     "shortName": "Other Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "ifrs-full:OtherCurrentLiabilities",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-57",
      "name": "ifrs-full:OtherReceivables",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails",
     "longName": "9955531 - Disclosure - Property and Equipment (Details)",
     "shortName": "Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "ifrs-full:PropertyPlantAndEquipment",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:LossesOnDisposalsOfPropertyPlantAndEquipment",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.oncolyticsbiotech.com/role/AccountsPayableandAccruedLiabilitiesDetails",
     "longName": "9955532 - Disclosure - Accounts Payable and Accrued Liabilities (Details)",
     "shortName": "Accounts Payable and Accrued Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "oncyf:DetailedDisclosureOfTradeAndOtherPayablesExplanatoryTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "oncyf:DetailedDisclosureOfTradeAndOtherPayablesExplanatoryTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.oncolyticsbiotech.com/role/LeasesNarrativeDetails",
     "longName": "9955533 - Disclosure - Leases - Narrative (Details)",
     "shortName": "Leases - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "ifrs-full:WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "ifrs-full:WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.oncolyticsbiotech.com/role/LeasesRightofuseAssetsandLeaseLiabilitiesDetails",
     "longName": "9955534 - Disclosure - Leases - Right-of-use Assets and Lease Liabilities (Details)",
     "shortName": "Leases - Right-of-use Assets and Lease Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "ifrs-full:RightofuseAssets",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "oncyf:ForeignExchangeImpactRightofUseAssets",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.oncolyticsbiotech.com/role/LeasesTotalUndiscountedLeaseLiabilityDetails",
     "longName": "9955535 - Disclosure - Leases - Total Undiscounted Lease Liability (Details)",
     "shortName": "Leases - Total Undiscounted Lease Liability (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "ifrs-full:GrossLeaseLiabilities",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "ifrs-full:GrossLeaseLiabilities",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.oncolyticsbiotech.com/role/WarrantDerivativeReconciliationofChangeinFairValueofWarrantDerivativeDetails",
     "longName": "9955536 - Disclosure - Warrant Derivative - Reconciliation of Change in Fair Value of Warrant Derivative (Details)",
     "shortName": "Warrant Derivative - Reconciliation of Change in Fair Value of Warrant Derivative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "oncyf:NumberOfWarrantsOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "ifrs-full:DerivativeFinancialLiabilities",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.oncolyticsbiotech.com/role/WarrantDerivativeWarrantDerivativeOutstandingDetails",
     "longName": "9955537 - Disclosure - Warrant Derivative - Warrant Derivative Outstanding (Details)",
     "shortName": "Warrant Derivative - Warrant Derivative Outstanding (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c-125",
      "name": "oncyf:WarrantExercisePrice",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R59": {
     "role": "http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails",
     "longName": "9955538 - Disclosure - Warrant Derivative - Narrative (Details)",
     "shortName": "Warrant Derivative - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c-125",
      "name": "oncyf:NumberOfWarrantsAndSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-125",
      "name": "oncyf:OtherEquityInstrumentsInShareBasedPaymentArrangementThresholdTradingPrice",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "oncyf:OtherEquityInstrumentsInShareBasedPaymentArrangementThresholdTradingPrice",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.oncolyticsbiotech.com/role/WarrantDerivativeSummaryofAssumptionsUsedintheBlackScholesOptionPricingModelforWarrantsDetails",
     "longName": "9955539 - Disclosure - Warrant Derivative - Summary of Assumptions Used in the Black Scholes Option Pricing Model for Warrants (Details)",
     "shortName": "Warrant Derivative - Summary of Assumptions Used in the Black Scholes Option Pricing Model for Warrants (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c-123",
      "name": "oncyf:WeightedAverageSharePriceOtherEquityInstrumentsGranted",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-123",
      "name": "oncyf:WeightedAverageSharePriceOtherEquityInstrumentsGranted",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails",
     "longName": "9955540 - Disclosure - Share Capital - Schedule of Share Capital (Details)",
     "shortName": "Share Capital - Schedule of Share Capital (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "ifrs-full:Equity",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-9",
      "name": "ifrs-full:NumberOfSharesIssued",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails",
     "longName": "9955541 - Disclosure - Share Capital - Schedule of Share Capital Footnotes (Details)",
     "shortName": "Share Capital - Schedule of Share Capital Footnotes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "c-128",
      "name": "oncyf:ProceedsFromIssueOfOrdinarySharesGross",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-125",
      "name": "oncyf:IssueOfEquitySharesNumberOfCommonShares",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationNarrativeDetails",
     "longName": "9955542 - Disclosure - Share-Based Compensation - Narrative (Details)",
     "shortName": "Share-Based Compensation - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "oncyf:NumberOfSharesReservedForIssueUnderOptionsAndContractsForSaleOfSharesPercentageOfCommonSharesMaximum",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "oncyf:NumberOfSharesReservedForIssueUnderOptionsAndContractsForSaleOfSharesPercentageOfCommonSharesMaximum",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsandWeightedAverageExercisePricesDetails",
     "longName": "9955543 - Disclosure - Share-Based Compensation - Schedule of Stock Options and Weighted Average Exercise Prices (Details)",
     "shortName": "Share-Based Compensation - Schedule of Stock Options and Weighted Average Exercise Prices (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "ifrs-full:NumberOfOutstandingShareOptions",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "unique": true
     }
    },
    "R65": {
     "role": "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails",
     "longName": "9955544 - Disclosure - Share-Based Compensation - Schedule of Stock Options Outstanding and Exercisable by Range of Exercise Price (Details)",
     "shortName": "Share-Based Compensation - Schedule of Stock Options Outstanding and Exercisable by Range of Exercise Price (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "ifrs-full:NumberOfOutstandingShareOptions",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory",
       "ifrs-full:DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "unique": true
     }
    },
    "R66": {
     "role": "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationDisclosureWeightedAverageAssumptionsandFairValueofOptionsDetails",
     "longName": "9955545 - Disclosure - Share-Based Compensation - Disclosure Weighted Average Assumptions and Fair Value of Options (Details)",
     "shortName": "Share-Based Compensation - Disclosure Weighted Average Assumptions and Fair Value of Options (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R67": {
     "role": "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofNumberofOtherEquityInstrumentsDetails",
     "longName": "9955546 - Disclosure - Share-Based Compensation - Schedule of Number of Other Equity Instruments (Details)",
     "shortName": "Share-Based Compensation - Schedule of Number of Other Equity Instruments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "c-191",
      "name": "ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-193",
      "name": "ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "unique": true
     }
    },
    "R68": {
     "role": "http://www.oncolyticsbiotech.com/role/LossPerShareDetails",
     "longName": "9955547 - Disclosure - Loss Per Share (Details)",
     "shortName": "Loss Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:WeightedAverageShares",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "ifrs-full:AdjustedWeightedAverageShares",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R69": {
     "role": "http://www.oncolyticsbiotech.com/role/ContractLiabilityNarrativeDetails",
     "longName": "9955548 - Disclosure - Contract Liability - Narrative (Details)",
     "shortName": "Contract Liability - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "oncyf:ContractLiabilityRecognitionPeriod",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ifrs-full:ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "oncyf:ContractLiabilityRecognitionPeriod",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ifrs-full:ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R70": {
     "role": "http://www.oncolyticsbiotech.com/role/ContractLiabilityScheduleofContractRevenuesandLiabilitiesDetails",
     "longName": "9955549 - Disclosure - Contract Liability - Schedule of Contract Revenues and Liabilities (Details)",
     "shortName": "Contract Liability - Schedule of Contract Revenues and Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "ifrs-full:ContractLiabilities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-25",
      "name": "ifrs-full:ContractLiabilities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "unique": true
     }
    },
    "R71": {
     "role": "http://www.oncolyticsbiotech.com/role/CommitmentsandContingenciesDetails",
     "longName": "9955550 - Disclosure - Commitments and Contingencies (Details)",
     "shortName": "Commitments and Contingencies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "oncyf:PurchaseObligation1",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "oncyf:PurchaseObligation1",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R72": {
     "role": "http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails",
     "longName": "9955551 - Disclosure - Income Taxes - Provision for Income Taxes (Details)",
     "shortName": "Income Taxes - Provision for Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:AccountingProfit",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "oncyf:ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:AccountingProfit",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "oncyf:ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R73": {
     "role": "http://www.oncolyticsbiotech.com/role/IncomeTaxesNarrativeDetails",
     "longName": "9955552 - Disclosure - Income Taxes - Narrative (Details)",
     "shortName": "Income Taxes - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "c-205",
      "name": "ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-205",
      "name": "ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R74": {
     "role": "http://www.oncolyticsbiotech.com/role/IncomeTaxesScheduleofUnrecognizedDeferredTaxAssetsDetails",
     "longName": "9955553 - Disclosure - Income Taxes - Schedule of Unrecognized Deferred Tax Assets (Details)",
     "shortName": "Income Taxes - Schedule of Unrecognized Deferred Tax Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R75": {
     "role": "http://www.oncolyticsbiotech.com/role/CapitalDisclosuresDetails",
     "longName": "9955554 - Disclosure - Capital Disclosures (Details)",
     "shortName": "Capital Disclosures (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "ifrs-full:CashAndCashEquivalents",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-233",
      "name": "oncyf:EquityAuthorized",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "unique": true
     }
    },
    "R76": {
     "role": "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails",
     "longName": "9955555 - Disclosure - Financial Instruments - Narrative (Details)",
     "shortName": "Financial Instruments - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "ifrs-full:CurrentDerivativeFinancialAssets",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-234",
      "name": "oncyf:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "unique": true
     }
    },
    "R77": {
     "role": "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsScheduleofBalancesinForeignCurrenciesDetails",
     "longName": "9955556 - Disclosure - Financial Instruments - Schedule of Balances in Foreign Currencies (Details)",
     "shortName": "Financial Instruments - Schedule of Balances in Foreign Currencies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "ifrs-full:CashAndCashEquivalents",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-238",
      "name": "ifrs-full:CashAndCashEquivalents",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "oncyf:ScheduleOfForeignCurrencyHeldTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "unique": true
     }
    },
    "R78": {
     "role": "http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails",
     "longName": "9955557 - Disclosure - Additional Cash Flow Disclosures - Net Change In Non-Cash Working Capital (Details)",
     "shortName": "Additional Cash Flow Disclosures - Net Change In Non-Cash Working Capital (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "78",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "oncyf:CashFlowOperatingCapital1TableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "oncyf:CashFlowOperatingCapital1TableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R79": {
     "role": "http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresOtherCashFlowDisclosuresDetails",
     "longName": "9955558 - Disclosure - Additional Cash Flow Disclosures - Other Cash Flow Disclosures (Details)",
     "shortName": "Additional Cash Flow Disclosures - Other Cash Flow Disclosures (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "79",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "oncyf:ProceedsfromInterestReceived",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "oncyf:ScheduleofCashFlowSupplementalDisclosures1TableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "oncyf:ProceedsfromInterestReceived",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "oncyf:ScheduleofCashFlowSupplementalDisclosures1TableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R80": {
     "role": "http://www.oncolyticsbiotech.com/role/EconomicDependenceDetails",
     "longName": "9955559 - Disclosure - Economic Dependence (Details)",
     "shortName": "Economic Dependence (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "80",
     "firstAnchor": {
      "contextRef": "c-242",
      "name": "oncyf:ConcentrationRiskNumber",
      "unitRef": "manufacturer",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-242",
      "name": "oncyf:ConcentrationRiskNumber",
      "unitRef": "manufacturer",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R81": {
     "role": "http://www.oncolyticsbiotech.com/role/ComponentsofExpensesDetails",
     "longName": "9955560 - Disclosure - Components of Expenses (Details)",
     "shortName": "Components of Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "81",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-243",
      "name": "oncyf:ClinicalTrialExpense",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "oncyf:OtherExpensesAndAdjustmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "unique": true
     }
    },
    "R82": {
     "role": "http://www.oncolyticsbiotech.com/role/SegmentDisclosuresDetails",
     "longName": "9955561 - Disclosure - Segment Disclosures (Details)",
     "shortName": "Segment Disclosures (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "82",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "oncyf:NumberOfReportableSegments1",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "oncyf:NumberOfReportableSegments1",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R83": {
     "role": "http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsDetails",
     "longName": "9955562 - Disclosure - Related Party Transactions (Details)",
     "shortName": "Related Party Transactions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "83",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R84": {
     "role": "http://www.oncolyticsbiotech.com/role/SubsequentEventsDetails",
     "longName": "9955563 - Disclosure - Subsequent Events (Details)",
     "shortName": "Subsequent Events (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "84",
     "firstAnchor": {
      "contextRef": "c-128",
      "name": "oncyf:ProceedsFromIssueOfOrdinarySharesGross",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-53",
      "name": "oncyf:ProceedsFromIssueOfOrdinarySharesGross",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20241231.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "oncyf_A2021SharesUnderAtTheMarketAgreementUnitedStatesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "A2021SharesUnderAtTheMarketAgreementUnitedStatesMember",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2021 United States ATM",
        "label": "2021 Shares Under At-the-market Agreement, United States [Member]",
        "documentation": "2021 Shares Under At-the-market Agreement, United States"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_A2022SharesUnderAtTheMarketAgreementUnitedStatesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "A2022SharesUnderAtTheMarketAgreementUnitedStatesMember",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2022 United States ATM",
        "label": "2022 Shares Under At-the-market Agreement, United States [Member]",
        "documentation": "2022 Shares Under At-the-market Agreement, United States"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_A2024SharesUnderAtTheMarketAgreementUnitedStatesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "A2024SharesUnderAtTheMarketAgreementUnitedStatesMember",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024 United States ATM",
        "label": "2024 Shares Under At-the-market Agreement, United States [Member]",
        "documentation": "2024 Shares Under At-the-market Agreement, United States"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AccountingProfit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AccountingProfit",
     "crdr": "credit",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss before income taxes",
        "label": "Accounting profit"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of profit (loss) for a period before deducting tax expense. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r32",
      "r33"
     ]
    },
    "ifrs-full_AccrualsClassifiedAsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AccrualsClassifiedAsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/AccountsPayableandAccruedLiabilitiesDetails": {
       "parentTag": "ifrs-full_TradeAndOtherCurrentPayables",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/AccountsPayableandAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued liabilities",
        "label": "Accruals classified as current"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of accruals classified as current. [Refer: Accruals]"
       }
      }
     },
     "auth_ref": [
      "r313"
     ]
    },
    "ifrs-full_AccumulatedDepreciationAndAmortisationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AccumulatedDepreciationAndAmortisationMember",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization",
        "label": "Accumulated depreciation and amortisation [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for accumulated depreciation and amortisation. [Refer: Depreciation and amortisation expense]"
       }
      }
     },
     "auth_ref": [
      "r44",
      "r316",
      "r319",
      "r320",
      "r321"
     ]
    },
    "ifrs-full_AccumulatedOtherComprehensiveIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AccumulatedOtherComprehensiveIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive income",
        "label": "Accumulated other comprehensive income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of accumulated items of income and expense (including reclassification adjustments) that are not recognised in profit or loss as required or permitted by other IFRSs. [Refer: IFRSs [member]; Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r312"
     ]
    },
    "ifrs-full_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Income",
        "label": "Accumulated other comprehensive income [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for accumulated other comprehensive income. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r309"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r244"
     ]
    },
    "oncyf_AdditionalCashFlowDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "AdditionalCashFlowDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Cash Flow Disclosures [Abstract]",
        "documentation": "Additional Cash Flow Disclosures"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdditionalPaidinCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdditionalPaidinCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contributed surplus (note 11)",
        "label": "Additional paid-in capital"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount received or receivable from the issuance of the entity's shares in excess of nominal value and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r312"
     ]
    },
    "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment",
     "crdr": "debit",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions, net of foreign exchange impact",
        "label": "Additions other than through business combinations, property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of additions to property, plant and equipment other than those acquired through business combinations. [Refer: Total for all business combinations [member]; Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "ifrs-full_AdditionsToRightofuseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdditionsToRightofuseAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/LeasesRightofuseAssetsandLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Additions to right-of-use assets",
        "terseLabel": "Additions",
        "label": "Additions to right-of-use assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of additions to right-of-use assets. [Refer: Right-of-use assets]"
       }
      }
     },
     "auth_ref": [
      "r106"
     ]
    },
    "dei_AddressTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AddressTypeDomain",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Address Type [Domain]",
        "label": "Address Type [Domain]",
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r257"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r257"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r257"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r257"
     ]
    },
    "ifrs-full_AdjustedWeightedAverageShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustedWeightedAverageShares",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average number of shares (diluted) (shares)",
        "label": "Weighted average number of ordinary shares used in calculating diluted earnings per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables",
     "crdr": "debit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails": {
       "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other receivables",
        "label": "Adjustments for decrease (increase) in other operating receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for decrease (increase) in other operating receivables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r324"
     ]
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForDecreaseIncreaseInPrepaidExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails": {
       "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses",
        "label": "Adjustments for decrease (increase) in prepaid expenses"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for the decrease (increase) in prepaid expenses to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Current prepaid expenses; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r326"
     ]
    },
    "ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForDepreciationAndAmortisationExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation - property and equipment (notes 6, 20)",
        "label": "Adjustments for depreciation and amortisation expense"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for depreciation and amortisation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Depreciation and amortisation expense; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r325"
     ]
    },
    "oncyf_AdjustmentsForDepreciationRightOfUseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "AdjustmentsForDepreciationRightOfUseAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation - right-of-use assets (notes 8, 20)",
        "label": "Adjustments For Depreciation, Right-of Use Assets",
        "documentation": "Adjustments For Depreciation, Right-of Use Assets"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives",
     "crdr": "credit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperations",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Change in fair value of warrant derivative (notes 9, 17)",
        "label": "Adjustments for gains (losses) on change in fair value of derivatives"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for gains (losses) on changes in the fair value of derivatives to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: At fair value [member]; Derivatives [member]; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r326"
     ]
    },
    "ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForIncreaseDecreaseInOtherOperatingPayables",
     "crdr": "debit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails": {
       "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other liabilities",
        "label": "Adjustments for increase (decrease) in other operating payables"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for increase (decrease) in other operating payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r324"
     ]
    },
    "ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables",
     "crdr": "debit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails": {
       "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable and accrued liabilities",
        "label": "Adjustments for increase (decrease) in trade and other payables"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for increase (decrease) in trade and other payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other payables; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r326"
     ]
    },
    "ifrs-full_AdjustmentsForSharebasedPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForSharebasedPayments",
     "crdr": "debit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation expense (notes 11, 20, 22)",
        "label": "Adjustments for share-based payments"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r325"
     ]
    },
    "ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForUnrealisedForeignExchangeLossesGains",
     "crdr": "debit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperations",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized foreign exchange (gain) loss",
        "label": "Adjustments for unrealised foreign exchange losses (gains)"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for unrealised foreign exchange losses (gains) to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r177",
      "r325"
     ]
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r302"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r215",
      "r226",
      "r236",
      "r269"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r218",
      "r229",
      "r239",
      "r272"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Pension Adjustments Service Cost [Member]",
        "terseLabel": "Aggregate Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r303"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r257"
     ]
    },
    "currency_AllCurrenciesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2024",
     "localname": "AllCurrenciesDomain",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsScheduleofBalancesinForeignCurrenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Currencies [Domain]",
        "label": "All Currencies [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r264"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r219",
      "r230",
      "r240",
      "r264",
      "r273",
      "r277",
      "r285"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r283"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AmortisationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AmortisationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ComponentsofExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation - property and equipment",
        "label": "Amortisation expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of amortisation expense. Amortisation is the systematic allocation of depreciable amounts of intangible assets over their useful lives."
       }
      }
     },
     "auth_ref": [
      "r310"
     ]
    },
    "ifrs-full_AnalysisOfIncomeAndExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AnalysisOfIncomeAndExpenseAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Analysis of income and expense [abstract]",
        "label": "Analysis of income and expense [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ApplicableTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ApplicableTaxRate",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statutory Canadian corporate tax rate",
        "label": "Applicable tax rate"
       }
      },
      "en": {
       "role": {
        "documentation": "The applicable income tax rate."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "ifrs-full_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r90",
      "r91",
      "r92",
      "r153",
      "r155"
     ]
    },
    "ifrs-full_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets",
        "label": "Assets [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Firm ID",
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r198",
      "r199",
      "r222"
     ]
    },
    "oncyf_AuditorInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "AuditorInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Information [Abstract]",
        "documentation": "Auditor Information"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Location",
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r198",
      "r199",
      "r222"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorName",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Name",
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r198",
      "r199",
      "r222"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r280"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r281"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r276"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r276"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r276"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r276"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r276"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r276"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r279"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r278"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r277"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r277"
     ]
    },
    "country_BB": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "BB",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BARBADOS",
        "label": "BARBADOS"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_BalanceHeldInForeignCurrencyNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "BalanceHeldInForeignCurrencyNet",
     "crdr": "debit",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsScheduleofBalancesinForeignCurrenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balances in foreign currencies",
        "label": "Balance Held In Foreign Currency, Net",
        "documentation": "Balance Held In Foreign Currency, Net"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_BasicEarningsLossPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "BasicEarningsLossPerShare",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic loss per common share (cad per share)",
        "label": "Basic earnings (loss) per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator)."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r56"
     ]
    },
    "ifrs-full_BottomOfRangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "BottomOfRangeMember",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Bottom of range [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the bottom of a range."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r94",
      "r117",
      "r133",
      "r179",
      "r180",
      "r329"
     ]
    },
    "dei_BusinessContactMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "BusinessContactMember",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Contact",
        "label": "Business Contact [Member]",
        "documentation": "Business contact for the entity"
       }
      }
     },
     "auth_ref": [
      "r199",
      "r222"
     ]
    },
    "country_CA": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "CA",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/SegmentDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Canada",
        "label": "CANADA"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]",
        "label": "Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r41",
      "r62",
      "r63",
      "r65",
      "r66",
      "r67",
      "r68",
      "r69",
      "r139",
      "r145",
      "r146"
     ]
    },
    "ifrs-full_CarryingAmountMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CarryingAmountMember",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Carrying amount",
        "label": "Carrying amount [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the amount at which an asset is recognised in the statement of financial position (after deducting any accumulated depreciation or amortisation and accumulated impairment losses). It also represents the standard value for the 'Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount' axis if no other member is used. [Refer: Depreciation and amortisation expense; Impairment loss]"
       }
      }
     },
     "auth_ref": [
      "r41",
      "r63",
      "r65",
      "r67",
      "r68",
      "r139",
      "r145",
      "r146"
     ]
    },
    "ifrs-full_CashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashAndCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION",
      "http://www.oncolyticsbiotech.com/role/CapitalDisclosuresDetails",
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsScheduleofBalancesinForeignCurrenciesDetails",
      "http://www.oncolyticsbiotech.com/role/NatureofOperationsandGoingConcernDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "periodStartLabel": "Cash and cash equivalents, beginning of year",
        "periodEndLabel": "Cash and cash equivalents, end of year",
        "verboseLabel": "Cash and cash equivalents",
        "label": "Cash and cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r11",
      "r76",
      "r88"
     ]
    },
    "ifrs-full_CashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SummaryofMaterialAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash equivalents",
        "label": "Cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value."
       }
      }
     },
     "auth_ref": [
      "r327"
     ]
    },
    "oncyf_CashFlowOperatingCapital1TableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "CashFlowOperatingCapital1TableTextBlock",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Net change in non-cash working capital",
        "label": "Cash Flow, Operating Capital1 [Table Text Block]",
        "documentation": "Cash Flow, Operating Capital1 [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Cash provided by financing activities",
        "label": "Cash flows from (used in) financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity, from continuing and discontinued operations."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r77"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financing Activities",
        "label": "Cash flows from (used in) financing activities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowsFromUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Cash (used in) provided by investing activities",
        "label": "Cash flows from (used in) investing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents, from continuing and discontinued operations."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r77"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investing Activities",
        "label": "Cash flows from (used in) investing activities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Activities",
        "label": "Cash flows from (used in) operating activities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowsFromUsedInOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInOperations",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Cash used in operating activities",
        "label": "Cash flows from (used in) operations"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash from (used in) the entity's operations."
       }
      }
     },
     "auth_ref": [
      "r175",
      "r177"
     ]
    },
    "ifrs-full_CashOutflowForLeases": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashOutflowForLeases",
     "crdr": "credit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.oncolyticsbiotech.com/role/LeasesRightofuseAssetsandLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payment of lease liabilities (note 8)",
        "negatedTerseLabel": "Payment of lease liabilities",
        "label": "Cash outflow for leases"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for leases."
       }
      }
     },
     "auth_ref": [
      "r105"
     ]
    },
    "oncyf_ChangeInFairValueWarrantDerivativeRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "ChangeInFairValueWarrantDerivativeRollForward",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeReconciliationofChangeinFairValueofWarrantDerivativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value of Warrant Derivative",
        "label": "Change In Fair Value Warrant Derivative [Roll Forward]",
        "documentation": "Change In Fair Value Warrant Derivative"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r255"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]",
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r252"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]",
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r250"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight1",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of common shares issuable per warrant (in shares)",
        "label": "Class Of Warrant Or Right, Number Of Securities Called By Each Warrant Or Right1",
        "documentation": "Class Of Warrant Or Right, Number Of Securities Called By Each Warrant Or Right1"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ClassesOfLiabilitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfLiabilitiesAxis",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeReconciliationofChangeinFairValueofWarrantDerivativeDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeSummaryofAssumptionsUsedintheBlackScholesOptionPricingModelforWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of liabilities [axis]",
        "label": "Classes of liabilities [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "ifrs-full_ClassesOfLiabilitiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfLiabilitiesDomain",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeReconciliationofChangeinFairValueofWarrantDerivativeDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeSummaryofAssumptionsUsedintheBlackScholesOptionPricingModelforWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of liabilities",
        "label": "Classes of liabilities [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits. It also represents the standard value for the 'Classes of liabilities' axis if no other member is used. [Refer: Liabilities]"
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "ifrs-full_ClassesOfOtherProvisionsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfOtherProvisionsDomain",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/OtherLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of other provisions",
        "label": "Classes of other provisions [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for provisions other than provisions for employee benefits. It also represents the standard value for the 'Classes of other provisions' axis if no other member is used. [Refer: Provisions]"
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfPropertyPlantAndEquipmentAxis",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails",
      "http://www.oncolyticsbiotech.com/role/SummaryofMaterialAccountingPoliciesScheduleofDepreciationRatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of property, plant and equipment [axis]",
        "label": "Classes of property, plant and equipment [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfPropertyPlantAndEquipmentDomain",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails",
      "http://www.oncolyticsbiotech.com/role/SummaryofMaterialAccountingPoliciesScheduleofDepreciationRatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of property, plant and equipment [domain]",
        "label": "Classes of property, plant and equipment [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Classes of property, plant and equipment' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "ifrs-full_ClassesOfProvisionsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfProvisionsAxis",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/OtherLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of other provisions [axis]",
        "label": "Classes of other provisions [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "ifrs-full_ClassesOfShareCapitalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfShareCapitalAxis",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of share capital [axis]",
        "label": "Classes of share capital [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "ifrs-full_ClassesOfShareCapitalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfShareCapitalDomain",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of share capital",
        "label": "Classes of share capital [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for share capital of the entity. It also represents the standard value for the 'Classes of share capital' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "oncyf_ClinicalTrialExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "ClinicalTrialExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ComponentsofExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Clinical trial expenses",
        "label": "Clinical Trial Expense",
        "documentation": "Clinical Trial Expense"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_ClinicalTrialMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "ClinicalTrialMember",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/OtherLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Clinical Trial",
        "label": "Clinical Trial [Member]",
        "documentation": "Clinical Trial"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r256"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r256"
     ]
    },
    "oncyf_CommitmentsAndContingencies1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "CommitmentsAndContingencies1",
     "crdr": "credit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies (note 14)",
        "label": "Commitments And Contingencies1",
        "documentation": "Commitments And Contingencies1"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_CommonSharesPerUnit": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "CommonSharesPerUnit",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common shares per unit (in shares)",
        "label": "Common Shares Per Unit",
        "documentation": "Common Shares Per Unit"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r261"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r260"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r262"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r259"
     ]
    },
    "oncyf_CompensationWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "CompensationWarrantsMember",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Warrants",
        "label": "Compensation Warrants [Member]",
        "documentation": "Compensation Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ComponentsOfEquityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ComponentsOfEquityAxis",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY",
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Components of equity [axis]",
        "label": "Components of equity [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "ifrs-full_ComponentsOfEquityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ComponentsOfEquityDomain",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY",
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Components of equity",
        "label": "Components of equity [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the residual interest in the assets of the entity after deducting all its liabilities. It also represents the standard value for the 'Components of equity' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "ifrs-full_ComprehensiveIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ComprehensiveIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY",
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive loss",
        "terseLabel": "Net loss and other comprehensive income (loss)",
        "label": "Comprehensive income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r24",
      "r82",
      "r84",
      "r87",
      "r178"
     ]
    },
    "ifrs-full_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails",
      "http://www.oncolyticsbiotech.com/role/SummaryofMaterialAccountingPoliciesScheduleofDepreciationRatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computer equipment",
        "verboseLabel": "Computer Equipment",
        "label": "Computer equipment [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of property, plant and equipment representing computer equipment. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r315"
     ]
    },
    "oncyf_ConcentrationRisk1Table": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "ConcentrationRisk1Table",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/EconomicDependenceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk1 [Table]",
        "label": "Concentration Risk1 [Table]",
        "documentation": "Concentration Risk1 [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_ConcentrationRiskNumber": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "ConcentrationRiskNumber",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/EconomicDependenceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration, number",
        "label": "Concentration Risk, Number",
        "documentation": "Concentration Risk, Number"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_ConcentrationRiskType1Axis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "ConcentrationRiskType1Axis",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/EconomicDependenceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Type1 [Axis]",
        "label": "Concentration Risk Type1 [Axis]",
        "documentation": "Concentration Risk Type1 [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_ConcentrationRiskType1Domain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "ConcentrationRiskType1Domain",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/EconomicDependenceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Type1 [Domain]",
        "label": "Concentration Risk Type1 [Domain]",
        "documentation": "[Domain] for Concentration Risk Type1 [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_ConcentrationRiskType1LineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "ConcentrationRiskType1LineItems",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/EconomicDependenceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Type1 [Line Items]",
        "label": "Concentration Risk Type1 [Line Items]",
        "documentation": "[Line Items] for Concentration Risk Type1 [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContactPersonnelEmailAddress": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContactPersonnelEmailAddress",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contact Personnel Email Address",
        "label": "Contact Personnel Email Address",
        "documentation": "Email address of contact personnel."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContactPersonnelName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContactPersonnelName",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contact Personnel Name",
        "label": "Contact Personnel Name",
        "documentation": "Name of contact personnel"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_ContingenciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "ContingenciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingencies [Abstract]",
        "label": "Contingencies [Abstract]",
        "documentation": "Contingencies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ContractLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ContractLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ContractLiabilityScheduleofContractRevenuesandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance, beginning of year",
        "periodEndLabel": "Balance, end of year",
        "label": "Contract liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of an entity\u2019s obligation to transfer goods or services to a customer for which the entity has received consideration (or the amount is due) from the customer."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r96"
     ]
    },
    "oncyf_ContractLiabilityRecognitionPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "ContractLiabilityRecognitionPeriod",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ContractLiabilityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected recognition period",
        "label": "Contract Liability, Recognition Period",
        "documentation": "Contract Liability, Recognition Period"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CorporateInformationAndStatementOfIFRSComplianceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate Information And Statement Of IFRS Compliance [Abstract]",
        "label": "Corporate information and statement of IFRS compliance [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_Currency1LineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "Currency1LineItems",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsScheduleofBalancesinForeignCurrenciesDetails",
      "http://www.oncolyticsbiotech.com/role/OtherLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Currency1 [Line Items]",
        "label": "Currency1 [Line Items]",
        "documentation": "[Line Items] for Currency1 [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_Currency1Table": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "Currency1Table",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsScheduleofBalancesinForeignCurrenciesDetails",
      "http://www.oncolyticsbiotech.com/role/OtherLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Currency1 [Table]",
        "label": "Currency1 [Table]",
        "documentation": "Currency1 [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_CurrencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CurrencyAxis",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsScheduleofBalancesinForeignCurrenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Currency [Axis]",
        "label": "Currency [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrencyRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrencyRiskMember",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Currency risk",
        "label": "Currency risk [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a type of market risk representing the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. [Refer: Classes of financial instruments [domain]]"
       }
      }
     },
     "auth_ref": [
      "r118",
      "r119",
      "r120",
      "r121",
      "r150"
     ]
    },
    "ifrs-full_CurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Current assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]"
       }
      }
     },
     "auth_ref": [
      "r16",
      "r85",
      "r178"
     ]
    },
    "ifrs-full_CurrentAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentAssetsAbstract",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets",
        "label": "Current assets [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentDerivativeFinancialAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentDerivativeFinancialAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION",
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant derivative (notes 9, 17)",
        "verboseLabel": "Warrant derivative asset",
        "label": "Current derivative financial assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current derivative financial assets. [Refer: Derivative financial assets]"
       }
      }
     },
     "auth_ref": [
      "r312"
     ]
    },
    "ifrs-full_CurrentDerivativeFinancialLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentDerivativeFinancialLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION",
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant derivative (notes 9, 17)",
        "verboseLabel": "Warrant derivative liability",
        "label": "Current derivative financial liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current derivative financial liabilities. [Refer: Derivative financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r312"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentLeaseLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liabilities (note 8)",
        "label": "Current lease liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current lease liabilities. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "ifrs-full_CurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Current liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r86",
      "r178"
     ]
    },
    "ifrs-full_CurrentLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentLiabilitiesAbstract",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities",
        "label": "Current liabilities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentPrepayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentPrepayments",
     "crdr": "debit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses",
        "label": "Current prepayments"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current prepayments. [Refer: Prepayments]"
       }
      }
     },
     "auth_ref": [
      "r165"
     ]
    },
    "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r207",
      "r296"
     ]
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r207",
      "r296"
     ]
    },
    "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r209",
      "r298"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]"
       }
      }
     },
     "auth_ref": [
      "r209",
      "r298"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]"
       }
      }
     },
     "auth_ref": [
      "r211",
      "r300"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r209",
      "r298"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r202",
      "r291"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r203",
      "r292"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r203",
      "r292"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r201",
      "r290"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r201",
      "r290"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Table]"
       }
      }
     },
     "auth_ref": [
      "r201",
      "r290"
     ]
    },
    "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Third Party Engaged [Flag]"
       }
      }
     },
     "auth_ref": [
      "r204",
      "r293"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r206",
      "r295"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r206",
      "r295"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r207",
      "r296"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r210",
      "r299"
     ]
    },
    "cyd_CybersecurityRiskRoleOfManagementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskRoleOfManagementTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Role of Management [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r208",
      "r297"
     ]
    },
    "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]"
       }
      }
     },
     "auth_ref": [
      "r205",
      "r294"
     ]
    },
    "ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ContractLiabilityScheduleofContractRevenuesandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue recognized",
        "label": "Decrease through performance obligation being satisfied, contract liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The decrease in contract liabilities resulting from the performance obligation being satisfied. [Refer: Contract liabilities; Performance obligations [domain]]"
       }
      }
     },
     "auth_ref": [
      "r181"
     ]
    },
    "ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesScheduleofUnrecognizedDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized deferred tax asset",
        "label": "Deductible temporary differences for which no deferred tax asset is recognised"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of deductible temporary differences for which no deferred tax asset is recognised in the statement of financial position. [Refer: Temporary differences [member]]"
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "ifrs-full_DepreciationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DepreciationPropertyPlantAndEquipment",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation expense",
        "label": "Depreciation, property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of depreciation of property, plant and equipment. [Refer: Depreciation and amortisation expense; Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r40",
      "r43"
     ]
    },
    "ifrs-full_DepreciationRightofuseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DepreciationRightofuseAssets",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ComponentsofExpensesDetails",
      "http://www.oncolyticsbiotech.com/role/LeasesRightofuseAssetsandLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Depreciation expense",
        "verboseLabel": "Depreciation - right-of-use assets",
        "label": "Depreciation, right-of-use assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of depreciation of right-of-use assets. [Refer: Depreciation and amortisation expense; Right-of-use assets]"
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "ifrs-full_DerivativeFinancialLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DerivativeFinancialLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeReconciliationofChangeinFairValueofWarrantDerivativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance at beginning of period",
        "periodEndLabel": "Balance at end of period",
        "label": "Derivative financial liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of financial liabilities classified as derivative instruments. [Refer: Financial assets; Derivatives [member]]"
       }
      }
     },
     "auth_ref": [
      "r312"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SummaryofMaterialAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred income taxes",
        "label": "Description of accounting policy for deferred income tax [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for deferred income tax. [Refer: Deferred tax expense (income)]"
       }
      }
     },
     "auth_ref": [
      "r311"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForDerecognitionOfFinancialInstrumentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForDerecognitionOfFinancialInstrumentsExplanatory",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SummaryofMaterialAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derecognition",
        "label": "Description of accounting policy for derecognition of financial instruments [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for the derecognition of financial instruments. [Refer: Classes of financial instruments [domain]]"
       }
      }
     },
     "auth_ref": [
      "r311"
     ]
    },
    "oncyf_DescriptionOfAccountingPolicyForDeterminingComponentsOfCashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "DescriptionOfAccountingPolicyForDeterminingComponentsOfCashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SummaryofMaterialAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Description Of Accounting Policy For Determining Components Of Cash And Cash Equivalents [Policy Text Block]",
        "documentation": "Description Of Accounting Policy For Determining Components Of Cash And Cash Equivalents"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForEarningsPerShareExplanatory",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SummaryofMaterialAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss per share",
        "label": "Description of accounting policy for earnings per share [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r311"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SummaryofMaterialAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurement",
        "label": "Description of accounting policy for fair value measurement [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for fair value measurement. [Refer: At fair value [member]]"
       }
      }
     },
     "auth_ref": [
      "r311"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForFinancialAssetsExplanatory",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SummaryofMaterialAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial assets",
        "label": "Description of accounting policy for financial assets [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for financial assets. [Refer: Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r311"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SummaryofMaterialAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial liabilities",
        "label": "Description of accounting policy for financial liabilities [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for financial liabilities. [Refer: Financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r311"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SummaryofMaterialAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency translation",
        "label": "Description of accounting policy for foreign currency translation [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for foreign currency translation."
       }
      }
     },
     "auth_ref": [
      "r311"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SummaryofMaterialAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment",
        "label": "Description of accounting policy for impairment of financial assets [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for the impairment of financial assets. [Refer: Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r311"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForLeasesExplanatory",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SummaryofMaterialAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Description of accounting policy for leases [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for leases. A lease is an agreement whereby the lessor conveys to the lessee in return for a payment or series of payments the right to use an asset for an agreed period of time."
       }
      }
     },
     "auth_ref": [
      "r311"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SummaryofMaterialAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment",
        "label": "Description of accounting policy for property, plant and equipment [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for property, plant and equipment. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r311"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForRecognitionOfRevenue",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SummaryofMaterialAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue recognition",
        "label": "Description of accounting policy for recognition of revenue [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for recognising revenue. [Refer: Revenue]"
       }
      }
     },
     "auth_ref": [
      "r311"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SummaryofMaterialAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development costs",
        "label": "Description of accounting policy for research and development expense [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for research and development expense. [Refer: Research and development expense]"
       }
      }
     },
     "auth_ref": [
      "r311"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SummaryofMaterialAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation",
        "label": "Description of accounting policy for share-based payment transactions [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Types of share-based payment arrangements [domain]]"
       }
      }
     },
     "auth_ref": [
      "r311"
     ]
    },
    "ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SummaryofMaterialAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Standards and Interpretations Issued but Not Yet Effective",
        "label": "Disclosure of expected impact of initial application of new standards or interpretations [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the known or reasonably estimable information relevant to assessing the possible impact that the application of a new IFRS, that has been issued but is not yet effective, will have."
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfExpectedVolatilityShareOptionsGranted",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationDisclosureWeightedAverageAssumptionsandFairValueofOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility",
        "label": "Expected volatility, share options granted"
       }
      },
      "en": {
       "role": {
        "documentation": "The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time."
       }
      }
     },
     "auth_ref": [
      "r135"
     ]
    },
    "ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfInitialApplicationOfStandardsOrInterpretations",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SummaryofMaterialAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adoption of New Accounting Standards",
        "label": "Disclosure of initial application of standards or interpretations [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the initial application of an IFRS. [Refer: IFRSs [member]]"
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "ifrs-full_DescriptionOfOptionLifeShareOptionsGranted": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfOptionLifeShareOptionsGranted",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationDisclosureWeightedAverageAssumptionsandFairValueofOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected life",
        "label": "Option life, share options granted"
       }
      },
      "en": {
       "role": {
        "documentation": "The option life of share options granted."
       }
      }
     },
     "auth_ref": [
      "r135"
     ]
    },
    "ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfRiskFreeInterestRateShareOptionsGranted",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationDisclosureWeightedAverageAssumptionsandFairValueofOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Risk-free interest rate",
        "label": "Risk free interest rate, share options granted"
       }
      },
      "en": {
       "role": {
        "documentation": "The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]"
       }
      }
     },
     "auth_ref": [
      "r135"
     ]
    },
    "ifrs-full_DescriptionOfUncertaintiesOfEntitysAbilityToContinueAsGoingConcern": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfUncertaintiesOfEntitysAbilityToContinueAsGoingConcern",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SummaryofMaterialAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Going concern",
        "label": "Disclosure of uncertainties of entity's ability to continue as going concern [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of material uncertainties related to events or conditions that may cast significant doubt upon the entity's ability to continue as a going concern."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "oncyf_DetailedDisclosureOfTradeAndOtherPayablesExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "DetailedDisclosureOfTradeAndOtherPayablesExplanatoryTableTextBlock",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/AccountsPayableandAccruedLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of accounts payables and accrued liabilities",
        "label": "Detailed Disclosure Of Trade And Other Payables Explanatory [Table Text Block]",
        "documentation": "Detailed Disclosure Of Trade And Other Payables Explanatory"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DilutedEarningsLossPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DilutedEarningsLossPerShare",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted loss per common share (cad per share)",
        "label": "Diluted earnings (loss) per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r55",
      "r56"
     ]
    },
    "srt_DirectorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "DirectorMember",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Director",
        "label": "Director [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfAccountingJudgementsAndEstimatesExplanatory",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SignificantJudgmentsEstimatesandAssumptions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Significant Judgments, Estimates and Assumptions",
        "label": "Disclosure of accounting judgements and estimates [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of judgements that management has made in the process of applying the entity's accounting policies that have the most significant effect on amounts recognised in the financial statements along with information about the assumptions that the entity makes about the future, and other major sources of estimation uncertainty at the end of the reporting period, that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next year. [Refer: Carrying amount [member]]"
       }
      }
     },
     "auth_ref": [
      "r307"
     ]
    },
    "ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/BasisofPresentation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Basis of Presentation",
        "label": "Disclosure of basis of preparation of financial statements [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the basis used for the preparation of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r307"
     ]
    },
    "oncyf_DisclosureOfCapitalComponentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "DisclosureOfCapitalComponentsTableTextBlock",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CapitalDisclosuresTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of capital components",
        "label": "Disclosure Of Capital Components [Table Text Block]",
        "documentation": "Disclosure Of Capital Components [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfCashFlowStatementExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfCashFlowStatementExplanatory",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosures"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Cash Flow Disclosures",
        "label": "Disclosure of cash flow statement [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for a statement of cash flows."
       }
      }
     },
     "auth_ref": [
      "r78"
     ]
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfClassesOfShareCapitalExplanatory",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of share capital",
        "label": "Disclosure of classes of share capital [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of classes of share capital. [Refer: Classes of share capital [domain]]"
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfClassesOfShareCapitalLineItems",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of classes of share capital [line items]",
        "label": "Disclosure of classes of share capital [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfClassesOfShareCapitalTable",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of classes of share capital [table]",
        "label": "Disclosure of classes of share capital [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to classes of share capital."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CommitmentsandContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies",
        "label": "Disclosure of commitments and contingent liabilities [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of commitments and contingent liabilities. [Refer: Classes of contingent liabilities [domain]]"
       }
      }
     },
     "auth_ref": [
      "r307"
     ]
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/PropertyandEquipmentTables",
      "http://www.oncolyticsbiotech.com/role/SummaryofMaterialAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of depreciation rates",
        "verboseLabel": "Schedule of property and equipment",
        "label": "Disclosure of detailed information about property, plant and equipment [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of detailed information about property, plant and equipment. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "ifrs-full_DisclosureOfEarningsPerShareExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfEarningsPerShareExplanatory",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss Per Share",
        "label": "Disclosure of earnings per share [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "oncyf_DisclosureOfEconomicDependenceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "DisclosureOfEconomicDependenceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Economic Dependence [Abstract]",
        "label": "Disclosure Of Economic Dependence [Abstract]",
        "documentation": "Disclosure Of Economic Dependence [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_DisclosureOfEconomicDependenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "DisclosureOfEconomicDependenceTextBlock",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/EconomicDependence"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Economic Dependence",
        "label": "Disclosure Of Economic Dependence [Text Block]",
        "documentation": "Disclosure Of Economic Dependence [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfEntitysReportableSegmentsExplanatory",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SegmentDisclosures"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Disclosures",
        "label": "Disclosure of entity's operating segments [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for operating segments."
       }
      }
     },
     "auth_ref": [
      "r159"
     ]
    },
    "ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfEventsAfterReportingPeriodExplanatory",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Events",
        "label": "Disclosure of events after reporting period [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for events after the reporting period."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "ifrs-full_DisclosureOfExpensesByNatureExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfExpensesByNatureExplanatory",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ComponentsofExpenses"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Components of Expenses",
        "label": "Disclosure of expenses by nature [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of expenses by nature. [Refer: Expenses, by nature]"
       }
      }
     },
     "auth_ref": [
      "r307"
     ]
    },
    "ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of change in fair value of warrant derivative",
        "label": "Disclosure of fair value measurement of liabilities [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the fair value measurement of liabilities."
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfFairValueMeasurementOfLiabilitiesLineItems",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeReconciliationofChangeinFairValueofWarrantDerivativeDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeSummaryofAssumptionsUsedintheBlackScholesOptionPricingModelforWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of fair value measurement of liabilities [line items]",
        "label": "Disclosure of fair value measurement of liabilities [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfFairValueMeasurementOfLiabilitiesTable",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeReconciliationofChangeinFairValueofWarrantDerivativeDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeSummaryofAssumptionsUsedintheBlackScholesOptionPricingModelforWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of fair value measurement of liabilities [table]",
        "label": "Disclosure of fair value measurement of liabilities [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the fair value measurement of liabilities."
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfFinancialInstrumentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of detailed information about financial instruments [abstract]",
        "label": "Disclosure of detailed information about financial instruments [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfFinancialInstrumentsExplanatory",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/FinancialInstruments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instruments",
        "label": "Disclosure of financial instruments [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for financial instruments."
       }
      }
     },
     "auth_ref": [
      "r151"
     ]
    },
    "ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfFinancialLiabilitiesExplanatory",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/WarrantDerivative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant Derivative",
        "label": "Disclosure of financial liabilities [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of financial liabilities. [Refer: Financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r149"
     ]
    },
    "ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/NatureofOperationsandGoingConcern"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nature of Operations and Going Concern",
        "label": "Disclosure of general information about financial statements [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for general information about financial statements."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "ifrs-full_DisclosureOfGeographicalAreasExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfGeographicalAreasExplanatory",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SegmentDisclosuresTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of geographical areas",
        "label": "Disclosure of geographical areas [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of geographical information."
       }
      }
     },
     "auth_ref": [
      "r158"
     ]
    },
    "ifrs-full_DisclosureOfGeographicalAreasLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfGeographicalAreasLineItems",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SegmentDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of geographical areas [line items]",
        "label": "Disclosure of geographical areas [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfGeographicalAreasTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfGeographicalAreasTable",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SegmentDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of geographical areas [table]",
        "label": "Disclosure of geographical areas [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to geographical areas."
       }
      }
     },
     "auth_ref": [
      "r158"
     ]
    },
    "ifrs-full_DisclosureOfIncomeTaxExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfIncomeTaxExplanatory",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Disclosure of income tax [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for income taxes."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure weighted average assumptions and fair value of options",
        "label": "Disclosure of indirect measurement of fair value of goods or services received, share options granted during period [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of information about indirect, by reference to the fair value of the equity instruments granted, measurement of the fair value of goods or services received as consideration for the entity's share options."
       }
      }
     },
     "auth_ref": [
      "r136"
     ]
    },
    "ifrs-full_DisclosureOfLeasesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfLeasesExplanatory",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Disclosure of leases [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for leases."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r114"
     ]
    },
    "ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfMaterialAccountingPolicyInformationExplanatory",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SummaryofMaterialAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Material Accounting Policies",
        "label": "Disclosure of material accounting policy information [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure of material accounting policy information applied by the entity."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Total undiscounted lease liability",
        "label": "Disclosure of maturity analysis of operating lease payments [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of a maturity analysis of operating lease payments. Operating lease is a lease that does not transfer substantially all the risks and rewards incidental to ownership of an underlying asset."
       }
      }
     },
     "auth_ref": [
      "r111"
     ]
    },
    "ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesTotalUndiscountedLeaseLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of maturity analysis of operating lease payments [line items]",
        "label": "Disclosure of maturity analysis of operating lease payments [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesTotalUndiscountedLeaseLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of maturity analysis of operating lease payments [table]",
        "label": "Disclosure of maturity analysis of operating lease payments [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the maturity analysis of operating lease payments."
       }
      }
     },
     "auth_ref": [
      "r111"
     ]
    },
    "ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of nature and extent of risks arising from financial instruments [line items]",
        "label": "Disclosure of nature and extent of risks arising from financial instruments [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of nature and extent of risks arising from financial instruments [table]",
        "label": "Disclosure of nature and extent of risks arising from financial instruments [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the nature and extent of risks arising from financial instruments."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r144"
     ]
    },
    "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/NatureofOperationsandGoingConcernDetails",
      "http://www.oncolyticsbiotech.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of non-adjusting events after reporting period [line items]",
        "label": "Disclosure of non-adjusting events after reporting period [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodTable",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/NatureofOperationsandGoingConcernDetails",
      "http://www.oncolyticsbiotech.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of non-adjusting events after reporting period [table]",
        "label": "Disclosure of non-adjusting events after reporting period [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to non-adjusting events after the reporting period."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "DisclosureOfNotesAndOtherExplanatoryInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Notes And Other Explanatory Information [Abstract]",
        "label": "Disclosure Of Notes And Other Explanatory Information [Abstract]",
        "documentation": "Disclosure Of Notes And Other Explanatory Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of number of other equity instruments",
        "label": "Disclosure of number and weighted average exercise prices of other equity instruments [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the number and weighted average exercise prices of other equity instruments (ie other than share options)."
       }
      }
     },
     "auth_ref": [
      "r328"
     ]
    },
    "ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of stock options and weighted average exercise prices of share options",
        "label": "Disclosure of number and weighted average exercise prices of share options [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the number and weighted average exercise prices of share options. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r132"
     ]
    },
    "ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of weighted average remaining contractual life and outstanding stock options by exercise price",
        "label": "Disclosure of number and weighted average remaining contractual life of outstanding share options [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the number and weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r133"
     ]
    },
    "ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]",
        "label": "Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of number and weighted average remaining contractual life of outstanding share options [table]",
        "label": "Disclosure of number and weighted average remaining contractual life of outstanding share options [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the number and weighted average remaining contractual life of outstanding share options."
       }
      }
     },
     "auth_ref": [
      "r133"
     ]
    },
    "ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CapitalDisclosures"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital Disclosures",
        "label": "Disclosure of objectives, policies and processes for managing capital [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of information that enables users of financial statements to evaluate the entity's objectives, policies and processes for managing capital."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "ifrs-full_DisclosureOfOtherLiabilitiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfOtherLiabilitiesExplanatory",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/OtherLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Liabilities",
        "label": "Disclosure of other liabilities [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of other liabilities. [Refer: Other liabilities]"
       }
      }
     },
     "auth_ref": [
      "r307"
     ]
    },
    "ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfPropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of detailed information about property, plant and equipment [abstract]",
        "label": "Disclosure of detailed information about property, plant and equipment [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfPropertyPlantAndEquipmentExplanatory",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/PropertyandEquipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment",
        "label": "Disclosure of property, plant and equipment [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for property, plant and equipment."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfPropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails",
      "http://www.oncolyticsbiotech.com/role/SummaryofMaterialAccountingPoliciesScheduleofDepreciationRatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of detailed information about property, plant and equipment [line items]",
        "label": "Disclosure of detailed information about property, plant and equipment [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails",
      "http://www.oncolyticsbiotech.com/role/SummaryofMaterialAccountingPoliciesScheduleofDepreciationRatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of detailed information about property, plant and equipment [table]",
        "label": "Disclosure of detailed information about property, plant and equipment [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of property, plant and equipment."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "oncyf_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTextBlock",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Lease liabilities",
        "label": "Disclosure Of Quantitative Information About Lease Liabilities [Text Block]",
        "documentation": "Disclosure Of Quantitative Information About Lease Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Right-of-use assets",
        "label": "Disclosure of quantitative information about right-of-use assets [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of quantitative information about right-of-use assets. [Refer: Right-of-use assets]"
       }
      }
     },
     "auth_ref": [
      "r108"
     ]
    },
    "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of quantitative information about right-of-use assets [line items]",
        "label": "Disclosure of quantitative information about right-of-use assets [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of quantitative information about right-of-use assets [table]",
        "label": "Disclosure of quantitative information about right-of-use assets [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to right-of-use assets."
       }
      }
     },
     "auth_ref": [
      "r108"
     ]
    },
    "ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of stock options outstanding and exercisable by range of exercise price",
        "label": "Disclosure of range of exercise prices of outstanding share options [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the range of exercise prices for outstanding share options."
       }
      }
     },
     "auth_ref": [
      "r133"
     ]
    },
    "ifrs-full_DisclosureOfRelatedPartyExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfRelatedPartyExplanatory",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/RelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transactions",
        "label": "Disclosure of related party [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for related parties."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfRevenueFromContractsWithCustomersExplanatory",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ContractLiability"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract Liability",
        "label": "Disclosure of revenue from contracts with customers [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for revenue from contracts with customers."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r100"
     ]
    },
    "oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "DisclosureOfShareBasedPaymentArrangementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Share-based Payment Arrangements [Abstract]",
        "label": "Disclosure of Share-based Payment Arrangements [Abstract]",
        "documentation": "Disclosure Of Share-based Payment Arrangements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapital"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Capital",
        "label": "Disclosure of share capital, reserves and other equity interest [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for share capital, reserves and other equity interest."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfSharebasedPaymentArrangementsExplanatory",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Compensation",
        "label": "Disclosure of share-based payment arrangements [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangements."
       }
      }
     },
     "auth_ref": [
      "r124"
     ]
    },
    "ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of unrecognized non-capital losses, non-refundable credits and deferred tax assets",
        "label": "Disclosure of temporary difference, unused tax losses and unused tax credits [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of types of temporary differences, unused tax losses and unused tax credits. [Refer: Unused tax credits [member]; Unused tax losses [member]; Temporary differences [member]]"
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesScheduleofUnrecognizedDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of temporary difference, unused tax losses and unused tax credits [line items]",
        "label": "Disclosure of temporary difference, unused tax losses and unused tax credits [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesScheduleofUnrecognizedDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of temporary difference, unused tax losses and unused tax credits [table]",
        "label": "Disclosure of temporary difference, unused tax losses and unused tax credits [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to temporary differences, unused tax losses and unused tax credits."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofNumberofOtherEquityInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of terms and conditions of share-based payment arrangement [line items]",
        "label": "Disclosure of terms and conditions of share-based payment arrangement [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofNumberofOtherEquityInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of terms and conditions of share-based payment arrangement [table]",
        "label": "Disclosure of terms and conditions of share-based payment arrangement [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to terms and conditions of share-based payment arrangements."
       }
      }
     },
     "auth_ref": [
      "r134"
     ]
    },
    "ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfTradeAndOtherPayablesExplanatory",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/AccountsPayableandAccruedLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Payable and Accrued Liabilities",
        "label": "Disclosure of trade and other payables [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of trade and other payables. [Refer: Trade and other payables]"
       }
      }
     },
     "auth_ref": [
      "r307"
     ]
    },
    "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of related party transactions",
        "label": "Disclosure of transactions between related parties [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of transactions between the entity and its related parties. [Refer: Total for all related parties [member]]"
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of Share Capital, Reserves And Other Equity Interest [Abstract]",
        "label": "Disclosure of Share Capital, Reserves And Other Equity Interest [Abstract]",
        "documentation": "Disclosure of Share Capital, Reserves And Other Equity Interest [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_DisclosureofeventsafterreportingperiodAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "DisclosureofeventsafterreportingperiodAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of events after reporting period [Abstract]",
        "label": "Disclosure of events after reporting period [Abstract]",
        "documentation": "Disclosure of events after reporting period [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_DisclosureofincometaxAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "DisclosureofincometaxAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of income tax [Abstract]",
        "label": "Disclosure of income tax [Abstract]",
        "documentation": "Disclosure of income tax [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_DisclosureofrelatedpartyAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "DisclosureofrelatedpartyAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of related party [Abstract]",
        "label": "Disclosure of related party [Abstract]",
        "documentation": "Disclosure of related party [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "DisclosureofrevenuefromcontractswithcustomersAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of revenue from contracts with customers [Abstract]",
        "label": "Disclosure of revenue from contracts with customers [Abstract]",
        "documentation": "Disclosure of revenue from contracts with customers [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_DisclosureofsharebasedpaymentarrangementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "DisclosureofsharebasedpaymentarrangementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of share-based payment arrangement [Abstract]",
        "label": "Disclosure of share-based payment arrangement [Abstract]",
        "documentation": "Disclosure of share-based payment arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisposalsPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisposalsPropertyPlantAndEquipment",
     "crdr": "credit",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposals, net of foreign exchange impact",
        "label": "Disposals, property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The decrease in property, plant and equipment resulting from disposals. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Accounting Standard",
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r199"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Annual Report",
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r198",
      "r199",
      "r222"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Financial Statement Error Correction [Flag]",
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r198",
      "r199",
      "r222",
      "r265"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Information [Line Items]",
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Information [Table]",
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Registration Statement",
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r194"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Shell Company Report",
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r199"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r243"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]",
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year"
       }
      }
     },
     "auth_ref": [
      "r254"
     ]
    },
    "currency_EUR": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2024",
     "localname": "EUR",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsScheduleofBalancesinForeignCurrenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Euro",
        "label": "Euro Member Countries, Euro"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings per share [abstract]",
        "label": "Earnings per share [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "EffectOfExchangeRateChangesOnCashAndCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impact of foreign exchange on cash and cash equivalents",
        "label": "Effect of exchange rate changes on cash and cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r72",
      "r73"
     ]
    },
    "ifrs-full_EmployeeBenefitsExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "EmployeeBenefitsExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ComponentsofExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee compensation and benefits expense",
        "label": "Employee benefits expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The expense of all forms of consideration given by an entity in exchange for a service rendered by employees or for the termination of employment."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r28",
      "r161"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Country",
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressesAddressTypeAxis",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Addresses, Address Type [Axis]",
        "label": "Entity Addresses, Address Type [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r196"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r196"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r196"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r305"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Public Float",
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r196"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r196"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Voluntary Filers",
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Well-known Seasoned Issuer",
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r306"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote [Text Block]",
        "terseLabel": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r248"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]",
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r301"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments [Member]",
        "terseLabel": "Equity Awards Adjustments"
       }
      }
     },
     "auth_ref": [
      "r301"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r301"
     ]
    },
    "ifrs-full_Equity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "Equity",
     "crdr": "credit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY",
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION",
      "http://www.oncolyticsbiotech.com/role/CapitalDisclosuresDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total shareholders\u2019 equity",
        "periodStartLabel": "Equity balance at beginning of period",
        "periodEndLabel": "Equity balance at end of period",
        "terseLabel": "Shareholders' equity",
        "label": "Equity"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of residual interest in the assets of the entity after deducting all its liabilities."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r19",
      "r81",
      "r83",
      "r90",
      "r91",
      "r92"
     ]
    },
    "ifrs-full_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "EquityAbstract",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION",
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITIONParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shareholders\u2019 equity",
        "label": "Equity [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EquityAndLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "EquityAndLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and shareholders' equity",
        "label": "Equity and liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]"
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "ifrs-full_EquityAndLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "EquityAndLiabilitiesAbstract",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities And Shareholders\u2019 Equity",
        "label": "Equity and liabilities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_EquityAuthorized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "EquityAuthorized",
     "crdr": "credit",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CapitalDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Base Shelf securities authorized",
        "label": "Equity Authorized",
        "documentation": "Equity Authorized"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r258"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r215",
      "r226",
      "r236",
      "r269"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r212",
      "r223",
      "r233",
      "r266"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r264"
     ]
    },
    "ifrs-full_ExercisePriceOfOutstandingShareOptions2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ExercisePriceOfOutstandingShareOptions2019",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price (cad per share)",
        "label": "Exercise price of outstanding share options"
       }
      },
      "en": {
       "role": {
        "documentation": "The exercise price of outstanding share options."
       }
      }
     },
     "auth_ref": [
      "r133"
     ]
    },
    "oncyf_ExercisePriceRangeFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "ExercisePriceRangeFiveMember",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$7.42 - $52.63",
        "label": "Exercise Price Range Five [Member]",
        "documentation": "Exercise Price Range Five [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_ExercisePriceRangeFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "ExercisePriceRangeFourMember",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$3.91 - $7.41",
        "label": "Exercise Price Range Four [Member]",
        "documentation": "Exercise Price Range Four [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_ExercisePriceRangeOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "ExercisePriceRangeOneMember",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$0.54 - $1.79",
        "label": "Exercise Price Range One [Member]",
        "documentation": "Exercise Price Range One [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_ExercisePriceRangeThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "ExercisePriceRangeThreeMember",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$3.02 - $3.90",
        "label": "Exercise Price Range Three [Member]",
        "documentation": "Exercise Price Range Three [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_ExercisePriceRangeTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "ExercisePriceRangeTwoMember",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$1.80 - $3.01",
        "label": "Exercise Price Range Two [Member]",
        "documentation": "Exercise Price Range Two [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "ExpectedDividendAsPercentageOtherEquityInstrumentsGranted",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeSummaryofAssumptionsUsedintheBlackScholesOptionPricingModelforWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected dividend yield",
        "label": "Expected Dividend As Percentage, Other Equity Instruments Granted",
        "documentation": "Expected Dividend As Percentage, Other Equity Instruments Granted"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ExpectedDividendAsPercentageShareOptionsGranted",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationDisclosureWeightedAverageAssumptionsandFairValueofOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected dividend yield",
        "label": "Expected dividend as percentage, share options granted"
       }
      },
      "en": {
       "role": {
        "documentation": "The percentage of an expected dividend used to calculate the fair value of share options granted."
       }
      }
     },
     "auth_ref": [
      "r135"
     ]
    },
    "oncyf_ExpectedVolatilityOtherEquityInstrumentsGranted": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "ExpectedVolatilityOtherEquityInstrumentsGranted",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeSummaryofAssumptionsUsedintheBlackScholesOptionPricingModelforWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility",
        "label": "Expected Volatility, Other Equity Instruments Granted",
        "documentation": "Expected Volatility, Other Equity Instruments Granted"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ExpenseByNatureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ExpenseByNatureAbstract",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expenses",
        "label": "Expenses by nature [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation warrant expenses (note 11)",
        "label": "Expense from equity-settled share-based payment transactions"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense arising from equity-settled share-based payment transactions in which the goods or services received did not qualify for recognition as assets. [Refer: Expense from share-based payment transactions]"
       }
      }
     },
     "auth_ref": [
      "r138"
     ]
    },
    "ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ExpenseFromSharebasedPaymentTransactionsWithEmployees",
     "crdr": "debit",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ComponentsofExpensesDetails",
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation expense",
        "label": "Expense from share-based payment transactions with employees"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense from share-based payment transactions with employees. [Refer: Expense from share-based payment transactions]"
       }
      }
     },
     "auth_ref": [
      "r310"
     ]
    },
    "ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees",
     "crdr": "debit",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expense from share-based payment transactions with parties other than employees",
        "label": "Expense from share-based payment transactions with parties other than employees"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense from share-based payment transactions with parties other than employees. [Refer: Expense from share-based payment transactions]"
       }
      }
     },
     "auth_ref": [
      "r310"
     ]
    },
    "oncyf_ExpirationPeriodOfOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "ExpirationPeriodOfOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration period, granted",
        "label": "Expiration Period Of Other Equity Instruments Granted In Share-Based Payment Arrangement",
        "documentation": "Expiration Period Of Other Equity Instruments Granted In Share-Based Payment Arrangement"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ContractLiabilityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Contract Liability",
        "label": "Explanation of significant changes in contract assets and contract liabilities [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The explanation of the significant changes in the contract assets and the contract liabilities. [Refer: Contract assets; Contract liabilities]"
       }
      }
     },
     "auth_ref": [
      "r97"
     ]
    },
    "oncyf_FairValueOfWarrantDerivativeExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "FairValueOfWarrantDerivativeExercised",
     "crdr": "debit",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeReconciliationofChangeinFairValueofWarrantDerivativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Exercised",
        "label": "Fair Value Of Warrant Derivative, Exercised",
        "documentation": "Fair Value Of Warrant Derivative, Exercised"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_FairValueOfWarrantDerivativeExpired": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "FairValueOfWarrantDerivativeExpired",
     "crdr": "debit",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeReconciliationofChangeinFairValueofWarrantDerivativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Expired",
        "label": "Fair Value Of Warrant Derivative, Expired",
        "documentation": "Fair Value Of Warrant Derivative, Expired"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_ForeignExchangeImpactRightofUseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "ForeignExchangeImpactRightofUseAssets",
     "crdr": "credit",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesRightofuseAssetsandLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign exchange impact",
        "label": "Foreign Exchange Impact, Right-of-Use Assets",
        "documentation": "Foreign Exchange Impact, Right-of-Use Assets"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r219",
      "r230",
      "r240",
      "r273"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r219",
      "r230",
      "r240",
      "r273"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r219",
      "r230",
      "r240",
      "r273"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r219",
      "r230",
      "r240",
      "r273"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r219",
      "r230",
      "r240",
      "r273"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]",
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year"
       }
      }
     },
     "auth_ref": [
      "r253"
     ]
    },
    "oncyf_GainsLossesFromForeignExchangeImpact": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "GainsLossesFromForeignExchangeImpact",
     "crdr": "credit",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesRightofuseAssetsandLeaseLiabilitiesDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeReconciliationofChangeinFairValueofWarrantDerivativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign exchange impact",
        "label": "Gains (Losses) From Foreign Exchange Impact",
        "documentation": "Gains (Losses) From Foreign Exchange Impact"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "GainsLossesOnChangeInFairValueOfDerivatives",
     "crdr": "credit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeReconciliationofChangeinFairValueofWarrantDerivativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value of warrant derivative (notes 9, 17)",
        "verboseLabel": "Change in fair value",
        "label": "Gains (losses) on change in fair value of derivatives"
       }
      },
      "en": {
       "role": {
        "documentation": "The gains (losses) resulting from change in the fair value of derivatives recognised in profit or loss. [Refer: Derivatives [member]]"
       }
      }
     },
     "auth_ref": [
      "r314"
     ]
    },
    "ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Foreign exchange gain (loss)",
        "label": "Foreign exchange gain (loss)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of exchange differences recognised in profit or loss that arise from foreign currency transactions, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: At fair value [member]; Classes of financial instruments [domain]]"
       }
      }
     },
     "auth_ref": [
      "r8",
      "r47"
     ]
    },
    "ifrs-full_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS",
      "http://www.oncolyticsbiotech.com/role/ComponentsofExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "General and administrative (note 20)",
        "terseLabel": "General and administrative expenses",
        "label": "General and administrative expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense relating to general and administrative activities of the entity."
       }
      }
     },
     "auth_ref": [
      "r310"
     ]
    },
    "oncyf_GeneralAndAdministrativeExpense1Abstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "GeneralAndAdministrativeExpense1Abstract",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ComponentsofExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative expenses",
        "label": "General And Administrative Expense 1 [Abstract]",
        "documentation": "General And Administrative Expense 1"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_GeneralAndAdministrativeExpense1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "GeneralAndAdministrativeExpense1Member",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ComponentsofExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative expenses",
        "label": "General And Administrative Expense 1 [Member]",
        "documentation": "General And Administrative Expense 1"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_GeographicalAreasAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "GeographicalAreasAxis",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SegmentDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical areas [axis]",
        "label": "Geographical areas [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r158",
      "r170",
      "r182",
      "r184"
     ]
    },
    "ifrs-full_GeographicalAreasDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "GeographicalAreasDomain",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SegmentDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical areas",
        "label": "Geographical areas [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated geographical areas. It also represents the standard value for the 'Geographical areas' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r158",
      "r170",
      "r182",
      "r184"
     ]
    },
    "ifrs-full_GrossCarryingAmountMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "GrossCarryingAmountMember",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost",
        "label": "Gross carrying amount [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the amount at which an asset is recognised before deducting any accumulated depreciation (amortisation) and accumulated impairment losses thereon. [Refer: Depreciation and amortisation expense; Impairment loss]"
       }
      }
     },
     "auth_ref": [
      "r37",
      "r62",
      "r66",
      "r69",
      "r139",
      "r146",
      "r147",
      "r185"
     ]
    },
    "ifrs-full_GrossLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "GrossLeaseLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesTotalUndiscountedLeaseLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total undiscounted lease liabilities",
        "label": "Gross lease liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of contractual undiscounted cash flows in relation to lease liabilities before deducting finance charges. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r109",
      "r188"
     ]
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ICFR Auditor Attestation Flag",
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r198",
      "r199",
      "r222"
     ]
    },
    "ifrs-full_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Profit or loss [abstract]",
        "label": "Profit or loss [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_IncomeStatementLocation1Axis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "IncomeStatementLocation1Axis",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ComponentsofExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location1 [Axis]",
        "label": "Income Statement Location1 [Axis]",
        "documentation": "Income Statement Location1 [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_IncomeStatementLocation1Domain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "IncomeStatementLocation1Domain",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ComponentsofExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location1 [Domain]",
        "label": "Income Statement Location1 [Domain]",
        "documentation": "[Domain] for Income Statement Location1 [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncomeTaxExpenseContinuingOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IncomeTaxExpenseContinuingOperations",
     "crdr": "debit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS": {
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": -1.0,
       "order": 2.0
      },
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS",
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Income tax expense (note 15)",
        "totalLabel": "Current income taxes",
        "label": "Tax expense (income)"
       }
      },
      "en": {
       "role": {
        "documentation": "The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]"
       }
      }
     },
     "auth_ref": [
      "r25",
      "r31",
      "r32",
      "r33",
      "r54",
      "r89",
      "r152"
     ]
    },
    "ifrs-full_IncomeTaxesPaidRefund": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IncomeTaxesPaidRefund",
     "crdr": "credit",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresOtherCashFlowDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash taxes paid",
        "label": "Income taxes paid (refund)"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from income taxes paid or refunded."
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IncreaseDecreaseInCashAndCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "(Decrease) increase in cash and cash equivalents",
        "label": "Increase (decrease) in cash and cash equivalents after effect of exchange rate changes"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in cash and cash equivalents after the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "ifrs-full_IncreaseDecreaseInWorkingCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IncreaseDecreaseInWorkingCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperations",
       "weight": -1.0,
       "order": 9.0
      },
      "http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails",
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Net change in non-cash working capital (note 18)",
        "negatedTotalLabel": "Change in non-cash working capital related to operating activities",
        "label": "Increase (decrease) in working capital"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in working capital."
       }
      }
     },
     "auth_ref": [
      "r326"
     ]
    },
    "ifrs-full_IncreaseDecreaseThroughExerciseOfOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IncreaseDecreaseThroughExerciseOfOptions",
     "crdr": "credit",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issued pursuant to stock option plan (note 11)",
        "label": "Increase (decrease) through exercise of options, equity"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from the exercise of options."
       }
      }
     },
     "auth_ref": [
      "r308"
     ]
    },
    "ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IncreaseDecreaseThroughExerciseOfWarrantsEquity",
     "crdr": "credit",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issued pursuant to warrant derivative exercised (notes 9, 10)",
        "label": "Increase (decrease) through exercise of warrants, equity"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from the exercise of warrants."
       }
      }
     },
     "auth_ref": [
      "r308"
     ]
    },
    "oncyf_IncreaseDecreaseThroughExpirationOfWarrantEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "IncreaseDecreaseThroughExpirationOfWarrantEquity",
     "crdr": "credit",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiry of equity warrant agreement",
        "label": "Increase (Decrease) Through Expiration Of Warrant, Equity",
        "documentation": "Increase (Decrease) Through Expiration Of Warrant, Equity"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails": {
       "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash impact of foreign exchange",
        "label": "Increase (Decrease) Through Foreign Exchange, Financial Assets (Liabilities), Net",
        "documentation": "Increase (Decrease) Through Foreign Exchange, Financial Assets (Liabilities), Net"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "IncreaseDecreaseThroughIncentiveShareAwardsEquity",
     "crdr": "credit",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issued pursuant to incentive share award plan (note 11)",
        "label": "Increase (Decrease) Through Incentive Share Awards, Equity",
        "documentation": "Increase (Decrease) Through Incentive Share Awards, Equity"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IncreaseDecreaseThroughSharebasedPaymentTransactions",
     "crdr": "credit",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation expense (note 11)",
        "label": "Increase (decrease) through share-based payment transactions, equity"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]"
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities",
     "crdr": "credit",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/LeasesRightofuseAssetsandLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Increase through new leases, liabilities arising from financing activities",
        "terseLabel": "Additions",
        "label": "Increase through new leases, liabilities arising from financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase in liabilities arising from financing activities resulting from new leases. [Refer: Liabilities arising from financing activities]"
       }
      }
     },
     "auth_ref": [
      "r176",
      "r177"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r219",
      "r230",
      "r240",
      "r264",
      "r273",
      "r277",
      "r285"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r283"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r200",
      "r289"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r200",
      "r289"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r200",
      "r289"
     ]
    },
    "oncyf_IntellectualPropertyExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "IntellectualPropertyExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ComponentsofExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intellectual property expenses",
        "label": "Intellectual Property Expense",
        "documentation": "Intellectual Property Expense"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_InterestExpenseOnLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "InterestExpenseOnLeaseLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesRightofuseAssetsandLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Interest expense on lease liabilities",
        "label": "Interest expense on lease liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of interest expense on lease liabilities. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r104"
     ]
    },
    "ifrs-full_InterestIncomeOnCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "InterestIncomeOnCashAndCashEquivalents",
     "crdr": "credit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income, net",
        "label": "Interest income on cash and cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of interest income on cash and cash equivalents. [Refer: Interest income; Cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r310"
     ]
    },
    "ifrs-full_InterestRevenueExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "InterestRevenueExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperations",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Interest expense (income), net",
        "label": "Interest income (expense)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of income or expense arising from interest. [Refer: Interest expense; Interest income]"
       }
      }
     },
     "auth_ref": [
      "r153",
      "r157",
      "r314"
     ]
    },
    "oncyf_InvestmentTaxCreditsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "InvestmentTaxCreditsMember",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesScheduleofUnrecognizedDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment tax credits",
        "label": "Investment Tax Credits [Member]",
        "documentation": "Investment Tax Credits [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IssueOfEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IssueOfEquity",
     "crdr": "credit",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeReconciliationofChangeinFairValueofWarrantDerivativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issue of equity",
        "verboseLabel": "Issued pursuant to public offering",
        "label": "Issue of equity"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase in equity through the issue of equity instruments."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "oncyf_IssueOfEquityShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "IssueOfEquityShares",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails",
      "http://www.oncolyticsbiotech.com/role/SubsequentEventsDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeReconciliationofChangeinFairValueofWarrantDerivativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issued pursuant to public offering (in shares)",
        "terseLabel": "Issued (in shares)",
        "label": "Issue Of Equity, Shares",
        "documentation": "Issue Of Equity, Shares"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_IssueOfEquitySharesNumberOfCommonShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "IssueOfEquitySharesNumberOfCommonShares",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of common shares (in shares)",
        "label": "Issue Of Equity, Shares, Number Of Common Shares",
        "documentation": "Issue Of Equity, Shares, Number Of Common Shares"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_IssueOfEquitySharesNumberOfWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "IssueOfEquitySharesNumberOfWarrants",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of warrants (in shares)",
        "label": "Issue Of Equity, Shares, Number Of Warrants",
        "documentation": "Issue Of Equity, Shares, Number Of Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_IssueOfOrdinarySharesPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "IssueOfOrdinarySharesPerShare",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of shares (in dollars per share)",
        "label": "Issue Of Ordinary Shares Per Share",
        "documentation": "Issue Of Ordinary Shares Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IssuedCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IssuedCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share capital (note 10) \u00a0\u00a0Authorized: unlimited \u00a0\u00a0Issued: December\u00a031, 2024 \u2013 80,020,131 December\u00a031, 2023 \u2013 74,423,960",
        "label": "Issued capital"
       }
      },
      "en": {
       "role": {
        "documentation": "The nominal value of capital issued."
       }
      }
     },
     "auth_ref": [
      "r166"
     ]
    },
    "ifrs-full_IssuedCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IssuedCapitalMember",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY",
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Capital",
        "label": "Issued capital [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing issued capital."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "ifrs-full_KeyManagementPersonnelCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "KeyManagementPersonnelCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Compensation of key management personnel",
        "label": "Key management personnel compensation"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of compensation to key management personnel. [Refer: Key management personnel of entity or parent [member]]"
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "KeyManagementPersonnelCompensationSharebasedPayment",
     "crdr": "debit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsDetails": {
       "parentTag": "ifrs-full_KeyManagementPersonnelCompensation",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation expense",
        "label": "Key management personnel compensation, share-based payment"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of compensation to key management personnel in the form of share-based payments. [Refer: Key management personnel of entity or parent [member]]"
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "KeyManagementPersonnelCompensationShorttermEmployeeBenefits",
     "crdr": "debit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsDetails": {
       "parentTag": "ifrs-full_KeyManagementPersonnelCompensation",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term employee compensation and benefits",
        "label": "Key management personnel compensation, short-term employee benefits"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of compensation to key management personnel in the form of short-term employee benefits. [Refer: Key management personnel of entity or parent [member]]"
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "KeyManagementPersonnelCompensationTerminationBenefits",
     "crdr": "debit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsDetails": {
       "parentTag": "ifrs-full_KeyManagementPersonnelCompensation",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination benefits",
        "label": "Key management personnel compensation, termination benefits"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of compensation to key management personnel in the form of termination benefits. [Refer: Termination benefits expense; Key management personnel of entity or parent [member]]"
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "ifrs-full_LaterThanFiveYearsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "LaterThanFiveYearsMember",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesTotalUndiscountedLeaseLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "More than five years",
        "label": "Later than five years [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than five years."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r111",
      "r123",
      "r187",
      "r189",
      "r191"
     ]
    },
    "ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "LaterThanOneYearAndNotLaterThanFiveYearsMember",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesTotalUndiscountedLeaseLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "One to five years",
        "label": "Later than one year and not later than five years [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than one year and not later than five years."
       }
      }
     },
     "auth_ref": [
      "r186",
      "r191"
     ]
    },
    "ifrs-full_LeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "LeaseLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesRightofuseAssetsandLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Lease liabilities, beginning balance",
        "periodEndLabel": "Lease liabilities, ending balance",
        "label": "Lease liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration."
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "ifrs-full_LeaseLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "LeaseLiabilitiesAbstract",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesRightofuseAssetsandLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease Liabilities [Abstract]",
        "label": "Lease liabilities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold Improvements",
        "label": "Leasehold improvements [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of property, plant and equipment representing improvements to assets held under a lease agreement."
       }
      }
     },
     "auth_ref": [
      "r315"
     ]
    },
    "ifrs-full_Level2OfFairValueHierarchyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "Level2OfFairValueHierarchyMember",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 2",
        "label": "Level 2 of fair value hierarchy [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r60",
      "r91"
     ]
    },
    "ifrs-full_LevelsOfFairValueHierarchyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "LevelsOfFairValueHierarchyAxis",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Levels of fair value hierarchy [axis]",
        "label": "Levels of fair value hierarchy [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r91"
     ]
    },
    "ifrs-full_LevelsOfFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "LevelsOfFairValueHierarchyDomain",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Levels of fair value hierarchy",
        "label": "Levels of fair value hierarchy [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all levels of the fair value hierarchy. It also represents the standard value for the 'Levels of fair value hierarchy' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r91"
     ]
    },
    "ifrs-full_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r90",
      "r91",
      "r92",
      "r153",
      "r156"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_LossesOnDisposalsOfPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "LossesOnDisposalsOfPropertyPlantAndEquipment",
     "crdr": "debit",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Losses on disposals of property, plant and equipment",
        "label": "Losses on disposals of property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The losses on the disposal of property, plant and equipment. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "ifrs-full_MajorOrdinaryShareTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "MajorOrdinaryShareTransactionsMember",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/NatureofOperationsandGoingConcernDetails",
      "http://www.oncolyticsbiotech.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share transactions",
        "label": "Major ordinary share transactions [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for major ordinary share transactions. [Refer: Ordinary shares [member]]"
       }
      }
     },
     "auth_ref": [
      "r168"
     ]
    },
    "oncyf_ManufacturingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "ManufacturingExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ComponentsofExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Manufacturing &amp; related process development expenses",
        "label": "Manufacturing Expense",
        "documentation": "Manufacturing Expense"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_MaturityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "MaturityAxis",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesTotalUndiscountedLeaseLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maturity [axis]",
        "label": "Maturity [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r98",
      "r110",
      "r111",
      "r115",
      "r116",
      "r117",
      "r123",
      "r142",
      "r148",
      "r171",
      "r187"
     ]
    },
    "ifrs-full_MaturityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "MaturityDomain",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesTotalUndiscountedLeaseLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maturity",
        "label": "Maturity [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated time bands. It also represents the standard value for the 'Maturity' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r98",
      "r110",
      "r111",
      "r115",
      "r116",
      "r117",
      "r123",
      "r142",
      "r171",
      "r187",
      "r190"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SummaryofMaterialAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum option expiration term",
        "label": "Maximum Term Of Options Granted For Share-based Payment Arrangement",
        "documentation": "Maximum Term Of Options Granted For Share-based Payment Arrangement"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r256"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r256"
     ]
    },
    "oncyf_MedicalEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "MedicalEquipmentMember",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails",
      "http://www.oncolyticsbiotech.com/role/SummaryofMaterialAccountingPoliciesScheduleofDepreciationRatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Medical equipment",
        "verboseLabel": "Medical Equipment",
        "label": "Medical Equipment [Member]",
        "documentation": "Medical Equipment [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_MiscellaneousOtherOperatingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "MiscellaneousOtherOperatingExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ComponentsofExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other expenses",
        "label": "Miscellaneous other operating expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of miscellaneous other operating expenses. [Refer: Other operating income (expense)]"
       }
      }
     },
     "auth_ref": [
      "r310"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r276"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r284"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r257"
     ]
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r256"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r219",
      "r230",
      "r240",
      "r264",
      "r273"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r247"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r246"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r264"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r284"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r284"
     ]
    },
    "ifrs-full_NonadjustingEventsAfterReportingPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NonadjustingEventsAfterReportingPeriodAxis",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/NatureofOperationsandGoingConcernDetails",
      "http://www.oncolyticsbiotech.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-adjusting events after reporting period [axis]",
        "label": "Non-adjusting events after reporting period [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "ifrs-full_NonadjustingEventsAfterReportingPeriodDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NonadjustingEventsAfterReportingPeriodDomain",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/NatureofOperationsandGoingConcernDetails",
      "http://www.oncolyticsbiotech.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-adjusting events after reporting period",
        "label": "Non-adjusting events after reporting period [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for events that occur between the end of the reporting period and the date when the financial statements are authorised for issue and are indicative of conditions that arose after the reporting period. It also represents the standard value for the 'Non-adjusting events after reporting period' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "ifrs-full_NoncurrentContractLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NoncurrentContractLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract liability (note 13)",
        "label": "Non-current contract liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current contract liabilities. [Refer: Contract liabilities]"
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "ifrs-full_NoncurrentLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NoncurrentLeaseLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liabilities (note 8)",
        "label": "Non-current lease liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current lease liabilities. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "ifrs-full_NotLaterThanOneYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NotLaterThanOneYearMember",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesTotalUndiscountedLeaseLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Less than one year",
        "label": "Not later than one year [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of not later than one year."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r110",
      "r111",
      "r123",
      "r187",
      "r191"
     ]
    },
    "ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NumberOfInstrumentsOtherEquityInstrumentsGranted",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofNumberofOtherEquityInstrumentsDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in shares)",
        "label": "Number of other equity instruments granted in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r328"
     ]
    },
    "ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofNumberofOtherEquityInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Released (in shares)",
        "label": "Number of other equity instruments exercised or vested in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r328"
     ]
    },
    "ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofNumberofOtherEquityInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Forfeited (in shares)",
        "label": "Number of other equity instruments forfeited in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of other equity instruments (ie other than share options) forfeited in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r328"
     ]
    },
    "ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofNumberofOtherEquityInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding, beginning of the year (in shares)",
        "periodEndLabel": "Outstanding, end of the year (in shares)",
        "label": "Number of other equity instruments outstanding in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r328"
     ]
    },
    "ifrs-full_NumberOfOutstandingShareOptions": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NumberOfOutstandingShareOptions",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails",
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsandWeightedAverageExercisePricesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding, beginning of the year (shares)",
        "periodEndLabel": "Outstanding, end of the year (shares)",
        "terseLabel": "Number Outstanding (shares)",
        "label": "Number of share options outstanding in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of share options outstanding in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r130",
      "r133"
     ]
    },
    "oncyf_NumberOfReportableSegments1": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "NumberOfReportableSegments1",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SegmentDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of reportable segments",
        "label": "Number Of Reportable Segments1",
        "documentation": "Number Of Reportable Segments1"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NumberOfShareOptionsExercisableInSharebasedPaymentArrangement",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails",
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsandWeightedAverageExercisePricesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options exercisable, end of the year (shares)",
        "verboseLabel": "Number Exercisable (shares)",
        "label": "Number of share options exercisable in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of share options exercisable in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NumberOfShareOptionsExercisedInSharebasedPaymentArrangement",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsandWeightedAverageExercisePricesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Exercised during the year (shares)",
        "label": "Number of share options exercised in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of share options exercised in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r128"
     ]
    },
    "ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NumberOfShareOptionsExpiredInSharebasedPaymentArrangement",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsandWeightedAverageExercisePricesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Expired during the year (shares)",
        "label": "Number of share options expired in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of share options expired in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r129"
     ]
    },
    "ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsandWeightedAverageExercisePricesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Forfeited during the year (shares)",
        "label": "Number of share options forfeited in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of share options forfeited in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r127"
     ]
    },
    "ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NumberOfShareOptionsGrantedInSharebasedPaymentArrangement",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsandWeightedAverageExercisePricesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted during the year (shares)",
        "label": "Number of share options granted in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of share options granted in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r126"
     ]
    },
    "ifrs-full_NumberOfSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NumberOfSharesIssued",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITIONParenthetical",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share capital issued (shares)",
        "periodStartLabel": "Share capital issued, beginning (shares)",
        "periodEndLabel": "Share capital issued ending (shares)",
        "label": "Number of shares issued"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of shares issued by the entity."
       }
      }
     },
     "auth_ref": [
      "r308"
     ]
    },
    "oncyf_NumberOfSharesReservedForIssueUnderOptionsAndContractsForSaleOfSharesPercentageOfCommonSharesMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "NumberOfSharesReservedForIssueUnderOptionsAndContractsForSaleOfSharesPercentageOfCommonSharesMaximum",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common shares reserved for issuance, maximum percentage",
        "label": "Number Of Shares Reserved For Issue Under Options And Contracts For Sale Of Shares, Percentage Of Common Shares, Maximum",
        "documentation": "Number Of Shares Reserved For Issue Under Options And Contracts For Sale Of Shares, Percentage Of Common Shares, Maximum"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_NumberOfStockOptionPlans": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "NumberOfStockOptionPlans",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SummaryofMaterialAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of plans",
        "label": "Number Of Stock Option Plans",
        "documentation": "Number Of Stock Option Plans"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_NumberOfWarrantsAndSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "NumberOfWarrantsAndSharesOutstanding",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of warrants and shares outstanding (in shares)",
        "label": "Number Of Warrants And Shares Outstanding",
        "documentation": "Number Of Warrants And Shares Outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_NumberOfWarrantsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "NumberOfWarrantsExercised",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeReconciliationofChangeinFairValueofWarrantDerivativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Exercised (in shares)",
        "terseLabel": "Exercised (in shares)",
        "label": "Number Of Warrants Exercised",
        "documentation": "Number Of Warrants Exercised"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_NumberOfWarrantsExpired": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "NumberOfWarrantsExpired",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeReconciliationofChangeinFairValueofWarrantDerivativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Expired (in shares)",
        "label": "Number Of Warrants Expired",
        "documentation": "Number Of Warrants Expired"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_NumberOfWarrantsOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "NumberOfWarrantsOutstanding",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeReconciliationofChangeinFairValueofWarrantDerivativeDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeWarrantDerivativeOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance at beginning of period (in shares)",
        "periodEndLabel": "Balance at end of period (in shares)",
        "terseLabel": "Number of Warrants Outstanding",
        "label": "Number Of Warrants Outstanding",
        "documentation": "Number Of Warrants Outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_NumberOfWarrantsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "NumberOfWarrantsOutstandingRollForward",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeReconciliationofChangeinFairValueofWarrantDerivativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Warrants Outstanding",
        "label": "Number Of Warrants Outstanding [Roll Forward]",
        "documentation": "Number Of Warrants Outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_OfficeEquipmentAndFurnitureMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "OfficeEquipmentAndFurnitureMember",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Office Equipment and Furniture",
        "label": "Office equipment and furniture [Member]",
        "documentation": "Office equipment and furniture"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OfficeEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OfficeEquipmentMember",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SummaryofMaterialAccountingPoliciesScheduleofDepreciationRatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Office equipment and furniture",
        "label": "Office equipment [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of property, plant and equipment representing equipment used to support office functions, not specifically used in the production process. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r169"
     ]
    },
    "oncyf_OfficeExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "OfficeExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ComponentsofExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Office expenses",
        "label": "Office Expenses",
        "documentation": "Office Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "srt_OfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "OfficerMember",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Officer",
        "label": "Officer [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_OperatingLeaseLeaseTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "OperatingLeaseLeaseTerm",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease term",
        "label": "Operating Lease, Lease Term",
        "documentation": "Operating Lease, Lease Term"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherComprehensiveIncomeAbstract",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive income (loss) items that may be reclassified to net loss",
        "label": "Other comprehensive income [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation",
     "crdr": "credit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS": {
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Translation adjustment",
        "label": "Other comprehensive income, net of tax, exchange differences on translation of foreign operations"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of other comprehensive income, net of tax, after reclassification adjustments, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r18",
      "r26"
     ]
    },
    "ifrs-full_OtherCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherCurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION",
      "http://www.oncolyticsbiotech.com/role/OtherLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other liabilities (note 5)",
        "verboseLabel": "Other liabilities",
        "label": "Other current liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Current liabilities]"
       }
      }
     },
     "auth_ref": [
      "r312"
     ]
    },
    "ifrs-full_OtherCurrentReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherCurrentReceivables",
     "crdr": "debit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other receivables",
        "label": "Other current receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current other receivables. [Refer: Other receivables]"
       }
      }
     },
     "auth_ref": [
      "r165"
     ]
    },
    "ifrs-full_OtherEmployeeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherEmployeeExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ComponentsofExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Personnel-related expenses",
        "label": "Other employee expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of employee expenses that the entity does not separately disclose in the same statement or note."
       }
      }
     },
     "auth_ref": [
      "r317"
     ]
    },
    "oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementAcceleratedThresholdTradingDays": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "OtherEquityInstrumentsInShareBasedPaymentArrangementAcceleratedThresholdTradingDays",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of warrant or right, accelerated threshold trading days",
        "label": "Other Equity Instruments In Share-Based Payment Arrangement, Accelerated Threshold Trading Days",
        "documentation": "Other Equity Instruments In Share-Based Payment Arrangement, Accelerated Threshold Trading Days"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementExpirationDays": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "OtherEquityInstrumentsInShareBasedPaymentArrangementExpirationDays",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of warrant or right, expiration days",
        "label": "Other Equity Instruments In Share-Based Payment Arrangement, Expiration Days",
        "documentation": "Other Equity Instruments In Share-Based Payment Arrangement, Expiration Days"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementThresholdConsecutiveTradingDays": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "OtherEquityInstrumentsInShareBasedPaymentArrangementThresholdConsecutiveTradingDays",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of warrant or right, threshold consecutive trading days",
        "label": "Other Equity Instruments In Share-Based Payment Arrangement, Threshold Consecutive Trading Days",
        "documentation": "Other Equity Instruments In Share-Based Payment Arrangement, Threshold Consecutive Trading Days"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementThresholdTradingPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "OtherEquityInstrumentsInShareBasedPaymentArrangementThresholdTradingPrice",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of warrant or right, threshold trading price (usd per share)",
        "label": "Other Equity Instruments In Share-Based Payment Arrangement, Threshold Trading Price",
        "documentation": "Other Equity Instruments In Share-Based Payment Arrangement, Threshold Trading Price"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_OtherEquityInstrumentsLifeOtherEquityInstrumentsGranted": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "OtherEquityInstrumentsLifeOtherEquityInstrumentsGranted",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeSummaryofAssumptionsUsedintheBlackScholesOptionPricingModelforWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected life",
        "label": "Other Equity Instruments Life, Other Equity Instruments Granted",
        "documentation": "Other Equity Instruments Life, Other Equity Instruments Granted"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_OtherExpensesAndAdjustmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "OtherExpensesAndAdjustmentsLineItems",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ComponentsofExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Expenses And Adjustments [Line Items]",
        "label": "Other Expenses And Adjustments [Line Items]",
        "documentation": "[Line Items] for Other Expenses And Adjustments [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_OtherExpensesAndAdjustmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "OtherExpensesAndAdjustmentsTable",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ComponentsofExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Expenses And Adjustments [Table]",
        "label": "Other Expenses And Adjustments [Table]",
        "documentation": "Other Expenses And Adjustments [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_OtherExpensesAndAdjustmentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "OtherExpensesAndAdjustmentsTableTextBlock",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ComponentsofExpensesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Other expenses and adjustments",
        "label": "Other Expenses And Adjustments [Table Text Block]",
        "documentation": "Other Expenses And Adjustments [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsScheduleofBalancesinForeignCurrenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Other liabilities",
        "label": "Other liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities that the entity does not separately disclose in the same statement or note."
       }
      }
     },
     "auth_ref": [
      "r312"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r256"
     ]
    },
    "ifrs-full_OtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherReceivables",
     "crdr": "debit",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/OtherLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other receivables",
        "label": "Other receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount receivable by the entity that it does not separately disclose in the same statement or note."
       }
      }
     },
     "auth_ref": [
      "r165"
     ]
    },
    "ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome",
     "crdr": "debit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails": {
       "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other permanent differences",
        "label": "Other tax effects for reconciliation between accounting profit and tax expense (income)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that the entity does not separately disclose in the same statement or note. [Refer: Accounting profit; Applicable tax rate]"
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r217",
      "r228",
      "r238",
      "r271"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r220",
      "r231",
      "r241",
      "r274"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r220",
      "r231",
      "r241",
      "r274"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r245"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r255"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r255"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r247"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r264"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r257"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r246"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Prior Service Cost [Member]",
        "terseLabel": "Pension Adjustments Prior Service Cost"
       }
      }
     },
     "auth_ref": [
      "r248"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Service Cost [Member]",
        "terseLabel": "Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r304"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote [Text Block]",
        "terseLabel": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r247"
     ]
    },
    "ifrs-full_PresentationOfLeasesForLesseeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "PresentationOfLeasesForLesseeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Presentation of leases for lessee [abstract]",
        "label": "Presentation of leases for lessee [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProceedsFromExerciseOfOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProceedsFromExerciseOfOptions",
     "crdr": "debit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from exercise of stock options (note 11)",
        "label": "Proceeds from exercise of options"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from the exercise of options."
       }
      }
     },
     "auth_ref": [
      "r323"
     ]
    },
    "ifrs-full_ProceedsFromExerciseOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProceedsFromExerciseOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from exercise of warrant derivative (note 9)",
        "label": "Proceeds from exercise of warrants"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from the exercise of share purchase warrants."
       }
      }
     },
     "auth_ref": [
      "r323"
     ]
    },
    "ifrs-full_ProceedsFromIssueOfOrdinaryShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProceedsFromIssueOfOrdinaryShares",
     "crdr": "debit",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/NatureofOperationsandGoingConcernDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails",
      "http://www.oncolyticsbiotech.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net proceeds from issue of ordinary shares",
        "label": "Proceeds from issue of ordinary shares"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from the issuing of ordinary shares. [Refer: Ordinary shares [member]]"
       }
      }
     },
     "auth_ref": [
      "r323"
     ]
    },
    "oncyf_ProceedsFromIssueOfOrdinarySharesGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "ProceedsFromIssueOfOrdinarySharesGross",
     "crdr": "debit",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails",
      "http://www.oncolyticsbiotech.com/role/SubsequentEventsDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross proceeds from shares",
        "label": "Proceeds From Issue Of Ordinary Shares, Gross",
        "documentation": "Proceeds From Issue Of Ordinary Shares, Gross"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProceedsFromIssuingShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProceedsFromIssuingShares",
     "crdr": "debit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from share issuance",
        "label": "Proceeds from issuing shares"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from issuing shares."
       }
      }
     },
     "auth_ref": [
      "r174"
     ]
    },
    "ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maturities of marketable securities",
        "label": "Proceeds from sales or maturity of financial instruments, classified as investing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from sales or maturity of financial instruments, classified as investing activities. [Refer: Classes of financial instruments [domain]]"
       }
      }
     },
     "auth_ref": [
      "r322"
     ]
    },
    "oncyf_ProceedsfromInterestReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "ProceedsfromInterestReceived",
     "crdr": "debit",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresOtherCashFlowDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash interest received",
        "label": "Proceeds from Interest Received",
        "documentation": "Proceeds from Interest Received"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_ProceedsfromWarrantExercises1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "ProceedsfromWarrantExercises1",
     "crdr": "debit",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross proceeds from warrant exercises",
        "label": "Proceeds from Warrant Exercises1",
        "documentation": "Proceeds from Warrant Exercises1"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS": {
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "terseLabel": "Net loss for the year",
        "label": "Profit (loss)"
       }
      },
      "en": {
       "role": {
        "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r2",
      "r23",
      "r71",
      "r82",
      "r84",
      "r153",
      "r154",
      "r178",
      "r183"
     ]
    },
    "ifrs-full_ProfitLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProfitLossBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS": {
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss before income taxes",
        "label": "Profit (loss) before tax"
       }
      },
      "en": {
       "role": {
        "documentation": "The profit (loss) before tax expense or income. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r140",
      "r161",
      "r162",
      "r192",
      "r193"
     ]
    },
    "ifrs-full_ProfitLossFromOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProfitLossFromOperatingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss before the following",
        "label": "Profit (loss) from operating activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r172",
      "r314"
     ]
    },
    "ifrs-full_PropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "PropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION",
      "http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails",
      "http://www.oncolyticsbiotech.com/role/SegmentDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment (note 6)",
        "periodStartLabel": "Property and equipment, beginning balance",
        "periodEndLabel": "Property and equipment, ending balance",
        "verboseLabel": "Property and equipment",
        "label": "Property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period. Note that right-of-use assets are not included. [Contrast: Property, plant and equipment including right-of-use assets]"
       }
      }
     },
     "auth_ref": [
      "r10",
      "r41"
     ]
    },
    "oncyf_PropertyPlantEquipmentRelatedTemporaryDifferencesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "PropertyPlantEquipmentRelatedTemporaryDifferencesMember",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesScheduleofUnrecognizedDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment",
        "label": "Property, Plant, Equipment Related Temporary Differences [Member]",
        "documentation": "Property, Plant, Equipment And Intellectual Property Related Temporary Differences [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_PropertyPlantandEquipmentAnnualDepreciationRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "PropertyPlantandEquipmentAnnualDepreciationRate",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SummaryofMaterialAccountingPoliciesScheduleofDepreciationRatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual depreciation rate",
        "label": "Property, Plant and Equipment, Annual Depreciation Rate",
        "documentation": "Property, Plant and Equipment, Annual Depreciation Rate"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_PublicCompanyExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "PublicCompanyExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ComponentsofExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Public company-related expenses",
        "label": "Public Company Expense",
        "documentation": "Public Company Expense"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_PurchaseObligation1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "PurchaseObligation1",
     "crdr": "credit",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitment for payment",
        "label": "Purchase Obligation1",
        "documentation": "Purchase Obligation1"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_PurchaseObligationCommitmentProductionServiceAgreementPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "PurchaseObligationCommitmentProductionServiceAgreementPercentage",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Production service agreement, percentage",
        "label": "Purchase Obligation, Commitment, Production Service Agreement, Percentage",
        "documentation": "Purchase Obligation, Commitment, Production Service Agreement, Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_PurchaseObligationCommitmentTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "PurchaseObligationCommitmentTerm",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitment term",
        "label": "Purchase Obligation, Commitment Term",
        "documentation": "Purchase Obligation, Commitment Term"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Acquisition of marketable securities",
        "label": "Purchase of financial instruments, classified as investing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for the purchase of financial instruments. [Refer: Classes of financial instruments [domain]]"
       }
      }
     },
     "auth_ref": [
      "r322"
     ]
    },
    "ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Acquisition of property and equipment (note 6)",
        "label": "Purchase of property, plant and equipment, classified as investing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r173"
     ]
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r245"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r245"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Axis]",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Range [axis]",
        "label": "Range [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r94",
      "r117",
      "r133",
      "r179",
      "r180",
      "r329"
     ]
    },
    "ifrs-full_RangeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RangeDomain",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Range",
        "label": "Range [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregate ranges. It also represents the standard value for the 'Range' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r94",
      "r117",
      "r133",
      "r179",
      "r180",
      "r329"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Domain]",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RangesOfExercisePricesForOutstandingShareOptionsAxis",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ranges of exercise prices for outstanding share options [axis]",
        "label": "Ranges of exercise prices for outstanding share options [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r133"
     ]
    },
    "ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RangesOfExercisePricesForOutstandingShareOptionsDomain",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ranges of exercise prices for outstanding share options",
        "label": "Ranges of exercise prices for outstanding share options [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated ranges of exercise prices for outstanding share options that are meaningful for assessing the number and timing of additional shares that may be issued and the cash that may be received upon exercise of those options. It also represents the standard value for the 'Ranges of exercise prices for outstanding share options' axis if no other member is used. [Refer: Range [domain]]"
       }
      }
     },
     "auth_ref": [
      "r133"
     ]
    },
    "ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reconciliation of changes in property, plant and equipment [abstract]",
        "label": "Reconciliation of changes in property, plant and equipment [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r212",
      "r223",
      "r233",
      "r266"
     ]
    },
    "ifrs-full_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS",
      "http://www.oncolyticsbiotech.com/role/ComponentsofExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development (note 20)",
        "verboseLabel": "Research and development expenses",
        "label": "Research and development expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expenditure directly attributable to research or development activities, recognised in profit or loss."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "oncyf_ResearchAndDevelopmentExpense1Abstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "ResearchAndDevelopmentExpense1Abstract",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ComponentsofExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development expenses",
        "label": "Research And Development Expense 1 [Abstract]",
        "documentation": "Research And Development Expense 1"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_ResearchAndDevelopmentExpense1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "ResearchAndDevelopmentExpense1Member",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ComponentsofExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development expenses",
        "label": "Research And Development Expense 1 [Member]",
        "documentation": "Research And Development Expense [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ReserveOfSharebasedPaymentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ReserveOfSharebasedPaymentsMember",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reserve of share-based payments",
        "label": "Reserve of share-based payments [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity resulting from share-based payments."
       }
      }
     },
     "auth_ref": [
      "r163"
     ]
    },
    "oncyf_RestOfWorldMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "RestOfWorldMember",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SegmentDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rest of world",
        "label": "Rest Of World [Member]",
        "documentation": "Rest Of World"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r213",
      "r224",
      "r234",
      "r267"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r214",
      "r225",
      "r235",
      "r268"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r221",
      "r232",
      "r242",
      "r275"
     ]
    },
    "ifrs-full_RestrictedShareUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RestrictedShareUnitsMember",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofNumberofOtherEquityInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted share units",
        "label": "Restricted share units [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for restricted share units."
       }
      }
     },
     "auth_ref": [
      "r318"
     ]
    },
    "ifrs-full_RetainedEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RetainedEarnings",
     "crdr": "credit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION",
      "http://www.oncolyticsbiotech.com/role/NatureofOperationsandGoingConcernDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained earnings"
       }
      },
      "en": {
       "role": {
        "documentation": "A component of equity representing the entity's cumulative undistributed earnings or deficit."
       }
      }
     },
     "auth_ref": [
      "r166",
      "r167"
     ]
    },
    "ifrs-full_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "label": "Retained earnings [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing an entity's cumulative undistributed earnings or deficit."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r163"
     ]
    },
    "oncyf_RightOfUseAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "RightOfUseAssetsAbstract",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesRightofuseAssetsandLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-Of-Use Assets [Abstract]",
        "label": "Right-Of-Use Assets [Abstract]",
        "documentation": "Right-Of-Use Assets"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RightofuseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RightofuseAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION",
      "http://www.oncolyticsbiotech.com/role/LeasesRightofuseAssetsandLeaseLiabilitiesDetails",
      "http://www.oncolyticsbiotech.com/role/SegmentDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use assets (note 8)",
        "periodStartLabel": "Right-of-use assets, beginning balance",
        "periodEndLabel": "Right-of-use assets, ending balance",
        "verboseLabel": "Right-of-use-assets",
        "label": "Right-of-use assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that represent a lessee's right to use an underlying asset for the lease term that do not meet the definition of investment property. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r107"
     ]
    },
    "oncyf_RiskFreeInterestRateOtherEquityInstrumentsGranted": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "RiskFreeInterestRateOtherEquityInstrumentsGranted",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeSummaryofAssumptionsUsedintheBlackScholesOptionPricingModelforWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate",
        "label": "Risk Free Interest Rate, Other Equity Instruments Granted",
        "documentation": "Risk Free Interest Rate, Other Equity Instruments Granted"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r284"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r284"
     ]
    },
    "oncyf_SaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "SaleOfStockAxis",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale Of Stock [Axis]",
        "label": "Sale Of Stock [Axis]",
        "documentation": "Sale Of Stock [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_SaleOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "SaleOfStockDomain",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale Of Stock [Domain]",
        "label": "Sale Of Stock [Domain]",
        "documentation": "[Domain] for Sale Of Stock [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "ScheduleOfForeignCurrencyHeldTableTextBlock",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of balances in foreign currencies",
        "label": "Schedule Of Foreign Currency Held [Table Text Block]",
        "documentation": "Schedule Of Foreign Currency Held [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "ScheduleofCashFlowSupplementalDisclosures1TableTextBlock",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Other cash flow disclosures",
        "label": "Schedule of Cash Flow, Supplemental Disclosures1 [Table Text Block]",
        "documentation": "Schedule of Cash Flow, Supplemental Disclosures1 [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Provision for income taxes",
        "label": "Schedule of Components of Income Tax Expense (Benefit)1 [Table Text Block]",
        "documentation": "Schedule of Components of Income Tax Expense (Benefit)1 [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r195"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r197"
     ]
    },
    "oncyf_SegmentDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "SegmentDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Disclosures [Abstract]",
        "documentation": "Segment Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical [Domain]",
        "label": "Geographical [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impact of increase in value of currency (cad per share)",
        "label": "Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Change In Risk Variable, Amount",
        "documentation": "A reference variable for a specific type of market risk, defined in non-percentage terms. Positive value indicates an increase; negative value indicates a decrease."
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings",
     "crdr": "credit",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (decrease) in net loss due to change in currency value",
        "label": "Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Change In Risk Variable, Impact On Pre-Tax Earnings",
        "documentation": "Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Change In Risk Variable, Impact On Pre-Tax Earnings"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_ShareCapitalAmountAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "ShareCapitalAmountAbstract",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amount",
        "label": "Share Capital, Amount [Abstract]",
        "documentation": "Share Capital, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_ShareCapitalNumberSharesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "ShareCapitalNumberSharesAbstract",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number",
        "label": "Share Capital, Number, Shares [Abstract]",
        "documentation": "Share Capital, Number, Shares"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_ShareIssueCostsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "ShareIssueCostsMember",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesScheduleofUnrecognizedDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share issue costs",
        "label": "Share Issue Costs [Member]",
        "documentation": "Share Issue Costs [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ShareIssueRelatedCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ShareIssueRelatedCost",
     "crdr": "debit",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Share issue costs (note 10)",
        "negatedLabel": "Share issue costs",
        "terseLabel": "Share issue related cost",
        "label": "Share issue related cost"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of cost related to the issuance of shares."
       }
      }
     },
     "auth_ref": [
      "r308"
     ]
    },
    "oncyf_ShareIssueRelatedCostCommissions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "ShareIssueRelatedCostCommissions",
     "crdr": "debit",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails",
      "http://www.oncolyticsbiotech.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share issue related cost, commissions",
        "label": "Share Issue Related Cost, Commissions",
        "documentation": "Share Issue Related Cost, Commissions"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_SharePremiumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "SharePremiumMember",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY",
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contributed Surplus",
        "label": "Share premium [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the amount received or receivable from issuance of the entity's shares in excess of nominal value."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "oncyf_SharePurchaseAgreementAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "SharePurchaseAgreementAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Agreement",
        "label": "Share Purchase Agreement, Amount",
        "documentation": "Share Purchase Agreement, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_SharePurchaseAgreementTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "SharePurchaseAgreementTerm",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Agreement term",
        "label": "Share Purchase Agreement, Term",
        "documentation": "Share Purchase Agreement, Term"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_ShareWarrantsIssuedOperatingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "ShareWarrantsIssuedOperatingExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share issue operating expense",
        "label": "Share Warrants Issued, Operating Expense",
        "documentation": "Share Warrants Issued, Operating Expense"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_ShareWarrantsIssuedTransactionCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "ShareWarrantsIssuedTransactionCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants issued, transaction costs",
        "label": "Share Warrants Issued, Transaction Costs",
        "documentation": "Share Warrants Issued, Transaction Costs"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Vesting period, if not immediately vested",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period1",
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period1"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_SharesIssuedPricePerShare1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "SharesIssuedPricePerShare1",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase price (cad and usd per share)",
        "label": "Shares Issued, Price Per Share1",
        "documentation": "Shares Issued, Price Per Share1"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_SharesPublicOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "SharesPublicOfferingMember",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Public offering",
        "label": "Shares Public Offering [Member]",
        "documentation": "Shares Public Offering [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_SharesPublicOfferingWarrantDerivativesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "SharesPublicOfferingWarrantDerivativesMember",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares Under Warrant Derivative Agreement",
        "verboseLabel": "Warrant derivatives",
        "label": "Shares Public Offering, Warrant Derivatives [Member]",
        "documentation": "Shares Public Offering, Warrant Derivatives"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common shares reserved for issuance (in shares)",
        "label": "Number of shares reserved for issue under options and contracts for sale of shares"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of shares reserved for issue under options and contracts for the sale of shares."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "oncyf_SharesUnderAtthemarketAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "SharesUnderAtthemarketAgreementMember",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "At-the-market equity distribution agreement",
        "label": "Shares Under At-the-market Agreement [Member]",
        "documentation": "Shares Under At-the-market Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_SharesUnderIncentiveAwardPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "SharesUnderIncentiveAwardPlanMember",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Incentive share award plan",
        "label": "Shares Under Incentive Award Plan [Member]",
        "documentation": "Shares Under Incentive Award Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_SharesUnderPublicOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "SharesUnderPublicOfferingMember",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Public offering",
        "label": "Shares Under Public Offering [Member]",
        "documentation": "Shares Under Public Offering"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_SharesUnderStockOptionPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "SharesUnderStockOptionPlanMember",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock option plan",
        "label": "Shares Under Stock Option Plan [Member]",
        "documentation": "Shares Under Stock Option Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_SignificantJudgmentsEstimatesAndAssumptionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "SignificantJudgmentsEstimatesAndAssumptionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Significant Judgments, Estimates And Assumptions [Abstract]",
        "label": "Significant Judgments, Estimates And Assumptions [Abstract]",
        "documentation": "Significant Judgments, Estimates And Assumptions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_Statement1LineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "Statement1LineItems",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement1 [Line Items]",
        "label": "Statement1 [Line Items]",
        "documentation": "[Line Items] for Statement1 [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_Statement1Table": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "Statement1Table",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement1 [Table]",
        "documentation": "Statement1 [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical [Axis]",
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of cash flows [abstract]",
        "label": "Statement of cash flows [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfChangesInEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "StatementOfChangesInEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of changes in equity [abstract]",
        "label": "Statement of changes in equity [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfChangesInEquityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "StatementOfChangesInEquityLineItems",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of changes in equity [line items]",
        "label": "Statement of changes in equity [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfChangesInEquityTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "StatementOfChangesInEquityTable",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of changes in equity [table]",
        "label": "Statement of changes in equity [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to changes in equity."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "ifrs-full_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of financial position [abstract]",
        "label": "Statement of financial position [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r216",
      "r227",
      "r237",
      "r270"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_StockOptionsOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "StockOptionsOutstandingAbstract",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsandWeightedAverageExercisePricesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of options",
        "label": "Stock Options, Outstanding [Abstract]",
        "documentation": "Stock Options, Outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subclassifications of assets, liabilities and equities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_SummaryOfSignificantAccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "SummaryOfSignificantAccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary Of Significant Accounting Policies [Abstract]",
        "label": "Summary Of Significant Accounting Policies [Abstract]",
        "documentation": "Summary Of Significant Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_SupplierConcentrationRisk1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "SupplierConcentrationRisk1Member",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/EconomicDependenceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Toll manufacturer",
        "label": "Supplier Concentration Risk1 [Member]",
        "documentation": "Supplier Concentration Risk1 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r263"
     ]
    },
    "ifrs-full_TaxEffectFromChangeInTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TaxEffectFromChangeInTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails": {
       "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impact of Barbados rate change",
        "label": "Tax effect from change in tax rate"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to changes in the tax rate. [Refer: Accounting profit]"
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "TaxEffectOfChangeinFairValueOfWarrantDerivative",
     "crdr": "debit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails": {
       "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value of warrant derivative",
        "label": "Tax Effect Of Change in Fair Value Of Warrant Derivative",
        "documentation": "Tax Effect Of Change in Fair Value Of Warrant Derivative"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_TaxEffectOfExpirationOfTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "TaxEffectOfExpirationOfTaxBenefits",
     "crdr": "debit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails": {
       "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiry of tax benefits",
        "label": "Tax Effect Of Expiration Of Tax Benefits",
        "documentation": "Tax Effect Of Expiration Of Tax Benefits"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TaxEffectOfForeignTaxRates": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TaxEffectOfForeignTaxRates",
     "crdr": "debit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails": {
       "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Difference in tax rates",
        "label": "Tax effect of foreign tax rates"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to foreign tax rates. [Refer: Accounting profit]"
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "oncyf_TaxEffectOfStockBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "TaxEffectOfStockBasedCompensation",
     "crdr": "credit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails": {
       "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Share-based compensation expense",
        "label": "Tax Effect Of Stock Based Compensation",
        "documentation": "Tax Effect Of Stock Based Compensation"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_TaxEffectOfTaxPools": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "TaxEffectOfTaxPools",
     "crdr": "debit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails": {
       "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revaluation of tax balances",
        "label": "Tax Effect Of Tax Pools",
        "documentation": "Tax Effect Of Tax Pools"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TaxExpenseIncomeAtApplicableTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TaxExpenseIncomeAtApplicableTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails": {
       "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Anticipated tax recovery",
        "label": "Tax expense (income) at applicable tax rate"
       }
      },
      "en": {
       "role": {
        "documentation": "The product of the accounting profit multiplied by the applicable tax rate(s). [Refer: Accounting profit; Applicable tax rate]"
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesScheduleofUnrecognizedDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Temporary difference, unused tax losses and unused tax credits [axis]",
        "label": "Temporary difference, unused tax losses and unused tax credits [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsDomain",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesScheduleofUnrecognizedDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Temporary difference, unused tax losses and unused tax credits",
        "label": "Temporary difference, unused tax losses and unused tax credits [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for temporary differences, unused tax losses and unused tax credits. It also represents the standard value for the 'Temporary difference, unused tax losses and unused tax credits' axis if no other member is used. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]"
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title and Position [Axis]",
        "label": "Title and Position [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title and Position [Domain]",
        "label": "Title and Position [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TopOfRangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TopOfRangeMember",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Top of range [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for top of a range."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r94",
      "r117",
      "r133",
      "r179",
      "r180",
      "r329"
     ]
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r255"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r262"
     ]
    },
    "ifrs-full_TradeAndOtherCurrentPayables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TradeAndOtherCurrentPayables",
     "crdr": "credit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.oncolyticsbiotech.com/role/AccountsPayableandAccruedLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/AccountsPayableandAccruedLiabilitiesDetails",
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION",
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsScheduleofBalancesinForeignCurrenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable and accrued liabilities (note 7)",
        "totalLabel": "Accounts payable and accrued liabilities",
        "negatedTerseLabel": "Accounts payable and accrued liabilities",
        "label": "Trade and other current payables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]"
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TradeAndOtherCurrentPayablesToTradeSuppliers",
     "crdr": "credit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/AccountsPayableandAccruedLiabilitiesDetails": {
       "parentTag": "ifrs-full_TradeAndOtherCurrentPayables",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/AccountsPayableandAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade payables",
        "label": "Current trade payables"
       }
      },
      "en": {
       "role": {
        "documentation": "The current amount of payment due to suppliers for goods and services used in entity's business. [Refer: Current liabilities; Trade payables]"
       }
      }
     },
     "auth_ref": [
      "r164",
      "r313"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r283"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r285"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_TranslationalScienceExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "TranslationalScienceExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ComponentsofExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Translational science expenses",
        "label": "Translational Science Expense",
        "documentation": "Translational Science Expense"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r286"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r287"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Expiration Date",
        "terseLabel": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r287"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r285"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r285"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r288"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r286"
     ]
    },
    "ifrs-full_TypesOfRisksAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TypesOfRisksAxis",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Types of risks [axis]",
        "label": "Types of risks [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r119",
      "r120",
      "r122",
      "r141",
      "r143",
      "r144",
      "r160"
     ]
    },
    "ifrs-full_TypesOfRisksDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TypesOfRisksDomain",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Types of risks",
        "label": "Types of risks [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all types of risks. It also represents the standard value for the 'Types of risks' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r119",
      "r120",
      "r122",
      "r141",
      "r143",
      "r144",
      "r160"
     ]
    },
    "ifrs-full_TypesOfSharebasedPaymentArrangementsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TypesOfSharebasedPaymentArrangementsAxis",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofNumberofOtherEquityInstrumentsDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Types of share-based payment arrangements [axis]",
        "label": "Types of share-based payment arrangements [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r134"
     ]
    },
    "ifrs-full_TypesOfSharebasedPaymentArrangementsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TypesOfSharebasedPaymentArrangementsDomain",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofNumberofOtherEquityInstrumentsDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Types of share-based payment arrangements",
        "label": "Types of share-based payment arrangements [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for an agreement between the entity or another group entity or any shareholder of the group entity and another party (including an employee) that entitles the other party to receive (a) cash or other assets of the entity for amounts that are based on the price (or value) of equity instruments (including shares or share options) of the entity or another group entity; or (b) equity instruments (including shares or share options) of the entity or another group entity, provided that the specified vesting conditions, if any, are met. It also represents the standard value for the 'Types of share-based payment arrangements' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r134"
     ]
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "US",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "UNITED STATES",
        "label": "UNITED STATES"
       }
      }
     },
     "auth_ref": []
    },
    "currency_USD": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2024",
     "localname": "USD",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsScheduleofBalancesinForeignCurrenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. dollars",
        "label": "United States of America, Dollars"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesScheduleofUnrecognizedDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unclaimed scientific research and experimental development expenditures",
        "verboseLabel": "Scientific research and experimental development",
        "label": "Unclaimed Scientific Research And Experimental Development Expenditures [Member]",
        "documentation": "Unclaimed Scientific Research And Experimental Development Expenditures [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r282"
     ]
    },
    "oncyf_UnusedCapitalLossCarryForwardNetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "UnusedCapitalLossCarryForwardNetMember",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesScheduleofUnrecognizedDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net capital losses carried forward",
        "label": "Unused Capital Loss Carry Forward, Net [Member]",
        "documentation": "Unused Capital Loss Carry Forward, Net [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_UnusedNetOperatingLossCarryForwardsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "UnusedNetOperatingLossCarryForwardsMember",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesScheduleofUnrecognizedDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-capital losses carried forward",
        "label": "Unused Net Operating Loss Carry Forwards [Member]",
        "documentation": "Unused Net Operating Loss Carry Forwards [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unused tax credits",
        "label": "Unused tax credits for which no deferred tax asset recognised"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of unused tax credits for which no deferred tax asset is recognised in the statement of financial position. [Refer: Unused tax credits [member]]"
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "ifrs-full_UnusedTaxCreditsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "UnusedTaxCreditsMember",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-refundable federal investment tax credits",
        "label": "Unused tax credits [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for tax credits that have been received and are carried forward for use against future taxable profit."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unused tax losses",
        "label": "Unused tax losses for which no deferred tax asset recognised"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of unused tax losses for which no deferred tax asset is recognised in the statement of financial position. [Refer: Unused tax losses [member]]"
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "ifrs-full_UnusedTaxLossesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "UnusedTaxLossesMember",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-capital losses",
        "label": "Unused tax losses [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for tax losses that have been incurred and are carried forward for use against future taxable profit."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1",
     "crdr": "credit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails": {
       "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Provision to offset deferred tax asset",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount1",
        "documentation": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount1"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]",
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r251"
     ]
    },
    "oncyf_WarrantExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "WarrantExercisePrice",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeWarrantDerivativeOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price (usd per share)",
        "label": "Warrant Exercise Price",
        "documentation": "Warrant Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_WarrantLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "WarrantLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant liability",
        "label": "Warrant liability"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of warrant liabilities."
       }
      }
     },
     "auth_ref": [
      "r312"
     ]
    },
    "oncyf_WarrantLiabilityAmortizedDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "WarrantLiabilityAmortizedDiscount",
     "crdr": "credit",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeReconciliationofChangeinFairValueofWarrantDerivativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of discount on warrants issued",
        "label": "Warrant Liability, Amortized Discount",
        "documentation": "Warrant Liability, Amortized Discount"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_WarrantLiabilityUnamortizedDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "WarrantLiabilityUnamortizedDiscount",
     "crdr": "debit",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeReconciliationofChangeinFairValueofWarrantDerivativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Discount on warrants issued",
        "terseLabel": "Warrant liability, unamortized discount",
        "label": "Warrant Liability, Unamortized Discount",
        "documentation": "Warrant Liability, Unamortized Discount"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_WarrantsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "WarrantsExercised",
     "crdr": "debit",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants exercised, fair value",
        "label": "Warrants Exercised",
        "documentation": "Warrants Exercised"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_WarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "WarrantsMember",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeReconciliationofChangeinFairValueofWarrantDerivativeDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeSummaryofAssumptionsUsedintheBlackScholesOptionPricingModelforWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants",
        "verboseLabel": "Warrants",
        "label": "Warrants [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for warrants."
       }
      }
     },
     "auth_ref": [
      "r318"
     ]
    },
    "oncyf_WarrantsTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "WarrantsTerm",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants, term",
        "label": "Warrants, Term",
        "documentation": "Warrants, Term"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase price (cad and usd per share)",
        "label": "Weighted average exercise price of other equity instruments granted in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of other equity instruments (ie other than share options) granted in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r328"
     ]
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails",
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsandWeightedAverageExercisePricesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options exercisable, end of the year (cad per share)",
        "verboseLabel": "Weighted Average Exercise Price (cad per share)",
        "label": "Weighted average exercise price of share options exercisable in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options exercisable in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsandWeightedAverageExercisePricesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercised during the year (cad per share)",
        "label": "Weighted average exercise price of share options exercised in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options exercised in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r128"
     ]
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsandWeightedAverageExercisePricesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expired during the year (cad per share)",
        "label": "Weighted average exercise price of share options expired in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options expired in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r129"
     ]
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsandWeightedAverageExercisePricesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeited during the year (cad per share)",
        "label": "Weighted average exercise price of share options forfeited in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options forfeited in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r127"
     ]
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsandWeightedAverageExercisePricesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted during the year (cad per share)",
        "label": "Weighted average exercise price of share options granted in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options granted in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r126"
     ]
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails",
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsandWeightedAverageExercisePricesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding, beginning of the year (cad per share)",
        "periodEndLabel": "Outstanding, beginning of the year (cad per share)",
        "terseLabel": "Weighted Average Exercise Price (cad per share)",
        "label": "Weighted average exercise price of share options outstanding in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r125",
      "r130"
     ]
    },
    "oncyf_WeightedAverageExercisePriceOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "WeightedAverageExercisePriceOutstandingAbstract",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsandWeightedAverageExercisePricesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price $",
        "label": "Weighted Average Exercise Price, Outstanding [Abstract]",
        "documentation": "Weighted Average Exercise Price, Outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted",
     "crdr": "credit",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofNumberofOtherEquityInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average fair value at measurement date, other equity instruments granted",
        "label": "Weighted average fair value at measurement date, other equity instruments granted"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average fair value at the measurement date of granted equity instruments other than share options. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r137"
     ]
    },
    "ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "WeightedAverageFairValueAtMeasurementDateShareOptionsGranted",
     "crdr": "credit",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationDisclosureWeightedAverageAssumptionsandFairValueofOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average fair value of options (cad per share)",
        "label": "Weighted average fair value at measurement date, share options granted"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average fair value of share options granted during the period at the measurement date. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r136"
     ]
    },
    "oncyf_WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeSummaryofAssumptionsUsedintheBlackScholesOptionPricingModelforWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Fair value per warrant (usd per share)",
        "label": "Weighted Average Fair Value Price At Measurement Date, Other Equity Instruments Granted",
        "documentation": "Weighted Average Fair Value Price At Measurement Date, Other Equity Instruments Granted"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average rate",
        "label": "Weighted average lessee's incremental borrowing rate applied to lease liabilities recognised at date of initial application of IFRS 16"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average lessee's incremental borrowing rate applied to lease liabilities recognised in the statement of financial position at the date of initial application of IFRS 16. The incremental borrowing rate is the rate of interest that a lessee would have to pay to borrow over a similar term, and with a similar security, the funds necessary to obtain an asset of a similar value to the right-of-use asset in a similar economic environment."
       }
      }
     },
     "auth_ref": [
      "r112"
     ]
    },
    "ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019": {
     "xbrltype": "durationItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted Average Remaining Contractual Life (years)",
        "label": "Weighted average remaining contractual life of outstanding share options"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r133"
     ]
    },
    "oncyf_WeightedAverageSharePriceOtherEquityInstrumentsGranted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20241231",
     "localname": "WeightedAverageSharePriceOtherEquityInstrumentsGranted",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeSummaryofAssumptionsUsedintheBlackScholesOptionPricingModelforWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying share price (usd per share)",
        "label": "Weighted Average Share Price, Other Equity Instruments Granted",
        "documentation": "Weighted Average Share Price, Other Equity Instruments Granted"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_WeightedAverageShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "WeightedAverageShares",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS",
      "http://www.oncolyticsbiotech.com/role/LossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average number of shares (basic) (shares)",
        "verboseLabel": "Weighted average number of common shares outstanding (shares)",
        "label": "Weighted average number of ordinary shares used in calculating basic earnings per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]",
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r249"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "104",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_104&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "106",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_106_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_106_d_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_106_d_iii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "106",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_106&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "117",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_117&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "134",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_134&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "25",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_25&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "35",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_35&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "51",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_51&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "54",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "54",
   "Subparagraph": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "54",
   "Subparagraph": "k",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_k&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "55",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_55&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "61",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_61_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "61",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_61&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "66",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_66&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "69",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_69&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "7",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_78_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r20": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "Clause": "vii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_79_a_vii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r21": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_79_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r22": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "79",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_79&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r23": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "81A",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_81A_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r24": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "81A",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_81A_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r25": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "82",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_82_d&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r26": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "91",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_91_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r27": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "98",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_98_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r28": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "99",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_99&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r29": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "10",
   "IssueDate": "2024-01-01",
   "Paragraph": "21",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2024-en-r&anchor=para_21&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r30": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "10",
   "IssueDate": "2024-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IAS10_g17-22_TI",
   "URIDate": "2024-03-27"
  },
  "r31": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "79",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2024-en-r&anchor=para_79&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r32": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "81",
   "Subparagraph": "c",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2024-en-r&anchor=para_81_c_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r33": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "81",
   "Subparagraph": "c",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2024-en-r&anchor=para_81_c_ii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r34": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "81",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2024-en-r&anchor=para_81_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r35": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "81",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2024-en-r&anchor=para_81_g&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r36": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IAS12_g79-88_TI",
   "URIDate": "2024-03-27"
  },
  "r37": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "73",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_73_d&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r38": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "73",
   "Subparagraph": "e",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_73_e_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r39": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "73",
   "Subparagraph": "e",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_73_e_ii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r40": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "73",
   "Subparagraph": "e",
   "Clause": "vii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_73_e_vii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r41": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_73_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r42": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "73",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_73&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r43": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "75",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_75_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r44": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "75",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_75_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r45": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IAS16_g73-79_TI",
   "URIDate": "2024-03-27"
  },
  "r46": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2024-01-01",
   "Paragraph": "142",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2024-en-r&anchor=para_142&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r47": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "21",
   "IssueDate": "2024-01-01",
   "Paragraph": "52",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2024-en-r&anchor=para_52_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r48": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2024-01-01",
   "Paragraph": "17",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2024-en-r&anchor=para_17_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r49": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2024-01-01",
   "Paragraph": "17",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2024-en-r&anchor=para_17_d&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r50": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2024-01-01",
   "Paragraph": "17",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2024-en-r&anchor=para_17_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r51": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2024-01-01",
   "Paragraph": "17",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2024-en-r&anchor=para_17&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r52": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2024-01-01",
   "Paragraph": "18",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2024-en-r&anchor=para_18&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r53": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2024-01-01",
   "Section": "Disclosures",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IAS24_g13-24_TI",
   "URIDate": "2024-03-27"
  },
  "r54": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "26",
   "IssueDate": "2024-01-01",
   "Paragraph": "35",
   "Subparagraph": "b",
   "Clause": "viii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2024-en-r&anchor=para_35_b_viii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r55": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2024-01-01",
   "Paragraph": "66",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2024-en-r&anchor=para_66&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r56": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2024-01-01",
   "Paragraph": "67",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2024-en-r&anchor=para_67&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r57": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2024-01-01",
   "Paragraph": "70",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2024-en-r&anchor=para_70_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r58": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2024-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IAS33_g70-73A_TI",
   "URIDate": "2024-03-27"
  },
  "r59": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2024-01-01",
   "Paragraph": "130",
   "Subparagraph": "f",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2024-en-r&anchor=para_130_f_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r60": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2024-01-01",
   "Paragraph": "134",
   "Subparagraph": "e",
   "Clause": "iiA",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2024-en-r&anchor=para_134_e_iiA&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r61": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "37",
   "IssueDate": "2024-01-01",
   "Paragraph": "84",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2024-en-r&anchor=para_84&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r62": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2024-01-01",
   "Paragraph": "118",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_118_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r63": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2024-01-01",
   "Paragraph": "118",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_118_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r64": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2024-01-01",
   "Paragraph": "126",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_126&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r65": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "40",
   "IssueDate": "2024-01-01",
   "Paragraph": "76",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2024-en-r&anchor=para_76&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r66": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "40",
   "IssueDate": "2024-01-01",
   "Paragraph": "79",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2024-en-r&anchor=para_79_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r67": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "40",
   "IssueDate": "2024-01-01",
   "Paragraph": "79",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2024-en-r&anchor=para_79_d&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r68": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "41",
   "IssueDate": "2024-01-01",
   "Paragraph": "50",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2024-en-r&anchor=para_50&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r69": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "41",
   "IssueDate": "2024-01-01",
   "Paragraph": "54",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2024-en-r&anchor=para_54_f&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r70": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "10",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_10&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r71": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "18",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_18_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r72": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "25",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_25&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r73": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "28",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_28&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r74": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "35",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_35&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r75": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "44H",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_44H_b_iii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r76": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r77": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "50",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_50_d&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r78": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Section": "Presentation of a statement of cash flows",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IAS07_g10-17_TI",
   "URIDate": "2024-03-27"
  },
  "r79": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "28",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2024-en-r&anchor=para_28&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r80": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "30",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2024-en-r&anchor=para_30_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r81": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "24",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2024-en-r&anchor=para_24_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "24",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2024-en-r&anchor=para_24_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "32",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2024-en-r&anchor=para_32_a_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "32",
   "Subparagraph": "a",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2024-en-r&anchor=para_32_a_ii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B12_b_i&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B12_b_iii&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "ix",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B12_b_ix&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B13",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B13",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B13_g&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2024-01-01",
   "Paragraph": "93",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_93_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2024-01-01",
   "Paragraph": "93",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_93_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2024-01-01",
   "Paragraph": "93",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_93_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2024-01-01",
   "Paragraph": "93",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_93&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "14",
   "IssueDate": "2024-01-01",
   "Paragraph": "33",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=14&code=ifrs-tx-2024-en-r&anchor=para_33_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2024-01-01",
   "Paragraph": "105",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2024-en-r&anchor=para_105&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2024-01-01",
   "Paragraph": "116",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2024-en-r&anchor=para_116_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2024-01-01",
   "Paragraph": "118",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2024-en-r&anchor=para_118&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2024-01-01",
   "Paragraph": "120",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2024-en-r&anchor=para_120_b_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2024-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IFRS15_g110-129_TI",
   "URIDate": "2024-03-27"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2024-01-01",
   "Section": "Presentation",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IFRS15_g105-109_TI",
   "URIDate": "2024-03-27"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "47",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_47_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "47",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_47_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "53",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_53_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "53",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_53_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "53",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_53_g&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "53",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_53_h&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "53",
   "Subparagraph": "j",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_53_j&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "53",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_53&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "58",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_58&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "94",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_94&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "97",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_97&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "C12",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_C12_a&doctype=Appendix&subtype=C",
   "URIDate": "2024-03-27"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IFRS16_g51-60_TI",
   "URIDate": "2024-03-27"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Section": "Presentation",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IFRS16_g47-50_TI",
   "URIDate": "2024-03-27"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2024-01-01",
   "Paragraph": "109",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_109&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2024-01-01",
   "Paragraph": "109A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_109A&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2024-01-01",
   "Paragraph": "120",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_120&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2024-01-01",
   "Paragraph": "124",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_124&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2024-01-01",
   "Paragraph": "125",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_125&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2024-01-01",
   "Paragraph": "127",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_127&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2024-01-01",
   "Paragraph": "128",
   "Subparagraph": "a",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_128_a_ii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2024-01-01",
   "Paragraph": "128",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_128_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2024-01-01",
   "Paragraph": "132",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_132_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "44",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_44&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45_b_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45_b_ii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45_b_iii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45_b_iv&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "v",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45_b_v&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "vi",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45_b_vi&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "vii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45_b_vii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "45",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45_d&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "47",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_47_a_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "47",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_47_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "47",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_47_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "51",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_51_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2024-01-01",
   "Paragraph": "B67",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2024-en-r&anchor=para_B67_d&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "5",
   "IssueDate": "2024-01-01",
   "Paragraph": "33",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2024-en-r&anchor=para_33_b_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "21C",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_21C&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "23B",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_23B_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "33",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_33&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "34",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_34&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "35H",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_35H&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "35I",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_35I&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "35M",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_35M&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "42E",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_42E_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "7",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Section": "Defined terms",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&doctype=Appendix&subtype=A&dita_xref=IFRS07_APPA_TI",
   "URIDate": "2024-03-27"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Section": "Scope",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IFRS07_g3-5A_TI",
   "URIDate": "2024-03-27"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "23",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_23_h&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "23",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_23&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "28",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_28_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "28",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_28_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "28",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_28_d&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "28",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_28_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "33",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_33&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IFRS08_g20-24_TI",
   "URIDate": "2024-03-27"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2025-01-01",
   "Name": "IAS",
   "Number": "21",
   "IssueDate": "2024-01-01",
   "Paragraph": "A19",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2024-en-r&anchor=para_A19_f&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "102",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_102&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "103",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_103&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "108",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_108&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "70",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_70&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "78",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_78_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_78_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "IG6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_IG6&doctype=Implementation%20Guidance",
   "URIDate": "2024-03-27"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "10",
   "IssueDate": "2024-01-01",
   "Paragraph": "22",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2024-en-r&anchor=para_22_f&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "37",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_37_h&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2024-01-01",
   "Paragraph": "138",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2024-en-r&anchor=para_138_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2024-01-01",
   "Paragraph": "147",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2024-en-r&anchor=para_147_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "32",
   "IssueDate": "2024-01-01",
   "Paragraph": "IE33",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=32&code=ifrs-tx-2024-en-r&anchor=para_IE33&doctype=Illustrative%20Examples",
   "URIDate": "2024-03-27"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "16",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_16_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "17",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_17_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "20",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_20&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "44B",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_44B&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Section": "A Statement of cash flows for an entity other than a financial institution",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_A_TI",
   "URIDate": "2024-03-27"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B10",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2024-01-01",
   "Paragraph": "B6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_B6&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2024-01-01",
   "Paragraph": "IE63",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_IE63&doctype=Illustrative%20Examples",
   "URIDate": "2024-03-27"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2024-01-01",
   "Paragraph": "118",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2024-en-r&anchor=para_118_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2024-01-01",
   "Paragraph": "B89",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2024-en-r&anchor=para_B89_b&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2024-01-01",
   "Paragraph": "113",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_113_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2024-01-01",
   "Paragraph": "96",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_96_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "35N",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_35N&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "B11",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_B11_d&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "B11",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_B11&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "B11D",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_B11D_a&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "B35",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_B35_g&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "B35",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_B35&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "IG31A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_IG31A&doctype=Implementation%20Guidance",
   "URIDate": "2024-03-27"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "23",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_23&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "28",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_28_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r307": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "10",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_10_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r308": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_106_d&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r309": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "108",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_108&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r310": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "112",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_112_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r311": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "117",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_117&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r312": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "55",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_55&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r313": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "78",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_78&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r314": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "85",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_85&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r315": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "37",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_37&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r316": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "73",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_73_d&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r317": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2024-01-01",
   "Paragraph": "5",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2024-en-r&anchor=para_5&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r318": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2024-01-01",
   "Paragraph": "70",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2024-en-r&anchor=para_70_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r319": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2024-01-01",
   "Paragraph": "118",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_118_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r320": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "40",
   "IssueDate": "2024-01-01",
   "Paragraph": "79",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2024-en-r&anchor=para_79_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r321": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "41",
   "IssueDate": "2024-01-01",
   "Paragraph": "54",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2024-en-r&anchor=para_54_f&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r322": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "16",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_16&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r323": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "17",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_17&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r324": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "20",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_20_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r325": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "20",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_20_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r326": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "20",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_20&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r327": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r328": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r329": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "7",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2024-03-27"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>112
<FILENAME>0001129928-25-000019-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001129928-25-000019-xbrl.zip
M4$L#!!0    ( !IF9UK2@\N'GP<  $TG   =    97@Q,C%C96]C97)T:69I
M8V%T:6]N,C R-"YH=&WMFMMRVS@2AN_W*;!.;>)42;*.D2TYKLK!J=7%3J92
MKLK>;4%D4\(:)+@$*%GS]/,W0%E'C^699*+))A>*"32 !OI#=P/DY=2E^NIR
M2C*^^MOEW^MU\=Y$94J9$U%!TE$L2JNRB?@<D[T5]7HE]<[DBT)-IDZTF^V>
M^&R*6S63H=XII^EJV<_E67B^//.#7(Y-O+BZC-5,J/CUB6KU>\V+5M1+QM3K
M1M21K7-J7IQW^U'O/(E>M?[3.D%3B(<VUBTTO3Y)55:?$H\_Z+8;_5[NAG,5
MN^F@U6S^X\2+7ETF)G,8KT#[\&?H9J<S1W>N+K6:9 ,_I9/0=%D=&6V*P;.F
M_S?DFGHB4Z47@Q<W*B4K?J*Y^&12F;VH69G9NJ5")4'0JE\(.D$]_S@/*O?1
MCU89+:?0ZG:A]/6__SEZ.[H1K7:CM:GQ?ETC+"X5WTC9=]>?;D8?1N_>W(P^
M_K2C[8-KOW\F_RVM4\GBJT^ENW<JHYKX+!<9B9\5NC$U$5'!Z@@WE>[YL][Y
M\.ES^.VIYS*.L:?JFA(WZ+R"EKL=A2*5Q;#RH,Y"WVAY6HWE//[\T8<;*]4^
M;_1X&49B*F<D"IHIFL-!N:FR0F99*34*<U,X83+QP10IG%/]@S")^)A!X853
MD15OE7$43<4HBQJP[L7#UOU#9OJ."&@?'0%OI87=8>1T(6XS,]<43Z@60*@(
MB U4R S"&$:0*@,@"U%FKB@),T!@\S$.:$B1XJE0@">1$8H*85+EA#-!;D<@
MHXBLE<6"15)Y2QAWK4^+LAC*8$CM R3&8(%(%0B($,O0')K$5(CY5(%$6_+/
MJOV<"JHZX0FDRFI$3@["<^6FF*#-*?(*<K\Y5#,QICE#LUB,%^O+\ /P0P#O
M_'4 )Y&H# @QC2MD:J ;XJ@NUNI5EL '2J?0C\HB7<;H$UBN\5$#TJK0"Y&#
M*MX0O%&T7A%?P6:WAL:FBA5W7&.)4D, F!NPZ(>S7I](VJE(M)G;^SU@TISW
MH>22H#14K*UQ;)>:[*CZ ^5#4.X>'<HW*[N_L!6C58;%+LTDB<+CJ7WI<1@)
M69"G#A2IL28&1!!0'VMEI]R"Q5)X=/;J_!PK&VECRX*\KR^,#OCEA8DH1K$5
MIP N)N ;J+J^BZ8RFY!X S?ZJ=20:'5DO=4[I:!%JQ>'I_"H.-'. O;<OV!?
MN[8; J"LR\$#)1L#)1B(Y[FQ1U#-><[7ST#[[>-F^E2^/!JHNXV+%B_$>[)8
M*EC9!^_'$:QQ7A')TA[>A /\F(!3-5)(&4Q9H ,XRYFRWO]"BC+?#Y]75IY[
MW?L7I*7GL\H9*L9J55C@&@47#D6LT2KVQWY;CJV*E2P4:Z]"6N.#4<;=E)93
M#;^=K<]+O+<VEJ -#OR^42ZQ*Z)22XXPF)/78)6RH$5(@-;S-OPU)A9$'$![
MBI_@]X\>Y/$Q@=SI[H)\L*?;X?EP'WDPUM@*,Q5S-)#69)*#@;0@G3-H%$YD
M$2^) N!*CI56;L&YQKYA>7-Y^#Q785]LB*YEX#[FW%43RLLB!]?6YT919(K8
M*^!S\0EE2'DT\$8-Y;QO6 3GC( P]I?*X?:_)XBC8X(X>./KF=2E]UIL84H2
MI*QJ!MO8[=03*<@!GC<\[L]#/:IH",=I0ZH[-J5[>.!#8H.\ER;.XY/'#W9B
MO#PA^-U'80&@CR>-!_A.:(N/B;;*90:+[I+!:5N5\/F:=>J>X!\YC)LH*@LV
M^V[8W ""MBZ^?..IM/=Y +LFCR7%WF=[;2M_NA!:W9*N+C*VY&N_=P*/$_C_
M<&W::XCGSUJOFL/=WZ>>B/QM9[R$KK;:^NR)4F,=UIY?!JQY ?8A3XCEFVDA
ME))("ITI['W4] 4LD"KGB':]ZM@@''-QK*"-;WL*W,"L92>)_SD=7:),_RL5
ME&6EDS*+_)W!RQ\GG6,\Z;S12(VP6 I42NC$Q]M($1BJ N7]B6-.\I8C7TB5
M?.SS29Z_4EU>#3V)S.I\$*X$]C@M&:.AI7N?M4UQE1%"$DPB<:N%J&L1<FV9
MICC;_$)^#I7WW'MW]KU%U",\A+Q!X$P*^)@:+$[>(8(9?_E=P54+D4UE,Z-G
MQ.$MDY/J#K^H?"BEN38+0NU\:H+7E!OH K4_$ID;#P( DB8JJSN3#WJ;UK]_
M2>O\^:62'X-%*NI8<RUS2X/E'T-X^5S+Q4!E?N5\HV'5^]@X9U(_P(RC121U
M-8@?+U17K\$O+AKGO0Z_"7?PC2Y>#ER])&_XE^1G+MZM>]5H]KL/UC8;K0?K
M?JO7#O2YZ'WQ;GN-_OG#+7]OK]T.%N_AZO5NS_SRAB6&$2V0>GW2.=ER#(-V
M?B=:FV#P!MBV8S#AR3ZT*N.S;]G<0HUV;ZW,?[]0%?[Y_L5_>_$>.W9/)%\N
MY1=<I6\QNW_) @&I7_.?O=S/\/&Y-84/IE]C&?[*L#Q_UNT/K?]=_P9C#SH'
M[K0GK/.7%:U<.H< R I_CRIX 8=;=A7\?R=8XIA)W[ ',NP1!S*5BG=318FX
MOJ.HY*L.\3$<5]9%?@[W7HB=NV+K6\;;],P'N2=^/+3U[5=NK'\;.0@7W3/:
M^1IL92:_-9JK)G(,6Y5NM\DC'Y!5O^%SMC/_&=VO4$L#!!0    ( !IF9UH@
M&,>8HP<  "\G   =    97@Q,C)C9F]C97)T:69I8V%T:6]N,C R-"YH=&WM
MFEMO&[<2@-_[*U@'31Q DG6-9,DQX#@)*O2<YB PT+X5U')6RYJ[W))<*>JO
M[PRYNJY\++5.JP;)@^(EA^20\W%FR-VKQ*7J^BH!+JZ_N?JV7F=O=52DD#D6
M&> .!"NLS*;L)P'VGM7KI=2MSA=&3A/'VLUVC_VDS;V<\5#OI%-PO>SGZB(\
M7UWX0:XF6BRNKX2<,2E>G\E.*YI 7[0Y#*#;Z?0'$>_'_<% -#O0B7KP2^L,
MFZ)X:&/=0L'KLU1F]01H_&&WW>CW<C>:2^&28:O9_.[,BUY?Q3IS.)[!]N'/
MT$VE,P>?7)TK.<V&?DIGH>FR.M)*F^&SIO\WHIIZS%.I%L,7=S(%RWZ$.?NH
M4YZ]J%F>V;H%(^,@:.7O@#JA>OYQ'E3N8S]*9K"<0JO;1:7?_?S]^,WXCK7:
MC?:VQOMUC7!QP?Q#RMZ^^W@W?C^^O;D;?_BQHNV#:[^J^WSZ=O?J.ZZQ'Z2Y
M9__1^K[&(C!.Q@OF$NZ>/^L-1D?-8*E[SH7 K5%7$+MAYQ7JL6&=7PM+0X0B
MF0DTUK!.0I_=8/L7H-58SN/O'WVTM5+M0:-'RS!F"9\!,S"3,$<_XQ)I&<^R
M@BLLS+5Q3&?LO38I^ICZ>Z9C]B%#A1=.1I:]D=I!E+!Q%C70A)=5$SZ)F;X@
M MHG1\ ;;M'N:.1TP>XS/5<@IE +()0$"(TJ9!JC$8[ 98: +%B1.5, S@#C
MDP]5B 9G*3X9B?#$/,(BPW0J'7,ZR%4$,HC 6FX6))+R>\!Q-_JT6"90&1Q2
M^3B'8Y! ) W&-13+L#EJ(L"P>2*11%O0S[K]' R4G= $4FD5!D"*I7/I$IR@
MS2'R"E*_.:JF!4YSALT$FRPVE^$KX(< WOGW  XLEADB1#2ND:DAW2B.U6:C
M7F8Q^D#N)/8CLT@5 OM$+#?XJ"'2TJ@%RY$JVA"T491:$U_"9G>&QDTE)'5<
M(XE"H0!BKI%%/YSU^D3<)BQ6>FY7>T"G.>U#3B5!:52QML&Q76I24?4KRH>@
MW#TYE._6=G]A2T;+-(I<FHYCB8_G]J7'8<RX 4\=4B0G"@@0!HCZ1$F;4 L2
M2]&CDU>G9R%MI+0M#'A?;[0*^.5&1R"PV+)S!$X XANH>O<I2G@V!7:#;O1C
MH5"BU>'U5N\<@A:MG@A/X5%2OIP%[*E_1KYV8S<$0$F7@P>*MP:*<2":Y]8>
MP6K*<_:GF7O2^A+%XYGNMT^;Z7/^\F2@[C8N6[00;\'B4J&5??!^',$:Y141
M+^SA32C 3P!Q*D<**8,N#': SG(FK?>_* 69[X<.)6O/O>G]#2CN^2QSAI*Q
M6AD6J$:B"T=%K%92^-.[+296"LF-).UE2&M\,,JHF\)2JN&WL_5YB??6V@)J
M@^=VWRCGN"NB0G&*,#@GK\$Z9<$6(0':S-OPKPF0(,8!; _B"+]_\B!/3@GD
M3K<*\L&>KL+SX3[R8*QQ*\RDH&C K<XX!0-ND73*H+%PRHU8$H6 2SZ12KH%
MY1K[AJ7-Y>'S7(5]L26ZD8'[F/.IG%!>F!RYMCXWBB)MA%? Y^)3R##E48@W
MUD!.^X9$\)P1$,;])7-T^U\2Q-$I01R\\;L95X7W6F1AB&-,6>4,;6-W4T],
M00[PO.%Q?Q[J4<6&Z#AM2'4GNG /#WQ(;. K:: \/G[\8,<FRQ."WWT0%@#U
M\:31 %\(;>*4:"M=9K!HE0Q*V\J$S]=L4G>$?Z0PKJ.H,&3V:MC< @)V+KY\
MXX3;51Y KLEC"<+[;*]MZ4\73,E[4.5%QHY\[<].X'$"GR)I/?6#6*_!GC]K
MO6J.JK_'GHC\;:=80E=;;WWR1*FV#M>>[O0WO #YD"-B^79:B$IQ3 J=-G85
M-7T!":32.8"J5YUH#,=4+"1JX]N>(V[(K"4GB?]3.KI$&7XK)"I+2L=%%OD[
M@Y=?3SJG>-*Y49@:X6))I)*C3G2\C20@0V6@7)TXYL#O*?*%5,G'/I_D^2O5
MY=704626YX-P);#':7&!#2VL?-8NQ65&B)+()"9NM1!U+89<6Z0IGFU^!S^'
MTGONO3O[TB+J"1Y";C!PQ@9]3 TM#MXA(C/^\KN$JQ8BF\QF6LV PEO&I^4=
MOBE]**2YT@O VGFB@]?D6^@B:G\E,C<>! !)FLJL/M'.Z71( %1CU;+$ORFN
MA*_P3G8O),Z??,J1)D@QF#I:2_'<PG#YQPCC0Z[X8B@SO^:^T6A;+WK9/:,X
M$W%5#NO'"]7E>_#+0>.R_XI>A3OTJDXL!R[?DC?\6_(+)ZIUO<:@VWZPMMEH
M/5CW_WKM7#8&K=Z3=XODO?H,O?8:O?[@H&XO_/*&)48C6H3Q]5GG;,>E($N?
M6&L;%4)JUX[!A&?'0-ENM'L5+$/AW^^9_,<7;W&O[\D!EDOYA*OT3\SNO]Q@
M*.O7_'<OJQD^/K<F\V'X<RS#OQF6Y\^Z_9'UOZOO,_9P<^ V.V*1GU:T].=.
MYT.49?[ZE='JC7:,RNC_3C##*6.^\;',[0UEYK>)A)B]7X73#^%X0U7_"_=C
M6'BSOC2C=*PJO;E?O$TO?(3;$XMWON[*M?4O*H?A#GP&E>^]UJ;P[#?73?@$
M[5&X:I-'/A$K?\,':Q?^0[D_ %!+ P04    "  :9F=:&0,LACH$   "$P
M'0   &5X,3,Q8V5O8V5R=&EF:6-A=&EO;C(P,C0N:'1MW5AM3]M($/Y^OV(N
MZ"A(=K#S"DF*%$)0(]T11(+H?:HV]ACOU=YU=]<$WZ^_63NAM-#"5<#E&B$+
M[\[,/C/S[,QZ![%)D\-!C"P\_&7PJ^O"L0SR%(6!0"$S&$*NN;B"RQ#U1W#=
ME=1(9H7B5[&!AM=HPZ54'_DUJ^8--PD>KNT,]JKWP5ZYR& AP^)P$/)KX.';
M&E]X 6M%H1\QUFEUVC[SO$X4=1;[[8,N:R/[X-=(E<0K'6V*!-_64B[<&.WZ
MO5:CWFUGIK_DH8E[ON?]5BM%#P>1%(;64Z1?_5N9N6?,X(UQ6<*O1*]TJ5:I
MKJ<#F4C5V_+*7]_.N!%+>5+TWLQYBAI.<0GG,F7BC:.9T*Y&Q:-*4/._D3 1
MO/)U64'NDIV$"UR[X+=:!'K\_MWD:#('OUGWOT3\,-: @HNJ]DT_7TSKM0,S
M&I_/)R>3T7 ^F9["V<7Y[&)X.H?Y=..1^_MP49_51W78WO([W;[?;'O.QJ,>
MSF!X/#V;CX__5\&>C4<E00Z\#DQ/8/YN#+/A^='P=#QSI^]_'_\)P]'<SC0\
MKW'/F^]MB!^=>R!"?^7:\*AX\1"U'@S11$ @A<# <"E@R4T,)D9@0N0L 869
M5 9D!%-!B K# PU'7!H,8IB(H X[5GI[:[_1\/HCF69,%.6;W]\%,G@B54K1
M=4\@DJJT''$=D.4"F0(4(7638PPP7:"R&\+K-WW'-I"6 TR3<$("MZAF&.2*
M&T[N,Q'"^":(F;A":CUIRK6V'M"?E0RI3T&,"BWVNQC/2X_6$!V8.'#)"H%P
MQBF,D@8L7WD*HYAC1$O0DH9?(TRCB >HK#UK;N6K S1FT^= EBN=,\J@D?#@
M+K<.L5!FMH/>%9ZM@F]9NK(^8VK!!&IW>I-@ <.@S(%EJ4/SC/"W]_L_1+R,
MA2$U;S?!R/2:'>+(?2I60YR2(TS/M4+_$3EW_-V*%$]_SBEZ58XARI.D(':G
M66(9<\LBA9]RKM">1+0-ZSK^?G.'$6D5^.V=</<V%9\Y=\NW53[\@V9%4Y:6
M3*:L'/0M,U\F^C]38AO_(K%@<\H%%9"4E8FB@F48V0QIE'+$]6W&&5>4\DRA
MMLEU[#Q+$B ]PEG6,YU1MK6S*D6"B<".D\60E[9M72&I/*FX(3-4Y:+ZJXU?
M?^9V\=H9V-YJ=?NZ?-ZM?QN"[L,COPV!N8&1>Z1];1C*,\5I V:T S<5Z1],
M!7%5A[I.]67[\QX&AZ )!-5525^]5!R3JNA1@5U2"S0H"!"5TO(N8-5%0U@4
M7YQ@8NJ'"R313,EK;L]W=,3YUNG15MLEIPJ]L&UY5=3)X/?DHUP)KN/*\%-/
MA0HX%71"'T609S1BX:,VSUW&G_.C^U4^X^]>;SROTT\!\M6%329UV85["A-F
MB\&]*YRUXD(:(].>]UF%+;1,<G-?Y9%;G]6SNH/:*^^^_@%02P,$%     @
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M3*B/W.*#78;UQ(4T1J8][\,4MM RR<W#*5_8F%B=JVV2PW)[YB]02P,$%
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MTS#U76,D#- $KN$%8,F#W]-@3(/=>,G4"&%&3@K#"S3S 1EQ\OPFV>OC!#[
M^<;T_B!,@"#)5$0B"0T'/DSH\TD8X:?&0CB1(0(7QG@KQF(V$A%OU+9%.[5C
M&C=3;SPUILZU@+F)P)A'8NY$@F;HC,?@6L"K!4_P(^[*@%8)<\F)<B'F(=AO
M\$XO$WB]$[F*"!_?7UQ* L#LO#A.8>31@B97'.T4WI4&2X/\&L+_J*%.+W_E
MH9H&\@Z'IAG*7\V!7&,/R &S-V*1X *0/D8;_]J.MAO3KVE\FX*(*%Z;X#J%
M,)=[L',;E@&[8>1D&D8@[\QM(NTZGCD@;V3[4,Q 3O$=3%;XQULO$N,DC(!=
M^#F1E[Z4/(.?K&KWIO%;X(L8I!X%[\:+\;TN>&^P-B2 #V^<P!1A"B";(8_Z
MFOY+PDE_N>B<1S%_"M-.D(QN<0<Z:@?.A(-/A"GL=Y=VVQE\YWKPJ1RG:91K
M(^EM)N&<5,.CJ]#-U,UID2YJR4IR,D(A'\["&;CX"_JWR1^?9WZV_NF-T/^5
MJN] 'N@OD,"<[+$'JT+9^@E;G(@<\X3PU?GPQJ\>;)HQ;O9QDWZ(,XK34>P!
MP2./]$T4IE=3J3J\!*7;3<<@Q![\_PCC5'B!::2E8G(;N[8T'ALZ9OVUT6LA
M#GD2X=C,OKX_O_A^>O&V\>G\_)\?OWPP+L'"D@=2[OCO8.Z;"?8W$(\)[,+P
M!K6PMH5!*A+'"TBUW8!.:?AA^ .?R;6>23J*]H*@78Y?P_:^%&P6;>N=TEF_
M!:1(+_&W<28]3[1@&O&-EX 8CC<@ 4PWC< K@'>\^SF>.L&5 'N6X-2M81LT
M-EKFF7B:2=OWG#2:F"<FXZWO5XY*032\ #Z9D4\ ZL,%Y>3,Y[ >RO-D2C_.
MZ>T[-V"\XA044;F8W?DJ=!DP781B=RW\!2M&]() -Z)WA88U9J5:_AKEG;R_
M1=Z]8.RGF(WY\Y^Z$-^CCS 2OB<F.#Z\#$5]#@H8?!KP#W#>,X$2Y<4S%"=G
MK.SX'(+@2(3@K8%X!3!N$H$/%X"-A.F[,.2U("]N-DL#TL#.7( 3,#; X0T2
M%DECC'X"^1WJ:YC64$Y+ZG&8/CBVXFIA&E>AX\,:)B%L<9,F%XY^9YKE#HPK
M@(+AG%*72_/,%D\O@*D)8"=X://( W6VX('1Z7#<:_20Y(/S*+R*G!D93?!Y
M9F& 3O18S,%S:7"(?XW.2Z=_8DQ3$$Q#S#V0G1E0\"H*;\ +FCCHYAAV(Q!7
ME#N0KQ"NI''B()> /!BHQXFBS-*78)4I&PM_HL%##KE \S'X2%X 6P(Y&(DK
MCT@&C&J( "07US&&_V*""Z@)%! LDK@X,,>PWQS%UG".KG0:L'0C3?7QX/<Z
M,8BOQA7,+@I!  182WR$YY[;:7S-A_-?/[W[9LQ])T&QIVDL<F;#+("//(MD
M"E%$SK8__VE@6_T3F/'(\[UD@6L4P90\3"\(D'_DK+G.G A+$H<,BN?@8L B
M-!7_[?,[^"=X0IB/9;%%>F)B&Z36F^':'9";*(3M#A**4\LHIPN6I(+BHI+&
M?#?1(LC# @42A0XZ*OPNF-$JD6'],( 2N.R5V6M@\&P_Z// +R!<2@+0@?AC
M?6 3HJJ8+5L8TY1GZ 3AZV +4K2H"0:O'\1TDL)2G<3A%4TFS$DY"/*)XD_8
M)W,'!)L%+@6VAK"!:*W7CJ_M8HT<$'?A3L.WXH#$*&!BO(A!/7&TH._6&X&2
ME)&-55,44J@G=1 L@?3KS324#">->0U^(LY0J1?<,LOZKZ"9B%KP>X%1$5(B
MR(3X!M4OK-N+B5S96+0OX(^88]>)X_FPF4/2%M<>AD\^+!5=AA$0>^(EMPC[
MC6"IA,G!U^CKHA2B O;#.):;E9Z "2OF >' 1_4FP#R:#2C?%![%:)05MW1_
M<Y+"3,8A6E#X[TQ$<JW7'AHW;7:PT)G,), :P9"0F#CQE$:E/\0?J0=L)MK#
M(J8DGX)L33J98!@,4P)&3%*4H3PS 4J"30SL#(@ _TA!=(%!P$H,[/(YP/8,
MXGR X"IDZ<X& E&*'(\.I/!P0>HF?#I7.Q0WP"1)K>&N@E7#9.,ID"-&3K'Z
M&@/[49-BF)I&M)?)G#N9Y0%M2V<YHU"]'M?KBI'D*;[(N08!4!H*#64^*]\#
M:KGXN8IF8,TSF38))_FJ-04'IC.%K8&: <6(M!P2)0!Y0O'!)% :<7P+\8J0
MRD=2"*@2I<$-J#BO,!,9^!,[ Q2E$;QBA$XR# N"'L![8:[P<FUA($]C;TZ)
M U>@R$E5E[ L2>*J+:<F*<W,.I:BC0 _C3X%60>E1.ZZE(SW;T])13G X, %
ME849AOD4%8 -NP\WA?@)_B"YZIIL_R=H ]!EB?-3^,CJD1>H'88[G/;TJFT5
M :AZGUX\\2+4DJQ2UBLP/@']^OY2V0;E. #]YV@!>9,Z&(S P\Q(5/T\?D >
ME<PI**MT$U+*)59Q!FS]*%'_('472W(N_A++^<Y*9X@QCQ=@DBOS2R*9(Y0F
MT,DM-#P-[@S^"#.#F=<'.H'-D4;>O^A&:P&O7*"JE?1D(Y1Y)DISLK131C!_
MI3))N8])S!Z/A4]*S<ULB&F,'%PZNF.&.G*!N<4S3/$4_)G%&C%3E&!W :@F
M79#,G> U"K<P/4IJBAMX#6P;L699DF;Q6FVN*TRF-?C#\"OEBZ*/!!)C"-21
MSGC!=G8"AEGY1V?,D:[B%D0:2.BIXT]NTY)J2Y&=!I8(,D-)"&H+1#4.QQZ1
M5B;DM$41]?CS#V>G%\PS)-@5N.G9?H1/9%S-RU*N%NN#7%=(_WG"$D&S0^[B
M7,$K3M$)3LE/D7[-\E+4PT@G"H92]H% JR6+U1\INR! 6M+,@T7I2!9S5DVY
MQG.B".-B&2BI&2O[H$5T'/91FA*5SN54 .V/'/2[)J0H.1X[UCWH4@'(#<+2
M@$#2&%DMF,]@<D6F?$E\P?+#[_4%!&[1%PI23,Z2'Y1M)B^ 4(@2JK3S9@[N
MU3RG#@/S$TJ^LDS?BDRE,6OHTV^?R=S#*ER, [P1IW*=JTBP8%/F'U0:ZD?.
M $\]<9WYLM*\9I':!GZ0OG=1-8#<R2GH7.38V)^#$2'5I%M 8(5F5]&'BM4F
M!(7]0\C"C8SKFE"I>>+P,S"-:!XQS )G)1'L_H!*%=$U6U_]Y<KX891\+7WP
M8LR9J2VV9%*D3?P# [KB-H&@PD5#Q]'7-:8(8IE,*-TAB<Q<*5<#@L=I"$Y1
M&C/[F3F"79PU/,D-R"P[FU(V'I>-V7CI_FC1$*P['V*OY^F[.\S=+,MDE9_J
M[^.$OG+9VX(.4/Z^U W2R55Z,4^EH2?O<43'MBL+SVZP_HS\6](ZN:+_/76O
M.&+&?)X\7B2]H+:FYGUG^H>25&QDX#,P_]K&<M"6P^Y# Q^ADDCX; +T&(8F
MHA#'N6$Z2M"5V?Q-ZQT\4)&8+$3GG5283C,M/B*G*C%\\L_(6,!^ &=3^-<8
MR0?)-&:_ [\;.3YE4^*I$ GZ)/+H#K^[,^[3K+\SSBV/,YF(<2(M /PRC4'&
M-PN!V<)1=$ R0+E2I$H@M,-J?&.I0BKD_8SP6AIT(D(,ST7 $O:Z@>[P:LR4
MDG;D= Y3/7=N2S)<>BX,?NRC1*#_?L6^Q]K$D1(?M4Y7*?4E+VV3P;:TI)Q=
MT,+!]6_.8TB2R7DZ\BD 7NLH4(*P)!#/)6/)V7?Q7"TSX5L=4^=CNAZ>*8,T
M"Y(T(I*:"><!1@LZE28/D;R'=1,B:F$HKWE:Z#6!FQ3Z'#V!J1Y+\WLMX)E$
M<ZXX9;9F5Y,UU]/8_/*90^J)PGN5$LG$7'<6]&C,!5%>T/<Q2 !^.W+&/_3D
M *D-UD+*6*_)5F*.BW(%] )GP=X;Y2*(\^C*@*:)8CK!Y;2%DH18Y"$DIIHR
M390&2@^1-R66Q8#]&"GUBE<R]:$48GYD&^4%+9HVH^.3E&P!+ 73=+HDH!CS
M&]")7A9GR8M"#IR<+YD"I_0'\Z0DC;FBVY#Q4K_)('VD.?K@6:''BFG4/,_F
M_3O/L"-SHI1R,"Z)NEQ++I1\A)>=QS@SK#%12Y1'E))_*EY1OEODL$\8PJZ]
MTLBGF<Q\52MJ@XI91(0994]DH25O0B^ G9 JHPNZ98;6 H;Q2M^LN> J"8Z[
M(\(4LH'1OLDA,08D_$_0#P)33$(>8[+HY!FTR(M_&+ 0^0;M!5J:BD*7B;00
M,\E>>/]8"% +9)Q=5&YSF6G!WT-DW5:ZCI+>DLS%I"'E82D&*9"19 $T!*7G
MY8 >5Q>Q"L;T Z>YY<](]"C]J)T2LN&4UGWJ81Q'XHK"1PE++GAPR"7R::EH
MLPH)NFS3QZKJ*#LW(/D1XVD KMT5L+=I?$1W9E%^<(E#\#MOA*K;P%,376["
MI0-$N4_E1I:YU$*(G/V"2Z7DN.R2786AB[GTA&TZ?D_/7LNC4$RU8S;(B4/6
M.R,'(D\3%IFP4J$C@Q&2$#5!&I$YEX<Q0EM96#":IK8,DFT8049*[FWGJ9F9
M^!&$-X',NO/?**FQ_$1S$%7!&^?<QHX*L^7F4?J/,BXHAIF?"79 .FPA5;+(
MA$O9S)K5+]RX1,DH(9.TA+C_9UC01GL%B,=>G*PY(PE9RKNSZ<=OLGP^$G.>
M1EB?5A[!1B&&PO(-67ZNZ$<6CJS5.9 IZY,X3:',$' +/29?**V_]OR5[9"Y
M[#[D%H2'R6R(*)R/%0FF:03=-3;U9;(V+:;BEH[(2P?%Y<!J>+<H X5BJ#3*
MPI0OSLPHJ=Q8GHWRJ=6*;</\9C@#I2N":R\* YSF <CN=]10$9T8)FHIM]1_
MS!Q7Y.?0A8)-T*RDU>B1 .QKA,<HJ+MF\Z648F$SX#C!59R7<11.C\81.+QR
M&Y!7*$ 8PX404MKR-(_V,_:%-$=8#R[7'X-#$+ BOE@:P0</*PZ5%*09UB!J
M9QE*G:ULDMS@Z;9Z\ZED^3L^:P+W=K$L\)IO23D'4*X^#AO+ TW)-7IO&D7X
M*MV:'8"L?LQRPK(&'*,LL#*T)GD$ZR]DQ6N0TCDA1AEQ'FAGE4_XT&_-RZ:>
M,"?74A9T<GR7!0!ZC5-8:A/EZ0X+W!UF[39C3-Y"=F:4[R!3J7?^ASS@5D4;
M1=]DHN<]I== <<6=)5X1[V$>5)X@WSD%@S(HG?Y)N'2.(/T#KN63504498TH
M=Q!&$:57T,]TQL *& S].<5I*BAS*%./>_P*ZR!IC]"^ACU-QM#W.-L1W$KQ
M[Q!LA^234JB1.#\$N8VYHT_G!7-*' &]XEM5(7CV8IZ@+<V..T8+O<K.=V[6
M;*H-[XBV5J_H[;J65AZI&.?7(KKVQ$W%Z\*_<QCO9%JU04DG8^2%<PAZ9LZ8
MZO(HD.&%2:U;/'\'L0=3YONP''60NV5)H Q_,)!RY*V2V^J[9#C%(9D F<1C
MJW068N9C0FH\*UR,Y2T);T:[*%YW-%<8E0-?O-3,WIZI\C;T C#G(5[Q2&.4
M9$]F/QQC!!&N:T2\8S&W,2:W2"L_:E;]DL#7W-GU*/D7A?/( P\BPEQ:B,X@
MY=E$",X:U6 :P"#0/NBIAJB'^-PJ"(,&EH>%P%BL50PAL!8-/,>B$_>++Z?&
MD1O#_QP;-) ,LS'&"5,ZWM+]09"]&XR"@'[:!+&2  S:32 KVSB'D]4ZD.I4
MY[ L&.!F1J$VKG'T[?.[8RD<?,L=%TW<92'%0)EKXR;.=1B1?H+?J" .W98T
M"E ZI%3)%ZV1#U4@DQ>0:44J)*&H.'-941$0+$3,]#(U^/?X!U>;>,'4&WFH
M\$TMH\!3;V3RIW(O,$55V(1'_=\,;="11\5O$]R,8)-'H>LI^WCV]I\=,E$]
M[7T%3GB882/2!2"&H#-X5R$I&EC_0MOVFS$&]8!%B<*?Q]).T$><FP:?@ZJM
M-#*J0BXJ ISXSFRV)JY YJM;:)3IS^^7X"R^OFU8-'OXXY/5-'Y=4X-X:PFB
M3#\\MVK$<K_U)9[2VI4^I=WWS;&MZJ!O])+!8@79C@NXI6*_PCU"N^B^Y=?F
MVMIK\];B:SY-=#ECNNP:J-U,QYIYI2*I'Z4M5) O%0*YX4H7%>O*]U;E?;<[
MHP6_)]40YG.M:I/+U;QX^>3W2>Y['/WCXC_I)_]X=V$WCC>\_W$T^_7L>.M;
M($=?WY["SS:^#,(G 3)L-]7)'M\,697L!UT*T6V>5GAIWGU99'-ILW<I;:6W
MWM9'AQ^HQ..,2SP.;_M\E]E*+AZGZ_HA>!-<3>>I#81_S+,R-,YK+-?DEM]U
MH(J,[-'2E+V83+ 05\]/Y&]ZDCL23>.4.AR4WXL'XKBWE<Q,C-=6UQR"9V!<
MPLKA.UE ><N0\KPR$$E^AHD#]<Q6QS*.8B$J=AN5KB&>X=HOU!$,?;3/RYX0
MY6'*/DR3LG(5TG,15V;(O_7J"KV\4[^ 02Q2Z;R\W&DM^TMJM6Z_%$/RC6^F
M!.K3WWDIN>EB%F>_<B.G:?PCO,'**M.XPI-P6:.#!VD0D=,9,\??#7BWK,%5
MTU#%$9Q@DLZ3K*'3MJ^:M"HF^>+$KO,')98"W$CC!2H!>IJ& XX@'67E.H4^
M?GACWG5.O/;F3G8HS,>-OE"W@\>HZ;@"A@IIN.X.E$;3>)]&^"I,!IAX$6>E
M8$:>MZR]H%.XC7/GG%6Y%\Y05>-D%['H.O'J=:(RB;[C2I'*5)34/SY*Z2-H
M1]!J$Z:??J4?J+4+5;*EPOM4N.!U)L6TJ/SNG])NK^L<49G.3%]E /A6L\R_
MT5$ ZX[S-*'BRHHG/HM-)'";+E\E3[5%A7)1%#IB"":U;>8&;]%,)]/<; /H
M$"6[&#@XV9AP)Y41B3,577PC_2 EY&'KR+I"SKTYZGNA]X!<_JR0QVJWNO?M
M^-@I=GS<(^&7A;BD2UHA=)P_!MVK$32]Q9M7M#'U=$06@/)&^;:8"^.,JA+5
MN7UV@0TW[:\7IV?O(*QL6/(JICHLV":+L;<C?/TV8-%#E(&'\%T@3QD1Z,S^
M/1;7(2G>8OGIJ7:W"$SK$=#I6+_II_L'>6GJ^H0"WV9"K3?7CP6,0L[#F/UZ
M1MX#L21+3&//I@E$-533G"<'ZORTQO]VI?/3^]\?ZA+>))1ZCP^ &I-(H#,:
M76,,9AQ]?7])?0"Y%)1O5"]?X3;E+0BZ).)K/S[GWSK&#[&0.U'_W2$F0Z5:
M61=W=F0FGR\PN]H-=DV/2@W:U#^[(1II=_<A@ @:$#,)>5>;(Q8N_H*O.P/M
MX PIOZ(S5(",O,QO7X/&UR[\'WW]]K_'U/P08BWX>VUJ?;GLJ^PY8-2T4/=)
M=:;"3V?."(^\.>>+X4V#3A75D2G'1IE=H3:)63U2\<ZW;/8DT[_4% !IE7<#
MH!U,5/>=O"T!43<C'1Z \ZEMWM127?MNZKU!US(OZT3@BED8<*L+-R^5IMY(
M@7%^*4N19+L(\)C&J2_K.^A!I.)_%L@5S0R7DWQ+UY05G\&[H#8)U =)J[$J
M3%7-SY2WOV""<:*NL.>SPQYG@Z:M+K5IDX)/0M7\ >;4-$ZI\DU$UYR1S[,V
M$VT\Y;HO+0CHU+:;EGR-J1&-CY)A&2N$R$M>'#Z%(H[":RR[0>/DVH5. ZCN
MAI(@\JXVCD@R+8^RLL?E(2[.2D7)0-%4,5'*@MV1KUE19GS9@HL8L(9",;[7
M^8\"HQ+9^I^HOK(^'@Z7IVX:VE)Z]45064>[?<? <IF%<PB6 VRW@6)OY>0G
M)JU,1W]IK]E9?E8J!R<C'LRGV^S+QU1:0VW>/(.12.U'AR]Q(D_1],14@%$>
MU;C(@FI-.D=T4]Q5ES'@2;QAI>O'CU_>-FVK+94CYH.R5IE%5:ATP#R<XPZD
MNKM;^5,J2KB8**1N/5(@\D84U*= UQ+%&7)92-YD5GK88$BO\+:8+"?DV^*Y
MIR@71VG,["U%7]7,/4(N 4T#EW^KND+0K[7;=4Z),RJM3"CO]VH4:8SDC<NU
MW6&*9B@[G\/$97[V5F1)X;!NFU+@ZC@ F&,F6X]G=5RP<A =>J1*O"T>H92H
M_#V=6?\D?0^[UQJT;O4Z%//IH]+#6:SSH=,PY7+*RF/I#33XEA]VV;ZBU-'1
MZ=NS^-CPO1_">!? HI/4I$'4G2^P%U=4+X;DQ8=-OO45JGY-JKB2OEPJ":A8
M?Z([=T/U\B<?;K_FO7F+YRKG4L[T\QV6_8MP/.4:G-./YXU+TO)!X^K#;/0/
M=K37GL=7J(W^VOEQ!>MXJ^6B>P">#%<GC!UP\NCJNSP#N6:O&%.;67'E512F
M<^GEPW;Y@%4@P4(963D-[KE#Q?*R[E!>42TV)UV-1&BJ6#F5QQKKRC_! 1/_
M#D%E8X1B''T3F*R(O#^>Y)BDU^QNP)@U>1G<'8UV<TWR%<F' ^#9L=7?\TFQ
M?B5#J[U=&$=78C;&6@?X#3<*<T:-W*29QK?3RX;5LDEIST*7X[+WYY_>?[SX
M^.7\?XVC6?Z/XV-3%G.290)%+:]#ESD>*P4U7(N^)&E\9TEZ2.R96WV#<U?Q
M>@']"[KKC65+(6$,G(F0QUIY7R15F$=1A$XMUXNI-%;=>.;O\712_#"L7M/X
M9R%S(FM#J/ML6'BU*GW63D:S\#EOYL1G,<7F7WFB<N2%=,I<)!%?@T/% (9-
MWG2070W16X[X>+WH&I#;T?")ZR5^0=XV#AS_JX!,HO8UEF.9<AQY?.WA[1@<
M4GN,1%Q00=?1V<79L;Q*1 3CA[$M X616ND4Q+7!0K7R4XG?>20:>6X@(]XX
M\NC4%B7ADA9OJ1YAF=B!4\!?V;K_I;%"48=A,#:@#B]__9IAG9LM4Z5^V..2
MEVNY(3LM0];(2;=$7[VZFZL6S_.6!%/B S2[@X$EP6LQX;VBP;4M+Q.+$?TO
M5J+46OL1M3:E1R@+G"= ON:%DF<L1*?<0>B+2+!3E'$$3YR=?CE&#9'=1CI5
MS2C1"<=K;.2.@Y6'G?';Y>NN ?/W892-/=Q*G&E3-A*)@NGK*3SFXZ.96R]=
M*-5-<W!R6+[N6F&FF;F@5]C[>T,E.RRQ[_*[QU3[K:Z+2#*LZIV#."/DO'V6
M<N9.1[)<6>E)U8.4,CYX4P9] U>E8>W#4S[!?E$DBBA2GU,_\? $U9O#L^CE
M((R7TCYG82 !>*C?C/( ;X1*PCJ8N9BK-&*9RZ7G]52J4-V8+X8::X.%+"?.
M"5&ZXW3%75WX>E[A8CZ\@S<%A2'+VZ*9^0IZLL4:%%PW,K&8UL@]AU/9 PK5
MMKQ6[V/Y'B;E,8<33RFIP#A<V8RYZ0?-096Z%RY=Z7>?-+]$Z]51H?[(3>-M
M?DBB6@OXU-AKHEWL"M4%\J?OHKS5$>;^M-Q_.4&*.RO+7.9:C(NTW(RG,M>,
M0L:L5&H.02)/9P+[*X$G'(X]P5>!L]JE<Q7@'YU>GIT?&RNYH3-YA^=R,4-1
M2F<<9BS/0#]=F5 ]Y42U85S=%UG/(2ITB63!A=SZ+/RE2@'&;;?_0]UTY@ *
MFS2*_.Q0=G^&+1H&5YP')R<Z'TE";T38S5<VV:'FB597.R;!Y"#(7Q!RW>M(
M<!<CK6%586;<C7N=(M(/Z,@]H?)<V2@&L[2MAMWYC\.S2%:CO4^31((8"4W7
M<=L(T*XRGI=EMEJ#CY6+I*"B$_VN\F),:>D4;^K0Q=[LQB[:&1\VP30<+T"6
MCKY]_'2,[:M)]6>^%6HLNC"BGXAQ\0&>Z\OKLH7@>Y)U/"-?!=-YJOJZ:7RD
MP\^Z2$CC>Z<N$KJ5/GJCO*S,0?-3\C-0Y=-0;)0;#[YXRJ>4>$JK5]C+ ]4L
MTX(I)>YW- O5C<V53<;NU:WGF*M!YGZ(=Z&@(V\/#B74>\,7D^1-NZ?"0P_\
MRB!YT[ &>^.^U=R?3CXID,5JH?D DCJA<6D: J^+-(VO=(#Z\:-,5%*7#0BF
MG<#W,#VDGT\?S9/X6+9L_2/%[J"QYA'+@%ZYBYA,O#S#ZZ#H(6LGE7EJ8$[=
ME]*9.A[7DMZ87 RP5RHB#$N7J(GN4\NX%/.$*MJ;AAMZ?% T39(Y%V=1#I#^
M U\VP^B*_H:E6RVK1W__WL0SS6#<Q-&:K4'3MOMV>4ZENI)E5TZR/CL1UMN!
MQ3[-Y0MX%6791BZ4%-<>-^=1&4WM4C(&!9EP"5^+N9C52RZVH)XOLB @QBM+
M,PR%67.J?V!^$R).52OPSW?_^G+^[5W#Z@Y4 /()7Y](;YN,:>@;_Q @^EC2
M!I)B&Y\=;N3</^H>TU0ZG5ZCT^UH8JB+V:7=Z0T:EMUM']G6<:O5'MB-SB&*
M6;MR8O8)S&;D>IH2NU@N" %]QK48",PB2R@Y\<"]RU83YL#^]*>7R6CA)&95
M8DV(&;@@2XFNN71N5A3B8O: I84:W)U>G)Z=7BHQ_"_C8]:/149Z)'V6\06L
M.5_C 1$<'ED6RZ!HM>SAL+<D@U9;JCHO&3?PYPWUV-?/']_R<^W.P.JVNQWN
M"_SU\YGZ OX<]"RKT[U%*>[_EONVB=>/V$0@.Z[#?D&K$$LR"5N2>-US=I4J
MI3RN"S2S9I9ZTHS/LUPZ0\KD%X]>51H-5TTG2OKAD/0QCY: H(ZIRB<_[N(+
MOA3%16G0\ )9L*JE.*CI)[7@=+6V5=D5BTQARS>]1;?WDH?\' 88F:-30##L
M5)"YDF_)1B_I\,GU1<N(5DGN??!=XBQ?F"-99HF<U64J>U/(X%R>G6^4F2D1
MHO6(WOLOQ=,J'?F*+-,)V9()T</@RTBJP*_3VX>K:G\&W'@$I++-V]U5XQ"I
M[(:KO#,=+9:JB7((K!Q ;4)F;>RGZKZR'G6NLH.,XT%D73/M1UX9MW<,*9U8
M1IXLN?3!#T>X+T.@>%;1>ZK:/5VH!A]'2,!CV1LDC.8AUX\L532O5(U2=3X=
M4\#/9:V4(O@R%IXJ[B\6C: ^+K2CS!OF 0/7-]Y1I8'9B<:9=BCC% N'5#T,
MS-24;2VS0QK*/*Q)#,2RF4F6O5NA0@9PH;T*'#&/?):54H.U&5B9S56=MZA+
M)R8NA&Q-+D\^\G,%U>%;[_U#[<Y5293*CN@-  B?(W:NJ:6P?G8%8V3)%WX?
MOWZ#/IE5V1*HKR7D5*8#RJJIZ5;--N",4L8X(<"U.%O ,AY@ 6[>4S)#Z5R#
M/K]_;WAC79D[-&0_\3"H6!2_#MR<VVFRGM)K$V[-N\>4>(^/@491" )! 3?X
MC$MHK.A*1IP$#[&72'*#.7GXI?8J>I(:<&;G.-+IVNS$[)2;B'_F4K0GBEKM
MS4[G]WD.LT::]0Z(?(2,3-/+<? V]&J#Y#6[@-5M=OY+MR[1OQ]A;*V/('OO
M*'D Z9(-<JK?CO@?&EWX1'/CTB0Z]:EL+@<%PN[ML6)N*:'3X83.MZE266.A
MRG-S_4.B2KW"5XP6*!)IUK!VTLL 6.2I<JAY.%DSV]QWJOGY1/S4>C3K#%#(
M@T6U+^.XD8]=(C!PP<.NS!DQ93&+*='$LDKE)68JUQH#4[K"C.J(3X_ULI::
MYT_&\T@TLO[0R.&5H_@"HR'6H=M=E&U@ST"A?Q9<@)A/H$KCGYJ?3ZB3U2&U
M.MOCFT#:]9^L.4$:T.U"O;+<S'N^48:M*!UE8D'Z&_U0=YVWFM6-2:3K-<?4
MU?(D^'(W.^'IU96($U7KE*/$<A-DNGT-CI+)^"B8.KUQ5CPV3F92J)O1HK2S
M^FW)QDV[P/4JW07N<P%2C'IK<(_^0E^XBLO(]ZGG<Y__K""5"DKS.@_&[518
M[1)/:@D#_K8VZ:;>V=95N'\2*EX3,=E+3F+$8N-+#AR\K#TNMZX.U6VQ#,.:
M*P-IFC(%(STY;*!%1;6%)20AWF\HWJ+.X$*Y^RW>$':I^3D=!N1IP)]BG":R
M9PGBT@JWD<Z-\8?/7XTC5<[Z 75)43B^(DZH-Q;'^@JC-,@C5 4Z-W(2O)I,
M:?TK2EAG!R\<^/!M,-B<X')XLED 7X'64BUT[#=R@A\2X8-\&T+[E.N4!RO:
M;##&HJ1@AB:NQLC3YMS;T<W:8&IP1GJ_@B ?&5&U$/^BKEG3]ERWTC5K>U9(
MV1:C*EY-BM@)IP[:$=7)AQ'F!>G8$?>Q-TIE0]V8VPX7</"*^JMIG,MFOJ/4
M_[$$#IG%@"Y5U/,15%$=88\CZI>DMP7()9^,0+X_FYEAT/:LIVT>PH:(TT@#
M;>63/XGA2S/'6XZRBY=$K=&Z%?^1.I1C4;<')$04UN[1Y7 =2;#8W"([SBQT
MJ9?95E,U%^/>(QD$0M6M6I:GQO46N:OZ&DC:2(NBV*R6*D/\_-XN/D!E#6Q3
M,MAP4]H$;M1(P'^^=EU7"<>2<=+TKA(7C#3 (W.BO/_+7$0T(/Z"&*QX7GPI
M69^B73$S(%;)RS+3H8#[R*@7MI%2Z*KK-67>I(AG" JE8E#JI#W,(1Q6VB'$
M6U'4X2SE#K# OV2U8T2U=LHIJQMJ?#TIMO2W.GT,=9=!FRR;&VNB0/1SD,SL
M2?+5?$K.@I9)"2$GA\CX'79A['ICF8M5T IT$PL&B-&3XZ$,]"XG$-!AD'[-
M:#-+_>EP=\BN4''6$SQEI.B"6\H';7+KY_X,]['AB><OF8ED&KI<BK^D.XJO
MC\&Y$M3P!Q_-H,^R;'?^N&JT)5<6<7I7-AS'LU/52ZS B[:UBE%"4U9[4@XG
M<20U,N#U=C7Z=/FU\IX6C[_K+6QW*[V%WV>]Z$]ED%_) \4MJSEHOU)'=B=I
M@$ T&(J /C&.3K]]/B;(AF3)!&2E'H=R,,VZ"Z( U^B:':ME6IWV$AH$0431
M86$!5Z1O]OHMXPAONIM=NW=,> 8!YIC(R9Q'WE@PDDFS8]-S5K-E<YU:5AFV
M-&*G/90CMGNM8YD9UG&#\3&[;?%PO=XQ[?8D3/ "(YVF*U<7IT[*5$CO]BA7
MQ]J Q_SBKK5I4[;V:D^V?9R+KV?I>ZR[4F5XW#F^2X <G[%PACO*]\R\?DRR
MO=VRS6&W=0>_>Z9M#XCP';-M]V_CM]6GYUK-P:W\EL@T-*(U[&,?D[4,MP8\
MGM5N'>_<@6I;E=:^1?R<A_06KHX8?Q<2"P'UDRQ>V@ KJ;(81YO@?ASO]2;H
MO3='I]*;XYSK\K,:P<^$]!,_ !^N.IOD/##>BU%$JKZOZ72]%3=BD$5-6C90
M83(1"Q."+!%[KJJD/IMZ8F*\X] 8W.1S3&$CGN#9NW/L/(81O^SH' G$,&;7
M/0- R1K=@2]^3>K?&:FR #4/[S90 NX9)IWSJ7!\W.SRVC&8#F<1"..K!X0*
M39BLXT79#;-%XHWCOW#].7[XUL.39DK*T+0C@=DL[KOAS0Q8D,1SHTM(P 3\
MQ,.B&G 8\K JK]3'7 85G'(34WA\XWK#-5Y"!<3$:IMKBO.=<F0LG\LUCI!B
MI*6^A)B29X657Q#X),\)_UM/N."1#J;05$KG6X[$=9F$XQ_HDR"VUZ=/9\81
M#T[?RL%5^9%LFFWF_;8C#_YJM[A'MQ3;''?56<1<.SOV0TKQCSQ7^B99>B9R
MN0Q9^CL^-S&0C7#D')66EK.\H6OI>%V!C@P@1IZE,W1U6BW,.4E_LY#:S\]O
M?$F?6]\P3R.,_ GE3SZAZ'J1^L+H=KNM(^?XR#[F!A+,"G6ZF,?RG!O 27FA
MRUW/6]B-76!2CNB3,\Z5#2&2;#RZ%<7;Y#2] @5G6+;F1T;BRN'+6! ^4Y(M
M*]Y6-,GI+:DQDTUXI<C-D^(;Z<9_$&(I&G;#A@D)4%3C# DL8ZV&A"=%(:/K
M9!U?5=]R4@8ZHB26$R.\&MU=B-+Y*O,9LXW;S8]_P)\DE.=?SO[5Y #PXX2]
MWP7WHQ^)"2*YKU(,S\DS>JR?)@FJH/LJJ&9&> M\6:Y8 2D*(T]O%7^YBL(U
M])O(@[U,#?(G7C3+:MHU5@)I4CZ\X])W@IR44B6!,U?Y/UJL+OM&J&:!A4;%
MVA5ZHMHZ>0)!"67B=D$#W5!E^4@4,O^8UY=%JLM[3!.Z3&5(%$$L..)NJMB!
M?8S'M@B&(]E ^ I ,,ZY\0FBGPV;'Q*H0=?N8LPR8T8K?_7MNV(Y5;5VM:22
M%^J%,'^J_0P2"0DZ3C,4,CY^QELXG'S3S*[&,E8-A]F%'/OB+[3=E7LS4JG\
M%GBRVR/6.E,"P%6I?W10(A>+-USR%12)BK_!RFJ\$,9.0N+ 5"=TX,&HX:A]
M0*@EW">I4DKH.J;Q6?STQJ&I'*O 8;7'0-JJ@Q[6.>9C+D%\2I\E@TIL$NGX
MJI LQI,_1DF;<],INC3"+<!9>&?P)"$T8M4_O,&YDLU>DX@F0CH;)RABH8%I
M\B4.=5"=(8#+ S Z[AA/"8@26V@6LKR<8E$E"3[>X&;\T>+-IU/7=SS0^U&R
M$,:O7CB'K3<#SRILFL:G!)PP=@3H,?8#./',M:2(U2,YQOR3IYOR'QJ9":.4
MU3S>H!"4.H>=G%,&\2:*I*=.6=@<TDODC1]9F!'?EO%]B6?QO?*S^,TCQTX.
M5[F/ _S]Q*.70H+YR*L/'P,ZK#R RRJ_,?XUZ9<;+\ZN!^#=9K2:>'4^2)2/
MC!LVO])"\5^8PNLY[Y>=?[EX#3"*"T:3'1XYW,;5HNNVA@0;5]L-%7^#+A[.
M8_%&_7$"*G+N.XLW7D"+IA_=!P42A ]\-A+ !*0N<=6;Y==-^NJOB;OZ7;??
M;/>'I5^WFE;I=[<-:]G-=K?\Z]N&O?V[]J!33[;;WFC8OY(PL$" S,5@:O_^
MJOTJ5WA4R?NF95BTM=5XMSQJSW_BPZLBO])GCL1S]S?T:!-@:B?;O'<OZCFN
MO_W"UV\7UG_'1L ;:0B1$;@-.<7Q6(C)Y.2696/Y^YX6O6(D6]S[#&+F5"SS
M_:XE2MM$%AZL('B!$"RJV>KK;QG5HL)ZUK]^NO7KZZ;*C$HMG&X]V/NZ&"*G
M@$>\3\8 _'9+1MRBT>[<\\M:\=ENI/7,? $;J4R*:2/5PEP+<RW,3RO,6[ME
M$_J_>[ME^VB;16SX(A+##^/X2:SS!EW"6_?N$GYDX:'?4?OXJ'.\E,VZ2XK6
M,*MJVN*A/N2Z)59%(:Q?VU';,OM6Z_@A2WQJV[7TRHUMUP$(W$/-4Y4%;OW:
MCNR^V>_:M<!5B2G/6^ ZYJ#=W8O [3K/M#>'YE<GEH"2KN?3[4^?2K95T<B+
M<G36,+%J:N"1DF655 ,ECDZKV;$V5P+K-V*50_0JB]LC1>&5%+<2JU.+6RUN
MNQ6W]E[$[<7D;+[AO3ZJ_$H.,6_3K=,U!Q7,E)UDF]:@?T"'>G7T7B7#5F6!
M7[^V]L <V*U:Z&JAVZ70]<UVN[,_H7L)Y4GL3B'\FFJ[-^'6'73/)6O5]2"?
MO6(;Z>4E7?H'Y:O407B5S$:5I7W]VNSAMHY*+7&UQ#UD;5:WOS^)>S&9'^IJ
M V_'JYUN;+AB[!,8U"&?;O5*TD&/Q,CJN2)?/']YDSQ&8/<,Z%52HE;3ZT'T
M6JL=K<&C!W&PVQ][Q8/--E28B+B(;'2_=3_<+"S=2MHE3,<RK4J.9ZQCP_C(
M8% N T@'5#Y+K=T#60U*]1-9W83>]I NHW)_1+S+Q9?Z"5?\1D0,8DZMR!!O
MZXJ[M4ZP.U'69.+&B2)LY^+"]*_)3!C4Z^((7\=M!RW3[MBF\;IKVH,NO^'U
MD=TZ-@E-18P9:W&YZ=!.9?VP>&X_*<_IF<:(NC!@UP01Q-PH !$X"?J&NE.:
M??PI,'=H]253;;/='RQQ]5&8^A(V<OM)F8J->X F> 6==C+O3P$[%'<KLW38
MLX"A1YU^]U@RU#)[O>Y3,/0E[-*G8ZC#?7$BA.U!;."9;$AJMMM#VI+MX4!R
ML-<:UAOR?OSK O\(986;ZW3-[K!G6GUK3=M@Y":9R6*?WV;+F"%Z *-)41O
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MVV:_;9GM[KYK=4H;9I>U5RII +5AEZ/!JU^JU73(N!#7'@P,*NP</$]N9W8
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M\3T^N2&4'ZP&HYR+]BE%4)35I/$Q)^PE'";A\WD^AF,KS&-"G =4E"<YG,A
MY ,N4,',FB]4-O+6XT%,]V2G>@<8=6V _$!>PP3CJ>QL3=8@0!3M@D1":$Z1
MUL-6?RB0#NU^<SC<#"%@J^"EU>Q9[4-!2:@G6T]63G8S9(^'!MQ6MVH1YW C
MA_M?F&!_5SB*-]J6^2QC\,THL@8^XL43X/'241M[F=5/U&R2J+I[N2^+9IL
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M\NBZ76Z!$;@WNC\!6H=\+ WNV/A'>(-;P#2N0,6ROG0]]$9 'W& -O/&4=B
M6<ADLIJ0]V^6#N:,QR$MHSCK>DD^3>:&(L< 56! F-(@8+C!R$G0R.1[8&5<
MMFE@ .'QW+]C='K$=YYS6AOD<D;4<L@51 CX"%\U"]'A\R8HCZ@#TX ?!Q,T
MDG%YSI<LTWLS!2(H*W?GG&]$/D,Y>.[*T3DG[&VA>TVBU&>BD.=G(A2OLET
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M?0?\NPW-GO^+\L9"@=8KLB\Z8O)HC,?8WU=1!HLS;]*[QN[,Z7G[G:O=N;/
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M:RKQ$AX9,1(I-GO6S3M9EKG?"0XQ!(F28T5XF:* 5/VTK/CP1L8:RA7$L#7
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M>(9#-/JG]='\_ *_\2Q(@0S9V)[:.NJ"V#>6O+?7\/E!T39A@M.W%XZ(.$[
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MD[N+8<Y^^R5X'\4,\=GQ@I>/17#67#<U;88'R,)YG%PB!S!!NH4FA';7TQE
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M&L LKO\\D;$V< B0)EL6TK>%',^*4>;A15:)\=R(^K7O"&/;KAH0HWG33Y'
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MPW :9AVM\F@;;1ZMA;(;H.'U-MK$>GHVT 00/;E-ML%:>!/@\^3&XN8JD4T
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MH?8T/A58K07$Q@G%_D[CG"]W",7W82K]/&FEXG/QU\8YA%H$:18':9S?";&
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M$'F8PE=@*512.TKDX::6/TE'PA<PV?,&?P.1$*N+K6 D*"QI9C#)@9X2QP'
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MC%6W=Z2*2CL5K\Z@7AO=MC!_A&!6^I4=V#'"T'.,0&!KS@$0683*66$'"2Z
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MF(BL0TY"2JS05$"6E0Y!5H?RE:;2@<J.<1Y->_1&-:J10(^8D!M5Q"3#ZNF
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M76J2+3<AY>,Z\;B1?3F#345V$/]E% '"12;/(B##1:@)U560FLL>TJR S.2
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MLKK>5Z<]%MD6U9RB\E)HN1:9&K01S;9MPX4E/6W+2[@D8LR2<KZD5AWB"JF
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M\*3"GOFN471J[4=7AZU^';[/-<="I5_HA^J>ASOY(;RQWW#R-.J_TG9TOG_
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MIYPKHC3G-$T;Q73"^.B/3-,0_M1/U?GIF7H=]OX#[\Y11;;KX=&P;S8_&[D
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M1IVDG9"6K2$\9EN.T8 +J+1;W%D2=WIK.C.R[IKCA$@T?G*09AASOTA>L(5
MJG/$,'A'G#/04F&M)3#GI<7>QED1ED'%A$LRSG$]BTCXF!'4Q()[M.";"OT
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M,&/U-/9#Z;KRSF9PZJA4%9MJPK/_#-_ZY EUEYT\.IZ\_EC/Q^RX$=^TAY<
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MUS060A/40RJLZ-BALXCH4%IAK%E9IL9B.?7F*5,1S[K9IHL?8?YK8YW!6<%
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ME'QX)^+@<V;C='*/LF_%HP.[X)(V%Y_V75^(P'R&F@XI+N-)>Z_HHEX2Q )
MX::1/LX1?0G\%=[YBJHVY$(LB64_EZC"D8OX+AEH"5+N8%[<;O3R@O#/83X&
M \B-I?+^7\1I,'#R46A*V; ]K;\AF7$>M#<<!K%12HIFF**$/WOD7)!<$QT(
MFR;,PLVNG_JE(UI<;LZQ!MMQ$QYO;LX3?!P:#7WU\83*\>2,O-YA=V"\)+E4
MYO:3+$=8_Z6Q3 K):02"*\)3S[4(K=WE>$Q4-ORRG)7"=APU!$:%R,>=XHU
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M1.SB>JN!'+_O .3O!XS-J!L@<=<9F,=*&H2WRP:*$^K=7?<P?V.!@:;J!1W
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MK?X@\T,_*ZHI#<!^D./W.4_'FS!05%NG/&Y/+NXSYH!XLIYE/>,JYZBH!#%
M\+K"9!M_ONNO##.$LR ZD8.,T2XG1-:=P]]-8])>NJ3W&.M;UR9_5_V,O?[>
M*S!-N\YQ<HC3?7<@CMA[.K+_'\B %/@JUB5!H]XP=5^6_,>;B*3=_9+J8UWQ
MV AZ_"J.5(^]WR&'=SJYA'4FAH+AS>#RT X-@6IV41 5&A[MF#IMXX,NEAOJ
M<NNT66_G4^<,&[P= )<R3; &DFSB4R?ZK4P:9 %H%B+H;=N)6JS#']#9*;FV
MZ20/M@!$-*1ZIZV=(U?1PA@E?5:, !J3L4=KH;3H::PDF8Q(X:VS&GD*0,VJ
M["3@QR'OSD&&I]Y(.:4W [Q*$D*;FCF5D?8G3(1^7"57.-.SK%4P) LG-0D0
M;GM4Y N5"C<T&J/BB/(KDD&I^&Q;(&8G 1*<KLK:QH+!Y#[\4G<%$4J(<?^A
M;F@"CGZJ:W0[OK9DFWK!I>3UI+P<?354CT\?'OTP@EU)=@ZY8&Y294F&%3%_
M&Y6C4K#=+V>OOS_[+SMKWKS^[VD,NB*Q?)X"Y7 W?$>*MWXK:"HDV1ZB"DE+
MG#T7MW?E.?VK]%<Y4Y(ONA#!&-GAIE+CSTX]"$G@\@L1N5)"09M*MYF36- '
MG35UENOMDZ>&5>EWD@Z&?<Q@'83=_: B<)KIID1LK+!*JO!<H@&QADE>D5:%
M?$PK66QK\X(2:<,</:]C_BO3NH_V[[I17Y;A?KF8]Y&<OZSE_AP-/\FWR@L'
M N_+2#'C($)_>6G92)&O:(0LYT9WZO,?NR]&:R62ZR52J<L=T\VR$Q0T^4XA
MA<?G,8_<ZQW:><%IDF]%[5(SKF.3MO_97@1S6<P:)A=Y!%#RUTA#6XXAPUJK
MX#AO>_2D14<Z=8!9W0OV.RR<>P\B>\-/\EC_Q1'87(S$]Z2L9$QM[ME>P_#*
M)OGII_/)_7O\EW!1*D3-,VELR;JI99C"<@W_>O20W7L!/OLZKG9&+&MTV<W*
MW%E_E#HT@)4!BW/:[1HWY/ X6,3.*:MRM5E-_I^3XX</R6)*:L R0T(?VIOQ
MO7?P:##YA(XG@<,F7W_]]</[V8/[IP_8M^/AC]R9FOX7]928Z3IY&L:*VBMS
M2IR%\8D3E@LM:V?7FW+W33AX)F>;"UK$)Z>Z2%!8N>#JR1![HF,2Q]LM<'YD
M++%UE]X1YU5%/2.K(D>/RKA6Z4 J8[ ->O.J53BD[7QW"IW)A ]!4JS9K(>3
M'Q,"X0G?AG_>>_'+^?\^OD=U2$GWH>=Q!AS>R$B%;\9QN*/6[Z$%OOF#H 4.
M[LP:LV[HB$/(1OE'0*/Z9FO!&5?9P&0R]EI7V2385]H5>-T0L5_%?:I.4=M9
M"@@;&Y-V<84R@1BMO!;P:M^\A-!EL+NN368KG%,7T/K &\1011N2!]<#!PTG
M"+<.?-=+ZEM8N??0MA.IG]_D&$P1%,[I(F=1E;E+(7GCR\:^:[WH#D^ TJMK
M=^O]1G=0,!][6YSP6[VA:QWGLVB^$?Z:'%A7. 52?I'&BEK$U63*^.3Y'67_
M;LJ>O*?ZDRP:=&3,K$4I.F!CAY\,WGXG3QCW%D/FHWC+O7>YZ?(C\."91@[:
MJ\]/FFH7AH6P$4ZS&T('S3-(Q2>"CS-"5#"?(>)=2TC@VIZ_=W>X<1P\Q33(
M05MV']M!E&,6;'27#1A9LR6Z3&&NI)Q)VXI%FG&Z%X#8./E7,D=<@T,8-[52
M9=J*[Q@9I2G?]>(#PRTYI6D4'1/"A%*AW=& >O56+P>M>NXNSI,"/>]9"IS*
M9K+M#0;R<\2L*H#SD2F[IJIF^%Y81NTEXLSPM=IQ(98)M'GG@AE;#!0>3"AS
M%$P:K(I(#$F16W(^RA6KI*76#L+(L>L17MN(#:%I0(6)VY@24BN2\.J#TH.C
M2=,:A]&]Q#[JJ\$*\YDO6U"ZW+ P.-5&HR^H&@+ZTP(I^OTE4WG)E.?=<2IX
M(@??[,BN:F]?8]SZM$+N8GP0T:?V[^8O#L'RTK9B7BXWZF*0@J;QGXOV(YD!
M*X12]?50CB.N@QW(PWAQ2%[C1JW:$X;T=JN@#L"N!P^!W<2^H4)_FVP4IM@?
M]+^("V-_=2L\6-@K(A$D.PW]A-XYX:%,PIS'+9+"/P^5LX71Q$+#Y2,^@'Z3
M ]7(W &/(KUITO\S5M_H&6OR11#!U\.<K_IFO<$XHVB4J!,S/6>)!T+],WN[
M-54VZDV[W'I6[MFFHTB8/I1;W)QFR0=C8>%UC[A&-^54-?BVGG]X*BK;HWO5
MU:#:#RG:'<)F/@P;Z;=&7A>M($&5$9/P0/.LI49CBMMHJY:&00YS4\ WXC5\
M9S-O&%_.7)':^9R4IIGC/BM91S<.<%N"M@E1E>*.P6N6(#(KH4&O%=2JP"%G
M7Z*9IAD3:=J^?18KD3 YW6XEU&,EVMW+ Y8G/"S12M6BK64H1I.?&)@WX#,L
M!4GD- 7UM2G5#=Y4OKT;,L2#%]Y!7UG,;OI&\8(1NW=5%M>$UA:T/V(9*9#N
M0 L[D7#@^J9"0ZOZ#CQ)KHH+(*$1S<=Z8IS1B+BTKPE[D,0U:6"7M&D2?M(<
MTNRB*?13+E/J(@LE)3(J_ CLEHKN@=G:<;NFB@2,:OGB7-?S6&JEILP]@4BR
M;V.;0E@ 5'<=L\J'1;>^,^$B)0HM.EN;0CVG-@7?DS$E^-;4Q(7]DE69YBC.
M3-2K)G5[7WTZRN^NR9!R3SL]$S5L;SU @SY+0+-( ?W X=Q[J8Z]<U4<\FR]
MYTK]U;*K+A[W?9B.^=:$FF,O1>2\#>]:-'V=] CL[!#+C5&O'M9ZEGSU.FN[
MJ5/]P%J&I^Y!(/M!&W*2E8E[C6L KS$^WN@<4%T[+TX7)XJ1L\U%(:4U LEN
M63LE?B'5SC@6Y,W2@757X34Z"VZ(1'$%;3TE/E25+;< 1M<%X44VI,?G5'3[
M))=>F"1J(=YRR;#WP ;!S*5J$AS >OH ,5X7;VNW1,_@,.5.7K94L60W@R&=
MGO>BBTI7]^\]?W/OP:3=MEVQ<C+&PF\D":'S5R]:HIRL-N0,A(5!>4P>6:6I
M%S(BP>AF%2\1IR8CGE>]7&8S,G\I2"QY9.[!\PI&4:%1GNCY&WJC)MMC0@\P
M%/RUX*9#[+/1^:B*CO0H)"7 LY*"S61VH+EV1)")K;&<29F-!E::U:#U@[!_
M57:B(MFAK8T0_$U=44^J%V4-=@PZ;O-P_''CH;BT4F??\=CI7$BIT $$%YM*
M.:[BNXRP.XHV5=S6_,S%BM!4%"5L*@6,<&#!1HF0A+*"[51J*8=?2@Z_WA "
MM54(Z:(D7IS%LJ[)^U_71')">?LP5C0PR7V,693^2&2<!+\*1B:;OZ4,?EC,
M=&E5Z&1]Q+M"OB_D/_V#%/(_S_"A!!Y6^U^7]8R.P<0L=I?46<;6@AJPN0.?
MW.H&,&)84J+)Y7H_@T9S41W#4;E:<U,02HN;RB7]%+2W]_S0;4?>2+V^I&!V
M;NK/[&V@WS9K0<Y+@H,5RCZ$"I]SA-U2'0EE?KR,\"V%<^W(J7!O!%E(,MZ6
MU(\/DDBK+.M-?L0MC>2*;=BRJ$Y;&O=JC9R!/I74<L)IU!:1/4348O2/!5LZ
M R]PH:_K4PG#TN9&B12/V/ ;TJ0+SF"S!:YH#87+)3E7>9DALQJ^&W8$I6P(
MQPL_SK4_1V\RV%E'+"I0)<Z2^!F[+!;=OH=%.C>8X4VGFEUYMLIT!84ULVDA
MQ#8IVC7]/?S%;."*MFI31)PYUNB1_3U&2S0;X7JEE"!Y2/J'1[C,LLAR$X *
M/[R%A2U*044P53!3463L"/KCT(Y!*A6'Q^U$B"OA]*;!D,,V*I+:.I5&G_!4
MH+]2'@+JA9TFL\DH67\FFPYJ[8J0./6]IN[59DF9"CF>>)46)&'=L#HR6\)2
M,S%ZL#@O2>DN!*X8K$1>"SFP0 8HS*4?PU)1T&8K?WL@:7; :^"OZPF)0K0X
M6U.O/^*<3GD*42!*\Q%Q#45H[]!)/83&^)L\->X6X1"N03Z)>3G6-:^176J;
MNC&4"7L%Z=QP;;,UPRRI[VUILG694]N %FB"%5)*#&=C(\4NN*7%=/:Q/*P(
M 3T E9Y.'Y;?3&[/<I,"**FE(9@:5YW%5UQXM0%EL?CC!FHP6ES:60P^684@
M@-A[G1V *?;%\Z%1QF.JN@YS^KX+]R@[VSO"E"HQKB)BZ&MC7 S?DN(\G2I3
MCGWM#YZ'M-TL&+[$H";K.#57=:HT&U$CN6\XR9'4T-\!16!(M<E:-C%]5P3E
M91S%KGQYX:D3;0(P+LV@%1VKM:8=6-6DJ(+%J[4MBM$)Z5'.V05E!_G\P[+7
M:CQ+7X>+NYX#!Y0B3G? )7^8)UR4=:_!Z<@ZRW-H:?-16:QF(=@NN)O\Z)]%
M4]L0L;.EWE/R(/(GKJ?&QAVC/U';'0LO#&V.-L,TZE,H4VQJDW.*W)JDTZUN
M+K)*5(;#LZ4#-$\:D%DSG*3LI&]/QHRX6O+<U#D442-<+%K9N:!8CFTD1\-)
MJ$E^U9QENECOU0 +[%V]#LN2(#>\.P5BWD)E3WB3-/.AEU)6[TN6T>7#M7@W
M+]=EH<D/RDPOEQF/#I(?*[BRO<%U,"93 !@F5PFM>J3Z$(ZP*,FRK G>=13.
M<JE\76Y;[#O>68QN2+:4RII%7! 1>2W9M>ROCQ[< ^BU+5VH?%]IK$F9_\>]
M\N2;;QX]/GWR]9]/GIP\?OSHZZ=?/SU9Y//BZWSQY/'BFZ?_Y]$W]SXS >C^
M3J\WSWZ>/!:* 2$F^>6'%Z]^/GOS_,4OD_#_;WY\-CE_\?/+LU_^]T'PF7Y(
M!?V6<_7XX=A<K>F,KRZ.EB'^^,NC)]KY7D+OZB]')T]_!UN]@Y7[=R(\&+O[
MM\FP/#T^Q3#\6+;<$ASVUO=IJ=YA@KZ$/.>+*MQI&]S4=O)=2:SPE\0[<8S^
M*)'HC<TSAT6?\9T:N_.(P8!DPN>DQYC</UO.B)/N 3E-9^NF7$Y.IY.3/__Y
M*1T[WWSSYV\>/9W(9R8_=;G8I!?ZX:?\880$;/@Y;*LR;H'8,6$'[FZ]@);[
M'J&5UB1&@B_^].'CZ>31Z>GDY.23S.63XZ]O\=0C.5\:Q:-'^#8@=.' EO.
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M*I<TZ:A6<766(+L-:N^4%UYGW64=)C;,;UYOPB@=P5\AA^_5+V>3^WD;_O.
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M5!V],(2LI-#/&44B6561]='Q?+1BV'.C?YQ(4.]4JR.&=I*S6^4.*]4OSR5
MDG,33U]<L8O#5')DKW/5B8PU%94ZD/-9L7HB"Q2U7L>8#2,>#<TUREWBJC;2
M84(CH*G8C4S_S7*HC*P+[7:1N9EP=S"&J-VQ2L73!ZLT.G:IH9V5=3^FJM2I
M+MNG)4D]CRN_I(G& 5QJ_L#@:AAV)$N4N[U+GCKE0.U90>N/E4FH5+2@S Y8
M=GAWZOM49TNN&U5=ADW<\L5EF5^ C(.L5J?Z!B512^+IGJ)GW',+CK-"*D?!
MG<8=/*1AF#- M$596/5,K=K.W0(%$KAP&Z1GQLP5DIXEDZ51XX\@8;;(R9#R
MO<)XJU@H@,VYQE2C!IDL =QTBA#\S(R3";L<,_O68&0T!;,F? 2WPDW@M"20
M!KI)LXVP<;K7P###\5AV:C&V!9M^PJ6>[\EL*H0HS'(&R)J#G56)XIFWQ\[O
M;]X3Q'4DRM@CWTX@D@P-P+0F89YS:5*:=F,6*"*VE?%ZT#5 !V3Q%XO<GN1[
MN&M+LF![YJQ(Y=X%-D^M\G@K=7-./.0Y2Y@(O\!8F:><S>@'(YX4>U03*X_*
MIC8&FE4Q@3!(RG+Z)#]W5JI*5.[Z@C"P,E'/8@@L9E0WB\2+'9WH$R*;1,KG
ML1B1+'7A;&3()2(@-C^/+Q;;;(3K<XT1)8(6BMH("6HM$]%MOVPEN1/!GUZR
MAV6#JE7ORTM/Z4X:;N(*L5!15":O'<[O\IV;,JYR!21,]R&K]IIAWU<T8YB)
MLOY!N9$^VW-C51!FZPZUJ62%V&HZC+D$>N+\#P:7N65FU7;VA?3TNQRL VX6
M2'67D>K2+ Y&_CFJ:]?^+0ENA-52EW!6/-NK[-2HS3TQFB?T5_&]>E*O%6$@
M+;BM;*H!*V2SL0AA_8TM/<U&=+F8=#%2;"'=!"2;>^92G<C8$R5C2.PB(TNI
M.OW8ABXP%Q5 5FVJV%8FK% ->SH$"8XN!860?!X"?\?(%AT[]9IJ-YI@R/L^
M[H1ZG-EM 1!RY#G8RUC#0,HVFJSD8Q1.)WU$X0^:$5S(_=; AKVX9>21Q]AF
MW"J'#93/)0 <*A^+':B44<HQ/G0[D  &OD$D/1;T-YF,0O:$G&M, -U6AR;*
M?[656DAXE-6#YVZM,YT(6">WG)/P<D9_N"A#66NW^G:OV9>XQ[>U\"/XQNJ=
MP?.@NJ]\!IN/Z<N@)X8S#@4HYW0((U@U!^9L>J,R7P&#PX"V@"Y71K1!4J%Q
M=):*T9Q0IJISV#QKB;;8N^_YNGX1I*YDS8J%.A'5K_5ZQ!.-BK(@E7 ?F><:
MV^+I##F5&"(%-+NU$E6#]E.[T05SD'DXV2O.=\XW E,*].\X@S8]_JU7O?O5
M6>O]6GJ]+BD%3%^O66+%H>^-+#6GQ;;.Q3S;<.:XH R^:ZGH5H_OZ'/!OK]>
M2;1,T_DY5A]\=-!!^S=G.GMO<9OPF)2EYX;:?[V2QYHDR2Q^]_9M+$!SDPH<
M6$EOD3&BVSI^.TFF_EMFBWM@D6&&5=S #ZT=QN,$UJ@A]_L$W]S;K?2)K)57
M69^ O$40>>BJL:US;PH"X0SEHX5VC]]0,'1?0!;$KC,CU9N$%W8Q,(1:7I3M
MG'PXW'VG\T R\P(=?MC)=/CIY.*_\-#>-\9JGS<DRMV'W#A:DK^S/AQ^PUA%
MPVIW[);5:K4;"*Y])-P&$D'+MD:A!\MNM%J#_;=QJ]/L#?;@\[UFJWO0WOOQ
MWCIW)R))O,"SK8\$-AN[86&5JJ#61E$[41$@V=MY>-)KDB!%:T0V @?3P4F(
M,YC;DF_F*1=F?3W[M;!+M)P^KJ9A=9&LBTMI=@9OXVZKU^[ 4II[3?C/8*]M
MG8A)XL!IP;0F<Z>PAK-(2(0^F!)E[^^_QYE9<!*1@_.C#_OOI==WB<J2GRE7
MNWL83:68V.=?#IL<ZHKU^GX-TRA@=XLN3#X-)%H,+;7;MJW6/BSRP#IQYA)Z
M'=;:"*.KM[C>=K/Y]M?#TP9^T^BV&ZW]_V+!E]\0K4ZK]]ZZ<#!-UPM"VSIS
M8.#"TND OL !2")B1OX.GLT.DXUY-3]-UF6KT/'<4*WB'3JRN8KYC^RYG-TL
MQ<@MN] 9V*V^M0-K;,(5:1WT6GNM@WT@9W7J:A=:!PW8A\'@O75T?'[Q^>M_
M]CY\.QZ>7S2["Y_LOY<]+"A?DHX[$%=L^(*A)/M;4&@6/;4N[@Y+-NGB&*K>
MW: =MIN=9FZ\,UB:H,9*H#%>49XZ?HX\[+WU38PNP_#[>^OSX?&W.K_)S&_J
MU_E-3[NMU,CB8L+YRS*]$*N() I5S)7**F9@),C<Z29:H@UFP6RPDKSD3MV0
M#4J<X5<5MY*_^!R :9<@^+5AXTVR?CU-R6KWZ$9@9QA9,,M+I9:./P'[;QPH
MPVT#W*EW)O1?>F&&C*X#?H@R#88XC!7K@'^4Z$P; [%=0J13YKJ9T:_JML#X
M'Z.J"&81=FMCX355/:4RD'J5KT#%[;)MF_3F4I;8*,SPJ!D=#BX1!M'\>0ZU
M7DN":>89!L55Y)*QC,%9\YFB^SP&@4&!C,R]GP_2VKA;Q8]DW-;81%>#V3I(
M%KZ/?Z:!1VGWB5&(=JW*]F?81][-="E/DJ).D9GKC"XY\S"2$5)C63X6$PFJ
M>X.]AWWV<'Z%A!.='BS;?*' ,6NP80Z\#>Q*OL&=;X 4CJ[$XNJ-I9)K12=:
MT=0RH, L*X4B-TKJ%D$*L 2+"@F6(-ZR.WRQDH3J$#A\;.R][HY2OD5ZLT&Y
MX B.5UCT^10[6T24&F+65F18Q<Y<QC[1V24=0F5T%F+0*-L>+'@AB%GVNF<=
MKS!&$T68*&/@J_NT]Q2*,EH%9K,(HT7B6D))&\Z/3@L$/N;0ETH/I0Y=>=C<
MJRA,9RQF%$S%NY56V=N0DNAE<$(O41)]JZ5<5@!M-MN29@=[5KT\U\RW$XM3
MH-\(_H*_SOEC9418U5SIL=XO/<'ZR.YY9-H1[TVG::#;R:&-QICPLN9LR9<F
MM^:"K_?+KU=]./<\'$[GTD=$JLL<73777I3&,HYAGHTZ+Y8>)8=3G\U3G8UR
M #DN-WXP=$*0M,@"J=6(_CX[%N9G%,E/IU3]&N[AE0*S'&X//E>?TI.=$FC7
M\IX8DDAE7A\.O^U=V-:%A8\1"N4,] I^GF7/UW_R=_K'E="1M"%D=F!6H7FJ
M!L3U<6UDK#"A9(M5LI07;0FS(UB&<(!)2+I F'-9(^['$<E\$\X?\C"ABGM1
MBYL"("A-!'_FXXS1$F";@!IJRW1P,U;+R5PRT54Q/5++C6 SY7=P?IBG,KRN
M1&+TDHC#,* AG,!LK]&PBDHF*?#\@5"MJ2QJV.M&J9>H%$:L/F;#1"&(+>3"
MPMDZ5S)1C'A$(/Q"-4RA( =S0Z4UN%B\0G@_>?YNFQ9EKC](SI#6G=/8'N46
M+B*6V<J4G,=877)C&"&,@"0Q>106@>EVA7Y2&W\SSHSJ(<Q!Q42YB0@P@CNR
M^7KDCMG,XY: >(K"LT:-3$VR@"#(6:RR?Q=0#W-\I1)?I@GCV/\/$ZS&U+X>
ML?6P L*+IXQ6Y;)CXR(C/7V3C%H5F0^-E\@@?FZT)R2"Y22\4=T!#<047<L@
MJZ1EE8/9.C=K/:G[V:"C)==$<K9D3[%+FDP'4SLDM]CWOA.$!V5YCFZYW.*'
MQ]T#E"6A#+B8QC";#5_ZH?O=&8D\CY=61=[86+ QC"(FHV+(X/>'8!DCT H>
MMVUVT5RV=F/!E+E!]KGT0O'M@EE(_N4$^GPY>3Q_N'H/#)#%635L=7+) =,/
M;Q"TPY;Y?Q*24JU6>G6PX37E@B_XW8JU%.S1T/>0G<1"?%>U#%)*%8W/K+:]
MH$-+9LCG3\ 35#V*28;LU@3=&@3:/$[$=)'Z"6PC2^[--0_*6(GORU+7\BH-
M!=JAQUG>PJ?V3SQ.&S19J"H,7<"8-,M,:WOIR?:>$5IMJ<!D,6N/&[DNW!T$
M9,SAP!4A:Z237]?],MYU?6)/=F+40G=97[GZCCP'?])M#0V?/U5"D040)4#@
MW")79;76G.L%? @Y<]=D5*9/>P1:9L E\K+L9TE;2D-1)TPZH^F[<O09=BUH
M(Y-YC DK ;G08ZJ#5Z527C3:0[J8 W7,P5BM3_W)3ATK&*GV30L8@A#$ !]I
MINHH#/VQ/H-G.0-;U^GK\E)J(^U1-I.0K21DZVJ5;Y I_&ED-+=G!VM]0D]U
M0@;P!:MQ@KTH"@'US]11I>YYUJ?;Z*"MO %Y,/<L*U1P%!GHWCFR?G$U7_]2
M[DSIX4W/E AI+6L<.,'R3.(Z<Q]Y!;>1)1LHW ]&M#-0-E49"GD\U?;H)(JY
M3.3ZP!V5,3D!:TLSL:JT?P,)J:#E.(49DU>&FUY0<21FS'$R@%GP&O,!(<JL
MJ4GI)E5WI5DL ->R/V)NCL ?2.QA#=C+E<Q@MEQ2G@5GNQ#>@]%A@]+@T&FG
M$MW&6=L$6B Y$C(-<7&"JC9;+8^38;2#\4J@'W<VX11:]+A0 VK5)-Q ^8T1
M5E>-EA#UR2HE\R!4"P8)7)]&IG];8BUC[KB#$R3?OP8?,-)],@P:GK6)+HXI
M32I;2[L@UW^_[LDJSF&G*1R8;#IO..4*>87[B )5T@,=GR[>4T7B&%P!BG=E
MF_HX6VB-DIC+(A[46<0O<M6^.3<@D240RH9?MJ(O66558H,Q6(8&8B!1$:AX
M7Q[1GL)SF4ZE<8PB8?23=ZX=S\>JV$T(&=SS0 _#:!92U2MF<\-N?",<?1VS
MIO+6\T\;L+#;L1MB1/4!BWY$^:64FFAKAZ9,&Y4YPDJ+()FO0+&Q2IJQ"A6L
M&C:[T^$DAY%)9*(#;L@LA V>*W.)0!VM7U0HAF/[:F>O0D*7B@0!!'J1@3-I
M@D@RIY?Z8F0"*L8F.(1MAMZ-)%;,B%<+Y=(>]FE1[(<Z?=+/66WDR<BZ;SF9
M;,+7CI\*'26%:Z#SPJ\B@G#/.<]LP_IC^U%,+R/'Y8YDG!4[)SP8+F8JVYQQ
MZ*;2G(0Y$OZ_.KR%_&G*.\[R+X3IPE.MK_ =Z ]G3"K53"+(>UBI12K/_%HL
M!$&9:5 &]2C6V0$^/!HWK&-$MD%X#M(;P^@[MF1E4&EW0BP'9R /'MT7A.^#
MOT5,&%]H@YO;14JT#-#-[;R6S*L%<J!3P/>(X-J+0D+,:5@, 4#)TD3%U)H"
MZ8)+,I1UKNDU0Q14*'YT"3CY'4L&O-CUD:*$+_5>F?2.(YB@]Z>T.H3NH1"/
M'ISBQI2S$.)^,(@B!HO=<$04+4 +=]4D@@Q%FVX#Y^"//80K5+A6OEK$C;@D
M("\X%%4BJT.-L;S:#5C86\;-"J,]G!_V,GNKJ6TOF_-;7H0:5>(5>H%^=F0A
MWH9'4)Z$&DYM<>\AU)%)>J._O_%:_7ZGV][O';3V6]UNIS?H#5KCD2MZH_%^
M=]P?_+>[_V9#725+A$;C9;PD=S>&&C3:M VG1N-1:H<=I>0R>>ZJYY5]2V9?
M[C5/YC3 BF"!07^>5Z=E2]9\@X#$(S+JM7IT,P&&--\+;PC$D]FM;/KAC3RP
MG=]S[2;=0^N#E+$['YSHTAF%\2XP?K=A[<CRT],/'V05Z2X"\:FGE$S.:M R
M;/^RT1%Z@T?&48Y 0[OA+KA\>5DJQ2;<5FX9V>21)\&<GNE>'U3K7A]MW+T^
MDTYGVSKS'>GU./XS]<A!LB'W::,N]^]FZIQ/%9\H/"<"KS4&6BAI_=#QK\CK
M-?0O4=VRL0+3&3EF<B/^3/XBQM)!<E&=PXJ./'$5XB]\#_2-P(-?:R0<=9]5
MP2#*5+ARU*V6)D/N//+EF6,7=#S54U?65@EUX.SHXU$93@]&4QWW9CX"H7%7
MIYCX/_>99^\I/IF-NMQ[8ICT?Z0Q(J[?;M.OR EZ[6<$H%GQ=G^^.#ZQND/)
M8OF_OWW]=GQ^^N5?QT?6^<7PXT?K\/3DY/CKQ?G]-VBKK]U7$)D/(*H-V;-5
MB;BW(43< ]W][/C;\.+SUT_6\.N1]?'SU^'7P\_#+]:WXW]]/OZ=/CS[=GI^
M=GQ80LM/<J,'U9+MPX:U9QW!QFD-[AL[HFWKBP<\<J2\/8?.#+U'^+6JQOZF
M:EGQ>Z-M.R*,)!)L;03#<)*[;5U$&"CZ;'1*O-\1K"E[G254+%AD$A3>219P
M.0+;.&5 &^IVKL! 0"H>_YAXEUYBM7J-EL8-CY_<F-QX&CMN6-8AMJ/  !C"
MJ:8!4=JQ!E/=<#?B5U LAKJ#QG.T=K[C;+<R>'.P/'BS.C_>;VE^7*F(SQK%
MZ'[#.OK\#23DZ;=SVSH__OKY])MU,OPZ_'2,.B )T>.3LR^G_SD^7B9$JZ7!
M['>K)K0WS2 _HJJ24(81SD6 W4PS*5D%.7^1PZ](",XVEMDZ,E4B<*:J*M!W
M5,Q08$VE HI'OW2J^E&H[8AY.\PL#<KT^"@N(T1C9.)5D(RY4D)N*19[62B#
M[>,8% >?@_\I@_7&Z@%N##T#@]GU9HBRYKKIS+E'[1+EE_T?N0%*C!#Z*L4@
M9K%XI_[R'AL%^,[\G1?0AM*/2K!8"PB.=(_XZXRE-IK,5I,(_C]2;Y9?-^"K
MMR6?=QNM9K?TJV:C=<_/.X/[C;1T4IW&_O[^ADVJUVUT>[T-FU2KU=AO=VX=
MZBV1 Y,$4!U2[]_?=-X4"',I++!D5N_:LQ]62W%P4U O@(O22"_/UXGVOSJR
MU?09LA=D*-\4=RD(N&2T;$?4BINX7KFSKW[CSE1T7F>U'7+@H-ZP)1NFQ<-I
M)A[JS2K?+*7<J*Q825O6.>RAR&W:7=S*<;]?$2S]GIR[ZPHQ'K^7^T6&XWTV
M"W6P!>$:SMZL1XUBRG*PUZ#G6,-@%(F;Q6RP]4P+A_E/&'VWK=_.A^M"Y6\^
M&.EZI[.[TRV ==]R39<2VJKW]^4(=1W$H"[T"@ROWLE;=_($; IYT:DW#;''
MXU/DE.?IU .>'5IGE+VOD9QM'9\OY.%%ICO93'A?AFX)0W'6&KI:J>_=M;!.
MR3Z*RF9P&,)KOR0C>OD5XSI/A.,G$W<A2X!*S=K-5I]1G=N=!;-, D/_PB'4
M#*@:4\B6OEF-VVZJ<;'#*EJ'\,\_0D[\HHJ$T$A=X18L+9A##"_&?<[6^R^,
MEIY)*U3VVYIX8HQ22A4#J3T!FQ/V?HX]M+%U$UJJF*Q&32T1)!='-Z$L*><P
M&R8W)7R1[Z0!]@@D>-^Q%\5)5AE"<)#XT1Z8@J[OQ-2J4/Y;H@[;"V4&UJ_.
M=V?L@;;;[[YO6.=RN00W$:D45)_GKY/]BFBEJHH=VQS[B3?S\]B?ZE6,OL,E
M-PK"E+>G89ET39:V@97APXES$8MIFB?6V1@N3L0GW#HX:.VUF\V!+?'?)?2K
M;T6A+V2E3\G1?9(]E-EUHC4."J1K"ON@%HY@S/FY(I26=\UQ!>ND\:$Q;&0=
M!'Y38*24WG+BN1/ORN&3Q,>SAS]$&)S/'B_L!S;DHUY"5J89<9D*I_?!X)_\
MN1N> *>A_)R=K\/SH^'_?6=]^O*?PUTX#'27X.5JU!SXL1Q8=?3HV;F&7@]3
M1\?TOXIIG$<"TV(G0.Y,N+9U\F$(4N;PJ'%404VOM;O3?O:V+"MN[2D"DGFA
MR@-ZA/Y9H*Q[W]G'4&;E5,QU;M:2<"97':]-QV2)A)*'I+'TJ!N2&,4J!=VY
MV_@R,'19ES'F%C1Y_2_&M'"7M)9IC"B*<4+RE"$B$NL8I2'< T,MP9)2I8CA
M$R='UKF(PB!4>EY3ZGFM+B)R^;HS;:8X@+!<JLS!=U]%&H6,-*NU2ZF6H0;\
MLVPWE]4[R(X[.:V"M E\==&3D8U"%QR["V4CR=J,5MNVLB/ 3<)V ?"+B>/I
M@73+AK/\SIL)V-9.$-[ F+JTX@3;-!!&*[.771DMB1ASE[3*#TJCR"),:FO[
M:FOY0++\QAA_*#42_7O\QR\?SL\.APUC.7@F=(X@,C)%Z?.UF&//HS"D)C5*
MW\*MM7[!0_O0.'=YHY$D,WV3?JR[56 ?&UW0DLW_B "9Y):0E-JU9#.+O(9V
M$0(I)6&C9KNKNWG":\I@M]HV*9A/XIVKS.H/)Q'VF9H!)1V)J]"+*;Z:R\C-
MG%_K4+DKLY-Y1FQG)I>1YE9OY"KNX*)S(RO; +$2-22ADCA=9=.14QXYI):B
M%P=G!9,=ZB).HQ$UR!GA*\S\^1XU5''#X(_T2C?PEFWFS(G$,#0EYL'?42W(
MVFX7E K=D0<%O^]97SPJ^J5^YPV;]1#XY1G,-%9-5#X'*&,=K(L#$?0+:Q'9
M,I5TAA&QXQ[EO)_Y87HU8=EY(B+W^ZX>5;EMI#92](_@G-E#PY'$*4Q[Q%]%
M$Y%.G23TL.0SF6!N7MS()6.8M/)\U+'TE2]%GK]@52R5%69-VI,;H+,Y>\:H
M-C'7(Z?<Z\3E!",\.73A!$B+MG5V],6V_@VSM.'32)7!#B6XZ06!C1$Y,3&0
M+N%3UW?MN&+7%%7>TNB$7/931S6RRB#5W7!O9*;@AFFRISU<MM%4)P=PAT6Z
MYF,X/^D9S2&G.%=P$ZCT<RO)Q. /.8U1XM-D8$0GSA^A= $>N^CI.T]G?_M+
MN]-Y#Q2$6$TCH1RS8N_\G\<G0]OZZF&E"_?57*M#K#)"Y>O;X?K\7.M8\! N
M>PS7\!=T"L-HP%H:Q\$5B)FSDS/T=UU8=$<*=5N5<SYL@JJG$,8>J^EMVSX.
M<><RQPJ0)SR"88\,PR'7C8^]"HJB23^$IXRJ7@YZ-8T &8=-G!F!S[,78M%C
M4G)^A5>I0*72MVQTD!AEAE1-*J=/98<R%MC9HX @^U="1&[0<1KU2!,?Z33R
M[Z.*X_+-V5'W>'AV_&FX6S(VZ1>Y'^_0G3\[^;S+C@\ID>#Y..&0T0<O5"TP
M+[)N$SO )G9! *$H7Q84TA6@5+79.'<;\@>9;^UP0IJDG]LB>CQ#\3]W25^*
M'R;.MNWFE(JSMY1+6]>"4&YVM_EZ@;SJ=.LZW;I.MZ[3K2NT<76Z=9UN7>5T
MZ\IHAA<3&".V#M$]"%^2Y7]R!,K_Y*@.[3PX2(;9D2?2/I*ID97;N?7E]]\6
MT#F*,DHM)%!DB0.R.K0D^U'ETAZJCD/%P(\(PNL0#4V.Q1BN 0S7(&)V]EAA
M-MG['_#B3S"B*QQ\<RQ-6_Z=XX?_FT_SOOQ"6(8;$6+V@7S)103;[ZN$"94$
M(?$.*<?DIJSGDA>,-$RX<OK?ANC9R*T?T=5:_?>Q&<T8IY%L^,=@ENAA\:YD
MG(LSJS%B-/6<;$6S2%PC/#F<*&7B<-Y-=JJ93T7F1^LM78860OOK.S_"\REH
M$_]$BN,P21PC]&PBE/># V.XD^>(DFE]"5,O-OT76<:&VM3\'LADC3TG328A
M1FLHF++?M&8"I"<N3-S IXPW::"'PELXL14Q2+G!*,7R$L2,S$Z0GOT<4*<S
M!' _XB1GCNUD.2)(J6.!=<:4N$0C+?Q&K53GU>BL$@I)_4)92YR 0H@B.!4:
MCCNBLA8[+T\K.7&BN0_/%38'#B>0TSLY*O_E(6+8(\B7)@>9F"V3CAT43+BB
M*5"%F_I.1'#(%.!:?^U*92346L,;:Q,LP^!*^([U2PB4[4QE$N_'P[,ZE7?K
M4GDE&MKFW,C*9O.N*U]7WF+6$<Q>LE@$$U UD9$"BV+8L5H'>P2=+;-N,M^"
M2DW-P[-^=2Z]V UE-5GDQ;(5[:4 62MNT3+9 /BH)R)- )GNVFQSE96,1\D<
M3(2;I?LCH=Y_"6.&0Z-J+\_]CJ/ZHPBK8A83F?A=XK:WVR;&/+Z?=@Y'IZWE
M;)0&Z)D1I0-1UQO>)WK8X>XS'CH9$M9/IG-0'?%O,*;#&./8N$8'M!+LR"RU
MB[&<X#@-7 -J) -1)[V4)H*(]*7]OQ!9?!SZ7EAL1S,5V!!: LQCHHP\=]IP
M2KMA(T%FW*CUT 8 X8@(%2,#59Q53M@FU2F'<GRS !7E:BGH<EPE:B;P[B $
M@@^C/<S_]A(P"#*$%DXJGR V.FA24TP3@Q^Z24:D,J0GR9HRNJ1P^GB(21SE
MB<2E^;S6'MRR!%4N0V'-;]G39!77T;>5"J@P%ZLUH'SA1Y9/54W1'$[GUJ>&
M]04LG\"VOGVUK0_G7VO'TA,EDFC+]U3ST<KMX]K45>2V1)<J/Y.4A.0&6\VC
M4X+,8.TE65HZ;HBP7!HGMH+PKACP5#9Q(>DH<KW/.&48QO2H745)J78Q7:7=
MY%P3GKI*-"GX1G*>IE.C4TEBG:531\'9JS296VJSU2#&,A,!\@FWH2PE6*>5
MRAQ//8#L51-32954I/ -NC%*B%WQ""'6N[1VOHK(GP<_JF>2<6'Y.E-)9=(.
M.4Y6JBP'.D)MC^K&G=APL&D2.N/# Z+#GR,9'8*2")ITCI"LG5]AVK' Y,%\
M)ONA+H^#4_[U;\YT]O[779OZRE"SJT!BRN'T"G?" B4<%9$(>T/ B E^MO/_
M_G/Q^5,%458V@CJ.G<CWN.H@T_)-KB(K(*\)*"!K,UG.#+DEJ/32)EQ!8/W+
M<;GNCORLTRL1E" #;A9$8T$H2&<E=@IQ83^8I\JL,Y7B!H]]32.Z6#N@U^PN
M5<O%#\9C'*+;(:@]E17Q5*YCP?_THN_6ES#\#NP7C;]#^/_)^:]U\O6C@K$+
MWI!Z[U8L2D%2+$F=5DA,67DW.C1"WV>Y,IQ%GH^^K@Y''9TX3J=2IR0]@V,]
M92=#7%47V39;[5N58CM?!V^^5\\>]50#[F:8CKQ$!0!3*HK!FOIK KTEG^!Q
M%,2)16J*]1\XP"OKRY<S;E^#]ZYA?90(/ .EQ0K"S<6/#HP7DQQ=*,;G]ZL)
M&6C&$KC>X8CE\DE@[[U&]A9*_CZ<8%$AAAQSF=S9D+*8?"&36XDT&/C7-/+B
M690RV/ .<!U#HIV+A,I#?+\\(/K%N>&3S@E,58ET1S9X[4>JL[B?)(N[56=Q
MUUG<=19WG<5=9W%OP,;56=QU%O?697&OS7?U*_4.N6@@=$=,R LGH/YK-T+U
MG*68W=1Y?=E-V^;"VP0L[,IL%EKU\OZB84]\;8F?9.?PX^DNF? B0L0["L:8
MB"^8\7-Q_N\]WXLQR4.[[Q48]I7@@-NUL*8JPUCC7C.$[BD<'/MAVEW*,C:R
ML[-\=YKEQU-./4?8F'2:RU>7G;AA+N^LBV^?O^QF>+W\3_(.#-.K-$[0Y=."
M$3D+"7'VC(P>;$<D09#S7J)VBZ*/B#5\=04KPR#1+(W<"396G$6>;)Z$L<8?
MU!$0YH^PAC^U&VV%=+,DUU^MB/TZZFR6)?OK5"R;Z@0\A\M %K;#5AMV%H4G
MG\\9A5%G_N]@ TN,@%K#:1B-O1_6%V\L=-$[ 7WOLD<'A\$_;\L(&X[ F$6P
M'0D]CI&(61+"UICE!GQ(^LU?PBB-<_/>;5BEY&F@-#(8(F>A&1^SRPN=05Z2
M",%HB\NVII%1Q]')\/"!24;;QC@XR6B?,)K;6YC<_;LSAPTX\V",D%*[*ZCO
M]';7&1FV'O&_,Q$$\=R_=A;RN38Q^WL#R9=J?;RI%/:+S2866"IQV@K2^/YC
M>LQLF\>?Q"VQ-"[T,W&)[J(8"N@$0JINQDB8^INI+UF+A;=$7Y@U#"2FLC^*
M:<X9T+7$K/SM7#;O1JM(IQ9G6(>=9BG.(;UY&=ZEAKPFE3.O9\[RF?;<">9?
MSH_/00!J'26Y1]XU:WC<P5+B=DK-EG5-U=, XXNH\)D!Q_W<;DDMA]6B\K>?
MPW-C#_0B4+/3"%N."'5+?2>Z$J#47G,^S.+VW821/Z)ERAAK?C!\K'5PT+<Y
M@HJQSUPVU[7P58]03L/S?.JF(8$_0=V=AI3@'19+%&#JE$_8[-NY$"76W,4I
M:#]Q/$Y]M8G83]LGM3@2"= +I3XR?%:K)#Y;W!$<<X8_ =6>J8$\@K#K6%)@
MZKOPRU'XOUV-5NE8ES*<^'-LI-U<>A*L' _S/&E8OX:3 '3>&!.:#C$,?06T
MH%IRJ1X^MV3.'SGS!%7CTXD7UM'(E7B3,[<.**>]LXW.MA#8#?*W;][5Y;RJ
M"N?&>->HTAJ!BQ^K/&Z;V5<[U^ZI3M%]1:F>=7- K]'HVHM9AGU*04J2GI63
M\4M\;"A6,[@"G8__"?9IME0UVX%!=SF.> U++PYJ5+_[E()*&?<&RB6^(5>#
M0,H&_-Z3J.-.FH02 YI$'Z9E77FN-=*  =FT;7/>:K7PQM'\!-[&S>QN)IX[
M4?-1OCG'8C>-A?Y%!=&(V<"XB]@X#(L;3=_.8=;^;HFO3;^7G6U\5FZX-T:J
M@^'^7W@E N]'UN#O\.OYGMH8T##0/XJ%@J6]_% ?35B/5F#:,/IOAQ]0H7!0
MP0UBAXH3#31L.$68XZ+CT/JIU3C(/(<?Q#BD!G\\5=P-/==L)0:>!6RRH<CE
MU3><C]$4#[>U%!/<J*5,6--<WI9&X7E0>K9M?: V#KYU,L>ZR7/8CLM+U=<%
M-#<_CS?"V/!G$USM+%;(-KM47HEWG_9,'J69(\CFBL1'->\>U28XUE2HHETJ
M0*0>-"<:V"$W@Y(N+:H$13LAI>D"M^G,3V-K:/B-D?2(8+XZ\<CY4[G$E6U@
MNI@EM; &*M/E/N")D\KZ2QC@N^&$2L!(I3HZ :;HX5%G*B:(M7_:6@TUNN:=
MA5$23\,4ALX_77L]5ZHOY)A!I[FU?L\/()A&UK<&2"CO?S!MJN20 %[54TC;
MBTV(U]K0^5>XD&).2BGWN4H##_LN?"+<Y7GMRJH!+IYELR+C/F?M4!DCBJ7F
M6U>)/$1B4%67[*Z33>C(#5;P?RUZ[HY3Q%<HY+2WF\T#=MMHYUL9Q$5I4^1/
M9X>J+I"$* G[I>!H9F/C(ZS\.T+,#3@)ZG2#W4,0=P(U6-\N^6T&5$"!3D83
M<RUL9^ PB%JBE)T]4]DI**"&JJ+W)X<ESUN:TZYB!?# .'#&>:'LGRE(,2RV
MC&7?.4KSCQ-G/,Z_$2;YBQ-=X^DJV$#.K,=F 1B(Q]Q[4S_@GGLQZ*L3T'T3
M&$+U]56X(=G6+[:MT^2B:(,(BUJUN'XJ6PBBITTI=]H1+)]\5Q(_MK'X0C@%
MH#H)V_XYN(8IU(ZUE2.YC!;1NT>^OY$JWBD%.WKY-+TV-\Q+1/QN0:874A?W
M\ Q@0T@_H+E[ =[Q=WOM]GHZ@]+D=UKK"LFV48DR]Z;5; RZN!$G.:NID%K1
MX(SD I2,$3G$?^F'JWHJ[4T_%<Q%%4'L2.-S\7"X.>@M1[-8+EV1L^EL^ME\
MRH">%D[&=%*\NI/I;OK)J%I$+GHT$5R-W<_K6@]A;EM9&=<NV*I5KXS;\+NV
MME2N6^Z:3FJP%[IKDWO5-M-"L/'X7HA6'>+M+15N-BL@ML%56>E?X2YC?D*Y
M#;9*?LO.&_W$\>F;W4*^2_5X=*O]UUQZU,N_?@G='''/LH2\ 6X(9_MG2L7F
M2 ^XVVS_GC@)GNUXC/ZRL\F1;>;-K.P\,,('% (!$AI1I("M8E\XUYS*?1GC
M=V:JCIV1=#:*1"4OB1_8MZ14'9]:(UXUKHP7I?'-]:L_!]9'<1G)1*)VSS:>
M)HCLJZ#@.K&7+9WOS,BH:#(V8I122"T,KD*<TH2AN>$D7,3DOH76#9,0"6!-
MO/ 0,4L\"LV$::07"1L981Z8Q& ?<7R% J&9KTJ%'J?.W+K"_8J\F#8#5C_V
M/3>1D32$/H@3J<5A5,IUPVA$.IZN/93H*5DW9",>B=&BY&5N7KF5S#/?69_0
M>/./X8?#X:YMG,_-!),%8=/A_B$"ET<Y>KS5%#,-YM9,8#$ /4HX%(@1.Z>0
M:?8;C76*D6F"<^4.Q O?TU&E3!B1X!@M]A^^I&Z%>.J2E,0/5\QD>V'X>.3%
MU-68([QZBA1NNXSI%Q1LNPX3"3>&4X=G4'>3L4O&H9-#J!D9!"4]8<S5\C2L
MIDK#P$0G(9!7(EMUP[NOPG!DC1U<G&SGBWT %'3()>\FSSDN7'WI1Z5X]X9?
M\Z\R[3%_QXF9$8M3>^7390<3Z]*'?;&!#"*@ DS70_(8A3-](G!&S XROJA'
MV_3=^%W0<H,0R/ &_X8R"Q8$BT402$[;B"Q,:XB 0CEE@*AC2@V>XPG\",//
M B55G,YF"-G&^XE[ A_.TBA.$2P&]HJYI'$A(S$6D:+)2R3L&TK[15!EE?AK
M;JOT36? RB4;[(W^_L9K]?N=;GN_=]#:;W6[G=Z@-VB-1Z[HC<;[W7%_\-_]
M_IN[3R6O:G3VBTI8:_ ")U?.B3\TUB<'\MLRD I8SIFT_N"H(:]>;C(TXCL,
M;'CN*H>XH.YMZ;[=.AD9,\(<L## '/\<HA?>1: [TMHSABY;L9"*IHD2<\X8
MP3-F("V4L2@(+M4YZ $:U@KVQ),I]:MI](M6Q0?A.FFLT_C30&H>":H-5_#6
M_$BP6S,0U$'B$3IFDD8DP3"!?H]RVT8I_!*-[N-3<W6D:'A!RGRZ=&L9]+=+
M6XQ6LMI@TX(OWVD4/BA1M'BYS<@^/D7H?[37L&\0G0\C#8F$4@I!,'D!&G..
M3)(BXT.=8Q(F,MM,SWOF>",]>5B<<%"-9S\"K0$3!N-,!C% YA%L 3["UZ33
MLMF<7T785PD?J=_H]PZ>!JNGV>AWVT\U5*O7?ZJANMTG6F"[T>F5?W7?H0:-
M_8/[82W=,JGV/0&NED]JT+U]I#ORV.X9UUX[DM(]X&SNNZ2U^MW+5_P1W9S'
MA"6\E(EMREQW?GH>Y^-BRF#9^Q\.$K-R%MXKHJMSM _W-IZDN)<16L"C10U\
MTR9;3?HO]G_;#OH_)3=1?0'J"_!$%V # >Z^ H&C:YDJ@G!^:!R"W1+D+"T*
MEALG]VJ6?P8KU,58KW:50]\W@EZO_E OT%-0NKJ'UHU+(Y\\R_=!M%RC<;2D
M[[F31)[K.=8P&$7BYE&MO)9NRL9B?);O2;]E'W1[]4Z ,/#\>AO>_*.S;W=;
M_7HG:H*HMZ'>AH5M:#4'=F=_+77 :UWWD8 3=";6B:PL>(I"JVJ<^.# ;K?:
MV[->CHS!=;>V9\VMGMWK#[9GO=MXQ@\58)5<[#8><*O9M?L'S75@Q:UUW</@
M2OB.JL9\"E27:ISW0=<^V'^4I5:M]3[R3E=RS8\0S)5<[S:>\2,MRVHM=AL/
MN-5JVKUN"=3$*[>9B_V2MD<5ZQ_8K6YS>]:[E>KVEMG,6V4_UHM]K8L%JZG?
M&FR=D6QV[]DFS:MGMQ[HO*[D@K=2O3ZPN_TM.N.MLA?KQ;[6Q;8Z7;LWZ&Z?
M59QK;+(]BM<C,LTJN=[:)G[]Z]TJRZE>[&M=[*!O]]IK:3*VUF4O=G;8'NT+
MCKS?[VS/>K?2,-ZRX/%6F4_U8E_K8EO-CMWIM1[6F:"77UYU.A,L0I35?0F*
M.+$Y4$3"_QD+;C=#'?..$'TGBB6FXL5$Q,)RIG ?$OF+"#XAU";X!?63]F!E
M(_Z5["Q]+;@3CAL&>">X1Y]#X[\]//J*P) 3Q->SJ"5,.,8V?=W.X&#%3@>;
M=LH;V.< 0:*H(I>ZA!,*A:QQAP-B\,8]L^B=CI8_D)TKKR($+1Q1SQYL:CV3
M/0QCC>-)%!# [<1^T6^>>0MHQ#)DN?(S8>"-#[0@$YCOC;6^HWKS#X_AU@AL
MRT% ;FK5'E =#^%MCCW$YD9XLCB!#ZCMT+TO18YIY^])U[@F2\#=U>!;";_?
MR6]'Y>'W\V!IK?;:>.0QXLJ5014J.#WN(1\C]"PB^#',X&_G/W6;-LQLH8<I
M0?*:C]L%M%\!V^E=<I=;A=B7Y)#SC*Y9) !Y;A)YV%7H]S#IZ]"_IJNXJ(2L
M"0(ZF_DWN?S8VOGM_&AWN9JT2 GOJXG*US]H='M/A \W:'2ZMP^U%1XLPJ2D
M1H7/9!]%^+:-6K/D*UL7-RST(7O$J=^]^ T\]?83G'H%;WA9+ZUMN_"M[;SP
MY2WNMNW>M]I;>>]7Z.ZT=6R@MY5L $'JZ*0+3<(*^L 6<83U:P(;9J??2B>&
M!@$V^PI\966PQU?"5VJV<G=CW>WA+OOEU'!7[$W=__4U1"IQL[GA]-+#%GF9
MJ\WH0&+=>+XO@P4=XJDRO("QH"#%MB74%,/H-44PFI2\2N,@^7!7"^Z400,J
MEUVG;_=*AFQ8",@9I^Y$?W4MVYUQ@Q.$887YSBUL=S473F2VS,A%-QJT=48[
M-7S]I: 1$C_?\L/!1A\>M0_A 8#<NSUST:H3'L]FB@T1X1TXX0MCST:AH+X?
MV&7MVAL):R9!5 DV]E($8NPE,;X9_\B:LJSJW5MC%T'N!HG;##P<IHW;]JL3
M4/=%[A/2LZT4]E8>'_5=<>)<MQ7AQ()63XU."PU0<HU9Z+#@3S^D-L-+N]X8
MK4R(R&R,/$ZHH:-?Z(@BQZ#>9\4W78K<:$QM5A3Z%&8SN[1LB*<8^YOY,1*P
M-[U,HU@4^N+A:KC)GA.' ;E_Q0_<"PH(NRGU)KNDED-3I&SXWG&3;.V><;%_
MMEQGYKA>,I>Q8Z.#$-U ]/R/=.\82[6-L<OZTF!,N-_MV(-^AWH%49Q:,J3R
MCD=\[S":YL482H,1Q@(#W'.*HM&(^ZCU'727!D$I$MWIV/W^P<;WZ[RC#1">
M+#7S43MDFXPWZXG$-Z!T,])$]R2ZK>W/NY5WJCRGI!)1AUZK<=!_FOXVK6ZC
MU^ULY%"/ZG CCT[)H)7Q*:O:_N99UKN![0:^IE*SW_C&"+$ B07JF=C\'@[4
M4=2? XE48*KBAXA<+ZY ;R1E#&S\1'?^4L4>'O=HXO10[KB!S1"XB8VE;@'E
MW<PBS[U/MXO7N!TSC[NRDQG]O$TB-E1_J#M$K+HGW47_Z/IV8NJ-1KY85V)^
MH[]?[P/LP]O>6S ?#^[#.*K$!;87Z[UGM_<?5A3XT.6NE9![C>[+ MNO]]JV
MWO;QWO8?<F^;N$#I8GB]I5>=Q=#R<Z]WK231:3P0I;*:JWT[0/K??Q'ZKR3_
M?P3]5Y,E-EK=[5GM_MO6_LM=@%H 5( DVH\T::JUVL';%EDN]X+_K"7 :^:)
M( &VR.!IM=^V!O>VW5]%0O6V=HG9-HE6FS2/OLZUI'N5O+^V=5[^9M0BHP*T
M4AM!M<RH949M'3W,.JJ2$?0D';DJ*=,>G\50,5I^J+97R=6^K&>[%ET5((D'
M*W657.W+>K8K*0&VS:IYL.Y6S=5NKV?[T:W=JBG/J+QX>SC\@_W:U5SM1OBU
MJRGG'GXQJLGY:TMG*\0<ER[7 NZULOS:8*LE7"WA:DMN"[SP6]H!]!$^^$KR
M^%9CL$49%X.WG>82S70I>-I6=JK(:.)5=:JHH8)RG]=009LBA&NHH%6VHX8*
MJJ&":JB@&BJHA@JJH8*>!"IHRWQ26Y9=4.=,U_EE6YU?5J=&;TG<\8.(@I'U
MK6&="^]_'H*5;T_6],/QH"K)YON-_2T2X?N<8].KZX!J85<GG]7)9[495">?
M5:*HNA89%:"5.IVKEAFUS*C3N6[S'-S55$^G%,@E[Z%SX%VOJQ;M42>I=WN=
M_;7U<C*B)2__^OR^M+N-3A<W8IAK^61TZ\KZ1<7<!8][Y(6IV>1OXHRL<8K-
M_[ 3'CPA?KABEE!;*NSA51P@#+)7M0;\*FN' @?8?ZKXW<'NG;WPUMR>ZS1K
MMI5UD</N@"&V3IMXL>Z65NAO1^W.U+;$$R<2JB'73BR$]<QT0B.^\Q*X\^X*
MJ\3\AY%U_$.X*77Z.QV//5=$\?JH^<T_K!C;#H;81]$/;W9M*\ >D.&X2*'"
M+^SO;4W.[FX'9_1>?+]2,M-+G^!"B&ZE$]S<5I,E#?!BZNPW\F(WC6-NYN@[
MB4#VE.LN2-T$J4%>%'"#0Z2-PXDGQHM;8>W K00RRO6@Y&<_>M@2&=N!9L]^
MQ&>IP6"*]S^".SL-XP2N_-4$V*&>![4HY+VV=HS6?#1\[ETX& Y+S.-&1,)L
M9ZG'N(UZK1U,CN-NG#YU<[3>+#OX-R6L=6,.V.QPZ 7PYY0/U T#F'N@VDV6
M-)14#23Q5)8M'3GS:I<=;W:/*+\2*8GM3J/3ZCU)\E^_T>D?/,E(^XW][N!)
M1AHT6JVG2;C<;W1Z^T^3)-EL] Z>9LLW<E(P5+][^ZP>D03:W)0\T(.5TT")
M3<] 6W6]&3 ?E3;UR(2?.S;B)0WQU;;BW/&=:/Y$Z4Z/(8.7S.1;<6M0V=RC
MK3$;[1;WZDEGUFL,'I?EUWJ1-+_7=="<]F:>]/J23%>;L;2 -GV:K-6:_ZWO
MS2NZ-Q_"(%UC/OYJDZPJQ>V_",5MGD+R%3BQ^#-%1QOH9C ]V#+.R_:=(&<C
MOHS2LGD[= 8;@";RM>.G3Y6H_KH8TQ!=WN2B6: 7RZHJ0VAO*4.X0.<0G5W.
M051*^$_>R/B1]^*9-VQ))].H89TX"=#_C748CL=B_E+T7C:?!]-[9_>Y_9JK
M;>=9)&(/0X[LV"UW.J]^-9^:!-=Y89<DU#8/[(/>\S2/KMQFM'K[]F#0KS>#
M-J.Y_U@0G]>S&5\]O]Z(>B/JC5C<B(,F\,Q6O1?$,^WF?M=NMQZ99'AW@N5&
MZK)E,,<5TV)WNANBR.HDA2=783<K-WM57:1MMU\X-WNM/+5M#YHOFYQ=15E:
MK[5>:[W6>JW/*GH.$!/S%8%YK[;L?WK1=^M+&'XGU^V2C,Q74&:_VF[T#OIV
MMW^P->MMMYIV]^!EX6/6>LG;^[#>1QFQE5KO(YT7]5KKM:Y]K?V^O=_9(A9E
M-UMM&PSAK70M89CT8@+#Q-9AP_I%P ,P9"6=3+T-\3"Q3G<B1CC-+?4K];L'
M=G^+'"WM;A/6^S ]IXKK?8Q>5\7U;I-A7J_U=:ZUU[7W^[VM66[+;O5;=J_?
MV38/T]#WO3@,K%^<*Q&A,H>.IG^!$F+I)"X;_AJ.4A=+;Z^%'\ZF\.'6:/S=
M=MO>;[>W9KVM9M_N=;;'"=,YL-N][3%@M\DW4:_U=:YU'\R)]O9<V?U.SQYT
M'@D_6U&/TW ZMSXUK"_BVJO]3(_9R*)*=PB/L,MI)KAQ1;QE7J=NOVNW][?'
M*S'HV(/VRT+QKU6O:X(:^S"UO8K+W2;?1+W6U[E6T.N:!]N37KK?ZRZ$/5:&
M^^SE5_?LF'NW(^R%B8C?+84UR*%O=IL-/7>%2]KNU[BD\$E/XI(B*AQ5JB.D
M(^$W[C'<'H.NF,@Z%H([\@=A0,!PA*M)3<@L)X[3J40A=6("#?1#?-0+K ".
MS&JUK#>;A;;) $(?:$&'1NWRF^=&!;UU5K!?"*I'.(-..O(0V="%7<42&8(Y
M'.N<O#B!#]!!&B^';]WH^]#>S/LP0IS!R'*FP/63&$$2)48B]0X%RD>XV=!/
MIP%="4;%'#$L9I!$WF7*]P ^P%L2B\ +(POFZUS1<?T<PV_B&0-(PE\3+Z+/
MK=A!',K8(BP-O(5J"K,HO 9C:D2 OQ/A^# 9EZZC",38@R<N&8<2Z=@)YK=
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MG-$J@BS?-(I%*3,R.+"^#MH-<8S+*%LN^AI]GQPF7I *T)02SS<9-1",\$@
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M_=CFKQ(@>@HK8*Q)^F683.\8E=FDI-62P1C0E"QHF^#483RPL6DX":NN5;L
MLUAE-':>%Y!5<-Q\+G##NQNZ6CMP0;0L10Y!G<B$WO4%4W67):TZ!28+RJ+%
M;<\:F4MEHSPZY7&<6PEG4Z<EQP4>>YZ]8HQID;ZE9DY#Y4]+Z>.+IO:8^_1*
M-CQFG\2M;7<E.="#Y?UV:UWWT;INH2UZD6X7;]]&Z#,RFCK*A6=5Q)74F*<(
MKY83LAI^(4R7*:TJC8&SH&W@BB-O[''BB:$.YUQU*L_$7%'1BH:?&S%H:R>?
MDA!(E8E>2TJ>G,?4&0E^A(3^%)V<W"@#%*\_TA'J_12C9H6BY,4J#^,.C:VH
M@*LUJ4Y])9K[;L,ZQX_X>%BZ<0JML/7O?6_J)8Q(LV(7X T+K2P/#4^9!4H:
MX;9.&9'H-.(%*B26CHV?U*V @RW$E@/]O2&^"X)C+A).:5JDXO?5W.KE>SUU
MOI//%BT=?45(7,LD2Z"U6'P78H:/P>ZGD6I65]6]6+X9=-\4>1$?B8D^6(#A
MYRJ_,0A8)&LU/Z.FBF[+]?+KZ+K"Q]9!N .H$LG[R.JYVJ[2 (%FC06N;&;_
M>;(9IE2A*<1&\=+=LO2R<D/ &,LT@W6G355(T"R-7I4&@9:G@&SP*=YRB#1G
MU,*=>.*C'U^3[EC0K8;==N:T;=1.+R;[,];MP-!XYU0H^!CW-'.#L!:+*9^@
ML8]2U_3H95%HXI_^_V?O79@:Q[)UP;^B8*9OPQGAPKPS\YZ*<8*I<G<FT$!V
M=<?$Q(2P9-!)VW))-J3[U\]Z[9>T9<PC061R(^[I2FQ+^['VVNOQK6_-Z\HS
MO I=$(,?T+[X01 %-\OI8A@_A\VS$!9UF'"$'U<*%WM(K;RL9;:4E?RE%C4I
M?Z(31?G-!!L;4@ ^HP@?F"\,]G:"(*$7R1?>#>7S6YE^\Y*=&+BX;[(4@:X(
M\D63:$K 3K"7_IPE8^QT)7D_QUCDX##82=R$3C<*GAK\<.WBU#O4/R/@:V?C
M!P%\-3+Z97LKVK%)"^._J92?G)LZK"H>O;*_Q3Y)*GV ZU&D#5:0]?H1CG8N
M>:#K)RQR?)4W_0(KENTRN. I1\;1>) A[5].D]J &GU/(NU6IKE<'_=*5ZQ^
MR3#,CB%HMX1.H7YR#%=8RS$@"XBCLU3&C<VNID/.(9E*E9P#,\'9V?DIV5+@
ML \1X/=J9:[>O%0+&&%1KR,[[I)2U.5'.XOURZ*.HLI'N["IRV2>2=!V%'U+
M1[.1"N_&(E3<S;KNL*X*]NP6PQ/4N]SZ]2V5%U!,8Q -A\G80$U+P)S7N>;U
MASE''T0N">WDZ'I#O?RA@NZ5:LSP2Z,H':N"%UEQ!J&B:Y2!\]\7. R:R?@7
MQ"32,_G.QAZK_2&B! =I7S !,*R4;73Z;RF[IG\6LTOUF2JQ1OHB@UW0>7@$
M.63Y531._Z.@!B.$SXSD7\Y/PV"4Y%>889U&7Q-J*GN9QK8J(@T7]26??Y,-
M;Y2]HG,RO#IIH98GQ,+0?C(<RNCR,M#"R#>L.2M!U RV;'I6/$_PJK:Q$F+V
M%-%(>>?K8C3)L@^S6W(OG!VF8.YEPIVHX<O<(=N$M@CH@/)QEWBL_6C'0@63
M<=X*HFYL MPO$U&V:V$6JNL?!^E_L\ \(/'AE5.Q:>-QU_N4C2JYKR%Y*5%Q
M-&G$WY5WIS=&%Q/Q3N4E: S%0-W>-)Q_YW6(T).P[Y2)M@*+M*7TF0_TPE@'
MFIE@2R15B5P*!2$F[=]0T"N(XAN);L/W-6R&\J\27G(P-%2KC'X;D:*A)VR-
MK A6&R#GI^>=QC"N),K3U;PW86#(BPPMCM(E8#80BU?3UO2L&6N*ZQ26BJAQ
MN\.&Z=<FK!7)7SG2\D@^K_+5]GWHO"JPK&?G\VK^G6-A=12B2Z52:T@3'"29
M=R=G8TKD&9Q;3<5;Z.HG-U;L?3H!WP2 5BV\L]&K3MD=7(#(TB,3"[FB#U01
M8_FL2BWT?^F?'$H+!K-< .;LF)B"EFR<L UNBP#RB!GH4XQ\V>3<X0^HE!-A
MHQA-A^L<!7B-EHM&<]J$T8QFPVDZ&:9FGZ2 -[I*&G%]_%-$\U0/JQ$*LE3+
MC#>)!>$BH6551F11G);D+!V<L.LTN=%,,(3E,D;1.E,0@9F51,5,8BU]T(V(
M"5M42VK;8+;9Q8E."[?E]4RL$9#VC7)AMD!W6,!Q$Y&_B(#I@W0,W\;ZXREH
MMF1::-AG^=F%E66"4<WRUT*"Y",0JB$(L:,4#LF!0/- *!YZQU4OK0U]:3T9
M_T^P_'Q+Y#6/F-HBSH'GFW7ERE%*UZT^GBZU0 \@EGK4 E:6:>=Q!LV/P15U
M8>4QZG;*)C2KW35_;88C_^C?+#)@X(IO_\7:-[N:S=H&FPK 9I8+5FNV(0S(
MY'JD6)*;[Z>:,*#B>]GHIM:/!9 Y+A3+X8#7RSH0_I?WX6=&J"/YN:;?T P:
MJV81*%;!:3^K0,W[^-<BPQ5A\A(B<&#%ACK:ORLS(E1H#0CT5'H.B@DMG_TD
MHVOHF5:EWAN]P?/3&]#VO#YB@R]+>HJU]BP9U%%PH$MA#J2$Z\Z:K3+7-Y=L
M:7H QS-5M:R@Y4"US&#1HJE0R<C75TL%>!Q,DH2@>'%5YX4J63<VP/2H,23=
ML@#OF%C#>HE'0G7+VR@;M!M,F-RN*M-I49H( BX3&\IIYV3Y=-]:3(%J7:L[
M(=$ 92SR2Q 90):Q-\2P?*>(GQ(%V?Y!4)"O5QV1053Z;O)M D<!BZP0( -W
MYO2:Y-N19E/3#SI:4Y<:@MP9HA^<"SMW. '8>.%H@6(_,,^\0BS%F&]V;Q$Z
MI60*'U%%^IS,%CCVR@MOX/2!5LQA6^]\>3WYC&=85+0>UK !4!!" .)>ZIDR
M98:CA#MJZ971SXK1^0Y!G=RRK45T":;D4**6]YZ"NZRK)68>C/+.R[\8>Q),
M:W?,W5^6_ ".%(?$CB^?-._/1OA:Q$OI8IOH$N2;1^6,I&SE^XLA[Y@(EHE(
M974M[0J6VF)-@I)PZS0V)3E_H,=W""-N0G0TO$<^H)X8IH849A'@.OD374VQ
M9TJDW^6<@QOYCH)!+I;.:F=-_1X#GAD]PG%NS).),*Z&@' J-%,R''>;*!\9
MK'Y<D\,^SD@%>%Y6#N/0*YVBLXJC=HL@S*)_G<0S63P2<K*<)3O2DPR_<^X8
M&> Q6EVCE(+=/M9V<W;<R3:E2MWK4JMZ<:^03)^^:-P%<Q3+%\Z_56(O4XE=
MWM[[%F([8O!6C?VP:NP?IT9R4:G&$Q9)@JZW"R-M*7ZVZL@',W$\3ZFD+)$'
MRMK(TCJO,B+8O/U75.)"@"<7BU;E=M94WP;3['46TM77I:A*NH5VG;</0ZUU
MOU3WA :O5OUBJ3+,Q;CY!=FHU[D>BPH,)\J!Z(.^N<KRE-6>(5+'6SPCE247
M5]7O51!!]47]C9I:Q1]C4>\JVRR5BKFWDE4PIK["B&$^@MJ!'^A$H@&2X8XA
MF7HZ=5@"?I!5O:NTTT36!\Q@P0SNRKZR-9FN"^-:6/QQ9'Y*,42>1C!*4'&&
M%-9!GWFN",*&YKZ5NZ2ZW%+.57X4>AJYA)MP&Z7 %&M&QXIWI;;F] <JQTF_
M+:./C9'L(<"X,[GQ8L2(RG"E9E5.;5JM 5/G*YN[65(]-KV9LFHXT<1T8QR&
MK.:XK4@0<ME.L=  G&6B]D9+FN0U'4VB-.<0B2%&JP0#7>>NK,66)+:MOT\]
M::HT_N^5M+VWM[6]N;OSKKW;WM[>VMG?V6\/XGZR$P]VMP=[^__?WKN5^H.A
M.MS?=2K:^R]6K774>KF0I[LL[UK;N J':8$-/6<Y@R""L^0*W G<U+\60:<O
MSAG\N4_5I]T\S\8);WU'@LEVL^*[=)?:HA=CM1W?#3778F3E\1 2G [F+R0U
M!^"?7D;@99YFX+'.&[[()^/@&(2%7))-+BFS:Z>B.)N0]RNST;7$(F.$U/#)
MF2[X6_](2"JG239E%59*"[6R5N*X8D_>O*;/J47TH^71'I 6A2/ZLSQ/I#T.
M(GZY;KD_H^2'JBHJ0U =/G'G XLKAF+T;!!04(%KUPQ,F#[BN,,@':H^OJ15
MNP>6CNVJ" 2<6GQSEL=L[?2S'.%;9.3 LN8"@BHT8Z;FN-1J?5TP"+Y12$@$
M,=LE5$-DGCB"!ZA?Z 8T]'(*LLN0#,A$+:_A,T<E!;.[XYNMH!,+%;I:>U<$
MB-8;1#I6469L\G0<%7'T)X5A4#+(':8[.47C#VO+7:RNL[1G,_!PVAN'ZVW&
MP99?F'(331/9"LZ%;&!K8UN;-E%^&8V38OWDVS"9TW/AD\V-C4V)'BDZ#K7/
MZ+CG:JOCM "7S71%O<S&LT+7("X0Y23*QRIQDVM-SXB3'!0^0NP'5<%FUX,^
M,Q*A/I-](12R2[L+XBH-?E&P/;)D$,(\@KIS<9E(,GR @H4^T*QO 2;S)!U=
MPG99J6D,?PUF5/*=62\ <8$%F<SKA 5K1"E2S2<-#3(.%18@ ]?I)1A5[_9:
M[3I#M ;@\5-#<#;K(3C+FWW[FRNO$K?S,N9"[Z+[.=AK!9\[?SLY"\Y_[YQU
M?S_Y=-@].P\ZQX?!6?=3YZ)[&)QVSB[^'5R<=8[/.P<7O9/C\X;X5^PD/M1%
MV-_QN0C-=0DZC7$)]EN;M R?H_]Q*;F+E[<XZ8GOTRD<S_XRE<$*=']R.X;Q
M7Z>3EY_"/4@QIA2U+[ Z3,'CJ,R,+O$RE_%E,D[@*J8[6<V6"^URQ3O$?4N.
MDLM\%N5S/E^;>V2;[X3XB@5I;VM]=AKB6R^ T>P^$Z;(#YRWUZ:]C7CYE5^I
M:%7:X&"D'&R<KV/8*+3"9@+V4AN(G37A$]-NA,N2<"?[G-GA#:T/\K[MUA/L
MEBRY+EQZ6^[ONMS'$::WN]KK.!'/P@9D'N8(_1\,P%G"0Y03^1ICIPZZ)^B$
M*.U&2FUM*3#%V[8]<-L([EHZ).2.U6QE4;.7:XQ"OLJSV63IN%Q3(.^8*^U'
M5FABD&73<39-3)]$[C7$;<0U8 TU^6R,QLDDQ^)P^ ]P0PM% JE1*:$\5!D%
MBM:5<%54WW.331E)@T- K"(YP*HW4QG"1=5/; ^4;QR=[1H1Q+%<:8(!"$+&
MA )&Y]OLFB'DN$:45>N3YUYKCQ ALGV+!<P^*,7,NQN,T22XI2%DY#X%ID>#
M#5\PW/8:X\^]_*RI8N)! 6AJ9AU-U8P(U)B[M4'N&V'9AW,?_:'"<^KF$T[M
MDF6+V>\KCXC98@IG\(AS$<"B"8)EH\F, 8L4=+1?II=<0?_MEF9W,]J]\"GK
M<N8V\AXTWEA02#F=Q$%@VU:R-&PZ7R9P:-#4VM_8#H.MS<V@W?XN2O0'+JD,
M.C?)>)8$YW^$@73X#8/.\!)CYOB7<11'P<7F6;!QL',?Y2W.C0IM851S'>8T
MC"9%\E[]QX<X+2;#:/X^'=/(Z$<?W RX9^WHWN:/39BGM<&AGFD._S]6;Y:/
M6_#1+]6_[VZW-G?\'VVTVMZ_USVJO=MJ[_A_\H!';;Y[M_!1O] L>::PF+@K
M_[VRM:+7.^I_Q>MV'*^+'/7[23(8?)"-4. ".(-$0QLH.1,[X/WFY%O0=I-C
M:!I4A)B>\_PA%=IIM$)(EW>,JOAH;B6*"6B!G<9/NE:+%HJCBHU:*D$*?K0O
M(ER?^&U]:'W<$N3E5NO>1W! _T\M&ZG*QYZ_41K'P^2%%FWG+W3Z?LL3S <Z
MD<3W#Y*KNQ9(K\X&KHVHQ^_TY(<JV(=NX$N$X6D7.V,TJXXHB_89;GO)-WXZ
M?2E#:N/!AM1J>ZV4H7F 5KNWXH*1/;\535NW'[;W=\*][:W':/%7--]WK>V]
MOSR)#F[P*?7KVL.EXB_/=&1]0WSHD=U<>Z&\&"WK^T?HBY(H/?1.>JF;YYGL
M+?])/HV0D3F-@LX83/?;XB=18-L[2,OUK)-]T6W^K_]Z"6W]HE,^3,#(C*Z#
MSZW@8Y[=CA]C"+\BR6YO;X>;)OCV++-]U:+]"I5V9WP%5WOP>S:<7D>CGT1E
M;[;WPLVM_3>=_0/K[+]%^+"+5G :4>[M)]'9>P^W1MY4]NN0[#^B^3@)3E-X
M1O:3*.RMC<UP>_MAELB;PGX=8OVW;!P1QN0LO;J<OZGK-W7]8ZCKCTF._:I:
MP7F2_@<&_;C\Y2N2[>WV1MC>W'U3VC^PTOY[FG\-/F79UY]$7^^WM\*MG><-
MB;S<;']";8T UXMK>$X1'+2"WQ/XPBAZ6,#O]6GLO9VM<&-K^TUC_\ :NS,<
MI@@.^#VZ(J+EGT25;6UOA[M;FV^6]@^LNSNC>?!;*_B4W*0_B\;>W-@/VSL/
M$^LWC7U_L7XY1-=PN&2]SBN$>#T77L2_M%8AT],A1UZ![@!/9I_09C^+"=#:
MW_0@S7ZA^H2[*PU?@%+*7]SQ7_\%5QRU@(-W8Z.]^]3)5VHFL4+2,[?&<"P<
M8U5>/07PHJGM;)?+05^25+']4DJN4@JZN=W:(@8Y)N.B BS#49!=(J\6,D@A
M>=:Y]%0(VEN_!?^3I>,IUM"E0K)9BS,.Y2/KC[^=!I\^'83!9_2PL_$\^)QE
M>:*^V(EOP"V!JZTW[K?X2YU1.H9;;GJ=95R(B7_\G"7_"?X>%44T"E9U;_L5
M>LC*&LY%%Q.WMYDE@>LB->LC5TAJ$H9H&N3)),NGX0-F8PT+YO+7PG2R4Y5N
MV MS%[8V.(R&0[AH3J/\ZVTT#X/S63I-@GW]21A<)-_@"WL[F]O[/-_:E>%%
MT2_GY:A[^WX[^!C-@_-IGB13]=[M37CQ19:#W,#BGAP'GW?^%FQ>;,&J%]1[
M;I@57+.(Y8]'(!RPE.M' 7-Q?8[R_G709H:X[04+YZO;W KW86<VW[U3E9+,
MFH6-3(2-<J>UL4OD";4EK\O50C9<(;R8U5.O$ XS>(%5M:JK?57%[3UK^1?L
M4^UU>@<3UW)W60/J_Y&P$H68#D?H%MPC]VQ.?ZJMNJ=2\3B%I2;./*D79][7
M!<OZ4Q*5;97L]A^D5V#SJ)E8&_R>#'4Y^Y=Q2IU$D>RO 5Q3]R9J4@7J<"2Y
MEU,=TY*O,95+B>#O-BZ%[]C.XEN*))N5ITAY'?XG$IQB/\32H\-2JXB[?\'D
M#U]:YRWI)<0&@7H4VCL6\:9-D^ ^YAJW&O2^>5+EW59#,Z?@\MX/PL0+=@"C
M?8G-3<0;5,M-P>_A9_++EJIHWWF!@O9W[UK[.UOWK6??WFIM;RRN'%^Z"'VS
MM?]4CVJW]O:W&S>JK=;N_J.J[)L:#O77.EW<I4N6B.V\[ADOHX-_N$4XUM-?
MH$]_X%G?^V[YX=;B]'%W;8FG]3$9PH=2'S0M/-Q^]RBHVH^R#/N[X?9F.]QY
M]ZBDXH^R&COO:E=A\PE782/PK 7Y^LU9BMW]\-W.1KB]O^E1'L;8>A*1H.78
M6&HQ?OFY=V7O'9CAC=J0EUF'91)[2X1G7C[&<B"]2+$A))%!-CRHTKDK:I(G
MW#@$NVWE.4Z..Z(PD[)J%2[=53@7,,($"?:T1.Y-;J8ZI=1#Z+0LZ>NE4KR9
M;A.7!M"2WG?S91Y@O)W@TC4^HJ9HS(MI:>V1_;:]]X&W>9C$5T+M:;71P>@.
M1\2'U'$/(SWJ7Y1OR/)23[]HS(288,%.,FXOO%JLA=RC),MA9./@"CL$46_!
M,'!8-*EA,P:/L$'-%?P'DT^&09' +SBWE*L4YWW;A"S9WV#_=?4W^-B@_@;[
ME* ZPS0&",-IA-R[%]@8,J(./4T_*7\DG-$A^Y8RJZ#YN!VK8?Z%J4CDUN8R
M'U.*J-JR2O?*Q!PPEX,&JT62!+UI,@IVUUIVW\:&+\\Y]CX270+#&4OS(6Y%
M5("!P4V*N%_T8=+G%F5;;96!GDWP)J&\-,]7WT"WF$6+2=G0VO/*&[60BT1-
M2**FED11% E_GM&O:?OP=\,L0NI>*V;.C8:H QAM3:@S?:A21M23PVINW91F
MF(]KUO*N_;J4V4&#E!DW:^F1+BBXCV?W&_*)L] =@+5>)%7+KU%B\F(]Z(..
MYEFOM_#N#2]84NBW5YYQ"1;TB-IO!4>]X\[Q0:_S*>@='YV<?>Y@(ZB&;-,C
M5<O>ZU(MS>L#!8X$^?.13LZSTX7:A3R+X$CW]#,?/[OP^)?SN17./9VT1JS<
M*U#5%]+X6LOA@L:H44$&&-M\*<KI> ;?8V0F]5+@[W'/5#)PV_OW=-*:(C^?
MR/L\S;-^DN#)K1.>YY[&G9OIUI^@;3XR8,]2_UPQFM'[5PU$5(=9A."R(X.M
M+00DPRXY/O<R&G_-9Y-IGYJLJ#4*HJLH'1?4<G3T@>!S:5'JV'N3#6]8EJ)@
M,H2OP[4_H%"1]7;KH=8 @F$Z3:\HHM 4J7K2[5#[@$&X\N)[EQE^A/A%PD>/
M\,5Z ;$GO>E./QA(?^)4C-D[8W"OXHP>IC<IF!5Q7=ONAHJ$VFYL[X/';Q*E
M,4E_+/.AQCW8G-C)&$NDP'["*(+C%]WU0]T^:3;%-O0I-L .KI)QDB.D#@5K
M +^1QW=P'$D_+:2W<N7QBQY]FPZ'V-%G%,6)-#P*+JDI.3;PT2<AXQ]=1D6J
M6WICYV24[="Z@*15L3&*5&!QS&4"19!\DQ;3< "*6?\ZF,)F/;_G?B\+:4GS
MNKVQ\;KLZ^;%(<_!L4P'X(2"JN6,S9L)Z/76@\):*4[8"+8]ZU,_^!B^H6)_
M:":JJ*=8@%Z;T>VI53$7L19%5:S41PA^2J3\MKL<KQXIWYBBS,=JY*V&Q)7>
MM8*+W[O!R=%1]XQ:CG_JG5_TCG][#180Q@9-#T:5'<%>>N0POFMU6MMTV<L_
M#YIBG"Z<U0DHPP.VC,ZE&F",QE,>W$3#&?:HQ([#.=A%\2]_SK(I5W2B.CV.
MBCCZ4WL'%^?_$O^9>BS.1Y?9L BH3>G&AY/C@W^OT%?-'^B_VA]"U8D2E.+W
MRHRV-W8;<@#:&V*N!IW#PQZ&5'_  &M[X]WKL@";%V&ELQ@<1!/T*9LM%,W,
MU#R)VFAOOBXY;IXG\SD993GH_=F(:\X1SS=,R'GN%$4&IC>:N V1J<9D!FJP
M<-;B(90K!:\$?)N&8R_^2,B$8. 4 ZW( 1LQVB*R)@6.EX%>!:MH1ZRH2:^L
M6=;%1\5$<&"^7P2=/H4'I1$M_U[,#?A(S(TUC@+S("[GZ]1@&[_*F[_RD?^T
MLM8*T#12#U,#2Y#@ =\L)4+@'6YN[.V]V]O:WY1?J E-\@RC3QSD9*0B=VU&
M@P=[&4F39HDIJ2G=)A0=ZT=Y/I<^V/*527:+51;R!=7ZNB5!M92"6GJ<L;5<
MN#"J8;2$IH@)09?A@_F%3G2042MRZIDM#:Q5H"S-K9W2"]=D"*1?&G53M)<?
M^6+$DM45'@40=H$=#I294'8.XX?P@>KD#K(O=?P9)R7@ PP<2$"4BH019*31
M8(J?9"CAU!3F#E-1J%D5]_QK =\9S2CL2APG)B"*@HA2!>]-\*WFC87[2IT?
MT>\FZ)+\T<)%8937?CF>L$C!IS*.E=K/L'Y*+=+MO$5.@+AT.F1QMR>!:9SB
M.AH.F8<&HZ\T;?S?RT3W;%>-X$'EJ&BP::M'N"PZSCK:RZW5 W"4<KCQ2*7%
M"29""&*L?ED>* 6LJ([[,AVF,%'WZ"*43_>Y1ZV5Y3D7F9-&"&D@V0S.^ S^
M-T__$]G5UQ8R3%Z,SYS@]*:%\RFO$:LF"7SQ W'IK_-L=G5-PD,A_+\6/H40
MK.*6Z._.QJ"71MG,>4\07>4)K=9:"&IOBDM(V^JH1=P\D.W),.HGM*JSHJ1?
M48^+ME;Y0-D):VEA2OA6%?7'!_TY UV!(4.6F>,DI> \K;8U(]IT>3P*7$29
MO@!+XH8IK%UEV_$'>3)5?[(3![SN*OD1B:\+PMF'_8RN2,L:.>'$PXA!B'DR
M3F[QB,BBXJ81FQ+\"?90QC*A/!(XZW$V$1?];R#KP=8& A7;"%3$"TADV2>4
M]M-@YXMDBJF)]B8A(V$"7[1(JG?5G(H19D8QRR?'N.CCHK * C,9LUZ161D!
M<M/;0SS[1O3[:=Z?C1 %V<>H!(]+TC8$":_)"9)@E&5;JO]1HE!SI'U4#<4,
M98*4("RR_ZR2(((>0^ V+&R>7,V&43Z<FU,WS HB?,!<$*+LT@0#SL@_B ,;
M9O 97 (W^!TC$"]__=SSXCS#_X9M.,T3XHRA/<&5/M0YMLYT&O6OA?J*@TDO
M/\T[DYI6\6JISE5I9:I%8N783U+BS5%33@<,X[U.QIA\!,E ]J@NPJM%V57)
M-B*=.A1V#<I+P.V+AS##NS))IH1: (&U[Z]HRJ=G3/_J1RCY<,;I[D4%1*AN
M^V5<JLOO$PUK7J@2CY+<@*?^@CAB- 7AGV8,VM*@ZT[9&F(B),.$;^T,-=6Z
M^:>C_"QCAA0(&L8%&[^<C1$]"VOC\)!2H0XL<3'%]*SH;5X+/%$)3LTB/2+
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MD 9M$0SBW"@93>R6;'D+%R&X&KP@#9C>?:-1K.F/$PR'(",?3$>J2U& V%[
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MEUD/"[]/R&YSN5J[E\QEZ)2QU?%2LUB$!D#I6T57R):,!W;Z?6*QNN)B&?>
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M:GD1:1P<CD;;#5=WG+D"XZI9SEDCV2YBXQP0DCV!HEJ)P<1.L4=9-<ZF692
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M! 6I$1/0N=OR-]UL*;:_9E5@9%C+8AVIDCN-<!),X:F3.L2&1ZCHY?'T;RT
M*!%5T,*MWK)7(.^+XD"V-]O\F: 3Z6'%Y2 !0B2$D)B+N/'2=;QU=2D/TMS>
M8@>64KK'A23 %:'+Y ISGG<W;WF()%=T0.7]WFC%\JO@<;87A(;+T25M\$SR
MC PG-VR/L\+:(J<CC9NV4"@X]^S#@3*58<ZO?0S&V@FGY*BZO&$SQS9KUUTO
M+-_ZGC>U@M],,:C<B>7YJ1LQ+6PK2Q8$OUPS,8+8X23P.^2RNE\2169  96)
MZB2(,MJ<5RO/3*V*-,+%%G0Z;&</P1[<0AE[K#@I.T];1?ZCZ,FC^2^\2L/>
MJ#\E#)$Q==F6K(1*W<P-_ODVN4'YJA@"BT=&:XO0U7$FI74*'X.+Z2G1YVI2
MPB.6UU.3/W/U^-@R2C75IP?A;#^D%?2\#0!][R,BC''E':&L:OGF#^V-5N:\
M(=$&@=6U\L0,  ;E?"0$22J4M*1\.*^JFMXTR<J.^BS>L,[.]> C?FB[]Y'W
M1J73N@?[AHJ'X8P4]&'0V_H 8WZ.WZF11NH12\4P\P1[;Q-&8QGMYIKY]$PR
M_^ A-TC):X!4%.X4412EX.@)(0)6B5AG8=1=Q*W6J)E=_;6)<DX\?2J^6B)Z
M0TMY,%3U#Q(@\ R2.6Y 78G[X%_E1>,N98^]ZL*C[RMM")5=[]YM.;>:>W"@
M\E6<IXMKZ9T8(]AWP!DKCE_;:V9XK9=EVZYY3$TJL"J2:(K0@<9[W'M=5U4>
M_T ;,SY)3PN^0EQ#6MV/I4-SK["]_WZUW*R2/8(JAO)R6G,Y X4C+&CE*==J
MY-F$F C<KZF2@\)I0U>Y4Q"HK+F=?,4=!(!FIA(3FZE<P6Y"\?X.RU.L<UA1
M;;B2Q51EFR0>MO0(*3AJ11!XC)Y[>90@E-! 46VT'=4>L:I1U^\, 5]7ND[9
M2F1_[T#",I$#6=HT]R&5I5-F-*^897A^]#IZ!,2K;S&L49:<>Z]25%CS%!$R
M*3B\4%'U2,UG9>\*+*GQ^+;..'FEA9.F&NNJQ>[X=^@!3G%E.0G)(2$I3 )X
M>@,JG!9[%T4RB?*RDBATFL!1?2J29I16R0J-%"S/HNC1]T 90Z6>BB_F!=%<
M4[A\"!K#[Q5W=YA^88RD[[;1\W!2%B:PMN#Z$H^%<Q2*TZ\<K-1].[T/2L=$
M\D>7':ZR"ES&BK-3RH38JJ2C<Y.9PCZ?V;34N54DWI%OS&YLV!.D#:L'3,RM
M$2.,%5'A:C3$1D97U[K:4^)0)L&Q9M+O2)II$NYU/BT[4'+MVH"]$L 5K,ML
ME&@?F#"FF5@D-5/VVB+F;G'LI,7@$'-42C!OC2&0HK[2./RS5O"F(GA-D5VG
M (E9_VBU^)I0#/%E&D(X+Q,-P44:OJGI&A.6*^1$UTI0/W("'EH/FN+%4B6E
M=ZU)+U=:HW('5/U3XS!1-41T=86Q']#-#D?6&W# !@ZTWX #CZ$=$#=>1R67
MBDA*WX *"8$<LLKQJE:A4@-%]D-,)X#J#5/U!Q=&9,@0PW>5#AKQUUDG5+56
M4-0E1ILC?"O"(!A"(^RR6Z[,7XHSR.5/0%=#1P?5PE46!*_M*5K;,,8IF,E_
M>%K9E>VG>CTC=8\J9$SNH%>7&*U8WC1&CS@$$T2 B3^]*^.K'F'B6>6A.^O@
MWGM2QVPOCGF._579'3%?J K:&-CZHOR@FUR$X"M*H-NQ0[C)+@W'KK0O%@R?
M9EFWEZ_B"BT'%GP^&#$Y@D[@0VA(/)S29;O<60Y1ARO3>]8.$KLATRJ2SA!#
M%V,,<8D!L3;48"4J2B:9:<6J]-*U53-O2Y(H#\RGE'6'Y#XD]UG:\<)7S:1L
M3C=\4(EEV-QONGIH@:/XH/PIJT_E<]2A& JO]M0\\5CL2X6M%/OP%"!Y/+'&
MR?:BQ'\-:+WYDZH>6!T)K /B4Z-B<U JU3SX;1)=BA/H.\OZ7A67+2&8\H^M
M\*G_;4Q;C7631,!*<5S"J ?,48)=KPT5-4@>=TY2:*X<.P9A1BHV]\.Y^3Y*
M:U?]!E^>%IS,4[ER_1*)615S>-K(\+UBG>8L+V814S04ZM"U->$JK;U^1Z?/
M]+#$MJU9SNZ8@:#>2"$P^S^7NT;!%2:DQR,NF%>]JC0RATB+RUZ%3"0M @$-
MAJ:7$_<?2-=8\:C1Z2%AZA-W 57##7;K2$+5G3JTV)90P0PSN M5?]Y9?I.
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M(6NFW<FZJ']MI)&MQ$K#_REU9/V,@"Q<65V.FX6,0-(-$;&2<UQPY1E7A#I
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M"" ?$YTG)75%[ $'QB?."CI^8_$?$7%RX2LD=8 Z.<(&;YDBB<#_7-XGT.7
M)/"P9\MDJ;? T>"1\.!"# 82\"Q;WQBSIQ#(')D%Z<9V?1^AZ:&3 /D@=1 F
MB)YNAB-\NFW1LST,()D<2Y14;&"=\[GO%(CEK]:O*\=U[L,IW#^B_05]^0=6
M2QA=ZA<:-I/Y[PN365=]H)K ]>[A@PNR'<:7[=K%=4'UDM1CKY'[-<22S1@!
MRF#!O"GU4)X8'I 6K/QWSQTS4NCB4]P@(1,)2.8\P>Z;2&*<E)XY51C:LQM7
MFO3AD6SBVHC4TH &J/HDE^Q_ =9V?03HCZBO%Y?#OS&'(<5_@].&*!BQ_3A9
MR1)$9/ 8RTO-@5\CM"T\E4A>N;;MOF THAB4).(5EQB<(&C=QR36[E+O'@UL
M1SJD?JQ0+?DPDFNC-W EXLU;KLP8M.6X;^-5K?6/>+G:J]WL%:XXXYHA'*[,
M]Z/ZK]$F+IXEA4>)V,S\73N)DS@K&U&6@>+*3]NQQTCMQ&4"F8.*#+=48,UD
M7T _;G?J3L':"ABCBTUN_W(A5"DXB5'C0M<2PW,4;O5.QV[)68@<'P.IR5QO
M!4I): >PQF/+MGFYC>@N"^Q3Q QS-' .P>6H.@E%GX^)_6+>R/+)3K(6'HX6
MJ>>&3]S:I1,SWC?)"O28"IA4%M@H%DJU*>A$J#%A)IF'EC&I;O%)8\HUB 9C
M)>A!0)_)/D@L 8<V SO^$A,R^ %.Y..#ZN*/Y[@\S!XO+E_D2LBL'&I2D0F%
M- B'[9-0U>"QW(19S3JA>R+C9,A@4^B4G8N72/,)'AOD$P1N(]<##)O;.NLX
M.)(:1.(%C@"/PZY@T[R4JVIA0P^4#:,@EX>"7!X/'%<27..9@6VBM2TYQ.]<
M85YG3%3GNF4*67G:DU3(RO61E1M&FM67Q_OR+8-AOUSN!@VKZZ<)[#B>4R)R
M[LK8'9CAPC^\&)Z@0+F/4:,%#UAD6Z_N!WN'B<E80XX'*W^$8 [J#>-2;[T;
MOR<S6F^9XB]*;:'W8;=V;*D4>MQTO_T%QKKSQ&03);W7:+Z_.@5_4"Y8YOO@
MQZ,VN-?N[A]O?]SWOVHW@_O''X.OVN!OMS^T+W?W_?N;._B87WEW_]MF J:\
M_E\]<C\<W?5;JU)RZ.MX(.;CN6OY$^EIDZ$]^MMD_PIY6#"/*_+X)X=3UO1N
MEG^/ZV7>8_1E4Z$$L3NQE_,!-]XEQ^P@$62.@@&/<+Z8<*SPNSB*Z]W-X&'P
M7AM[QI2]N*"IOZO7],9[%'AWDB9N!$U<TD=/O#[-E^@.Q$T\&S;1T;) Q/IB
M^.R(JU%VXHJ0!+O?S%=C2SQR@B. QXA*?N0A)U31ZN]X0>2('#:^T16>=H(T
M:7U8 8Z]L.<5;2BQ3;R>2 1DJ22U"I/!NZ>D"-"# H(5O> /QXV0,?"!\1.7
MB6 ^NPJX:9\$>H:"$_AB&! A #ES5S2_&'A2_$Z)M9EY!,=!1 ;.$G04E SI
M: %> 7-V81#R7<D5<1%E%B_XR'"BZ+WK$.0K!R="81.IJL$C<J(&K\)8STXL
M-$LG%AX/S?X1XH1"9ERWS\1R*UDPB.L1-H4(1^(*+4\:"SS@Q]L$^%3(R,JA
M'A5"4B&DTPDAG9D/406,RK#^9TE4Y[IE*F!TVI-4 2-5BF.]Z$-]-]&'YDZB
M#\?)*4TKQ;1R94DS_2%*D(ZUNX1YPCOK<J!].+2M43)1[HOE39=5 "R8ZG&+
M53YR:.!#"O$O8(\Y>$'X(YNP3\GGQ5C][/2/5=,RG6>P4C&%4]C#/QG'9$I3
M^_54O(1#*)5V(^7H:WO\+N$R>"_<<9EFT40_\$NC(G"@'#[]RB HCXARR!#'
MRR;8%@;F@Q]7-!YR(S<<EB..LN/\B3:VW1>.864&#%&X-(()@L+GY"(0*5(B
MD9+E=[>N1!0OQ\H;<;Q#LYZ[3&Q1P=WC3C+#I\M%HO12R*S,H*["*A)&/95?
MO!QQ*W/SQH;EH:,34X-M.W96"M^;SY^7OZ6)G4OZ;?)V3<+E$P]B'J4 HK=/
M?KO;'8#+L!4(O 1WF#R*ZZ0TO[O[\N/!?[]Y:G.Q%ZGDG$\IJ4GVKQ1ECOO1
MC,4VB6-,4D5B<0;/5*-[$H@SX-T?#DD6$I2PS.^^W_0'G]Y7MLE+R1,="1_^
MR+.(NN.@)_<'+D:R+G/C6&DBV#ZRAH&T.+#VOG(8_VY!K9?C.9<OKI'[48()
MAVRV?4L+,WT]D;[J:*'SKQ X98R% F2>'X5<\MS^I=,8'G,\Y(9,4W&)!"TG
MI,"4H?WF(DW!9V !.2<I3AZWJW8ABEQ@8&@:910ESYT7R^:R(5ZT)U>\!Q>M
MJO5]F9;%N?T>LU)UF<"27]HD^08,._@A)KDS3-S"['M\/FH2F+1$R>YP%,EP
M&X5(-61I&H7(N$>@T,C"B@%Q&%,$)$0,<XBRE%I6F6XX#(#DP31 TG##(#>L
MDB":5^<?AV]!G(I(?.( 3Z;;NPZ/??H""9+)/)K90 KIP@0^DUELE"%$9X?)
M?)"UP^1ZKYH)9+H4=Y3E+TBU,)&$^=<\)8J.$5Z2@&\ 3@36"<B,124&DK4,
MRB\6/AE8)P>U'F%2G"JW^_D\1<3!]>%49EXF$36FNJHVH%,A=;U%B7+B/,#3
M8"'3NQB/E!A+I!'@L4,ZCE_54/%! M9F7(=)%$VAO'@O-M8C_8=T%EY$P8MZ
MF\B8=S(0N1C/3@J8 MV*D()C9E(6O!\C!FWC);:GJ6#.B!=""&WFB^S2)]'.
M.-) $HA#O")"'284$OE(FM/)ZJXHPT(J(!/O[>K:*TT=)!5A&:)OQ;YRX?/"
M2 IRQ &W8?A.4!8B)@P/J7]A+JR!2_.7":-J5T7G#Q$3I2$G:CBE@!>5Z!DF
M2'UD",\#T8$)M!X,A'-.-'D!EA&CI2I HJ((SUKFL!;.G50*INBU<IWR#\U7
MAU1)+MCB$'!=.9^+Q%)<?QI*57M =$_BXF@Z[!>0D$,IU4B]6H#-'8<H1BMP
MJ&$#2"H3DJRA8TR1HSD+H$X 9[AX9N&T4DN9K-5C1F>I?'BBR!)H""-KAOP8
M]2S"ZBF@LXZP75)< FEJP"&W4"4)#O$7ALGH_N(KT/9!*SVO8%O^X/]$3<JV
MX)#GJYQ@"@G",9*D.HR.H81/X02.SQL4;B,TQXD-OW&-Y"2%6#05+E&2RE7\
MN^73N21U'UD22KA$1 V48L*0HHR*64VGH0,O))GI+1YBJ:_%P<4?/XHL8-FN
MZTI[I[\7#B^2*YPCJ)Y/DMVB2F:1D'E%&:>GOZLCY/39M9^%8*>3E)>;@I/,
MMIGS1)( ].A_<O=:!=^*=H?-?L45R8@C\O%Z!H?KC7*7ORQ=BC[X'[*8)U[;
MISPL6D#72XL*E<K?_[I?'&Y_YL6TTMJK )R!M,?31^_U>BM',9HP@$1CIV*A
M=%C86+-3[;4:ZZ+&>F\*ZK5VN:ZO[H@.[ZADEP[\8=B@J\PKV@WH J:Q6*SK
M7)$.*4??MFFA"Q  0O"^D?A_8S?Q_XZ*_ZOX_W[B_VO%_DL^\Z5H@$QV%,:_
M<B..)9_I:OB @EW<+ =@1V$\>GG]XU&">0+6,'@81,,M"-5++V!<4O6U8'R<
M1[/UBB9SFQ:&>LQ0Y%JHGU(QQ/'#YCL#Y9PY#(=_O*.8LZS^+;R"<#'<:8,.
M#R?<7,,,-9 ^L\F"*W+#:%[)>6/%V-9ILGA>Y'[Z:G)],I=^(\DM*N:2[WFA
MB'I.\MWJ#XZH-:_*?DY?#ZF^YN@U;H%>LY/HW>HSRH;T5$3O;"-Z90WH;<+C
MF(Z>**=?I/J=YO8-$CLF) Y?32[=>%T<VA=J?;"&"),=#>1YBM%"$5C(9MP+
M,$V%8H12L"[$UGA_ ZX8<#A/4F@7BMB4$AV51L#19"*>5*> ]SE*Q#,IVL=;
MBI@DBN+V+GG-&%X)Z<F(GK]*2*_L1W"^)O$9ZRU94<;_G2QX\#4N>,!]+&=M
M?/>UT<;G)%:QX.3G^W%/CV5M.]*Z*^^]$>%WBC074L^7=^3@6KXLAST+/3!0
M6"YFXXFWA, ^4:,1F^&1D!MTKVI;K9#LQ<-A"#.P;$;RE%T$+6"\<\919E('
M(%G.'!HUS%BV)\'+*UKZ&#$9W&A7<!*AQYMOD<9'D'S9"HD;/HNM?C"Z(^RX
MZ+ 3;56B!FZT !\I=KJ\)TOZ#9[LJ\)C7+%(0D+!V&FPTLYNL8>5**I,?4&L
MF2PV\@L5,"N@/4A/E88]9+Q\B:PNDC,$V5@FEA<+]=G-I'\RM984BVXL6<^8
M643U%%HB3PM !F!]=JJC(I8MU>;&&(%:PC>U@L"1B@B<+^9<+-*VV'A:+%A*
MVQ1>B/@@Y.>8/*96:%%UDG(Q60J'J"^O',[.:^" M+%]MX(T\4\VBF@*"3*-
MMDTK$UC4AC>\XBX,T0^)XQ>D,(FUFJC%$XYJR CI"F.6!=J&\=037I48T$ND
M%(&G3?8DT&4$D+#26G0D\=R4HD+-OA Y8;D>54HJ;9=@!:4HZN!\P('JK61>
MB<(LE"WNGH$;*'C!&T<0-'>"(*C73K-^\>'V0U\MEGQ_,_CZ]\>[FP?MT]W@
M\?;F=^WN_F:ERF1''??-X/YA\/7N<__Q]K,6===^P/;:<?G?[X.'N\>[P7V)
M9I//%>_(!^.&\ SN521I"0J39N*AY6%(]A?:,;S!H428OR]6H/-F=MC3L0<'
M8%=?]W1L=ZK-1F\G=>#T9K516^]1Q9\WF_6=#4H_P],_PZ4D2_M^)F-_NSI"
MG)9+-4<, *\QJ1I.26S_.<R]L8Y*-S1&/Y\\D%WFI1CB:,3 8/UX6D2-?I 5
MMKQPMD+V$OX:93IZ230Y\%>6PL-1E$KO7;DVV-*=7\(7;W,MUV:G,?UW4NQT
M(Y**C,W9:OFLC[G;^=/>@G,6IKLVYY1[N?;''*4^:XK<)_XDAJLAGN#9L%/E
MO@3AK#/IFE:NJ><SR']N-<6R4'/^W$0FSQ>/A\*TT+%$'H]A7BPD]@!%FVQD
M30W;_^\+_(NG^5ACS[_$;M)72"-]Q\1_;F,"N="H[E4 5_X*KIQP>FFZP:5X
M$C )K 0C=A&I0?6+:[U5Z37K,B-(#B[R9)2$[=>D!%0*UJ*(]560/$%\ROR8
MOQ7GP8^O9M:MQ(_-P_!CX^*ZT:ST]"P_'H<GSDL5S2># :&F" CPC&ZO8FVT
MOM[$<SG\S(\E6DRAW/^(ES2'U)L7U^WN*1\[^:2^MV-G%?W_U GT ')Z=0)M
MH6ZTK1S>$9&\!:OG.X*^+('"\C<4PZLJ6F<NA@6!TY+.IYMH(FV@_DJWFV6
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M>1GD^>?AH+ _O4 B:E; IKX63(Q FQIS;<@TCXULP_>ML<5,+7 1,_"ZGG&
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M("UGJ&BMD*]VEHOP)V]HM$J^WEG.'TM5>-:0P!0/H3>SPS>[%/W1*)R&8 /
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M"/+2 6GFC2P'" )GX+$GK&-*Q\$E<]"Z-B/*!A(+38O! MPY&AK8>!5)?^0
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M?M[0+M>;WTJU$[:97X>7GVYDF[:4R<;-Y^_/;,P\;N=3>#8P?KV2G7Q*K%T
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MYN:BP!(NP:0M0<*KDK-8!=?BL%#!+Y!M>%="/.4OSH(\H.HR/D^T9\3JE!Z
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MN: ?[:?COCBG*8[R- 51\4=2&"E625(7MC!(Y#BE0)Y^/-F,' FPK&1NXXE
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M0Q(YP:=Z60JTKLGJ#XGT%@VG6AH7]^L)FH6(*IS#(IZJ\2J<ZIXP6(,Q+<6
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M_F4H$1=^:PI?"H:TLF7IL\"\M&T+5A:,/#89$:@GHC,]D3MQ.JHT<*.QA!T
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MF#9XM>J^19V "&:?Y/4T**>VJ1,P<3XA9X[$V=0)M%%8\4H%"B!(9ZZ@1:U
MJZ]G5_OI&+4")M8\R6:O*,V$U27*!=HFRH2%=7H6UK9% DZG;Q8'BIZ-C77L
M0@%^OS^_4$!OK%"@>?C)]@'7UPS U0N_[=#V;O76]2">T%2@!DFJW:4.9P76
MNNL<L2:/IMT"I)8?4=V+J%TP82F=OF,7145MSZ!%V*RMPY=[0E T"J1%L=,8
M0%;R"HN#AT04@BM8R'P>'->Z83N5L+G*P<@.B]<%U-_M,15:![!+M;N6JC>&
MLE7O2:6+4KNJ4_?'+W-1O:ZAKQ^D5!&/[!3TW=<E+,A+A15#) 300$0:NO'%
M'@)-@\XN^@AJ@.YMZX)7MBY:(C;X'M(?C_]1:A0FT? ["2D:33$TLU1&JW)S
M7YE(^HX2B><W8MULUR[FY2M0[7;I@7U=:_OB;-?)"QA;DKW2CR$.M)$#M?=V
MH*(U9D-1V9Z;8RR$<&2QK-.OZ#^+>O2M-931@(;2F]105;(^NUU>^_C[D4QC
M%O*W=E!%EWAR#2@<D6:LK%;VA1&<"1*L5T:5TB*8QEUSC]L:A.+[C=A_YY7Q
M;(2-]Y7QS)C8;!!KM7T9C-61.ZW+:#SXTK);*R\!$KM('W!<[Z$7Q\1?!2B6
MI7>2%IU+>_8ZKOTAP_#=):ENK7-$Z(HC.@?G!8<FXIP=("@V*ZO<7N86V9CK
MBFR^I\_%"IL49O8AA/VX80I33&<VUBT.M&SLF)85#OZ ]&&#P=^.#3B@SPVX
M&DY3"2;-7!:&Q]O8VG^QUO@O;.D,E9LZ+]EC% XIV3WT8E3.64_!+L?%="7@
MK8*IOLQ>., G 'D"HF02L#%,P91N9SX[27J>T8_-V9"$>:X#!D6IE8ZBVK.)
MU@0/VLHZJZU)'K0/3\*VVNEK<L\JEL)MP8+'6+\&5"VKG(MIC .=QCA0W\R!
M7W&>&OX1EQ%Y$0YF@\7791.MMY9-;NC$.;9X6/$?\+2E@P?=/,##?P?+(R(^
M;R]&??=*4_:]*##- I]PXC2K![XT<@_'TM7>RWHD_P;V8FUQP.M-WP8695<]
MX+20))M&2&>Z>:^O9.BY,9G,I(A,W9"6?^#IIZJ!O4C?I[/BO&ANMZ6<D=6G
M@-[QX@D8E:AHQL$$- V;1I$.3ZQ]<NM-NYN)&T5SK?(0_D![--,UCV20A+3(
MZ0:4(AE^GN%2ES^KU#UH9XO;7Z\:#[X'I[<=-^*<R)6AEKO(;\W</0+L*&NN
M8^V/KS/?JOYX>8*T8(M,D0O63ZM$0SF_"EHG0)MTO],QGJ"6@:E"-D;BSH_B
M,$$S#]0SK)4,[Y@ ^0Q<-OSNSO"M:]S&"QUL622181+"W<;CQ7:TSH9YFFA'
M''6%"*+1*WC"*W^7Z)?2 :LHAK#2 @G52ZM/Z)13-EMTMC*--))>W9GT3.>:
MD@D)Z?S5U&P&*0U>]8SQ ;P$OC,R01!FYC=9%'9('GOL6S"!54G,;T8;&RQT
M]R5CG@_P*7<Z!3<8!:Z,%7UPXA@4@(_"0W/#9&FM'S[QL^O_G$]<!BLJH)8(
M+I2:NO@1D$%3,J U@G'HTO+!H3O[F&UU;NX/ERH,\[P>82LX?O8I".$P ^DQ
M#@8_I:QY P>U1@E(_0"O&S?C#[PI. T1_=B\PPG[R:F6P4<M/Q\%RH194;B0
M=!MT!^F20<>\T &XN"D0/'LIA>#3ZWI"?1K#!E"U/;&5EHJ'=9;8UJFQO:X8
MS#2SRVT26!5H>%/(!:4;W!0(**C!G39V S8Y:$JD^72/7]Q9Q-OB.NMMD^=T
MK#73<$PE=3U_8I[S(QF%1\J)*+7RT@SDG4R'5X-A=]S+O%Z(W%6"+3N8=<;8
M02ZS]IJ-'H+@5KG,YR3R?!)%V0W.?ZF@:T _H4S'VT:W&K\3PF?1W'9]/TA
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M_I$V@L<SA"R(0^\YH13AOH2$YOVRZVET!V;7J+ %#OH0NB)76I<3Q\?V>'Q
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M-?6&$-=[7<,Q&H.!U\]Z46:/_U9-;/JS E?&>1N7"BP->]<N>._JO@O(_IF
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M.0K/:3ARRN;,%SHA,YG/67O3ME5:@$^=X)M0,AM+HXY"\#H2O*47L^^"Z,Z
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M+XLQE^S+F#SH;Y2!K3@<<RO)I"_4=J=\TYF:_?R8\DA'%UXZ6>&F/%'V+AP
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M\.7^YOKI]H;<W?>N>]W[ZR^D_P0/OM[VGOH2#>7(W!][A(]^DF5P'WC0K!M
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M.4=VA:I"*^&*D,F)T-'PKA4Z6!LKJQR+"F(R02R30XZC(59'B#6TK%R=W_H
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M<U;D[Z'IC%\/+#-<A+ %#!%V0XT0&1$VEJ0VB2N*<H>T=8VIY1MV1-W,8&1
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M"Q6#+X/RH0XW2HQGCPI=Q?N\-FW#XGL\GKF(P;K HDD04\+;0)N(_V.%<RR
M)4ZL:*#R?<HM:E!>R\'"O+WBIH'6@L4(L_P03R9H?=N=LG)<" B)&^<J:]R&
MK'&MS5GC?AFXYAS^-_8G=N?_ 5!+ P04    "  :9F=:"#^ <+P8   G* $
M$@   &]N8WEF+3(P,C0Q,C,Q+GAS9.U=47?;-K)^[Z_@]5/O.:O8LI,VR6FR
M1Y'MU'L<RVO9S=ZG'H@$+=Q0A J2CK6_?C$ *5($28"45*%+[T,WIC"#F?D
M$(,9#'_Y^_,B<)XPBP@-/QP-7YT<.3ATJ4?"QP]'#_>7@[='?__XPP^__,]@
M\*]/=]?..763!0YC9\PPBK'G?"?QW(GGV/E*V3?RA)S; ,4^98O!X*,@&]/E
MBI''>>R<GIR^R9IEO[+W_NG9VW?NR4^#TW?(';Q^>WHVF'F^.W"'L[-W,\_S
M_;<G?WM\_VXV&_[\[LP;N/[9V>#U$.'!;#AT!WCV^F2(O+<_OYZ]%4R?H_>1
M.\<+Y'#5PNC]<_3A:!['R_?'Q]^_?W_U_>P598_'IR<GP^-_?;F>BJ9':=N
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MNKZ=3*_NKR8W[4>_,><&O-Z]>W,Z? ,S9,HMC+,I4F#MY+R=R:6SYNYD[%_
M5$U^B_CF.9YC#AP*]H?L9C=:F$^W@=GY<:.W_WV!_?)Z,IV.;L['DR^W=Q>_
M7MQ,KWZ[@&<[ [RV RW49^90 T.']^)L=",>OV!\.?YU=//Y8GIU<_'/AZO[
M_]L9M&6^6D1?FR.:\G:N;AS)_07'R_%H^BN?3U]W-SESCEKLWK3 CG-U!-L>
M@7:#XH1AZD^XNR)$B5#H?:8D?!QS8#!KOV?5<]2"]A-L8DGD!C3BK/@?DJ=#
M?2?GZG"VCN#KI(Q[!-LG%)&(^K<%)5H#5<5#"\W/96@$%T"FR*='2$R3Q0*Q
M%?6_\$6&$12,7'&$S,?E+0V(2W#4&AD3GEJDWI:12KD"5AE?)V?L9)S[A!UY
M#(G/]]1A_(_$>X171'01Q82[RAA6K5$4)8NE6&W:8]B"MQ;+=PJ6.7=GS?YO
MSKH#L3@6NN@1J!/N)[%K@F8D('&7V:<PT,'STTD9'L'"*?#HD?UOY='GBH_
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MT3ZB5Q5;Z[PUJ&6EQ4HY"J@.UO41(37DUG5W7<=(BXZ:K:Q&\/H(35T$KB-
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M&->NSQ'P<3,5KQ@M7GQ>OI1'_?K#_P-02P,$%     @ &F9G6B](?+T\7P
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M^>@)GPM)(107UR_R?[_^E[<D(*C'TW%=/7ZA']?_O [20A;\<XG3C-?+QLU
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MD7>'\9VQ3PWIPQ6[ >]6<;+UF>@;G"]FTRE.5AZ#9=R$FJ)K"AJR'1Q"5"Z
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M[&A[S=9+TD1MUQV<A!"C ^%,"1BRRF(X&_J "7S[;.H;M5XVLBUR,1^#\;9
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M'&<,8LG,ZRB,Q<9I=7<???)617N%=G@!]X$P:_HV$6>S_= $YV-L^QVH?1N
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M>:YD>HN36C+]Q6RQ'#D=')$O '.Y;FK*$$$C@LLFYVHX>32#\6"CB"?#A_8
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M_K$+]'Z=]]LZB>L"F28YS@2"\F3W*R$3N,0X."$8*YX9ZX>+47X1ZVG<_1N
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M@U\__A4N</X)-TA[4SY*\:)9JN<YK!2R!:,"G[! MEHS%#9X/:#7]9BX3[S
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M78W5=$@E>SF5.@4Q<2*$J)P&&:RD^=/4G4B$T2I;#)G9+'7=OV[+HDZH;Y)
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MIY>^JX65A,1R)\KHW>;!H+,$G],EQJWHCV[\%Y1(NCP2XI(,;J+Z?I\PIK*
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MMBM=)2]E(I$.D1VB#AN,BZU=U*C*(1KWZ LH@S$P1^9<JUX^P).UBVQIR%=
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ML'-*H9M9U6!ERACDG'>>==EQ^AOZ5^$M\F%K]2-3["&)X4![1KVU9HV) *=
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MXS&W"E.?L(H7)GVVO"?B)SPT8+@>E$7<WI#P]F\Q.P]++'>1+.?[%Z7*ALK
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M04JU>ZG9X2.DR7Q>@O4E<!TE*/++[6:.SP2VJX=*1,7 +)-OC"?'>>#2W 7
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MV#,S*H967A=-0I.]@88#@LU9HJ6Q/5:0^O'\00Z:4W%Q#I?E9='R@\73ELH
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M1>KQE@Q,*.PH.DY*/(;'/BQ.?6"88"!5F4JZZ"OT@*C7_O=S!@\5 6KZTJ2
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M#8*<*6(JQ@YWY4VE>VZ5]]_Q/L#2?BI\,_VBO"$UQX,U[4/#^L11^?/X9NH
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M<)\=?BY%\1OB%/8Z2+>'P?X>FFM=!M[=&6-("^?,)<EV9\ [F.<!1@ 8KG-
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M5[O_ ,$B2P_X*+?#W^[_ ,3+_P!-EW7@M]<?:J^@_P#@D;;;?^"AOP_;LO\
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M6YR2=SN-$AQ:+SNP*34;A;6/ C4Y]JM^&+96M0W]X5->:1]HD^[1<TL[&'%
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M/Z$C'E2BAU[#YBMQ6//;M&6K>O;I0@7%9MS;-=J=HH*D9R$R,%R?IV-?3O\
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M)VNP1<_>8K'(P4<X1O2J>G*U^/48XKHYHR;2>JW\CFY)Q2E).SV??IIW(5B
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MV2OLN9N5ELKMONV<)X:T1KR/]YZ=ZMMX'VW&[^'.00.M=K9^&19<!?EJY=6
M^R-M7YL5I<Q]GT.8MD%C"J XI\6I*TFU6^85E^);B33(Y)&SZ"L3PSJLE_JJ
MI_>(Q5=">:SL>@P/YJY(JGJAD+ +]WVK:MM-\FV7=5;4;4)'[5,78KE9C69$
M<S;L9K6BB^U0_P"%8IA8WG'<UTVE6ZQ6P+-S1H$2G_9H KU1O$NC_ []EJ^N
MM0O=2T35-<TV?5HK\+F*&,W26<?EH"));G<,Q1J&,A=U7!)-<GI.B17=M->7
MC?9[&V7,LI_0#U)Z 5ZQ:^.O"=YI4GBHZS>6.FZOID>G:CX8DBGM[RTN8H1
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MRY(7F_+;[STL-EM6LN;1+SW^X^';*22X<J<L?05T7@?X-:Y\5]3:UT>R,VW
MEE=MD4(/]YOZ=:^P--O? GP\\,WFLZI9:/96^G6QO+F:6U#>3$,#>V%)4'(
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MEQ="*&.' ,,LK89T' ##)^8?CWJ/QK^T_<?"73+74-+?S)99"LWDR'Y$)PK
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MPQMM6*)  B >P %<9\ ?'.G_  >U>\U#Q''&HGA1;>1HO.DB#MN\S805*X4
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MH+'QG??&:6S_ +*C6>.0%Q/"Y\N#']]L8'T^E13R7&^P^N-+V:^TG'3Y7O\
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M/0;<(K =) XR<5^?/P4O?!4?QU^'^IZI>RV.CZ=XDTZYU%9\,H@2YC+G.,8
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MB?%8D1#W2=->N5_KZ0T3CSL6:G=&6X:.7\@;Q428EVTH]G68UX/+9>#[1=<
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M2@9-NYI)B]9= U@OMH%ZB8-2QMW?3=*\0&H< :>3(Q@VXY[Q0@$3$:#]V36
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MJX^7(Z"O(?V+OA[X9\#_  _;P[JW@K3UD^(9<:AIVI6SQIJ2VK?N;6=)%)5
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MO+/'?A^+0EDN;F[?IMWMS@]B .^>,?SZUSUW^T>N@Z]Y<"-,PS%<1(<,!D9
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MI:='=G3=.O"+568.ZIYC(4B=/+9I2/NAV0#<<']OX7G0KY31JT=K:[_%K?\
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MC?X[0Z3JGAW1&M[C1]4UMIY#/-IR1I#!; $1AW3#-.#RP90"3G KT3]E^_\
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MNZT3Q,9!IZ(BM,DL(59]Q[ 2' '?K7*^'OV*O!-M-]ML--#3<95Y0R(?H?\
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MHN1MD"GJ" PP#V(_2+2/^+K^'K.ZMY%\5>'=:3SM-O+><&50>-B,V3D'AHI
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MC'!#O@@<< FO#SS/*N*K1JQU?2RT7Z?B>R\CQF'A[.A23EUYGT]%K;[CY&\
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MR-4L^7:O<GT4"DF*9=L!$G)M$U06:-SYV6YR:U$%Y1?DS]6W;'/",I<68B\
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M?@]['F(250!<S^!^H[#5R:1MQ#M7U7J=.GVTZ5FO4#2^TJY1=32$0Z@7@8E
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M9KB!-"2)Z!?P 6-6_&7X,XRFJ%!'5K5IWZHZ8V*WK^#U!>"[ D,443%8R5)
M[AO^48&QB57;:5#\E%?5877C:743@AB:<%1JWE&P8Z[64//6^+Y<%_8;PV;
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M9-!BBY%$9Q?G0 BRBMEZ1J/9#VR]ME$U"V<!V64TII*FGT4;UU I8-3>KPN
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M@//3)>#>QTK8AI#NT,HY9#ODPS0IGW#0F>'Q 2V"*Q50;DB,SD#LRK;!N@-
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MV*;1$#4O>+TC:YOE%L\_E".]SPQ8'6\'6,H[400FJO=5\N-(^O9[;];WAB\
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MXJQ^B!'_;I6&10>.T@ITS>.N%V\+!(^G'X5:OPF\R:X+,_GU.;4^;R&MA+C
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MJ(*/'E4BL?'R_3496DF^C3S:^&SV3->E#K?KRE&+VEUS6Q;^"]<1BC@&FIZ
M8I=*.-BB5LS?(:A@2OLT))?]26\RS,F,/YI2*Y*@ 8<'^FS\JBZG7)5VWF9^
MG[*-=<^1J5+UJ2#*#+D8A4*?[VN&>A57?C51I,4FI*H;-<:0_!/U:QHEM2=A
MHRGLU-9.=ZHK"CU4.C&/F\<I%[A%"2'JS,\^8-AY'K_X!&T^>P<2R=^<!QV
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M]K79.=ZZ<Z%*,P+'P(AX0/P0Z495=A;P#66&3^,-ZZ)6DK P]'_:R5(VU#R
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M8K,@/ZQA*E"P*88 6DK,+'/RFG?:#<#.]K&;/BU^\G4=)'$%N+.=[ST"N95
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MC?*7^HO2U?S] 5.[;$5R*LMZB=S%JT#*T$O1=D3!%IWTUX;?*C2L 9P7UES
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M-09FQ+:'Z'#LN 6I75Z/:Z<E"N)0L0Q]NC1F;;\"'=J*U"[R2ET3^,11$E>
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MG=Y#UJK0VZH8>-<(ON<\^*.AJMTQ+;'[/>]+Z+Z64M &])  /@%ST,-_@!>
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M+[R@8^H6J0VLF"]X>%:PD*,COSUJ%(>@Y1O?N0+<"[F:^1]02P,$%     @
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MU+^X:%\C:2?(Y(E?%/TL>H_+V<G93+[X:X\[S_M!NH\KM)EK?Z$4,3CHRU'
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M.R]/L[&^4OI&7U76+W^'R.(>K?[D0!,WE]Z ,#3/&MIM<NS+H9)FU5 7*7.
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MF\;WT]>F7S:,'_Y,A*T.Y2=A@GNNNYL(:J^GF=M1T)%X:7,?:D.?@54J^<I
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MN)>#?W2-'I*5J5/'^2YK:DE&[X:#EXV!;'J&N,'?^R$/$ MXRF-DA=6J/K
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MI(C(F2+%=@YN=LG&_7<O9!J62M4O9;+*UJH#O@>4_1DV?9;Z@%Z\W_U"N&'
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MVY9J>%?M,)P_?;0^<1\QV8+R_W7"__^V09=V4SR@@7,[B"GV;A3@AD2"#:=
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M^OE, K^Q2;*J\*VY.XB-;&UX+B(A]MO[*HGE*$HY"K@=NLK)C,"WGHY0Q;D
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M1+QVL;/#+E6Z-RJNZO2Z>/6$\?Z(KWO*CUY/J&Q:W/A3R4.NC;^,L$M_=(X
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MEKP;P/VQ\6-3"1;?J7.$8H,-=+F*@O2+*X8YLB!.#3%A$*'\UL!]S;[.K"[
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M#6W>RJT)T($?QWVV7YU_S3GY@V-U@M#]T_==CCXI'GA3'7HX%' 7ON=)FJ
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M1YA60IR!0)/ [0;BW.%2N8?[<?GXJ;^8!Z+TYTTR;$>7V6L$DT+I\"D\DZV
M"[56T&;CJ/@NE-!\CEYI$EA8F'-J<.V(^7STJ^+1#U2P9X5C[2@8FH(Q@  =
M<L/;XA2P+\3^)AB<)=C'[$0<LA;7LA_4??]-NO= X N4L4/*1JB"K&( F_-
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M;O];]DX]F)G^-+[N(B'K[057J([K@>!M8X+ -$EMV8A3;RTJL40112;YN'3
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M)=M'\B;HR0<=DIIMGPI4Y5<&1=;;2[KDJ%36J%04YW?YF C2M<&^\6>K-D\
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M F_^_69:.KSRKB^/]E0[#E:V9D*MAR-H$#*SL;%JRT'\2S(1.XF; 66&1AA
M(6(OFY7_HWI\^],8UH>9L@D(I<&(<#&DM2Z5J2F+<0'^-G%XV ]?DFZV]?$G
M+<;J50&B?</1N1_?GH;[L7OZ->SXD#Z?U/=R[%T_4@I=T-',EDLS&=$)WCTY
M@FWMR)?:7AO1V/$:_I 3XY(E%A_J2E)6_HSN!M>$8##G8[QK[%IL"#U"Y$[)
MV[FWD^K>UJO\-\[Z";+_N]I\^1_?)Q$ILF$_N15)E5J)1\P!:6;H #5E^1:I
M.[X3QR/G=/=%4?([H0,3&N<:4=Z-\:"WSKW9]MG"\:D;.#2\*'M>S\.*7J30
M8R1%+LBCI$Q8T_<'O"!1G7NQ^:YQE9L_E]B FN>UPT;^Y[6$</'GTQ .F?--
M\=I-YH[Q5WN^.G&V7K8^HB5R<:4^'7)0%2QL0A^4J<J T146>"D8CKXAV'M"
MB,A;[;X69VJ>/JGR8 /)<W+H@Y?2X[[XF,K1HQ?N-G=GDYT-2;<[>E]\OEPY
M3%C'7CVM&8]CFM:?> )<V.N&+NY'885Y28\K);*MB*,B$KIY[JD18/BLP6EN
M4_ALG^Z5H*]*D\='OK1T-GLV0G)\TG<'(4B7W5NFYX& 3KN8DWFKNSX!"MRX
MM2< R;R=KFG)#J14M 3V:KB&XD0CN'M(,UEH[#F_S,37E'Q6V,'(-]')DXWY
MQT:)N]_:6$--%\+H6;>-$@A6VJ@QO'NV\3 &UZ2'.+KQ1O^%P,' H#R:!W '
M]8J_'D+1K-&W/V-U8_QY'U+:E))E-9T:FM9:#G,O=B(*&C [X8!0];JV[K-S
M(,)\ZZ*N.7R8K3%:RI&WP9:%EJTN2 ]E'XG\%A87KJ?S]\6J40D#^/9N^&44
M;(PR4QJ6[SEW=G0,Z):5Z(D76IY490J1@VQPA;4.!JM!MG-&T-%'YR0!%^PB
M*'-G9;7T61OA;UF;OH./ASJ]&M+3\STZ#8"#?D7'+(/:LT-/@/3\?0=_X8="
M_IKP6Y'?303=&[28AM9'%#3%HHL:>!J90W$_0H3&&5X8;9>%B8ILF."9>!^L
M!T9:37 V/%>ZC8_PG&^MU9"D$Q;*6H[J&MO (Q^0A"^6"X+U$+J;+'^*H=;D
M960XPJQ%KGK=2>-X_J?^-]<)4"%=Z"IZ.5K;T@%=86P9$['M]<G6K,'U$R"<
M6E1I[_!"S& CHHOXE*FW_[0QPMG>VH\B"J+\:EF!Y1T2;T_&C2NTB HIN0 @
M[7W4ZDR^C_.Y>.'U> A_S$XP#UV+*P5*\N\J+=P(>I1V_Z/3Q77_ &(HK=[4
M47&H3&=&>% %VH!YLMII3]-K52?9C_E?U^*9<W4?<N-3=Z\,]CM3.\"?/NOF
M/9;RLN?8?K;+[YT=&9\X+PUSEWMA<UDAWS/#.UJKL@*Y_;A!,WG'?L]53V%<
MLPEVX;$%8A,.H3LN GB:Q0MX!O*/1I*&9Q,/;J&SL?ZJ7H$\?.E9.4<BKUC,
M6^(]RP^"A ">R!V#S0A%>X\[JOEN]TJ!E +CO5;'7D5',A]G +)UI$40UJ]?
M\MW"ZMTHQ-EKX\^]3;H"D+/[@)%/@"]</<!/^5:V[$ORE79>0K2M/-_9]2Q(
ML,Y"7-#<T'<O$.DIQ/H#.97:;MOJ0.:!MQPF^B+M+WQ+2I*6V=^J)_"E<]1\
MOK05O'8\$U=M@S.VE.E__K;Y 4;7.. _SVZI-7C7+SFXJ;?EM%M>4W8O>R?K
MSSMC^F9Q_PE _%(OABQ6HS\V[TNX:(*:Y*C_R68N<-S@5 P*C6KSLS5@O9:+
MXHN@JG\^,"%_,5[!L#4[:2D<+D' 1&5,.U^=D/4$8./+S+7C,\>U43F!@&_K
MJ:I7;'2[2P)_*-5X;]&<N6:!^ <V-;\/9Q7R^L\5F*=<EU9).RI-;R[U0%XV
M+C$C%RI_RX9VI)I9S/5I.QS: 3))4M-M2Z5AI06$+?GER(2UV^:4.D>(7]8+
MWTLI2]GVI'BX;,Y.DALG.S0/V5[(&]5%KX9S3";X8K(H9/JR;BZXPZ(QMGDY
MPBE+]-^?:RH<\1TVVC#;Y^SD1"6S%%MHP7:3)'TP-5&.9TAIZ49MZM",4U.K
MY&N?[TDIA3%U'^@<K;J,FC/TP?*^NGTEU,<)E0H$NBI=E#L%:Q?PT^5>B[,:
MV%QI6SD.@.>IARX*,+C[>:12-(\VB2D?%E TGL5BL/:QY:4BB1@<Z%0-&!Q(
MOGCE2+3971;<H,E@BF:#U/]=J.I!AHM;M1UH'R]^)/,$:#N0/#3+EF$JL;6=
M) NJ0&6+3^6S3?@HQZX7Y\(J$@G'D:>\;Z@9!YJQ\1E#C7=F7?9TC9X 7E.@
MX;MR2B^VA054T/?N%I]*./3W^$_FYT=N:*$X"AR(/<U.!>4+O P0GW1 :K:7
M8QH[.G_#7KN>EH39$C/#KWK(PQK8^V7/],?ZA676&?EH ,C5INJMNS9,#'QM
MKV*#J-24_CZ!"COY4D8EILD^\L']?H9X1C%7\)=39K&B"7,\M^ZKSZ=0^ZA'
M7V084\0VT>ZZFQV;CV BJ^VK85I?E(R2EUN3._X-BN3C)<+F0WM2;\-/TK)D
MB1F2CI"+F-""2#\6TS/FYH"%))4![X9"E7,<(Z$1$;0*X=NNU$CFPN$X)M.>
M6SK^T?KME5?9+=( >VS4RN2DYNFR= ?O4:T[&8L!FV4D!OLT8E^H9U;X)(I9
M0V$,JBLLB%VO4P'6Y,_(QDGF(D5<9$]N63 L4YW>30Q%^-0;IF7XHAC)!"V2
MJ;G+[3NNNN'939Z6A4NLFS\.YQ.U"9'ZI[]EG\6OT6S';]U<=>,P7QB%^.KZ
MP%F]CT7U7<T%IG%+;!EPRPI1W238I^;&2F<EJ"^P\M^BBA?H2IO3_$ERSE'W
M H_/$*'5O^OB:HKM=$DL"!):V)@W?[-I*OH'*UV25.[ DF,SJD'2Z<_9,J<-
MR"ZK8^134-7DI_=.PFYAJ2 +L+GML4*" JQA7[@ Q_X#_\>ON-^*IFE=;]I9
MMR(%K*F9<<,_+_J8^D[3-7<?)*G;U>\8XD*-6;P())L$=(^G0\TR[7B?,Q9;
MC//A:0B;7'M7YA\P5#CI%?EINRP:K 1Q2=% R^J.BJ.\Z,IX)J@Y)??)W.4I
M'(D90F+T'B?=J237?JXCW2;RWDYP?ID8;(9^4;A,6,B^$CQ%/TRIM'7=3X>]
MA<97Q6VMZ@\,$0Y'[(:%6H0#0+@^Z/$15"=?Q+&,O ?7QF/];:D?&DCR<-+&
MR(^,!7@,LR.82PR$*.6&QM6E", 8TLIBM/?<_;B\\FQ.[XTZ@Q^?&WL?K*W&
MB]JB%=H[VZ\%UGW^-K]IE7QPQ$,V^Q$=Q99<>/^M.AQO#1=R]Q[Q;6=0.7E6
M>?I3,\6)-HQ+7E&,%1^#B]YUJ+L+G2FE"_7+%=N"-./BHOLOB$C@FYW*7BN@
M5/^G/.:IPXM.?&/@G!U+E;[!\&2O?R(?BV=1W'[<.< WR&<  Z5$78_H$]'P
MDD>T(QDHSV1(^YME7&WJ\EZ>W4]A(AP0\;9JCJN2M_PFL7"2HH=&;Z,]M-.\
M)O26:9 VVC<OI4;6XW5J=;!?^0!=3L^* VL)CRR#FYO(!&NR6DS*W*E?##_'
M5&E3TYRX^KENU6/_$P"]P22!]@6$FJF/>UG>UG'];EG^6=L R?DW;69YJJ2A
MS78?F?R7-IM6^\,8]^6,/"I.U#&T5C<^!TKX6?6)TOP/-GP[+P40U*SM?4P?
M0?ONZLJD&<P89,G =80QCL&T8V-6\Q5#=!:6"6>(M%Y=+BND_UN9$/CY='2\
MM[LDT;I1L79Q(E%E=1CE0M:48P$82U-V][7&YS?HRXVE(0%YJ:()$%Y)X+;>
MQ_DI,!L)L&+W_M(*92>>F207><V1%E@Y^A.D2T#(PUJAFL^'XH7$N:EBM9$F
M5#<3_T.^@+^QR-:30OE^JO*8[_D[7J7%4957XT"9!+0@5N.$KYB5.4(@75!T
M:73_(!$2I,R<V$P#65N$I ?/SJ#BYJ"KX-G7Z:,4CM^L#;PW-4!/]6.B((B%
MY^9"X\75 !O/ N<<F%+N*FE/:<PHSF;1D\U 640 )DJPB=;(]_<]H(+=)*@M
M-B$__X(_\TQGO3B=;;(UTM;9^&0P[3AQSYX&'KL.++V"$NO.9S84M7(33C=A
MR:&=,&ZRV-M#O[Y[%':*HHI5QPC-.WL9ZY^"Q$R_N%O#/^WDM9EU:_Z();;.
M7?@(;0VHI]B@);31.3\>?+9A%7F^M,:T9\*VY_[UXRBZ$;EQEG6AMYG_Q@\<
M<2Y^=-^U>R8)A9,&6R_FZX*YJ8;Z7C^=@2QRBO)%W)L#H$ 9$1+(<4;7'JZX
M:06!8PW:;N#@';J-F29/[<#.:-_"'E>4T,.U?BY5 <:>"P-VFKUY7'7PK<&H
MPZR*J8=^'=EWIGOB1)W*NCV=SP-HO)W[7"W79J#6/P3<:&]LL7D$TV+Q6%U<
M]XPE0/NZOL<5'N4FJJ^AVQ?CKJZB<2W;24-6GF)##"E:8#SZJ9H@3*U+QERA
M7BVKI=QH98T7]U!G_10[XJK4Q% M&P?@R YF(I6V$=,.L?=@LQJJ,Q-8J\6_
M7>^'C'2ERGP!_SZP*<91M6E[5,K,BVME3Z?Q-!HM">NRO,?_":"0V;'];A!/
M,FJ=,ISUEWVP]A$IEZ[F\02*GEG<*@=#LJF[>B:BP).N(\8WY[IJH.XU2+_#
M_%SS@X*(&LG+[TUG #!S2G0-A>-NB2I1034S+0OTG@HQ4G7_['38?H%V;CNC
MZRI=H"GQ!M;4>(;40:Y)[_8=130T$=>^K?:AAJ\3PX01M&[R)1#/7WA#*,J;
MGU__^''P)>W!RW"9L\G@;15<,1SO(5-IF?%^MB)R]2^Y"X^=ZJV7E^.1_ :@
MNX,HSA/G4K^8J"W'<?9X1=[:8WF&K#)GITJ[WGK:GJ+HS$(KK  >&QN>%2@[
MQU>B*D%,S/;(--RW6FZ]\7:#F:.X@CEJI-S'1TU-*%F.D$).(;"Z96L:VZO2
M$.FF&"PCY^[QV  Z!,HIYGA?!T6;O?*[F:-/#AE.&PPDT=KCO^+B<Z6Z4?%Q
MW#T;1]F'*!(R%VV& !8YV'F VZP+/*+'$1IQ>'780XG'.FC/H=$GW,!!M3:P
M35O>P2](MMU=IW_BVR;%M+K;I%&)U_;G1RGFTJHK,<U-YVX\O$=8'J =40/_
M-N3H$6.RXMW4X[HV:LN""NG#Y&XQ0%W#?C,$>&-9PX3@.OW\,7Z\9X4A]UB4
MER^;H]0Y]\*6:M/7ZTURH _&6FPB"L >;VUUP 3_<?P)@%]UK[R>/5ZW3U)F
M7V31ZT5 UZ!1+;/MX/8V-.0Y'<6U:MP3 /43WL+B^O9)OW,82: %C*,[I3_O
M10*:O;S<ZVHZ]>O4[RJ ?Q&57AL'N[*@3%UKH.^Y:I$1^;A"\?<IX-[DU5F
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M>SI] 3/)G.)?0P8LH6G]>U,5-WX6CQZUKL-9WR8Y]W^D#/,(/$Q>5I+RX =
M?.!?@EAS>MG%&_J@,13N'P?=@4H2GL^K[IXM'  Q STDH[T4SZU+"!A)#U1;
M#"LJ#UB(B/U2#&N&M&G!2E.9A$5G7H)W#83B2,T):>"!#&+JUF? 3(,L-&CD
M,:F#5<7(3WZGH_"%$O9\\074]U=&ETXKU/EA C2I0BX@^;!,3?7L$;1ZFO50
MG=S[ +L<'8>T7[G2;_@N?BQW69>##Q3#+(F'@2U?<*$59:OGT8"]CRYR8#:B
MI9Z6.X.QO-0)6W<TY!":<'!)XSQO].J4IE!5NY!/-)N[0D22U#ASUM7@JU;:
M\(7T*]WX3RWUP;M?F.8[-.\/\H,%KD$D[OSM2VXU>DM"MZ%)FO3"=E7^U$^
M9R_@$?=T)HW7\4=0T>::X\V9#;*N15&%K023C*9-8]?B96NRFE*)-8@Q\>/8
M0\$]TP9S^G7 *_@MZ,TQ_*?L8\B!"9N-YHEZEE^NM\^?9&=>ICK5RL%J:#K+
M42(N69T@[T"@-)EKG,XH"<[F:A-C0U<*0.=O,:?K*L#)%8/W5,L+:(&M#6A\
M0':+62$M2G=S'>XGZL#N5JE!XK+7G5DVX<OF3OG\J&D.ZZA(>SI&;R#$/QS[
M5>GO&Y!2*[ EIBJ_.=M! MSSKRK;Z\P4 )V8Z\]$<S#M/I518!H0.UDNL'R2
MKP<M!LY:/ $FPG1F\LVU?(T6>BL6>:DKZT#<8@!L#(DPU/PB6@I1^=)[K8?*
M#L9[@M/7?9XP&G8_MA/<E:&?T_P>M1%.8B2&IL$S6QZ^\!, PD -3GOH>B=I
MLP"IG]_/4@$5 9??+9LG.1D2Y*U=HA>B$G17VU]M(=*+[]\_@/UE-[BP]N'[
M%/X[PXHB=X(BBK*.F&DZ7=VZ[WCGHB\3HO,;!D,?WP0,&'-T-,^P'XJ_]L[C
MX!S7G7;1AF XE)&U2L5[]=V(QCH,.EF;_XH3?I=#"!0WN.&#=?)W9L;</??G
M:48LWO'<.\!'P=MIF8S%MX*9/IYWIO51C,GRK\T'L2BX!V1<8^._J2XBK\QV
MY===?_FT&N8%N\Y_?DD9]1$*83.5AE54RFS10G*0B;X,<P*$J$Q?^PQVC4=1
M<(5U6JC&9>'L@)^E03:DI])5&JS9.'[+SPT3>?7D9[R8N"X-&.RD^A3XW-">
MYMEI+U\^KK\7Z3R$_?PAW44":LRD@9GX(Y(:.8>ZX,6O%LVL"M;<+,^3;_=^
M/GF"QKEW+^]?U",>3I\ DO"50M[%/?=,SIIE2ON'/+)?\95^) ND8O5YT&[O
MV=ZKQQ>GGD6E"W:-;[=S<XZH*,**7N!LF=[7<0%B8RUH(N@AGA)U38//'O("
M1'[3L.;-GS@XY,EQF2J1)J]H<0\UN& !Y@&)& !"7BTO;;=4P:'V!C$>U47[
M7C7O\;O7 81_]V,/<^)4;JE[',$I;Z\^*E5ML/;*;=I!GXV]+@^TI U^)$2<
MW,DA*AT%%6&0!%2$\?"N0=VDM6E3ZS?0LQ!H=+*XE<.+/$E GO+;ZRMSA('?
M1A3_C\ X&M*8KA/WJX0Z>>S51>XNE4U A)-2$'70H]"1_FK]R6 "VOW+/[-*
M"P8#PM+ABP,D@A0OCC*+9_CN;+GK-EU$FM@XY5 3R8*3T:QV*9OHKUA65@*A
MXQYPO- VCU/= 9T BM/KPX/U9;9NBH9\2Y^+=E8VD78<@Y>,\M 1ZHAG\<+D
M0H?^JU?L<#9_WH=:4;_U%L:[][_?<K:49;HF\ Z_1#&OI4.V*\V'9_>*4\Y(
M-%QV+BB(*?;4.B6^+UXU%J_]5"1"\)'AB^<:H1MZZ5MWDUK9O@?T+HD&C^6=
M]LK1LCV*G=S TD";U13ZGNF:XZV,V#,YI 2EG%VJ24?L&Y/Z?$[8POCE/O )
M$&+-N!J?-=CTA5_B@21U71P/#BO<6-885)XZ/.;'>0>//#H";_(HBIB+:,O(
M"Z&NZ4Z:U/-XFUR9/923#&J=#D9XQ#%I3W V['F ^=K2=-S&OM!YTC-1HLF1
M40ZHHB9PG:J&;SWDB=//T>(@IN5GN2[F8#O4!N^28G7.<D<@^D$CS[;6\%',
MJVVBH!C&53F^)8[W(VQWK_TU%I\ #"<#@0B6OV^XEX[<,=QKT#_*K\8^ >":
M?]=2&]!?01%-"3?, 8Q/@*[@OVN%E>_L_(UQG@"O7_2M(O E$%E^"0]%=YU1
M0XC!-=VX#DI;Q7+OF![C5Q.'-%+/FSN^)S^/290S^@48 JQY];O7=F?=TJ\%
M'JW62%4:_>XDJJYN\UE3Q9?A\& S6'N=!?53QN@2UASC30F2PD:JPENHN=)-
M67-H#*"#/^S>,YC@WDM'?8HSHV^C<TA"[<-&1Z$C1#ND04%&GG,!O>94J!P]
MFG\"=(LZFJ+E3'"R\N>[:W4WJ=.71W()E7A?X_DF:7*H8F0)(J<L./&K',^.
MF.\!JYY7-BDVJT4E91,Z5#B97+_+,U-74W*GX59U)<;:<?#5R<N8!XYJK0I"
M;.>JH:6O?,(Q*GE*&6YA7YH7M:KC!XB(/_YNEE"(WG-9!4J)<#!\:2DD?(<W
MJ@.>%K-C+NQ^ OB"!Y"9"P2H:C_:814V0&/C(#I['8'7-FP9-2X_1F6)JTV\
M/JJLME?V^=DP?+*M5;:V>[%>"[22BA[M:%I9Y0!HA^REJ5^"'UA_6_C! $W,
M#ZS;X*'(Z&<S!T=6.L1%%E+5UBH=PY=@,,\AJ>%U@6K+M.VILPEPIK9I/GIT
M:NLG<;LEO@L.NF@<![\ YL0CK;FV@]F-&*\N=ZWK*A]9'NV?+O@5/GMUW<,5
M9LPJO71U(I[.B_2PI:NF"A.H^?*I88A*=Z_L:'L] :$2N)8'; CV&EUW!*Y<
M^'Z[R::\^#J[,QK6C*JALBM#N=9DY>SM9,(J9;03X8O,Q;^[8.[CAKE_+^;F
M%>_&DHON:NW:ACE3[P^CR9A';CP<D"MPU(,V>#(MU# O1Q?:+$H;ARA%/RNT
M0OG^)P]-JP9KJS=1)&4+%5B**7#QN^MO$)J4."K]2"N\XZD1*E"5G%Z;*UII
M2'M#6J+]Y0BD/G0V\<Q@^V'9LHFKL>%DE>$.\Q=;^[DD*;NF70XT.GK)45UC
M-QHS"J?WL))#\.0M%"QY% 7B.B+C(W2VW?TU.%5MCEQW(7P&*7\"\$P\4XPZ
M^QPF0^OR;5L@Y4!)I0%)<(68 1.<,T,5K% #^3-X>=K#IPN%'*$:/3^2D\!-
M%+HX??%*,UUX"E&O7G:DOL7&-+/K]_GV=_PSB42:%W4QMV9B\-&)<+?4^AMP
M+_9>$)LRI4<[))WPH;/H" 'EW[VJ_Y%866"1K ) :6%L-2&]9YM]I '7VP,M
M^Z.78_L.W[/0652PRF&+A$C1I,:9[P"-!OF4Z_2H+60N++O1X:\ZTN #^1ZG
ML]V""VEYCO?O*8[>EH8RE#B!$[Q4MJ7&!HUS*:E"ST6ELLW.]C3 *OEB;! 1
M?X6K;7L#K_;[5-BN%4D<:Z5"<8N)ROC,3=6[ JT83//C6<7-FO S1( B*$ZX
MM.U[4Z\J533)?M>+P9R\W"^AK'YKIX9MSDD'QC \ZO>DTKJ](UE<M_4&95N7
MPON:J<)N0WKR](,*%S7!)@W7T>(8J^^=G3W<0=Z^LLB;LGDZ-KGN0U^V,BQH
M>X;BO>EBH\]3SBE:ONW/BM/.?&MK\(C?0%;@EG9I074CP_<6ZZ[L4X^STRC3
M8)6_\),PHMU290TDN$ _TH;3RYXV>.9QPI5X?( E=<N_TG$3&[:;+2W-,,?*
MPE']E]US7NS0XE@CXNZX$1O3_4":W$J]97U3!?\4CO9?LL^^9;#0%=(4X[M(
MH:(8=&)W.JB2^DMT)IH8XGC)M:C5Z_U*DJ$?E T+(:#$O<>7124P4;DG0=RM
MKR[8*[1/3/<\,KU8>K^=J\QWIZ<Q&G)?LAOYK1F=BFQH4*@FZ2HS3U.JXFPL
MQVDZ!9)^UF)\ZY"=<,-10B6:'#M]>+NW C,14Y&9[7ZK>D2^CA,XN(J1VV#T
M7B>>^=YDG<[%L900S7;3$!O$>=Z%U$R/_1PD3H,(=8;3=]%X]-F^,BCT^!A"
MO9B(<30.O,"+T'DK<;BZ@2/T'L1^&UW*>4STD4%#TI*)B?6-'+I0%SU:Z^JB
M^UI"> #=/6.VQG=[FTNL*$(Y)8T=MBX5%5VAO3$9L=O97[/=T^/%YYBU6_*O
MF05;&^-$F#[S&X%KWM?C)>C)8J.T50S=U4':-3NE)Y\ O7DL\$W=CM,-O!>&
M[UNV GEX##R[? &=TV!/&E9$:1[6Y.,D8Z$_I[F&SO+WHAIA#3F45:8]PYI>
M.=7>$T"JAV>2>9R9S8BU"P.W]BY*P1#559DW>G?:$X# XP8B9L?HIX_V\UOF
M& /=PX8(,WWP:D7-1-TC24\O9D>9"G>* :2Z_3J0/H4\4QCJP79 ]H,A[U'1
MJ!W'^J'87\KOVWO"]]A[;GFF\0RVGBA=Y&2 VS6DRVH1-43^)@Y0MZFV]H>\
MP+'<)@1SZV)MK6E[U _6S.$O5K!W:QS?V&K?(9G%K!4\+62<>5V#?;H[\%FV
MY_K<<&%5V-Y'Z9UMMFT*ME8N* QPBR_#MNG.B99KS0PZYP#;2W \ 91Q[^LC
M6< L&CK.UC>'Q@A7^*S>+$38 X^T+;&?X2-#0XO9]%@9 H,AH_M8A2R>6!7X
MN^-MP,@*-6)Y7=%>)WQ3J66**%L>#,!"QD=2IW'1>J:&- APS\G:I'OXUG;E
M%U/ON -0%P"4"AR_\:5U88T(?N2WTS5^8Q 3*(QVZ<SF*=UC@<8D/M@$ZV0O
MB_SU76]$(Z9XK]WYA]^?%!*8[I>W\E;%/J](53EM)1_6Z;J]D'#([[P>-0\Q
M(9+G\V:OL#6O_8E.K1^)_AO'-4]B0E0"/CSQ.:%7%Q@+BINVTU6190*P,D[(
M'TPO=!2?YA6Y<D4[:0C1J-6UX3-.M[Y3 0P6B*FJ]'1X( Y.*S3[=77$:9/\
M#_RE/"JQR1DLUY-18E^A).JY#0K1F4MXI.WHK[A&7A%4'D(<_2HX!+?EER^,
M_%./O&,YT9&DM5+YEAH[P/?9=4TZY@@VV<^>/;:7-1$4%=]3W8EAF65+ Z><
MXG#:/M['(>*R-:[YM-6-T:N*AX@-LJE9E2_"^D=42^CF0;$%V,QB>FL)QUGG
ME)^=]BDG/:BWIPPKL!GU,^3S6I9S=D]KK! >=]ISB,#NA;"!VH?O_I;/VK[/
M&R]4\@$S/K'&N,D_4[+8]<9I=@V249W9X/$_>4;C_P-_7UA?:,3 (=MPM$;$
MR)=WMRBZ5VM'N]!I- #(V9$?O.86TH(S8T'C=\&/GM1Y;SMV!S#<!>"!Y3%J
M.D3CBX[6%M +RB_1SS;Y3>609TCM=SE9B*"Q/I9F=L?IGN_6KLHMZRR/Y/'/
M9$MX5*(7?O-H%CM>QMCZOL=LXRQ'MC4[9PTO^IBV'#W9E.WK-S&RXR*-XK3#
M1](&G9N-@_#,K^^-$U8L3P7-A4=38ML4U%Z_^2*>"E1A>Z\6@VE/L[-K/O$A
M1CVNIY3 ,:%$IS90A/I _>/25]S7KUQ8>)Y7<*983U6*#?2>4Z!D)$XW.996
M50Y=E@[WGA4D?\BXG?'"25**N]9:YV'&4;!W;&FOG,K]%L1"WCB!<FWJJ@TA
MXOD Y9/E9V_,_G99("B\20,#4[_2B9UVNMA9/HMG;C1Y'>Y=@/.S^)P09#3@
M]>) 'F>LOR(4X\5*(O$[\P.5@&<JIJA6&? SEM1AF:"L%F1+:0&AJRM0VN01
M-:M/Z->$PT6=0CW/%"!.#]3J)B/+7FTNQA8Y"^]$6H_ F6C2/C.49B:;(?GY
M-?9TR49QN+A81?U@^HVO^B\;'B*1RE]JIVH#&1M@&>_!$C$R?)5L)/Y,CH'9
M:T8(UX#I+8P]YC']$,T&16'NA-C2O*N<;TVTL\1 /45F[35/P#/%E\B%3(Q1
M2#H?PR5@%<.Q Q"K4%^H/MW<,HN3RL"GR*53I7CJT5$3;A?O<AAM7MQ[E\90
M4Q#F&Q8SM6AE*88?<M>5&+B9@MB^4%V(Y34(\ZY2VFBN0(#U=;V B-8!0/W:
M;M\@*)<EV>#H1%*NR/6,0]<@QPM$6F!-K#O4>Z?&6/76]AH7HAQU_O8"I%1$
MUO]^R_+VLL"XN/$HZZM[M(/GKXJITG J"ET*SV>0%19:55UB6_JN$O,L,VYG
M]BONJV+(4KPXQ/.!9W!)FRR?,!JEHKVL>J,(\HE"?:&G99F_;M]/5ZILJ#$5
MTL)E7CJ5C:HK6S;4P.'6:@ES';/W'?C<I<F=^8,J.\*8%=IR Q)8,68]:AG
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M"R1X-3_*/J[?4&V%P"M^PV&/WZU(.6P/X]$'2JPUDU]L@+7VKLJV'N(^,Q?
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M-TPQ1([5%H;P,6+]G3]-N$[RYS> =9M,!4] 0=E30NGZ"54S4Q*WJDJJXX9
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M,2DGT.P7L*A2MA31'KJ^1/O^IRM)7U%>LI\EMTSBH,2!-96<[1(58%WUWH,
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M5@W TK+TE2@22R &[K/Y@474VE8[9VD@1S&S=E5W^*O)OPDWL]N>M!>8X"E
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ML;OE4V%[,60[-PKM(ZJ$)1 Z([D&W\7R="CX3-2?4)=.!W@^FFZ( SPR@ZV
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M0P/NQV<]&K][/3R3^>QX?X3^$EH+JWTW3K/1=9UBWE5]1MIH3)O3>I15W9W
MY (C=#@DD@'CUKPYX7L_ 7CN:QF\%Z3HK_;3');V\7[][0G=%*LCG"Y.00 P
M^4 D$XKF_C1%\/\ XC?'[5KCP?*VCR+.JVPMXVA%U(4!9T1@%$>[DX  )W$$
M\5TVA^$+KP[;0KKEZVJW*69BBN--E.H1E=YD8%\%O-C8!F P3\N. 17LQP--
MQCK9M;6_X-CYV,:]2?)4KRDV^[:\M]-?Z1-K>A>$?'VJ:IJ=E:6'BRTGM49]
M+:Q07ENRH&81.@1F="<,8R?4J>!7D?CW]E:S\<7<=W\."TGVE#(VB7M]$US
MP!S&C9!+ @@I( PXY).*]A\*>$K7Q;<6-WIVIJFJ1QN1<^9O2W;G<8@ -FX
M'!(QR#@@U6\<_#6XT348M26_N=:UH;7N;N1X$CNPA8Y,8.1(%"@\D/C)P37-
MB\OA!\OEZ/YG=3QN8Y=)3A+FCNT[VMUT;;37EMY;'R#!I[Z9=2PSQ203P.8Y
M(Y%*O&P."".""#U!J>9\#T%?0W[3?@^7XQ>%=(\6:79S7OB.%([34O(4,]^@
M0E)0JDDLN,'@,0<\@ U\UZC<LL''7I_^NO!J4W!V9^C97F=+&4%6I_-=OZZ"
MSZCM?:M$$C32_,<[JQ3=,\C#'*FMK2&,B@L.N*E;'H:LE:T4G.*@,FQ^!6P8
MU* =:R]; M5+#BIN4T1S:KY*%>AJ;P/X9F^)7CC2M#C69FU&X$;>4NZ0)@EB
M!ZA0<9XSC-<G<Z@SW'WLC/K7T[_P3$\$V_B7XF>+-:N-H;P[X?>:W+=4D>1!
MO'?(56'XXIG+BJWLZ4IKHC.^(_POU;2_&@\+QRWC?9;19;*UBMG<:< ,BW0Q
MG+$8)<\C)YZU-\,_B9XCT_0X=-T^*XGA>;[5.Z6PFD=^%R"Q"AA@@$@A>I&<
M5ZEXQL-0^(]UJUWJ&H/X;$EU)/I]L]PUJD480EIYEX>0MNSP0/FX'.0W]GWP
M/9&X_P!(5;:WTV#YMBF9BD1!9PJX.)7)<$D AN>A%>IE4(\\JLUI%?B]#Y.B
ME*3E-77^9P.O?"K5/&OCO3V6;R9]45WCGE!BV%$))+[@6(&=Q' ';!KU71OV
M4YM6\ 6=QJ"Z3I<T%HC0-'(TXGDX!D 7EMY.>"1SVXKTO3H&\20RP2FWO+"2
M5I(I6A'F1*00ZHQ!;D'!&2.< X KFI_M.ARM'H_G7DD;FVV7<I94^<!-G&Y0
M!C(.<=B1Q7JRS&O44:-'1JWW[?\  -*E3G<5'>/Y_P##'SYXX^"36^LR-:W\
MU]%S).@M'@5'X&5+] 2""#CFKNG^%9?%]M:Q>;;:?/;(GF'S]JCK@,.@(88
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M5P2Z@X+E<!L'C( Q@BOC?XW:=-;>*Q]J:.2[V/%.\4 ACD*2NJ.B#@*T?ED
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MO%QCT/G\%%4,2I2ZMV.1_;S\*Z?X._:-U+^S84MX=5M+?4I(T7:BS2J=Y4=
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M:X&<<5#=Q[8N*T&G53ZBHGC6=#VJ448H9D?-:EM+OB%4;N+$F.E6;0XB%&[
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M)KDP_P!9=2?MDN6_NVWMYGH8J."5&D\,Y.=G[3F2LI7=N6SNURVO>SO?H2!
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MKN&&[NK9")([8"$;0!PW9AG&"02,=@>?5/BO%8^%-+W2037AB4)'!"AE9CD
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M>Z=*&6;3KF2UD!ZAD<J0?Q%?LA\,=6&E>.]-?.-\AC_[Z! _I7Y;?MI^!O\
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M2(VEMM/U2UND\ISAC([.,;CT &?IC\*O?M"Z7':75Q+:R?9$MY$(B"@B4D@
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M4@P2>5(TS8R>%7(!'').>!Z ^0_$>]T7PG'!XCUW6;CP1'=3LI@2 _;KU5&
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M/&2V[)(]\' R!BNC^&WAG5/B=I&H>+/%VK6ND)IXCN[F\U698;:PB4[1AB
M,D8!&2>.:[,5F"IKVU62T6K>G_ /C_[1K8K$PIX;][5E[L8Q3>KTT2U;;V1X
MY\+=?\7?M#?'W^QULY'EFU.. 0.Q!M-IPL1& "% !.< $'CC-?3GQ(^'NC>
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M">P8Y)(/?%)J/P3T.ZL6>&W96QQ^^)/M3EGV'3Y4V_.QEA<F<(<T(J*?WO\
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MOJEQ#!Y$;R2.C2Q@Q85EC8!@ < C-<#\0/VEYO&OCRZN[JQ97U"7*K  8XE
M 5!SP%4 #/85T93FM6=::Q,U;HM%_6AZ>?<-X>G@L-++J%15%']ZY:KFLOAL
ME97YK:M<KC?WDSK-)U"ZTRXDDMY63S$*.NT,LBGDJRL-K#(S@@C//6K/Q3^,
M<7[/7BO2_"_AOX:W/C/Q1-!82W>JWP6/3;=[R"2:*)))"((V 0!?,!!._&"
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MNVR:VGC*/$>X96 (KR/P];7.GPIK%G:ZA!IB J;G:1%NSC /0D$C(&:O>/?
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M@SW,2X@LA!$H3  !=N69B.I/YUXO\3/$$U_IS7EK-=/J$TPW77EGRHMWMR,
M=.,]_:HK'P3#X1TY+Z_O'U>:90]L8W)?+<D 1D%L]L@\=NU5"FY.R/"EB:]:
M7O2_&R/9/B)^U1I TFWTY;"WL6*XA>V *1#H!G/ QVK&A^*VLAH[;3;19K>=
M@6EN&6,=@6P#G./<5Y#I^@^?XLANKC1H;YDR\;QH5\O)(*%'"X<=>,>HKNFT
MWP7X*\*7_B3Q#XP7P]H<=Y%:R/=039CN9 S+$J('.2%8Y.  IR!3Q4(X>FZM
M2245N[Z(VPN58O%XB.%PD74J2=E&*<I-OLDKL])UWX(:7\4+);R*]L[77'0[
MT@<'S".FY>Y/;!!['-<*G[+VNW\4DD,NENBYVAY61R1D$%=I((QR#TK:N_'N
MI_"K6FM5B76?[/97\RR 66>%D#1R)P RE2"0,'/;-!\;>*?C!JZZUX-M-:N+
ME0#?6T4!"I(IRH?L"P./<CC.:YZD5R<U[7ZFF&QV)P\E3DF[:6=_^'7]:',:
MA^S[K6C1><([6^A !+6DPD(YZ;>"<=> ?SXI=%^'5]J;E5MFMHT8*\D^8E3G
M!ZXR1W R?:O0/"GCRXU^ZDM?$FBW&EWY+*45#$'=1RCJP# ]QC&:UIVT>[N!
M-?:M<"8J/+7Y0D2] %7& !TKYW%X_$X=\E2SZIH^TP-3!XJG[6+:MHXO=/\
MKK^3,'PS\)?#.C6_F:Q,^K798XA1C' ,9P!C#,2""<X (XR*V[^33;5&2RTV
MPL;=B?N6J?)DY.>,\GT%97BS25NH/M&@ZM;7$J@%8KE=FXCL&7(!)SC('UKR
MOQ7\;->^'TA76M-FLT$FP3.NZWD[\2*2IZ\#.?:N*-'$8I\SE\F[?<O^ =\:
M]*GK!+U/6M>\+:;=:5+--;PHI&XS6R%3DXY[@].XKM?A?XUU30/!@BTYK>[L
M8W"HFH!FWJ."%9<$8'&2./PQ7D7[/_C1OB1!<ZE=,MOI,,A0L&P;EP 3&H]@
M02<8 (ZDBN^;Q-+>YMK*U:WM;5=B1HI50O.,=SGUHCC<3@ZCA"5WUOJO^',,
M9EN%S*GRU8W6Z:T=_5?J<?\ 'SPC??%35A<06]O:QP[I 'N58.WH#D$>V1^5
M>8Z)^SI>>,=1E@N?ME@JXVL555)'4!@2"/R_I7H'CGQ)+9RMY<-U"_()*D#)
M]>/QKA[GQBUM,YFE96!&1DCCZU]7@.(,;4@VJ5TENKZ>KU/SG%>&6!JSYXU9
MQ=];I._;;EMZ_@+JG[&$^A6T-U)J]Q9_9V+R21$,\BD_+P"6(]< ?6K/AS6O
M"O@WPSJVDZM%_P )99ZU:K:W]MJ:F>WN-KAEPF[=D$< '.?IQD:[\8[?0+,R
MVT\B3$'.#SP.Q[5S7PNN_P#A97B+7K[5DODL]-LI[V]^PJIO+A8@,V\ [,=^
M6;!(&3P.OA<0<45W0=*:]V2VWO\ ?^A]OP/X88##XJ&.HRE*I3DFG=QM+IRV
M:U\VSI/B3^VSJ>F8T_P[IECHEO%$D$:01K&L<:*%5 JDA0J@  DGUKR#4OVR
M/%6EW6]M;#2E^ R\#/KW%7_V@]!T_P )>$/#_B;0K?4-)L=9O+O3&T^^N4NR
M'@('FQR* &1@<$$9# C)'->5_P#"!IKOEG?']IG8>6CL$))[<D<YKXBGB)3<
M;7O)V22U;VM;\C]IQ%' 9?S1Q,$N6_,VTVFM[N[6FMVG;S/H#P/^VG>:W-H9
MU[P_HOB>]\,WAU+1Y[@'[3IURRA3)$-RAB>."3R < @5[+X!_:YLO$EZEO?0
MR6<TG5)E* GOC.,'Z&OFC5/V;-1^'/A.SU.XNK!Y+C34U,00N&D>(EE?:&()
MD3;EEQ@ @@FNS_8#L_"_QJ^,,7A'6+Z.&?7X)H[< C9)<"-BF3R5;(&".<]"
M,\^OC,OQN"KPI8J'*ZEFKZ7OI?RMLTUHU;H?/87/<BS;"U:N JN2HJ6BNTK7
MDU%:K767NZ/FYNI]:Z=^T#:V6GSZ3I.IPV>M:A:7,.F7,YS'9W;P.('<C.%$
MFWDC XS7D/@Z+XA_#S3OB%J'CWQ!K<VGWNF0:?I\.NX2*]NECCQ/#$LTC;HW
M$H+I@2 @DY(QZ-^TA^R':_L]_#OPOINCZDD.VS>76M3FPTUT^,R3,W4(!PBC
MMP 3DGX6U7X[VFIWR!?._LV-REN9929)%!^^W;)]!P.@KS,TAB5B'!*W);K^
MFW^?X'N<)QH3RNI.CRN%?>\4YI1E?W97O&]OE>_Q)-=/XK^(&HZI<,H3[3..
M2TJ Y [[<E5'MS[DTS1?'MVS1Q:AH^EWS2Y5%:U12_'." "2!WJSIWCK0I8D
MDMX+=KB1#MC9L[I,?+D=<9QG^5;'B#Q/%XF\2)I>E>%K[4(=8L!J[%9$6+2/
M*F((61VV&/&"J@ACLY&"!7T>0\%U<WP4L9-M-723>K>C5V_A5G\^Z/CN*_%+
M 9%C:>5QPZ?-9N5ME=IVLFV[JUUMVDSGGCFTBX:XM1J&ES#YA]EN& 3ZHP9<
M?@*]+^$OQ.\<:/IT=QIKKK23,?,4KY=VB]" ,E6'?C!/H:\-F^-F^X::.97W
M] _<>I^M=U\!_C5</XMMXUM[::WW$SA&V[ .0?05\HY5Z$I4W9VTNG=:=NZ\
MS]-C1PV-HQ=:C9R2:NK23:ND^J?1KHSZ(TSQWXD^+?B_3_"6FPR:?X@U4B)$
MNMR1KD9+L",_*.2,9_2OG?XUZCXF^'GQ;U7POJ5Y>1W6FS"-YI&,2E2,JRJ.
M@8'(&3]:_2C]G?X2+XP\1>"?'ED]NT.GQW2W!E.Z4J\6V-%_W69CR1C)P.>/
MR^_;J\;6VJ?ME_$2XM+AKJ/^VID61WW$[3M('H%(P .@ KV\10DL'3KW<7+I
M\OQL?"\,XFG6S.O@YQ35-;M7:ES-6UTV1JVDLD5J?+U)IG"[GD:=P4SZ?-Q6
M0_Q*\0: TD>G:Y<J8W^<0W!W D \JV03@@].AJA\)UOM1M-5U!5TNUM-'TZ6
MZNM5U*Y\FUT97(B61UP?,SO.U ,DA<$8-;WQ/\):?X)T7POK<9MK^R\3V O[
M35K2Y#VNJ@81W1,!XRC*0RN."0,D@FG+(JU+ _7%B8N;BI>SYE>W-;FOL^W(
MM;]6URODJ<45O[3>#C@92H*?L_:ND^1SY.?DT5T[:\STLMK/F4ND_M7^)M&U
M&-KK4VU"* @/'.A'7N2I)(^@%>[_  E_;*6>\TU=4TBW;2);F-+J[M'$I@CW
M ,S+@. !R>/6ODFSOM#U:ZF\Z*XEEDPH,>6;.>..O?%=9I?@77/AA-'YEK<6
M+3,7CCOE,9*'J&&20#V)QZUXU&MB*D)2A%M1M?317[M;;;[+J>WBJF5RFL/B
M_P!U*6UFE?;9/UZ:GUI::MX]^).M?$72OB@VBV7PEUK2+JQMDTFW\O,<DLBV
MYMKDX,DK1K&S*I9"&^;:P(K=_9B\-^"/V?O#.J:3X7B6:/6+S[?<2R6(M4B5
M2QCBC3>[':7?YF<GG P.*^,M5T.X?4O,LKB]T69,OY*SB>TW'G*KD 9/4KCZ
M5ZU\+_C!I_@_XD>"/AOK\GB*X\8^-[-=1M;FQLQ)IMI&Y<1!WX9MQ0[BOW.I
M& :UPM;#**J5)>]MK?KZ;_\ !-LPH9KB7/ X.$?8./-*%-)1?LUS.;6_-:*;
MUUY5\32/L"#XQ:?>E=C*.W& 3^/7\JFO/%%E?;59H8V?IND 8GT&>]>&^*/@
MYKG_  FK3_VA;Z7H\\*3F5FW-YAX957.>HSD\5N/X3TB 1S745]X@F7'[RYD
MZ8QC"+@8_,U[E'!X23_?R?RU?IJTD?"14E=J.G]?-FUX]LO+DD\F13P=RN>"
M#VK@;/X;Z&8;_P 3:S<)IN@:%&)KE20%GD.?+B!_VF'(&3@$#DBKVH>+DO+M
MX=BVZ0\!2O"+Z?2M/78;S6=.T;19/#7AFY^%=]ILMWKVOSWI%Y;7^)$\I(PP
M*.N(BG#!]Q7 Y([,#46%Q$5)-QNM$KO7TT//S:A5Q.$J0PE2$:BC)ISDHKW4
MV[-]6DU%+5NQ\-_%O5;'XG>(;G7K6S:U::>17;)Q<,"!O /('48Z>PK@HK9O
M[2&V%;A8<-MVY''0GC&#7LFK_#*.3P!<-.[:>+"=+1(V!S(S?,6)[%MQ(&3C
M!![&H_AU\'KC11->3.TT<8D0F1,118 8[LGJ!C ]J_;\#1B_?>RLC^5<OII-
MUZNVR]6<?X<,VF>$&N&TZ&Y$EP98)<LHC8@*V0,\$ 8)'&.^>,[Q5X:O_%U^
MRW,MO"-.4SQ1*P3:H&<@<''''<\5V6B637\EMI\C?:XI;AF,4+A)(E.3D#D8
M';)Y'05LZQX"A\,*FJ/:?:(HXQ)$,Y653\I7D$DXR0,''7&*]:NH1?LVM7_F
M>Y6M&?+RZOM;J_Z3L<UX4^+TP\-Z?IFGO<&ZN' A2.,.\C8P8U7!(R2>QSZU
MUUQ\;O$'@*:-)K":XMT*K<6R7R.T1! !=D)\M@>P'/.:\P\-W%Y;>/CJ-C;7
M(O$W20QG&^!<X9!\HX*MP?0G&"*^@_!5G9ZAX&%K;SKLN"'>-(T*2(% 8G=D
MX!R,]>#TZ57U.ER+G_KU.N6'H4J2YTWKTZ7]-7^ISMM)JWCO7-4NH]'U71EO
M;='64CS8O-&</N4<ACR<#MSS61X+^'>L&*7^T$5I(7VMF0 1JPR%(X)4\?7.
M> "*]L^ \FFRV\NFM?6<,MJSNL:2DOL4 @DXX4CD$<$U1^-LVB^"?,>Q*75V
M_EB&W$^6D89 E88)"Y( )/(P,'FO+J8APJO#PCV_K4Y:CE3<H4>NG]7]>IXY
MXF^)>O?#3Q5;Z>@AO;+Q)?170NIX=]]$(TV>0LN=P4#C:.,;>N!7N\G[/]O\
M8=!FOK!OL_B5D$L<;D[+U@ #&QR0'./E/&2<-GJ/+=2M8]7TR.\N$MY[G2KD
M'<P CMV8A&9AU&TG.0.@/<8KW;X#:];Z ]K8C5[/4;Z*X+*]L2T7E@]0Y )+
M$YZ9P!7AXZ@FG%HX\LQM? X[VE-V[KIOJK=5_P .?.\<303^6RLC1L596&""
M#@@CL1T-;%D-Z+7J/Q)_9.\37_C[7+^RDT?[%>W<UW;![K;(ZNY8*05 !Y]<
M5PFN?#CQ!X&CW:IITT$8;:)%(DC)QGAE)%?'QQ=&4N2,E?U/Z!C&4H*I;1J_
MWE6*18L5JZ9(C$>M<\7+-6QHGS-SQ6]]#)ZG16W*UJ:8^<K6;8Q$@$<UJZ>,
M-3.>42S=0LR<=Z\]_;U\+?\ "9_L!:A,J[IO"^KP78_V%+[&_#$M>F")9HN,
M[JK^+/"O_">?LW_$WPWMWO>:/-+$O^VJ%EQ[[D6@QGHU+LT?D_9MY6*Z#1[W
MRB#GI7-V%V)57<.2!6D)=A JM4>BST#0]6\]L9KL=%A,KK7FGA.9C.N.]>I>
M&X695['BI''4Z;2;;RPO\5;=E'SGUJCI-MA!ZUKZ;8S:A?0VMO$\UQ.XBCC4
M9:1B< 8]2:GF+L2>7GK4B6^.>]:7BOP1JW@.."34;>-8[AGC22&=)TWH<,A9
M"0&4GH<$5G6T_GJ>V*(RC*/-%W0ZD'&7+)69#(F)OK6YK?Q1\1>)-'_L^_U:
MYN;/"AD8*&E"_=#L &8+V#$XK(N8,@-TQ4^B^'[S6YMEK;7%P3P B%N?P%$N
M3XII:$QE):+J4;.4FX"]ST'KCK7HOP;^#.N_%[4WCTNV865JZB]O9"%@M%)Y
M))(RV,D*,D^G>K'P[_9>\2>,F,T-HMI&Q*>;=L(@,'! 7[QY]N:^C? FH6/[
M.7PXL/#-\]M=W2K+?73Q/B%Y&)((.,L4 48[XQV!K.G6IU).,'=K<X\?B)X:
MFI6U>U_S/GOXV:U>>"M9LO#>EV=_I]EL:.V=F)NKP*_#-QA5=F)V)R21G.!7
MTU^R9\%H?@5\+7UK5&=M?UB$M)&^&-I'DD(.3DL<%CGK@=CGRS]FSX$QZG)!
M\0/&&MW5[=-*USI\!?S/E+$!W9B<#IM QCC!KUZ]U";QKID>G:7.UHK':)&!
M81*O.<#)/ / ZGCK70M%S,^1]ZI+NV<O\3QJ5E ?$TTFV!')CM,99%SP2<C)
M)YQT[5@7/QUNM,T%;S4-7AO8(8S*Y@<J"HXVA1EMPR!@CKD5%X*_:*T'XT_!
MS^T-)-WJ^GO?RZ5&+JP-G<)/$@=F568ED*L#CDCG(!&*\[TWX?VM]J5Y+JTW
MV6T$C- D<6 Q&=N?<YST![&MLMQ%.K36*I/FB]GT/7QF68O*\7/#9C3<*E-V
ME&6C3[,MZM^T=8_$YO*L8+F?R9 9;,L5N(ESRY!&"!CN".>N:])^'NI7GBC2
M5C;2H=*EA7]Q-*F3<XYP"",DC'8<]<5X+XB^$T?A?Q!IVHR7DEI<W\^8?*<J
M\4;#D%E((!ZE>0.,BNL\.7]YHT1>QU6ZN&LAM_?[C)M(R-O'''0XY]Z]:%&6
M(I\ZZ=+:??T]#'V=3$P<Z?3OM]^Z\SV3Q)\6&^&MHEYJ#1WBPKLE$!S(BGH2
MIZ8((R.G?->7_'/XEV/QFMENEW!H(@L3E@SR0A>0>?O!N1CL2.E8'C?1KZ&Q
MM;Q;R19KB7;.67?A<9Z8/)^GY5Z?\ _#?AS6]"_LJ\L;;5'UA60R&("X1N>
MR@$>@(P0>]>;7@E[JU.*5K66K74\A^"FIW6EZ)YC2-)!O/\ HTBB2.1,<YXX
M)_GWKV+P?\*]'\>^)],AN;*ZM=/OIA++<B0A4C# ,".<$?W<@C.1Q7J%U^SK
MX8\/^!I+2U1M$DO8A!!NQ))DGDA<EB#R,GL<@UY?J-SJGPW\;S>&S);.M],\
M<<,4Q8(L:J4D!QU8%@0<$ ?0GQ<=AY3@ZE-VDEWW\F>KD^92H5%0EK"3^YO2
MZ_7HRQ\*=0\5:EXI\96/BKPAHO@[PWH]F?LCVNGR6\]M<"X98XQ<,BK<"2(
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M. Q<Z"E&7*WMJM]M.O<^MX;SQYME=+'6<542?+)./1.Z3;T?1]5]Q]U_L^_
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M:7*K6?5WM'Q._CN-%TXS6DTGS_,L>XDGG!&.E7/!_P 9]?\ A_JT:R-,UNS
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M_A%(]'7QC)9+_8DNNP'^STD\U#)N8@*&,>\(6(7=CD"NBI3C1ESX5.W1;O\
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MB)@AE;(RC28&#WXKZ@^$OQ9^('A;PMX!T_Q]+X=L/&%U=W=L8-$BA6.WL0$
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M"MU;06;D+&R@$AF&1P, @=22,\$UKS^+KSQ#,LMT-UK(OELY02,Z@@A06!)
MVYXQR2>]=+X>O?#GA+PQ>^*O%E[#HWA[298H/,N82QGF<DI B9!8L5<D9 (!
MR:\+'4Z>&IN=9VBM6^WE<PP>2UIU(X:A!RG.6D8IMWV27=M]#6^&GQA5[:"'
M5K%(]=(1WN7(*SMD)TP0,#DDYZ'OC/E_[5'QE;X$^/OMVHVDE[>ZTK)%=1("
M@8C)4=3N*GC/;/4YQW%[H-MX_N- U;1]0@O-"\26?VJQO1;O )(2Y#(T3 ,C
MJ05*GH1UQS7QG_P66_:C\0?!KX[?#SX??V/>:='9:9_:[:N[9&KR.QB")\N
M(57YCDDF4=!@GY'-,1_L<JM#6ZTMUN>GPUDLJN>PR_%PY6I-24M'%J]TUW3T
MLUZHZ[6/VL_$5U;EH=%O_))!#2$(/7U[UC0_M/:ZT[+<^'[Z:#@/'M292#Z
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M0\S\!?ML^(?%E[=:A$Z6DL\I>,*@D89ZDNX9B3U."!Z <5Z/HO[0OBKQG/\
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M$TQ$F+K),A1]H9U8D'+<Y)ZC)KL/!]W>7]W%MG=$E.$?^$^F3VSTKQ\ZP/\
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MI^TI)IRC?E<H]5S).U]KVT/4==^$2_"WXIWVF6M^US&%BF@>2%5:W\V(/LE
M)". P!'J#T!K9\#?#ZZ\179OIK.2,3N8V="OER*.-W(RI Y..GO7(?!NZ_X2
MCQW:?VWJR6]G>RM]KU.XD:66/!&&<\ECCIG.,]A7V?XF\2^"=0^'-QI/A$1Z
MQ#9+(%NVMS%+>-M.UXGR%$8 7H.2&.2:^LH8V5-PHRM*5DF_/34RJ5*;JRG3
M@FGLF]EV;\CPSP)<S/I\:QQ1Z@L-R/*+3!&O%XR <955(ZG&3D#I7I7@S47N
MK^Z:SMMDEN T]N/OQXZ'<6 ()SR<X!_"LWX;:]8^']*C6/1(YM;C#J1<R VG
M#$DE3\ROT7D')R5Y.1WW@CPW=ZYK4-Q)I.E6-WJUTEK):6RN22H+NLBDYRH/
M4D9)'!X)Z)8N:=1UH6C??T_/OH=M&;]M*52"4;6OU>GXHO>#= DTS6)99K.Z
MN)W*O&;="RHI'&3GL!G.>XS@UW4VJMJ'Q)T3PS=>&O%4W]HZ+)K<VOQ6RC2;
M9DR$@E?.2QV@ #H64X.21Z)X4\"27SW%NNGW2'<T8G9=KX5,A!T&!D  ]><Y
M/-8:^$M>\'27IU&XDDAD0O;HC$B-<X!8= S8Z<\<U\CF6)G7:]G+EU5W:]UU
M2OLGW_4TH9AAHRE[:ESIQ<8ZN-FU92TWY7K9Z/J9#^"O^$DG@738II[J!PRQ
MQ< 8&223TQC\37 ?M-J=7GTG3;/[+8:UK-VQ$]W\L5E;6T)EN)W?&0H49(]/
M?FOH;X=O9_"+0[WQ)-,ETJVR23R-DK%N;;@?0L!]:\@_:/T&;5YU^)%CI\>K
MV'@];[4Y(BF8KVVFM3%+ XXRFQR6&,G:.AKP\XDX8:I*FN9I-KJ<N54X3S&E
M3;T;2WMOLK^;TU^9\G^/OA=I_P 5?#UQKUEXVL?&6A:%=)8726=J]E+;NXWK
MN=B2\+A208S@E<'!!Q2C\=>%] MM%NK?P_H?]K>$[>6RT:_ <2644A;< -VU
MFR[8)!(S7$_%;]JY?%7A%_"^AZ#:^$=(O;T7]Y%'>RWDUS(%VJ&=SA8U P$
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M>_&S<=>FCMIHUUTW-:'P%X=\):5HUCYL.J7'!6YBG*(6)!<Y49!7:<;B,Y.
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M27[NF[^6WY&53%5%"].-H=[?UVZ'B?\ PCFH?$GQZD.GW%K) DBHTFX[9&(
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M]KG]COP]_P %/?V/=+TO5I#H?CKPSJAGT#5$B!EMWP5VD'&Z&50 RY'(!!!
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MY?F.TZN3M+DG<2!V&> .P '!S7!>./BLNB:/:Z/9SR/':Q2B[9G&;NZF8EW
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MF/";R&+28)55. 201^FA_:/\*? OPU!X1\/6-OX3TW28F$-A%;%+=U&,I&Z
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M1D*-I'.,\XY[5P<E[>?&WQ-/%X@NM2UM=*1+?3([JZ=8D5<[G<9R020<8Z#
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M!OQ-FTO0[NQCT*TMHY(C>Z?'=(-12,YGB$@+1.-H0'() 4X!Q6/$&%Q<J?\
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MZ/MHS:ZK;^D>CC*-7$XF=;#4?9QD](J6B\ES:O\ JR2T./U[]H.YU#XK:AK
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M/B"]O[6SL!>"Q6?!F,3%"RO(H(98R5V[CD!B 1CFL?QAXKO?"&IVL<@>&14
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M1U?_  EZQF..+<MO"!'$F<@+_B>Y[FMM/B*OA]K66*1$G*$,,$G8>#@=">N
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MI(4L22HW$D8P!TK@]8^!W_"'7>K7EC+=6PT3=YWG6$LI-R,@P9"E5;: QW$
M#N2*YO[0I.UH>\MKG/+-K1<513T[[^J_$XBPU74-(\;V[PQPVVH6N9=HPT1
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M\QV"M'([JL19C@@U^5/Q9^*.I_M#_&+7/&7B21;J^U6X:ZDP,(.?E0#LJC
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MD3A3M8@ 87)P0"2<$'Z>0_&+P5+XZ^'LL?ARXVW=O>+/<6Y^26XC"D+M&02
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M?;(X]:^&?AQ^SQHOP=\<MIWC*QD18@9+6?S3]GNU4X&#G)/3(ZCO[_5'AO\
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M F.1>5E7LPSW]1VK@]*\5M#+\I92I#8!_,5W=[I$GQ6\)+8R*S/@O!,OWXF
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MN8C/852^'W[6D?@SQKJ^O/X,T?P]XFOK2Y-_XGTN*2>XC=QE[M;1F,(D/5V
M!.6(P3SAA\5C<TQE+#8'W%)J\I6MJUTUZ>C?J>W/A/ 9%E6+S'/H/$.-.3C&
MDW[LDG9N[C?7>RE:VL6G=<1XF^//BK0?B7<>(+U];6\N;V1KF&\GE0RAB&,9
M4X( 4@ @ 8 ^E?1'[!K>"_'OQM\2-I-G'I9^(7A=-.FTV7&_[;:N70J<[2&
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M_P .&LWEDL+J.^AC3=*L",XC4\'=Q@#V/\JY+6_ -QH=ZK>9-&6<,C2)OC#
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MFF@W\%H  L23@AFC/W22,C@9(!QA^-O#4GAO4[6UUAHQ!=0QEVC</]G! P&
M)VD@@X(P0<BO.PN49[@,#_:%5<U!6W=W;77HTM+6[Z;LY\PS;A7,,Y>3*;CB
M;:V7VD]5I%*S332=VDF^9HXWP5_P4%T30/ACI^D:]X=@\42668K"1=2GTZY@
MA\T3&"1HL&2$2J'"'!!Z$9-?37@S4]'^-'C#P;_;FC>(M0\1_$S3;>]34=/D
MCATG08720001(Q+3"-8OG )(!))!X/RU\4_V*='U^!-4TP6?VHC>C1-MCD[[
M6V_=)[,!C.,\'(]4_98^/TGP0^'RZ#'JVI6#6KR1?8)Y _V8-RXBR"R!B<D
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M\.^.OV^+'7?#7B/5+[7]0C\600WEM'IGGE+[3+B6W5(GLVBPJP1MM&"?E4N
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ML'!"]F!SD$5QWAG7X?'.JVFDKID-U<7K&.,QAFE. 23A<EL $D 9XKT3Q_\
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M^UM*N/$$ E&[38IQ;R7.T%\9/7E5&W@G)QTKW>'\MEB<VCA<(U+5V;:C=?\
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MT2:\M+Y[FZ:VF8S[",>7&P"JK%MIVY*@D@GXMLC:_P!KR1J<2H2H?K%(?0'
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MKU1ZK\&?CO9>![LV\DMU)H[Z>D-W$T\<>&1AY)3R]K,-VT,"22&8G@<^U/\
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M0$D\9/)X'J*V/$_AWP__ &+_ &E:7#6LT\)(W.A\UB"=K*<G/!&, UY[X/\
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MLH48 8E0I(X*@XZ\=G^TAXBCCT'P%?7EGIXNKJPNX[F[^R))>W=O"@53$S$
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MW*+4Z;::L]^O1KL?%G[3'[+6F_#_ $?4)XXYK*VTUX[.47L8W7ETQ)/D,
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M8_%'C5_%7@JY4#0[9-"":A9#?EMQ155@%RN.23@X'(-J7P7IUC")$AUJU8D
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MCDE/$6FG'YZ/]5^)\[G&!CAL7*KF%"LUWH2YX13VM'2HDMVW%13VTT/*=?\
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M#"GDD5\3BL4J5/D6W;I]VQ]YAL/S5/:O?H_U[_U;=F/\</V@_P"R]:&V\O\
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M&347%3O%/2]_>@[QN]))7VL?.O[17[0&O0>(!HFBW+:=I;P+)/>VL9FGD!)
MPW"J& X4'=CDD XKR'Q#\01_;</V>ZDU01JOV:YNY=DQ?')"1N$7DX!9W/H
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MEG;:A]KE:YFO*Z^=K>29S'B'Q#<?#S]IZT\!^*[BWM]+N+N.U_M6S8@?9KV
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M3'".5)W&(8;) Q\I!(/73.HGPKJJ:]X9FU0:=%,+9;EXPL<DBH&)A?.&3'?
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M325WWUMY;*^IXCXV2Q\0+;ZC'<R:;=6EQ$L=[;92:#/\0Y&"/4$''MQ7U/\
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MN-E0IX.E#F?-+EC&*<G*7+'=+FE>RM'57V5VS*3X:>+_ !3X/76H=<CD@EW
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M:N/,Q>,TA;8K2?.RHIVAC@GTQUJVG[$_QR\"::L-EI]CXLT8,-@MKR*;8O\
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MD$FO!?B_X.ETSQG%K-K<1ZG%J)D)5Y"+C<&($4J?=$GEO'(5&!M88SC)^O\
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M%F?(;KM )W+@$$<YKN?ANOB[Q/%<1^)?$]OX%OM;D5Y ERL5J\S$DK(Z ,)
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M_)::[W\RO[0]M.4IV5VWHK+[EHODC!\>V7_",:*MF\$EO=R$O,DB%"@.1P"
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MM(L&U$C[,BVNH1HH:00NK$B1%^8QR $CD=#BWK5PMMI*7T=K#(DA93&KDR
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M7]E-K5OFW3NWUZ^FAZ&?BA8Z9?O#"LT)CD"LTET]RUP>29&9CG+$L2!@#H
M *Z[PMXCN=6B)N)DV9PG)R".JD]QUQT/IWKY0N_%:F]65Y7(C<8)8_,<#)]
M,_A^%='IOQ\N-"CDLM/=GNKI-F<DF#'4GN!C@YZ]LFOH<9B/=EB,0]7JV_Z_
MK8]C#X>C@<)#!X96A!)17DOZ^>[U.E^+6N1:;XGF:QO+_3;1[ORYI()-LD9(
M"-AB0 2"1DD=>O-<'HT=OXA?Q!'I=AK"WOAPRMJ:&X6ZM[8*0%&]57<2,EL
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M\DEU,(;>W7U9CU/H "3V%3>'/B+#KVNQC5+&'3+G3HY)IQ*A41!%+%V!&0%
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MLTVOSO\ Y)=#ZO\ !/C6XT7X3Z-:ZKL.EZ,LYM;&.Z>W6Y\TAC$[*2YC#*)
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M8*&$6) >A)*'! ST_P"S;\</#?A#X=Z+#_PE,?AJYLM7EO/$%L^E&[?Q#:G
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MC!JFJ:[XS.K7L]Y<F9%C"RRM*+= #M1,\JBYX'0<]\U<\$:LUQ"_*@0J&.6
M)!. 0.IY]/?TKM-:BA\6^+M/L]/U"UTZ1 ;B_>:Z-NC6P(5D+;2 7#E2"" ,
MG!'7ZW^)W@CP;XS\%7FCZ%X<T32?#+^';?4H;R[5(K7PXT Q,D=P@#&1U).&
M#?.1W8@S_JO5SBO6Q\)*#2;=[).6KWZ=6W;I9:[>+Q)QUE_##PV30I.46XQB
MHMMQBK*R3W=K**YNMWMKP'_!/?\ X*$:Q^Q+\1%%P;C4_ FM2!=8TL$MY?\
MT\PC.!(HZC@..#S@C]AO#?BCPK\7O =CXJ\)W%KK6@ZM$)K>XMOFC<=P1U#
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M 2H',@(&TD$<X R":POBE\,19Z4FH_V7)HTFI*MQ)!)$QCGD()!A<LQV\,&
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MT:>Z=]TT]4T8OB#Q1:V^A:;H^DV*:3HVD(T5G9QRO.06(+,TCDLS' &2>
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M_B3XA^'_  .OA_5+CPMX1LM%MK=O#5A=V7-S'>.\\_VIY5'EF-E99HB3E K
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M@^(M%L;G3T%Q"]O,D@+2)C:.020V"<DC!]1Q7DUC\.U\2RSZ]Y\-Q:RS%4#
M-Y29(4 =@,9/<FOIZ.98?,L+2PE.DJ<J?Q2ZR;M;2W75VOH[]]?B,KRW%87,
M*]>O6<X3VB[VBK^N^RO;56/F:+2&\:3G0_#\>I-+J(C@:PL$D1KPCH"JX#=,
MDGW/K7&ZK\%4CO9(XUDMID8[E,) C(8@K[[2".,XQUX-?87C;X8S)I%Q+ITK
M";4('MPD8,23Y&4)=0S* R EAR 6[D FL^ ]-MTM[9);ZY2TMXQNN/+;RRR
MM&C*JEHPV[!<;OF.3C&/MGP_@ZN5+$_692J7^%ZVL]=UYKRT=KL\>CF.-6?2
MR^EA%&A:_M%97=M-NNDM/BU3=D<_^P7^UMXP_8SU!5COFU;PO,<WFF2.=O\
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MCEU.TTWP=;WBC;-XHU*#2O,7KD),PD(Y[(:\>?\ ;%^*GC:"*TM/%%SI,<@
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M=C]:RA3@OWD(I26JWZ=]=3LHXBM-<LJC:UT]VVN_3K9>ME?0_37XI_MB^&?
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MD?<W8L'32KWZ6_,YWX?_  <6)$O+S]W"F#@]2>PQ[U[!8ZA:M;0VL,$<<4(
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M;4FG:W\,K+6KB-$M[V_@T_0]1L+&4HFG+;;UDCGPJ3(6+*QD;>3TR5(KYO\
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M&"2!P,XR<="?2L/XB^&)+'2;6^:-091U XR._P!3W!Z5BGXAK%H)MQ-C<I#
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MI=BT<VZWLHVF+7)>W=RO[UH$;YHHV=-^"3DL23G@>=_&[PBFKZ'<P:5:,O\
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MS>9RQP>%P,US/Q'^,MW:VCZ5?6LUI<0PF0#:<%AW!YR"3V/-<7\-/C#K$WB
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M%YSM R23Z^I-?0OPJ@M?AYXG.H6FFK'KGCB^E.B:<@9PA^4S7;*Q.R-1MX&
M2R@ %C7?FG'2KY.LK]DEMKH]I-Z1:=K)[KK=6UN?!X/P]^K\03SQUG+FO:-V
MMXI7<KJ^JU6UDFWI9-_:I_86\$_$'X)Z[X7LK+3_  CKOBB]B\27.IV5NB^9
MJ2!E,\R\-)E6=6P1]XD<]?B3XF?\$D?"WA3X?3:QXX^/4?AS^SRA%ZFE(EK
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MF/'=6J%+R/(*A#R0&S@@8Z UQ'Q ^-5]JUS]K32KP7-N[>7YD31BX0' (+
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M7JWY7,XXAN'+U%M_"=U;-&L<:R!R"1MSD5[?^SQ\']2\S[5=(+>T=BVPGYL
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M1_\ @I1^SI<:-\/]-U;Q!X@UB/9=1VMM/JDJ7%Q!/=/]I:T$BJ@6&WCCD2,
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M"L/1]9NO$=Q<ZI:_:6N8XV+VLQ(:W/0,#W0=SU'TKURQ\/W6NZM'8VD#3RR
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M\,>E?!']EC4/[0@DU*Z\N-,8B4?ZP=>37O7Q+\:Q^#]""^<NV "*-%',C]
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ME X/J0 "1UGA_P "^(+7PU!J$VBWU^%EA3[)9*IG*O(J%P'91M4,7;)!"JQ
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MA4B0ELJ0& (&X =OG#XV>,-:^./B*STN./PO8R7LP9+?3M/ALYKR7H 7^\Q
MYP"!P>"<"OJ3]JSX5_\ "C]>\1>&;NYU#_A!K]9+W0KFW4L=/:5@PD5?O$ [
ME8 D '( (Y^;8?VCOA_X">SL+Q=*N]2MP8FU"/2FARH!P3(V'R>A(&2?3J/3
MI5*F/QL:N.UY;1>R=NNJ3]=GWU/GL/@*>7X*=7)U923E!N\E=[73:VV:O&VU
MUN>K)^R[H?P!U/4;G1AX7\8>.M($$B2W-PJ6MON@#.]NFYV21'#;DD < 9!
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MK=?*0;G"]1GN!Z5G3C&,N9&=:G5ISM/_ (!R/AKQ/:Z)<VUGYJW&S#K)D <
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M/%$T*H8I9@EF[+GJ5!.,=AC/ ) YKZ;_ ."2O[4_BS]N'7/'DWC+3['0=/\
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M323Z7OOUO?16:TZGY_BJ.#QM"O@L!4;JTVN:;3;76W+YVM:][I^:?Z??"/\
M;ID\*:3INA^++C3=9M]0!82VER;@11DD!F9FW!LJ1TX/3C%?6'P4\7V-WI$E
MQIFHQWVDW$9<;USM&"Q##U'Y$5^6,_P6\,_\*TL9M!U+7-9UZTT2/4KW4?)D
MDLK>Y:5RJNZA4%O(O8$LC<N<$9^EO^"5GQ1U;7+.]\+730S7GV&=DC9LN&5&
MP,=AGCZ5\3QWPSB<GS*.-A'EA.3<4KZ+:SZ7UU2;3O=:/7TN$,^R_-\DGAX3
M<JM%+G>EI6^TE:_31V3^R]4[>0_%O_@K'\9K'X@Z]9VV@> IM(L=0EM;-9M+
MW.R*V,ELYZ<<=361I7_!6;QA;0^7XJ^%/A76XW;YI=,F:SE"GK\K*ZD^G0>]
M>;7>F-XBU>_\SYIFNY X/.&WD$?@:ZZQ^%S7IAC:+[PV@D8'H?P'7)KTJ65T
M,73A&I!-M+79].JU/H,16E1Q$HX;W8WT2.+^/7[4FO\ [0%^D/A?P[<>!;":
M P7+27/GS[23NV$#"Y!P2.<=#7)^ OA%'H*)';V[/(WWGZLY[DFOI:V^ &FV
MVF&9DW>5@' *G<<Y&/0<>_I77:;\._!OA3Q%X5\,WUGXJO-<\7Q6]PL^G0(+
M32HIY)(XF=FYD.Z)BRJ00.0"0175C,MIY104W:S=NK>IV4<'F6:U?8TES-)R
MLK*R2NWTZ?-[+L<7^S=\/QI?B. 3\R2D!_8$X %>*>/_  $NC>/==B ;RX;^
M6./(YQO/)K['\&^ Y?#WC$6I56-K<F$R+TD96*Y'L<5X'\5-#6]^(NM($V;=
M0DW9_P!XC^=<=&LW._<Y(X?FH/R//M%\+;X]NW<@ YZXJ/4_#"V\@P.AKT&U
MT2/3K'C;D<<UCZG:KYG*-CU/]:Z')WNCS&K'G/B72X[#6]/UC8T;V;!)F7/$
M1/)([@=_09]3G5\5?!"TOKVXN(V:6SBM!?1(F"SQ$C(4_P 6T,#QV.>@-=3<
M>%(]3M]BIOW@@@CL?6J?PV\.WEQXG@\(SZA)IYMF-YI%UW2,$":+U.Q2S ?W
M<]EKR<PA:2JKY_YGT64UE7INC+XH[%'X5^&-(\/66J0Z7I5M>ZW>P/+Y-ZQE
MB=0@1LV^"LHPY;.004!P>E>W>,?V8[[P?X2\)^&;>RM8(+VX2'3_ +,-PGDE
M?'F.< D[<D+@!0<')Z<[\,?&6K>&/CWJ=U:Z)I?AJQ0D:KJFH(S6]HJ_NRL*
M\ L[(2$7)))R !7?:U_P4]\(^'/B%8KI.C7/BO\ X1R*5M-M[>(1F6]<%1.S
MGA5 +   GDGK@#T<PSR6(RVEEL*2O'[6K;W\]-]>GDCYW*^'JU'-JV9JK*2F
MK*#LDMNNE[VTZKNSYC_:7O6\8?M,:UI.FF1].\*NOA_3\C^&V'ERR'U)E\PY
M]2?6NM\'?#;0_B3\.?\ A"?%&AWVI:7'JT&KVYLM0-K,ES&A0;OE970J3P1P
M3GK@C5^ 'P&OM9T+3-0GMY)M=UEIYYPY)8R-*[."6P<Y)/XUZZWPU@\$?O)+
M;[1.%9&7:-PR,'CU':G1CAJ=..'Q,.:"T:[OJ_O/?CF6)P6/6/P\W&I%IQ:T
M:M:UOD<#XV\/2>,O%.I75Q:1V4;&...WC);REB0(L99LDL$0<\9QSU%/T[PS
M'X=U./:L+1?*Y= <IQT.1P0<].Q%:2:#>2ZB\T-E?N%/R$HQ/KCW^M=UX*^!
M>J>-S&EY,NFP'JFW=)CW'0?B:^@S#B*$\,\-AJ?*K6N^B[)(\Z>(4Y<[WW/,
M_'5S_;4BK;HKA 22!Z=376_LVZ;#+XD%E=,JV^H(ZYD^ZC8R"?;U]J['Q1\#
M;/P2RPQ7+7"YQN9 #[USWBB>/P9X?GO+=5@NI T=DV/F+$8)4=U7KD]Z^6CL
MDC;!QG4F^1:RT^_0J>+_ (7C4?-N/#=T@G"[Y+4-D3*>CQGN#[=*\UUR]\0:
M>C6\EO,C(?0XR/;UIO@SXR:)X "Z7J%Y>/Y+ETE\PB2W8G)VD= 3VZ5Z-:?%
MS0O$.WR]8L;H-@?Z4@##W++U_*G42YKQ=T.ME->]MWUM_P "YY3X:\ Z]XGE
MN)BBQHPPV[*D\8QZ$8KLO"'P'O+9U-U(TB#[J9PN<8.3C)^F<5VFE2W4TI:S
MGT.Y5SE4:_$8]A]W^=6M<\2^)]#TQYI8/#T<4:DYCN3.V/8 <FO7HYIBZ=/D
MIO1>1S+#XA/D?YHM>'?A[8V4,WF6=ONVX)8#(...>M4]%T)WU21+1(8H(R&D
MF;B.)<]2>@'MU-><O\?)(;:]NKJXFNC!CS(HH3'LR< 9;IGUQ6MX8^)-YXOT
MX;0EO OS+"F=B>Y[LQ]3^&*\ZO4J.7//=]SHHX6/Q56DCKO'>LQVUF=/M9,6
MV?G8<->,.A/HH/0?B:RM&^'-WJUHMRS31(YRK<C\JT/ _A)=>O7N)&DF(/5S
MW^E>U>&_#\+Z:L.WY40*/PJ5+E5S'$XQSM3IZ11XE+H.I:, 89YCMZ'>36OX
M$\7ZE=^-M*L;C>PDN8P=W/ .21^ KT#Q;X2A@'[L*&]*I?"[PJESX]MY9$4"
MS1Y2?3 P#^M;T91FT>74Q%6%VI,^.OV_1)X__;+\174,;?9[&*WL(P!D K$"
M^/JSM5OX4_">:"W2:1A@*&V '<?:F^,/$4'B#XD:]JLC*$O-1FFWO\HP6..6
MP ,"JOB#X]Z7:>%=1LM*O[6ZOUC".ENQD,:L<$ENF>V!GK6-2+G)R>Q[U*4H
M0C%;Z'H]AXD74G:.UD46&GMY,8!XEFZL_P!%& /Q-=+X>EC#MNEW _>YZCKC
MVKROP!N_X1;3ED+([H'<#LS<D9]>:]#\.>0S/;QKFX*>;@L%^48&<^Y.*X_8
MU<34]G25V]DCU%%0AR+KOW8[QYX&M/&5J4D.TQY:*0?>3VSW![BO-M"@OO"'
MB(6LPVJCY5^<2*.ZGO\ S%=]XFUR71%\FZ7[/YF3&Q.0<<8)'0GJ,XXYK8\&
M:18^,K-(;U4; W(^1D'J"#V_R*UK8>OAGR5HM>OZ'FXBG:7,MSNOAKH5OXDT
MAI(3R2#Y3\,"1G*GH03GCK4GB#1+S0[C?"&;:N[8!W_K4WAJR'A>+R8W3R4/
M'/;^8SU]C79^&_%5GK<!MYD61W! W@?/CKSV(_4<CO7#**D]0Q%*HX>TCJG^
M'J>.:CXR_P"$FND@NIEA\E@^\D9C89QD=>>A'H:Z+P+XQM[^\,2I'O7:N)#@
M.%!/ 7.0<#GKGCCBF>)?A?:C69;B2)A'</\ (ZGIZ GUKNOA3\(=/LG7SD<J
M>C=,9[$U[V4Y_7P$7"G'F3Z/OW_S1SPQ,H:(L^"OAG<:E8F81;FD)8^6GJ23
MQVKHM#\&0V5_\R>0D?+E\@Y';%>I^"M+T_PW;E;4,N0!R<TNKV6G^*?%%I:M
M(A\AC)<'C&!R 3_C7@5*-1S=:MO)_BWN3A:RE-[VM>YY3^UMXDL?#?P7M[.X
M3S)]492ML.LJ@X1".X)YQWKYVO?V<_%U[:17<>N1QRRHI^RJA1(,C)48X&.G
M2O1?B]XNM?B_^TTMENSIOA\,P"_<WK@+GVZ?C701:_\ 9+CRU;/E-R<]1VK?
M$5I4_P!U2>BW\_,VPM)->T>C?WI=/P_$^9=?_9X\91WI\ZTDO)&_B6=6'XY(
MP:PKS]G[7MADN-&O@ZG[WE_R/>OJ'4OB!/=:L8=-MT:5#AFDZ9SC@=^>">WZ
MTV^GU2ZM RRVTS;>5DPF6QRHY!'MP:[L+E>98BG[6$5;LW9O^O,IX>3=T?&?
MB3PQJ&A2^5<VUQ&1T#J5_ YX_$&O3OV?OC3JND7-MI=S<?;[-FV&&<@R1@^A
M8$$#T.?J*]%U?3?[:OO)N$V8&6##*OQGY3T/X=:Y]_A7I,6K_:88=KL06"\?
M,.X';-<];VM*7LJ\>62*CB'!\M3WEV9];?!KQI]EM$\JSLVB(&=D8C8#W4<?
MEQ78_$OPZGQFT31;.+Q+XD\-1:=J]MJDSZ->_8Y;]86+"VDD&6$+MM+A2"P4
M G!(/C?P&U!G6/3;@>9%(NP$_>Q@C!/T->>^!?$,_ACXG>*86O;FYM-#=DBA
M>0E=Q;"DCVK3"<E2[D[6W.7$48N:JTEZ?UL?5>LZIX?\#W][IGAW3])TV]\0
M737NJSV5K'"]W,P^>64J!N<@8W')/<TS5-7M=-THLTR*B+DEF   '4FO _!'
MC.ZF\2S74XDDDEC)5CDY)()_2NHN?%%MX@TZ:.YN[>,1$.RRMM$FTYV=#R>V
M>,XS1*7MJL:;?+&ZU[+N<E.*CN_5_P!?@<_\1_B19Z]<7:6,Z+%9127%Q<R,
M(H+2*-2SRO*V%55 ))SQ7C7Q'\0W]_J40N+6W-K<8U*.:PAA^SWIN45S<AX@
M!(TJA"9#DG R>*[G6/BG:S:G<-;1QVI&Z!TN%#1D."#'MY612"P.0003FK'A
MWPKJ_P 6M4+PPI<QPA(E9%$<2;1A<!0%4!0 %&,   "OJ%PW@J4E6G43A;>Z
MO?O?:UO74]J,J2H.*DTV]=?=MTT[WZW^0?"?2VT^>SUFYT1;>ZN-.71H]69)
M@TUHLYG$(RWEG$A)R%#$#!.!7G/P1_9M^'OQH^(>H_%WQ5X0O/"?Q'LM7OY;
M'PW?:B6@N!&\:#6EMG4.9&^52ZYBWKD D!J^FK/]G.^BN]1U14<:EK4%E!??
MZ=-+;[;5"D1BA8[(B0Q+E1\QYXYS4\8^!]/\.:?#JD^GV$FNI%+81WQMU^U1
M6Y(9HA)C<(V8!BH."0#C-?(0Y8N5DK7?S\^FKW.E8SFDHTJLI^[&-V[-)+6"
M7,_=3O%;72NE%NQYZW@&Q\5/<W5U$EP8VVHKC(R1DDCH3]:Y+XV_L\^ OBE_
MPB.I>,&U*QNO JRVUF+6!;BWN[>243-&8695$A(8!R&&UB""0".T\&:T\$!#
M;O+>=@0?H #5?Q2\?_"7!KX2+;0*A5E!("G(+$< @GJ,YX'..*UPN4_VCB5A
MY/W=_N)RC,L5EV)CBL'/DFKV:MU5GO=;'Q[^U98-\5OBGK=]-H[QV]XZBS##
M.R%$5$4GJ6"J,GUYZ5\XZI\*M1TC5'&FWUU9LO(C+DKS^/2OT&^,6CV.I6*1
MV[PBZB_>(%^XX(.<L<9( Y   -?-NO?#Z\UN_>\5-N"0%8X.W/';O7TV9Y7A
M\'244]=DO(\O%2=.?/&3N]3R_P"''Q2^(7PCUN.XCO+Z2/A7>W?8Y7T.W:2/
MQKU36OVNKSPC\*88?!_ABX%]8B1B\LCB0LY)8AB2P&222#D\#@ UZ!H?[%OB
MFXTZP6:Z\/6VJZI";BST6XU!$U&[C"ASLCQ@D*0VW.['.*P=>^$O]AZ*9;J*
M-A'(#*@/RE01D''(! (-?*^QP56?,K.W2_YGOX/B/-,+!4&FE-73:=VMM&^F
M_1ZGT7^Q9X0TVS\(:!XLUC0]$_M'4M/@U*+4]<,O]G12R#.+:Q0EKR9"I9IG
M("%D4%2"3D_MG_\ !5!?AKXUBT_2?%WA/[9IR;7O]5TW^T+R5@<GRK2,-%;(
M"<*')D; ).,5\0?M2?M>?%/QGXCLEOO&UYY.KZ7 D,-JD<45E"P!2W4*JD!1
M@$]N3@\YY/Q_^Q59:6D,UKXC;6KF"!6O3%&4CN)'S^\5F;)*R9C92,E55P2"
M<=66Y1B<QYWA?=IQU;T5M>O3\&[)ZV/1S[/LOP%>A#,?WF(JKE2:;C=KH]]=
MFKQC=I\M]3ZNA_:\\;?M.^,]&\2)XET_[##; 7^IWE[+;6[W;2A8HDMU8+"H
M7D[0,\@G(Y[VQ^-VF_%3Q7-:ZM=6<&N6Y$-OJHD+P7_!P'8$Y /W7[>XKY%^
M ?PCT^?XBZ/#XBU._P!!TZ]N+>&?[-BVBO(P0K1@X*HP R"0<'G&2#7H?[0W
MP\@^'J:5XF\"VVJ6^F76I2QG^UK>6%;^UCF8)/#O8N)%&U9 1DA@X 4X/U7$
MO#,\;E2Q>%IJ*I7YG>[E9+56O;NT]4FG=I-GY_P9Q?3X=XGEE>8UI2>(Y>1)
M)*%V]+O1K9)K1N+BTFXH^V/B%\<_%7@#]EC4/M-MHNI7FB1LVGVE];M<HF5)
MYYP<XR,'*^P.*^'?$'[4_P 1/$,\'V[0/";3*H<B"*>W!SSL.R0$CUY_&OK7
MXCWS>,/^"=4?BBW=&:*Y6SO-DA*QJQ4 J>I(90">IS[5\R>&_!_]KW\3QIN"
MID\9K\WX9G#&4)RK+FL^57LVK65C[;B#-IT*TI9?)T_>ES<K:3=^WG>_5ZZM
MF&?VM/$$&8;KP8LJ$!?+BO!)!QUP)$W $]MQ/OWKA]9T?6OB]?0G5((].TFV
M8R16,"A0[-R6D;JQ)/<FOHSPU\&X]7U _:8]D:9+D+D@#T'?CD^E=QH7[/&G
MZAXGTK3U6.*75)XX1(22L>]PH8C(&0"#SP><"OLL-PO3A%XBFE%_-_YGC5L^
MS3$4?95*KY7_ %O^?<\-^&7@ZS?PIJGA?5/#6F^(/#>M&![JUNR\822%BT4B
M.A#*RDG&*]R\3>'K7Q'^SGK.GVVGVVE:=HNFQP:=96V=ENB."!N8[F)))))R
M2:Z+PIX5\)^.9/%5KX=T?Q5ILO@U=S7FIF-8=3VW!@<"( -$VY"RYR& /<&M
M34O#[V'PF\3[HL8LCE>G&1BOG8UJ-:I]8I+WMK]=#KQ&'S3 VRC&RE&*:GR<
MUXIRCI*R;7-ROU6SZH^,;'PHL$L:L,MC<U=);>%!-9@LO('IUKH+3PRMU>AV
M&U=HP/IUK5O["."((NWIVZUZWM+H^<K4>2HXGG7]B?8KHD*K8[>M<B_AF.U\
M<Q626336FNRO'(%D"<E&/?C(8 C'<D@=:]6EL%DG*NNW-9_BCX>?V]IS>26B
ME3#Q2IPT;]0P/7(-<^(I^TIN+W.S)\P>$Q,9O:^IX/\ $WX%Z9X2TV'6XUN=
M6TZZNOL]P@41RVSC)R#@@JZ@@$C!(8=0:]R^&'PKT?XD^"?#_AS1M.THZ.KR
M;I;AGDFDNX(@RH)F4FW+$D,%^4E1ST YWPKX8N/$D7V^]L;G4ET.]6'4].2Z
M\I;I<%E!R<#DLZG!R,C@Y-:ESXEU/Q'IPTSQ/>6/PU\#^&;C;::59HSZKJA1
MAP"?F RO,C84GD!L9K7)L^>6JHW!3<E;7IY]GK;1K7NNOTO&G#$<WE0=*M*G
M&,E/W>JMMY:77-?3L^FI^R=<"Q^+?BGQ=>01W:^%;::\;RX5A!G566*(#[H"
MA7(]QGDX->;^$]/U/XA:S>ZS?EI[J^N'N[MVS^\F<EB![#.,>@KT#1_CZOC'
MPOJWAKPKX3M;*TUV:.UFNX% C@M0^#N7!+/L+ R$DDL23GBO:/ /[.+1+=QV
MMOBSLY")V&,H3R..N"*\[+8U(*=>HK.6WHO^'+XLKPJQI4Z3NHZOU>WE=:_>
M<[X2\/Z3J_B>W\>GPRC^.-*T!=#CU'[>[6\<*QM&KF#'#JK$<'!)R0>,5=)^
M&T<OV1KC:GR%%<J=B#!PPXR01R.21^->U?#;P)II\?Z5I-SIZW-K+<%\$A5G
ME"$I&S9&%9@HQG!SS7,?LX>/_B[\;OBGJFB_$2RT&PT5=$:YO=#@7>VB.$EV
M2YV#[-.DRJIB+896& 3S7O8?BC!98E2P^&?--W=GHWM?S]"LOR_'9Y@:V)G7
M7+A*:24Y._+[S48*STO>VRNTKZG,>&=N@>9YR)&H&U0HP&QZ=\>E<_K=K)JF
MJ/+Y;")VVC [FO>O"G[,7_"0V)N]6U)E9!N$<2#:#Z$GKS[5FZI\/K70KYXE
MW3!!M4!<L['ICU.>E>;7Q,JU:5:>[/C>;G:BNA'\/=*TW5_A3<0ZDT):UN8X
MD60[6E5P0JJ?[P(X_*N)\8?#74](C-[HERVH:<2<+SYD![JPZ@CI5?XZW\=G
MI<>DK*UO'&ZW-\(&"D,O**6Z CJ<=ZRO!O[2_AQI5CN+N\L[I5"-.C?ZW']\
M$$,??K4V3CH]4>EB,NK5%[26E[6N_*W?R1S6OSZ]?9C\F8$X7&"?85H:%\%-
M8U6PMO.=(\D, ,@CC X]?\\5Z)!\1=(\01%8-6TIG<#8\H\ILGKDC(XK9TF?
M5A&&L;GPS<,.C2WQ!_+;75@<56H.]%[_ #//E@<32Z6_#\S"\(?!9M)B#706
MYD4#<9/H!@# &/S-=E?>$[&P\/(HM[=-O0@ '!Z5RGQ"^(?B#PM89NI]+B5N
M";*-YR@[G.!Q7)7'QW:P2QC6.2\DN\O'),NV,8.-Q7J2>P) ]:TQ6*Q-?WJK
MO;[AQPM27QM?\ ]9\.Z7]GLOM%Z5AM=I,40X>YYZ+Z#/<\5SGBJ_F\3:P(PW
MS\1QQQ9V0+V51_,]2>35.'7;K7K,37%Q(3,,%R?F?Z=@/0 8KOOAQX*BM!!<
M,N6R&R>22.E<<7U9M6Q$*$?9X?=[O_(Y6/X6W%FJR-))%*!G:6(_,^M1/#JO
MA^7=#))A>HW'FO>W\.0WMB-RKG'-<3XB\*JUYY<(4[V"X]SQ5QK)NS/(J3FM
M5)GSY_P4T\77@_9G\ :"S,)]0U!M0E0]2$C.,_C)7QMHEW/*558Y%8$!BN>Q
M]*^LO^"IOC32XOCOX9\(SNL<NF:(LR*W"N9'(('N B\=>17B_@[X>V=UJ$4B
M7>P,065AC(]*['*5.7-'2QVX*,Y4U/=LL> ?A7=:@(YU21U;YCSG/2OI'X*_
M!:?4W221UMP" -R]?<5E_#^PL]$LHU165<?>9<+^;8%=KIO[1WA3P+=V]G-K
M&GF\N&"1PPMY\KL> ,+D+D]R>!7E5HU*TKZO^NYW2J2A&RT]3T"]U"/PG<1^
M'[65H[NY4O<RJV&BMQR<^[\ =P.>].M]0AEN$9I54CA5' 0#I@5Y'\,?&%UX
MVUWQ!JUUO5[B?RTZ$[1DGCL!QBN_TN^M=,2.:8;P6"C)Y+,<*/Q)KAFI5)*G
M#T275GI48JG"\OBEO_EZ?F;OBNWM=8LFAPCK(I256&1(#US7@7Q ^'TW@K5?
MM&FEI;-N6ZL8/KZCT/;O7LGB^2ZT6WDG6))(4!#>6^]CC .T<$XYR/09]JY#
MPKX@AUG4Y?G2:!F (/;ZCMGT-=U3+<9@U>O!I?>OO5T<>*IW5V:GP1GAUX6\
M%PS)*N1YN"RG(Z,/KT(KOO$W@B2"W:2#CD;2AR.??TK*T;PI8^'IA-IY2-6!
M++GIQR/3W]NU=+H/C:/3KGRYF:1<;F(&<>I ]?4=^HYZ\,K2>I'L:E2ESQU:
MW7ZGF?B#QC>>'Y/L<P\L$X7=T<'CZ&H_#_BNUT.:VM8V\^'*N&;[L9&>#T)Q
MZYKT+XI^#+?Q=<1744$;HJAV"_Q@]"*S? 7PIL;F]2X6%V7(!7Z'GZ8KU,KS
M2K@)\])>JZ,Y(UITWH;GA;PU)XPU**11&56)54*N.3EB3WSD\_2NND^&TFDN
MOFVLBR-@JSJ<>_/L*[;P!X5TG1EBDCA99 1SD\'M74>*];LTTAH977S+D&.-
M<C.3WQ7'F%2MBZT\;B-+Z_=HE]R)IXAU*Z25^YRVAW=EX/\ !FIWTDB_9]/A
M.).F^0@X ]Q7R/9_"R^^-?V[4K/4I='T\W+>0J)EKLY.YV.03D]*]O\ VV?&
M]OX(^'.E>%=-93=:ICS=G7)X)/X?SK!TB"V\&:+96=H-L4<(C /4$#DGW)ZU
M-2I[.FH4WJ]7_D=%&FJE1U'WT_5_-W^X\-\4?LM>*HHMPNX[]!]T&8HQY]#Q
M^M<W<_LT>*L[9M*>2/&1LD1A^)SQ7TIXC\?_ -FVL42QK)/)]W=D*,=V/7&?
M2H+?4-6U&V/G7,<4A'[M %"8 .?J<]L@UU9?E^/QD>:DDEW>E_2US25%R>A\
MG>)?A!K7A:!F;3KJ.,9)PNX#UY7.*H?#[Q9J?P^\0F:UNIK%VX93DI)CLR],
M^_6OIGQA%>X?SE293]V6 $@*1D%AV/TXX/:MC7?AC_;'B#5['4/"'A6'X;6.
MB+<Z5XDCFWZE>WQBC;);((;SBZ&(@Y49XXSEC8XG R5/%P?O;-:K[SJP6'JR
MYUS12A%R:DTKI6TC?>3OHEJ]3IOV?OB?=:[96UUMMOM# %]P#JY]0V,\^A_.
MOHK0OB!'<6Y@F*V]RR;1Y; $$C@@9.#W'6OD3X,V_P#PA]W']E78A8;EZ@__
M %\=ZU_VI8UL_&OA&XM9Y+276@L4FQBH.",$X/7M3PLE4J<C9Y^*IT:RYXQL
M?0?PW\*^%OV:?A9I-E;W=]KEQHWG_8]1UF\.I:D9)G9YG,\F6#.S'(4A0,
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M^5RS?:4)\N0G))?/(P?7J>2?3$MO$6J?$6:'3;6X>\#N"L:(<H%  )'#-\O
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MH&C_ +0_AO6($\G5IHEP/W=T!* .^#P>*UM/\1VNJW1EL=?T%@YX25G4#Z@
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M0+;@.?SK+'8RKB?=KN_Y?<81Q$D]'_3T9YA'<6GA+P[=ZQ<;#_9L$ETQW9Y
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MI6N&\V4C]S;YSDCH9#V ]!R:\2^(OQ%U#QMJDT-N_P!INI (VFX"QJ.,(.@
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M8)Y))P>G0U]!E>!AB6U-[=%U,:L55G=GE\NGK<7!5E^9C@YK>T?2XY$5<Y8
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M$ !UY./TKOO!EE?>"-1ECO(71CD9.,<<?2KWV/\ LGXFV.LS1!8[X%)\CCS
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M;?2G58WVSS,(XRY$:;CTR3R3[ 5X/^TAXP_MV]GTNQF9[:+_ %[KD"9^<_\
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MX<]7<M4_GR1T)59VA6>-[JT_*N\0?LXI3<I%A-/-]K2[(>-<Y-9F,^L_#DQ
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MC[8K1?5 _FH/&H4-BOW?W6.3L;!)"#O72"*(,VN@GE=W'I09BV)J009GY&S
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M0=S>>;<\_Z"-,8VW1@E>D3XIF#31YV3>D9425I[+86Z>EE$K_6;$7E$SJN>
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M[R-YX+3;00/^ML2 /",C'>$:<"3S$>NX.U1L*V51.K(?74XU<4L)[ZJGNP@
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MS>_6>SW.Q])[.VSS0B!',JH0_^8G6!._B8O< $=-ZU)F9JWN%](J*=CC;=Z
M292IO9S!KTH#DV+;$I</42T^5NZ^T_)65W&JQ88W"%C-P^W9*8C"#X5 [US>
M-_84D+<</B'OTJ4\BJ*+\@D[/D6:EV)DJAS*,C9K-'@ +PK^4'B[FJS)ORWW
M=O0"M^/#V7VU"\61-\KVO!DS6#KSH)L]&9R&8VK9I'*=:)P]C<(HA@D2F$NB
MEZ\!U-NZ9^9$4@K?*(=Z.;F(OKUP'DZZ@(74>QF+2^6<EB6<=JIIT],W7=S
MSCD<N.N+E7#P$/M^DG,V$W1C;,6IX%,-7+CE!COY1,2RG_Y_Q=\)B_VG?96@
MWH GJ2@HS,##_^(7KP&!BKB ]< ;E58TX#@AY@;BSE2.J0/@%0EAC6P<J7CA
M?+[P]L([6[.XPGVRYW"+T:J;;A00X:[]+O$)#B&%:F=S-*A40KYB:0L"O-1>
M9,9?P'G0)XCIT(Y_VZHB$0BG6UO_U(\Z?9WEGUN\2MLC$/>+YRU$0X*QJ=>
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M+XKM'F#9BN-9;E1R>U()'#*-!F>^V, 6JX*7SL(JI]X@VZ\!#/8:X8$SHM>
M:2P$]A^PP!,)I B^%75MXN:;E@\LV2B'B5P)P,)WKP%!!*XPTZC1MZ&E/I2K
ML9N\@R"K2R&H.99AQ_.&?#*D1-=U>)EBUE S+#B-*9C[1=T-06&:]@?R-DYL
M\"]TS_^K#VJK2R8HQ+[P&D"VTW$_CQ/'N7<-("K> 4]MK(QI4.,R0*^;9SFO
M 2N%)[8AD]O.^ZYC SMJ1D,G8+ZEJP2"\-:W<QD*[(/G;"\0>.,OL'^0LK,.
MY$\4.128&4FZ(S:0*U%?^W9*5.DC$U@,5*&[E4U'*"378W VV$G6JC=&A->
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MZ,]5^;P!B@Q':."_^A.M[#5^?!3YI@\IZ"P=,@+3]/4@LU*I0U,#3R<#O(R
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MJES% KS<X<Z#P<U+IY'3B7PZOU2=*\.ZDUE=2][W_M&K,B=&@2?DP_Z:JK<
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M6*KX/U0OGM();(@;!=/S/.WR$Z3@R3Y5.G($9R/CICO[$FH :&%/KJ15CIV
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MWGI:_.)%?GX=>.4E]%*9H-O]3F0)M 'RP/T7@/A:<&K4VFEL?W<)*>;:2;L
M.,[GA727@A?**\(=2HHSDXU-B>"P#ZT&/G <5EBR=T* F2_397;"&P#)\(1G
M<N 83U(BK48^2R%E!&[H-_:_&^_M3BKH\>H/\KLD$OBZR]UTY,N7*XD7DC?
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MH-^G/$#',?[$?;F(40#\G98$W"(1->>!0]U(4N:A8KBGRI%STMMTO[A(/9>
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M5Y(!Y!)!4]2>QRJX<RO?^OT&VFH7W@*_1;W2[8V<H))L86:6)CT5%5?F7M@
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M4'KP03]*GM]*DGO[:.R\4:Q(]V"6F4PRO'W",K(0HZXX!'<T22:U*E--6?\
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MRO+\-I0HPCZ12_)&;#X3\,Q7&[^Q;%CG[SQ[S^);)K:-SI^D1#[+IMG#Q_!
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M&D+&+S0VFG4;8/L>G%X[88Q@'DK^//?VJK)HUA<:E'<+I:6LH4(9FLTC^?\
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MC./,1\C=<XY*OE21ST/./3-6+B]U1;V.ZN-,N5DA&V*UAF1T<X/(;C@]\@$
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M<B_?:=I,LL:G>DR,]LR@YW#(R3VQZU/-INJ6EJDC?V;:Q08,<BH2JL>A=>,
M=!@\#K0'M+:-_B<V]AI-E=1S?V.UC:QG#2+IK-<NW0[=H!$8'<9)S[5:L+#P
MW?WD<-OIOEZ>9"\YOH&C20XR'#2<D@CO@UT%_P"(6NM'M8YA;7&H,=[K$?W:
M[3U.<D \<=>:SQ-?>)!Y$EGH,Q&=D)$GE.<='W*.@Z8!%+4?M&]_S([FY\++
M-);WUSI\,RR%H'E(/EJ,8*NV5&<=<YK)F^SA19M>#^S(&\][>TA=FDR<Y8XV
ME2>0H(SU.:Z"*^N[73A8VEMIHNO-(V-$/*@7&<*@(+<\#.!227UY91&TNK..
M:WDY#J"DJ2=<E>FW/H<@>HIH<9-?\/\ B0>*M!T6"6T-JR6EZG[^,VBKYZ*>
M3(HQG)Z="#TK,>"UOD+:O;>(M8A/W5N+39-GU"1A<+USG@]ZT;)-/T*\2:UM
MK\+O#%(;2621V ^8DMC !X'.,= 16LGC#3X]0DNG6^261!'% UNZS2,.JA2.
M3T]L<YZT:]"?:-:*[,"RT+PWJ=JT<UG9V5]:J3;K,3$T2GE54Y!(!X(!Z\&E
MN=&TTQ1S6\5B4N OVI H)+#KO!YP>V>,5IW,1U:22YD\-K=*6W?Z1)$KVQ Y
M)!)!)ZD _K36T:^(\[^RM%ABEVJ73!GN?3<VT  ]^I'O2&JNN_XF3J5GX5@E
MFCA@N4@1CSIXF0^<#QLVD+^(XSUYJ#RM-OH0UU'XHU.,'Y/-#K,&!XW;2ORC
ML3QUK>32KB)XT;3VT>0Y6+[/=QNI/4;,CC!XP1SGI0FF:F;.%0RA;EQYC2R"
M2>5U)PAQA-H(R<=>@Q3&JB[_ (F-%9Z;:79NH]%U"XNHQMN3/"VV5",$1LQ(
M..P& :LW6IZ/?VFV#0[R&%.95GL3''(@X*YY&<<@8YQBMJ3Q-=W&FRVMU:W$
M5XQ*&:")S;D9Y(;!P<9R#],]*+G6QJ]M':V-I?,8V7;+<6[10.0.%);#')]J
M6O4GVCNK_F8]_IVGZ"(X[)M:6VFB#1_8B9)(U;D"($':O!R ,#/05#;W/AT6
M<<=_IM]8OMV,T]JTBR*>@,H4J03S@D#)K0M-'N-*^TVZZ9;J]R#Y_P#9LIS
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MGT_I5<S,W2/Z=_\ @C!_RC8^&/\ V#S_ .AFBI/^"+PQ_P $U_AC_P!@\_\
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M_:))"(SZX)SMQZ<>HQ6EI.BZ7J$'E_9+&2.-R8UV A0>A"XX';WZTB74LO\
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MVKNSA<%M+:P1WIA9C^E]<579G5(\KC,F:CG 9!<1'7/$;&"<<MO*?KS5MO3
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MN^)E$@CL4,BDA0AX_/8Q:P@?97]S>J(KX_OTFAW-<<YZ:E2JS$F%M%65/N>
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MOJ"3SM\6F7_:Y;N\M#LGRF]T+<PSA*K]SI<5=SR6:UOHW_;M^2+2=CQNE\6
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MF=7GO/(J:IJ#QP:2D>%I##$140\+.Q2HI !JA0)&/I% [>) LQ=H]9'LP/V
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MKI:SJRY7 K6+H.V<@+W9H:X 622'S:[7*F2L:@^Z% >N#3WXA "' )Q]]0L
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M[KYO&C+V'^J N3(=5D9PJ*GF<E:H0B\#)8=W98X 9"D26BM>X6UG3N4.W9:
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M4/ULXC483K'WUCQEA[%"\Q@T5!ESU>8X\PYQ10L;Q<R1E <+7R$J=TO>]5B
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M8ZT#J<'S0G8%LU>,Y1*%_8#[!F,E3:.JX_&_B+!-"U9.7RQD#-O<Q^MC *E
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M""- @8DGRB<2 M?D&]J:NIFK#XS\TKT#M&[N52Z+3@0H";_6B'^>PO O%QS
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MHW6K!'303MLQEP #Z-[B6?):L<=GMVZ[F=/\=]%5-(OT][I2!:C+"7D9_]7
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M?TC^O+JZHCX\1N;+JY"KPQTZPPEC@;P!IUW<7*NY&51X%\A&=!CDG93$]&6
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M+K1IS7B$(.3'J3%*F0I>'C^6VP:#8I:Z?*-?->CTWXYD[7L=/,:BN&9$6AZ
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MV#EP!G0$MJ6%;#PX]LB!URA'A64JG2_YFN'PM5H8R[]3ENB#TP;>017>HXM
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M,A$(B#&]H[$!-&5F:-SH9MTJ0V?C>>1F%2P:1Q=JHX8"YM"-A[;_*X2H,CM
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MN6W,3\.@\7!SK(6=W&_IYV1F1\0:FE//POZCWH$@6A9Y<5]]DDWH>W?(: ]
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M8-:"Y3XQ7E<F]S[O;>+)U7U)GQY, ])K4_;<]!U=,!B% N($(*)PD_]')4L
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M=5,\QT).4C5S69S)G9(SI&?V+"X+?^H>=#SK/3M)_.>F*:,S>>ROQWU^-)7
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M\K-<4GTDWZRJ]0(REB@14Y#&6:9-#9$"%DMM:@@I"<-AAB1?%/+>?.#.:1+
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MXC#_J#=@O?DNKSC+INL5:+O9^A]TWV0FH83R]2>]RJHHY/)7^JCUNE0Q@[$
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MVIWF/&%<'QXBC5WW[V"N)M_PN^X_VY8_A?RSJ<'0&O*PZ)8V? ;FO0=JRVE
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M+C)K8T(;<5[W)K3ZC'L*XKOV>_ AKSA=-F.%/NC?58LHP5$2"PB(,M.N!8H
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M7Y:I+X9_YI-S!NXO,_XJ6M_QH(_&;2?+OO\F2YY7\E.9<[D(%3=I]@JPD$J
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MI @[<#*QACYV3XI5 7:,!;+F+*"&-6V5M+R9'@&:N3%2A%U>B(_G-Q',0QS
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M01*9P5AE@*!4:.64"8#3D )*!=<^.E$LM2I1]Z#]!J']AO"0X'X/G!YA__%
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MLMS6&"N6 IK!%.1$$EUF%&?8,R'9E73LS(U#JO[CWN^W &^/XU+)-^DS*SD
M8N><B@C >>9(C(;9D(('1_&GJW_H8^A:Y1".0'541[BN$*R&ZG%=[?O/73X
MS"E'>:Y!"6EJO!LB 2V4!D00DN<4I:GR+8RZ2"RVJJD)^W?0<0+*67V,(KZG
MPCB5/%8#_%[IXNN#RRQ,K0%ZP3ASYON?"3WE'S:;)R6;(JM9D6,N.8< 4D0
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ML$R:/MG)T!4S)%V ZDZ"=%K!3VU)-9_=/LFYV?'W\_7#!SD3,N<%XQG0@B&
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M>B\[H0X.%?E8.0>OXI\(^;;Y:GWYKA8+>SW EL^?U>-JO9TIG%.5:@8@3 E
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M:HD58*@H 2Q+BDL!<\2PWW2JP^)>Y]-_"M6?@;UX6](KA521$R,STQE "&>
M"F3^D(RG(M>2%=A[.&V(] &M%1KIJ[227;[F "A<%5.8@'[:J*;1=!(=>=KJ
M"^:GF).Z(SG]A-,7PIZ=3?KR,R&I-'=:&U_FT&AO*=\_K9=S6V'<)#:H,J62
M:PI21"E J<P!PSD#V+;\I)F2@C@E63O2B^U05/23/0-5"&+/@D]>2#]RW0<S
M AY^9[6!0AU!H7?4@W)E^C'Q29,9%9NP#)ENC,;*C7$6M"<MIG^="3-BG(4Z
M3H9Q?\R_?K2^^!;/MS_GFQE)"\D+G@&>*PR0G9? <RJ,YX-316"*J72*D+]<
M.+9OTY!*OEEBCJ?S1/ANU31$)#\=Y"J-5PGI.=8'5) >+3=9 >DY(=KUHV=_
M/\H=5-U>9"G?_=R: WBG/\\W_]K<KN>;^?+>UHJ=&WQ>943/,(-0L#(#."\0
M0 QJ0$ISPHPK0@K.F<B)9]+8.(Q%/I(OKC;JYCG5A73%J/WAVK*:L)K7NN+R
MT-[K^$*C.[<\[@8&W3U-LBV#+INB[LC0VZ7!\$U[G13.[C7OCP:#W'-A-'S]
M$.>MS<(;]CC?LFK"\6JY7_ZK^<*_MG<!,Z8151GB@&>I[<-D9Z-FN0!4441+
MF7.E'8?,>=.>-#5+U+Q4XXYJ9GP<&!]$7=R[2"@%:\,[G31L) <^FH*FQ+*2
MO.Z^.1J(F8_[%PF[,$=P3 P]O<, ''K\1)\5)_08 P0]]AU#%@@J:&WTS4H?
MEE_I?<1_UZE/+96>;^&+(Y!"C;*,0I!GV/J=0@,&F31O7ETJ58C2_,.C\G4
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M-A(N/D;VR/B$F=Q#<?*TP#UD[K''75::T#KW$.S85O=Y,-1RKYL '<_+:!H
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MQD1>4HH0(#@WIH4P.I% #H' 3#-><L&YDR:<B-_HNK09C/!8S>JJLI&K(&;
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M$(BUBZZ-CZ"?[MWQDS0,U07+2<7235)7YS?ENRVVDH:O"4#UT<[QP0W3UI%
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MK'TUS>0(AJF?EIW$G8=+>S63[1%/R9^6J43ON!IUD]$06*;?<Q3%W=Q;D(9
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MU>.WA\']CR'X^_KI,Z :K:-/YQ+]QYZGIL!WC_ <W9,1T,Q:Z1O"WPN6_$;
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MW)41U\6_4/;0\>'H4[OBRZ>JK.Y,L\J@'A)1W_I65-L-E]L%R87,)8, 2J,
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MQ$N<C[SEH62MP:A<R&[7IXPE:4!DQGMF+-?;*F+;A=4S1/83RAT75VWH8Q#
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M$*C[@(LPGF!^$V83<@3GHV1LM-EQ\%J1H$0=#I;(,!?C/5EIE[/NSH5Z2-U
M8K5V\'20Z <!GI4X1E8XPY(-H'D=]L-<!F]00DXE"V$$R[BMP=XQO.Z!!&_M
M &4/,0\BL?U4R$&*8Y$EM, PDH7,R4/ 4, QS5"IXDOHSKU^BL)&T&F]^UJ7
M@=K^"FD-5KVWXWB_U,87I*^00WR/O;9[<]Q?JJ=&'5OX[;9K!QUB+(7H 9?M
MWG*4$*UBP(+"Y R2H]Z="]M-UXX'AT%VCB)=+4#6(GVE!$(,,= ?F1LO<C2^
MZ^-R*!6CK2/HQ635+LH8A,^UF@%^458S%U=9E%&1G%R#:KEE'2/!3 $?4)#&
MT187 [.VNSX+3U'8-[ .T?KC&[I#57"R7:U^N_CX\>S=ZU<7O[__\.;?W[S[
M>/Z?;^K/6CU GUVDFZ.S&8^M'9JKQ,&MX;OKML:TM]PFL'5X*GG[D9P\9H&[
M(G0F*>K4W0.Z9XALX6C\_A4G<_SEQ[NPN)[A+??%<.5X0I"F<J^#@YB9 2.$
M322:)%5WY<C/$-FW36L#.4^<CRUH9! 'Y0?2!Y%0&^&\QF]X.5T^K5VS-^(J
M:<8UQ='.9JCCBNO0G-IW0C.676)^ZS"TMM-<6TCM&V:M .*)Y%=;VAD$V'[%
M"<[")7%SEJ_&DW&542UXO6-(D ?@!&3'.2CK&>W)Q($+%-R*$KGM#FXO$-O[
M]=!1 ->FAO:&W#><Q6EKH'L_FY;QXK?I?/Z6Q'CQ%2M'D\]G=:[I*K>3&(5$
MP5D@X=2.7W6TJ8@,@G*!/%\=\];IY>W"[D5R^P;><0[4=K4TB,3NKV$\F5>.
M<'XQ>?4E3#[C^>1M&,_^,UQ>XT6Y*_B?CZ1B7ALRX-QP8@ZC)N9437U;%X(-
MWK/NLAT[$-[WU>5QP'@LS0WC$-YD[LWWM&3O];@0.3A)]8>?9F$ROUQJ\0.F
MZ6<Z!C"?3U9;]&)6_^ZHH+>HC #:>HX<D.@AUA8_W-HHHI0RZ&V3@(X(V'U9
MZOO6M ,H=Z+M@1S[R^'E.%^LQ$K;^.ENGT65F)RUY- H00Y-(/>Y6 E68A1:
M)NY8=V=_,YK[OK4]#E"/H*]!F-L[Q^87+-,9?@K?1PE%"L@*1*-C[=\H(3(6
M03#ELBK">]5=(OH) ONNPCVVB[F?)@;A5*Y$0Z2O([)5:?HUN<IKGWDZ(5<Y
M:L^=\6"RJ>,HDP$?,4,6.6A,J!SK.BNZG>*^JPF.9=):UM7N"/0K!$[P<RW(
M^W04NS82T@3/4(-PEJ04> &?1 1O!>>R#CSKL/O*'5V-0-7Z3+CNK-A.<A^$
M\7JN('2CLY8V(D@ZV*-@Y&<J!/(U [%E,=3^HYYOFU'<+I)>HK81OORIX:M5
M'0W" WN.HW>XN"A+Z[P]*AIQ@995$VU5H.B':=IG-C-(7GB7I2JIPQCA4&[Z
MOBAI%U^-X7L490\"WD\5V#N>F4_DUJ*I3/!2A]7GZM9:A[5[A P==A+:\\7#
MW2OM4[&=AZIB$(?T+V$^3C?5]M7/>(^S90W/"&GG6=H"P'7M&1*+!J>L(.$P
MHP1F'3OL&?0LF<VP=7(5!^VH91 6Z_7X\GIQ]Z+C'C.<]D8L7D,V@K:+()_6
M\52 :1%<M"D5U5WA^Q9"FZ'LY*[AVE+-('#V5ZQ-OS&??:-H^S.N"A%'14EG
M;.$@=9%DD",=\%DYH"\8$HXR.6^;5=PNPIXDL1FV3NY6[7!U# )59_F_K^?$
MQM/L. PL,0P@71W?7$A$H2 #FQCW7O.H.QRWN9749B@[N0NO]M1SLO7'K_[]
M[-VO;SZ>OWOS'W\Y__1?K98=/_QV-]7&6SDZQLN<U:7__'SRH"3>%A.*U18$
M092P*>L316DH0N7&<Q^=SMU=>[],[^'6[ODU/M7>SB-&WJ7G(4'$VD @D_D.
MD44PWG"T%*OSW%U+QQ>([3OUT3*^'MN^-I4UB+.V!M332;WXO2AK27T?ST=)
M,\&#-X L+9^ ._!)(V@7M'9,6\,Z;%[[)(W#Q=H>4'@RT7&@7@:*K]?3JS">
MC$QVTFB=:]?G1)PH15LP,L@YUML5QGSL+DAXCLJ^,=8&"AI :P^5# )<]WHW
M_8[U-=R(J9(1?03.*7Q6+I%LG"#[[FI[P62L+-T=ET\0.#Q([:/][6VT]E#%
M(/#TUS";!9+,FOZ8E;),%-"U#YA"68AT*:"H)!$3,EVZBS3OT]9WB?J14'2
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MR2(Q&53MVT\QJ^ ,F"LQ.%6,[="3/IR? =YA=W$B=*+^(1T+S>0\LAJS<KZ
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M>#**$>22J6TJ!0/'<WT-KUF.+B9436\AGER@79NV(;&S#8DMGDE',\/J/M+
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M]>.=[LE0W_:R?;1N=TB[T'O_?4$:,KP4]Z:7=GL@%.]4*9X#)L9!62' 1Y]
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M0H<.WK*QOCM7*3)52$:L"&(CQP#1F0+!,V()78P/']4=$8E/DCA\V.V#B$?
M.UP]_4??F.N;G4<\Z)2$U0D8TP%4M I<\1F*S4ER9=FC*1?/1]9/KM#W'=I1
M$=*:: =AA.ISZ^O%JH/X)B-U  R7KHZLTZ(VG:S9!)D@>RV#3Z[>W71W(#Y-
M9-\78QT9HC94- BL-7)G[^X.94SD(3@+VDFQ:D/ILI. R2@32PSR84.HOF/:
MWX982W74P.&(*NW]]+S'3]CT:B>3ZW#Y,.4U$BISST,$D9D#I5R$R$V=_1!%
M4)$[49K>#^ZX=-\>V3%1,.U*)8-/3R_?^6STI#\DX?S<M]I-(3>BN+W>L=<Q
MU1-YF<M;7F)<E%5/_PT2UHA<W$OM299\YA:D)2@J80W$VFG82.UT8CKJ#D.N
M?;DXL"W:NB7@JB722/*"/$=!%/(ZSBQ0R!Z*@")]2/0_SGG35]OWO]RWI>H$
M(P]ZG^TOVD%X;9M>[K?QO,ILF=9)R$WBM?&#Y&3%@TC@6'"@N: P.''VJ!RF
MHY39!I%]WB\<HO>M6;!]E3 L-"W/ACMNUI$2VB*<0PW&T5FM>+(0C;) YX-"
MY91*FG4/JB=I[=N4M0*)YX%VN'YZ=^!?T8]KDN93O;U>!\TH?,@H#3A9!W66
M'"!(*R%)(U2Q:# W[NOY^/.#P40+VINV*<K^L7!CC>_"D)B]UP894!" H+*,
M$%(6$)QV/!>I*3+>U<GI.0/0VLG3BM &<> L=\)JONBR"=)(Y%QGA$J(1?.:
MC!,0(]G';'W2+G.F0G=O4!Y2-PB'94]M/[Y!.43TPP'/2BZ;T^!&EDQEC(IL
M 59&-$H(V18@84GCD47789^Z9X@<A 5J%4H'*N($AF[<Y+<V4UN'I'FV?:_=
M5$]CRH\R=^/Y H2[ZECA(C,&K#<$/R88!!5E;8 34X[(BAO894(O=82<(6J5
M),AZQZV4#&2A$P*GN %%-#'S[NI@AEY'V 46#RHEW$6;@SAO&U84R21L[2P*
MR6E=7Q5J"*$V7 F%/ O,Z$2'E]-_;Z6$.Z%FWU+"751X(M!<!]G>>N4#DF<C
MH@,E*$".)C'0W%K:]9S)#GLJ_)V5$NZ$FOU+"7=18>^9C6<JD4A"RM;.SZ7>
MM*H@.43Z&1")&B,K.<6F XL/*/(:0AG@3MIL4N2UBVA;##J.4>;E<I:R4/P4
MHZEO3LD5B:CK+9=447NGDB_=&:L#RKR&4$VX#]#:55&O:%O/L+A?-DMB>GL]
MFXQKE]XU0R$RVB7D4,3(4^VIS"$8CH"<Y5PB9F=M0\OTXF(G4R*XOY%J5^"#
M\+5^PS#'+]/+?'[U=3;]MGQJ>M-;CB>64P@!>!8UX^-K#C%%\DZ+-S9E1:YJ
M9Q9K"Z&-D*=.%'GMJVH0N'L59K,?X\GGLZOZ"O LI>NKZV5G^,W",OJ/L\5X
MOOK_D\IW&,_6.^_7V70^?_"5ZK?JR!$+)Q?!+M_LU[WHE .N' _!A>)<=VU7
MC\5EW^=T=R'N$& RP UST_V36\XB.<4J>J0_)"/38DC"WC'OG(Y"='<Y\A2%
MO4<N@\#/"[#>0YF#@.03LKEQ@W+BR14&=*[102=KVM66 HJ[S$411N3N</DL
MF<,"YSXH> 2L=E0R"'0]MUDG>7._KKECEF=IF 9RHS3Q%,GOUD)#*HGK;&A#
MRNX MPOE?9_D1\#@T10W"%CN^  #<S:2W&\(&$B>0A1P7!5(4CJAA+*Z]-.R
MNJ6751TUPSRJDWE$E0X"LA\P32=I?+G:AQ?EU9?:5&I^/GGY_I1GIG+-9UA3
M.T^YY.HPFPC,R_J@4B34W5W_[<]'WR?],1'V1$OK3M0]"&@_R]*(J&4AF@PV
MH: SS$3P(7M0J"3G+ECGN^N!\RR9?0.S*ZP\U6^X!<7MC<&OR^;)'Q=AMFC+
M7<UYO'KE5.OG/I$</WV93:\_?_GE>DX;F[SRZ54<3U8OH9[G7F?GD!<#SDH)
M*F1#7A?Y7R6KX K/(HKN9EVUPU/?+FYO&.\!$H,PRIM>_Q:V+ 46H@00Y*^!
M2BF 3R[02<?0)VTBDQW6OS4AN6^'N#<@MZ_08>!T//\ZG8?++7M/4D :4XSD
M>FD'RF@ZC-QRT)+'7!!+R9T6:;Y ;]\W8?TAM%U5#@*>S[,BL)8E"#H1LJDS
M:HP")Q*!!J4-*O@0.DS['P9&_7<(QG84=Z!O^V:2VRH1F"YOMR>W>VQ+##NR
M0L64' 6L=10=[3(/+E+\*M%[QI(1V797Y;0+Y7U[J9VF"(ZFTL%W=EFW'9Z_
M#S]JYC!,,OUD=DU4MM/M99?OM_LL:&_.^N\*8Q*/3-D ,B<"<\KD-*)EP+B4
M2$&/TZ*[&2E==X6Y6_G3+&2\F3*^?H&WUN;\TW3Y7S]>?_UZ.::],O*.O!8C
M.3A=9S$B>3*^WN?EZ%3BP1>KNNL)L@OE?:>\.D'I8Y-[-.4.PE==FAHZ1UZM
M)8OY;+YF<F1ES%G2V<1+(&<J8(8HJ@3):BJ)R+CHKHQP"Z%]>P ] ;,MU0T"
MA]MVV<CPK(U 12>VK7*JY=WUF;1&KJ5E6'SHSC?=1FG?B:8!FLB=E+<_%*>+
M<-F!%[HLY6UGPN SGVK7MVQ";VMNY/L->B_*:NFWT]EO2 C$6Z@1S$I6IK:R
M#!1*.V7 9Q8@TXG)D@A:A>YNIAN1W&[MR7]<4YPV7BSU<3XIT]G5RD#$Z?7B
MP_CSE\6T7,]QM6M711*T08P3PD-DM:I'FTQQG&-0K%?!8HI.=]=[\2!6^G8A
MVT?H]J*4X^JZQX-[/EN,/M2LW+*FED55@N/5T1"&O%XR]DY&XH$,O'361;MU
M5G )\[BDD+ZZQ.;/>+F8UW];6LPE .\MV#>,.E3Q]%!Y#P$DZY)!XP5W.2<(
MNE2R*4**]#-0,9M09)'TH[9@TF>A\ '*>JCN/237L\)_'T_JH,0UX25FH;*+
M(#BC>+B^J/.A#N)D(2ITA@F][<*CJ<KO+=JSTO=1V;0-^?6M^-6$S)OWW]Q[
M5M]_*T^6CNR:A" 80N1%A.*D2'';_6MCQ6\NVD\>H#7%[RV_003P^YZ)=S<C
MDFNO6!8@BR/!!9?!1^+;2L--H"/3V>X2HP>STW=2JGL?I2\L]-Y=Y.(KUO!Z
M\GD94"S_J'."1R'X+)WW$$)](E%JS[U<<W)>2N=L]EX]J&1]_A'_TTN<JB.\
MIZ*G;4M]$);SKUBE@_GL&S'T&5?!Z/Q\DF;+E^+A\I?I;#;]@SBM\SK.EE<-
M^=-TQ?9=6J]637R>C.?TH<5K^L6+<CZA_Q NEW\CK6/>\[<?/G(S8H(%:S('
M1)G(KT@%G"Y5["$6)J76N;MJU1X$<*K6^;"-<SJ8&\3&O"T#_C1]J(>1XXG8
MB J,)CZ4*P&"]0PLYU(98DN&[FZ^MQ#:]XU$WT!O2X<#Z5&UW*'UI%O5H[_#
M/U9)S,WKG=EX3OOV+2GC[7@2)JD^$DTD\U4W8-ID*3N?(7BLL\P,ATC^'1V4
M3D;&4N:EN];>![/3=]ULW_#N%@\GT!UZQ?Y#<8=)?GAT'7YUM\,BQ[C4VY?'
MCJ_[7"V<C80OYRTC5#%67Z.7^B:&(=J,OL.ZTJ->]ZW"DJ5:+LI?;M1R*PB*
MFUUR3D!)L8XBE1("CQ&\,D(%(1+*IA.%GUNC[W"P?43<#_E:D>T@7,O'ODB1
MVM6):4P'7_N .7!!+?NW!NVMDZ7#B1M[.9%'FKC1CLX?O[4^1 %#?+WZA']+
M495(I78"UK5SC(^TY4*6D M+TD9%''=G>@^-48XTA>-(\&I++8,P5O=&QC[D
MIIAD33(!3+#D/[*BP57_U5$X[XPE?];JSD"VC=)^(N&CHJPUQ>P.,[^"V00_
MUW9!+231R4_ \>?)F^]I^=JK]G)+-V'3K=Q&G@6EO.-0=$RU>QL'7Q-)4KED
MG<@LZ]S0B6JT8#_QY1% <RPA#\) /<*^1XDZ>@E>% XJ9PJJ*<H%ED0T6;I@
ML3NCM)<A:OUY9;?>U"X*&,Y[R0?A\]TP&D?D.B,@8&*UO3B9TA0,H'?,&LV(
MV>Z>[3Y'9=]7&L<+_EK6T"!,UD-.1IR.8VUM AT$'=<*$_B"@HQND,AY]J%#
MD_60NKX3"^WH_44X[:2$ 06!AV>!C=71AN)!)DLQK]4!*.Q-8(PURI",O>^N
MVV$WMP)'-(5'@FNW:AZ$F7P5YE\NKA?E<OK'\BRI[(Z2H@@YV #DF]39,A1%
M!ZX4\*)YX$:1'%5G8'V*PKXO78^$OX.5<6B8^:E%9)U/"*<X7[SY_A4G<[R8
M/#H,D#SB;,ASC;S6P'F)$'5*P'T1,9($->L.9B^2V_=-Z-%L7IMJ&L#LGU_#
M>#)?M?%86NFG(O*1C\9)&1 TKQVY,D]U!G F/R2AK0^04GCPXNO9-$>3]?IN
M^-,J=HXDYD$<AX_ [Q(6PP*AW7D'"ITB444/K-!&,)+YTJ'?MI=),B<"JY:4
MT&JRX[A%%)_JF^J_3/)XONQ/@_?+"WX<7D#1<(%C%$_LPUO'A1-&&*U\1 BL
MEDLF8<A79P9D-)GD&-!T.,2KAW?2OX?%]8QT<38)ES_FX_E%N5_Q_3[\6 [2
M6CU8$"5$X2*'PM'3EO9DRLD#@,QI)P:F+'?]M.O?B8V^\RSM(W/[XY#CZ7@0
MQ_4M>_4=:,Q6*2\$>"4CQ=ZN0,CT1S8R\))**;H[A&Y2UC?H.@+$(R#NK9U!
M8>MF0J$V01J>H:@ZO](7BH(\A>'&1*>R](6'[M$UC+G9^^OY6<CL(?1!@.;=
M=/%;6*Q:FE],\+\PS-;O36/61OM0@-.> 263A:"Y 1Z#4U$D(U-WUP_/DCD4
M*.VC_T=@:D<9@\#50S[.)GF3N[?C;\L?WPP]+4$;6Z*"%!39[1@X^$!,*E5#
M+VNE8=TUY]Z-]KZO%EI%X!'5-BQ8/N1$6$E1/J^ X*56.WB(7'"PGML@',;2
MX6EY$-2.>(MP'*@=HHI!@&H?=_6WN^<^6>;$<@;-E -5BJ,]1-R34Q)\8?1'
MAQUS#V*E;TO85]C0G?X' ??E8-)'*4_:E48ISJ"$5!_9+X>2$E<YLQBBYXZ5
M[N[&GB2Q;U>Q0Y@\/4SV()V=P$N_O]:FEI/%:YR-ORW?7-X?&S%=CXT83]Z&
M\>P_P^4U3LNCOW-($KM5 MI-<A]/-@<FP5>7<W=[8UH^?J$-]2I\'2_"Y0=B
M?/9MV:%VV4IVV:;VQ\T5\&W^T0J"K+:2@&PR**P7.6IEOQ4Z';U^V _SV=O1
MPRAIUYFXU<7OM'.O5XT8+LK&#EZ=7AA3D;4I%&*N[:&B!2]X "T8_8#E*$NG
MDXUVI+_/MV0=XFZ[WW $50_"65BV(L?Y/5:6:3=RJZQ#DAJ%B72*%2GJW&@&
MSC ;HRTV==AUX#DJA^0R' ,ACPNZVE#78(&WCENS$(K)( !YY<472;NV1'#6
M,?H/C-CI[A7D\W3V#;YVL- (8GLH9A @6WM(-YD+9XN0PB.X(NM<.@HC?8Z:
M]EY,K@B'S';80^L>;4,$TSY:?]RW:G\5#*2#STY&_BX@U,6H')FM+Q,$*&?K
MB!DEP2F.65JEK>FN:_Y^/ PI8=3)\=J!JGOO??GNNF[$BYOH<7YQO9@OPB37
MSG'3R\NWT]D?899'T2A.3&5(/!3:J(5!M"J LG2Z8$Z\"-$P9&NV8M\6L O=
M3X^LB"&#JP[7SEHJ 9*YL)K(&0.Q5##EE)#.E-2TG<Z69?J,5H^AT::0V4F\
MO;^$6[%S/I]?TVY;!>_+\'X^JB5I6B=>B2<V>%%U*UD()HHH WD,BC5$R1.?
M[[-QR='1<:@X!_#6XJ&,WGS'6:K=2D>A...1Q5JX&"FHX0P\]QJXS"5;%742
M>D_K<;M(GPU'.K<=^XFV_P=ASW'S=4RDC(SW2CEA( 7'03$AB:OH(,M,9[.S
M*)3:&R;+)?IL,-(#2'87ZU ALGE8UI8H*?CE7'J"?*V%#HS,HJ?XU%JKI7@X
M*/-HOLB1^H;TZHOL(MZ>FXFLF%G=KIW?W:X]OH_;$!IC*G*I+,2\G!G+' 2)
MM#FBH#V2:$NHT! ].RU\4O%X&R'2\=0RB/3D'1OKI__A<O/Z7X68/8D'$JL/
MM8NEO5G;@Z68R7<C5\X\[#]ZU$9MVVCM,^HZ(DB>Z-_6FL9ZC\$VGFQO!@XC
M9,PI4R/';&HG*$YFW'@'Y V*_[^]+_MN\\CU?)__!7-K7U[F',=)^N9,.O:Q
MG>Y'GEI0-B<RZ4M*Z?;\]8/B(LL217TDOZ68.P^M:'&S"L"O4  *"XLY,Q''
M*V/[;FM3>F]CHNQ\>33@PNWX<E^9^?LB?%ZN;N?_%_./N^+-&2N,5#\W8 3W
MH"21%!)=$"(Z2S>%C\2@CA=HA^6F=.N&A\TP7&_%B+_GVYNGZ4[?/%C.,06;
M%1CG:N=,CV3%2@092F:VF&)TU[E-G1:<T@<<"U']<_XZ,+5U>-$@L08="%??
M*;DQI'2)@W2%6V45UC/3"Z*ZQQ0&<A3;P-/I7&\%38\U[ZNG>E='5SA3()4G
MSUJ5 I$I#C%:EC+1JUS78,.+BTW3P6/:N^XRCC?A"3YH?O-F\82/;\HW%JYG
MPBCO.>-0A",GPV=1.[56"H5B++-4DAG-/C]AXYV@::\5FL/+L@';OE./IOK0
MZ&I3)E];ZJ@8%=%$/K'S# 6S4L3<]9VWMU98[EIA-1#?FU!Z+P13 EIFHM6U
MPU>=ZJ$,Z>^4P'&CB\%$IN6(:?.7A[_\M6)P$(E=15NM)ZQ\\HL'KQZ]5B9U
M66C@"J23:6VATD@)65@R$@QSHH[$(_VGF"!$9BV*%5&:KI?/-)5&WYFX>S_[
M[6J><!9M3.B"!W*KR3N*CHZ7(!<I*8YDY[IHPHE1L^\^_XKK?$Z1^D%?XGQ&
M-YUR5X)5OL[3MAB($"T9Z7WE(6&@_\J@[.-0_F#/W .%Y2<#3E]L[PT_H]V!
MO]5?]%Z*^^13![[=CE/1PE6&*FL="P.A+0=5NU_%VOI6Z!I8M<[DV#65Z0J+
M9BTF62?90D27R3.V!KR7!8Q,0B0?=&3C37#Y;U4T>PKN>BF:/47433BN'^A?
MKM]L>1O#&O.N'<2KJF,^;LC<5>(93EX/3R!RG4["$X,0K 1)UD7!$IS%\8IH
MN^[ZJ@HQSD#0$\@.(LZK >JNRD^F5$JT"KQ!4YOR6_ E)V!6Z)!KPMZ(XVR[
M[WMJL Z#G;,@>H8@)W=>ME4*;^_BS3R]*;0!,I^?F&KWC<<8:J]M FM<-:M+
M(F.]9 C6)&&]$4GPC@;1*>M> \3.D?UR%$$T";$='4K6\A>%4"1=%LH%HL-I
M"4G*D%T(1&+7MC3/KS)UTNYD\#F#R4U<FO>E\ ]MYXT.K[-4N3$:G""ND X7
M$*(B\QAM$D8X%XL8[8Y\=IM3 VYT^ZT?@;6+O=WI9-PJC-& 5IQ.IV$./+):
M[UEDT2I+'#$=_,A&I[XO>X)#-YB=(9LF@+9),<X[(O;7.E% ^A[!)4VG4*H$
M,4L#3$0ER$Z-P;+1 '9@@TT"ZQP '$[XOD :34#JV7Y$4>L<ZLP1G^I<>^\"
MN.PSR*1(P1L3THAS-"YJ)39@[^;I;LU+Q-4L\';',LB8BZB]_X@G=7AUM6T9
M(UIDLJAY+!@GA5YC5^9%6#BEE=@I@FD"9(_Z6'&N?98.P>J:J5SJ$[$T#EA.
M2:EBBXCC)6%>32NQDZ3^4BNQ4T30!(1^Q3_Q9OU O?_G'%>TIT_;03=6%U<<
M2K QVSJLP8,74M(7E5TJB;G'Z1V#3H8\MM>I1]>.?EGV*+K&H;@[J4Y+;4/-
M27:>[%G'R4OB2,:HT$(RY9+0X_D"+^UV:HW7)SI.@-X9HFH'?.(017O-+GDE
MBD-TF8,*,H./18'F*#2W4J,9KP+YI=VV"[YS\'$8?GT)JPGXO5Y^_K)<U+#W
MOL1Z<TKK3& 5R;;512KRX#G141N>IF)-SD)Q;\=+.#F\QZFG?H_OHUXNJD8A
MMS>(-7-,HZTO+DCL"9R.I65 =X(N&6TT?+P:A^=V.;6&ZP,%':!UADB: ->A
MX*$O*&P(#KRNX]X*G3V?H@=#LL?LN?0XWM"J%D.YO4B_4QSW%%%,_U@>;DBW
MO[]=IC\V9\QDGIV7$635X72Y&W"<'/98,O,Z"F.Q<\K%]Q\]3:'RZ'?9Y6QM
M"1.[0R(,<2)H(K^4VF0[:W LB5I>K;A"XT3JVASAR8=/F3A[D9B>$_@9/)M>
MY*=D Z64!5INR*M@1)DKI."(()*V5-GFA/EQC/V*T[)Z$>_YF5>G\+H)X^3,
MEH%>:9=#0K#T':BH ]&I!5CM$T.44C]NX]I*]O^O)PU/Z+W=P83.V@BBGEPQ
M/J[Z>K7(V_/[L/PK970Z2P>%&TG7AB(V6L6@"):+L3'()#LJQ"[K36U+CR'W
MHZ5W%PMA<EB]72T38MXT=]@U_WNS(C+":M?'?3,?=,:R]\D;!;Q$7ANI(ETW
MDH%5NA2;F0VR:T58MQ6O*I6P#V@-((C)P;7=^-8UW=0WO\75YG=\IKD39$-H
MH/^).LH[00S6 @^.W%U?7)1=&QD_O\I59=;T :*>&#XY<%XO/W]>+G;V*:Y^
M7\QO:U9:8$I),*IVN$V%N"*C!YVMSLJE[&W7L4 '/OZJWI7[@,JE+)X>(S79
MX_XJ?K-Z-__XZ79_0;_'5*=H$Z]>AYL;S#]\_2FD3]__6S[CQO'@M0<>?:PM
M)'W-RLW@8J#[FV.)W;NI7[R;JWIBZ06!XPIP<L >;/AAZ#97(ENPKHZWX'2I
M>Q$49&]*3D+)+'Q'")[=6:656&<?H+J8R9/#9-.1=".BMYM^4V0'/BR97]^N
M[C:54W^K=&+^9:O#?SA<7S5SROD4N =O:G8XAD(G) I2Z3Y[5-*@Z]J?N->-
M756,H@]@3B?6R1%]F-#C%'X@,*X_+6_RAU6H7O6N/9)*1EDD!2_K=!=O/<2(
M!B0R&5A63,FNH[AZV]0T72 G1/(TXKQN%+]>+M9DT=2 ^HX#/X:OY,W'Z,GY
M(B'8$&LY<X# Z8KRM2=B0<ZYSV/@^?#VINDM>:W([D'$5XGQ5RGA#:XVC<T?
MG?(- T0,7(28(,4D@:ZF!,&E5!F0D)C 9>PZ5G. [74+8;/_YB#O4\97"?)O
MUMN&7F0LV6P%$$2)WIP4N.PL2.-#-IY[^[@<OU=,?[^;;A#^*SW#C"S!)IZS
MOY_,I&P@M[44T%80[VR4$#4R* %M,9$;$\>KR#]]4A;_:[S<]"&=27OK/ZEP
MNY]L,=,YF&!*@J($V2T<:_,4#.1A2D$4:5]&S ]^O+MN(/MKO.ST)*/)K]TN
M<\(B<S9[Y*25Q2:Q6H,/5@,O1$I]G/"J:P_MOJ:S\;_2HT_?,F@%5.L/N/H\
M$\+G6AP.VGM=@V(20G0(.CEEBPS2VJ[)H0\_MQM,_DHO,V=S]?I:2K^_^_PY
MK+XNRRNZP3]_J0NM?R<#<KX@&_.'FY#^>)_(V\'UF\W?:MRJ-AA;9KPIR]6>
M4;WVH^YW2P,WLQZ0?RUTPN:YH*OI-J00#;D)EAS;4"*0 <<YXXSLO*YM[*^P
M$[8)P@5F''";:N>$33=Y4:!X+DU-_#5LO%+L_U:=L$_!72^=L$\1=1/^\+.-
M8UA0-IL8Z-JC&T_5@F"OB9(DA<R2+C^3]6B@O:CG4RLAFS,0TKWGTRGB:A9X
M^U(,+GG1WH+C9"\I6R.@4B*Y9SX5D:(P>=IV8XU4U?:"A5-Z/ITBF"9 ]JCA
MD"Z13AA&B*)V+Y)%0&3, 5ICBI.Z\#A>B_2KZ?ETDM1?ZOETB@@:B>F=Z3=R
M+3DQ#$&H2+9'$09<J<7N= (Q&"9E"6U:?;^>5 '52@RZC^MU!%%/'^O!FO2)
M^16=DO 1-U;U)H_D:"+53(4D&!)Y3A@."GTMC60,$!T7=:R:3)UCBF?M8&H-
M.08VEB,+:G(POINO__AYA;CWW-Z%VQ?(2S$D:[T"*02O![S&58V &E1UW&;%
M3-?HY,F+7Y4^[ ."PXIG<O0=)N77>7GIB'G%BW0*HDG$T. ,!"4S&'0.>0Y%
ML:[AK#.W<*4E6><C<0Q138['G_[]!1/M^A_+&Y)E?5EZX; 5&Y*I;^.LD*/'
M,MGH 1&892($]$SXKLU=3ESZ2NN\SL??D*)I!G<_SO^<9USD5[64+56)?GSA
M>(7 O0]*@"/E#DI9#MYD!3HQFTT1+F+7B<9G;^)**[XNQ^*PXIH<E8_LWWO6
M;FS@5[</./SCBV:)2-IQ+22X.LB(F)UJLKP@ZI.SB RU[9HAWN.VKK2LK#>7
M9C21]AA)&NI)_>'KUOOT"?/=S:,WKTM>Q[M_>K\/W6=2U<*;M>19!BXR,*XB
M*%L<!);(<K1<\TW>A^W:%:NE-^N#,W"VL3/T(CA$#1B9 !6]A*A4+;1@$3%Z
MY?@T/9N>W_,5OTV?@J_CD<J>1-K$BTWG<:R)AY1CLI *+Z"P#CT,)@(S7"J,
MIC@Q7H/4:YS,W!=JSI_&?(H(KP:<NT>SJ 1+J;:K,K+&P1B'B#R#RYQG%5.-
MA34%SS;>M(?!SB73F$\1Y.0NT[8/S>]D.JTVO2UWV8(W8;&?21>-<4QFR!*)
M&N]3?1P@2SXEDWC1U8+N:-2\M-8U0.D<&1_H%-43PUN"SR^+&E"8_XFO_A56
M^0%!'.L<X3KRB7%&9HNSX*5PH&IQ8LQH1#EMAO?1Y:9^<1D;1+VPO1$<'1PF
M[2V3QM@(,26R>I4+$)V(D-$IFX4I%CMWGKYL8O> KR,CHN9B)C<)EF?;)_OH
MG$J1U9[^DBA3"8*T&EP4(1ONZ4QT[?/4>ZOJ 9\[)@-4+X)HPG9_9@:)"4)[
M)C287-]IN$<(J5@(OLB<A0\91YS)??[0H)&R#@9S&GL03Z,PVYU+A5KH2+Z*
MD((<%L&("!,=E&2*DIR4,A,3 JT-]Z\/%'0?%'2*2)H UZ'I-"7SI)044#02
M;XQA$(4GZ] '7E#501?CI9E>TZ"@DZ3?:5#0*:*8WNQZ-"HE(VU>UC,6:^(6
M.100T'-P,A:43JK4N8GK.8."1LI5ZOG^NIR5+>%@=S"TY F+"<"=RN1JZ@B!
M="R48K6R#*/$KIVFFAX.=)*87A@.= K/IA?YMWC#J]O;3_@YK/[ VU<?5[CQ
M)';:3&5I-VDBF7%7Z]X+Q!(1F,Y.2JMR>&RP= GT/+]@(] X1Z#/17-ZXFXC
M@.GH&4IR,F.M#\(2$QEKU3,4F$!'8RQ:I40X#3<]NNB]>TE#P6< 7D]:3?5B
MR(IE9VR(I'U-;20F0X3H#(+(QL0L!7>=)Z.T%A<<!R-G\+$)G^9%Z^S7^[PS
MG;W4F1'0%9+.K ,XO D!I V2O,-2)!NO)+W[OJ<.'HX2OQE(C&U<?3L2MD,5
MMH?O/HW'D.:59#="B;7%1/ ./),%DC#$MY*%T^84Q75DK:E=Z:%D_%2W]<7P
M)C3<_2R.!U.%9D6F8KFQX)-5Q* 2P"DR D7RSM2!D[;$T739H1U.:H[WBH$G
MNNIB@9P-JR^;F07O;\/JM@?=]%VWS"TQ,R\%TU'7-H:*[O^""![)'+!"L."U
M425V+<@X\/&3&ME#@*(?1K:K9GP.W*=2N\X93:0(PG?6%F(2,C(C,)KQ7AW.
M5C-#F>03J)E3!'*AFOEID7LV@%Y]KJTM[]E3+&JK PF[.%;GG)'%Z&J\.[B4
M2W:ZF*YC4I]?I?G7S[Z-G@N8W(0>VC5O]IH[ZUV!J.M,L82B!E89%):-4IQK
MJ<;KM7-*3^WA=<TE$GZB9<Y@]^3FRW,-OSG+0DL3@:="^E9X!=&[#"PFCKQV
M[N/C-?XZO1W["(9/K] YG_F-=&;:<&9#Q3N\J5,U7B_7MS.G@R/ !V NURM6
M&3H4$<%EDW.UY#V:T5!T<(NM&#V]HNER89R.*K]%U0(_U@7[OL"R$S9%B%G7
MG6>$@%83<Z1+KD1?W'C5<"=HH=XCB6-=8-W9W:MA/%U![\_+Y>V"_E\7];T^
M8YFQ2WR/T]E$K:]AA4EF #5:4,RJFLTJ@>LD,6'-;.WJR5Q)K2^GL\6+2^3+
M)G)8-$H(.OD:^$)I$DLLC)?W^M>O]3T!7V?7^IXBTNG?51XEXP@?A>6)@3&\
M)N,H!\'8#(6<%\:E5-YUC5N>DWXV?<WM2=([FGYV"BM;PL'N61RC-;1.A%P*
MDA^2#7B?'9 3HI2K?FXX PGMI9^=)*87TL].X=GD(G]%DN+?94E]^(1__SY+
MZO?%G SZ]R2;^UP7SBV+7+MJ$190GBMPDGR*^FZCR,V(LG2M'#MO!XV YQR1
M+T?F?Q,8$Z?3B(I)A;B;\*/H)_#6"C):G%?.,!Y<UR3H\W;05A;;91@;F/^3
M8^Q(%I8JRH>2)-CD(C&.%_"\SI93*H>L#&>EZX#U:\EF.Q\K/?%Q<CQ4S*LS
M]*K2.K*J2"4+H&04X#-S]&.T03!'1D'7=/OS=C!I5*EGG3,P_YMX8'MV[D>1
M4D1!K/..C$F55(80-LDL*4GB*L<X7L^9BT;V3%_->HX[UK.(F@7;[J3F)+VQ
M,@.BS-NY("%:#MK1$0TL&YE&K&B]OC$])V'AE#$]IPBF"9 ]FA%CK&?6\@PI
M*;("0Q#@3'4\C&$VE<0-\Z,!ZVK&])PD]9?&])PB@B8@U+EQ&'FO.5H90&*A
MLX:)@4=7B$TFD(%IF'QL;EU+W\#I2V@ONS0'$>'5@'-WBDW(:#P=MZ!J7SOK
M*FV%@TN9/IF\X*#&>W7^"_8-/ D[E_0-/$60D[NNM4D"+M8;@3VZ":*2RK$8
M(<I:%N2E!L?)/8J99>6=ET9W#8D]O\HUP.<<N2X'8'(3&NVY1BU,&Y0^@2Z*
M?&DA-'A+RB64PC)QB''&QW,)SN^F-'TUWH7^Y^7B:11F^RB1\9&58J'$6OAL
MC8?(-*^M5E#H1.PJ(XZ(O;)N2J>@H'LWI5-$T@2X=@/U\//\[O-.#SMG..G=
M#$)7Z\#8 C'Q6@C+2 U;Z8K&T6#U='_M >H<V1_.'#U?$$V Z80R$8-,:<<8
M6"]D;?U!JMV; #EY'Y%K6?)X^<D]E[&/-&9IL(MS(#%.;N!OC]C=*GTBZ_;^
M-62;QSN+D6Q/12S+R87*,H3@?(:<,U&AG"/^G?):^<PZ4VNOH63[]#&S#T8W
M"ID/N/H\LXRINF<(/!,=H;HK+M=&=S(E[[0/CXO73P1,7:7YAZ+AX'(RDR<'
MRZ$*:A2%&\,]B%A;WX=0((0L(;N@3&1!,=-U2NJYI>A3AD3[@,>E;)T<%V]7
MRX28US\3!W?$O%GE^2*L=N3\;;5<KV<J,ZU0)S#D@X!BM7^1CA),-$P:R5A*
M7?-ENJW8?!2@#_0,P/S) ?6PF'XS-?#MKFJ?SZ0AVX][XHRH?JW+B0Y&BF"<
M0E9<(=/OI$X\!U=IW@KN[5:ZG,E-.&8O'H(9IF *L@@%8R:K;#-:0WMP)0DA
MDN/9C=>*Y\7MMC0S=   #B6X-A37X_+8U\O/G^?K-0FO=H^(PM>&,RQ(.EFE
M%/",O%?AM636IH*Y<]O=%];JA"%[M1@:@.%-J++#%=919]JU<,!-C'1]8TTC
M0@=1!*MBR9&K\;HBGE_N[JX6;GT*:'(UM6]:M'^@?+7(6VW[YNYV?1L6I( _
MSKC.(7OG@2S#5 N^$8+U'GR*7//(0W!=2W&ZK-<)/_YJ\3,0XR>'T@'G=4]D
M5</+Q>X:CT21CBY#Y GK(%Q?A])G$-P%(5 R\UB!G1(G.+1DMT@DNW)$#<'_
MED&U/SDSE[CRS#K(GG2MBI9!=%)!-$$+PXN,J>N(P@[+=0/3M<>U^^9[$P;5
M]PV0 @_%6U7[M1&'% \17%2^3CC37K.D#!NO?.+T[E/\>F/A?4BDD994N\.P
M3\_^.M/H$S)6 *6O+]F2@W-UBI7(SEG#:X.DL9/9[W?7#5C7&T7O22Y-**N]
MNOUEL;Y=W6U2$K]K.7+_V[]50C'/G!1)$!1 >UD;NA<+D;D$2-HX:2;0I?'R
M#$[=?3=D7F^$?B2Y3FZO;3BVMQ"V$>4/]/TZI"K+ZA^O9T)S;6L:FI&Y@')*
M@@]D//@HE5?.6OFXT]KQR-?QY;HAZR\1PN^1[TVHP)_^71.HL4:$GZ1J/Z!N
M_<_Y[:>W856+HS9'Z<.GL/CI\Y>;Y5<D?\>F8#4+'- $2TZT-A!%4:3^)7G4
M2C#B]6AZL1>2ND'ZK_ H,#X"6M2@;[[@BL2[^+ACQ\SY:#"C!XF."#(UL:@H
M#742=+#&$5&=>R:]O%PWN/TEW@]ZY/OD0'KLK__T;URE.9V?F;(B257[T>=,
MMC#3!0(K#K20PD537T-R1_@\NT@WT%SO*T"?/)X<*@>VGV+(W MRE\A"4(4I
MB(H;0(4869)!Q-(1(F="X]H#_)?Q=')([)_C*_]VI.PI6?,93U)*GBP(4GM0
MJ]D@9B4@,\&+B2HJ/#6!Z^!"W9)"KSURWQ^O>X/-H%V2?ZA6W,/RR-\JT770
MY<6=D5_^Z &Z(9](3\\=D'=X_.&Y,NA]4]J@N8I.!-"\%NT$)\&I@""$8F37
M)"-3ZGAF3UZ\WX*;FB]='TQ?+Q=YOK'_C]?R;BM%1)V+@9E!,(;4+WH-T9 C
MS"/7&H7/C(^7]W4Q.6UT1QX">\>K=(:7?1.ACW=U_]N^L28YS@2"\N1I*"$3
MN,0X.$$K%\^,]>.%=>^WU5)QSPB0> +)\^33#K3V,XG)ZG2"F!"SKA3(VI*@
MUG6&Z,AO23R*\7IZ/=C8U/ Z4[R'87(&KYL R@_+V]OEYS=E0\1^WC01K#VS
M( TYLXIK T&)!#XKEKA3SOCQ>G4=V& 3P#E'X$^@<RGWFX#0A^67[REP7!86
M"WDOY.Z2,X,./-<%G$VD?(W4B8UGA#W>W=0EB/V!YR*^MX&<KAV>,G%$1HO
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M):#5PS(<2IIY43A9<[P<<]XZ;$E:*6, J3TQ@]PT\"5P,,$XFX)1@K5I@IU
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MA@": -'KNU5]IOM:B=AI7[1)EA@4H$X&E,8 D;D F2R,$KS3Q>)H('JZOY9
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M4$L! A0#%     @ &F9G6M*#RX>?!P  32<  !T              ( !
M &5X,3(Q8V5O8V5R=&EF:6-A=&EO;C(P,C0N:'1M4$L! A0#%     @ &F9G
M6B 8QYBC!P  +R<  !T              ( !V@<  &5X,3(R8V9O8V5R=&EF
M:6-A=&EO;C(P,C0N:'1M4$L! A0#%     @ &F9G6AD#+(8Z!    A,  !T
M             ( !N \  &5X,3,Q8V5O8V5R=&EF:6-A=&EO;C(P,C0N:'1M
M4$L! A0#%     @ &F9G6@DCG4DM!   I1$  !T              ( !+10
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M9G-E8W5R:70N:'1M4$L! A0#%     @ &F9G6BGJ+B6A @  2@T  !@
M         ( !I+   &5X.#!S=6)S:61I87)I97,R,#(T+FAT;5!+ 0(4 Q0
M   ( !IF9UJ6=W2],,P" !OK&@ 2              "  7NS  !O;F-Y9BTR
M,#(T,3(S,2YH=&U02P$"% ,4    "  :9F=:"#^ <+P8   G* $ $@
M        @ ';?P, ;VYC>68M,C R-#$R,S$N>'-D4$L! A0#%     @ &F9G
M6E,@W<MK%   2+X  !8              ( !QY@# &]N8WEF+3(P,C0Q,C,Q
M7V-A;"YX;6Q02P$"% ,4    "  :9F=:+TA\O3Q?   "- 0 %@
M    @ %FK0, ;VYC>68M,C R-#$R,S%?9&5F+GAM;%!+ 0(4 Q0    ( !IF
M9UJRM&UVIT$" (9" @ 5              "  =8,! !O;F-Y9BTR,#(T,3(S
M,5]G,2YJ<&=02P$"% ,4    "  :9F=:2>9%!+S4!@ [!P< %0
M    @ &P3@8 ;VYC>68M,C R-#$R,S%?9S(N:G!G4$L! A0#%     @ &F9G
M6C1?CMJ4Z@  6SD) !8              ( !GR,- &]N8WEF+3(P,C0Q,C,Q
M7VQA8BYX;6Q02P$"% ,4    "  :9F=:&?%1B)&8  "/X08 %@
M    @ %G#@X ;VYC>68M,C R-#$R,S%?<')E+GAM;%!+!08     $  0 %<$
(   LIPX    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>oncyf-20241231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2024"
  xmlns:currency="http://xbrl.sec.gov/currency/2024"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2024"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:oncyf="http://www.oncolyticsbiotech.com/20241231"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="oncyf-20241231.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderPublicOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderPublicOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ifrs-full:MajorOrdinaryShareTransactionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-06</endDate>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">oncyf:ClinicalTrialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">oncyf:ClinicalTrialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
        </entity>
        <period>
            <instant>2023-08-08</instant>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
        </entity>
        <period>
            <instant>2023-09-07</instant>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
        </entity>
        <period>
            <startDate>2023-08-08</startDate>
            <endDate>2023-08-08</endDate>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingWarrantDerivativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-08</instant>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
        </entity>
        <period>
            <startDate>2023-09-07</startDate>
            <endDate>2023-09-07</endDate>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingWarrantDerivativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-07</instant>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:SharesPublicOfferingWarrantDerivativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-07</instant>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:SharesPublicOfferingWarrantDerivativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-08</instant>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:SharesPublicOfferingWarrantDerivativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-08</instant>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:SharesPublicOfferingWarrantDerivativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-07</instant>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:SharesPublicOfferingWarrantDerivativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-08</instant>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:SharesPublicOfferingWarrantDerivativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-07</instant>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-07</instant>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-08</instant>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:SharesUnderStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:SharesUnderIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:SharesUnderStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:SharesUnderIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingWarrantDerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2021SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-05</instant>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2021SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-05</startDate>
            <endDate>2021-03-05</endDate>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2021SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2021SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2022SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-17</instant>
        </period>
    </context>
    <context id="c-150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2022SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-17</startDate>
            <endDate>2022-06-17</endDate>
        </period>
    </context>
    <context id="c-151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2022SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2022SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2022SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2022SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2022SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2022SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:CompensationWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-08</startDate>
            <endDate>2023-08-08</endDate>
        </period>
    </context>
    <context id="c-158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:CompensationWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-07</startDate>
            <endDate>2023-09-07</endDate>
        </period>
    </context>
    <context id="c-159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:CompensationWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-08</startDate>
            <endDate>2023-08-08</endDate>
        </period>
    </context>
    <context id="c-160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:CompensationWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-07</startDate>
            <endDate>2023-09-07</endDate>
        </period>
    </context>
    <context id="c-161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-07</startDate>
            <endDate>2023-09-07</endDate>
        </period>
    </context>
    <context id="c-162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-08</startDate>
            <endDate>2023-08-08</endDate>
        </period>
    </context>
    <context id="c-163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2024SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-02</instant>
        </period>
    </context>
    <context id="c-164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2024SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-02</startDate>
            <endDate>2024-08-02</endDate>
        </period>
    </context>
    <context id="c-165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2024SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2024SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:CompensationWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:CompensationWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:CompensationWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BB</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BB</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnusedNetOperatingLossCarryForwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnusedNetOperatingLossCarryForwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnusedNetOperatingLossCarryForwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:InvestmentTaxCreditsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:InvestmentTaxCreditsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:InvestmentTaxCreditsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:PropertyPlantEquipmentRelatedTemporaryDifferencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:PropertyPlantEquipmentRelatedTemporaryDifferencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:PropertyPlantEquipmentRelatedTemporaryDifferencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:ShareIssueCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:ShareIssueCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:ShareIssueCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnusedCapitalLossCarryForwardNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnusedCapitalLossCarryForwardNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-232">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnusedCapitalLossCarryForwardNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-233">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
        </entity>
        <period>
            <instant>2024-06-19</instant>
        </period>
    </context>
    <context id="c-234">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-235">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-236">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-237">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-238">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-239">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-240">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-241">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-242">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:ConcentrationRiskType1Axis">oncyf:SupplierConcentrationRisk1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-243">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:IncomeStatementLocation1Axis">oncyf:ResearchAndDevelopmentExpense1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-244">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:IncomeStatementLocation1Axis">oncyf:ResearchAndDevelopmentExpense1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-245">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:IncomeStatementLocation1Axis">oncyf:ResearchAndDevelopmentExpense1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-246">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:IncomeStatementLocation1Axis">oncyf:GeneralAndAdministrativeExpense1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-247">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:IncomeStatementLocation1Axis">oncyf:GeneralAndAdministrativeExpense1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-248">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:IncomeStatementLocation1Axis">oncyf:GeneralAndAdministrativeExpense1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-249">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-250">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-251">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">oncyf:RestOfWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-252">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">oncyf:RestOfWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="cad">
        <measure>iso4217:CAD</measure>
    </unit>
    <unit id="cadPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:CAD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="plan">
        <measure>oncyf:plan</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="d">
        <measure>utr:D</measure>
    </unit>
    <unit id="year">
        <measure>oncyf:year</measure>
    </unit>
    <unit id="eur">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="manufacturer">
        <measure>oncyf:manufacturer</measure>
    </unit>
    <unit id="segment">
        <measure>oncyf:segment</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-37">0001129928</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-38">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-39">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag contextRef="c-1" id="f-40">false</dei:AmendmentFlag>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-41">A0</dei:EntityIncorporationStateCountryCode>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-42">false</dei:EntityEmergingGrowthCompany>
    <oncyf:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1 contextRef="c-189" id="f-735">P1Y</oncyf:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1>
    <oncyf:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1 contextRef="c-203" id="f-779">P2Y</oncyf:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1>
    <oncyf:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1 contextRef="c-204" id="f-780">P2Y</oncyf:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1>
    <oncyf:PurchaseObligationCommitmentProductionServiceAgreementPercentage contextRef="c-1" decimals="4" id="f-800" unitRef="number">0.3333</oncyf:PurchaseObligationCommitmentProductionServiceAgreementPercentage>
    <dei:DocumentType contextRef="c-1" id="f-1">20-F</dei:DocumentType>
    <dei:DocumentRegistrationStatement contextRef="c-1" id="f-2">false</dei:DocumentRegistrationStatement>
    <dei:DocumentAnnualReport contextRef="c-1" id="f-3">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-4">2024-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-5">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-6">false</dei:DocumentTransitionReport>
    <dei:DocumentShellCompanyReport contextRef="c-1" id="f-7">false</dei:DocumentShellCompanyReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-8">001-38512</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-9">ONCOLYTICS BIOTECH INC.</dei:EntityRegistrantName>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-10">804, 322 11th Avenue SW</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-11">Calgary</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-12">AB</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressCountry contextRef="c-1" id="f-13">CA</dei:EntityAddressCountry>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-14">T2R 0C5</dei:EntityAddressPostalZipCode>
    <dei:ContactPersonnelName contextRef="c-2" id="f-15">Kirk Look</dei:ContactPersonnelName>
    <dei:EntityAddressAddressLine1 contextRef="c-2" id="f-16">804, 322 11th Avenue SW</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-2" id="f-17">Calgary</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-2" id="f-18">AB</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressCountry contextRef="c-2" id="f-19">CA</dei:EntityAddressCountry>
    <dei:EntityAddressPostalZipCode contextRef="c-2" id="f-20">T2R 0C5</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-2" id="f-21">403</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-2" id="f-22">670-7377</dei:LocalPhoneNumber>
    <dei:ContactPersonnelEmailAddress contextRef="c-2" id="f-23">info@oncolytics.ca</dei:ContactPersonnelEmailAddress>
    <dei:Security12bTitle contextRef="c-1" id="f-24">no</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-25">ONCY</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-26">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-27" unitRef="shares">80020131</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityWellKnownSeasonedIssuer contextRef="c-1" id="f-28">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="c-1" id="f-29">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-30">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-31">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-32">Accelerated Filer</dei:EntityFilerCategory>
    <dei:IcfrAuditorAttestationFlag contextRef="c-1" id="f-33">true</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="c-1" id="f-34">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:DocumentAccountingStandard contextRef="c-1" id="f-35">International Financial Reporting Standards</dei:DocumentAccountingStandard>
    <dei:EntityShellCompany contextRef="c-1" id="f-36">false</dei:EntityShellCompany>
    <dei:AuditorFirmId contextRef="c-1" id="f-43">1263</dei:AuditorFirmId>
    <ecd:InsiderTrdPoliciesProcAdoptedFlag contextRef="c-1" id="f-44">true</ecd:InsiderTrdPoliciesProcAdoptedFlag>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock contextRef="c-1" id="f-45">&lt;div style="margin-bottom:10pt;margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has a cybersecurity program, which uses technology and Governance, Risk, and Compliance processes to help mitigate cybersecurity risks, with our management team working to monitor, assess, identify, and respond to potential cybersecurity incidents that threaten the Company. The program also focuses on security awareness and training for employees and contractors with access to Company facilities or systems. Cybersecurity risks for the Company include financial loss, loss of data, and business interruption. The Company maintains technology and non-technology based system controls, cybersecurity insurance, a robust backup program, and disaster recovery testing to mitigate these risks.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The company has implemented a comprehensive cybersecurity risk management program to identify, assess, and manage material risks from cybersecurity threats. This program is integrated into our overall enterprise risk management framework and includes the following key components:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt"&gt;Risk Assessment Process: We conduct regular cybersecurity risk assessments using industry-standard frameworks such as NIST CSF and CIS. These assessments help us identify potential vulnerabilities and prioritize our mitigation efforts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt"&gt;Threat Detection and Response: We have deployed advanced threat detection technologies and maintain an incident response plan that is regularly tested and updated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt"&gt;Third-Party Risk Management: We assess and monitor the cybersecurity practices of our key vendors and partners to mitigate supply chain risks.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt"&gt;Employee Training and Awareness: We provide ongoing cybersecurity awareness training to all employees and conduct simulated phishing exercises to reinforce best practices.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our cybersecurity program also follows defense in depth principles, which aim to implement various layered access control, detection, prevention, and response measures. We also engage with independent third parties to assess our vulnerabilities and help us mitigate cybersecurity-related risks. Our security posture is also tested by internal personnel and independent third parties to gauge its effectiveness from time to time. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Management&#x2019;s Role in Assessing and Managing Cybersecurity Risks &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s cybersecurity risk management and strategy processes for assessing, identifying, and managing material risks from cybersecurity threats are managed by members of the Company&#x2019;s management team, primarily the Chief Executive Officer and the Chief Financial Officer. Per the Company&#x2019;s policies, cybersecurity incidents are to be immediately reported to the management team for resolution with outsourced IT support team. Information technology general controls, including controls to mitigate cybersecurity risks, are included with management&#x2019;s testing of internal control over financial reporting. A virtual Chief Information Security Officer is in place to help lead the Company's cybersecurity program. This individual, who &lt;/span&gt;&lt;/div&gt;reports directly to the Chief Financial Officer, is well positioned, with over 25 years of experience in the field. He holds various industry-leading certifications along with a Master of Laws in cybersecurity and privacy law.</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock contextRef="c-1" id="f-47">&lt;div style="margin-bottom:10pt;margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has a cybersecurity program, which uses technology and Governance, Risk, and Compliance processes to help mitigate cybersecurity risks, with our management team working to monitor, assess, identify, and respond to potential cybersecurity incidents that threaten the Company. The program also focuses on security awareness and training for employees and contractors with access to Company facilities or systems. Cybersecurity risks for the Company include financial loss, loss of data, and business interruption. The Company maintains technology and non-technology based system controls, cybersecurity insurance, a robust backup program, and disaster recovery testing to mitigate these risks.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The company has implemented a comprehensive cybersecurity risk management program to identify, assess, and manage material risks from cybersecurity threats. This program is integrated into our overall enterprise risk management framework and includes the following key components:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt"&gt;Risk Assessment Process: We conduct regular cybersecurity risk assessments using industry-standard frameworks such as NIST CSF and CIS. These assessments help us identify potential vulnerabilities and prioritize our mitigation efforts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt"&gt;Threat Detection and Response: We have deployed advanced threat detection technologies and maintain an incident response plan that is regularly tested and updated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt"&gt;Third-Party Risk Management: We assess and monitor the cybersecurity practices of our key vendors and partners to mitigate supply chain risks.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt"&gt;Employee Training and Awareness: We provide ongoing cybersecurity awareness training to all employees and conduct simulated phishing exercises to reinforce best practices.&lt;/span&gt;&lt;/div&gt;</cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedFlag contextRef="c-1" id="f-46">true</cyd:CybersecurityRiskManagementProcessesIntegratedFlag>
    <cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag contextRef="c-1" id="f-48">true</cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag>
    <cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock contextRef="c-1" id="f-50">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s cybersecurity risk management and strategy processes for assessing, identifying, and managing material risks from cybersecurity threats are managed by members of the Company&#x2019;s management team, primarily the Chief Executive Officer and the Chief Financial Officer. Per the Company&#x2019;s policies, cybersecurity incidents are to be immediately reported to the management team for resolution with outsourced IT support team. Information technology general controls, including controls to mitigate cybersecurity risks, are included with management&#x2019;s testing of internal control over financial reporting. A virtual Chief Information Security Officer is in place to help lead the Company's cybersecurity program. This individual, who &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;reports directly to the Chief Financial Officer, is well positioned, with over 25 years of experience in the field. He holds various industry-leading certifications along with a Master of Laws in cybersecurity and privacy law.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Board of Director&#x2019;s Oversight of Risks from Cybersecurity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cybersecurity risks are included in an overall risk management assessment, which is reviewed annually by the Company&#x2019;s audit committee. The Company engages third-party specialists on a periodic basis to review key information technology systems and provide recommendations for system updates and improvements. Results of these reviews are used to update information technology systems within the Company&#x2019;s information system governance policies. The Company's management regularly discusses cyber trends and, should they arise, any material incidents with audit committee. The Company&#x2019;s management will also review the Company&#x2019;s cybersecurity program with the Board once every year.&lt;/span&gt;&lt;/div&gt;</cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskRoleOfManagementTextBlock contextRef="c-1" id="f-49">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s cybersecurity risk management and strategy processes for assessing, identifying, and managing material risks from cybersecurity threats are managed by members of the Company&#x2019;s management team, primarily the Chief Executive Officer and the Chief Financial Officer. Per the Company&#x2019;s policies, cybersecurity incidents are to be immediately reported to the management team for resolution with outsourced IT support team. Information technology general controls, including controls to mitigate cybersecurity risks, are included with management&#x2019;s testing of internal control over financial reporting. A virtual Chief Information Security Officer is in place to help lead the Company's cybersecurity program. This individual, who &lt;/span&gt;&lt;/div&gt;reports directly to the Chief Financial Officer, is well positioned, with over 25 years of experience in the field. He holds various industry-leading certifications along with a Master of Laws in cybersecurity and privacy law.</cyd:CybersecurityRiskRoleOfManagementTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag contextRef="c-1" id="f-51">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag contextRef="c-1" id="f-52">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag>
    <cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock contextRef="c-1" id="f-53">A virtual Chief Information Security Officer is in place to help lead the Company's cybersecurity program. This individual, who reports directly to the Chief Financial Officer, is well positioned, with over 25 years of experience in the field. He holds various industry-leading certifications along with a Master of Laws in cybersecurity and privacy law.</cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock>
    <cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock contextRef="c-1" id="f-56">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cybersecurity risks are included in an overall risk management assessment, which is reviewed annually by the Company&#x2019;s audit committee. The Company engages third-party specialists on a periodic basis to review key information technology systems and provide recommendations for system updates and improvements. Results of these reviews are used to update information technology systems within the Company&#x2019;s information system governance policies. The Company's management regularly discusses cyber trends and, should they arise, any material incidents with audit committee. The Company&#x2019;s management will also review the Company&#x2019;s cybersecurity program with the Board once every year.&lt;/span&gt;&lt;/div&gt;</cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock contextRef="c-1" id="f-55">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cybersecurity risks are included in an overall risk management assessment, which is reviewed annually by the Company&#x2019;s audit committee. The Company engages third-party specialists on a periodic basis to review key information technology systems and provide recommendations for system updates and improvements. Results of these reviews are used to update information technology systems within the Company&#x2019;s information system governance policies. The Company's management regularly discusses cyber trends and, should they arise, any material incidents with audit committee. The Company&#x2019;s management will also review the Company&#x2019;s cybersecurity program with the Board once every year.&lt;/span&gt;&lt;/div&gt;</cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock contextRef="c-1" id="f-54">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cybersecurity risks are included in an overall risk management assessment, which is reviewed annually by the Company&#x2019;s audit committee. The Company engages third-party specialists on a periodic basis to review key information technology systems and provide recommendations for system updates and improvements. Results of these reviews are used to update information technology systems within the Company&#x2019;s information system governance policies. The Company's management regularly discusses cyber trends and, should they arise, any material incidents with audit committee. The Company&#x2019;s management will also review the Company&#x2019;s cybersecurity program with the Board once every year.&lt;/span&gt;&lt;/div&gt;</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementThirdPartyEngagedFlag contextRef="c-1" id="f-57">true</cyd:CybersecurityRiskManagementThirdPartyEngagedFlag>
    <cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock contextRef="c-1" id="f-58">The Company's management regularly discusses cyber trends and, should they arise, any material incidents with audit committee. The Company&#x2019;s management will also review the Company&#x2019;s cybersecurity program with the Board once every year.</cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag contextRef="c-1" id="f-59">false</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <dei:AuditorName contextRef="c-1" id="f-60">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="c-1" id="f-61">Calgary, Canada</dei:AuditorLocation>
    <ifrs-full:CashAndCashEquivalents contextRef="c-3" decimals="-3" id="f-62" unitRef="cad">15942000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-4" decimals="-3" id="f-63" unitRef="cad">34912000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:OtherCurrentReceivables contextRef="c-3" decimals="-3" id="f-64" unitRef="cad">68000</ifrs-full:OtherCurrentReceivables>
    <ifrs-full:OtherCurrentReceivables contextRef="c-4" decimals="-3" id="f-65" unitRef="cad">15000</ifrs-full:OtherCurrentReceivables>
    <ifrs-full:CurrentPrepayments contextRef="c-3" decimals="-3" id="f-66" unitRef="cad">1885000</ifrs-full:CurrentPrepayments>
    <ifrs-full:CurrentPrepayments contextRef="c-4" decimals="-3" id="f-67" unitRef="cad">3246000</ifrs-full:CurrentPrepayments>
    <ifrs-full:CurrentDerivativeFinancialAssets contextRef="c-3" decimals="-3" id="f-68" unitRef="cad">980000</ifrs-full:CurrentDerivativeFinancialAssets>
    <ifrs-full:CurrentDerivativeFinancialAssets contextRef="c-4" decimals="-3" id="f-69" unitRef="cad">0</ifrs-full:CurrentDerivativeFinancialAssets>
    <ifrs-full:CurrentAssets contextRef="c-3" decimals="-3" id="f-70" unitRef="cad">18875000</ifrs-full:CurrentAssets>
    <ifrs-full:CurrentAssets contextRef="c-4" decimals="-3" id="f-71" unitRef="cad">38173000</ifrs-full:CurrentAssets>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-3" decimals="-3" id="f-72" unitRef="cad">411000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-4" decimals="-3" id="f-73" unitRef="cad">282000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:RightofuseAssets contextRef="c-3" decimals="-3" id="f-74" unitRef="cad">901000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets contextRef="c-4" decimals="-3" id="f-75" unitRef="cad">365000</ifrs-full:RightofuseAssets>
    <ifrs-full:Assets contextRef="c-3" decimals="-3" id="f-76" unitRef="cad">20187000</ifrs-full:Assets>
    <ifrs-full:Assets contextRef="c-4" decimals="-3" id="f-77" unitRef="cad">38820000</ifrs-full:Assets>
    <ifrs-full:TradeAndOtherCurrentPayables contextRef="c-3" decimals="-3" id="f-78" unitRef="cad">4792000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherCurrentPayables contextRef="c-4" decimals="-3" id="f-79" unitRef="cad">3572000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:OtherCurrentLiabilities contextRef="c-3" decimals="-3" id="f-80" unitRef="cad">1618000</ifrs-full:OtherCurrentLiabilities>
    <ifrs-full:OtherCurrentLiabilities contextRef="c-4" decimals="-3" id="f-81" unitRef="cad">332000</ifrs-full:OtherCurrentLiabilities>
    <ifrs-full:CurrentLeaseLiabilities contextRef="c-3" decimals="-3" id="f-82" unitRef="cad">277000</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:CurrentLeaseLiabilities contextRef="c-4" decimals="-3" id="f-83" unitRef="cad">133000</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:CurrentDerivativeFinancialLiabilities contextRef="c-3" decimals="-3" id="f-84" unitRef="cad">0</ifrs-full:CurrentDerivativeFinancialLiabilities>
    <ifrs-full:CurrentDerivativeFinancialLiabilities contextRef="c-4" decimals="-3" id="f-85" unitRef="cad">200000</ifrs-full:CurrentDerivativeFinancialLiabilities>
    <ifrs-full:CurrentLiabilities contextRef="c-3" decimals="-3" id="f-86" unitRef="cad">6687000</ifrs-full:CurrentLiabilities>
    <ifrs-full:CurrentLiabilities contextRef="c-4" decimals="-3" id="f-87" unitRef="cad">4237000</ifrs-full:CurrentLiabilities>
    <ifrs-full:NoncurrentContractLiabilities contextRef="c-3" decimals="-3" id="f-88" unitRef="cad">6730000</ifrs-full:NoncurrentContractLiabilities>
    <ifrs-full:NoncurrentContractLiabilities contextRef="c-4" decimals="-3" id="f-89" unitRef="cad">6730000</ifrs-full:NoncurrentContractLiabilities>
    <ifrs-full:NoncurrentLeaseLiabilities contextRef="c-3" decimals="-3" id="f-90" unitRef="cad">787000</ifrs-full:NoncurrentLeaseLiabilities>
    <ifrs-full:NoncurrentLeaseLiabilities contextRef="c-4" decimals="-3" id="f-91" unitRef="cad">290000</ifrs-full:NoncurrentLeaseLiabilities>
    <ifrs-full:Liabilities contextRef="c-3" decimals="-3" id="f-92" unitRef="cad">14204000</ifrs-full:Liabilities>
    <ifrs-full:Liabilities contextRef="c-4" decimals="-3" id="f-93" unitRef="cad">11257000</ifrs-full:Liabilities>
    <oncyf:CommitmentsAndContingencies1 contextRef="c-3" id="f-94" unitRef="cad" xsi:nil="true"/>
    <oncyf:CommitmentsAndContingencies1 contextRef="c-4" id="f-95" unitRef="cad" xsi:nil="true"/>
    <ifrs-full:NumberOfSharesIssued contextRef="c-5" decimals="INF" id="f-96" unitRef="shares">80020131</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:NumberOfSharesIssued contextRef="c-6" decimals="INF" id="f-97" unitRef="shares">74423960</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:IssuedCapital contextRef="c-3" decimals="-3" id="f-98" unitRef="cad">438193000</ifrs-full:IssuedCapital>
    <ifrs-full:IssuedCapital contextRef="c-4" decimals="-3" id="f-99" unitRef="cad">430906000</ifrs-full:IssuedCapital>
    <ifrs-full:AdditionalPaidinCapital contextRef="c-3" decimals="-3" id="f-100" unitRef="cad">44542000</ifrs-full:AdditionalPaidinCapital>
    <ifrs-full:AdditionalPaidinCapital contextRef="c-4" decimals="-3" id="f-101" unitRef="cad">42116000</ifrs-full:AdditionalPaidinCapital>
    <ifrs-full:AccumulatedOtherComprehensiveIncome contextRef="c-3" decimals="-3" id="f-102" unitRef="cad">961000</ifrs-full:AccumulatedOtherComprehensiveIncome>
    <ifrs-full:AccumulatedOtherComprehensiveIncome contextRef="c-4" decimals="-3" id="f-103" unitRef="cad">544000</ifrs-full:AccumulatedOtherComprehensiveIncome>
    <ifrs-full:RetainedEarnings contextRef="c-3" decimals="-3" id="f-104" unitRef="cad">-477713000</ifrs-full:RetainedEarnings>
    <ifrs-full:RetainedEarnings contextRef="c-4" decimals="-3" id="f-105" unitRef="cad">-446003000</ifrs-full:RetainedEarnings>
    <ifrs-full:Equity contextRef="c-3" decimals="-3" id="f-106" unitRef="cad">5983000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-4" decimals="-3" id="f-107" unitRef="cad">27563000</ifrs-full:Equity>
    <ifrs-full:EquityAndLiabilities contextRef="c-3" decimals="-3" id="f-108" unitRef="cad">20187000</ifrs-full:EquityAndLiabilities>
    <ifrs-full:EquityAndLiabilities contextRef="c-4" decimals="-3" id="f-109" unitRef="cad">38820000</ifrs-full:EquityAndLiabilities>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c-1" decimals="-3" id="f-110" unitRef="cad">21647000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c-7" decimals="-3" id="f-111" unitRef="cad">17709000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c-8" decimals="-3" id="f-112" unitRef="cad">15432000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:GeneralAndAdministrativeExpense contextRef="c-1" decimals="-3" id="f-113" unitRef="cad">13335000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense contextRef="c-7" decimals="-3" id="f-114" unitRef="cad">16082000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense contextRef="c-8" decimals="-3" id="f-115" unitRef="cad">11492000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:ProfitLossFromOperatingActivities contextRef="c-1" decimals="-3" id="f-116" unitRef="cad">-34982000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities contextRef="c-7" decimals="-3" id="f-117" unitRef="cad">-33791000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities contextRef="c-8" decimals="-3" id="f-118" unitRef="cad">-26924000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives contextRef="c-1" decimals="-3" id="f-119" unitRef="cad">1242000</ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives>
    <ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives contextRef="c-7" decimals="-3" id="f-120" unitRef="cad">5285000</ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives>
    <ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives contextRef="c-8" decimals="-3" id="f-121" unitRef="cad">-20000</ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss contextRef="c-1" decimals="-3" id="f-122" unitRef="cad">961000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss contextRef="c-7" decimals="-3" id="f-123" unitRef="cad">-475000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss contextRef="c-8" decimals="-3" id="f-124" unitRef="cad">1665000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss>
    <ifrs-full:InterestIncomeOnCashAndCashEquivalents contextRef="c-1" decimals="-3" id="f-125" unitRef="cad">1199000</ifrs-full:InterestIncomeOnCashAndCashEquivalents>
    <ifrs-full:InterestIncomeOnCashAndCashEquivalents contextRef="c-7" decimals="-3" id="f-126" unitRef="cad">1326000</ifrs-full:InterestIncomeOnCashAndCashEquivalents>
    <ifrs-full:InterestIncomeOnCashAndCashEquivalents contextRef="c-8" decimals="-3" id="f-127" unitRef="cad">528000</ifrs-full:InterestIncomeOnCashAndCashEquivalents>
    <ifrs-full:ProfitLossBeforeTax contextRef="c-1" decimals="-3" id="f-128" unitRef="cad">-31580000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax contextRef="c-7" decimals="-3" id="f-129" unitRef="cad">-27655000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax contextRef="c-8" decimals="-3" id="f-130" unitRef="cad">-24751000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="c-1" decimals="-3" id="f-131" unitRef="cad">130000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="c-7" decimals="-3" id="f-132" unitRef="cad">97000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="c-8" decimals="-3" id="f-133" unitRef="cad">84000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:ProfitLoss contextRef="c-1" decimals="-3" id="f-134" unitRef="cad">-31710000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c-7" decimals="-3" id="f-135" unitRef="cad">-27752000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c-8" decimals="-3" id="f-136" unitRef="cad">-24835000</ifrs-full:ProfitLoss>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation contextRef="c-1" decimals="-3" id="f-137" unitRef="cad">417000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation contextRef="c-7" decimals="-3" id="f-138" unitRef="cad">-118000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation contextRef="c-8" decimals="-3" id="f-139" unitRef="cad">274000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:ComprehensiveIncome contextRef="c-1" decimals="-3" id="f-140" unitRef="cad">-31293000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-7" decimals="-3" id="f-141" unitRef="cad">-27870000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-8" decimals="-3" id="f-142" unitRef="cad">-24561000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="c-1"
      decimals="2"
      id="f-143"
      unitRef="cadPerShare">-0.41</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="c-1"
      decimals="2"
      id="f-144"
      unitRef="cadPerShare">-0.41</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="c-7"
      decimals="2"
      id="f-145"
      unitRef="cadPerShare">-0.41</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="c-7"
      decimals="2"
      id="f-146"
      unitRef="cadPerShare">-0.41</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="c-8"
      decimals="2"
      id="f-147"
      unitRef="cadPerShare">-0.43</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="c-8"
      decimals="2"
      id="f-148"
      unitRef="cadPerShare">-0.43</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:AdjustedWeightedAverageShares contextRef="c-1" decimals="0" id="f-149" unitRef="shares">76482914</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:WeightedAverageShares contextRef="c-1" decimals="0" id="f-150" unitRef="shares">76482914</ifrs-full:WeightedAverageShares>
    <ifrs-full:WeightedAverageShares contextRef="c-7" decimals="0" id="f-151" unitRef="shares">67624036</ifrs-full:WeightedAverageShares>
    <ifrs-full:AdjustedWeightedAverageShares contextRef="c-7" decimals="0" id="f-152" unitRef="shares">67624036</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:WeightedAverageShares contextRef="c-8" decimals="0" id="f-153" unitRef="shares">58029745</ifrs-full:WeightedAverageShares>
    <ifrs-full:AdjustedWeightedAverageShares contextRef="c-8" decimals="0" id="f-154" unitRef="shares">58029745</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:Equity contextRef="c-9" decimals="-3" id="f-155" unitRef="cad">391348000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-10" decimals="-3" id="f-156" unitRef="cad">3618000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-11" decimals="-3" id="f-157" unitRef="cad">34161000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-12" decimals="-3" id="f-158" unitRef="cad">388000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-13" decimals="-3" id="f-159" unitRef="cad">-393416000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-14" decimals="-3" id="f-160" unitRef="cad">36099000</ifrs-full:Equity>
    <ifrs-full:ComprehensiveIncome contextRef="c-15" decimals="-3" id="f-161" unitRef="cad">274000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-16" decimals="-3" id="f-162" unitRef="cad">-24835000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-8" decimals="-3" id="f-163" unitRef="cad">-24561000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="c-17" decimals="-3" id="f-164" unitRef="cad">20000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="c-18" decimals="-3" id="f-165" unitRef="cad">-8000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="c-8" decimals="-3" id="f-166" unitRef="cad">12000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity contextRef="c-17" decimals="-3" id="f-167" unitRef="cad">98000</oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity>
    <oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity contextRef="c-18" decimals="-3" id="f-168" unitRef="cad">-98000</oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity>
    <oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity contextRef="c-8" decimals="-3" id="f-169" unitRef="cad">0</oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity>
    <oncyf:IncreaseDecreaseThroughExpirationOfWarrantEquity contextRef="c-19" decimals="-3" id="f-170" unitRef="cad">-3618000</oncyf:IncreaseDecreaseThroughExpirationOfWarrantEquity>
    <oncyf:IncreaseDecreaseThroughExpirationOfWarrantEquity contextRef="c-18" decimals="-3" id="f-171" unitRef="cad">3618000</oncyf:IncreaseDecreaseThroughExpirationOfWarrantEquity>
    <oncyf:IncreaseDecreaseThroughExpirationOfWarrantEquity contextRef="c-8" decimals="-3" id="f-172" unitRef="cad">0</oncyf:IncreaseDecreaseThroughExpirationOfWarrantEquity>
    <ifrs-full:IssueOfEquity contextRef="c-17" decimals="-3" id="f-173" unitRef="cad">13338000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity contextRef="c-8" decimals="-3" id="f-174" unitRef="cad">13338000</ifrs-full:IssueOfEquity>
    <ifrs-full:ShareIssueRelatedCost contextRef="c-17" decimals="-3" id="f-175" unitRef="cad">764000</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:ShareIssueRelatedCost contextRef="c-8" decimals="-3" id="f-176" unitRef="cad">764000</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="c-18" decimals="-3" id="f-177" unitRef="cad">2378000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="c-8" decimals="-3" id="f-178" unitRef="cad">2378000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:Equity contextRef="c-20" decimals="-3" id="f-179" unitRef="cad">404040000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-21" decimals="-3" id="f-180" unitRef="cad">0</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-22" decimals="-3" id="f-181" unitRef="cad">40051000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-23" decimals="-3" id="f-182" unitRef="cad">662000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-24" decimals="-3" id="f-183" unitRef="cad">-418251000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-25" decimals="-3" id="f-184" unitRef="cad">26502000</ifrs-full:Equity>
    <ifrs-full:ComprehensiveIncome contextRef="c-26" decimals="-3" id="f-185" unitRef="cad">-118000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-27" decimals="-3" id="f-186" unitRef="cad">-27752000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-7" decimals="-3" id="f-187" unitRef="cad">-27870000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="c-28" decimals="-3" id="f-188" unitRef="cad">1271000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="c-29" decimals="-3" id="f-189" unitRef="cad">-490000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="c-7" decimals="-3" id="f-190" unitRef="cad">781000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IssueOfEquity contextRef="c-30" decimals="-3" id="f-191" unitRef="cad">10676000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity contextRef="c-31" decimals="-3" id="f-192" unitRef="cad">10676000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity contextRef="c-32" decimals="-3" id="f-193" unitRef="cad">17724000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity contextRef="c-33" decimals="-3" id="f-194" unitRef="cad">638000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity contextRef="c-34" decimals="-3" id="f-195" unitRef="cad">18362000</ifrs-full:IssueOfEquity>
    <ifrs-full:ShareIssueRelatedCost contextRef="c-28" decimals="-3" id="f-196" unitRef="cad">2805000</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:ShareIssueRelatedCost contextRef="c-7" decimals="-3" id="f-197" unitRef="cad">2805000</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="c-29" decimals="-3" id="f-198" unitRef="cad">1917000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="c-7" decimals="-3" id="f-199" unitRef="cad">1917000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:Equity contextRef="c-6" decimals="-3" id="f-200" unitRef="cad">430906000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-35" decimals="-3" id="f-201" unitRef="cad">0</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-36" decimals="-3" id="f-202" unitRef="cad">42116000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-37" decimals="-3" id="f-203" unitRef="cad">544000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-38" decimals="-3" id="f-204" unitRef="cad">-446003000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-4" decimals="-3" id="f-205" unitRef="cad">27563000</ifrs-full:Equity>
    <ifrs-full:ComprehensiveIncome contextRef="c-39" decimals="-3" id="f-206" unitRef="cad">417000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-40" decimals="-3" id="f-207" unitRef="cad">-31710000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-1" decimals="-3" id="f-208" unitRef="cad">-31293000</ifrs-full:ComprehensiveIncome>
    <oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity contextRef="c-41" decimals="-3" id="f-209" unitRef="cad">297000</oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity>
    <oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity contextRef="c-42" decimals="-3" id="f-210" unitRef="cad">-297000</oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity>
    <oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity contextRef="c-1" decimals="-3" id="f-211" unitRef="cad">0</oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity contextRef="c-41" decimals="-3" id="f-212" unitRef="cad">71000</ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity contextRef="c-1" decimals="-3" id="f-213" unitRef="cad">71000</ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity>
    <ifrs-full:IssueOfEquity contextRef="c-43" decimals="-3" id="f-214" unitRef="cad">7670000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity contextRef="c-44" decimals="-3" id="f-215" unitRef="cad">7670000</ifrs-full:IssueOfEquity>
    <ifrs-full:ShareIssueRelatedCost contextRef="c-41" decimals="-3" id="f-216" unitRef="cad">751000</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:ShareIssueRelatedCost contextRef="c-1" decimals="-3" id="f-217" unitRef="cad">751000</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="c-42" decimals="-3" id="f-218" unitRef="cad">2723000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="c-1" decimals="-3" id="f-219" unitRef="cad">2723000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:Equity contextRef="c-5" decimals="-3" id="f-220" unitRef="cad">438193000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-45" decimals="-3" id="f-221" unitRef="cad">0</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-46" decimals="-3" id="f-222" unitRef="cad">44542000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-47" decimals="-3" id="f-223" unitRef="cad">961000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-48" decimals="-3" id="f-224" unitRef="cad">-477713000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-3" decimals="-3" id="f-225" unitRef="cad">5983000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss contextRef="c-1" decimals="-3" id="f-226" unitRef="cad">-31710000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c-7" decimals="-3" id="f-227" unitRef="cad">-27752000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c-8" decimals="-3" id="f-228" unitRef="cad">-24835000</ifrs-full:ProfitLoss>
    <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense contextRef="c-1" decimals="-3" id="f-229" unitRef="cad">120000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense>
    <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense contextRef="c-7" decimals="-3" id="f-230" unitRef="cad">81000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense>
    <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense contextRef="c-8" decimals="-3" id="f-231" unitRef="cad">93000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense>
    <oncyf:AdjustmentsForDepreciationRightOfUseAssets contextRef="c-1" decimals="-3" id="f-232" unitRef="cad">304000</oncyf:AdjustmentsForDepreciationRightOfUseAssets>
    <oncyf:AdjustmentsForDepreciationRightOfUseAssets contextRef="c-7" decimals="-3" id="f-233" unitRef="cad">322000</oncyf:AdjustmentsForDepreciationRightOfUseAssets>
    <oncyf:AdjustmentsForDepreciationRightOfUseAssets contextRef="c-8" decimals="-3" id="f-234" unitRef="cad">299000</oncyf:AdjustmentsForDepreciationRightOfUseAssets>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c-1" decimals="-3" id="f-235" unitRef="cad">2723000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c-7" decimals="-3" id="f-236" unitRef="cad">1917000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c-8" decimals="-3" id="f-237" unitRef="cad">2378000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets contextRef="c-1" decimals="-3" id="f-238" unitRef="cad">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets contextRef="c-7" decimals="-3" id="f-239" unitRef="cad">151000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets contextRef="c-8" decimals="-3" id="f-240" unitRef="cad">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:InterestRevenueExpense contextRef="c-1" decimals="-3" id="f-241" unitRef="cad">-139000</ifrs-full:InterestRevenueExpense>
    <ifrs-full:InterestRevenueExpense contextRef="c-7" decimals="-3" id="f-242" unitRef="cad">-71000</ifrs-full:InterestRevenueExpense>
    <ifrs-full:InterestRevenueExpense contextRef="c-8" decimals="-3" id="f-243" unitRef="cad">76000</ifrs-full:InterestRevenueExpense>
    <ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains contextRef="c-1" decimals="-3" id="f-244" unitRef="cad">-838000</ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains>
    <ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains contextRef="c-7" decimals="-3" id="f-245" unitRef="cad">282000</ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains>
    <ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains contextRef="c-8" decimals="-3" id="f-246" unitRef="cad">-1625000</ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains>
    <ifrs-full:AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives contextRef="c-1" decimals="-3" id="f-247" unitRef="cad">1242000</ifrs-full:AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives>
    <ifrs-full:AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives contextRef="c-7" decimals="-3" id="f-248" unitRef="cad">5285000</ifrs-full:AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives>
    <ifrs-full:AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives contextRef="c-8" decimals="-3" id="f-249" unitRef="cad">-20000</ifrs-full:AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives>
    <ifrs-full:IncreaseDecreaseInWorkingCapital contextRef="c-1" decimals="-3" id="f-250" unitRef="cad">-3538000</ifrs-full:IncreaseDecreaseInWorkingCapital>
    <ifrs-full:IncreaseDecreaseInWorkingCapital contextRef="c-7" decimals="-3" id="f-251" unitRef="cad">-1765000</ifrs-full:IncreaseDecreaseInWorkingCapital>
    <ifrs-full:IncreaseDecreaseInWorkingCapital contextRef="c-8" decimals="-3" id="f-252" unitRef="cad">-391000</ifrs-full:IncreaseDecreaseInWorkingCapital>
    <ifrs-full:CashFlowsFromUsedInOperations contextRef="c-1" decimals="-3" id="f-253" unitRef="cad">-26966000</ifrs-full:CashFlowsFromUsedInOperations>
    <ifrs-full:CashFlowsFromUsedInOperations contextRef="c-7" decimals="-3" id="f-254" unitRef="cad">-28448000</ifrs-full:CashFlowsFromUsedInOperations>
    <ifrs-full:CashFlowsFromUsedInOperations contextRef="c-8" decimals="-3" id="f-255" unitRef="cad">-23355000</ifrs-full:CashFlowsFromUsedInOperations>
    <ifrs-full:PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities contextRef="c-1" decimals="-3" id="f-256" unitRef="cad">0</ifrs-full:PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities contextRef="c-7" decimals="-3" id="f-257" unitRef="cad">0</ifrs-full:PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities contextRef="c-8" decimals="-3" id="f-258" unitRef="cad">20348000</ifrs-full:PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities>
    <ifrs-full:ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities contextRef="c-1" decimals="-3" id="f-259" unitRef="cad">0</ifrs-full:ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities>
    <ifrs-full:ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities contextRef="c-7" decimals="-3" id="f-260" unitRef="cad">20230000</ifrs-full:ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities>
    <ifrs-full:ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities contextRef="c-8" decimals="-3" id="f-261" unitRef="cad">0</ifrs-full:ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="c-1" decimals="-3" id="f-262" unitRef="cad">239000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="c-7" decimals="-3" id="f-263" unitRef="cad">8000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="c-8" decimals="-3" id="f-264" unitRef="cad">55000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="c-1" decimals="-3" id="f-265" unitRef="cad">-239000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="c-7" decimals="-3" id="f-266" unitRef="cad">20222000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="c-8" decimals="-3" id="f-267" unitRef="cad">-20403000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:ProceedsFromExerciseOfOptions contextRef="c-1" decimals="-3" id="f-268" unitRef="cad">0</ifrs-full:ProceedsFromExerciseOfOptions>
    <ifrs-full:ProceedsFromExerciseOfOptions contextRef="c-7" decimals="-3" id="f-269" unitRef="cad">781000</ifrs-full:ProceedsFromExerciseOfOptions>
    <ifrs-full:ProceedsFromExerciseOfOptions contextRef="c-8" decimals="-3" id="f-270" unitRef="cad">12000</ifrs-full:ProceedsFromExerciseOfOptions>
    <ifrs-full:ProceedsFromExerciseOfWarrants contextRef="c-1" decimals="-3" id="f-271" unitRef="cad">65000</ifrs-full:ProceedsFromExerciseOfWarrants>
    <ifrs-full:ProceedsFromExerciseOfWarrants contextRef="c-7" decimals="-3" id="f-272" unitRef="cad">0</ifrs-full:ProceedsFromExerciseOfWarrants>
    <ifrs-full:ProceedsFromExerciseOfWarrants contextRef="c-8" decimals="-3" id="f-273" unitRef="cad">0</ifrs-full:ProceedsFromExerciseOfWarrants>
    <ifrs-full:ProceedsFromIssuingShares contextRef="c-44" decimals="-3" id="f-274" unitRef="cad">6919000</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:ProceedsFromIssuingShares contextRef="c-31" decimals="-3" id="f-275" unitRef="cad">10261000</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:ProceedsFromIssuingShares contextRef="c-49" decimals="-3" id="f-276" unitRef="cad">12574000</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:ProceedsFromIssuingShares contextRef="c-50" decimals="-3" id="f-277" unitRef="cad">0</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:ProceedsFromIssuingShares contextRef="c-51" decimals="-3" id="f-278" unitRef="cad">21359000</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:ProceedsFromIssuingShares contextRef="c-52" decimals="-3" id="f-279" unitRef="cad">0</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:CashOutflowForLeases contextRef="c-1" decimals="-3" id="f-280" unitRef="cad">348000</ifrs-full:CashOutflowForLeases>
    <ifrs-full:CashOutflowForLeases contextRef="c-7" decimals="-3" id="f-281" unitRef="cad">407000</ifrs-full:CashOutflowForLeases>
    <ifrs-full:CashOutflowForLeases contextRef="c-8" decimals="-3" id="f-282" unitRef="cad">381000</ifrs-full:CashOutflowForLeases>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="c-1" decimals="-3" id="f-283" unitRef="cad">6636000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="c-7" decimals="-3" id="f-284" unitRef="cad">31994000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="c-8" decimals="-3" id="f-285" unitRef="cad">12205000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents contextRef="c-1" decimals="-3" id="f-286" unitRef="cad">-20569000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents contextRef="c-7" decimals="-3" id="f-287" unitRef="cad">23768000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents contextRef="c-8" decimals="-3" id="f-288" unitRef="cad">-31553000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-4" decimals="-3" id="f-289" unitRef="cad">34912000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-25" decimals="-3" id="f-290" unitRef="cad">11666000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-14" decimals="-3" id="f-291" unitRef="cad">41262000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents contextRef="c-1" decimals="-3" id="f-292" unitRef="cad">1599000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents contextRef="c-7" decimals="-3" id="f-293" unitRef="cad">-522000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents contextRef="c-8" decimals="-3" id="f-294" unitRef="cad">1957000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-3" decimals="-3" id="f-295" unitRef="cad">15942000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-4" decimals="-3" id="f-296" unitRef="cad">34912000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-25" decimals="-3" id="f-297" unitRef="cad">11666000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory contextRef="c-1" id="f-298">Nature of Operations and Going Concern&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Oncolytics Biotech Inc. was incorporated on April 2, 1998, under the Business Corporations Act (Alberta) as 779738 Alberta Ltd. On April 8, 1998, we changed our name to Oncolytics Biotech Inc. We are a limited company incorporated and domiciled in Canada. Our shares are publicly traded on the Nasdaq Capital Market and the Toronto Stock Exchange. Our principal place of business is located at 804, 322 11&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;th&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Avenue S.W., Calgary, Alberta, Canada.   &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are a clinical-stage biopharmaceutical company developing pelareorep, a well-tolerated intravenously delivered&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. Our primary focus is to advance our programs in hormone receptor-positive / human epidermal growth factor 2-negative (HR+/HER2-) advanced and metastatic breast cancer and metastatic pancreatic ductal adenocarcinoma to registration-enabled clinical studies. In addition, we are exploring opportunities for registrational programs in other gastrointestinal cancers through our GOBLET platform study. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have not been profitable since our inception and expect to continue to incur substantial losses as we continue our research and development efforts. As at December&#160;31, 2024, we had an accumulated deficit of $477,713. We do not expect to generate significant revenues until and unless pelareorep becomes commercially viable. To date, we have funded our operations mainly through issuing additional capital via public offerings, equity distribution arrangements, and the exercise of warrants and stock options. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Going concern&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management assesses our ability to continue as a going concern when preparing our consolidated financial statements. In assessing whether the going concern assumption is appropriate, management takes into account all available information about the future, which is at least, but not limited to, twelve months from the end of the reporting period. As at December&#160;31, 2024, we had cash and cash equivalents of $15,942. Subsequent to December&#160;31, 2024, we further raised net proceeds of $6,041 (see note 23). Without raising additional funding or reducing or eliminating our planned expenditures, we estimated our cash and cash equivalents to fund our operations into the third quarter of 2025. Factors that will affect our anticipated cash needs for the next twelve months include, but are not limited to, expansion of our clinical trial program, the timing of patient enrollment in our clinical trials, the actual costs incurred to support each clinical trial, the number of treatments each patient will receive, the timing of activity with our clinical trial research collaborations, the number, timing and costs of manufacturing runs required to conclude the validation process and supply product to our clinical trial program, and the level of collaborative activity undertaken. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our ability to continue as a going concern is dependent upon raising additional financing through equity or strategic collaborations and transactions. We plan on raising additional funds through the sale of our common shares or other capital resources, such as collaborations and debt, to fund our ongoing operations. However, given the difficulty for micro-cap market capitalization companies to raise significant capital and the matter in note 23(b), there can be no assurance that additional liquidity will be available under acceptable terms or at all. Furthermore, if we are unable to obtain additional financing when required, there can be no assurance that we will be able to sufficiently reduce or eliminate our planned expenditures to extend our operating runway. These material uncertainties raise substantial doubt on our ability to continue as a going concern and meet our obligations as they come due and, accordingly, the appropriateness of the use of accounting principles applicable to a going concern.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These consolidated financial statements were prepared in accordance with International Financial Reporting Standards ("IFRS") applicable to a going concern. However, the use of the going concern assumption on which these consolidated financial statements are prepared may not be appropriate based on the factors described above.&lt;/span&gt;&lt;/div&gt;These consolidated financial statements do not reflect the adjustments to the carrying values of assets and liabilities and the reported expenses and statements of financial position classifications that would be necessary if we were unable to realize our assets and settle our liabilities as a going concern in the normal course of operations. Such adjustments could be material.</ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory>
    <ifrs-full:RetainedEarnings contextRef="c-3" decimals="-3" id="f-299" unitRef="cad">-477713000</ifrs-full:RetainedEarnings>
    <ifrs-full:DescriptionOfUncertaintiesOfEntitysAbilityToContinueAsGoingConcern contextRef="c-1" id="f-300">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Going concern&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management assesses our ability to continue as a going concern when preparing our consolidated financial statements. In assessing whether the going concern assumption is appropriate, management takes into account all available information about the future, which is at least, but not limited to, twelve months from the end of the reporting period. As at December&#160;31, 2024, we had cash and cash equivalents of $15,942. Subsequent to December&#160;31, 2024, we further raised net proceeds of $6,041 (see note 23). Without raising additional funding or reducing or eliminating our planned expenditures, we estimated our cash and cash equivalents to fund our operations into the third quarter of 2025. Factors that will affect our anticipated cash needs for the next twelve months include, but are not limited to, expansion of our clinical trial program, the timing of patient enrollment in our clinical trials, the actual costs incurred to support each clinical trial, the number of treatments each patient will receive, the timing of activity with our clinical trial research collaborations, the number, timing and costs of manufacturing runs required to conclude the validation process and supply product to our clinical trial program, and the level of collaborative activity undertaken. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our ability to continue as a going concern is dependent upon raising additional financing through equity or strategic collaborations and transactions. We plan on raising additional funds through the sale of our common shares or other capital resources, such as collaborations and debt, to fund our ongoing operations. However, given the difficulty for micro-cap market capitalization companies to raise significant capital and the matter in note 23(b), there can be no assurance that additional liquidity will be available under acceptable terms or at all. Furthermore, if we are unable to obtain additional financing when required, there can be no assurance that we will be able to sufficiently reduce or eliminate our planned expenditures to extend our operating runway. These material uncertainties raise substantial doubt on our ability to continue as a going concern and meet our obligations as they come due and, accordingly, the appropriateness of the use of accounting principles applicable to a going concern.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These consolidated financial statements were prepared in accordance with International Financial Reporting Standards ("IFRS") applicable to a going concern. However, the use of the going concern assumption on which these consolidated financial statements are prepared may not be appropriate based on the factors described above.&lt;/span&gt;&lt;/div&gt;These consolidated financial statements do not reflect the adjustments to the carrying values of assets and liabilities and the reported expenses and statements of financial position classifications that would be necessary if we were unable to realize our assets and settle our liabilities as a going concern in the normal course of operations. Such adjustments could be material.</ifrs-full:DescriptionOfUncertaintiesOfEntitysAbilityToContinueAsGoingConcern>
    <ifrs-full:CashAndCashEquivalents contextRef="c-3" decimals="-3" id="f-301" unitRef="cad">15942000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:ProceedsFromIssueOfOrdinaryShares contextRef="c-53" decimals="-3" id="f-302" unitRef="cad">6041000</ifrs-full:ProceedsFromIssueOfOrdinaryShares>
    <ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory contextRef="c-1" id="f-303">Basis of Presentation&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Statement of compliance&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These consolidated financial statements have been prepared in accordance with IFRS as issued by the International Accounting Standards Board ("IASB"). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our consolidated financial statements for the year ended December&#160;31, 2024, were authorized for issue in accordance with a resolution of the Board of Directors (the "Board") on March&#160;6, 2025. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basis of presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our consolidated financial statements include our financial statements and the financial statements of our subsidiaries, Oncolytics Biotech (Barbados) Inc. and Oncolytics Biotech (U.S.) Inc., and are presented in Canadian dollars, our functional currency. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subsidiaries are entities over which we have control which is achieved when we are exposed, or have the rights, to variable returns from our involvement with the investee and have the ability to affect those returns through our power to govern. The accounting policies of our subsidiaries are consistent with our accounting policies, and all intercompany transactions, balances, income, and expenses are eliminated on consolidation. &lt;/span&gt;&lt;/div&gt;Our accounts are prepared on the historical cost basis, except for certain assets and liabilities, which are measured at fair value as explained in the notes to these financial statements.</ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory>
    <ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory contextRef="c-1" id="f-304">Summary of Material Accounting Policies&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements have, in management's opinion, been properly prepared within reasonable limits of materiality and within the framework of the material accounting policies summarized below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cash and cash equivalents &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents include interest-bearing deposits with our bank totaling $12,312 as at December&#160;31, 2024 (December&#160;31, 2023 - $31,534). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Deferred income taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We follow the liability method of accounting for income taxes. Under the liability method, deferred income taxes are recognized for the difference between the financial statement carrying values and the respective income tax basis of assets and liabilities (temporary differences). Deferred income tax assets and liabilities are measured using substantively enacted income tax rates and laws expected to apply in the years in which temporary differences are expected to be recovered or settled. The effect on deferred income tax assets and liabilities of a change in tax rates is charged or credited to income, except when it is related to items charged or credited to either other comprehensive income or directly to equity.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Financial instruments &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Classification and measurement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial assets are initially measured at fair value. In the case of a financial asset not at fair value through profit or loss, the financial asset is initially measured at fair value plus or minus transaction costs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial assets are subsequently measured at amortised cost, fair value through profit or loss (FVPL), or fair value through other comprehensive income (FVOCI). The classification is based on two criteria: the Company&#x2019;s business model for managing the assets; and whether the financial asset&#x2019;s contractual cash flows represent 'solely payments of principal and interest' on the principal amount outstanding (the 'SPPI criterion'). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The classification and measurement of our cash and cash equivalents and other receivables are financial assets at amortized cost, as these assets are held within our business model with the objective to hold the financial assets in order to collect contractual cash flows that meet the SPPI criterion. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial liabilities are initially measured at fair value and are subsequently measured at amortised cost or FVPL. The classification and measurement of our accounts payable and accrued liabilities and other liabilities are financial liabilities at amortized cost. The classification and measurement of the warrant derivative is financial liabilities at FVPL.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounting for impairment losses for financial assets uses a forward-looking expected credit loss (ECL) approach. We are required to record a loss allowance for ECLs on all financial assets not held at FVPL. ECLs are based on the difference between the contractual cash flows due in accordance with the contract and all the cash flows that the Company expects to receive. The shortfall is then discounted at an approximation to the asset&#x2019;s original effective interest rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Derecognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A financial asset is derecognized when the contractual rights to the cash flows from the financial asset expire, or we transfer the financial asset and substantially all the risks and rewards of ownership of the financial asset to another entity. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A financial liability is derecognized when our obligations specified in the contract are discharged or canceled, or expired. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is the price that would be received to sell an asset, or paid to transfer a liability in an orderly transaction between market participants, at the measurement date. In determining the fair value measurement of our financial instruments, we prioritize the related inputs used in measuring fair value into the following hierarchy: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2 - Inputs other than quoted prices included within Level 1 that are either directly or indirectly observable;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3 - Unobservable inputs in which little or no market activity exists, therefore requiring an entity to develop its own assumptions about the assumptions that market participants would use in pricing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Foreign currency translation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The financial statements for each of our subsidiaries are prepared using their functional currency. Our functional and presentation currency is the Canadian dollar. Foreign currency transactions are translated into the functional currency using exchange rates prevailing at the dates of the transactions. Exchange differences resulting from the settlement of such transactions and from the translation at exchange rates ruling at the statement of financial position date of monetary assets and liabilities denominated in currencies other than the functional currency are recognized directly in the consolidated statement of loss and comprehensive loss.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exceptions to this are where the monetary items form part of the net investment in a foreign operation, and the foreign operation's functional currency is the local currency. These exchange differences are initially recognized in equity. The statement of financial position of foreign operations is translated into Canadian dollars using the exchange rate at the statement of financial position date and the income statements are translated into Canadian dollars using the average exchange rate for the period. Where this average is not a reasonable approximation of the cumulative effect of the rates prevailing on the transaction dates, the exchange rate on the transaction date is used. Exchange differences on translation into Canadian dollars are recognized as a separate component of equity. On disposal of a foreign operation, any cumulative exchange differences held in equity are transferred to the consolidated statement of loss and comprehensive loss.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the inception of a contract, we assess whether a contract is, or contains, a lease by determining whether the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. To assess whether a contract conveys the right to control the use of an identified asset, we assess whether:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;the contract involves the use of an identified asset;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;we have the right to obtain substantially all of the economic benefits from the use of the identified asset throughout the period of use; and&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;we have the right to direct the use of the identified asset. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A right-of-use asset and corresponding lease liability are recognized on the lease commencement date. The right-of-use asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, plus any initial direct costs incurred and an estimate of costs to dismantle and remove the underlying asset or to restore the underlying asset or the site on which it is located, less any lease incentives received. The right-of-use asset is subsequently depreciated using the straight-line method from the commencement date to the end of the lease term. In addition, the right-of-use asset is reduced by impairment losses and adjusted for certain remeasurements of the lease liabilities, if any. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date. The lease payments are discounted using the implicit interest rate in the lease. If the rate cannot be readily determined, our incremental rate of borrowing is used. The lease liability is subsequently measured at amortized cost using the effective interest method. The lease liability is remeasured when there is a change in future lease payments arising from a change in an index or rate, if there is a change in our estimate of the amount expected to be payable under a residual value guarantee, if we change our assessment of whether we will exercise a purchase, extension or termination option, or if the underlying lease contract is amended.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have elected not to separate fixed non-lease components from lease components and instead account for each lease component and associated fixed non-lease components as a single lease component.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have elected not to recognize right-of-use assets and lease liabilities for short-term leases that have a lease term of 12 months or less. We recognize the lease payments associated with these leases as an expense on a straight-line basis over the lease term. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Loss per share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic loss per share is calculated by dividing the loss attributable to common shareholders by the weighted average number of common shares outstanding during the year. Diluted loss per share is computed in a manner consistent with basic loss per share except that the weighted average common shares outstanding are adjusted to include the effects of all dilutive potential common shares, which comprise stock options, share awards, and warrants. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Property and equipment &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are recorded at cost. Depreciation is provided on bases and at rates designed to amortize the cost of the assets over their estimated useful lives. Depreciation is recorded using the declining balance method at the following annual rates:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:49.192%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.608%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office equipment and furniture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medical equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Straight-line over the term of the lease&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Research and development costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are expensed as incurred, net of recoveries. We record accruals for the estimated costs of our research and development activities performed by third parties. Advance payments for goods or services that will be used or rendered for future research and development activities are capitalized as prepaid expenses and recognized as an expense as the related goods are delivered or the related services are performed. Development costs that meet specific criteria related to technical, market, and financial feasibility will be capitalized. To date, all development costs have been expensed. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revenue recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue relates to a long-term contract associated with a regional licensing agreement (the "Licensing Agreement") with Adlai Nortye Biopharma Co., Ltd. ("Adlai"). The pricing for the contract was based on the specific negotiations with Adlai and included non-refundable upfront license fees, development and regulatory milestone payments, royalties, and sales-based milestone payments. We account for a contract with a customer when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance, and the collectability of consideration is probable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Licensing Agreement, we have granted a regional license to our intellectual property. The granting of this license is accounted for as one performance obligation. We have determined that we provide Adlai with a right to access our intellectual property and, therefore, recognize revenue related to the upfront license fee over time. Revenue is recognized based on the extent of progress toward completion of the performance obligation using the input method. Under the input method, the extent of progress toward completion is measured based on the ratio of costs incurred to date to the total estimated costs at completion of the performance obligation. We use this method because Adlai receives and consumes the benefit of our intellectual property as we undertake activities that impact the intellectual property. Management must use judgment in making assumptions and estimates regarding total estimated costs, the complexity of the work to be performed, and the length of time to complete the performance obligation, among other variables.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The contract also provides for development and regulatory milestone payments, royalties, and sales-based milestone payments. These amounts are contingent on the occurrence of a future event and, therefore, give rise to variable consideration. We estimate variable consideration at the most likely amount to which we expect to be entitled. We include estimated amounts in the transaction price when it becomes highly probable that the amount will not be subject to significant reversal when the uncertainty associated with the variable consideration is resolved. Our estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of our anticipated performance and all information (historical, current, and forecasted) that is reasonably available to us. Based on this information and related analysis, any quarterly adjustments to revenue are recognized as necessary in the period they become known.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The upfront license fee is not considered a significant financing component because it is used to meet working capital demands that can be higher in the early stages of a contract and to protect us from the other party failing to adequately complete some or all of its obligations under the contract. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue from sales-based royalties and the achievement of annual sales volumes will be recognized when the subsequent sale occurs, as the license of the intellectual property is the predominant item to which the royalty relates. We consider payments associated with the achievement of annual sales volumes to be, in substance, royalty payments, and we will recognize such sales-based payments upon achievement of such sales volumes, provided that collection is reasonably assured.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contract liability&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; - Our contract liability includes upfront license fees and billings in excess of the revenue recognized. Contract liabilities are recognized as revenue as or when we perform under the contract. We classify our contract liability as current or non-current based on the timing of when we expect to recognize revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Share-based compensation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock option plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have one stock option plan (the "Stock Option Plan") available to directors, officers, employees, and consultants with grants under the Stock Option Plan approved from time to time by our Board of Directors (the "Board"). Under the Stock Option Plan, no option shall be granted with an exercise price at a discount to the closing price of our stock on the Toronto Stock Exchange &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;on the last trading date prior to the date of the grant. Vesting is provided at the discretion of the Board, and the expiration of options is to be no greater than ten years from the date of grant. Exercised stock options are settled with common shares issued from treasury. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We use the fair value-based method of accounting for stock option awards granted under the Stock Option Plan. We recognize compensation expense and a corresponding adjustment to contributed surplus equal to the fair value of the stock options granted using the Black-Scholes valuation model over the vesting periods of the respective options. Compensation expense is adjusted for subsequent changes in management&#x2019;s estimate of the number of options that are expected to vest.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock options awarded to non-employees are accounted for at the fair value of the goods received or the services rendered. The fair value is measured at the date the Company obtains the goods or the date the counterparty renders the service. If the fair value of the goods or services cannot be reliably measured, the fair value of the options granted will be used.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share award plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our share award plan (the "Share Award Plan") is available to directors, officers, employees, and consultants. Under our Share Award Plan, performance and restricted share awards may be approved from time to time by the Board. Performance share awards  ("PSAs") can be awarded to certain officers and employees to which common shares shall be issued based upon achieving the applicable performance criteria. Restricted share awards ("RSAs") can be awarded to certain officers, employees, non-employee directors, and consultants to which common shares shall be issued in accordance with the Share Award Plan.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize compensation expense and a corresponding adjustment to contributed surplus equal to the market value of our common shares at the grant date based on the number of PSAs/RSAs expected to vest, recognized over the vesting period. Compensation expense is adjusted for subsequent changes in management&#x2019;s estimate of the number of PSAs/RSAs that are expected to vest. The effect of these changes is recognized in the period of the change. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Adoption of New Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;IAS 1 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Classification of Liabilities as Current or Non-Current&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2022, the IASB issued amendments to clarify how conditions with which an entity must comply within 12 months after the reporting period affect the classification of a liability. This is in addition to the amendment from January 2020 where the IASB issued amendments to IAS 1 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Presentation of Financial Statements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to provide a more general approach to the presentation of liabilities as current or non-current based on contractual arrangements in place at the reporting date. These amendments specify that the rights and conditions existing at the end of the reporting period are relevant in determining whether the Company has a right to defer settlement of a liability by at least 12 months, provided that management's expectations are not a relevant consideration as to whether the Company will exercise its rights to defer settlement of a liability and clarify when a liability is considered settled. The amendments became effective on January 1, 2024. Adopting the amendments did not have a material impact on our consolidated financial statements.   &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accounting Standards and Interpretations Issued but Not Yet Effective&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;IFRS 18 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Presentation and Disclosure in Financial Statements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2024, the IASB issued IFRS 18 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Presentation and Disclosure in Financial Statements &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;which replaces IAS 1 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Presentation of Financial Statements. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;IFRS 18 introduces new requirements on presentation within the statement of profit or loss, including specified totals and subtotals. It also requires disclosure of management-defined performance measures and includes new requirements for aggregation and disaggregation of financial information based on the identified roles of the primary financial statements and the notes. Narrow scope amendments have been made to IAS 7 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Statement of Cash Flows&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and some requirements previously included within IAS 1 have been moved to IAS 8 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounting Policies, Changes in Accounting Estimates and Errors, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;which has also been renamed IAS 8 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Basis of Preparation of Financial Statements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. IAS 34 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Interim Financial Reporting &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;has also been amended to require disclosure of management-defined performance measures. IFRS 18 and the amendments to the other standards are effective for annual periods beginning on or after January 1, 2027, with early application permitted. IFRS 18 applies retrospectively to both annual and interim financial statements. We are assessing the impact of adopting this standard on our consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory>
    <oncyf:DescriptionOfAccountingPolicyForDeterminingComponentsOfCashAndCashEquivalentsPolicyTextBlock contextRef="c-1" id="f-305">Cash equivalents include interest-bearing deposits with our bank</oncyf:DescriptionOfAccountingPolicyForDeterminingComponentsOfCashAndCashEquivalentsPolicyTextBlock>
    <ifrs-full:CashEquivalents contextRef="c-3" decimals="-3" id="f-306" unitRef="cad">12312000</ifrs-full:CashEquivalents>
    <ifrs-full:CashEquivalents contextRef="c-4" decimals="-3" id="f-307" unitRef="cad">31534000</ifrs-full:CashEquivalents>
    <ifrs-full:DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory contextRef="c-1" id="f-308">We follow the liability method of accounting for income taxes. Under the liability method, deferred income taxes are recognized for the difference between the financial statement carrying values and the respective income tax basis of assets and liabilities (temporary differences). Deferred income tax assets and liabilities are measured using substantively enacted income tax rates and laws expected to apply in the years in which temporary differences are expected to be recovered or settled. The effect on deferred income tax assets and liabilities of a change in tax rates is charged or credited to income, except when it is related to items charged or credited to either other comprehensive income or directly to equity.</ifrs-full:DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForFinancialAssetsExplanatory contextRef="c-1" id="f-309">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial assets are initially measured at fair value. In the case of a financial asset not at fair value through profit or loss, the financial asset is initially measured at fair value plus or minus transaction costs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial assets are subsequently measured at amortised cost, fair value through profit or loss (FVPL), or fair value through other comprehensive income (FVOCI). The classification is based on two criteria: the Company&#x2019;s business model for managing the assets; and whether the financial asset&#x2019;s contractual cash flows represent 'solely payments of principal and interest' on the principal amount outstanding (the 'SPPI criterion'). &lt;/span&gt;&lt;/div&gt;The classification and measurement of our cash and cash equivalents and other receivables are financial assets at amortized cost, as these assets are held within our business model with the objective to hold the financial assets in order to collect contractual cash flows that meet the SPPI criterion.</ifrs-full:DescriptionOfAccountingPolicyForFinancialAssetsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory contextRef="c-1" id="f-310">Financial liabilities are initially measured at fair value and are subsequently measured at amortised cost or FVPL. The classification and measurement of our accounts payable and accrued liabilities and other liabilities are financial liabilities at amortized cost. The classification and measurement of the warrant derivative is financial liabilities at FVPL.</ifrs-full:DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory contextRef="c-1" id="f-311">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounting for impairment losses for financial assets uses a forward-looking expected credit loss (ECL) approach. We are required to record a loss allowance for ECLs on all financial assets not held at FVPL. ECLs are based on the difference between the contractual cash flows due in accordance with the contract and all the cash flows that the Company expects to receive. The shortfall is then discounted at an approximation to the asset&#x2019;s original effective interest rate.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForDerecognitionOfFinancialInstrumentsExplanatory contextRef="c-1" id="f-312">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A financial asset is derecognized when the contractual rights to the cash flows from the financial asset expire, or we transfer the financial asset and substantially all the risks and rewards of ownership of the financial asset to another entity. &lt;/span&gt;&lt;/div&gt;A financial liability is derecognized when our obligations specified in the contract are discharged or canceled, or expired.</ifrs-full:DescriptionOfAccountingPolicyForDerecognitionOfFinancialInstrumentsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory contextRef="c-1" id="f-313">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is the price that would be received to sell an asset, or paid to transfer a liability in an orderly transaction between market participants, at the measurement date. In determining the fair value measurement of our financial instruments, we prioritize the related inputs used in measuring fair value into the following hierarchy: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2 - Inputs other than quoted prices included within Level 1 that are either directly or indirectly observable;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3 - Unobservable inputs in which little or no market activity exists, therefore requiring an entity to develop its own assumptions about the assumptions that market participants would use in pricing.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory contextRef="c-1" id="f-314">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The financial statements for each of our subsidiaries are prepared using their functional currency. Our functional and presentation currency is the Canadian dollar. Foreign currency transactions are translated into the functional currency using exchange rates prevailing at the dates of the transactions. Exchange differences resulting from the settlement of such transactions and from the translation at exchange rates ruling at the statement of financial position date of monetary assets and liabilities denominated in currencies other than the functional currency are recognized directly in the consolidated statement of loss and comprehensive loss.  &lt;/span&gt;&lt;/div&gt;Exceptions to this are where the monetary items form part of the net investment in a foreign operation, and the foreign operation's functional currency is the local currency. These exchange differences are initially recognized in equity. The statement of financial position of foreign operations is translated into Canadian dollars using the exchange rate at the statement of financial position date and the income statements are translated into Canadian dollars using the average exchange rate for the period. Where this average is not a reasonable approximation of the cumulative effect of the rates prevailing on the transaction dates, the exchange rate on the transaction date is used. Exchange differences on translation into Canadian dollars are recognized as a separate component of equity. On disposal of a foreign operation, any cumulative exchange differences held in equity are transferred to the consolidated statement of loss and comprehensive loss.</ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory contextRef="c-1" id="f-315">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the inception of a contract, we assess whether a contract is, or contains, a lease by determining whether the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. To assess whether a contract conveys the right to control the use of an identified asset, we assess whether:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;the contract involves the use of an identified asset;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;we have the right to obtain substantially all of the economic benefits from the use of the identified asset throughout the period of use; and&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;we have the right to direct the use of the identified asset. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A right-of-use asset and corresponding lease liability are recognized on the lease commencement date. The right-of-use asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, plus any initial direct costs incurred and an estimate of costs to dismantle and remove the underlying asset or to restore the underlying asset or the site on which it is located, less any lease incentives received. The right-of-use asset is subsequently depreciated using the straight-line method from the commencement date to the end of the lease term. In addition, the right-of-use asset is reduced by impairment losses and adjusted for certain remeasurements of the lease liabilities, if any. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date. The lease payments are discounted using the implicit interest rate in the lease. If the rate cannot be readily determined, our incremental rate of borrowing is used. The lease liability is subsequently measured at amortized cost using the effective interest method. The lease liability is remeasured when there is a change in future lease payments arising from a change in an index or rate, if there is a change in our estimate of the amount expected to be payable under a residual value guarantee, if we change our assessment of whether we will exercise a purchase, extension or termination option, or if the underlying lease contract is amended.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have elected not to separate fixed non-lease components from lease components and instead account for each lease component and associated fixed non-lease components as a single lease component.  &lt;/span&gt;&lt;/div&gt;We have elected not to recognize right-of-use assets and lease liabilities for short-term leases that have a lease term of 12 months or less. We recognize the lease payments associated with these leases as an expense on a straight-line basis over the lease term.</ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForEarningsPerShareExplanatory contextRef="c-1" id="f-316">Basic loss per share is calculated by dividing the loss attributable to common shareholders by the weighted average number of common shares outstanding during the year. Diluted loss per share is computed in a manner consistent with basic loss per share except that the weighted average common shares outstanding are adjusted to include the effects of all dilutive potential common shares, which comprise stock options, share awards, and warrants.</ifrs-full:DescriptionOfAccountingPolicyForEarningsPerShareExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory contextRef="c-1" id="f-317">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are recorded at cost. Depreciation is provided on bases and at rates designed to amortize the cost of the assets over their estimated useful lives. Depreciation is recorded using the declining balance method at the following annual rates:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:49.192%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.608%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office equipment and furniture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medical equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Straight-line over the term of the lease&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory>
    <ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory contextRef="c-1" id="f-318">Depreciation is recorded using the declining balance method at the following annual rates:&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:49.192%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.608%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office equipment and furniture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medical equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Straight-line over the term of the lease&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:32.328%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.042%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.371%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.042%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.371%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.471%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.371%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.471%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.371%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.762%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Medical Equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Computer Equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Office Equipment and Furniture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Leasehold Improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at December 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions, net of foreign exchange impact&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at December 31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Disposals, net of foreign exchange impact&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(59)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(43)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(47)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(173)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As at December 31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at December 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at December 31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Disposals, net of foreign exchange impact&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(54)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(41)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(47)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(165)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As at December 31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net book value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at December 31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As at December 31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;119&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;250&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;41&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;411&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;For the year ended December&#160;31, 2024, we incurred losses on disposal of property and equipment of $18, which was included in depreciation expense on our consolidated statement of cash flows.</ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory>
    <oncyf:PropertyPlantandEquipmentAnnualDepreciationRate
      contextRef="c-54"
      decimals="INF"
      id="f-319"
      unitRef="number">0.20</oncyf:PropertyPlantandEquipmentAnnualDepreciationRate>
    <oncyf:PropertyPlantandEquipmentAnnualDepreciationRate
      contextRef="c-55"
      decimals="INF"
      id="f-320"
      unitRef="number">0.20</oncyf:PropertyPlantandEquipmentAnnualDepreciationRate>
    <oncyf:PropertyPlantandEquipmentAnnualDepreciationRate
      contextRef="c-56"
      decimals="INF"
      id="f-321"
      unitRef="number">0.30</oncyf:PropertyPlantandEquipmentAnnualDepreciationRate>
    <ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory contextRef="c-1" id="f-322">Research and development costs are expensed as incurred, net of recoveries. We record accruals for the estimated costs of our research and development activities performed by third parties. Advance payments for goods or services that will be used or rendered for future research and development activities are capitalized as prepaid expenses and recognized as an expense as the related goods are delivered or the related services are performed. Development costs that meet specific criteria related to technical, market, and financial feasibility will be capitalized. To date, all development costs have been expensed.</ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue contextRef="c-1" id="f-323">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue relates to a long-term contract associated with a regional licensing agreement (the "Licensing Agreement") with Adlai Nortye Biopharma Co., Ltd. ("Adlai"). The pricing for the contract was based on the specific negotiations with Adlai and included non-refundable upfront license fees, development and regulatory milestone payments, royalties, and sales-based milestone payments. We account for a contract with a customer when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance, and the collectability of consideration is probable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Licensing Agreement, we have granted a regional license to our intellectual property. The granting of this license is accounted for as one performance obligation. We have determined that we provide Adlai with a right to access our intellectual property and, therefore, recognize revenue related to the upfront license fee over time. Revenue is recognized based on the extent of progress toward completion of the performance obligation using the input method. Under the input method, the extent of progress toward completion is measured based on the ratio of costs incurred to date to the total estimated costs at completion of the performance obligation. We use this method because Adlai receives and consumes the benefit of our intellectual property as we undertake activities that impact the intellectual property. Management must use judgment in making assumptions and estimates regarding total estimated costs, the complexity of the work to be performed, and the length of time to complete the performance obligation, among other variables.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The contract also provides for development and regulatory milestone payments, royalties, and sales-based milestone payments. These amounts are contingent on the occurrence of a future event and, therefore, give rise to variable consideration. We estimate variable consideration at the most likely amount to which we expect to be entitled. We include estimated amounts in the transaction price when it becomes highly probable that the amount will not be subject to significant reversal when the uncertainty associated with the variable consideration is resolved. Our estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of our anticipated performance and all information (historical, current, and forecasted) that is reasonably available to us. Based on this information and related analysis, any quarterly adjustments to revenue are recognized as necessary in the period they become known.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The upfront license fee is not considered a significant financing component because it is used to meet working capital demands that can be higher in the early stages of a contract and to protect us from the other party failing to adequately complete some or all of its obligations under the contract. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue from sales-based royalties and the achievement of annual sales volumes will be recognized when the subsequent sale occurs, as the license of the intellectual property is the predominant item to which the royalty relates. We consider payments associated with the achievement of annual sales volumes to be, in substance, royalty payments, and we will recognize such sales-based payments upon achievement of such sales volumes, provided that collection is reasonably assured.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contract liability&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; - Our contract liability includes upfront license fees and billings in excess of the revenue recognized. Contract liabilities are recognized as revenue as or when we perform under the contract. We classify our contract liability as current or non-current based on the timing of when we expect to recognize revenue.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue>
    <ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory contextRef="c-1" id="f-324">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock option plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have one stock option plan (the "Stock Option Plan") available to directors, officers, employees, and consultants with grants under the Stock Option Plan approved from time to time by our Board of Directors (the "Board"). Under the Stock Option Plan, no option shall be granted with an exercise price at a discount to the closing price of our stock on the Toronto Stock Exchange &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;on the last trading date prior to the date of the grant. Vesting is provided at the discretion of the Board, and the expiration of options is to be no greater than ten years from the date of grant. Exercised stock options are settled with common shares issued from treasury. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We use the fair value-based method of accounting for stock option awards granted under the Stock Option Plan. We recognize compensation expense and a corresponding adjustment to contributed surplus equal to the fair value of the stock options granted using the Black-Scholes valuation model over the vesting periods of the respective options. Compensation expense is adjusted for subsequent changes in management&#x2019;s estimate of the number of options that are expected to vest.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock options awarded to non-employees are accounted for at the fair value of the goods received or the services rendered. The fair value is measured at the date the Company obtains the goods or the date the counterparty renders the service. If the fair value of the goods or services cannot be reliably measured, the fair value of the options granted will be used.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share award plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our share award plan (the "Share Award Plan") is available to directors, officers, employees, and consultants. Under our Share Award Plan, performance and restricted share awards may be approved from time to time by the Board. Performance share awards  ("PSAs") can be awarded to certain officers and employees to which common shares shall be issued based upon achieving the applicable performance criteria. Restricted share awards ("RSAs") can be awarded to certain officers, employees, non-employee directors, and consultants to which common shares shall be issued in accordance with the Share Award Plan.  &lt;/span&gt;&lt;/div&gt;We recognize compensation expense and a corresponding adjustment to contributed surplus equal to the market value of our common shares at the grant date based on the number of PSAs/RSAs expected to vest, recognized over the vesting period. Compensation expense is adjusted for subsequent changes in management&#x2019;s estimate of the number of PSAs/RSAs that are expected to vest. The effect of these changes is recognized in the period of the change.</ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory>
    <oncyf:NumberOfStockOptionPlans contextRef="c-3" decimals="INF" id="f-325" unitRef="plan">1</oncyf:NumberOfStockOptionPlans>
    <oncyf:MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement contextRef="c-1" id="f-326">P10Y</oncyf:MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement>
    <ifrs-full:DescriptionOfInitialApplicationOfStandardsOrInterpretations contextRef="c-1" id="f-327">&lt;div style="margin-bottom:10pt;margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Adoption of New Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;IAS 1 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Classification of Liabilities as Current or Non-Current&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2022, the IASB issued amendments to clarify how conditions with which an entity must comply within 12 months after the reporting period affect the classification of a liability. This is in addition to the amendment from January 2020 where the IASB issued amendments to IAS 1 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Presentation of Financial Statements&lt;/span&gt;, to provide a more general approach to the presentation of liabilities as current or non-current based on contractual arrangements in place at the reporting date. These amendments specify that the rights and conditions existing at the end of the reporting period are relevant in determining whether the Company has a right to defer settlement of a liability by at least 12 months, provided that management's expectations are not a relevant consideration as to whether the Company will exercise its rights to defer settlement of a liability and clarify when a liability is considered settled. The amendments became effective on January 1, 2024. Adopting the amendments did not have a material impact on our consolidated financial statements.</ifrs-full:DescriptionOfInitialApplicationOfStandardsOrInterpretations>
    <ifrs-full:DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations contextRef="c-1" id="f-328">&lt;div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accounting Standards and Interpretations Issued but Not Yet Effective&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;IFRS 18 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Presentation and Disclosure in Financial Statements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2024, the IASB issued IFRS 18 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Presentation and Disclosure in Financial Statements &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;which replaces IAS 1 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Presentation of Financial Statements. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;IFRS 18 introduces new requirements on presentation within the statement of profit or loss, including specified totals and subtotals. It also requires disclosure of management-defined performance measures and includes new requirements for aggregation and disaggregation of financial information based on the identified roles of the primary financial statements and the notes. Narrow scope amendments have been made to IAS 7 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Statement of Cash Flows&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and some requirements previously included within IAS 1 have been moved to IAS 8 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounting Policies, Changes in Accounting Estimates and Errors, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;which has also been renamed IAS 8 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Basis of Preparation of Financial Statements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. IAS 34 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Interim Financial Reporting &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;has also been amended to require disclosure of management-defined performance measures. IFRS 18 and the amendments to the other standards are effective for annual periods beginning on or after January 1, 2027, with early application permitted. IFRS 18 applies retrospectively to both annual and interim financial statements. We are assessing the impact of adopting this standard on our consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations>
    <ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory contextRef="c-1" id="f-329">Significant Judgments, Estimates, and Assumptions&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The preparation of our consolidated financial statements in conformity with IFRS requires us to make judgments, estimates, and assumptions that affect the application of accounting policies, the reported amount, and disclosures in our consolidated financial statements and accompanying notes. Management makes estimates based on our best knowledge of current events and actions that the Company may undertake in the future. We consider the potential impact of certain external factors outside of our control, including global political conflicts, supply chain disruptions, inflation, fluctuating interest rates, and liquidity, when making certain estimates and judgments relating to the preparation of these consolidated financial statements. Estimates and underlying assumptions are reviewed on an ongoing basis. Actual results could differ from these estimates, and such differences could be material. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant estimates made by management affecting our consolidated financial statements include:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue recognition&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We entered into a Licensing Agreement which provides, among other payments, upfront license fees in exchange for a regional license to our intellectual property. Management uses its judgment in applying the input method when determining the extent of progress toward completion of the performance obligation. Revenue recognition requires assumptions and estimates regarding total estimated costs, the complexity of the work to be performed, and the length of time to complete the performance obligation, among other variables.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Clinical trial and manufacturing expenses&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Clinical trial and manufacturing expenses represent significant components of our research and development expenses, and we outsource a significant portion of these activities to third-party contract research/manufacturing organizations. The financial terms of these agreements are subject to negotiation, vary from contract to contract, and may result in uneven payment flows to these organizations. Payments under the contracts depend on factors such as achieving certain milestones. As part of preparing the consolidated financial statements, we estimate the expense to recognize based on services that the contract research/manufacturing organizations have performed. When making these estimates, we use operational and contractual information from third-party service providers, operational data from internal personnel, and considerable judgment. We base our estimates on the best information available at the time. However, additional information may become available to us which may allow us to make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain. Such increases or decreases in cost are generally considered to be changes in estimates and will be reflected in research and development expenses in the period identified.   &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Valuation of share-based compensation &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Estimating the fair value of share-based compensation requires determining the most appropriate valuation model, which is dependent on the terms and conditions of the grant. This estimate also requires determining the most appropriate inputs to the valuation model, including the expected life, volatility, and dividend yield, and making assumptions about them. The assumptions and inputs used for estimating fair value of share-based compensation are disclosed in note 11. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Valuation of warrant derivative &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Estimating the fair value of the warrant derivative at initial measurement, at each exercise date and at each reporting period requires determining the most appropriate valuation model. This estimate also requires determining the most appropriate inputs to the valuation model, including the expected life, volatility, and dividend yield, and making assumptions about them. The assumptions and inputs used for estimating fair value for warrant derivative issued are disclosed in note 9.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income taxes&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Uncertainties exist with respect to the interpretation of complex tax regulations and the amount and timing of future taxable income. Currently, we are accumulating tax loss carry-forward balances in various tax jurisdictions creating a deferred tax asset. Deferred tax assets are recognized for all unused tax losses to the extent that it is probable that taxable profit will be available against which the losses can be utilized. Management's judgment is required to determine the amount of deferred tax assets that can be recognized based on the likely timing and the level of future taxable profits together with future tax planning strategies.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To date, we have determined that none of our deferred tax assets should be recognized. Our deferred tax assets are mainly comprised of our net operating losses from prior years, prior year research and development expenses, and non-refundable &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;investment tax credits. These tax pools relate to entities that have a history of losses, have varying expiry dates, and may not be used to offset taxable income within our other subsidiaries. There are also no taxable temporary differences or any tax planning opportunities available that could partly support the recognition of these losses as deferred tax assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Functional currency&lt;/span&gt;&lt;/div&gt;We assess the relevant factors related to the primary economic environment in which our entities operate to determine the functional currency. Where the assessment of primary indicators are mixed, we assess the secondary indicators, including the relationship between the foreign operations and reporting entity.</ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory>
    <ifrs-full:DisclosureOfOtherLiabilitiesExplanatory contextRef="c-1" id="f-330">Other Liabilities In 2023, we were selected by the Pancreatic Cancer Action Network (PanCAN) as the recipient of its Therapeutic Accelerator Award to conduct a clinical trial with pelareorep in combination with modified FOLFIRINOX chemotherapy with or without an immune checkpoint inhibitor in pancreatic cancer patients. Under the terms of the award agreement, we are entitled to receive up to US$5&#160;million in funding for eligible research expenses, and we must comply with the conditions set out with the award agreement, including providing periodic performance progress reports. As at December&#160;31, 2024, we recorded US$1,125 ($1,618) (December&#160;31, 2023 - US$225 ($298)) in other liabilities representing unapplied funding received from PanCAN.</ifrs-full:DisclosureOfOtherLiabilitiesExplanatory>
    <ifrs-full:OtherReceivables contextRef="c-57" decimals="-6" id="f-331" unitRef="cad">5000000</ifrs-full:OtherReceivables>
    <ifrs-full:OtherCurrentLiabilities contextRef="c-57" decimals="-3" id="f-332" unitRef="usd">1125000</ifrs-full:OtherCurrentLiabilities>
    <ifrs-full:OtherCurrentLiabilities contextRef="c-57" decimals="-3" id="f-333" unitRef="cad">1618000</ifrs-full:OtherCurrentLiabilities>
    <ifrs-full:OtherCurrentLiabilities contextRef="c-58" decimals="-3" id="f-334" unitRef="usd">225000</ifrs-full:OtherCurrentLiabilities>
    <ifrs-full:OtherCurrentLiabilities contextRef="c-58" decimals="-3" id="f-335" unitRef="cad">298000</ifrs-full:OtherCurrentLiabilities>
    <ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory contextRef="c-1" id="f-336">Property and Equipment&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:32.328%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.042%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.371%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.042%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.371%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.471%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.371%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.471%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.371%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.762%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Medical Equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Computer Equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Office Equipment and Furniture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Leasehold Improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at December 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions, net of foreign exchange impact&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at December 31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Disposals, net of foreign exchange impact&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(59)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(43)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(47)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(173)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As at December 31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at December 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at December 31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Disposals, net of foreign exchange impact&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(54)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(41)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(47)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(165)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As at December 31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net book value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at December 31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As at December 31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;119&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;250&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;41&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;411&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;For the year ended December&#160;31, 2024, we incurred losses on disposal of property and equipment of $18, which was included in depreciation expense on our consolidated statement of cash flows.</ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-59" decimals="-3" id="f-337" unitRef="cad">62000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-60" decimals="-3" id="f-338" unitRef="cad">429000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-61" decimals="-3" id="f-339" unitRef="cad">248000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-62" decimals="-3" id="f-340" unitRef="cad">231000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-63" decimals="-3" id="f-341" unitRef="cad">970000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-64" decimals="-3" id="f-342" unitRef="cad">0</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-65" decimals="-3" id="f-343" unitRef="cad">7000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-66" decimals="-3" id="f-344" unitRef="cad">0</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-67" decimals="-3" id="f-345" unitRef="cad">0</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-68" decimals="-3" id="f-346" unitRef="cad">7000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-69" decimals="-3" id="f-347" unitRef="cad">62000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-70" decimals="-3" id="f-348" unitRef="cad">436000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-71" decimals="-3" id="f-349" unitRef="cad">248000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-72" decimals="-3" id="f-350" unitRef="cad">231000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-73" decimals="-3" id="f-351" unitRef="cad">977000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-74" decimals="-3" id="f-352" unitRef="cad">0</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-75" decimals="-3" id="f-353" unitRef="cad">71000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-76" decimals="-3" id="f-354" unitRef="cad">168000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-77" decimals="-3" id="f-355" unitRef="cad">0</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-78" decimals="-3" id="f-356" unitRef="cad">239000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment contextRef="c-74" decimals="-3" id="f-357" unitRef="cad">59000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment contextRef="c-75" decimals="-3" id="f-358" unitRef="cad">43000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment contextRef="c-76" decimals="-3" id="f-359" unitRef="cad">24000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment contextRef="c-77" decimals="-3" id="f-360" unitRef="cad">47000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment contextRef="c-78" decimals="-3" id="f-361" unitRef="cad">173000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-79" decimals="-3" id="f-362" unitRef="cad">3000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-80" decimals="-3" id="f-363" unitRef="cad">464000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-81" decimals="-3" id="f-364" unitRef="cad">392000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-82" decimals="-3" id="f-365" unitRef="cad">184000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-83" decimals="-3" id="f-366" unitRef="cad">1043000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-84" decimals="-3" id="f-367" unitRef="cad">-53000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-85" decimals="-3" id="f-368" unitRef="cad">-321000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-86" decimals="-3" id="f-369" unitRef="cad">-92000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-87" decimals="-3" id="f-370" unitRef="cad">-148000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-88" decimals="-3" id="f-371" unitRef="cad">-614000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="c-89" decimals="-3" id="f-372" unitRef="cad">2000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="c-90" decimals="-3" id="f-373" unitRef="cad">30000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="c-91" decimals="-3" id="f-374" unitRef="cad">28000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="c-92" decimals="-3" id="f-375" unitRef="cad">21000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="c-93" decimals="-3" id="f-376" unitRef="cad">81000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-94" decimals="-3" id="f-377" unitRef="cad">-55000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-95" decimals="-3" id="f-378" unitRef="cad">-351000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-96" decimals="-3" id="f-379" unitRef="cad">-120000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-97" decimals="-3" id="f-380" unitRef="cad">-169000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-98" decimals="-3" id="f-381" unitRef="cad">-695000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="c-99" decimals="-3" id="f-382" unitRef="cad">1000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="c-100" decimals="-3" id="f-383" unitRef="cad">35000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="c-101" decimals="-3" id="f-384" unitRef="cad">45000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="c-102" decimals="-3" id="f-385" unitRef="cad">21000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="c-103" decimals="-3" id="f-386" unitRef="cad">102000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment contextRef="c-99" decimals="-3" id="f-387" unitRef="cad">-54000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment contextRef="c-100" decimals="-3" id="f-388" unitRef="cad">-41000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment contextRef="c-101" decimals="-3" id="f-389" unitRef="cad">-23000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment contextRef="c-102" decimals="-3" id="f-390" unitRef="cad">-47000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:DisposalsPropertyPlantAndEquipment contextRef="c-103" decimals="-3" id="f-391" unitRef="cad">-165000</ifrs-full:DisposalsPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-104" decimals="-3" id="f-392" unitRef="cad">-2000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-105" decimals="-3" id="f-393" unitRef="cad">-345000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-106" decimals="-3" id="f-394" unitRef="cad">-142000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-107" decimals="-3" id="f-395" unitRef="cad">-143000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-108" decimals="-3" id="f-396" unitRef="cad">-632000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-109" decimals="-3" id="f-397" unitRef="cad">7000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-110" decimals="-3" id="f-398" unitRef="cad">85000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-111" decimals="-3" id="f-399" unitRef="cad">128000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-112" decimals="-3" id="f-400" unitRef="cad">62000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-4" decimals="-3" id="f-401" unitRef="cad">282000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-113" decimals="-3" id="f-402" unitRef="cad">1000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-114" decimals="-3" id="f-403" unitRef="cad">119000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-115" decimals="-3" id="f-404" unitRef="cad">250000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-116" decimals="-3" id="f-405" unitRef="cad">41000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-3" decimals="-3" id="f-406" unitRef="cad">411000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:LossesOnDisposalsOfPropertyPlantAndEquipment contextRef="c-1" decimals="-3" id="f-407" unitRef="cad">18000</ifrs-full:LossesOnDisposalsOfPropertyPlantAndEquipment>
    <ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory contextRef="c-1" id="f-408">Accounts payable and accrued liabilities&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.005%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.861%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trade payables&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,087&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,082&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,705&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,792&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory>
    <oncyf:DetailedDisclosureOfTradeAndOtherPayablesExplanatoryTableTextBlock contextRef="c-1" id="f-409">&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.005%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.861%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trade payables&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,087&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,082&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,705&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,792&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</oncyf:DetailedDisclosureOfTradeAndOtherPayablesExplanatoryTableTextBlock>
    <ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers contextRef="c-3" decimals="-3" id="f-410" unitRef="cad">1087000</ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers>
    <ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers contextRef="c-4" decimals="-3" id="f-411" unitRef="cad">1082000</ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers>
    <ifrs-full:AccrualsClassifiedAsCurrent contextRef="c-3" decimals="-3" id="f-412" unitRef="cad">3705000</ifrs-full:AccrualsClassifiedAsCurrent>
    <ifrs-full:AccrualsClassifiedAsCurrent contextRef="c-4" decimals="-3" id="f-413" unitRef="cad">2490000</ifrs-full:AccrualsClassifiedAsCurrent>
    <ifrs-full:TradeAndOtherCurrentPayables contextRef="c-3" decimals="-3" id="f-414" unitRef="cad">4792000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherCurrentPayables contextRef="c-4" decimals="-3" id="f-415" unitRef="cad">3572000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:DisclosureOfLeasesExplanatory contextRef="c-1" id="f-416">Leases&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have office space leases with initial lease terms generally between 3 to 6 years. We currently do not have leases with residual value guarantees or leases not yet commenced to which we have committed. We have variable lease payments related to office space lease operating costs that are not material. Lease liabilities have been measured by discounting future lease payments using our incremental borrowing rate as rates implicit in the leases were not readily determinable. The weighted-average rate applied was 15%. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31, 2024, we recorded an addition of $794 to the right-of-use asset and $785 to the lease liabilities relating to one of our subsidiaries' office leases. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our right-of-use assets activity for the years ended December&#160;31:      &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;         &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:65.274%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.420%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.422%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;365&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;794&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(304)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(322)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange impact&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;46&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at end of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;901&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our lease liabilities activity for the years ended December&#160;31:    &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;              &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:65.274%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.420%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.422%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;423&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;785&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payment of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(348)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(407)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;139&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange impact&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;65&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at end of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,064&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our total undiscounted lease liabilities as at December&#160;31, 2024 was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:81.252%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.548%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than one year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;One to five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;More than five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total undiscounted lease liabilities &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfLeasesExplanatory>
    <oncyf:OperatingLeaseLeaseTerm contextRef="c-117" id="f-417">P3Y</oncyf:OperatingLeaseLeaseTerm>
    <oncyf:OperatingLeaseLeaseTerm contextRef="c-118" id="f-418">P6Y</oncyf:OperatingLeaseLeaseTerm>
    <ifrs-full:WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16 contextRef="c-3" decimals="2" id="f-419" unitRef="number">0.15</ifrs-full:WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16>
    <ifrs-full:AdditionsToRightofuseAssets contextRef="c-1" decimals="-3" id="f-420" unitRef="cad">794000</ifrs-full:AdditionsToRightofuseAssets>
    <ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities contextRef="c-1" decimals="-3" id="f-421" unitRef="cad">785000</ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory contextRef="c-1" id="f-422">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our right-of-use assets activity for the years ended December&#160;31:      &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;         &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:65.274%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.420%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.422%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;365&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;794&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(304)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(322)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange impact&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;46&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at end of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;901&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory>
    <ifrs-full:RightofuseAssets contextRef="c-4" decimals="-3" id="f-423" unitRef="cad">365000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets contextRef="c-25" decimals="-3" id="f-424" unitRef="cad">296000</ifrs-full:RightofuseAssets>
    <ifrs-full:AdditionsToRightofuseAssets contextRef="c-1" decimals="-3" id="f-425" unitRef="cad">794000</ifrs-full:AdditionsToRightofuseAssets>
    <ifrs-full:AdditionsToRightofuseAssets contextRef="c-7" decimals="-3" id="f-426" unitRef="cad">392000</ifrs-full:AdditionsToRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets contextRef="c-1" decimals="-3" id="f-427" unitRef="cad">304000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets contextRef="c-7" decimals="-3" id="f-428" unitRef="cad">322000</ifrs-full:DepreciationRightofuseAssets>
    <oncyf:ForeignExchangeImpactRightofUseAssets contextRef="c-1" decimals="-3" id="f-429" unitRef="cad">46000</oncyf:ForeignExchangeImpactRightofUseAssets>
    <oncyf:ForeignExchangeImpactRightofUseAssets contextRef="c-7" decimals="-3" id="f-430" unitRef="cad">-1000</oncyf:ForeignExchangeImpactRightofUseAssets>
    <ifrs-full:RightofuseAssets contextRef="c-3" decimals="-3" id="f-431" unitRef="cad">901000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets contextRef="c-4" decimals="-3" id="f-432" unitRef="cad">365000</ifrs-full:RightofuseAssets>
    <oncyf:DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTextBlock contextRef="c-1" id="f-433">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our lease liabilities activity for the years ended December&#160;31:    &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;              &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:65.274%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.420%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.422%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;423&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;785&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payment of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(348)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(407)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;139&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange impact&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;65&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at end of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,064&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</oncyf:DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTextBlock>
    <ifrs-full:LeaseLiabilities contextRef="c-4" decimals="-3" id="f-434" unitRef="cad">423000</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities contextRef="c-25" decimals="-3" id="f-435" unitRef="cad">373000</ifrs-full:LeaseLiabilities>
    <ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities contextRef="c-1" decimals="-3" id="f-436" unitRef="cad">785000</ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities contextRef="c-7" decimals="-3" id="f-437" unitRef="cad">392000</ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:CashOutflowForLeases contextRef="c-1" decimals="-3" id="f-438" unitRef="cad">348000</ifrs-full:CashOutflowForLeases>
    <ifrs-full:CashOutflowForLeases contextRef="c-7" decimals="-3" id="f-439" unitRef="cad">407000</ifrs-full:CashOutflowForLeases>
    <ifrs-full:InterestExpenseOnLeaseLiabilities contextRef="c-1" decimals="-3" id="f-440" unitRef="cad">139000</ifrs-full:InterestExpenseOnLeaseLiabilities>
    <ifrs-full:InterestExpenseOnLeaseLiabilities contextRef="c-7" decimals="-3" id="f-441" unitRef="cad">71000</ifrs-full:InterestExpenseOnLeaseLiabilities>
    <oncyf:GainsLossesFromForeignExchangeImpact contextRef="c-1" decimals="-3" id="f-442" unitRef="cad">65000</oncyf:GainsLossesFromForeignExchangeImpact>
    <oncyf:GainsLossesFromForeignExchangeImpact contextRef="c-7" decimals="-3" id="f-443" unitRef="cad">-6000</oncyf:GainsLossesFromForeignExchangeImpact>
    <ifrs-full:LeaseLiabilities contextRef="c-3" decimals="-3" id="f-444" unitRef="cad">1064000</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities contextRef="c-4" decimals="-3" id="f-445" unitRef="cad">423000</ifrs-full:LeaseLiabilities>
    <ifrs-full:DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory contextRef="c-1" id="f-446">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our total undiscounted lease liabilities as at December&#160;31, 2024 was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:81.252%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.548%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than one year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;One to five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;More than five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total undiscounted lease liabilities &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory>
    <ifrs-full:GrossLeaseLiabilities contextRef="c-119" decimals="-3" id="f-447" unitRef="cad">418000</ifrs-full:GrossLeaseLiabilities>
    <ifrs-full:GrossLeaseLiabilities contextRef="c-120" decimals="-3" id="f-448" unitRef="cad">995000</ifrs-full:GrossLeaseLiabilities>
    <ifrs-full:GrossLeaseLiabilities contextRef="c-121" decimals="-3" id="f-449" unitRef="cad">0</ifrs-full:GrossLeaseLiabilities>
    <ifrs-full:GrossLeaseLiabilities contextRef="c-3" decimals="-3" id="f-450" unitRef="cad">1413000</ifrs-full:GrossLeaseLiabilities>
    <ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory contextRef="c-1" id="f-451">Warrant Derivative&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our common share purchase warrants ("warrants") with a U.S. dollar exercise price, which differs from our functional currency, are treated as a derivative measured at fair value, and revalued each period end at fair value through profit and loss. There is no cash flow impact as a result of the accounting treatment for changes in the fair value of the warrant derivative or when warrants expire unexercised. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in the value of our warrant derivative were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.098%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.080%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.387%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.935%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of Warrants Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value of Warrant Derivative&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at December 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to public offering&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,667,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount on warrants issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,822)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of discount on warrants issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,431)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange impact&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(132)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at December 31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,731,085&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52,456)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,579)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of discount on warrants issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,605)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange impact&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As at December 31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7,667,050&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(980)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our outstanding warrant derivative as at December&#160;31, 2024:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:28.724%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.291%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.291%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.542%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Exercise price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Issuance date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Expiry date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of Warrants Outstanding&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US$2.81&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;August 8, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;August 8, 2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,667,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US$2.81&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 7, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;August 8, 2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,667,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 8, 2023, pursuant to an underwritten public offering, we issued 6,667,000 units for gross proceeds of $20,185 (US$15,001) at a price of US$2.25 per unit. On September 7, 2023, pursuant to the over-allotment option exercised by the underwriter, we issued an additional 1,000,050 units for gross proceeds of $3,077 (US$2,250) at a price of US$2.25 per unit. Each unit consisted of one common share and one warrant, which were immediately separable and issued separately in this offering. Each warrant entitles the holder to purchase one common share at an exercise price of US$2.81 up to 60 months from the date of issuance. The expiry of the warrants may be accelerated by the Company at any time prior to the expiry date if the volume weighted average price (if applicable, as converted to U.S. dollars at the Bank of Canada posted rate for the respective trading day) of the issued and outstanding common shares on the Toronto Stock Exchange or such other principal stock exchange on which the common shares are listed and posted for trading is greater than US$6.50 for any 20 consecutive trading days, at which time the Company may, within 10 business days, accelerate the expiry date by issuing a press release announcing the reduced warrant term whereupon the warrants will expire on or after the 75th calendar day after the date of such press release.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Proceeds were allocated amongst common shares and warrants by applying a relative fair value approach, which resulted in $17,724 recorded in share capital and an initial warrant derivative liability of $7,360. The difference between the fair value of the warrants and their allocated proceeds was a discount of $1,822, which is amortized on a straight-line basis over the five-year &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;expected life of the warrants and recorded under change in fair value of warrant derivative on our consolidated statement of loss and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2024, as the unamortized discount balance was greater than the fair value of the warrant derivative liability, the net balance was presented as an asset on our consolidated statement of financial position. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We use the Black-Scholes valuation model to estimate fair value. The expected volatility is based on the Company's common share historical volatility less an estimated market participant risk adjustment. The risk-free interest rate is based on the Government of Canada benchmark bond yield rates with an approximate equivalent remaining term in effect at the time of valuation, and the expected life represents the estimated length of time the warrants are expected to remain outstanding. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of the warrant derivative with an exercise price of US$2.81 was determined using the following assumptions: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.104%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.005%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.007%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Underlying share price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;US$0.92&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US$1.35&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2.9%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.6 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.6 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;36.5%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36.5%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nil&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nil&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value per warrant&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;US$0.03&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US$0.18&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory>
    <ifrs-full:DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory contextRef="c-1" id="f-452">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in the value of our warrant derivative were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.098%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.080%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.387%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.935%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of Warrants Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value of Warrant Derivative&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at December 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to public offering&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,667,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount on warrants issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,822)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of discount on warrants issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,431)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange impact&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(132)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at December 31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,731,085&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52,456)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,579)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of discount on warrants issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,605)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange impact&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As at December 31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7,667,050&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(980)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our outstanding warrant derivative as at December&#160;31, 2024:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:28.724%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.291%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.291%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.542%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Exercise price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Issuance date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Expiry date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of Warrants Outstanding&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US$2.81&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;August 8, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;August 8, 2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,667,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US$2.81&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 7, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;August 8, 2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,667,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of the warrant derivative with an exercise price of US$2.81 was determined using the following assumptions: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.104%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.005%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.007%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Underlying share price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;US$0.92&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US$1.35&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2.9%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.6 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.6 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;36.5%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36.5%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nil&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nil&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value per warrant&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;US$0.03&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US$0.18&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory>
    <oncyf:NumberOfWarrantsOutstanding
      contextRef="c-25"
      decimals="INF"
      id="f-453"
      unitRef="shares">64035</oncyf:NumberOfWarrantsOutstanding>
    <ifrs-full:DerivativeFinancialLiabilities contextRef="c-25" decimals="-3" id="f-454" unitRef="cad">79000</ifrs-full:DerivativeFinancialLiabilities>
    <oncyf:IssueOfEquityShares
      contextRef="c-122"
      decimals="INF"
      id="f-455"
      unitRef="shares">7667050</oncyf:IssueOfEquityShares>
    <ifrs-full:IssueOfEquity contextRef="c-122" decimals="-3" id="f-456" unitRef="cad">7360000</ifrs-full:IssueOfEquity>
    <oncyf:WarrantLiabilityUnamortizedDiscount contextRef="c-122" decimals="-3" id="f-457" unitRef="cad">1822000</oncyf:WarrantLiabilityUnamortizedDiscount>
    <oncyf:WarrantLiabilityAmortizedDiscount contextRef="c-122" decimals="-3" id="f-458" unitRef="cad">146000</oncyf:WarrantLiabilityAmortizedDiscount>
    <ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives contextRef="c-122" decimals="-3" id="f-459" unitRef="cad">-5431000</ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives>
    <oncyf:GainsLossesFromForeignExchangeImpact contextRef="c-122" decimals="-3" id="f-460" unitRef="cad">-132000</oncyf:GainsLossesFromForeignExchangeImpact>
    <oncyf:NumberOfWarrantsOutstanding contextRef="c-4" decimals="INF" id="f-461" unitRef="shares">7731085</oncyf:NumberOfWarrantsOutstanding>
    <ifrs-full:DerivativeFinancialLiabilities contextRef="c-4" decimals="-3" id="f-462" unitRef="cad">200000</ifrs-full:DerivativeFinancialLiabilities>
    <oncyf:NumberOfWarrantsExercised contextRef="c-123" decimals="0" id="f-463" unitRef="shares">52456</oncyf:NumberOfWarrantsExercised>
    <oncyf:FairValueOfWarrantDerivativeExercised contextRef="c-123" decimals="-3" id="f-464" unitRef="cad">6000</oncyf:FairValueOfWarrantDerivativeExercised>
    <oncyf:NumberOfWarrantsExpired
      contextRef="c-123"
      decimals="INF"
      id="f-465"
      unitRef="shares">11579</oncyf:NumberOfWarrantsExpired>
    <oncyf:FairValueOfWarrantDerivativeExpired contextRef="c-123" decimals="-3" id="f-466" unitRef="cad">1000</oncyf:FairValueOfWarrantDerivativeExpired>
    <oncyf:WarrantLiabilityAmortizedDiscount contextRef="c-123" decimals="-3" id="f-467" unitRef="cad">365000</oncyf:WarrantLiabilityAmortizedDiscount>
    <ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives contextRef="c-123" decimals="-3" id="f-468" unitRef="cad">-1605000</ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives>
    <oncyf:GainsLossesFromForeignExchangeImpact contextRef="c-123" decimals="-3" id="f-469" unitRef="cad">67000</oncyf:GainsLossesFromForeignExchangeImpact>
    <oncyf:NumberOfWarrantsOutstanding contextRef="c-3" decimals="INF" id="f-470" unitRef="shares">7667050</oncyf:NumberOfWarrantsOutstanding>
    <ifrs-full:DerivativeFinancialLiabilities contextRef="c-3" decimals="-3" id="f-471" unitRef="cad">-980000</ifrs-full:DerivativeFinancialLiabilities>
    <oncyf:WarrantExercisePrice
      contextRef="c-124"
      decimals="2"
      id="f-472"
      unitRef="usdPerShare">2.81</oncyf:WarrantExercisePrice>
    <oncyf:NumberOfWarrantsOutstanding
      contextRef="c-124"
      decimals="INF"
      id="f-473"
      unitRef="shares">6667000</oncyf:NumberOfWarrantsOutstanding>
    <oncyf:WarrantExercisePrice
      contextRef="c-125"
      decimals="2"
      id="f-474"
      unitRef="usdPerShare">2.81</oncyf:WarrantExercisePrice>
    <oncyf:NumberOfWarrantsOutstanding
      contextRef="c-125"
      decimals="INF"
      id="f-475"
      unitRef="shares">1000050</oncyf:NumberOfWarrantsOutstanding>
    <oncyf:NumberOfWarrantsOutstanding contextRef="c-3" decimals="INF" id="f-476" unitRef="shares">7667050</oncyf:NumberOfWarrantsOutstanding>
    <oncyf:NumberOfWarrantsAndSharesOutstanding
      contextRef="c-124"
      decimals="INF"
      id="f-477"
      unitRef="shares">6667000</oncyf:NumberOfWarrantsAndSharesOutstanding>
    <oncyf:ProceedsFromIssueOfOrdinarySharesGross contextRef="c-126" decimals="-3" id="f-478" unitRef="cad">20185000</oncyf:ProceedsFromIssueOfOrdinarySharesGross>
    <oncyf:ProceedsFromIssueOfOrdinarySharesGross contextRef="c-126" decimals="-3" id="f-479" unitRef="usd">15001000</oncyf:ProceedsFromIssueOfOrdinarySharesGross>
    <oncyf:SharesIssuedPricePerShare1
      contextRef="c-127"
      decimals="2"
      id="f-480"
      unitRef="usdPerShare">2.25</oncyf:SharesIssuedPricePerShare1>
    <oncyf:NumberOfWarrantsAndSharesOutstanding
      contextRef="c-125"
      decimals="INF"
      id="f-481"
      unitRef="shares">1000050</oncyf:NumberOfWarrantsAndSharesOutstanding>
    <oncyf:ProceedsFromIssueOfOrdinarySharesGross contextRef="c-128" decimals="-3" id="f-482" unitRef="cad">3077000</oncyf:ProceedsFromIssueOfOrdinarySharesGross>
    <oncyf:ProceedsFromIssueOfOrdinarySharesGross contextRef="c-128" decimals="-3" id="f-483" unitRef="usd">2250000</oncyf:ProceedsFromIssueOfOrdinarySharesGross>
    <oncyf:SharesIssuedPricePerShare1
      contextRef="c-129"
      decimals="2"
      id="f-484"
      unitRef="usdPerShare">2.25</oncyf:SharesIssuedPricePerShare1>
    <oncyf:CommonSharesPerUnit
      contextRef="c-130"
      decimals="INF"
      id="f-485"
      unitRef="shares">1</oncyf:CommonSharesPerUnit>
    <oncyf:CommonSharesPerUnit
      contextRef="c-131"
      decimals="INF"
      id="f-486"
      unitRef="shares">1</oncyf:CommonSharesPerUnit>
    <oncyf:CommonSharesPerUnit
      contextRef="c-132"
      decimals="INF"
      id="f-487"
      unitRef="shares">1</oncyf:CommonSharesPerUnit>
    <oncyf:CommonSharesPerUnit
      contextRef="c-133"
      decimals="INF"
      id="f-488"
      unitRef="shares">1</oncyf:CommonSharesPerUnit>
    <oncyf:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight1
      contextRef="c-134"
      decimals="INF"
      id="f-489"
      unitRef="shares">1</oncyf:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight1>
    <oncyf:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight1
      contextRef="c-135"
      decimals="INF"
      id="f-490"
      unitRef="shares">1</oncyf:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight1>
    <oncyf:WarrantExercisePrice
      contextRef="c-136"
      decimals="2"
      id="f-491"
      unitRef="usdPerShare">2.81</oncyf:WarrantExercisePrice>
    <oncyf:WarrantExercisePrice
      contextRef="c-137"
      decimals="2"
      id="f-492"
      unitRef="usdPerShare">2.81</oncyf:WarrantExercisePrice>
    <oncyf:ExpirationPeriodOfOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement contextRef="c-126" id="f-493">P60M</oncyf:ExpirationPeriodOfOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement>
    <oncyf:ExpirationPeriodOfOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement contextRef="c-128" id="f-494">P60M</oncyf:ExpirationPeriodOfOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement>
    <oncyf:OtherEquityInstrumentsInShareBasedPaymentArrangementThresholdTradingPrice
      contextRef="c-124"
      decimals="2"
      id="f-495"
      unitRef="usdPerShare">6.50</oncyf:OtherEquityInstrumentsInShareBasedPaymentArrangementThresholdTradingPrice>
    <oncyf:OtherEquityInstrumentsInShareBasedPaymentArrangementThresholdTradingPrice
      contextRef="c-125"
      decimals="2"
      id="f-496"
      unitRef="usdPerShare">6.50</oncyf:OtherEquityInstrumentsInShareBasedPaymentArrangementThresholdTradingPrice>
    <oncyf:OtherEquityInstrumentsInShareBasedPaymentArrangementThresholdConsecutiveTradingDays contextRef="c-126" decimals="INF" id="f-497" unitRef="d">20</oncyf:OtherEquityInstrumentsInShareBasedPaymentArrangementThresholdConsecutiveTradingDays>
    <oncyf:OtherEquityInstrumentsInShareBasedPaymentArrangementThresholdConsecutiveTradingDays contextRef="c-128" decimals="INF" id="f-498" unitRef="d">20</oncyf:OtherEquityInstrumentsInShareBasedPaymentArrangementThresholdConsecutiveTradingDays>
    <oncyf:OtherEquityInstrumentsInShareBasedPaymentArrangementAcceleratedThresholdTradingDays contextRef="c-126" decimals="INF" id="f-499" unitRef="d">10</oncyf:OtherEquityInstrumentsInShareBasedPaymentArrangementAcceleratedThresholdTradingDays>
    <oncyf:OtherEquityInstrumentsInShareBasedPaymentArrangementAcceleratedThresholdTradingDays contextRef="c-128" decimals="INF" id="f-500" unitRef="d">10</oncyf:OtherEquityInstrumentsInShareBasedPaymentArrangementAcceleratedThresholdTradingDays>
    <oncyf:OtherEquityInstrumentsInShareBasedPaymentArrangementExpirationDays contextRef="c-126" decimals="INF" id="f-501" unitRef="d">75</oncyf:OtherEquityInstrumentsInShareBasedPaymentArrangementExpirationDays>
    <oncyf:OtherEquityInstrumentsInShareBasedPaymentArrangementExpirationDays contextRef="c-128" decimals="INF" id="f-502" unitRef="d">75</oncyf:OtherEquityInstrumentsInShareBasedPaymentArrangementExpirationDays>
    <ifrs-full:IssueOfEquity contextRef="c-126" decimals="-3" id="f-503" unitRef="cad">17724000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity contextRef="c-128" decimals="-3" id="f-504" unitRef="cad">17724000</ifrs-full:IssueOfEquity>
    <ifrs-full:WarrantLiability contextRef="c-124" decimals="-3" id="f-505" unitRef="cad">7360000</ifrs-full:WarrantLiability>
    <ifrs-full:WarrantLiability contextRef="c-125" decimals="-3" id="f-506" unitRef="cad">7360000</ifrs-full:WarrantLiability>
    <oncyf:WarrantLiabilityUnamortizedDiscount contextRef="c-7" decimals="-3" id="f-507" unitRef="cad">1822000</oncyf:WarrantLiabilityUnamortizedDiscount>
    <oncyf:WarrantsTerm contextRef="c-7" id="f-508">P5Y</oncyf:WarrantsTerm>
    <oncyf:WarrantExercisePrice
      contextRef="c-136"
      decimals="2"
      id="f-509"
      unitRef="usdPerShare">2.81</oncyf:WarrantExercisePrice>
    <oncyf:WarrantExercisePrice
      contextRef="c-137"
      decimals="2"
      id="f-510"
      unitRef="usdPerShare">2.81</oncyf:WarrantExercisePrice>
    <oncyf:WeightedAverageSharePriceOtherEquityInstrumentsGranted
      contextRef="c-123"
      decimals="2"
      id="f-511"
      unitRef="usdPerShare">0.92</oncyf:WeightedAverageSharePriceOtherEquityInstrumentsGranted>
    <oncyf:WeightedAverageSharePriceOtherEquityInstrumentsGranted
      contextRef="c-122"
      decimals="2"
      id="f-512"
      unitRef="usdPerShare">1.35</oncyf:WeightedAverageSharePriceOtherEquityInstrumentsGranted>
    <oncyf:RiskFreeInterestRateOtherEquityInstrumentsGranted contextRef="c-123" decimals="3" id="f-513" unitRef="number">0.029</oncyf:RiskFreeInterestRateOtherEquityInstrumentsGranted>
    <oncyf:RiskFreeInterestRateOtherEquityInstrumentsGranted contextRef="c-122" decimals="3" id="f-514" unitRef="number">0.032</oncyf:RiskFreeInterestRateOtherEquityInstrumentsGranted>
    <oncyf:OtherEquityInstrumentsLifeOtherEquityInstrumentsGranted contextRef="c-123" decimals="1" id="f-515" unitRef="year">3.6</oncyf:OtherEquityInstrumentsLifeOtherEquityInstrumentsGranted>
    <oncyf:OtherEquityInstrumentsLifeOtherEquityInstrumentsGranted contextRef="c-122" decimals="1" id="f-516" unitRef="year">4.6</oncyf:OtherEquityInstrumentsLifeOtherEquityInstrumentsGranted>
    <oncyf:ExpectedVolatilityOtherEquityInstrumentsGranted contextRef="c-123" decimals="3" id="f-517" unitRef="number">0.365</oncyf:ExpectedVolatilityOtherEquityInstrumentsGranted>
    <oncyf:ExpectedVolatilityOtherEquityInstrumentsGranted contextRef="c-122" decimals="3" id="f-518" unitRef="number">0.365</oncyf:ExpectedVolatilityOtherEquityInstrumentsGranted>
    <oncyf:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted
      contextRef="c-123"
      decimals="INF"
      id="f-519"
      unitRef="number">0</oncyf:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted>
    <oncyf:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted
      contextRef="c-122"
      decimals="INF"
      id="f-520"
      unitRef="number">0</oncyf:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted>
    <oncyf:WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted
      contextRef="c-123"
      decimals="2"
      id="f-521"
      unitRef="usdPerShare">0.03</oncyf:WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted>
    <oncyf:WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted
      contextRef="c-122"
      decimals="2"
      id="f-522"
      unitRef="usdPerShare">0.18</oncyf:WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted>
    <ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory contextRef="c-1" id="f-523">Share Capital&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Authorized:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unlimited number of no par value common shares&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.104%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.005%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.007%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at December 31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,043,789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;391,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to stock option plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to incentive share award plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to "At the Market" (ATM) equity distribution agreement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,235,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share issue costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(764)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at December 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,327,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;404,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to stock option plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;450,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to "At the Market" (ATM) equity distribution agreement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,978,605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to public offering&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,667,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share issue costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,805)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at December 31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,423,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;430,906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to incentive share award plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to "At the Market" (ATM) equity distribution agreement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(b)(d)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,410,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to warrant derivative exercised&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(e)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share issue costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(751)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As at December 31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;80,020,131&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;438,193&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt"&gt;On March 5, 2021, we entered into an ATM equity distribution agreement with Canaccord Genuity Inc. The ATM allowed us to issue common shares, at prevailing market prices, with an aggregate offering value of up to US$80,000 over a 16-month period through the facilities of the Nasdaq Capital Market in the United States. This sales agreement was terminated on June 16, 2022. During the year ended December&#160;31, 2022, we sold 2,719,770 common shares for gross proceeds of &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$5,744 (US$4,560) at an average price of $2.11 (US$1.68). We received proceeds of $5,572 (US$4,423) after commissions of $172 (US$137). In total, we incurred share issue costs (including commissions) of $209. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;On June 17, 2022, we entered into an ATM equity distribution agreement with Canaccord Genuity Inc. The ATM allowed us to issue common shares, at prevailing market prices, with an aggregate offering value of up to US$65,000 over a 25-month period through the facilities of the Nasdaq Capital Market in the United States. This sales agreement was terminated on July 17, 2024. During the year ended December&#160;31, 2024, we sold 2,560,933 (2023 - 4,978,605; 2022 - 3,515,462) common shares for gross proceeds of $4,016 (US$2,964) (2023 - $10,676 (US$7,904); 2022 - $7,594 (US$5,632)) at an average price of $1.57 (US$1.16) (2023 - $2.14 (US$1.59); 2022 - $2.16 (US$1.60)). We received proceeds of $3,895 (US$2,875) (2023 - $10,356 (US$7,667); 2022 - $7,366 (US$5,463)) after commissions of $121 (US$89) (2023 - $320 (US$237); 2022 - $228 (US$169)). In total, we incurred share issue costs (including commissions) of $187 (2023 - $415; 2022 - $555).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt"&gt;On August 8, 2023, pursuant to an underwritten public offering, we issued 6,667,000 units for gross proceeds of $20,185 (US$15,001) at a price of US$2.25 per unit. On September 7, 2023, pursuant to the over-allotment option exercised by the underwriter, we issued an additional 1,000,050 units for gross proceeds of $3,077 (US$2,250) at a price of US$2.25 per unit. Each unit consisted of one common share and one warrant, which were immediately separable and issued separately in this offering. These warrants were classified as a financial liability (see note 9). Proceeds were allocated amongst common shares and warrants by applying a relative fair value approach, which resulted in $17,724 recorded in share capital and an initial warrant derivative liability of $7,360. In consideration of the services rendered by the underwriter, we issued 536,693 compensation warrants (see note 11). In total, we incurred transaction costs of $3,130 (including a fair value of $638 (US$473) for the compensation warrants), of which $2,390 were allocated to share issue costs and $740 were allocated to operating expenses, based on the relative fair values of the common share and warrant of each unit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(d)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;On August 2, 2024, we entered into an ATM equity distribution agreement with Cantor Fitzgerald &amp;amp; Co. The ATM allows us to issue common shares, at prevailing market prices, with an aggregate offering value of up to US$50,000 over a 25-month period through the facilities of the Nasdaq Capital Market in the United States. During the year ended December&#160;31, 2024, we sold 2,849,210 common shares for gross proceeds of $3,654 (US$2,562) at an average price of $1.28 (US$0.90). We received proceeds of $3,544 (US$2,485) after commissions of $110 (US$77). In total, we incurred share issue costs (including commissions) of $564. &lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(e)&lt;/span&gt;On August 16, 2019, pursuant to an underwritten public offering, we issued units consisting of common shares and warrants. During the year ended December&#160;31, 2024, 52,456 warrants with a fair value of $6 were exercised for gross proceeds of $65 (US$47). During the years ended December&#160;31, 2023 and 2022, no warrants were exercised.</ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory>
    <ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory contextRef="c-1" id="f-524">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unlimited number of no par value common shares&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.104%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.005%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.007%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at December 31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,043,789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;391,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to stock option plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to incentive share award plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to "At the Market" (ATM) equity distribution agreement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,235,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share issue costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(764)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at December 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,327,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;404,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to stock option plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;450,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to "At the Market" (ATM) equity distribution agreement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,978,605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to public offering&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,667,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share issue costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,805)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at December 31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,423,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;430,906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to incentive share award plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to "At the Market" (ATM) equity distribution agreement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(b)(d)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,410,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to warrant derivative exercised&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(e)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share issue costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(751)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As at December 31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;80,020,131&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;438,193&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt"&gt;On March 5, 2021, we entered into an ATM equity distribution agreement with Canaccord Genuity Inc. The ATM allowed us to issue common shares, at prevailing market prices, with an aggregate offering value of up to US$80,000 over a 16-month period through the facilities of the Nasdaq Capital Market in the United States. This sales agreement was terminated on June 16, 2022. During the year ended December&#160;31, 2022, we sold 2,719,770 common shares for gross proceeds of &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$5,744 (US$4,560) at an average price of $2.11 (US$1.68). We received proceeds of $5,572 (US$4,423) after commissions of $172 (US$137). In total, we incurred share issue costs (including commissions) of $209. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;On June 17, 2022, we entered into an ATM equity distribution agreement with Canaccord Genuity Inc. The ATM allowed us to issue common shares, at prevailing market prices, with an aggregate offering value of up to US$65,000 over a 25-month period through the facilities of the Nasdaq Capital Market in the United States. This sales agreement was terminated on July 17, 2024. During the year ended December&#160;31, 2024, we sold 2,560,933 (2023 - 4,978,605; 2022 - 3,515,462) common shares for gross proceeds of $4,016 (US$2,964) (2023 - $10,676 (US$7,904); 2022 - $7,594 (US$5,632)) at an average price of $1.57 (US$1.16) (2023 - $2.14 (US$1.59); 2022 - $2.16 (US$1.60)). We received proceeds of $3,895 (US$2,875) (2023 - $10,356 (US$7,667); 2022 - $7,366 (US$5,463)) after commissions of $121 (US$89) (2023 - $320 (US$237); 2022 - $228 (US$169)). In total, we incurred share issue costs (including commissions) of $187 (2023 - $415; 2022 - $555).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt"&gt;On August 8, 2023, pursuant to an underwritten public offering, we issued 6,667,000 units for gross proceeds of $20,185 (US$15,001) at a price of US$2.25 per unit. On September 7, 2023, pursuant to the over-allotment option exercised by the underwriter, we issued an additional 1,000,050 units for gross proceeds of $3,077 (US$2,250) at a price of US$2.25 per unit. Each unit consisted of one common share and one warrant, which were immediately separable and issued separately in this offering. These warrants were classified as a financial liability (see note 9). Proceeds were allocated amongst common shares and warrants by applying a relative fair value approach, which resulted in $17,724 recorded in share capital and an initial warrant derivative liability of $7,360. In consideration of the services rendered by the underwriter, we issued 536,693 compensation warrants (see note 11). In total, we incurred transaction costs of $3,130 (including a fair value of $638 (US$473) for the compensation warrants), of which $2,390 were allocated to share issue costs and $740 were allocated to operating expenses, based on the relative fair values of the common share and warrant of each unit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(d)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;On August 2, 2024, we entered into an ATM equity distribution agreement with Cantor Fitzgerald &amp;amp; Co. The ATM allows us to issue common shares, at prevailing market prices, with an aggregate offering value of up to US$50,000 over a 25-month period through the facilities of the Nasdaq Capital Market in the United States. During the year ended December&#160;31, 2024, we sold 2,849,210 common shares for gross proceeds of $3,654 (US$2,562) at an average price of $1.28 (US$0.90). We received proceeds of $3,544 (US$2,485) after commissions of $110 (US$77). In total, we incurred share issue costs (including commissions) of $564. &lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(e)&lt;/span&gt;On August 16, 2019, pursuant to an underwritten public offering, we issued units consisting of common shares and warrants. During the year ended December&#160;31, 2024, 52,456 warrants with a fair value of $6 were exercised for gross proceeds of $65 (US$47). During the years ended December&#160;31, 2023 and 2022, no warrants were exercised.</ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory>
    <ifrs-full:NumberOfSharesIssued contextRef="c-9" decimals="INF" id="f-525" unitRef="shares">55043789</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:Equity contextRef="c-9" decimals="-3" id="f-526" unitRef="cad">391348000</ifrs-full:Equity>
    <oncyf:IssueOfEquityShares
      contextRef="c-138"
      decimals="INF"
      id="f-527"
      unitRef="shares">8333</oncyf:IssueOfEquityShares>
    <ifrs-full:IssueOfEquity contextRef="c-138" decimals="-3" id="f-528" unitRef="cad">20000</ifrs-full:IssueOfEquity>
    <oncyf:IssueOfEquityShares
      contextRef="c-139"
      decimals="INF"
      id="f-529"
      unitRef="shares">40560</oncyf:IssueOfEquityShares>
    <ifrs-full:IssueOfEquity contextRef="c-139" decimals="-3" id="f-530" unitRef="cad">98000</ifrs-full:IssueOfEquity>
    <oncyf:IssueOfEquityShares
      contextRef="c-140"
      decimals="INF"
      id="f-531"
      unitRef="shares">6235232</oncyf:IssueOfEquityShares>
    <ifrs-full:IssueOfEquity contextRef="c-140" decimals="-3" id="f-532" unitRef="cad">13338000</ifrs-full:IssueOfEquity>
    <ifrs-full:ShareIssueRelatedCost contextRef="c-17" decimals="-3" id="f-533" unitRef="cad">764000</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:NumberOfSharesIssued
      contextRef="c-20"
      decimals="INF"
      id="f-534"
      unitRef="shares">61327914</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:Equity contextRef="c-20" decimals="-3" id="f-535" unitRef="cad">404040000</ifrs-full:Equity>
    <oncyf:IssueOfEquityShares
      contextRef="c-141"
      decimals="INF"
      id="f-536"
      unitRef="shares">450391</oncyf:IssueOfEquityShares>
    <ifrs-full:IssueOfEquity contextRef="c-141" decimals="-3" id="f-537" unitRef="cad">1271000</ifrs-full:IssueOfEquity>
    <oncyf:IssueOfEquityShares
      contextRef="c-30"
      decimals="INF"
      id="f-538"
      unitRef="shares">4978605</oncyf:IssueOfEquityShares>
    <ifrs-full:IssueOfEquity contextRef="c-30" decimals="-3" id="f-539" unitRef="cad">10676000</ifrs-full:IssueOfEquity>
    <oncyf:IssueOfEquityShares
      contextRef="c-142"
      decimals="INF"
      id="f-540"
      unitRef="shares">7667050</oncyf:IssueOfEquityShares>
    <ifrs-full:IssueOfEquity contextRef="c-142" decimals="-3" id="f-541" unitRef="cad">17724000</ifrs-full:IssueOfEquity>
    <ifrs-full:ShareIssueRelatedCost contextRef="c-28" decimals="-3" id="f-542" unitRef="cad">2805000</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:NumberOfSharesIssued contextRef="c-6" decimals="INF" id="f-543" unitRef="shares">74423960</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:Equity contextRef="c-6" decimals="-3" id="f-544" unitRef="cad">430906000</ifrs-full:Equity>
    <oncyf:IssueOfEquityShares
      contextRef="c-143"
      decimals="INF"
      id="f-545"
      unitRef="shares">133572</oncyf:IssueOfEquityShares>
    <ifrs-full:IssueOfEquity contextRef="c-143" decimals="-3" id="f-546" unitRef="cad">297000</ifrs-full:IssueOfEquity>
    <oncyf:IssueOfEquityShares
      contextRef="c-43"
      decimals="INF"
      id="f-547"
      unitRef="shares">5410143</oncyf:IssueOfEquityShares>
    <ifrs-full:IssueOfEquity contextRef="c-43" decimals="-3" id="f-548" unitRef="cad">7670000</ifrs-full:IssueOfEquity>
    <oncyf:IssueOfEquityShares
      contextRef="c-144"
      decimals="INF"
      id="f-549"
      unitRef="shares">52456</oncyf:IssueOfEquityShares>
    <ifrs-full:IssueOfEquity contextRef="c-144" decimals="-3" id="f-550" unitRef="cad">71000</ifrs-full:IssueOfEquity>
    <ifrs-full:ShareIssueRelatedCost contextRef="c-41" decimals="-3" id="f-551" unitRef="cad">751000</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:NumberOfSharesIssued contextRef="c-5" decimals="INF" id="f-552" unitRef="shares">80020131</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:Equity contextRef="c-5" decimals="-3" id="f-553" unitRef="cad">438193000</ifrs-full:Equity>
    <oncyf:SharePurchaseAgreementAmount contextRef="c-145" decimals="-3" id="f-554" unitRef="usd">80000000</oncyf:SharePurchaseAgreementAmount>
    <oncyf:SharePurchaseAgreementTerm contextRef="c-146" id="f-555">P16M</oncyf:SharePurchaseAgreementTerm>
    <oncyf:IssueOfEquityShares
      contextRef="c-147"
      decimals="INF"
      id="f-556"
      unitRef="shares">2719770</oncyf:IssueOfEquityShares>
    <oncyf:ProceedsFromIssueOfOrdinarySharesGross contextRef="c-147" decimals="-3" id="f-557" unitRef="cad">5744000</oncyf:ProceedsFromIssueOfOrdinarySharesGross>
    <oncyf:ProceedsFromIssueOfOrdinarySharesGross contextRef="c-147" decimals="-3" id="f-558" unitRef="usd">4560000</oncyf:ProceedsFromIssueOfOrdinarySharesGross>
    <oncyf:SharesIssuedPricePerShare1
      contextRef="c-148"
      decimals="2"
      id="f-559"
      unitRef="cadPerShare">2.11</oncyf:SharesIssuedPricePerShare1>
    <oncyf:SharesIssuedPricePerShare1
      contextRef="c-148"
      decimals="2"
      id="f-560"
      unitRef="usdPerShare">1.68</oncyf:SharesIssuedPricePerShare1>
    <ifrs-full:ProceedsFromIssueOfOrdinaryShares contextRef="c-147" decimals="-3" id="f-561" unitRef="cad">5572000</ifrs-full:ProceedsFromIssueOfOrdinaryShares>
    <ifrs-full:ProceedsFromIssueOfOrdinaryShares contextRef="c-147" decimals="-3" id="f-562" unitRef="usd">4423000</ifrs-full:ProceedsFromIssueOfOrdinaryShares>
    <oncyf:ShareIssueRelatedCostCommissions contextRef="c-147" decimals="-3" id="f-563" unitRef="cad">172000</oncyf:ShareIssueRelatedCostCommissions>
    <oncyf:ShareIssueRelatedCostCommissions contextRef="c-147" decimals="-3" id="f-564" unitRef="usd">137000</oncyf:ShareIssueRelatedCostCommissions>
    <ifrs-full:ShareIssueRelatedCost contextRef="c-147" decimals="-3" id="f-565" unitRef="cad">209000</ifrs-full:ShareIssueRelatedCost>
    <oncyf:SharePurchaseAgreementAmount contextRef="c-149" decimals="-3" id="f-566" unitRef="usd">65000000</oncyf:SharePurchaseAgreementAmount>
    <oncyf:SharePurchaseAgreementTerm contextRef="c-150" id="f-567">P25M</oncyf:SharePurchaseAgreementTerm>
    <oncyf:IssueOfEquityShares
      contextRef="c-151"
      decimals="INF"
      id="f-568"
      unitRef="shares">2560933</oncyf:IssueOfEquityShares>
    <oncyf:IssueOfEquityShares
      contextRef="c-152"
      decimals="INF"
      id="f-569"
      unitRef="shares">4978605</oncyf:IssueOfEquityShares>
    <oncyf:IssueOfEquityShares
      contextRef="c-153"
      decimals="INF"
      id="f-570"
      unitRef="shares">3515462</oncyf:IssueOfEquityShares>
    <oncyf:ProceedsFromIssueOfOrdinarySharesGross contextRef="c-151" decimals="-3" id="f-571" unitRef="cad">4016000</oncyf:ProceedsFromIssueOfOrdinarySharesGross>
    <oncyf:ProceedsFromIssueOfOrdinarySharesGross contextRef="c-151" decimals="-3" id="f-572" unitRef="usd">2964000</oncyf:ProceedsFromIssueOfOrdinarySharesGross>
    <oncyf:ProceedsFromIssueOfOrdinarySharesGross contextRef="c-152" decimals="-3" id="f-573" unitRef="cad">10676000</oncyf:ProceedsFromIssueOfOrdinarySharesGross>
    <oncyf:ProceedsFromIssueOfOrdinarySharesGross contextRef="c-152" decimals="-3" id="f-574" unitRef="usd">7904000</oncyf:ProceedsFromIssueOfOrdinarySharesGross>
    <oncyf:ProceedsFromIssueOfOrdinarySharesGross contextRef="c-153" decimals="-3" id="f-575" unitRef="cad">7594000</oncyf:ProceedsFromIssueOfOrdinarySharesGross>
    <oncyf:ProceedsFromIssueOfOrdinarySharesGross contextRef="c-153" decimals="-3" id="f-576" unitRef="usd">5632000</oncyf:ProceedsFromIssueOfOrdinarySharesGross>
    <oncyf:SharesIssuedPricePerShare1
      contextRef="c-154"
      decimals="2"
      id="f-577"
      unitRef="cadPerShare">1.57</oncyf:SharesIssuedPricePerShare1>
    <oncyf:SharesIssuedPricePerShare1
      contextRef="c-154"
      decimals="2"
      id="f-578"
      unitRef="usdPerShare">1.16</oncyf:SharesIssuedPricePerShare1>
    <oncyf:SharesIssuedPricePerShare1
      contextRef="c-155"
      decimals="2"
      id="f-579"
      unitRef="cadPerShare">2.14</oncyf:SharesIssuedPricePerShare1>
    <oncyf:SharesIssuedPricePerShare1
      contextRef="c-155"
      decimals="2"
      id="f-580"
      unitRef="usdPerShare">1.59</oncyf:SharesIssuedPricePerShare1>
    <oncyf:SharesIssuedPricePerShare1
      contextRef="c-156"
      decimals="2"
      id="f-581"
      unitRef="cadPerShare">2.16</oncyf:SharesIssuedPricePerShare1>
    <oncyf:SharesIssuedPricePerShare1
      contextRef="c-156"
      decimals="2"
      id="f-582"
      unitRef="usdPerShare">1.60</oncyf:SharesIssuedPricePerShare1>
    <ifrs-full:ProceedsFromIssueOfOrdinaryShares contextRef="c-151" decimals="-3" id="f-583" unitRef="cad">3895000</ifrs-full:ProceedsFromIssueOfOrdinaryShares>
    <ifrs-full:ProceedsFromIssueOfOrdinaryShares contextRef="c-151" decimals="-3" id="f-584" unitRef="usd">2875000</ifrs-full:ProceedsFromIssueOfOrdinaryShares>
    <ifrs-full:ProceedsFromIssueOfOrdinaryShares contextRef="c-152" decimals="-3" id="f-585" unitRef="cad">10356000</ifrs-full:ProceedsFromIssueOfOrdinaryShares>
    <ifrs-full:ProceedsFromIssueOfOrdinaryShares contextRef="c-152" decimals="-3" id="f-586" unitRef="usd">7667000</ifrs-full:ProceedsFromIssueOfOrdinaryShares>
    <ifrs-full:ProceedsFromIssueOfOrdinaryShares contextRef="c-153" decimals="-3" id="f-587" unitRef="cad">7366000</ifrs-full:ProceedsFromIssueOfOrdinaryShares>
    <ifrs-full:ProceedsFromIssueOfOrdinaryShares contextRef="c-153" decimals="-3" id="f-588" unitRef="usd">5463000</ifrs-full:ProceedsFromIssueOfOrdinaryShares>
    <oncyf:ShareIssueRelatedCostCommissions contextRef="c-151" decimals="-3" id="f-589" unitRef="cad">121000</oncyf:ShareIssueRelatedCostCommissions>
    <oncyf:ShareIssueRelatedCostCommissions contextRef="c-151" decimals="-3" id="f-590" unitRef="usd">89000</oncyf:ShareIssueRelatedCostCommissions>
    <oncyf:ShareIssueRelatedCostCommissions contextRef="c-152" decimals="-3" id="f-591" unitRef="cad">320000</oncyf:ShareIssueRelatedCostCommissions>
    <oncyf:ShareIssueRelatedCostCommissions contextRef="c-152" decimals="-3" id="f-592" unitRef="usd">237000</oncyf:ShareIssueRelatedCostCommissions>
    <oncyf:ShareIssueRelatedCostCommissions contextRef="c-153" decimals="-3" id="f-593" unitRef="cad">228000</oncyf:ShareIssueRelatedCostCommissions>
    <oncyf:ShareIssueRelatedCostCommissions contextRef="c-153" decimals="-3" id="f-594" unitRef="usd">169000</oncyf:ShareIssueRelatedCostCommissions>
    <ifrs-full:ShareIssueRelatedCost contextRef="c-151" decimals="-3" id="f-595" unitRef="cad">187000</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:ShareIssueRelatedCost contextRef="c-152" decimals="-3" id="f-596" unitRef="cad">415000</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:ShareIssueRelatedCost contextRef="c-153" decimals="-3" id="f-597" unitRef="cad">555000</ifrs-full:ShareIssueRelatedCost>
    <oncyf:NumberOfWarrantsAndSharesOutstanding
      contextRef="c-124"
      decimals="INF"
      id="f-598"
      unitRef="shares">6667000</oncyf:NumberOfWarrantsAndSharesOutstanding>
    <oncyf:ProceedsFromIssueOfOrdinarySharesGross contextRef="c-126" decimals="-3" id="f-599" unitRef="cad">20185000</oncyf:ProceedsFromIssueOfOrdinarySharesGross>
    <oncyf:ProceedsFromIssueOfOrdinarySharesGross contextRef="c-126" decimals="-3" id="f-600" unitRef="usd">15001000</oncyf:ProceedsFromIssueOfOrdinarySharesGross>
    <oncyf:SharesIssuedPricePerShare1
      contextRef="c-124"
      decimals="2"
      id="f-601"
      unitRef="usdPerShare">2.25</oncyf:SharesIssuedPricePerShare1>
    <oncyf:NumberOfWarrantsAndSharesOutstanding
      contextRef="c-125"
      decimals="INF"
      id="f-602"
      unitRef="shares">1000050</oncyf:NumberOfWarrantsAndSharesOutstanding>
    <oncyf:ProceedsFromIssueOfOrdinarySharesGross contextRef="c-128" decimals="-3" id="f-603" unitRef="cad">3077000</oncyf:ProceedsFromIssueOfOrdinarySharesGross>
    <oncyf:ProceedsFromIssueOfOrdinarySharesGross contextRef="c-128" decimals="-3" id="f-604" unitRef="usd">2250000</oncyf:ProceedsFromIssueOfOrdinarySharesGross>
    <oncyf:SharesIssuedPricePerShare1
      contextRef="c-125"
      decimals="2"
      id="f-605"
      unitRef="usdPerShare">2.25</oncyf:SharesIssuedPricePerShare1>
    <oncyf:IssueOfEquitySharesNumberOfCommonShares
      contextRef="c-125"
      decimals="INF"
      id="f-606"
      unitRef="shares">1</oncyf:IssueOfEquitySharesNumberOfCommonShares>
    <oncyf:IssueOfEquitySharesNumberOfCommonShares
      contextRef="c-124"
      decimals="INF"
      id="f-607"
      unitRef="shares">1</oncyf:IssueOfEquitySharesNumberOfCommonShares>
    <oncyf:IssueOfEquitySharesNumberOfWarrants
      contextRef="c-124"
      decimals="INF"
      id="f-608"
      unitRef="shares">1</oncyf:IssueOfEquitySharesNumberOfWarrants>
    <oncyf:IssueOfEquitySharesNumberOfWarrants
      contextRef="c-125"
      decimals="INF"
      id="f-609"
      unitRef="shares">1</oncyf:IssueOfEquitySharesNumberOfWarrants>
    <ifrs-full:IssueOfEquity contextRef="c-126" decimals="-3" id="f-610" unitRef="cad">17724000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity contextRef="c-128" decimals="-3" id="f-611" unitRef="cad">17724000</ifrs-full:IssueOfEquity>
    <ifrs-full:WarrantLiability contextRef="c-124" decimals="-3" id="f-612" unitRef="cad">7360000</ifrs-full:WarrantLiability>
    <ifrs-full:WarrantLiability contextRef="c-125" decimals="-3" id="f-613" unitRef="cad">7360000</ifrs-full:WarrantLiability>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="c-157"
      decimals="INF"
      id="f-614"
      unitRef="shares">536693</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="c-158"
      decimals="INF"
      id="f-615"
      unitRef="shares">536693</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <oncyf:ShareWarrantsIssuedTransactionCosts contextRef="c-159" decimals="-3" id="f-616" unitRef="cad">3130000</oncyf:ShareWarrantsIssuedTransactionCosts>
    <oncyf:ShareWarrantsIssuedTransactionCosts contextRef="c-160" decimals="-3" id="f-617" unitRef="cad">3130000</oncyf:ShareWarrantsIssuedTransactionCosts>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees contextRef="c-161" decimals="-3" id="f-618" unitRef="cad">638000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees contextRef="c-162" decimals="-3" id="f-619" unitRef="cad">638000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees contextRef="c-162" decimals="-3" id="f-620" unitRef="usd">473000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees contextRef="c-161" decimals="-3" id="f-621" unitRef="usd">473000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees>
    <ifrs-full:ShareIssueRelatedCost contextRef="c-160" decimals="-3" id="f-622" unitRef="cad">2390000</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:ShareIssueRelatedCost contextRef="c-159" decimals="-3" id="f-623" unitRef="cad">2390000</ifrs-full:ShareIssueRelatedCost>
    <oncyf:ShareWarrantsIssuedOperatingExpense contextRef="c-159" decimals="-3" id="f-624" unitRef="cad">740000</oncyf:ShareWarrantsIssuedOperatingExpense>
    <oncyf:ShareWarrantsIssuedOperatingExpense contextRef="c-160" decimals="-3" id="f-625" unitRef="cad">740000</oncyf:ShareWarrantsIssuedOperatingExpense>
    <oncyf:SharePurchaseAgreementAmount contextRef="c-163" decimals="-3" id="f-626" unitRef="usd">50000000</oncyf:SharePurchaseAgreementAmount>
    <oncyf:SharePurchaseAgreementTerm contextRef="c-164" id="f-627">P25M</oncyf:SharePurchaseAgreementTerm>
    <oncyf:IssueOfEquityShares
      contextRef="c-165"
      decimals="INF"
      id="f-628"
      unitRef="shares">2849210</oncyf:IssueOfEquityShares>
    <oncyf:ProceedsFromIssueOfOrdinarySharesGross contextRef="c-165" decimals="-3" id="f-629" unitRef="cad">3654000</oncyf:ProceedsFromIssueOfOrdinarySharesGross>
    <oncyf:ProceedsFromIssueOfOrdinarySharesGross contextRef="c-165" decimals="-3" id="f-630" unitRef="usd">2562000</oncyf:ProceedsFromIssueOfOrdinarySharesGross>
    <oncyf:SharesIssuedPricePerShare1
      contextRef="c-166"
      decimals="2"
      id="f-631"
      unitRef="cadPerShare">1.28</oncyf:SharesIssuedPricePerShare1>
    <oncyf:SharesIssuedPricePerShare1
      contextRef="c-166"
      decimals="2"
      id="f-632"
      unitRef="usdPerShare">0.90</oncyf:SharesIssuedPricePerShare1>
    <ifrs-full:ProceedsFromIssueOfOrdinaryShares contextRef="c-165" decimals="-3" id="f-633" unitRef="cad">3544000</ifrs-full:ProceedsFromIssueOfOrdinaryShares>
    <ifrs-full:ProceedsFromIssueOfOrdinaryShares contextRef="c-165" decimals="-3" id="f-634" unitRef="usd">2485000</ifrs-full:ProceedsFromIssueOfOrdinaryShares>
    <oncyf:ShareIssueRelatedCostCommissions contextRef="c-165" decimals="-3" id="f-635" unitRef="cad">110000</oncyf:ShareIssueRelatedCostCommissions>
    <oncyf:ShareIssueRelatedCostCommissions contextRef="c-165" decimals="-3" id="f-636" unitRef="usd">77000</oncyf:ShareIssueRelatedCostCommissions>
    <ifrs-full:ShareIssueRelatedCost contextRef="c-165" decimals="-3" id="f-637" unitRef="cad">564000</ifrs-full:ShareIssueRelatedCost>
    <oncyf:NumberOfWarrantsExercised
      contextRef="c-123"
      decimals="INF"
      id="f-638"
      unitRef="shares">52456</oncyf:NumberOfWarrantsExercised>
    <oncyf:WarrantsExercised contextRef="c-123" decimals="-3" id="f-639" unitRef="cad">-6000</oncyf:WarrantsExercised>
    <oncyf:ProceedsfromWarrantExercises1 contextRef="c-1" decimals="-3" id="f-640" unitRef="cad">65000</oncyf:ProceedsfromWarrantExercises1>
    <oncyf:ProceedsfromWarrantExercises1 contextRef="c-1" decimals="-3" id="f-641" unitRef="usd">47000</oncyf:ProceedsfromWarrantExercises1>
    <oncyf:NumberOfWarrantsExercised
      contextRef="c-122"
      decimals="INF"
      id="f-642"
      unitRef="shares">0</oncyf:NumberOfWarrantsExercised>
    <oncyf:NumberOfWarrantsExercised
      contextRef="c-167"
      decimals="INF"
      id="f-643"
      unitRef="shares">0</oncyf:NumberOfWarrantsExercised>
    <ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory contextRef="c-1" id="f-644">Share-Based Compensation&lt;div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock options and share awards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt"&gt;Our amended and restated Stock Option Plan and Share Award Plan (collectively, the "Equity Incentive Plans") were approved by our shareholders at the annual general meeting of shareholders on May 9, 2023. Pursuant to our Equity Incentive Plans, we may grant stock options, restricted share awards, and performance share awards. The number of common shares reserved for issuance under our Equity Incentive Plans in aggregate shall not exceed 14% of the total number of issued and outstanding common shares from time to time. As at December&#160;31, 2024, we reserved 11,202,818 common shares for issuance relating to our Equity Incentive Plans. Our share-based compensation expense for the year ended December&#160;31, 2024, was $2,723 (2023 - $1,917; 2022 - $2,378). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;Our stock option activity for the years ended December&#160;31 was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.923%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.034%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.034%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.034%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.034%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.034%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.039%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;br/&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;br/&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;br/&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7,063,333&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2.72&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,963,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.91&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,334,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.53&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,016,800&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1.22&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,145,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.23&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,005,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.04&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(175,534)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2.46&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(280,288)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.86&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(62,962)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.83&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(2,028,254)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.22&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(314,573)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.17&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(304,940)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.80&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(450,391)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.74&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,333)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.45&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,876,345&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2.14&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,063,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.72&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,963,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.91&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable, end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,718,058&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2.43&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,039,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.85&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,420,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.01&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes information about the stock options outstanding and exercisable at December&#160;31, 2024:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.208%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.382%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.456%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.382%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.456%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.382%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.456%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.382%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.456%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.382%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.458%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Range of Exercise Prices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Number Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted Average Remaining Contractual Life (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;br/&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Number Exercisable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;br/&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.13 - $1.50&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,799,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.14&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;637,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.13&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.51 - $2.20&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,232,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.88&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,434,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.94&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$2.21 - $2.70&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;699,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.36&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;699,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.36&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$2.71 - $3.11&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;940,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.78&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;742,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.78&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$3.12 - $7.60&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,203,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.51&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,203,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.51&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,876,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.14&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,718,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.43&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:7pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Option grants vest either immediately or annually over periods ranging from &lt;span style="-sec-ix-hidden:f-735"&gt;one&lt;/span&gt; to three years.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We use the Black-Scholes valuation model to estimate fair value. We use historical data to estimate the expected dividend yield&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and expected volatility of our stock in determining the fair value of the stock options. The risk-free interest rate is based on the&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Government of Canada benchmark bond yield rates in effect at the time of grant. The expected life of the options represents the&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;estimated length of time the options are expected to remain outstanding. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of stock options granted during the years ended December&#160;31 were determined using the following weighted average assumptions: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.642%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.600%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.1%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.0 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;66.4%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96.0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nil&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nil&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nil&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average fair value of options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$0.57&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.24&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt"&gt;Our share award activity for the years ended December&#160;31 was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.642%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.600%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;398,440&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;853,642&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;403,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,760)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(133,572)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40,560)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,118,510&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;398,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; (1) The weighted average fair value of the RSAs granted was $1.15 in 2024 (2023&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; - &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$2.23).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31, 2024 and 2023, we granted restricted share awards to officers and a board of director member in his capacity as interim chief executive officer of the Company. Restricted share award granted to officers vest immediately or over a three-year period. Restricted share award granted to the board of director member vest on the second anniversary from the grant date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Compensation warrants &lt;/span&gt;&lt;/div&gt;In consideration of the services rendered by the underwriter as part of a public offering in 2023 (see note 10(c)), we issued 536,693 compensation warrants. Each compensation warrant is exercisable into one common share at an exercise price of US$2.25 up to 60 months from the date of issuance. At issuance date, we used the Black-Scholes valuation model to estimate the fair value of the services rendered. As at December&#160;31, 2024 and 2023, there were 536,693 compensation warrants outstanding.</ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory>
    <oncyf:NumberOfSharesReservedForIssueUnderOptionsAndContractsForSaleOfSharesPercentageOfCommonSharesMaximum contextRef="c-3" decimals="2" id="f-645" unitRef="number">0.14</oncyf:NumberOfSharesReservedForIssueUnderOptionsAndContractsForSaleOfSharesPercentageOfCommonSharesMaximum>
    <ifrs-full:SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares
      contextRef="c-168"
      decimals="INF"
      id="f-646"
      unitRef="shares">11202818</ifrs-full:SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="c-1" decimals="-3" id="f-647" unitRef="cad">2723000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="c-7" decimals="-3" id="f-648" unitRef="cad">1917000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="c-8" decimals="-3" id="f-649" unitRef="cad">2378000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory contextRef="c-1" id="f-650">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;Our stock option activity for the years ended December&#160;31 was as follows:&lt;/span&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.923%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.034%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.034%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.034%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.034%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.034%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.039%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;br/&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;br/&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;br/&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7,063,333&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2.72&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,963,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.91&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,334,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.53&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,016,800&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1.22&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,145,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.23&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,005,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.04&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(175,534)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2.46&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(280,288)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.86&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(62,962)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.83&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(2,028,254)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.22&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(314,573)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.17&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(304,940)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.80&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(450,391)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.74&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,333)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.45&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,876,345&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2.14&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,063,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.72&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,963,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.91&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable, end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,718,058&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2.43&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,039,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.85&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,420,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.01&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory>
    <ifrs-full:NumberOfOutstandingShareOptions contextRef="c-4" decimals="INF" id="f-651" unitRef="shares">7063333</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c-4"
      decimals="2"
      id="f-652"
      unitRef="cadPerShare">2.72</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c-25"
      decimals="INF"
      id="f-653"
      unitRef="shares">5963185</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c-25"
      decimals="2"
      id="f-654"
      unitRef="cadPerShare">2.91</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c-14"
      decimals="INF"
      id="f-655"
      unitRef="shares">5334420</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c-14"
      decimals="2"
      id="f-656"
      unitRef="cadPerShare">3.53</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement contextRef="c-1" decimals="INF" id="f-657" unitRef="shares">2016800</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019
      contextRef="c-1"
      decimals="2"
      id="f-658"
      unitRef="cadPerShare">1.22</ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement contextRef="c-7" decimals="INF" id="f-659" unitRef="shares">2145400</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019
      contextRef="c-7"
      decimals="2"
      id="f-660"
      unitRef="cadPerShare">2.23</ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement contextRef="c-8" decimals="INF" id="f-661" unitRef="shares">1005000</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019
      contextRef="c-8"
      decimals="2"
      id="f-662"
      unitRef="cadPerShare">2.04</ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement contextRef="c-1" decimals="INF" id="f-663" unitRef="shares">175534</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019
      contextRef="c-1"
      decimals="2"
      id="f-664"
      unitRef="cadPerShare">2.46</ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement contextRef="c-7" decimals="INF" id="f-665" unitRef="shares">280288</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019
      contextRef="c-7"
      decimals="2"
      id="f-666"
      unitRef="cadPerShare">2.86</ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement contextRef="c-8" decimals="INF" id="f-667" unitRef="shares">62962</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019
      contextRef="c-8"
      decimals="2"
      id="f-668"
      unitRef="cadPerShare">3.83</ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement contextRef="c-1" decimals="INF" id="f-669" unitRef="shares">2028254</ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019
      contextRef="c-1"
      decimals="2"
      id="f-670"
      unitRef="cadPerShare">3.22</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement contextRef="c-7" decimals="INF" id="f-671" unitRef="shares">314573</ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019
      contextRef="c-7"
      decimals="2"
      id="f-672"
      unitRef="cadPerShare">4.17</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement contextRef="c-8" decimals="INF" id="f-673" unitRef="shares">304940</ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019
      contextRef="c-8"
      decimals="2"
      id="f-674"
      unitRef="cadPerShare">10.80</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement contextRef="c-1" decimals="INF" id="f-675" unitRef="shares">0</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019
      contextRef="c-1"
      decimals="2"
      id="f-676"
      unitRef="cadPerShare">0</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement contextRef="c-7" decimals="INF" id="f-677" unitRef="shares">450391</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019
      contextRef="c-7"
      decimals="2"
      id="f-678"
      unitRef="cadPerShare">1.74</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement contextRef="c-8" decimals="INF" id="f-679" unitRef="shares">8333</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019
      contextRef="c-8"
      decimals="2"
      id="f-680"
      unitRef="cadPerShare">1.45</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions contextRef="c-3" decimals="INF" id="f-681" unitRef="shares">6876345</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c-3"
      decimals="2"
      id="f-682"
      unitRef="cadPerShare">2.14</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions contextRef="c-4" decimals="INF" id="f-683" unitRef="shares">7063333</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c-4"
      decimals="2"
      id="f-684"
      unitRef="cadPerShare">2.72</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c-25"
      decimals="INF"
      id="f-685"
      unitRef="shares">5963185</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c-25"
      decimals="2"
      id="f-686"
      unitRef="cadPerShare">2.91</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement contextRef="c-3" decimals="INF" id="f-687" unitRef="shares">4718058</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="c-3"
      decimals="2"
      id="f-688"
      unitRef="cadPerShare">2.43</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement contextRef="c-4" decimals="INF" id="f-689" unitRef="shares">5039604</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="c-4"
      decimals="2"
      id="f-690"
      unitRef="cadPerShare">2.85</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="c-25"
      decimals="INF"
      id="f-691"
      unitRef="shares">4420482</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="c-25"
      decimals="2"
      id="f-692"
      unitRef="cadPerShare">3.01</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <ifrs-full:DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory contextRef="c-1" id="f-694">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes information about the stock options outstanding and exercisable at December&#160;31, 2024:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.208%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.382%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.456%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.382%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.456%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.382%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.456%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.382%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.456%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.382%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.458%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Range of Exercise Prices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Number Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted Average Remaining Contractual Life (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;br/&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Number Exercisable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;br/&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.13 - $1.50&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,799,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.14&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;637,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.13&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.51 - $2.20&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,232,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.88&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,434,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.94&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$2.21 - $2.70&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;699,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.36&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;699,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.36&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$2.71 - $3.11&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;940,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.78&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;742,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.78&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$3.12 - $7.60&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,203,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.51&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,203,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.51&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,876,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.14&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,718,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.43&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory>
    <ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory contextRef="c-1" id="f-693">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes information about the stock options outstanding and exercisable at December&#160;31, 2024:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.208%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.382%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.456%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.382%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.456%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.382%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.456%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.382%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.456%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.382%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.458%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Range of Exercise Prices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Number Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted Average Remaining Contractual Life (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;br/&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Number Exercisable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;br/&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.13 - $1.50&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,799,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.14&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;637,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.13&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.51 - $2.20&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,232,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.88&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,434,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.94&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$2.21 - $2.70&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;699,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.36&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;699,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.36&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$2.71 - $3.11&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;940,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.78&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;742,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.78&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$3.12 - $7.60&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,203,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.51&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,203,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.51&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,876,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.14&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,718,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.43&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="c-169"
      decimals="2"
      id="f-695"
      unitRef="cadPerShare">1.13</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="c-170"
      decimals="2"
      id="f-696"
      unitRef="cadPerShare">1.50</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c-171"
      decimals="INF"
      id="f-697"
      unitRef="shares">1799300</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="c-172" id="f-698">P4Y7M6D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c-171"
      decimals="2"
      id="f-699"
      unitRef="cadPerShare">1.14</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="c-171"
      decimals="INF"
      id="f-700"
      unitRef="shares">637257</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="c-171"
      decimals="2"
      id="f-701"
      unitRef="cadPerShare">1.13</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="c-173"
      decimals="2"
      id="f-702"
      unitRef="cadPerShare">1.51</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="c-174"
      decimals="2"
      id="f-703"
      unitRef="cadPerShare">2.20</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c-175"
      decimals="INF"
      id="f-704"
      unitRef="shares">2232850</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="c-176" id="f-705">P3Y3M18D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c-175"
      decimals="2"
      id="f-706"
      unitRef="cadPerShare">1.88</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="c-175"
      decimals="INF"
      id="f-707"
      unitRef="shares">1434792</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="c-175"
      decimals="2"
      id="f-708"
      unitRef="cadPerShare">1.94</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="c-177"
      decimals="2"
      id="f-709"
      unitRef="cadPerShare">2.21</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="c-178"
      decimals="2"
      id="f-710"
      unitRef="cadPerShare">2.70</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c-179"
      decimals="INF"
      id="f-711"
      unitRef="shares">699689</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="c-180" id="f-712">P1Y10M24D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c-179"
      decimals="2"
      id="f-713"
      unitRef="cadPerShare">2.36</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="c-179"
      decimals="INF"
      id="f-714"
      unitRef="shares">699689</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="c-179"
      decimals="2"
      id="f-715"
      unitRef="cadPerShare">2.36</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="c-181"
      decimals="2"
      id="f-716"
      unitRef="cadPerShare">2.71</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="c-182"
      decimals="2"
      id="f-717"
      unitRef="cadPerShare">3.11</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c-183"
      decimals="INF"
      id="f-718"
      unitRef="shares">940800</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="c-184" id="f-719">P3Y2M12D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c-183"
      decimals="2"
      id="f-720"
      unitRef="cadPerShare">2.78</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="c-183"
      decimals="INF"
      id="f-721"
      unitRef="shares">742614</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="c-183"
      decimals="2"
      id="f-722"
      unitRef="cadPerShare">2.78</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="c-185"
      decimals="2"
      id="f-723"
      unitRef="cadPerShare">3.12</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="c-186"
      decimals="2"
      id="f-724"
      unitRef="cadPerShare">7.60</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c-187"
      decimals="INF"
      id="f-725"
      unitRef="shares">1203706</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="c-188" id="f-726">P1Y2M12D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c-187"
      decimals="2"
      id="f-727"
      unitRef="cadPerShare">3.51</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="c-187"
      decimals="INF"
      id="f-728"
      unitRef="shares">1203706</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="c-187"
      decimals="2"
      id="f-729"
      unitRef="cadPerShare">3.51</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions contextRef="c-3" decimals="INF" id="f-730" unitRef="shares">6876345</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="c-1" id="f-731">P3Y1M6D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c-3"
      decimals="2"
      id="f-732"
      unitRef="cadPerShare">2.14</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement contextRef="c-3" decimals="INF" id="f-733" unitRef="shares">4718058</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="c-3"
      decimals="2"
      id="f-734"
      unitRef="cadPerShare">2.43</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <oncyf:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1 contextRef="c-190" id="f-736">P3Y</oncyf:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1>
    <ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory contextRef="c-1" id="f-737">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of stock options granted during the years ended December&#160;31 were determined using the following weighted average assumptions: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.642%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.600%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.1%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.0 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;66.4%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96.0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nil&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nil&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nil&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average fair value of options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$0.57&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.24&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted contextRef="c-1" decimals="4" id="f-738" unitRef="number">0.031</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted contextRef="c-7" decimals="4" id="f-739" unitRef="number">0.041</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted contextRef="c-8" decimals="4" id="f-740" unitRef="number">0.034</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted contextRef="c-1" decimals="1" id="f-741" unitRef="year">3.0</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted contextRef="c-7" decimals="1" id="f-742" unitRef="year">3.0</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted contextRef="c-8" decimals="1" id="f-743" unitRef="year">3.0</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted contextRef="c-1" decimals="4" id="f-744" unitRef="number">0.664</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted contextRef="c-7" decimals="4" id="f-745" unitRef="number">0.720</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted contextRef="c-8" decimals="4" id="f-746" unitRef="number">0.960</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted contextRef="c-1" decimals="INF" id="f-747" unitRef="number">0</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted contextRef="c-7" decimals="INF" id="f-748" unitRef="number">0</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted contextRef="c-8" decimals="INF" id="f-749" unitRef="number">0</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted contextRef="c-3" decimals="2" id="f-750" unitRef="cad">0.57</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted contextRef="c-4" decimals="2" id="f-751" unitRef="cad">1.12</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted contextRef="c-25" decimals="2" id="f-752" unitRef="cad">1.24</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory contextRef="c-1" id="f-753">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt"&gt;Our share award activity for the years ended December&#160;31 was as follows:&lt;/span&gt;&lt;div style="margin-top:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.642%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.600%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;398,440&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;853,642&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;403,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,760)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(133,572)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40,560)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,118,510&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;398,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; (1) The weighted average fair value of the RSAs granted was $1.15 in 2024 (2023&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; - &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$2.23).&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="c-191"
      decimals="INF"
      id="f-754"
      unitRef="shares">398440</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="c-192"
      decimals="INF"
      id="f-755"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="c-193"
      decimals="INF"
      id="f-756"
      unitRef="shares">40560</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="c-194"
      decimals="INF"
      id="f-757"
      unitRef="shares">853642</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="c-195"
      decimals="INF"
      id="f-758"
      unitRef="shares">403200</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="c-196"
      decimals="INF"
      id="f-759"
      unitRef="shares">0</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="c-194"
      decimals="INF"
      id="f-760"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="c-195"
      decimals="INF"
      id="f-761"
      unitRef="shares">4760</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="c-196"
      decimals="INF"
      id="f-762"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="c-194"
      decimals="INF"
      id="f-763"
      unitRef="shares">133572</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="c-195"
      decimals="INF"
      id="f-764"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="c-196"
      decimals="INF"
      id="f-765"
      unitRef="shares">40560</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="c-197"
      decimals="INF"
      id="f-766"
      unitRef="shares">1118510</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="c-191"
      decimals="INF"
      id="f-767"
      unitRef="shares">398440</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="c-192"
      decimals="INF"
      id="f-768"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted contextRef="c-197" decimals="2" id="f-769" unitRef="cad">1.15</ifrs-full:WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted contextRef="c-191" decimals="2" id="f-770" unitRef="cad">2.23</ifrs-full:WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted>
    <oncyf:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1 contextRef="c-198" id="f-771">P3Y</oncyf:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1>
    <oncyf:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1 contextRef="c-199" id="f-772">P3Y</oncyf:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="c-200"
      decimals="INF"
      id="f-773"
      unitRef="shares">536693</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <oncyf:IssueOfEquitySharesNumberOfCommonShares
      contextRef="c-201"
      decimals="INF"
      id="f-774"
      unitRef="shares">1</oncyf:IssueOfEquitySharesNumberOfCommonShares>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019
      contextRef="c-200"
      decimals="2"
      id="f-775"
      unitRef="usdPerShare">2.25</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019>
    <oncyf:ExpirationPeriodOfOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement contextRef="c-200" id="f-776">P60M</oncyf:ExpirationPeriodOfOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="c-202"
      decimals="INF"
      id="f-777"
      unitRef="shares">536693</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="c-200"
      decimals="INF"
      id="f-778"
      unitRef="shares">536693</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:DisclosureOfEarningsPerShareExplanatory contextRef="c-1" id="f-781">Loss Per Share&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Loss per common share is calculated by dividing net loss for the year by the weighted average number of common shares outstanding for the year ended December&#160;31, 2024, of 76,482,914 (2023 - 67,624,036; 2022 - 58,029,745). The effect of any potential exercise of our stock options, share awards, and warrants outstanding during the year has been excluded from the calculation of diluted loss per common share, as it would be anti-dilutive.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfEarningsPerShareExplanatory>
    <ifrs-full:AdjustedWeightedAverageShares contextRef="c-1" decimals="0" id="f-782" unitRef="shares">76482914</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:WeightedAverageShares contextRef="c-1" decimals="0" id="f-783" unitRef="shares">76482914</ifrs-full:WeightedAverageShares>
    <ifrs-full:WeightedAverageShares contextRef="c-7" decimals="0" id="f-784" unitRef="shares">67624036</ifrs-full:WeightedAverageShares>
    <ifrs-full:AdjustedWeightedAverageShares contextRef="c-7" decimals="0" id="f-785" unitRef="shares">67624036</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:WeightedAverageShares contextRef="c-8" decimals="0" id="f-786" unitRef="shares">58029745</ifrs-full:WeightedAverageShares>
    <ifrs-full:AdjustedWeightedAverageShares contextRef="c-8" decimals="0" id="f-787" unitRef="shares">58029745</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory contextRef="c-1" id="f-788">Contract Liability&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We entered into a regional licensing agreement (the "Licensing Agreement") with Adlai Nortye Biopharma Co., Ltd. ("Adlai") in November 2017. Under the terms of the Licensing Agreement, Adlai will have exclusive development and commercialization rights to pelareorep in China, Hong Kong, Macau, Singapore, South Korea, and Taiwan. We are entitled to receive upfront license fees, development and regulatory milestone payments, royalties, and sales-based milestone payments. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our contract liability balance at &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31&lt;/span&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which w&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;e expect to record in revenue over the next five years, is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.104%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.005%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.007%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,730&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue recognized &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, end of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,730&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory>
    <ifrs-full:ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory contextRef="c-1" id="f-789">&lt;div&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our contract liability balance at &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31&lt;/span&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which w&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;e expect to record in revenue over the next five years, is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.104%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.005%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.007%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,730&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue recognized &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, end of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,730&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory>
    <oncyf:ContractLiabilityRecognitionPeriod contextRef="c-1" id="f-790">P5Y</oncyf:ContractLiabilityRecognitionPeriod>
    <ifrs-full:ContractLiabilities contextRef="c-4" decimals="-3" id="f-791" unitRef="usd">6730000</ifrs-full:ContractLiabilities>
    <ifrs-full:ContractLiabilities contextRef="c-25" decimals="-3" id="f-792" unitRef="usd">6730000</ifrs-full:ContractLiabilities>
    <ifrs-full:DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities contextRef="c-1" decimals="-3" id="f-793" unitRef="usd">0</ifrs-full:DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities>
    <ifrs-full:DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities contextRef="c-7" decimals="-3" id="f-794" unitRef="usd">0</ifrs-full:DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities>
    <ifrs-full:ContractLiabilities contextRef="c-3" decimals="-3" id="f-795" unitRef="usd">6730000</ifrs-full:ContractLiabilities>
    <ifrs-full:ContractLiabilities contextRef="c-4" decimals="-3" id="f-796" unitRef="usd">6730000</ifrs-full:ContractLiabilities>
    <ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory contextRef="c-1" id="f-797">Commitments and Contingencies &lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are committed to payments of approximately $7,793 for activities mainly related to our clinical trial and manufacturing programs, which are expected to occur over the next two years. Approximately one-third of the committed payments relate to a&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;production service agreement with our primary toll manufacturer, which cannot be canceled without a significant penalty. We&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;are able to cancel most of the remaining agreements with notice. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Indemnification of Officers and Directors&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our corporate by-laws require that, except to the extent expressly prohibited by law, we will indemnify our officers and directors against all costs, charges, and expenses, including an amount paid to settle an action or satisfy a judgment reasonably incurred in respect of any civil, criminal, or administrative action or proceeding as it relates to their services to the Company.&#160;The by-laws provide no limit to the amount of the indemnification.&#160;We have purchased directors&#x2019; and officers&#x2019; insurance coverage to cover claims made against the directors and officers during the applicable policy periods.&#160;The amounts and types of coverage have varied from period to period as dictated by market conditions.&#160;We believe that we have adequate insurance coverage; however, there is no guarantee that all indemnification payments will be covered under our existing insurance policies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There is no pending litigation or proceeding involving any of our officers or directors as to which indemnification is being sought, nor are we aware of any threatened litigation that may result in claims for indemnification.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory>
    <oncyf:PurchaseObligation1 contextRef="c-3" decimals="-3" id="f-798" unitRef="cad">7793000</oncyf:PurchaseObligation1>
    <oncyf:PurchaseObligationCommitmentTerm contextRef="c-1" id="f-799">P2Y</oncyf:PurchaseObligationCommitmentTerm>
    <ifrs-full:DisclosureOfIncomeTaxExplanatory contextRef="c-1" id="f-801">Income Taxes&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The provision for income taxes recorded in the consolidated financial statements differs from the amount which would be obtained by applying the statutory income tax rate to the loss before income taxes as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.379%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.350%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.350%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.353%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(31,580)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27,655)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24,751)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Statutory Canadian corporate tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;23.00%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.00%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.00%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Anticipated tax recovery&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(7,263)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,361)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,693)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Difference in tax rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,323&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,841&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,552&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;668&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;441&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;547&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revaluation of tax balances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(639)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(338)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impact of Barbados rate change&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,088)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other permanent differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;94&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;325&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(368)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expiry of tax benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,804&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,382&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,614&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of warrant derivative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(286)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,215)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision to offset deferred tax asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,429&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,770&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;765&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;130&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2024, we have non-capital losses of $117,096 and $145,104 in Canada and Barbados, respectively (December&#160;31, 2023 - $110,450 and $129,884, respectively). These losses are expected to expire between 2025 and 2044, if not utilized. At December&#160;31, 2024, we have Canadian investment tax credits of $3,839 (December&#160;31, 2023 - $4,056) that are expected to expire between 2025 and 2044, if not utilized. As well, we have unclaimed Canadian scientific research and experimental development expenditures available to reduce future years' taxable income of $28,470 (December&#160;31, 2023 - $28,376).&#160;We also have unclaimed U.S. credits for research activities available to reduce future years' taxable income of $1,313 (December&#160;31, 2023 - $1,232) expiring between 2031 and 2044. We have not recorded the potential benefits of these tax pools in these consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax assets are recognized, to the extent that it is probable that taxable income will be available to utilize the deductible temporary differences. The components of our unrecognized deferred tax asset are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.379%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.350%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.350%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.353%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-capital losses carried forward&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;40,078&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Scientific research and experimental development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7,861&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,956&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;453&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share issue costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;666&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net capital losses carried forward&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized deferred tax asset&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;52,020&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The Company currently files income tax returns in the various jurisdictions in which it operates. These tax returns are subject to periodic examinations in the normal course by the applicable tax authorities. Management is not aware of any material income tax examinations currently in progress by any taxing jurisdiction.</ifrs-full:DisclosureOfIncomeTaxExplanatory>
    <oncyf:ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock contextRef="c-1" id="f-802">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The provision for income taxes recorded in the consolidated financial statements differs from the amount which would be obtained by applying the statutory income tax rate to the loss before income taxes as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.379%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.350%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.350%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.353%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(31,580)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27,655)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24,751)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Statutory Canadian corporate tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;23.00%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.00%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.00%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Anticipated tax recovery&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(7,263)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,361)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,693)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Difference in tax rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,323&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,841&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,552&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;668&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;441&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;547&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revaluation of tax balances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(639)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(338)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impact of Barbados rate change&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,088)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other permanent differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;94&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;325&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(368)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expiry of tax benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,804&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,382&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,614&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of warrant derivative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(286)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,215)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision to offset deferred tax asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,429&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,770&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;765&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;130&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</oncyf:ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock>
    <ifrs-full:AccountingProfit contextRef="c-1" decimals="-3" id="f-803" unitRef="cad">-31580000</ifrs-full:AccountingProfit>
    <ifrs-full:AccountingProfit contextRef="c-7" decimals="-3" id="f-804" unitRef="cad">-27655000</ifrs-full:AccountingProfit>
    <ifrs-full:AccountingProfit contextRef="c-8" decimals="-3" id="f-805" unitRef="cad">-24751000</ifrs-full:AccountingProfit>
    <ifrs-full:ApplicableTaxRate contextRef="c-1" decimals="INF" id="f-806" unitRef="number">0.2300</ifrs-full:ApplicableTaxRate>
    <ifrs-full:ApplicableTaxRate contextRef="c-7" decimals="INF" id="f-807" unitRef="number">0.2300</ifrs-full:ApplicableTaxRate>
    <ifrs-full:ApplicableTaxRate contextRef="c-8" decimals="INF" id="f-808" unitRef="number">0.2300</ifrs-full:ApplicableTaxRate>
    <ifrs-full:TaxExpenseIncomeAtApplicableTaxRate contextRef="c-1" decimals="-3" id="f-809" unitRef="cad">-7263000</ifrs-full:TaxExpenseIncomeAtApplicableTaxRate>
    <ifrs-full:TaxExpenseIncomeAtApplicableTaxRate contextRef="c-7" decimals="-3" id="f-810" unitRef="cad">-6361000</ifrs-full:TaxExpenseIncomeAtApplicableTaxRate>
    <ifrs-full:TaxExpenseIncomeAtApplicableTaxRate contextRef="c-8" decimals="-3" id="f-811" unitRef="cad">-5693000</ifrs-full:TaxExpenseIncomeAtApplicableTaxRate>
    <ifrs-full:TaxEffectOfForeignTaxRates contextRef="c-1" decimals="-3" id="f-812" unitRef="cad">3323000</ifrs-full:TaxEffectOfForeignTaxRates>
    <ifrs-full:TaxEffectOfForeignTaxRates contextRef="c-7" decimals="-3" id="f-813" unitRef="cad">2841000</ifrs-full:TaxEffectOfForeignTaxRates>
    <ifrs-full:TaxEffectOfForeignTaxRates contextRef="c-8" decimals="-3" id="f-814" unitRef="cad">3552000</ifrs-full:TaxEffectOfForeignTaxRates>
    <oncyf:TaxEffectOfStockBasedCompensation contextRef="c-1" decimals="-3" id="f-815" unitRef="cad">-668000</oncyf:TaxEffectOfStockBasedCompensation>
    <oncyf:TaxEffectOfStockBasedCompensation contextRef="c-7" decimals="-3" id="f-816" unitRef="cad">-441000</oncyf:TaxEffectOfStockBasedCompensation>
    <oncyf:TaxEffectOfStockBasedCompensation contextRef="c-8" decimals="-3" id="f-817" unitRef="cad">-547000</oncyf:TaxEffectOfStockBasedCompensation>
    <oncyf:TaxEffectOfTaxPools contextRef="c-1" decimals="-3" id="f-818" unitRef="cad">-639000</oncyf:TaxEffectOfTaxPools>
    <oncyf:TaxEffectOfTaxPools contextRef="c-7" decimals="-3" id="f-819" unitRef="cad">2000</oncyf:TaxEffectOfTaxPools>
    <oncyf:TaxEffectOfTaxPools contextRef="c-8" decimals="-3" id="f-820" unitRef="cad">-338000</oncyf:TaxEffectOfTaxPools>
    <ifrs-full:TaxEffectFromChangeInTaxRate contextRef="c-1" decimals="-3" id="f-821" unitRef="cad">0</ifrs-full:TaxEffectFromChangeInTaxRate>
    <ifrs-full:TaxEffectFromChangeInTaxRate contextRef="c-7" decimals="-3" id="f-822" unitRef="cad">-9088000</ifrs-full:TaxEffectFromChangeInTaxRate>
    <ifrs-full:TaxEffectFromChangeInTaxRate contextRef="c-8" decimals="-3" id="f-823" unitRef="cad">0</ifrs-full:TaxEffectFromChangeInTaxRate>
    <ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome contextRef="c-1" decimals="-3" id="f-824" unitRef="cad">94000</ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome>
    <ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome contextRef="c-7" decimals="-3" id="f-825" unitRef="cad">325000</ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome>
    <ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome contextRef="c-8" decimals="-3" id="f-826" unitRef="cad">-368000</ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome>
    <oncyf:TaxEffectOfExpirationOfTaxBenefits contextRef="c-1" decimals="-3" id="f-827" unitRef="cad">1804000</oncyf:TaxEffectOfExpirationOfTaxBenefits>
    <oncyf:TaxEffectOfExpirationOfTaxBenefits contextRef="c-7" decimals="-3" id="f-828" unitRef="cad">3382000</oncyf:TaxEffectOfExpirationOfTaxBenefits>
    <oncyf:TaxEffectOfExpirationOfTaxBenefits contextRef="c-8" decimals="-3" id="f-829" unitRef="cad">1614000</oncyf:TaxEffectOfExpirationOfTaxBenefits>
    <oncyf:TaxEffectOfChangeinFairValueOfWarrantDerivative contextRef="c-1" decimals="-3" id="f-830" unitRef="cad">-286000</oncyf:TaxEffectOfChangeinFairValueOfWarrantDerivative>
    <oncyf:TaxEffectOfChangeinFairValueOfWarrantDerivative contextRef="c-7" decimals="-3" id="f-831" unitRef="cad">-1215000</oncyf:TaxEffectOfChangeinFairValueOfWarrantDerivative>
    <oncyf:TaxEffectOfChangeinFairValueOfWarrantDerivative contextRef="c-8" decimals="-3" id="f-832" unitRef="cad">5000</oncyf:TaxEffectOfChangeinFairValueOfWarrantDerivative>
    <oncyf:ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1 contextRef="c-1" decimals="-3" id="f-833" unitRef="cad">-2429000</oncyf:ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1>
    <oncyf:ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1 contextRef="c-7" decimals="-3" id="f-834" unitRef="cad">-9770000</oncyf:ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1>
    <oncyf:ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1 contextRef="c-8" decimals="-3" id="f-835" unitRef="cad">-765000</oncyf:ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="c-1" decimals="-3" id="f-836" unitRef="cad">130000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="c-7" decimals="-3" id="f-837" unitRef="cad">97000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="c-8" decimals="-3" id="f-838" unitRef="cad">84000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised contextRef="c-205" decimals="-3" id="f-839" unitRef="cad">117096000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised contextRef="c-206" decimals="-3" id="f-840" unitRef="cad">145104000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised contextRef="c-207" decimals="-3" id="f-841" unitRef="cad">110450000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised contextRef="c-208" decimals="-3" id="f-842" unitRef="cad">129884000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised contextRef="c-209" decimals="-3" id="f-843" unitRef="cad">3839000</ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised contextRef="c-210" decimals="-3" id="f-844" unitRef="cad">4056000</ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised contextRef="c-211" decimals="-3" id="f-845" unitRef="cad">28470000</ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised contextRef="c-212" decimals="-3" id="f-846" unitRef="cad">28376000</ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised contextRef="c-213" decimals="-3" id="f-847" unitRef="cad">1313000</ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised contextRef="c-214" decimals="-3" id="f-848" unitRef="cad">1232000</ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory contextRef="c-1" id="f-849">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax assets are recognized, to the extent that it is probable that taxable income will be available to utilize the deductible temporary differences. The components of our unrecognized deferred tax asset are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.379%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.350%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.350%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.353%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-capital losses carried forward&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;40,078&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Scientific research and experimental development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7,861&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,956&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;453&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share issue costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;666&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net capital losses carried forward&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized deferred tax asset&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;52,020&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised contextRef="c-215" decimals="-3" id="f-850" unitRef="cad">40078000</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised contextRef="c-216" decimals="-3" id="f-851" unitRef="cad">37174000</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised contextRef="c-217" decimals="-3" id="f-852" unitRef="cad">26726000</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised contextRef="c-218" decimals="-3" id="f-853" unitRef="cad">7861000</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised contextRef="c-219" decimals="-3" id="f-854" unitRef="cad">7742000</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised contextRef="c-220" decimals="-3" id="f-855" unitRef="cad">7648000</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised contextRef="c-221" decimals="-3" id="f-856" unitRef="cad">2956000</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised contextRef="c-222" decimals="-3" id="f-857" unitRef="cad">3123000</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised contextRef="c-223" decimals="-3" id="f-858" unitRef="cad">3363000</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised contextRef="c-224" decimals="-3" id="f-859" unitRef="cad">453000</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised contextRef="c-225" decimals="-3" id="f-860" unitRef="cad">382000</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised contextRef="c-226" decimals="-3" id="f-861" unitRef="cad">366000</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised contextRef="c-227" decimals="-3" id="f-862" unitRef="cad">666000</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised contextRef="c-228" decimals="-3" id="f-863" unitRef="cad">833000</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised contextRef="c-229" decimals="-3" id="f-864" unitRef="cad">518000</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised contextRef="c-230" decimals="-3" id="f-865" unitRef="cad">6000</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised contextRef="c-231" decimals="-3" id="f-866" unitRef="cad">6000</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised contextRef="c-232" decimals="-3" id="f-867" unitRef="cad">6000</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised contextRef="c-3" decimals="-3" id="f-868" unitRef="cad">52020000</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised contextRef="c-4" decimals="-3" id="f-869" unitRef="cad">49260000</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised contextRef="c-25" decimals="-3" id="f-870" unitRef="cad">38627000</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory contextRef="c-1" id="f-871">Capital Disclosures&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our objective when managing capital is to maintain adequate cash resources to support planned activities, including our clinical trial program, product manufacturing, administrative costs, and intellectual property expansion and protection.&#160;See note 1 for the discussion on our ability to continue as a going concern. We include shareholders' equity and cash and cash equivalents in the definition of capital.    &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.104%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.005%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.007%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;15,942&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shareholders' equity&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5,983&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have no debt other than accounts payable and accrued liabilities and lease liabilities. We also have commitments and potential contingent obligations relating to the completion of our research and development of pelareorep.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In managing our capital, we estimate our future cash requirements by preparing a budget and a multi-year plan annually for review and approval by our Board. The budget establishes the approved activities for the upcoming year and estimates the associated costs. The multi-year plan estimates future activity along with the potential cash requirements and is based on our assessment of our current clinical trial progress along with the expected results from the coming year&#x2019;s activity.&#160;Budget to actual variances are prepared and reviewed by management and are presented quarterly to the Board.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Historically, funding for our plan is primarily managed through the issuance of additional common shares and common share purchase warrants that upon exercise are converted to common shares.&#160;Management regularly monitors the capital markets attempting to balance the timing of issuing additional equity with our progress through our clinical trial program, general market conditions, and the availability of capital.&#160;There are no assurances that funds will be made available to us when required.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 19, 2024, we renewed our short form base shelf prospectus (the "Base Shelf") that qualifies for distribution of up to $150 million of common shares, subscription receipts, warrants, or units (the "Securities") in either Canada, the U.S. or both. The Base Shelf will be effective until August 19, 2026. Under the Base Shelf, we may sell Securities to or through underwriters, dealers, placement agents, or other intermediaries. We may also sell Securities directly to purchasers or through agents, subject to obtaining any applicable exemption from registration requirements. The distribution of Securities may be performed from time to time in one or more transactions at a fixed price or prices, which may be subject to change, at market prices prevailing at the time of sale, or at prices related to such prevailing market prices to be negotiated with purchasers and as set forth in an accompanying Prospectus Supplement.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Renewing our Base Shelf provides additional flexibility when managing our cash resources as, under certain circumstances, it shortens the time required to close a financing and is expected to increase the number of potential investors that may be &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;prepared to invest in the Company. Funds received from using our Base Shelf would be used in line with our Board approved budget and multi-year plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our Base Shelf allowed us to enter into our ATM equity distribution agreement (see note 10). We plan on using this equity arrangement to assist us in achieving our capital objectives. This arrangement provided us with the opportunity to raise capital and better manage our cash resources.   &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are not subject to externally imposed capital requirements, and there have been no changes in how we define or manage our capital in 2024.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory>
    <oncyf:DisclosureOfCapitalComponentsTableTextBlock contextRef="c-1" id="f-872">&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.104%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.005%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.007%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;15,942&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shareholders' equity&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5,983&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</oncyf:DisclosureOfCapitalComponentsTableTextBlock>
    <ifrs-full:CashAndCashEquivalents contextRef="c-3" decimals="-3" id="f-873" unitRef="cad">15942000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-4" decimals="-3" id="f-874" unitRef="cad">34912000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:Equity contextRef="c-3" decimals="-3" id="f-875" unitRef="cad">5983000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-4" decimals="-3" id="f-876" unitRef="cad">27563000</ifrs-full:Equity>
    <oncyf:EquityAuthorized contextRef="c-233" decimals="-6" id="f-877" unitRef="cad">150000000</oncyf:EquityAuthorized>
    <ifrs-full:DisclosureOfFinancialInstrumentsExplanatory contextRef="c-1" id="f-878">Financial Instruments&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair value of financial instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As at December&#160;31, 2024, and December&#160;31, 2023, the carrying amount of our cash and cash equivalents, other receivables, accounts payable and accrued liabilities, and other liabilities approximated their fair value due to their short-term maturity. The warrant derivative is a recurring Level 2 fair value measurement as these warrants have not been listed on an exchange and, therefore, do not trade on an active market. As at December&#160;31, 2024, the fair value of our warrant derivative was presented as an asset of $980 (December&#160;31, 2023 - liability of $200) (see note 9). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Financial risk management&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Credit risk&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Credit risk is the risk of a financial loss if a counterparty to a financial instrument fails to meet its contractual obligations.&#160;As at December&#160;31, 2024, we were exposed to credit risk on our cash and cash equivalents in the event of non-performance by counterparties, but we do not anticipate such non-performance. Our maximum exposure to credit risk at the end of the period is the carrying value of our cash and cash equivalents. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We mitigate our exposure to credit risk connected to our cash and cash equivalents by maintaining our primary operating and investment bank accounts with Schedule I banks in Canada.&#160;For our foreign-domiciled bank accounts, we use referrals or recommendations from our Canadian banks to open foreign bank accounts. Our foreign-domiciled bank accounts are used solely for the purpose of settling accounts payable and accrued liabilities or payroll.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Interest rate risk &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates.&#160;We hold our cash and cash equivalents in bank accounts or high-interest investment accounts with variable interest rates. We mitigate interest rate risk through our investment policy that only allows the investment of excess cash resources in investment-grade vehicles while matching maturities with our operational requirements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fluctuations in market interest rates do not significantly impact our results of operations due to the short-term maturity of the investments held.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign exchange risk&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign exchange risk arises from changes in foreign exchange rates that may affect the fair value or future cash flows of our financial assets or liabilities. For the year ended December&#160;31, 2024, we were primarily exposed to the risk of changes in the Canadian dollar relative to the U.S. dollar and Euro as a portion of our financial assets and liabilities were denominated in such currencies. The impact of a $0.01 increase in the value of the U.S. dollar against the Canadian dollar would have increased our comprehensive loss for the year ended December&#160;31, 2024, by approximately $34 (December&#160;31, 2023 - decreased by approximately $139). The impact of a $0.01 increase in the value of the Euro against the Canadian dollar would have increased our comprehensive loss for the year ended December&#160;31, 2024, by approximately $30 (December&#160;31, 2023 - $15). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant balances denominated in U.S. dollars were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.104%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.005%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.007%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;9,534&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable and accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,722)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,476)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,125)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(251)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,687&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant balances denominated in Euros were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.104%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.005%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.007%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable and accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,114)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(673)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We mitigate our foreign exchange risk by maintaining sufficient foreign currencies by purchasing foreign currencies or receiving foreign currencies from financing activities to settle our foreign accounts payable and accrued liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liquidity risk&lt;/span&gt;&lt;/div&gt;Liquidity risk is the risk that we will encounter difficulty in meeting obligations associated with financial liabilities. See note 1 for the discussion on our ability to continue as a going concern.&#160;We manage liquidity risk by managing our capital structure as outlined in note 16. Accounts payable and accrued liabilities are all due within the current operating period. Other liabilities associated with funding received from PanCAN (see note 5) are expected to be applied within the current operating period. See note 8 for a maturity analysis of our lease liabilities.</ifrs-full:DisclosureOfFinancialInstrumentsExplanatory>
    <ifrs-full:CurrentDerivativeFinancialAssets contextRef="c-3" decimals="-3" id="f-879" unitRef="cad">980000</ifrs-full:CurrentDerivativeFinancialAssets>
    <ifrs-full:CurrentDerivativeFinancialLiabilities contextRef="c-4" decimals="-3" id="f-880" unitRef="cad">200000</ifrs-full:CurrentDerivativeFinancialLiabilities>
    <oncyf:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount contextRef="c-234" decimals="2" id="f-881" unitRef="cad">0.01</oncyf:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount>
    <oncyf:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings contextRef="c-234" decimals="-3" id="f-882" unitRef="cad">34000</oncyf:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings>
    <oncyf:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings contextRef="c-235" decimals="-3" id="f-883" unitRef="cad">-139000</oncyf:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings>
    <oncyf:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount contextRef="c-236" decimals="2" id="f-884" unitRef="cad">0.01</oncyf:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount>
    <oncyf:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings contextRef="c-236" decimals="-3" id="f-885" unitRef="cad">30000</oncyf:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings>
    <oncyf:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings contextRef="c-237" decimals="-3" id="f-886" unitRef="cad">15000</oncyf:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings>
    <oncyf:ScheduleOfForeignCurrencyHeldTableTextBlock contextRef="c-1" id="f-887">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant balances denominated in U.S. dollars were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.104%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.005%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.007%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;9,534&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable and accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,722)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,476)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,125)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(251)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,687&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant balances denominated in Euros were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.104%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.005%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.007%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable and accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,114)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(673)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</oncyf:ScheduleOfForeignCurrencyHeldTableTextBlock>
    <ifrs-full:CashAndCashEquivalents contextRef="c-238" decimals="-3" id="f-888" unitRef="usd">9534000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-239" decimals="-3" id="f-889" unitRef="usd">24294000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:TradeAndOtherCurrentPayables contextRef="c-238" decimals="-3" id="f-890" unitRef="usd">1722000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherCurrentPayables contextRef="c-239" decimals="-3" id="f-891" unitRef="usd">1476000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:OtherLiabilities contextRef="c-238" decimals="-3" id="f-892" unitRef="usd">1125000</ifrs-full:OtherLiabilities>
    <ifrs-full:OtherLiabilities contextRef="c-239" decimals="-3" id="f-893" unitRef="usd">251000</ifrs-full:OtherLiabilities>
    <oncyf:BalanceHeldInForeignCurrencyNet contextRef="c-238" decimals="-3" id="f-894" unitRef="usd">6687000</oncyf:BalanceHeldInForeignCurrencyNet>
    <oncyf:BalanceHeldInForeignCurrencyNet contextRef="c-239" decimals="-3" id="f-895" unitRef="usd">22567000</oncyf:BalanceHeldInForeignCurrencyNet>
    <ifrs-full:TradeAndOtherCurrentPayables contextRef="c-240" decimals="-3" id="f-896" unitRef="eur">1114000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherCurrentPayables contextRef="c-241" decimals="-3" id="f-897" unitRef="eur">673000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:DisclosureOfCashFlowStatementExplanatory contextRef="c-1" id="f-898">Additional Cash Flow Disclosures&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net Change In Non-Cash Working Capital&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.379%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.350%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.350%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.353%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Change in:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,361&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,247)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable and accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,220&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(78)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,286&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(352)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-cash impact of foreign exchange&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(276)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in non-cash working capital related to operating activities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,538&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other Cash Flow Disclosures&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.379%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.350%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.350%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.353%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash interest received&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,339&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash taxes paid&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;184&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfCashFlowStatementExplanatory>
    <oncyf:CashFlowOperatingCapital1TableTextBlock contextRef="c-1" id="f-899">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net Change In Non-Cash Working Capital&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.379%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.350%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.350%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.353%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Change in:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,361&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,247)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable and accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,220&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(78)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,286&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(352)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-cash impact of foreign exchange&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(276)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in non-cash working capital related to operating activities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,538&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</oncyf:CashFlowOperatingCapital1TableTextBlock>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables contextRef="c-1" decimals="-3" id="f-900" unitRef="cad">-53000</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables contextRef="c-7" decimals="-3" id="f-901" unitRef="cad">506000</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables contextRef="c-8" decimals="-3" id="f-902" unitRef="cad">345000</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInPrepaidExpenses contextRef="c-1" decimals="-3" id="f-903" unitRef="cad">1361000</ifrs-full:AdjustmentsForDecreaseIncreaseInPrepaidExpenses>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInPrepaidExpenses contextRef="c-7" decimals="-3" id="f-904" unitRef="cad">777000</ifrs-full:AdjustmentsForDecreaseIncreaseInPrepaidExpenses>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInPrepaidExpenses contextRef="c-8" decimals="-3" id="f-905" unitRef="cad">-1247000</ifrs-full:AdjustmentsForDecreaseIncreaseInPrepaidExpenses>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables contextRef="c-1" decimals="-3" id="f-906" unitRef="cad">1220000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables contextRef="c-7" decimals="-3" id="f-907" unitRef="cad">-78000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables contextRef="c-8" decimals="-3" id="f-908" unitRef="cad">1662000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInOtherOperatingPayables contextRef="c-1" decimals="-3" id="f-909" unitRef="cad">1286000</ifrs-full:AdjustmentsForIncreaseDecreaseInOtherOperatingPayables>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInOtherOperatingPayables contextRef="c-7" decimals="-3" id="f-910" unitRef="cad">332000</ifrs-full:AdjustmentsForIncreaseDecreaseInOtherOperatingPayables>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInOtherOperatingPayables contextRef="c-8" decimals="-3" id="f-911" unitRef="cad">-352000</ifrs-full:AdjustmentsForIncreaseDecreaseInOtherOperatingPayables>
    <oncyf:IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet contextRef="c-1" decimals="-3" id="f-912" unitRef="cad">-276000</oncyf:IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet>
    <oncyf:IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet contextRef="c-7" decimals="-3" id="f-913" unitRef="cad">228000</oncyf:IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet>
    <oncyf:IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet contextRef="c-8" decimals="-3" id="f-914" unitRef="cad">-17000</oncyf:IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet>
    <ifrs-full:IncreaseDecreaseInWorkingCapital contextRef="c-1" decimals="-3" id="f-915" unitRef="cad">-3538000</ifrs-full:IncreaseDecreaseInWorkingCapital>
    <ifrs-full:IncreaseDecreaseInWorkingCapital contextRef="c-7" decimals="-3" id="f-916" unitRef="cad">-1765000</ifrs-full:IncreaseDecreaseInWorkingCapital>
    <ifrs-full:IncreaseDecreaseInWorkingCapital contextRef="c-8" decimals="-3" id="f-917" unitRef="cad">-391000</ifrs-full:IncreaseDecreaseInWorkingCapital>
    <oncyf:ScheduleofCashFlowSupplementalDisclosures1TableTextBlock contextRef="c-1" id="f-918">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other Cash Flow Disclosures&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.379%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.350%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.350%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.353%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash interest received&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,339&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash taxes paid&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;184&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</oncyf:ScheduleofCashFlowSupplementalDisclosures1TableTextBlock>
    <oncyf:ProceedsfromInterestReceived contextRef="c-1" decimals="-3" id="f-919" unitRef="cad">1339000</oncyf:ProceedsfromInterestReceived>
    <oncyf:ProceedsfromInterestReceived contextRef="c-7" decimals="-3" id="f-920" unitRef="cad">1554000</oncyf:ProceedsfromInterestReceived>
    <oncyf:ProceedsfromInterestReceived contextRef="c-8" decimals="-3" id="f-921" unitRef="cad">452000</oncyf:ProceedsfromInterestReceived>
    <ifrs-full:IncomeTaxesPaidRefund contextRef="c-1" decimals="-3" id="f-922" unitRef="cad">184000</ifrs-full:IncomeTaxesPaidRefund>
    <ifrs-full:IncomeTaxesPaidRefund contextRef="c-7" decimals="-3" id="f-923" unitRef="cad">120000</ifrs-full:IncomeTaxesPaidRefund>
    <ifrs-full:IncomeTaxesPaidRefund contextRef="c-8" decimals="-3" id="f-924" unitRef="cad">46000</ifrs-full:IncomeTaxesPaidRefund>
    <oncyf:DisclosureOfEconomicDependenceTextBlock contextRef="c-1" id="f-925">Economic Dependence&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are economically dependent on our toll manufacturers. We primarily use one toll manufacturer in the U.S. to produce the clinical-grade pelareorep active ingredient and a second toll manufacturer to formulate finished product required for our clinical trial program.&#160;Any significant disruption of the services provided by our primary toll manufacturers has the potential to delay the progress of our clinical trial program.&#160;We have attempted to mitigate this risk by identifying an alternative toll manufacturer, establishing stability profiles for long-term storage of pelareorep, and producing sufficient pelareorep in advance of patient enrollment in a particular clinical trial.&lt;/span&gt;&lt;/div&gt;</oncyf:DisclosureOfEconomicDependenceTextBlock>
    <oncyf:ConcentrationRiskNumber
      contextRef="c-242"
      decimals="INF"
      id="f-926"
      unitRef="manufacturer">1</oncyf:ConcentrationRiskNumber>
    <ifrs-full:DisclosureOfExpensesByNatureExplanatory contextRef="c-1" id="f-927">Components of Expenses&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.379%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.350%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.350%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.353%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical trial expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5,463&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Manufacturing &amp;amp; related process development expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8,267&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intellectual property expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;433&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Translational science expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;101&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Personnel-related expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5,451&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,717&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;215&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;21,647&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;General and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Public company-related expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8,565&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Personnel-related expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,848&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;492&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,006&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation - property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;120&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation - right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;304&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;13,335&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,082&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the year ended December&#160;31, 2024, our research and development personnel-related expenses included employee compensation and benefits of $5,328 (2023 - $6,324; 2022 - $5,983).&lt;/span&gt;&lt;/div&gt;For the year ended December&#160;31, 2024, our general and administrative office expenses included employee compensation and benefits of $2,650 (2023 - $3,332; 2022 - $2,870).</ifrs-full:DisclosureOfExpensesByNatureExplanatory>
    <oncyf:OtherExpensesAndAdjustmentsTableTextBlock contextRef="c-1" id="f-928">&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.379%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.350%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.350%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.353%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical trial expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5,463&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Manufacturing &amp;amp; related process development expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8,267&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intellectual property expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;433&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Translational science expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;101&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Personnel-related expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5,451&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,717&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;215&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;21,647&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;General and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Public company-related expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8,565&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Personnel-related expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,848&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;492&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,006&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation - property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;120&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation - right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;304&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;13,335&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,082&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</oncyf:OtherExpensesAndAdjustmentsTableTextBlock>
    <oncyf:ClinicalTrialExpense contextRef="c-243" decimals="-3" id="f-929" unitRef="cad">5463000</oncyf:ClinicalTrialExpense>
    <oncyf:ClinicalTrialExpense contextRef="c-244" decimals="-3" id="f-930" unitRef="cad">3675000</oncyf:ClinicalTrialExpense>
    <oncyf:ClinicalTrialExpense contextRef="c-245" decimals="-3" id="f-931" unitRef="cad">4970000</oncyf:ClinicalTrialExpense>
    <oncyf:ManufacturingExpense contextRef="c-243" decimals="-3" id="f-932" unitRef="cad">8267000</oncyf:ManufacturingExpense>
    <oncyf:ManufacturingExpense contextRef="c-244" decimals="-3" id="f-933" unitRef="cad">5789000</oncyf:ManufacturingExpense>
    <oncyf:ManufacturingExpense contextRef="c-245" decimals="-3" id="f-934" unitRef="cad">2148000</oncyf:ManufacturingExpense>
    <oncyf:IntellectualPropertyExpense contextRef="c-243" decimals="-3" id="f-935" unitRef="cad">433000</oncyf:IntellectualPropertyExpense>
    <oncyf:IntellectualPropertyExpense contextRef="c-244" decimals="-3" id="f-936" unitRef="cad">397000</oncyf:IntellectualPropertyExpense>
    <oncyf:IntellectualPropertyExpense contextRef="c-245" decimals="-3" id="f-937" unitRef="cad">544000</oncyf:IntellectualPropertyExpense>
    <oncyf:TranslationalScienceExpense contextRef="c-243" decimals="-3" id="f-938" unitRef="cad">101000</oncyf:TranslationalScienceExpense>
    <oncyf:TranslationalScienceExpense contextRef="c-244" decimals="-3" id="f-939" unitRef="cad">0</oncyf:TranslationalScienceExpense>
    <oncyf:TranslationalScienceExpense contextRef="c-245" decimals="-3" id="f-940" unitRef="cad">264000</oncyf:TranslationalScienceExpense>
    <ifrs-full:OtherEmployeeExpense contextRef="c-243" decimals="-3" id="f-941" unitRef="cad">5451000</ifrs-full:OtherEmployeeExpense>
    <ifrs-full:OtherEmployeeExpense contextRef="c-244" decimals="-3" id="f-942" unitRef="cad">6324000</ifrs-full:OtherEmployeeExpense>
    <ifrs-full:OtherEmployeeExpense contextRef="c-245" decimals="-3" id="f-943" unitRef="cad">6023000</ifrs-full:OtherEmployeeExpense>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="c-243" decimals="-3" id="f-944" unitRef="cad">1717000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="c-244" decimals="-3" id="f-945" unitRef="cad">1305000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="c-245" decimals="-3" id="f-946" unitRef="cad">1371000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:MiscellaneousOtherOperatingExpense contextRef="c-243" decimals="-3" id="f-947" unitRef="cad">215000</ifrs-full:MiscellaneousOtherOperatingExpense>
    <ifrs-full:MiscellaneousOtherOperatingExpense contextRef="c-244" decimals="-3" id="f-948" unitRef="cad">219000</ifrs-full:MiscellaneousOtherOperatingExpense>
    <ifrs-full:MiscellaneousOtherOperatingExpense contextRef="c-245" decimals="-3" id="f-949" unitRef="cad">112000</ifrs-full:MiscellaneousOtherOperatingExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c-1" decimals="-3" id="f-950" unitRef="cad">21647000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c-7" decimals="-3" id="f-951" unitRef="cad">17709000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c-8" decimals="-3" id="f-952" unitRef="cad">15432000</ifrs-full:ResearchAndDevelopmentExpense>
    <oncyf:PublicCompanyExpense contextRef="c-246" decimals="-3" id="f-953" unitRef="cad">8565000</oncyf:PublicCompanyExpense>
    <oncyf:PublicCompanyExpense contextRef="c-247" decimals="-3" id="f-954" unitRef="cad">11278000</oncyf:PublicCompanyExpense>
    <oncyf:PublicCompanyExpense contextRef="c-248" decimals="-3" id="f-955" unitRef="cad">6790000</oncyf:PublicCompanyExpense>
    <ifrs-full:OtherEmployeeExpense contextRef="c-246" decimals="-3" id="f-956" unitRef="cad">2848000</ifrs-full:OtherEmployeeExpense>
    <ifrs-full:OtherEmployeeExpense contextRef="c-247" decimals="-3" id="f-957" unitRef="cad">3332000</ifrs-full:OtherEmployeeExpense>
    <ifrs-full:OtherEmployeeExpense contextRef="c-248" decimals="-3" id="f-958" unitRef="cad">2870000</ifrs-full:OtherEmployeeExpense>
    <oncyf:OfficeExpenses contextRef="c-246" decimals="-3" id="f-959" unitRef="cad">492000</oncyf:OfficeExpenses>
    <oncyf:OfficeExpenses contextRef="c-247" decimals="-3" id="f-960" unitRef="cad">457000</oncyf:OfficeExpenses>
    <oncyf:OfficeExpenses contextRef="c-248" decimals="-3" id="f-961" unitRef="cad">433000</oncyf:OfficeExpenses>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="c-246" decimals="-3" id="f-962" unitRef="cad">1006000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="c-247" decimals="-3" id="f-963" unitRef="cad">612000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="c-248" decimals="-3" id="f-964" unitRef="cad">1007000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:AmortisationExpense contextRef="c-246" decimals="-3" id="f-965" unitRef="cad">120000</ifrs-full:AmortisationExpense>
    <ifrs-full:AmortisationExpense contextRef="c-247" decimals="-3" id="f-966" unitRef="cad">81000</ifrs-full:AmortisationExpense>
    <ifrs-full:AmortisationExpense contextRef="c-248" decimals="-3" id="f-967" unitRef="cad">93000</ifrs-full:AmortisationExpense>
    <ifrs-full:DepreciationRightofuseAssets contextRef="c-246" decimals="-3" id="f-968" unitRef="cad">304000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets contextRef="c-247" decimals="-3" id="f-969" unitRef="cad">322000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets contextRef="c-248" decimals="-3" id="f-970" unitRef="cad">299000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:GeneralAndAdministrativeExpense contextRef="c-1" decimals="-3" id="f-971" unitRef="cad">13335000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense contextRef="c-7" decimals="-3" id="f-972" unitRef="cad">16082000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense contextRef="c-8" decimals="-3" id="f-973" unitRef="cad">11492000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:EmployeeBenefitsExpense contextRef="c-243" decimals="-3" id="f-974" unitRef="cad">5328000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense contextRef="c-244" decimals="-3" id="f-975" unitRef="cad">6324000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense contextRef="c-245" decimals="-3" id="f-976" unitRef="cad">5983000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense contextRef="c-246" decimals="-3" id="f-977" unitRef="cad">2650000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense contextRef="c-247" decimals="-3" id="f-978" unitRef="cad">3332000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense contextRef="c-248" decimals="-3" id="f-979" unitRef="cad">2870000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory contextRef="c-1" id="f-980">Segment Disclosures&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our operations have one reportable segment engaged in the research and development and commercialization of oncology&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;treatments, which is consistent with the way we report information to our chief decision maker and Board of Directors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following geographic information reflects non-current assets by location:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.104%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.005%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.007%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canada&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;203&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rest of world&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;208&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;411&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.104%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.005%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.007%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Right-of-use-assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canada&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;74&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rest of world&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;827&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;901&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory>
    <oncyf:NumberOfReportableSegments1
      contextRef="c-3"
      decimals="INF"
      id="f-981"
      unitRef="segment">1</oncyf:NumberOfReportableSegments1>
    <ifrs-full:DisclosureOfGeographicalAreasExplanatory contextRef="c-1" id="f-982">&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following geographic information reflects non-current assets by location:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.104%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.005%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.007%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canada&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;203&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rest of world&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;208&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;411&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.104%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.005%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.007%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Right-of-use-assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canada&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;74&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rest of world&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;827&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;901&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfGeographicalAreasExplanatory>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-249" decimals="-3" id="f-983" unitRef="cad">203000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-250" decimals="-3" id="f-984" unitRef="cad">246000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-251" decimals="-3" id="f-985" unitRef="cad">208000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-252" decimals="-3" id="f-986" unitRef="cad">36000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-3" decimals="-3" id="f-987" unitRef="cad">411000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-4" decimals="-3" id="f-988" unitRef="cad">282000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:RightofuseAssets contextRef="c-249" decimals="-3" id="f-989" unitRef="cad">74000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets contextRef="c-250" decimals="-3" id="f-990" unitRef="cad">111000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets contextRef="c-251" decimals="-3" id="f-991" unitRef="cad">827000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets contextRef="c-252" decimals="-3" id="f-992" unitRef="cad">254000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets contextRef="c-3" decimals="-3" id="f-993" unitRef="cad">901000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets contextRef="c-4" decimals="-3" id="f-994" unitRef="cad">365000</ifrs-full:RightofuseAssets>
    <ifrs-full:DisclosureOfRelatedPartyExplanatory contextRef="c-1" id="f-995">Related Party Transactions&lt;div style="margin-bottom:10pt;margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Compensation of Key Management Personnel&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Key management personnel are those persons having authority and responsibility for planning, directing, and controlling our activities as a whole. We have determined that key management personnel comprise the Board of Directors, Executive Officers, President, and Vice Presidents. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.379%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.350%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.350%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.353%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term employee compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,267&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Termination benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,349&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,616&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfRelatedPartyExplanatory>
    <ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory contextRef="c-1" id="f-996">We have determined that key management personnel comprise the Board of Directors, Executive Officers, President, and Vice Presidents. &lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.379%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.350%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.350%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.353%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term employee compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,267&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Termination benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,349&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,616&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits contextRef="c-1" decimals="-3" id="f-997" unitRef="cad">4267000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits contextRef="c-7" decimals="-3" id="f-998" unitRef="cad">4870000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits contextRef="c-8" decimals="-3" id="f-999" unitRef="cad">4308000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationTerminationBenefits contextRef="c-1" decimals="-3" id="f-1000" unitRef="cad">0</ifrs-full:KeyManagementPersonnelCompensationTerminationBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationTerminationBenefits contextRef="c-7" decimals="-3" id="f-1001" unitRef="cad">319000</ifrs-full:KeyManagementPersonnelCompensationTerminationBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationTerminationBenefits contextRef="c-8" decimals="-3" id="f-1002" unitRef="cad">0</ifrs-full:KeyManagementPersonnelCompensationTerminationBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment contextRef="c-1" decimals="-3" id="f-1003" unitRef="cad">2349000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment contextRef="c-7" decimals="-3" id="f-1004" unitRef="cad">1496000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment contextRef="c-8" decimals="-3" id="f-1005" unitRef="cad">1615000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:KeyManagementPersonnelCompensation contextRef="c-1" decimals="-3" id="f-1006" unitRef="cad">6616000</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:KeyManagementPersonnelCompensation contextRef="c-7" decimals="-3" id="f-1007" unitRef="cad">6685000</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:KeyManagementPersonnelCompensation contextRef="c-8" decimals="-3" id="f-1008" unitRef="cad">5923000</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory contextRef="c-1" id="f-1009">Subsequent Events&lt;div style="margin-bottom:3pt;margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt"&gt;From January 1, 2025, to March&#160;6, 2025, we sold 5,302,950 shares for gross proceeds of $6,228 (US$4,327) at an average price of $1.17 (US$0.82). We received proceeds of $6,041 (US$4,197), after commissions of $187 (US$130). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;On February 13, 2025, we received a delinquency notification letter (the "Notice") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") indicating that, for the prior 30 consecutive business days, the closing bid price for our ordinary shares listed on the Nasdaq Capital Market was below the minimum $1.00 per share required for continued listing on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2). The Notice provides that we have a period of 180 calendar days from the date of the Notice, or until August 12, 2025, to regain compliance with the minimum bid price requirement. The receipt of the Notice has no immediate effect on our business operations or the listing of our ordinary shares, which will continue to trade uninterrupted on the Nasdaq under the ticker "ONCY." If at any time before August 12, 2025, the bid price of our ordinary shares closes at or above $1.00 per share for a minimum of 10 consecutive business days, Nasdaq will provide written confirmation of compliance to us. In the event that we do not regain compliance by August 12, 2025, we may be eligible for additional time to regain compliance. To qualify, we would be required to meet the continued listing requirement for the market value of publicly held shares and all other initial listing standards for the Nasdaq Capital Market, except for the minimum bid price requirement. In addition, we would be required to notify Nasdaq of its intent to cure the deficiency during the second compliance period.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(c)&lt;/span&gt;In early 2025, the President of the United States issued executive orders directing the United States to impose new tariffs on imports originating from Canada, Mexico, and China. The impacts of these tariffs on our operations remain uncertain. New or increased tariffs, export controls, or other measures discouraging contracts with Chinese companies could materially impact our supply chain and manufacturing costs and our licensing agreement with Adlai. We are assessing the direct and indirect impacts of such trade protectionist measures to our operations as this situation develops.</ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory>
    <oncyf:IssueOfEquityShares
      contextRef="c-53"
      decimals="INF"
      id="f-1010"
      unitRef="shares">5302950</oncyf:IssueOfEquityShares>
    <oncyf:ProceedsFromIssueOfOrdinarySharesGross contextRef="c-53" decimals="-3" id="f-1011" unitRef="cad">6228000</oncyf:ProceedsFromIssueOfOrdinarySharesGross>
    <oncyf:ProceedsFromIssueOfOrdinarySharesGross contextRef="c-53" decimals="-3" id="f-1012" unitRef="usd">4327000</oncyf:ProceedsFromIssueOfOrdinarySharesGross>
    <oncyf:IssueOfOrdinarySharesPerShare
      contextRef="c-53"
      decimals="2"
      id="f-1013"
      unitRef="cadPerShare">1.17</oncyf:IssueOfOrdinarySharesPerShare>
    <oncyf:IssueOfOrdinarySharesPerShare
      contextRef="c-53"
      decimals="2"
      id="f-1014"
      unitRef="usdPerShare">0.82</oncyf:IssueOfOrdinarySharesPerShare>
    <ifrs-full:ProceedsFromIssueOfOrdinaryShares contextRef="c-53" decimals="-3" id="f-1015" unitRef="cad">6041000</ifrs-full:ProceedsFromIssueOfOrdinaryShares>
    <ifrs-full:ProceedsFromIssueOfOrdinaryShares contextRef="c-53" decimals="-3" id="f-1016" unitRef="usd">4197000</ifrs-full:ProceedsFromIssueOfOrdinaryShares>
    <oncyf:ShareIssueRelatedCostCommissions contextRef="c-53" decimals="-3" id="f-1017" unitRef="cad">187000</oncyf:ShareIssueRelatedCostCommissions>
    <oncyf:ShareIssueRelatedCostCommissions contextRef="c-53" decimals="-3" id="f-1018" unitRef="usd">130000</oncyf:ShareIssueRelatedCostCommissions>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
